Token	True Label	Predicted Label
famotidine	B-chem	B-chem
-	O	O
associated	O	O
delirium	O	O
.	O	O

a	O	O
series	O	O
of	O	O
six	O	O
cases	O	O
.	O	O

famotidine	B-chem	B-chem
is	O	O
a	O	O
histamine	O	B-chem
h2	O	O
-	O	O
receptor	O	O
antagonist	O	O
used	O	O
in	O	O
inpatient	O	O
settings	O	O
for	O	O
prevention	O	O
of	O	O
stress	O	O
ulcers	O	O
and	O	O
is	O	O
showing	O	O
increasing	O	O
popularity	O	O
because	O	O
of	O	O
its	O	O
low	O	O
cost	O	O
.	O	O

although	O	O
all	O	O
of	O	O
the	O	O
currently	O	O
available	O	O
h2	O	O
-	O	O
receptor	O	O
antagonists	O	O
have	O	O
shown	O	O
the	O	O
propensity	O	O
to	O	O
cause	O	O
delirium	O	O
,	O	O
only	O	O
two	O	O
previously	O	O
reported	O	O
cases	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
famotidine	B-chem	B-chem
.	O	O

the	O	O
authors	O	O
report	O	O
on	O	O
six	O	O
cases	O	O
of	O	O
famotidine	B-chem	B-chem
-	O	O
associated	O	O
delirium	O	O
in	O	O
hospitalized	O	O
patients	O	O
who	O	O
cleared	O	O
completely	O	O
upon	O	O
removal	O	O
of	O	O
famotidine	B-chem	B-chem
.	O	O

the	O	O
pharmacokinetics	O	O
of	O	O
famotidine	B-chem	B-chem
are	O	O
reviewed	O	O
,	O	O
with	O	O
no	O	O
change	O	O
in	O	O
its	O	O
metabolism	O	O
in	O	O
the	O	O
elderly	O	O
population	O	O
seen	O	O
.	O	O

the	O	O
implications	O	O
of	O	O
using	O	O
famotidine	B-chem	B-chem
in	O	O
elderly	O	O
persons	O	O
are	O	O
discussed	O	O
.	O	O

indomethacin	B-chem	B-chem
induced	O	O
hypotension	O	O
in	O	O
sodium	B-chem	B-chem
and	O	O
volume	O	O
depleted	O	O
rats	O	O
.	O	O

after	O	O
a	O	O
single	O	O
oral	O	O
dose	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
indomethacin	B-chem	B-chem
(	O	O
idm	B-chem	B-chem
)	O	O
to	O	O
sodium	B-chem	B-chem
and	O	O
volume	O	O
depleted	O	O
rats	O	O
plasma	O	O
renin	O	O
activity	O	O
(	O	O
pra	O	B-chem
)	O	O
and	O	O
systolic	O	O
blood	O	O
pressure	O	O
fell	O	O
significantly	O	O
within	O	O
four	O	O
hours	O	O
.	O	O

in	O	O
sodium	B-chem	B-chem
repleted	O	O
animals	O	O
indomethacin	B-chem	B-chem
did	O	O
not	O	O
change	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
bp	O	O
)	O	O
although	O	O
plasma	O	O
renin	O	O
activity	O	O
was	O	O
decreased	O	O
.	O	O

thus	O	O
,	O	O
indomethacin	B-chem	B-chem
by	O	O
inhibition	O	O
of	O	O
prostaglandin	B-chem	B-chem
synthesis	O	O
may	O	O
diminish	O	O
the	O	O
blood	O	O
pressure	O	O
maintaining	O	O
effect	O	O
of	O	O
the	O	O
stimulated	O	O
renin	O	O
-	O	O
angiotensin	B-chem	B-chem
system	O	O
in	O	O
sodium	B-chem	B-chem
and	O	O
volume	O	O
depletion	O	O
.	O	O

late	O	O
-	O	O
onset	O	O
scleroderma	O	O
renal	O	O
crisis	O	O
induced	O	O
by	O	O
tacrolimus	B-chem	B-chem
and	O	O
prednisolone	B-chem	B-chem
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

scleroderma	O	O
renal	O	O
crisis	O	O
(	O	O
src	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
systemic	O	O
sclerosis	O	O
(	O	O
ssc	O	O
)	O	O
but	O	O
can	O	O
be	O	O
severe	O	O
enough	O	O
to	O	O
require	O	O
temporary	O	O
or	O	O
permanent	O	O
renal	O	O
replacement	O	O
therapy	O	O
.	O	O

moderate	O	O
to	O	O
high	O	O
dose	O	O
corticosteroid	B-chem	O
use	O	O
is	O	O
recognized	O	O
as	O	O
a	O	O
major	O	O
risk	O	O
factor	O	O
for	O	O
src	O	O
.	O	O

furthermore	O	O
,	O	O
there	O	O
have	O	O
been	O	O
reports	O	O
of	O	O
thrombotic	O	O
microangiopathy	O	O
precipitated	O	O
by	O	O
cyclosporine	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
ssc	O	O
.	O	O

in	O	O
this	O	O
article	O	O
,	O	O
we	O	O
report	O	O
a	O	O
patient	O	O
with	O	O
src	O	O
induced	O	O
by	O	O
tacrolimus	B-chem	B-chem
and	O	O
corticosteroids	B-chem	O
.	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
work	O	O
is	O	O
to	O	O
call	O	O
attention	O	O
to	O	O
the	O	O
risk	O	O
of	O	O
tacrolimus	B-chem	B-chem
use	O	O
in	O	O
patients	O	O
with	O	O
ssc	O	O
.	O	O

the	O	O
risk	O	O
and	O	O
associated	O	O
factors	O	O
of	O	O
methamphetamine	B-chem	B-chem
psychosis	O	O
in	O	O
methamphetamine	B-chem	B-chem
-	O	O
dependent	O	O
patients	O	O
in	O	O
malaysia	O	O
.	O	O

objective	O	O
:	O	O
the	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
risk	O	O
of	O	O
lifetime	O	O
and	O	O
current	O	O
methamphetamine	B-chem	B-chem
-	O	O
induced	O	O
psychosis	O	O
in	O	O
patients	O	O
with	O	O
methamphetamine	B-chem	B-chem
dependence	O	O
.	O	O

the	O	O
association	O	O
between	O	O
psychiatric	O	O
co	O	O
-	O	O
morbidity	O	O
and	O	O
methamphetamine	B-chem	B-chem
-	O	O
induced	O	O
psychosis	O	O
was	O	O
also	O	O
studied	O	O
.	O	O

methods	O	O
:	O	O

this	O	O
was	O	O
a	O	O
cross	O	O
-	O	O
sectional	O	O
study	O	O
conducted	O	O
concurrently	O	O
at	O	O
a	O	O
teaching	O	O
hospital	O	O
and	O	O
a	O	O
drug	O	O
rehabilitation	O	O
center	O	O
in	O	O
malaysia	O	O
.	O	O

patients	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
methamphetamine	B-chem	B-chem
based	O	O
on	O	O
dsm	O	O
-	O	O
iv	O	O
were	O	O
interviewed	O	O
using	O	O
the	O	O
mini	O	O
international	O	O
neuropsychiatric	O	O
interview	O	O
(	O	O
m	O	O
.	O	O
i	O	O
.	O	O
n	O	O
.	O	O
i	O	O
.	O	O
)	O	O
for	O	O
methamphetamine	B-chem	B-chem
-	O	O
induced	O	O
psychosis	O	O
and	O	O
other	O	O
axis	O	O
i	O	O
psychiatric	O	O
disorders	O	O
.	O	O

the	O	O
information	O	O
on	O	O
sociodemographic	O	O
background	O	O
and	O	O
drug	O	O
use	O	O
history	O	O
was	O	O
obtained	O	O
from	O	O
interview	O	O
or	O	O
medical	O	O
records	O	O
.	O	O

results	O	O
:	O	O

of	O	O
292	O	O
subjects	O	O
,	O	O
47	O	O
.	O	O
9	O	O
%	O	O
of	O	O
the	O	O
subjects	O	O
had	O	O
a	O	O
past	O	O
history	O	O
of	O	O
psychotic	O	O
symptoms	O	O
and	O	O
13	O	O
.	O	O
0	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
having	O	O
current	O	O
psychotic	O	O
symptoms	O	O
.	O	O

co	O	O
-	O	O
morbid	O	O
major	O	O
depressive	O	O
disorder	O	O

(	O	O
or	O	O
=	O	O
7	O	O
.	O	O
18	O	O
,	O	O
95	O	O
ci	O	O
=	O	O
2	O	O
.	O	O
612	O	O
-	O	O
19	O	O
.	O	O
708	O	O
)	O	O
,	O	O
bipolar	O	O
disorder	O	O
(	O	O
or	O	O
=	O	O
13	O	O
.	O	O
807	O	O
,	O	O
95	O	O
ci	O	O
=	O	O
5	O	O
.	O	O
194	O	O
-	O	O
36	O	O
.	O	O
706	O	O
)	O	O
,	O	O
antisocial	O	O
personality	O	O
disorder	O	O
(	O	O
or	O	O
=	O	O
12	O	O
.	O	O
619	O	O
,	O	O
95	O	O
ci	O	O
=	O	O
6	O	O
.	O	O
702	O	O
-	O	O
23	O	O
.	O	O
759	O	O
)	O	O
and	O	O
heavy	O	O
methamphetamine	B-chem	B-chem
uses	O	O
were	O	O
significantly	O	O
associated	O	O
with	O	O
lifetime	O	O
methamphetamine	B-chem	B-chem
-	O	O
induced	O	O
psychosis	O	O
after	O	O
adjusted	O	O
for	O	O
other	O	O
factors	O	O
.	O	O

major	O	O
depressive	O	O
disorder	O	O
(	O	O
or	O	O
=	O	O
2	O	O
.	O	O
870	O	O
,	O	O
ci	O	O
=	O	O
1	O	O
.	O	O
154	O	O
-	O	O
7	O	O
.	O	O
142	O	O
)	O	O
and	O	O
antisocial	O	O
personality	O	O
disorder	O	O
(	O	O
or	O	O
=	O	O
3	O	O
.	O	O
299	O	O
,	O	O
95	O	O
ci	O	O
=	O	O
1	O	O
.	O	O
375	O	O
-	O	O
7	O	O
.	O	O
914	O	O
)	O	O
were	O	O
the	O	O
only	O	O
factors	O	O
associated	O	O
with	O	O
current	O	O
psychosis	O	O
.	O	O

conclusion	O	O
:	O	O

there	O	O
was	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
psychosis	O	O
in	O	O
patients	O	O
with	O	O
methamphetamine	B-chem	B-chem
dependence	O	O
.	O	O

it	O	O
was	O	O
associated	O	O
with	O	O
co	O	O
-	O	O
morbid	O	O
affective	O	O
disorder	O	O
,	O	O
antisocial	O	O
personality	O	O
,	O	O
and	O	O
heavy	O	O
methamphetamine	B-chem	B-chem
use	O	O
.	O	O

it	O	O
is	O	O
recommended	O	O
that	O	O
all	O	O
cases	O	O
of	O	O
methamphetamine	B-chem	B-chem
dependence	O	O
should	O	O
be	O	O
screened	O	O
for	O	O
psychotic	O	O
symptoms	O	O
.	O	O

cerebellar	O	O
sensory	O	O
processing	O	O
alterations	O	O
impact	O	O
motor	O	O
cortical	O	O
plasticity	O	O
in	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
:	O	O
clues	O	O
from	O	O
dyskinetic	O	O
patients	O	O
.	O	O

the	O	O
plasticity	O	O
of	O	O
primary	O	O
motor	O	O
cortex	O	O
(	O	O
m1	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
(	O	O
pd	O	O
)	O	O
and	O	O
levodopa	B-chem	B-chem
-	O	O
induced	O	O
dyskinesias	O	O
(	O	O
lids	O	O
)	O	O
is	O	O
severely	O	O
impaired	O	O
.	O	O

we	O	O
recently	O	O
reported	O	O
in	O	O
young	O	O
healthy	O	O
subjects	O	O
that	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
enhanced	O	O
the	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
m1	O	O
that	O	O
was	O	O
induced	O	O
by	O	O
paired	O	O
associative	O	O
stimulation	O	O
(	O	O
pas	O	O
)	O	O
.	O	O

this	O	O
study	O	O
demonstrates	O	O
that	O	O
the	O	O
deficient	O	O
sensorimotor	O	O
m1	O	O
plasticity	O	O
in	O	O
16	O	O
patients	O	O
with	O	O
lids	O	O
could	O	O
be	O	O
reinstated	O	O
by	O	O
a	O	O
single	O	O
session	O	O
of	O	O
real	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
but	O	O
not	O	O
sham	O	O
stimulation	O	O
.	O	O

this	O	O
was	O	O
evident	O	O
only	O	O
when	O	O
a	O	O
sensory	O	O
component	O	O
was	O	O
involved	O	O
in	O	O
the	O	O
induction	O	O
of	O	O
plasticity	O	O
,	O	O
indicating	O	O
that	O	O
cerebellar	O	O
sensory	O	O
processing	O	O
function	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
resurgence	O	O
of	O	O
m1	O	O
plasticity	O	O
.	O	O

the	O	O
benefit	O	O
of	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
on	O	O
lids	O	O
is	O	O
known	O	O
.	O	O

to	O	O
explore	O	O
whether	O	O
this	O	O
benefit	O	O
is	O	O
linked	O	O
to	O	O
the	O	O
restoration	O	O
of	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
m1	O	O
,	O	O
we	O	O
conducted	O	O
an	O	O
additional	O	O
study	O	O
looking	O	O
at	O	O
changes	O	O
in	O	O
lids	O	O
and	O	O
pas	O	O
-	O	O
induced	O	O
plasticity	O	O
after	O	O
10	O	O
sessions	O	O
of	O	O
either	O	O
bilateral	O	O
,	O	O
real	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
or	O	O
sham	O	O
stimulation	O	O
.	O	O

only	O	O
real	O	O
and	O	O
not	O	O
sham	O	O
stimulation	O	O
had	O	O
an	O	O
antidyskinetic	O	O
effect	O	O
and	O	O
it	O	O
was	O	O
paralleled	O	O
by	O	O
a	O	O
resurgence	O	O
in	O	O
the	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
m1	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
that	O	O
alterations	O	O
in	O	O
cerebellar	O	O
sensory	O	O
processing	O	O
function	O	O
,	O	O
occurring	O	O
secondary	O	O
to	O	O
abnormal	O	O
basal	O	O
ganglia	O	O
signals	O	O
reaching	O	O
it	O	O
,	O	O
may	O	O
be	O	O
an	O	O
important	O	O
element	O	O
contributing	O	O
to	O	O
the	O	O
maladaptive	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
m1	O	O
and	O	O
the	O	O
emergence	O	O
of	O	O
abnormal	O	O
involuntary	O	O
movements	O	O
.	O	O

the	O	O
function	O	O
of	O	O
p2x3	O	B-chem
receptor	O	O
and	O	O
nk1	O	O
receptor	O	O
antagonists	O	O
on	O	O
cyclophosphamide	B-chem	B-chem
-	O	O
induced	O	O
cystitis	O	O
in	O	O
rats	O	O
.	O	O

purpose	O	O
:	O	O

the	O	O
purpose	O	O
of	O	O
the	O	O
study	O	O
is	O	O
to	O	O
explore	O	O
the	O	O
function	O	O
of	O	O
p2x3	O	B-chem
and	O	O
nk1	O	O
receptors	O	O
antagonists	O	O
on	O	O
cyclophosphamide	B-chem	B-chem
(	O	O
cyp	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
cystitis	O	O
in	O	O
rats	O	O
.	O	O

methods	O	O
:	O	O

sixty	O	O
female	O	O
sprague	O	O
-	O	O
dawley	O	O
(	O	O
sd	O	O
)	O	O
rats	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
.	O	O

the	O	O
rats	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
intraperitoneally	O	O
(	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
injected	O	O
with	O	O
0	O	O
.	O	O
9	O	O
%	O	O
saline	O	O
(	O	O
4	O	O
ml	O	O
/	O	O
kg	O	O
)	O	O
;	O	O
the	O	O
rats	O	O
in	O	O
the	O	O
model	O	O
group	O	O
were	O	O
i	O	O
.	O	O
p	O	O
.	O	O

injected	O	O
with	O	O
cyp	B-chem	B-chem
(	O	O
150	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
;	O	O
and	O	O
the	O	O
rats	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
were	O	O
i	O	O
.	O	O
p	O	O
.	O	O

injected	O	O
with	O	O
cyp	B-chem	O
with	O	O
subsequently	O	O
perfusion	O	O
of	O	O
bladder	O	O
with	O	O
p2x3	O	B-chem
and	O	O
nk1	O	O
receptors	O	O
'	O	O
antagonists	O	O
,	O	O
suramin	B-chem	B-chem
and	O	O
gr	B-chem	B-chem
82334	I-chem	O
.	O	O

spontaneous	O	O
pain	O	O
behaviors	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
cyp	B-chem	O
were	O	O
observed	O	O
.	O	O

urodynamic	O	O
parameters	O	O
,	O	O
bladder	O	O
pressure	O	O
-	O	O
volume	O	O
curve	O	O
,	O	O
maximum	O	O
voiding	O	O
pressure	O	O
(	O	O
mvp	O	O
)	O	O
,	O	O
and	O	O
maximum	O	O
cystometric	O	O
capacity	O	O
(	O	O
mcc	O	O
)	O	O
,	O	O
were	O	O
recorded	O	O
.	O	O

pathological	O	O
changes	O	O
in	O	O
bladder	O	O
tissue	O	O
were	O	O
observed	O	O
.	O	O

immunofluorescence	O	O
was	O	O
used	O	O
to	O	O
detect	O	O
the	O	O
expression	O	O
of	O	O
p2x3	O	O
and	O	O
nk1	O	O
receptors	O	O
in	O	O
bladder	O	O
.	O	O

results	O	O
:	O	O

cyclophosphamide	B-chem	B-chem
treatment	O	O
increased	O	O
the	O	O
spontaneous	O	O
pain	O	O
behaviors	O	O
scores	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
bladder	O	O
instability	O	O
during	O	O
urine	O	O
storage	O	O
period	O	O
of	O	O
model	O	O
group	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
intervention	O	O
group	O	O
(	O	O
x	O	O
(	O	O
2	O	O
)	O	O
=	O	O

7	O	O
.	O	O
619	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
007	O	O
)	O	O
and	O	O
control	O	O
group	O	O
(	O	O
x	O	O
(	O	O
2	O	O
)	O	O
=	O	O

13	O	O
.	O	O
755	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
000	O	O
)	O	O
.	O	O

mcc	O	O
in	O	O
the	O	O
model	O	O
group	O	O
was	O	O
lower	O	O
than	O	O
the	O	O
control	O	O
and	O	O
intervention	O	O
groups	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

histological	O	O
changes	O	O
evident	O	O
in	O	O
model	O	O
and	O	O
intervention	O	O
groups	O	O
rats	O	O
'	O	O
bladder	O	O
included	O	O
edema	O	O
,	O	O
vasodilation	O	O
,	O	O
and	O	O
infiltration	O	O
of	O	O
inflammatory	O	O
cells	O	O
.	O	O

in	O	O
model	O	O
group	O	O
,	O	O
the	O	O
expression	O	O
of	O	O
p2x3	O	O
receptor	O	O
increased	O	O
in	O	O
urothelium	O	O
and	O	O
suburothelium	O	O
,	O	O
and	O	O
nk1	O	O
receptor	O	O
increased	O	O
in	O	O
suburothelium	O	O
,	O	O
while	O	O
the	O	O
expression	O	O
of	O	O
them	O	O
in	O	O
intervention	O	O
group	O	O
was	O	O
lower	O	O
.	O	O

conclusions	O	O
:	O	O

in	O	O
cyp	B-chem	B-chem
-	O	O
induced	O	O
cystitis	O	O
,	O	O
the	O	O
expression	O	O
of	O	O
p2x3	O	O
and	O	O
nk1	O	O
receptors	O	O
increased	O	O
in	O	O
urothelium	O	O
and	O	O
/	O	O
or	O	O
suburothelium	O	O
.	O	O

perfusion	O	O
of	O	O
bladder	O	O
with	O	O
p2x3	O	B-chem
and	O	O
nk1	O	O
receptors	O	O
antagonists	O	O
ameliorated	O	O
the	O	O
bladder	O	O
function	O	O
.	O	O

acute	O	O
hepatitis	O	O
associated	O	O
with	O	O
clopidogrel	B-chem	B-chem
:	O	O
a	O	O
case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

drug	O	O
-	O	O
induced	O	O
hepatotoxicity	O	O
is	O	O
a	O	O
common	O	O
cause	O	O
of	O	O
acute	O	O
hepatitis	O	O
,	O	O
and	O	O
the	O	O
recognition	O	O
of	O	O
the	O	O
responsible	O	O
drug	O	O
may	O	O
be	O	O
difficult	O	O
.	O	O

we	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
clopidogrel	B-chem	B-chem
-	O	O
related	O	O
acute	O	O
hepatitis	O	O
.	O	O

the	O	O
diagnosis	O	O
is	O	O
strongly	O	O
suggested	O	O
by	O	O
an	O	O
accurate	O	O
medical	O	O
history	O	O
and	O	O
liver	O	O
biopsy	O	O
.	O	O

reports	O	O
about	O	O
cases	O	O
of	O	O
hepatotoxicity	O	O
due	O	O
to	O	O
clopidogrel	B-chem	B-chem
are	O	O
increasing	O	O
in	O	O
the	O	O
last	O	O
few	O	O
years	O	O
,	O	O
after	O	O
the	O	O
increased	O	O
use	O	O
of	O	O
this	O	O
drug	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
we	O	O
believe	O	O
that	O	O
physicians	O	O
should	O	O
carefully	O	O
consider	O	O
the	O	O
risk	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
hepatic	O	O
injury	O	O
when	O	O
clopidogrel	B-chem	B-chem
is	O	O
prescribed	O	O
.	O	O

bortezomib	B-chem	B-chem
and	O	O
dexamethasone	B-chem	B-chem
as	O	O
salvage	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
:	O	O
analysis	O	O
of	O	O
long	O	O
-	O	O
term	O	O
clinical	O	O
outcomes	O	O
.	O	O

bortezomib	B-chem	B-chem
(	O	O
bort	B-chem	O
)	O	O
-	O	O
dexamethasone	B-chem	B-chem
(	O	O
dex	B-chem	B-chem
)	O	O
is	O	O
an	O	O
effective	O	O
therapy	O	O
for	O	O
relapsed	O	O
/	O	O
refractory	O	O
(	O	O
r	O	O
/	O	O
r	O	O
)	O	O
multiple	O	O
myeloma	O	O
(	O	O
mm	O	O
)	O	O
.	O	O

this	O	O
retrospective	O	O
study	O	O
investigated	O	O
the	O	O
combination	O	O
of	O	O
bort	B-chem	O
(	O	O
1	O	O
.	O	O
3	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
on	O	O
days	O	O
1	O	O
,	O	O
4	O	O
,	O	O
8	O	O
,	O	O
and	O	O
11	O	O
every	O	O
3	O	O
weeks	O	O
)	O	O
and	O	O
dex	B-chem	B-chem
(	O	O
20	O	O
mg	O	O
on	O	O
the	O	O
day	O	O
of	O	O
and	O	O
the	O	O
day	O	O
after	O	O
bort	B-chem	O
)	O	O
as	O	O
salvage	O	O
treatment	O	O
in	O	O
85	O	O
patients	O	O
with	O	O
r	O	O
/	O	O
r	O	O
mm	O	O
after	O	O
prior	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
or	O	O
conventional	O	O
chemotherapy	O	O
.	O	O

the	O	O
median	O	O
number	O	O
of	O	O
prior	O	O
lines	O	O
of	O	O
therapy	O	O
was	O	O
2	O	O
.	O	O

eighty	O	O
-	O	O
seven	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
received	O	O
immunomodulatory	O	O
drugs	O	O
included	O	O
in	O	O
some	O	O
line	O	O
of	O	O
therapy	O	O
before	O	O
bort	B-chem	O
-	O	O
dex	B-chem	B-chem
.	O	O

the	O	O
median	O	O
number	O	O
of	O	O
bort	B-chem	O
-	O	O
dex	B-chem	B-chem
cycles	O	O
was	O	O
6	O	O
,	O	O
up	O	O
to	O	O
a	O	O
maximum	O	O
of	O	O
12	O	O
cycles	O	O
.	O	O

on	O	O
an	O	O
intention	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
basis	O	O
,	O	O
55	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
achieved	O	O
at	O	O
least	O	O
partial	O	O
response	O	O
,	O	O
including	O	O
19	O	O
%	O	O
cr	O	O
and	O	O
35	O	O
%	O	O
achieved	O	O
at	O	O
least	O	O
very	O	O
good	O	O
partial	O	O
response	O	O
.	O	O

median	O	O
durations	O	O
of	O	O
response	O	O
,	O	O
time	O	O
to	O	O
next	O	O
therapy	O	O
and	O	O
treatment	O	O
-	O	O
free	O	O
interval	O	O
were	O	O
8	O	O
,	O	O
11	O	O
.	O	O
2	O	O
,	O	O
and	O	O
5	O	O
.	O	O
1	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

the	O	O
most	O	O
relevant	O	O
adverse	O	O
event	O	O
was	O	O
peripheral	O	O
neuropathy	O	O
,	O	O
which	O	O
occurred	O	O
in	O	O
78	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
(	O	O
grade	O	O
ii	O	O
,	O	O
38	O	O
%	O	O
;	O	O
grade	O	O
iii	O	O
,	O	O
21	O	O
%	O	O
)	O	O
and	O	O
led	O	O
to	O	O
treatment	O	O
discontinuation	O	O
in	O	O
6	O	O
%	O	O
.	O	O

with	O	O
a	O	O
median	O	O
follow	O	O
up	O	O
of	O	O
22	O	O
months	O	O
,	O	O
median	O	O
time	O	O
to	O	O
progression	O	O
,	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
(	O	O
pfs	O	O
)	O	O
and	O	O
overall	O	O
survival	O	O
(	O	O
os	O	O
)	O	O
were	O	O
8	O	O
.	O	O
9	O	O
,	O	O
8	O	O
.	O	O
7	O	O
,	O	O
and	O	O
22	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

prolonged	O	O
pfs	O	O
and	O	O
os	O	O
were	O	O
observed	O	O
in	O	O
patients	O	O
achieving	O	O
cr	O	O
and	O	O
receiving	O	O
bort	B-chem	O
-	O	O
dex	B-chem	B-chem
a	O	O
single	O	O
line	O	O
of	O	O
prior	O	O
therapy	O	O
.	O	O

bort	B-chem	O
-	O	O
dex	B-chem	B-chem
was	O	O
an	O	O
effective	O	O
salvage	O	O
treatment	O	O
for	O	O
mm	O	O
patients	O	O
,	O	O
particularly	O	O
for	O	O
those	O	O
in	O	O
first	O	O
relapse	O	O
.	O	O

pubertal	O	O
exposure	O	O
to	O	O
bisphenol	B-chem	B-chem
a	I-chem	O
increases	O	O
anxiety	O	O
-	O	O
like	O	O
behavior	O	O
and	O	O
decreases	O	O
acetylcholinesterase	O	O
activity	O	O
of	O	O
hippocampus	O	O
in	O	O
adult	O	O
male	O	O
mice	O	O
.	O	O

the	O	O
negative	O	O
effects	O	O
of	O	O
bisphenol	B-chem	B-chem
a	I-chem	O
(	O	O
bpa	B-chem	B-chem
)	O	O
on	O	O
neurodevelopment	O	O
and	O	O
behaviors	O	O
have	O	O
been	O	O
well	O	O
established	O	O
.	O	O

acetylcholinesterase	O	O
(	O	O
ache	O	O
)	O	O
is	O	O
a	O	O
regulatory	O	O
enzyme	O	O
which	O	O
is	O	O
involved	O	O
in	O	O
anxiety	O	O
-	O	O
like	O	O
behavior	O	O
.	O	O

this	O	O
study	O	O
investigated	O	O
behavioral	O	O
phenotypes	O	O
and	O	O
ache	O	O
activity	O	O
in	O	O
male	O	O
mice	O	O
following	O	O
bpa	B-chem	B-chem
exposure	O	O
during	O	O
puberty	O	O
.	O	O

on	O	O
postnatal	O	O
day	O	O
(	O	O
pnd	O	O
)	O	O
35	O	O
,	O	O
male	O	O
mice	O	O
were	O	O
exposed	O	O
to	O	O
50	O	O
mg	O	O
bpa	B-chem	O
/	O	O
kg	O	O
diet	O	O
per	O	O
day	O	O
for	O	O
a	O	O
period	O	O
of	O	O
35	O	O
days	O	O
.	O	O

on	O	O
pnd71	O	O
,	O	O
a	O	O
behavioral	O	O
assay	O	O
was	O	O
performed	O	O
using	O	O
the	O	O
elevated	O	O
plus	O	O
maze	O	O
(	O	O
epm	O	O
)	O	O
and	O	O
the	O	O
light	O	O
/	O	O
dark	O	O
test	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
ache	O	O
activity	O	O
was	O	O
measured	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hypothalamus	O	O
,	O	O
cerebellum	O	O
and	O	O
hippocampus	O	O
.	O	O

results	O	O
from	O	O
our	O	O
behavioral	O	O
phenotyping	O	O
indicated	O	O
that	O	O
anxiety	O	O
-	O	O
like	O	O
behavior	O	O
was	O	O
increased	O	O
in	O	O
mice	O	O
exposed	O	O
to	O	O
bpa	B-chem	B-chem
.	O	O

ache	O	O
activity	O	O
was	O	O
significantly	O	O
decreased	O	O
in	O	O
the	O	O
hippocampus	O	O
of	O	O
mice	O	O
with	O	O
bpa	B-chem	O
compared	O	O
to	O	O
control	O	O
mice	O	O
,	O	O
whereas	O	O
no	O	O
difference	O	O
was	O	O
found	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hypothalamus	O	O
and	O	O
cerebellum	O	O
.	O	O

our	O	O
findings	O	O
showed	O	O
that	O	O
pubertal	O	O
bpa	B-chem	O
exposure	O	O
increased	O	O
anxiety	O	O
-	O	O
like	O	O
behavior	O	O
,	O	O
which	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
decreased	O	O
ache	O	O
activity	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
adult	O	O
male	O	O
mice	O	O
.	O	O

further	O	O
studies	O	O
are	O	O
necessary	O	O
to	O	O
investigate	O	O
the	O	O
cholinergic	O	O
signaling	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
pbe	O	O
induced	O	O
anxiety	O	O
-	O	O
like	O	O
behaviors	O	O
.	O	O

biochemical	O	O
effects	O	O
of	O	O
solidago	O	O
virgaurea	O	B-chem
extract	O	I-chem
on	O	O
experimental	O	O
cardiotoxicity	O	O
.	O	O

cardiovascular	O	O
diseases	O	O
(	O	O
cvds	O	O
)	O	O
are	O	O
the	O	O
major	O	O
health	O	O
problem	O	O
of	O	O
advanced	O	O
as	O	O
well	O	O
as	O	O
developing	O	O
countries	O	O
of	O	O
the	O	O
world	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
the	O	O
solidago	O	O
virgaurea	O	B-chem
extract	O	I-chem
on	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
in	O	O
rats	O	O
.	O	O

the	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B-chem	B-chem
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
into	O	O
rats	O	O
twice	O	O
at	O	O
an	O	O
interval	O	O
of	O	O
24	O	O
h	O	O
,	O	O
for	O	O
two	O	O
consecutive	O	O
days	O	O
,	O	O
led	O	O
to	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
serum	O	O
lactate	B-chem	B-chem
dehydrogenase	O	O
,	O	O
creatine	B-chem	B-chem
phosphokinase	O	O
,	O	O
alanine	B-chem	B-chem
transaminase	O	O
,	O	O
aspartate	B-chem	B-chem
transaminase	O	O
,	O	O
and	O	O
angiotensin	B-chem	B-chem
-	O	O
converting	O	O
enzyme	O	O
activities	O	O
,	O	O
total	O	O
cholesterol	B-chem	B-chem
,	O	O
triglycerides	B-chem	B-chem
,	O	O
free	O	O
serum	O	O
fatty	B-chem	B-chem
acid	I-chem	I-chem
,	O	O
cardiac	O	O
tissue	O	O
malondialdehyde	B-chem	B-chem
(	O	O
mda	B-chem	B-chem
)	O	O
,	O	O
and	O	O
nitric	B-chem	B-chem
oxide	I-chem	I-chem
levels	O	O
and	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
levels	O	O
of	O	O
glutathione	B-chem	B-chem
and	O	O
superoxide	B-chem	B-chem
dismutase	O	O
in	O	O
cardiac	O	O
tissue	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
normal	O	O
control	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

pretreatment	O	O
with	O	O
s	O	O
.	O	O
virgaurea	O	B-chem
extract	O	I-chem
for	O	O
5	O	O
weeks	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
250	O	O
mg	O	O
/	O	O
kg	O	O
followed	O	O
by	O	O
isoproterenol	B-chem	B-chem
injection	O	O
significantly	O	O
prevented	O	O
the	O	O
observed	O	O
alterations	O	O
.	O	O

captopril	B-chem	B-chem
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
,	O	O
given	O	O
orally	O	O
)	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
angiotensin	B-chem	B-chem
-	O	O
converting	O	O
enzyme	O	O
used	O	O
as	O	O
a	O	O
standard	O	O
cardioprotective	O	O
drug	O	O
,	O	O
was	O	O
used	O	O
as	O	O
a	O	O
positive	O	O
control	O	O
in	O	O
this	O	O
study	O	O
.	O	O

the	O	O
data	O	O
of	O	O
the	O	O
present	O	O
study	O	O
suggest	O	O
that	O	O
s	O	O
.	O	O
virgaurea	O	B-chem
extract	O	I-chem
exerts	O	O
its	O	O
protective	O	O
effect	O	O
by	O	O
decreasing	O	O
mda	B-chem	B-chem
level	O	O
and	O	O
increasing	O	O
the	O	O
antioxidant	O	O
status	O	O
in	O	O
isoproterenol	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
.	O	O

the	O	O
study	O	O
emphasizes	O	O
the	O	O
beneficial	O	O
action	O	O
of	O	O
s	O	O
.	O	O
virgaurea	O	B-chem
extract	O	I-chem
as	O	O
a	O	O
cardioprotective	O	O
agent	O	O
.	O	O

"	O	O
"	O	O
"	O	O
"	O	O
real	O	O
-	O	O
world	O	O
"	O	O
"	O	O
"	O	O
"	O	O
data	O	O
on	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
lenalidomide	B-chem	B-chem
and	O	O
dexamethasone	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
who	O	O
were	O	O
treated	O	O
according	O	O
to	O	O
the	O	O
standard	O	O
clinical	O	O
practice	O	O
:	O	O
a	O	O
study	O	O
of	O	O
the	O	O
greek	O	O
myeloma	O	O
study	O	O
group	O	O
.	O	O

lenalidomide	B-chem	B-chem
and	O	O
dexamethasone	B-chem	B-chem
(	O	O
rd	B-chem	O
)	O	O
is	O	O
a	O	O
standard	O	O
of	O	O
care	O	O
for	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
(	O	O
rrmm	O	O
)	O	O
,	O	O
but	O	O
there	O	O
is	O	O
limited	O	O
published	O	O
data	O	O
on	O	O
its	O	O
efficacy	O	O
and	O	O
safety	O	O
in	O	O
the	O	O
"	O	O
"	O	O
"	O	O
"	O	O
real	O	O
world	O	O
"	O	O
"	O	O
"	O	O
"	O	O
(	O	O
rw	O	O
)	O	O
,	O	O
according	O	O
to	O	O
the	O	O
international	O	O
society	O	O
of	O	O
pharmacoeconomics	O	O
and	O	O
outcomes	O	O
research	O	O
definition	O	O
.	O	O

we	O	O
studied	O	O
212	O	O
rrmm	O	O
patients	O	O
who	O	O
received	O	O
rd	B-chem	O
in	O	O
rw	O	O
.	O	O

objective	O	O
response	O	O
(	O	O
>	O	O
pr	O	O
(	O	O
partial	O	O
response	O	O
)	O	O
)	O	O
rate	O	O
was	O	O
77	O	O
.	O	O
4	O	O
%	O	O
(	O	O
complete	O	O
response	O	O
(	O	O
cr	O	O
)	O	O
,	O	O
20	O	O
.	O	O
2	O	O
%	O	O
)	O	O
.	O	O

median	O	O
time	O	O
to	O	O
first	O	O
and	O	O
best	O	O
response	O	O
was	O	O
2	O	O
and	O	O
5	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

median	O	O
time	O	O
to	O	O
cr	O	O
when	O	O
rd	B-chem	O
was	O	O
given	O	O
as	O	O
2nd	O	O
or	O	O
>	O	O
2	O	O
(	O	O
nd	O	O
)	O	O
-	O	O
line	O	O
treatment	O	O
at	O	O
4	O	O
and	O	O
11	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

quality	O	O
of	O	O
response	O	O
was	O	O
independent	O	O
of	O	O
previous	O	O
lines	O	O
of	O	O
therapies	O	O
or	O	O
previous	O	O
exposure	O	O
to	O	O
thalidomide	B-chem	B-chem
or	O	O
bortezomib	B-chem	B-chem
.	O	O

median	O	O
duration	O	O
of	O	O
response	O	O
was	O	O
34	O	O
.	O	O
4	O	O
months	O	O
,	O	O
and	O	O
it	O	O
was	O	O
higher	O	O
in	O	O
patients	O	O
who	O	O
received	O	O
rd	B-chem	O
until	O	O
progression	O	O
(	O	O
not	O	O
reached	O	O
versus	O	O
19	O	O
months	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

improvement	O	O
of	O	O
humoral	O	O
immunity	O	O
occurred	O	O
in	O	O
60	O	O
%	O	O
of	O	O
responders	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
patients	O	O
who	O	O
achieved	O	O
stable	O	O
disease	O	O
.	O	O

adverse	O	O
events	O	O
were	O	O
reported	O	O
in	O	O
68	O	O
.	O	O
9	O	O
%	O	O
of	O	O
patients	O	O
(	O	O
myelosuppression	O	O
in	O	O
49	O	O
.	O	O
4	O	O
%	O	O
)	O	O
and	O	O
12	O	O
.	O	O
7	O	O
%	O	O
of	O	O
patients	O	O
needed	O	O
hospitalization	O	O
.	O	O

peripheral	O	O
neuropathy	O	O
was	O	O
observed	O	O
only	O	O
in	O	O
2	O	O
.	O	O
5	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
deep	O	O
vein	O	O
thrombosis	O	O
in	O	O
5	O	O
.	O	O
7	O	O
%	O	O
.	O	O

dose	O	O
reductions	O	O
were	O	O
needed	O	O
in	O	O
31	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
permanent	O	O
discontinuation	O	O
in	O	O
38	O	O
.	O	O
9	O	O
%	O	O
.	O	O

median	O	O
time	O	O
to	O	O
treatment	O	O
discontinuation	O	O
was	O	O
16	O	O
.	O	O
8	O	O
months	O	O
.	O	O

performance	O	O
status	O	O
(	O	O
ps	O	O
)	O	O
and	O	O
initial	O	O
lenalidomide	B-chem	B-chem
dose	O	O
predicted	O	O
for	O	O
treatment	O	O
discontinuation	O	O
.	O	O

extra	O	O
-	O	O
medullary	O	O
relapses	O	O
occurred	O	O
in	O	O
3	O	O
.	O	O
8	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

our	O	O
study	O	O
confirms	O	O
that	O	O
rd	B-chem	O
is	O	O
effective	O	O
and	O	O
safe	O	O
in	O	O
rrmm	O	O
in	O	O
the	O	O
rw	O	O
;	O	O
it	O	O
produces	O	O
durable	O	O
responses	O	O
especially	O	O
in	O	O
patients	O	O
who	O	O
continue	O	O
on	O	O
treatment	O	O
till	O	O
progression	O	O
and	O	O
improves	O	O
humoral	O	O
immunity	O	O
even	O	O
in	O	O
patients	O	O
with	O	O
stable	O	O
disease	O	O
.	O	O

the	O	O
cytogenetic	O	O
action	O	O
of	O	O
ifosfamide	B-chem	B-chem
,	O	O
mesna	B-chem	B-chem
,	O	O
and	O	O
their	O	O
combination	O	O
on	O	O
peripheral	O	O
rabbit	O	O
lymphocytes	O	O
:	O	O
an	O	O
in	O	O
vivo	O	O
/	O	O
in	O	O
vitro	O	O
cytogenetic	O	O
study	O	O
.	O	O

ifosfamide	B-chem	B-chem
(	O	O
ifo	B-chem	B-chem
)	O	O
is	O	O
an	O	O
alkylating	O	O
nitrogen	B-chem	B-chem
mustard	O	I-chem
,	O	O
administrated	O	O
as	O	O
an	O	O
antineoplasmic	O	O
agent	O	O
.	O	O

it	O	O
is	O	O
characterized	O	O
by	O	O
its	O	O
intense	O	O
urotoxic	O	O
action	O	O
,	O	O
leading	O	O
to	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

this	O	O
side	O	O
effect	O	O
of	O	O
ifo	B-chem	B-chem
raises	O	O
the	O	O
requirement	O	O
for	O	O
the	O	O
co	O	O
-	O	O
administration	O	O
with	O	O
sodium	B-chem	B-chem
2	I-chem	I-chem
-	I-chem	I-chem
sulfanylethanesulfonate	I-chem	I-chem
(	O	O
mesna	B-chem	B-chem
)	O	O
aiming	O	O
to	O	O
avoid	O	O
or	O	O
minimize	O	O
this	O	O
effect	O	O
.	O	O

ifo	B-chem	B-chem
and	O	O
mesna	B-chem	B-chem
were	O	O
administrated	O	O
separately	O	O
on	O	O
rabbit	O	O
'	O	O
s	O	O
lymphocytes	O	O
in	O	O
vivo	O	O
,	O	O
which	O	O
were	O	O
later	O	O
developed	O	O
in	O	O
vitro	O	O
.	O	O

cytogenetic	O	O
markers	O	O
for	O	O
sister	O	O
chromatid	O	O
exchanges	O	O
(	O	O
sces	O	O
)	O	O
,	O	O
proliferation	O	O
rate	O	O
index	O	O
(	O	O
pri	O	O
)	O	O
and	O	O
mitotic	O	O
index	O	O
were	O	O
recorded	O	O
.	O	O

mesna	B-chem	B-chem
'	O	O
s	O	O
action	O	O
,	O	O
in	O	O
conjunction	O	O
with	O	O
ifo	B-chem	B-chem
reduces	O	O
the	O	O
frequency	O	O
of	O	O
sces	O	O
,	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
sces	O	O
recordings	O	O
obtained	O	O
when	O	O
ifo	B-chem	B-chem
is	O	O
administered	O	O
alone	O	O
.	O	O

in	O	O
addition	O	O
to	O	O
this	O	O
,	O	O
when	O	O
high	O	O
concentrations	O	O
of	O	O
mesna	B-chem	B-chem
were	O	O
administered	O	O
alone	O	O
significant	O	O
reductions	O	O
of	O	O
the	O	O
pri	O	B-chem
were	O	O
noted	O	O
,	O	O
than	O	O
with	O	O
ifo	B-chem	O
acting	O	O
at	O	O
the	O	O
same	O	O
concentration	O	O
on	O	O
the	O	O
lymphocytes	O	O
.	O	O

mesna	B-chem	B-chem
significantly	O	O
reduces	O	O
ifo	B-chem	O
'	O	O
s	O	O
genotoxicity	O	B-chem
,	O	O
while	O	O
when	O	O
administered	O	O
in	O	O
high	O	O
concentrations	O	O
it	O	O
acts	O	O
in	O	O
an	O	O
inhibitory	O	O
fashion	O	O
on	O	O
the	O	O
cytostatic	O	O
action	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

risk	O	O
factors	O	O
and	O	O
predictors	O	O
of	O	O
levodopa	B-chem	B-chem
-	O	O
induced	O	O
dyskinesia	O	O
among	O	O
multiethnic	O	O
malaysians	O	O
with	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

chronic	O	O
pulsatile	O	O
levodopa	B-chem	B-chem
therapy	O	O
for	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
(	O	O
pd	O	O
)	O	O
leads	O	O
to	O	O
the	O	O
development	O	O
of	O	O
motor	O	O
fluctuations	O	O
and	O	O
dyskinesia	O	O
.	O	O

we	O	O
studied	O	O
the	O	O
prevalence	O	O
and	O	O
predictors	O	O
of	O	O
levodopa	B-chem	B-chem
-	O	O
induced	O	O
dyskinesia	O	O
among	O	O
multiethnic	O	O
malaysian	O	O
patients	O	O
with	O	O
pd	O	O
.	O	O

methods	O	O
:	O	O

this	O	O
is	O	O
a	O	O
cross	O	O
-	O	O
sectional	O	O
study	O	O
involving	O	O
95	O	O
patients	O	O
with	O	O
pd	O	O
on	O	O
uninterrupted	O	O
levodopa	B-chem	B-chem
therapy	O	O
for	O	O
at	O	O
least	O	O
6	O	O
months	O	O
.	O	O

the	O	O
instrument	O	O
used	O	O
was	O	O
the	O	O
updrs	O	O
questionnaires	O	O
.	O	O

the	O	O
predictors	O	O
of	O	O
dyskinesia	O	O
were	O	O
determined	O	O
using	O	O
multivariate	O	O
logistic	O	O
regression	O	O
analysis	O	O
.	O	O

results	O	O
:	O	O

the	O	O
mean	O	O
age	O	O
was	O	O
65	O	O
.	O	O
6	O	O
+	O	O
8	O	O
.	O	O
5	O	O
years	O	O
.	O	O

the	O	O
mean	O	O
onset	O	O
age	O	O
was	O	O
58	O	O
.	O	O
5	O	O
+	O	O
9	O	O
.	O	O
8	O	O
years	O	O
.	O	O

the	O	O
median	O	O
disease	O	O
duration	O	O
was	O	O
6	O	O
(	O	O
7	O	O
)	O	O
years	O	O
.	O	O

dyskinesia	O	O
was	O	O
present	O	O
in	O	O
44	O	O
%	O	O
(	O	O
n	O	O
=	O	O
42	O	O
)	O	O
with	O	O
median	O	O
levodopa	B-chem	B-chem
therapy	O	O
of	O	O
3	O	O
years	O	O
.	O	O

there	O	O
were	O	O
64	O	O
.	O	O
3	O	O
%	O	O
chinese	O	O
,	O	O
31	O	O
%	O	O
malays	O	O
,	O	O
and	O	O
3	O	O
.	O	O
7	O	O
%	O	O
indians	O	O
and	O	O
other	O	O
ethnic	O	O
groups	O	O
.	O	O

eighty	O	O
-	O	O
one	O	O
percent	O	O
of	O	O
patients	O	O
with	O	O
dyskinesia	O	O
had	O	O
clinical	O	O
fluctuations	O	O
.	O	O

patients	O	O
with	O	O
dyskinesia	O	O
had	O	O
lower	O	O
onset	O	O
age	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
longer	O	O
duration	O	O
of	O	O
levodopa	B-chem	B-chem
therapy	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
longer	O	O
disease	O	O
duration	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
higher	O	O
total	O	O
daily	O	O
levodopa	B-chem	B-chem
dose	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
and	O	O
higher	O	O
total	O	O
updrs	O	O
scores	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
005	O	O
)	O	O
than	O	O
patients	O	O
without	O	O
dyskinesia	O	O
.	O	O

the	O	O
three	O	O
significant	O	O
predictors	O	O
of	O	O
dyskinesia	O	O
were	O	O
duration	O	O
of	O	O
levodopa	B-chem	B-chem
therapy	O	O
,	O	O
onset	O	O
age	O	O
,	O	O
and	O	O
total	O	O
daily	O	O
levodopa	B-chem	B-chem
dose	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
prevalence	O	O
of	O	O
levodopa	B-chem	B-chem
-	O	O
induced	O	O
dyskinesia	O	O
in	O	O
our	O	O
patients	O	O
was	O	O
44	O	O
%	O	O
.	O	O

the	O	O
most	O	O
significant	O	O
predictors	O	O
were	O	O
duration	O	O
of	O	O
levodopa	B-chem	B-chem
therapy	O	O
,	O	O
total	O	O
daily	O	O
levodopa	B-chem	B-chem
dose	O	O
,	O	O
and	O	O
onset	O	O
age	O	O
.	O	O

an	O	O
unexpected	O	O
diagnosis	O	O
in	O	O
a	O	O
renal	O	O
-	O	O
transplant	O	O
patient	O	O
with	O	O
proteinuria	O	O
treated	O	O
with	O	O
everolimus	B-chem	B-chem
:	O	O
al	O	O
amyloidosis	O	O
.	O	O

proteinuria	O	O
is	O	O
an	O	O
expected	O	O
complication	O	O
in	O	O
transplant	O	O
patients	O	O
treated	O	O
with	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B-chem	B-chem
inhibitors	O	O
(	O	O
mtor	O	O
-	O	O
i	O	O
)	O	O
.	O	O

however	O	O
,	O	O
clinical	O	O
suspicion	O	O
should	O	O
always	O	O
be	O	O
supported	O	O
by	O	O
histological	O	O
evidence	O	O
in	O	O
order	O	O
to	O	O
investigate	O	O
potential	O	O
alternate	O	O
diagnoses	O	O
such	O	O
as	O	O
acute	O	O
or	O	O
chronic	O	O
rejection	O	O
,	O	O
interstitial	O	O
fibrosis	O	O
and	O	O
tubular	O	O
atrophy	O	O
,	O	O
or	O	O
recurrent	O	O
or	O	O
de	O	O
novo	O	O
glomerulopathy	O	O
.	O	O

in	O	O
this	O	O
case	O	O
we	O	O
report	O	O
the	O	O
unexpected	O	O
diagnosis	O	O
of	O	O
amyloidosis	O	O
in	O	O
a	O	O
renal	O	O
-	O	O
transplant	O	O
patient	O	O
with	O	O
pre	O	O
-	O	O
transplant	O	O
monoclonal	O	O
gammapathy	O	O
of	O	O
undetermined	O	O
significance	O	O
who	O	O
developed	O	O
proteinuria	O	O
after	O	O
conversion	O	O
from	O	O
tacrolimus	B-chem	B-chem
to	O	O
everolimus	B-chem	B-chem
.	O	O

an	O	O
investigation	O	O
of	O	O
the	O	O
pattern	O	O
of	O	O
kidney	O	O
injury	O	O
in	O	O
hiv	O	O
-	O	O
positive	O	O
persons	O	O
exposed	O	O
to	O	O
tenofovir	B-chem	B-chem
disoproxil	I-chem	I-chem
fumarate	I-chem	I-chem
:	O	O
an	O	O
examination	O	O
of	O	O
a	O	O
large	O	O
population	O	O
database	O	O
(	O	O
mhra	O	O
database	O	O
)	O	O
.	O	O

the	O	O
potential	O	O
for	O	O
tenofovir	B-chem	B-chem
to	O	O
cause	O	O
a	O	O
range	O	O
of	O	O
kidney	O	O
syndromes	O	O
has	O	O
been	O	O
established	O	O
from	O	O
mechanistic	O	O
and	O	O
randomised	O	O
clinical	O	O
trials	O	O
.	O	O

however	O	O
,	O	O
the	O	O
exact	O	O
pattern	O	O
of	O	O
kidney	O	O
involvement	O	O
is	O	O
still	O	O
uncertain	O	O
.	O	O

we	O	O
undertook	O	O
a	O	O
descriptive	O	O
analysis	O	O
of	O	O
yellow	O	O
card	O	O
records	O	O
of	O	O
407	O	O
hiv	O	O
-	O	O
positive	O	O
persons	O	O
taking	O	O
tenofovir	B-chem	B-chem
disoproxil	I-chem	I-chem
fumarate	I-chem	I-chem
(	O	O
tdf	B-chem	B-chem
)	O	O
as	O	O
part	O	O
of	O	O
their	O	O
antiretroviral	O	O
therapy	O	O
regimen	O	O
and	O	O
submitted	O	O
to	O	O
the	O	O
medicines	O	O
and	O	O
healthcare	O	O
products	O	O
regulatory	O	O
agency	O	O
(	O	O
mhra	O	O
)	O	O
with	O	O
suspected	O	O
kidney	O	O
adverse	O	O
effects	O	O
.	O	O

reports	O	O
that	O	O
satisfy	O	O
defined	O	O
criteria	O	O
were	O	O
classified	O	O
as	O	O
acute	O	O
kidney	O	O
injury	O	O
,	O	O
kidney	O	O
tubular	O	O
dysfunction	O	O
and	O	O
fanconi	O	O
syndrome	O	O
.	O	O

of	O	O
the	O	O
407	O	O
yellow	O	O
card	O	O
records	O	O
analysed	O	O
,	O	O
106	O	O
satisfied	O	O
criteria	O	O
for	O	O
tdf	B-chem	O
-	O	O
related	O	O
kidney	O	O
disease	O	O
,	O	O
of	O	O
which	O	O
53	O	O
(	O	O
50	O	O
%	O	O
)	O	O
had	O	O
features	O	O
of	O	O
kidney	O	O
tubular	O	O
dysfunction	O	O
,	O	O
35	O	O
(	O	O
33	O	O
%	O	O
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
features	O	O
of	O	O
glomerular	O	O
dysfunction	O	O
and	O	O
18	O	O
(	O	O
17	O	O
%	O	O
)	O	O
had	O	O
fanconi	O	O
syndrome	O	O
.	O	O

the	O	O
median	O	O
tdf	B-chem	B-chem
exposure	O	O
was	O	O
316	O	O
days	O	O
(	O	O
interquartile	O	O
range	O	O
120	O	O
-	O	O
740	O	O
)	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
hospitalisation	O	O
for	O	O
tdf	B-chem	O
kidney	O	O
adverse	O	O
effects	O	O
was	O	O
high	O	O
,	O	O
particularly	O	O
amongst	O	O
patients	O	O
with	O	O
features	O	O
of	O	O
fanconi	O	O
syndrome	O	O
.	O	O

the	O	O
pattern	O	O
of	O	O
kidney	O	O
syndromes	O	O
in	O	O
this	O	O
population	O	O
series	O	O
mirrors	O	O
that	O	O
reported	O	O
in	O	O
randomised	O	O
clinical	O	O
trials	O	O
.	O	O

cessation	O	O
of	O	O
tdf	B-chem	B-chem
was	O	O
associated	O	O
with	O	O
complete	O	O
restoration	O	O
of	O	O
kidney	O	O
function	O	O
in	O	O
up	O	O
half	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
this	O	O
report	O	O
.	O	O

incidence	O	O
of	O	O
postoperative	O	O
delirium	O	O
is	O	O
high	O	O
even	O	O
in	O	O
a	O	O
population	O	O
without	O	O
known	O	O
risk	O	O
factors	O	O
.	O	O

purpose	O	O
:	O	O

postoperative	O	O
delirium	O	O
is	O	O
a	O	O
recognized	O	O
complication	O	O
in	O	O
populations	O	O
at	O	O
risk	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
assess	O	O
the	O	O
prevalence	O	O
of	O	O
early	O	O
postoperative	O	O
delirium	O	O
in	O	O
a	O	O
population	O	O
without	O	O
known	O	O
risk	O	O
factors	O	O
admitted	O	O
to	O	O
the	O	O
icu	O	O
for	O	O
postoperative	O	O
monitoring	O	O
after	O	O
elective	O	O
major	O	O
surgery	O	O
.	O	O

the	O	O
secondary	O	O
outcome	O	O
investigated	O	O
is	O	O
to	O	O
identify	O	O
eventual	O	O
independent	O	O
risk	O	O
factors	O	O
among	O	O
demographic	O	O
data	O	O
and	O	O
anesthetic	O	O
drugs	O	O
used	O	O
.	O	O

methods	O	O
:	O	O

an	O	O
observational	O	O
,	O	O
prospective	O	O
study	O	O
was	O	O
conducted	O	O
on	O	O
a	O	O
consecutive	O	O
cohort	O	O
of	O	O
patients	O	O
admitted	O	O
to	O	O
our	O	O
icu	O	O
within	O	O
and	O	O
for	O	O
at	O	O
least	O	O
24	O	O
h	O	O
after	O	O
major	O	O
surgical	O	O
procedures	O	O
.	O	O

exclusion	O	O
criteria	O	O
were	O	O
any	O	O
preexisting	O	O
predisposing	O	O
factor	O	O
for	O	O
delirium	O	O
or	O	O
other	O	O
potentially	O	O
confounding	O	O
neurological	O	O
dysfunctions	O	O
.	O	O

patients	O	O
were	O	O
assessed	O	O
daily	O	O
using	O	O
the	O	O
confusion	O	O
assessment	O	O
method	O	O
for	O	O
the	O	O
icu	O	O
scale	O	O
for	O	O
3	O	O
days	O	O
after	O	O
the	O	O
surgical	O	O
procedure	O	O
.	O	O

early	O	O
postoperative	O	O
delirium	O	O
incidence	O	O
risk	O	O
factors	O	O
were	O	O
then	O	O
assessed	O	O
through	O	O
three	O	O
different	O	O
multiple	O	O
regression	O	O
models	O	O
.	O	O

results	O	O
:	O	O

according	O	O
to	O	O
the	O	O
confusion	O	O
assessment	O	O
method	O	O
for	O	O
the	O	O
icu	O	O
scale	O	O
,	O	O
28	O	O
%	O	O
of	O	O
patients	O	O
were	O	O
diagnosed	O	O
with	O	O
early	O	O
postoperative	O	O
delirium	O	O
.	O	O

the	O	O
use	O	O
of	O	O
thiopentone	B-chem	B-chem
was	O	O
significantly	O	O
associated	O	O
with	O	O
an	O	O
eight	O	O
-	O	O
fold	O	O
-	O	O
higher	O	O
risk	O	O
for	O	O
delirium	O	O
compared	O	O
to	O	O
propofol	B-chem	B-chem
(	O	O
57	O	O
.	O	O
1	O	O
%	O	O
vs	O	O
.	O	O
7	O	O
.	O	O
1	O	O
%	O	O
,	O	O
rr	O	O
=	O	O
8	O	O
.	O	O
0	O	O
,	O	O
x2	O	O
=	O	O
4	O	O
.	O	O
256	O	O
;	O	O
df	O	O
=	O	O
1	O	O
;	O	O
0	O	O
.	O	O
05	O	O
<	O	O
p	O	O
<	O	O
0	O	O
.	O	O
02	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

in	O	O
this	O	O
study	O	O
early	O	O
postoperative	O	O
delirium	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
very	O	O
common	O	O
complication	O	O
after	O	O
major	O	O
surgery	O	O
,	O	O
even	O	O
in	O	O
a	O	O
population	O	O
without	O	O
known	O	O
risk	O	O
factors	O	O
.	O	O

thiopentone	B-chem	B-chem
was	O	O
independently	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
its	O	O
relative	O	O
risk	O	O
.	O	O

a	O	O
single	O	O
neurotoxic	O	O
dose	O	O
of	O	O
methamphetamine	B-chem	B-chem
induces	O	O
a	O	O
long	O	O
-	O	O
lasting	O	O
depressive	O	O
-	O	O
like	O	O
behaviour	O	O
in	O	O
mice	O	O
.	O	O

methamphetamine	B-chem	B-chem
(	O	O
meth	B-chem	B-chem
)	O	O
triggers	O	O
a	O	O
disruption	O	O
of	O	O
the	O	O
monoaminergic	O	O
system	O	O
and	O	O
meth	B-chem	B-chem
abuse	O	O
leads	O	O
to	O	O
negative	O	O
emotional	O	O
states	O	O
including	O	O
depressive	O	O
symptoms	O	O
during	O	O
drug	O	O
withdrawal	O	O
.	O	O

however	O	O
,	O	O
it	O	O
is	O	O
currently	O	O
unknown	O	O
if	O	O
the	O	O
acute	O	O
toxic	O	O
dosage	O	O
of	O	O
meth	B-chem	B-chem
also	O	O
causes	O	O
a	O	O
long	O	O
-	O	O
lasting	O	O
depressive	O	O
phenotype	O	O
and	O	O
persistent	O	O
monoaminergic	O	O
deficits	O	O
.	O	O

thus	O	O
,	O	O
we	O	O
now	O	O
assessed	O	O
the	O	O
depressive	O	O
-	O	O
like	O	O
behaviour	O	O
in	O	O
mice	O	O
at	O	O
early	O	O
and	O	O
long	O	O
-	O	O
term	O	O
periods	O	O
following	O	O
a	O	O
single	O	O
high	O	O
meth	B-chem	B-chem
dose	O	O
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
.	O	O

meth	B-chem	B-chem
did	O	O
not	O	O
alter	O	O
the	O	O
motor	O	O
function	O	O
and	O	O
procedural	O	O
memory	O	O
of	O	O
mice	O	O
as	O	O
assessed	O	O
by	O	O
swimming	O	O
speed	O	O
and	O	O
escape	O	O
latency	O	O
to	O	O
find	O	O
the	O	O
platform	O	O
in	O	O
a	O	O
cued	O	O
version	O	O
of	O	O
the	O	O
water	O	O
maze	O	O
task	O	O
.	O	O

however	O	O
,	O	O
meth	B-chem	B-chem
significantly	O	O
increased	O	O
the	O	O
immobility	O	O
time	O	O
in	O	O
the	O	O
tail	O	O
suspension	O	O
test	O	O
at	O	O
3	O	O
and	O	O
49	O	O
days	O	O
post	O	O
-	O	O
administration	O	O
.	O	O

this	O	O
depressive	O	O
-	O	O
like	O	O
profile	O	O
induced	O	O
by	O	O
meth	B-chem	B-chem
was	O	O
accompanied	O	O
by	O	O
a	O	O
marked	O	O
depletion	O	O
of	O	O
frontostriatal	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
neurotransmission	O	O
,	O	O
indicated	O	O
by	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
dopamine	B-chem	B-chem
,	O	O
dopac	B-chem	B-chem
and	O	O
hva	B-chem	B-chem
,	O	O
tyrosine	B-chem	B-chem
hydroxylase	O	O
and	O	O
serotonin	B-chem	B-chem
,	O	O
observed	O	O
at	O	O
both	O	O
3	O	O
and	O	O
49	O	O
days	O	O
post	O	O
-	O	O
administration	O	O
.	O	O

in	O	O
parallel	O	O
,	O	O
another	O	O
neurochemical	O	O
feature	O	O
of	O	O
depression	O	O
-	O	O
-	O	O
astroglial	O	O
dysfunction	O	O
-	O	O
-	O	O
was	O	O
unaffected	O	O
in	O	O
the	O	O
cortex	O	O
and	O	O
the	O	O
striatal	O	O
levels	O	O
of	O	O
the	O	O
astrocytic	O	O
protein	O	O
marker	O	O
,	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
,	O	O
were	O	O
only	O	O
transiently	O	O
increased	O	O
at	O	O
3	O	O
days	O	O
.	O	O

these	O	O
findings	O	O
demonstrate	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
a	O	O
single	O	O
high	O	O
dose	O	O
of	O	O
meth	B-chem	B-chem
induces	O	O
long	O	O
-	O	O
lasting	O	O
depressive	O	O
-	O	O
like	O	O
behaviour	O	O
in	O	O
mice	O	O
associated	O	O
with	O	O
a	O	O
persistent	O	O
disruption	O	O
of	O	O
frontostriatal	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
homoeostasis	O	O
.	O	O

linezolid	B-chem	B-chem
-	O	O
induced	O	O
optic	O	O
neuropathy	O	O
.	O	O

many	O	O
systemic	O	O
antimicrobials	O	O
have	O	O
been	O	O
implicated	O	O
to	O	O
cause	O	O
ocular	O	O
adverse	O	O
effects	O	O
.	O	O

this	O	O
is	O	O
especially	O	O
relevant	O	O
in	O	O
multidrug	O	O
therapy	O	O
where	O	O
more	O	O
than	O	O
one	O	O
drug	O	O
can	O	O
cause	O	O
a	O	O
similar	O	O
ocular	O	O
adverse	O	O
effect	O	O
.	O	O

we	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
progressive	O	O
loss	O	O
of	O	O
vision	O	O
associated	O	O
with	O	O
linezolid	B-chem	B-chem
therapy	O	O
.	O	O

a	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
who	O	O
was	O	O
on	O	O
treatment	O	O
with	O	O
multiple	O	O
second	O	O
-	O	O
line	O	O
anti	O	O
-	O	O
tuberculous	O	O
drugs	O	O
including	O	O
linezolid	B-chem	B-chem
and	O	O
ethambutol	B-chem	B-chem
for	O	O
extensively	O	O
drug	O	O
-	O	O
resistant	O	O
tuberculosis	O	O
(	O	O
xdr	O	O
-	O	O
tb	O	O
)	O	O
presented	O	O
to	O	O
us	O	O
with	O	O
painless	O	O
progressive	O	O
loss	O	O
of	O	O
vision	O	O
in	O	O
both	O	O
eyes	O	O
.	O	O

color	O	O
vision	O	O
was	O	O
defective	O	O
and	O	O
fundus	O	O
examination	O	O
revealed	O	O
optic	O	O
disc	O	O
edema	O	O
in	O	O
both	O	O
eyes	O	O
.	O	O

ethambutol	B-chem	B-chem
-	O	O
induced	O	O
toxic	O	O
optic	O	O
neuropathy	O	O
was	O	O
suspected	O	O
and	O	O
tablet	O	O
ethambutol	B-chem	B-chem
was	O	O
withdrawn	O	O
.	O	O

deterioration	O	O
of	O	O
vision	O	O
occurred	O	O
despite	O	O
withdrawal	O	O
of	O	O
ethambutol	B-chem	B-chem
.	O	O

discontinuation	O	O
of	O	O
linezolid	B-chem	B-chem
resulted	O	O
in	O	O
marked	O	O
improvement	O	O
of	O	O
vision	O	O
.	O	O

our	O	O
report	O	O
emphasizes	O	O
the	O	O
need	O	O
for	O	O
monitoring	O	O
of	O	O
visual	O	O
function	O	O
in	O	O
patients	O	O
on	O	O
long	O	O
-	O	O
term	O	O
linezolid	B-chem	B-chem
treatment	O	O
.	O	O

resuscitation	O	O
with	O	O
lipid	O	O
,	O	O
epinephrine	B-chem	B-chem
,	O	O
or	O	O
both	O	O
in	O	O
levobupivacaine	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
toxicity	O	O
in	O	O
newborn	O	O
piglets	O	O
.	O	O

background	O	O
:	O	O

the	O	O
optimal	O	O
dosing	O	O
regimens	O	O
of	O	O
lipid	O	O
emulsion	O	O
,	O	O
epinephrine	B-chem	B-chem
,	O	O
or	O	O
both	O	O
are	O	O
not	O	O
yet	O	O
determined	O	O
in	O	O
neonates	O	O
in	O	O
cases	O	O
of	O	O
local	O	O
anaesthetic	O	O
systemic	O	O
toxicity	O	O
(	O	O
last	O	O
)	O	O
.	O	O

methods	O	O
:	O	O

newborn	O	O
piglets	O	O
received	O	O
levobupivacaine	B-chem	B-chem
until	O	O
cardiovascular	O	O
collapse	O	O
occurred	O	O
.	O	O

standard	O	O
cardiopulmonary	O	O
resuscitation	O	O
was	O	O
started	O	O
and	O	O
electrocardiogram	O	O
(	O	O
ecg	O	O
)	O	O
was	O	O
monitored	O	O
for	O	O
ventricular	O	O
tachycardia	O	O
,	O	O
fibrillation	O	O
,	O	O
or	O	O
qrs	O	O
prolongation	O	O
.	O	O

piglets	O	O
were	O	O
then	O	O
randomly	O	O
allocated	O	O
to	O	O
four	O	O
groups	O	O
:	O	O
control	O	O
(	O	O
saline	O	O
)	O	O
,	O	O
intralipid	O	O
(	O	O
)	O	O
alone	O	O
,	O	O
epinephrine	B-chem	B-chem
alone	O	O
,	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
intralipd	O	O
plus	O	O
epinephrine	B-chem	B-chem
.	O	O

resuscitation	O	O
continued	O	O
for	O	O
30	O	O
min	O	O
or	O	O
until	O	O
there	O	O
was	O	O
a	O	O
return	O	O
of	O	O
spontaneous	O	O
circulation	O	O
(	O	O
rosc	O	O
)	O	O
accompanied	O	O
by	O	O
a	O	O
mean	O	O
arterial	O	O
pressure	O	O
at	O	O
or	O	O
superior	O	O
to	O	O
the	O	O
baseline	O	O
pressure	O	O
and	O	O
normal	O	O
sinus	O	O
rhythm	O	O
for	O	O
a	O	O
period	O	O
of	O	O
30	O	O
min	O	O
.	O	O

results	O	O
:	O	O

rosc	O	B-chem
was	O	O
achieved	O	O
in	O	O
only	O	O
one	O	O
of	O	O
the	O	O
control	O	O
piglets	O	O
compared	O	O
with	O	O
most	O	O
of	O	O
the	O	O
treated	O	O
piglets	O	O
.	O	O

mortality	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
three	O	O
treatment	O	O
groups	O	O
,	O	O
but	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
all	O	O
the	O	O
treatment	O	O
groups	O	O
compared	O	O
with	O	O
control	O	O
.	O	O

the	O	O
number	O	O
of	O	O
ecg	O	O
abnormalities	O	O
was	O	O
zero	O	O
in	O	O
the	O	O
intralipid	O	O
only	O	O
group	O	O
,	O	O
but	O	O
14	O	O
and	O	O
17	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
epinephrine	B-chem	B-chem
and	O	O
epinephrine	B-chem	B-chem
plus	O	O
lipid	O	O
groups	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

lipid	O	O
emulsion	O	O
with	O	O
or	O	O
without	O	O
epinephrine	B-chem	B-chem
,	O	O
or	O	O
epinephrine	B-chem	B-chem
alone	O	O
were	O	O
equally	O	O
effective	O	O
in	O	O
achieving	O	O
a	O	O
return	O	O
to	O	O
spontaneous	O	O
circulation	O	O
in	O	O
this	O	O
model	O	O
of	O	O
last	O	O
.	O	O

epinephrine	B-chem	B-chem
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
lipid	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
number	O	O
of	O	O
ecg	O	O
abnormalities	O	O
compared	O	O
with	O	O
lipid	O	O
emulsion	O	O
alone	O	O
.	O	O

incidence	O	O
of	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
type	O	O
ii	O	O
and	O	O
postoperative	O	O
recovery	O	O
of	O	O
platelet	O	O
count	O	O
in	O	O
liver	O	O
graft	O	O
recipients	O	O
:	O	O
a	O	O
retrospective	O	O
cohort	O	O
analysis	O	O
.	O	O

background	O	O
:	O	O
thrombocytopenia	O	O
in	O	O
patients	O	O
with	O	O
end	O	O
-	O	O
stage	O	O
liver	O	O
disease	O	O
is	O	O
a	O	O
common	O	O
disorder	O	O
caused	O	O
mainly	O	O
by	O	O
portal	O	O
hypertension	O	O
,	O	O
low	O	O
levels	O	O
of	O	O
thrombopoetin	O	O
,	O	O
and	O	O
endotoxemia	O	O
.	O	O

the	O	O
impact	O	O
of	O	O
immune	O	O
-	O	O
mediated	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
type	O	O
ii	O	O
(	O	O
hit	O	O
type	O	O
ii	O	O
)	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
thrombocytopenia	O	O
after	O	O
liver	O	O
transplantation	O	O
is	O	O
not	O	O
yet	O	O
understood	O	O
,	O	O
with	O	O
few	O	O
literature	O	O
citations	O	O
reporting	O	O
contradictory	O	O
results	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
our	O	O
study	O	O
was	O	O
to	O	O
demonstrate	O	O
the	O	O
perioperative	O	O
course	O	O
of	O	O
thrombocytopenia	O	O
after	O	O
liver	O	O
transplantation	O	O
and	O	O
determine	O	O
the	O	O
occurrence	O	O
of	O	O
clinical	O	O
hit	O	O
type	O	O
ii	O	O
.	O	O

method	O	O
:	O	O

we	O	O
retrospectively	O	O
evaluated	O	O
the	O	O
medical	O	O
records	O	O
of	O	O
205	O	O
consecutive	O	O
adult	O	O
patients	O	O
who	O	O
underwent	O	O
full	O	O
-	O	O
size	O	O
liver	O	O
transplantation	O	O
between	O	O
january	O	O
2006	O	O
and	O	O
december	O	O
2010	O	O
due	O	O
to	O	O
end	O	O
-	O	O
stage	O	O
or	O	O
malignant	O	O
liver	O	O
disease	O	O
.	O	O

preoperative	O	O
platelet	O	O
count	O	O
,	O	O
postoperative	O	O
course	O	O
of	O	O
platelets	O	O
,	O	O
and	O	O
clinical	O	O
signs	O	O
of	O	O
hit	O	O
type	O	O
ii	O	O
were	O	O
analyzed	O	O
.	O	O

results	O	O
:	O	O

a	O	O
total	O	O
of	O	O
155	O	O
(	O	O
75	O	O
.	O	O
6	O	O
%	O	O
)	O	O
of	O	O
205	O	O
patients	O	O
had	O	O
thrombocytopenia	O	O
before	O	O
transplantation	O	O
,	O	O
significantly	O	O
influenced	O	O
by	O	O
model	O	O
of	O	O
end	O	O
-	O	O
stage	O	O
liver	O	O
disease	O	O
score	O	O
and	O	O
liver	O	O
cirrhosis	O	O
.	O	O

the	O	O
platelet	O	O
count	O	O
exceeded	O	O
100	O	O
,	O	O
000	O	O
/	O	O
ul	O	O
in	O	O
most	O	O
of	O	O
the	O	O
patients	O	O
(	O	O
n	O	O
=	O	O
193	O	O
)	O	O
at	O	O
a	O	O
medium	O	O
of	O	O
7	O	O
d	O	O
.	O	O
regarding	O	O
hit	O	O
ii	O	O
,	O	O
there	O	O
were	O	O
four	O	O
(	O	O
1	O	O
.	O	O
95	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
a	O	O
background	O	O
of	O	O
hit	O	O
type	O	O
ii	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
incidence	O	O
of	O	O
hit	O	O
in	O	O
patients	O	O
with	O	O
end	O	O
-	O	O
stage	O	O
hepatic	O	O
failure	O	O
is	O	O
,	O	O
with	O	O
about	O	O
1	O	O
.	O	O
95	O	O
%	O	O
,	O	O
rare	O	O
.	O	O

for	O	O
further	O	O
reduction	O	O
of	O	O
hit	O	O
type	O	O
ii	O	O
,	O	O
the	O	O
use	O	O
of	O	O
intravenous	O	O
heparin	B-chem	B-chem
should	O	O
be	O	O
avoided	O	O
and	O	O
the	O	O
prophylactic	O	O
anticoagulation	O	O
should	O	O
be	O	O
performed	O	O
with	O	O
low	O	O
-	O	O
molecular	O	O
-	O	O
weight	O	O
heparin	B-chem	B-chem
after	O	O
normalization	O	O
of	O	O
platelet	O	O
count	O	O
.	O	O

takotsubo	O	O
syndrome	O	O
(	O	O
or	O	O
apical	O	O
ballooning	O	O
syndrome	O	O
)	O	O
secondary	O	O
to	O	O
zolmitriptan	B-chem	B-chem
.	O	O

takotsubo	O	O
syndrome	O	O
(	O	O
ts	O	O
)	O	O
,	O	O
also	O	O
known	O	O
as	O	O
broken	O	O
heart	O	O
syndrome	O	O
,	O	O
is	O	O
characterized	O	O
by	O	O
left	O	O
ventricle	O	O
apical	O	O
ballooning	O	O
with	O	O
elevated	O	O
cardiac	O	O
biomarkers	O	O
and	O	O
electrocardiographic	O	O
changes	O	O
suggestive	O	O
of	O	O
an	O	O
acute	O	O
coronary	O	O
syndrome	O	O
(	O	O
ie	O	O
,	O	O
st	O	O
-	O	O
segment	O	O
elevation	O	O
,	O	O
t	O	O
wave	O	O
inversions	O	O
,	O	O
and	O	O
pathologic	O	O
q	O	O
waves	O	O
)	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
medical	O	O
history	O	O
of	O	O
mitral	O	O
valve	O	O
prolapse	O	O
and	O	O
migraines	O	O
,	O	O
who	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
substernal	O	O
chest	O	O
pain	O	O
and	O	O
electrocardiogram	O	O
demonstrated	O	O
1	O	O
/	O	O
2	O	O
mm	O	O
st	O	O
-	O	O
segment	O	O
elevation	O	O
in	O	O
leads	O	O
ii	O	O
,	O	O
iii	O	O
,	O	O
avf	O	O
,	O	O
v5	O	O
,	O	O
and	O	O
v6	O	O
and	O	O
positive	O	O
troponin	O	O
i	O	O
.	O	O
emergent	O	O
coronary	O	O
angiogram	O	O
revealed	O	O
normal	O	O
coronary	O	O
arteries	O	O
with	O	O
moderately	O	O
reduced	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
with	O	O
wall	O	O
motion	O	O
abnormalities	O	O
consistent	O	O
with	O	O
ts	O	O
.	O	O

detailed	O	O
history	O	O
obtained	O	O
retrospectively	O	O
revealed	O	O
that	O	O
the	O	O
patient	O	O
took	O	O
zolmitriptan	B-chem	B-chem
sparingly	O	O
only	O	O
when	O	O
she	O	O
had	O	O
migraines	O	O
.	O	O

but	O	O
before	O	O
this	O	O
event	O	O
,	O	O
she	O	O
was	O	O
taking	O	O
zolmitriptan	B-chem	B-chem
2	O	O
-	O	O
3	O	O
times	O	O
daily	O	O
for	O	O
several	O	O
days	O	O
because	O	O
of	O	O
a	O	O
persistent	O	O
migraine	O	O
headache	O	O
.	O	O

she	O	O
otherwise	O	O
reported	O	O
that	O	O
she	O	O
is	O	O
quite	O	O
active	O	O
,	O	O
rides	O	O
horses	O	O
,	O	O
and	O	O
does	O	O
show	O	O
jumping	O	O
without	O	O
any	O	O
limitations	O	O
in	O	O
her	O	O
physical	O	O
activity	O	O
.	O	O

there	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
any	O	O
recent	O	O
stress	O	O
or	O	O
status	O	O
migrainosus	O	O
.	O	O

extensive	O	O
literature	O	O
search	O	O
revealed	O	O
multiple	O	O
cases	O	O
of	O	O
coronary	O	O
artery	O	O
vasospasm	O	O
secondary	O	O
to	O	O
zolmitriptan	B-chem	B-chem
,	O	O
but	O	O
none	O	O
of	O	O
the	O	O
cases	O	O
were	O	O
associated	O	O
with	O	O
ts	O	O
.	O	O

depression	O	O
,	O	O
impulsiveness	O	O
,	O	O
sleep	O	O
,	O	O
and	O	O
memory	O	O
in	O	O
past	O	O
and	O	O
present	O	O
polydrug	O	O
users	O	O
of	O	O
3	B-chem	B-chem
,	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
methylenedioxymethamphetamine	I-chem	I-chem
(	O	O
mdma	B-chem	B-chem
,	O	O
ecstasy	B-chem	B-chem
)	O	O
.	O	O

rationale	O	O
:	O	O
ecstasy	B-chem	B-chem
(	O	O
3	B-chem	B-chem
,	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
methylenedioxymethamphetamine	I-chem	I-chem

,	O	O
mdma	B-chem	B-chem
)	O	O
is	O	O
a	O	O
worldwide	O	O
recreational	O	O
drug	O	O
of	O	O
abuse	O	O
.	O	O

unfortunately	O	O
,	O	O
the	O	O
results	O	O
from	O	O
human	O	O
research	O	O
investigating	O	O
its	O	O
psychological	O	O
effects	O	O
have	O	O
been	O	O
inconsistent	O	O
.	O	O

objectives	O	O
:	O	O

the	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
be	O	O
the	O	O
largest	O	O
to	O	O
date	O	O
in	O	O
sample	O	O
size	O	O
and	O	O
5ht	O	O
-	O	O
related	O	O
behaviors	O	O
;	O	O
the	O	O
first	O	O
to	O	O
compare	O	O
present	O	O
ecstasy	B-chem	B-chem
users	O	O
with	O	O
past	O	O
users	O	O
after	O	O
an	O	O
abstinence	O	O
of	O	O
4	O	O
or	O	O
more	O	O
years	O	O
,	O	O
and	O	O
the	O	O
first	O	O
to	O	O
include	O	O
robust	O	O
controls	O	O
for	O	O
other	O	O
recreational	O	O
substances	O	O
.	O	O

methods	O	O
:	O	O

a	O	O
sample	O	O
of	O	O
997	O	O
participants	O	O
(	O	O
52	O	O
%	O	O
male	O	O
)	O	O
was	O	O
recruited	O	O
to	O	O
four	O	O
control	O	O
groups	O	O
(	O	O
non	O	O
-	O	O
drug	O	O
(	O	O
nd	O	O
)	O	O
,	O	O
alcohol	B-chem	B-chem
/	O	O
nicotine	B-chem	B-chem
(	O	O
an	B-chem	O
)	O	O
,	O	O
cannabis	B-chem	B-chem
/	O	O
alcohol	B-chem	B-chem
/	O	O
nicotine	B-chem	B-chem
(	O	O
can	B-chem	O
)	O	O
,	O	O
non	O	O
-	O	O
ecstasy	B-chem	B-chem
polydrug	O	O
(	O	O
pd	O	O
)	O	O
)	O	O
,	O	O
and	O	O
two	O	O
ecstasy	B-chem	B-chem
polydrug	O	O
groups	O	O
(	O	O
present	O	O
(	O	O
mdma	B-chem	B-chem
)	O	O
and	O	O
past	O	O
users	O	O
(	O	O
ex	O	B-chem
-	O	O
mdma	B-chem	B-chem
)	O	O
.	O	O

participants	O	O
completed	O	O
a	O	O
drug	O	O
history	O	O
questionnaire	O	O
,	O	O
beck	O	O
depression	O	O
inventory	O	O
,	O	O
barratt	O	O
impulsiveness	O	O
scale	O	O
,	O	O
pittsburgh	O	O
sleep	O	O
quality	O	O
index	O	O
,	O	O
and	O	O
wechsler	O	O
memory	O	O
scale	O	O
-	O	O
revised	O	O
which	O	O
,	O	O
in	O	O
total	O	O
,	O	O
provided	O	O
13	O	O
psychometric	O	O
measures	O	O
.	O	O

results	O	O
:	O	O

while	O	O
the	O	O
can	B-chem	O
and	O	O
pd	O	O
groups	O	O
tended	O	O
to	O	O
record	O	O
greater	O	O
deficits	O	O
than	O	O
the	O	O
non	O	O
-	O	O
drug	O	O
controls	O	O
,	O	O
the	O	O
mdma	B-chem	B-chem
and	O	O
ex	O	B-chem
-	O	O
mdma	B-chem	B-chem
groups	O	O
recorded	O	O
greater	O	O
deficits	O	O
than	O	O
all	O	O
the	O	O
control	O	O
groups	O	O
on	O	O
ten	O	O
of	O	O
the	O	O
13	O	O
psychometric	O	O
measures	O	O
.	O	O

strikingly	O	O
,	O	O
despite	O	O
prolonged	O	O
abstinence	O	O
(	O	O
mean	O	O
,	O	O
4	O	O
.	O	O
98	O	O
;	O	O
range	O	O
,	O	O
4	O	O
-	O	O
9	O	O
years	O	O
)	O	O
,	O	O
past	O	O
ecstasy	B-chem	B-chem
users	O	O
showed	O	O
few	O	O
signs	O	O
of	O	O
recovery	O	O
.	O	O

compared	O	O
with	O	O
present	O	O
ecstasy	B-chem	B-chem
users	O	O
,	O	O
the	O	O
past	O	O
users	O	O
showed	O	O
no	O	O
change	O	O
for	O	O
ten	O	O
measures	O	O
,	O	O
increased	O	O
impairment	O	O
for	O	O
two	O	O
measures	O	O
,	O	O
and	O	O
improvement	O	O
on	O	O
just	O	O
one	O	O
measure	O	O
.	O	O

conclusions	O	O
:	O	O

given	O	O
this	O	O
record	O	O
of	O	O
impaired	O	O
memory	O	O
and	O	O
clinically	O	O
significant	O	O
levels	O	O
of	O	O
depression	O	O
,	O	O
impulsiveness	O	O
,	O	O
and	O	O
sleep	O	O
disturbance	O	O
,	O	O
the	O	O
prognosis	O	O
for	O	O
the	O	O
current	O	O
generation	O	O
of	O	O
ecstasy	B-chem	B-chem
users	O	O
is	O	O
a	O	O
major	O	O
cause	O	O
for	O	O
concern	O	O
.	O	O

association	O	O
of	O	O
common	O	O
genetic	O	O
variants	O	O
of	O	O
homer1	O	O
gene	O	O
with	O	O
levodopa	B-chem	B-chem
adverse	O	O
effects	O	O
in	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
patients	O	O
.	O	O

levodopa	B-chem	B-chem
is	O	O
the	O	O
most	O	O
effective	O	O
symptomatic	O	O
therapy	O	O
for	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
,	O	O
but	O	O
its	O	O
chronic	O	O
use	O	O
could	O	O
lead	O	O
to	O	O
chronic	O	O
adverse	O	O
outcomes	O	O
,	O	O
such	O	O
as	O	O
motor	O	O
fluctuations	O	O
,	O	O
dyskinesia	O	O
and	O	O
visual	O	O
hallucinations	O	O
.	O	O

homer1	O	O
is	O	O
a	O	O
protein	O	O
with	O	O
pivotal	O	O
function	O	O
in	O	O
glutamate	B-chem	B-chem
transmission	O	O
,	O	O
which	O	O
has	O	O
been	O	O
related	O	O
to	O	O
the	O	O
pathogenesis	O	O
of	O	O
these	O	O
complications	O	O
.	O	O

this	O	O
study	O	O
investigates	O	O
whether	O	O
polymorphisms	O	O
in	O	O
the	O	O
homer1	O	O
gene	O	O
promoter	O	O
region	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
occurrence	O	O
of	O	O
the	O	O
chronic	O	O
complications	O	O
of	O	O
levodopa	B-chem	B-chem
therapy	O	O
.	O	O

a	O	O
total	O	O
of	O	O
205	O	O
patients	O	O
with	O	O
idiopathic	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
were	O	O
investigated	O	O
.	O	O

patients	O	O
were	O	O
genotyped	O	O
for	O	O
rs4704559	O	O
,	O	O
rs10942891	O	O
and	O	O
rs4704560	O	O
by	O	O
allelic	O	O
discrimination	O	O
with	O	O
taqman	O	O
assays	O	O
.	O	O

the	O	O
rs4704559	O	O
g	O	O
allele	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
lower	O	O
prevalence	O	O
of	O	O
dyskinesia	O	O
(	O	O
prevalence	O	O
ratio	O	O
(	O	O
pr	O	O
)	O	O
=	O	O
0	O	O
.	O	O
615	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
ci	O	O
)	O	O
0	O	O
.	O	O
426	O	O
-	O	O
0	O	O
.	O	O
887	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
009	O	O
)	O	O
and	O	O
visual	O	O
hallucinations	O	O
(	O	O
pr	O	O
=	O	O
0	O	O
.	O	O
515	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
0	O	O
.	O	O
295	O	O
-	O	O
0	O	O
.	O	O
899	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
020	O	O
)	O	O
.	O	O

our	O	O
data	O	O
suggest	O	O
that	O	O
homer1	O	O
rs4704559	O	O
g	O	O
allele	O	O
has	O	O
a	O	O
protective	O	O
role	O	O
for	O	O
the	O	O
development	O	O
of	O	O
levodopa	B-chem	B-chem
adverse	O	O
effects	O	O
.	O	O

crocin	B-chem	B-chem
improves	O	O
lipid	O	O
dysregulation	O	O
in	O	O
subacute	O	O
diazinon	B-chem	B-chem
exposure	O	O
through	O	O
erk1	O	O
/	O	O
2	O	O
pathway	O	O
in	O	O
rat	O	O
liver	O	O
.	O	O

introduction	O	O
:	O	O

diazinon	B-chem	B-chem
yis	O	O
one	O	O
of	O	O
the	O	O
most	O	O
broadly	O	O
used	O	O
organophosphorus	B-chem	B-chem
insecticides	O	O
in	O	O
agriculture	O	O
.	O	O

it	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
exposure	O	O
to	O	O
diazinon	B-chem	B-chem
may	O	O
interfere	O	O
with	O	O
lipid	O	O
metabolism	O	O
.	O	O

moreover	O	O
,	O	O
the	O	O
hypolipidemic	O	O
effect	O	O
of	O	O
crocin	B-chem	B-chem
has	O	O
been	O	O
established	O	O
.	O	O

earlier	O	O
studies	O	O
revealed	O	O
the	O	O
major	O	O
role	O	O
of	O	O
extracellular	O	O
signal	O	O
-	O	O
regulated	O	O
kinase	O	O
(	O	O
erk	O	B-chem
)	O	O
pathways	O	O
in	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
receptor	O	O
(	O	O
ldlr	O	O
)	O	O
expression	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
changes	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
lipid	O	O
metabolism	O	O
,	O	O
erk	O	B-chem
and	O	O
ldlr	O	O
expression	O	O
in	O	O
the	O	O
liver	O	O
of	O	O
rats	O	O
exposed	O	O
to	O	O
subacute	O	O
diazinon	B-chem	B-chem
.	O	O

furthermore	O	O
ameliorating	O	O
effect	O	O
of	O	O
crocin	B-chem	B-chem
on	O	O
diazinon	B-chem	B-chem
induced	O	O
disturbed	O	O
cholesterol	B-chem	B-chem
homeostasis	O	O
was	O	O
studied	O	O
.	O	O

methods	O	O
:	O	O

24	O	O
rats	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
and	O	O
received	O	O
following	O	O
treatments	O	O
for	O	O
4	O	O
weeks	O	O
;	O	O
corn	O	O
oil	O	O
(	O	O
control	O	O
)	O	O
,	O	O
diazinon	B-chem	B-chem
(	O	O
15mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
,	O	O
orally	O	O
)	O	O
and	O	O
crocin	B-chem	B-chem
(	O	O
12	O	O
.	O	O
5	O	O
and	O	O
25mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
,	O	O
intraperitoneally	O	O
)	O	O
in	O	O
combination	O	O
with	O	O
diazinon	B-chem	B-chem
(	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

the	O	O
levels	O	O
of	O	O
cholesterol	B-chem	B-chem
,	O	O
triglyceride	B-chem	B-chem
and	O	O
ldl	O	O
in	O	O
blood	O	O
of	O	O
rats	O	O
were	O	O
analyzed	O	O
.	O	O

moreover	O	O
mrna	O	O
levels	O	O
of	O	O
ldlr	O	B-chem
and	O	O
erk1	O	O
/	O	O
2	O	O
as	O	O
well	O	O
as	O	O
protein	O	O
levels	O	O
of	O	O
total	O	O
and	O	O
activated	O	O
forms	O	O
of	O	O
erk1	O	O
/	O	O
2	O	O
in	O	O
rat	O	O
liver	O	O
were	O	O
evaluated	O	O
by	O	O
western	O	O
blotting	O	O
and	O	O
quantitative	O	O
real	O	O
time	O	O
polymerase	O	O
chain	O	O
reaction	O	O
analysis	O	O
.	O	O

results	O	O
:	O	O

our	O	O
data	O	O
showed	O	O
that	O	O
subacute	O	O
exposure	O	O
to	O	O
diazinon	B-chem	B-chem
significantly	O	O
increased	O	O
concentrations	O	O
of	O	O
cholesterol	B-chem	B-chem
,	O	O
triglyceride	B-chem	B-chem
and	O	O
ldl	O	O
.	O	O

moreover	O	O
diazinon	B-chem	B-chem
decreased	O	O
erk1	O	O
/	O	O
2	O	O
protein	O	O
phosphorylation	O	O
and	O	O
ldlr	O	O
transcript	O	O
.	O	O

crocin	B-chem	B-chem
reduced	O	O
inhibition	O	O
of	O	O
erk	O	B-chem
activation	O	O
and	O	O
diazinon	B-chem	B-chem
-	O	O
induced	O	O
hyperlipemia	O	O
and	O	O
increased	O	O
levels	O	O
of	O	O
ldlr	O	O
transcript	O	O
.	O	O

conclusions	O	O
:	O	O

crocin	B-chem	B-chem
may	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
novel	O	O
protective	O	O
agent	O	O
in	O	O
diazinon	B-chem	B-chem
-	O	O
induced	O	O
hyperlipemia	O	O
through	O	O
modulating	O	O
of	O	O
erk	O	B-chem
pathway	O	O
and	O	O
increase	O	O
of	O	O
ldlr	O	O
expression	O	O
.	O	O

gem	B-chem	B-chem
-	O	O
p	O	O
chemotherapy	O	O
is	O	O
active	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
relapsed	O	O
hodgkin	O	O
lymphoma	O	O
.	O	O

hodgkin	O	O
lymphoma	O	O
(	O	O
hl	O	O
)	O	O
is	O	O
a	O	O
relatively	O	O
chemosensitive	O	O
malignancy	O	O
.	O	O

however	O	O
,	O	O
for	O	O
those	O	O
who	O	O
relapse	O	O
,	O	O
high	O	O
-	O	O
dose	O	O
chemotherapy	O	O
with	O	O
autologous	O	O
stem	O	O
cell	O	O
transplant	O	O
is	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
which	O	O
relies	O	O
on	O	O
adequate	O	O
disease	O	O
control	O	O
with	O	O
salvage	O	O
chemotherapy	O	O
.	O	O

regimens	O	O
commonly	O	O
used	O	O
often	O	O
require	O	O
inpatient	O	O
administration	O	O
and	O	O
can	O	O
be	O	O
difficult	O	O
to	O	O
deliver	O	O
due	O	O
to	O	O
toxicity	O	O
.	O	O

gemcitabine	B-chem	B-chem
and	O	O
cisplatin	B-chem	B-chem
have	O	O
activity	O	O
in	O	O
hl	O	O
,	O	O
non	O	O
-	O	O
overlapping	O	O
toxicity	O	O
with	O	O
first	O	O
-	O	O
line	O	O
chemotherapeutics	O	O
,	O	O
and	O	O
may	O	O
be	O	O
delivered	O	O
in	O	O
an	O	O
outpatient	O	O
setting	O	O
.	O	O

in	O	O
this	O	O
retrospective	O	O
single	O	O
-	O	O
centre	O	O
analysis	O	O
,	O	O
patients	O	O
with	O	O
relapsed	O	O
or	O	O
refractory	O	O
hl	O	O
treated	O	O
with	O	O
gemcitabine	B-chem	B-chem
1	O	O
,	O	O
000	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
day	O	O
(	O	O
d	O	O
)	O	O
1	O	O
,	O	O
d8	O	B-chem
and	O	O
d15	O	O
;	O	O
methylprednisolone	B-chem	B-chem
1	O	O
,	O	O
000	O	O
mg	O	I-chem
d1	O	I-chem
-	O	I-chem
5	O	I-chem
;	O	O
and	O	O
cisplatin	B-chem	B-chem
100	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
d15	O	O
,	O	O
every	O	O
28	O	O
days	O	O
(	O	O
gem	B-chem	B-chem
-	O	O
p	O	O
)	O	O
were	O	O
included	O	O
.	O	O

demographic	O	O
,	O	O
survival	O	O
,	O	O
response	O	O
and	O	O
toxicity	O	O
data	O	O
were	O	O
recorded	O	O
.	O	O

forty	O	O
-	O	O
one	O	O
eligible	O	O
patients	O	O
were	O	O
identified	O	O
:	O	O
median	O	O
age	O	O
27	O	O
.	O	O

one	O	O
hundred	O	O
and	O	O
twenty	O	O
-	O	O
two	O	O
cycles	O	O
of	O	O
gem	B-chem	B-chem
-	O	O
p	O	O
were	O	O
administered	O	O
in	O	O
total	O	O
(	O	O
median	O	O
3	O	O
cycles	O	O
;	O	O
range	O	O
1	O	O
-	O	O
6	O	O
)	O	O
.	O	O

twenty	O	O
of	O	O
41	O	O
(	O	O
48	O	O
%	O	O
)	O	O
patients	O	O
received	O	O
gem	B-chem	B-chem
-	O	O
p	O	O
as	O	O
second	O	O
-	O	O
line	O	O
treatment	O	O
and	O	O
11	O	O
/	O	O
41	O	O
(	O	O
27	O	O
%	O	O
)	O	O
as	O	O
third	O	O
-	O	O
line	O	O
therapy	O	O
.	O	O

overall	O	O
response	O	O
rate	O	O
(	O	O
orr	O	O
)	O	O
to	O	O
gem	B-chem	B-chem
-	O	O
p	O	O
in	O	O
the	O	O
entire	O	O
cohort	O	O
was	O	O
80	O	O
%	O	O
(	O	O
complete	O	O
response	O	O
(	O	O
cr	O	O
)	O	O
37	O	O
%	O	O
,	O	O
partial	O	O
response	O	O
44	O	O
%	O	O
)	O	O
with	O	O
14	O	O
/	O	O
15	O	O
cr	O	O
confirmed	O	O
as	O	O
a	O	O
metabolic	O	O
cr	O	O
on	O	O
pet	O	O
and	O	O
orr	O	O
of	O	O
85	O	O
%	O	O
in	O	O
the	O	O
20	O	O
second	O	O
-	O	O
line	O	O
patients	O	O
.	O	O

the	O	O
most	O	O
common	O	O
grade	O	O
3	O	O
/	O	O
4	O	O
toxicities	O	O
were	O	O
haematological	O	O
:	O	O
neutropenia	O	O
54	O	O
%	O	O
and	O	O
thrombocytopenia	O	O
51	O	O
%	O	O
.	O	O

median	O	O
follow	O	O
-	O	O
up	O	O
from	O	O
the	O	O
start	O	O
of	O	O
gem	B-chem	B-chem
-	O	O
p	O	O
was	O	O
4	O	O
.	O	O
5	O	O
years	O	O
.	O	O

following	O	O
gem	B-chem	B-chem
-	O	O
p	O	O
,	O	O
5	O	O
-	O	O
year	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
was	O	O
46	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
ci	O	O
)	O	O
,	O	O
30	O	O
-	O	O
62	O	O
%	O	O
)	O	O
and	O	O
5	O	O
-	O	O
year	O	O
overall	O	O
survival	O	O
was	O	O
59	O	O
%	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
,	O	O
43	O	O
-	O	O
74	O	O
%	O	O
)	O	O
.	O	O

fourteen	O	O
of	O	O
41	O	O
patients	O	O
proceeded	O	O
directly	O	O
to	O	O
autologous	O	O
transplant	O	O
.	O	O

gem	B-chem	B-chem
-	O	O
p	O	O
is	O	O
a	O	O
salvage	O	O
chemotherapy	O	O
with	O	O
relatively	O	O
high	O	O
response	O	O
rates	O	O
,	O	O
leading	O	O
to	O	O
successful	O	O
transplantation	O	O
in	O	O
appropriate	O	O
patients	O	O
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
relapsed	O	O
or	O	O
refractory	O	O
hl	O	O
.	O	O

basal	O	O
functioning	O	O
of	O	O
the	O	O
hypothalamic	O	O
-	O	O
pituitary	O	O
-	O	O
adrenal	O	O
(	O	O
hpa	O	O
)	O	O
axis	O	O
and	O	O
psychological	O	O
distress	O	O
in	O	O
recreational	O	O
ecstasy	B-chem	B-chem
polydrug	O	O
users	O	O
.	O	O

rationale	O	O
:	O	O
ecstasy	B-chem	B-chem
(	O	O
mdma	B-chem	B-chem
)	O	O
is	O	O
a	O	O
psychostimulant	O	O
drug	O	O
which	O	O
is	O	O
increasingly	O	O
associated	O	O
with	O	O
psychobiological	O	O
dysfunction	O	O
.	O	O

while	O	O
some	O	O
recent	O	O
studies	O	O
suggest	O	O
acute	O	O
changes	O	O
in	O	O
neuroendocrine	O	O
function	O	O
,	O	O
less	O	O
is	O	O
known	O	O
about	O	O
long	O	O
-	O	O
term	O	O
changes	O	O
in	O	O
hpa	O	O
functionality	O	O
in	O	O
recreational	O	O
users	O	O
.	O	O

objectives	O	O
:	O	O

the	O	O
current	O	O
study	O	O
is	O	O
the	O	O
first	O	O
to	O	O
explore	O	O
the	O	O
effects	O	O
of	O	O
ecstasy	B-chem	B-chem
-	O	O
polydrug	O	B-chem
use	O	O
on	O	O
psychological	O	O
distress	O	O
and	O	O
basal	O	O
functioning	O	O
of	O	O
the	O	O
hpa	O	O
axis	O	O
through	O	O
assessing	O	O
the	O	O
secretion	O	O
of	O	O
cortisol	B-chem	B-chem
across	O	O
the	O	O
diurnal	O	O
period	O	O
.	O	O

method	O	O
:	O	O
seventy	O	O
-	O	O
six	O	O
participants	O	O
(	O	O
21	O	O
nonusers	O	O
,	O	O
29	O	O
light	O	O
ecstasy	B-chem	B-chem
-	O	O
polydrug	O	O
users	O	O
,	O	O
26	O	O
heavy	O	O
ecstasy	B-chem	B-chem
-	O	O
polydrug	O	O
users	O	O
)	O	O
completed	O	O
a	O	O
substance	O	O
use	O	O
inventory	O	O
and	O	O
measures	O	O
of	O	O
psychological	O	O
distress	O	O
at	O	O
baseline	O	O
,	O	O
then	O	O
two	O	O
consecutive	O	O
days	O	O
of	O	O
cortisol	B-chem	B-chem
sampling	O	O
(	O	O
on	O	O
awakening	O	O
,	O	O
30	O	O
min	O	O
post	O	O
awakening	O	O
,	O	O
between	O	O
1400	O	O
and	O	O
1600	O	O
hours	O	O
and	O	O
pre	O	O
bedtime	O	O
)	O	O
.	O	O

on	O	O
day	O	O
2	O	O
,	O	O
participants	O	O
also	O	O
attended	O	O
the	O	O
laboratory	O	O
to	O	O
complete	O	O
a	O	O
20	O	O
-	O	O
min	O	O
multitasking	O	O
stressor	O	O
.	O	O

results	O	O
:	O	O

both	O	O
user	O	O
groups	O	O
exhibited	O	O
significantly	O	O
greater	O	O
levels	O	O
of	O	O
anxiety	O	O
and	O	O
depression	O	O
than	O	O
nonusers	O	O
.	O	O

on	O	O
day	O	O
1	O	O
,	O	O
all	O	O
participants	O	O
exhibited	O	O
a	O	O
typical	O	O
cortisol	B-chem	O
profile	O	O
,	O	O
though	O	O
light	O	O
users	O	O
had	O	O
significantly	O	O
elevated	O	O
levels	O	O
pre	O	O
-	O	O
bed	O	O
.	O	O

on	O	O
day	O	O
2	O	O
,	O	O
heavy	O	O
users	O	O
demonstrated	O	O
elevated	O	O
levels	O	O
upon	O	O
awakening	O	O
and	O	O
all	O	O
ecstasy	B-chem	B-chem
-	O	O
polydrug	O	O
users	O	O
demonstrated	O	O
elevated	O	O
pre	O	O
-	O	O
bed	O	O
levels	O	O
compared	O	O
to	O	O
non	O	O
-	O	O
users	O	O
.	O	O

significant	O	O
between	O	O
group	O	O
differences	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
afternoon	O	O
cortisol	B-chem	B-chem
levels	O	O
and	O	O
in	O	O
overall	O	O
cortisol	B-chem	B-chem
secretion	O	O
across	O	O
the	O	O
day	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
increases	O	O
in	O	O
anxiety	O	O
and	O	O
depression	O	O
are	O	O
in	O	O
line	O	O
with	O	O
previous	O	O
observations	O	O
in	O	O
recreational	O	O
ecstasy	B-chem	B-chem
-	O	O
polydrug	O	O
users	O	O
.	O	O

dysregulated	O	O
diurnal	O	O
cortisol	B-chem	B-chem
may	O	O
be	O	O
indicative	O	O
of	O	O
inappropriate	O	O
anticipation	O	O
of	O	O
forthcoming	O	O
demands	O	O
and	O	O
hypersecretion	O	O
may	O	O
lead	O	O
to	O	O
the	O	O
increased	O	O
psychological	O	O
and	O	O
physical	O	O
morbidity	O	O
associated	O	O
with	O	O
heavy	O	O
recreational	O	O
use	O	O
of	O	O
ecstasy	B-chem	B-chem
.	O	O

ifosfamide	B-chem	B-chem
related	O	O
encephalopathy	O	O
:	O	O
the	O	O
need	O	O
for	O	O
a	O	O
timely	O	O
eeg	O	O
evaluation	O	O
.	O	O

background	O	O
:	O	O
ifosfamide	B-chem	B-chem
is	O	O
an	O	O
alkylating	O	O
agent	O	O
useful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
cancers	O	O
including	O	O
sarcomas	O	O
,	O	O
lymphoma	O	O
,	O	O
gynecologic	O	O
and	O	O
testicular	O	O
cancers	O	O
.	O	O

encephalopathy	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
10	O	O
-	O	O
40	O	O
%	O	O
of	O	O
patients	O	O
receiving	O	O
high	O	O
-	O	O
dose	O	O
iv	O	O
ifosfamide	B-chem	B-chem
.	O	O

objective	O	O
:	O	O

to	O	O
highlight	O	O
the	O	O
role	O	O
of	O	O
electroencephalogram	O	O
(	O	O
eeg	O	O
)	O	O
in	O	O
the	O	O
early	O	O
detection	O	O
and	O	O
management	O	O
of	O	O
ifosfamide	B-chem	B-chem
related	O	O
encephalopathy	O	O
.	O	O

methods	O	O
:	O	O

retrospective	O	O
chart	O	O
review	O	O
including	O	O
clinical	O	O
data	O	O
and	O	O
eeg	O	O
recordings	O	O
was	O	O
done	O	O
on	O	O
five	O	O
patients	O	O
,	O	O
admitted	O	O
to	O	O
md	O	O
anderson	O	O
cancer	O	O
center	O	O
between	O	O
years	O	O
2009	O	O
and	O	O
2012	O	O
,	O	O
who	O	O
developed	O	O
ifosfamide	B-chem	B-chem
related	O	O
acute	O	O
encephalopathy	O	O
.	O	O

results	O	O
:	O	O

all	O	O
five	O	O
patients	O	O
experienced	O	O
symptoms	O	O
of	O	O
encephalopathy	O	O
soon	O	O
after	O	O
(	O	O
within	O	O
12	O	O
h	O	O
-	O	O
2	O	O
days	O	O
)	O	O
receiving	O	O
ifosfamide	B-chem	B-chem
.	O	O

two	O	O
patients	O	O
developed	O	O
generalized	O	O
convulsions	O	O
while	O	O
one	O	O
patient	O	O
developed	O	O
continuous	O	O
non	O	O
-	O	O
convulsive	O	O
status	O	O
epilepticus	O	O
(	O	O
ncse	O	O
)	O	O
that	O	O
required	O	O
icu	O	O
admission	O	O
and	O	O
intubation	O	O
.	O	O

initial	O	O
eeg	O	O
showed	O	O
epileptiform	O	O
discharges	O	O
in	O	O
three	O	O
patients	O	O
;	O	O
run	O	O
of	O	O
triphasic	O	O
waves	O	O
in	O	O
one	O	O
patient	O	O
and	O	O
moderate	O	O
degree	O	O
diffuse	O	O
generalized	O	O
slowing	O	O
.	O	O

mixed	O	O
pattern	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
both	O	O
sharps	O	O
and	O	O
triphasic	O	O
waves	O	O
were	O	O
also	O	O
noted	O	O
.	O	O

repeat	O	O
eegs	O	O
within	O	O
24	O	O
_	O	O
h	O	O
of	O	O
symptom	O	O
onset	O	O
showed	O	O
marked	O	O
improvement	O	O
that	O	O
was	O	O
correlated	O	O
with	O	O
clinical	O	O
improvement	O	O
.	O	O

conclusions	O	O
:	O	O

severity	O	O
of	O	O
ifosfamide	B-chem	B-chem
related	O	O
encephalopathy	O	O
correlates	O	O
with	O	O
eeg	O	O
changes	O	O
.	O	O

we	O	O
suggest	O	O
a	O	O
timely	O	O
eeg	O	O
evaluation	O	O
for	O	O
patients	O	O
receiving	O	O
ifosfamide	B-chem	B-chem
who	O	O
develop	O	O
features	O	O
of	O	O
encephalopathy	O	O
.	O	O

incidence	O	O
of	O	O
contrast	B-chem	B-chem
-	O	O
induced	O	O
nephropathy	O	O
in	O	O
hospitalised	O	O
patients	O	O
with	O	O
cancer	O	O
.	O	O

objectives	O	O
:	O	O

to	O	O
determine	O	O
the	O	O
frequency	O	O
of	O	O
and	O	O
possible	O	O
factors	O	O
related	O	O
to	O	O
contrast	B-chem	O
-	O	O
induced	O	O
nephropathy	O	O
(	O	O
cin	O	O
)	O	O
in	O	O
hospitalised	O	O
patients	O	O
with	O	O
cancer	O	O
.	O	O

methods	O	O
:	O	O

ninety	O	O
adult	O	O
patients	O	O
were	O	O
enrolled	O	O
.	O	O

patients	O	O
with	O	O
risk	O	O
factors	O	O
for	O	O
acute	O	O
renal	O	O
failure	O	O
were	O	O
excluded	O	O
.	O	O

blood	O	O
samples	O	O
were	O	O
examined	O	O
the	O	O
day	O	O
before	O	O
contrast	B-chem	O
-	O	O
enhanced	O	O
computed	O	O
tomography	O	O
(	O	O
ct	O	O
)	O	O
and	O	O
serially	O	O
for	O	O
3	O	O
days	O	O
thereafter	O	O
.	O	O

cin	O	O
was	O	O
defined	O	O
as	O	O
an	O	O
increase	O	O
in	O	O
serum	O	O
creatinine	B-chem	B-chem
(	O	O
cr	B-chem	B-chem
)	O	O
of	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
dl	O	O
or	O	O
more	O	O
,	O	O
or	O	O
elevation	O	O
of	O	O
cr	B-chem	O
to	O	O
25	O	O
%	O	O
over	O	O
baseline	O	O
.	O	O

relationships	O	O
between	O	O
cin	O	O
and	O	O
possible	O	O
risk	O	O
factors	O	O
were	O	O
investigated	O	O
.	O	O

results	O	O
:	O	O

cin	O	O
was	O	O
detected	O	O
in	O	O
18	O	O
/	O	O
90	O	O
(	O	O
20	O	O
%	O	O
)	O	O
patients	O	O
.	O	O

cin	O	O
developed	O	O
in	O	O
25	O	O
.	O	O
5	O	O
%	O	O
patients	O	O
who	O	O
underwent	O	O
chemotherapy	O	O
and	O	O
in	O	O
11	O	O
%	O	O
patients	O	O
who	O	O
did	O	O
not	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
1	O	O
)	O	O
.	O	O

cin	O	O
more	O	O
frequently	O	O
developed	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
undergone	O	O
ct	O	O
within	O	O
45	O	O
days	O	O
after	O	O
the	O	O
last	O	O
chemotherapy	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
005	O	O
)	O	O
;	O	O
it	O	O
was	O	O
also	O	O
an	O	O
independent	O	O
risk	O	O
factor	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
017	O	O
)	O	O
.	O	O

cin	O	O
was	O	O
significantly	O	O
more	O	O
after	O	O
treatment	O	O
with	O	O
bevacizumab	B-chem	B-chem
/	O	O
irinotecan	B-chem	B-chem
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
021	O	O
)	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
hypertension	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
044	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
incidence	O	O
of	O	O
cin	O	O
after	O	O
ct	O	O
in	O	O
hospitalised	O	O
oncological	O	O
patients	O	O
was	O	O
20	O	O
%	O	O
.	O	O

cin	O	O
developed	O	O
4	O	O
.	O	O
5	O	O
-	O	O
times	O	O
more	O	O
frequently	O	O
in	O	O
patients	O	O
with	O	O
cancer	O	O
who	O	O
had	O	O
undergone	O	O
recent	O	O
chemotherapy	O	O
.	O	O

hypertension	O	O
and	O	O
the	O	O
combination	O	O
of	O	O
bevacizumab	B-chem	B-chem
/	O	O
irinotecan	B-chem	B-chem
may	O	O
be	O	O
additional	O	O
risk	O	O
factors	O	O
for	O	O
cin	O	O
development	O	O
.	O	O

key	O	O
points	O	O
:	O	O
.	O	O

contrast	B-chem	B-chem
-	O	O
induced	O	O
nephropathy	O	O
(	O	O
cin	O	O
)	O	O
is	O	O
a	O	O
concern	O	O
for	O	O
oncological	O	O
patients	O	O
undergoing	O	O
ct	O	O
.	O	O
.	O	O

cin	O	O
occurs	O	O
more	O	O
often	O	O
when	O	O
ct	O	O
is	O	O
performed	O	O
<	O	O
45	O	O
days	O	O
after	O	O
chemotherapy	O	O
.	O	O
.	O	O

hypertension	O	O
and	O	O
treatment	O	O
with	O	O
bevacizumab	B-chem	B-chem
appear	O	O
to	O	O
be	O	O
additional	O	O
risk	O	O
factors	O	O
.	O	O

syndrome	O	O
of	O	O
inappropriate	O	O
antidiuretic	O	O
hormone	O	O
secretion	O	O
associated	O	O
with	O	O
desvenlafaxine	B-chem	B-chem
.	O	O

objective	O	O
:	O	O

to	O	O
report	O	O
a	O	O
case	O	O
of	O	O
syndrome	O	O
of	O	O
inappropriate	O	O
anti	O	O
-	O	O
diuretic	O	O
hormone	O	O
(	O	O
siadh	O	O
)	O	O
secretion	O	O
associated	O	O
with	O	O
desvenlafaxine	B-chem	B-chem
.	O	O

case	O	O
summary	O	O
:	O	O

a	O	O
57	O	O
-	O	O
year	O	O
old	O	O
female	O	O
with	O	O
hyponatraemia	O	O
.	O	O

her	O	O
medications	O	O
included	O	O
desvenlafaxine	B-chem	B-chem
,	O	O
and	O	O
symptoms	O	O
included	O	O
nausea	O	O
,	O	O
anxiety	O	O
and	O	O
confusion	O	O
.	O	O

the	O	O
serum	O	O
sodium	B-chem	B-chem
at	O	O
this	O	O
time	O	O
was	O	O
120	O	O
mmol	O	O
/	O	O
l	O	O
,	O	O
serum	O	O
osmolality	O	O
was	O	O
263	O	O
mosmol	O	O
/	O	O
kg	O	O
,	O	O
urine	O	O
osmolality	O	O
410	O	O
mosmol	O	O
/	O	O
kg	O	O
and	O	O
urine	O	O
sodium	B-chem	B-chem
63	O	O
mmol	O	O
/	O	O
l	O	O
,	O	O
consistent	O	O
with	O	O
a	O	O
diagnosis	O	O
of	O	O
siadh	O	O
.	O	O

desvenlafaxine	B-chem	B-chem
was	O	O
ceased	O	O
and	O	O
fluid	O	O
restriction	O	O
implemented	O	O
.	O	O

after	O	O
4	O	O
days	O	O
the	O	O
sodium	B-chem	B-chem
increased	O	O
to	O	O
128	O	O
mmol	O	O
/	O	O
l	O	O
and	O	O
fluid	O	O
restriction	O	O
was	O	O
relaxed	O	O
.	O	O

during	O	O
her	O	O
further	O	O
3	O	O
weeks	O	O
inpatient	O	O
admission	O	O
the	O	O
serum	O	O
sodium	B-chem	B-chem
ranged	O	O
from	O	O
134	O	O
to	O	O
137	O	O
mmol	O	O
/	O	O
l	O	O
during	O	O
treatment	O	O
with	O	O
mirtazapine	B-chem	B-chem
.	O	O

discussion	O	O
:	O	O

siadh	O	O
has	O	O
been	O	O
widely	O	O
reported	O	O
with	O	O
a	O	O
range	O	O
of	O	O
antidepressants	O	B-chem
.	O	O

this	O	O
case	O	O
report	O	O
suggests	O	O
that	O	O
desvenlafaxine	B-chem	B-chem
might	O	O
cause	O	O
clinically	O	O
significant	O	O
hyponatremia	O	O
.	O	O

conclusions	O	O
:	O	O

clinicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
potential	O	O
for	O	O
antidepressants	O	B-chem
to	O	O
cause	O	O
hyponatremia	O	O
,	O	O
and	O	O
take	O	O
appropriate	O	O
corrective	O	O
action	O	O
where	O	O
necessary	O	O
.	O	O

oxidative	O	O
stress	O	O
on	O	O
cardiotoxicity	O	O
after	O	O
treatment	O	O
with	O	O
single	O	O
and	O	O
multiple	O	O
doses	O	O
of	O	O
doxorubicin	B-chem	B-chem
.	O	O

the	O	O
mechanism	O	O
of	O	O
doxorubicin	B-chem	B-chem
(	O	O
dox	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
cardiotoxicity	O	O
remains	O	O
controversial	O	O
.	O	O

wistar	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
66	O	O
)	O	O
received	O	O
dox	B-chem	B-chem
injections	O	O
intraperitoneally	O	O
and	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
2	O	O
experimental	O	O
protocols	O	O
:	O	O
(	O	O
1	O	O
)	O	O
rats	O	O
were	O	O
killed	O	O
before	O	O
(	O	O
-	O	O
24	O	O
h	O	O
,	O	O
n	O	O
=	O	O
8	O	O
)	O	O
and	O	O
24	O	O
h	O	O
after	O	O
(	O	O
+	O	O
24	O	O
h	O	O
,	O	O
n	O	O
=	O	O
8	O	O
)	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
dox	B-chem	B-chem
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
)	O	O
to	O	O
determine	O	O
the	O	O
dox	B-chem	B-chem
acute	O	O
effect	O	O
and	O	O
(	O	O
2	O	O
)	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
58	O	O
)	O	O
received	O	O
4	O	O
injections	O	O
of	O	O
dox	B-chem	B-chem
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
/	O	O
week	O	O
)	O	O
and	O	O
were	O	O
killed	O	O
before	O	O
the	O	O
first	O	O
injection	O	O
(	O	O
m0	O	O
)	O	O
and	O	O
1	O	O
week	O	O
after	O	O
each	O	O
injection	O	O
(	O	O
m1	O	O
,	O	O
m2	O	O
,	O	O
m3	O	O
,	O	O
and	O	O
m4	O	O
)	O	O
to	O	O
determine	O	O
the	O	O
chronological	O	O
effects	O	O
.	O	O

animals	O	O
used	O	O
at	O	O
m0	O	O
(	O	O
n	O	O
=	O	O
8	O	O
)	O	O
were	O	O
also	O	O
used	O	O
at	O	O
moment	O	O
-	O	O
24	O	O

h	O	O
of	O	O
acute	O	O
study	O	O
.	O	O

cardiac	O	O
total	O	O
antioxidant	O	O
performance	O	O
(	O	O
tap	O	O
)	O	O
,	O	O
dna	O	O
damage	O	O
,	O	O
and	O	O
morphology	O	O
analyses	O	O
were	O	O
carried	O	O
out	O	O
at	O	O
each	O	O
time	O	O
point	O	O
.	O	O

single	O	O
dose	O	O
of	O	O
dox	B-chem	B-chem
was	O	O
associated	O	O
with	O	O
increased	O	O
cardiac	O	O
disarrangement	O	O
,	O	O
necrosis	O	O
,	O	O
and	O	O
dna	O	O
damage	O	O
(	O	O
strand	O	O
breaks	O	O
(	O	O
sbs	O	O
)	O	O
and	O	O
oxidized	O	O
pyrimidines	O	B-chem
)	O	O
and	O	O
decreased	O	O
tap	O	O
.	O	O

the	O	O
chronological	O	O
study	O	O
showed	O	O
an	O	O
effect	O	O
of	O	O
a	O	O
cumulative	O	O
dose	O	O
on	O	O
body	O	O
weight	O	O
(	O	O
r	O	O
=	O	O
-	O	O
0	O	O
.	O	O
99	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
011	O	O
)	O	O
,	O	O
necrosis	O	O
(	O	O
r	O	O
=	O	O
1	O	O
.	O	O
00	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
004	O	O
)	O	O
,	O	O
tap	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
95	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
049	O	O
)	O	O
,	O	O
and	O	O
dna	O	O
sbs	O	O
(	O	O
r	O	O
=	O	O
-	O	O
0	O	O
.	O	O
95	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
049	O	O
)	O	O
.	O	O

dna	O	O
sbs	O	O
damage	O	O
was	O	O
negatively	O	O
associated	O	O
with	O	O
tap	O	O
(	O	O
r	O	O
=	O	O
-	O	O
0	O	O
.	O	O
98	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
018	O	O
)	O	O
,	O	O
and	O	O
necrosis	O	O
(	O	O
r	O	O
=	O	O
-	O	O
0	O	O
.	O	O
97	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
027	O	O
)	O	O
.	O	O

our	O	O
results	O	O
suggest	O	O
that	O	O
oxidative	O	O
damage	O	O
is	O	O
associated	O	O
with	O	O
acute	O	O
cardiotoxicity	O	O
induced	O	O
by	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
dox	B-chem	B-chem
only	O	O
.	O	O

increased	O	O
resistance	O	O
to	O	O
the	O	O
oxidative	O	O
stress	O	O
is	O	O
plausible	O	O
for	O	O
the	O	O
multiple	O	O
dose	O	O
of	O	O
dox	B-chem	B-chem
.	O	O

thus	O	O
,	O	O
different	O	O
mechanisms	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
acute	O	O
toxicity	O	O
versus	O	O
chronic	O	O
toxicity	O	O
.	O	O

tacrolimus	B-chem	B-chem
-	O	O
related	O	O
seizure	O	O
after	O	O
pediatric	O	O
liver	O	O
transplantation	O	O
-	O	O
-	O	O
a	O	O
single	O	O
-	O	O
center	O	O
experience	O	O
.	O	O

to	O	O
identify	O	O
the	O	O
risk	O	O
factors	O	O
for	O	O
new	O	O
-	O	O
onset	O	O
seizures	O	O
after	O	O
pediatric	O	O
lt	O	O
and	O	O
to	O	O
assess	O	O
their	O	O
clinical	O	O
implications	O	O
and	O	O
long	O	O
-	O	O
term	O	O
prognosis	O	O
.	O	O

the	O	O
clinical	O	O
and	O	O
laboratory	O	O
data	O	O
of	O	O
27	O	O
consecutive	O	O
children	O	O
who	O	O
underwent	O	O
lt	O	O
from	O	O
january	O	O
2007	O	O
to	O	O
december	O	O
2010	O	O
in	O	O
our	O	O
center	O	O
were	O	O
analyzed	O	O
retrospectively	O	O
.	O	O

patients	O	O
were	O	O
divided	O	O
into	O	O
seizures	O	O
group	O	O
and	O	O
a	O	O
non	O	O
-	O	O
seizures	O	O
group	O	O
.	O	O

pre	O	O
-	O	O
operative	O	O
,	O	O
intra	O	O
-	O	O
operative	O	O
,	O	O
and	O	O
post	O	O
-	O	O
operative	O	O
data	O	O
were	O	O
collected	O	O
.	O	O

seizures	O	O
occurred	O	O
in	O	O
four	O	O
children	O	O
,	O	O
an	O	O
incidence	O	O
of	O	O
14	O	O
.	O	O
8	O	O
%	O	O
.	O	O

all	O	O
exhibited	O	O
generalized	O	O
tonic	O	O
-	O	O
clonic	O	O
seizures	O	O
within	O	O
the	O	O
first	O	O
two	O	O
wk	O	O
after	O	O
lt	O	O
.	O	O

univariate	O	O
analysis	O	O
showed	O	O
that	O	O
the	O	O
risk	O	O
factors	O	O
associated	O	O
with	O	O
seizures	O	O
after	O	O
pediatric	O	O
lt	O	O
included	O	O
gender	O	O
,	O	O
pediatric	O	O
end	O	O
-	O	O
stage	O	O
liver	O	O
disease	O	O
score	O	O
before	O	O
surgery	O	O
,	O	O
child	O	O
-	O	O

pugh	O	O
score	O	O
before	O	O
surgery	O	O
,	O	O
serum	O	O
total	O	O
bilirubin	B-chem	B-chem
after	O	O
surgery	O	O
,	O	O
and	O	O
trough	O	O
tac	B-chem	B-chem
level	O	O
.	O	O

multivariate	O	O
analysis	O	O
showed	O	O
that	O	O
trough	O	O

tac	B-chem	B-chem
level	O	O
was	O	O
the	O	O
only	O	O
independent	O	O
risk	O	O
factor	O	O
associated	O	O
with	O	O
the	O	O
seizures	O	O
.	O	O

all	O	O
children	O	O
who	O	O
experienced	O	O
seizures	O	O
survived	O	O
with	O	O
good	O	O
graft	O	O
function	O	O
and	O	O
remained	O	O
seizure	O	O
-	O	O
free	O	O
without	O	O
anti	O	O
-	O	O
epileptic	O	O
drugs	O	O
over	O	O
a	O	O
mean	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
of	O	O
33	O	O
.	O	O
7	O	O
+	O	O
14	O	O
.	O	O
6	O	O
months	O	O
.	O	O

high	O	O
trough	O	O

tac	B-chem	B-chem
level	O	O
was	O	O
the	O	O
predominant	O	O
factor	O	O
that	O	O
contributed	O	O
to	O	O
seizures	O	O
in	O	O
the	O	O
early	O	O
post	O	O
-	O	O
operative	O	O
period	O	O
after	O	O
pediatric	O	O
lt	O	O
.	O	O

high	O	O
peld	O	O
and	O	O
child	O	O
-	O	O
pugh	O	O
scores	O	O
before	O	O
lt	O	O
and	O	O
high	O	O
post	O	O
-	O	O
operative	O	O
serum	O	O
tbil	O	B-chem
may	O	O
be	O	O
contributory	O	O
risk	O	O
factors	O	O
for	O	O
tac	B-chem	B-chem
-	O	O
related	O	O
seizures	O	O
.	O	O

the	O	O
flavonoid	B-chem	B-chem
apigenin	B-chem	O
delays	O	O
forgetting	O	O
of	O	O
passive	O	O
avoidance	O	O
conditioning	O	O
in	O	O
rats	O	O
.	O	O

the	O	O
present	O	O
experiments	O	O
were	O	O
performed	O	O
to	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
flavonoid	B-chem	B-chem
apigenin	B-chem	I-chem
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
intraperitoneally	O	O
(	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
,	O	O

1	O	O
h	O	O
before	O	O
acquisition	O	O
)	O	O
,	O	O
on	O	O
24	O	O
h	O	O
retention	O	O
performance	O	O
and	O	O
forgetting	O	O
of	O	O
a	O	O
step	O	O
-	O	O
through	O	O
passive	O	O
avoidance	O	O
task	O	O
,	O	O
in	O	O
young	O	O
male	O	O
wistar	O	O
rats	O	O
.	O	O

there	O	O
were	O	O
no	O	O
differences	O	O
between	O	O
saline	O	O
-	O	O
and	O	O
apigenin	B-chem	B-chem
-	O	O
treated	O	O
groups	O	O
in	O	O
the	O	O
24	O	O
h	O	O
retention	O	O
trial	O	O
.	O	O

furthermore	O	O
,	O	O
apigenin	B-chem	B-chem
did	O	O
not	O	O
prevent	O	O
the	O	O
amnesia	O	O
induced	O	O
by	O	O
scopolamine	B-chem	B-chem
(	O	O
1mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O

,	O	O
30	O	O
min	O	O
before	O	O
the	O	O
acquisition	O	O
)	O	O
.	O	O

the	O	O
saline	O	O
-	O	O
and	O	O
apigenin	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
that	O	O
did	O	O
not	O	O
step	O	O
through	O	O
into	O	O
the	O	O
dark	O	O
compartment	O	O
during	O	O
the	O	O
cut	O	O
-	O	O
off	O	O
time	O	O
(	O	O
540	O	O
s	O	O
)	O	O
were	O	O
retested	O	O
weekly	O	O
for	O	O
up	O	O
to	O	O
eight	O	O
weeks	O	O
.	O	O

in	O	O
the	O	O
saline	O	O
treated	O	O
group	O	O
,	O	O
the	O	O
first	O	O
significant	O	O
decline	O	O
in	O	O
passive	O	O
avoidance	O	O
response	O	O
was	O	O
observed	O	O
at	O	O
four	O	O
weeks	O	O
,	O	O
and	O	O
complete	O	O
memory	O	O
loss	O	O
was	O	O
found	O	O
five	O	O
weeks	O	O
after	O	O
the	O	O
acquisition	O	O
of	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
.	O	O

at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
experimental	O	O
period	O	O
,	O	O
60	O	O
%	O	O
of	O	O
the	O	O
animals	O	O
treated	O	O
with	O	O
apigenin	B-chem	B-chem
still	O	O
did	O	O
not	O	O
step	O	O
through	O	O
.	O	O

these	O	O
data	O	O
suggest	O	O
that	O	O
1	O	O
)	O	O
apigenin	B-chem	B-chem
delays	O	O
the	O	O
long	O	O
-	O	O
term	O	O
forgetting	O	O
but	O	O
did	O	O
not	O	O
modulate	O	O
the	O	O
24	O	O
h	O	O
retention	O	O
of	O	O
fear	O	O
memory	O	O
and	O	O
2	O	O
)	O	O
the	O	O
obtained	O	O
beneficial	O	O
effect	O	O
of	O	O
apigenin	B-chem	B-chem
on	O	O
the	O	O
passive	O	O
avoidance	O	O
conditioning	O	O
is	O	O
mediated	O	O
by	O	O
mechanisms	O	O
that	O	O
do	O	O
not	O	O
implicate	O	O
its	O	O
action	O	O
on	O	O
the	O	O
muscarinic	O	O
cholinergic	O	O
system	O	O
.	O	O

cholecystokinin	B-chem	B-chem
-	I-chem	I-chem
octapeptide	I-chem	I-chem
restored	O	O
morphine	B-chem	B-chem
-	O	O
induced	O	O
hippocampal	O	O
long	O	O
-	O	O
term	O	O
potentiation	O	O
impairment	O	O
in	O	O
rats	O	O
.	O	O

cholecystokinin	B-chem	B-chem
-	I-chem	I-chem
octapeptide	I-chem	I-chem
(	O	O
cck	B-chem	B-chem
-	I-chem	I-chem
8	I-chem	I-chem
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
typical	O	O
brain	O	O
-	O	O
gut	O	O
peptide	O	O
,	O	O
exerts	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
biological	O	O
activities	O	O
on	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

we	O	O
have	O	O
previously	O	O
reported	O	O
that	O	O
cck	B-chem	B-chem
-	I-chem	O
8	I-chem	I-chem
significantly	O	O
alleviated	O	O
morphine	B-chem	B-chem
-	O	O
induced	O	O
amnesia	O	O
and	O	O
reversed	O	O
spine	O	O
density	O	O
decreases	O	O
in	O	O
the	O	O
ca1	O	O
region	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
morphine	B-chem	B-chem
-	O	O
treated	O	O
animals	O	O
.	O	O

here	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
cck	B-chem	B-chem
-	I-chem	O
8	I-chem	O
on	O	O
long	O	O
-	O	O
term	O	O
potentiation	O	O
(	O	O
ltp	O	O
)	O	O
in	O	O
the	O	O
lateral	O	O
perforant	O	O
path	O	O
(	O	O
lpp	O	O
)	O	O
-	O	O
granule	O	O
cell	O	O
synapse	O	O
of	O	O
rat	O	O
dentate	O	O
gyrus	O	O
(	O	O
dg	O	O
)	O	O
in	O	O
acute	O	O
saline	O	O
or	O	O
morphine	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
.	O	O

population	O	O
spikes	O	O
(	O	O
ps	O	O
)	O	O
,	O	O
which	O	O
were	O	O
evoked	O	O
by	O	O
stimulation	O	O
of	O	O
the	O	O
lpp	O	O
,	O	O
were	O	O
recorded	O	O
in	O	O
the	O	O
dg	O	O
region	O	O
.	O	O

acute	O	O
morphine	B-chem	B-chem
(	O	O
30mg	O	B-chem
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O
c	O	O
.	O	O
)	O	O

treatment	O	O
significantly	O	O
attenuated	O	O
hippocampal	O	O
ltp	O	O
and	O	O
cck	B-chem	B-chem
-	I-chem	O
8	I-chem	O
(	O	O
1ug	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
.	O	O
)	O	O
restored	O	O
the	O	O
amplitude	O	O
of	O	O
ps	O	O
that	O	O
was	O	O
attenuated	O	O
by	O	O
morphine	B-chem	B-chem
injection	O	O
.	O	O

furthermore	O	O
,	O	O
microinjection	O	O
of	O	O
cck	B-chem	B-chem
-	I-chem	O
8	I-chem	I-chem
(	O	O
0	O	O
.	O	O
1	O	O
and	O	O
1ug	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
.	O	O
)	O	O

also	O	O
significantly	O	O
augmented	O	O
hippocampal	O	O
ltp	O	O
in	O	O
saline	O	O
-	O	O
treated	O	O
(	O	O
1ml	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O
c	O	O
.	O	O
)	O	O
rats	O	O
.	O	O

pre	O	O
-	O	O

treatment	O	O
of	O	O
the	O	O
cck2	O	B-chem
receptor	O	O
antagonist	O	O
l	O	O
-	O	O
365	O	I-chem
,	O	O
260	O	O
(	O	O
10ug	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
)	O	O
reversed	O	O
the	O	O
effects	O	O
of	O	O
cck	B-chem	B-chem
-	I-chem	O
8	I-chem	O
,	O	O
but	O	O
the	O	O
cck1	O	O
receptor	O	O
antagonist	O	O
l	O	B-chem
-	O	O
364	O	I-chem
,	O	O
718	O	O
(	O	O
10ug	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
)	O	O
did	O	O
not	O	O
.	O	O

the	O	O
present	O	O
results	O	O
demonstrate	O	O
that	O	O
cck	B-chem	O
-	I-chem	O
8	I-chem	O
attenuates	O	O
the	O	O
effect	O	O
of	O	O
morphine	B-chem	B-chem
on	O	O
hippocampal	O	O
ltp	O	O
through	O	O
cck2	O	O
receptors	O	O
and	O	O
suggest	O	O
an	O	O
ameliorative	O	O
function	O	O
of	O	O
cck	B-chem	B-chem
-	I-chem	O
8	I-chem	I-chem
on	O	O
morphine	B-chem	B-chem
-	O	O
induced	O	O
memory	O	O
impairment	O	O
.	O	O

glial	O	O
activation	O	O
and	O	O
post	O	O
-	O	O
synaptic	O	O
neurotoxicity	O	O
:	O	O
the	O	O
key	O	O
events	O	O
in	O	O
streptozotocin	B-chem	B-chem
(	O	O
icv	O	B-chem
)	O	O
induced	O	O
memory	O	O
impairment	O	O
in	O	O
rats	O	O
.	O	O

in	O	O
the	O	O
present	O	O
study	O	O
the	O	O
role	O	O
of	O	O
glial	O	O
activation	O	O
and	O	O
post	O	O
synaptic	O	O
toxicity	O	O
in	O	O
icv	O	B-chem
streptozotocin	B-chem	I-chem
(	O	O
stz	B-chem	B-chem
)	O	O
induced	O	O
memory	O	O
impaired	O	O
rats	O	O
was	O	O
explored	O	O
.	O	O

in	O	O
experiment	O	O
set	O	O
up	O	O
1	O	O
:	O	O
memory	O	O
deficit	O	O
was	O	O
found	O	O
in	O	O
morris	O	O
water	O	O
maze	O	O
test	O	O
on	O	O
14	O	O
-	O	O
16	O	O
days	O	O
after	O	O
stz	B-chem	O
(	O	O
icv	O	O
;	O	O
3mg	O	B-chem
/	O	O
kg	O	O
)	O	O
administration	O	O
.	O	O

stz	B-chem	O
causes	O	O
increased	O	O
expression	O	O
of	O	O
gfap	O	O
,	O	O
cd11b	O	O
and	O	O
tnf	O	O
-	O	O
a	O	O
indicating	O	O
glial	O	O
activation	O	O
and	O	O
neuroinflammation	O	O
.	O	O

stz	B-chem	O
also	O	O
significantly	O	O
increased	O	O
the	O	O
level	O	O
of	O	O
ros	O	O
,	O	O
nitrite	B-chem	B-chem
,	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
and	O	O
reduced	O	O
the	O	O
mitochondrial	O	O
activity	O	O
in	O	O
synaptosomal	O	O
preparation	O	O
illustrating	O	O
free	O	O
radical	O	O
generation	O	O
and	O	O
excitotoxicity	O	O
.	O	O

increased	O	O
expression	O	O
and	O	O
activity	O	O
of	O	O
caspase	O	O
-	O	O
3	O	O
was	O	O
also	O	O
observed	O	O
in	O	O
stz	B-chem	O
treated	O	O
rat	O	O
which	O	O
specify	O	O
apoptotic	O	O
cell	O	O
death	O	O
in	O	O
hippocampus	O	O
and	O	O
cortex	O	O
.	O	O

stz	B-chem	B-chem
treatment	O	O
showed	O	O
decrease	O	O
expression	O	O
of	O	O
post	O	O
synaptic	O	O
markers	O	O
camkiia	O	O
and	O	O
psd	O	O
-	O	O
95	O	O
,	O	O
while	O	O
,	O	O
expression	O	O
of	O	O
pre	O	O
synaptic	O	O
markers	O	O
(	O	O
synaptophysin	O	O
and	O	O
snap	O	O
-	O	O
25	O	O
)	O	O
remains	O	O
unaltered	O	O
indicating	O	O
selective	O	O
post	O	O
synaptic	O	O
neurotoxicity	O	O
.	O	O

oral	O	O
treatment	O	O
with	O	O
memantine	B-chem	B-chem
(	O	O
10mg	O	B-chem
/	O	O
kg	O	O
)	O	O
and	O	O
ibuprofen	B-chem	B-chem
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
daily	O	O
for	O	O
13	O	O
days	O	O
attenuated	O	O
stz	B-chem	O
induced	O	O
glial	O	O
activation	O	O
,	O	O
apoptotic	O	O
cell	O	O
death	O	O
and	O	O
post	O	O
synaptic	O	O
neurotoxicity	O	O
in	O	O
rat	O	O
brain	O	O
.	O	O

further	O	O
,	O	O
in	O	O
experiment	O	O
set	O	O
up	O	O
2	O	O
:	O	O
where	O	O
memory	O	O
function	O	O
was	O	O
not	O	O
affected	O	O
i	O	O
.	O	O
e	O	O
.	O	O
7	O	O
-	O	O
9	O	O
days	O	O
after	O	O
stz	B-chem	B-chem
treatment	O	O
.	O	O

the	O	O
level	O	O
of	O	O
gfap	O	O
,	O	O
cd11b	O	O
,	O	O
tnf	O	O
-	O	O
a	O	O
,	O	O
ros	O	O
and	O	O
nitrite	B-chem	B-chem
levels	O	O
were	O	O
increased	O	O
.	O	O

on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
apoptotic	O	O
marker	O	O
,	O	O
synaptic	O	O
markers	O	O
,	O	O
mitochondrial	O	O
activity	O	O
and	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
levels	O	O
remained	O	O
unaffected	O	O
.	O	O

collective	O	O
data	O	O
indicates	O	O
that	O	O
neuroinflammatory	O	O
process	O	O
and	O	O
oxidative	O	O
stress	O	O
occurs	O	O
earlier	O	O
to	O	O
apoptosis	O	O
and	O	O
does	O	O
not	O	O
affect	O	O
memory	O	O
function	O	O
.	O	O

present	O	O
study	O	O
clearly	O	O
suggests	O	O
that	O	O
glial	O	O
activation	O	O
and	O	O
post	O	O
synaptic	O	O
neurotoxicity	O	O
are	O	O
the	O	O
key	O	O
factors	O	O
in	O	O
stz	B-chem	O
induced	O	O
memory	O	O
impairment	O	O
and	O	O
neuronal	O	O
cell	O	O
death	O	O
.	O	O

comparison	O	O
of	O	O
effects	O	O
of	O	O
isotonic	O	O
sodium	B-chem	B-chem
chloride	I-chem	I-chem
with	O	O
diltiazem	B-chem	B-chem
in	O	O
prevention	O	O
of	O	O
contrast	B-chem	B-chem
-	O	O
induced	O	O
nephropathy	O	O
.	O	O

introduction	O	O
and	O	O
objective	O	O
:	O	O

contrast	B-chem	B-chem
-	O	O
induced	O	O
nephropathy	O	O
(	O	O
cin	O	O
)	O	O
significantly	O	O
increases	O	O
the	O	O
morbidity	O	O
and	O	O
mortality	O	O
of	O	O
patients	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
and	O	O
compare	O	O
the	O	O
protective	O	O
effects	O	O
of	O	O
isotonic	O	O
sodium	B-chem	B-chem
chloride	I-chem	I-chem
with	O	O
sodium	B-chem	B-chem
bicarbonate	I-chem	I-chem
infusion	O	O
and	O	O
isotonic	O	O
sodium	B-chem	B-chem
chloride	I-chem	I-chem
infusion	O	O
with	O	O
diltiazem	B-chem	B-chem
,	O	O
a	O	O
calcium	B-chem	B-chem
channel	O	O
blocker	O	O
,	O	O
in	O	O
preventing	O	O
cin	O	O
.	O	O

materials	O	O
and	O	O
methods	O	O
:	O	O

our	O	O
study	O	O
included	O	O
patients	O	O
who	O	O
were	O	O
administered	O	O
30	O	O
-	O	O
60	O	O
ml	O	O
of	O	O
iodinated	O	O
contrast	B-chem	O
agent	O	O
for	O	O
percutaneous	O	O
coronary	O	O
angiography	O	O
(	O	O
pcag	O	O
)	O	O
,	O	O
all	O	O
with	O	O
creatinine	B-chem	B-chem
values	O	O
between	O	O
1	O	O
.	O	O
1	O	O
and	O	O
3	O	O
.	O	O
1	O	O
mg	O	O
/	O	O
dl	O	O
.	O	O
patients	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
and	O	O
each	O	O
group	O	O
had	O	O
20	O	O
patients	O	O
.	O	O

the	O	O
first	O	O
group	O	O
of	O	O
patients	O	O
was	O	O
administered	O	O
isotonic	O	O
sodium	B-chem	B-chem
chloride	I-chem	I-chem
;	O	O
the	O	O
second	O	O
group	O	O
was	O	O
administered	O	O
a	O	O
solution	O	O
that	O	O
of	O	O
5	O	O
%	O	O
dextrose	B-chem	B-chem
and	O	O
sodium	B-chem	B-chem
bicarbonate	I-chem	I-chem
,	O	O
while	O	O
the	O	O
third	O	O
group	O	O
was	O	O
administered	O	O
isotonic	O	O
sodium	B-chem	B-chem
chloride	I-chem	I-chem
before	O	O
and	O	O
after	O	O
the	O	O
contrast	B-chem	O
injection	O	O
.	O	O

the	O	O
third	O	O
group	O	O
received	O	O
an	O	O
additional	O	O
injection	O	O
of	O	O
diltiazem	B-chem	B-chem
the	O	O
day	O	O
before	O	O
and	O	O
first	O	O
2	O	O
days	O	O
after	O	O
the	O	O
contrast	B-chem	O
injection	O	O
.	O	O

all	O	O
of	O	O
the	O	O
patients	O	O
'	O	O
plasma	O	O
blood	B-chem	B-chem
urea	I-chem	I-chem
nitrogen	I-chem	I-chem
(	O	O
bun	B-chem	B-chem
)	O	O
and	O	O
creatinine	B-chem	B-chem
levels	O	O
were	O	O
measured	O	O
on	O	O
the	O	O
second	O	O
and	O	O
seventh	O	O
day	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
intravenous	O	O
contrast	B-chem	O
material	O	O
.	O	O

results	O	O
:	O	O

the	O	O
basal	O	O
creatinine	B-chem	B-chem
levels	O	O
were	O	O
similar	O	O
for	O	O
all	O	O
three	O	O
groups	O	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

among	O	O
a	O	O
total	O	O
of	O	O
60	O	O
patients	O	O
included	O	O
in	O	O
the	O	O
study	O	O
,	O	O
16	O	O
patients	O	O
developed	O	O
acute	O	O
renal	O	O
failure	O	O
(	O	O
arf	O	O
)	O	O
on	O	O
the	O	O
second	O	O
day	O	O
after	O	O
contrast	B-chem	O
material	O	O
was	O	O
injected	O	O
(	O	O
26	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

the	O	O
number	O	O
of	O	O
patients	O	O
who	O	O
developed	O	O
arf	O	O
on	O	O
the	O	O
second	O	O
day	O	O
after	O	O
the	O	O
injection	O	O
in	O	O
the	O	O
first	O	O
group	O	O
was	O	O
five	O	O
(	O	O
25	O	O
%	O	O
)	O	O
,	O	O
in	O	O
the	O	O
second	O	O
group	O	O
was	O	O
six	O	O
(	O	O
30	O	O
%	O	O
)	O	O
and	O	O
the	O	O
third	O	O
group	O	O
was	O	O
five	O	O
(	O	O
25	O	O
%	O	O
)	O	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

there	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
isotonic	O	O
sodium	B-chem	B-chem
chloride	I-chem	I-chem
,	O	O
sodium	B-chem	B-chem
bicarbonate	I-chem	I-chem
and	O	O
isotonic	O	O
sodium	B-chem	B-chem
chloride	I-chem	I-chem
with	O	O
diltiazem	B-chem	B-chem
application	O	O
in	O	O
prevention	O	O
of	O	O
cin	O	O
.	O	O

neurocognitive	O	O
and	O	O
neuroradiologic	O	O
central	O	O
nervous	O	O
system	O	O
late	O	O
effects	O	O
in	O	O
children	O	O
treated	O	O
on	O	O
pediatric	O	O
oncology	O	O
group	O	O
(	O	O
pog	O	B-chem
)	O	O
p9605	O	O
(	O	O
standard	O	O
risk	O	O
)	O	O
and	O	O
p9201	O	O
(	O	O
lesser	O	O
risk	O	O
)	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
protocols	O	O
(	O	O
accl0131	O	O
)	O	O
:	O	O
a	O	O
methotrexate	B-chem	B-chem
consequence	O	O
?	O	O

a	O	O
report	O	O
from	O	O
the	O	O
children	O	O
'	O	O
s	O	O
oncology	O	O
group	O	O
.	O	O

concerns	O	O
about	O	O
long	O	O
-	O	O
term	O	O
methotrexate	B-chem	B-chem
(	O	O
mtx	B-chem	B-chem
)	O	O
neurotoxicity	O	O
in	O	O
the	O	O
1990s	O	O
led	O	O
to	O	O
modifications	O	O
in	O	O
intrathecal	O	O
(	O	O
it	O	O
)	O	O
therapy	O	O
,	O	O
leucovorin	O	B-chem
rescue	O	O
,	O	O
and	O	O
frequency	O	O
of	O	O
systemic	O	O
mtx	B-chem	B-chem
administration	O	O
in	O	O
children	O	O
with	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
.	O	O

in	O	O
this	O	O
study	O	O
,	O	O
neurocognitive	O	O
outcomes	O	O
and	O	O
neuroradiologic	O	O
evidence	O	O
of	O	O
leukoencephalopathy	O	O
were	O	O
compared	O	O
in	O	O
children	O	O
treated	O	O
with	O	O
intense	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
cns	O	O
)	O	O
-	O	O
directed	O	O
therapy	O	O
(	O	O
p9605	O	O
)	O	O
versus	O	O
those	O	O
receiving	O	O
fewer	O	O
cns	O	O
-	O	O
directed	O	O
treatment	O	O
days	O	O
during	O	O
intensive	O	O
consolidation	O	O
(	O	O
p9201	O	O
)	O	O
.	O	O

a	O	O
total	O	O
of	O	O
66	O	O
children	O	O
from	O	O
16	O	O
pediatric	O	O
oncology	O	O
group	O	O
institutions	O	O
with	O	O
"	O	O
"	O	O
"	O	O
"	O	O
standard	O	O
-	O	O
risk	O	O
"	O	O
"	O	O
"	O	O
"	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
,	O	O
1	O	O
.	O	O
00	O	O
to	O	O
9	O	O
.	O	O
99	O	O
years	O	O
at	O	O
diagnosis	O	O
,	O	O
without	O	O
evidence	O	O
of	O	O
cns	O	O
leukemia	O	O
at	O	O
diagnosis	O	O
were	O	O
enrolled	O	O
on	O	O
accl0131	O	O
:	O	O
28	O	O
from	O	O
p9201	O	O
and	O	O
38	O	O
from	O	O
p9605	O	O
.	O	O

magnetic	O	O
resonance	O	O
imaging	O	O
scans	O	O
and	O	O
standard	O	O
neuropsychological	O	O
tests	O	O
were	O	O
performed	O	O
>	O	O
2	O	O
.	O	O
6	O	O
years	O	O
after	O	O
the	O	O
end	O	O
of	O	O
treatment	O	O
.	O	O

significantly	O	O
more	O	O
p9605	O	O
patients	O	O
developed	O	O
leukoencephalopathy	O	O
compared	O	O
with	O	O
p9201	O	O
patients	O	O
(	O	O
68	O	O
%	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
49	O	O
%	O	O
-	O	O
83	O	O
%	O	O
vs	O	O
.	O	O
22	O	O
%	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
5	O	O
%	O	O
-	O	O
44	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
identified	O	O
as	O	O
late	O	O
as	O	O
7	O	O
.	O	O
7	O	O
years	O	O
after	O	O
the	O	O
end	O	O
of	O	O
treatment	O	O
.	O	O

overall	O	O
,	O	O
40	O	O
%	O	O
of	O	O
patients	O	O
scored	O	O
<	O	O
85	O	O
on	O	O
either	O	O
verbal	O	O
or	O	O
performance	O	O
iq	O	O
.	O	O

children	O	O
on	O	O
both	O	O
studies	O	O
had	O	O
significant	O	O
attention	O	O
problems	O	O
,	O	O
but	O	O
p9605	O	O
children	O	O
scored	O	O
below	O	O
average	O	O
on	O	O
more	O	O
neurocognitive	O	O
measures	O	O
than	O	O
those	O	O
treated	O	O
on	O	O
p9201	O	O
(	O	O
82	O	O
%	O	O
,	O	O
14	O	O
/	O	O
17	O	O
measures	O	O
vs	O	O
.	O	O
24	O	O
%	O	O
,	O	O
4	O	O
/	O	O
17	O	O
measures	O	O
)	O	O
.	O	O

this	O	O
supports	O	O
ongoing	O	O
concerns	O	O
about	O	O
intensive	O	O
mtx	B-chem	B-chem
exposure	O	O
as	O	O
a	O	O
major	O	O
contributor	O	O
to	O	O
cns	O	O
late	O	O
effects	O	O
.	O	O

tranexamic	B-chem	B-chem
acid	I-chem	I-chem
overdosage	O	O
-	O	O
induced	O	O
generalized	O	O
seizure	O	O
in	O	O
renal	O	O
failure	O	O
.	O	O

we	O	O
report	O	O
a	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
lady	O	O
with	O	O
chronic	O	O
kidney	O	O
disease	O	O
stage	O	O
4	O	O
due	O	O
to	O	O
chronic	O	O
tubulointerstial	O	O
disease	O	O
.	O	O

she	O	O
was	O	O
admitted	O	O
to	O	O
our	O	O
center	O	O
for	O	O
severe	O	O
anemia	O	O
due	O	O
to	O	O
menorrhagia	O	O
and	O	O
deterioration	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

she	O	O
was	O	O
infused	O	O
three	O	O
units	O	O
of	O	O
packed	O	O
cells	O	O
during	O	O
a	O	O
session	O	O
of	O	O
hemodialysis	O	O
.	O	O

tranexamic	B-chem	B-chem
acid	I-chem	I-chem
(	O	O
tna	B-chem	O
)	O	O

1	O	O
g	O	O
8	O	O
-	O	O
hourly	O	O
was	O	O
administered	O	O
to	O	O
her	O	O
to	O	O
control	O	O
bleeding	O	O
per	O	O
vaginum	O	O
.	O	O

two	O	O
hours	O	O
after	O	O
the	O	O
sixth	O	O
dose	O	O
of	O	O
tna	B-chem	O
,	O	O
she	O	O
had	O	O
an	O	O
episode	O	O
of	O	O
generalized	O	O
tonic	O	O
clonic	O	O
convulsions	O	O
.	O	O

tna	B-chem	O
was	O	O
discontinued	O	O
.	O	O

investigations	O	O
of	O	O
the	O	O
patient	O	O
revealed	O	O
no	O	O
biochemical	O	O
or	O	O
structural	O	O
central	O	O
nervous	O	O
system	O	O
abnormalities	O	O
that	O	O
could	O	O
have	O	O
provoked	O	O
the	O	O
convulsions	O	O
.	O	O

she	O	O
did	O	O
not	O	O
require	O	O
any	O	O
further	O	O
dialytic	O	O
support	O	O
.	O	O

she	O	O
had	O	O
no	O	O
further	O	O
episodes	O	O
of	O	O
convulsion	O	O
till	O	O
dis	O	O
-	O	O
charge	O	O
and	O	O
during	O	O
the	O	O
two	O	O
months	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

thus	O	O
,	O	O
the	O	O
precipitating	O	O
cause	O	O
of	O	O
convulsions	O	O
was	O	O
believed	O	O
to	O	O
be	O	O
an	O	O
overdose	O	O
of	O	O
tna	B-chem	O
.	O	O

pre	O	O
-	O	O
treatment	O	O
of	O	O
bupivacaine	B-chem	B-chem
-	O	O
induced	O	O
cardiovascular	O	O
depression	O	O
using	O	O
different	O	O
lipid	O	O
formulations	O	O
of	O	O
propofol	B-chem	B-chem
.	O	O

background	O	O
:	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
lipid	O	O
emulsions	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
increase	O	O
lethal	O	O
doses	O	O
of	O	O
bupivacaine	B-chem	B-chem
,	O	O
and	O	O
the	O	O
lipid	O	O
content	O	O
of	O	O
propofol	B-chem	B-chem
may	O	O
alleviate	O	O
bupivacaine	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
propofol	B-chem	B-chem
in	O	O
intralipid	O	B-chem
or	O	O
medialipid	O	O
emulsions	O	O
on	O	O
bupivacaine	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
.	O	O

methods	O	O
:	O	O

rats	O	O
were	O	O
anaesthetised	O	O
with	O	O
ketamine	B-chem	B-chem
and	O	O
were	O	O
given	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
propofol	B-chem	B-chem
in	O	O
intralipid	O	B-chem
(	O	O
group	O	O
p	O	O
)	O	O
,	O	O
propofol	B-chem	B-chem
in	O	O
medialipid	O	O
(	O	O
group	O	O
l	O	O
)	O	O
,	O	O
or	O	O
saline	O	O
(	O	O
group	O	O
c	O	O
)	O	O
over	O	O
20	O	O
min	O	O
.	O	O

thereafter	O	O
,	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
bupivacaine	B-chem	B-chem
0	O	O
.	O	O
5	O	O
%	O	O
was	O	O
infused	O	O
.	O	O

we	O	O
recorded	O	O
time	O	O
to	O	O
first	O	O
dysrhythmia	O	O
occurrence	O	O
,	O	O
respective	O	O
times	O	O
to	O	O
25	O	O
%	O	O
and	O	O
50	O	O
%	O	O
reduction	O	O
of	O	O
the	O	O
heart	O	O
rate	O	O
(	O	O
hr	O	O
)	O	O
and	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
and	O	O
time	O	O
to	O	O
asystole	O	O
and	O	O
total	O	O
amount	O	O
of	O	O
bupivacaine	B-chem	B-chem
consumption	O	O
.	O	O

blood	O	O
and	O	O
tissue	O	O
samples	O	O
were	O	O
collected	O	O
following	O	O
asystole	O	O
.	O	O

results	O	O
:	O	O

the	O	O
time	O	O
to	O	O
first	O	O
dysrhythmia	O	O
occurrence	O	O
,	O	O
time	O	O
to	O	O
25	O	O
%	O	O
and	O	O
50	O	O
%	O	O
reductions	O	O
in	O	O
hr	O	O
,	O	O
and	O	O
time	O	O
to	O	O
asystole	O	O
were	O	O
longer	O	O
in	O	O
group	O	O
p	O	O
than	O	O
the	O	O
other	O	O
groups	O	O
.	O	O

the	O	O
cumulative	O	O
bupivacaine	B-chem	B-chem
dose	O	O
given	O	O
at	O	O
those	O	O
time	O	O
points	O	O
was	O	O
higher	O	O
in	O	O
group	O	O
p	O	O
.	O	O
plasma	O	O
bupivacaine	B-chem	B-chem
levels	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
p	O	O
than	O	O
in	O	O
group	O	O
c	O	O
.	O	O
bupivacaine	B-chem	B-chem
levels	O	O
in	O	O
the	O	O
brain	O	O
and	O	O
heart	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
p	O	O
and	O	O
group	O	O
l	O	O
than	O	O
in	O	O
group	O	O
c	O	O
.	O	O
conclusion	O	O
:	O	O

we	O	O
conclude	O	O
that	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
propofol	B-chem	B-chem
in	O	O
intralipid	O	O
,	O	O
compared	O	O
with	O	O
propofol	B-chem	B-chem
in	O	O
medialipid	O	B-chem
or	O	O
saline	O	O
,	O	O
delayed	O	O
the	O	O
onset	O	O
of	O	O
bupivacaine	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxic	O	O
effects	O	O
as	O	O
well	O	O
as	O	O
reduced	O	O
plasma	O	O
bupivacaine	B-chem	B-chem
levels	O	O
.	O	O

further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
explore	O	O
tissue	O	O
bupivacaine	B-chem	B-chem
levels	O	O
of	O	O
propofol	B-chem	B-chem
in	O	O
medialipid	O	O
and	O	O
adapt	O	O
these	O	O
results	O	O
to	O	O
clinical	O	O
practice	O	O
.	O	O

drug	O	O
-	O	O
induced	O	O
acute	O	O
liver	O	O
injury	O	O

within	O	O
12	O	O
hours	O	O

after	O	O
fluvastatin	B-chem	B-chem
therapy	O	O
.	O	O

although	O	O
statins	B-chem	B-chem
are	O	O
generally	O	O
well	O	O
-	O	O
tolerated	O	O
drugs	O	O
,	O	O
recent	O	O
cases	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
liver	O	O
injury	O	O
associated	O	O
with	O	O
their	O	O
use	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

a	O	O
52	O	O
-	O	O
year	O	O
-	O	O
old	O	O
chinese	O	O
man	O	O
reported	O	O
with	O	O
liver	O	O
damage	O	O
,	O	O
which	O	O
appeared	O	O
12	O	O
hours	O	O
after	O	O
beginning	O	O
treatment	O	O
with	O	O
fluvastatin	B-chem	B-chem
.	O	O

patient	O	O
presented	O	O
with	O	O
complaints	O	O
of	O	O
increasing	O	O
nausea	O	O
,	O	O
anorexia	O	O
,	O	O
and	O	O
upper	O	O
abdominal	O	O
pain	O	O
.	O	O

his	O	O
laboratory	O	O
values	O	O
showed	O	O
elevated	O	O
creatine	B-chem	B-chem
kinase	O	O
and	O	O
transaminases	O	O
.	O	O

testing	O	O
for	O	O
autoantibodies	O	O
was	O	O
also	O	O
negative	O	O
.	O	O

the	O	O
liver	O	O
biochemistries	O	O
eventually	O	O
normalized	O	O
within	O	O
3	O	O
weeks	O	O
of	O	O
stopping	O	O
the	O	O
fluvastatin	B-chem	B-chem
.	O	O

therefore	O	O
,	O	O
when	O	O
prescribing	O	O
statins	O	B-chem
,	O	O
the	O	O
possibility	O	O
of	O	O
hepatic	O	O
damage	O	O
should	O	O
be	O	O
taken	O	O
into	O	O
account	O	O
.	O	O

fluconazole	B-chem	B-chem
associated	O	O
agranulocytosis	O	O
and	O	O
thrombocytopenia	O	O
.	O	O

case	O	O
:	O	O

we	O	O
describe	O	O
a	O	O
second	O	O
case	O	O
of	O	O
fluconazole	B-chem	B-chem
associated	O	O
agranulocytosis	O	O
with	O	O
thrombocytopenia	O	O
and	O	O
recovery	O	O
upon	O	O
discontinuation	O	O
of	O	O
therapy	O	O
.	O	O

the	O	O
patient	O	O
began	O	O
to	O	O
have	O	O
changes	O	O
in	O	O
white	O	O
blood	O	O
cells	O	O
and	O	O
platelets	O	O
within	O	O
48	O	O
h	O	O
of	O	O
administration	O	O
of	O	O
fluconazole	B-chem	B-chem
and	O	O
began	O	O
to	O	O
recover	O	O
with	O	O
48	O	O
h	O	O
of	O	O
discontinuation	O	O
.	O	O

this	O	O
case	O	O
highlights	O	O
that	O	O
drug	O	O
-	O	O
induced	O	O
blood	O	O
dyscrasias	O	O
can	O	O
occur	O	O
unexpectedly	O	O
as	O	O
a	O	O
result	O	O
of	O	O
treatment	O	O
with	O	O
a	O	O
commonly	O	O
used	O	O
drug	O	O
thought	O	O
to	O	O
be	O	O
"	O	O
"	O	O
"	O	O
"	O	O
safe	O	O
"	O	O
"	O	O
"	O	O
"	O	O
.	O	O

conclusion	O	O
:	O	O

according	O	O
to	O	O
naranjo	O	O
'	O	O
s	O	O
algorithm	O	O
the	O	O
likelihood	O	O
that	O	O
our	O	O
patient	O	O
'	O	O
s	O	O
agranulocytosis	O	O
and	O	O
thrombocytopenia	O	O
occurred	O	O
as	O	O
a	O	O
result	O	O
of	O	O
therapy	O	O
with	O	O
fluconazole	B-chem	B-chem
is	O	O
probable	O	O
,	O	O
with	O	O
a	O	O
total	O	O
of	O	O
six	O	O
points	O	O
.	O	O

we	O	O
feel	O	O
that	O	O
the	O	O
weight	O	O
of	O	O
the	O	O
overall	O	O
evidence	O	O
of	O	O
this	O	O
evidence	O	O
is	O	O
strong	O	O
.	O	O

in	O	O
particular	O	O
the	O	O
temporal	O	O
relationship	O	O
of	O	O
bone	O	O
marrow	O	O
suppression	O	O
to	O	O
the	O	O
initiation	O	O
of	O	O
fluconazole	B-chem	B-chem
and	O	O
the	O	O
abatement	O	O
of	O	O
symptoms	O	O
that	O	O
rapidly	O	O
reversed	O	O
immediately	O	O
following	O	O
discontinuation	O	O
.	O	O

two	O	O
-	O	O
dimensional	O	O
speckle	O	O
tracking	O	O
echocardiography	O	O
combined	O	O
with	O	O
high	O	O
-	O	O
sensitive	O	O
cardiac	O	O
troponin	O	O
t	O	O
in	O	O
early	O	O
detection	O	O
and	O	O
prediction	O	O
of	O	O
cardiotoxicity	O	O
during	O	O
epirubicine	B-chem	B-chem
-	O	O
based	O	O
chemotherapy	O	O
.	O	O

aims	O	O
:	O	O

to	O	O
investigate	O	O
whether	O	O
alterations	O	O
of	O	O
myocardial	O	O
strain	O	O
and	O	O
high	O	O
-	O	O
sensitive	O	O
cardiac	O	O
troponin	O	O
t	O	O
(	O	O
ctnt	O	O
)	O	O
could	O	O
predict	O	O
future	O	O
cardiac	O	O
dysfunction	O	O
in	O	O
patients	O	O
after	O	O
epirubicin	B-chem	B-chem
exposure	O	O
.	O	O

methods	O	O
:	O	O
seventy	O	O
-	O	O
five	O	O
patients	O	O
with	O	O
non	O	O
-	O	O
hodgkin	O	O
lymphoma	O	O
treated	O	O
with	O	O
epirubicin	B-chem	B-chem
were	O	O
studied	O	O
.	O	O

blood	O	O
collection	O	O
and	O	O
echocardiography	O	O
were	O	O
performed	O	O
at	O	O
baseline	O	O
,	O	O
1	O	O
day	O	O
after	O	O
the	O	O
third	O	O
cycle	O	O
,	O	O
and	O	O
1	O	O
day	O	O
after	O	O
completion	O	O
of	O	O
chemotherapy	O	O
.	O	O

patients	O	O
were	O	O
studied	O	O
using	O	O
echocardiography	O	O
during	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

global	O	O
longitudinal	O	O
(	O	O
gls	O	O
)	O	O
,	O	O
circumferential	O	O
(	O	O
gcs	O	O
)	O	O
,	O	O
and	O	O
radial	O	O
strain	O	O
(	O	O
grs	O	O
)	O	O
were	O	O
calculated	O	O
using	O	O
speckle	O	O
tracking	O	O
echocardiography	O	O
.	O	O

left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
was	O	O
analysed	O	O
by	O	O
real	O	O
-	O	O
time	O	O
3d	O	O
echocardiography	O	O
.	O	O

cardiotoxicity	O	O
was	O	O
defined	O	O
as	O	O
a	O	O
reduction	O	O
of	O	O
the	O	O
lvef	O	O
of	O	O
>	O	O
5	O	O
%	O	O
to	O	O
<	O	O
55	O	O
%	O	O
with	O	O
symptoms	O	O
of	O	O
heart	O	O
failure	O	O
or	O	O
an	O	O
asymptomatic	O	O
reduction	O	O
of	O	O
the	O	O
lvef	O	O
of	O	O
>	O	O
10	O	O
%	O	O
to	O	O
<	O	O
55	O	O
%	O	O
.	O	O

results	O	O
:	O	O

fourteen	O	O
patients	O	O
(	O	O
18	O	O
.	O	O
67	O	O
%	O	O
)	O	O
developed	O	O
cardiotoxicity	O	O
after	O	O
treatment	O	O
.	O	O

gls	O	B-chem
(	O	O
-	O	O
18	O	O
.	O	O
48	O	O
+	O	O
1	O	O
.	O	O
72	O	O
%	O	O
vs	O	O
.	O	O
-	O	O
15	O	O
.	O	O
96	O	O
+	O	O
1	O	O
.	O	O
6	O	O
%	O	O
)	O	O
,	O	O
gcs	O	O
(	O	O
-	O	O
20	O	O
.	O	O
93	O	O
+	O	O
2	O	O
.	O	O
86	O	O
%	O	O
vs	O	O
.	O	O
-	O	O
19	O	O
.	O	O
20	O	O
+	O	O
3	O	O
.	O	O
21	O	O
%	O	O
)	O	O
,	O	O
and	O	O
grs	O	O
(	O	O
39	O	O
.	O	O
23	O	O
+	O	O
6	O	O
.	O	O
44	O	O
%	O	O
vs	O	O
.	O	O
34	O	O
.	O	O
98	O	O
+	O	O
6	O	O
.	O	O
2	O	O
%	O	O
)	O	O
were	O	O
markedly	O	O
reduced	O	O
and	O	O
ctnt	O	O
was	O	O
elevated	O	O
from	O	O
0	O	O
.	O	O
0010	O	O
+	O	O
0	O	O
.	O	O
0020	O	O
to	O	O
0	O	O
.	O	O
0073	O	O
+	O	O
0	O	O
.	O	O
0038	O	O
ng	O	O
/	O	O
ml	O	O
(	O	O
p	O	O
all	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
at	O	O
the	O	O
completion	O	O
of	O	O
chemotherapy	O	O
compared	O	O
with	O	O
baseline	O	O
values	O	O
.	O	O

a	O	O
>	O	O
15	O	O
.	O	O
9	O	O
%	O	O
decrease	O	O
in	O	O
gls	O	O
[	O	O
sensitivity	O	O
,	O	O
86	O	O
%	O	O
;	O	O
specificity	O	O
,	O	O
75	O	O
%	O	O
;	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
(	O	O
auc	O	O
)	O	O
=	O	O

0	O	O
.	O	O
815	O	O

;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
001	O	O
]	O	O
and	O	O
a	O	O
>	O	O
0	O	O
.	O	O
004	O	O
ng	O	O
/	O	O
ml	O	O
elevation	O	O
in	O	O
ctnt	O	O

(	O	O
sensitivity	O	O
,	O	O
79	O	O
%	O	O
;	O	O
specificity	O	O
,	O	O
64	O	O
%	O	O
;	O	O
auc	O	O
=	O	O
0	O	O
.	O	O
757	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
005	O	O
)	O	O
from	O	O
baseline	O	O
to	O	O
the	O	O
third	O	O
cycle	O	O
of	O	O
chemotherapy	O	O
predicted	O	O
later	O	O
cardiotoxicity	O	O
.	O	O

the	O	O
decrease	O	O
in	O	O
gls	O	B-chem
remained	O	O
the	O	O
only	O	O
independent	O	O
predictor	O	O
of	O	O
cardiotoxicity	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
000	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

gls	O	B-chem
combined	O	O
with	O	O
ctnt	O	O
may	O	O
provide	O	O
a	O	O
reliable	O	O
and	O	O
non	O	O
-	O	O
invasive	O	O
method	O	O
to	O	O
predict	O	O
cardiac	O	O
dysfunction	O	O
in	O	O
patients	O	O
receiving	O	O
anthracycline	B-chem	B-chem
-	O	O
based	O	O
chemotherapy	O	O
.	O	O

prevention	O	O
of	O	O
etomidate	B-chem	B-chem
-	O	O
induced	O	O
myoclonus	O	O
:	O	O
which	O	O
is	O	O
superior	O	O
:	O	O
fentanyl	B-chem	B-chem
,	O	O
midazolam	B-chem	B-chem
,	O	O
or	O	O
a	O	O
combination	O	O
?	O	O

a	O	O
retrospective	O	O
comparative	O	O
study	O	O
.	O	O

background	O	O
:	O	O

in	O	O
this	O	O
retrospective	O	O
comparative	O	O
study	O	O
,	O	O
we	O	O
aimed	O	O
to	O	O
compare	O	O
the	O	O
effectiveness	O	O
of	O	O
fentanyl	B-chem	B-chem
,	O	O
midazolam	B-chem	B-chem
,	O	O
and	O	O
a	O	O
combination	O	O
of	O	O
fentanyl	B-chem	B-chem
and	O	O
midazolam	B-chem	B-chem
to	O	O
prevent	O	O
etomidate	B-chem	B-chem
-	O	O
induced	O	O
myoclonus	O	O
.	O	O

material	O	O
and	O	O
methods	O	O
:	O	O

this	O	O
study	O	O
was	O	O
performed	O	O
based	O	O
on	O	O
anesthesia	O	O
records	O	O
.	O	O

depending	O	O
on	O	O
the	O	O
drugs	O	O
that	O	O
would	O	O
be	O	O
given	O	O
before	O	O
the	O	O
induction	O	O
of	O	O
anesthesia	O	O
with	O	O
etomidate	B-chem	B-chem
,	O	O
the	O	O
patients	O	O
were	O	O
separated	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
no	O	O
pretreatment	O	O
(	O	O
group	O	O
np	O	O
)	O	O
,	O	O
fentanyl	B-chem	B-chem
1	O	O
ug	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
(	O	O
group	O	O
f	O	O
)	O	O
,	O	O
midazolam	B-chem	B-chem
0	O	O
.	O	O
03	O	O
mg	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
(	O	O
group	O	O
m	O	O
)	O	O
,	O	O
and	O	O
midazolam	B-chem	B-chem
0	O	O
.	O	O
015	O	O
mg	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
+	O	O
fentanyl	B-chem	B-chem
0	O	O
.	O	O
5	O	O
ug	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
(	O	O
group	O	O
fm	O	O
)	O	O
.	O	O

patients	O	O
who	O	O
received	O	O
the	O	O
same	O	O
anesthetic	O	O
procedure	O	O
were	O	O
selected	O	O
:	O	O
2	O	O
minutes	O	O
after	O	O
intravenous	O	O
injections	O	O
of	O	O
the	O	O
pretreatment	O	O
drugs	O	O
,	O	O
anesthesia	O	O
is	O	O
induced	O	O
with	O	O
0	O	O
.	O	O
3	O	O
mg	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
etomidate	B-chem	B-chem
injected	O	O
intravenously	O	O
over	O	O
a	O	O
period	O	O
of	O	O
20	O	O
-	O	O
30	O	O
seconds	O	O
.	O	O

myoclonic	O	O
movements	O	O
are	O	O
evaluated	O	O
,	O	O
which	O	O
were	O	O
observed	O	O
and	O	O
graded	O	O
according	O	O
to	O	O
clinical	O	O
severity	O	O
during	O	O
the	O	O
2	O	O
minutes	O	O
after	O	O
etomidate	B-chem	B-chem
injection	O	O
.	O	O

the	O	O
severity	O	O
of	O	O
pain	O	O
due	O	O
to	O	O
etomidate	B-chem	B-chem
injection	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
adverse	O	O
effects	O	O
were	O	O
also	O	O
evaluated	O	O
.	O	O

results	O	O
:	O	O

study	O	O
results	O	O
showed	O	O
that	O	O
myoclonus	O	O
incidence	O	O
was	O	O
85	O	O
%	O	O
,	O	O
40	O	O
%	O	O
,	O	O
70	O	O
%	O	O
,	O	O
and	O	O
25	O	O
%	O	O
in	O	O
group	O	O
np	O	O
,	O	O
group	O	O
f	O	O
,	O	O
group	O	O
m	O	O
,	O	O
and	O	O
group	O	O
fm	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
group	O	O
f	O	O
and	O	O
group	O	O
fm	O	O
.	O	O

conclusions	O	O
:	O	O

we	O	O
conclude	O	O
that	O	O
pretreatment	O	O
with	O	O
fentanyl	B-chem	B-chem
or	O	O
combination	O	O
of	O	O
fentanyl	B-chem	B-chem
and	O	O
midazolam	B-chem	B-chem
was	O	O
effective	O	O
in	O	O
preventing	O	O
etomidate	B-chem	B-chem
-	O	O
induced	O	O
myoclonus	O	O
.	O	O

cholestatic	O	O
presentation	O	O
of	O	O
yellow	O	B-chem
phosphorus	B-chem	I-chem
poisoning	O	O
.	O	O

yellow	O	O
phosphorus	B-chem	I-chem
,	O	O
a	O	O
component	O	O
of	O	O
certain	O	O
pesticide	O	O
pastes	O	O
and	O	O
fireworks	O	O
,	O	O
is	O	O
well	O	O
known	O	O
to	O	O
cause	O	O
hepatotoxicity	O	O
.	O	O

poisoning	O	O
with	O	O
yellow	O	B-chem
phosphorus	B-chem	I-chem
classically	O	O
manifests	O	O
with	O	O
acute	O	O
hepatitis	O	O
leading	O	O
to	O	O
acute	O	O
liver	O	O
failure	O	O
which	O	O
may	O	O
need	O	O
liver	O	O
transplantation	O	O
.	O	O

we	O	O
present	O	O
a	O	O
case	O	O
of	O	O
yellow	O	O
phosphorus	B-chem	I-chem
poisoning	O	O
in	O	O
which	O	O
a	O	O
patient	O	O
presented	O	O
with	O	O
florid	O	O
clinical	O	O
features	O	O
of	O	O
cholestasis	O	O
highlighting	O	O
the	O	O
fact	O	O
that	O	O
cholestasis	O	O
can	O	O
rarely	O	O
be	O	O
a	O	O
presenting	O	O
feature	O	O
of	O	O
yellow	O	O
phosphorus	B-chem	O
hepatotoxicity	O	O
.	O	O

vasovagal	O	O
syncope	O	O
and	O	O
severe	O	O
bradycardia	O	O
following	O	O
intranasal	O	O
dexmedetomidine	B-chem	B-chem
for	O	O
pediatric	O	O
procedural	O	O
sedation	O	O
.	O	O

we	O	O
report	O	O
syncope	O	O
and	O	O
bradycardia	O	O
in	O	O
an	O	O
11	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
following	O	O
administration	O	O
of	O	O
intranasal	O	O
dexmedetomidine	B-chem	B-chem
for	O	O
sedation	O	O
for	O	O
a	O	O
voiding	O	O
cystourethrogram	O	O
.	O	O

following	O	O
successful	O	O
completion	O	O
of	O	O
vcug	O	B-chem
and	O	O
a	O	O
60	O	O
-	O	O
min	O	O
recovery	O	O
period	O	O
,	O	O
the	O	O
patient	O	O
'	O	O
s	O	O
level	O	O
of	O	O
consciousness	O	O
and	O	O
vital	O	O
signs	O	O
returned	O	O
to	O	O
presedation	O	O
levels	O	O
.	O	O

upon	O	O
leaving	O	O
the	O	O
sedation	O	O
area	O	O
,	O	O
the	O	O
patient	O	O
collapsed	O	O
,	O	O
with	O	O
no	O	O
apparent	O	O
inciting	O	O
event	O	O
.	O	O

the	O	O
patient	O	O
quickly	O	O
regained	O	O
consciousness	O	O
and	O	O
no	O	O
injury	O	O
occurred	O	O
.	O	O

the	O	O
primary	O	O
abnormality	O	O
found	O	O
was	O	O
persistent	O	O
bradycardia	O	O
,	O	O
and	O	O
she	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
telemetric	O	O
observation	O	O
.	O	O

the	O	O
bradycardia	O	O
lasted	O	O
~	O	O
2	O	O
h	O	O
,	O	O
and	O	O
further	O	O
cardiac	O	O
workup	O	O
revealed	O	O
no	O	O
underlying	O	O
abnormality	O	O
.	O	O

unanticipated	O	O
and	O	O
previously	O	O
unreported	O	O
outcomes	O	O
may	O	O
be	O	O
witnessed	O	O
as	O	O
we	O	O
expand	O	O
the	O	O
use	O	O
of	O	O
certain	O	O
sedatives	O	O
to	O	O
alternative	O	O
routes	O	O
of	O	O
administration	O	O
.	O	O

paradoxical	O	O
severe	O	O
agitation	O	O
induced	O	O
by	O	O
add	O	O
-	O	O
on	O	O
high	O	O
-	O	O
doses	O	O
quetiapine	B-chem	B-chem
in	O	O
schizo	O	O
-	O	O
affective	O	O
disorder	O	O
.	O	O

we	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
35	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
suffering	O	O
from	O	O
schizo	O	O
-	O	O
affective	O	O
disorder	O	O
since	O	O
the	O	O
age	O	O
of	O	O
19	O	O
years	O	O
,	O	O
treated	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
first	O	O
-	O	O
generation	O	O
antipsychotics	O	O
,	O	O
zuclopenthixol	B-chem	B-chem
(	O	O
100	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
and	O	O
lithium	B-chem	B-chem
(	O	O
1200	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
(	O	O
serum	O	O
lithium	B-chem	B-chem
=	O	O
0	O	O
.	O	O
85	O	O
meq	O	O
/	O	O
l	O	O
)	O	O
.	O	O

this	O	O
patient	O	O
had	O	O
no	O	O
associated	O	O
personality	O	O
disorder	O	O
(	O	O
particularly	O	O
no	O	O
antisocial	O	O
disorder	O	O
)	O	O
and	O	O
no	O	O
substance	O	O
abuse	O	O
disorder	O	O
.	O	O

within	O	O
the	O	O
48	O	O
h	O	O
following	O	O
the	O	O
gradual	O	O
introduction	O	O
of	O	O
quetiapine	B-chem	B-chem
(	O	O
up	O	O
to	O	O
600	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
,	O	O
the	O	O
patient	O	O
presented	O	O
severe	O	O
agitation	O	O
without	O	O
an	O	O
environmental	O	O
explanation	O	O
,	O	O
contrasting	O	O
with	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
history	O	O
of	O	O
aggressiveness	O	O
or	O	O
personality	O	O
disorder	O	O
.	O	O

the	O	O
diagnoses	O	O
of	O	O
manic	O	O
shift	O	O
and	O	O
akathisia	O	O
were	O	O
dismissed	O	O
.	O	O

the	O	O
withdrawal	O	O
and	O	O
the	O	O
gradual	O	O
reintroduction	O	O
of	O	O
quetiapine	B-chem	B-chem
2	O	O
weeks	O	O
later	O	O
,	O	O
which	O	O
led	O	O
to	O	O
another	O	O
severe	O	O
agitation	O	O
,	O	O
enabled	O	O
us	O	O
to	O	O
attribute	O	O
the	O	O
agitation	O	O
specifically	O	O
to	O	O
quetiapine	B-chem	B-chem
.	O	O

antioxidant	O	O
effects	O	O
of	O	O
bovine	O	O
lactoferrin	O	O
on	O	O
dexamethasone	B-chem	B-chem
-	O	O
induced	O	O
hypertension	O	O
in	O	O
rat	O	O
.	O	O

dexamethasone	B-chem	B-chem
-	O	O
(	O	O
dex	B-chem	B-chem
-	O	O
)	O	O
induced	O	O
hypertension	O	O
is	O	O
associated	O	O
with	O	O
enhanced	O	O
oxidative	O	O
stress	O	O
.	O	O

lactoferrin	O	O
(	O	O
lf	O	O
)	O	O
is	O	O
an	O	O
iron	B-chem	B-chem
-	O	O
binding	O	O
glycoprotein	O	O
with	O	O
antihypertensive	O	O
properties	O	O
.	O	O

in	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
administration	O	O
of	O	O
lf	O	O
on	O	O
oxidative	O	O
stress	O	O
and	O	O
hypertension	O	O
upon	O	O
dex	B-chem	B-chem
administration	O	O
.	O	O

male	O	O
wistar	O	O
rats	O	O
were	O	O
treated	O	O
by	O	O
dex	B-chem	B-chem
(	O	O
30	O	O
u	O	O
g	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
subcutaneously	O	O
)	O	O
or	O	O
saline	O	O
for	O	O
14	O	O
days	O	O
.	O	O

oral	O	O
bovine	O	O
lf	O	O
(	O	O
30	O	O
,	O	O
100	O	O
,	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
given	O	O
from	O	O
day	O	O
8	O	O
to	O	O
14	O	O
in	O	O
a	O	O
reversal	O	O
study	O	O
.	O	O

in	O	O
a	O	O
prevention	O	O
study	O	O
,	O	O
rats	O	O
received	O	O
4	O	O
days	O	O
of	O	O
lf	O	O
treatment	O	O
followed	O	O
by	O	O
dex	B-chem	B-chem
and	O	O
continued	O	O
during	O	O
the	O	O
test	O	O
period	O	O
.	O	O

systolic	O	O
blood	O	O
pressure	O	O
(	O	O
sbp	O	O
)	O	O
was	O	O
measured	O	O
using	O	O
tail	O	O
-	O	O
cuff	O	O
method	O	O
.	O	O

thymus	O	O
weight	O	O
was	O	O
used	O	O
as	O	O
a	O	O
marker	O	O
of	O	O
glucocorticoid	O	O
activity	O	O
.	O	O

plasma	O	O
hydrogen	B-chem	B-chem
peroxide	I-chem	I-chem
(	O	I-chem
h2o2	B-chem	I-chem
)	O	O
concentration	O	O
and	O	O
ferric	O	B-chem
reducing	O	O
antioxidant	O	O
power	O	O
(	O	O
frap	O	O
)	O	O
value	O	O
were	O	O
determined	O	O
.	O	O

dexamethasone	B-chem	B-chem
significantly	O	O
increased	O	O
sbp	O	O
and	O	O
plasma	O	O
h2o2	B-chem	B-chem
level	O	O
and	O	O
decreased	O	O
thymus	O	O
and	O	O
body	O	O
weights	O	O
.	O	O

lf	O	O
lowered	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
and	O	O
dose	O	O
dependently	O	O
prevented	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O

dex	B-chem	B-chem
-	O	O
induced	O	O
hypertension	O	O
.	O	O

lf	O	O
prevented	O	O
body	O	O
weight	O	O
loss	O	O
and	O	O
significantly	O	O
reduced	O	O
the	O	O
elevated	O	O
plasma	O	O
h2o2	B-chem	B-chem
and	O	O
increased	O	O
frap	O	O
values	O	O
.	O	O

chronic	O	O
administration	O	O
of	O	O
lf	O	O
strongly	O	O
reduced	O	O
the	O	O
blood	O	O
pressure	O	O
and	O	O
production	O	O
of	O	O
ros	O	O
and	O	O
improved	O	O
antioxidant	O	O
capacity	O	O
in	O	O
dex	B-chem	B-chem
-	O	O
induced	O	O
hypertension	O	O
,	O	O
suggesting	O	O
the	O	O
role	O	O
of	O	O
inhibition	O	O
of	O	O
oxidative	O	O
stress	O	O
as	O	O
another	O	O
mechanism	O	O
of	O	O
antihypertensive	O	O
action	O	O
of	O	O
lf	O	O
.	O	O

the	O	O
association	O	O
between	O	O
tranexamic	B-chem	B-chem
acid	I-chem	I-chem
and	O	O
convulsive	O	O
seizures	O	O
after	O	O
cardiac	O	O
surgery	O	O
:	O	O
a	O	O
multivariate	O	O
analysis	O	O
in	O	O
11	O	O
529	O	O
patients	O	O
.	O	O

because	O	O
of	O	O
a	O	O
lack	O	O
of	O	O
contemporary	O	O
data	O	O
regarding	O	O
seizures	O	O
after	O	O
cardiac	O	O
surgery	O	O
,	O	O
we	O	O
undertook	O	O
a	O	O
retrospective	O	O
analysis	O	O
of	O	O
prospectively	O	O
collected	O	O
data	O	O
from	O	O
11	O	O
529	O	O
patients	O	O
in	O	O
whom	O	O
cardiopulmonary	O	O
bypass	O	O
was	O	O
used	O	O
from	O	O
january	O	O
2004	O	O
to	O	O
december	O	O
2010	O	O
.	O	O

a	O	O
convulsive	O	O
seizure	O	O
was	O	O
defined	O	O
as	O	O
a	O	O
transient	O	O
episode	O	O
of	O	O
disturbed	O	O
brain	O	O
function	O	O
characterised	O	O
by	O	O
abnormal	O	O
involuntary	O	O
motor	O	O
movements	O	O
.	O	O

multivariate	O	O
regression	O	O
analysis	O	O
was	O	O
performed	O	O
to	O	O
identify	O	O
independent	O	O
predictors	O	O
of	O	O
postoperative	O	O
seizures	O	O
.	O	O

a	O	O
total	O	O
of	O	O
100	O	O
(	O	O
0	O	O
.	O	O
9	O	O
%	O	O
)	O	O
patients	O	O
developed	O	O
postoperative	O	O
convulsive	O	O
seizures	O	O
.	O	O

generalised	O	O
and	O	O
focal	O	O
seizures	O	O
were	O	O
identified	O	O
in	O	O
68	O	O
and	O	O
32	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

the	O	O
median	O	O
(	O	O
iqr	O	O
[	O	O
range	O	O
]	O	O
)	O	O
time	O	O
after	O	O
surgery	O	O
when	O	O
the	O	O
seizure	O	O
occurred	O	O
was	O	O
7	O	O
(	O	O
6	O	O
-	O	O
12	O	O
[	O	O
1	O	O
-	O	O
216	O	O
]	O	O
)	O	O
h	O	O
and	O	O
8	O	O
(	O	O
6	O	O
-	O	O
11	O	O
[	O	O
4	O	O
-	O	O
18	O	O
]	O	O
)	O	O
h	O	O
,	O	O
respectively	O	O
.	O	O

epileptiform	O	O
findings	O	O
on	O	O
electroencephalography	O	O
were	O	O
seen	O	O
in	O	O
19	O	O
patients	O	O
.	O	O

independent	O	O
predictors	O	O
of	O	O
postoperative	O	O
seizures	O	O
included	O	O
age	O	O
,	O	O
female	O	O
sex	O	O
,	O	O
redo	O	O
cardiac	O	O
surgery	O	O
,	O	O
calcification	O	O
of	O	O
ascending	O	O
aorta	O	O
,	O	O
congestive	O	O
heart	O	O
failure	O	O
,	O	O
deep	O	O
hypothermic	O	O
circulatory	O	O
arrest	O	O
,	O	O
duration	O	O
of	O	O
aortic	O	O
cross	O	O
-	O	O
clamp	O	O
and	O	O
tranexamic	B-chem	B-chem
acid	I-chem	I-chem
.	O	O

when	O	O
tested	O	O
in	O	O
a	O	O
multivariate	O	O
regression	O	O
analysis	O	O
,	O	O
tranexamic	B-chem	B-chem
acid	I-chem	I-chem
was	O	O
a	O	O
strong	O	O
independent	O	O
predictor	O	O
of	O	O
seizures	O	O
(	O	O
or	O	O
14	O	O
.	O	O
3	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
5	O	O
.	O	O
5	O	O
-	O	O
36	O	O
.	O	O
7	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

patients	O	O
with	O	O
convulsive	O	O
seizures	O	O
had	O	O
2	O	O
.	O	O
5	O	O
times	O	O
higher	O	O
in	O	O
-	O	O
hospital	O	O
mortality	O	O
rates	O	O
and	O	O
twice	O	O
the	O	O
length	O	O
of	O	O
hospital	O	O
stay	O	O
compared	O	O
with	O	O
patients	O	O
without	O	O
convulsive	O	O
seizures	O	O
.	O	O

mean	O	O
(	O	O
iqr	O	O
[	O	O
range	O	O
]	O	O
)	O	O

length	O	O
of	O	O
stay	O	O
in	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
was	O	O
115	O	O
(	O	O
49	O	O
-	O	O
228	O	O
[	O	O
32	O	O
-	O	O
481	O	O
]	O	O
)	O	O
h	O	O
in	O	O
patients	O	O
with	O	O
convulsive	O	O
seizures	O	O
compared	O	O
with	O	O
26	O	O
(	O	O
22	O	O
-	O	O
69	O	O
[	O	O
14	O	O
-	O	O
1080	O	O
]	O	O
)	O	O
h	O	O
in	O	O
patients	O	O
without	O	O
seizures	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

convulsive	O	O
seizures	O	O
are	O	O
a	O	O
serious	O	O
postoperative	O	O
complication	O	O
after	O	O
cardiac	O	O
surgery	O	O
.	O	O

as	O	O
tranexamic	B-chem	B-chem
acid	I-chem	I-chem
is	O	O
the	O	O
only	O	O
modifiable	O	O
factor	O	O
,	O	O
its	O	O
administration	O	O
,	O	O
particularly	O	O
in	O	O
doses	O	O
exceeding	O	O
80	O	O
mg	O	O
.	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
should	O	O
be	O	O
weighed	O	O
against	O	O
the	O	O
risk	O	O
of	O	O
postoperative	O	O
seizures	O	O
.	O	O

dysfunctional	O	O
overnight	O	O
memory	O	O
consolidation	O	O
in	O	O
ecstasy	B-chem	B-chem
users	O	O
.	O	O

sleep	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
consolidation	O	O
and	O	O
integration	O	O
of	O	O
memory	O	O
in	O	O
a	O	O
process	O	O
called	O	O
overnight	O	O
memory	O	O
consolidation	O	O
.	O	O

previous	O	O
studies	O	O
indicate	O	O
that	O	O
ecstasy	B-chem	B-chem
users	O	O
have	O	O
marked	O	O
and	O	O
persistent	O	O
neurocognitive	O	O
and	O	O
sleep	O	O
-	O	O
related	O	O
impairments	O	O
.	O	O

we	O	O
extend	O	O
past	O	O
research	O	O
by	O	O
examining	O	O
overnight	O	O
memory	O	O
consolidation	O	O
among	O	O
regular	O	O
ecstasy	B-chem	B-chem
users	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
and	O	O
drug	O	O
naive	O	O
healthy	O	O
controls	O	O
(	O	O
n	O	O
=	O	O
26	O	O
)	O	O
.	O	O

memory	O	O
recall	O	O
of	O	O
word	O	O
pairs	O	O
was	O	O
evaluated	O	O
before	O	O
and	O	O
after	O	O
a	O	O
period	O	O
of	O	O
sleep	O	O
,	O	O
with	O	O
and	O	O
without	O	O
interference	O	O
prior	O	O
to	O	O
testing	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
we	O	O
assessed	O	O
neurocognitive	O	O
performances	O	O
across	O	O
tasks	O	O
of	O	O
learning	O	O
,	O	O
memory	O	O
and	O	O
executive	O	O
functioning	O	O
.	O	O

ecstasy	B-chem	B-chem
users	O	O
demonstrated	O	O
impaired	O	O
overnight	O	O
memory	O	O
consolidation	O	O
,	O	O
a	O	O
finding	O	O
that	O	O
was	O	O
more	O	O
pronounced	O	O
following	O	O
associative	O	O
interference	O	O
.	O	O

additionally	O	O
,	O	O
ecstasy	B-chem	B-chem
users	O	O
demonstrated	O	O
impairments	O	O
on	O	O
tasks	O	O
recruiting	O	O
frontostriatal	O	O
and	O	O
hippocampal	O	O
neural	O	O
circuitry	O	O
,	O	O
in	O	O
the	O	O
domains	O	O
of	O	O
proactive	O	O
interference	O	O
memory	O	O
,	O	O
long	O	O
-	O	O
term	O	O
memory	O	O
,	O	O
encoding	O	O
,	O	O
working	O	O
memory	O	O
and	O	O
complex	O	O
planning	O	O
.	O	O

we	O	O
suggest	O	O
that	O	O
ecstasy	B-chem	B-chem
-	O	O
associated	O	O
dysfunction	O	O
in	O	O
fronto	O	O
-	O	O
temporal	O	O
circuitry	O	O
may	O	O
underlie	O	O
overnight	O	O
consolidation	O	O
memory	O	O
impairments	O	O
in	O	O
regular	O	O
ecstasy	B-chem	B-chem
users	O	O
.	O	O

normoammonemic	O	O
encephalopathy	O	O
:	O	O
solely	O	O
valproate	B-chem	B-chem
induced	O	O
or	O	O
multiple	O	O
mechanisms	O	O
?	O	O

a	O	O
77	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
presented	O	O
with	O	O
subacute	O	O
onset	O	O
progressive	O	O
confusion	O	O
,	O	O
aggression	O	O
,	O	O
auditory	O	O
hallucinations	O	O
and	O	O
delusions	O	O
.	O	O

in	O	O
the	O	O
preceding	O	O
months	O	O
,	O	O
the	O	O
patient	O	O
had	O	O
a	O	O
number	O	O
of	O	O
admissions	O	O
with	O	O
transient	O	O
unilateral	O	O
hemiparesis	O	O
with	O	O
facial	O	O
droop	O	O
,	O	O
and	O	O
had	O	O
been	O	O
started	O	O
on	O	O
valproate	B-chem	B-chem
for	O	O
presumed	O	O
hemiplegic	O	O
migraine	O	O
.	O	O

valproate	B-chem	B-chem
was	O	O
withdrawn	O	O
soon	O	O
after	O	O
admission	O	O
and	O	O
her	O	O
cognitive	O	O
abilities	O	O
have	O	O
gradually	O	O
improved	O	O
over	O	O
3	O	O
months	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

valproate	B-chem	B-chem
levels	O	O
taken	O	O
prior	O	O
to	O	O
withdrawal	O	O
were	O	O
subtherapeutic	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
normoammonaemic	O	O
.	O	O

eeg	O	O
undertaken	O	O
during	O	O
inpatient	O	O
stay	O	O
showed	O	O
changes	O	O
consistent	O	O
with	O	O
encephalopathy	O	O
,	O	O
and	O	O
low	O	O
titre	O	O
n	B-chem	B-chem
-	I-chem	I-chem
methyl	I-chem	I-chem
-	I-chem	I-chem
d	I-chem	I-chem
-	I-chem	I-chem
aspartate	I-chem	I-chem
(	O	O
nmda	B-chem	B-chem
)	O	O
receptor	O	O
antibodies	O	O
were	O	O
present	O	O
in	O	O
this	O	O
patient	O	O
.	O	O

the	O	O
possible	O	O
aetiologies	O	O
of	O	O
valproate	B-chem	B-chem
-	O	O
induced	O	O
encephalopathy	O	O
and	O	O
nmda	B-chem	B-chem
receptor	O	O
-	O	O
associated	O	O
encephalitis	O	O
present	O	O
a	O	O
diagnostic	O	O
dilemma	O	O
.	O	O

we	O	O
present	O	O
a	O	O
putative	O	O
combinatorial	O	O
hypothesis	O	O
to	O	O
explain	O	O
this	O	O
patient	O	O
'	O	O
s	O	O
symptoms	O	O
.	O	O

cerebellar	O	O
and	O	O
oculomotor	O	O
dysfunction	O	O
induced	O	O
by	O	O
rapid	O	O
infusion	O	O
of	O	O
pethidine	B-chem	B-chem
.	O	O

pethidine	B-chem	B-chem
is	O	O
an	O	O
opioid	O	O
that	O	O
gains	O	O
its	O	O
popularity	O	O
for	O	O
the	O	O
effective	O	O
pain	O	O
control	O	O
through	O	O
acting	O	O
on	O	O
the	O	O
opioid	O	O
-	O	O
receptors	O	O
.	O	O

however	O	O
,	O	O
rapid	O	O
pain	O	O
relief	O	O
sometimes	O	O
brings	O	O
about	O	O
unfavourable	O	O
side	O	O
effects	O	O
that	O	O
largely	O	O
limit	O	O
its	O	O
clinical	O	O
utility	O	O
.	O	O

common	O	O
side	O	O
effects	O	O
include	O	O
nausea	O	O
,	O	O
vomiting	O	O
and	O	O
hypotension	O	O
.	O	O

in	O	O
patients	O	O
with	O	O
impaired	O	O
renal	O	O
and	O	O
liver	O	O
function	O	O
,	O	O
and	O	O
those	O	O
who	O	O
need	O	O
long	O	O
-	O	O
term	O	O
pain	O	O
control	O	O
,	O	O
pethidine	B-chem	B-chem
may	O	O
cause	O	O
excitatory	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
cns	O	O
)	O	O
effects	O	O
through	O	O
its	O	O
neurotoxic	O	O
metabolite	O	O
,	O	O
norpethidine	B-chem	B-chem
,	O	O
resulting	O	O
in	O	O
irritability	O	O
and	O	O
seizure	O	O
attack	O	O
.	O	O

on	O	O
the	O	O
contrary	O	O
,	O	O
though	O	O
not	O	O
clinically	O	O
apparent	O	O
,	O	O
pethidine	B-chem	B-chem
potentially	O	O
causes	O	O
inhibitory	O	O
impacts	O	O
on	O	O
the	O	O
cns	O	O
and	O	O
impairs	O	O
normal	O	O
cerebellar	O	O
and	O	O
oculomotor	O	O
function	O	O
in	O	O
the	O	O
short	O	O
term	O	O
.	O	O

in	O	O
this	O	O
case	O	O
report	O	O
,	O	O
we	O	O
highlight	O	O
opioid	O	O
'	O	O
s	O	O
inhibitory	O	O
side	O	O
effects	O	O
on	O	O
the	O	O
cerebellar	O	O
structure	O	O
that	O	O
causes	O	O
dysmetria	O	O
,	O	O
dysarthria	O	O
,	O	O
reduced	O	O
smooth	O	O
pursuit	O	O
gain	O	O
and	O	O
decreased	O	O
saccadic	O	O
velocity	O	O
.	O	O

baboon	O	O
syndrome	O	O
induced	O	O
by	O	O
ketoconazole	B-chem	B-chem
.	O	O

a	O	O
27	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
presented	O	O
with	O	O
a	O	O
maculopapular	O	O
eruption	O	O
on	O	O
the	O	O
flexural	O	O
areas	O	O
and	O	O
buttocks	O	O
after	O	O
using	O	O
oral	O	O
ketoconazole	B-chem	B-chem
.	O	O

the	O	O
patient	O	O
was	O	O
diagnosed	O	O
with	O	O
drug	O	O
-	O	O
induced	O	O
baboon	O	O
syndrome	O	O
based	O	O
on	O	O
his	O	O
history	O	O
,	O	O
which	O	O
included	O	O
prior	O	O
sensitivity	O	O
to	O	O
topical	O	O
ketoconazole	B-chem	B-chem
,	O	O
a	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
histopathological	O	O
findings	O	O
.	O	O

baboon	O	O
syndrome	O	O
is	O	O
a	O	O
drug	O	O
-	O	O
or	O	O
contact	O	O
allergen	O	O
-	O	O
related	O	O
maculopapular	O	O
eruption	O	O
that	O	O
typically	O	O
involves	O	O
the	O	O
flexural	O	O
and	O	O
gluteal	O	O
areas	O	O
.	O	O

to	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
ketoconazole	B-chem	B-chem
-	O	O
induced	O	O
baboon	O	O
syndrome	O	O
in	O	O
the	O	O
english	O	O
literature	O	O
.	O	O

a	O	O
case	O	O
of	O	O
sudden	O	O
cardiac	O	O
death	O	O
due	O	O
to	O	O
pilsicainide	B-chem	B-chem
-	O	O
induced	O	O
torsades	O	O
de	O	O
pointes	O	O
.	O	O

an	O	O
84	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
received	O	O
oral	O	O
pilsicainide	B-chem	B-chem
,	O	O
a	O	O
pure	O	O
sodium	B-chem	B-chem
channel	O	O
blocker	O	O
with	O	O
slow	O	O
recovery	O	O
kinetics	O	O
,	O	O
to	O	O
convert	O	O
his	O	O
paroxysmal	O	O
atrial	O	O
fibrillation	O	O
to	O	O
a	O	O
sinus	O	O
rhythm	O	O
;	O	O
the	O	O
patient	O	O
developed	O	O
sudden	O	O
cardiac	O	O
death	O	O
two	O	O
days	O	O
later	O	O
.	O	O

the	O	O
holter	O	O
electrocardiogram	O	O
,	O	O
which	O	O
was	O	O
worn	O	O
by	O	O
chance	O	O
,	O	O
revealed	O	O
torsade	O	O
de	O	O
pointes	O	O
with	O	O
gradually	O	O
prolonged	O	O
qt	O	O
intervals	O	O
.	O	O

this	O	O
drug	O	O
is	O	O
rapidly	O	O
absorbed	O	O
from	O	O
the	O	O
gastrointestinal	O	O
tract	O	O
,	O	O
and	O	O
most	O	O
of	O	O
it	O	O
is	O	O
excreted	O	O
from	O	O
the	O	O
kidney	O	O
.	O	O

although	O	O
the	O	O
patient	O	O
'	O	O
s	O	O
renal	O	O
function	O	O
was	O	O
not	O	O
highly	O	O
impaired	O	O
and	O	O
the	O	O
dose	O	O
of	O	O
pilsicainide	B-chem	B-chem
was	O	O
low	O	O
,	O	O
the	O	O
plasma	O	O
concentration	O	O
of	O	O
pilsicainide	B-chem	B-chem
may	O	O
have	O	O
been	O	O
high	O	O
,	O	O
which	O	O
can	O	O
produce	O	O
torsades	O	O
de	O	O
pointes	O	O
in	O	O
the	O	O
octogenarian	O	O
.	O	O

although	O	O
the	O	O
oral	O	O
administration	O	O
of	O	O
class	O	O
ic	O	O
drugs	O	O
,	O	O
including	O	O
pilsicainide	B-chem	B-chem
,	O	O
is	O	O
effective	O	O
to	O	O
terminate	O	O
atrial	O	O
fibrillation	O	O
,	O	O
careful	O	O
consideration	O	O
must	O	O
be	O	O
taken	O	O
before	O	O
giving	O	O
these	O	O
drugs	O	O
to	O	O
octogenarians	O	O
.	O	O

all	B-chem	O
-	I-chem	O
trans	I-chem	B-chem
retinoic	I-chem	I-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
inflammatory	O	O
myositis	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
acute	O	O
promyelocytic	O	O
leukemia	O	O
.	O	O

all	B-chem	O
-	I-chem	O
trans	I-chem	B-chem
retinoic	I-chem	I-chem
acid	I-chem	I-chem
(	O	O
atra	B-chem	B-chem
)	O	O
,	O	O
a	O	O
component	O	O
of	O	O
standard	O	O
therapy	O	O
for	O	O
acute	O	O
promyelocytic	O	O
leukemia	O	O
(	O	O
apl	O	O
)	O	O
,	O	O
is	O	O
associated	O	O
with	O	O
potentially	O	O
serious	O	O
but	O	O
treatable	O	O
adverse	O	O
effects	O	O
involving	O	O
numerous	O	O
organ	O	O
systems	O	O
,	O	O
including	O	O
rare	O	O
skeletal	O	O
muscle	O	O
involvement	O	O
.	O	O

only	O	O
a	O	O
handful	O	O
of	O	O
cases	O	O
of	O	O
atra	B-chem	B-chem
-	O	O
induced	O	O
myositis	O	O
in	O	O
children	O	O
have	O	O
been	O	O
reported	O	O
,	O	O
and	O	O
none	O	O
in	O	O
the	O	O
radiology	O	O
literature	O	O
.	O	O

we	O	O
present	O	O
such	O	O
a	O	O
case	O	O
in	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
with	O	O
apl	O	O
,	O	O
where	O	O
recognition	O	O
of	O	O
imaging	O	O
findings	O	O
played	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
making	O	O
the	O	O
diagnosis	O	O
and	O	O
facilitated	O	O
prompt	O	O
,	O	O
effective	O	O
treatment	O	O
.	O	O

tolerability	O	O
of	O	O
lomustine	B-chem	B-chem
in	O	O
combination	O	O
with	O	O
cyclophosphamide	B-chem	B-chem
in	O	O
dogs	O	O
with	O	O
lymphoma	O	O
.	O	O

this	O	O
retrospective	O	O
study	O	O
describes	O	O
toxicity	O	O
associated	O	O
with	O	O
a	O	O
protocol	O	O
of	O	O
lomustine	B-chem	B-chem
(	O	O
ccnu	B-chem	B-chem
)	O	O
and	O	O
cyclophosphamide	B-chem	B-chem
(	O	O
ctx	B-chem	B-chem
)	O	O
in	O	O
dogs	O	O
with	O	O
lymphoma	O	O
.	O	O

ccnu	B-chem	B-chem
was	O	O
administered	O	O
per	O	O
os	O	O
(	O	O
po	O	O
)	O	O
at	O	O
a	O	O
targeted	O	O
dosage	O	O
of	O	O
60	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
body	O	O
surface	O	O
area	O	O
on	O	O
day	O	O
0	O	O
,	O	O
ctx	B-chem	B-chem
was	O	O
administered	O	O
po	O	O
at	O	O
a	O	O
targeted	O	O
dosage	O	O
of	O	O
250	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
divided	O	O
over	O	O
days	O	O
0	O	O
through	O	O
4	O	O
,	O	O
and	O	O
all	O	O
dogs	O	O
received	O	O
prophylactic	O	O
antibiotics	O	O
.	O	O

ninety	O	O
treatments	O	O
were	O	O
given	O	O
to	O	O
the	O	O
57	O	O
dogs	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

neutropenia	O	O
was	O	O
the	O	O
principal	O	O
toxic	O	O
effect	O	O
,	O	O
and	O	O
the	O	O
overall	O	O
frequency	O	O
of	O	O
grade	O	O
4	O	O
neutropenia	O	O
after	O	O
the	O	O
first	O	O
treatment	O	O
of	O	O
ccnu	B-chem	O
/	O	O
ctx	B-chem	B-chem
was	O	O
30	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
19	O	O
-	O	O
43	O	O
%	O	O
)	O	O
.	O	O

the	O	O
mean	O	O
body	O	O
weight	O	O
of	O	O
dogs	O	O
with	O	O
grade	O	O
4	O	O
neutropenia	O	O
(	O	O
19	O	O
.	O	O
7	O	O
kg	O	O
+	O	O
13	O	O
.	O	O
4	O	O
kg	O	O
)	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
the	O	O
mean	O	O
body	O	O
weight	O	O
of	O	O
dogs	O	O
that	O	O
did	O	O
not	O	O
develop	O	O
grade	O	O
4	O	O
neutropenia	O	O
(	O	O
31	O	O
.	O	O
7	O	O
kg	O	O
+	O	O
12	O	O
.	O	O
4	O	O
kg	O	O
;	O	O
p	O	O
=	O	O
.	O	O
005	O	O
)	O	O
.	O	O

one	O	O
dog	O	O
(	O	O
3	O	O
%	O	O
)	O	O
developed	O	O
hematologic	O	O
changes	O	O
suggestive	O	O
of	O	O
hepatotoxicity	O	O
.	O	O

no	O	O
dogs	O	O
had	O	O
evidence	O	O
of	O	O
either	O	O
renal	O	O
toxicity	O	O
or	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

adverse	O	O
gastrointestinal	O	O
effects	O	O
were	O	O
uncommon	O	O
.	O	O

on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
findings	O	O
reported	O	O
herein	O	O
,	O	O
a	O	O
dose	O	O
of	O	O
60	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
of	O	O
ccnu	B-chem	O
combined	O	O
with	O	O
250	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
of	O	O
ctx	B-chem	B-chem
(	O	O
divided	O	O
over	O	O
5	O	O
days	O	O
)	O	O
q	O	O
4	O	O
wk	O	O
is	O	O
tolerable	O	O
in	O	O
tumor	O	O
-	O	O
bearing	O	O
dogs	O	O
.	O	O

nelarabine	B-chem	B-chem
neurotoxicity	O	O
with	O	O
concurrent	O	O
intrathecal	O	O
chemotherapy	O	O
:	O	O

case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
literature	O	O
.	O	O

severe	O	O
nelarabine	B-chem	B-chem
neurotoxicity	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
received	O	O
concurrent	O	O
intrathecal	O	O
(	O	O
it	O	O
)	O	O
chemotherapy	O	O
is	O	O
reported	O	O
.	O	O

a	O	O
37	O	O
-	O	O
year	O	O
-	O	O
old	O	O
caucasian	O	O
woman	O	O
with	O	O
a	O	O
history	O	O
of	O	O
t	O	O
-	O	O
cell	O	O
lymphoblastic	O	O
lymphoma	O	O
was	O	O
admitted	O	O
for	O	O
relapsed	O	O
disease	O	O
.	O	O

she	O	O
was	O	O
originally	O	O
treated	O	O
with	O	O
induction	O	O
chemotherapy	O	O
followed	O	O
by	O	O
an	O	O
autologous	O	O
transplant	O	O
.	O	O

she	O	O
developed	O	O
relapsed	O	O
disease	O	O
10	O	O
months	O	O
later	O	O
with	O	O
leukemic	O	O
involvement	O	O
.	O	O

she	O	O
was	O	O
re	O	O
-	O	O
induced	O	O
with	O	O
nelarabine	B-chem	B-chem
1500	O	O

mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
on	O	O
days	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
5	O	O
with	O	O
1	O	O
dose	O	O
of	O	O
it	O	O
cytarabine	B-chem	B-chem
100	O	O
mg	O	O
on	O	O
day	O	O
2	O	O
as	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
cns	O	O
)	O	O
prophylaxis	O	O
.	O	O

at	O	O
the	O	O
time	O	O
of	O	O
treatment	O	O
,	O	O
she	O	O
was	O	O
on	O	O
continuous	O	O
renal	O	O
replacement	O	O
therapy	O	O
due	O	O
to	O	O
sequelae	O	O
of	O	O
tumor	O	O
lysis	O	O
syndrome	O	O
(	O	O
tls	O	O
)	O	O
.	O	O

she	O	O
tolerated	O	O
therapy	O	O
well	O	O
,	O	O
entered	O	O
a	O	O
complete	O	O
remission	O	O
,	O	O
and	O	O
recovered	O	O
her	O	O
renal	O	O
function	O	O
.	O	O

she	O	O
received	O	O
a	O	O
second	O	O
cycle	O	O
of	O	O
nelarabine	B-chem	B-chem
without	O	O
additional	O	O
it	O	O
prophylaxis	O	O
one	O	O
month	O	O
later	O	O
.	O	O

a	O	O
week	O	O
after	O	O
this	O	O
second	O	O
cycle	O	O
,	O	O
she	O	O
noted	O	O
numbness	O	O
in	O	O
her	O	O
lower	O	O
extremities	O	O
.	O	O

predominantly	O	O
sensory	O	O
,	O	O
though	O	O
also	O	O
motor	O	O
and	O	O
autonomic	O	O
,	O	O
peripheral	O	O
neuropathy	O	O
started	O	O
in	O	O
her	O	O
feet	O	O
,	O	O
ascended	O	O
proximally	O	O
to	O	O
the	O	O
mid	O	O
-	O	O
thoracic	O	O
region	O	O
,	O	O
and	O	O
eventually	O	O
included	O	O
her	O	O
distal	O	O
upper	O	O
extremities	O	O
.	O	O

a	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
mri	O	O
)	O	O
of	O	O
her	O	O
spine	O	O
demonstrated	O	O
changes	O	O
from	O	O
c2	O	O
to	O	O
c6	O	O
consistent	O	O
with	O	O
subacute	O	O
combined	O	O
degeneration	O	O
.	O	O

nelarabine	B-chem	B-chem
was	O	O
felt	O	O
to	O	O
be	O	O
the	O	O
cause	O	O
of	O	O
her	O	O
symptoms	O	O
.	O	O

her	O	O
neuropathy	O	O
stabilized	O	O
and	O	O
showed	O	O
slight	O	O
improvement	O	O
and	O	O
ultimately	O	O
received	O	O
an	O	O
unrelated	O	O
,	O	O
reduced	O	O
-	O	O
intensity	O	O
allogeneic	O	O
transplant	O	O
while	O	O
in	O	O
complete	O	O
remission	O	O
,	O	O
but	O	O
relapsed	O	O
disease	O	O
10	O	O
weeks	O	O
later	O	O
.	O	O

she	O	O
is	O	O
currently	O	O
being	O	O
treated	O	O
with	O	O
best	O	O
supportive	O	O
care	O	O
.	O	O

to	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
published	O	O
case	O	O
report	O	O
of	O	O
severe	O	O
neurotoxicity	O	O
caused	O	O
by	O	O
nelarabine	B-chem	B-chem
in	O	O
a	O	O
patient	O	O
who	O	O
received	O	O
concurrent	O	O
it	O	O
chemotherapy	O	O
.	O	O

valproate	B-chem	B-chem
-	O	O
induced	O	O
hyperammonemic	O	O
encephalopathy	O	O
in	O	O
a	O	O
renal	O	O
transplanted	O	O
patient	O	O
.	O	O

neurological	O	O
complications	O	O
after	O	O
renal	O	O
transplantation	O	O
constitute	O	O
an	O	O
important	O	O
cause	O	O
of	O	O
morbidity	O	O
and	O	O
mortality	O	O
.	O	O

their	O	O
differential	O	O
diagnosis	O	O
is	O	O
difficult	O	O
and	O	O
essential	O	O
for	O	O
subsequent	O	O
patient	O	O
'	O	O
s	O	O
management	O	O
.	O	O

valproate	B-chem	B-chem
-	O	O
induced	O	O
hyperammonemic	O	O
encephalopathy	O	O
is	O	O
an	O	O
uncommon	O	O
but	O	O
serious	O	O
effect	O	O
of	O	O
valproate	B-chem	B-chem
treatment	O	O
.	O	O

here	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
who	O	O
was	O	O
on	O	O
a	O	O
long	O	O
-	O	O
term	O	O
therapy	O	O
with	O	O
valproate	B-chem	B-chem
due	O	O
to	O	O
epilepsy	O	O
and	O	O
revealed	O	O
impaired	O	O
consciousness	O	O
with	O	O
hyperammonemia	O	O
12	O	O
days	O	O
after	O	O
renal	O	O
transplantation	O	O
.	O	O

after	O	O
withdraw	O	O
of	O	O
valproate	B-chem	B-chem
,	O	O
patients	O	O
'	O	O
symptoms	O	O
resolved	O	O
within	O	O
24	O	O
h	O	O
.	O	O
clinicians	O	O
should	O	O
increase	O	O
their	O	O
awareness	O	O
for	O	O
potential	O	O
complication	O	O
of	O	O
valproate	B-chem	B-chem
,	O	O
especially	O	O
in	O	O
transplanted	O	O
patients	O	O
.	O	O

necrotising	O	O
fasciitis	O	O
after	O	O
bortezomib	B-chem	B-chem
and	O	O
dexamethasone	B-chem	B-chem
-	O	O
containing	O	O
regimen	O	O
in	O	O
an	O	O
elderly	O	O
patient	O	O
of	O	O
waldenstrom	O	O
macroglobulinaemia	O	O
.	O	O

bortezomib	B-chem	B-chem
and	O	O
high	O	O
-	O	O
dose	O	O
dexamethasone	B-chem	B-chem
-	O	O
containing	O	O
regimens	O	O
are	O	O
considered	O	O
to	O	O
be	O	O
generally	O	O
tolerable	O	O
with	O	O
few	O	O
severe	O	O
bacterial	O	O
infections	O	O
in	O	O
patients	O	O
with	O	O
b	O	O
-	O	O
cell	O	O
malignancies	O	O
.	O	O

however	O	O
,	O	O
information	O	O
is	O	O
limited	O	O
concerning	O	O
the	O	O
safety	O	O
of	O	O
the	O	O
regimen	O	O
in	O	O
elderly	O	O
patients	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
76	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
waldenstrom	O	O
macroglobulinaemia	O	O
who	O	O
suffered	O	O
necrotising	O	O
fasciitis	O	O
without	O	O
neutropenia	O	O
after	O	O
the	O	O
combination	O	O
treatment	O	O
with	O	O
bortezomib	B-chem	B-chem
,	O	O
high	O	O
-	O	O
dose	O	O
dexamethasone	B-chem	B-chem
and	O	O
rituximab	O	B-chem
.	O	O

despite	O	O
immediate	O	O
intravenous	O	O
antimicrobial	O	O
therapy	O	O
,	O	O
he	O	O
succumbed	O	O
23	O	O
h	O	O
after	O	O
the	O	O
onset	O	O
.	O	O

physicians	O	O
should	O	O
recognise	O	O
the	O	O
possibility	O	O
of	O	O
fatal	O	O
bacterial	O	O
infections	O	O
related	O	O
to	O	O
bortezomib	B-chem	B-chem
plus	O	O
high	O	O
-	O	O
dose	O	O
dexamethasone	B-chem	B-chem
in	O	O
elderly	O	O
patients	O	O
,	O	O
and	O	O
we	O	O
believe	O	O
this	O	O
case	O	O
warrants	O	O
further	O	O
investigation	O	O
.	O	O

an	O	O
integrated	O	O
characterization	O	O
of	O	O
serological	O	O
,	O	O
pathological	O	O
,	O	O
and	O	O
functional	O	O
events	O	O
in	O	O
doxorubicin	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
.	O	O

many	O	O
efficacious	O	O
cancer	O	O
treatments	O	O
cause	O	O
significant	O	O
cardiac	O	O
morbidity	O	O
,	O	O
yet	O	O
biomarkers	O	O
or	O	O
functional	O	O
indices	O	O
of	O	O
early	O	O
damage	O	O
,	O	O
which	O	O
would	O	O
allow	O	O
monitoring	O	O
and	O	O
intervention	O	O
,	O	O
are	O	O
lacking	O	O
.	O	O

in	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
utilized	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
progressive	O	O
doxorubicin	B-chem	B-chem
(	O	O
dox	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
cardiomyopathy	O	O
,	O	O
applying	O	O
multiple	O	O
approaches	O	O
,	O	O
including	O	O
cardiac	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
mri	O	O
)	O	O
,	O	O
to	O	O
provide	O	O
the	O	O
most	O	O
comprehensive	O	O
characterization	O	O
to	O	O
date	O	O
of	O	O
the	O	O
timecourse	O	O
of	O	O
serological	O	O
,	O	O
pathological	O	O
,	O	O
and	O	O
functional	O	O
events	O	O
underlying	O	O
this	O	O
toxicity	O	O
.	O	O

hannover	O	O
wistar	O	O
rats	O	O
were	O	O
dosed	O	O
with	O	O
1	O	O
.	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
dox	B-chem	B-chem
weekly	O	O
for	O	O
8	O	O
weeks	O	O
followed	O	O
by	O	O
a	O	O
4	O	O
week	O	O
off	O	O
-	O	O
dosing	O	O
"	O	O
"	O	O
"	O	O
"	O	O
recovery	O	O
"	O	O
"	O	O
"	O	O
"	O	O
period	O	O
.	O	O

electron	O	O
microscopy	O	O
of	O	O
the	O	O
myocardium	O	O
revealed	O	O
subcellular	O	O
degeneration	O	O
and	O	O
marked	O	O
mitochondrial	O	O
changes	O	O
after	O	O
a	O	O
single	O	O
dose	O	O
.	O	O

histopathological	O	O
analysis	O	O
revealed	O	O
progressive	O	O
cardiomyocyte	O	O
degeneration	O	O
,	O	O
hypertrophy	O	O
/	O	O
cytomegaly	O	O
,	O	O
and	O	O
extensive	O	O
vacuolation	O	O
after	O	O
two	O	O
doses	O	O
.	O	O

extensive	O	O
replacement	O	O
fibrosis	O	O
(	O	O
quantified	O	O
by	O	O
sirius	O	O
red	O	O
staining	O	O
)	O	O
developed	O	O
during	O	O
the	O	O
off	O	O
-	O	O
dosing	O	O
period	O	O
.	O	O

functional	O	O
indices	O	O
assessed	O	O
by	O	O
cardiac	O	O
mri	O	O
(	O	O
including	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
(	O	O
lvef	O	O
)	O	O
,	O	O
cardiac	O	O
output	O	O
,	O	O
and	O	O
e	O	O
/	O	O
a	O	O
ratio	O	O
)	O	O
declined	O	O
progressively	O	O
,	O	O
reaching	O	O
statistical	O	O
significance	O	O
after	O	O
two	O	O
doses	O	O
and	O	O
culminating	O	O
in	O	O
"	O	O
"	O	O
"	O	O
"	O	O
clinical	O	O
"	O	O
"	O	O
"	O	O
"	O	O
lv	O	O
dysfunction	O	O
by	O	O
12	O	O
weeks	O	O
.	O	O

significant	O	O
increases	O	O
in	O	O
peak	O	O
myocardial	O	O
contrast	O	O
enhancement	O	O
and	O	O
serological	O	O
cardiac	O	O
troponin	O	O

i	O	O
(	O	O
ctni	O	O
)	O	O
emerged	O	O
after	O	O
eight	O	O
doses	O	O
,	O	O
importantly	O	O
preceding	O	O
the	O	O
lvef	O	O
decline	O	O
to	O	O
<	O	O
50	O	O
%	O	O
.	O	O

troponin	O	O
i	O	O
levels	O	O
positively	O	O
correlated	O	O
with	O	O
delayed	O	O
and	O	O
peak	O	O
gadolinium	B-chem	O
contrast	O	O
enhancement	O	O
,	O	O
histopathological	O	O
grading	O	O
,	O	O
and	O	O
diastolic	O	O
dysfunction	O	O
.	O	O

in	O	O
summary	O	O
,	O	O
subcellular	O	O
cardiomyocyte	O	O
degeneration	O	O
was	O	O
the	O	O
earliest	O	O
marker	O	O
,	O	O
followed	O	O
by	O	O
progressive	O	O
functional	O	O
decline	O	O
and	O	O
histopathological	O	O
manifestations	O	O
.	O	O

myocardial	O	O
contrast	O	O
enhancement	O	O
and	O	O
elevations	O	O
in	O	O
ctni	O	O
occurred	O	O
later	O	O
.	O	O

however	O	O
,	O	O
all	O	O
indices	O	O
predated	O	O
"	O	O
"	O	O
"	O	O
"	O	O
clinical	O	O
"	O	O
"	O	O
"	O	O
"	O	O
lv	O	O
dysfunction	O	O
and	O	O
thus	O	O
warrant	O	O
further	O	O
evaluation	O	O
as	O	O
predictive	O	O
biomarkers	O	O
.	O	O

intradermal	O	O
glutamate	B-chem	B-chem
and	O	O
capsaicin	B-chem	B-chem
injections	O	O
:	O	O
intra	O	O
-	O	O
and	O	O
interindividual	O	O
variability	O	O
of	O	O
provoked	O	O
hyperalgesia	O	O
and	O	O
allodynia	O	O
.	O	O

intradermal	O	O
injections	O	O
of	O	O
glutamate	B-chem	B-chem
and	O	O
capsaicin	B-chem	B-chem
are	O	O
attractive	O	O
to	O	O
use	O	O
in	O	O
human	O	O
experimental	O	O
pain	O	O
models	O	O
because	O	O
hyperalgesia	O	O
and	O	O
allodynia	O	O
mimic	O	O
isolated	O	O
aspects	O	O
of	O	O
clinical	O	O
pain	O	O
disorders	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
reproducibility	O	O
of	O	O
these	O	O
models	O	O
.	O	O

twenty	O	O
healthy	O	O
male	O	O
volunteers	O	O
(	O	O
mean	O	O
age	O	O
24	O	O
years	O	O
;	O	O
range	O	O
18	O	O
-	O	O
38	O	O
years	O	O
)	O	O
received	O	O
intradermal	O	O
injections	O	O
of	O	O
glutamate	B-chem	B-chem
and	O	O
capsaicin	B-chem	B-chem
in	O	O
the	O	O
volar	O	O
forearm	O	O
.	O	O

magnitudes	O	O
of	O	O
secondary	O	O
pinprick	O	O
hyperalgesia	O	O
and	O	O
brush	O	O
-	O	O
evoked	O	O
allodynia	O	O
were	O	O
investigated	O	O
using	O	O
von	O	O
frey	O	O
filaments	O	O
(	O	O
gauges	O	O
10	O	O
,	O	O
15	O	O
,	O	O
60	O	O
and	O	O
100	O	O
g	O	O
)	O	O
and	O	O
brush	O	O
strokes	O	O
.	O	O

areas	O	O
of	O	O
secondary	O	O
hyperalgesia	O	O
and	O	O
allodynia	O	O
were	O	O
quantified	O	O
immediately	O	O
after	O	O
injection	O	O
and	O	O
after	O	O
15	O	O
,	O	O
30	O	O
and	O	O
60	O	O
min	O	O
.	O	O

two	O	O
identical	O	O
experiments	O	O
separated	O	O
by	O	O
at	O	O
least	O	O
7	O	O
days	O	O
were	O	O
performed	O	O
.	O	O

reproducibility	O	O
across	O	O
and	O	O
within	O	O
volunteers	O	O
(	O	O
inter	O	O
-	O	O
and	O	O
intra	O	O
-	O	O
individual	O	O
variation	O	O
,	O	O
respectively	O	O
)	O	O
was	O	O
assessed	O	O
using	O	O
intraclass	O	O
correlation	O	O
coefficient	O	O
(	O	O
icc	O	O
)	O	O
and	O	O
coefficient	O	O
of	O	O
variation	O	O
(	O	O
cv	O	O
)	O	O
.	O	O

secondary	O	O
pinprick	O	O
hyperalgesia	O	O
was	O	O
observed	O	O
as	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
the	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
vas	O	O
)	O	O
response	O	O
to	O	O
von	O	O
frey	O	O
gauges	O	O
60	O	O
and	O	O
100	O	O
g	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
after	O	O
glutamate	B-chem	B-chem
injection	O	O
.	O	O

for	O	O
capsaicin	B-chem	B-chem
,	O	O
secondary	O	O
pinprick	O	O
hyperalgesia	O	O
was	O	O
detected	O	O
with	O	O
all	O	O
von	O	O
frey	O	O
gauges	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

glutamate	B-chem	B-chem
evoked	O	O
reproducible	O	O
vas	O	O
response	O	O
to	O	O
all	O	O
von	O	O
frey	O	O
gauges	O	O
(	O	O
icc	O	O
>	O	O
0	O	O
.	O	O
60	O	O
)	O	O
and	O	O
brush	O	O
strokes	O	O
(	O	O
icc	O	O
>	O	O
0	O	O
.	O	O
83	O	O
)	O	O
.	O	O

capsaicin	B-chem	B-chem
injection	O	O
was	O	O
reproducible	O	O
for	O	O
secondary	O	O
hyperalgesia	O	O
(	O	O
icc	O	O
>	O	O
0	O	O
.	O	O
70	O	O
)	O	O
and	O	O
allodynia	O	O
(	O	O
icc	O	O
>	O	O
0	O	O
.	O	O
71	O	O
)	O	O
.	O	O

intra	O	O
-	O	O
individual	O	O
variability	O	O
was	O	O
generally	O	O
lower	O	O
for	O	O
the	O	O
vas	O	O
response	O	O
to	O	O
von	O	O
frey	O	O
and	O	O
brush	O	O
compared	O	O
with	O	O
areas	O	O
of	O	O
secondary	O	O
hyperalgesia	O	O
and	O	O
allodynia	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
glutamate	B-chem	B-chem
and	O	O
capsaicin	B-chem	B-chem
yield	O	O
reproducible	O	O
hyperalgesic	O	O
and	O	O
allodynic	O	O
responses	O	O
,	O	O
and	O	O
the	O	O
present	O	O
model	O	O
is	O	O
well	O	O
suited	O	O
for	O	O
basic	O	O
research	O	O
,	O	O
as	O	O
well	O	O
as	O	O
for	O	O
assessing	O	O
the	O	O
modulation	O	O
of	O	O
central	O	O
phenomena	O	O
.	O	O

ocular	O	O
-	O	O
specific	O	O
er	O	O
stress	O	O
reduction	O	O
rescues	O	O
glaucoma	O	O
in	O	O
murine	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	O	O
.	O	O

administration	O	O
of	O	O
glucocorticoids	O	B-chem
induces	O	O
ocular	O	O
hypertension	O	O
in	O	O
some	O	O
patients	O	O
.	O	O

if	O	O
untreated	O	O
,	O	O
these	O	O
patients	O	O
can	O	O
develop	O	O
a	O	O
secondary	O	O
glaucoma	O	O
that	O	O
resembles	O	O
primary	O	O
open	O	O
-	O	O
angle	O	O
glaucoma	O	O
(	O	O
poag	O	O
)	O	O
.	O	O

the	O	O
underlying	O	O
pathology	O	O
of	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	O	O
is	O	O
not	O	O
fully	O	O
understood	O	O
,	O	O
due	O	O
in	O	O
part	O	O
to	O	O
lack	O	O
of	O	O
an	O	O
appropriate	O	O
animal	O	O
model	O	O
.	O	O

here	O	O
,	O	O
we	O	O
developed	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	O	O
that	O	O
exhibits	O	O
glaucoma	O	O
features	O	O
that	O	O
are	O	O
observed	O	O
in	O	O
patients	O	O
.	O	O

treatment	O	O
of	O	O
wt	O	O
mice	O	O
with	O	O
topical	O	O
ocular	O	O
0	O	O
.	O	O
1	O	O
%	O	O
dexamethasone	B-chem	B-chem
led	O	O
to	O	O
elevation	O	O
of	O	O
intraocular	O	O
pressure	O	O
(	O	O
iop	O	O
)	O	O
,	O	O
functional	O	O
and	O	O
structural	O	O
loss	O	O
of	O	O
retinal	O	O
ganglion	O	O
cells	O	O
,	O	O
and	O	O
axonal	O	O
degeneration	O	O
,	O	O
resembling	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	O	O
in	O	O
human	O	O
patients	O	O
.	O	O

furthermore	O	O
,	O	O
dexamethasone	B-chem	B-chem
-	O	O
induced	O	O
ocular	O	O
hypertension	O	O
was	O	O
associated	O	O
with	O	O
chronic	O	O
er	O	O
stress	O	O
of	O	O
the	O	O
trabecular	O	O
meshwork	O	O
(	O	O
tm	O	O
)	O	O
.	O	O

similar	O	O
to	O	O
patients	O	O
,	O	O
withdrawal	O	O
of	O	O
dexamethasone	B-chem	B-chem
treatment	O	O
reduced	O	O
elevated	O	O
iop	O	O
and	O	O
er	O	O
stress	O	O
in	O	O
this	O	O
animal	O	O
model	O	O
.	O	O

dexamethasone	B-chem	B-chem
induced	O	O
the	O	O
transcriptional	O	O
factor	O	O
chop	O	B-chem
,	O	O
a	O	O
marker	O	O
for	O	O
chronic	O	O
er	O	O
stress	O	O
,	O	O
in	O	O
the	O	O
anterior	O	O
segment	O	O
tissues	O	O
,	O	O
and	O	O
chop	O	O
deletion	O	O
reduced	O	O
er	O	O
stress	O	O
in	O	O
these	O	O
tissues	O	O
and	O	O
prevented	O	O
dexamethasone	B-chem	B-chem
-	O	O
induced	O	O
ocular	O	O
hypertension	O	O
.	O	O

furthermore	O	O
,	O	O
reduction	O	O
of	O	O
er	O	O
stress	O	O
in	O	O
the	O	O
tm	O	O
with	O	O
sodium	B-chem	B-chem
4	I-chem	I-chem
-	I-chem	I-chem
phenylbutyrate	I-chem	I-chem
prevented	O	O
dexamethasone	B-chem	B-chem
-	O	O
induced	O	O
ocular	O	O
hypertension	O	O
in	O	O
wt	O	O
mice	O	O
.	O	O

our	O	O
data	O	O
indicate	O	O
that	O	O
er	O	O
stress	O	O
contributes	O	O
to	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
ocular	O	O
hypertension	O	O
and	O	O
suggest	O	O
that	O	O
reducing	O	O
er	O	O
stress	O	O
has	O	O
potential	O	O
as	O	O
a	O	O
therapeutic	O	O
strategy	O	O
for	O	O
treating	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	O	O
.	O	O

effects	O	O
of	O	O
ginsenosides	B-chem	B-chem
on	O	O
opioid	O	O
-	O	O
induced	O	O
hyperalgesia	O	O
in	O	O
mice	O	O
.	O	O

opioid	O	O
-	O	O
induced	O	O
hyperalgesia	O	O
(	O	O
oih	O	B-chem
)	O	O
is	O	O
characterized	O	O
by	O	O
nociceptive	O	O
sensitization	O	O
caused	O	O
by	O	O
the	O	O
cessation	O	O
of	O	O
chronic	O	O
opioid	O	O
use	O	O
.	O	O

oih	O	B-chem
can	O	O
limit	O	O
the	O	O
clinical	O	O
use	O	O
of	O	O
opioid	O	O
analgesics	O	O
and	O	O
complicate	O	O
withdrawal	O	O
from	O	O
opioid	O	O
addiction	O	O
.	O	O

in	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
re	B-chem	O
,	I-chem	O
rg1	I-chem	B-chem
,	I-chem	O
and	I-chem	O
rb1	I-chem	O
ginsenosides	I-chem	I-chem
,	O	O
the	O	O
bioactive	O	O
components	O	O
of	O	O
ginseng	O	O
,	O	O
on	O	O
oih	O	O
.	O	O

oih	O	B-chem
was	O	O
achieved	O	O
in	O	O
mice	O	O
after	O	O
subcutaneous	O	O
administration	O	O
of	O	O
morphine	B-chem	B-chem
for	O	O
7	O	O
consecutive	O	O
days	O	O
three	O	O
times	O	O
per	O	O
day	O	O
.	O	O

during	O	O
withdrawal	O	O
(	O	O
days	O	O
8	O	O
and	O	O
9	O	O
)	O	O
,	O	O
these	O	O
mice	O	O
were	O	O
administered	O	O
re	B-chem	O
,	O	O
rg1	B-chem	B-chem
,	O	O
or	O	O
rb1	B-chem	O
intragastrically	O	O
two	O	O
times	O	O
per	O	O
day	O	O
.	O	O

on	O	O
the	O	O
test	O	O
day	O	O
(	O	O
day	O	O
10	O	O
)	O	O
,	O	O
mice	O	O
were	O	O
subjected	O	O
to	O	O
the	O	O
thermal	O	O
sensitivity	O	O
test	O	O
and	O	O
the	O	O
acetic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
writhing	O	O
test	O	O
.	O	O

re	B-chem	O
(	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
inhibited	O	O
oih	O	B-chem
in	O	O
both	O	O
the	O	O
thermal	O	O
sensitivity	O	O
test	O	O
and	O	O
the	O	O
acetic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
writhing	O	O
test	O	O
.	O	O

however	O	O
,	O	O
the	O	O
rg1	B-chem	B-chem
and	I-chem	O
rb1	I-chem	B-chem
ginsenosides	I-chem	I-chem
failed	O	O
to	O	O
prevent	O	O
oih	O	O
in	O	O
either	O	O
test	O	O
.	O	O

furthermore	O	O
,	O	O
rg1	B-chem	B-chem
showed	O	O
a	O	O
tendency	O	O
to	O	O
aggravate	O	O
oih	O	B-chem
in	O	O
the	O	O
acetic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
writhing	O	O
test	O	O
.	O	O

our	O	O
data	O	O
suggested	O	O
that	O	O
the	O	O
ginsenoside	B-chem	B-chem
re	I-chem	O
,	O	O
but	O	O
not	O	O
rg1	B-chem	B-chem
or	O	O
rb1	B-chem	O
,	O	O
may	O	O
contribute	O	O
toward	O	O
reversal	O	O
of	O	O
oih	O	B-chem
.	O	O

a	O	O
comparison	O	O
of	O	O
severe	O	O
hemodynamic	O	O
disturbances	O	O
between	O	O
dexmedetomidine	B-chem	B-chem
and	O	O
propofol	B-chem	B-chem
for	O	O
sedation	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
.	O	O

objective	O	O
:	O	O

dexmedetomidine	B-chem	B-chem
and	O	O
propofol	B-chem	B-chem
are	O	O
commonly	O	O
used	O	O
sedatives	O	O
in	O	O
neurocritical	O	O
care	O	O
as	O	O
they	O	O
allow	O	O
for	O	O
frequent	O	O
neurologic	O	O
examinations	O	O
.	O	O

however	O	O
,	O	O
both	O	O
agents	O	O
are	O	O
associated	O	O
with	O	O
significant	O	O
hemodynamic	O	O
side	O	O
effects	O	O
.	O	O

the	O	O
primary	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
compare	O	O
the	O	O
prevalence	O	O
of	O	O
severe	O	O
hemodynamic	O	O
effects	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
receiving	O	O
dexmedetomidine	B-chem	B-chem
and	O	O
propofol	B-chem	B-chem
.	O	O

design	O	O
:	O	O

multicenter	O	O
,	O	O
retrospective	O	O
,	O	O
propensity	O	O
-	O	O
matched	O	O
cohort	O	O
study	O	O
.	O	O

setting	O	O
:	O	O

neurocritical	O	O
care	O	O
units	O	O
at	O	O
two	O	O
academic	O	O
medical	O	O
centers	O	O
with	O	O
dedicated	O	O
neurocritical	O	O
care	O	O
teams	O	O
and	O	O
board	O	O
-	O	O
certified	O	O
neurointensivists	O	O
.	O	O

patients	O	O
:	O	O

neurocritical	O	O
care	O	O
patients	O	O
admitted	O	O
between	O	O
july	O	O
2009	O	O
and	O	O
september	O	O
2012	O	O
were	O	O
evaluated	O	O
and	O	O
then	O	O
matched	O	O
1	O	O
:	O	O
1	O	O
based	O	O
on	O	O
propensity	O	O
scoring	O	O
of	O	O
baseline	O	O
characteristics	O	O
.	O	O

interventions	O	O
:	O	O

continuous	O	O
sedation	O	O
with	O	O
dexmedetomidine	B-chem	B-chem
or	O	O
propofol	B-chem	B-chem
.	O	O

measurements	O	O
and	O	O
main	O	O
results	O	O
:	O	O

a	O	O
total	O	O
of	O	O
342	O	O
patients	O	O
(	O	O
105	O	O
dexmedetomidine	B-chem	B-chem
and	O	O
237	O	O
propofol	B-chem	B-chem
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
,	O	O
with	O	O
190	O	O
matched	O	O
(	O	O
95	O	O
in	O	O
each	O	O
group	O	O
)	O	O
by	O	O
propensity	O	O
score	O	O
.	O	O

the	O	O
primary	O	O
outcome	O	O
of	O	O
this	O	O
study	O	O
was	O	O
a	O	O
composite	O	O
of	O	O
severe	O	O
hypotension	O	O
(	O	O
mean	O	O
arterial	O	O
pressure	O	O
<	O	O
60	O	O
mm	O	O
hg	O	O
)	O	O
and	O	O
bradycardia	O	O
(	O	O
heart	O	O
rate	O	O
<	O	O
50	O	O
beats	O	O
/	O	O
min	O	O
)	O	O
during	O	O
sedative	O	O
infusion	O	O
.	O	O

no	O	O
difference	O	O
in	O	O
the	O	O
primary	O	O
composite	O	O
outcome	O	O
in	O	O
both	O	O
the	O	O
unmatched	O	O
(	O	O
30	O	O
%	O	O
vs	O	O
30	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
94	O	O
)	O	O
or	O	O
matched	O	O
cohorts	O	O
(	O	O
28	O	O
%	O	O
vs	O	O
34	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
35	O	O
)	O	O
could	O	O
be	O	O
found	O	O
.	O	O

when	O	O
analyzed	O	O
separately	O	O
,	O	O
no	O	O
differences	O	O
could	O	O
be	O	O
found	O	O
in	O	O
the	O	O
prevalence	O	O
of	O	O
severe	O	O
hypotension	O	O
or	O	O
bradycardia	O	O
in	O	O
either	O	O
the	O	O
unmatched	O	O
or	O	O
matched	O	O
cohorts	O	O
.	O	O

conclusions	O	O
:	O	O

severe	O	O
hypotension	O	O
and	O	O
bradycardia	O	O
occur	O	O
at	O	O
similar	O	O
prevalence	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
who	O	O
receive	O	O
dexmedetomidine	B-chem	B-chem
or	O	O
propofol	B-chem	B-chem
.	O	O

providers	O	O
should	O	O
similarly	O	O
consider	O	O
the	O	O
likelihood	O	O
of	O	O
hypotension	O	O
or	O	O
bradycardia	O	O
before	O	O
starting	O	O
either	O	O
sedative	O	O
.	O	O

hydroxytyrosol	B-chem	O
ameliorates	O	O
oxidative	O	O
stress	O	O
and	O	O
mitochondrial	O	O
dysfunction	O	O
in	O	O
doxorubicin	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
in	O	O
rats	O	O
with	O	O
breast	O	O
cancer	O	O
.	O	O

oxidative	O	O
stress	O	O
is	O	O
involved	O	O
in	O	O
several	O	O
processes	O	O
including	O	O
cancer	O	O
,	O	O
aging	O	O
and	O	O
cardiovascular	O	O
disease	O	O
,	O	O
and	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
potentiate	O	O
the	O	O
therapeutic	O	O
effect	O	O
of	O	O
drugs	O	O
such	O	O
as	O	O
doxorubicin	B-chem	B-chem
.	O	O

doxorubicin	B-chem	B-chem
causes	O	O
significant	O	O
cardiotoxicity	O	O
characterized	O	O
by	O	O
marked	O	O
increases	O	O
in	O	O
oxidative	O	O
stress	O	O
and	O	O
mitochondrial	O	O
dysfunction	O	O
.	O	O

herein	O	O
,	O	O
we	O	O
investigate	O	O
whether	O	O
doxorubicin	B-chem	B-chem
-	O	O
associated	O	O
chronic	O	O
cardiac	O	O
toxicity	O	O
can	O	O
be	O	O
ameliorated	O	O
with	O	O
the	O	O
antioxidant	O	O
hydroxytyrosol	B-chem	O
in	O	O
rats	O	O
with	O	O
breast	O	O
cancer	O	O
.	O	O

thirty	O	O
-	O	O
six	O	O
rats	O	O
bearing	O	O
breast	O	O
tumors	O	O
induced	O	O
chemically	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
control	O	O
,	O	O
hydroxytyrosol	B-chem	B-chem
(	O	O
0	O	O
.	O	O
5mg	O	O
/	O	O
kg	O	O
,	O	O
5days	O	O
/	O	O
week	O	O
)	O	O
,	O	O
doxorubicin	B-chem	B-chem
(	O	O
1mg	O	O
/	O	O
kg	O	O
/	O	O
week	O	O
)	O	O
,	O	O
and	O	O
doxorubicin	B-chem	B-chem
plus	O	O
hydroxytyrosol	B-chem	B-chem
.	O	O

cardiac	O	O
disturbances	O	O
at	O	O
the	O	O
cellular	O	O
and	O	O
mitochondrial	O	O
level	O	O
,	O	O
mitochondrial	O	O
electron	O	O
transport	O	O
chain	O	O
complexes	O	O
i	O	O
-	O	O
iv	O	O
and	O	O
apoptosis	O	O
-	O	O
inducing	O	O
factor	O	O
,	O	O
and	O	O
oxidative	O	O
stress	O	O
markers	O	O
have	O	O
been	O	O
analyzed	O	O
.	O	O

hydroxytyrosol	B-chem	B-chem
improved	O	O
the	O	O
cardiac	O	O
disturbances	O	O
enhanced	O	O
by	O	O
doxorubicin	B-chem	B-chem
by	O	O
significantly	O	O
reducing	O	O
the	O	O
percentage	O	O
of	O	O
altered	O	O
mitochondria	O	O
and	O	O
oxidative	O	O
damage	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
that	O	O
hydroxytyrosol	B-chem	B-chem
improve	O	O
the	O	O
mitochondrial	O	O
electron	O	O
transport	O	O
chain	O	O
.	O	O

this	O	O
study	O	O
demonstrates	O	O
that	O	O
hydroxytyrosol	B-chem	O
protect	O	O
rat	O	O
heart	O	O
damage	O	O
provoked	O	O
by	O	O
doxorubicin	B-chem	B-chem
decreasing	O	O
oxidative	O	O
damage	O	O
and	O	O
mitochondrial	O	O
alterations	O	O
.	O	O

amiodarone	B-chem	B-chem
-	O	O
induced	O	O
myxoedema	O	O
coma	O	O
.	O	O

a	O	O
62	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
was	O	O
found	O	O
to	O	O
have	O	O
bradycardia	O	O
,	O	O
hypothermia	O	O
and	O	O
respiratory	O	O
failure	O	O
3	O	O
weeks	O	O
after	O	O
initiation	O	O
of	O	O
amiodarone	B-chem	B-chem
therapy	O	O
for	O	O
atrial	O	O
fibrillation	O	O
.	O	O

thyroid	O	O
-	O	O
stimulating	O	O
hormone	O	O
was	O	O
found	O	O
to	O	O
be	O	O
168	O	O
uiu	O	O
/	O	O
ml	O	O
(	O	O
nl	O	O
.	O	O
0	O	O
.	O	O
3	O	O
-	O	O
5	O	O
uiu	O	O
/	O	O
ml	O	O
)	O	O
and	O	O
free	O	O
thyroxine	B-chem	B-chem
(	O	O
ft4	O	B-chem
)	O	O
was	O	O
<	O	O
0	O	O
.	O	O
2	O	O
ng	O	O
/	O	O
dl	O	O
(	O	O
nl	O	O
.	O	O
0	O	O
.	O	O
8	O	O
-	O	O
1	O	O
.	O	O
8	O	O
ng	O	O
/	O	O
dl	O	O
)	O	O
.	O	O

he	O	O
received	O	O
intravenous	O	O
fluids	O	O
,	O	O
vasopressor	O	O
therapy	O	O
and	O	O
stress	O	O
dose	O	O
steroids	B-chem	B-chem
;	O	O
he	O	O
was	O	O
intubated	O	O
and	O	O
admitted	O	O
to	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
.	O	O

he	O	O
received	O	O
500	O	O
ug	O	O
of	O	O
intravenous	O	O
levothyroxine	B-chem	B-chem
in	O	O
the	O	O
first	O	O
18	O	O
h	O	O
of	O	O
therapy	O	O
,	O	O
and	O	O
150	O	O
ug	O	O
intravenous	O	O
daily	O	O
thereafter	O	O
.	O	O

haemodynamic	O	O
improvement	O	O
,	O	O
along	O	O
with	O	O
complete	O	O
recovery	O	O
of	O	O
mental	O	O
status	O	O
,	O	O
occurred	O	O
after	O	O
48	O	O
h	O	O
.	O	O

twelve	O	O
hours	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
therapy	O	O
,	O	O
ft4	O	B-chem
was	O	O
0	O	O
.	O	O
96	O	O
ng	O	O
/	O	O
dl	O	O
.	O	O
the	O	O
patient	O	O
was	O	O
maintained	O	O
on	O	O
levothyroxine	B-chem	B-chem
175	O	O
(	O	O
g	O	O
poorally	O	O
daily	O	O
.	O	O

a	O	O
thyroid	O	O
ultrasound	O	O
showed	O	O
diffuse	O	O
heterogeneity	O	O
.	O	O

the	O	O
24	O	O
hour	O	O
excretion	O	O
of	O	O
iodine	B-chem	B-chem
was	O	O
3657	O	O
(	O	O
mcg	O	O
(	O	O
25	O	O
-	O	O
756	O	O
(	O	O
mcg	O	O
)	O	O
.	O	O

the	O	O
only	O	O
two	O	O
cases	O	O
of	O	O
amiodarone	B-chem	B-chem
-	O	O
induced	O	O
myxoedema	O	O
coma	O	O
in	O	O
the	O	O
literature	O	O
report	O	O
patient	O	O
death	O	O
despite	O	O
supportive	O	O
therapy	O	O
and	O	O
thyroid	O	O
hormone	O	O
replacement	O	O
.	O	O

this	O	O
case	O	O
represents	O	O
the	O	O
most	O	O
thoroughly	O	O
investigated	O	O
case	O	O
of	O	O
amiodarone	B-chem	B-chem
-	O	O
induced	O	O
myxoedema	O	O
coma	O	O
with	O	O
a	O	O
history	O	O
significant	O	O
for	O	O
subclinical	O	O
thyroid	O	O
disease	O	O
.	O	O

use	O	O
of	O	O
argatroban	B-chem	B-chem
and	O	O
catheter	O	O
-	O	O
directed	O	O
thrombolysis	O	O
with	O	O
alteplase	O	O
in	O	O
an	O	O
oncology	O	O
patient	O	O
with	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
with	O	O
thrombosis	O	O
.	O	O

purpose	O	O
:	O	O

the	O	O
case	O	O
of	O	O
an	O	O
oncology	O	O
patient	O	O
who	O	O
developed	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
with	O	O
thrombosis	O	O
(	O	O
hitt	O	O
)	O	O
and	O	O
was	O	O
treated	O	O
with	O	O
argatroban	B-chem	B-chem
plus	O	O
catheter	O	O
-	O	O
directed	O	O
thrombolysis	O	O
(	O	O
cdt	O	B-chem
)	O	O
with	O	O
alteplase	O	O
is	O	O
presented	O	O
.	O	O

summary	O	O
:	O	O

a	O	O
63	O	O
-	O	O
year	O	O
-	O	O
old	O	O
caucasian	O	O
man	O	O
with	O	O
renal	O	O
amyloidosis	O	O
undergoing	O	O
peripheral	O	O
blood	O	O
stem	O	O
cell	O	O
collection	O	O
for	O	O
an	O	O
autologous	O	O
stem	O	O
cell	O	O
transplant	O	O
developed	O	O
extensive	O	O
bilateral	O	O
upper	O	O
-	O	O
extremity	O	O
deep	O	O
venous	O	O
thrombosis	O	O
(	O	O
dvt	O	O
)	O	O
and	O	O
pulmonary	O	O
embolism	O	O
secondary	O	O
to	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
.	O	O

a	O	O
continuous	O	O
i	O	O
.	O	O
v	O	O
.	O	O

infusion	O	O
of	O	O
argatroban	B-chem	B-chem
was	O	O
initiated	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
managed	O	O
on	O	O
the	O	O
general	O	O
medical	O	O
floor	O	O
.	O	O

after	O	O
one	O	O
week	O	O
of	O	O
therapy	O	O
,	O	O
he	O	O
was	O	O
transferred	O	O
to	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
with	O	O
cardiopulmonary	O	O
compromise	O	O
related	O	O
to	O	O
superior	O	O
vena	O	O
cava	O	O
(	O	O
svc	O	O
)	O	O
syndrome	O	O
.	O	O

a	O	O
percutaneous	O	O
mechanical	O	O
thrombectomy	O	O
and	O	O
cdt	O	O
with	O	O
alteplase	O	O
were	O	O
attempted	O	O
,	O	O
but	O	O
the	O	O
procedure	O	O
was	O	O
aborted	O	O
due	O	O
to	O	O
epistaxis	O	O
.	O	O

the	O	O
epistaxis	O	O
resolved	O	O
the	O	O
next	O	O
day	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
restarted	O	O
on	O	O
argatroban	B-chem	B-chem
.	O	O

a	O	O
second	O	O
percutaneous	O	O
mechanical	O	O
thrombectomy	O	O
was	O	O
performed	O	O
six	O	O
days	O	O
later	O	O
and	O	O
resulted	O	O
in	O	O
partial	O	O
revascularization	O	O
of	O	O
the	O	O
svc	O	O
and	O	O
central	O	O
veins	O	O
.	O	O

postthrombectomy	O	B-chem
continuous	O	O
cdt	O	B-chem
with	O	O
alteplase	O	O
was	O	O
commenced	O	O
while	O	O
argatroban	B-chem	B-chem
was	O	O
withheld	O	O
,	O	O
and	O	O
complete	O	O
patency	O	O
of	O	O
the	O	O
svc	O	O
and	O	O
central	O	O
veins	O	O
was	O	O
achieved	O	O
after	O	O
three	O	O
days	O	O
of	O	O
therapy	O	O
.	O	O

alteplase	O	O
was	O	O
discontinued	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
reinitiated	O	O
on	O	O
argatroban	B-chem	B-chem
;	O	O
ultimately	O	O
,	O	O
he	O	O
was	O	O
transitioned	O	O
to	O	O
warfarin	B-chem	B-chem
for	O	O
long	O	O
-	O	O
term	O	O
anticoagulation	O	O
.	O	O

although	O	O
the	O	O
patient	O	O
recovered	O	O
,	O	O
he	O	O
experienced	O	O
permanent	O	O
vision	O	O
and	O	O
hearing	O	O
loss	O	O
,	O	O
as	O	O
well	O	O
as	O	O
end	O	O
-	O	O
stage	O	O
renal	O	O
disease	O	O
.	O	O

conclusion	O	O
:	O	O

a	O	O
63	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
renal	O	O
amyloidosis	O	O
and	O	O
svc	O	O
syndrome	O	O
secondary	O	O
to	O	O
hitt	O	O
was	O	O
successfully	O	O
treated	O	O
with	O	O
argatroban	B-chem	B-chem
and	O	O
cdt	O	B-chem
with	O	O
alteplase	O	O
.	O	O

effects	O	O
of	O	O
dehydroepiandrosterone	B-chem	B-chem
in	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
schizophrenia	O	O
models	O	O
in	O	O
mice	O	O
.	O	O

objective	O	O
:	O	O

to	O	O
examine	O	O
the	O	O
effects	O	O
of	O	O
dehydroepiandrosterone	B-chem	B-chem
(	O	O
dhea	B-chem	B-chem
)	O	O
on	O	O
animal	O	O
models	O	O
of	O	O
schizophrenia	O	O
.	O	O

methods	O	O
:	O	O

seventy	O	O
swiss	O	O
albino	O	O
female	O	O
mice	O	O
(	O	O
25	O	O
-	O	O
35	O	O
g	O	O
)	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
amphetamine	B-chem	B-chem
-	O	O
free	O	O
(	O	O
control	O	O
)	O	O
,	O	O
amphetamine	B-chem	B-chem
,	O	O
50	O	O
,	O	O
and	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
dhea	B-chem	B-chem
.	O	O

the	O	O
dhea	B-chem	B-chem
was	O	O
administered	O	O
intraperitoneally	O	O
(	O	O
ip	O	O
)	O	O
for	O	O
5	O	O
days	O	O
.	O	O

amphetamine	B-chem	B-chem
(	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
induced	O	O
hyper	O	O
locomotion	O	O
,	O	O
apomorphine	B-chem	B-chem
(	O	O
1	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
subcutaneously	O	O
[	O	O
sc	O	O
]	O	O
)	O	O
induced	O	O
climbing	O	O
,	O	O
and	O	O
haloperidol	B-chem	B-chem
(	O	O
1	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
)	O	O
induced	O	O
catalepsy	O	O
tests	O	O
were	O	O
used	O	O
as	O	O
animal	O	O
models	O	O
of	O	O
schizophrenia	O	O
.	O	O

the	O	O
study	O	O
was	O	O
conducted	O	O
at	O	O
the	O	O
animal	O	O
experiment	O	O
laboratories	O	O
,	O	O
department	O	O
of	O	O
pharmacology	O	O
,	O	O
medical	O	O
school	O	O
,	O	O
eskisehir	O	O
osmangazi	O	O
university	O	O
,	O	O
eskisehir	O	O
,	O	O
turkey	O	O
between	O	O
march	O	O
and	O	O
may	O	O
2012	O	O
.	O	O

statistical	O	O
analysis	O	O
was	O	O
carried	O	O
out	O	O
using	O	O
kruskal	O	B-chem
-	O	O
wallis	O	O
test	O	O
for	O	O
hyper	O	O
locomotion	O	O
,	O	O
and	O	O
one	O	O
-	O	O
way	O	O
anova	O	O
for	O	O
climbing	O	O
and	O	O
catalepsy	O	O
tests	O	O
.	O	O

results	O	O
:	O	O

in	O	O
the	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
locomotion	O	O
test	O	O
,	O	O
there	O	O
were	O	O
significant	O	O
increases	O	O
in	O	O
all	O	O
movements	O	O
compared	O	O
with	O	O
the	O	O
amphetamine	B-chem	B-chem
-	O	O
free	O	O
group	O	O
.	O	O

both	O	O
dhea	B-chem	B-chem
50	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
and	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
significantly	O	O
decreased	O	O
all	O	O
movements	O	O
compared	O	O
with	O	O
the	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
locomotion	O	O
group	O	O
.	O	O

there	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
between	O	O
groups	O	O
in	O	O
the	O	O
haloperidol	B-chem	B-chem
-	O	O
induced	O	O
catalepsy	O	O
test	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

there	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
groups	O	O
in	O	O
terms	O	O
of	O	O
total	O	O
climbing	O	O
time	O	O
in	O	O
the	O	O
apomorphine	B-chem	B-chem
-	O	O
induced	O	O
climbing	O	O
test	O	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

we	O	O
observed	O	O
that	O	O
dhea	B-chem	B-chem
reduced	O	O
locomotor	O	O
activity	O	O
and	O	O
increased	O	O
catalepsy	O	O
at	O	O
both	O	O
doses	O	O
,	O	O
while	O	O
it	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
climbing	O	O
behavior	O	O
.	O	O

we	O	O
suggest	O	O
that	O	O
dhea	B-chem	B-chem
displays	O	O
typical	O	O
neuroleptic	O	O
-	O	O
like	O	O
effects	O	O
,	O	O
and	O	O
may	O	O
be	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
schizophrenia	O	O
.	O	O

availability	O	O
of	O	O
human	O	O
induced	O	O
pluripotent	O	O
stem	O	O
cell	O	O
-	O	O
derived	O	O
cardiomyocytes	O	O
in	O	O
assessment	O	O
of	O	O
drug	O	O
potential	O	O
for	O	O
qt	O	O
prolongation	O	O
.	O	O

field	O	O
potential	O	O
duration	O	O
(	O	O
fpd	O	O
)	O	O
in	O	O
human	O	O
-	O	O
induced	O	O
pluripotent	O	O
stem	O	O
cell	O	O
-	O	O
derived	O	O
cardiomyocytes	O	O
(	O	O
hips	O	O
-	O	O
cms	O	O
)	O	O
,	O	O
which	O	O
can	O	O
express	O	O
qt	O	O
interval	O	O
in	O	O
an	O	O
electrocardiogram	O	O
,	O	O
is	O	O
reported	O	O
to	O	O
be	O	O
a	O	O
useful	O	O
tool	O	O
to	O	O
predict	O	O
k	B-chem	O
(	O	O
+	O	O
)	O	O
channel	O	O
and	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
channel	O	O
blocker	O	O
effects	O	O
on	O	O
qt	O	O
interval	O	O
.	O	O

however	O	O
,	O	O
there	O	O
is	O	O
no	O	O
report	O	O
showing	O	O
that	O	O
this	O	O
technique	O	O
can	O	O
be	O	O
used	O	O
to	O	O
predict	O	O
multichannel	O	O
blocker	O	O
potential	O	O
for	O	O
qt	O	O
prolongation	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
show	O	O
that	O	O
fpd	O	O
from	O	O
mea	O	O
(	O	O
multielectrode	O	O
array	O	O
)	O	O
of	O	O
hips	O	B-chem
-	O	O
cms	O	I-chem
can	O	O
detect	O	O
qt	O	O
prolongation	O	O
induced	O	O
by	O	O
multichannel	O	O
blockers	O	O
.	O	O

hips	O	B-chem
-	O	O
cms	O	O
were	O	O
seeded	O	O
onto	O	O
mea	O	O
and	O	O
fpd	O	O
was	O	O
measured	O	O
for	O	O
2min	O	O
every	O	O
10min	O	O
for	O	O
30min	O	O
after	O	O
drug	O	O
exposure	O	O
for	O	O
the	O	O
vehicle	O	O
and	O	O
each	O	O
drug	O	O
concentration	O	O
.	O	O

ikr	O	O
and	O	O
iks	O	O
blockers	O	O
concentration	O	O
-	O	O
dependently	O	O
prolonged	O	O
corrected	O	O
fpd	O	O
(	O	O
fpdc	O	O
)	O	O
,	O	O
whereas	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O

)	O	O
channel	O	O
blockers	O	O
concentration	O	O
-	O	O
dependently	O	O
shortened	O	O
fpdc	O	O
.	O	O

also	O	O
,	O	O
the	O	O
multichannel	O	O
blockers	O	O
amiodarone	B-chem	B-chem
,	O	O
paroxetine	B-chem	B-chem
,	O	O
terfenadine	B-chem	B-chem
and	O	O
citalopram	B-chem	B-chem
prolonged	O	O
fpdc	O	B-chem
in	O	O
a	O	O
concentration	O	O
dependent	O	O
manner	O	O
.	O	O

finally	O	O
,	O	O
the	O	O
ikr	O	O
blockers	O	O
,	O	O
terfenadine	B-chem	B-chem
and	O	O
citalopram	B-chem	B-chem
,	O	O
which	O	O
are	O	O
reported	O	O
to	O	O
cause	O	O
torsade	O	O
de	O	O
pointes	O	O
(	O	O
tdp	O	O
)	O	O
in	O	O
clinical	O	O
practice	O	O
,	O	O
produced	O	O
early	O	O
afterdepolarization	O	O
(	O	O
ead	O	O
)	O	O
.	O	O

hips	O	B-chem
-	O	O
cms	O	O
using	O	O
mea	O	O
system	O	O
and	O	O
fpdc	O	B-chem
can	O	O
predict	O	O
the	O	O
effects	O	O
of	O	O
drug	O	O
candidates	O	O
on	O	O
qt	O	O
interval	O	O
.	O	O

this	O	O
study	O	O
also	O	O
shows	O	O
that	O	O
this	O	O
assay	O	O
can	O	O
help	O	O
detect	O	O
ead	O	O
for	O	O
drugs	O	O
with	O	O
tdp	O	O
potential	O	O
.	O	O

dermal	O	O
developmental	O	O
toxicity	O	O
of	O	O
n	O	B-chem
-	O	I-chem
phenylimide	O	I-chem
herbicides	O	O
in	O	O
rats	O	O
.	O	O

background	O	O
:	O	O

s	B-chem	B-chem
-	I-chem	I-chem
53482	I-chem	I-chem
and	O	O
s	B-chem	B-chem
-	I-chem	I-chem
23121	I-chem	I-chem
are	O	O
n	O	B-chem
-	O	I-chem
phenylimide	O	I-chem
herbicides	O	I-chem
and	O	O
produced	O	O
embryolethality	O	O
,	O	O
teratogenicity	O	O
(	O	O
mainly	O	O
ventricular	O	O
septal	O	O
defects	O	O
and	O	O
wavy	O	O
ribs	O	O
)	O	O
,	O	O
and	O	O
growth	O	O
retardation	O	O
in	O	O
rats	O	O
in	O	O
conventional	O	O
oral	O	O
developmental	O	O
toxicity	O	O
studies	O	O
.	O	O

our	O	O
objective	O	O
in	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
the	O	O
compounds	O	O
induce	O	O
developmental	O	O
toxicity	O	O
via	O	O
the	O	O
dermal	O	O
route	O	O
,	O	O
which	O	O
is	O	O
more	O	O
relevant	O	O
to	O	O
occupational	O	O
exposure	O	O
,	O	O
hence	O	O
better	O	O
addressing	O	O
human	O	O
health	O	O
risks	O	O
.	O	O

methods	O	O
:	O	O

s	B-chem	B-chem
-	I-chem	I-chem
53482	I-chem	I-chem
was	O	O
administered	O	O
dermally	O	O
to	O	O
rats	O	O
at	O	O
30	O	O
,	O	O
100	O	O
,	O	O
and	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
during	O	O
organogenesis	O	O
,	O	O
and	O	O
s	B-chem	O
-	I-chem	O
23121	I-chem	O
was	O	O
administered	O	O
at	O	O
200	O	O
,	O	O
400	O	O
,	O	O
and	O	O
800	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
the	O	O
maximum	O	O
applicable	O	O
dose	O	O
level	O	O
)	O	O
.	O	O

fetuses	O	O
were	O	O
obtained	O	O
by	O	O
a	O	O
cesarean	O	O
section	O	O
and	O	O
examined	O	O
for	O	O
external	O	O
,	O	O
visceral	O	O
,	O	O
and	O	O
skeletal	O	O
alterations	O	O
.	O	O

results	O	O
:	O	O

dermal	O	O
exposure	O	O
of	O	O
rats	O	O
to	O	O
s	B-chem	O
-	I-chem	O
53482	I-chem	O
at	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
produced	O	O
patterns	O	O
of	O	O
developmental	O	O
toxicity	O	O
similar	O	O
to	O	O
those	O	O
resulting	O	O
from	O	O
oral	O	O
exposure	O	O
.	O	O

toxicity	O	O
included	O	O
embryolethality	O	O
,	O	O
teratogenicity	O	O
,	O	O
and	O	O
growth	O	O
retardation	O	O
.	O	O

dermal	O	O
administration	O	O
of	O	O
s	B-chem	B-chem
-	I-chem	I-chem
23121	I-chem	I-chem
at	O	O
800	O	O
mg	O	O
/	O	O
kg	O	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
embryonic	O	O
death	O	O
and	O	O
ventricular	O	O
septal	O	O
defect	O	O
,	O	O
but	O	O
retarded	O	O
fetal	O	O
growth	O	O
was	O	O
not	O	O
observed	O	O
as	O	O
it	O	O
was	O	O
following	O	O
oral	O	O
exposure	O	O
to	O	O
s	B-chem	B-chem
-	I-chem	I-chem
23121	I-chem	I-chem
.	O	O

conclusions	O	O
:	O	O

based	O	O
on	O	O
the	O	O
results	O	O
,	O	O
s	B-chem	O
-	I-chem	O
53482	I-chem	O
and	O	O
s	B-chem	B-chem
-	I-chem	I-chem
23121	I-chem	I-chem
were	O	O
teratogenic	O	O
when	O	O
administered	O	O
dermally	O	O
to	O	O
pregnant	O	O
rats	O	O
as	O	O
were	O	O
the	O	O
compounds	O	O
administered	O	O
orally	O	O
.	O	O

thus	O	O
,	O	O
investigation	O	O
of	O	O
the	O	O
mechanism	O	O
and	O	O
its	O	O
human	O	O
relevancy	O	O
become	O	O
more	O	O
important	O	O
.	O	O

rates	O	O
of	O	O
renal	O	O
toxicity	O	O
in	O	O
cancer	O	O
patients	O	O
receiving	O	O
cisplatin	B-chem	B-chem
with	O	O
and	O	O
without	O	O
mannitol	B-chem	B-chem
.	O	O

background	O	O
:	O	O

cisplatin	B-chem	B-chem
is	O	O
a	O	O
widely	O	O
used	O	O
antineoplastic	O	O
.	O	O

one	O	O
of	O	O
the	O	O
major	O	O
complications	O	O
of	O	O
cisplatin	B-chem	B-chem
use	O	O
is	O	O
dose	O	O
-	O	O
limiting	O	O
nephrotoxicity	O	O
.	O	O

there	O	O
are	O	O
many	O	O
strategies	O	O
to	O	O
prevent	O	O
this	O	O
toxicity	O	O
,	O	O
including	O	O
the	O	O
use	O	O
of	O	O
mannitol	B-chem	B-chem
as	O	O
a	O	O
nephroprotectant	O	O
in	O	O
combination	O	O
with	O	O
hydration	O	O
.	O	O

objective	O	O
:	O	O
we	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
rates	O	O
of	O	O
cisplatin	B-chem	B-chem
-	O	O
induced	O	O
nephrotoxicity	O	O
in	O	O
cancer	O	O
patients	O	O
receiving	O	O
single	O	O
-	O	O
agent	O	O
cisplatin	B-chem	B-chem
with	O	O
and	O	O
without	O	O
mannitol	B-chem	B-chem
.	O	O

methods	O	O
:	O	O

this	O	O
single	O	O
-	O	O
center	O	O
retrospective	O	O
analysis	O	O
was	O	O
a	O	O
quasi	O	O
experiment	O	O
created	O	O
by	O	O
the	O	O
national	O	O
mannitol	B-chem	B-chem
shortage	O	O
.	O	O

data	O	O
were	O	O
collected	O	O
on	O	O
adult	O	O
cancer	O	O
patients	O	O
receiving	O	O
single	O	O
-	O	O
agent	O	O
cisplatin	B-chem	B-chem
as	O	O
an	O	O
outpatient	O	O
from	O	O
january	O	O
2011	O	O
to	O	O
september	O	O
2012	O	O
.	O	O

the	O	O
primary	O	O
outcome	O	O
was	O	O
acute	O	O
kidney	O	O
injury	O	O
(	O	O
aki	O	O
)	O	O
.	O	O

results	O	O
:	O	O

we	O	O
evaluated	O	O
143	O	O
patients	O	O
who	O	O
received	O	O
single	O	O
-	O	O
agent	O	O
cisplatin	B-chem	B-chem
;	O	O
97	O	O
.	O	O
2	O	O
%	O	O
of	O	O
patients	O	O
had	O	O
head	O	O
and	O	O
neck	O	O
cancer	O	O
as	O	O
their	O	O
primary	O	O
malignancy	O	O
.	O	O

patients	O	O
who	O	O
did	O	O
not	O	O
receive	O	O
mannitol	B-chem	B-chem
were	O	O
more	O	O
likely	O	O
to	O	O
develop	O	O
nephrotoxicity	O	O
:	O	O
odds	O	O
ratio	O	O
[	O	O
or	O	O
]	O	O

=	O	O
2	O	O
.	O	O
646	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
1	O	O
.	O	O
008	O	O
,	O	O
6	O	O
.	O	O
944	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
048	O	O
)	O	O
.	O	O

patients	O	O
who	O	O
received	O	O
the	O	O
100	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
dosing	O	O
and	O	O
patients	O	O
who	O	O
had	O	O
a	O	O
history	O	O
of	O	O
hypertension	O	O
also	O	O
had	O	O
a	O	O
higher	O	O
likelihood	O	O
of	O	O
developing	O	O
nephrotoxicity	O	O
:	O	O
or	O	O
=	O	O
11	O	O
.	O	O
494	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
4	O	O
.	O	O
149	O	O
,	O	O
32	O	O
.	O	O
258	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
and	O	O
or	O	O
=	O	O
3	O	O
.	O	O
219	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
1	O	O
.	O	O
228	O	O
,	O	O
8	O	O
.	O	O
439	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
017	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

conclusions	O	O
:	O	O

when	O	O
limited	O	O
quantities	O	O
of	O	O
mannitol	B-chem	B-chem
are	O	O
available	O	O
,	O	O
it	O	O
should	O	O
preferentially	O	O
be	O	O
given	O	O
to	O	O
patients	O	O
at	O	O
particularly	O	O
high	O	O
risk	O	O
of	O	O
nephrotoxicity	O	O
.	O	O

our	O	O
analysis	O	O
suggests	O	O
that	O	O
those	O	O
patients	O	O
receiving	O	O
the	O	O
dosing	O	O
schedule	O	O
of	O	O
100	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
cisplatin	B-chem	B-chem
every	O	O
3	O	O
weeks	O	O
and	O	O
those	O	O
with	O	O
hypertension	O	O
are	O	O
at	O	O
the	O	O
greatest	O	O
risk	O	O
of	O	O
nephrotoxicity	O	O
and	O	O
would	O	O
benefit	O	O
from	O	O
the	O	O
addition	O	O
of	O	O
mannitol	B-chem	B-chem
.	O	O

metformin	B-chem	B-chem
protects	O	O
against	O	O
seizures	O	O
,	O	O
learning	O	O
and	O	O
memory	O	O
impairments	O	O
and	O	O
oxidative	O	O
damage	O	O
induced	O	O
by	O	O
pentylenetetrazole	B-chem	B-chem
-	O	O
induced	O	O
kindling	O	O
in	O	O
mice	O	O
.	O	O

cognitive	O	O
impairment	O	O
,	O	O
the	O	O
most	O	O
common	O	O
and	O	O
severe	O	O
comorbidity	O	O
of	O	O
epilepsy	O	O
,	O	O
greatly	O	O
diminishes	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

however	O	O
,	O	O
current	O	O
therapeutic	O	O
interventions	O	O
for	O	O
epilepsy	O	O
can	O	O
also	O	O
cause	O	O
untoward	O	O
cognitive	O	O
effects	O	O
.	O	O

thus	O	O
,	O	O
there	O	O
is	O	O
an	O	O
urgent	O	O
need	O	O
for	O	O
new	O	O
kinds	O	O
of	O	O
agents	O	O
targeting	O	O
both	O	O
seizures	O	O
and	O	O
cognition	O	O
deficits	O	O
.	O	O

oxidative	O	O
stress	O	O
is	O	O
considered	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
epileptogenesis	O	O
and	O	O
cognitive	O	O
deficits	O	O
,	O	O
and	O	O
antioxidants	O	O
have	O	O
a	O	O
putative	O	O
antiepileptic	O	O
potential	O	O
.	O	O

metformin	B-chem	B-chem
,	O	O
the	O	O
most	O	O
commonly	O	O
prescribed	O	O
antidiabetic	O	O
oral	O	O
drug	O	O
,	O	O
has	O	O
antioxidant	O	O
properties	O	O
.	O	O

this	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
ameliorative	O	O
effects	O	O
of	O	O
metformin	B-chem	B-chem
on	O	O
seizures	O	O
,	O	O
cognitive	O	O
impairment	O	O
and	O	O
brain	O	O
oxidative	O	O
stress	O	O
markers	O	O
observed	O	O
in	O	O
pentylenetetrazole	B-chem	B-chem
-	O	O
induced	O	O
kindling	O	O
animals	O	O
.	O	O

male	O	O
c57bl	O	O
/	O	O
6	O	O
mice	O	O
were	O	O
administered	O	O
with	O	O
subconvulsive	O	O
dose	O	O
of	O	O
pentylenetetrazole	B-chem	B-chem
(	O	O
37	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O

every	O	O
other	O	O
day	O	O
for	O	O
14	O	O
injections	O	O
.	O	O

metformin	B-chem	B-chem
was	O	O
injected	O	O
intraperitoneally	O	O
in	O	O
dose	O	O
of	O	O
200mg	O	O
/	O	O
kg	O	O
along	O	O
with	O	O
alternate	O	O
-	O	O
day	O	O
ptz	B-chem	B-chem
.	O	O

we	O	O
found	O	O
that	O	O
metformin	B-chem	B-chem
suppressed	O	O
the	O	O
progression	O	O
of	O	O
kindling	O	O
,	O	O
ameliorated	O	O
the	O	O
cognitive	O	O
impairment	O	O
and	O	O
decreased	O	O
brain	O	O
oxidative	O	O
stress	O	O
.	O	O

thus	O	O
the	O	O
present	O	O
study	O	O
concluded	O	O
that	O	O
metformin	B-chem	B-chem
may	O	O
be	O	O
a	O	O
potential	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
epilepsy	O	O
as	O	O
well	O	O
as	O	O
a	O	O
protective	O	O
medicine	O	O
against	O	O
cognitive	O	O
impairment	O	O
induced	O	O
by	O	O
seizures	O	O
.	O	O

p53	O	O
inhibition	O	O
exacerbates	O	O
late	O	O
-	O	O
stage	O	O
anthracycline	B-chem	B-chem
cardiotoxicity	O	O
.	O	O

aims	O	O
:	O	O

doxorubicin	B-chem	B-chem
(	O	O
dox	B-chem	B-chem
)	O	O
is	O	O
an	O	O
effective	O	O
anti	O	O
-	O	O
cancer	O	O
therapeutic	O	O
,	O	O
but	O	O
is	O	O
associated	O	O
with	O	O
both	O	O
acute	O	O
and	O	O
late	O	O
-	O	O
stage	O	O
cardiotoxicity	O	O
.	O	O

children	O	O
are	O	O
particularly	O	O
sensitive	O	O
to	O	O
dox	B-chem	B-chem
-	O	O
induced	O	O
heart	O	O
failure	O	O
.	O	O

here	O	O
,	O	O
the	O	O
impact	O	O
of	O	O
p53	O	O
inhibition	O	O
on	O	O
acute	O	O
vs	O	O
.	O	O
late	O	O
-	O	O
stage	O	O
dox	B-chem	B-chem
cardiotoxicity	O	O
was	O	O
examined	O	O
in	O	O
a	O	O
juvenile	O	O
model	O	O
.	O	O

methods	O	O
and	O	O
results	O	O
:	O	O

two	O	O
-	O	O
week	O	O
-	O	O
old	O	O
mhc	O	O
-	O	O
cb7	O	O
mice	O	O
(	O	O
which	O	O
express	O	O
dominant	O	O
-	O	O
interfering	O	O
p53	O	O
in	O	O
cardiomyocytes	O	O
)	O	O
and	O	O
their	O	O
non	O	O
-	O	O
transgenic	O	O
(	O	O
non	O	O
-	O	O
txg	O	O
)	O	O
littermates	O	O
received	O	O
weekly	O	O
dox	B-chem	B-chem
injections	O	O
for	O	O
5	O	O
weeks	O	O
(	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
cumulative	O	O
dose	O	O
)	O	O
.	O	O

one	O	O
week	O	O
after	O	O
the	O	O
last	O	O
dox	B-chem	B-chem
treatment	O	O
(	O	O
acute	O	O
stage	O	O
)	O	O
,	O	O
mhc	O	O
-	O	O
cb7	O	O
mice	O	O
exhibited	O	O
improved	O	O
cardiac	O	O
function	O	O
and	O	O
lower	O	O
levels	O	O
of	O	O
cardiomyocyte	O	O
apoptosis	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
non	O	O
-	O	O
txg	O	O
mice	O	O
.	O	O

surprisingly	O	O
,	O	O
by	O	O
13	O	O
weeks	O	O
following	O	O
the	O	O
last	O	O
dox	B-chem	B-chem
treatment	O	O
(	O	O
late	O	O
stage	O	O
)	O	O
,	O	O
mhc	O	O
-	O	O
cb7	O	O
exhibited	O	O
a	O	O
progressive	O	O
decrease	O	O
in	O	O
cardiac	O	O
function	O	O
and	O	O
higher	O	O
rates	O	O
of	O	O
cardiomyocyte	O	O
apoptosis	O	O
when	O	O
compared	O	O
with	O	O
non	O	O
-	O	O
txg	O	O
mice	O	O
.	O	O

p53	O	O
inhibition	O	O
blocked	O	O
transient	O	O
dox	B-chem	B-chem
-	O	O
induced	O	O
stat3	O	O
activation	O	O
in	O	O
mhc	O	O
-	O	O
cb7	O	O
mice	O	O
,	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
enhanced	O	O
induction	O	O
of	O	O
the	O	O
dna	O	O
repair	O	O
proteins	O	O
ku70	O	O
and	O	O
ku80	O	O
.	O	O

mice	O	O
with	O	O
cardiomyocyte	O	O
-	O	O
restricted	O	O
deletion	O	O
of	O	O
stat3	O	O
exhibited	O	O
worse	O	O
cardiac	O	O
function	O	O
,	O	O
higher	O	O
levels	O	O
of	O	O
cardiomyocyte	O	O
apoptosis	O	O
,	O	O
and	O	O
a	O	O
greater	O	O
induction	O	O
of	O	O
ku70	O	O
and	O	O
ku80	O	O
in	O	O
response	O	O
to	O	O
dox	B-chem	B-chem
treatment	O	O
during	O	O
the	O	O
acute	O	O
stage	O	O
when	O	O
compared	O	O
with	O	O
control	O	O
animals	O	O
.	O	O

conclusion	O	O
:	O	O

these	O	O
data	O	O
support	O	O
a	O	O
model	O	O
wherein	O	O
a	O	O
p53	O	O
-	O	O
dependent	O	O
cardioprotective	O	O
pathway	O	O
,	O	O
mediated	O	O
via	O	O
stat3	O	O
activation	O	O
,	O	O
mitigates	O	O
dox	B-chem	B-chem
-	O	O
induced	O	O
myocardial	O	O
stress	O	O
during	O	O
drug	O	O
delivery	O	O
.	O	O

furthermore	O	O
,	O	O
these	O	O
data	O	O
suggest	O	O
an	O	O
explanation	O	O
as	O	O
to	O	O
how	O	O
p53	O	O
inhibition	O	O
can	O	O
result	O	O
in	O	O
cardioprotection	O	O
during	O	O
drug	O	O
treatment	O	O
and	O	O
,	O	O
paradoxically	O	O
,	O	O
enhanced	O	O
cardiotoxicity	O	O
long	O	O
after	O	O
the	O	O
cessation	O	O
of	O	O
drug	O	O
treatment	O	O
.	O	O

metronidazole	B-chem	B-chem
-	O	O
induced	O	O
encephalopathy	O	O
:	O	O
an	O	O
uncommon	O	O
scenario	O	O
.	O	O

metronidazole	B-chem	B-chem
can	O	O
produce	O	O
neurological	O	O
complications	O	O
although	O	O
it	O	O
is	O	O
not	O	O
a	O	O
common	O	O
scenario	O	O
.	O	O

we	O	O
present	O	O
a	O	O
case	O	O
where	O	O
a	O	O
patient	O	O
developed	O	O
features	O	O
of	O	O
encephalopathy	O	O
following	O	O
prolonged	O	O
metronidazole	B-chem	B-chem
intake	O	O
.	O	O

magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
mri	O	O
)	O	O
brain	O	O
showed	O	O
abnormal	O	O
signal	O	O
intensity	O	O
involving	O	O
both	O	O
dentate	O	O
nuclei	O	O
of	O	O
cerebellum	O	O
and	O	O
splenium	O	O
of	O	O
corpus	O	O
callosum	O	O
.	O	O

the	O	O
diagnosis	O	O
of	O	O
metronidazole	B-chem	B-chem
toxicity	O	O
was	O	O
made	O	O
by	O	O
the	O	O
mri	O	O
findings	O	O
and	O	O
supported	O	O
clinically	O	O
.	O	O

aconitine	B-chem	B-chem
-	O	O
induced	O	O
ca2	B-chem	B-chem
+	O	O
overload	O	O
causes	O	O
arrhythmia	O	O
and	O	O
triggers	O	O
apoptosis	O	O
through	O	O
p38	O	O
mapk	O	O
signaling	O	O
pathway	O	O
in	O	O
rats	O	O
.	O	O

aconitine	B-chem	B-chem
is	O	O
a	O	O
major	O	O
bioactive	O	O
diterpenoid	O	O
alkaloid	O	B-chem
with	O	O
high	O	O
content	O	O
derived	O	O
from	O	O
herbal	O	O
aconitum	O	O
plants	O	O
.	O	O

emerging	O	O
evidence	O	O
indicates	O	O
that	O	O
voltage	O	O
-	O	O
dependent	O	O
na	B-chem	B-chem
(	O	O
+	O	O
)	O	O
channels	O	O
have	O	O
pivotal	O	O
roles	O	O
in	O	O
the	O	O
cardiotoxicity	O	O
of	O	O
aconitine	B-chem	B-chem
.	O	O

however	O	O
,	O	O
no	O	O
reports	O	O
are	O	O
available	O	O
on	O	O
the	O	O
role	O	O
of	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
in	O	O
aconitine	B-chem	B-chem
poisoning	O	O
.	O	O

in	O	O
this	O	O
study	O	O
,	O	O
we	O	O
explored	O	O
the	O	O
importance	O	O
of	O	O
pathological	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
signaling	O	O
in	O	O
aconitine	B-chem	B-chem
poisoning	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

we	O	O
found	O	O
that	O	O
ca	B-chem	B-chem
(	O	O
2	O	I-chem

+	O	O
)	O	O
overload	O	O
lead	O	O
to	O	O
accelerated	O	O
beating	O	O
rhythm	O	O
in	O	O
adult	O	O
rat	O	O
ventricular	O	O
myocytes	O	O
and	O	O
caused	O	O
arrhythmia	O	O
in	O	O
conscious	O	O
freely	O	O
moving	O	O
rats	O	O
.	O	O

to	O	O
investigate	O	O
effects	O	O
of	O	O
aconitine	B-chem	B-chem
on	O	O
myocardial	O	O
injury	O	O
,	O	O
we	O	O
performed	O	O
cytotoxicity	O	O
assay	O	O
in	O	O
neonatal	O	O
rat	O	O
ventricular	O	O
myocytes	O	O
(	O	O
nrvms	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
measured	O	O
lactate	B-chem	B-chem
dehydrogenase	O	O
level	O	O
in	O	O
the	O	O
culture	O	O
medium	O	O
of	O	O
nrvms	O	O
and	O	O
activities	O	O
of	O	O
serum	O	O
cardiac	O	O
enzymes	O	O
in	O	O
rats	O	O
.	O	O

the	O	O
results	O	O
showed	O	O
that	O	O
aconitine	B-chem	B-chem
resulted	O	O
in	O	O
myocardial	O	O
injury	O	O
and	O	O
reduced	O	O
nrvms	O	O
viability	O	O
dose	O	O
-	O	O
dependently	O	O
.	O	O

to	O	O
confirm	O	O
the	O	O
pro	O	O
-	O	O
apoptotic	O	O
effects	O	O
,	O	O
we	O	O
performed	O	O
flow	O	O
cytometric	O	O
detection	O	O
,	O	O
cardiac	O	O
histology	O	O
,	O	O
transmission	O	O
electron	O	O
microscopy	O	O
and	O	O
terminal	O	O
deoxynucleotidyl	O	O
transferase	O	O
-	O	O
mediated	O	O
dutp	B-chem	B-chem
-	O	I-chem
biotin	B-chem	B-chem
nick	O	O
end	O	O
labeling	O	O
assay	O	O
.	O	O

the	O	O
results	O	O
showed	O	O
that	O	O
aconitine	B-chem	B-chem
stimulated	O	O
apoptosis	O	O
time	O	O
-	O	O
dependently	O	O
.	O	O

the	O	O
expression	O	O
analysis	O	O
of	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
handling	O	O
proteins	O	O
demonstrated	O	O
that	O	O
aconitine	B-chem	B-chem
promoted	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
overload	O	O
through	O	O
the	O	O
expression	O	O
regulation	O	O
of	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
handling	O	O
proteins	O	O
.	O	O

the	O	O
expression	O	O
analysis	O	O
of	O	O
apoptosis	O	O
-	O	O
related	O	O
proteins	O	O
revealed	O	O
that	O	O
pro	O	O
-	O	O
apoptotic	O	O
protein	O	O
expression	O	O
was	O	O
upregulated	O	O
,	O	O
and	O	O
anti	O	O
-	O	O
apoptotic	O	O
protein	O	O
bcl	O	B-chem
-	O	O
2	O	O
expression	O	O
was	O	O
downregulated	O	O
.	O	O

furthermore	O	O
,	O	O
increased	O	O
phosphorylation	O	O
of	O	O
mapk	O	O
family	O	O
members	O	O
,	O	O
especially	O	O
the	O	O
p	O	O
-	O	O
p38	O	O
/	O	O
p38	O	O
ratio	O	O
was	O	O
found	O	O
in	O	O
cardiac	O	O
tissues	O	O
.	O	O

hence	O	O
,	O	O
our	O	O
results	O	O
suggest	O	O
that	O	O
aconitine	B-chem	B-chem
significantly	O	O
aggravates	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
overload	O	O
and	O	O
causes	O	O
arrhythmia	O	O
and	O	O
finally	O	O
promotes	O	O
apoptotic	O	O
development	O	O
via	O	O
phosphorylation	O	O
of	O	O
p38	O	O
mitogen	O	O
-	O	O
activated	O	O
protein	O	O
kinase	O	O
.	O	O

chronic	O	O
treatment	O	O
with	O	O
metformin	B-chem	B-chem
suppresses	O	O
toll	O	B-chem
-	O	O
like	O	O
receptor	O	O
4	O	O
signaling	O	O
and	O	O
attenuates	O	O
left	O	O
ventricular	O	O
dysfunction	O	O
following	O	O
myocardial	O	O
infarction	O	O
.	O	O

acute	O	O
treatment	O	O
with	O	O
metformin	B-chem	B-chem
has	O	O
a	O	O
protective	O	O
effect	O	O
in	O	O
myocardial	O	O
infarction	O	O
by	O	O
suppression	O	O
of	O	O
inflammatory	O	O
responses	O	O
due	O	O
to	O	O
activation	O	O
of	O	O
amp	B-chem	B-chem
-	O	O
activated	O	O
protein	O	O
kinase	O	O
(	O	O
ampk	O	O
)	O	O
.	O	O

in	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
metformin	B-chem	B-chem
on	O	O
cardiac	O	O
dysfunction	O	O
and	O	O
toll	O	O
-	O	O
like	O	O
receptor	O	O
4	O	O
(	O	O
tlr4	O	O
)	O	O
activities	O	O
following	O	O
myocardial	O	O
infarction	O	O
and	O	O
their	O	O
relation	O	O
with	O	O
ampk	O	B-chem
were	O	O
assessed	O	O
.	O	O

male	O	O
wistar	O	O
rats	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
5	O	O
groups	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
:	O	O
normal	O	O
control	O	O
and	O	O
groups	O	O
were	O	O
injected	O	O
isoproterenol	B-chem	B-chem
after	O	O
chronic	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
0	O	O
,	O	O
25	O	O
,	O	O
50	O	O
,	O	O
or	O	O
100mg	O	O
/	O	O
kg	O	O
of	O	O
metformin	B-chem	B-chem
twice	O	O
daily	O	O
for	O	O
14	O	O
days	O	O
.	O	O

isoproterenol	B-chem	B-chem
(	O	O
100mg	O	B-chem
/	O	O
kg	O	O
)	O	O
was	O	O
injected	O	O
subcutaneously	O	O
on	O	O
the	O	O
13th	O	O
and	O	O
14th	O	O
days	O	O
to	O	O
induce	O	O
acute	O	O
myocardial	O	O
infarction	O	O
.	O	O

isoproterenol	B-chem	B-chem
alone	O	O
decreased	O	O
left	O	O
ventricular	O	O
systolic	O	O
pressure	O	O
and	O	O
myocardial	O	O
contractility	O	O
indexed	O	O
as	O	O
lvdp	O	O
/	O	O
dtmax	O	O
and	O	O
lvdp	O	O
/	O	O
dtmin	O	O
.	O	O

the	O	O
left	O	O
ventricular	O	O
dysfunction	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
groups	O	O
treated	O	O
with	O	O
25	O	O
and	O	O
50mg	O	O
/	O	O
kg	O	O
of	O	O
metformin	B-chem	B-chem
.	O	O

metfromin	O	B-chem
markedly	O	O
lowered	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
elevation	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
tlr4	O	O
mrna	O	O
,	O	O
myeloid	O	O
differentiation	O	O
protein	O	O
88	O	O
(	O	O
myd88	O	O
)	O	O
,	O	O
tumor	O	O
necrosis	O	O
factor	O	O
-	O	O
alpha	O	O
(	O	O
tnf	O	O
-	O	O
a	O	O
)	O	O
,	O	O
and	O	O
interleukin	O	O
6	O	O
(	O	O
il	O	O
-	O	O
6	O	O
)	O	O
in	O	O
the	O	O
heart	O	O
tissues	O	O
.	O	O

similar	O	O
changes	O	O
were	O	O
also	O	O
seen	O	O
in	O	O
the	O	O
serum	O	O
levels	O	O
of	O	O
tnf	O	O
-	O	O
a	O	O
and	O	O
il	O	O
-	O	O
6	O	O
.	O	O

however	O	O
,	O	O
the	O	O
lower	O	O
doses	O	O
of	O	O
25	O	O
and	O	O
50mg	O	O
/	O	O
kg	O	O
were	O	O
more	O	O
effective	O	O
than	O	O
100mg	O	O
/	O	O
kg	O	O
.	O	O

phosphorylated	O	B-chem
ampka	O	I-chem
(	O	O
p	O	B-chem
-	O	I-chem
ampk	O	I-chem
)	O	O
in	O	O
the	O	O
myocardium	O	O
was	O	O
significantly	O	O
elevated	O	O
by	O	O
25mg	O	O
/	O	O
kg	O	O
of	O	O
metformin	B-chem	B-chem
,	O	O
slightly	O	O
by	O	O
50mg	O	B-chem
/	O	O
kg	O	O
,	O	O
but	O	O
not	O	O
by	O	O
100mg	O	O
/	O	O
kg	O	O
.	O	O

chronic	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
metformin	B-chem	B-chem
reduces	O	O
post	O	O
-	O	O
myocardial	O	O
infarction	O	O
cardiac	O	O
dysfunction	O	O
and	O	O
suppresses	O	O
inflammatory	O	O
responses	O	O
,	O	O
possibly	O	O
through	O	O
inhibition	O	O
of	O	O
tlr4	O	O
activities	O	O
.	O	O

this	O	O
mechanism	O	O
can	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
target	O	O
to	O	O
protect	O	O
infarcted	O	O
myocardium	O	O
.	O	O

neuroleptic	O	O
malignant	O	O
syndrome	O	O
induced	O	O
by	O	O
combination	O	O
therapy	O	O
with	O	O
tetrabenazine	B-chem	B-chem
and	O	O
tiapride	B-chem	B-chem
in	O	O
a	O	O
japanese	O	O
patient	O	O
with	O	O
huntington	O	O
'	O	O
s	O	O
disease	O	O
at	O	O
the	O	O
terminal	O	O
stage	O	O
of	O	O
recurrent	O	O
breast	O	O
cancer	O	O
.	O	O

we	O	O
herein	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
an	O	O
81	O	O
-	O	O
year	O	O
-	O	O
old	O	O
japanese	O	O
woman	O	O
with	O	O
neuroleptic	O	O
malignant	O	O
syndrome	O	O
that	O	O
occurred	O	O
36	O	O
days	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
combination	O	O
therapy	O	O
with	O	O
tiapride	B-chem	B-chem
(	O	O
75	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
and	O	O
tetrabenazine	B-chem	B-chem
(	O	O
12	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
for	O	O
huntington	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

the	O	O
patient	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
tiapride	B-chem	B-chem
or	O	O
tetrabenazine	B-chem	B-chem
alone	O	O
without	O	O
any	O	O
adverse	O	O
effects	O	O
before	O	O
the	O	O
administration	O	O
of	O	O
the	O	O
combination	O	O
therapy	O	O
.	O	O

she	O	O
also	O	O
had	O	O
advanced	O	O
breast	O	O
cancer	O	O
when	O	O
the	O	O
combination	O	O
therapy	O	O
was	O	O
initiated	O	O
.	O	O

to	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
the	O	O
occurrence	O	O
of	O	O
neuroleptic	O	O
malignant	O	O
syndrome	O	O
due	O	O
to	O	O
combination	O	O
therapy	O	O
with	O	O
tetrabenazine	B-chem	B-chem
and	O	O
tiapride	B-chem	B-chem
has	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O

tetrabenazine	B-chem	B-chem
should	O	O
be	O	O
administered	O	O
very	O	O
carefully	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
neuroleptic	B-chem	O
drugs	I-chem	O
,	O	O
particularly	O	O
in	O	O
patients	O	O
with	O	O
a	O	O
worsening	O	O
general	O	O
condition	O	O
.	O	O

a	O	O
metoprolol	B-chem	B-chem
-	O	O
terbinafine	B-chem	B-chem
combination	O	O
induced	O	O
bradycardia	O	O
.	O	O

to	O	O
report	O	O
a	O	O
sinus	O	O
bradycardia	O	O
induced	O	O
by	O	O
metoprolol	B-chem	B-chem
and	O	O
terbinafine	B-chem	B-chem
drug	O	O
-	O	O
drug	O	O
interaction	O	O
and	O	O
its	O	O
management	O	O
.	O	O

a	O	O
63	O	O
year	O	O
-	O	O
old	O	O
caucasian	O	O
man	O	O
on	O	O
metoprolol	B-chem	B-chem
200	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
stable	O	O
coronary	O	O
artery	O	O
disease	O	O
was	O	O
prescribed	O	O
a	O	O
90	O	O
-	O	O
day	O	O
course	O	O
of	O	O
oral	O	O
terbinafine	B-chem	B-chem
250	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
onychomycosis	O	O
.	O	O

on	O	O
the	O	O
49th	O	O
day	O	O
of	O	O
terbinafine	B-chem	B-chem
therapy	O	O
,	O	O
he	O	O
was	O	O
brought	O	O
to	O	O
the	O	O
emergency	O	O
room	O	O
for	O	O
a	O	O
decrease	O	O
of	O	O
his	O	O
global	O	O
health	O	O
status	O	O
,	O	O
confusion	O	O
and	O	O
falls	O	O
.	O	O

the	O	O
electrocardiogram	O	O
revealed	O	O
a	O	O
37	O	O
beats	O	O
/	O	O
min	O	O
sinus	O	O
bradycardia	O	O
.	O	O

a	O	O
score	O	O
of	O	O
7	O	O
on	O	O
the	O	O
naranjo	O	O
adverse	O	O
drug	O	O
reaction	O	O
probability	O	O
scale	O	O
indicates	O	O
a	O	O
probable	O	O
relationship	O	O
between	O	O
the	O	O
patient	O	O
'	O	O
s	O	O
sinus	O	O
bradycardia	O	O
and	O	O
the	O	O
drug	O	O
interaction	O	O
between	O	O
metoprolol	B-chem	B-chem
and	O	O
terbinafine	B-chem	B-chem
.	O	O

the	O	O
heart	O	O
rate	O	O
ameliorated	O	O
first	O	O
with	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
dose	O	O
of	O	O
metoprolol	B-chem	B-chem
.	O	O

it	O	O
was	O	O
subsequently	O	O
changed	O	O
to	O	O
bisoprolol	B-chem	B-chem
and	O	O
the	O	O
heart	O	O
rate	O	O
remained	O	O
normal	O	O
.	O	O

by	O	O
inhibiting	O	O
the	O	O
cytochrome	O	O
p450	O	O
2d6	O	O
,	O	O
terbinafine	B-chem	B-chem
had	O	O
decreased	O	O
metoprolol	B-chem	B-chem
'	O	O
s	O	O
clearance	O	O
,	O	O
leading	O	O
in	O	O
metoprolol	B-chem	B-chem
accumulation	O	O
which	O	O
has	O	O
resulted	O	O
in	O	O
clinically	O	O
significant	O	O
sinus	O	O
bradycardia	O	O
.	O	O

optochiasmatic	O	O
and	O	O
peripheral	O	O
neuropathy	O	O
due	O	O
to	O	O
ethambutol	B-chem	B-chem
overtreatment	O	O
.	O	O

ethambutol	B-chem	B-chem
is	O	O
known	O	O
to	O	O
cause	O	O
optic	O	O
neuropathy	O	O
and	O	O
,	O	O
more	O	O
rarely	O	O
,	O	O
axonal	O	O
polyneuropathy	O	O
.	O	O

we	O	O
characterize	O	O
the	O	O
clinical	O	O
,	O	O
neurophysiological	O	O
,	O	O
and	O	O
neuroimaging	O	O
findings	O	O
in	O	O
a	O	O
72	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
developed	O	O
visual	O	O
loss	O	O
and	O	O
paresthesias	O	O
after	O	O
11	O	O
weeks	O	O
of	O	O
exposure	O	O
to	O	O
a	O	O
supratherapeutic	O	O
dose	O	O
of	O	O
ethambutol	B-chem	B-chem
.	O	O

this	O	O
case	O	O
demonstrates	O	O
the	O	O
selective	O	O
vulnerability	O	O
of	O	O
the	O	O
anterior	O	O
visual	O	O
pathways	O	O
and	O	O
peripheral	O	O
nerves	O	O
to	O	O
ethambutol	B-chem	B-chem
toxicity	O	O
.	O	O

testosterone	B-chem	B-chem
ameliorates	O	O
streptozotocin	B-chem	B-chem
-	O	O
induced	O	O
memory	O	O
impairment	O	O
in	O	O
male	O	O
rats	O	O
.	O	O

aim	O	O
:	O	O

to	O	O
study	O	O
the	O	O
effects	O	O
of	O	O
testosterone	B-chem	B-chem
on	O	O
streptozotocin	B-chem	B-chem
(	O	O
stz	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
memory	O	O
impairment	O	O
in	O	O
male	O	O
rats	O	O
.	O	O

methods	O	O
:	O	O

adult	O	O
male	O	O
wistar	O	O
rats	O	O
were	O	O
intracerebroventricularly	O	O
(	O	O
icv	O	O
)	O	O
infused	O	O
with	O	O
stz	B-chem	B-chem
(	O	O
750	O	O
ug	O	O
)	O	O
on	O	O
d	O	O
1	O	O
and	O	O
d	O	O
3	O	O
,	O	O
and	O	O
a	O	O
passive	O	O
avoidance	O	O
task	O	O
was	O	O
assessed	O	O
2	O	O
weeks	O	O
after	O	O
the	O	O
first	O	O
injection	O	O
of	O	O
stz	B-chem	O
.	O	O

castration	O	O
surgery	O	O
was	O	O
performed	O	O
in	O	O
another	O	O
group	O	O
of	O	O
rats	O	O
,	O	O
and	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
was	O	O
assessed	O	O
4	O	O
weeks	O	O
after	O	O
the	O	O
operation	O	O
.	O	O

testosterone	B-chem	B-chem
(	O	O
1	O	O
mg	O	O
.	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O
d	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
sc	O	O
)	O	O
,	O	O
the	O	O
androgen	B-chem	O
receptor	O	O
antagonist	O	O
flutamide	B-chem	B-chem
(	O	O
10	O	O
mg	O	O
.	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O
d	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
ip	O	O
)	O	O
,	O	O
the	O	O
estrogen	B-chem	B-chem
receptor	O	O
antagonist	O	O
tamoxifen	B-chem	B-chem
(	O	O
1	O	O
mg	O	O
.	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O
d	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
ip	O	O
)	O	O
or	O	O
the	O	O
aromatase	O	O
inhibitor	O	O
letrozole	B-chem	B-chem
(	O	O
4	O	O
mg	O	O
.	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O
d	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
ip	O	O
)	O	O
were	O	O
administered	O	O
for	O	O
6	O	O
d	O	O
after	O	O
the	O	O
first	O	O
injection	O	O
of	O	O
stz	B-chem	O
.	O	O

results	O	O
:	O	O

stz	B-chem	B-chem
administration	O	O
and	O	O
castration	O	O
markedly	O	O
decreased	O	O
both	O	O
stl1	O	O
(	O	O
the	O	O
short	O	O
memory	O	O
)	O	O
and	O	O
stl2	O	O
(	O	O
the	O	O
long	O	O
memory	O	O
)	O	O
in	O	O
passive	O	O
avoidance	O	O
tests	O	O
.	O	O

testosterone	B-chem	B-chem
replacement	O	O
almost	O	O
restored	O	O
the	O	O
stl1	O	B-chem
and	O	O
stl2	O	O
in	O	O
castrated	O	O
rats	O	O
,	O	O
and	O	O
significantly	O	O
prolonged	O	O
the	O	O
stl1	O	O
and	O	O
stl2	O	O
in	O	O
stz	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
.	O	O

administration	O	O
of	O	O
flutamide	B-chem	B-chem
,	O	O
letrozole	B-chem	B-chem
or	O	O
tamoxifen	B-chem	B-chem
significantly	O	O
impaired	O	O
the	O	O
memory	O	O
in	O	O
intact	O	O
rats	O	O
,	O	O
and	O	O
significantly	O	O
attenuated	O	O
the	O	O
testosterone	B-chem	B-chem
replacement	O	O
in	O	O
improving	O	O
stz	B-chem	B-chem
-	O	O
and	O	O
castration	O	O
-	O	O
induced	O	O
memory	O	O
impairment	O	O
.	O	O

conclusion	O	O
:	O	O

testosterone	B-chem	B-chem
administration	O	O
ameliorates	O	O
stz	B-chem	B-chem
-	O	O
and	O	O
castration	O	O
-	O	O
induced	O	O
memory	O	O
impairment	O	O
in	O	O
male	O	O
wistar	O	O
rats	O	O
.	O	O

behavioral	O	O
and	O	O
neurochemical	O	O
studies	O	O
in	O	O
mice	O	O
pretreated	O	O
with	O	O
garcinielliptone	B-chem	O
fc	I-chem	O
in	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
.	O	O

garcinielliptone	B-chem	O
fc	I-chem	O
(	O	O
gfc	B-chem	B-chem
)	O	O
isolated	O	O
from	O	O
hexanic	O	O
fraction	O	O
seed	O	B-chem
extract	O	I-chem
of	O	O
species	O	O
platonia	O	O
insignis	O	O
mart	O	O
.	O	O

it	O	O
is	O	O
widely	O	O
used	O	O
in	O	O
folk	O	O
medicine	O	O
to	O	O
treat	O	O
skin	O	O
diseases	O	O
in	O	O
both	O	O
humans	O	O
and	O	O
animals	O	O
as	O	O
well	O	O
as	O	O
the	O	O
seed	O	B-chem
decoction	O	O
has	O	O
been	O	O
used	O	O
to	O	O
treat	O	O
diarrheas	O	O
and	O	O
inflammatory	O	O
diseases	O	O
.	O	O

however	O	O
,	O	O
there	O	O
is	O	O
no	O	O
research	O	O
on	O	O
gfc	B-chem	O
effects	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
of	O	O
rodents	O	O
.	O	O

the	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
gfc	B-chem	O
effects	O	O
at	O	O
doses	O	O
of	O	O
25	O	O
,	O	O
50	O	O
or	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
on	O	O
seizure	O	O
parameters	O	O
to	O	O
determine	O	O
their	O	O
anticonvulsant	O	O
activity	O	O
and	O	O
its	O	O
effects	O	O
on	O	O
amino	B-chem	B-chem
acid	I-chem	I-chem
(	O	O
r	B-chem	B-chem
-	I-chem	I-chem
aminobutyric	I-chem	I-chem
acid	I-chem	I-chem
(	O	O
gaba	B-chem	B-chem
)	O	O
,	O	O
glutamine	B-chem	B-chem
,	O	O
aspartate	B-chem	B-chem
and	O	O
glutathione	B-chem	B-chem
)	O	O
levels	O	O
as	O	O
well	O	O
as	O	O
on	O	O
acetylcholinesterase	O	O
(	O	O
ache	O	O
)	O	O
activity	O	O
in	O	O
mice	O	O
hippocampus	O	O
after	O	O
seizures	O	O
.	O	O

gfc	B-chem	B-chem
produced	O	O
an	O	O
increased	O	O
latency	O	O
to	O	O
first	O	O
seizure	O	O
,	O	O
at	O	O
doses	O	O
25mg	O	O
/	O	O
kg	O	O
(	O	O
20	O	O
.	O	O
12	O	O
+	O	O
2	O	O
.	O	O
20	O	O
min	O	O
)	O	O
,	O	O
50mg	O	O
/	O	O
kg	O	O
(	O	O
20	O	O
.	O	O
95	O	O
+	O	O
2	O	O
.	O	O
21	O	O
min	O	O
)	O	O
or	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
23	O	O
.	O	O
43	O	O
+	O	O
1	O	O
.	O	O
99	O	O
min	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
gaba	B-chem	B-chem
content	O	O
of	O	O
mice	O	O
hippocampus	O	O
treated	O	O
with	O	O
gfc75	O	O
plus	O	O
p400	O	B-chem
showed	O	O
an	O	O
increase	O	O
of	O	O
46	O	O
.	O	O
90	O	O
%	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

in	O	O
aspartate	B-chem	B-chem
,	O	O
glutamine	B-chem	B-chem
and	O	O
glutamate	B-chem	B-chem
levels	O	O
detected	O	O
a	O	O
decrease	O	O
of	O	O
5	O	O
.	O	O
21	O	O
%	O	O
,	O	O
13	O	O
.	O	O
55	O	O
%	O	O
and	O	O
21	O	O
.	O	O
80	O	O
%	O	O
,	O	O
respectively	O	O
in	O	O
mice	O	O
hippocampus	O	O
treated	O	O
with	O	O
gfc75	O	O
plus	O	O
p400	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

hippocampus	O	O
mice	O	O
treated	O	O
with	O	O
gfc75	O	O
plus	O	O
p400	O	B-chem
showed	O	O
an	O	O
increase	O	O
in	O	O
ache	O	O
activity	O	O
(	O	O
63	O	O
.	O	O
30	O	O
%	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

the	O	O
results	O	O
indicate	O	O
that	O	O
gfc	B-chem	B-chem
can	O	O
exert	O	O
anticonvulsant	O	O
activity	O	O
and	O	O
reduce	O	O
the	O	O
frequency	O	O
of	O	O
installation	O	O
of	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
status	O	O
epilepticus	O	O
,	O	O
as	O	O
demonstrated	O	O
by	O	O
increase	O	O
in	O	O
latency	O	O
to	O	O
first	O	O
seizure	O	O
and	O	O
decrease	O	O
in	O	O
mortality	O	O
rate	O	O
of	O	O
animals	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
gfc	B-chem	B-chem
may	O	O
influence	O	O
in	O	O
epileptogenesis	O	O
and	O	O
promote	O	O
anticonvulsant	O	O
actions	O	O
in	O	O
pilocarpine	B-chem	B-chem
model	O	O
by	O	O
modulating	O	O
the	O	O
gaba	B-chem	B-chem
and	O	O
glutamate	B-chem	B-chem
contents	O	O
and	O	O
of	O	O
ache	O	O
activity	O	O
in	O	O
seized	O	O
mice	O	O
hippocampus	O	O
.	O	O

this	O	O
compound	O	O
may	O	O
be	O	O
useful	O	O
to	O	O
produce	O	O
neuronal	O	O
protection	O	O
and	O	O
it	O	O
can	O	O
be	O	O
considered	O	O
as	O	O
an	O	O
anticonvulsant	O	O
agent	O	O
.	O	O

standard	O	O
operating	O	O
procedures	O	O
for	O	O
antibiotic	O	O
therapy	O	O
and	O	O
the	O	O
occurrence	O	O
of	O	O
acute	O	O
kidney	O	O
injury	O	O
:	O	O
a	O	O
prospective	O	O
,	O	O
clinical	O	O
,	O	O
non	O	O
-	O	O
interventional	O	O
,	O	O
observational	O	O
study	O	O
.	O	O

introduction	O	O
:	O	O

acute	O	O
kidney	O	O
injury	O	O
(	O	O
aki	O	O
)	O	O
occurs	O	O
in	O	O
7	O	O
%	O	O
of	O	O
hospitalized	O	O
and	O	O
66	O	O
%	O	O
of	O	O
intensive	O	O
care	O	O
unit	O	O
(	O	O
icu	O	O
)	O	O
patients	O	O
.	O	O

it	O	O
increases	O	O
mortality	O	O
,	O	O
hospital	O	O
length	O	O
of	O	O
stay	O	O
,	O	O
and	O	O
costs	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
,	O	O
whether	O	O
there	O	O
is	O	O
an	O	O
association	O	O
between	O	O
adherence	O	O
to	O	O
guidelines	O	O
(	O	O
standard	O	O
operating	O	O
procedures	O	O
(	O	O
sop	O	O
)	O	O
)	O	O
for	O	O
potentially	O	O
nephrotoxic	O	O
antibiotics	O	O
and	O	O
the	O	O
occurrence	O	O
of	O	O
aki	O	O
.	O	O

methods	O	O
:	O	O

this	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
as	O	O
a	O	O
prospective	O	O
,	O	O
clinical	O	O
,	O	O
non	O	O
-	O	O
interventional	O	O
,	O	O
observational	O	O
study	O	O
.	O	O

data	O	O
collection	O	O
was	O	O
performed	O	O
over	O	O
a	O	O
total	O	O
of	O	O
170	O	O
days	O	O
in	O	O
three	O	O
icus	O	O
at	O	O
charite	O	O
-	O	O
universitaetsmedizin	O	O
berlin	O	O
.	O	O

a	O	O
total	O	O
of	O	O
675	O	O
patients	O	O
were	O	O
included	O	O
;	O	O
163	O	O
of	O	O
these	O	O
had	O	O
therapy	O	O
with	O	O
vancomycin	B-chem	B-chem
,	O	O
gentamicin	B-chem	B-chem
,	O	O
or	O	O
tobramycin	B-chem	B-chem
;	O	O
were	O	O
>	O	O
18	O	O
years	O	O
;	O	O
and	O	O
treated	O	O
in	O	O
the	O	O
icu	O	O
for	O	O
>	O	O
24	O	O
hours	O	O
.	O	O

patients	O	O
with	O	O
an	O	O
adherence	O	O
to	O	O
sop	O	O
>	O	O
70	O	O
%	O	O
were	O	O
classified	O	O
into	O	O
the	O	O
high	O	O
adherence	O	O
group	O	O
(	O	O
hag	O	O
)	O	O
and	O	O
patients	O	O
with	O	O
an	O	O
adherence	O	O
of	O	O
<	O	O
70	O	O
%	O	O
into	O	O
the	O	O
low	O	O
adherence	O	O
group	O	O
(	O	O
lag	O	O
)	O	O
.	O	O

aki	O	O
was	O	O
defined	O	O
according	O	O
to	O	O
rifle	O	O
criteria	O	O
.	O	O

adherence	O	O
to	O	O
sops	O	O
was	O	O
evaluated	O	O
by	O	O
retrospective	O	O
expert	O	O
audit	O	B-chem
.	O	O

development	O	O
of	O	O
aki	O	O
was	O	O
compared	O	O
between	O	O
groups	O	O
with	O	O
exact	O	O
chi2	O	O
-	O	O
test	O	O
and	O	O
multivariate	O	O
logistic	O	O
regression	O	O
analysis	O	O
(	O	O
two	O	O
-	O	O
sided	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

results	O	O
:	O	O

lag	O	O
consisted	O	O
of	O	O
75	O	O
patients	O	O
(	O	O
46	O	O
%	O	O
)	O	O
versus	O	O
88	O	O
hag	O	O
patients	O	O
(	O	O
54	O	O
%	O	O
)	O	O
.	O	O

aki	O	O
occurred	O	O
significantly	O	O
more	O	O
often	O	O
in	O	O
lag	O	O
with	O	O
36	O	O
%	O	O
versus	O	O
21	O	O
%	O	O
in	O	O
hag	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
035	O	O
)	O	O
.	O	O

basic	O	O
characteristics	O	O
were	O	O
comparable	O	O
,	O	O
except	O	O
an	O	O
increased	O	O
rate	O	O
of	O	O
soft	O	O
tissue	O	O
infections	O	O
in	O	O
lag	O	O
.	O	O

multivariate	O	O
analysis	O	O
revealed	O	O
an	O	O
odds	O	O
ratio	O	O
of	O	O
2	O	O
.	O	O
5	O	O
-	O	O
fold	O	O
for	O	O
lag	O	O
to	O	O
develop	O	O
aki	O	O
compared	O	O
with	O	O
hag	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
1	O	O
.	O	O
195	O	O
to	O	O
5	O	O
.	O	O
124	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
039	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

low	O	O
adherence	O	O
to	O	O
sops	O	O
for	O	O
potentially	O	O
nephrotoxic	O	O
antibiotics	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
higher	O	O
occurrence	O	O
of	O	O
aki	O	O
.	O	O

trial	O	O
registration	O	O
:	O	O

current	O	O
controlled	O	O
trials	O	O
isrctn54598675	O	O
.	O	O

registered	O	O
17	O	O
august	O	O
2007	O	O
.	O	O

rhabdomyolysis	O	O
in	O	O
a	O	O
hepatitis	O	O
c	O	O
virus	O	O
infected	O	O
patient	O	O
treated	O	O
with	O	O
telaprevir	B-chem	B-chem
and	O	O
simvastatin	B-chem	B-chem
.	O	O

a	O	O
46	O	O
-	O	O
year	O	O
old	O	O
man	O	O
with	O	O
a	O	O
chronic	O	O
hepatitis	O	O
c	O	O
virus	O	O
infection	O	O
received	O	O
triple	O	O
therapy	O	O
with	O	O
ribavirin	B-chem	B-chem
,	O	O
pegylated	B-chem	B-chem
interferon	I-chem	I-chem
and	O	O
telaprevir	B-chem	I-chem
.	O	O

the	O	O
patient	O	O
also	O	O
received	O	O
simvastatin	B-chem	B-chem
.	O	O

one	O	O
month	O	O
after	O	O
starting	O	O
the	O	O
antiviral	O	O
therapy	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
because	O	O
he	O	O
developed	O	O
rhabdomyolysis	O	O
.	O	O

at	O	O
admission	O	O
simvastatin	B-chem	B-chem
and	O	O
all	O	O
antiviral	O	O
drugs	O	O
were	O	O
discontinued	O	O
because	O	O
toxicity	O	O
due	O	O
to	O	O
a	O	O
drug	O	O
-	O	O
drug	O	O
interaction	O	O
was	O	O
suspected	O	O
.	O	O

the	O	O
creatine	B-chem	B-chem
kinase	O	O
peaked	O	O
at	O	O
62	O	O
,	O	O
246	O	O
iu	O	O
/	O	O
l	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
intravenous	O	O
normal	O	O
saline	O	O
.	O	O

the	O	O
patient	O	O
'	O	O
s	O	O
renal	O	O
function	O	O
remained	O	O
unaffected	O	O
.	O	O

fourteen	O	O
days	O	O
after	O	O
hospitalization	O	O
,	O	O
creatine	B-chem	B-chem
kinase	O	O
level	O	O
had	O	O
returned	O	O
to	O	O
230	O	O
iu	O	O
/	O	O
l	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
discharged	O	O
.	O	O

telaprevir	B-chem	B-chem
was	O	O
considered	O	O
the	O	O
probable	O	O
causative	O	O
agent	O	O
of	O	O
an	O	O
interaction	O	O
with	O	O
simvastatin	B-chem	B-chem
according	O	O
to	O	O
the	O	O
drug	O	O
interaction	O	O
probability	O	O
scale	O	O
.	O	O

the	O	O
interaction	O	O
is	O	O
due	O	O
to	O	O
inhibition	O	O
of	O	O
cyp3a4	O	O
-	O	O
mediated	O	O
simvastatin	B-chem	B-chem
clearance	O	O
.	O	O

simvastatin	B-chem	B-chem
plasma	O	O
concentration	O	O
increased	O	O
30	O	O
times	O	O
in	O	O
this	O	O
patient	O	O
and	O	O
statin	B-chem	B-chem
induced	O	O
muscle	O	O
toxicity	O	O
is	O	O
related	O	O
to	O	O
the	O	O
concentration	O	O
of	O	O
the	O	O
statin	B-chem	B-chem
in	O	O
blood	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
with	O	O
this	O	O
case	O	O
we	O	O
illustrate	O	O
that	O	O
telaprevir	B-chem	B-chem
as	O	O
well	O	O
as	O	O
statins	B-chem	B-chem
are	O	O
susceptible	O	O
to	O	O
clinical	O	O
relevant	O	O
drug	O	O
-	O	O
drug	O	O
interactions	O	O
.	O	O

combination	O	O
of	O	O
bortezomib	B-chem	B-chem
,	O	O
thalidomide	B-chem	B-chem
,	O	O
and	O	O
dexamethasone	B-chem	B-chem
(	O	O
vtd	O	B-chem
)	O	O
as	O	O
a	O	O
consolidation	O	O
therapy	O	O
after	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
for	O	O
symptomatic	O	O
multiple	O	O
myeloma	O	O
in	O	O
japanese	O	O
patients	O	O
.	O	O

consolidation	O	O
therapy	O	O
for	O	O
patients	O	O
with	O	O
multiple	O	O
myeloma	O	O
(	O	O
mm	O	O
)	O	O
has	O	O
been	O	O
widely	O	O
adopted	O	O
to	O	O
improve	O	O
treatment	O	O
response	O	O
following	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
.	O	O

in	O	O
this	O	O
study	O	O
,	O	O
we	O	O
retrospectively	O	O
analyzed	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
combination	O	O
regimen	O	O
of	O	O
bortezomib	B-chem	B-chem
,	O	O
thalidomide	B-chem	B-chem
,	O	O
and	O	O
dexamethasone	B-chem	B-chem
(	O	O
vtd	O	O
)	O	O
as	O	O
consolidation	O	O
therapy	O	O
in	O	O
24	O	O
japanese	O	O
patients	O	O
with	O	O
newly	O	O
diagnosed	O	O
mm	O	O
.	O	O

vtd	O	O
consisted	O	O
of	O	O
bortezomib	B-chem	B-chem
at	O	O
a	O	O
dose	O	O
of	O	O
1	O	O
.	O	O
3	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
and	O	O
dexamethasone	B-chem	B-chem
at	O	O
a	O	O
dose	O	O
of	O	O
40	O	O
mg	O	O
/	O	O
day	O	O
on	O	O
days	O	O
1	O	O
,	O	O
8	O	O
,	O	O
15	O	O
,	O	O
and	O	O
22	O	O
of	O	O
a	O	O
35	O	O
-	O	O
day	O	O
cycle	O	O
,	O	O
with	O	O
daily	O	O
oral	O	O
thalidomide	B-chem	B-chem
at	O	O
a	O	O
dose	O	O
of	O	O
100	O	O
mg	O	O
/	O	O
day	O	O
.	O	O

grade	O	O
3	O	O
-	O	O
4	O	O
neutropenia	O	O
and	O	O
thrombocytopenia	O	O
were	O	O
documented	O	O
in	O	O
four	O	O
and	O	O
three	O	O
patients	O	O
(	O	O
17	O	O
and	O	O
13	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
but	O	O
drug	O	O
dose	O	O
reduction	O	O
due	O	O
to	O	O
cytopenia	O	O
was	O	O
not	O	O
required	O	O
in	O	O
any	O	O
case	O	O
.	O	O

peripheral	O	O
neuropathy	O	O
was	O	O
common	O	O
(	O	O
63	O	O
%	O	O
)	O	O
,	O	O
but	O	O
severe	O	O
grade	O	O
3	O	O
-	O	O
4	O	O
peripheral	O	O
neuropathy	O	O
was	O	O
not	O	O
observed	O	O
.	O	O

very	O	O
good	O	O
partial	O	O
response	O	O
or	O	O
better	O	O
response	O	O
(	O	O
>	O	O
vgpr	O	O
)	O	O
rates	O	O
before	O	O
and	O	O
after	O	O
consolidation	O	O
therapy	O	O
were	O	O
54	O	O
and	O	O
79	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

patients	O	O
had	O	O
a	O	O
significant	O	O
probability	O	O
of	O	O
improving	O	O
from	O	O
<	O	O
vgpr	O	O
before	O	O
consolidation	O	O
therapy	O	O
to	O	O
>	O	O
vgpr	O	O
after	O	O
consolidation	O	O
therapy	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
041	O	O
)	O	O
.	O	O

the	O	O
vtd	O	O
regimen	O	O
may	O	O
be	O	O
safe	O	O
and	O	O
effective	O	O
as	O	O
a	O	O
consolidation	O	O
therapy	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
mm	O	O
in	O	O
japanese	O	O
population	O	O
.	O	O

conversion	O	O
to	O	O
sirolimus	B-chem	B-chem
ameliorates	O	O
cyclosporine	B-chem	B-chem
-	O	O
induced	O	O
nephropathy	O	O
in	O	O
the	O	O
rat	O	O
:	O	O
focus	O	O
on	O	O
serum	O	O
,	O	O
urine	O	O
,	O	O
gene	O	O
,	O	O
and	O	O
protein	O	O
renal	O	O
expression	O	O
biomarkers	O	O
.	O	O

protocols	O	O
of	O	O
conversion	O	O
from	O	O
cyclosporin	B-chem	B-chem
a	I-chem	I-chem
(	O	O
csa	B-chem	B-chem
)	O	O
to	O	O
sirolimus	B-chem	B-chem
(	O	O
srl	B-chem	B-chem
)	O	O
have	O	O
been	O	O
widely	O	O
used	O	O
in	O	O
immunotherapy	O	O
after	O	O
transplantation	O	O
to	O	O
prevent	O	O
csa	B-chem	B-chem
-	O	O
induced	O	O
nephropathy	O	O
,	O	O
but	O	O
the	O	O
molecular	O	O
mechanisms	O	O
underlying	O	O
these	O	O
protocols	O	O
remain	O	O
nuclear	O	O
.	O	O

this	O	O
study	O	O
aimed	O	O
to	O	O
identify	O	O
the	O	O
molecular	O	O
pathways	O	O
and	O	O
putative	O	O
biomarkers	O	O
of	O	O
csa	B-chem	B-chem
-	O	O
to	O	O
-	O	O
srl	B-chem	B-chem
conversion	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
.	O	O

four	O	O
animal	O	O
groups	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
were	O	O
tested	O	O
during	O	O
9	O	O
weeks	O	O
:	O	O
control	O	O
,	O	O
csa	B-chem	B-chem
,	O	O
srl	B-chem	B-chem
,	O	O
and	O	O
conversion	O	O
(	O	O
csa	B-chem	B-chem
for	O	O
3	O	O
weeks	O	O
followed	O	O
by	O	O
srl	B-chem	B-chem
for	O	O
6	O	O
weeks	O	O
)	O	O
.	O	O

classical	O	O
and	O	O
emergent	O	O
serum	O	O
,	O	O
urinary	O	O
,	O	O
and	O	O
kidney	O	O
tissue	O	O
(	O	O
gene	O	O
and	O	O
protein	O	O
expression	O	O
)	O	O
markers	O	O
were	O	O
assessed	O	O
.	O	O

renal	O	O
lesions	O	O
were	O	O
analyzed	O	O
in	O	O
hematoxylin	B-chem	B-chem
and	O	O
eosin	B-chem	B-chem
,	O	O
periodic	O	B-chem
acid	O	I-chem
-	O	I-chem
schiff	O	I-chem
,	O	O
and	O	O
masson	O	O
'	O	O
s	O	O
trichrome	O	O
stains	O	O
.	O	O

srl	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
presented	O	O
proteinuria	O	O
and	O	O
ngal	O	O
(	O	O
serum	O	O
and	O	O
urinary	O	O
)	O	O
as	O	O
the	O	O
best	O	O
markers	O	O
of	O	O
renal	O	O
impairment	O	O
.	O	O

short	O	O
csa	B-chem	B-chem
treatment	O	O
presented	O	O
slight	O	O
or	O	O
even	O	O
absent	O	O
kidney	O	O
lesions	O	O
and	O	O
tgf	O	B-chem
-	O	O
b	O	O
,	O	O
nf	O	O
-	O	O
kb	O	O
,	O	O
mtor	O	O
,	O	O
pcna	O	O
,	O	O
tp53	O	O
,	O	O
kim	O	B-chem
-	O	O
1	O	O
,	O	O
and	O	O
ctgf	O	O
as	O	O
relevant	O	O
gene	O	O
and	O	O
protein	O	O
changes	O	O
.	O	O

prolonged	O	O
csa	B-chem	B-chem
exposure	O	O
aggravated	O	O
renal	O	O
damage	O	O
,	O	O
without	O	O
clear	O	O
changes	O	O
on	O	O
the	O	O
traditional	O	O
markers	O	O
,	O	O
but	O	O
with	O	O
changes	O	O
in	O	O
serums	O	O
tgf	O	B-chem
-	O	O
b	O	O
and	O	O
il	O	O
-	O	O
7	O	O
,	O	O
tbars	O	O
clearance	O	O
,	O	O
and	O	O
kidney	O	O
tgf	O	B-chem
-	O	O
b	O	O
and	O	O
mtor	O	O
.	O	O

conversion	O	O
to	O	O
srl	B-chem	B-chem
prevented	O	O
csa	B-chem	B-chem
-	O	O
induced	O	O
renal	O	O
damage	O	O
evolution	O	O
(	O	O
absent	O	O
/	O	O
mild	O	O
grade	O	O
lesions	O	O
)	O	O
,	O	O
while	O	O
ngal	O	O
(	O	O
serum	O	O
versus	O	O
urine	O	O
)	O	O
seems	O	O
to	O	O
be	O	O
a	O	O
feasible	O	O
biomarker	O	O
of	O	O
csa	B-chem	B-chem
replacement	O	O
to	O	O
srl	B-chem	B-chem
.	O	O

kinin	O	O
b2	O	O
receptor	O	O
deletion	O	O
and	O	O
blockage	O	B-chem
ameliorates	O	O
cisplatin	B-chem	B-chem
-	O	O
induced	O	O
acute	O	O
renal	O	O
injury	O	O
.	O	O

cisplatin	B-chem	B-chem
treatment	O	O
has	O	O
been	O	O
adopted	O	O
in	O	O
some	O	O
chemotherapies	O	O
;	O	O
however	O	O
,	O	O
this	O	O
drug	O	O
can	O	O
induce	O	O
acute	O	O
kidney	O	O
injury	O	O
due	O	O
its	O	O
ability	O	O
to	O	O
negatively	O	O
affect	O	O
renal	O	O
function	O	O
,	O	O
augment	O	O
serum	O	O
levels	O	O
of	O	O
creatinine	B-chem	B-chem
and	O	O
urea	B-chem	B-chem
,	O	O
increase	O	O
the	O	O
acute	O	O
tubular	O	O
necrosis	O	O
score	O	O
and	O	O
up	O	O
-	O	O
regulate	O	O
cytokines	O	O
(	O	O
e	O	O
.	O	O
g	O	O
.	O	O
,	O	O
il	O	O
-	O	O
1b	O	O
and	O	O
tnf	O	O
-	O	O
a	O	O
)	O	O
.	O	O

the	O	O
kinin	O	O
b2	O	O
receptor	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
inflammation	O	O
process	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
regulation	O	O
of	O	O
cytokine	O	O
expression	O	O
,	O	O
and	O	O
its	O	O
deletion	O	O
resulted	O	O
in	O	O
an	O	O
improvement	O	O
in	O	O
the	O	O
diabetic	O	O
nephropathy	O	O
status	O	O
.	O	O

to	O	O
examine	O	O
the	O	O
role	O	O
of	O	O
the	O	O
kinin	O	O
b2	O	O
receptor	O	O
in	O	O
cisplatin	B-chem	B-chem
-	O	O
induced	O	O
acute	O	O
kidney	O	O
injury	O	O
,	O	O
kinin	O	O
b2	O	O
receptor	O	O
knockout	O	O
mice	O	O
were	O	O
challenged	O	O
with	O	O
cisplatin	B-chem	B-chem
.	O	O

additionally	O	O
,	O	O
wt	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
b2	O	O
receptor	O	O
antagonist	O	O
after	O	O
cisplatin	B-chem	B-chem
administration	O	O
.	O	O

b2	O	O
receptor	O	O
-	O	O
deficient	O	O
mice	O	O
were	O	O
less	O	O
sensitive	O	O
to	O	O
this	O	O
drug	O	O
than	O	O
the	O	O
wt	O	O
mice	O	O
,	O	O
as	O	O
shown	O	O
by	O	O
reduced	O	O
weight	O	O
loss	O	O
,	O	O
better	O	O
preservation	O	O
of	O	O
kidney	O	O
function	O	O
,	O	O
down	O	O
regulation	O	O
of	O	O
inflammatory	O	O
cytokines	O	O
and	O	O
less	O	O
acute	O	O
tubular	O	O
necrosis	O	O
.	O	O

moreover	O	O
,	O	O
treatment	O	O
with	O	O
the	O	O
kinin	O	O
b2	O	O
receptor	O	O
antagonist	O	O
effectively	O	O
reduced	O	O
the	O	O
levels	O	O
of	O	O
serum	O	O
creatinine	B-chem	B-chem
and	O	O
blood	O	B-chem
urea	B-chem	I-chem
after	O	O
cisplatin	B-chem	B-chem
administration	O	O
.	O	O

thus	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
kinin	O	O
b2	O	O
receptor	O	O
is	O	O
involved	O	O
in	O	O
cisplatin	B-chem	B-chem
-	O	O
induced	O	O
acute	O	O
kidney	O	O
injury	O	O
by	O	O
mediating	O	O
the	O	O
necrotic	O	O
process	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
inflammatory	O	O
cytokines	O	O
,	O	O
thus	O	O
resulting	O	O
in	O	O
declined	O	O
renal	O	O
function	O	O
.	O	O

these	O	O
results	O	O
highlight	O	O
the	O	O
kinin	O	O
b2	O	O
receptor	O	O
antagonist	O	O
treatment	O	O
in	O	O
amelioration	O	O
of	O	O
nephrotoxicity	O	O
induced	O	O
by	O	O
cisplatin	B-chem	B-chem
therapy	O	O
.	O	O

safety	O	O
and	O	O
efficacy	O	O
of	O	O
fluocinolone	B-chem	B-chem
acetonide	I-chem	I-chem
intravitreal	O	O
implant	O	O
(	O	O
0	O	O
.	O	O
59	O	O
mg	O	O
)	O	O
in	O	O
birdshot	O	O
retinochoroidopathy	O	O
.	O	O

purpose	O	O
:	O	O

to	O	O
report	O	O
the	O	O
treatment	O	O
outcomes	O	O
of	O	O
the	O	O
fluocinolone	B-chem	B-chem
acetonide	I-chem	I-chem
intravitreal	O	O
implant	O	O
(	O	O
0	O	O
.	O	O
59	O	O
mg	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
birdshot	O	O
retinochoroidopathy	O	O
whose	O	O
disease	O	O
is	O	O
refractory	O	O
or	O	O
intolerant	O	O
to	O	O
conventional	O	O
immunomodulatory	O	O
therapy	O	O
.	O	O

methods	O	O
:	O	O

a	O	O
retrospective	O	O
case	O	O
series	O	O
involving	O	O
11	O	O
birdshot	O	O
retinochoroidopathy	O	O
patients	O	O
(	O	O
11	O	O
eyes	O	O
)	O	O
.	O	O

eleven	O	O
patients	O	O
(	O	O
11	O	O
eyes	O	O
)	O	O
underwent	O	O
surgery	O	O
for	O	O
fluocinolone	B-chem	B-chem
acetonide	I-chem	I-chem
implant	O	O
(	O	O
0	O	O
.	O	O
59	O	O
mg	O	O
)	O	O
.	O	O

treatment	O	O
outcomes	O	O
of	O	O
interest	O	O
were	O	O
noted	O	O
at	O	O
baseline	O	O
,	O	O
before	O	O
fluocinolone	B-chem	B-chem
acetonide	I-chem	I-chem
implant	O	O
,	O	O
and	O	O
then	O	O
at	O	O
6	O	O
months	O	O
,	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
3	O	O
years	O	O
,	O	O
and	O	O
beyond	O	O
3	O	O
years	O	O
.	O	O

disease	O	O
activity	O	O
markers	O	O
,	O	O
including	O	O
signs	O	O
of	O	O
ocular	O	O
inflammation	O	O
,	O	O
evidence	O	O
of	O	O
retinal	O	O
vasculitis	O	O
,	O	O
swedish	O	O
interactive	O	O
threshold	O	O
algorithm	O	O
-	O	O
short	O	O
wavelength	O	O
automated	O	O
perimetry	O	O
humphrey	O	O
visual	O	O
field	O	O
analysis	O	O
,	O	O
electroretinographic	O	O
parameters	O	O
,	O	O
and	O	O
optical	O	O
coherence	O	O
tomography	O	O
were	O	O
recorded	O	O
.	O	O

data	O	O
on	O	O
occurrence	O	O
of	O	O
cataract	O	O
and	O	O
raised	O	O
intraocular	O	O
pressure	O	O
were	O	O
collected	O	O
in	O	O
all	O	O
eyes	O	O
.	O	O

results	O	O
:	O	O

intraocular	O	O
inflammation	O	O
was	O	O
present	O	O
in	O	O
54	O	O
.	O	O
5	O	O
,	O	O
9	O	O
.	O	O
9	O	O
,	O	O
11	O	O
.	O	O
1	O	O
,	O	O
and	O	O
0	O	O
%	O	O
of	O	O
patients	O	O
at	O	O
baseline	O	O
,	O	O
6	O	O
months	O	O
,	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
3	O	O
years	O	O
,	O	O
and	O	O
beyond	O	O
3	O	O
years	O	O
after	O	O
receiving	O	O
the	O	O
implant	O	O
,	O	O
respectively	O	O
.	O	O

active	O	O
vasculitis	O	O
was	O	O
noted	O	O
in	O	O
36	O	O
.	O	O
3	O	O
%	O	O
patients	O	O
at	O	O
baseline	O	O
and	O	O
0	O	O
%	O	O
at	O	O
3	O	O
years	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

more	O	O
than	O	O
20	O	O
%	O	O
(	O	O
47	O	O
.	O	O
61	O	O
-	O	O
67	O	O
.	O	O
2	O	O
%	O	O
)	O	O
reduction	O	O
in	O	O
central	O	O
retinal	O	O
thickness	O	O
was	O	O
noted	O	O
in	O	O
all	O	O
patients	O	O
with	O	O
cystoid	O	O
macular	O	O
edema	O	O
at	O	O
6	O	O
months	O	O
,	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
and	O	O
3	O	O
years	O	O
postimplant	O	O
.	O	O

at	O	O
baseline	O	O
,	O	O
54	O	O
.	O	O
5	O	O
%	O	O
patients	O	O
were	O	O
on	O	O
immunomodulatory	O	O
agents	O	O
.	O	O

this	O	O
percentage	O	O
decreased	O	O
to	O	O
45	O	O
.	O	O
45	O	O
,	O	O
44	O	O
.	O	O
4	O	O
,	O	O
and	O	O
14	O	O
.	O	O
28	O	O
%	O	O
at	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
and	O	O
3	O	O
years	O	O
postimplant	O	O
,	O	O
respectively	O	O
.	O	O

adverse	O	O
events	O	O
included	O	O
increased	O	O
intraocular	O	O
pressure	O	O
(	O	O
54	O	O
.	O	O
5	O	O
%	O	O
)	O	O
and	O	O
cataract	O	O
formation	O	O
(	O	O
100	O	O
%	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

the	O	O
data	O	O
suggest	O	O
that	O	O
fluocinolone	B-chem	B-chem
acetonide	I-chem	I-chem
implant	O	O
(	O	O
0	O	O
.	O	O
59	O	O
mg	O	O
)	O	O
helps	O	O
to	O	O
control	O	O
inflammation	O	O
in	O	O
otherwise	O	O
treatment	O	O
-	O	O
refractory	O	O
cases	O	O
of	O	O
birdshot	O	O
retinochoroidopathy	O	O
.	O	O

it	O	O
is	O	O
associated	O	O
with	O	O
significant	O	O
side	O	O
effects	O	O
of	O	O
cataract	O	O
and	O	O
ocular	O	O
hypertension	O	O
requiring	O	O
treatment	O	O
.	O	O

optimal	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B-chem	B-chem
to	O	O
decrease	O	O
fasciculation	O	O
and	O	O
myalgia	O	O
following	O	O
succinylcholine	B-chem	B-chem
administration	O	O
.	O	O

background	O	O
:	O	O
succinylcholine	B-chem	B-chem
commonly	O	O
produces	O	O
frequent	O	O
adverse	O	O
effects	O	O
,	O	O
including	O	O
muscle	O	O
fasciculation	O	O
and	O	O
myalgia	O	O
.	O	O

the	O	O
current	O	O
study	O	O
identified	O	O
the	O	O
optimal	O	O
dose	O	O
of	O	O
rocuronium	B-chem	B-chem
to	O	O
prevent	O	O
succinylcholine	B-chem	B-chem
-	O	O
induced	O	O
fasciculation	O	O
and	O	O
myalgia	O	O
and	O	O
evaluated	O	O
the	O	O
influence	O	O
of	O	O
rocuronium	B-chem	B-chem
on	O	O
the	O	O
speed	O	O
of	O	O
onset	O	O
produced	O	O
by	O	O
succinylcholine	B-chem	B-chem
.	O	O

methods	O	O
:	O	O

this	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blinded	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
100	O	O
patients	O	O
randomly	O	O
allocated	O	O
into	O	O
five	O	O
groups	O	O
of	O	O
20	O	O
patients	O	O
each	O	O
.	O	O

patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
0	O	O
.	O	O
02	O	O
,	O	O
0	O	O
.	O	O
03	O	O
,	O	O
0	O	O
.	O	O
04	O	O
,	O	O
0	O	O
.	O	O
05	O	O
and	O	O
0	O	O
.	O	O
06	O	O
mg	O	O
/	O	O
kg	O	O
rocuronium	B-chem	B-chem
as	O	O
a	O	O
precurarizing	O	O
dose	O	O
.	O	O

neuromuscular	O	O
monitoring	O	O
after	O	O
each	O	O
precurarizing	O	O
dose	O	O
was	O	O
recorded	O	O
from	O	O
the	O	O
adductor	O	O
pollicis	O	O
muscle	O	O
using	O	O
acceleromyography	O	O
with	O	O
train	O	O
-	O	O
of	O	O
-	O	O
four	O	O
stimulation	O	O
of	O	O
the	O	O
ulnar	O	O
nerve	O	O
.	O	O

all	O	O
patients	O	O
received	O	O
succinylcholine	B-chem	B-chem
1	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
at	O	O
2	O	O
minutes	O	O
after	O	O
the	O	O
precurarization	O	O
,	O	O
and	O	O
were	O	O
assessed	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
fasciculations	O	O
,	O	O
while	O	O
myalgia	O	O
was	O	O
assessed	O	O
at	O	O
24	O	O
hours	O	O
after	O	O
surgery	O	O
.	O	O

results	O	O
:	O	O

the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
visible	O	O
muscle	O	O
fasciculation	O	O
was	O	O
significantly	O	O
less	O	O
with	O	O
increasing	O	O
the	O	O
amount	O	O
of	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B-chem	B-chem
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

those	O	O
of	O	O
myalgia	O	O
tend	O	O
to	O	O
decrease	O	O
according	O	O
to	O	O
increasing	O	O
the	O	O
amount	O	O
of	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B-chem	B-chem
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
significance	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
072	O	O
)	O	O
.	O	O

the	O	O
onset	O	O
time	O	O
of	O	O
succinylcholine	B-chem	B-chem
was	O	O
significantly	O	O
longer	O	O
with	O	O
increasing	O	O
the	O	O
amount	O	O
of	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B-chem	B-chem
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

precurarization	O	O
with	O	O
0	O	O
.	O	O
04	O	O
mg	O	O
/	O	O
kg	O	O
rocuronium	B-chem	B-chem
was	O	O
the	O	O
optimal	O	O
dose	O	O
considering	O	O
the	O	O
reduction	O	O
in	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
fasciculation	O	O
and	O	O
myalgia	O	O
with	O	O
acceptable	O	O
onset	O	O
time	O	O
,	O	O
and	O	O
the	O	O
safe	O	O
and	O	O
effective	O	O
precurarization	O	O
.	O	O

absence	O	O
of	O	O
pkc	O	O
-	O	O
alpha	O	O
attenuates	O	O
lithium	B-chem	B-chem
-	O	O
induced	O	O
nephrogenic	O	O
diabetes	O	O
insipidus	O	O
.	O	O

lithium	B-chem	B-chem
,	O	O
an	O	O
effective	O	O
antipsychotic	O	O
,	O	O
induces	O	O
nephrogenic	O	O
diabetes	O	O
insipidus	O	O
(	O	O
ndi	O	O
)	O	O
in	O	O
40	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

the	O	O
decreased	O	O
capacity	O	O
to	O	O
concentrate	O	O
urine	O	O
is	O	O
likely	O	O
due	O	O
to	O	O
lithium	B-chem	B-chem
acutely	O	O
disrupting	O	O
the	O	O
camp	B-chem	O
pathway	O	O
and	O	O
chronically	O	O
reducing	O	O
urea	B-chem	B-chem
transporter	O	O
(	O	O
ut	O	O
-	O	O
a1	O	O
)	O	O
and	O	O
water	O	O
channel	O	O
(	O	O
aqp2	O	O
)	O	O
expression	O	O
in	O	O
the	O	O
inner	O	O
medulla	O	O
.	O	O

targeting	O	O
an	O	O
alternative	O	O
signaling	O	O
pathway	O	O
,	O	O
such	O	O
as	O	O
pkc	O	O
-	O	O
mediated	O	O
signaling	O	O
,	O	O
may	O	O
be	O	O
an	O	O
effective	O	O
method	O	O
of	O	O
treating	O	O
lithium	B-chem	B-chem
-	O	O
induced	O	O
polyuria	O	O
.	O	O

pkc	O	B-chem
-	O	O
alpha	O	O
null	O	O
mice	O	O
(	O	O
pkca	O	O
ko	O	O
)	O	O
and	O	O
strain	O	O
-	O	O
matched	O	O
wild	O	O
type	O	O
(	O	O
wt	O	O
)	O	O
controls	O	O
were	O	O
treated	O	O
with	O	O
lithium	B-chem	B-chem
for	O	O
0	O	O
,	O	O
3	O	O
or	O	O
5	O	O
days	O	O
.	O	O

wt	O	O
mice	O	O
had	O	O
increased	O	O
urine	O	O
output	O	O
and	O	O
lowered	O	O
urine	O	O
osmolality	O	O
after	O	O
3	O	O
and	O	O
5	O	O
days	O	O
of	O	O
treatment	O	O
whereas	O	O
pkca	O	O
ko	O	O
mice	O	O
had	O	O
no	O	O
change	O	O
in	O	O
urine	O	O
output	O	O
or	O	O
concentration	O	O
.	O	O

western	O	O
blot	O	O
analysis	O	O
revealed	O	O
that	O	O
aqp2	O	O
expression	O	O
in	O	O
medullary	O	O
tissues	O	O
was	O	O
lowered	O	O
after	O	O
3	O	O
and	O	O
5	O	O
days	O	O
in	O	O
wt	O	O
mice	O	O
;	O	O
however	O	O
,	O	O
aqp2	O	O
was	O	O
unchanged	O	O
in	O	O
pkca	O	O
ko	O	O
.	O	O

similar	O	O
results	O	O
were	O	O
observed	O	O
with	O	O
ut	O	O
-	O	O
a1	O	O
expression	O	O
.	O	O

animals	O	O
were	O	O
also	O	O
treated	O	O
with	O	O
lithium	B-chem	B-chem
for	O	O
6	O	O
weeks	O	O
.	O	O

lithium	B-chem	B-chem
-	O	O
treated	O	O
wt	O	O
mice	O	O
had	O	O
19	O	O
-	O	O
fold	O	O
increased	O	O
urine	O	O
output	O	O
whereas	O	O
treated	O	O
pkca	O	O
ko	O	O
animals	O	O
had	O	O
a	O	O
4	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
output	O	O
.	O	O

aqp2	O	O
and	O	O
ut	O	O
-	O	O
a1	O	O
expression	O	O
was	O	O
lowered	O	O
in	O	O
6	O	O
week	O	O
lithium	B-chem	B-chem
-	O	O
treated	O	O
wt	O	O
animals	O	O
whereas	O	O
in	O	O
treated	O	O
pkca	O	O
ko	O	O
mice	O	O
,	O	O
aqp2	O	O
was	O	O
only	O	O
reduced	O	O
by	O	O
2	O	O
-	O	O
fold	O	O
and	O	O
ut	O	O
-	O	O
a1	O	O
expression	O	O
was	O	O
unaffected	O	O
.	O	O

urinary	O	O
sodium	B-chem	B-chem
,	O	O
potassium	B-chem	B-chem
and	O	O
calcium	B-chem	B-chem
were	O	O
elevated	O	O
in	O	O
lithium	B-chem	B-chem
-	O	O
fed	O	O
wt	O	O
but	O	O
not	O	O
in	O	O
lithium	B-chem	B-chem
-	O	O
fed	O	O
pkca	O	O
ko	O	O
mice	O	O
.	O	O

our	O	O
data	O	O
show	O	O
that	O	O
ablation	O	O
of	O	O
pkca	O	B-chem
preserves	O	O
aqp2	O	O
and	O	O
ut	O	O
-	O	O
a1	O	O
protein	O	O
expression	O	O
and	O	O
localization	O	O
in	O	O
lithium	B-chem	B-chem
-	O	O
induced	O	O
ndi	O	B-chem
,	O	O
and	O	O
prevents	O	O
the	O	O
development	O	O
of	O	O
the	O	O
severe	O	O
polyuria	O	O
associated	O	O
with	O	O
lithium	B-chem	B-chem
therapy	O	O
.	O	O

is	O	O
dysguesia	O	O
going	O	O
to	O	O
be	O	O
a	O	O
rare	O	O
or	O	O
a	O	O
common	O	O
side	O	O
-	O	O
effect	O	O
of	O	O
amlodipine	B-chem	B-chem
?	O	O

a	O	O
very	O	O
rare	O	O
side	O	O
-	O	O
effect	O	O
of	O	O
amlodipine	B-chem	B-chem
is	O	O
dysguesia	O	O
.	O	O

a	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
produced	O	O
only	O	O
one	O	O
case	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
about	O	O
a	O	O
female	O	O
with	O	O
essential	O	O
hypertension	O	O
on	O	O
drug	O	O
treatment	O	O
with	O	O
amlodipine	B-chem	B-chem
developed	O	O
loss	O	O
of	O	O
taste	O	O
sensation	O	O
.	O	O

condition	O	O
moderately	O	O
improved	O	O
on	O	O
stoppage	O	O
of	O	O
the	O	O
drug	O	O
for	O	O
25	O	O
days	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
amlodipine	B-chem	B-chem
can	O	O
cause	O	O
dysguesia	O	O
.	O	O

here	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
clinical	O	O
presentation	O	O
and	O	O
review	O	O
the	O	O
relevant	O	O
literature	O	O
on	O	O
amlodipine	B-chem	B-chem
and	O	O
dysguesia	O	O
.	O	O

rhabdomyolysis	O	O
in	O	O
association	O	O
with	O	O
simvastatin	B-chem	B-chem
and	O	O
dosage	O	O
increment	O	O
in	O	O
clarithromycin	B-chem	B-chem
.	O	O

clarithromycin	B-chem	B-chem
is	O	O
the	O	O
most	O	O
documented	O	O
cytochrome	O	O
p450	O	O
3a4	O	O
(	O	O
cyp3a4	O	O
)	O	O
inhibitor	O	O
to	O	O
cause	O	O
an	O	O
adverse	O	O
interaction	O	O
with	O	O
simvastatin	B-chem	B-chem
.	O	O

this	O	O
particular	O	O
case	O	O
is	O	O
of	O	O
interest	O	O
as	O	O
rhabdomyolysis	O	O
only	O	O
occurred	O	O
after	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
dose	O	O
of	O	O
clarithromycin	B-chem	B-chem
.	O	O

the	O	O
patient	O	O
developed	O	O
raised	O	O
cardiac	O	O
biomarkers	O	O
without	O	O
any	O	O
obvious	O	O
cardiac	O	O
issues	O	O
,	O	O
a	O	O
phenomenon	O	O
that	O	O
has	O	O
been	O	O
linked	O	O
to	O	O
rhabdomyolysis	O	O
previously	O	O
.	O	O

to	O	O
date	O	O
,	O	O
there	O	O
has	O	O
been	O	O
no	O	O
reported	O	O
effect	O	O
of	O	O
rhabdomyolysis	O	O
on	O	O
the	O	O
structure	O	O
and	O	O
function	O	O
of	O	O
cardiac	O	O
muscle	O	O
.	O	O

clinicians	O	O
need	O	O
to	O	O
be	O	O
aware	O	O
of	O	O
prescribing	O	O
concomitant	O	O
medications	O	O
that	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
myopathy	O	O
or	O	O
inhibit	O	O
the	O	O
cyp3a4	O	O
enzyme	O	O
.	O	O

our	O	O
case	O	O
suggests	O	O
that	O	O
troponin	O	O
elevation	O	O
could	O	O
be	O	O
associated	O	O
with	O	O
statin	B-chem	B-chem
induced	O	O
rhabdomyolysis	O	O
,	O	O
which	O	O
may	O	O
warrant	O	O
further	O	O
studies	O	O
.	O	O

characterization	O	O
of	O	O
a	O	O
novel	O	O
bche	O	O
"	O	O
"	O	O
"	O	O
"	O	O
silent	O	O
"	O	O
"	O	O
"	O	O
"	O	O
allele	O	O
:	O	O
point	O	O
mutation	O	O
(	O	O
p	O	O
.	O	O

val204asp	O	B-chem
)	O	O
causes	O	O
loss	O	O
of	O	O
activity	O	O
and	O	O
prolonged	O	O
apnea	O	O
with	O	O
suxamethonium	B-chem	B-chem
.	O	O

butyrylcholinesterase	O	O
deficiency	O	O
is	O	O
characterized	O	O
by	O	O
prolonged	O	O
apnea	O	O
after	O	O
the	O	O
use	O	O
of	O	O
muscle	O	O
relaxants	O	O
(	O	O
suxamethonium	B-chem	B-chem
or	O	O
mivacurium	B-chem	B-chem
)	O	O
in	O	O
patients	O	O
who	O	O
have	O	O
mutations	O	O
in	O	O
the	O	O
bche	O	O
gene	O	O
.	O	O

here	O	O
,	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
prolonged	O	O
neuromuscular	O	O
block	O	O
after	O	O
administration	O	O
of	O	O
suxamethonium	B-chem	B-chem
leading	O	O
to	O	O
the	O	O
discovery	O	O
of	O	O
a	O	O
novel	O	O
bche	O	O
variant	O	O
(	O	O
c	O	O
.	O	O
695t	O	O
>	O	O

a	O	O
,	O	O
p	O	O
.	O	O

val204asp	O	O
)	O	O
.	O	O

inhibition	O	O
studies	O	O
,	O	O
kinetic	O	O
analysis	O	O
and	O	O
molecular	O	O
dynamics	O	O
were	O	O
undertaken	O	O
to	O	O
understand	O	O
how	O	O
this	O	O
mutation	O	O
disrupts	O	O
the	O	O
catalytic	O	O
triad	O	O
and	O	O
determines	O	O
a	O	O
"	O	O
"	O	O
"	O	O
"	O	O
silent	O	O
"	O	O
"	O	O
"	O	O
"	O	O
phenotype	O	O
.	O	O

low	O	O
activity	O	O
of	O	O
patient	O	O
plasma	O	O
butyrylcholinesterase	O	O
with	O	O
butyrylthiocholine	B-chem	B-chem
(	O	O
btc	B-chem	B-chem
)	O	O
and	O	O
benzoylcholine	B-chem	B-chem
,	O	O
and	O	O
values	O	O
of	O	O
dibucaine	B-chem	B-chem
and	O	O
fluoride	B-chem	B-chem
numbers	O	O
fit	O	O
with	O	O
heterozygous	O	O
atypical	O	O
silent	O	O
genotype	O	O
.	O	O

electrophoretic	O	O
analysis	O	O
of	O	O
plasma	O	O
bche	O	O
of	O	O
the	O	O
proband	O	O
and	O	O
his	O	O
mother	O	O
showed	O	O
that	O	O
patient	O	O
has	O	O
a	O	O
reduced	O	O
amount	O	O
of	O	O
tetrameric	O	O
enzyme	O	O
in	O	O
plasma	O	O
and	O	O
that	O	O
minor	O	O
fast	O	O
-	O	O
moving	O	O
bche	O	O
components	O	O
:	O	O
monomer	O	O
,	O	O
dimer	O	O
,	O	O
and	O	O
monomer	O	O
-	O	O
albumin	O	O
conjugate	O	O
are	O	O
missing	O	O
.	O	O

kinetic	O	O
analysis	O	O
showed	O	O
that	O	O
the	O	O
p	O	O
.	O	O

val204asp	O	O
/	O	O
p	O	O
.	O	O

asp70gly	O	O
-	O	O
p	O	O
.	O	O

ala539thr	O	O
bche	O	O
displays	O	O
a	O	O
pure	O	O
michaelian	O	O
behavior	O	O
with	O	O
btc	B-chem	O
as	O	O
the	O	O
substrate	O	O
.	O	O

both	O	O
catalytic	O	O
parameters	O	O
km	O	O
=	O	O
265	O	O
um	O	B-chem
for	O	O
btc	B-chem	O
,	O	O
two	O	O
times	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
the	O	O
atypical	O	O
enzyme	O	O
,	O	O
and	O	O
a	O	O
low	O	O
vmax	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
absence	O	O
of	O	O
activity	O	O
against	O	O
suxamethonium	B-chem	B-chem
.	O	O

molecular	O	O
dynamic	O	O
(	O	O
md	O	O
)	O	O
simulations	O	O
showed	O	O
that	O	O
the	O	O
overall	O	O
effect	O	O
of	O	O
the	O	O
mutation	O	O
p	O	O
.	O	O

val204asp	O	O
is	O	O
disruption	O	O
of	O	O
hydrogen	B-chem	O
bonding	O	O
between	O	O
gln223	O	O
and	O	O
glu441	O	O
,	O	O
leading	O	O
ser198	O	O
and	O	O
his438	O	O
to	O	O
move	O	O
away	O	O
from	O	O
each	O	O
other	O	O
with	O	O
subsequent	O	O
disruption	O	O
of	O	O
the	O	O
catalytic	O	O
triad	O	O
functionality	O	O
regardless	O	O
of	O	O
the	O	O
type	O	O
of	O	O
substrate	O	O
.	O	O

md	O	O
also	O	O
showed	O	O
that	O	O
the	O	O
enzyme	O	O
volume	O	O
is	O	O
increased	O	O
,	O	O
suggesting	O	O
a	O	O
pre	O	O
-	O	O
denaturation	O	O
state	O	O
.	O	O

this	O	O
fits	O	O
with	O	O
the	O	O
reduced	O	O
concentration	O	O
of	O	O
p	O	O
.	O	O

ala204asp	O	O
/	O	O
p	O	O
.	O	O

asp70gly	O	O
-	O	O
p	O	O
.	O	O

ala539thr	O	O
tetrameric	O	O
enzyme	O	O
in	O	O
the	O	O
plasma	O	O
and	O	O
non	O	O
-	O	O
detectable	O	O
fast	O	O
moving	O	O
-	O	O
bands	O	O
on	O	O
electrophoresis	O	O
gels	O	O
.	O	O

delayed	O	O
anemia	O	O
after	O	O
treatment	O	O
with	O	O
injectable	O	O
artesunate	B-chem	B-chem
in	O	O
the	O	O
democratic	O	O
republic	O	O
of	O	O
the	O	O
congo	O	O
:	O	O
a	O	O
manageable	O	O
issue	O	O
.	O	O

cases	O	O
of	O	O
delayed	O	O
hemolytic	O	O
anemia	O	O
have	O	O
been	O	O
described	O	O
after	O	O
treatment	O	O
with	O	O
injectable	O	O
artesunate	B-chem	B-chem
,	O	O
the	O	O
current	O	O
world	O	O
health	O	O
organization	O	O
(	O	O
who	O	O
)	O	O
-	O	O
recommended	O	O
first	O	O
-	O	O
line	O	O
drug	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
malaria	O	O
.	O	O

a	O	O
total	O	O
of	O	O
350	O	O
patients	O	O
(	O	O
215	O	O
[	O	O
61	O	O
.	O	O
4	O	O
%	O	O
]	O	O
<	O	O
5	O	O
years	O	O
of	O	O
age	O	O
and	O	O
135	O	O
[	O	O
38	O	O
.	O	O
6	O	O
%	O	O
]	O	O
>	O	O
5	O	O
years	O	O
of	O	O
age	O	O
)	O	O
were	O	O
followed	O	O
-	O	O
up	O	O
after	O	O
treatment	O	O
with	O	O
injectable	O	O
artesunate	B-chem	B-chem
for	O	O
severe	O	O
malaria	O	O
in	O	O
hospitals	O	O
and	O	O
health	O	O
centers	O	O
of	O	O
the	O	O
democratic	O	O
republic	O	O
of	O	O
the	O	O
congo	O	O
.	O	O

complete	O	O
series	O	O
of	O	O
hemoglobin	O	O
(	O	O
hb	O	O
)	O	O
measurements	O	O
were	O	O
available	O	O
for	O	O
201	O	O
patients	O	O
.	O	O

a	O	O
decrease	O	O
in	O	O
hb	O	O
levels	O	O
between	O	O
2	O	O
and	O	O
5	O	O
g	O	O
/	O	O
dl	O	O
was	O	O
detected	O	O
in	O	O
23	O	O
(	O	O
11	O	O
.	O	O
4	O	O
%	O	O
)	O	O
patients	O	O
during	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
.	O	O

for	O	O
five	O	O
patients	O	O
,	O	O
hb	O	O
levels	O	O
decreased	O	O
below	O	O
5	O	O
g	O	O
/	O	O
dl	O	O
during	O	O
at	O	O
least	O	O
one	O	O
follow	O	O
-	O	O
up	O	O
visit	O	O
.	O	O

all	O	O
cases	O	O
of	O	O
delayed	O	O
anemia	O	O
were	O	O
clinically	O	O
manageable	O	O
and	O	O
resolved	O	O
within	O	O
one	O	O
month	O	O
.	O	O

regulation	O	O
of	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
3	O	O
and	O	O
apoptotic	O	O
pathways	O	O
by	O	O
betaine	B-chem	B-chem
attenuates	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
acute	O	O
myocardial	O	O
injury	O	O
in	O	O
rats	O	O
.	O	O

the	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
cardioprotective	O	O
effects	O	O
of	O	O
betaine	B-chem	B-chem
on	O	O
acute	O	O
myocardial	O	O
ischemia	O	O
induced	O	O
experimentally	O	O
in	O	O
rats	O	O
focusing	O	O
on	O	O
regulation	O	O
of	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
3	O	O
(	O	O
stat3	O	O
)	O	O
and	O	O
apoptotic	O	O
pathways	O	O
as	O	O
the	O	O
potential	O	O
mechanism	O	O
underlying	O	O
the	O	O
drug	O	O
effect	O	O
.	O	O

male	O	O
sprague	O	O
dawley	O	O
rats	O	O
were	O	O
treated	O	O
with	O	O
betaine	B-chem	B-chem
(	O	O
100	O	O
,	O	O
200	O	O
,	O	O
and	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
orally	O	O
for	O	O
40	O	O
days	O	O
.	O	O

acute	O	O
myocardial	O	O
ischemic	O	O
injury	O	O
was	O	O
induced	O	O
in	O	O
rats	O	O
by	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B-chem	B-chem
(	O	O
85	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
for	O	O
two	O	O
consecutive	O	O
days	O	O
.	O	O

serum	O	O
cardiac	O	O
marker	O	O
enzyme	O	O
,	O	O
histopathological	O	O
variables	O	O
and	O	O
expression	O	O
of	O	O
protein	O	O
levels	O	O
were	O	O
analyzed	O	O
.	O	O

oral	O	O
administration	O	O
of	O	O
betaine	B-chem	B-chem
(	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
significantly	O	O
reduced	O	O
the	O	O
level	O	O
of	O	O
cardiac	O	O
marker	O	O
enzyme	O	O
in	O	O
the	O	O
serum	O	O
and	O	O
prevented	O	O
left	O	O
ventricular	O	O
remodeling	O	O
.	O	O

western	O	O
blot	O	O
analysis	O	O
showed	O	O
that	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
phosphorylation	O	O
of	O	O
stat3	O	O
was	O	O
maintained	O	O
or	O	O
further	O	O
enhanced	O	O
by	O	O
betaine	B-chem	B-chem
treatment	O	O
in	O	O
myocardium	O	O
.	O	O

furthermore	O	O
,	O	O
betaine	B-chem	B-chem
(	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
treatment	O	O
increased	O	O
the	O	O
ventricular	O	O
expression	O	O
of	O	O
bcl	O	B-chem
-	O	O
2	O	O
and	O	O
reduced	O	O
the	O	O
level	O	O
of	O	O
bax	O	B-chem
,	O	O
therefore	O	O
causing	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
ratio	O	O
of	O	O
bcl	O	B-chem
-	O	O
2	O	O
/	O	O
bax	O	O
.	O	O

the	O	O
protective	O	O
role	O	O
of	O	O
betaine	B-chem	B-chem
on	O	O
myocardial	O	O
damage	O	O
was	O	O
further	O	O
confirmed	O	O
by	O	O
histopathological	O	O
examination	O	O
.	O	O

in	O	O
summary	O	O
,	O	O
our	O	O
results	O	O
showed	O	O
that	O	O
betaine	B-chem	B-chem
pretreatment	O	O
attenuated	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
acute	O	O
myocardial	O	O
ischemia	O	O
via	O	O
the	O	O
regulation	O	O
of	O	O
stat3	O	O
and	O	O
apoptotic	O	O
pathways	O	O
.	O	O

quetiapine	B-chem	B-chem
-	O	O
induced	O	O
neutropenia	O	O
in	O	O
a	O	O
bipolar	O	O
patient	O	O
with	O	O
hepatocellular	O	O
carcinoma	O	O
.	O	O

objective	O	O
:	O	O
quetiapine	B-chem	B-chem
is	O	O
a	O	O
dibenzothiazepine	O	B-chem
derivative	O	O
,	O	O
similar	O	O
to	O	O
clozapine	B-chem	B-chem
,	O	O
which	O	O
has	O	O
the	O	O
highest	O	O
risk	O	O
of	O	O
causing	O	O
blood	O	O
dyscrasias	O	O
,	O	O
especially	O	O
neutropenia	O	O
.	O	O

there	O	O
are	O	O
some	O	O
case	O	O
reports	O	O
about	O	O
this	O	O
side	O	O
effect	O	O
of	O	O
quetiapine	B-chem	B-chem
,	O	O
but	O	O
possible	O	O
risk	O	O
factors	O	O
are	O	O
seldom	O	O
discussed	O	O
and	O	O
identified	O	O
.	O	O

a	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
hepatocellular	O	O
carcinoma	O	O
that	O	O
developed	O	O
neutropenia	O	O
after	O	O
treatment	O	O
with	O	O
quetiapine	B-chem	B-chem
is	O	O
described	O	O
here	O	O
.	O	O

case	O	O
report	O	O
:	O	O

a	O	O
62	O	O
-	O	O
year	O	O
-	O	O
old	O	O
taiwanese	O	O
widow	O	O
with	O	O
bipolar	O	O
disorder	O	O
was	O	O
diagnosed	O	O
with	O	O
hepatocellular	O	O
carcinoma	O	O
at	O	O
age	O	O
60	O	O
.	O	O

she	O	O
developed	O	O
leucopenia	O	O
after	O	O
being	O	O
treated	O	O
with	O	O
quetiapine	B-chem	B-chem
.	O	O

after	O	O
quetiapine	B-chem	B-chem
was	O	O
discontinued	O	O
,	O	O
her	O	O
white	O	O
blood	O	O
cell	O	O
count	O	O
returned	O	O
to	O	O
normal	O	O
.	O	O

conclusions	O	O
:	O	O

although	O	O
neutropenia	O	O
is	O	O
not	O	O
a	O	O
common	O	O
side	O	O
effect	O	O
of	O	O
quetiapine	B-chem	B-chem
,	O	O
physicians	O	O
should	O	O
be	O	O
cautious	O	O
about	O	O
its	O	O
presentation	O	O
and	O	O
associated	O	O
risk	O	O
factors	O	O
.	O	O

hepatic	O	O
dysfunction	O	O
may	O	O
be	O	O
one	O	O
of	O	O
the	O	O
possible	O	O
risk	O	O
factors	O	O
,	O	O
and	O	O
concomitant	O	O
fever	O	O
may	O	O
be	O	O
a	O	O
diagnostic	O	O
marker	O	O
for	O	O
adverse	O	O
reaction	O	O
to	O	O
quetiapine	B-chem	B-chem
.	O	O

lateral	O	O
antebrachial	O	O
cutaneous	O	O
neuropathy	O	O
after	O	O
steroid	B-chem	B-chem
injection	O	O
at	O	O
lateral	O	O
epicondyle	O	O
.	O	O

background	O	O
and	O	O
objectives	O	O
:	O	O

this	O	O
report	O	O
aimed	O	O
to	O	O
present	O	O
a	O	O
case	O	O
of	O	O
lateral	O	O
antebrachial	O	O
cutaneous	O	O
neuropathy	O	O
(	O	O
lacnp	O	O
)	O	O
that	O	O
occurred	O	O
after	O	O
a	O	O
steroid	B-chem	B-chem
injection	O	O
in	O	O
the	O	O
lateral	O	O
epicondyle	O	O
to	O	O
treat	O	O
lateral	O	O
epicondylitis	O	O
in	O	O
a	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
.	O	O

material	O	O
and	O	O
method	O	O
:	O	O

a	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
presented	O	O
with	O	O
decreased	O	O
sensation	O	O
and	O	O
paresthesia	O	O
over	O	O
her	O	O
right	O	O
lateral	O	O
forearm	O	O
;	O	O
the	O	O
paresthesia	O	O
had	O	O
occurred	O	O
after	O	O
a	O	O
steroid	B-chem	B-chem
injection	O	O
in	O	O
the	O	O
right	O	O
lateral	O	O
epicondyle	O	O
3	O	O
months	O	O
before	O	O
.	O	O

her	O	O
sensation	O	O
of	O	O
light	O	O
touch	O	O
and	O	O
pain	O	O
was	O	O
diminished	O	O
over	O	O
the	O	O
lateral	O	O
side	O	O
of	O	O
the	O	O
right	O	O
forearm	O	O
and	O	O
wrist	O	O
area	O	O
.	O	O

results	O	O
:	O	O

the	O	O
sensory	O	O
action	O	O
potential	O	O
amplitude	O	O
of	O	O
the	O	O
right	O	O
lateral	O	O
antebrachial	O	O
cutaneous	O	O
nerve	O	O
(	O	O
lacn	O	O
)	O	O
(	O	O
6	O	O
.	O	O
2	O	O
uv	O	O
)	O	O
was	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
the	O	O
left	O	O
(	O	O
13	O	O
.	O	O
1	O	O
uv	O	O
)	O	O
.	O	O

the	O	O
difference	O	O
of	O	O
amplitude	O	O
between	O	O
both	O	O
sides	O	O
was	O	O
significant	O	O
because	O	O
there	O	O
was	O	O
more	O	O
than	O	O
a	O	O
50	O	O
%	O	O
reduction	O	O
.	O	O

she	O	O
was	O	O
diagnosed	O	O
with	O	O
right	O	O
lacnp	O	O
(	O	O
mainly	O	O
axonal	O	O
involvement	O	O
)	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
clinical	O	O
manifestation	O	O
and	O	O
the	O	O
electrodiagnostic	O	O
findings	O	O
.	O	O

her	O	O
symptoms	O	O
improved	O	O
through	O	O
physical	O	O
therapy	O	O
but	O	O
persisted	O	O
to	O	O
some	O	O
degree	O	O
.	O	O

conclusion	O	O
:	O	O

this	O	O
report	O	O
describes	O	O
the	O	O
case	O	O
of	O	O
a	O	O
woman	O	O
with	O	O
lacnp	O	O
that	O	O
developed	O	O
after	O	O
a	O	O
steroid	B-chem	B-chem
injection	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
lateral	O	O
epicondylitis	O	O
.	O	O

an	O	O
electrodiagnostic	O	O
study	O	O
,	O	O
including	O	O
a	O	O
nerve	O	O
conduction	O	O
study	O	O
of	O	O
the	O	O
lacn	O	O
,	O	O
was	O	O
helpful	O	O
to	O	O
diagnose	O	O
right	O	O
lacnp	O	O
and	O	O
to	O	O
find	O	O
the	O	O
passage	O	O
of	O	O
the	O	O
lacn	O	O
on	O	O
the	O	O
lateral	O	O
epicondyle	O	O
.	O	O

curcumin	B-chem	B-chem
prevents	O	O
maleate	B-chem	B-chem
-	O	O
induced	O	O
nephrotoxicity	O	O
:	O	O
relation	O	O
to	O	O
hemodynamic	O	O
alterations	O	O
,	O	O
oxidative	O	O
stress	O	O
,	O	O
mitochondrial	O	O
oxygen	B-chem	B-chem
consumption	O	O
and	O	O
activity	O	O
of	O	O
respiratory	O	O
complex	O	O
i	O	O
.	O	O

the	O	O
potential	O	O
protective	O	O
effect	O	O
of	O	O
the	O	O
dietary	O	O
antioxidant	O	O
curcumin	B-chem	B-chem
(	O	O
120	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
for	O	O
6	O	O
days	O	O
)	O	O
against	O	O
the	O	O
renal	O	O
injury	O	O
induced	O	O
by	O	O
maleate	B-chem	O
was	O	O
evaluated	O	O
.	O	O

tubular	O	O
proteinuria	O	O
and	O	O
oxidative	O	O
stress	O	O
were	O	O
induced	O	O
by	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
maleate	B-chem	O
(	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
in	O	O
rats	O	O
.	O	O

maleate	B-chem	B-chem
-	O	O
induced	O	O
renal	O	O
injury	O	O
included	O	O
increase	O	O
in	O	O
renal	O	O
vascular	O	O
resistance	O	O
and	O	O
in	O	O
the	O	O
urinary	O	O
excretion	O	O
of	O	O
total	O	O
protein	O	O
,	O	O
glucose	B-chem	B-chem
,	O	O
sodium	B-chem	B-chem
,	O	O
neutrophil	O	O
gelatinase	O	O
-	O	O
associated	O	O
lipocalin	O	O
(	O	O
ngal	O	O
)	O	O
and	O	O
n	O	B-chem
-	O	I-chem
acetyl	O	I-chem
b	O	I-chem
-	O	I-chem
d	O	I-chem
-	O	I-chem
glucosaminidase	O	I-chem
(	O	O
nag	O	O
)	O	O
,	O	O
upregulation	O	O
of	O	O
kidney	O	O
injury	O	O
molecule	O	O
(	O	O
kim	O	B-chem
)	O	O
-	O	O
1	O	O
,	O	O
decrease	O	O
in	O	O
renal	O	O
blood	O	O
flow	O	O
and	O	O
claudin	O	B-chem
-	O	O
2	O	O
expression	O	O
besides	O	O
of	O	O
necrosis	O	O
and	O	O
apoptosis	O	O
of	O	O
tubular	O	O
cells	O	O
on	O	O
24	O	O
h	O	O
.	O	O
oxidative	O	O
stress	O	O
was	O	O
determined	O	O
by	O	O
measuring	O	O
the	O	O
oxidation	O	O
of	O	O
lipids	O	O
and	O	O
proteins	O	O
and	O	O
diminution	O	O
in	O	O
renal	O	O
nrf2	O	O
levels	O	O
.	O	O

studies	O	O
were	O	O
also	O	O
conducted	O	O
in	O	O
renal	O	O
epithelial	O	O
llc	O	O
-	O	O
pk1	O	O
cells	O	O
and	O	O
in	O	O
mitochondria	O	O
isolated	O	O
from	O	O
kidneys	O	O
of	O	O
all	O	O
the	O	O
experimental	O	O
groups	O	O
.	O	O

maleate	B-chem	O
induced	O	O
cell	O	O
damage	O	O
and	O	O
reactive	O	O
oxygen	B-chem	B-chem
species	O	O
(	O	O
ros	O	O
)	O	O
production	O	O
in	O	O
llc	O	O
-	O	O
pk1	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
maleate	B-chem	O
treatment	O	O
reduced	O	O
oxygen	B-chem	B-chem
consumption	O	O
in	O	O
adp	B-chem	B-chem
-	O	O
stimulated	O	O
mitochondria	O	O
and	O	O
diminished	O	O
respiratory	O	O
control	O	O
index	O	O
when	O	O
using	O	O
malate	B-chem	B-chem
/	O	O
glutamate	B-chem	B-chem
as	O	O
substrate	O	O
.	O	O

the	O	O
activities	O	O
of	O	O
both	O	O
complex	O	O
i	O	O
and	O	O
aconitase	O	O
were	O	O
also	O	O
diminished	O	O
.	O	O

all	O	O
the	O	O
above	O	O
-	O	O
described	O	O
alterations	O	O
were	O	O
prevented	O	O
by	O	O
curcumin	B-chem	B-chem
.	O	O

it	O	O
is	O	O
concluded	O	O
that	O	O
curcumin	B-chem	B-chem
is	O	O
able	O	O
to	O	O
attenuate	O	O
in	O	O
vivo	O	O
maleate	B-chem	O
-	O	O
induced	O	O
nephropathy	O	O
and	O	O
in	O	O
vitro	O	O
cell	O	O
damage	O	O
.	O	O

the	O	O
in	O	O
vivo	O	O
protection	O	O
was	O	O
associated	O	O
to	O	O
the	O	O
prevention	O	O
of	O	O
oxidative	O	O
stress	O	O
and	O	O
preservation	O	O
of	O	O
mitochondrial	O	O
oxygen	B-chem	B-chem
consumption	O	O
and	O	O
activity	O	O
of	O	O
respiratory	O	O
complex	O	O
i	O	O
,	O	O
and	O	O
the	O	O
in	O	O
vitro	O	O
protection	O	O
was	O	O
associated	O	O
to	O	O
the	O	O
prevention	O	O
of	O	O
ros	O	O
production	O	O
.	O	O

incidence	O	O
of	O	O
solid	O	O
tumours	O	O
among	O	O
pesticide	O	O
applicators	O	O
exposed	O	O
to	O	O
the	O	O
organophosphate	B-chem	B-chem
insecticide	O	I-chem
diazinon	B-chem	I-chem
in	O	O
the	O	O
agricultural	O	O
health	O	O
study	O	O
:	O	O
an	O	O
updated	O	O
analysis	O	O
.	O	O

objective	O	O
:	O	O
diazinon	B-chem	B-chem
,	O	O
a	O	O
common	O	O
organophosphate	B-chem	B-chem
insecticide	O	O
with	O	O
genotoxic	O	O
properties	O	O
,	O	O
was	O	O
previously	O	O
associated	O	O
with	O	O
lung	O	O
cancer	O	O
in	O	O
the	O	O
agricultural	O	O
health	O	O
study	O	O
(	O	O
ahs	O	O
)	O	O
cohort	O	O
,	O	O
but	O	O
few	O	O
other	O	O
epidemiological	O	O
studies	O	O
have	O	O
examined	O	O
diazinon	B-chem	B-chem
-	O	O
associated	O	O
cancer	O	O
risk	O	O
.	O	O

we	O	O
used	O	O
updated	O	O
diazinon	B-chem	B-chem
exposure	O	O
and	O	O
cancer	O	O
incidence	O	O
information	O	O
to	O	O
evaluate	O	O
solid	O	O
tumour	O	O
risk	O	O
in	O	O
the	O	O
ahs	O	O
.	O	O

methods	O	O
:	O	O

male	O	O
pesticide	O	O
applicators	O	O
in	O	O
iowa	O	O
and	O	O
north	O	O
carolina	O	O
reported	O	O
lifetime	O	O
diazinon	B-chem	B-chem
use	O	O
at	O	O
enrolment	O	O
(	O	O
1993	O	O
-	O	O
1997	O	O
)	O	O
and	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
1998	O	O
-	O	O
2005	O	O
)	O	O
;	O	O
cancer	O	O
incidence	O	O
was	O	O
assessed	O	O
through	O	O
2010	O	O
(	O	O
north	O	O
carolina	O	O
)	O	O
/	O	O
2011	O	O
(	O	O
iowa	O	O
)	O	O
.	O	O

among	O	O
applicators	O	O
with	O	O
usage	O	O
information	O	O
sufficient	O	O
to	O	O
evaluate	O	O
exposure	O	O
-	O	O
response	O	O
patterns	O	O
,	O	O
we	O	O
used	O	O
poisson	O	O
regression	O	O
to	O	O
estimate	O	O
adjusted	O	O
rate	O	O
ratios	O	O
(	O	O
rrs	O	O
)	O	O
and	O	O
95	O	O
%	O	O
ci	O	O
for	O	O
cancer	O	O
sites	O	O
with	O	O
>	O	O
10	O	O
exposed	O	O
cases	O	O
for	O	O
both	O	O
lifetime	O	O
(	O	O
lt	O	O
)	O	O
exposure	O	O
days	O	O
and	O	O
intensity	O	O
-	O	O
weighted	O	O
(	O	O
iw	O	O
)	O	O
lifetime	O	O
exposure	O	O
days	O	O
(	O	O
accounting	O	O
for	O	O
factors	O	O
impacting	O	O
exposure	O	O
)	O	O
.	O	O

results	O	O
:	O	O

we	O	O
observed	O	O
elevated	O	O
lung	O	O
cancer	O	O
risks	O	O
(	O	O
n	O	O
=	O	O
283	O	O
)	O	O
among	O	O
applicators	O	O
with	O	O
the	O	O
greatest	O	O
number	O	O
of	O	O
lt	O	O
(	O	O
rr	O	O
=	O	O
1	O	O
.	O	O
60	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
1	O	O
.	O	O
11	O	O
to	O	O
2	O	O
.	O	O
31	O	O
;	O	O
ptrend	O	O
=	O	O
0	O	O
.	O	O
02	O	O
)	O	O
and	O	O
iw	O	O
days	O	O
of	O	O
diazinon	B-chem	B-chem
use	O	O
(	O	O
rr	O	O
=	O	O
1	O	O
.	O	O
41	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
0	O	O
.	O	O
98	O	O
to	O	O
2	O	O
.	O	O
04	O	O
;	O	O
ptrend	O	O
=	O	O
0	O	O
.	O	O
08	O	O
)	O	O
.	O	O

kidney	O	O
cancer	O	O
(	O	O
n	O	O
=	O	O
94	O	O
)	O	O
risks	O	O
were	O	O
non	O	O
-	O	O
significantly	O	O
elevated	O	O
(	O	O
rrlt	O	O
days	O	O
=	O	O
1	O	O
.	O	O
77	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
0	O	O
.	O	O
90	O	O
to	O	O
3	O	O
.	O	O
51	O	O
;	O	O
ptrend	O	O
=	O	O
0	O	O
.	O	O
09	O	O
;	O	O
rriw	O	O
days	O	O
1	O	O
.	O	O
37	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
0	O	O
.	O	O
64	O	O
to	O	O
2	O	O
.	O	O
92	O	O
;	O	O
ptrend	O	O
=	O	O
0	O	O
.	O	O
50	O	O
)	O	O
,	O	O
as	O	O
were	O	O
risks	O	O
for	O	O
aggressive	O	O
prostate	O	O
cancer	O	O
(	O	O
n	O	O
=	O	O
656	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

our	O	O
updated	O	O
evaluation	O	O
of	O	O
diazinon	B-chem	B-chem
provides	O	O
additional	O	O
evidence	O	O
of	O	O
an	O	O
association	O	O
with	O	O
lung	O	O
cancer	O	O
risk	O	O
.	O	O

newly	O	O
identified	O	O
links	O	O
to	O	O
kidney	O	O
cancer	O	O
and	O	O
associations	O	O
with	O	O
aggressive	O	O
prostate	O	O
cancer	O	O
require	O	O
further	O	O
evaluation	O	O
.	O	O

associations	O	O
of	O	O
ozone	B-chem	B-chem
and	O	O
pm2	O	O
.	O	O
5	O	O
concentrations	O	O
with	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
among	O	O
participants	O	O
in	O	O
the	O	O
agricultural	O	O
health	O	O
study	O	O
.	O	O

objective	O	O
:	O	O

this	O	O
study	O	O
describes	O	O
associations	O	O
of	O	O
ozone	B-chem	B-chem
and	O	O
fine	O	O
particulate	B-chem	O
matter	I-chem	O
with	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
observed	O	O
among	O	O
farmers	O	O
in	O	O
north	O	O
carolina	O	O
and	O	O
iowa	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
used	O	O
logistic	O	O
regression	O	O
to	O	O
determine	O	O
the	O	O
associations	O	O
of	O	O
these	O	O
pollutants	O	O
with	O	O
self	O	O
-	O	O
reported	O	O
,	O	O
doctor	O	O
-	O	O
diagnosed	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

daily	O	O
predicted	O	O
pollutant	O	O
concentrations	O	O
were	O	O
used	O	O
to	O	O
derive	O	O
surrogates	O	O
of	O	O
long	O	O
-	O	O
term	O	O
exposure	O	O
and	O	O
link	O	O
them	O	O
to	O	O
study	O	O
participants	O	O
'	O	O
geocoded	O	O
addresses	O	O
.	O	O

results	O	O
:	O	O

we	O	O
observed	O	O
positive	O	O
associations	O	O
of	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
with	O	O
ozone	B-chem	B-chem
(	O	O
odds	O	O
ratio	O	O
=	O	O
1	O	O
.	O	O
39	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
:	O	O
0	O	O
.	O	O
98	O	O
to	O	O
1	O	O
.	O	O
98	O	O
)	O	O
and	O	O
fine	O	O
particulate	B-chem	O
matter	I-chem	O
(	O	O
odds	O	O
ratio	O	O
=	O	O
1	O	O
.	O	O
34	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
:	O	O
0	O	O
.	O	O
93	O	O
to	O	O
1	O	O
.	O	O
93	O	O
)	O	O
in	O	O
north	O	O
carolina	O	O
but	O	O
not	O	O
in	O	O
iowa	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
plausibility	O	O
of	O	O
an	O	O
effect	O	O
of	O	O
ambient	O	O
concentrations	O	O
of	O	O
these	O	O
pollutants	O	O
on	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
risk	O	O
is	O	O
supported	O	O
by	O	O
experimental	O	O
data	O	O
demonstrating	O	O
damage	O	O
to	O	O
dopaminergic	O	O
neurons	O	O
at	O	O
relevant	O	O
concentrations	O	O
.	O	O

additional	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
address	O	O
uncertainties	O	O
related	O	O
to	O	O
confounding	O	O
and	O	O
to	O	O
examine	O	O
temporal	O	O
aspects	O	O
of	O	O
the	O	O
associations	O	O
we	O	O
observed	O	O
.	O	O

low	O	O
functional	O	O
programming	O	O
of	O	O
renal	O	O
at2r	O	O
mediates	O	O
the	O	O
developmental	O	O
origin	O	O
of	O	O
glomerulosclerosis	O	O
in	O	O
adult	O	O
offspring	O	O
induced	O	O
by	O	O
prenatal	O	O
caffeine	B-chem	B-chem
exposure	O	O
.	O	O

unassigned	O	O
:	O	O

our	O	O
previous	O	O
study	O	O
has	O	O
indicated	O	O
that	O	O
prenatal	O	O
caffeine	B-chem	B-chem
exposure	O	O
(	O	O
pce	O	O
)	O	O
could	O	O
induce	O	O
intrauterine	O	O
growth	O	O
retardation	O	O
(	O	O
iugr	O	O
)	O	O
of	O	O
offspring	O	O
.	O	O

recent	O	O
research	O	O
suggested	O	O
that	O	O
iugr	O	O
is	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
glomerulosclerosis	O	O
.	O	O

however	O	O
,	O	O
whether	O	O
pce	O	O
could	O	O
induce	O	O
glomerulosclerosis	O	O
and	O	O
its	O	O
underlying	O	O
mechanisms	O	O
remain	O	O
unknown	O	O
.	O	O

this	O	O
study	O	O
aimed	O	O
to	O	O
demonstrate	O	O
the	O	O
induction	O	O
to	O	O
glomerulosclerosis	O	O
in	O	O
adult	O	O
offspring	O	O
by	O	O
pce	O	O
and	O	O
its	O	O
intrauterine	O	O
programming	O	O
mechanisms	O	O
.	O	O

a	O	O
rat	O	O
model	O	O
of	O	O
iugr	O	O
was	O	O
established	O	O
by	O	O
pce	O	O
,	O	O
male	O	O
fetuses	O	O
and	O	O
adult	O	O
offspring	O	O
at	O	O
the	O	O
age	O	O
of	O	O
postnatal	O	O
week	O	O
24	O	O
were	O	O
euthanized	O	O
.	O	O

the	O	O
results	O	O
revealed	O	O
that	O	O
the	O	O
adult	O	O
offspring	O	O
kidneys	O	O
in	O	O
the	O	O
pce	O	O
group	O	O
exhibited	O	O
glomerulosclerosis	O	O
as	O	O
well	O	O
as	O	O
interstitial	O	O
fibrosis	O	O
,	O	O
accompanied	O	O
by	O	O
elevated	O	O
levels	O	O
of	O	O
serum	O	O
creatinine	B-chem	B-chem
and	O	O
urine	O	O
protein	O	O
.	O	O

renal	O	O
angiotensin	B-chem	B-chem
ii	I-chem	I-chem
receptor	O	O
type	O	O
2	O	O
(	O	O
at2r	O	O
)	O	O
gene	O	O
expression	O	O
in	O	O
adult	O	O
offspring	O	O
was	O	O
reduced	O	O
by	O	O
pce	O	O
,	O	O
whereas	O	O
the	O	O
renal	O	O
angiotensin	B-chem	B-chem
ii	I-chem	I-chem
receptor	O	O
type	O	O
1a	O	O
(	O	O
at1ar	O	O
)	O	O
/	O	O
at2r	O	O
expression	O	O
ratio	O	O
was	O	O
increased	O	O
.	O	O

the	O	O
fetal	O	O
kidneys	O	O
in	O	O
the	O	O
pce	O	O
group	O	O
displayed	O	O
an	O	O
enlarged	O	O
bowman	O	O
'	O	O
s	O	O
space	O	O
and	O	O
a	O	O
shrunken	O	O
glomerular	O	O
tuft	O	O
,	O	O
accompanied	O	O
by	O	O
a	O	O
reduced	O	O
cortex	O	O
width	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
nephrogenic	O	O
zone	O	O
/	O	O
cortical	O	O
zone	O	O
ratio	O	O
.	O	O

observation	O	O
by	O	O
electronic	O	O
microscope	O	O
revealed	O	O
structural	O	O
damage	O	O
of	O	O
podocytes	O	O
;	O	O
the	O	O
reduced	O	O
expression	O	O
level	O	O
of	O	O
podocyte	O	O
marker	O	O
genes	O	O
,	O	O
nephrin	O	O
and	O	O
podocin	O	B-chem
,	O	O
was	O	O
also	O	O
detected	O	O
by	O	O
q	O	O
-	O	O
pcr	O	O
.	O	O

moreover	O	O
,	O	O
at2r	O	O
gene	O	O
and	O	O
protein	O	O
expressions	O	O
in	O	O
fetal	O	O
kidneys	O	O
were	O	O
inhibited	O	O
by	O	O
pce	O	O
,	O	O
associated	O	O
with	O	O
the	O	O
repression	O	O
of	O	O
the	O	O
gene	O	O
expression	O	O
of	O	O
glial	O	O
-	O	O
cell	O	O
-	O	O
line	O	O
-	O	O
derived	O	O
neurotrophic	O	O
factor	O	O
(	O	O
gdnf	O	O
)	O	O
/	O	O
tyrosine	B-chem	O
kinase	O	O
receptor	O	O
(	O	O
c	O	O
-	O	O
ret	O	O
)	O	O
signaling	O	O
pathway	O	O
.	O	O

these	O	O
results	O	O
demonstrated	O	O
that	O	O
pce	O	O
could	O	O
induce	O	O
dysplasia	O	O
of	O	O
fetal	O	O
kidneys	O	O
as	O	O
well	O	O
as	O	O
glomerulosclerosis	O	O
of	O	O
adult	O	O
offspring	O	O
,	O	O
and	O	O
the	O	O
low	O	O
functional	O	O
programming	O	O
of	O	O
renal	O	O
at2r	O	O
might	O	O
mediate	O	O
the	O	O
developmental	O	O
origin	O	O
of	O	O
adult	O	O
glomerulosclerosis	O	O
.	O	O

1	B-chem	B-chem
,	I-chem	I-chem
3	I-chem	B-chem
-	I-chem	I-chem
butadiene	I-chem	I-chem
,	O	O
cml	O	B-chem
and	O	O
the	O	O
t	O	O
(	O	O
9	O	O
:	O	O
22	O	O
)	O	O
translocation	O	O
:	O	O

a	O	O
reality	O	O
check	O	O
.	O	O

unassigned	O	O
:	O	O

epidemiological	O	O
studies	O	O
of	O	O
1	B-chem	O
,	I-chem	O
3	I-chem	B-chem
-	I-chem	I-chem
butadiene	I-chem	I-chem
have	O	O
suggest	O	O
that	O	O
exposures	O	O
to	O	O
humans	O	O
are	O	O
associated	O	O
with	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
(	O	O
cml	O	O
)	O	O
.	O	O

cml	O	B-chem
has	O	O
a	O	O
well	O	O
-	O	O
documented	O	O
association	O	O
with	O	O
ionizing	O	O
radiation	O	O
,	O	O
but	O	O
reports	O	O
of	O	O
associations	O	O
with	O	O
chemical	O	O
exposures	O	O
have	O	O
been	O	O
questioned	O	O
.	O	O

ionizing	O	O
radiation	O	O
is	O	O
capable	O	O
of	O	O
inducing	O	O
the	O	O
requisite	O	O
cml	O	B-chem
-	O	O
associated	O	O
t	O	O
(	O	O
9	O	O
:	O	O
22	O	O
)	O	O
translocation	O	O
(	O	O
philadelphia	O	O
chromosome	O	O
)	O	O
in	O	O
appropriate	O	O
cells	O	O
in	O	O
vitro	O	O
but	O	O
,	O	O
thus	O	O
far	O	O
,	O	O
chemicals	O	O
have	O	O
not	O	O
shown	O	O
this	O	O
capacity	O	O
.	O	O

we	O	O
have	O	O
proposed	O	O
that	O	O
1	B-chem	O
,	I-chem	O
3	I-chem	B-chem
-	I-chem	I-chem
butadiene	I-chem	I-chem
metabolites	O	O
be	O	O
so	O	O
tested	O	O
as	O	O
a	O	O
reality	O	O
check	O	O
on	O	O
the	O	O
epidemiological	O	O
reports	O	O
.	O	O

in	O	O
order	O	O
to	O	O
conduct	O	O
reliable	O	O
testing	O	O
in	O	O
this	O	O
regard	O	O
,	O	O
it	O	O
is	O	O
essential	O	O
that	O	O
a	O	O
positive	O	O
control	O	O
for	O	O
induction	O	O
be	O	O
available	O	O
.	O	O

we	O	O
have	O	O
used	O	O
ionizing	O	O
radiation	O	O
to	O	O
develop	O	O
such	O	O
a	O	O
control	O	O
.	O	O

results	O	O
described	O	O
here	O	O
demonstrate	O	O
that	O	O
this	O	O
agent	O	O
does	O	O
in	O	O
fact	O	O
induce	O	O
pathogenic	O	O
t	O	O
(	O	O
9	O	O
:	O	O
22	O	O
)	O	O
translocations	O	O
in	O	O
a	O	O
human	O	O
myeloid	O	O
cell	O	O
line	O	O
in	O	O
vitro	O	O
,	O	O
but	O	O
does	O	O
so	O	O
at	O	O
low	O	O
frequencies	O	O
.	O	O

conditions	O	O
that	O	O
will	O	O
be	O	O
required	O	O
for	O	O
studies	O	O
of	O	O
1	B-chem	B-chem
,	I-chem	O
3	I-chem	I-chem
-	I-chem	I-chem
butadiene	I-chem	I-chem
are	O	O
discussed	O	O
.	O	O

cancer	O	O
incidence	O	O
and	O	O
metolachlor	B-chem	B-chem
use	O	O
in	O	O
the	O	O
agricultural	O	O
health	O	O
study	O	O
:	O	O

an	O	O
update	O	O
.	O	O

unassigned	O	O
:	O	O
metolachlor	B-chem	B-chem
,	O	O
a	O	O
widely	O	O
used	O	O
herbicide	O	O
,	O	O
is	O	O
classified	O	O
as	O	O
a	O	O
group	O	O
c	O	O
carcinogen	O	O
by	O	O
the	O	O
u	O	O
.	O	O
s	O	O
.	O	O
environmental	O	O
protection	O	O
agency	O	O
based	O	O
on	O	O
increased	O	O
liver	O	O
neoplasms	O	O
in	O	O
female	O	O
rats	O	O
.	O	O

epidemiologic	O	O
studies	O	O
of	O	O
the	O	O
health	O	O
effects	O	O
of	O	O
metolachlor	B-chem	B-chem
have	O	O
been	O	O
limited	O	O
.	O	O

the	O	O
agricultural	O	O
health	O	O
study	O	O
(	O	O
ahs	O	O
)	O	O
is	O	O
a	O	O
prospective	O	O
cohort	O	O
study	O	O
including	O	O
licensed	O	O
private	O	O
and	O	O
commercial	O	O
pesticide	O	O
applicators	O	O
in	O	O
iowa	O	O
and	O	O
north	O	O
carolina	O	O
enrolled	O	O
1993	O	O
-	O	O
1997	O	O
.	O	O

we	O	O
evaluated	O	O
cancer	O	O
incidence	O	O
through	O	O
2010	O	O
/	O	O
2011	O	O
(	O	O
nc	O	O
/	O	O
ia	O	O
)	O	O
for	O	O
49	O	O
,	O	O
616	O	O
applicators	O	O
,	O	O
53	O	O
%	O	O
of	O	O
whom	O	O
reported	O	O
ever	O	O
using	O	O
metolachlor	B-chem	B-chem
.	O	O

we	O	O
used	O	O
poisson	O	O
regression	O	O
to	O	O
evaluate	O	O
relations	O	O
between	O	O
two	O	O
metrics	O	O
of	O	O
metolachlor	B-chem	B-chem
use	O	O
(	O	O
lifetime	O	O
days	O	O
,	O	O
intensity	O	O
-	O	O
weighted	O	O
lifetime	O	O
days	O	O
)	O	O
and	O	O
cancer	O	O
incidence	O	O
.	O	O

we	O	O
saw	O	O
no	O	O
association	O	O
between	O	O
metolachlor	B-chem	B-chem
use	O	O
and	O	O
incidence	O	O
of	O	O
all	O	O
cancers	O	O
combined	O	O
(	O	O
n	O	O
=	O	O
5	O	O
,	O	O
701	O	O
with	O	O
a	O	O
5	O	O
-	O	O
year	O	O
lag	O	O
)	O	O
or	O	O
most	O	O
site	O	O
-	O	O
specific	O	O
cancers	O	O
.	O	O

for	O	O
liver	O	O
cancer	O	O
,	O	O
in	O	O
analyses	O	O
restricted	O	O
to	O	O
exposed	O	O
workers	O	O
,	O	O
elevations	O	O
observed	O	O
at	O	O
higher	O	O
categories	O	O
of	O	O
use	O	O
were	O	O
not	O	O
statistically	O	O
significant	O	O
.	O	O

however	O	O
,	O	O
trends	O	O
for	O	O
both	O	O
lifetime	O	O
and	O	O
intensity	O	O
-	O	O
weighted	O	O
lifetime	O	O
days	O	O
of	O	O
metolachor	B-chem	B-chem
use	O	O
were	O	O
positive	O	O
and	O	O
statistically	O	O
significant	O	O
with	O	O
an	O	O
unexposed	O	O
reference	O	O
group	O	O
.	O	O

a	O	O
similar	O	O
pattern	O	O
was	O	O
observed	O	O
for	O	O
follicular	O	O
cell	O	O
lymphoma	O	O
,	O	O
but	O	O
no	O	O
other	O	O
lymphoma	O	O
subtypes	O	O
.	O	O

an	O	O
earlier	O	O
suggestion	O	O
of	O	O
increased	O	O
lung	O	O
cancer	O	O
risk	O	O
at	O	O
high	O	O
levels	O	O
of	O	O
metolachlor	B-chem	B-chem
use	O	O
in	O	O
this	O	O
cohort	O	O
was	O	O
not	O	O
confirmed	O	O
in	O	O
this	O	O
update	O	O
.	O	O

this	O	O
suggestion	O	O
of	O	O
an	O	O
association	O	O
between	O	O
metolachlor	B-chem	B-chem
and	O	O
liver	O	O
cancer	O	O
among	O	O
pesticide	O	O
applicators	O	O
is	O	O
a	O	O
novel	O	O
finding	O	O
and	O	O
echoes	O	O
observation	O	O
of	O	O
increased	O	O
liver	O	O
neoplasms	O	O
in	O	O
some	O	O
animal	O	O
studies	O	O
.	O	O

however	O	O
,	O	O
our	O	O
findings	O	O
for	O	O
both	O	O
liver	O	O
cancer	O	O
and	O	O
follicular	O	O
cell	O	O
lymphoma	O	O
warrant	O	O
follow	O	O
-	O	O
up	O	O
to	O	O
better	O	O
differentiate	O	O
effects	O	O
of	O	O
metolachlor	B-chem	B-chem
use	O	O
from	O	O
other	O	O
factors	O	O
.	O	O

mechanisms	O	O
underlying	O	O
latent	O	O
disease	O	O
risk	O	O
associated	O	O
with	O	O
early	O	O
-	O	O
life	O	O
arsenic	B-chem	O
exposure	O	O
:	O	O
current	O	O
research	O	O
trends	O	O
and	O	O
scientific	O	O
gaps	O	O
.	O	O

background	O	O
:	O	O

millions	O	O
of	O	O
individuals	O	O
worldwide	O	O
,	O	O
particularly	O	O
those	O	O
living	O	O
in	O	O
rural	O	O
and	O	O
developing	O	O
areas	O	O
,	O	O
are	O	O
exposed	O	O
to	O	O
harmful	O	O
levels	O	O
of	O	O
inorganic	B-chem	B-chem
arsenic	I-chem	I-chem
(	O	O
ias	B-chem	O
)	O	O
in	O	O
their	O	O
drinking	O	O
water	O	O
.	O	O

inorganic	B-chem	B-chem
as	I-chem	O
exposure	O	O
during	O	O
key	O	O
developmental	O	O
periods	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
adverse	O	O
health	O	O
effects	O	O
including	O	O
those	O	O
that	O	O
are	O	O
evident	O	O
in	O	O
adulthood	O	O
.	O	O

there	O	O
is	O	O
considerable	O	O
interest	O	O
in	O	O
identifying	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
relate	O	O
early	O	O
-	O	O
life	O	O
ias	B-chem	O
exposure	O	O
to	O	O
the	O	O
development	O	O
of	O	O
these	O	O
latent	O	O
diseases	O	O
,	O	O
particularly	O	O
in	O	O
relationship	O	O
to	O	O
cancer	O	O
.	O	O

objectives	O	O
:	O	O

this	O	O
work	O	O
summarizes	O	O
research	O	O
on	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
underlie	O	O
the	O	O
increased	O	O
risk	O	O
of	O	O
cancer	O	O
development	O	O
in	O	O
adulthood	O	O
that	O	O
is	O	O
associated	O	O
with	O	O
early	O	O
-	O	O
life	O	O
ias	B-chem	O
exposure	O	O
.	O	O

discussion	O	O
:	O	O

epigenetic	O	O
reprogramming	O	O
that	O	O
imparts	O	O
functional	O	O
changes	O	O
in	O	O
gene	O	O
expression	O	O
,	O	O
the	O	O
development	O	O
of	O	O
cancer	O	O
stem	O	O
cells	O	O
,	O	O
and	O	O
immunomodulation	O	O
are	O	O
plausible	O	O
underlying	O	O
mechanisms	O	O
by	O	O
which	O	O
early	O	O
-	O	O
life	O	O
ias	B-chem	O
exposure	O	O
elicits	O	O
latent	O	O
carcinogenic	O	O
effects	O	O
.	O	O

conclusions	O	O
:	O	O

evidence	O	O
is	O	O
mounting	O	O
that	O	O
relates	O	O
early	O	O
-	O	O
life	O	O
ias	B-chem	O
exposure	O	O
and	O	O
cancer	O	O
development	O	O
later	O	O
in	O	O
life	O	O
.	O	O

future	O	O
research	O	O
should	O	O
include	O	O
animal	O	O
studies	O	O
that	O	O
address	O	O
mechanistic	O	O
hypotheses	O	O
and	O	O
studies	O	O
of	O	O
human	O	O
populations	O	O
that	O	O
integrate	O	O
early	O	O
-	O	O
life	O	O
exposure	O	O
,	O	O
molecular	O	O
alterations	O	O
,	O	O
and	O	O
latent	O	O
disease	O	O
outcomes	O	O
.	O	O

on	O	O
the	O	O
antiarrhythmic	O	O
activity	O	O
of	O	O
one	O	B-chem
n	O	I-chem
-	O	I-chem
substituted	O	I-chem
piperazine	B-chem	I-chem
derivative	O	O
of	O	O
trans	B-chem	B-chem
-	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
amino	I-chem	I-chem
-	I-chem	I-chem
3	I-chem	I-chem
-	I-chem	I-chem
hydroxy	I-chem	I-chem
-	I-chem	I-chem
1	I-chem	I-chem
,	I-chem	I-chem
2	I-chem	I-chem
,	I-chem	I-chem
3	I-chem	I-chem
,	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
tetrahydroanaphthalene	I-chem	I-chem
.	O	O

the	O	O
antiarrhythmic	O	O
activity	O	O
of	O	O
the	O	O
compound	O	B-chem
n	B-chem	I-chem
-	I-chem	I-chem
(	I-chem	I-chem
trans	I-chem	I-chem
-	I-chem	I-chem
3	I-chem	I-chem
-	I-chem	I-chem
hydroxy	I-chem	I-chem
-	I-chem	I-chem
1	I-chem	I-chem
,	I-chem	I-chem
2	I-chem	I-chem
,	I-chem	I-chem
3	I-chem	I-chem
,	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
tetrahydro	I-chem	I-chem
-	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
naphthyl	I-chem	I-chem
)	I-chem	I-chem
-	I-chem	I-chem
n	I-chem	I-chem
-	I-chem	I-chem
(	I-chem	I-chem
3	I-chem	I-chem
-	I-chem	I-chem
oxo	I-chem	I-chem
-	I-chem	I-chem
3	I-chem	I-chem
-	I-chem	I-chem
phenyl	I-chem	I-chem
-	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
methylpropyl	I-chem	I-chem
)	I-chem	I-chem
-	I-chem	I-chem
piperazine	I-chem	I-chem
hydrochloride	I-chem	O
,	O	O
referred	O	O
to	O	O
as	O	O
p11	B-chem	O
,	O	O
is	O	O
studied	O	O
on	O	O
anaesthesized	O	O
cats	O	O
and	O	O
wistar	O	O
albino	O	O
rats	O	O
,	O	O
as	O	O
well	O	O
as	O	O
on	O	O
non	O	O
-	O	O
anaesthesized	O	O
rabbits	O	O
.	O	O

four	O	O
types	O	O
of	O	O
experimental	O	O
arrhythmia	O	O
are	O	O
used	O	O
-	O	O
-	O	O
with	O	O
bacl2	B-chem	O
,	O	O
with	O	O
chloroform	B-chem	B-chem
-	O	O
adrenaline	B-chem	B-chem
,	O	O
with	O	O
strophantine	B-chem	O
g	I-chem	O
and	O	O
with	O	O
aconitine	B-chem	B-chem
.	O	O

the	O	O
compound	O	O
p11	B-chem	O
is	O	O
introduced	O	O
in	O	O
doses	O	O
of	O	O
0	O	O
.	O	O
25	O	O
and	O	O
0	O	O
.	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
intravenously	O	O
and	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
orally	O	O
.	O	O

the	O	O
compound	O	O
manifests	O	O
antiarrhythmic	O	O
activity	O	O
in	O	O
all	O	O
models	O	O
of	O	O
experimental	O	O
arrhythmia	O	O
used	O	O
,	O	O
causing	O	O
greatest	O	O
inhibition	O	O
on	O	O
the	O	O
arrhythmia	O	O
induced	O	O
by	O	O
chloroform	B-chem	B-chem
-	O	O
adrenaline	B-chem	B-chem
(	O	O
in	O	O
90	O	O
per	O	O
cent	O	O
)	O	O
and	O	O
with	O	O
bacl2	B-chem	O
(	O	O
in	O	O
84	O	O
per	O	O
cent	O	O
)	O	O
.	O	O

the	O	O
results	O	O
obtained	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
beta	O	O
-	O	O
adrenoblocking	O	O
and	O	O
with	O	O
the	O	O
membrane	O	O
-	O	O
stabilizing	O	O
action	O	O
of	O	O
the	O	O
compound	O	O
.	O	O

experimental	O	O
progressive	O	O
muscular	O	O
dystrophy	O	O
and	O	O
its	O	O
treatment	O	O
with	O	O
high	O	O
doses	O	O
anabolizing	O	O
agents	O	O
.	O	O

we	O	O
are	O	O
still	O	O
a	O	O
long	O	O
way	O	O
from	O	O
discovering	O	O
an	O	O
unequivocal	O	O
pathogenetic	O	O
interpretation	O	O
of	O	O
progressive	O	O
muscular	O	O
dystrophy	O	O
in	O	O
man	O	O
.	O	O

noteworthy	O	O
efforts	O	O
have	O	O
been	O	O
made	O	O
in	O	O
the	O	O
experimental	O	O
field	O	O
;	O	O
a	O	O
recessive	O	O
autosomic	O	O
form	O	O
found	O	O
in	O	O
the	O	O
mouse	O	O
seems	O	O
to	O	O
bear	O	O
the	O	O
closest	O	O
resemblance	O	O
to	O	O
the	O	O
human	O	O
form	O	O
from	O	O
the	O	O
genetic	O	O
point	O	O
of	O	O
view	O	O
.	O	O

myopathy	O	O
due	O	O
to	O	O
lack	O	O
of	O	O
vitamin	B-chem	B-chem
e	I-chem	I-chem
and	O	O
myopathy	O	O
induced	O	O
by	O	O
certain	O	O
viruses	O	O
have	O	O
much	O	O
in	O	O
common	O	O
anatomically	O	O
and	O	O
pathologically	O	O
with	O	O
the	O	O
human	O	O
form	O	O
.	O	O

the	O	O
authors	O	O
induced	O	O
myodystrophy	O	O
in	O	O
the	O	O
rat	O	O
by	O	O
giving	O	O
it	O	O
a	O	O
diet	O	O
lacking	O	O
in	O	O
vitamin	B-chem	B-chem
e	I-chem	I-chem
.	O	O

the	O	O
pharmacological	O	O
characteristics	O	O
of	O	O
vitamin	B-chem	B-chem
e	I-chem	I-chem
and	O	O
the	O	O
degenerative	O	O
changes	O	O
brought	O	O
about	O	O
by	O	O
its	O	O
deficiency	O	O
,	O	O
especially	O	O
in	O	O
the	O	O
muscles	O	O
,	O	O
are	O	O
illustrated	O	O
.	O	O

it	O	O
is	O	O
thus	O	O
confirmed	O	O
that	O	O
the	O	O
histological	O	O
characteristics	O	O
of	O	O
myopathic	O	O
rat	O	O
muscle	O	O
induced	O	O
experimentally	O	O
are	O	O
extraordinarily	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
human	O	O
myopathy	O	O
as	O	O
confirmed	O	O
during	O	O
biopsies	O	O
performed	O	O
at	O	O
the	O	O
orthopaedic	O	O
traumatological	O	O
centre	O	O
,	O	O
florence	O	O
.	O	O

the	O	O
encouraging	O	O
results	O	O
obtained	O	O
in	O	O
various	O	O
authoratative	O	O
departments	O	O
in	O	O
myopathic	O	O
patients	O	O
by	O	O
using	O	O
anabolizing	O	O
steroids	B-chem	B-chem
have	O	O
encouraged	O	O
the	O	O
authors	O	O
to	O	O
investigate	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
one	O	O
anabolizing	O	O
agent	O	O
(	O	O
dianabol	B-chem	B-chem
,	O	O
ciba	B-chem	O
)	O	O
at	O	O
high	O	O
doses	O	O
in	O	O
rats	O	O
rendered	O	O
myopathic	O	O
by	O	O
a	O	O
diet	O	O
deficient	O	O
in	O	O
vitamin	B-chem	B-chem
e	I-chem	I-chem
.	O	O

in	O	O
this	O	O
way	O	O
they	O	O
obtained	O	O
appreciable	O	O
changes	O	O
in	O	O
body	O	O
weight	O	O
(	O	O
increased	O	O
from	O	O
50	O	O
to	O	O
70	O	O
g	O	O
after	O	O
forty	O	O
days	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
mg	O	O
per	O	O
day	O	O
of	O	O
anabolizing	O	O
agent	O	O
)	O	O
,	O	O
but	O	O
most	O	O
of	O	O
all	O	O
they	O	O
found	O	O
histological	O	O
changes	O	O
due	O	O
to	O	O
"	O	O
"	O	O
"	O	O
"	O	O
regenerative	O	O
"	O	O
"	O	O
"	O	O
"	O	O
changes	O	O
in	O	O
the	O	O
muscle	O	O
tissue	O	O
,	O	O
which	O	O
however	O	O
maintained	O	O
its	O	O
myopathic	O	O
characteristics	O	O
in	O	O
the	O	O
control	O	O
animals	O	O
that	O	O
were	O	O
not	O	O
treated	O	O
with	O	O
the	O	O
anabolizing	O	O
agent	O	O
.	O	O

the	O	O
authors	O	O
conclude	O	O
by	O	O
affirming	O	O
the	O	O
undoubted	O	O
efficacy	O	O
of	O	O
the	O	O
anabolizing	O	O
steroids	B-chem	B-chem
in	O	O
experimental	O	O
myopathic	O	O
disease	O	O
,	O	O
but	O	O
they	O	O
have	O	O
reservations	O	O
as	O	O
to	O	O
the	O	O
transfer	O	O
of	O	O
the	O	O
results	O	O
into	O	O
the	O	O
human	O	O
field	O	O
,	O	O
where	O	O
high	O	O
dosage	O	O
can	O	O
not	O	O
be	O	O
carried	O	O
out	O	O
continuously	O	O
because	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
drug	O	O
on	O	O
virility	O	O
;	O	O
because	O	O
the	O	O
tissue	O	O
injury	O	O
too	O	O
often	O	O
occurs	O	O
at	O	O
an	O	O
irreversible	O	O
stage	O	O
vis	O	O
-	O	O
a	O	O
-	O	O
vis	O	O
the	O	O
"	O	O
"	O	O
"	O	O
"	O	O
regeneration	O	O
"	O	O
"	O	O
"	O	O
"	O	O
of	O	O
the	O	O
muscle	O	O
tissue	O	O
;	O	O
and	O	O
finally	O	O
because	O	O
the	O	O
dystrophic	O	O
injurious	O	O
agent	O	O
is	O	O
certainly	O	O
not	O	O
the	O	O
lack	O	O
of	O	O
vitamin	B-chem	B-chem
e	I-chem	I-chem
but	O	O
something	O	O
as	O	O
yet	O	O
unknown	O	O
.	O	O

fetal	O	O
risks	O	O
due	O	O
to	O	O
warfarin	B-chem	B-chem
therapy	O	O
during	O	O
pregnancy	O	O
.	O	O

two	O	O
mothers	O	O
with	O	O
heart	O	O
valve	O	O
prosthesis	O	O
were	O	O
treated	O	O
with	O	O
warfarin	B-chem	B-chem
during	O	O
pregnancy	O	O
.	O	O

in	O	O
the	O	O
first	O	O
case	O	O
a	O	O
caesarean	O	O
section	O	O
was	O	O
done	O	O
one	O	O
week	O	O
after	O	O
replacement	O	O
of	O	O
warfarin	B-chem	B-chem
with	O	O
heparin	B-chem	B-chem
.	O	O

the	O	O
baby	O	O
died	O	O
of	O	O
cerebral	O	O
and	O	O
pulmonary	O	O
hemorrhage	O	O
.	O	O

the	O	O
second	O	O
mother	O	O
had	O	O
a	O	O
male	O	O
infant	O	O
by	O	O
caesarean	O	O
section	O	O
.	O	O

the	O	O
baby	O	O
showed	O	O
warfarin	B-chem	B-chem
-	O	O
induced	O	O
embryopathy	O	O
with	O	O
nasal	O	O
hypoplasia	O	O
and	O	O
stippled	O	O
epiphyses	O	O
(	O	O
chondrodysplasia	O	O
punctata	O	O
)	O	O
.	O	O

nasal	O	O
hypoplasia	O	O
with	O	O
or	O	O
without	O	O
stippled	O	O
epiphyses	O	O
has	O	O
now	O	O
been	O	O
reported	O	O
in	O	O
11	O	O
infants	O	O
born	O	O
to	O	O
mothers	O	O
treated	O	O
with	O	O
warfarin	B-chem	B-chem
during	O	O
the	O	O
first	O	O
trimester	O	O
,	O	O
and	O	O
a	O	O
causal	O	O
association	O	O
is	O	O
probable	O	O
.	O	O

in	O	O
view	O	O
of	O	O
the	O	O
risks	O	O
to	O	O
both	O	O
mother	O	O
and	O	O
fetus	O	O
in	O	O
women	O	O
with	O	O
prosthetic	O	O
cardiac	O	O
valves	O	O
it	O	O
is	O	O
recommended	O	O
that	O	O
therapeutic	O	O
abortion	O	O
be	O	O
advised	O	O
as	O	O
the	O	O
first	O	O
alternative	O	O
.	O	O

isradipine	B-chem	B-chem
treatment	O	O
for	O	O
hypertension	O	O
in	O	O
general	O	O
practice	O	O
in	O	O
hong	O	O
kong	O	O
.	O	O

a	O	O
6	O	O
-	O	O
week	O	O
open	O	O
study	O	O
of	O	O
the	O	O
introduction	O	O
of	O	O
isradipine	B-chem	B-chem
treatment	O	O
was	O	O
conducted	O	O
in	O	O
general	O	O
practice	O	O
in	O	O
hong	O	O
kong	O	O
.	O	O

303	O	O
chinese	O	O
patients	O	O
with	O	O
mild	O	O
to	O	O
moderate	O	O
hypertension	O	O
entered	O	O
the	O	O
study	O	O
.	O	O

side	O	O
effects	O	O
were	O	O
reported	O	O
in	O	O
21	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
caused	O	O
withdrawal	O	O
from	O	O
the	O	O
study	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

the	O	O
main	O	O
side	O	O
-	O	O
effects	O	O
were	O	O
headache	O	O
,	O	O
dizziness	O	O
,	O	O
palpitation	O	O
and	O	O
flushing	O	O
and	O	O
these	O	O
were	O	O
not	O	O
more	O	O
frequent	O	O
than	O	O
reported	O	O
in	O	O
other	O	O
studies	O	O
with	O	O
isradipine	B-chem	B-chem
or	O	O
with	O	O
placebo	O	O
.	O	O

supine	O	O
blood	O	O
pressure	O	O
was	O	O
reduced	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
from	O	O
170	O	O
+	O	O
/	O	O
-	O	O

20	O	O
/	O	O
102	O	O
+	O	O
/	O	O
-	O	O

6	O	O
mmhg	O	O
to	O	O
153	O	O
+	O	O
/	O	O
-	O	O

19	O	O
/	O	O
92	O	O
+	O	O
/	O	O
-	O	O

8	O	O
,	O	O
147	O	O
+	O	O
/	O	O
-	O	O

18	O	O
/	O	O
88	O	O
+	O	O
/	O	O
-	O	O
7	O	O
and	O	O
144	O	O
+	O	O
/	O	O
-	O	O

14	O	O
/	O	O
87	O	O
+	O	O
/	O	O
-	O	O

6	O	O
mmhg	O	O
at	O	O
2	O	O
,	O	O
4	O	O
and	O	O
6	O	O
weeks	O	O
respectively	O	O
in	O	O
evaluable	O	O
patients	O	O
.	O	O

similar	O	O
reductions	O	O
occurred	O	O
in	O	O
standing	O	O
blood	O	O
pressure	O	O
and	O	O
there	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
postural	O	O
hypotension	O	O
.	O	O

normalization	O	O
and	O	O
responder	O	O
rates	O	O
at	O	O
6	O	O
weeks	O	O
were	O	O
86	O	O
%	O	O
and	O	O
69	O	O
%	O	O
respectively	O	O
.	O	O

dosage	O	O
was	O	O
increased	O	O
from	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
b	O	O
.	O	O
d	O	O
.	O	O

to	O	O
5	O	O
mg	O	O
b	O	O
.	O	O
d	O	O
.	O	O

at	O	O
4	O	O
weeks	O	O
in	O	O
patients	O	O
with	O	O
diastolic	O	O
blood	O	O
pressure	O	O
greater	O	O
than	O	O
90	O	O
mmhg	O	O
and	O	O
their	O	O
further	O	O
response	O	O
was	O	O
greater	O	O
than	O	O
those	O	O
remaining	O	O
on	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
b	O	O
.	O	O
d	O	O
.	O	O

tachyphylaxis	O	O
to	O	O
systemic	O	O
but	O	O
not	O	O
to	O	O
airway	O	O
responses	O	O
during	O	O
prolonged	O	O
therapy	O	O
with	O	O
high	O	O
dose	O	O
inhaled	O	O
salbutamol	B-chem	B-chem
in	O	O
asthmatics	O	O
.	O	O

high	O	O
doses	O	O
of	O	O
inhaled	O	O
salbutamol	B-chem	B-chem
produce	O	O
substantial	O	O
improvements	O	O
in	O	O
airway	O	O
response	O	O
in	O	O
patients	O	O
with	O	O
asthma	O	O
,	O	O
and	O	O
are	O	O
associated	O	O
with	O	O
dose	O	O
-	O	O
dependent	O	O
systemic	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
responses	O	O
.	O	O

the	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
tachyphylaxis	O	O
occurs	O	O
during	O	O
prolonged	O	O
treatment	O	O
with	O	O
high	O	O
dose	O	O
inhaled	O	O
salbutamol	B-chem	B-chem
.	O	O

twelve	O	O
asthmatic	O	O
patients	O	O
(	O	O
fev1	O	O
,	O	O
81	O	O
+	O	O
/	O	O
-	O	O

4	O	O
%	O	O
predicted	O	O
)	O	O
,	O	O
requiring	O	O
only	O	O
occasional	O	O
inhaled	O	O
beta	O	O
-	O	O
agonists	O	O
as	O	O
their	O	O
sole	O	O
therapy	O	O
,	O	O
were	O	O
given	O	O
a	O	O
14	O	O
-	O	O
day	O	O
treatment	O	O
with	O	O
high	O	O
dose	O	O
inhaled	O	O
salbutamol	B-chem	B-chem
(	O	O
hds	O	B-chem
)	O	O
,	O	O
4	O	O
,	O	O
000	O	O
micrograms	O	O
daily	O	O
,	O	O
low	O	O
dose	O	O
inhaled	O	O
salbutamol	B-chem	B-chem
(	O	O
lds	O	O
)	O	O
,	O	O
800	O	O
micrograms	O	O
daily	O	O
,	O	O
or	O	O
placebo	O	O
(	O	O
pi	O	O
)	O	O
by	O	O
metered	O	B-chem
-	O	O
dose	O	O
inhaler	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
randomized	O	O
crossover	O	O
design	O	O
.	O	O

during	O	O
the	O	O
14	O	O
-	O	O
day	O	O
run	O	O
-	O	O
in	O	O
and	O	O
during	O	O
washout	O	O
periods	O	O
,	O	O
inhaled	O	O
beta	O	O
-	O	O
agonists	O	O
were	O	O
withheld	O	O
and	O	O
ipratropium	B-chem	B-chem
bromide	I-chem	I-chem
was	O	O
substituted	O	O
for	O	O
rescue	O	O
purposes	O	O
.	O	O

at	O	O
the	O	O
end	O	O
of	O	O
each	O	O
14	O	O
-	O	O
day	O	O
treatment	O	O
,	O	O
a	O	O
dose	O	O
-	O	O
response	O	O
curve	O	O
(	O	O
drc	O	O
)	O	O
was	O	O
performed	O	O
,	O	O
and	O	O
airway	O	O
(	O	O
fev1	O	O
,	O	O
fef25	O	O
-	O	O
75	O	O
)	O	O
chronotropic	O	O
(	O	O
hr	O	O
)	O	O
,	O	O
tremor	O	O
,	O	O
and	O	O
metabolic	O	O
(	O	O
k	B-chem	O
,	O	O
glu	B-chem	B-chem
)	O	O
responses	O	O
were	O	O
measured	O	O
at	O	O
each	O	O
step	O	O
(	O	O
from	O	O
100	O	O
to	O	O
4	O	O
,	O	O
000	O	O
micrograms	O	O
)	O	O
.	O	O

treatment	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
baseline	O	O
values	O	O
.	O	O

there	O	O
were	O	O
dose	O	O
-	O	O
dependent	O	O
increases	O	O
in	O	O
fev1	O	O
and	O	O
fef25	O	O
-	O	O
75	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
and	O	O
pretreatment	O	O
with	O	O
hds	O	O
did	O	O
not	O	O
displace	O	O
the	O	O
drc	O	O
to	O	O
the	O	O
right	O	O
.	O	O

drc	O	O
for	O	O
hr	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
k	B-chem	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
and	O	O
glu	B-chem	B-chem
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
005	O	O
)	O	O
were	O	O
attenuated	O	O
after	O	O
treatment	O	O
with	O	O
hds	O	O
compared	O	O
with	O	O
pi	O	O
.	O	O

there	O	O
were	O	O
also	O	O
differences	O	O
between	O	O
hds	O	O
and	O	O
lds	O	O
for	O	O
hr	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
glu	B-chem	B-chem
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
responses	O	O
.	O	O

frequency	O	O
and	O	O
severity	O	O
of	O	O
subjective	O	O
adverse	O	O
effects	O	O
were	O	O
also	O	O
reduced	O	O
after	O	O
hds	O	O
:	O	O
tremor	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
palpitations	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O
(	O	O
abstract	O	O

truncated	O	O
at	O	O
250	O	O
words	O	O
)	O	O

increased	O	O
anxiogenic	O	O
effects	O	O
of	O	O
caffeine	B-chem	B-chem
in	O	O
panic	O	O
disorders	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
oral	O	O
administration	O	O
of	O	O
caffeine	B-chem	B-chem
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
on	O	O
behavioral	O	O
ratings	O	O
,	O	O
somatic	O	O
symptoms	O	O
,	O	O
blood	O	O
pressure	O	O
and	O	O
plasma	O	O
levels	O	O
of	O	O
3	B-chem	B-chem
-	I-chem	I-chem
methoxy	I-chem	I-chem
-	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
hydroxyphenethyleneglycol	I-chem	I-chem
(	O	O
mhpg	B-chem	B-chem
)	O	O
and	O	O
cortisol	B-chem	B-chem
were	O	O
determined	O	O
in	O	O
17	O	O
healthy	O	O
subjects	O	O
and	O	O
21	O	O
patients	O	O
meeting	O	O
dsm	O	O
-	O	O
iii	O	O
criteria	O	O
for	O	O
agoraphobia	O	O
with	O	O
panic	O	O
attacks	O	O
or	O	O
panic	O	O
disorder	O	O
.	O	O

caffeine	B-chem	B-chem
produced	O	O
significantly	O	O
greater	O	O
increases	O	O
in	O	O
subject	O	O
-	O	O
rated	O	O
anxiety	O	O
,	O	O
nervousness	O	O
,	O	O
fear	O	O
,	O	O
nausea	O	O
,	O	O
palpitations	O	O
,	O	O
restlessness	O	O
,	O	O
and	O	O
tremors	O	O
in	O	O
the	O	O
patients	O	O
compared	O	O
with	O	O
healthy	O	O
subjects	O	O
.	O	O

in	O	O
the	O	O
patients	O	O
,	O	O
but	O	O
not	O	O
the	O	O
healthy	O	O
subjects	O	O
,	O	O
these	O	O
symptoms	O	O
were	O	O
significantly	O	O
correlated	O	O
with	O	O
plasma	O	O
caffeine	B-chem	B-chem
levels	O	O
.	O	O

seventy	O	O
-	O	O
one	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
reported	O	O
that	O	O
the	O	O
behavioral	O	O
effects	O	O
of	O	O
caffeine	B-chem	B-chem
were	O	O
similar	O	O
to	O	O
those	O	O
experienced	O	O
during	O	O
panic	O	O
attacks	O	O
.	O	O

caffeine	B-chem	B-chem
did	O	O
not	O	O
alter	O	O
plasma	O	O
mhpg	B-chem	B-chem
levels	O	O
in	O	O
either	O	O
the	O	O
healthy	O	O
subjects	O	O
or	O	O
patients	O	O
.	O	O

caffeine	B-chem	B-chem
increased	O	O
plasma	O	O
cortisol	B-chem	B-chem
levels	O	O
equally	O	O
in	O	O
the	O	O
patient	O	O
and	O	O
healthy	O	O
groups	O	O
.	O	O

because	O	O
caffeine	B-chem	B-chem
is	O	O
an	O	O
adenosine	B-chem	B-chem
receptor	O	O
antagonist	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
some	O	O
panic	O	O
disorder	O	O
patients	O	O
may	O	O
have	O	O
abnormalities	O	O
in	O	O
neuronal	O	O
systems	O	O
involving	O	O
adenosine	B-chem	B-chem
.	O	O

patients	O	O
with	O	O
anxiety	O	O
disorders	O	O
may	O	O
benefit	O	O
by	O	O
avoiding	O	O
caffeine	B-chem	B-chem
-	O	O
containing	O	O
foods	O	O
and	O	O
beverages	O	O
.	O	O

human	O	O
and	O	O
canine	O	O
ventricular	O	O
vasoactive	O	O
intestinal	O	O
polypeptide	O	O
:	O	O
decrease	O	O
with	O	O
heart	O	O
failure	O	O
.	O	O

vasoactive	O	O
intestinal	O	O
polypeptide	O	O
(	O	O
vip	O	O
)	O	O
is	O	O
a	O	O
systemic	O	O
and	O	O
coronary	O	O
vasodilator	O	O
that	O	O
may	O	O
have	O	O
positive	O	O
inotropic	O	O
properties	O	O
.	O	O

myocardial	O	O
levels	O	O
of	O	O
vip	O	O
were	O	O
assayed	O	O
before	O	O
and	O	O
after	O	O
the	O	O
development	O	O
of	O	O
heart	O	O
failure	O	O
in	O	O
two	O	O
canine	O	O
models	O	O
.	O	O

in	O	O
the	O	O
first	O	O
,	O	O
cobalt	B-chem	O
cardiomyopathy	O	O
was	O	O
induced	O	O
in	O	O
eight	O	O
dogs	O	O
;	O	O
vip	O	O
(	O	O
by	O	O
radioimmunoassay	O	O
)	O	O
decreased	O	O
from	O	O
35	O	O
+	O	O
/	O	O
-	O	O

11	O	O
pg	O	B-chem
/	O	O
mg	O	O
protein	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O

sd	O	O
)	O	O
to	O	O
5	O	O
+	O	O
/	O	O
-	O	O

4	O	O
pg	O	B-chem
/	O	O
mg	O	O
protein	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

in	O	O
six	O	O
dogs	O	O
with	O	O
doxorubicin	B-chem	B-chem
-	O	O
induced	O	O
heart	O	O
failure	O	O
,	O	O
vip	O	O
decreased	O	O
from	O	O
31	O	O
+	O	O
/	O	O
-	O	O

7	O	O
to	O	O
11	O	O
+	O	O
/	O	O
-	O	O

4	O	O
pg	O	B-chem
/	O	O
mg	O	O
protein	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
vip	O	O
content	O	O
of	O	O
left	O	O
ventricular	O	O
muscle	O	O
of	O	O
resected	O	O
failing	O	O
hearts	O	O
in	O	O
10	O	O
patients	O	O
receiving	O	O
a	O	O
heart	O	O
transplant	O	O
was	O	O
compared	O	O
with	O	O
the	O	O
papillary	O	O
muscles	O	O
in	O	O
14	O	O
patients	O	O
(	O	O
five	O	O
with	O	O
rheumatic	O	O
disease	O	O
,	O	O
nine	O	O
with	O	O
myxomatous	O	O
degeneration	O	O
)	O	O
receiving	O	O
mitral	O	O
valve	O	O
prostheses	O	O
.	O	O

the	O	O
lowest	O	O
myocardial	O	O
vip	O	O
concentration	O	O
was	O	O
found	O	O
in	O	O
the	O	O
hearts	O	O
of	O	O
patients	O	O
with	O	O
coronary	O	O
disease	O	O
(	O	O
one	O	O
patient	O	O
receiving	O	O
a	O	O
transplant	O	O
and	O	O
three	O	O
receiving	O	O
mitral	O	O
prostheses	O	O
)	O	O
(	O	O
6	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
9	O	O
pg	O	B-chem
/	O	O
mg	O	O
protein	O	O
)	O	O
.	O	O

the	O	O
other	O	O
patients	O	O
undergoing	O	O
transplantation	O	O
had	O	O
an	O	O
average	O	O
ejection	O	O
fraction	O	O
of	O	O
17	O	O
%	O	O
+	O	O
/	O	O
-	O	O

6	O	O
%	O	O
and	O	O
a	O	O
vip	O	O
level	O	O
of	O	O
8	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

3	O	O
.	O	O
9	O	O
pg	O	B-chem
/	O	O
mg	O	O
protein	O	O
.	O	O

the	O	O
hearts	O	O
without	O	O
coronary	O	O
artery	O	O
disease	O	O
(	O	O
average	O	O
ejection	O	O
fraction	O	O
of	O	O
this	O	O
group	O	O
62	O	O
%	O	O
+	O	O
/	O	O
-	O	O

10	O	O
%	O	O
)	O	O
had	O	O
a	O	O
vip	O	O
concentration	O	O
of	O	O
14	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O

7	O	O
.	O	O
9	O	O
pg	O	B-chem
/	O	O
mg	O	O
protein	O	O
,	O	O
and	O	O
this	O	O
was	O	O
greater	O	O
than	O	O
in	O	O
hearts	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
coronary	O	O
disease	O	O
and	O	O
the	O	O
hearts	O	O
of	O	O
patients	O	O
receiving	O	O
a	O	O
transplant	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

myocardial	O	O
catecholamines	B-chem	B-chem
were	O	O
also	O	O
determined	O	O
in	O	O
14	O	O
subjects	O	O
;	O	O
a	O	O
weak	O	O
correlation	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
57	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
between	O	O
the	O	O
tissue	O	O
concentrations	O	O
of	O	O
vip	O	O
and	O	O
norepinephrine	B-chem	B-chem
was	O	O
noted	O	O
.	O	O
(	O	O
abstract	O	O
truncated	O	O
at	O	O
250	O	O
words	O	O
)	O	O

interstrain	O	O
variation	O	O
in	O	O
acute	O	O
toxic	O	O
response	O	O
to	O	O
caffeine	B-chem	B-chem
among	O	O
inbred	O	O
mice	O	O
.	O	O

acute	O	O
toxic	O	O
dosage	O	O
-	O	O
dependent	O	O
behavioral	O	O
effects	O	O
of	O	O
caffeine	B-chem	B-chem
were	O	O
compared	O	O
in	O	O
adult	O	O
males	O	O
from	O	O
seven	O	O
inbred	O	O
mouse	O	O
strains	O	O
(	O	O
a	O	O
/	O	O
j	O	O
,	O	O
balb	O	O
/	O	O
cj	O	O
,	O	O
cba	O	O
/	O	O
j	O	O
,	O	O
c3h	O	O
/	O	O
hej	O	O
,	O	O
c57bl	O	O
/	O	O
6j	O	O
,	O	O
dba	O	O
/	O	O
2j	O	O
,	O	O
swr	O	O
/	O	O
j	O	O
)	O	O
.	O	O

c57bl	O	O
/	O	O
6j	O	O
,	O	O
chosen	O	O
as	O	O
a	O	O
"	O	O
"	O	O
"	O	O
"	O	O
prototypic	O	O
"	O	O
"	O	O
"	O	O
"	O	O
mouse	O	O
strain	O	O
,	O	O
was	O	O
used	O	O
to	O	O
determine	O	O
behavioral	O	O
responses	O	O
to	O	O
a	O	O
broad	O	O
range	O	O
(	O	O
5	O	O
-	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
of	O	O
caffeine	B-chem	B-chem
doses	O	O
.	O	O

five	O	O
phenotypic	O	O
characteristics	O	O
-	O	O
-	O	O
locomotor	O	O
activity	O	O
,	O	O
righting	O	O
ability	O	O
,	O	O
clonic	O	O
seizure	O	O
induction	O	O
,	O	O
stress	O	O
-	O	O
induced	O	O
lethality	O	O
,	O	O
death	O	O
without	O	O
external	O	O
stress	O	O
-	O	O
-	O	O
were	O	O
scored	O	O
at	O	O
various	O	O
caffeine	B-chem	B-chem
doses	O	O
in	O	O
drug	O	O
-	O	O
naive	O	O
animals	O	O
under	O	O
empirically	O	O
optimized	O	O
,	O	O
rigidly	O	O
constant	O	O
experimental	O	O
conditions	O	O
.	O	O

mice	O	O
(	O	O
n	O	O
=	O	O
12	O	O
for	O	O
each	O	O
point	O	O
)	O	O
received	O	O
single	O	O
ip	O	O
injections	O	O
of	O	O
a	O	O
fixed	O	O
volume	O	O
/	O	O
g	O	O
body	O	O
weight	O	O
of	O	O
physiological	O	O
saline	O	O
carrier	O	O
with	O	O
or	O	O
without	O	O
caffeine	B-chem	B-chem
in	O	O
doses	O	O
ranging	O	O
from	O	O
125	O	O
-	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

loss	O	O
of	O	O
righting	O	O
ability	O	O
was	O	O
scored	O	O
at	O	O
1	O	O
,	O	O
3	O	O
,	O	O
5	O	O
min	O	O
post	O	O
dosing	O	O
and	O	O
at	O	O
5	O	O
min	O	O
intervals	O	O
thereafter	O	O
for	O	O
20	O	O
min	O	O
.	O	O

in	O	O
the	O	O
same	O	O
animals	O	O
the	O	O
occurrence	O	O
of	O	O
clonic	O	O
seizures	O	O
was	O	O
scored	O	O
as	O	O
to	O	O
time	O	O
of	O	O
onset	O	O
and	O	O
severity	O	O
for	O	O
20	O	O
min	O	O
after	O	O
drug	O	O
administration	O	O
.	O	O

when	O	O
these	O	O
proceeded	O	O
to	O	O
tonic	O	O
seizures	O	O
,	O	O
death	O	O
occurred	O	O
in	O	O
less	O	O
than	O	O
20	O	O
min	O	O
.	O	O

animals	O	O
surviving	O	O
for	O	O
20	O	O
min	O	O
were	O	O
immediately	O	O
stressed	O	O
by	O	O
a	O	O
swim	O	O
test	O	O
in	O	O
25	O	O
degrees	O	O
c	O	O
water	O	O
,	O	O
and	O	O
death	O	O
-	O	O
producing	O	O
tonic	O	O
seizures	O	O
were	O	O
scored	O	O
for	O	O
2	O	O
min	O	O
.	O	O

in	O	O
other	O	O
animals	O	O
locomotor	O	O
activity	O	O
was	O	O
measured	O	O
15	O	O
or	O	O
60	O	O
min	O	O
after	O	O
caffeine	B-chem	B-chem
administration	O	O
.	O	O

by	O	O
any	O	O
single	O	O
behavioral	O	O
criterion	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
these	O	O
criteria	O	O
,	O	O
marked	O	O
differences	O	O
in	O	O
response	O	O
to	O	O
toxic	O	O
caffeine	B-chem	B-chem
doses	O	O
were	O	O
observed	O	O
between	O	O
strains	O	O
.	O	O

these	O	O
results	O	O
indicate	O	O
that	O	O
behavioral	O	O
toxicity	O	O
testing	O	O
of	O	O
alkylxanthines	B-chem	B-chem
in	O	O
a	O	O
single	O	O
mouse	O	O
strain	O	O
may	O	O
be	O	O
misleading	O	O
and	O	O
suggest	O	O
that	O	O
toxic	O	O
responses	O	O
of	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
to	O	O
this	O	O
class	O	O
of	O	O
compounds	O	O
are	O	O
genetically	O	O
influenced	O	O
in	O	O
mammals	O	O
.	O	O

invasive	O	O
carcinoma	O	O
of	O	O
the	O	O
renal	O	O
pelvis	O	O
following	O	O
cyclophosphamide	B-chem	B-chem
therapy	O	O
for	O	O
nonmalignant	O	O
disease	O	O
.	O	O

a	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
right	O	O
hydroureteronephrosis	O	O
due	O	O
to	O	O
ureterovesical	O	O
junction	O	O
obstruction	O	O
had	O	O
gross	O	O
hematuria	O	O
after	O	O
being	O	O
treated	O	O
for	O	O
five	O	O
years	O	O
wtih	O	O
cyclophosphamide	B-chem	B-chem
for	O	O
cerebral	O	O
vasculitis	O	O
.	O	O

a	O	O
right	O	O
nephroureterectomy	O	O
was	O	O
required	O	O
for	O	O
control	O	O
of	O	O
bleeding	O	O
.	O	O

the	O	O
pathology	O	O
specimen	O	O
contained	O	O
clinically	O	O
occult	O	O
invasive	O	O
carcinoma	O	O
of	O	O
the	O	O
renal	O	O
pelvis	O	O
.	O	O

although	O	O
the	O	O
ability	O	O
of	O	O
cyclophosphamide	B-chem	B-chem
to	O	O
cause	O	O
hemorrhagic	O	O
cystitis	O	O
and	O	O
urine	O	O
cytologic	O	O
abnormalities	O	O
indistinguishable	O	O
from	O	O
high	O	O
grade	O	O
carcinoma	O	O
is	O	O
well	O	O
known	O	O
,	O	O
it	O	O
is	O	O
less	O	O
widely	O	O
appreciated	O	O
that	O	O
it	O	O
is	O	O
also	O	O
associated	O	O
with	O	O
carcinoma	O	O
of	O	O
the	O	O
urinary	O	O
tract	O	O
.	O	O

twenty	O	O
carcinomas	O	O
of	O	O
the	O	O
urinary	O	O
bladder	O	O
and	O	O
one	O	O
carcinoma	O	O
of	O	O
the	O	O
prostate	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
its	O	O
use	O	O
.	O	O

the	O	O
present	O	O
case	O	O
is	O	O
the	O	O
first	O	O
carcinoma	O	O
of	O	O
the	O	O
renal	O	O
pelvis	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
cyclophosphamide	B-chem	B-chem
treatment	O	O
.	O	O

it	O	O
is	O	O
the	O	O
third	O	O
urinary	O	O
tract	O	O
cancer	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
cyclophosphamide	B-chem	B-chem
treatment	O	O
for	O	O
nonmalignant	O	O
disease	O	O
.	O	O

the	O	O
association	O	O
of	O	O
the	O	O
tumor	O	O
with	O	O
preexisting	O	O
hydroureteronephrosis	O	O
suggests	O	O
that	O	O
stasis	O	O
prolonged	O	O
and	O	O
intensified	O	O
exposure	O	O
of	O	O
upper	O	O
urinary	O	O
tract	O	O
epithelium	O	O
to	O	O
cyclophosphamide	B-chem	B-chem
.	O	O

patients	O	O
who	O	O
are	O	O
candidates	O	O
for	O	O
long	O	O
-	O	O
term	O	O
cyclophosphamide	B-chem	B-chem
treatment	O	O
should	O	O
be	O	O
routinely	O	O
evaluated	O	O
for	O	O
obstructive	O	O
uropathy	O	O
.	O	O

ascending	O	O
dose	O	O
tolerance	O	O
study	O	O
of	O	O
intramuscular	O	O
carbetocin	B-chem	B-chem
administered	O	O
after	O	O
normal	O	O
vaginal	O	O
birth	O	O
.	O	O

objective	O	O
:	O	O

to	O	O
determine	O	O
the	O	O
maximum	O	O
tolerated	O	O
dose	O	O
(	O	O
mtd	O	O
)	O	O
of	O	O
carbetocin	B-chem	B-chem
(	O	O
a	O	O
long	O	O
-	O	O
acting	O	O
synthetic	O	O
analogue	O	O
of	O	O
oxytocin	B-chem	B-chem
)	O	O
,	O	O
when	O	O
administered	O	O
immediately	O	O
after	O	O
vaginal	O	O
delivery	O	O
at	O	O
term	O	O
.	O	O

materials	O	O
and	O	O
methods	O	O
:	O	O

carbetocin	B-chem	B-chem
was	O	O
given	O	O
as	O	O
an	O	O
intramuscular	O	O
injection	O	O
immediately	O	O
after	O	O
the	O	O
birth	O	O
of	O	O
the	O	O
infant	O	O
in	O	O
45	O	O
healthy	O	O
women	O	O
with	O	O
normal	O	O
singleton	O	O
pregnancies	O	O
who	O	O
delivered	O	O
vaginally	O	O
at	O	O
term	O	O
.	O	O

dosage	O	O
groups	O	O
of	O	O
15	O	O
,	O	O
30	O	O
,	O	O
50	O	O
,	O	O
75	O	O
,	O	O
100	O	O
,	O	O
125	O	O
,	O	O
150	O	O
,	O	O
175	O	O
or	O	O
200	O	O
microg	O	O
carbetocin	B-chem	B-chem
were	O	O
assigned	O	O
to	O	O
blocks	O	O
of	O	O
three	O	O
women	O	O
according	O	O
to	O	O
the	O	O
continual	O	O
reassessment	O	O
method	O	O
(	O	O
crm	O	O
)	O	O
.	O	O

results	O	O
:	O	O

all	O	O
dosage	O	O
groups	O	O
consisted	O	O
of	O	O
three	O	O
women	O	O
,	O	O
except	O	O
those	O	O
with	O	O
100	O	O
microg	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
and	O	O
200	O	O
microg	O	O
(	O	O
n	O	O
=	O	O
18	O	O
)	O	O
.	O	O

recorded	O	O
were	O	O
dose	O	O
-	O	O
limiting	O	O
adverse	O	O
events	O	O
:	O	O
hyper	O	O
-	O	O
or	O	O
hypotension	O	O
(	O	O
three	O	O
)	O	O
,	O	O
severe	O	O
abdominal	O	O
pain	O	O
(	O	O
0	O	O
)	O	O
,	O	O
vomiting	O	O
(	O	O
0	O	O
)	O	O
and	O	O
retained	O	O
placenta	O	O
(	O	O
four	O	O
)	O	O
.	O	O

serious	O	O
adverse	O	O
events	O	O
occurred	O	O
in	O	O
seven	O	O
women	O	O
:	O	O
six	O	O
cases	O	O
with	O	O
blood	O	O
loss	O	O
>	O	O
or	O	O
=	O	O
1000	O	O
ml	O	O
,	O	O
four	O	O
cases	O	O
of	O	O
manual	O	O
placenta	O	O
removal	O	O
,	O	O
five	O	O
cases	O	O
of	O	O
additional	O	O
oxytocics	O	B-chem
administration	O	O
and	O	O
five	O	O
cases	O	O
of	O	O
blood	O	O
transfusion	O	O
.	O	O

maximum	O	O
blood	O	O
loss	O	O
was	O	O
greatest	O	O
at	O	O
the	O	O
upper	O	O
and	O	O
lower	O	O
dose	O	O
levels	O	O
,	O	O
and	O	O
lowest	O	O
in	O	O
the	O	O
70	O	O
-	O	O
125	O	O
microg	O	O
dose	O	O
range	O	O
.	O	O

four	O	O
out	O	O
of	O	O
six	O	O
cases	O	O
with	O	O
blood	O	O
loss	O	O
>	O	O
or	O	O
=	O	O
1000	O	O
ml	O	O
occurred	O	O
in	O	O
the	O	O
200	O	O
microg	O	O
group	O	O
.	O	O

the	O	O
majority	O	O
of	O	O
additional	O	O
administration	O	O
of	O	O
oxytocics	O	B-chem
(	O	O
4	O	O
/	O	O
5	O	O
)	O	O
and	O	O
blood	O	O
transfusion	O	O
(	O	O
3	O	O
/	O	O
5	O	O
)	O	O
occurred	O	O
in	O	O
the	O	O
dose	O	O
groups	O	O
of	O	O
200	O	O
microg	O	O
.	O	O

all	O	O
retained	O	O
placentae	O	O
were	O	O
found	O	O
in	O	O
the	O	O
group	O	O
of	O	O
200	O	O
microg	O	O
.	O	O

conclusion	O	O
:	O	O

the	O	O
mtd	O	O
was	O	O
calculated	O	O
to	O	O
be	O	O
at	O	O
200	O	O
microg	O	O
carbetocin	B-chem	B-chem
.	O	O

a	O	O
pilot	O	O
study	O	O
to	O	O
assess	O	O
the	O	O
safety	O	O
of	O	O
dobutamine	B-chem	B-chem
stress	O	O
echocardiography	O	O
in	O	O
the	O	O
emergency	O	O
department	O	O
evaluation	O	O
of	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
.	O	O

study	O	O
objective	O	O
:	O	O
chest	O	O
pain	O	O
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B-chem	B-chem
use	O	O
poses	O	O
a	O	O
diagnostic	O	O
dilemma	O	O
.	O	O

dobutamine	B-chem	B-chem
stress	O	O
echocardiography	O	O
(	O	O
dse	O	O
)	O	O
is	O	O
a	O	O
widely	O	O
available	O	O
and	O	O
sensitive	O	O
test	O	O
for	O	O
evaluating	O	O
cardiac	O	O
ischemia	O	O
.	O	O

because	O	O
of	O	O
the	O	O
theoretical	O	O
concern	O	O
regarding	O	O
administration	O	O
of	O	O
dobutamine	B-chem	B-chem
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B-chem	B-chem
use	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
pilot	O	O
study	O	O
to	O	O
assess	O	O
the	O	O
safety	O	O
of	O	O
dse	O	O
in	O	O
emergency	O	O
department	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
.	O	O

methods	O	O
:	O	O

a	O	O
prospective	O	O
case	O	O
series	O	O
was	O	O
conducted	O	O
in	O	O
the	O	O
intensive	O	O
diagnostic	O	O
and	O	O
treatment	O	O
unit	O	O
in	O	O
the	O	O
ed	O	O
of	O	O
an	O	O
urban	O	O
tertiary	O	O
-	O	O
care	O	O
teaching	O	O
hospital	O	O
.	O	O

patients	O	O
were	O	O
eligible	O	O
for	O	O
dse	O	O
if	O	O
they	O	O
had	O	O
used	O	O
cocaine	B-chem	B-chem
within	O	O
24	O	O
hours	O	O
preceding	O	O
the	O	O
onset	O	O
of	O	O
chest	O	O
pain	O	O
and	O	O
had	O	O
a	O	O
normal	O	O
ecg	O	O
and	O	O
tropinin	O	O

i	O	O
level	O	O
.	O	O

patients	O	O
exhibiting	O	O
signs	O	O
of	O	O
continuing	O	O
cocaine	B-chem	B-chem
toxicity	O	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
.	O	O

all	O	O
patients	O	O
were	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
serial	O	O
testing	O	O
after	O	O
the	O	O
dse	O	O
testing	O	O
in	O	O
the	O	O
intensive	O	O
diagnostic	O	O
and	O	O
treatment	O	O
unit	O	O
.	O	O

results	O	O
:	O	O

twenty	O	O
-	O	O
four	O	O
patients	O	O
were	O	O
enrolled	O	O
.	O	O

two	O	O
patients	O	O
had	O	O
inadequate	O	O
resting	O	O
images	O	O
,	O	O
one	O	O
dse	O	O
was	O	O
terminated	O	O
because	O	O
of	O	O
inferior	O	O
hypokinesis	O	O
,	O	O
another	O	O
dse	O	O
was	O	O
terminated	O	O
because	O	O
of	O	O
a	O	O
rate	O	O
-	O	O
related	O	O
atrial	O	O
conduction	O	O
deficit	O	O
,	O	O
and	O	O
1	O	O
patient	O	O
did	O	O
not	O	O
reach	O	O
the	O	O
target	O	O
heart	O	O
rate	O	O
.	O	O

thus	O	O
,	O	O
19	O	O
patients	O	O
completed	O	O
a	O	O
dse	O	O
and	O	O
reached	O	O
their	O	O
target	O	O
heart	O	O
rates	O	O
.	O	O

none	O	O
of	O	O
the	O	O
patients	O	O
experienced	O	O
signs	O	O
of	O	O
exaggerated	O	O
adrenergic	O	O
response	O	O
,	O	O
which	O	O
was	O	O
defined	O	O
as	O	O
a	O	O
systolic	O	O
blood	O	O
pressure	O	O
of	O	O
greater	O	O
than	O	O
200	O	O
mm	O	O
hg	O	O
or	O	O
the	O	O
occurrence	O	O
of	O	O
tachydysrhythmias	O	O
(	O	O
excluding	O	O
sinus	O	O
tachycardia	O	O
)	O	O
.	O	O

further	O	O
suggesting	O	O
lack	O	O
of	O	O
exaggerated	O	O
adrenergic	O	O
response	O	O
,	O	O
13	O	O
(	O	O
65	O	O
%	O	O
)	O	O
of	O	O
20	O	O
patients	O	O
required	O	O
supplemental	O	O
atropine	B-chem	B-chem
to	O	O
reach	O	O
their	O	O
target	O	O
heart	O	O
rates	O	O
.	O	O

conclusion	O	O
:	O	O

no	O	O
exaggerated	O	O
adrenergic	O	O
response	O	O
was	O	O
detected	O	O
when	O	O
dobutamine	B-chem	B-chem
was	O	O
administered	O	O
to	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
related	O	O
chest	O	O
pain	O	O
.	O	O

amiodarone	B-chem	B-chem
-	O	O
induced	O	O
torsade	O	O
de	O	O
pointes	O	O
during	O	O
bladder	O	O
irrigation	O	O
:	O	O
an	O	O
unusual	O	O
presentation	O	O
-	O	O
-	O	O
a	O	O
case	O	O
report	O	O
.	O	O

the	O	O
authors	O	O
present	O	O
a	O	O
case	O	O
of	O	O
early	O	O
(	O	O
within	O	O
4	O	O
days	O	O
)	O	O
development	O	O
of	O	O
torsade	O	O
de	O	O
pointes	O	O
(	O	O
tdp	O	O
)	O	O
associated	O	O
with	O	O
oral	O	O
amiodarone	B-chem	B-chem
therapy	O	O
.	O	O

consistent	O	O
with	O	O
other	O	O
reports	O	O
this	O	O
case	O	O
of	O	O
tdp	O	O
occurred	O	O
in	O	O
the	O	O
context	O	O
of	O	O
multiple	O	O
exacerbating	O	O
factors	O	O
including	O	O
hypokalemia	O	O
and	O	O
digoxin	B-chem	B-chem
excess	O	O
.	O	O

transient	O	O
prolongation	O	O
of	O	O
the	O	O
qt	O	O
during	O	O
bladder	O	O
irrigation	O	O
prompted	O	O
the	O	O
episode	O	O
of	O	O
tdp	O	O
.	O	O

it	O	O
is	O	O
well	O	O
known	O	O
that	O	O
bradycardia	O	O
exacerbates	O	O
acquired	O	O
tdp	O	O
.	O	O

the	O	O
authors	O	O
speculate	O	O
that	O	O
the	O	O
increased	O	O
vagal	O	O
tone	O	O
during	O	O
bladder	O	O
irrigation	O	O
,	O	O
a	O	O
vagal	O	O
maneuver	O	O
,	O	O
in	O	O
the	O	O
context	O	O
of	O	O
amiodarone	B-chem	B-chem
therapy	O	O
resulted	O	O
in	O	O
amiodarone	B-chem	B-chem
-	O	O
induced	O	O
proarrhythmia	O	O
.	O	O

in	O	O
the	O	O
absence	O	O
of	O	O
amiodarone	B-chem	B-chem
therapy	O	O
,	O	O
a	O	O
second	O	O
bladder	O	O
irrigation	O	O
did	O	O
not	O	O
induce	O	O
tdp	O	O
despite	O	O
hypokalemia	O	O
and	O	O
hypomagnesemia	O	O
.	O	O

acute	O	O
renal	O	O
insufficiency	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
melphalan	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
primary	O	O
systemic	O	O
amyloidosis	O	O
during	O	O
stem	O	O
cell	O	O
transplantation	O	O
.	O	O

background	O	O
:	O	O

patients	O	O
with	O	O
primary	O	O
systemic	O	O
amyloidosis	O	O
(	O	O
al	O	O
)	O	O
have	O	O
a	O	O
poor	O	O
prognosis	O	O
.	O	O

median	O	O
survival	O	O
time	O	O
from	O	O
standard	O	O
treatments	O	O
is	O	O
only	O	O
17	O	O
months	O	O
.	O	O

high	O	O
-	O	O
dose	O	O
intravenous	O	O
melphalan	B-chem	B-chem
followed	O	O
by	O	O
peripheral	O	O
blood	O	O
stem	O	O
cell	O	O
transplant	O	O
(	O	O
pbsct	O	O
)	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
most	O	O
promising	O	O
therapy	O	O
,	O	O
but	O	O
treatment	O	O
mortality	O	O
can	O	O
be	O	O
high	O	O
.	O	O

the	O	O
authors	O	O
have	O	O
noted	O	O
the	O	O
development	O	O
of	O	O
acute	O	O
renal	O	O
insufficiency	O	O
immediately	O	O
after	O	O
melphalan	B-chem	B-chem
conditioning	O	O
.	O	O

this	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
further	O	O
examine	O	O
its	O	O
risk	O	O
factors	O	O
and	O	O
impact	O	O
on	O	O
posttransplant	O	O
mortality	O	O
.	O	O

methods	O	O
:	O	O

consecutive	O	O
al	O	O
patients	O	O
who	O	O
underwent	O	O
pbsct	O	O
were	O	O
studied	O	O
retrospectively	O	O
.	O	O

acute	O	O
renal	O	O
insufficiency	O	O
(	O	O
ari	O	O
)	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
melphalan	B-chem	B-chem
was	O	O
defined	O	O
by	O	O
a	O	O
minimum	O	O
increase	O	O
of	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
dl	O	O
(	O	O
44	O	O
micromol	O	O
/	O	O
l	O	O
)	O	O
in	O	O
the	O	O
serum	O	O
creatinine	B-chem	B-chem
level	O	O
that	O	O
is	O	O
greater	O	O
than	O	O
50	O	O
%	O	O
of	O	O
baseline	O	O
immediately	O	O
after	O	O
conditioning	O	O
.	O	O

urine	O	O
sediment	O	O
score	O	O
was	O	O
the	O	O
sum	O	O
of	O	O
the	O	O
individual	O	O
types	O	O
of	O	O
sediment	O	O
identified	O	O
on	O	O
urine	O	O
microscopy	O	O
.	O	O

results	O	O
:	O	O

of	O	O
the	O	O
80	O	O
patients	O	O
studied	O	O
,	O	O
ari	O	O
developed	O	O
in	O	O
18	O	O
.	O	O
8	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
melphalan	B-chem	B-chem
.	O	O

univariate	O	O
analysis	O	O
identified	O	O
age	O	O
,	O	O
hypoalbuminemia	O	O
,	O	O
heavy	O	O
proteinuria	O	O
,	O	O
diuretic	O	O
use	O	O
,	O	O
and	O	O
urine	O	O
sediment	O	O
score	O	O
(	O	O
>	O	O
3	O	O
)	O	O
as	O	O
risk	O	O
factors	O	O
.	O	O

age	O	O
and	O	O
urine	O	O
sediment	O	O
score	O	O
remained	O	O
independently	O	O
significant	O	O
risk	O	O
factors	O	O
in	O	O
the	O	O
multivariate	O	O
analysis	O	O
.	O	O

patients	O	O
who	O	O
had	O	O
ari	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
melphalan	B-chem	B-chem
underwent	O	O
dialysis	O	O
more	O	O
often	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
007	O	O
)	O	O
,	O	O
and	O	O
had	O	O
a	O	O
worse	O	O
1	O	O
-	O	O
year	O	O
survival	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
03	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

the	O	O
timing	O	O
of	O	O
renal	O	O
injury	O	O
strongly	O	O
suggests	O	O
melphalan	B-chem	B-chem
as	O	O
the	O	O
causative	O	O
agent	O	O
.	O	O

ongoing	O	O
tubular	O	O
injury	O	O
may	O	O
be	O	O
a	O	O
prerequisite	O	O
for	O	O
renal	O	O
injury	O	O
by	O	O
melphalan	B-chem	B-chem
as	O	O
evidenced	O	O
by	O	O
the	O	O
active	O	O
urinary	O	O
sediment	O	O
.	O	O

development	O	O
of	O	O
ari	O	B-chem
adversely	O	O
affected	O	O
the	O	O
outcome	O	O
after	O	O
pbsct	O	O
.	O	O

effective	O	O
preventive	O	O
measures	O	O
may	O	O
help	O	O
decrease	O	O
the	O	O
treatment	O	O
mortality	O	O
of	O	O
pbsct	O	O
in	O	O
al	O	O
patients	O	O
.	O	O

impaired	O	O
fear	O	O
recognition	O	O
in	O	O
regular	O	O
recreational	O	O
cocaine	B-chem	B-chem
users	O	O
.	O	O

introduction	O	O
:	O	O

the	O	O
ability	O	O
to	O	O
read	O	O
facial	O	O
expressions	O	O
is	O	O
essential	O	O
for	O	O
normal	O	O
human	O	O
social	O	O
interaction	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
conduct	O	O
the	O	O
first	O	O
investigation	O	O
of	O	O
facial	O	O
expression	O	O
recognition	O	O
performance	O	O
in	O	O
recreational	O	O
cocaine	B-chem	B-chem
users	O	O
.	O	O

materials	O	O
and	O	O
methods	O	O
:	O	O

three	O	O
groups	O	O
,	O	O
comprised	O	O
of	O	O
21	O	O
cocaine	B-chem	B-chem
naive	O	O
participants	O	O
(	O	O
cn	O	O
)	O	O
,	O	O
30	O	O
occasional	O	O
cocaine	B-chem	B-chem
(	O	O
oc	O	B-chem
)	O	O
,	O	O
and	O	O
48	O	O
regular	O	O
recreational	O	O
cocaine	B-chem	B-chem
(	O	O
rc	O	O
)	O	O
users	O	O
,	O	O
were	O	O
compared	O	O
.	O	O

an	O	O
emotional	O	O
facial	O	O
expression	O	O
(	O	O
efe	O	O
)	O	O
task	O	O
consisting	O	O
of	O	O
a	O	O
male	O	O
and	O	O
female	O	O
face	O	O
expressing	O	O
six	O	O
basic	O	O
emotions	O	O
(	O	O
happiness	O	O
,	O	O
surprise	O	O
,	O	O
sadness	O	O
,	O	O
anger	O	O
,	O	O
fear	O	O
,	O	O
and	O	O
disgust	O	O
)	O	O
was	O	O
administered	O	O
.	O	O

mean	O	O
percent	O	O
accuracy	O	O
and	O	O
latencies	O	O
for	O	O
correct	O	O
responses	O	O
across	O	O
eight	O	O
presentations	O	O
of	O	O
each	O	O
basic	O	O
emotion	O	O
were	O	O
derived	O	O
.	O	O

participants	O	O
were	O	O
also	O	O
assessed	O	O
with	O	O
the	O	O
"	O	O
"	O	O
"	O	O
"	O	O
eyes	O	O
task	O	O
"	O	O
"	O	O
"	O	O
"	O	O
to	O	O
investigate	O	O
their	O	O
ability	O	O
to	O	O
recognize	O	O
more	O	O
complex	O	O
emotional	O	O
states	O	O
and	O	O
the	O	O
symptom	O	O
checklist	O	O
-	O	O
90	O	O
-	O	O
revised	O	O
to	O	O
measure	O	O
psychopathology	O	O
.	O	O

results	O	O
:	O	O

there	O	O
were	O	O
no	O	O
group	O	O
differences	O	O
in	O	O
psychopathology	O	O
or	O	O
"	O	O
"	O	O
"	O	O
"	O	O
eyes	O	O
task	O	O
"	O	O
"	O	O
"	O	O
"	O	O
performance	O	O
,	O	O
but	O	O
the	O	O
rc	O	O
group	O	O
,	O	O
who	O	O
otherwise	O	O
had	O	O
similar	O	O
illicit	O	O
substance	O	O
use	O	O
histories	O	O
to	O	O
the	O	O
oc	O	B-chem
group	O	O
,	O	O
exhibited	O	O
impaired	O	O
fear	O	O
recognition	O	O
accuracy	O	O
compared	O	O
to	O	O
the	O	O
oc	O	B-chem
and	O	O
cn	O	O
groups	O	O
.	O	O

the	O	O
rc	O	O
group	O	O
also	O	O
correctly	O	O
identified	O	O
anger	O	O
,	O	O
fear	O	O
,	O	O
happiness	O	O
,	O	O
and	O	O
surprise	O	O
,	O	O
more	O	O
slowly	O	O
than	O	O
cn	O	O
,	O	O
but	O	O
not	O	O
oc	O	O
participants	O	O
.	O	O

the	O	O
oc	O	B-chem
group	O	O
was	O	O
slower	O	O
than	O	O
cn	O	O
when	O	O
correctly	O	O
identifying	O	O
disgust	O	O
.	O	O

the	O	O
selective	O	O
deficit	O	O
in	O	O
fear	O	O
recognition	O	O
accuracy	O	O
manifested	O	O
by	O	O
the	O	O
rc	O	O
group	O	O
can	O	O
not	O	O
be	O	O
explained	O	O
by	O	O
the	O	O
subacute	O	O
effects	O	O
of	O	O
cocaine	B-chem	B-chem
,	O	O
or	O	O
ecstasy	B-chem	B-chem
,	O	O
because	O	O
recent	O	O
and	O	O
less	O	O
recent	O	O
users	O	O
of	O	O
these	O	O
drugs	O	O
within	O	O
this	O	O
group	O	O
were	O	O
similarly	O	O
impaired	O	O
.	O	O

possible	O	O
parallels	O	O
between	O	O
rc	O	O
users	O	O
and	O	O
psychopaths	O	O
with	O	O
respect	O	O
to	O	O
impaired	O	O
fear	O	O
recognition	O	O
,	O	O
amygdala	O	O
dysfunction	O	O
,	O	O
and	O	O
etiology	O	O
are	O	O
discussed	O	O
.	O	O

corneal	O	O
ulcers	O	O
associated	O	O
with	O	O
aerosolized	O	O
crack	B-chem	B-chem
cocaine	I-chem	I-chem
use	O	O
.	O	O

purpose	O	O
:	O	O

we	O	O
report	O	O
4	O	O
cases	O	O
of	O	O
corneal	O	O
ulcers	O	O
associated	O	O
with	O	O
drug	O	O
abuse	O	O
.	O	O

the	O	O
pathogenesis	O	O
of	O	O
these	O	O
ulcers	O	O
and	O	O
management	O	O
of	O	O
these	O	O
patients	O	O
are	O	O
also	O	O
reviewed	O	O
.	O	O

methods	O	O
:	O	O

review	O	O
of	O	O
all	O	O
cases	O	O
of	O	O
corneal	O	O
ulcers	O	O
associated	O	O
with	O	O
drug	O	O
abuse	O	O
seen	O	O
at	O	O
our	O	O
institution	O	O
from	O	O
july	O	O
2006	O	O
to	O	O
december	O	O
2006	O	O
.	O	O

results	O	O
:	O	O

four	O	O
patients	O	O
with	O	O
corneal	O	O
ulcers	O	O
associated	O	O
with	O	O
crack	B-chem	B-chem
cocaine	I-chem	I-chem
use	O	O
were	O	O
reviewed	O	O
.	O	O

all	O	O
corneal	O	O
ulcers	O	O
were	O	O
cultured	O	O
,	O	O
and	O	O
the	O	O
patients	O	O
were	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
intensive	O	O
topical	O	O
antibiotic	O	O
treatment	O	O
.	O	O

each	O	O
patient	O	O
received	O	O
comprehensive	O	O
health	O	O
care	O	O
,	O	O
including	O	O
medical	O	O
and	O	O
substance	O	O
abuse	O	O
consultations	O	O
.	O	O

streptococcal	O	O
organisms	O	O
were	O	O
found	O	O
in	O	O
3	O	O
cases	O	O
and	O	O
capnocytophaga	O	O
and	O	O
brevibacterium	O	O
casei	O	O
in	O	O
1	O	O
patient	O	O
.	O	O

the	O	O
infections	O	O
responded	O	O
to	O	O
antibiotic	O	O
treatment	O	O
.	O	O

two	O	O
patients	O	O
needed	O	O
a	O	O
lateral	O	O
tarsorrhaphy	O	O
for	O	O
persistent	O	O
epithelial	O	O
defects	O	O
.	O	O

conclusions	O	O
:	O	O

aerosolized	O	O
crack	B-chem	B-chem
cocaine	I-chem	I-chem
use	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
corneal	O	O
ulcers	O	O
.	O	O

drug	O	O
abuse	O	O
provides	O	O
additional	O	O
challenges	O	O
for	O	O
management	O	O
.	O	O

not	O	O
only	O	O
treatment	O	O
of	O	O
their	O	O
infections	O	O
but	O	O
also	O	O
the	O	O
overall	O	O
poor	O	O
health	O	O
of	O	O
the	O	O
patients	O	O
and	O	O
increased	O	O
risk	O	O
of	O	O
noncompliance	O	O
need	O	O
to	O	O
be	O	O
addressed	O	O
.	O	O

comprehensive	O	O
care	O	O
may	O	O
provide	O	O
the	O	O
patient	O	O
the	O	O
opportunity	O	O
to	O	O
discontinue	O	O
their	O	O
substance	O	O
abuse	O	O
,	O	O
improve	O	O
their	O	O
overall	O	O
health	O	O
,	O	O
and	O	O
prevent	O	O
future	O	O
corneal	O	O
complications	O	O
.	O	O

levetiracetam	B-chem	B-chem
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B-chem	B-chem
treatment	O	O
in	O	O
cats	O	O
with	O	O
suspected	O	O
idiopathic	O	O
epilepsy	O	O
.	O	O

objective	O	O
:	O	O

to	O	O
assess	O	O
pharmacokinetics	O	O
,	O	O
efficacy	O	O
,	O	O
and	O	O
tolerability	O	O
of	O	O
oral	O	O
levetiracetam	B-chem	B-chem
administered	O	O
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B-chem	B-chem
treatment	O	O
in	O	O
cats	O	O
with	O	O
poorly	O	O
controlled	O	O
suspected	O	O
idiopathic	O	O
epilepsy	O	O
.	O	O

design	O	O
-	O	O
open	O	O
-	O	O
label	O	O
,	O	O
noncomparative	O	O
clinical	O	O
trial	O	O
.	O	O

animals	O	O
:	O	O
12	O	O
cats	O	O
suspected	O	O
to	O	O
have	O	O
idiopathic	O	O
epilepsy	O	O
that	O	O
was	O	O
poorly	O	O
controlled	O	O
with	O	O
phenobarbital	B-chem	B-chem
or	O	O

that	O	O
had	O	O
unacceptable	O	O
adverse	O	O
effects	O	O
when	O	O
treated	O	O
with	O	O
phenobarbital	B-chem	B-chem
.	O	O

procedures	O	O
:	O	O

cats	O	O
were	O	O
treated	O	O
with	O	O
levetiracetam	B-chem	B-chem
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O

[	O	O
9	O	O
.	O	O
1	O	O
mg	O	O
/	O	O
lb	O	O
]	O	O
,	O	O
po	O	O
,	O	O
q	O	O
8	O	O
h	O	O
)	O	O
.	O	O

after	O	O
a	O	O
minimum	O	O
of	O	O
1	O	O
week	O	O
of	O	O
treatment	O	O
,	O	O
serum	O	O
levetiracetam	B-chem	B-chem
concentrations	O	O
were	O	O
measured	O	O
before	O	O
and	O	O
2	O	O
,	O	O
4	O	O
,	O	O
and	O	O
6	O	O
hours	O	O
after	O	O
drug	O	O
administration	O	O
,	O	O
and	O	O
maximum	O	O
and	O	O
minimum	O	O
serum	O	O
concentrations	O	O
and	O	O
elimination	O	O
half	O	O
-	O	O
life	O	O
were	O	O
calculated	O	O
.	O	O

seizure	O	O
frequencies	O	O
before	O	O
and	O	O
after	O	O
initiation	O	O
of	O	O
levetiracetam	B-chem	B-chem
treatment	O	O
were	O	O
compared	O	O
,	O	O
and	O	O
adverse	O	O
effects	O	O
were	O	O
recorded	O	O
.	O	O

results	O	O
:	O	O

median	O	O
maximum	O	O
serum	O	O
levetiracetam	B-chem	B-chem
concentration	O	O
was	O	O
25	O	O
.	O	O
5	O	O
microg	O	O
/	O	O
ml	O	O
,	O	O
median	O	O
minimum	O	O
serum	O	O
levetiracetam	B-chem	B-chem
concentration	O	O
was	O	O
8	O	O
.	O	O
3	O	O
microg	O	O
/	O	O
ml	O	O
,	O	O
and	O	O
median	O	O
elimination	O	O
half	O	O
-	O	O
life	O	O
was	O	O
2	O	O
.	O	O
9	O	O
hours	O	O
.	O	O

median	O	O
seizure	O	O
frequency	O	O
prior	O	O
to	O	O
treatment	O	O
with	O	O
levetiracetam	B-chem	B-chem
(	O	O
2	O	O
.	O	O
1	O	O
seizures	O	O
/	O	O
mo	O	O
)	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
median	O	O
seizure	O	O
frequency	O	O
after	O	O
initiation	O	O
of	O	O
levetiracetam	B-chem	B-chem
treatment	O	O
(	O	O
0	O	O
.	O	O
42	O	O
seizures	O	O
/	O	O
mo	O	O
)	O	O
,	O	O
and	O	O
7	O	O
of	O	O
10	O	O
cats	O	O
were	O	O
classified	O	O
as	O	O
having	O	O
responded	O	O
to	O	O
levetiracetam	B-chem	B-chem
treatment	O	O
(	O	O
ie	O	O
,	O	O
reduction	O	O
in	O	O
seizure	O	O
frequency	O	O
of	O	O
>	O	O

or	O	O
=	O	O
50	O	O
%	O	O
)	O	O
.	O	O

two	O	O
cats	O	O
had	O	O
transient	O	O
lethargy	O	O
and	O	O
inappetence	O	O
.	O	O

conclusions	O	O
and	O	O
clinical	O	O
relevance	O	O
:	O	O

results	O	O
suggested	O	O
that	O	O
levetiracetam	B-chem	B-chem
is	O	O
well	O	O
tolerated	O	O
in	O	O
cats	O	O
and	O	O
may	O	O
be	O	O
useful	O	O
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B-chem	B-chem
treatment	O	O
in	O	O
cats	O	O
with	O	O
idiopathic	O	O
epilepsy	O	O
.	O	O

bilateral	O	O
haemorrhagic	O	O
infarction	O	O
of	O	O
the	O	O
globus	O	O
pallidus	O	O
after	O	O
cocaine	B-chem	B-chem
and	O	O
alcohol	B-chem	O
intoxication	O	O
.	O	O

cocaine	B-chem	B-chem
is	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
both	O	O
ischemic	O	O
and	O	O
haemorrhagic	O	O
stroke	O	O
.	O	O

we	O	O
present	O	O
the	O	O
case	O	O
of	O	O
a	O	O
31	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
bilateral	O	O
ischemia	O	O
of	O	O
the	O	O
globus	O	O
pallidus	O	O
after	O	O
excessive	O	O
alcohol	B-chem	B-chem
and	O	O
intranasal	O	O
cocaine	B-chem	B-chem
use	O	O
.	O	O

drug	O	O
-	O	O
related	O	O
globus	O	O
pallidus	O	O
infarctions	O	O
are	O	O
most	O	O
often	O	O
associated	O	O
with	O	O
heroin	B-chem	B-chem
.	O	O

bilateral	O	O
basal	O	O
ganglia	O	O
infarcts	O	O
after	O	O
the	O	O
use	O	O
of	O	O
cocaine	B-chem	B-chem
,	O	O
without	O	O
concurrent	O	O
heroin	B-chem	B-chem
use	O	O
,	O	O
have	O	O
never	O	O
been	O	O
reported	O	O
.	O	O

in	O	O
our	O	O
patient	O	O
,	O	O
transient	O	O
cardiac	O	O
arrhythmia	O	O
or	O	O
respiratory	O	O
dysfunction	O	O
related	O	O
to	O	O
cocaine	B-chem	B-chem
and	O	O
/	O	O
or	O	O
ethanol	B-chem	B-chem
use	O	O
were	O	O
the	O	O
most	O	O
likely	O	O
causes	O	O
of	O	O
cerebral	O	O
hypoperfusion	O	O
.	O	O

acute	O	O
renal	O	O
failure	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
methotrexate	B-chem	B-chem
therapy	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
ileostomy	O	O
.	O	O

high	O	O
-	O	O
dose	O	O
methotrexate	B-chem	B-chem
(	O	O
hd	O	B-chem
-	O	O
mtx	B-chem	B-chem
)	O	O
is	O	O
an	O	O
important	O	O
treatment	O	O
for	O	O
burkitt	O	O
lymphoma	O	O
,	O	O
but	O	O
can	O	O
cause	O	O
hepatic	O	O
and	O	O
renal	O	O
toxicity	O	O
when	O	O
its	O	O
clearance	O	O
is	O	O
delayed	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	O	O
renal	O	O
failure	O	O
after	O	O
hd	O	B-chem
-	O	O
mtx	B-chem	B-chem
therapy	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
ileostomy	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
a	O	O
3	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
who	O	O
had	O	O
received	O	O
a	O	O
living	O	O
-	O	O
related	O	O
liver	O	O
transplantation	O	O
for	O	O
congenital	O	O
biliary	O	O
atresia	O	O
.	O	O

at	O	O
day	O	O
833	O	O
after	O	O
the	O	O
transplantation	O	O
,	O	O
he	O	O
was	O	O
diagnosed	O	O
with	O	O
ptld	O	O
(	O	O
post	O	O
-	O	O
transplantation	O	O
lymphoproliferative	O	O
disorder	O	O
,	O	O
burkitt	O	O
-	O	O
type	O	O
malignant	O	O
lymphoma	O	O
)	O	O
.	O	O

during	O	O
induction	O	O
therapy	O	O
,	O	O
he	O	O
suffered	O	O
ileal	O	O
perforation	O	O
and	O	O
ileostomy	O	O
was	O	O
performed	O	O
.	O	O

subsequent	O	O
hd	O	B-chem
-	O	I-chem
mtx	B-chem	B-chem
therapy	O	O
caused	O	O
acute	O	O
renal	O	O
failure	O	O
that	O	O
required	O	O
continuous	O	O
hemodialysis	O	O
.	O	O

we	O	O
supposed	O	O
that	O	O
intravascular	O	O
hypovolemia	O	O
due	O	O
to	O	O
substantial	O	O
drainage	O	O
from	O	O
the	O	O
ileostoma	O	O
caused	O	O
acute	O	O
prerenal	O	O
failure	O	O
.	O	O

after	O	O
recovery	O	O
of	O	O
his	O	O
renal	O	O
function	O	O
,	O	O
we	O	O
could	O	O
safely	O	O
treat	O	O
the	O	O
patient	O	O
with	O	O
hd	O	B-chem
-	O	O
mtx	B-chem	B-chem
therapy	O	O
by	O	O
controlling	O	O
drainage	O	O
from	O	O
ileostoma	O	O
with	O	O
total	O	O
parenteral	O	O
nutrition	O	O
.	O	O

antithrombotic	O	O
drug	O	O
use	O	O
,	O	O
cerebral	O	O
microbleeds	O	O
,	O	O
and	O	O
intracerebral	O	O
hemorrhage	O	O
:	O	O
a	O	O
systematic	O	O
review	O	O
of	O	O
published	O	O
and	O	O
unpublished	O	O
studies	O	O
.	O	O

background	O	O
and	O	O
purpose	O	O
:	O	O

cerebral	O	O
microbleeds	O	O
(	O	O
mb	O	O
)	O	O
are	O	O
potential	O	O
risk	O	O
factors	O	O
for	O	O
intracerebral	O	O
hemorrhage	O	O
(	O	O
ich	O	O
)	O	O
,	O	O
but	O	O
it	O	O
is	O	O
unclear	O	O
if	O	O
they	O	O
are	O	O
a	O	O
contraindication	O	O
to	O	O
using	O	O
antithrombotic	O	O
drugs	O	O
.	O	O

insights	O	O
could	O	O
be	O	O
gained	O	O
by	O	O
pooling	O	O
data	O	O
on	O	O
mb	O	O
frequency	O	O
stratified	O	O
by	O	O
antithrombotic	O	O
use	O	O
in	O	O
cohorts	O	O
with	O	O
ich	O	O
and	O	O
ischemic	O	O
stroke	O	O
(	O	O
is	O	O
)	O	O
/	O	O
transient	O	O
ischemic	O	O
attack	O	O
(	O	O
tia	O	O
)	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
performed	O	O
a	O	O
systematic	O	O
review	O	O
of	O	O
published	O	O
and	O	O
unpublished	O	O
data	O	O
from	O	O
cohorts	O	O
with	O	O
stroke	O	O
or	O	O
tia	O	O
to	O	O
compare	O	O
the	O	O
presence	O	O
of	O	O
mb	O	O
in	O	O
:	O	O
(	O	O
1	O	O
)	O	O
antithrombotic	O	O
users	O	O
vs	O	O
nonantithrombotic	O	O
users	O	O
with	O	O
ich	O	O
;	O	O
(	O	O
2	O	O
)	O	O
antithrombotic	O	O
users	O	O
vs	O	O
nonusers	O	O
with	O	O
is	O	O
/	O	O
tia	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
ich	O	O
vs	O	O
ischemic	O	O
events	O	O
stratified	O	O
by	O	O
antithrombotic	O	O
use	O	O
.	O	O

we	O	O
also	O	O
analyzed	O	O
published	O	O
and	O	O
unpublished	O	O
follow	O	O
-	O	O
up	O	O
data	O	O
to	O	O
determine	O	O
the	O	O
risk	O	O
of	O	O
ich	O	O
in	O	O
antithrombotic	O	O
users	O	O
with	O	O
mb	O	O
.	O	O

results	O	O
:	O	O

in	O	O
a	O	O
pooled	O	O
analysis	O	O
of	O	O
1460	O	O
ich	O	O
and	O	O
3817	O	O
is	O	O
/	O	O
tia	O	O
,	O	O
mb	O	O
were	O	O
more	O	O
frequent	O	O
in	O	O
ich	O	O
vs	O	O
is	O	O
/	O	O
tia	O	O
in	O	O
all	O	O
treatment	O	O
groups	O	O
,	O	O
but	O	O
the	O	O
excess	O	O
increased	O	O
from	O	O
2	O	O
.	O	O
8	O	O
(	O	O
odds	O	O
ratio	O	O
;	O	O
range	O	O
,	O	O
2	O	O
.	O	O
3	O	O
-	O	O
3	O	O
.	O	O
5	O	O
)	O	O
in	O	O
nonantithrombotic	O	O
users	O	O
to	O	O
5	O	O
.	O	O
7	O	O
(	O	O
range	O	O
,	O	O
3	O	O
.	O	O
4	O	O
-	O	O
9	O	O
.	O	O
7	O	O
)	O	O
in	O	O
antiplatelet	O	O
users	O	O
and	O	O
8	O	O
.	O	O
0	O	O
(	O	O
range	O	O
,	O	O
3	O	O
.	O	O
5	O	O
-	O	O
17	O	O
.	O	O
8	O	O
)	O	O
in	O	O
warfarin	B-chem	B-chem
users	O	O
(	O	O
p	O	O
difference	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

there	O	O
was	O	O
also	O	O
an	O	O
excess	O	O
of	O	O
mb	O	O
in	O	O
warfarin	B-chem	B-chem
users	O	O
vs	O	O
nonusers	O	O
with	O	O
ich	O	O
(	O	O
or	O	O
,	O	O
2	O	O
.	O	O
7	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
,	O	O
1	O	O
.	O	O
6	O	O
-	O	O
4	O	O
.	O	O
4	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
but	O	O
none	O	O
in	O	O
warfarin	B-chem	B-chem
users	O	O
with	O	O
is	O	O
/	O	O
tia	O	O
(	O	O

or	O	O

,	O	O
1	O	O
.	O	O
3	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
,	O	O
0	O	O
.	O	O
9	O	O
-	O	O
1	O	O
.	O	O
7	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
33	O	O
;	O	O
p	O	O
difference	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

there	O	O
was	O	O
a	O	O
smaller	O	O
excess	O	O
of	O	O
mb	O	O
in	O	O
antiplatelet	O	O
users	O	O
vs	O	O
nonusers	O	O
with	O	O
ich	O	O
(	O	O
or	O	O
,	O	O
1	O	O
.	O	O
7	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
,	O	O
1	O	O
.	O	O
3	O	O
-	O	O
2	O	O
.	O	O
3	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
but	O	O
findings	O	O
were	O	O
similar	O	O
for	O	O
antiplatelet	O	O
users	O	O
with	O	O
is	O	O
/	O	O
tia	O	O
(	O	O

or	O	O
,	O	O
1	O	O
.	O	O
4	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
,	O	O
1	O	O
.	O	O
2	O	O
-	O	O
1	O	O
.	O	O
7	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
;	O	O
p	O	O
difference	O	O
=	O	O
0	O	O
.	O	O
25	O	O
)	O	O
.	O	O

in	O	O
pooled	O	O
follow	O	O
-	O	O
up	O	O
data	O	O
for	O	O
768	O	O
antithrombotic	O	O
users	O	O
,	O	O
presence	O	O
of	O	O
mb	O	O
at	O	O
baseline	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
substantially	O	O
increased	O	O
risk	O	O
of	O	O
subsequent	O	O
ich	O	O
(	O	O
or	O	O
,	O	O
12	O	O
.	O	O
1	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
,	O	O
3	O	O
.	O	O
4	O	O
-	O	O
42	O	O
.	O	O
5	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
excess	O	O
of	O	O
mb	O	O
in	O	O
warfarin	B-chem	B-chem
users	O	O
with	O	O
ich	O	O
compared	O	O
to	O	O
other	O	O
groups	O	O
suggests	O	O
that	O	O
mb	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
warfarin	B-chem	B-chem
-	O	O
associated	O	O
ich	O	O
.	O	O

limited	O	O
prospective	O	O
data	O	O
corroborate	O	O
these	O	O
findings	O	O
,	O	O
but	O	O
larger	O	O
prospective	O	O
studies	O	O
are	O	O
urgently	O	O
required	O	O
.	O	O

verapamil	B-chem	B-chem
stimulation	O	O
test	O	O
in	O	O
hyperprolactinemia	O	O
:	O	O
loss	O	O
of	O	O
prolactin	O	O
response	O	O
in	O	O
anatomic	O	O
or	O	O
functional	O	O
stalk	O	O
effect	O	O
.	O	O

aim	O	O
:	O	O

verapamil	B-chem	B-chem
stimulation	O	O
test	O	O
was	O	O
previously	O	O
investigated	O	O
as	O	O
a	O	O
tool	O	O
for	O	O
differential	O	O
diagnosis	O	O
of	O	O
hyperprolactinemia	O	O
,	O	O
but	O	O
with	O	O
conflicting	O	O
results	O	O
.	O	O

macroprolactinemia	O	O
was	O	O
never	O	O
considered	O	O
in	O	O
those	O	O
previous	O	O
studies	O	O
.	O	O

here	O	O
,	O	O
we	O	O
aimed	O	O
to	O	O
re	O	O
-	O	O
investigate	O	O
the	O	O
diagnostic	O	O
value	O	O
of	O	O
verapamil	B-chem	B-chem
in	O	O
a	O	O
population	O	O
who	O	O
were	O	O
all	O	O
screened	O	O
for	O	O
macroprolactinemia	O	O
.	O	O

prolactin	O	O
responses	O	O
to	O	O
verapamil	B-chem	B-chem
in	O	O
65	O	O
female	O	O
patients	O	O
(	O	O
age	O	O
:	O	O
29	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

8	O	O
.	O	O
1	O	O
years	O	O
)	O	O
with	O	O
hyperprolactinemia	O	O
were	O	O
tested	O	O
in	O	O
a	O	O
descriptive	O	O
,	O	O
matched	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

methods	O	O
:	O	O

verapamil	B-chem	B-chem
80	O	O
mg	O	O
,	O	O
p	O	O
.	O	O
o	O	O
.	O	O
was	O	O
administered	O	O
,	O	O
and	O	O
then	O	O
prl	O	O
levels	O	O
were	O	O
measured	O	O
at	O	O
8th	O	O
and	O	O
16th	O	O
hours	O	O
,	O	O
by	O	O
immunometric	O	O
chemiluminescence	O	O
.	O	O

verapamil	B-chem	B-chem
responsiveness	O	O
was	O	O
determined	O	O
by	O	O
peak	O	O
percent	O	O
change	O	O
in	O	O
basal	O	O
prolactin	O	O
levels	O	O
(	O	O
prl	O	O
)	O	O
.	O	O

results	O	O
:	O	O

verapamil	B-chem	B-chem
significantly	O	O
increased	O	O
prl	O	O
levels	O	O
in	O	O
healthy	O	O
controls	O	O
(	O	O
n	O	O
.	O	O
8	O	O
,	O	O
prl	O	O
:	O	O
183	O	O
%	O	O
)	O	O
,	O	O
macroprolactinoma	O	O
(	O	O
n	O	O
.	O	O
8	O	O
,	O	O
prl	O	O
:	O	O
7	O	O
%	O	O
)	O	O
,	O	O
microprolactinoma	O	O
(	O	O
n	O	O
.	O	O
19	O	O
,	O	O
prl	O	O
:	O	O
21	O	O
%	O	O
)	O	O
,	O	O
macroprolactinemia	O	O
(	O	O
n	O	O
.	O	O
23	O	O
,	O	O
prl	O	O
:	O	O
126	O	O
%	O	O
)	O	O
,	O	O
but	O	O
not	O	O
in	O	O
pseudoprolactinoma	O	O
(	O	O
n	O	O
.	O	O
8	O	O
,	O	O
prl	O	O
:	O	O
0	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
and	O	O
risperidone	B-chem	B-chem
-	O	O
induced	O	O
hyperprolactinemia	O	O
(	O	O
n	O	O
.	O	O
7	O	O
,	O	O
prl	O	O
:	O	O
3	O	O
%	O	O
)	O	O
.	O	O

roc	O	B-chem
curve	O	O
analysis	O	O
revealed	O	O
that	O	O
unresponsiveness	O	O
to	O	O
verapamil	B-chem	B-chem
defined	O	O
as	O	O
prl	O	O
<	O	O
7	O	O
%	O	O
,	O	O
discriminated	O	O
anatomical	O	O
or	O	O
functional	O	O
stalk	O	O
effect	O	O
(	O	O
sensitivity	O	O
:	O	O
74	O	O
%	O	O
,	O	O
specificity	O	O
:	O	O
73	O	O
%	O	O
,	O	O
auc	O	O
:	O	O
0	O	O
.	O	O
855	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
04	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
,	O	O
ci	O	O
:	O	O
0	O	O
.	O	O
768	O	O
-	O	O
0	O	O
.	O	O
942	O	O
)	O	O
associated	O	O
with	O	O
pseudoprolactinoma	O	B-chem
or	O	O
risperidone	B-chem	B-chem
-	O	O
induced	O	O
hyperprolactinemia	O	O
,	O	O
respectively	O	O
.	O	O

conclusion	O	O
:	O	O

verapamil	B-chem	B-chem
responsiveness	O	O
is	O	O
not	O	O
a	O	O
reliable	O	O
finding	O	O
for	O	O
the	O	O
differential	O	O
diagnosis	O	O
of	O	O
hyperprolactinemia	O	O
.	O	O

however	O	O
,	O	O
verapamil	B-chem	B-chem
unresponsiveness	O	O
discriminates	O	O
stalk	O	O
effect	O	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
anatomically	O	O
or	O	O
functionally	O	O
inhibited	O	O
dopaminergic	O	O
tonus	O	O
)	O	O
from	O	O
other	O	O
causes	O	O
of	O	O
hyperprolactinemia	O	O
with	O	O
varying	O	O
degrees	O	O
of	O	O
responsiveness	O	O
.	O	O

central	O	O
action	O	O
of	O	O
narcotic	O	O
analgesics	O	O
.	O	O

part	O	O
iv	O	O
.	O	O

noradrenergic	O	O
influences	O	O
on	O	O
the	O	O
activity	O	O
of	O	O
analgesics	O	O
in	O	O
rats	O	O
.	O	O

the	O	O
effect	O	O
of	O	O
clonidine	B-chem	B-chem
,	O	O
naphazoline	B-chem	B-chem
and	O	O
xylometazoline	B-chem	B-chem
on	O	O
analgesia	O	O
induced	O	O
by	O	O
morphine	B-chem	B-chem
,	O	O
codeine	B-chem	B-chem
,	O	O
fentanyl	B-chem	B-chem
and	O	O
pentazocine	B-chem	B-chem
,	O	O
and	O	O
on	O	O
cataleptic	O	O
effect	O	O
of	O	O
morphine	B-chem	B-chem
,	O	O
codine	B-chem	B-chem
and	O	O
fentanyl	B-chem	B-chem
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

the	O	O
biochemical	O	O
assays	O	O
on	O	O
the	O	O
influence	O	O
of	O	O
four	O	O
analgesics	O	O
on	O	O
the	O	O
brain	O	O
concentration	O	O
and	O	O
turnover	O	O
of	O	O
noradrenaline	B-chem	B-chem
(	O	O
na	B-chem	B-chem
)	O	O
were	O	O
also	O	O
performed	O	O
.	O	O

it	O	O
was	O	O
found	O	O
that	O	O
three	O	O
drugs	O	O
stimulating	O	O
central	O	O
na	B-chem	B-chem
receptors	O	O
failed	O	O
to	O	O
affect	O	O
the	O	O
analgesic	O	O
ed50	O	O
of	O	O
all	O	O
antinociceptive	O	O
agents	O	O
and	O	O
they	O	O
enhanced	O	O
catalepsy	O	O
induced	O	O
by	O	O
morphine	B-chem	B-chem
and	O	O
fentanyl	B-chem	B-chem
.	O	O

codeine	B-chem	B-chem
catalepsy	O	O
was	O	O
increased	O	O
by	O	O
clonidine	B-chem	B-chem
and	O	O
decreased	O	O
by	O	O
naphazoline	B-chem	B-chem
and	O	O
xylometazoline	B-chem	B-chem
.	O	O

the	O	O
brain	O	O
concentration	O	O
of	O	O
na	B-chem	B-chem
was	O	O
not	O	O
changed	O	O
by	O	O
morphine	B-chem	B-chem
and	O	O
fentanyl	B-chem	B-chem
,	O	O
but	O	O
one	O	O
of	O	O
the	O	O
doses	O	O
of	O	O
codeine	B-chem	B-chem
(	O	O
45	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
slightly	O	O
enhanced	O	O
it	O	O
.	O	O

pentazocine	B-chem	B-chem
dose	O	O
-	O	O
dependently	O	O
decreased	O	O
the	O	O
brain	O	O
level	O	O
of	O	O
na	B-chem	B-chem
.	O	O

the	O	O
rate	O	O
of	O	O
na	B-chem	B-chem
turnover	O	O
was	O	O
not	O	O
altered	O	O
by	O	O
analgesics	O	O
except	O	O
for	O	O
the	O	O
higher	O	O
dose	O	O
of	O	O
fentanyl	B-chem	B-chem
(	O	O
0	O	O
.	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
following	O	O
which	O	O
the	O	O
disappearance	O	O
of	O	O
na	B-chem	B-chem
from	O	O
the	O	O
brain	O	O
was	O	O
diminished	O	O
.	O	O

the	O	O
results	O	O
are	O	O
discussed	O	O
in	O	O
the	O	O
light	O	O
of	O	O
various	O	O
and	O	O
non	O	O
-	O	O
uniform	O	O
data	O	O
from	O	O
the	O	O
literature	O	O
.	O	O

it	O	O
is	O	O
suggested	O	O
that	O	O
in	O	O
rats	O	O
the	O	O
brain	O	O
na	B-chem	B-chem
plays	O	O
a	O	O
less	O	O
important	O	O
function	O	O
than	O	O
the	O	O
other	O	O
monoamines	B-chem	O
in	O	O
the	O	O
behavioural	O	O
activity	O	O
of	O	O
potent	O	O
analgesics	O	O
.	O	O

modification	O	O
by	O	O
propranolol	B-chem	B-chem
of	O	O
cardiovascular	O	O
effects	O	O
of	O	O
induced	O	O
hypoglycaemia	O	O
.	O	O

the	O	O
cardiovascular	O	O
effects	O	O
of	O	O
hypoglycaemia	O	O
,	O	O
with	O	O
and	O	O
without	O	O
beta	O	O
-	O	O
blockade	O	O
,	O	O
were	O	O
compared	O	O
in	O	O
fourteen	O	O
healthy	O	O
men	O	O
.	O	O

eight	O	O
received	O	O
insulin	O	B-chem
alone	O	O
,	O	O
and	O	O
eight	O	O
,	O	O
including	O	O
two	O	O
of	O	O
the	O	O
original	O	O
insulin	O	B-chem
-	O	O
only	O	O
group	O	O
,	O	O
were	O	O
given	O	O
propranolol	B-chem	B-chem
and	O	O
insulin	O	B-chem
.	O	O

in	O	O
the	O	O
insulin	O	B-chem
-	O	O
group	O	O
the	O	O
period	O	O
of	O	O
hypoglycaemia	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
heart	O	O
-	O	O
rate	O	O
and	O	O
a	O	O
fall	O	O
in	O	O
diastolic	O	O
blood	O	O
-	O	O
pressure	O	O
.	O	O

in	O	O
the	O	O
propranolol	B-chem	B-chem
-	O	O
insulin	O	B-chem
group	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
fall	O	O
in	O	O
heart	O	O
-	O	O
rate	O	O
in	O	O
most	O	O
subjects	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
diastolic	O	O
pressure	O	O
.	O	O

typical	O	O
s	O	O
-	O	O
t	O	O
/	O	O
t	O	O
changes	O	O
occurred	O	O
in	O	O
the	O	O
insulin	O	B-chem
-	O	O
group	O	O
but	O	O
in	O	O
none	O	O
of	O	O
the	O	O
propranolol	B-chem	B-chem
-	O	O
insulin	O	B-chem
group	O	O
.	O	O

hypertension	O	O
in	O	O
diabetics	O	O
prone	O	O
to	O	O
hypoglycaemia	O	O
attacks	O	O
should	O	O
not	O	O
be	O	O
treated	O	O
with	O	O
beta	O	O
-	O	O
blockers	O	O
because	O	O
these	O	O
drugs	O	O
may	O	O
cause	O	O
a	O	O
sharp	O	O
rise	O	O
in	O	O
blood	O	O
-	O	O
pressure	O	O
in	O	O
such	O	O
patients	O	O
.	O	O

prevention	O	O
and	O	O
treatment	O	O
of	O	O
endometrial	O	O
disease	O	O
in	O	O
climacteric	O	O
women	O	O
receiving	O	O
oestrogen	B-chem	O
therapy	O	O
.	O	O

the	O	O
treatment	O	O
regimens	O	O
are	O	O
described	O	O
in	O	O
74	O	O
patients	O	O
with	O	O
endometrial	O	O
disease	O	O
among	O	O
850	O	O
climacteric	O	O
women	O	O
receiving	O	O
oestrogen	B-chem	O
therapy	O	O
.	O	O

cystic	O	O
hyperplasia	O	O
was	O	O
associated	O	O
with	O	O
unopposed	O	O
oestrogen	B-chem	B-chem
therapy	O	O
without	O	O
progestagen	B-chem	B-chem
.	O	O

two	O	O
courses	O	O
of	O	O
21	O	O
days	O	O
of	O	O
5	O	O
mg	O	O
norethisterone	B-chem	O
daily	O	O
caused	O	O
reversion	O	O
to	O	O
normal	O	O
in	O	O
all	O	O
57	O	O
cases	O	O
of	O	O
cystic	O	O
hyperplasia	O	O
and	O	O
6	O	O
of	O	O
the	O	O
8	O	O
cases	O	O
of	O	O
atypical	O	O
hyperplasia	O	O
.	O	O

4	O	O
cases	O	O
of	O	O
endometrial	O	O
carcinoma	O	O
referred	O	O
from	O	O
elsewhere	O	O
demonstrated	O	O
the	O	O
problems	O	O
of	O	O
inappropriate	O	O
and	O	O
unsupervised	O	O
unopposed	O	O
oestrogen	B-chem	B-chem
therapy	O	O
and	O	O
the	O	O
difficulty	O	O
in	O	O
distinguishing	O	O
severe	O	O
hyperplasia	O	O
from	O	O
malignancy	O	O
.	O	O

cyclical	O	O
low	O	O
-	O	O
dose	O	O
oestrogen	B-chem	B-chem
therapy	O	O
with	O	O
7	O	O
-	O	O
-	O	O
13	O	O
days	O	O
of	O	O
progestagen	B-chem	B-chem
does	O	O
not	O	O
seem	O	O
to	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
endometrial	O	O
hyperplasia	O	O
or	O	O
carcinoma	O	O
.	O	O

pure	O	O
red	O	O
cell	O	O
aplasia	O	O
,	O	O
toxic	O	O
dermatitis	O	O
and	O	O
lymphadenopathy	O	O
in	O	O
a	O	O
patient	O	O
taking	O	O
diphenylhydantoin	B-chem	B-chem
.	O	O

a	O	O
patient	O	O
taking	O	O
diphenylhydantoin	B-chem	B-chem
for	O	O
3	O	O
weeks	O	O
developed	O	O
a	O	O
generalized	O	O
skin	O	O
rash	O	O
,	O	O
lymphadenopathy	O	O
and	O	O
pure	O	O
red	O	O
cell	O	O
aplasia	O	O
.	O	O

after	O	O
withdrawal	O	O
of	O	O
the	O	O
pharmacon	O	O
all	O	O
symptoms	O	O
disappeared	O	O
spontaneously	O	O
.	O	O

skin	O	O
rash	O	O
is	O	O
a	O	O
well	O	O
-	O	O
known	O	O
complication	O	O
of	O	O
diphenylhydantoin	B-chem	B-chem
treatment	O	O
as	O	O
is	O	O
benign	O	O
and	O	O
malignant	O	O
lymphadenopathy	O	O
.	O	O

pure	O	O
red	O	O
cell	O	O
aplasia	O	O
associated	O	O
with	O	O
diphenylhydantoin	B-chem	B-chem
medication	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

the	O	O
exact	O	O
mechanism	O	O
by	O	O
which	O	O
diphenylhydantoin	B-chem	B-chem
exerts	O	O
its	O	O
toxic	O	O
effects	O	O
is	O	O
not	O	O
known	O	O
.	O	O

in	O	O
this	O	O
patient	O	O
the	O	O
time	O	O
relation	O	O
between	O	O
the	O	O
ingestion	O	O
of	O	O
diphenylhydantoin	B-chem	B-chem
and	O	O
the	O	O
occurrence	O	O
of	O	O
the	O	O
skin	O	O
rash	O	O
,	O	O
lymphadenopathy	O	O
and	O	O
pure	O	O
red	O	O
cell	O	O
aplasia	O	O
is	O	O
very	O	O
suggestive	O	O
of	O	O
a	O	O
direct	O	O
connection	O	O
.	O	O

continuous	O	O
infusion	O	O
tobramycin	B-chem	B-chem
combined	O	O
with	O	O
carbenicillin	B-chem	B-chem
for	O	O
infections	O	O
in	O	O
cancer	O	O
patients	O	O
.	O	O

the	O	O
cure	O	O
rate	O	O
of	O	O
infections	O	O
in	O	O
cancer	O	O
patients	O	O
is	O	O
adversely	O	O
affected	O	O
by	O	O
neutropenia	O	O
(	O	O
less	O	O
than	O	O
1	O	O
,	O	O
000	O	O
/	O	O
mm3	O	O
)	O	O
.	O	O

in	O	O
particular	O	O
,	O	O
patients	O	O
with	O	O
severe	O	O
neutropenia	O	O
(	O	O
less	O	O
than	O	O
100	O	O
/	O	O
mm3	O	O
)	O	O
have	O	O
shown	O	O
a	O	O
poor	O	O
response	O	O
to	O	O
antibiotics	O	O
.	O	O

to	O	O
overcome	O	O
the	O	O
adverse	O	O
effects	O	O
of	O	O
neutropenia	O	O
,	O	O
tobramycin	B-chem	B-chem
was	O	O
given	O	O
by	O	O
continuous	O	O
infusion	O	O
and	O	O
combined	O	O
with	O	O
intermittent	O	O
carbenicillin	B-chem	B-chem
.	O	O

tobramycin	B-chem	B-chem
was	O	O
given	O	O
to	O	O
a	O	O
total	O	O
daily	O	O
dose	O	O
of	O	O
300	O	O
mg	O	O
/	O	O
m2	O	O
and	O	O
carbenicillin	B-chem	B-chem
was	O	O
given	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
gm	O	B-chem
every	O	O
four	O	O
hours	O	O
.	O	O

there	O	O
were	O	O
125	O	O
infectious	O	O
episodes	O	O
in	O	O
116	O	O
cancer	O	O
patients	O	O
receiving	O	O
myelosuppressive	O	O
chemotherapy	O	O
.	O	O

the	O	O
overall	O	O
cure	O	O
rate	O	O
was	O	O
70	O	O
%	O	O
.	O	O

pneumonia	O	O
was	O	O
the	O	O
most	O	O
common	O	O
infection	O	O
and	O	O
61	O	O
%	O	O
of	O	O
59	O	O
episodes	O	O
were	O	O
cured	O	O
.	O	O

gram	O	O
-	O	O
negative	O	O
bacilli	O	B-chem
were	O	O
the	O	O
most	O	O
common	O	O
causative	O	O
organisms	O	O
and	O	O
69	O	O
%	O	O
of	O	O
these	O	O
infections	O	O
were	O	O
cured	O	O
.	O	O

the	O	O
most	O	O
common	O	O
pathogen	O	O
was	O	O
klebsiella	O	O
pneumoniae	O	O
and	O	O
this	O	O
,	O	O
together	O	O
with	O	O
escherichia	O	O
coli	O	O
and	O	O
pseudomonas	O	O
aeruginosa	O	O
,	O	O
accounted	O	O
for	O	O
74	O	O
%	O	O
of	O	O
all	O	O
gram	O	O
-	O	O
negative	O	O
bacillary	O	O
infections	O	O
.	O	O

response	O	O
was	O	O
not	O	O
influenced	O	O
by	O	O
the	O	O
initial	O	O
neutrophil	O	O
count	O	O
,	O	O
with	O	O
a	O	O
62	O	O
%	O	O
cure	O	O
rate	O	O
for	O	O
39	O	O
episodes	O	O
associated	O	O
with	O	O
severe	O	O
neutropenia	O	O
.	O	O

however	O	O
,	O	O
failure	O	O
of	O	O
the	O	O
neutrophil	O	O
count	O	O
to	O	O
increase	O	O
during	O	O
therapy	O	O
adversely	O	O
affected	O	O
response	O	O
.	O	O

azotemia	O	O
was	O	O
the	O	O
major	O	O
side	O	O
effect	O	O
recognized	O	O
,	O	O
and	O	O
it	O	O
occurred	O	O
in	O	O
11	O	O
%	O	O
of	O	O
episodes	O	O
.	O	O

major	O	O
azotemia	O	O
(	O	O
serum	O	O
creatinine	B-chem	B-chem
greater	O	O
than	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
dl	O	O
or	O	O
bun	O	O
greater	O	O
than	O	O
50	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
occurred	O	O
in	O	O
only	O	O
2	O	O
%	O	O
.	O	O

azotemia	O	O
was	O	O
not	O	O
related	O	O
to	O	O
duration	O	O
of	O	O
therapy	O	O
or	O	O
serum	O	O
tobramycin	B-chem	B-chem
concentration	O	O
.	O	O

this	O	O
antibiotic	O	O
regimen	O	O
showed	O	O
both	O	O
therapeutic	O	O
efficacy	O	O
and	O	O
acceptable	O	O
renal	O	O
toxicity	O	O
for	O	O
these	O	O
patients	O	O
.	O	O

recurrent	O	O
subarachnoid	O	O
hemorrhage	O	O
associated	O	O
with	O	O
aminocaproic	B-chem	B-chem
acid	I-chem	I-chem
therapy	O	O
and	O	O
acute	O	O
renal	O	O
artery	O	O
thrombosis	O	O
.	O	O

case	O	O
report	O	O
.	O	O

epsilon	B-chem	B-chem
aminocaproic	I-chem	I-chem
acid	I-chem	I-chem
(	O	O
eaca	B-chem	B-chem
)	O	O
has	O	O
been	O	O
used	O	O
to	O	O
prevent	O	O
rebleeding	O	O
in	O	O
patients	O	O
with	O	O
subarachnoid	O	O
hemorrhage	O	O
(	O	O
sah	O	O
)	O	O
.	O	O

although	O	O
this	O	O
agent	O	O
does	O	O
decrease	O	O
the	O	O
frequency	O	O
of	O	O
rebleeding	O	O
,	O	O
several	O	O
reports	O	O
have	O	O
described	O	O
thrombotic	O	O
complications	O	O
of	O	O
eaca	B-chem	O
therapy	O	O
.	O	O

these	O	O
complications	O	O
have	O	O
included	O	O
clinical	O	O
deterioration	O	O
and	O	O
intracranial	O	O
vascular	O	O
thrombosis	O	O
in	O	O
patients	O	O
with	O	O
sah	O	O
,	O	O
arteriolar	O	O
and	O	O
capillary	O	O
fibrin	O	O
thrombi	O	O
in	O	O
patients	O	O
with	O	O
fibrinolytic	O	O
syndromes	O	O
treated	O	O
with	O	O
eaca	B-chem	O
,	O	O
or	O	O
other	O	O
thromboembolic	O	O
phenomena	O	O
.	O	O

since	O	O
intravascular	O	O
fibrin	O	O
thrombi	O	O
are	O	O
often	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
fibrinolytic	O	O
disorders	O	O
,	O	O
eaca	B-chem	O
should	O	O
not	O	O
be	O	O
implicated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
fibrin	O	O
thrombi	O	O
in	O	O
patients	O	O
with	O	O
disseminated	O	O
intravascular	O	O
coagulation	O	O
or	O	O
other	O	O
"	O	O
"	O	O
"	O	O
"	O	O
consumption	O	O
coagulopathies	O	O
.	O	O

"	O	O
"	O	O
"	O	O
"	O	O
this	O	O
report	O	O
describes	O	O
subtotal	O	O
infarction	O	O
of	O	O
the	O	O
kidney	O	O
due	O	O
to	O	O
thrombosis	O	O
of	O	O
a	O	O
normal	O	O
renal	O	O
artery	O	O
.	O	O

this	O	O
occlusion	O	O
occurred	O	O
after	O	O
eaca	B-chem	O
therapy	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
sah	O	O
and	O	O
histopathological	O	O
documentation	O	O
of	O	O
recurrent	O	O
sah	O	O
.	O	O

the	O	O
corresponding	O	O
clinical	O	O
event	O	O
was	O	O
characterized	O	O
by	O	O
marked	O	O
hypertension	O	O
and	O	O
abrupt	O	O
neurological	O	O
deterioration	O	O
.	O	O

long	O	O
-	O	O
term	O	O
propranolol	B-chem	B-chem
therapy	O	O
in	O	O
pregnancy	O	O
:	O	O
maternal	O	O
and	O	O
fetal	O	O
outcome	O	O
.	O	O

propranolol	B-chem	B-chem
,	O	O
a	O	O
beta	O	O
-	O	O
adrenergic	O	O
blocking	O	O
agent	O	O
,	O	O
has	O	O
found	O	O
an	O	O
important	O	O
position	O	O
in	O	O
the	O	O
practice	O	O
of	O	O
medicine	O	O
.	O	O

its	O	O
use	O	O
in	O	O
pregnancy	O	O
,	O	O
however	O	O
,	O	O
is	O	O
an	O	O
open	O	O
question	O	O
as	O	O
a	O	O
number	O	O
of	O	O
detrimental	O	O
side	O	O
effects	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
fetus	O	O
and	O	O
neonate	O	O
.	O	O

ten	O	O
patients	O	O
and	O	O
12	O	O
pregnancies	O	O
are	O	O
reported	O	O
where	O	O
chronic	O	O
propranolol	B-chem	B-chem
has	O	O
been	O	O
administered	O	O
.	O	O

five	O	O
patients	O	O
with	O	O
serial	O	O
pregnancies	O	O
with	O	O
and	O	O
without	O	O
propranolol	B-chem	B-chem
therapy	O	O
are	O	O
also	O	O
examined	O	O
.	O	O

maternal	O	O
,	O	O
fetal	O	O
,	O	O
and	O	O
neonatal	O	O
complications	O	O
are	O	O
examined	O	O
.	O	O

an	O	O
attempt	O	O
is	O	O
made	O	O
to	O	O
differentiate	O	O
drug	O	O
-	O	O
related	O	O
complications	O	O
from	O	O
maternal	O	O
disease	O	O
-	O	O
-	O	O
related	O	O
complications	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
previously	O	O
reported	O	O
hypoglycemia	O	O
,	O	O
hyperbilirubinemia	O	O
,	O	O
polycythemia	O	O
,	O	O
neonatal	O	O
apnea	O	O
,	O	O
and	O	O
bradycardia	O	O
are	O	O
not	O	O
invariable	O	O
and	O	O
can	O	O
not	O	O
be	O	O
statistically	O	O
correlated	O	O
with	O	O
chronic	O	O
propranolol	B-chem	B-chem
therapy	O	O
.	O	O

growth	O	O
retardation	O	O
,	O	O
however	O	O
,	O	O
appears	O	O
to	O	O
be	O	O
significant	O	O
in	O	O
both	O	O
of	O	O
our	O	O
series	O	O
.	O	O

use	O	O
of	O	O
propranolol	B-chem	B-chem
in	O	O
the	O	O
treatment	O	O
of	O	O
idiopathic	O	O
orthostatic	O	O
hypotension	O	O
.	O	O

five	O	O
patients	O	O
with	O	O
idiopathic	O	O
orthostatic	O	O
hypotension	O	O
who	O	O
had	O	O
physiologic	O	O
and	O	O
biochemical	O	O
evidence	O	O
of	O	O
severe	O	O
autonomic	O	O
dysfunction	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

they	O	O
all	O	O
exhibited	O	O
markedly	O	O
reduced	O	O
plasma	O	O
catecholamines	B-chem	B-chem
and	O	O
plasma	O	O
renin	O	O
activity	O	O
in	O	O
both	O	O
recumbent	O	O
and	O	O
upright	O	O
positions	O	O
and	O	O
had	O	O
marked	O	O
hypersensitivity	O	O
to	O	O
the	O	O
pressor	O	O
effects	O	O
of	O	O
infused	O	O
norepinephrine	B-chem	B-chem
.	O	O

treatment	O	O
with	O	O
propanolol	B-chem	B-chem
administered	O	O
intravenously	O	O
(	O	O
1	O	O
-	O	O
5	O	I-chem
mg	O	O
)	O	O
produced	O	O
increases	O	O
in	O	O
supine	O	O
and	O	O
upright	O	O
blood	O	O
pressure	O	O
in	O	O
4	O	O
of	O	O
the	O	O
5	O	O
individuals	O	O
with	O	O
rises	O	O
ranging	O	O
from	O	O
11	O	O
/	O	O
6	O	O
to	O	O
22	O	O
/	O	O
11	O	O
mmhg	O	O
.	O	O

chronic	O	O
oral	O	O
administration	O	O
of	O	O
propranolol	B-chem	B-chem
(	O	O
40	O	O
-	O	O
160	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
also	O	O
elevated	O	O
the	O	O
blood	O	O
pressures	O	O
of	O	O
these	O	O
individuals	O	O
with	O	O
increases	O	O
in	O	O
the	O	O
order	O	O
of	O	O
20	O	O
-	O	O
35	O	O
/	O	O
15	O	O
-	O	O
25	O	O
mmg	O	O
being	O	O
observed	O	O
.	O	O

in	O	O
1	O	O
patient	O	O
,	O	O
marked	O	O
hypertension	O	O
was	O	O
induced	O	O
by	O	O
propranolol	B-chem	B-chem
and	O	O
the	O	O
drug	O	O
had	O	O
to	O	O
be	O	O
withdrawn	O	O
.	O	O

it	O	O
otherwise	O	O
was	O	O
well	O	O
tolerated	O	O
and	O	O
no	O	O
important	O	O
side	O	O
effects	O	O
were	O	O
observed	O	O
.	O	O

treatment	O	O
has	O	O
been	O	O
continued	O	O
in	O	O
3	O	O
individuals	O	O
for	O	O
6	O	O
-	O	O
13	O	O
months	O	O
with	O	O
persistence	O	O
of	O	O
the	O	O
pressor	O	O
effect	O	O
,	O	O
although	O	O
there	O	O
appears	O	O
to	O	O
have	O	O
been	O	O
some	O	O
decrease	O	O
in	O	O
the	O	O
degree	O	O
of	O	O
response	O	O
with	O	O
time	O	O
.	O	O

hemodynamic	O	O
measurements	O	O
in	O	O
1	O	O
of	O	O
the	O	O
patients	O	O
demonstrated	O	O
an	O	O
increase	O	O
in	O	O
total	O	O
peripheral	O	O
resistance	O	O
and	O	O
essentially	O	O
no	O	O
change	O	O
in	O	O
cardiac	O	O
output	O	O
following	O	O
propranolol	B-chem	B-chem
therapy	O	O
.	O	O

the	O	O
studies	O	O
suggest	O	O
that	O	O
propranolol	B-chem	B-chem
is	O	O
a	O	O
useful	O	O
drug	O	O
in	O	O
selected	O	O
patients	O	O
with	O	O
severe	O	O
idiopathic	O	O
orthostatic	O	O
hypotension	O	O
.	O	O

total	O	O
intravenous	O	O
anesthesia	O	O
with	O	O
etomidate	B-chem	B-chem
.	O	O

iii	O	O
.	O	O

some	O	O
observations	O	O
in	O	O
adults	O	O
.	O	O

an	O	O
investigation	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
the	O	O
dosage	O	O
of	O	O
etomidate	B-chem	B-chem
required	O	O
to	O	O
maintain	O	O
sleep	O	O
in	O	O
adults	O	O
undergoing	O	O
surgery	O	O
under	O	O
regional	O	O
local	O	O
anesthesia	O	O
.	O	O

premedication	O	O
of	O	O
diazepam	B-chem	B-chem
10	O	O
mg	O	O
and	O	O
atropine	B-chem	B-chem
0	O	O
.	O	O
5	O	O
mg	O	O
was	O	O
given	O	O
,	O	O
and	O	O
sleep	O	O
was	O	O
induced	O	O
and	O	O
maintained	O	O
by	O	O
intermittent	O	O
intravenous	O	O
injections	O	O
of	O	O
etomidate	B-chem	B-chem
0	O	O
.	O	O
1	O	O
/	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
given	O	O
whenever	O	O
the	O	O
patient	O	O
would	O	O
open	O	O
his	O	O
eyes	O	O
on	O	O
request	O	O
.	O	O

a	O	O
mean	O	O
overall	O	O
dose	O	O
of	O	O
etomidate	B-chem	B-chem
17	O	O
.	O	O
4	O	O
microgram	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
.	O	O
was	O	O
required	O	O
to	O	O
maintain	O	O
sleep	O	O
,	O	O
but	O	O
great	O	O
individual	O	O
variation	O	O
occurred	O	O
,	O	O
with	O	O
older	O	O
patients	O	O
requiring	O	O
less	O	O
drug	O	O
.	O	O

the	O	O
investigation	O	O
was	O	O
discontinued	O	O
after	O	O
18	O	O
patients	O	O
because	O	O
of	O	O
the	O	O
frequency	O	O
and	O	O
intensity	O	O
of	O	O
side	O	O
-	O	O
effects	O	O
,	O	O
particularly	O	O
pain	O	O
and	O	O
myoclonia	O	O
,	O	O
which	O	O
caused	O	O
the	O	O
technique	O	O
to	O	O
be	O	O
abandoned	O	O
in	O	O
two	O	O
cases	O	O
.	O	O

it	O	O
is	O	O
considered	O	O
unlikely	O	O
that	O	O
etomidate	B-chem	B-chem
will	O	O
prove	O	O
to	O	O
be	O	O
the	O	O
hypnotic	O	O
of	O	O
choice	O	O
for	O	O
a	O	O
totally	O	O
intravenous	O	O
anesthetic	O	O
technique	O	O
in	O	O
adults	O	O
because	O	O
of	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
myoclonia	O	O
after	O	O
prolonged	O	O
administration	O	O
.	O	O

in	O	O
several	O	O
patients	O	O
uncontrollable	O	O
muscle	O	O
movements	O	O
persisted	O	O
for	O	O
many	O	O
minutes	O	O
after	O	O
complete	O	O
recovery	O	O
of	O	O
consciousness	O	O
.	O	O

a	O	O
method	O	O
for	O	O
the	O	O
measurement	O	O
of	O	O
tremor	O	O
,	O	O
and	O	O
a	O	O
comparison	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
tocolytic	O	O
beta	O	O
-	O	O
mimetics	O	O
.	O	O

a	O	O
method	O	O
permitting	O	O
measurement	O	O
of	O	O
finger	O	O
tremor	O	O
as	O	O
a	O	O
displacement	O	O
-	O	O
time	O	O
curve	O	O
is	O	O
described	O	O
,	O	O
using	O	O
a	O	O
test	O	O
system	O	O
with	O	O
simple	O	O
amplitude	O	O
calibration	O	O
.	O	O

the	O	O
coordinates	O	O
of	O	O
the	O	O
inversion	O	O
points	O	O
of	O	O
the	O	O
displacement	O	O
-	O	O
time	O	O
curves	O	O
were	O	O
transferred	O	O
through	O	O
graphical	O	O
input	O	O
equipment	O	O
to	O	O
punched	O	O
tape	O	O
.	O	O

by	O	O
means	O	O
of	O	O
a	O	O
computer	O	O
program	O	O
,	O	O
periods	O	O
and	O	O
amplitudes	O	O
of	O	O
tremor	O	O
oscillations	O	O
were	O	O
calculated	O	O
and	O	O
classified	O	O
.	O	O

the	O	O
event	O	O
frequency	O	O
for	O	O
each	O	O
class	O	O
of	O	O
periods	O	O
and	O	O
amplitudes	O	O
was	O	O
determined	O	O
.	O	O

the	O	O
actions	O	O
of	O	O
fenoterol	B-chem	B-chem
-	I-chem	O
hydrobromide	I-chem	B-chem
,	O	O
ritodrin	B-chem	B-chem
-	I-chem	I-chem
hcl	I-chem	I-chem
and	O	O
placebo	O	O
given	O	O
to	O	O
10	O	O
healthy	O	O
subjects	O	O
by	O	O
intravenous	O	O
infusion	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
crossover	O	O
study	O	O
were	O	O
tested	O	O
by	O	O
this	O	O
method	O	O
.	O	O

at	O	O
therapeutic	O	O
doses	O	O
both	O	O
substances	O	O
raised	O	O
the	O	O
mean	O	O
tremor	O	O
amplitude	O	O
to	O	O
about	O	O
three	O	O
times	O	O
the	O	O
control	O	O
level	O	O
.	O	O

at	O	O
the	O	O
same	O	O
time	O	O
,	O	O
the	O	O
mean	O	O
period	O	O
within	O	O
each	O	O
class	O	O
of	O	O
amplitudes	O	O
shortened	O	O
by	O	O
10	O	O
-	O	O
-	O	O
20	O	O
ms	O	O
,	O	O
whereas	O	O
the	O	O
mean	O	O
periods	O	O
calculated	O	O
from	O	O
all	O	O
oscillations	O	O
together	O	O
did	O	O
not	O	O
change	O	O
significantly	O	O
.	O	O

after	O	O
the	O	O
end	O	O
of	O	O
fenoterol	B-chem	B-chem
-	I-chem	O
hydrobromide	I-chem	B-chem
infusion	O	O
,	O	O
tremor	O	O
amplitudes	O	O
decreased	O	O
significantly	O	O
faster	O	O
than	O	O
those	O	O
following	O	O
ritodrin	B-chem	B-chem
-	I-chem	I-chem
hcl	I-chem	I-chem
infusion	O	O
.	O	O

bilateral	O	O
retinal	O	O
artery	O	O
and	O	O
choriocapillaris	O	O
occlusion	O	O
following	O	O
the	O	O
injection	O	O
of	O	O
long	O	O
-	O	O
acting	O	O
corticosteroid	B-chem	O
suspensions	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
drugs	O	O
:	O	O
i	O	O
.	O	O
clinical	O	O
studies	O	O
.	O	O

two	O	O
well	O	O
-	O	O
documented	O	O
cases	O	O
of	O	O
bilateral	O	O
retinal	O	O
artery	O	O
and	O	O
choriocapillaris	O	O
occlusions	O	O
with	O	O
blindness	O	O
following	O	O
head	O	O
and	O	O
neck	O	O
soft	O	O
-	O	O
tissue	O	O
injection	O	O
with	O	O
methylprednisolone	B-chem	B-chem
acetate	I-chem	I-chem
in	O	O
combination	O	O
with	O	O
lidocaine	B-chem	B-chem
,	O	O
epinephrine	B-chem	B-chem
,	O	O
or	O	O
penicillin	B-chem	B-chem
are	O	O
reported	O	O
.	O	O

one	O	O
case	O	O
had	O	O
only	O	O
a	O	O
unilateral	O	O
injection	O	O
.	O	O

the	O	O
acute	O	O
observations	O	O
included	O	O
hazy	O	O
sensorium	O	O
,	O	O
superior	O	O
gaze	O	O
palsy	O	O
,	O	O
pupillary	O	O
abnormalities	O	O
,	O	O
and	O	O
conjunctival	O	O
hemorrhages	O	O
with	O	O
edema	O	O
.	O	O

follow	O	O
-	O	O
up	O	O
changes	O	O
showed	O	O
marked	O	O
visual	O	O
loss	O	O
,	O	O
constricted	O	O
visual	O	O
fields	O	O
,	O	O
optic	O	O
nerve	O	O
pallor	O	O
,	O	O
vascular	O	O
attenuation	O	O
,	O	O
and	O	O
chorioretinal	O	O
atrophy	O	O
.	O	O

the	O	O
literature	O	O
is	O	O
reviewed	O	O
,	O	O
and	O	O
possible	O	O
causes	O	O
are	O	O
discussed	O	O
.	O	O

cephalothin	B-chem	B-chem
-	O	O
induced	O	O
immune	O	O
hemolytic	O	O
anemia	O	O
.	O	O

a	O	O
patient	O	O
with	O	O
renal	O	O
disease	O	O
developed	O	O
coombs	O	O
-	O	O
positive	O	O
hemolytic	O	O
anemia	O	O
while	O	O
receiving	O	O
cephalothin	B-chem	B-chem
therapy	O	O
.	O	O

an	O	O
anti	O	O
-	O	O
cephalothin	B-chem	B-chem
igg	O	O
antibody	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
patient	O	O
'	O	O
s	O	O
serum	O	O
and	O	O
in	O	O
the	O	O
eluates	O	O
from	O	O
her	O	O
erythrocytes	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
nonimmunologic	O	O
binding	O	O
of	O	O
normal	O	O
and	O	O
patient	O	O
'	O	O
s	O	O
serum	O	O
proteins	O	O
to	O	O
her	O	O
own	O	O
and	O	O
cephalothin	B-chem	B-chem
-	O	O
coated	O	O
normal	O	O
red	O	O
cells	O	O
was	O	O
demonstrated	O	O
.	O	O

skin	O	O
tests	O	O
and	O	O
in	O	O
vitro	O	O
lymphocyte	O	O
stimulation	O	O
revealed	O	O
that	O	O
the	O	O
patient	O	O
was	O	O
sensitized	O	O
to	O	O
cephalothin	B-chem	B-chem
and	O	O
also	O	O
to	O	O
ampicillin	B-chem	B-chem
.	O	O

careful	O	O
investigation	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
hemolytic	O	O
anemias	O	O
reveals	O	O
the	O	O
complexity	O	O
of	O	O
the	O	O
immune	O	O
mechanisms	O	O
involved	O	O
.	O	O

kaliuretic	O	B-chem
effect	O	O
of	O	O
l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
treatment	O	O
in	O	O
parkinsonian	O	O
patients	O	O
.	O	O

hypokalemia	O	O
,	O	O
sometimes	O	O
severe	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
some	O	O
l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
-	O	O
treated	O	O
parkinsonian	O	O
patients	O	O
.	O	O

the	O	O
influence	O	O
of	O	O
l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
on	O	O
the	O	O
renal	O	O
excretion	O	O
of	O	O
potassium	B-chem	B-chem
was	O	O
studied	O	O
in	O	O
3	O	O
patients	O	O
with	O	O
hypokalemia	O	O
and	O	O
in	O	O
5	O	O
normokalemic	O	O
patients	O	O
by	O	O
determination	O	O
of	O	O
renal	O	O
plasma	O	O
flow	O	O
,	O	O
glomerular	O	O
filtration	O	O
rate	O	O
,	O	O
plasma	O	O
concentration	O	O
of	O	O
potassium	B-chem	B-chem
and	O	O
sodium	B-chem	B-chem
as	O	O
well	O	O
as	O	O
urinary	O	O
excretion	O	O
of	O	O
potassium	B-chem	B-chem
,	O	O
sodium	B-chem	B-chem
and	O	O
aldosterone	B-chem	B-chem
.	O	O

l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
intake	O	O
was	O	O
found	O	O
to	O	O
cause	O	O
an	O	O
increased	O	O
excretion	O	O
of	O	O
potassium	B-chem	B-chem
,	O	O
and	O	O
sometimes	O	O
also	O	O
of	O	O
sodium	B-chem	B-chem
,	O	O
in	O	O
the	O	O
hypokalemic	O	O
but	O	O
not	O	O
in	O	O
the	O	O
normokalemic	O	O
patients	O	O
.	O	O

this	O	O
effect	O	O
on	O	O
the	O	O
renal	O	O
function	O	O
could	O	O
be	O	O
prohibited	O	O
by	O	O
the	O	O
administration	O	O
of	O	O
a	O	O
peripheral	O	O
dopa	O	B-chem
decarbodylase	O	O
inhibitor	O	O
.	O	O

it	O	O
is	O	O
not	O	O
known	O	O
why	O	O
this	O	O
effect	O	O
occurred	O	O
in	O	O
some	O	O
individuals	O	O
but	O	O
not	O	O
in	O	O
others	O	O
,	O	O
but	O	O
our	O	O
results	O	O
indicate	O	O
a	O	O
correlation	O	O
between	O	O
aldosterone	B-chem	B-chem
production	O	O
and	O	O
this	O	O
renal	O	O
effect	O	O
of	O	O
l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
.	O	O

phenytoin	B-chem	B-chem
encephalopathy	O	O
as	O	O
probable	O	O
idiosyncratic	O	O
reaction	O	O
:	O	O
case	O	O
report	O	O
.	O	O

a	O	O
case	O	O
of	O	O
phenytoin	B-chem	B-chem
(	O	O
dph	B-chem	B-chem
)	O	O
encephalopathy	O	O
with	O	O
increasing	O	O
seizures	O	O
and	O	O
eeg	O	O
and	O	O
mental	O	O
changes	O	O
is	O	O
described	O	O
.	O	O

despite	O	O
adequate	O	O
oral	O	O
dosage	O	O
of	O	O
dph	B-chem	B-chem
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
daily	O	O
)	O	O
the	O	O
plasma	O	O
level	O	O
was	O	O
very	O	O
low	O	O
(	O	O
2	O	O
.	O	O
8	O	O
microgramg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

the	O	O
encephalopathy	O	O
was	O	O
probably	O	O
an	O	O
idiosyncratic	O	O
and	O	O
not	O	O
toxic	O	O
or	O	O
allergic	O	O
reaction	O	O
.	O	O

in	O	O
fact	O	O
the	O	O
concentration	O	O
of	O	O
free	O	O
dph	B-chem	B-chem
was	O	O
normal	O	O
,	O	O
the	O	O
patient	O	O
presented	O	O
a	O	O
retarded	O	O
morbilliform	O	O
rash	O	O
during	O	O
dph	B-chem	B-chem
treatment	O	O
,	O	O
the	O	O
protidogram	O	O
was	O	O
normal	O	O
,	O	O
and	O	O
an	O	O
intradermic	O	O
dph	B-chem	B-chem
injection	O	O
had	O	O
no	O	O
local	O	O
effect	O	O
.	O	O

the	O	O
authors	O	O
conclude	O	O
that	O	O
in	O	O
a	O	O
patient	O	O
starting	O	O
dph	B-chem	B-chem
treatment	O	O
an	O	O
unexpected	O	O
increase	O	O
in	O	O
seizures	O	O
,	O	O
with	O	O
eeg	O	O
and	O	O
mental	O	O
changes	O	O
occurring	O	O
simultaneously	O	O
,	O	O
should	O	O
alert	O	O
the	O	O
physician	O	O
to	O	O
the	O	O
possible	O	O
need	O	O
for	O	O
eliminating	O	O
dph	B-chem	B-chem
from	O	O
the	O	O
therapeutic	O	O
regimen	O	O
,	O	O
even	O	O
if	O	O
plasma	O	O
concentrations	O	O
are	O	O
low	O	O
.	O	O

effects	O	O
of	O	O
exercise	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
myocardial	O	O
infarction	O	O
.	O	O

the	O	O
effect	O	O
of	O	O
exercise	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
myocardial	O	O
infarction	O	O
was	O	O
studied	O	O
in	O	O
male	O	O
rats	O	O
.	O	O

ninety	O	O
-	O	O
three	O	O
rats	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
.	O	O

the	O	O
exercise	O	O
-	O	O
isoproterenol	B-chem	B-chem
(	O	O
e	O	O
-	O	O
1	O	O
)	O	O
and	O	O
exercise	O	O
control	O	O
(	O	O
ec	O	O
)	O	O
groups	O	O
exercised	O	O
daily	O	O
for	O	O
thirty	O	O
days	O	O
on	O	O
a	O	O
treadmill	O	O
at	O	O
1	O	O
mph	O	O
,	O	O
2	O	O
%	O	O
grade	O	O
while	O	O
animals	O	O
of	O	O
the	O	O
sedentary	O	O
-	O	O
isoproterenol	B-chem	B-chem
(	O	O
s	O	O
-	O	O
i	O	O
)	O	O
group	O	O
remained	O	O
sedentary	O	O
.	O	O

eight	O	O
animals	O	O
were	O	O
assigned	O	O
to	O	O
the	O	O
sedentary	O	O
control	O	O
(	O	O
sc	O	O
)	O	O
group	O	O
which	O	O
remained	O	O
sedentary	O	O
throughout	O	O
the	O	O
experimental	O	O
period	O	O
.	O	O

forty	O	O
-	O	O
eight	O	O
hours	O	O
after	O	O
the	O	O
final	O	O
exercise	O	O
period	O	O
,	O	O
s	O	O
-	O	O
i	O	O
and	O	O
e	O	O
-	O	O
i	O	O
animals	O	O
received	O	O
a	O	O
single	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B-chem	B-chem
(	O	O
250	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
)	O	O
.	O	O

animals	O	O
of	O	O
the	O	O
s	O	O
-	O	O
i	O	O
group	O	O
exhibited	O	O
significantly	O	O
(	O	O
pp	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
greater	O	O
mortality	O	O
from	O	O
the	O	O
effects	O	O
of	O	O
isoproterenol	B-chem	B-chem
than	O	O
animals	O	O
of	O	O
the	O	O
e	O	O
-	O	O
i	O	O
group	O	O
.	O	O

serum	O	O
cpk	O	O
activity	O	O
for	O	O
e	O	O
-	O	O
i	O	O
animals	O	O
was	O	O
significantly	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
greater	O	O
than	O	O
for	O	O
animals	O	O
in	O	O
the	O	O
s	O	O
-	O	O
i	O	O
and	O	O
ec	O	O
groups	O	O
twenty	O	O
hours	O	O
following	O	O
isoproterenol	B-chem	B-chem
injection	O	O
.	O	O

no	O	O
statistically	O	O
significant	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
two	O	O
isoproterenol	B-chem	B-chem
treated	O	O
groups	O	O
for	O	O
severity	O	O
of	O	O
the	O	O
induced	O	O
lesions	O	O
,	O	O
changes	O	O
in	O	O
heart	O	O
weight	O	O
,	O	O
or	O	O
heart	O	O
weight	O	O
to	O	O
body	O	O
weight	O	O
ratios	O	O
.	O	O

the	O	O
results	O	O
indicated	O	O
that	O	O
exercise	O	O
reduced	O	O
the	O	O
mortality	O	O
associated	O	O
with	O	O
the	O	O
effects	O	O
of	O	O
large	O	O
dosages	O	O
of	O	O
isoproterenol	B-chem	B-chem
but	O	O
had	O	O
little	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
infarction	O	O
.	O	O

effect	O	O
of	O	O
d	B-chem	B-chem
-	I-chem	I-chem
glucarates	I-chem	I-chem
on	O	O
basic	O	O
antibiotic	O	O
-	O	O
induced	O	O
renal	O	O
damage	O	O
in	O	O
rats	O	O
.	O	O

dehydrated	O	O
rats	O	O
regularly	O	O
develop	O	O
acute	O	O
renal	O	O
failure	O	O
following	O	O
single	O	O
injection	O	O
of	O	O
aminoglycoside	B-chem	B-chem
antibiotics	O	O
combined	O	O
with	O	O
dextran	O	B-chem
or	O	O
of	O	O
antibiotics	O	O
only	O	O
.	O	O

oral	O	O
administration	O	O
of	O	O
2	B-chem	B-chem
,	I-chem	I-chem
5	I-chem	I-chem
-	I-chem	I-chem
di	I-chem	I-chem
-	I-chem	I-chem
o	I-chem	I-chem
-	I-chem	I-chem
acetyl	I-chem	I-chem
-	I-chem	I-chem
d	I-chem	I-chem
-	I-chem	I-chem
glucaro	I-chem	I-chem
-	I-chem	I-chem
1	I-chem	I-chem
,	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
6	I-chem	I-chem
,	I-chem	I-chem
3	I-chem	I-chem
-	I-chem	I-chem
dilactone	I-chem	I-chem
protected	O	O
rats	O	O
against	O	O
renal	O	O
failure	O	O
induced	O	O
by	O	O
kanamycin	B-chem	B-chem
-	O	O
dextran	O	B-chem
.	O	O

the	O	O
protective	O	O
effect	O	O
was	O	O
prevalent	O	O
among	O	O
d	B-chem	O
-	I-chem	O
glucarates	I-chem	O
,	O	O
and	O	O
also	O	O
to	O	O
other	O	O
saccharic	B-chem	B-chem
acid	I-chem	I-chem
,	O	O
hexauronic	B-chem	I-chem
acids	I-chem	I-chem
and	O	O
hexaaldonic	B-chem	I-chem
acids	I-chem	O
,	O	O
although	O	O
to	O	O
a	O	O
lesser	O	O
degree	O	O
,	O	O
but	O	O
not	O	O
to	O	O
a	O	O
hexaaldose	O	O
,	O	O
sugar	B-chem	B-chem
alcohols	I-chem	I-chem
,	O	O
substances	O	O
inthe	O	O
tca	B-chem	B-chem
cycle	O	O
and	O	O
other	O	O
acidic	O	O
compounds	O	O
.	O	O

d	B-chem	B-chem
-	I-chem	I-chem
glucarates	I-chem	O
were	O	O
effective	O	O
against	O	O
renal	O	O
damage	O	O
induced	O	O
by	O	O
peptide	O	B-chem
antibiotics	O	O
as	O	O
well	O	O
as	O	O
various	O	O
aminoglycoside	B-chem	B-chem
antibitocis	O	O
.	O	O

dose	O	O
-	O	O
responses	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
d	B-chem	O
-	I-chem	O
glucarates	I-chem	O
.	O	O

with	O	O
a	O	O
d	B-chem	O
-	I-chem	O
glucarate	I-chem	I-chem
of	O	O
a	O	O
fixed	O	O
size	O	O
of	O	O
dose	O	O
,	O	O
approximately	O	O
the	O	O
same	O	O
degree	O	O
of	O	O
protection	O	O
was	O	O
obtained	O	O
against	O	O
renal	O	O
damages	O	O
induced	O	O
by	O	O
different	O	O
basic	O	O
antibiotics	O	O
despite	O	O
large	O	O
disparities	O	O
in	O	O
administration	O	O
doses	O	O
of	O	O
different	O	O
antibiotics	O	O
.	O	O

d	B-chem	O
-	I-chem	O
glucarates	I-chem	O
had	O	O
the	O	O
ability	O	O
to	O	O
prevent	O	O
renal	O	O
damage	O	O
but	O	O
not	O	O
to	O	O
cure	O	O
it	O	O
.	O	O

rats	O	O
excreted	O	O
acidic	O	O
urine	O	O
when	O	O
they	O	O
were	O	O
spared	O	O
from	O	O
renal	O	O
lesions	O	O
by	O	O
monosaccharides	B-chem	O
.	O	O

the	O	O
reduction	O	O
effect	O	O
of	O	O
d	B-chem	B-chem
-	I-chem	I-chem
glucarates	I-chem	I-chem
against	O	O
nephrotoxicity	O	O
of	O	O
basic	O	O
antibiotics	O	O
was	O	O
discussed	O	O
.	O	O

paraplegia	O	O
following	O	O
intrathecal	O	O
methotrexate	B-chem	B-chem
:	O	O
report	O	O
of	O	O
a	O	O
case	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

a	O	O
patient	O	O
who	O	O
developed	O	O
paraplegia	O	O
following	O	O
the	O	O
intrathecal	O	O
instillation	O	O
of	O	O
methotrexate	B-chem	B-chem
is	O	O
discribed	O	O
.	O	O

the	O	O
ten	O	O
previously	O	O
reported	O	O
cases	O	O
of	O	O
this	O	O
unusual	O	O
complication	O	O
are	O	O
reviewed	O	O
.	O	O

the	O	O
following	O	O
factors	O	O
appear	O	O
to	O	O
predispose	O	O
to	O	O
the	O	O
development	O	O
of	O	O
this	O	O
complication	O	O
:	O	O
abnormal	O	O
cerebrospinal	O	O
dynamics	O	O
related	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
leukemia	O	O
,	O	O
and	O	O
epidural	O	O
cerebrospinal	O	O
leakage	O	O
;	O	O
elevated	O	O
cerebrospinal	O	O
fluid	O	O
methothexate	B-chem	B-chem
concentration	O	O
related	O	O
to	O	O
abnormal	O	O
cerebrospinal	O	O
fluid	O	O
dynamics	O	O
and	O	O
to	O	O
inappropriately	O	O
high	O	O
methotrexate	B-chem	B-chem
doses	O	O
based	O	O
on	O	O
body	O	O
surface	O	O
area	O	O
calculations	O	O
in	O	O
older	O	O
children	O	O
and	O	O
adults	O	O
;	O	O
the	O	O
presence	O	O
of	O	O
neurotoxic	O	O
preservatives	O	O
in	O	O
commercially	O	O
available	O	O
methotrexate	B-chem	B-chem
preparations	O	O
and	O	O
diluents	O	O
;	O	O
and	O	O
the	O	O
use	O	O
of	O	O
methotrexate	B-chem	B-chem
diluents	O	O
of	O	O
unphysiologic	O	O
ph	O	O
,	O	O
ionic	O	O
content	O	O
and	O	O
osmolarity	O	O
.	O	O

the	O	O
role	O	O
of	O	O
methotrexate	B-chem	B-chem
contaminants	O	O
,	O	O
local	O	O
folate	O	B-chem
deficiency	O	O
,	O	O
and	O	O
cranial	O	O
irradiation	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
intrathecal	O	O
methotrexate	B-chem	B-chem
toxicity	O	O
is	O	O
unclear	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
neurotoxicity	O	O
may	O	O
be	O	O
reduced	O	O
by	O	O
employing	O	O
lower	O	O
doses	O	O
of	O	O
methotrexate	B-chem	B-chem
in	O	O
the	O	O
presence	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
leukemia	O	O
,	O	O
in	O	O
older	O	O
children	O	O
and	O	O
adults	O	O
,	O	O
and	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
epidural	O	O
leakage	O	O
.	O	O

only	O	O
preservative	O	O
-	O	O
free	O	O
methotrexate	B-chem	B-chem
in	O	O
elliott	O	O
'	O	O
s	O	O
b	O	I-chem
solution	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
not	O	O
more	O	O
than	O	O
1	O	O
mg	O	O
/	O	O
ml	O	O
should	O	O
be	O	O
used	O	O
for	O	O
intrathecal	O	O
administration	O	O
.	O	O

periodic	O	O
monitoring	O	O
of	O	O
cerebruspinal	O	O
fluid	O	O
methotrexate	B-chem	B-chem
levels	O	O
may	O	O
be	O	O
predictive	O	O
of	O	O
the	O	O
development	O	O
of	O	O
serious	O	O
neurotoxicity	O	O
.	O	O

centrally	O	O
mediated	O	O
cardiovascular	O	O
effects	O	O
of	O	O
intracisternal	O	O
application	O	O
of	O	O
carbachol	B-chem	B-chem
in	O	O
anesthetized	O	O
rats	O	O
.	O	O

the	O	O
pressor	O	O
response	O	O
to	O	O
the	O	O
intracisternal	O	O
(	O	O
i	O	O
.	O	O
c	O	O
.	O	O
)	O	O
injection	O	O
of	O	O
carbachol	B-chem	B-chem
(	O	O
1	O	O
mug	O	O
)	O	O
in	O	O
anesthetized	O	O
rats	O	O
was	O	O
analyzed	O	O
.	O	O

this	O	O
response	O	O
was	O	O
significantly	O	O
reduced	O	O
by	O	O
the	O	O
intravenous	O	O
(	O	O
i	O	O
.	O	O
v	O	O
.	O	O
)	O	O
injection	O	O
of	O	O
guanethidine	B-chem	B-chem
(	O	O
5	O	O
mg	O	O
)	O	O
,	O	O
hexamethonium	B-chem	B-chem
(	O	O
10	O	O
mg	O	O
)	O	O
or	O	O
phentolamine	B-chem	B-chem
(	O	O
5	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
conversely	O	O
,	O	O
potentiated	O	O
by	O	O
i	O	O
.	O	O
v	O	O
.	O	O

desmethylimipramine	B-chem	B-chem
(	O	O
0	O	O
.	O	O
3	O	O
mg	O	O
)	O	O
,	O	O

while	O	O
propranolol	B-chem	B-chem
(	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
)	O	O
i	O	O
.	O	O
v	O	O
.	O	O

selectively	O	O
inhibited	O	O
the	O	O
enlargement	O	O
of	O	O
pulse	O	O
pressure	O	O
and	O	O
the	O	O
tachycardia	O	O
following	O	O
i	O	O
.	O	O
c	O	O
.	O	O

carbachol	B-chem	B-chem
(	O	O
1	O	O
mug	O	O
)	O	O
.	O	O

on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
pressor	O	O
response	O	O
to	O	O
i	O	O
.	O	O
c	O	O
.	O	O
carbachol	B-chem	B-chem
(	O	O
1	O	O
mug	O	O
)	O	O
was	O	O
almost	O	O
completely	O	O
blocked	O	O
by	O	O
i	O	O
.	O	O
c	O	O
.	O	O

atropine	B-chem	B-chem
(	O	O
3	O	O
mug	O	O
)	O	O
or	O	O
hexamethonium	B-chem	B-chem
(	O	O
500	O	O
mug	O	O
)	O	O
,	O	O
and	O	O
significantly	O	O
reduced	O	O
by	O	O
i	O	O
.	O	O
c	O	O
.	O	O

chlorpromazine	B-chem	B-chem
(	O	O
50	O	O
mug	O	O
)	O	O
but	O	O
significantly	O	O
potentiated	O	O
by	O	O
i	O	O
.	O	O
c	O	O
.	O	O

desmethylimipramine	B-chem	B-chem
(	O	O
30	O	O
mug	O	O
)	O	O
.	O	O

the	O	O
pressor	O	O
response	O	O
to	O	O
i	O	O
.	O	O
c	O	O
.	O	O
carbachol	B-chem	B-chem
(	O	O
1	O	O
mug	O	O
)	O	O
remained	O	O
unchanged	O	O
after	O	O
sectioning	O	O
of	O	O
the	O	O
bilateral	O	O
cervical	O	O
vagal	O	O
nerves	O	O
but	O	O
disappeared	O	O
after	O	O
sectioning	O	O
of	O	O
the	O	O
spinal	O	O
cord	O	O
(	O	O
c7	O	O
-	O	O
c8	O	O
)	O	O
.	O	O

from	O	O
the	O	O
above	O	O
result	O	O
it	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
pressor	O	O
response	O	O
to	O	O
i	O	O
.	O	O
c	O	O
.	O	O

carbachol	B-chem	B-chem
ortral	O	O
and	O	O
peripheral	O	O
adrenergic	O	O
mechanisms	O	O
,	O	O
and	O	O
that	O	O
the	O	O
sympathetic	O	O
trunk	O	O
is	O	O
the	O	O
main	O	O
pathway	O	O
.	O	O

hyperglycemic	O	O
effect	O	O
of	O	O
amino	B-chem	B-chem
compounds	O	O
structurally	O	O
related	O	O
to	O	O
caproate	B-chem	O
in	O	O
rats	O	O
.	O	O

the	O	O
chronic	O	O
feeding	O	O
of	O	O
small	O	O
amounts	O	O
(	O	O
0	O	O
.	O	O
3	O	O
-	O	O
3	O	O
%	O	O
of	O	O
diet	O	O
weight	O	O
)	O	O
of	O	O
certain	O	O
amino	B-chem	B-chem
derivatives	O	O
of	O	O
caproate	B-chem	B-chem
resulted	O	O
in	O	O
hyperglycemia	O	O
,	O	O
an	O	O
elevated	O	O
glucose	B-chem	B-chem
tolerance	O	O
curve	O	O
and	O	O
,	O	O
occasionally	O	O
,	O	O
glucosuria	O	O
.	O	O

effective	O	O
compounds	O	O
included	O	O
norleucine	B-chem	B-chem
,	O	O
norvaline	B-chem	B-chem
,	O	O
glutamate	B-chem	B-chem
,	O	O
epsilon	B-chem	B-chem
-	I-chem	I-chem
aminocaproate	I-chem	I-chem
,	O	O
methionine	B-chem	B-chem
,	O	O
and	O	O
leucine	B-chem	B-chem
.	O	O

fatty	O	O
liver	O	O
induced	O	O
by	O	O
tetracycline	B-chem	B-chem
in	O	O
the	O	O
rat	O	O
.	O	O

dose	O	O
-	O	O
response	O	O
relationships	O	O
and	O	O
effect	O	O
of	O	O
sex	O	O
.	O	O

dose	O	O
-	O	O
response	O	O
relationships	O	O
,	O	O
biochemical	O	O
mechanisms	O	O
,	O	O
and	O	O
sex	O	O
differences	O	O
in	O	O
the	O	O
experimental	O	O
fatty	O	O
liver	O	O
induced	O	O
by	O	O
tetracycline	B-chem	B-chem
were	O	O
studied	O	O
in	O	O
the	O	O
intact	O	O
rat	O	O
and	O	O
with	O	O
the	O	O
isolated	O	O
perfused	O	O
rat	O	O
liver	O	O
in	O	O
vitro	O	O
.	O	O

in	O	O
the	O	O
intact	O	O
male	O	O
and	O	O
female	O	O
rat	O	O
,	O	O
no	O	O
direct	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
dose	O	O
of	O	O
tetracycline	B-chem	B-chem
and	O	O
hepatic	O	O
accumulation	O	O
of	O	O
triglyceride	B-chem	B-chem
.	O	O

with	O	O
provision	O	O
of	O	O
adequate	O	O
oleic	B-chem	B-chem
acid	I-chem	I-chem
as	O	O
a	O	O
substrate	O	O
for	O	O
the	O	O
isolated	O	O
perfused	O	O
liver	O	O
,	O	O
a	O	O
direct	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
dose	O	O
of	O	O
tetracycline	B-chem	B-chem
and	O	O
both	O	O
accumulation	O	O
of	O	O
triglyceride	B-chem	B-chem
in	O	O
the	O	O
liver	O	O
and	O	O
depression	O	O
of	O	O
output	O	O
of	O	O
triglyceride	B-chem	B-chem
by	O	O
livers	O	O
from	O	O
male	O	O
and	O	O
female	O	O
rats	O	O
.	O	O

marked	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
female	O	O
and	O	O
male	O	O
rats	O	O
with	O	O
regard	O	O
to	O	O
base	O	O
line	O	O
(	O	O
control	O	O
)	O	O
hepatic	O	O
concentration	O	O
of	O	O
triglyceride	B-chem	B-chem
and	O	O
output	O	O
of	O	O
triglyceride	B-chem	B-chem
.	O	O

accumulation	O	O
of	O	O
hepatic	O	O
triglyceride	B-chem	B-chem
,	O	O
as	O	O
a	O	O
per	O	O
cent	O	O
of	O	O
control	O	O
values	O	O
,	O	O
in	O	O
response	O	O
to	O	O
graded	O	O
doses	O	O
of	O	O
tetracycline	B-chem	B-chem
,	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
male	O	O
,	O	O
female	O	O
and	O	O
pregnant	O	O
rat	O	O
livers	O	O
.	O	O

however	O	O
,	O	O
livers	O	O
from	O	O
female	O	O
,	O	O
and	O	O
especially	O	O
pregnant	O	O
female	O	O
rats	O	O
,	O	O
were	O	O
strikingly	O	O
resistant	O	O
to	O	O
the	O	O
effects	O	O
of	O	O
tetracycline	B-chem	B-chem
on	O	O
depression	O	O
of	O	O
output	O	O
of	O	O
triglyceride	B-chem	B-chem
under	O	O
these	O	O
experimental	O	O
conditions	O	O
.	O	O

these	O	O
differences	O	O
between	O	O
the	O	O
sexes	O	O
could	O	O
not	O	O
be	O	O
related	O	O
to	O	O
altered	O	O
disposition	O	O
of	O	O
tetracycline	B-chem	B-chem
or	O	O
altered	O	O
uptake	O	O
of	O	O
oleic	B-chem	B-chem
acid	I-chem	I-chem
.	O	O

depressed	O	O
hepatic	O	O
secretion	O	O
of	O	O
triglyceride	B-chem	B-chem
accounted	O	O
only	O	O
for	O	O
30	O	O
to	O	O
50	O	O
%	O	O
of	O	O
accumulated	O	O
hepatic	O	O
triglyceride	B-chem	B-chem
,	O	O
indicating	O	O
that	O	O
additional	O	O
mechanisms	O	O
must	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
production	O	O
of	O	O
the	O	O
triglyceride	B-chem	B-chem
-	O	O
rich	O	O
fatty	O	O
liver	O	O
in	O	O
response	O	O
to	O	O
tetracycline	B-chem	B-chem
.	O	O

fatal	O	O
myeloencephalopathy	O	O
due	O	O
to	O	O
intrathecal	O	O
vincristine	B-chem	B-chem
administration	O	O
.	O	O

vincristine	B-chem	B-chem
was	O	O
accidentally	O	O
given	O	O
intrathecally	O	O
to	O	O
a	O	O
child	O	O
with	O	O
leukaemia	O	O
,	O	O
producing	O	O
sensory	O	O
and	O	O
motor	O	O
dysfunction	O	O
followed	O	O
by	O	O
encephalopathy	O	O
and	O	O
death	O	O
.	O	O

separate	O	O
times	O	O
for	O	O
administering	O	O
vincristine	B-chem	B-chem
and	O	O
intrathecal	O	O
therapy	O	O
is	O	O
recommended	O	O
.	O	O

progesterone	B-chem	B-chem
potentiation	O	O
of	O	O
bupivacaine	B-chem	B-chem
arrhythmogenicity	O	O
in	O	O
pentobarbital	B-chem	B-chem
-	O	O
anesthetized	O	O
rats	O	O
and	O	O
beating	O	O
rat	O	O
heart	O	O
cell	O	O
cultures	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
progesterone	B-chem	B-chem
treatment	O	O
on	O	O
bupivacaine	B-chem	B-chem
arrhythmogenicity	O	O
in	O	O
beating	O	O
rat	O	O
heart	O	O
myocyte	O	O
cultures	O	O
and	O	O
on	O	O
anesthetized	O	O
rats	O	O
were	O	O
determined	O	O
.	O	O

after	O	O
determining	O	O
the	O	O
bupivacaine	B-chem	B-chem
ad50	O	O
(	O	O
the	O	O
concentration	O	O
of	O	O
bupivacaine	B-chem	B-chem
that	O	O
caused	O	O
50	O	O
%	O	O
of	O	O
all	O	O
beating	O	O
rat	O	O
heart	O	O
myocyte	O	O
cultures	O	O
to	O	O
become	O	O
arrhythmic	O	O
)	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
effect	O	O
of	O	O
1	O	O
-	O	O
hour	O	O
progesterone	B-chem	B-chem
hcl	B-chem	I-chem
exposure	O	O
on	O	O
myocyte	O	O
contractile	O	O
rhythm	O	O
.	O	O

each	O	O
concentration	O	O
of	O	O
progesterone	B-chem	B-chem
(	O	O
6	O	O
.	O	O
25	O	O
,	O	O
12	O	O
.	O	O
5	O	O
,	O	O
25	O	O
,	O	O
and	O	O
50	O	O
micrograms	O	O
/	O	O
ml	O	O
)	O	O
caused	O	O
a	O	O
significant	O	O
and	O	O
concentration	O	O
-	O	O
dependent	O	O
reduction	O	O
in	O	O
the	O	O
ad50	O	O
for	O	O
bupivacaine	B-chem	B-chem
.	O	O

estradiol	B-chem	B-chem
treatment	O	O
also	O	O
increased	O	O
the	O	O
arrhythmogenicity	O	O
of	O	O
bupivacaine	B-chem	B-chem
in	O	O
myocyte	O	O
cultures	O	O
,	O	O
but	O	O
was	O	O
only	O	O
one	O	O
fourth	O	O
as	O	O
potent	O	O
as	O	O
progesterone	B-chem	B-chem
.	O	O

neither	O	O
progesterone	B-chem	B-chem
nor	O	O
estradiol	B-chem	B-chem
effects	O	O
on	O	O
bupivacaine	B-chem	B-chem
arrhythmogenicity	O	O
were	O	O
potentiated	O	O
by	O	O
epinephrine	B-chem	B-chem
.	O	O

chronic	O	O
progesterone	B-chem	B-chem
pretreatment	O	O
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
for	O	O
21	O	O
days	O	O
)	O	O
caused	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
bupivacaine	B-chem	B-chem
arrhythmogenicity	O	O
in	O	O
intact	O	O
pentobarbital	B-chem	B-chem
-	O	O
anesthetized	O	O
rats	O	O
.	O	O

there	O	O
was	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
the	O	O
time	O	O
to	O	O
onset	O	O
of	O	O
arrhythmia	O	O
as	O	O
compared	O	O
with	O	O
control	O	O
nonprogesterone	O	B-chem
-	O	O
treated	O	O
rats	O	O
(	O	O
6	O	O
.	O	O
2	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
3	O	O
vs	O	O
.	O	O
30	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

2	O	O
.	O	O
5	O	O
min	O	O
,	O	O
mean	O	O
+	O	O
/	O	O
-	O	O

se	O	O
)	O	O
.	O	O

the	O	O
results	O	O
of	O	O
this	O	O
study	O	O
indicate	O	O
that	O	O
progesterone	B-chem	B-chem
can	O	O
potentiate	O	O
bupivacaine	B-chem	B-chem
arrhythmogenicity	O	O
both	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
.	O	O

potentiation	O	O
of	O	O
bupivacaine	B-chem	B-chem
arrhythmia	O	O
in	O	O
myocyte	O	O
cultures	O	O
suggests	O	O
that	O	O
this	O	O
effect	O	O
is	O	O
at	O	O
least	O	O
partly	O	O
mediated	O	O
at	O	O
the	O	O
myocyte	O	O
level	O	O
.	O	O

acute	O	O
renal	O	O
failure	O	O
occurring	O	O
during	O	O
intravenous	O	O
desferrioxamine	B-chem	B-chem
therapy	O	O
:	O	O
recovery	O	O
after	O	O
haemodialysis	O	O
.	O	O

a	O	O
patient	O	O
with	O	O
transfusion	O	O
-	O	O
dependent	O	O
thalassemia	O	O
was	O	O
undergoing	O	O
home	O	O
intravenous	O	O
desferrioxamine	B-chem	B-chem
(	O	O
dfx	B-chem	B-chem
)	O	O
treatment	O	O
by	O	O
means	O	O
of	O	O
a	O	O
totally	O	O
implanted	O	O
system	O	O
because	O	O
of	O	O
his	O	O
poor	O	O
compliance	O	O
with	O	O
the	O	O
nightly	O	O
subcutaneous	O	O
therapy	O	O
.	O	O

due	O	O
to	O	O
an	O	O
accidental	O	O
malfunctioning	O	O
of	O	O
the	O	O
infusion	O	O
pump	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
inadvertently	O	O
administered	O	O
a	O	O
toxic	O	O
dosage	O	O
of	O	O
the	O	O
drug	O	O
which	O	O
caused	O	O
renal	O	O
insufficiency	O	O
.	O	O

given	O	O
the	O	O
progressive	O	O
deterioration	O	O
of	O	O
the	O	O
symptoms	O	O
and	O	O
of	O	O
the	O	O
laboratory	O	O
values	O	O
,	O	O
despite	O	O
adequate	O	O
medical	O	O
treatment	O	O
,	O	O
a	O	O
decision	O	O
was	O	O
made	O	O
to	O	O
introduce	O	O
haemodialytical	O	O
therapy	O	O
in	O	O
order	O	O
to	O	O
remove	O	O
the	O	O
drug	O	O
and	O	O
therapy	O	O
reduce	O	O
the	O	O
nephrotoxicity	O	O
.	O	O

from	O	O
the	O	O
results	O	O
obtained	O	O
,	O	O
haemodialysis	O	O
can	O	O
therefore	O	O
be	O	O
suggested	O	O
as	O	O
a	O	O
useful	O	O
therapy	O	O
in	O	O
rare	O	O
cases	O	O
of	O	O
progressive	O	O
acute	O	O
renal	O	O
failure	O	O
caused	O	O
by	O	O
desferrioxamine	B-chem	B-chem
.	O	O

neuroleptic	B-chem	O
-	O	O
associated	O	O
hyperprolactinemia	O	O
.	O	O

can	O	O
it	O	O
be	O	O
treated	O	O
with	O	O
bromocriptine	B-chem	B-chem
?	O	O

six	O	O
stable	O	O
psychiatric	O	O
outpatients	O	O
with	O	O
hyperprolactinemia	O	O
and	O	O
amenorrhea	O	O
/	O	O
oligomenorrhea	O	O
associated	O	O
with	O	O
their	O	O
neuroleptic	B-chem	O
medications	I-chem	O
were	O	O
treated	O	O
with	O	O
bromocriptine	B-chem	B-chem
.	O	O

daily	O	O
dosages	O	O
of	O	O
5	O	O
-	O	O
10	O	O
mg	O	O
corrected	O	O
the	O	O
hyperprolactinemia	O	O
and	O	O
restored	O	O
menstruation	O	O
in	O	O
four	O	O
of	O	O
the	O	O
six	O	O
patients	O	O
.	O	O

one	O	O
woman	O	O
,	O	O
however	O	O
,	O	O
developed	O	O
worsened	O	O
psychiatric	O	O
symptoms	O	O
while	O	O
taking	O	O
bromocriptine	B-chem	B-chem
,	O	O
and	O	O
it	O	O
was	O	O
discontinued	O	O
.	O	O

thus	O	O
,	O	O
three	O	O
of	O	O
six	O	O
patients	O	O
had	O	O
their	O	O
menstrual	O	O
irregularity	O	O
successfully	O	O
corrected	O	O
with	O	O
bromocriptine	B-chem	B-chem
.	O	O

this	O	O
suggests	O	O
that	O	O
bromocriptine	B-chem	B-chem
should	O	O
be	O	O
further	O	O
evaluated	O	O
as	O	O
potential	O	O
therapy	O	O
for	O	O
neuroleptic	B-chem	O
-	O	O
associated	O	O
hyperprolactinemia	O	O
and	O	O
amenorrhea	O	O
/	O	O
galactorrhea	O	O
.	O	O

ethacrynic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
convulsions	O	O
and	O	O
brain	O	O
neurotransmitters	O	O
in	O	O
mice	O	O
.	O	O

intracerebroventricular	O	O
injection	O	O
of	O	O
ethacrynic	B-chem	B-chem
acid	I-chem	I-chem
(	O	O
50	O	O
%	O	O
convulsive	O	O
dose	O	O
;	O	O
50	O	O
micrograms	O	O
/	O	O
mouse	O	O
)	O	O
accelerated	O	O
the	O	O
synthesis	O	O
/	O	O
turnover	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
hydroxytryptamine	I-chem	I-chem
(	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
)	O	O
but	O	O
suppressed	O	O
the	O	O
synthesis	O	O
of	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
aminobutyric	I-chem	I-chem
acid	I-chem	I-chem
and	O	O
acetylcholine	B-chem	B-chem
in	O	O
mouse	O	O
brain	O	O
.	O	O

these	O	O
effects	O	O
were	O	O
completely	O	O
antagonized	O	O
by	O	O
pretreatment	O	O
with	O	O
a	O	O
glutamate	B-chem	B-chem
/	O	O
n	B-chem	B-chem
-	I-chem	I-chem
methyl	I-chem	I-chem
-	I-chem	I-chem
d	I-chem	I-chem
-	I-chem	I-chem
aspartate	I-chem	I-chem
antagonist	O	O
,	O	O
aminophosphonovaleric	B-chem	B-chem
acid	I-chem	I-chem
.	O	O

in	O	O
ethacrynic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
convulsions	O	O
,	O	O
these	O	O
neurotransmitter	O	O
systems	O	O
may	O	O
be	O	O
differentially	O	O
modulated	O	O
,	O	O
probably	O	O
through	O	O
activation	O	O
of	O	O
glutaminergic	O	O
neurons	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

pharmacology	O	O
of	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
aminobutyric	I-chem	I-chem
acida	O	O
receptor	O	O
complex	O	O
after	O	O
the	O	O
in	O	O
vivo	O	O
administration	O	O
of	O	O
the	O	O
anxioselective	O	O
and	O	O
anticonvulsant	O	O
beta	B-chem	B-chem
-	I-chem	I-chem
carboline	I-chem	I-chem
derivative	O	O
abecarnil	B-chem	B-chem
.	O	O

in	O	O
rodents	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
beta	B-chem	B-chem
-	I-chem	I-chem
carboline	I-chem	I-chem
derivative	O	O
isopropyl	B-chem	B-chem
-	I-chem	I-chem
6	I-chem	I-chem
-	I-chem	I-chem
benzyloxy	I-chem	I-chem
-	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
methoxymethyl	I-chem	I-chem
-	I-chem	I-chem
beta	I-chem	I-chem
-	I-chem	I-chem
carboline	I-chem	I-chem
-	I-chem	I-chem
3	I-chem	I-chem
-	I-chem	I-chem
carboxylate	I-chem	I-chem
(	O	O
abecarrnil	B-chem	B-chem
)	O	O
,	O	O
a	O	O
new	O	O
ligand	O	B-chem
for	O	O
benzodiazepine	B-chem	B-chem
receptors	O	O
possessing	O	O
anxiolytic	O	O
and	O	O
anticonvulsant	O	O
properties	O	O
,	O	O
was	O	O
evaluated	O	O
on	O	O
the	O	O
function	O	O
of	O	O
central	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
aminobutyric	I-chem	I-chem
acid	I-chem	I-chem
(	O	O
gaba	B-chem	B-chem
)	O	O
a	O	O
receptor	O	O
complex	O	O
,	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

added	O	O
in	O	O
vitro	O	O
to	O	O
rat	O	O
cortical	O	O
membrane	O	O
preparation	O	O
,	O	O
abecarnil	B-chem	B-chem
increased	O	O
[	O	B-chem
3h	O	I-chem
]	O	I-chem
gaba	B-chem	I-chem
binding	O	O
,	O	O
enhanced	O	O
muscimol	B-chem	B-chem
-	O	O
stimulated	O	O
36cl	O	O
-	O	O
uptake	O	O
and	O	O
reduced	O	O
the	O	O
binding	O	O
of	O	O
t	B-chem	B-chem
-	I-chem	I-chem
[	I-chem	I-chem
35s	I-chem	I-chem
]	I-chem	I-chem
butylbicyclophosphorothionate	I-chem	I-chem
(	O	O
[	B-chem	B-chem
35s	I-chem	I-chem
]	I-chem	O
tbps	I-chem	I-chem
)	O	O
.	O	O

these	O	O
effects	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
induced	O	O
by	O	O
diazepam	B-chem	B-chem
,	O	O
whereas	O	O
the	O	O
partial	O	O
agonist	O	O
ro	B-chem	B-chem
16	I-chem	I-chem
-	I-chem	O
6028	I-chem	I-chem
(	O	O
tert	B-chem	O
-	I-chem	O
butyl	I-chem	I-chem
-	I-chem	O
(	I-chem	O
s	I-chem	B-chem
)	I-chem	I-chem
-	I-chem	I-chem
8	I-chem	I-chem
-	I-chem	I-chem
bromo	I-chem	I-chem
-	I-chem	O
11	I-chem	O
,	I-chem	O
12	I-chem	O
,	I-chem	O
13	I-chem	O
,	I-chem	O
13a	I-chem	O
-	I-chem	O
tetrahydro	I-chem	B-chem
-	I-chem	I-chem
9	I-chem	I-chem
-	I-chem	I-chem
oxo	I-chem	I-chem
-	I-chem	I-chem
9h	I-chem	I-chem
-	I-chem	I-chem
imidazo	I-chem	I-chem
[	I-chem	I-chem
1	I-chem	I-chem
,	I-chem	I-chem
5	I-chem	I-chem
-	I-chem	I-chem
a	I-chem	I-chem
]	I-chem	I-chem
-	I-chem	I-chem
pyrrolo	I-chem	I-chem
-	I-chem	I-chem
[	I-chem	I-chem
2	I-chem	I-chem
,	I-chem	I-chem
1	I-chem	I-chem
-	I-chem	I-chem
c	I-chem	I-chem
]	I-chem	I-chem
[	I-chem	I-chem
1	I-chem	I-chem
,	I-chem	I-chem
4	I-chem	I-chem
]	I-chem	I-chem
benzodiazepine	I-chem	I-chem
-	I-chem	I-chem
1	I-chem	I-chem
-	I-chem	I-chem
carboxylate	I-chem	I-chem
)	O	O
showed	O	O
very	O	O
weak	O	O
efficacy	O	O
in	O	O
these	O	O
biochemical	O	O
tests	O	O
.	O	O

after	O	O
i	O	O
.	O	O
p	O	O
.	O	O

injection	O	O
to	O	O
rats	O	O
,	O	O
abecarnil	B-chem	B-chem
and	O	O
diazepam	B-chem	B-chem
decreased	O	O
in	O	O
a	O	O
time	O	O
-	O	O
dependent	O	O
and	O	O
dose	O	O
-	O	O
related	O	O
(	O	O
0	O	O
.	O	O
25	O	O
-	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O

manner	O	O

[	B-chem	B-chem
35s	I-chem	I-chem
]	I-chem	O
tbps	I-chem	I-chem
binding	O	O
measured	O	O
ex	O	O
vivo	O	O
in	O	O
the	O	O
cerebral	O	O
cortex	O	O
.	O	O

moreover	O	O
,	O	O
both	O	O
drugs	O	O
at	O	O
the	O	O
dose	O	O
of	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
antagonized	O	O
completely	O	O
the	O	O
convulsant	O	O
activity	O	O
and	O	O
the	O	O
increase	O	O
of	O	O
[	B-chem	B-chem
35s	I-chem	I-chem
]	I-chem	I-chem
tbps	I-chem	I-chem
binding	O	O
induced	O	O
by	O	O
isoniazide	B-chem	B-chem
(	O	O
350	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O
c	O	O
.	O	O
)	O	O
as	O	O
well	O	O
as	O	O
the	O	O
increase	O	O
of	O	O
[	B-chem	B-chem
35s	I-chem	I-chem
]	I-chem	I-chem
tbps	I-chem	I-chem
binding	O	O
induced	O	O
by	O	O
foot	O	O
-	O	O
shock	O	O
stress	O	O
.	O	O

to	O	O
better	O	O
correlate	O	O
the	O	O
biochemical	O	O
and	O	O
the	O	O
pharmacological	O	O
effects	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
action	O	O
of	O	O
abecarnil	B-chem	B-chem
on	O	O
[	B-chem	B-chem
35s	I-chem	I-chem
]	I-chem	O
tbps	I-chem	I-chem
binding	O	O
,	O	O
exploratory	O	O
motility	O	O
and	O	O
on	O	O
isoniazid	B-chem	B-chem
-	O	O
induced	O	O
biochemical	O	O
and	O	O
pharmacological	O	O
effects	O	O
in	O	O
mice	O	O
.	O	O

in	O	O
these	O	O
animals	O	O
,	O	O
abecarnil	B-chem	B-chem
produced	O	O
a	O	O
paralleled	O	O
dose	O	O
-	O	O
dependent	O	O
(	O	O
0	O	O
.	O	O
05	O	O
-	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
reduction	O	O
of	O	O
both	O	O
motor	O	O
behavior	O	O
and	O	O
cortical	O	O
[	O	O
35s	O	O
]	O	O
tbps	O	O
binding	O	O
.	O	O

moreover	O	O
,	O	O
0	O	O
.	O	O
05	O	O
mg	O	O
/	O	O
kg	O	O
of	O	O
this	O	O
beta	B-chem	B-chem
-	I-chem	I-chem
carboline	I-chem	I-chem
reduced	O	O
markedly	O	O
the	O	O
increase	O	O
of	O	O
[	B-chem	B-chem
35s	I-chem	I-chem
]	I-chem	I-chem
tbps	I-chem	I-chem
binding	O	O
and	O	O
the	O	O
convulsions	O	O
induced	O	O
by	O	O
isoniazid	B-chem	B-chem
(	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O
c	O	O
.	O	O
)	O	O
.	O	O
(	O	O
abstract	O	O
truncated	O	O
at	O	O
250	O	O
words	O	O
)	O	O

recurrent	O	O
myocardial	O	O
infarction	O	O
in	O	O
a	O	O
postpartum	O	O
patient	O	O
receiving	O	O
bromocriptine	B-chem	B-chem
.	O	O

myocardial	O	O
infarction	O	O
in	O	O
puerperium	O	O
is	O	O
infrequently	O	O
reported	O	O
.	O	O

spasm	O	O
,	O	O
coronary	O	O
dissection	O	O
,	O	O
or	O	O
atheromatous	O	O
etiology	O	O
has	O	O
been	O	O
described	O	O
.	O	O

bromocriptine	B-chem	B-chem
has	O	O
been	O	O
implicated	O	O
in	O	O
several	O	O
previous	O	O
case	O	O
reports	O	O
of	O	O
myocardial	O	O
infarction	O	O
in	O	O
the	O	O
puerperium	O	O
.	O	O

our	O	O
case	O	O
(	O	O
including	O	O
an	O	O
inadvertent	O	O
rechallenge	O	O
)	O	O
suggests	O	O
such	O	O
a	O	O
relationship	O	O
.	O	O

although	O	O
generally	O	O
regarded	O	O
as	O	O
"	O	O
"	O	O
"	O	O
"	O	O
safe	O	O
,	O	O
"	O	O
"	O	O
"	O	O
"	O	O
possible	O	O
serious	O	O
cardiac	O	O
effects	O	O
of	O	O
bromocriptine	B-chem	B-chem
should	O	O
be	O	O
acknowledged	O	O
.	O	O

asterixis	O	O
induced	O	O
by	O	O
carbamazepine	B-chem	B-chem
therapy	O	O
.	O	O

there	O	O
are	O	O
very	O	O
few	O	O
reports	O	O
about	O	O
asterixis	O	O
as	O	O
a	O	O
side	O	O
effect	O	O
of	O	O
treatment	O	O
with	O	O
psychopharmacologic	O	O
agents	O	O
.	O	O

in	O	O
this	O	O
report	O	O
we	O	O
present	O	O
four	O	O
patients	O	O
treated	O	O
with	O	O
a	O	O
combination	O	O
of	O	O
different	O	O
psychotropic	O	O
drugs	O	O
,	O	O
in	O	O
whom	O	O
asterixis	O	O
was	O	O
triggered	O	O
either	O	O
by	O	O
adding	O	O
carbamazepine	B-chem	B-chem
(	O	O
cbz	B-chem	B-chem
)	O	O
to	O	O
a	O	O
treatment	O	O
regimen	O	O
,	O	O
or	O	O
by	O	O
increasing	O	O
its	O	O
dosage	O	O
.	O	O

neither	O	O
dosage	O	O
nor	O	O
serum	O	O
levels	O	O
of	O	O
cbz	B-chem	B-chem
were	O	O
in	O	O
a	O	O
higher	O	O
range	O	O
.	O	O

we	O	O
consider	O	O
asterixis	O	O
to	O	O
be	O	O
an	O	O
easily	O	O
overlooked	O	O
sign	O	O
of	O	O
neurotoxicity	O	O
,	O	O
which	O	O
may	O	O
occur	O	O
even	O	O
at	O	O
low	O	O
or	O	O
moderate	O	O
dosage	O	O
levels	O	O
,	O	O
if	O	O
certain	O	O
drugs	O	O
as	O	O
lithium	B-chem	B-chem
or	O	O
clozapine	B-chem	B-chem
are	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
cbz	B-chem	B-chem
.	O	O

pharmacodynamics	O	O
of	O	O
the	O	O
hypotensive	O	O
effect	O	O
of	O	O
levodopa	B-chem	B-chem
in	O	O
parkinsonian	O	O
patients	O	O
.	O	O

blood	O	O
pressure	O	O
effects	O	O
of	O	O
i	O	O
.	O	O
v	O	O
.	O	O

levodopa	B-chem	B-chem
were	O	O
examined	O	O
in	O	O
parkinsonian	O	O
patients	O	O
with	O	O
stable	O	O
and	O	O
fluctuating	O	O
responses	O	O
to	O	O
levodopa	B-chem	B-chem
.	O	O

the	O	O
magnitude	O	O
of	O	O
the	O	O
hypotensive	O	O
effect	O	O
of	O	O
levodopa	B-chem	B-chem
was	O	O
concentration	O	O
dependent	O	O
and	O	O
was	O	O
fit	O	O
to	O	O
an	O	O
emax	O	O
model	O	O
in	O	O
fluctuating	O	O
responders	O	O
.	O	O

stable	O	O
responders	O	O
demonstrated	O	O
a	O	O
small	O	O
hypotensive	O	O
response	O	O
.	O	O

baseline	O	O
blood	O	O
pressures	O	O
were	O	O
higher	O	O
in	O	O
fluctuating	O	O
patients	O	O
;	O	O
a	O	O
higher	O	O
baseline	O	O
blood	O	O
pressure	O	O
correlated	O	O
with	O	O
greater	O	O
hypotensive	O	O
effects	O	O
.	O	O

antiparkinsonian	O	O
effects	O	O
of	O	O
levodopa	B-chem	B-chem
temporally	O	O
correlated	O	O
with	O	O
blood	O	O
pressure	O	O
changes	O	O
.	O	O

phenylalanine	B-chem	B-chem
,	O	O
a	O	O
large	O	O
neutral	O	B-chem
amino	B-chem	I-chem
acid	I-chem	I-chem
(	O	O
lnaa	O	O
)	O	O
competing	O	O
with	O	O
levodopa	B-chem	B-chem
for	O	O
transport	O	O
across	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
,	O	O
reduced	O	O
the	O	O
hypotensive	O	O
and	O	O
antiparkinsonian	O	O
effects	O	O
of	O	O
levodopa	B-chem	B-chem
.	O	O

we	O	O
conclude	O	O
that	O	O
levodopa	B-chem	B-chem
has	O	O
a	O	O
central	O	O
hypotensive	O	O
action	O	O
that	O	O
parallels	O	O
the	O	O
motor	O	O
effects	O	O
in	O	O
fluctuating	O	O
patients	O	O
.	O	O

the	O	O
hypotensive	O	O
effect	O	O
appears	O	O
to	O	O
be	O	O
related	O	O
to	O	O
the	O	O
higher	O	O
baseline	O	O
blood	O	O
pressure	O	O
we	O	O
observed	O	O
in	O	O
fluctuating	O	O
patients	O	O
relative	O	O
to	O	O
stable	O	O
patients	O	O
.	O	O

syndrome	O	O
of	O	O
inappropriate	O	O
secretion	O	O
of	O	O
antidiuretic	O	O
hormone	O	O
after	O	O
infusional	O	O
vincristine	B-chem	B-chem
.	O	O

a	O	O
77	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
was	O	O
treated	O	O
with	O	O
a	O	O
4	O	O
-	O	O
day	O	O
continuous	O	O
intravenous	O	O
infusion	O	O
of	O	O
vincristine	B-chem	B-chem
and	O	O
doxorubicin	B-chem	B-chem
and	O	O
4	O	O
days	O	O
of	O	O
oral	O	O
dexamethasone	B-chem	B-chem
.	O	O

nine	O	O
days	O	O
after	O	O
her	O	O
second	O	O
cycle	O	O
she	O	O
presented	O	O
with	O	O
lethargy	O	O
and	O	O
weakness	O	O
associated	O	O
with	O	O
hyponatremia	O	O
.	O	O

evaluation	O	O
revealed	O	O
the	O	O
syndrome	O	O
of	O	O
inappropriate	O	O
secretion	O	O
of	O	O
antidiuretic	O	O
hormone	O	O
,	O	O
which	O	O
was	O	O
attributed	O	O
to	O	O
the	O	O
vincristine	B-chem	B-chem
infusion	O	O
.	O	O

after	O	O
normal	O	O
serum	O	O
sodium	B-chem	B-chem
levels	O	O
returned	O	O
,	O	O
further	O	O
doxorubicin	B-chem	B-chem
and	O	O
dexamethasone	B-chem	B-chem
chemotherapy	O	O
without	O	O
vincristine	B-chem	B-chem
did	O	O
not	O	O
produce	O	O
this	O	O
complication	O	O
.	O	O

heart	O	O
failure	O	O
:	O	O
to	O	O
digitalise	O	O
or	O	O
not	O	O
?	O	O

the	O	O
view	O	O
against	O	O
.	O	O

despite	O	O
extensive	O	O
clinical	O	O
experience	O	O
the	O	O
role	O	O
of	O	O
digoxin	B-chem	B-chem
is	O	O
still	O	O
not	O	O
well	O	O
defined	O	O
.	O	O

in	O	O
patients	O	O
with	O	O
atrial	O	O
fibrillation	O	O
digoxin	B-chem	B-chem
is	O	O
beneficial	O	O
for	O	O
ventricular	O	O
rate	O	O
control	O	O
.	O	O

for	O	O
patients	O	O
in	O	O
sinus	O	O
rhythm	O	O
and	O	O
heart	O	O
failure	O	O
the	O	O
situation	O	O
is	O	O
less	O	O
clear	O	O
.	O	O

digoxin	B-chem	B-chem
has	O	O
a	O	O
narrow	O	O
therapeutic	O	O
:	O	O
toxic	O	O
ratio	O	O
and	O	O
concentrations	O	O
are	O	O
affected	O	O
by	O	O
a	O	O
number	O	O
of	O	O
drugs	O	O
.	O	O

also	O	O
,	O	O
digoxin	B-chem	B-chem
has	O	O
undesirable	O	O
effects	O	O
such	O	O
as	O	O
increasing	O	O
peripheral	O	O
resistance	O	O
and	O	O
myocardial	O	O
demands	O	O
,	O	O
and	O	O
causing	O	O
arrhythmias	O	O
.	O	O

there	O	O
is	O	O
a	O	O
paucity	O	O
of	O	O
data	O	O
from	O	O
well	O	O
-	O	O
designed	O	O
trials	O	O
.	O	O

the	O	O
trials	O	O
that	O	O
are	O	O
available	O	O
are	O	O
generally	O	O
small	O	O
with	O	O
limitations	O	O
in	O	O
design	O	O
and	O	O
these	O	O
show	O	O
variation	O	O
in	O	O
patient	O	O
benefit	O	O
.	O	O

more	O	O
convincing	O	O
evidence	O	O
is	O	O
required	O	O
showing	O	O
that	O	O
digoxin	B-chem	B-chem
improves	O	O
symptoms	O	O
or	O	O
exercise	O	O
capacity	O	O
.	O	O

furthermore	O	O
,	O	O
no	O	O
trial	O	O
has	O	O
had	O	O
sufficient	O	O
power	O	O
to	O	O
evaluate	O	O
mortality	O	O
.	O	O

pooled	O	O
analysis	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
other	O	O
inotropic	O	O
drugs	O	O
shows	O	O
an	O	O
excess	O	O
mortality	O	O
and	O	O
there	O	O
is	O	O
a	O	O
possibility	O	O
that	O	O
digoxin	B-chem	B-chem
may	O	O
increase	O	O
mortality	O	O
after	O	O
myocardial	O	O
infarction	O	O
(	O	O
mi	O	O
)	O	O
.	O	O

angiotensin	B-chem	B-chem
-	O	I-chem
converting	O	O
enzyme	O	I-chem
(	O	O
ace	O	I-chem
)	O	I-chem
inhibitors	O	O
should	O	O
be	O	O
used	O	O
first	O	O
as	O	O
they	O	O
are	O	O
safer	O	O
,	O	O
do	O	O
not	O	O
require	O	O
blood	O	O
level	O	O
monitoring	O	O
,	O	O
modify	O	O
progression	O	O
of	O	O
disease	O	O
,	O	O
relieve	O	O
symptoms	O	O
,	O	O
improve	O	O
exercise	O	O
tolerance	O	O
and	O	O
reduce	O	O
mortality	O	O
.	O	O

caution	O	O
should	O	O
be	O	O
exercised	O	O
in	O	O
using	O	O
digoxin	B-chem	B-chem
until	O	O
large	O	O
mortality	O	O
trials	O	O
are	O	O
completed	O	O
showing	O	O
either	O	O
benefit	O	O
or	O	O
harm	O	O
.	O	O

until	O	O
then	O	O
digoxin	B-chem	B-chem
should	O	O
be	O	O
considered	O	O
a	O	O
third	O	O
-	O	O
line	O	O
therapy	O	O
.	O	O

intravascular	O	O
hemolysis	O	O
and	O	O
acute	O	O
renal	O	O
failure	O	O
following	O	O
intermittent	O	O
rifampin	B-chem	B-chem
therapy	O	O
.	O	O

renal	O	O
failure	O	O
is	O	O
a	O	O
rare	O	O
complication	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
rifampin	B-chem	B-chem
.	O	O

intravascular	O	O
hemolysis	O	O
leading	O	O
to	O	O
acute	O	O
renal	O	O
failure	O	O
following	O	O
rifampin	B-chem	B-chem
therapy	O	O
is	O	O
extremely	O	O
rare	O	O
.	O	O

two	O	O
patients	O	O
with	O	O
leprosy	O	O
who	O	O
developed	O	O
hemolysis	O	O
and	O	O
acute	O	O
renal	O	O
failure	O	O
following	O	O
rifampin	B-chem	B-chem
are	O	O
reported	O	O
.	O	O

zidovudine	B-chem	B-chem
-	O	O
induced	O	O
hepatitis	O	O
.	O	O

a	O	O
case	O	O
of	O	O
acute	O	O
hepatitis	O	O
induced	O	O
by	O	O
zidovudine	B-chem	B-chem
in	O	O
a	O	O
38	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
with	O	O
aids	O	O
is	O	O
presented	O	O
.	O	O

the	O	O
mechanism	O	O
whereby	O	O
the	O	O
hepatitis	O	O
was	O	O
induced	O	O
is	O	O
not	O	O
known	O	O
.	O	O

however	O	O
,	O	O
the	O	O
patient	O	O
tolerated	O	O
well	O	O
an	O	O
alternative	O	O
reverse	O	O
transcriptase	O	O
inhibitor	O	O
,	O	O
2	B-chem	O
'	I-chem	O
3	I-chem	I-chem
'	I-chem	O
dideoxyinosine	I-chem	B-chem
.	O	O

physicians	O	O
caring	O	O
for	O	O
patients	O	O
with	O	O
aids	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
hitherto	O	O
rarely	O	O
reported	O	O
complication	O	O
.	O	O

thoracic	O	O
hematomyelia	O	O
secondary	O	O
to	O	O
coumadin	B-chem	B-chem
anticoagulant	O	O
therapy	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

a	O	O
case	O	O
of	O	O
thoracic	O	O
hematomyelia	O	O
secondary	O	O
to	O	O
anticoagulant	O	O
therapy	O	O
is	O	O
presented	O	O
.	O	O

clinical	O	O
features	O	O
,	O	O
similar	O	O
to	O	O
2	O	O
other	O	O
previously	O	O
reported	O	O
cases	O	O
,	O	O
are	O	O
discussed	O	O
.	O	O

a	O	O
high	O	O
index	O	O
of	O	O
suspicion	O	O
may	O	O
lead	O	O
to	O	O
a	O	O
quick	O	O
diagnostic	O	O
procedure	O	O
and	O	O
successful	O	O
decompressive	O	O
surgery	O	O
.	O	O

mania	O	O
associated	O	O
with	O	O
fluoxetine	B-chem	B-chem
treatment	O	O
in	O	O
adolescents	O	O
.	O	O

fluoxetine	B-chem	B-chem
,	O	O
a	O	O
selective	O	I-chem
serotonin	B-chem	I-chem
reuptake	O	I-chem
inhibitor	O	I-chem
,	O	O
is	O	O
gaining	O	O
increased	O	O
acceptance	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
adolescent	O	O
depression	O	O
.	O	O

generally	O	O
safe	O	O
and	O	O
well	O	O
tolerated	O	O
by	O	O
adults	O	O
,	O	O
fluoxetine	B-chem	B-chem
has	O	O
been	O	O
reported	O	O
to	O	O
induce	O	O
mania	O	O
.	O	O

the	O	O
cases	O	O
of	O	O
five	O	O
depressed	O	O
adolescents	O	O
,	O	O
14	O	O
-	O	O
16	O	O
years	O	O
of	O	O
age	O	O
,	O	O
who	O	O
developed	O	O
mania	O	O
during	O	O
pharmacotherapy	O	O
with	O	O
fluoxetine	B-chem	B-chem
,	O	O
are	O	O
reported	O	O
here	O	O
.	O	O

apparent	O	O
risk	O	O
factors	O	O
for	O	O
the	O	O
development	O	O
of	O	O
mania	O	O
or	O	O
hypomania	O	O
during	O	O
fluoxetine	B-chem	B-chem
pharmacotherapy	O	O
in	O	O
this	O	O
population	O	O
were	O	O
the	O	O
combination	O	O
of	O	O
attention	O	O
-	O	O
deficit	O	O
hyperactivity	O	O
disorder	O	O
and	O	O
affective	O	O
instability	O	O
;	O	O
major	O	O
depression	O	O
with	O	O
psychotic	O	O
features	O	O
;	O	O
a	O	O
family	O	O
history	O	O
of	O	O
affective	O	O
disorder	O	O
,	O	O
especially	O	O
bipolar	O	O
disorder	O	O
;	O	O
and	O	O
a	O	O
diagnosis	O	O
of	O	O
bipolar	O	O
disorder	O	O
.	O	O

further	O	O
study	O	O
is	O	O
needed	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
dosage	O	O
and	O	O
to	O	O
identify	O	O
risk	O	O
factors	O	O
that	O	O
increase	O	O
individual	O	O
vulnerability	O	O
to	O	O
fluoxetine	B-chem	B-chem
induced	O	O
mania	O	O
in	O	O
adolescents	O	O
.	O	O

gemfibrozil	B-chem	B-chem
-	O	O
lovastatin	B-chem	B-chem
therapy	O	O
for	O	O
primary	O	O
hyperlipoproteinemias	O	O
.	O	O

the	O	O
specific	O	O
aim	O	O
of	O	O
this	O	O
retrospective	O	O
,	O	O
observational	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
long	O	O
-	O	O
term	O	O
(	O	O
21	O	O
months	O	O
/	O	O
patient	O	O
)	O	O
,	O	O
open	O	O
-	O	O
label	O	O
,	O	O
gemfibrozil	B-chem	B-chem
-	O	O
lovastatin	B-chem	B-chem
treatment	O	O
in	O	O
80	O	O
patients	O	O
with	O	O
primary	O	O
mixed	O	O
hyperlipidemia	O	O
(	O	O
68	O	O
%	O	O
of	O	O
whom	O	O
had	O	O
atherosclerotic	O	O
vascular	O	O
disease	O	O
)	O	O
.	O	O

because	O	O
ideal	O	O
lipid	O	O
targets	O	O
were	O	O
not	O	O
reached	O	O
(	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
ldl	O	O
)	O	O
cholesterol	B-chem	B-chem
less	O	O
than	O	O
130	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
high	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
hdl	O	O
)	O	O
cholesterol	B-chem	B-chem
greater	O	O
than	O	O
35	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
or	O	O
total	O	O
cholesterol	B-chem	B-chem
/	O	O
hdl	O	O
cholesterol	B-chem	O
less	O	O
than	O	O
4	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
with	O	O
diet	O	O
plus	O	O
a	O	O
single	O	O
drug	O	O
,	O	O
gemfibrozil	B-chem	B-chem
(	O	O
1	O	O
.	O	O
2	O	O
g	O	O
/	O	O
day	O	O
)	O	O
-	O	O
lovastatin	B-chem	B-chem
(	O	O
primarily	O	O
20	O	O
or	O	O
40	O	O
mg	O	O
)	O	O
treatment	O	O
was	O	O
given	O	O
.	O	O

follow	O	O
-	O	O
up	O	O
visits	O	O
were	O	O
scheduled	O	O
with	O	O
2	O	O
-	O	O
drug	O	O
therapy	O	O
every	O	O
6	O	O
to	O	O
8	O	O
weeks	O	O
,	O	O
an	O	O
average	O	O
of	O	O
10	O	O
.	O	O
3	O	O
visits	O	O
per	O	O
patient	O	O
,	O	O
with	O	O
741	O	O
batteries	O	O
of	O	O
6	O	O
liver	O	O
function	O	O
tests	O	O
and	O	O
714	O	O
creatine	B-chem	B-chem
phosphokinase	O	O
levels	O	O
measured	O	O
.	O	O

only	O	O
1	O	O
of	O	O
the	O	O
4	O	O
,	O	O
446	O	O
liver	O	O
function	O	O
tests	O	O
(	O	O
0	O	O
.	O	O
02	O	O
%	O	O
)	O	O
,	O	O
a	O	O
gamma	O	O
glutamyl	O	O
transferase	O	O
,	O	O
was	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
normal	O	O
limit	O	O
.	O	O

of	O	O
the	O	O
714	O	O
creatine	B-chem	B-chem
phosphokinase	O	O
levels	O	O
,	O	O
9	O	O
%	O	O
were	O	O
high	O	O
;	O	O
only	O	O
1	O	O
(	O	O
0	O	O
.	O	O
1	O	O
%	O	O
)	O	O
was	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
normal	O	O
limit	O	O
.	O	O

with	O	O
2	O	O
-	O	O
drug	O	O
therapy	O	O
,	O	O
mean	O	O
total	O	O
cholesterol	B-chem	B-chem
decreased	O	O
22	O	O
%	O	O
from	O	O
255	O	O
to	O	O
200	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
triglyceride	B-chem	B-chem
levels	O	O
decreased	O	O
35	O	O
%	O	O
from	O	O
236	O	O
to	O	O
154	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
ldl	O	O
cholesterol	B-chem	B-chem
decreased	O	O
26	O	O
%	O	O
from	O	O
176	O	O
to	O	O
131	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
and	O	O
the	O	O
total	O	O
cholesterol	B-chem	B-chem
/	O	O
hdl	O	O
cholesterol	B-chem	O
ratio	O	O
decreased	O	O
24	O	O
%	O	O
from	O	O
7	O	O
.	O	O
1	O	O
to	O	O
5	O	O
.	O	O
4	O	O
,	O	O
all	O	O
p	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
0	O	O
.	O	O
0001	O	O
.	O	O

myositis	O	O
,	O	O
attributable	O	O
to	O	O
the	O	O
drug	O	O
combination	O	O
and	O	O
symptomatic	O	O
enough	O	O
to	O	O
discontinue	O	O
it	O	O
,	O	O
occurred	O	O
in	O	O
3	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
and	O	O
in	O	O
1	O	O
%	O	O
with	O	O
concurrent	O	O
high	O	O
creatine	B-chem	B-chem
phosphokinase	O	O
(	O	O
769	O	O
u	O	O
/	O	O
liter	O	O
)	O	O
;	O	O
no	O	O
patients	O	O
had	O	O
rhabdomyolysis	O	O
or	O	O
myoglobinuria	O	O
.	O	O
(	O	O
abstract	O	O
truncated	O	O
at	O	O
250	O	O
words	O	O
)	O	O

hepatocellular	O	O
carcinoma	O	O
in	O	O
fanconi	O	O
'	O	O
s	O	O
anemia	O	O
treated	O	O
with	O	O
androgen	B-chem	O
and	O	O
corticosteroid	B-chem	O
.	O	O

the	O	O
case	O	O
of	O	O
an	O	O
11	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
is	O	O
reported	O	O
who	O	O
was	O	O
known	O	O
to	O	O
have	O	O
fanconi	O	O
'	O	O
s	O	O
anemia	O	O
for	O	O
3	O	O
years	O	O
and	O	O
was	O	O
treated	O	O
with	O	O
androgens	B-chem	O
,	O	O
corticosteroids	B-chem	O
and	O	O
transfusions	O	O
.	O	O

two	O	O
weeks	O	O
before	O	O
his	O	O
death	O	O
he	O	O
was	O	O
readmitted	O	O
because	O	O
of	O	O
aplastic	O	O
crisis	O	O
with	O	O
septicemia	O	O
and	O	O
marked	O	O
abnormalities	O	O
in	O	O
liver	O	O
function	O	O
and	O	O
died	O	O
of	O	O
hemorrhagic	O	O
bronchopneumonia	O	O
.	O	O

at	O	O
autopsy	O	O
peliosis	O	O
and	O	O
multiple	O	O
hepatic	O	O
tumors	O	O
were	O	O
found	O	O
which	O	O
histologically	O	O
proved	O	O
to	O	O
be	O	O
well	O	O
-	O	O
differentiated	O	O
hepatocellular	O	O
carcinoma	O	O
.	O	O

this	O	O
case	O	O
contributes	O	O
to	O	O
the	O	O
previous	O	O
observations	O	O
that	O	O
non	O	O
-	O	O
metastasizing	O	O
hepatic	O	O
neoplasms	O	O
and	O	O
peliosis	O	O
can	O	O
develop	O	O
in	O	O
patients	O	O
with	O	O
androgen	B-chem	O
-	O	O
and	O	O
corticosteroid	B-chem	O
-	O	O
treated	O	O
fanconi	O	O
'	O	O
s	O	O
anemia	O	O
.	O	O

chronic	O	O
lesion	O	O
of	O	O
rostral	O	O
ventrolateral	O	O
medulla	O	O
in	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
.	O	O

we	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
chronic	O	O
selective	O	O
neuronal	O	O
lesion	O	O
of	O	O
rostral	O	O
ventrolateral	O	O
medulla	O	O
on	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
neurogenic	O	O
tone	O	O
in	O	O
conscious	O	O
,	O	O
unrestrained	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
.	O	O

the	O	O
lesions	O	O
were	O	O
placed	O	O
via	O	O
bilateral	O	O
microinjections	O	O
of	O	O
30	O	O
nmol	O	O
/	O	O
200	O	O
nl	O	O
n	B-chem	B-chem
-	I-chem	I-chem
methyl	I-chem	I-chem
-	I-chem	I-chem
d	I-chem	I-chem
-	I-chem	I-chem
aspartic	I-chem	I-chem
acid	I-chem	I-chem
.	O	O

the	O	O
restimulation	O	O
of	O	O
this	O	O
area	O	O
with	O	O
n	B-chem	B-chem
-	I-chem	I-chem
methyl	I-chem	I-chem
-	I-chem	I-chem
d	I-chem	I-chem
-	I-chem	I-chem
aspartic	I-chem	I-chem
acid	I-chem	I-chem
15	O	O
days	O	O
postlesion	O	O
failed	O	O
to	O	O
produce	O	O
a	O	O
pressor	O	O
response	O	O
.	O	O

one	O	O
day	O	O
postlesion	O	O
,	O	O
the	O	O
resting	O	O
mean	O	O
arterial	O	O
pressure	O	O
was	O	O
significantly	O	O
decreased	O	O
in	O	O
lesioned	O	O
rats	O	O
when	O	O
compared	O	O
with	O	O
sham	O	O
rats	O	O
(	O	O
100	O	O
+	O	O
/	O	O
-	O	O
7	O	O
versus	O	O
173	O	O
+	O	O
/	O	O
-	O	O

4	O	O
mm	O	O
hg	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

fifteen	O	O
days	O	O
later	O	O
,	O	O
the	O	O
lesioned	O	O
group	O	O
still	O	O
showed	O	O
values	O	O
significantly	O	O
lower	O	O
than	O	O
the	O	O
sham	O	O
group	O	O
(	O	O
150	O	O
+	O	O
/	O	O
-	O	O

6	O	O
versus	O	O
167	O	O
+	O	O
/	O	O
-	O	O

5	O	O
mm	O	O
hg	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

no	O	O
significant	O	O
heart	O	O
rate	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
sham	O	O
and	O	O
lesioned	O	O
groups	O	O
.	O	O

the	O	O
ganglionic	O	O
blocker	O	O
trimethaphan	B-chem	B-chem
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
v	O	O
.	O	O
)	O	O

caused	O	O
similar	O	O
reductions	O	O
in	O	O
mean	O	O
arterial	O	O
pressure	O	O
in	O	O
both	O	O
lesioned	O	O
and	O	O
sham	O	O
groups	O	O
.	O	O

the	O	O
trimethaphan	B-chem	B-chem
-	O	O
induced	O	O
hypotension	O	O
was	O	O
accompanied	O	O
by	O	O
a	O	O
significant	O	O
bradycardia	O	O
in	O	O
lesioned	O	O
rats	O	O
(	O	O
-	O	O
32	O	O
+	O	O
/	O	O
-	O	O

13	O	O
beats	O	O
per	O	O
minute	O	O
)	O	O
but	O	O
a	O	O
tachycardia	O	O
in	O	O
sham	O	O
rats	O	O
(	O	O
+	O	O
33	O	O
+	O	O
/	O	O
-	O	O

12	O	O
beats	O	O
per	O	O
minute	O	O
)	O	O
1	O	O
day	O	O
postlesion	O	O
.	O	O

therefore	O	O
,	O	O
rostral	O	O
ventrolateral	O	O
medulla	O	O
neurons	O	O
appear	O	O
to	O	O
play	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
maintaining	O	O
hypertension	O	O
in	O	O
conscious	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
.	O	O

spinal	O	O
or	O	O
suprabulbar	O	O
structures	O	O
could	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
gradual	O	O
recovery	O	O
of	O	O
the	O	O
hypertension	O	O
in	O	O
the	O	O
lesioned	O	O
rats	O	O
.	O	O

damage	O	O
of	O	O
substantia	O	O
nigra	O	O
pars	O	O
reticulata	O	O
during	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
status	O	O
epilepticus	O	O
in	O	O
the	O	O
rat	O	O
:	O	O
immunohistochemical	O	O
study	O	O
of	O	O
neurons	O	O
,	O	O
astrocytes	O	O
and	O	O
serum	O	O
-	O	O
protein	O	O
extravasation	O	O
.	O	O

the	O	O
substantia	O	O
nigra	O	O
has	O	O
a	O	O
gating	O	O
function	O	O
controlling	O	O
the	O	O
spread	O	O
of	O	O
epileptic	O	O
seizure	O	O
activity	O	O
.	O	O

additionally	O	O
,	O	O
in	O	O
models	O	O
of	O	O
prolonged	O	O
status	O	O
epilepticus	O	O
the	O	O
pars	O	O
reticulata	O	O
of	O	O
substantia	O	O
nigra	O	O
(	O	O
snr	O	O
)	O	O
suffers	O	O
from	O	O
a	O	O
massive	O	O
lesion	O	O
which	O	O
may	O	O
arise	O	O
from	O	O
a	O	O
massive	O	O
metabolic	O	O
derangement	O	O
and	O	O
hyperexcitation	O	O
developing	O	O
in	O	O
the	O	O
activated	O	O
snr	O	O
.	O	O

in	O	O
this	O	O
study	O	O
,	O	O
status	O	O
epilepticus	O	O
was	O	O
induced	O	O
by	O	O
systemic	O	O
injection	O	O
of	O	O
pilocarpine	B-chem	B-chem
in	O	O
rats	O	O
.	O	O

the	O	O
neuropathology	O	O
of	O	O
snr	O	B-chem
was	O	O
investigated	O	O
using	O	O
immunohistochemical	O	O
techniques	O	O
with	O	O
the	O	O
major	O	O
emphasis	O	O
on	O	O
the	O	O
time	O	O
-	O	O
course	O	O
of	O	O
changes	O	O
in	O	O
neurons	O	O
and	O	O
astrocytes	O	O
.	O	O

animals	O	O
surviving	O	O
20	O	O
,	O	O
30	O	O
,	O	O
40	O	O
,	O	O
60	O	O
min	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
6	O	O
hours	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
3	O	O
days	O	O
after	O	O
induction	O	O
of	O	O
status	O	O
epilepticus	O	O
were	O	O
perfusion	O	O
-	O	O
fixed	O	O
,	O	O
and	O	O
brains	O	O
processed	O	O
for	O	O
immunohistochemical	O	O
staining	O	O
of	O	O
snr	O	O
.	O	O

nissl	O	B-chem
-	O	O
staining	O	O
and	O	O
antibodies	O	O
against	O	O
the	O	O
neuron	O	O
-	O	O
specific	O	O
calcium	B-chem	B-chem
-	O	O
binding	O	O
protein	O	O
,	O	O
parvalbumin	O	O
,	O	O
served	O	O
to	O	O
detect	O	O
neuronal	O	O
damage	O	O
in	O	O
snr	O	O
.	O	O

antibodies	O	O
against	O	O
the	O	O
astroglia	O	O
-	O	O
specific	O	O
cytoskeletal	O	O
protein	O	O
,	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
(	O	O
gfap	O	O
)	O	O
,	O	O
and	O	O
against	O	O
the	O	O
glial	O	O
calcium	B-chem	B-chem
-	O	O
binding	O	O
protein	O	O
,	O	O
s	O	O
-	O	O
100	O	O
protein	O	O
,	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
status	O	O
of	O	O
astrocytes	O	O
.	O	O

immunohistochemical	O	O
staining	O	O
for	O	O
serum	O	O
-	O	O
albumin	O	O
and	O	O
immunoglobulins	O	O
in	O	O
brain	O	O
tissue	O	O
was	O	O
taken	O	O
as	O	O
indicator	O	O
of	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
disturbances	O	O
and	O	O
vasogenic	O	O
edema	O	O
formation	O	O
.	O	O

immunohistochemical	O	O
staining	O	O
indicated	O	O
loss	O	O
of	O	O
gfap	O	O
-	O	O
staining	O	O
already	O	O
at	O	O
30	O	O
min	O	O
after	O	O
induction	O	O
of	O	O
seizures	O	O
in	O	O
an	O	O
oval	O	O
focus	O	O
situated	O	O
in	O	O
the	O	O
center	O	O
of	O	O
snr	O	O
while	O	O
sparing	O	O
medial	O	O
and	O	O
lateral	O	O
aspects	O	O
.	O	O

at	O	O
1	O	O
h	O	O
there	O	O
was	O	O
additional	O	O
vacuolation	O	O
in	O	O
s	O	O
-	O	O
100	O	O
protein	O	O
staining	O	O
.	O	O

by	O	O
2	O	O
hours	O	O
,	O	O
parvalbumin	O	O
-	O	O
staining	O	O
changed	O	O
in	O	O
the	O	O
central	O	O
snr	O	O
indicating	O	O
neuronal	O	O
damage	O	O
,	O	O
and	O	O
nissl	O	O
-	O	O
staining	O	O
visualized	O	O
some	O	O
neuronal	O	O
distortion	O	O
.	O	O

staining	O	O
for	O	O
serum	O	O
-	O	O
proteins	O	O
occurred	O	O
in	O	O
a	O	O
patchy	O	O
manner	O	O
throughout	O	O
the	O	O
forebrain	O	O
during	O	O
the	O	O
first	O	O
hours	O	O
.	O	O

by	O	O
6	O	O
h	O	O
,	O	O
vasogenic	O	O
edema	O	O
covered	O	O
the	O	O
lesioned	O	O
snr	O	O
.	O	O

by	O	O
24	O	O
h	O	O
,	O	O
glial	O	O
and	O	O
neuronal	O	O
markers	O	O
indicated	O	O
a	O	O
massive	O	O
lesion	O	O
in	O	O
the	O	O
center	O	O
of	O	O
snr	O	O
.	O	O

by	O	O
48	O	O
-	O	O
72	O	O
h	O	O
,	O	O
astrocytes	O	O
surrounding	O	O
the	O	O
lesion	O	O
increased	O	O
in	O	O
size	O	O
,	O	O
and	O	O
polymorphic	O	O
phagocytotic	O	O
cells	O	O
invaded	O	O
the	O	O
damaged	O	O
area	O	O
.	O	O

in	O	O
a	O	O
further	O	O
group	O	O
of	O	O
animals	O	O
surviving	O	O
1	O	O
to	O	O
5	O	O
days	O	O
,	O	O
conventional	O	O
paraffin	O	B-chem
-	O	O
sections	O	O
confirmed	O	O
the	O	O
neuronal	O	O
and	O	O
glial	O	O
damage	O	O
of	O	O
snr	O	O
.	O	O

additional	O	O
pathology	O	O
of	O	O
similar	O	O
quality	O	O
was	O	O
found	O	O
in	O	O
the	O	O
globus	O	O
pallidus	O	O
.	O	O

since	O	O
astrocytes	O	O
were	O	O
always	O	O
damaged	O	O
in	O	O
parallel	O	O
with	O	O
neurons	O	O
in	O	O
snr	O	O
it	O	O
is	O	O
proposed	O	O
that	O	O
the	O	O
anatomical	O	O
and	O	O
functional	O	O
interrelationship	O	O
between	O	O
neurons	O	O
and	O	O
astrocytes	O	O
is	O	O
particularly	O	O
tight	O	O
in	O	O
snr	O	O
.	O	O

both	O	O
cell	O	O
elements	O	O
may	O	O
suffer	O	O
in	O	O
common	O	O
from	O	O
metabolic	O	O
disturbance	O	O
and	O	O
neurotransmitter	O	O
dysfunction	O	O
as	O	O
occur	O	O
during	O	O
massive	O	O
status	O	O
epilepticus	O	O
.	O	O

reduced	O	O
cardiotoxicity	O	O
of	O	O
doxorubicin	B-chem	B-chem
given	O	O
in	O	O
the	O	O
form	O	O
of	O	O
n	B-chem	B-chem
-	I-chem	I-chem
(	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
hydroxypropyl	I-chem	I-chem
)	I-chem	O
methacrylamide	I-chem	I-chem
conjugates	O	O
:	O	O
and	O	O
experimental	O	O
study	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

a	O	O
rat	O	O
model	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
general	O	O
acute	O	O
toxicity	O	O
and	O	O
the	O	O
late	O	O
cardiotoxicity	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
doxorubicin	B-chem	B-chem
(	O	O
dox	B-chem	B-chem
)	O	O
given	O	O
either	O	O
as	O	O
free	O	O
drug	O	O
or	O	O
in	O	O
the	O	O
form	O	O
of	O	O
three	O	B-chem
n	B-chem	I-chem
-	I-chem	I-chem
(	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
hydroxypropyl	I-chem	I-chem
)	I-chem	O
methacrylamide	I-chem	I-chem
(	O	O
hpma	B-chem	B-chem
)	O	O
copolymer	O	O
conjugates	O	O
.	O	O

in	O	O
these	O	O
hpma	B-chem	O
copolymers	O	O
,	O	O
dox	B-chem	B-chem
was	O	O
covalently	O	O
bound	O	O
via	O	O
peptide	O	O
linkages	O	O
that	O	O
were	O	O
either	O	O
non	O	O
-	O	O
biodegradable	O	O
(	O	O
gly	O	B-chem
-	O	I-chem
gly	O	I-chem
)	O	O
or	O	O
degradable	O	B-chem
by	O	O
lysosomal	O	B-chem
proteinases	O	O
(	O	O
gly	B-chem	B-chem
-	I-chem	I-chem
phe	I-chem	I-chem
-	I-chem	I-chem
leu	I-chem	I-chem
-	I-chem	I-chem
gly	I-chem	I-chem
)	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
one	O	O
biodegradable	O	O
conjugate	O	O
containing	O	O
galactosamine	B-chem	B-chem
was	O	O
used	O	O
;	O	O
this	O	O
residue	O	O
was	O	O
targeted	O	O
to	O	O
the	O	O
liver	O	O
.	O	O

over	O	O
the	O	O
first	O	O
3	O	O
weeks	O	O
after	O	O
the	O	O
i	O	O
.	O	O
v	O	O
.	O	O

administration	O	O
of	O	O
free	O	O
and	O	O
polymer	O	B-chem
-	O	O
bound	O	O
dox	B-chem	B-chem
,	O	O
all	O	O
animals	O	O
showed	O	O
a	O	O
transient	O	O
reduction	O	O
in	O	O
body	O	O
weight	O	O
.	O	O

however	O	O
,	O	O
the	O	O
maximal	O	O
reduction	O	O
in	O	O
body	O	O
weight	O	O
seen	O	O
in	O	O
animals	O	O
that	O	O
received	O	O
polymer	O	B-chem
-	O	O
bound	O	O
dox	B-chem	B-chem
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
than	O	O
that	O	O
observed	O	O
in	O	O
those	O	O
that	O	O
received	O	O
free	O	O
dox	B-chem	B-chem
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
a	O	O
mixture	O	O
of	O	O
the	O	O
unmodified	O	O
parent	O	O
hpma	B-chem	O
copolymer	O	O
and	O	O
free	O	O
dox	B-chem	B-chem
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

throughout	O	O
the	O	O
study	O	O
(	O	O
20	O	O
weeks	O	O
)	O	O
,	O	O
deaths	O	O
related	O	O
to	O	O
cardiotoxicity	O	O
were	O	O
observed	O	O
only	O	O
in	O	O
animals	O	O
that	O	O
received	O	O
either	O	O
free	O	O
dox	B-chem	B-chem
or	O	O
the	O	O
mixture	O	O
of	O	O
hpma	B-chem	B-chem
copolymer	O	O
and	O	O
free	O	O
dox	B-chem	B-chem
;	O	O
in	O	O
these	O	O
cases	O	O
,	O	O
histological	O	O
investigations	O	O
revealed	O	O
marked	O	O
changes	O	O
in	O	O
the	O	O
heart	O	O
that	O	O
were	O	O
consistent	O	O
with	O	O
dox	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
.	O	O

sequential	O	O
measurements	O	O
of	O	O
cardiac	O	O
output	O	O
in	O	O
surviving	O	O
animals	O	O
that	O	O
received	O	O
either	O	O
free	O	O
dox	B-chem	B-chem
or	O	O
the	O	O
mixture	O	O
of	O	O
hpma	B-chem	B-chem
copolymer	O	O
and	O	O
free	O	O
dox	B-chem	B-chem
showed	O	O
a	O	O
reduction	O	O
of	O	O
approximately	O	O
30	O	O
%	O	O
in	O	O
function	O	O
beginning	O	O
at	O	O
the	O	O
4th	O	O
week	O	O
after	O	O
drug	O	O
administration	O	O
.	O	O

the	O	O
heart	O	O
rate	O	O
in	O	O
these	O	O
animals	O	O
was	O	O
approximately	O	O
12	O	O
%	O	O
lower	O	O
than	O	O
that	O	O
measured	O	O
in	O	O
age	O	O
-	O	O
matched	O	O
control	O	O
rats	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

animals	O	O
that	O	O
were	O	O
given	O	O
the	O	O
hpma	B-chem	O
copolymer	O	O
conjugates	O	O
containing	O	O
dox	B-chem	B-chem
exhibited	O	O
no	O	O
significant	O	O
change	O	O
in	O	O
cardiac	O	O
output	O	O
throughout	O	O
the	O	O
study	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
no	O	O
significant	O	O
histological	O	O
change	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
heart	O	O
of	O	O
animals	O	O
that	O	O
received	O	O
dox	B-chem	B-chem
in	O	O
the	O	O
form	O	O
of	O	O
hpma	B-chem	B-chem
copolymer	O	O
conjugates	O	O
and	O	O
were	O	O
killed	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
study	O	O
.	O	O

however	O	O
,	O	O
these	O	O
animals	O	O
had	O	O
shown	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
beginning	O	O
at	O	O
8	O	O
weeks	O	O
after	O	O
drug	O	O
administration	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O
(	O	O
abstract	O	O

truncated	O	O
at	O	O
400	O	O
words	O	O
)	O	O

topical	O	O
0	O	O
.	O	O
025	O	O
%	O	O
capsaicin	B-chem	B-chem
in	O	O
chronic	O	O
post	O	O
-	O	O
herpetic	O	O
neuralgia	O	O
:	O	O
efficacy	O	O
,	O	O
predictors	O	O
of	O	O
response	O	O
and	O	O
long	O	O
-	O	O
term	O	O
course	O	O
.	O	O

in	O	O
order	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
,	O	O
time	O	O
-	O	O
course	O	O
of	O	O
action	O	O
and	O	O
predictors	O	O
of	O	O
response	O	O
to	O	O
topical	O	O
capsaicin	B-chem	B-chem
,	O	O
39	O	O
patients	O	O
with	O	O
chronic	O	O
post	O	O
-	O	O
herpetic	O	O
neuralgia	O	O
(	O	O
phn	O	O
)	O	O
,	O	O
median	O	O
duration	O	O
24	O	O
months	O	O
,	O	O
were	O	O
treated	O	O
with	O	O
0	O	O
.	O	O
025	O	O
%	O	O
capsaicin	B-chem	B-chem
cream	O	O
for	O	O
8	O	O
weeks	O	O
.	O	O

during	O	O
therapy	O	O
the	O	O
patients	O	O
rated	O	O
their	O	O
pain	O	O
on	O	O
a	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
vas	O	O
)	O	O
and	O	O
a	O	O
verbal	O	O
outcome	O	O
scale	O	O
.	O	O

a	O	O
follow	O	O
-	O	O
up	O	O
investigation	O	O
was	O	O
performed	O	O
10	O	O
-	O	O
12	O	O
months	O	O
after	O	O
study	O	O
onset	O	O
on	O	O
the	O	O
patients	O	O
who	O	O
had	O	O
improved	O	O
.	O	O

nineteen	O	O
patients	O	O
(	O	O
48	O	O
.	O	O
7	O	O
%	O	O
)	O	O
substantially	O	O
improved	O	O
after	O	O
the	O	O
8	O	O
-	O	O
week	O	O
trial	O	O
;	O	O
5	O	O
(	O	O
12	O	O
.	O	O
8	O	O
%	O	O
)	O	O
discontinued	O	O
therapy	O	O
due	O	O
to	O	O
side	O	O
-	O	O
effects	O	O
such	O	O
as	O	O
intolerable	O	O
capsaicin	B-chem	B-chem
-	O	O
induced	O	O
burning	O	O
sensations	O	O
(	O	O
4	O	O
)	O	O
or	O	O
mastitis	O	O
(	O	O
1	O	O
)	O	O
;	O	O
15	O	O
(	O	O
38	O	O
.	O	O
5	O	O
%	O	O
)	O	O
reported	O	O
no	O	O
benefit	O	O
.	O	O

the	O	O
decrease	O	O
in	O	O
vas	O	O
ratings	O	O
was	O	O
significant	O	O
after	O	O
2	O	O
weeks	O	O
of	O	O
continuous	O	O
application	O	O
.	O	O

of	O	O
the	O	O
responders	O	O
72	O	O
.	O	O
2	O	O
%	O	O
were	O	O
still	O	O
improved	O	O
at	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
;	O	O
only	O	O
one	O	O
-	O	O
third	O	O
of	O	O
them	O	O
had	O	O
continued	O	O
application	O	O
irregularly	O	O
.	O	O

treatment	O	O
effect	O	O
was	O	O
not	O	O
dependent	O	O
on	O	O
patient	O	O
'	O	O
s	O	O
age	O	O
,	O	O
duration	O	O
or	O	O
localization	O	O
of	O	O
phn	O	B-chem
(	O	O
trigeminal	O	O
involvement	O	O
was	O	O
excluded	O	O
)	O	O
,	O	O
sensory	O	O
disturbance	O	O
or	O	O
pain	O	O
character	O	O
.	O	O

treatment	O	O
response	O	O
was	O	O
not	O	O
correlated	O	O
with	O	O
the	O	O
incidence	O	O
,	O	O
time	O	O
-	O	O
course	O	O
or	O	O
severity	O	O
of	O	O
capsaicin	B-chem	B-chem
-	O	O
induced	O	O
burning	O	O
.	O	O

if	O	O
confirmed	O	O
in	O	O
controlled	O	O
trials	O	O
,	O	O
the	O	O
long	O	O
-	O	O
term	O	O
results	O	O
of	O	O
this	O	O
open	O	O
,	O	O
non	O	O
-	O	O
randomized	O	O
study	O	O
might	O	O
indicate	O	O
that	O	O
the	O	O
analgesic	O	O
effect	O	O
of	O	O
capsaicin	B-chem	B-chem
in	O	O
phn	O	B-chem
is	O	O
mediated	O	O
by	O	O
both	O	O
interference	O	O
with	O	O
neuropeptide	O	B-chem
metabolism	O	O
and	O	O
morphological	O	O
changes	O	O
(	O	O
perhaps	O	O
degeneration	O	O
)	O	O
of	O	O
nociceptive	O	O
afferents	O	O
.	O	O

serotonin	B-chem	B-chem
reuptake	O	I-chem
inhibitors	O	O
,	O	O
paranoia	O	B-chem
,	O	O
and	O	O
the	O	O
ventral	O	O
basal	O	O
ganglia	O	O
.	O	O

antidepressants	O	B-chem
have	O	O
previously	O	O
been	O	O
associated	O	O
with	O	O
paranoid	O	O
reactions	O	O
in	O	O
psychiatric	O	O
patients	O	O
.	O	O

five	O	O
cases	O	O
of	O	O
paranoid	O	O
exacerbation	O	O
with	O	O
the	O	O
serotonin	B-chem	B-chem
reuptake	O	I-chem
inhibitors	O	O
fluoxetine	B-chem	B-chem
and	O	O
amitriptyline	B-chem	B-chem
are	O	O
reported	O	O
here	O	O
.	O	O

elements	O	O
common	O	O
to	O	O
these	O	O
cases	O	O
included	O	O
a	O	O
history	O	O
of	O	O
paranoid	O	O
symptomatology	O	O
and	O	O
the	O	O
concomitant	O	O
occurrence	O	O
of	O	O
depressive	O	O
and	O	O
psychotic	O	O
symptoms	O	O
.	O	O

complicated	O	O
depressive	O	O
disorders	O	O
(	O	O
including	O	O
atypicality	O	O
of	O	O
course	O	O
and	O	O
symptomatology	O	O
,	O	O
chronicity	O	O
,	O	O
psychosis	O	O
,	O	O
bipolarity	O	O
,	O	O
and	O	O
secondary	O	O
onset	O	O
in	O	O
the	O	O
course	O	O
of	O	O
a	O	O
primary	O	O
psychosis	O	O
)	O	O
may	O	O
present	O	O
particular	O	O
vulnerability	O	O
to	O	O
paranoid	O	O
exacerbations	O	O
associated	O	O
with	O	O
serotonin	B-chem	B-chem
reuptake	O	I-chem
inhibitors	O	O
.	O	O

although	O	O
the	O	O
pharmacology	O	O
and	O	O
neurobiology	O	O
of	O	O
paranoia	O	B-chem
remain	O	O
cryptic	O	O
,	O	O
several	O	O
mechanisms	O	O
,	O	O
including	O	O
5ht3	O	O
receptor	O	O
-	O	O
mediated	O	O
dopamine	B-chem	B-chem
release	O	O
,	O	O
beta	O	O
-	O	O
noradrenergic	O	O
receptor	O	O
downregulation	O	O
,	O	O
or	O	O
gabab	O	B-chem
receptor	O	O
upregulation	O	O
acting	O	O
in	O	O
the	O	O
vicinity	O	O
of	O	O
the	O	O
ventral	O	O
basal	O	O
ganglia	O	O
(	O	O
possibly	O	O
in	O	O
lateral	O	O
orbitofrontal	O	O
or	O	O
anterior	O	O
cingulate	O	O
circuits	O	O
)	O	O
,	O	O
might	O	O
apply	O	O
to	O	O
this	O	O
phenomenon	O	O
.	O	O

these	O	O
cases	O	O
call	O	O
attention	O	O
to	O	O
possible	O	O
paranoid	O	O
exacerbations	O	O
with	O	O
serotonin	B-chem	B-chem
reuptake	O	O
blockers	O	O
in	O	O
select	O	O
patients	O	O
and	O	O
raise	O	O
neurobiological	O	O
considerations	O	O
regarding	O	O
paranoia	O	O
.	O	O

five	O	O
cases	O	O
of	O	O
encephalitis	O	O
during	O	O
treatment	O	O
of	O	O
loiasis	O	O
with	O	O
diethylcarbamazine	B-chem	B-chem
.	O	O

five	O	O
cases	O	O
of	O	O
encephalitis	O	O
following	O	O
treatment	O	O
with	O	O
diethylcarbamazine	B-chem	B-chem

(	O	O
dec	B-chem	B-chem
)	O	O
were	O	O
observed	O	O
in	O	O
congolese	O	O
patients	O	O
with	O	O
loa	O	O
loa	O	O
filariasis	O	O
.	O	O

two	O	O
cases	O	O
had	O	O
a	O	O
fatal	O	O
outcome	O	O
and	O	O
one	O	O
resulted	O	O
in	O	O
severe	O	O
sequelae	O	O
.	O	O

the	O	O
notable	O	O
fact	O	O
was	O	O
that	O	O
this	O	O
complication	O	O
occurred	O	O
in	O	O
three	O	O
patients	O	O
hospitalized	O	O
before	O	O
treatment	O	O
began	O	O
,	O	O
with	O	O
whom	O	O
particularly	O	O
strict	O	O
therapeutic	O	O
precautions	O	O
were	O	O
taken	O	O
,	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
initial	O	O
dose	O	O
less	O	O
than	O	O
10	O	O
mg	O	O
of	O	O
dec	B-chem	B-chem
,	O	O
very	O	O
gradual	O	O
dose	O	O
increases	O	O
,	O	O
and	O	O
associated	O	O
anti	O	O
-	O	O
allergic	O	O
treatment	O	O
.	O	O

this	O	O
type	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
complication	O	O
may	O	O
not	O	O
be	O	O
that	O	O
uncommon	O	O
in	O	O
highly	O	O
endemic	O	O
regions	O	O
.	O	O

it	O	O
occurs	O	O
primarily	O	O
,	O	O
but	O	O
not	O	O
exclusively	O	O
,	O	O
in	O	O
subjects	O	O
presenting	O	O
with	O	O
a	O	O
high	O	O
microfilarial	O	O
load	O	O
.	O	O

the	O	O
relationship	O	O
between	O	O
the	O	O
occurrence	O	O
of	O	O
encephalitis	O	O
and	O	O
the	O	O
decrease	O	O
in	O	O
microfilaremia	O	O
is	O	O
evident	O	O
.	O	O

the	O	O
pathophysiological	O	O
mechanisms	O	O
are	O	O
discussed	O	O
in	O	O
the	O	O
light	O	O
of	O	O
these	O	O
observations	O	O
and	O	O
the	O	O
few	O	O
other	O	O
comments	O	O
on	O	O
this	O	O
subject	O	O
published	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

delirium	O	O
in	O	O
an	O	O
elderly	O	O
woman	O	O
possibly	O	O
associated	O	O
with	O	O
administration	O	O
of	O	O
misoprostol	B-chem	B-chem
.	O	O

misoprostol	B-chem	B-chem
has	O	O
been	O	O
associated	O	O
with	O	O
adverse	O	O
reactions	O	O
,	O	O
including	O	O
gastrointestinal	O	O
symptoms	O	O
,	O	O
gynecologic	O	O
problems	O	O
,	O	O
and	O	O
headache	O	O
.	O	O

changes	O	O
in	O	O
mental	O	O
status	O	O
,	O	O
however	O	O
,	O	O
have	O	O
not	O	O
been	O	O
reported	O	O
.	O	O

we	O	O
present	O	O
a	O	O
case	O	O
in	O	O
which	O	O
an	O	O
89	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
in	O	O
a	O	O
long	O	O
-	O	O
term	O	O
care	O	O
facility	O	O
became	O	O
confused	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
misoprostol	B-chem	B-chem
therapy	O	O
.	O	O

the	O	O
patient	O	O
'	O	O
s	O	O
change	O	O
in	O	O
mental	O	O
status	O	O
was	O	O
first	O	O
reported	O	O
nine	O	O
days	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
therapy	O	O
.	O	O

her	O	O
delirium	O	O
significantly	O	O
improved	O	O
after	O	O
misoprostol	B-chem	B-chem
was	O	O
discontinued	O	O
and	O	O
her	O	O
mental	O	O
status	O	O
returned	O	O
to	O	O
normal	O	O
within	O	O
a	O	O
week	O	O
.	O	O

because	O	O
no	O	O
other	O	O
factors	O	O
related	O	O
to	O	O
this	O	O
patient	O	O
changed	O	O
significantly	O	O
,	O	O
the	O	O
delirium	O	O
experienced	O	O
by	O	O
this	O	O
patient	O	O
possibly	O	O
resulted	O	O
from	O	O
misoprostol	B-chem	B-chem
therapy	O	O
.	O	O

hepatocellular	O	O
oxidant	O	O
stress	O	O
following	O	O
intestinal	O	O
ischemia	O	O
-	O	O
reperfusion	O	O
injury	O	O
.	O	O

reperfusion	O	O
of	O	O
ischemic	O	O
intestine	O	O
results	O	O
in	O	O
acute	O	O
liver	O	O
dysfunction	O	O
characterized	O	O
by	O	O
hepatocellular	O	O
enzyme	O	O
release	O	O
into	O	O
plasma	O	O
,	O	O
reduction	O	O
in	O	O
bile	O	O
flow	O	O
rate	O	O
,	O	O
and	O	O
neutrophil	O	O
sequestration	O	O
within	O	O
the	O	O
liver	O	O
.	O	O

the	O	O
pathophysiology	O	O
underlying	O	O
this	O	O
acute	O	O
hepatic	O	O
injury	O	O
is	O	O
unknown	O	O
.	O	O

this	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
whether	O	O
oxidants	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
hepatic	O	O
injury	O	O
and	O	O
to	O	O
determine	O	O
the	O	O
relative	O	O
value	O	O
of	O	O
several	O	O
indirect	O	O
methods	O	O
of	O	O
assessing	O	O
oxidant	O	O
exposure	O	O
in	O	O
vivo	O	O
.	O	O

rats	O	O
were	O	O
subjected	O	O
to	O	O
a	O	O
standardized	O	O
intestinal	O	O
ischemia	O	O
-	O	O
reperfusion	O	O
injury	O	O
.	O	O

hepatic	O	O
tissue	O	O
was	O	O
assayed	O	O
for	O	O
lipid	O	O
peroxidation	O	O
products	O	O
and	O	O
oxidized	B-chem	O
and	I-chem	O
reduced	I-chem	O
glutathione	I-chem	B-chem
.	O	O

there	O	O
was	O	O
no	O	O
change	O	O
in	O	O
hepatic	O	O
tissue	O	O
total	O	O
glutathione	B-chem	B-chem
following	O	O
intestinal	O	O
ischemia	O	O
-	O	O
reperfusion	O	O
injury	O	O
.	O	O

oxidized	B-chem	B-chem
glutathione	I-chem	I-chem
(	O	O
gssg	B-chem	B-chem
)	O	O
increased	O	O
significantly	O	O
following	O	O
30	O	O
and	O	O
60	O	O
min	O	O
of	O	O
reperfusion	O	O
.	O	O

there	O	O
was	O	O
no	O	O
increase	O	O
in	O	O
any	O	O
of	O	O
the	O	O
products	O	O
of	O	O
lipid	O	O
peroxidation	O	O
associated	O	O
with	O	O
this	O	O
injury	O	O
.	O	O

an	O	O
increase	O	O
in	O	O
gssg	B-chem	B-chem
within	O	O
hepatic	O	O
tissue	O	O
during	O	O
intestinal	O	O
reperfusion	O	O
suggests	O	O
exposure	O	O
of	O	O
hepatocytes	O	O
to	O	O
an	O	O
oxidant	O	O
stress	O	O
.	O	O

the	O	O
lack	O	O
of	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
products	O	O
of	O	O
lipid	O	O
peroxidation	O	O
suggests	O	O
that	O	O
the	O	O
oxidant	O	O
stress	O	O
is	O	O
of	O	O
insufficient	O	O
magnitude	O	O
to	O	O
result	O	O
in	O	O
irreversible	O	O
injury	O	O
to	O	O
hepatocyte	O	O
cell	O	O
membranes	O	O
.	O	O

these	O	O
data	O	O
also	O	O
suggest	O	O
that	O	O
the	O	O
measurement	O	O
of	O	O
tissue	O	O
gssg	B-chem	B-chem
may	O	O
be	O	O
a	O	O
more	O	O
sensitive	O	O
indicator	O	O
of	O	O
oxidant	O	O
stress	O	O
than	O	O
measurement	O	O
of	O	O
products	O	O
of	O	O
lipid	O	O
peroxidation	O	O
.	O	O

diphenhydramine	B-chem	B-chem
prevents	O	O
the	O	O
haemodynamic	O	O
changes	O	O
of	O	O
cimetidine	B-chem	B-chem
in	O	O
icu	O	O
patients	O	O
.	O	O

cimetidine	B-chem	B-chem
,	O	O
a	O	O
histamine	B-chem	B-chem
2	O	O
(	O	O
h2	O	O
)	O	O
antagonist	O	O
,	O	O
produces	O	O
a	O	O
decrease	O	O
in	O	O
arterial	O	O
pressure	O	O
due	O	O
to	O	O
vasodilatation	O	O
,	O	O
especially	O	O
in	O	O
critically	O	O
ill	O	O
patients	O	O
.	O	O

this	O	O
may	O	O
be	O	O
because	O	O
cimetidine	B-chem	B-chem
acts	O	O
as	O	O
a	O	O
histamine	B-chem	B-chem
agonist	O	O
.	O	O

we	O	O
,	O	O
therefore	O	O
,	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
histamine	B-chem	B-chem
1	O	I-chem
(	O	O
h1	O	B-chem
)	O	I-chem
receptor	O	O
antagonist	O	O
,	O	O
diphenhydramine	B-chem	B-chem
,	O	O
on	O	O
the	O	O
haemodynamic	O	O
changes	O	O
observed	O	O
after	O	O
cimetidine	B-chem	B-chem
in	O	O
icu	O	O
patients	O	O
.	O	O

each	O	O
patient	O	O
was	O	O
studied	O	O
on	O	O
two	O	O
separate	O	O
days	O	O
.	O	O

in	O	O
a	O	O
random	O	O
fashion	O	O
,	O	O
they	O	O
received	O	O
cimetidine	B-chem	B-chem
200	O	O
mg	O	O
iv	O	O
on	O	O
one	O	O
day	O	O
,	O	O
and	O	O
on	O	O
the	O	O
other	O	O
,	O	O
a	O	O
pretreatment	O	O
of	O	O
diphenhydramine	B-chem	B-chem
40	O	O
mg	O	O
iv	O	O
with	O	O
cimetidine	B-chem	B-chem
200	O	O
mg	O	O
iv	O	O
.	O	O

in	O	O
the	O	O
non	O	O
-	O	O
pretreatment	O	O
group	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
map	O	O
)	O	O
decreased	O	O
from	O	O
107	O	O
.	O	O
4	O	O
+	O	O
/	O	O
-	O	O

8	O	O
.	O	O
4	O	O
mmhg	O	O
to	O	O
86	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

11	O	O
.	O	O
4	O	O
mmhg	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
two	O	O
minutes	O	O
after	O	O
cimetidine	B-chem	B-chem
.	O	O

also	O	O
,	O	O
systemic	O	O
vascular	O	O
resistance	O	O
(	O	O
svr	O	O
)	O	O
decreased	O	O
during	O	O
the	O	O
eight	O	O
-	O	O
minute	O	O
observation	O	O
period	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

in	O	O
contrast	O	O
,	O	O
in	O	O
the	O	O
pretreatment	O	O
group	O	O
,	O	O
little	O	O
haemodynamic	O	O
change	O	O
was	O	O
seen	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
an	O	O
h1	O	B-chem
antagonist	O	O
may	O	O
be	O	O
useful	O	O
in	O	O
preventing	O	O
hypotension	O	O
caused	O	O
by	O	O
iv	O	O
cimetidine	B-chem	B-chem
,	O	O
since	O	O
the	O	O
vasodilating	O	O
activity	O	O
of	O	O
cimetidine	B-chem	B-chem
is	O	O
mediated	O	O
,	O	O
in	O	O
part	O	O
,	O	O
through	O	O
the	O	O
h1	O	B-chem
receptor	O	O
.	O	O

acute	O	O
renal	O	O
failure	O	O
due	O	O
to	O	O
rifampicin	B-chem	B-chem
.	O	O

a	O	O
23	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
with	O	O
bacteriologically	O	O
proven	O	O
pulmonary	O	O
tuberculosis	O	O
was	O	O
treated	O	O
with	O	O
the	O	O
various	O	O
regimens	O	O
of	O	O
antituberculosis	O	O
drugs	O	O
for	O	O
nearly	O	O
15	O	O
months	O	O
.	O	O

rifampicin	B-chem	B-chem
was	O	O
administered	O	O
thrice	O	O
as	O	O
one	O	O
of	O	O
the	O	O
3	O	O
-	O	O
4	O	O
drug	O	O
regimen	O	O
and	O	O
each	O	O
time	O	O
he	O	O
developed	O	O
untoward	O	O
side	O	O
effects	O	O
like	O	O
nausea	O	O
,	O	O
vomiting	O	O
and	O	O
fever	O	O
with	O	O
chills	O	O
and	O	O
rigors	O	O
.	O	O

the	O	O
last	O	O
such	O	O
episode	O	O
was	O	O
of	O	O
acute	O	O
renal	O	O
failure	O	O
at	O	O
which	O	O
stage	O	O
the	O	O
patient	O	O
was	O	O
seen	O	O
by	O	O
the	O	O
authors	O	O
of	O	O
this	O	O
report	O	O
.	O	O

the	O	O
patient	O	O
,	O	O
however	O	O
,	O	O
made	O	O
a	O	O
full	O	O
recovery	O	O
.	O	O

severe	O	O
polyneuropathy	O	O
and	O	O
motor	O	O
loss	O	O
after	O	O
intrathecal	O	O
thiotepa	B-chem	B-chem
combination	O	O
chemotherapy	O	O
:	O	O
description	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

two	O	O
cases	O	O
of	O	O
severe	O	O
delayed	O	O
neurologic	O	O
toxicity	O	O
related	O	O
to	O	O
the	O	O
administration	O	O
of	O	O
intrathecal	O	O
(	O	O
it	O	O
)	O	O
combination	O	O
chemotherapy	O	O
including	O	O
thiotepa	B-chem	B-chem
(	O	O
tspa	B-chem	B-chem
)	O	O
are	O	O
presented	O	O
.	O	O

both	O	O
cases	O	O
developed	O	O
axonal	O	O
neuropathy	O	O
with	O	O
motor	O	O
predominance	O	O
in	O	O
the	O	O
lower	O	O
extremities	O	O
1	O	O
and	O	O
6	O	O
months	O	O
after	O	O
it	O	O
chemotherapy	O	O
was	O	O
administered	O	O
.	O	O

neurologic	O	O
toxicities	O	O
have	O	O
been	O	O
described	O	O
with	O	O
it	O	O
-	O	O
methotrexate	B-chem	B-chem
,	O	O
it	O	O
-	O	O
cytosine	B-chem	B-chem
arabinoside	I-chem	I-chem
and	O	O
it	O	O
-	O	O
tspa	B-chem	B-chem
.	O	O

to	O	O
our	O	O
knowledge	O	O
,	O	O
however	O	O
,	O	O
axonal	O	O
neuropathy	O	O
following	O	O
administration	O	O
of	O	O
these	O	O
three	O	O
agents	O	O
has	O	O
not	O	O
been	O	O
previously	O	O
described	O	O
.	O	O

in	O	O
spite	O	O
of	O	O
the	O	O
fact	O	O
that	O	O
tspa	B-chem	B-chem
is	O	O
a	O	O
useful	O	O
it	O	O
agent	O	O
,	O	O
its	O	O
combination	O	O
with	O	O
mtx	B-chem	B-chem
,	O	O
ara	B-chem	B-chem
-	I-chem	O
c	I-chem	O
and	O	O
radiotherapy	O	O
could	O	O
cause	O	O
severe	O	O
neurotoxicity	O	O
.	O	O

this	O	O
unexpected	O	O
complication	O	O
indicates	O	O
the	O	O
need	O	O
for	O	O
further	O	O
toxicology	O	O
research	O	O
on	O	O
it	O	O
-	O	O
tspa	B-chem	B-chem
.	O	O

effects	O	O
of	O	O
cromakalim	B-chem	B-chem
and	O	O
pinacidil	B-chem	B-chem
on	O	O
large	O	O
epicardial	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
in	O	O
conscious	O	O
dogs	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
i	O	O
.	O	O
v	O	O
.	O	O

bolus	O	O
administration	O	O
of	O	O
cromakalim	B-chem	B-chem
(	O	O
1	O	O
-	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
pinacidil	B-chem	B-chem
(	O	O
3	O	O
-	O	O
100	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
on	O	O
large	O	O
(	O	O
circumflex	O	O
artery	O	O
)	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
and	O	O
on	O	O
systemic	O	O
hemodynamics	O	O
were	O	O
investigated	O	O
in	O	O
chronically	O	O
instrumented	O	O
conscious	O	O
dogs	O	O
and	O	O
compared	O	O
to	O	O
those	O	O
of	O	O
nitroglycerin	B-chem	B-chem
(	O	O
0	O	O
.	O	O
03	O	O
-	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

nitroglycerin	B-chem	B-chem
,	O	O
up	O	O
to	O	O
0	O	O
.	O	O
3	O	O
micrograms	O	O
/	O	O
kg	O	O
,	O	O
selectively	O	O
increased	O	O
circumflex	O	O
artery	O	O
diameter	O	O
(	O	O
cxad	O	O
)	O	O
without	O	O
simultaneously	O	O
affecting	O	O
any	O	O
other	O	O
cardiac	O	O
or	O	O
systemic	O	O
hemodynamic	O	O
parameter	O	O
.	O	O

in	O	O
contrast	O	O
,	O	O
cromakalim	B-chem	B-chem
and	O	O
pinacidil	B-chem	B-chem
at	O	O
all	O	O
doses	O	O
and	O	O
nitroglycerin	B-chem	B-chem
at	O	O
doses	O	O
higher	O	O
than	O	O
0	O	O
.	O	O
3	O	O
micrograms	O	O
/	O	O
kg	O	O
simultaneously	O	O
and	O	O
dose	O	O
-	O	O
dependently	O	O
increased	O	O
cxad	O	O
,	O	O
coronary	O	O
blood	O	O
flow	O	O
and	O	O
heart	O	O
rate	O	O
and	O	O
decreased	O	O
coronary	O	O
vascular	O	O
resistance	O	O
and	O	O
aortic	O	O
pressure	O	O
.	O	O

cromakalim	B-chem	B-chem
was	O	O
approximately	O	O

8	O	O
-	O	O

to	O	O
9	O	O
.	O	O
5	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
pinacidil	B-chem	B-chem
in	O	O
increasing	O	O
cxad	O	O
.	O	O

vasodilation	O	O
of	O	O
large	O	O
and	O	O
small	O	O
coronary	O	O
vessels	O	O
and	O	O
hypotension	O	O
induced	O	O
by	O	O
cromakalim	B-chem	B-chem
and	O	O
pinacidil	B-chem	B-chem
were	O	O
not	O	O
affected	O	O
by	O	O
prior	O	O
combined	O	O
beta	B-chem	O
adrenergic	I-chem	O
and	I-chem	O
muscarinic	I-chem	O
receptors	I-chem	O
blockade	I-chem	O
but	O	O
drug	O	O
-	O	O
induced	O	O
tachycardia	O	O
was	O	O
abolished	O	O
.	O	O

when	O	O
circumflex	O	O
artery	O	O
blood	O	O
flow	O	O
was	O	O
maintained	O	O
constant	O	O
,	O	O
the	O	O
increases	O	O
in	O	O
cxad	O	O
induced	O	O
by	O	O
cromakalim	B-chem	B-chem
(	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
pinacidil	B-chem	B-chem
(	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
nitroglycerin	B-chem	B-chem
(	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
were	O	O
reduced	O	O
by	O	O
68	O	O
+	O	O
/	O	O
-	O	O

7	O	O
,	O	O
54	O	O
+	O	O
/	O	O
-	O	O

9	O	O
and	O	O
1	O	O
+	O	O
/	O	O
-	O	O

1	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

thus	O	O
,	O	O
whereas	O	O
nitroglycerin	B-chem	B-chem
preferentially	O	O
and	O	O
flow	O	O
-	O	O
independently	O	O
dilates	O	O
large	O	O
coronary	O	O
arteries	O	O
,	O	O
cromakalim	B-chem	B-chem
and	O	O
pinacidil	B-chem	B-chem
dilate	O	O
both	O	O
large	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
and	O	O
this	O	O
effect	O	O
is	O	O
not	O	O
dependent	O	O
upon	O	O
the	O	O
simultaneous	O	O
beta	O	O
adrenoceptors	O	O
-	O	O
mediated	O	O
rise	O	O
in	O	O
myocardial	O	O
metabolic	O	O
demand	O	O
.	O	O

finally	O	O
,	O	O
two	O	O
mechanisms	O	O
at	O	O
least	O	O
,	O	O
direct	O	O
vasodilation	O	O
and	O	O
flow	O	O
dependency	O	O
,	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
cromakalim	B-chem	B-chem
-	O	O
and	O	O
pinacidil	B-chem	B-chem
-	O	O
induced	O	O
increase	O	O
in	O	O
cxad	O	O
.	O	O

mefenamic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
neutropenia	O	O
and	O	O
renal	O	O
failure	O	O
in	O	O
elderly	O	O
females	O	O
with	O	O
hypothyroidism	O	O
.	O	O

we	O	O
report	O	O
mefenamic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
non	O	O
-	O	O
oliguric	O	O
renal	O	O
failure	O	O
and	O	O
severe	O	O
neutropenia	O	O
occurring	O	O
simultaneously	O	O
in	O	O
two	O	O
elderly	O	O
females	O	O
.	O	O

the	O	O
neutropenia	O	O
was	O	O
due	O	O
to	O	O
maturation	O	O
arrest	O	O
of	O	O
the	O	O
myeloid	O	O
series	O	O
in	O	O
one	O	O
patient	O	O
.	O	O

both	O	O
patients	O	O
were	O	O
also	O	O
hypothyroid	O	O
,	O	O
but	O	O
it	O	O
is	O	O
not	O	O
clear	O	O
whether	O	O
this	O	O
was	O	O
a	O	O
predisposing	O	O
factor	O	O
to	O	O
the	O	O
development	O	O
of	O	O
these	O	O
adverse	O	O
reactions	O	O
.	O	O

however	O	O
,	O	O
it	O	O
would	O	O
seem	O	O
prudent	O	O
not	O	O
to	O	O
use	O	O
mefenamic	B-chem	B-chem
acid	I-chem	I-chem
in	O	O
hypothyroid	O	O
patients	O	O
until	O	O
the	O	O
hypothyroidism	O	O
has	O	O
been	O	O
corrected	O	O
.	O	O

etiology	O	O
of	O	O
hypercalcemia	O	O
in	O	O
hemodialysis	O	O
patients	O	O
on	O	O
calcium	B-chem	B-chem
carbonate	I-chem	I-chem
therapy	O	O
.	O	O

fourteen	O	O
of	O	O
39	O	O
dialysis	O	O
patients	O	O
(	O	O
36	O	O
%	O	O
)	O	O
became	O	O
hypercalcemic	O	O
after	O	O
switching	O	O
to	O	O
calcium	B-chem	B-chem
carbonate	I-chem	I-chem
as	O	O
their	O	O
principal	O	O
phosphate	B-chem	B-chem
binder	O	O
.	O	O

in	O	O
order	O	O
to	O	O
identify	O	O
risk	O	O
factors	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
hypercalcemia	O	O
,	O	O
indirect	O	O
parameters	O	O
of	O	O
intestinal	O	O
calcium	B-chem	B-chem
reabsorption	O	O
and	O	O
bone	O	O
turnover	O	O
rate	O	O
in	O	O
these	O	O
14	O	O
patients	O	O
were	O	O
compared	O	O
with	O	O
results	O	O
in	O	O
14	O	O
eucalcemic	O	O
patients	O	O
matched	O	O
for	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
length	O	O
of	O	O
time	O	O
on	O	O
dialysis	O	O
,	O	O
and	O	O
etiology	O	O
of	O	O
renal	O	O
disease	O	O
.	O	O

in	O	O
addition	O	O
to	O	O
experiencing	O	O
hypercalcemic	O	O
episodes	O	O
with	O	O
peak	O	O
calcium	B-chem	B-chem
values	O	O
of	O	O
2	O	O
.	O	O
7	O	O
to	O	O
3	O	O
.	O	O
8	O	O
mmol	O	O
/	O	O
l	O	O
(	O	O
10	O	O
.	O	O
7	O	O
to	O	O
15	O	O
.	O	O
0	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
,	O	O
patients	O	O
in	O	O
the	O	O
hypercalcemic	O	O
group	O	O
exhibited	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
mean	O	O
calcium	B-chem	B-chem
concentration	O	O
obtained	O	O
during	O	O
6	O	O
months	O	O
before	O	O
the	O	O
switch	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
mean	O	O
value	O	O
obtained	O	O
during	O	O
the	O	O
7	O	O
months	O	O
of	O	O
observation	O	O
after	O	O
the	O	O
switch	O	O
(	O	O
2	O	O
.	O	O
4	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
03	O	O
to	O	O
2	O	O
.	O	O
5	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
03	O	O
mmol	O	O
/	O	O
l	O	O
[	O	O
9	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
2	O	O
to	O	O
10	O	O
.	O	O
2	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
1	O	O
mg	O	O
/	O	O
dl	O	O
]	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
006	O	O
)	O	O
.	O	O

in	O	O
contrast	O	O
,	O	O
eucalcemic	O	O
patients	O	O
exhibited	O	O
no	O	O
change	O	O
in	O	O
mean	O	O
calcium	B-chem	B-chem
values	O	O
over	O	O
the	O	O
same	O	O
time	O	O
period	O	O
(	O	O
2	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
05	O	O
to	O	O
2	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
05	O	O
mmol	O	O
/	O	O
l	O	O
[	O	O
9	O	O
.	O	O
2	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
2	O	O
to	O	O
9	O	O
.	O	O
2	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
2	O	O
mg	O	O
/	O	O
dl	O	O
]	O	O
)	O	O
.	O	O

caco3	B-chem	B-chem
dosage	O	O
,	O	O
calculated	O	O
dietary	O	O
calcium	B-chem	B-chem
intake	O	O
,	O	O
and	O	O
circulating	O	O
levels	O	O
of	O	O
vitamin	B-chem	B-chem
d	I-chem	I-chem
metabolites	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

physical	O	O
activity	O	O
index	O	O
and	O	O
predialysis	O	O
serum	O	O
bicarbonate	B-chem	B-chem
levels	O	O
also	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

however	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
parameters	O	O
reflecting	O	O
bone	O	O
turnover	O	O
rates	O	O
between	O	O
groups	O	O
.	O	O
(	O	O
abstract	O	O
truncated	O	O
at	O	O
250	O	O
words	O	O
)	O	O

methyldopa	B-chem	B-chem
-	O	O
induced	O	O
hemolytic	O	O
anemia	O	O
in	O	O
a	O	O
15	O	O
year	O	O
old	O	O
presenting	O	O
as	O	O
near	O	O
-	O	O
syncope	O	O
.	O	O

methyldopa	B-chem	B-chem
is	O	O
an	O	O
antihypertensive	O	O
medication	O	O
which	O	O
is	O	O
available	O	O
generically	O	O
and	O	O
under	O	O
the	O	O
trade	O	O
name	O	O
aldomet	B-chem	B-chem
that	O	O
is	O	O
widely	O	O
prescribed	O	O
in	O	O
the	O	O
adult	O	O
population	O	O
and	O	O
infrequently	O	O
used	O	O
in	O	O
children	O	O
.	O	O

methyldopa	B-chem	B-chem
causes	O	O
an	O	O
autoimmune	O	O
hemolytic	O	O
anemia	O	O
in	O	O
a	O	O
small	O	O
percentage	O	O
of	O	O
patients	O	O
who	O	O
take	O	O
the	O	O
drug	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
methyldopa	B-chem	B-chem
-	O	O
induced	O	O
hemolytic	O	O
anemia	O	O
in	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
who	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
with	O	O
near	O	O
-	O	O
syncope	O	O
.	O	O

the	O	O
boy	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
intravenous	O	O
methyldopa	B-chem	B-chem
during	O	O
a	O	O
trauma	O	O
admission	O	O
seven	O	O
weeks	O	O
prior	O	O
to	O	O
presentation	O	O
.	O	O

evaluation	O	O
revealed	O	O
a	O	O
hemoglobin	O	O
of	O	O
three	O	O
grams	O	O
,	O	O
3	O	O
+	O	O
coombs	O	O
'	O	O
test	O	O
with	O	O
polyspecific	O	O
anti	O	O
-	O	O
human	O	O
globulin	O	O
and	O	O
monospecific	O	O
igg	O	O
reagents	O	O
,	O	O
and	O	O
a	O	O
warm	O	O
reacting	O	O
autoantibody	O	O
.	O	O

transfusion	O	O
and	O	O
corticosteroid	B-chem	O
therapy	O	O
resulted	O	O
in	O	O
a	O	O
complete	O	O
recovery	O	O
of	O	O
the	O	O
patient	O	O
.	O	O

emergency	O	O
physicians	O	O
treating	O	O
children	O	O
must	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
syndrome	O	O
in	O	O
order	O	O
to	O	O
diagnose	O	O
and	O	O
treat	O	O
it	O	O
correctly	O	O
.	O	O

a	O	O
brief	O	O
review	O	O
of	O	O
autoimmune	O	O
and	O	O
drug	O	O
-	O	O
induced	O	O
hemolytic	O	O
anemias	O	O
is	O	O
provided	O	O
.	O	O

the	O	O
long	O	O
-	O	O
term	O	O
safety	O	O
of	O	O
danazol	B-chem	B-chem
in	O	O
women	O	O
with	O	O
hereditary	O	O
angioedema	O	O
.	O	O

although	O	O
the	O	O
short	O	O
-	O	O
term	O	O
safety	O	O
(	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
6	O	O
months	O	O
)	O	O
of	O	O
danazol	B-chem	B-chem
has	O	O
been	O	O
established	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
settings	O	O
,	O	O
no	O	O
information	O	O
exists	O	O
as	O	O
to	O	O
its	O	O
long	O	O
-	O	O
term	O	O
safety	O	O
.	O	O

we	O	O
therefore	O	O
investigated	O	O
the	O	O
long	O	O
-	O	O
term	O	O
safety	O	O
of	O	O
danazol	B-chem	B-chem
by	O	O
performing	O	O
a	O	O
retrospective	O	O
chart	O	O
review	O	O
of	O	O
60	O	O
female	O	O
patients	O	O
with	O	O
hereditary	O	O
angioedema	O	O
treated	O	O
with	O	O
danazol	B-chem	B-chem
for	O	O
a	O	O
continuous	O	O
period	O	O
of	O	O
6	O	O
months	O	O
or	O	O
longer	O	O
.	O	O

the	O	O
mean	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
35	O	O
.	O	O
2	O	O
years	O	O
and	O	O
the	O	O
mean	O	O
duration	O	O
of	O	O
therapy	O	O
was	O	O
59	O	O
.	O	O
7	O	O
months	O	O
.	O	O

virtually	O	O
all	O	O
patients	O	O
experienced	O	O
one	O	O
or	O	O
more	O	O
adverse	O	O
reactions	O	O
.	O	O

menstrual	O	O
abnormalities	O	O
(	O	O
79	O	O
%	O	O
)	O	O
,	O	O
weight	O	O
gain	O	O
(	O	O
60	O	O
%	O	O
)	O	O
,	O	O
muscle	O	O
cramps	O	O
/	O	O
myalgias	O	O
(	O	O
40	O	O
%	O	O
)	O	O
,	O	O
and	O	O
transaminase	O	O
elevations	O	O
(	O	O
40	O	O
%	O	O
)	O	O
were	O	O
the	O	O
most	O	O
common	O	O
adverse	O	O
reactions	O	O
.	O	O

the	O	O
drug	O	O
was	O	O
discontinued	O	O
due	O	O
to	O	O
adverse	O	O
reactions	O	O
in	O	O
8	O	O
patients	O	O
.	O	O

no	O	O
patient	O	O
has	O	O
died	O	O
or	O	O
suffered	O	O
any	O	O
apparent	O	O
long	O	O
-	O	O
term	O	O
sequelae	O	O
that	O	O
were	O	O
directly	O	O
attributable	O	O
to	O	O
the	O	O
drug	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
,	O	O
despite	O	O
a	O	O
relatively	O	O
high	O	O
incidence	O	O
of	O	O
adverse	O	O
reactions	O	O
,	O	O
danazol	B-chem	B-chem
has	O	O
proven	O	O
to	O	O
be	O	O
remarkably	O	O
safe	O	O
over	O	O
the	O	O
long	O	O
-	O	O
term	O	O
in	O	O
this	O	O
group	O	O
of	O	O
patients	O	O
.	O	O

patient	O	O
tolerance	O	O
study	O	O
of	O	O
topical	O	O
chlorhexidine	B-chem	B-chem
diphosphanilate	I-chem	I-chem
:	O	O
a	O	O
new	O	O
topical	O	O
agent	O	O
for	O	O
burns	O	O
.	O	O

effective	O	O
topical	O	O
antimicrobial	O	O
agents	O	O
decrease	O	O
infection	O	O
and	O	O
mortality	O	O
in	O	O
burn	O	O
patients	O	O
.	O	O

chlorhexidine	B-chem	B-chem
phosphanilate	I-chem	I-chem
(	O	O
chp	B-chem	O
)	O	O
,	O	O
a	O	O
new	O	O
broad	O	O
-	O	O
spectrum	O	O
antimicrobial	O	O
agent	O	O
,	O	O
has	O	O
been	O	O
evaluated	O	O
as	O	O
a	O	O
topical	O	O
burn	O	O
wound	O	O
dressing	O	O
in	O	O
cream	O	O
form	O	O
,	O	O
but	O	O
preliminary	O	O
clinical	O	O
trials	O	O
reported	O	O
that	O	O
it	O	O
was	O	O
painful	O	O
upon	O	O
application	O	O
.	O	O

this	O	O
study	O	O
compared	O	O
various	O	O
concentrations	O	O
of	O	O
chp	B-chem	O
to	O	O
determine	O	O
if	O	O
a	O	O
tolerable	O	O
concentration	O	O
could	O	O
be	O	O
identified	O	O
with	O	O
retention	O	O
of	O	O
antimicrobial	O	O
efficacy	O	O
.	O	O

twenty	O	O
-	O	O
nine	O	O
burn	O	O
patients	O	O
,	O	O
each	O	O
with	O	O
two	O	O
similar	O	O
burns	O	O
which	O	O
could	O	O
be	O	O
separately	O	O
treated	O	O
,	O	O
were	O	O
given	O	O
pairs	O	O
of	O	O
treatments	O	O
at	O	O
successive	O	O
12	O	O
-	O	O
h	O	O
intervals	O	O
over	O	O
a	O	O
3	O	O
-	O	O
day	O	O
period	O	O
.	O	O

one	O	O
burn	O	O
site	O	O
was	O	O
treated	O	O
with	O	O
each	O	O
of	O	O
four	O	O
different	O	O
chp	B-chem	O
concentrations	O	O
,	O	O
from	O	O
0	O	O
.	O	O
25	O	O
per	O	O
cent	O	O
to	O	O
2	O	O
per	O	O
cent	O	O
,	O	O
their	O	O
vehicle	O	O
,	O	O
and	O	O
1	O	O
per	O	O
cent	O	O
silver	B-chem	B-chem
sulphadiazine	I-chem	I-chem
(	O	O
agsd	B-chem	B-chem
)	O	O
cream	O	O
,	O	O
an	O	O
antimicrobial	O	O
agent	O	O
frequently	O	O
used	O	O
for	O	O
topical	O	O
treatment	O	O
of	O	O
burn	O	O
wounds	O	O
.	O	O

the	O	O
other	O	O
site	O	O
was	O	O
always	O	O
treated	O	O
with	O	O
agsd	B-chem	B-chem
cream	O	O
.	O	O

there	O	O
was	O	O
a	O	O
direct	O	O
relationship	O	O
between	O	O
chp	B-chem	O
concentration	O	O
and	O	O
patients	O	O
'	O	O
ratings	O	O
of	O	O
pain	O	O
on	O	O
an	O	O
analogue	O	O
scale	O	O
.	O	O

the	O	O
0	O	O
.	O	O
25	O	O
per	O	O
cent	O	O
chp	B-chem	O
cream	O	O
was	O	O
closest	O	O
to	O	O
agsd	B-chem	O
in	O	O
pain	O	O
tolerance	O	O
;	O	O
however	O	O
,	O	O
none	O	O
of	O	O
the	O	O
treatments	O	O
differed	O	O
statistically	O	O
from	O	O
agsd	B-chem	O
or	O	O
from	O	O
each	O	O
other	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
ease	O	O
of	O	O
application	O	O
of	O	O
chp	B-chem	O
creams	O	O
was	O	O
less	O	O
satisfactory	O	O
than	O	O
that	O	O
of	O	O
agsd	B-chem	O
.	O	O

it	O	O
was	O	O
concluded	O	O
that	O	O
formulations	O	O
at	O	O
or	O	O
below	O	O
0	O	O
.	O	O
5	O	O
per	O	O
cent	O	O
chp	B-chem	O
may	O	O
prove	O	O
acceptable	O	O
for	O	O
wound	O	O
care	O	O
,	O	O
but	O	O
the	O	O
vehicle	O	O
system	O	O
needs	O	O
pharmaceutical	O	O
improvement	O	O
to	O	O
render	O	O
it	O	O
more	O	O
tolerable	O	O
and	O	O
easier	O	O
to	O	O
use	O	O
.	O	O

dose	O	O
-	O	O
dependent	O	O
neurotoxicity	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
busulfan	B-chem	B-chem
in	O	O
children	O	O
:	O	O
a	O	O
clinical	O	O
and	O	O
pharmacological	O	O
study	O	O
.	O	O

busulfan	B-chem	B-chem
is	O	O
known	O	O
to	O	O
be	O	O
neurotoxic	O	O
in	O	O
animals	O	O
and	O	O
humans	O	O
,	O	O
but	O	O
its	O	O
acute	O	O
neurotoxicity	O	O
remains	O	O
poorly	O	O
characterized	O	O
in	O	O
children	O	O
.	O	O

we	O	O
report	O	O
here	O	O
a	O	O
retrospective	O	O
study	O	O
of	O	O
123	O	O
children	O	O
(	O	O
median	O	O
age	O	O
,	O	O
6	O	O
.	O	O
5	O	O
years	O	O
)	O	O
receiving	O	O
high	O	O
-	O	O
dose	O	O
busulfan	B-chem	B-chem
in	O	O
combined	O	O
chemotherapy	O	O
before	O	O
bone	O	O
marrow	O	O
transplantation	O	O
for	O	O
malignant	O	O
solid	O	O
tumors	O	O
,	O	O
brain	O	O
tumors	O	O
excluded	O	O
.	O	O

busulfan	B-chem	B-chem
was	O	O
given	O	O
p	O	O
.	O	O
o	O	O
.	O	O
,	O	O
every	O	O
6	O	O
hours	O	O
for	O	O
16	O	O
doses	O	O
over	O	O
4	O	O
days	O	O
.	O	O

two	O	O
total	O	O
doses	O	O
were	O	O
consecutively	O	O
used	O	O
:	O	O
16	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
then	O	O
600	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

the	O	O
dose	O	O
calculation	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
body	O	O
surface	O	O
area	O	O
results	O	O
in	O	O
higher	O	O
doses	O	O
in	O	O
young	O	O
children	O	O
than	O	O
in	O	O
older	O	O
patients	O	O
(	O	O
16	O	O
to	O	O
28	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

ninety	O	O
-	O	O
six	O	O
patients	O	O
were	O	O
not	O	O
given	O	O
anticonvulsive	O	O
prophylaxis	O	O
;	O	O
7	O	O
(	O	O
7	O	O
.	O	O
5	O	O
%	O	O
)	O	O
developed	O	O
seizures	O	O
during	O	O
the	O	O
4	O	O
days	O	O
of	O	O
the	O	O
busulfan	B-chem	B-chem
course	O	O
or	O	O
within	O	O
24	O	O
h	O	O
after	O	O
the	O	O
last	O	O
dosing	O	O
.	O	O

when	O	O
the	O	O
total	O	O
busulfan	B-chem	B-chem
dose	O	O
was	O	O
taken	O	O
into	O	O
account	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
terms	O	O
of	O	O
neurotoxicity	O	O
incidence	O	O
among	O	O
patients	O	O
under	O	O
16	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
1	O	O
of	O	O
57	O	O
,	O	O
1	O	O
.	O	O
7	O	O
%	O	O
)	O	O
and	O	O
patients	O	O
under	O	O
600	O	O
mg	O	O
/	O	O
m2	O	O
(	O	O
6	O	O
of	O	O
39	O	O
,	O	O
15	O	O
.	O	O
4	O	O
%	O	O
)	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
02	O	O
)	O	O
.	O	O

twenty	O	O
-	O	O
seven	O	O
patients	O	O
were	O	O
given	O	O
a	O	O
600	O	O
-	O	O
mg	O	O
/	O	O
m2	O	O
busulfan	B-chem	B-chem
total	O	O
dose	O	O
with	O	O
continuous	O	O
i	O	O
.	O	O
v	O	O
.	O	O

infusion	O	O
of	O	O
clonazepam	B-chem	B-chem
;	O	O
none	O	O
had	O	O
any	O	O
neurological	O	O
symptoms	O	O
.	O	O

busulfan	B-chem	B-chem
levels	O	O
were	O	O
measured	O	O
by	O	O
a	O	O
gas	O	O
chromatographic	O	O
-	O	O
mass	O	O
spectrometry	O	O
assay	O	O
in	O	O
the	O	O
plasma	O	O
and	O	O
cerebrospinal	O	O
fluid	O	O
of	O	O
9	O	O
children	O	O
without	O	O
central	O	O
nervous	O	O
system	O	O
disease	O	O
under	O	O
600	O	O
mg	O	O
/	O	O
m2	O	O
busulfan	B-chem	B-chem
with	O	O
clonazepam	B-chem	B-chem
:	O	O
busulfan	B-chem	B-chem
cerebrospinal	O	O
fluid	O	O
:	O	O
plasma	O	O
ratio	O	O
was	O	O
1	O	O
.	O	O
39	O	O
.	O	O

this	O	O
was	O	O
significantly	O	O
different	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
02	O	O
)	O	O
from	O	O
the	O	O
cerebrospinal	O	O
fluid	O	O
:	O	O
plasma	O	O
ratio	O	O
previously	O	O
defined	O	O
in	O	O
children	O	O
receiving	O	O
a	O	O
16	O	O
-	O	O
mg	O	O
/	O	O
kg	O	O
total	O	O
dose	O	O
of	O	O
busulfan	B-chem	B-chem
.	O	O

this	O	O
study	O	O
shows	O	O
that	O	O
busulfan	B-chem	B-chem
neurotoxicity	O	O
is	O	O
dose	O	O
-	O	O
dependent	O	O
in	O	O
children	O	O
and	O	O
efficiently	O	O
prevented	O	O
by	O	O
clonazepam	B-chem	B-chem
.	O	O

a	O	O
busulfan	B-chem	B-chem
dose	O	O
calculated	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
resulting	O	O
in	O	O
higher	O	O
doses	O	O
in	O	O
young	O	O
children	O	O
,	O	O
was	O	O
followed	O	O
by	O	O
increased	O	O
neurotoxicity	O	O
,	O	O
close	O	O
to	O	O
neurotoxicity	O	O
incidence	O	O
observed	O	O
in	O	O
adults	O	O
.	O	O

since	O	O
plasma	O	O
pharmacokinetic	O	O
studies	O	O
showed	O	O
a	O	O
faster	O	O
busulfan	B-chem	B-chem
clearance	O	O
in	O	O
children	O	O
than	O	O
in	O	O
adults	O	O
,	O	O
this	O	O
new	O	O
dose	O	O
may	O	O
approximate	O	O
more	O	O
closely	O	O
the	O	O
adult	O	O
systemic	O	O
exposure	O	O
obtained	O	O
after	O	O
the	O	O
usual	O	O
16	O	O
-	O	O
mg	O	O
/	O	O
kg	O	O
total	O	O
dose	O	O
,	O	O
with	O	O
potential	O	O
inferences	O	O
in	O	O
terms	O	O
of	O	O
anticancer	O	O
or	O	O
myeloablative	O	O
effects	O	O
.	O	O

the	O	O
busulfan	B-chem	B-chem
dose	O	O
in	O	O
children	O	O
and	O	O
infants	O	O
undergoing	O	O
bone	O	O
marrow	O	O
transplantation	O	O
should	O	O
be	O	O
reconsidered	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
pharmacokinetic	O	O
studies	O	O
.	O	O

histamine	B-chem	B-chem
antagonists	O	O
and	O	O
d	B-chem	B-chem
-	I-chem	I-chem
tubocurarine	I-chem	I-chem
-	O	O
induced	O	O
hypotension	O	O
in	O	O
cardiac	O	O
surgical	O	O
patients	O	O
.	O	O

hemodynamic	O	O
effects	O	O
and	O	O
histamine	B-chem	B-chem
release	O	O
by	O	O
bolus	O	O
injection	O	O
of	O	O
0	O	O
.	O	O
35	O	O
mg	O	O
/	O	O
kg	O	O
of	O	O
d	B-chem	B-chem
-	I-chem	I-chem
tubocurarine	I-chem	I-chem
were	O	O
studied	O	O
in	O	O
24	O	O
patients	O	O
.	O	O

h1	O	B-chem
-	O	O
and	O	O
h2	O	O
-	O	O
histamine	B-chem	B-chem
antagonists	O	O
or	O	O
placebo	O	O
were	O	O
given	O	O
before	O	O
dosing	O	O
with	O	O
d	B-chem	B-chem
-	I-chem	I-chem
tubocurarine	I-chem	I-chem
in	O	O
a	O	O
randomized	O	O
double	O	O
-	O	O
blind	O	O
fashion	O	O
to	O	O
four	O	O
groups	O	O
:	O	O
group	O	O
1	O	O
-	O	O
-	O	O
placebo	O	O
;	O	O
group	O	O
2	O	B-chem
-	O	I-chem
-	O	I-chem
cimetidine	B-chem	B-chem
,	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
plus	O	O
placebo	O	O
;	O	O
group	O	O
3	O	B-chem
-	O	I-chem
-	O	I-chem
chlorpheniramine	B-chem	B-chem
,	O	O
0	O	O
.	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
plus	O	O
placebo	O	O
;	O	O
and	O	O
group	O	O
4	O	B-chem
-	O	I-chem
-	O	I-chem
cimetidine	B-chem	I-chem
plus	O	O
chlorpheniramine	B-chem	B-chem
.	O	O

histamine	B-chem	B-chem
release	O	O
occurred	O	O
in	O	O
most	O	O
patients	O	O
,	O	O
the	O	O
highest	O	O
level	O	O
2	O	O
minutes	O	O
after	O	O
d	B-chem	B-chem
-	I-chem	I-chem
tubocurarine	I-chem	I-chem
dosing	O	O
.	O	O

group	O	O
1	O	O
had	O	O
a	O	O
moderate	O	O
negative	O	O
correlation	O	O
between	O	O
plasma	O	O
histamine	B-chem	B-chem
change	O	O
and	O	O
systemic	O	O
vascular	O	O
resistance	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
58	O	O
;	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
not	O	O
present	O	O
in	O	O
group	O	O
4	O	O
.	O	O

prior	O	O
dosing	O	O
with	O	O
antagonists	O	O
partially	O	O
prevented	O	O
the	O	O
fall	O	O
in	O	O
systemic	O	O
vascular	O	O
resistance	O	O
.	O	O

these	O	O
data	O	O
demonstrate	O	O
that	O	O
the	O	O
hemodynamic	O	O
changes	O	O
associated	O	O
with	O	O
d	B-chem	B-chem
-	I-chem	I-chem
tubocurarine	I-chem	I-chem
dosing	O	O
are	O	O
only	O	O
partially	O	O
explained	O	O
by	O	O
histamine	B-chem	B-chem
release	O	O
.	O	O

thus	O	O
prior	O	O
dosing	O	O
with	O	O
h1	O	B-chem
-	O	O
and	O	O
h2	O	O
-	O	O
antagonists	O	O
provides	O	O
only	O	O
partial	O	O
protection	O	O
.	O	O

convulsant	O	O
effect	O	O
of	O	O
lindane	B-chem	B-chem
and	O	O
regional	O	O
brain	O	O
concentration	O	O
of	O	O
gaba	B-chem	B-chem
and	O	O
dopamine	B-chem	B-chem
.	O	O

lindane	B-chem	B-chem
(	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
hexachlorocyclohexane	I-chem	I-chem
)	O	O
is	O	O
an	O	O
organochlorine	O	B-chem
insecticide	O	O
with	O	O
known	O	O
neurotoxic	O	O
effects	O	O
.	O	O

its	O	O
mechanism	O	O
of	O	O
action	O	O
is	O	O
not	O	O
well	O	O
understood	O	O
although	O	O
it	O	O
has	O	O
been	O	O
proposed	O	O
that	O	O
lindane	B-chem	B-chem
acts	O	O
as	O	O
a	O	O
non	O	O
-	O	O
competitive	O	O
antagonist	O	O
at	O	O
the	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
aminobutyric	I-chem	I-chem
acid	I-chem	I-chem
(	O	O
gaba	B-chem	B-chem
)	O	O
-	O	O
a	O	O
receptor	O	O
.	O	O

we	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
lindane	B-chem	B-chem
(	O	O
150	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
on	O	O
the	O	O
gabaergic	O	O
and	O	O
dopaminergic	O	O
systems	O	O
by	O	O
measuring	O	O
the	O	O
concentration	O	O
of	O	O
gaba	B-chem	B-chem
,	O	O
dopamine	B-chem	B-chem
and	O	O
its	O	O
metabolites	O	O
in	O	O
7	O	O
brain	O	O
areas	O	O
at	O	O
the	O	O
onset	O	O
of	O	O
seizures	O	O
.	O	O

all	O	O
animals	O	O
suffered	O	O
tonic	O	O
convulsions	O	O
at	O	O
18	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
4	O	O
min	O	O
after	O	O
lindane	B-chem	B-chem
administration	O	O
.	O	O

the	O	O
concentration	O	O
of	O	O
gaba	B-chem	B-chem
was	O	O
only	O	O
slightly	O	O
but	O	O
significantly	O	O
decreased	O	O
in	O	O
the	O	O
colliculi	O	O
without	O	O
modifications	O	O
in	O	O
the	O	O
other	O	O
areas	O	O
.	O	O

the	O	O
concentration	O	O
of	O	O
dopamine	B-chem	B-chem
was	O	O
increased	O	O
in	O	O
the	O	O
mesencephalon	O	O
and	O	O
that	O	O
of	O	O
its	O	O
metabolite	O	O
dopac	B-chem	B-chem
was	O	O
also	O	O
increased	O	O
in	O	O
the	O	O
mesencephalon	O	O
and	O	O
the	O	O
striatum	O	O
.	O	O

unusual	O	O
complications	O	O
of	O	O
antithyroid	O	O
drug	O	O
therapy	O	O
:	O	O
four	O	O
case	O	O
reports	O	O
and	O	O
review	O	O
of	O	O
literature	O	O
.	O	O

two	O	O
cases	O	O
of	O	O
propylthiouracil	B-chem	B-chem
-	O	O
associated	O	O
acute	O	O
hepatitis	O	O
,	O	O
one	O	O
case	O	O
of	O	O
fatal	O	O
methimazole	B-chem	B-chem
-	O	O
associated	O	O
hepatocellular	O	O
necrosis	O	O
and	O	O
one	O	O
case	O	O
of	O	O
propylthiouracil	B-chem	B-chem
-	O	O
associated	O	O
lupus	O	O
-	O	O
like	O	O
syndrome	O	O
are	O	O
described	O	O
.	O	O

the	O	O
literature	O	O
related	O	O
to	O	O
antithyroid	O	O
drug	O	O
side	O	O
effects	O	O
and	O	O
the	O	O
mechanisms	O	O
for	O	O
their	O	O
occurrence	O	O
are	O	O
reviewed	O	O
and	O	O
the	O	O
efficacy	O	O
and	O	O
complications	O	O
of	O	O
thyroidectomy	O	O
and	O	O
radioiodine	O	O
compared	O	O
to	O	O
those	O	O
of	O	O
antithyroid	O	O
drugs	O	O
.	O	O

it	O	O
is	O	O
concluded	O	O
that	O	O
in	O	O
most	O	O
circumstances	O	O
131i	O	O
is	O	O
the	O	O
therapy	O	O
of	O	O
choice	O	O
for	O	O
hyperthyroidism	O	O
.	O	O

anticonvulsant	O	O
actions	O	O
of	O	O
mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
on	O	O
the	O	O
lithium	B-chem	B-chem
-	O	O
pilocarpine	B-chem	B-chem
model	O	O
of	O	O
status	O	O
epilepticus	O	O
in	O	O
rats	O	O
.	O	O
mk	B-chem	B-chem
-	I-chem	O
801	I-chem	B-chem
,	O	O
a	O	O
noncompetitive	O	O
n	B-chem	B-chem
-	I-chem	I-chem
methyl	I-chem	I-chem
-	I-chem	I-chem
d	I-chem	I-chem
-	I-chem	I-chem
aspartate	I-chem	I-chem
(	O	O
nmda	B-chem	B-chem
)	O	O
receptor	O	O
antagonist	O	O
,	O	O
was	O	O
tested	O	O
for	O	O
anticonvulsant	O	O
effects	O	O
in	O	O
rats	O	O
using	O	O
two	O	O
seizure	O	O
models	O	O
,	O	O
coadministration	O	O
of	O	O
lithium	B-chem	B-chem
and	O	O
pilocarpine	B-chem	B-chem
and	O	O
administration	O	O
of	O	O
a	O	O
high	O	O
dose	O	O
of	O	O
pilocarpine	B-chem	B-chem
alone	O	O
.	O	O

three	O	O
major	O	O
results	O	O
are	O	O
reported	O	O
.	O	O

first	O	O
,	O	O
pretreatment	O	O
with	O	O
mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
produced	O	O
an	O	O
effective	O	O
and	O	O
dose	O	O
-	O	O
dependent	O	O
anticonvulsant	O	O
action	O	O
with	O	O
the	O	O
lithium	B-chem	B-chem
-	O	O
pilocarpine	B-chem	B-chem
model	O	O
but	O	O
not	O	O
with	O	O
rats	O	O
treated	O	O
with	O	O
pilocarpine	B-chem	B-chem
alone	O	O
,	O	O
suggesting	O	O
that	O	O
different	O	O
biochemical	O	O
mechanisms	O	O
control	O	O
seizures	O	O
in	O	O
these	O	O
two	O	O
models	O	O
.	O	O

second	O	O
,	O	O
the	O	O
anticonvulsant	O	O
effect	O	O
of	O	O
mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
in	O	O
the	O	O
lithium	B-chem	B-chem
-	O	O
pilocarpine	B-chem	B-chem
model	O	O
only	O	O
occurred	O	O
after	O	O
initial	O	O
periods	O	O
of	O	O
seizure	O	O
activity	O	O
.	O	O

this	O	O
observation	O	O
is	O	O
suggested	O	O
to	O	O
be	O	O
an	O	O
in	O	O
vivo	O	O
demonstration	O	O
of	O	O
the	O	O
conclusion	O	O
derived	O	O
from	O	O
in	O	O
vitro	O	O
experiments	O	O
that	O	O
mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
binding	O	O
requires	O	O
agonist	O	O
-	O	O
induced	O	O
opening	O	O
of	O	O
the	O	O
channel	O	O
sites	O	O
of	O	O
the	O	O
nmda	B-chem	B-chem
receptor	O	O
.	O	O

third	O	O
,	O	O
although	O	O
it	O	O
is	O	O
relatively	O	O
easy	O	O
to	O	O
block	O	O
seizures	O	O
induced	O	O
by	O	O
lithium	B-chem	B-chem
and	O	O
pilocarpine	B-chem	B-chem
by	O	O
administration	O	O
of	O	O
anticonvulsants	O	O
prior	O	O
to	O	O
pilocarpine	B-chem	B-chem
,	O	O
it	O	O
is	O	O
more	O	O
difficult	O	O
to	O	O
terminate	O	O
ongoing	O	O
status	O	O
epilepticus	O	O
and	O	O
block	O	O
the	O	O
lethality	O	O
of	O	O
the	O	O
seizures	O	O
.	O	O

administration	O	O
of	O	O
mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
30	O	O
or	O	O
60	O	O
min	O	O
after	O	O
pilocarpine	B-chem	B-chem
,	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
during	O	O
status	O	O
epilepticus	O	O
,	O	O
gradually	O	O
reduced	O	O
electrical	O	O
and	O	O
behavioral	O	O
seizure	O	O
activity	O	O
and	O	O
greatly	O	O
enhanced	O	O
the	O	O
survival	O	O
rate	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
that	O	O
activation	O	O
of	O	O
nmda	B-chem	B-chem
receptors	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
status	O	O
epilepticus	O	O
and	O	O
brain	O	O
damage	O	O
in	O	O
the	O	O
lithium	B-chem	B-chem
-	O	O
pilocarpine	B-chem	B-chem
model	O	O
.	O	O

this	O	O
was	O	O
further	O	O
supported	O	O
by	O	O
results	O	O
showing	O	O
that	O	O
nonconvulsive	O	O
doses	O	O
of	O	O
nmda	B-chem	B-chem
and	O	O
pilocarpine	B-chem	B-chem
were	O	O
synergistic	O	O
,	O	O
resulting	O	O
in	O	O
status	O	O
epilepticus	O	O
and	O	O
subsequent	O	O
mortality	O	O
.	O	O

nifedipine	B-chem	B-chem
induced	O	O
bradycardia	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
autonomic	O	O
neuropathy	O	O
.	O	O

an	O	O
80	O	O
year	O	O
old	O	O
diabetic	O	O
male	O	O
with	O	O
evidence	O	O
of	O	O
peripheral	O	O
and	O	O
autonomic	O	O
neuropathy	O	O
was	O	O
admitted	O	O
with	O	O
chest	O	O
pain	O	O
.	O	O

he	O	O
was	O	O
found	O	O
to	O	O
have	O	O
atrial	O	O
flutter	O	O
at	O	O
a	O	O
ventricular	O	O
rate	O	O
of	O	O
70	O	O
/	O	O
min	O	O
which	O	O
slowed	O	O
down	O	O
to	O	O
30	O	O
-	O	O
40	O	O
/	O	O
min	O	O
when	O	O
nifedipine	B-chem	B-chem
(	O	O
60	O	O
mg	O	O
)	O	O
in	O	O
3	O	O
divided	O	O
doses	O	O
,	O	O
during	O	O
which	O	O
he	O	O
was	O	O
paced	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
70	O	O
/	O	O
min	O	O
.	O	O

this	O	O
is	O	O
inconsistent	O	O
with	O	O
the	O	O
well	O	O
-	O	O
established	O	O
finding	O	O
that	O	O
nifedipine	B-chem	B-chem
induces	O	O
tachycardia	O	O
in	O	O
normally	O	O
innervated	O	O
hearts	O	O
.	O	O

however	O	O
,	O	O
in	O	O
hearts	O	O
deprived	O	O
of	O	O
compensatory	O	O
sympathetic	O	O
drive	O	O
,	O	O
it	O	O
may	O	O
lead	O	O
to	O	O
bradycardia	O	O
.	O	O

the	O	O
effect	O	O
of	O	O
haloperidol	B-chem	B-chem
in	O	O
cocaine	B-chem	B-chem
and	O	O
amphetamine	B-chem	O
intoxication	O	O
.	O	O

the	O	O
effectiveness	O	O
of	O	O
haloperidol	B-chem	B-chem
pretreatment	O	O
in	O	O
preventing	O	O
the	O	O
toxic	O	O
effects	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
amphetamine	B-chem	B-chem
and	O	O
cocaine	B-chem	B-chem
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

in	O	O
this	O	O
model	O	O
,	O	O
toxic	O	O
effects	O	O
were	O	O
induced	O	O
by	O	O
intraperitoneal	O	O
(	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
injection	O	O
of	O	O
amphetamine	B-chem	B-chem
75	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
100	O	O
%	O	O
death	O	O
rate	O	O
)	O	O
or	O	O
cocaine	B-chem	B-chem
70	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
82	O	O
%	O	O
death	O	O
rate	O	O
)	O	O
.	O	O

haloperidol	B-chem	B-chem
failed	O	O
to	O	O
prevent	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
,	O	O
but	O	O
did	O	O
lower	O	O
the	O	O
mortality	O	O
rate	O	O
at	O	O
most	O	O
doses	O	O
tested	O	O
.	O	O

haloperidol	B-chem	B-chem
decreased	O	O
the	O	O
incidence	O	O
of	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
at	O	O
the	O	O
two	O	O
highest	O	O
doses	O	O
,	O	O
but	O	O
the	O	O
lowering	O	O
of	O	O
the	O	O
mortality	O	O
rate	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
at	O	O
any	O	O
dose	O	O
.	O	O

these	O	O
data	O	O
suggest	O	O
a	O	O
protective	O	O
role	O	O
for	O	O
the	O	O
central	O	O
dopamine	B-chem	B-chem
blocker	O	O
haloperidol	B-chem	B-chem
against	O	O
death	O	O
from	O	O
high	O	O
-	O	O
dose	O	O
amphetamine	B-chem	B-chem
exposure	O	O
without	O	O
reducing	O	O
the	O	O
incidence	O	O
of	O	O
seizures	O	O
.	O	O

in	O	O
contrast	O	O
,	O	O
haloperidol	B-chem	B-chem
demonstrated	O	O
an	O	O
ability	O	O
to	O	O
reduce	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
without	O	O
significantly	O	O
reducing	O	O
mortality	O	O
.	O	O

autoradiographic	O	O
evidence	O	O
of	O	O
estrogen	B-chem	B-chem
binding	O	O
sites	O	O
in	O	O
nuclei	O	O
of	O	O
diethylstilbesterol	B-chem	O
induced	O	O
hamster	O	O
renal	O	O
carcinomas	O	O
.	O	O

estrogen	B-chem	B-chem
binding	O	O
sites	O	O
were	O	O
demonstrated	O	O
by	O	O
autoradiography	O	O
in	O	O
one	O	O
transplantable	O	O
and	O	O
five	O	O
primary	O	O
diethylstilbesterol	B-chem	O
induced	O	O
renal	O	O
carcinomas	O	O
in	O	O
three	O	O
hamsters	O	O
.	O	O

radiolabelling	O	O
,	O	O
following	O	O
the	O	O
in	O	O
vivo	O	O
injection	O	O
of	O	O
3h	O	B-chem
-	O	I-chem
17	O	I-chem
beta	O	I-chem
estradiol	B-chem	I-chem
,	O	O
was	O	O
increased	O	O
only	O	O
over	O	O
the	O	O
nuclei	O	O
of	O	O
tumor	O	O
cells	O	O
;	O	O
stereologic	O	O
analysis	O	O
revealed	O	O
a	O	O
4	O	O
.	O	O
5	O	O
-	O	O
to	O	O
6	O	O
.	O	O
7	O	O
-	O	O
times	O	O
higher	O	O
concentration	O	O
of	O	O
reduced	O	O
silver	B-chem	B-chem
grains	O	O
over	O	O
nuclei	O	O
than	O	O
cytoplasm	O	O
of	O	O
these	O	O
cells	O	O
.	O	O

despite	O	O
rapid	O	O
tubular	O	O
excretion	O	O
of	O	O
estradiol	B-chem	B-chem
which	O	O
peaked	O	O
in	O	O
less	O	O
than	O	O
1	O	O
h	O	O
,	O	O
the	O	O
normal	O	O
cells	O	O
did	O	O
not	O	O
appear	O	O
to	O	O
bind	O	O
the	O	O
ligand	O	O
.	O	O

this	O	O
is	O	O
the	O	O
first	O	O
published	O	O
report	O	O
documenting	O	O
the	O	O
preferential	O	O
in	O	O
vivo	O	O
binding	O	O
of	O	O
estrogen	B-chem	B-chem
to	O	O
nuclei	O	O
of	O	O
cells	O	O
in	O	O
estrogen	B-chem	B-chem
induced	O	O
hamster	O	O
renal	O	O
carcinomas	O	O
.	O	O

bradycardia	O	O
due	O	O
to	O	O
biperiden	B-chem	B-chem
.	O	O

in	O	O
a	O	O
38	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
suffering	O	O
from	O	O
a	O	O
severe	O	O
postzosteric	O	O
trigeminal	O	O
neuralgia	O	O
,	O	O
intravenous	O	O
application	O	O
of	O	O
10	O	O
mg	O	O
biperiden	B-chem	B-chem
lactate	I-chem	I-chem
led	O	O
to	O	O
a	O	O
long	O	O
-	O	O
lasting	O	O
paradoxical	O	O
reaction	O	O
characterized	O	O
by	O	O
considerable	O	O
bradycardia	O	O
,	O	O
dysarthria	O	O
,	O	O
and	O	O
dysphagia	O	O
.	O	O

the	O	O
heart	O	O
rate	O	O
was	O	O
back	O	O
to	O	O
normal	O	O
within	O	O
12	O	O
hours	O	O
upon	O	O
administration	O	O
of	O	O
orciprenaline	B-chem	B-chem
under	O	O
cardiac	O	O
monitoring	O	O
in	O	O
an	O	O
intensive	O	O
care	O	O
unit	O	O
.	O	O

bradycardia	O	O
induced	O	O
by	O	O
biperiden	B-chem	B-chem
is	O	O
attributed	O	O
to	O	O
the	O	O
speed	O	O
of	O	O
injection	O	O
and	O	O
to	O	O
a	O	O
dose	O	O
-	O	O
related	O	O
dual	O	O
effect	O	O
of	O	O
atropine	B-chem	B-chem
-	O	O
like	O	O
drugs	O	O
on	O	O
muscarine	B-chem	B-chem
receptors	O	O
.	O	O

deliberate	O	O
hypotension	O	O
induced	O	O
by	O	O
labetalol	B-chem	B-chem
with	O	O
halothane	B-chem	B-chem
,	O	O
enflurane	B-chem	B-chem
or	O	O
isoflurane	B-chem	B-chem
for	O	O
middle	O	O
-	O	O
ear	O	O
surgery	O	O
.	O	O

the	O	O
feasibility	O	O
of	O	O
using	O	O
labetalol	B-chem	B-chem
,	O	O
an	O	O
alpha	O	O
-	O	O
and	O	O
beta	O	O
-	O	O
adrenergic	O	O
blocking	O	O
agent	O	O
,	O	O
as	O	O
a	O	O
hypotensive	O	O
agent	O	O
in	O	O
combination	O	O
with	O	O
inhalation	O	O
anaesthetics	O	O
(	O	O
halothane	B-chem	B-chem
,	O	O
enflurane	B-chem	B-chem
or	O	O
isoflurane	B-chem	B-chem
)	O	O
was	O	O
studied	O	O
in	O	O
23	O	O
adult	O	O
patients	O	O
undergoing	O	O
middle	O	O
-	O	O
ear	O	O
surgery	O	O
.	O	O

the	O	O
mean	O	O
arterial	O	O
pressure	O	O
was	O	O
decreased	O	O
from	O	O
86	O	O
+	O	O
/	O	O
-	O	O

5	O	O
(	O	O
s	O	O
.	O	O
e	O	O
.	O	O

mean	O	O
)	O	O

mmhg	O	O
to	O	O
52	O	O
+	O	O
/	O	O
-	O	O

1	O	O
mmhg	O	O
(	O	O
11	O	O
.	O	O
5	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
7	O	O
to	O	O
6	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
1	O	O
kpa	O	O
)	O	O
for	O	O
98	O	O
+	O	O
/	O	O
-	O	O

10	O	O
min	O	O
in	O	O
the	O	O
halothane	B-chem	B-chem
(	O	O
h	B-chem	O
)	O	O
group	O	O
,	O	O
from	O	O
79	O	O
+	O	O
/	O	O
-	O	O

5	O	O
to	O	O
53	O	O
+	O	O
/	O	O
-	O	O

1	O	O
mmhg	O	O
(	O	O
10	O	O
.	O	O
5	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
7	O	O
to	O	O
7	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
1	O	O
kpa	O	O
)	O	O
for	O	O
129	O	O
+	O	O
/	O	O
-	O	O

11	O	O
min	O	O
in	O	O
the	O	O
enflurane	B-chem	B-chem
(	O	O
e	B-chem	O
)	O	O
group	O	O
,	O	O
and	O	O
from	O	O
80	O	O
+	O	O
/	O	O
-	O	O

4	O	O
to	O	O
49	O	O
+	O	O
/	O	O
-	O	O

1	O	O
mmhg	O	O
(	O	O
10	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
5	O	O
to	O	O
6	O	O
.	O	O
5	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
1	O	O
kpa	O	O
)	O	O
for	O	O
135	O	O
+	O	O
/	O	O
-	O	O

15	O	O
min	O	O
in	O	O
the	O	O
isoflurane	B-chem	B-chem
(	O	O
i	B-chem	O
)	O	O
group	O	O
.	O	O

the	O	O
mean	O	O
h	B-chem	O
concentration	O	O
during	O	O
hypotension	O	O
in	O	O
the	O	O
inspiratory	O	O
gas	O	O
was	O	O
0	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
1	O	O
vol	O	O
%	O	O
,	O	O
the	O	O
mean	O	O
e	B-chem	O
concentration	O	O
1	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
2	O	O
vol	O	O
%	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
i	B-chem	O
concentration	O	O
1	O	O
.	O	O
0	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
1	O	O
vol	O	O
%	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
the	O	O
patients	O	O
received	O	O
fentanyl	B-chem	B-chem
and	O	O
d	B-chem	B-chem
-	I-chem	I-chem
tubocurarine	I-chem	I-chem
.	O	O

the	O	O
initial	O	O
dose	O	O
of	O	O
labetalol	B-chem	B-chem
for	O	O
lowering	O	O
blood	O	O
pressure	O	O
was	O	O
similar	O	O
,	O	O
0	O	O
.	O	O
52	O	O
-	O	O
0	O	O
.	O	O
59	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
in	O	O
all	O	O
the	O	O
groups	O	O
.	O	O

during	O	O
hypotension	O	O
,	O	O
the	O	O
heart	O	O
rate	O	O
was	O	O
stable	O	O
without	O	O
tachy	O	O
-	O	O
or	O	O
bradycardia	O	O
.	O	O

the	O	O
operating	O	O
conditions	O	O
regarding	O	O
bleeding	O	O
were	O	O
estimated	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
manner	O	O
,	O	O
and	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
groups	O	O
.	O	O

during	O	O
hypotension	O	O
,	O	O
the	O	O
serum	O	O
creatinine	B-chem	B-chem
concentration	O	O
rose	O	O
significantly	O	O
in	O	O
all	O	O
groups	O	O
from	O	O
the	O	O
values	O	O
before	O	O
hypotension	O	O
and	O	O
returned	O	O
postoperatively	O	O
to	O	O
the	O	O
initial	O	O
level	O	O
in	O	O
the	O	O
other	O	O
groups	O	O
,	O	O
except	O	O
the	O	O
isoflurane	B-chem	B-chem
group	O	O
.	O	O

after	O	O
hypotension	O	O
there	O	O
was	O	O
no	O	O
rebound	O	O
phenomenon	O	O
in	O	O
either	O	O
blood	O	O
pressure	O	O
or	O	O
heart	O	O
rate	O	O
.	O	O

these	O	O
results	O	O
indicate	O	O
that	O	O
labetalol	B-chem	B-chem
induces	O	O
easily	O	O
adjustable	O	O
hypotension	O	O
without	O	O
compensatory	O	O
tachycardia	O	O
and	O	O
rebound	O	O
hypertension	O	O
.	O	O

convulsion	O	O
following	O	O
intravenous	O	O
fluorescein	B-chem	B-chem
angiography	O	O
.	O	O

tonic	O	O
-	O	O
clonic	O	O
seizures	O	O
followed	O	O
intravenous	O	O
fluorescein	B-chem	B-chem
injection	O	O
for	O	O
fundus	O	O
angiography	O	O
in	O	O
a	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
.	O	O

despite	O	O
precautions	O	O
this	O	O
adverse	O	O
reaction	O	O
recurred	O	O
on	O	O
re	O	O
-	O	O
exposure	O	O
to	O	O
intravenous	O	O
fluorescein	B-chem	B-chem
.	O	O

pharmacology	O	O
of	O	O
acc	B-chem	B-chem
-	I-chem	I-chem
9653	I-chem	I-chem
(	O	O
phenytoin	B-chem	B-chem
prodrug	O	O
)	O	O
.	O	O

acc	B-chem	B-chem
-	I-chem	O
9653	I-chem	O
,	O	O
the	O	O
disodium	B-chem	B-chem
phosphate	I-chem	I-chem
ester	I-chem	I-chem
of	O	O
3	B-chem	B-chem
-	I-chem	I-chem
hydroxymethyl	I-chem	I-chem
-	I-chem	I-chem
5	I-chem	I-chem
,	I-chem	I-chem
5	I-chem	I-chem
-	I-chem	I-chem
diphenylhydantoin	I-chem	I-chem
,	O	O
is	O	O
a	O	O
prodrug	O	O
of	O	O
phenytoin	B-chem	B-chem
with	O	O
advantageous	O	O
physicochemical	O	O
properties	O	O
.	O	O

acc	B-chem	B-chem
-	I-chem	O
9653	I-chem	O
is	O	O
rapidly	O	O
converted	O	O
enzymatically	O	O
to	O	O
phenytoin	B-chem	B-chem
in	O	O
vivo	O	O
.	O	O

acc	B-chem	B-chem
-	I-chem	I-chem
9653	I-chem	I-chem
and	O	O
phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
have	O	O
equivalent	O	O
anticonvulsant	O	O
activity	O	O
against	O	O
seizures	O	O
induced	O	O
by	O	O
maximal	O	O
electroshock	O	O
(	O	O
mes	O	O
)	O	O
in	O	O
mice	O	O
following	O	O
i	O	O
.	O	O
p	O	O
.	O	O

,	O	O
oral	O	O
,	O	O
or	O	O
i	O	O
.	O	O
v	O	O
.	O	O

administration	O	O
.	O	O

the	O	O
ed50	O	O
doses	O	O
were	O	O
16	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
i	O	O
.	O	O
v	O	O
.	O	O

acc	B-chem	B-chem
-	I-chem	O
9653	I-chem	O
and	O	O
8	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
i	O	O
.	O	O
v	O	O
.	O	O

phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
.	O	O

acc	B-chem	B-chem
-	I-chem	I-chem
9653	I-chem	I-chem
and	O	O
phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
have	O	O
similar	O	O
antiarrhythmic	O	O
activity	O	O
against	O	O
ouabain	B-chem	B-chem
-	O	O
induced	O	O
ventricular	O	O
tachycardia	O	O
in	O	O
anesthetized	O	O
dogs	O	O
.	O	O

the	O	O
total	O	O
doses	O	O
of	O	O
acc	B-chem	B-chem
-	I-chem	I-chem
9653	I-chem	I-chem
or	O	O
phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
necessary	O	O
to	O	O
convert	O	O
the	O	O
arrhythmia	O	O
to	O	O
a	O	O
normal	O	O
sinus	O	O
rhythm	O	O
were	O	O
24	O	O
+	O	O
/	O	O
-	O	O

6	O	O
and	O	O
14	O	O
+	O	O
/	O	O
-	O	O

3	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
respectively	O	O
.	O	O

only	O	O
phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
displayed	O	O
in	O	O
vitro	O	O
antiarrhythmic	O	O
activity	O	O
against	O	O
strophanthidin	B-chem	B-chem
-	O	O
induced	O	O
arrhythmias	O	O
in	O	O
guinea	O	O
pig	O	O
right	O	O
atria	O	O
.	O	O

in	O	O
anesthetized	O	O
dogs	O	O
,	O	O
a	O	O
high	O	O
dose	O	O
of	O	O
acc	B-chem	B-chem
-	I-chem	O
9653	I-chem	O
(	O	O
31	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
infused	O	O
over	O	O
15	O	O
,	O	O
20	O	O
,	O	O
and	O	O
30	O	O
min	O	O
and	O	O
the	O	O
responses	O	O
were	O	O
compared	O	O
to	O	O
an	O	O
equimolar	O	O
dose	O	O
of	O	O
phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
(	O	O
21	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

the	O	O
acc	B-chem	B-chem
-	I-chem	O
9653	I-chem	I-chem
and	O	O
phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
treatments	O	O
produced	O	O
similar	O	O
marked	O	O
reductions	O	O
in	O	O
diastolic	O	O
blood	O	O
pressure	O	O
and	O	O
contractile	O	O
force	O	O
(	O	O
lvdp	O	O
/	O	O
dt	O	O
)	O	O
.	O	O

the	O	O
maximum	O	O
effects	O	O
of	O	O
each	O	O
treatment	O	O
occurred	O	O
at	O	O
the	O	O
time	O	O
of	O	O
maximum	O	O
phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
levels	O	O
.	O	O

acute	O	O
toxicity	O	O
studies	O	O
of	O	O
acc	B-chem	B-chem
-	I-chem	I-chem
9653	I-chem	I-chem
and	O	O
phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
were	O	O
carried	O	O
out	O	O
in	O	O
mice	O	O
,	O	O
rats	O	O
,	O	O
rabbits	O	O
,	O	O
and	O	O
dogs	O	O
by	O	O
i	O	O
.	O	O
v	O	O
.	O	O

,	O	O
i	O	O
.	O	O
m	O	O
.	O	O
,	O	O
and	O	O
i	O	O
.	O	O
p	O	O
.	O	O
routes	O	O
of	O	O
administration	O	O
.	O	O

the	O	O
systemic	O	O
toxic	O	O
signs	O	O
of	O	O
both	O	O
agents	O	O
were	O	O
similar	O	O
and	O	O
occurred	O	O
at	O	O
approximately	O	O
equivalent	O	O
doses	O	O
.	O	O

importantly	O	O
,	O	O
the	O	O
local	O	O
irritation	O	O
of	O	O
acc	B-chem	B-chem
-	I-chem	O
9653	I-chem	O
was	O	O
markedly	O	O
less	O	O
than	O	O
phenytoin	B-chem	B-chem
sodium	I-chem	I-chem
following	O	O
i	O	O
.	O	O
m	O	O
.	O	O

administration	O	O
.	O	O
(	O	O
abstract	O	O
truncated	O	O
at	O	O
250	O	O
words	O	O
)	O	O

phenytoin	B-chem	B-chem
induced	O	O
fatal	O	O
hepatic	O	O
injury	O	O
.	O	O

a	O	O
61	O	O
year	O	O
old	O	O
female	O	O
developed	O	O
fatal	O	O
hepatic	O	O
failure	O	O
after	O	O
phenytoin	B-chem	B-chem
administration	O	O
.	O	O

a	O	O
typical	O	O
multisystem	O	O
clinical	O	O
pattern	O	O
precedes	O	O
the	O	O
manifestations	O	O
of	O	O
hepatic	O	O
injury	O	O
.	O	O

the	O	O
hematologic	O	O
,	O	O
biochemical	O	O
and	O	O
pathologic	O	O
features	O	O
indicate	O	O
a	O	O
mixed	O	O
hepatocellular	O	O
damage	O	O
due	O	O
to	O	O
drug	O	O
hypersensitivity	O	O
.	O	O

in	O	O
a	O	O
patient	O	O
receiving	O	O
phenytoin	B-chem	B-chem
who	O	O
presents	O	O
a	O	O
viral	O	O
-	O	O
like	O	O
illness	O	O
,	O	O
early	O	O
recognition	O	O
and	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
are	O	O
mandatory	O	O
.	O	O

treatment	O	O
of	O	O
lethal	O	O
pertussis	B-chem	O
vaccine	I-chem	O
reaction	O	O
with	O	O
histamine	B-chem	B-chem
h1	O	I-chem
antagonists	O	O
.	O	O

we	O	O
studied	O	O
mortality	O	O
after	O	O
pertussis	O	O
immunization	O	O
in	O	O
the	O	O
mouse	O	O
.	O	O

without	O	O
treatment	O	O
,	O	O
73	O	O
of	O	O
92	O	O
animals	O	O
(	O	O
80	O	O
%	O	O
)	O	O
died	O	O
after	O	O
injection	O	O
of	O	O
bovine	O	O
serum	O	O
albumin	O	O
(	O	O
bsa	O	O
)	O	O
on	O	O
day	O	O
+	O	O
7	O	O
of	O	O
pertussis	O	O
immunization	O	O
.	O	O

after	O	O
pretreatment	O	O
with	O	O
3	O	O
mg	O	O
of	O	O
cyproheptadine	B-chem	B-chem
,	O	O
2	O	O
mg	O	O
mianserin	B-chem	B-chem
,	O	O
or	O	O
2	O	O
mg	O	O
chlorpheniramine	B-chem	B-chem
,	O	O
only	O	O
5	O	O
of	O	O
105	O	O
animals	O	O
(	O	O
5	O	O
%	O	O
)	O	O
died	O	O
after	O	O
receiving	O	O
bsa	O	O
on	O	O
day	O	O
+	O	O
7	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

blockade	O	O
of	O	O
histamine	B-chem	B-chem
h1	O	I-chem
receptors	O	O
may	O	O
reduce	O	O
mortality	O	O
in	O	O
pertussis	O	O
immunization	O	O
-	O	O
induced	O	O
encephalopathy	O	O
in	O	O
mice	O	O
.	O	O

support	O	O
for	O	O
adrenaline	B-chem	B-chem
-	O	O
hypertension	O	O
hypothesis	O	O
:	O	O
18	O	O
hour	O	O
pressor	O	O
effect	O	O
after	O	O
6	O	O
hours	O	O
adrenaline	B-chem	B-chem
infusion	O	O
.	O	O

in	O	O
a	O	O
double	O	O
blind	O	O
,	O	O
crossover	O	O
study	O	O
6	O	O
h	O	O
infusions	O	O
of	O	O
adrenaline	B-chem	B-chem
(	O	O
15	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
;	O	O
1	O	O
ng	O	O
=	O	O
5	O	O
.	O	O
458	O	O
pmol	O	O
)	O	O
,	O	O
noradrenaline	B-chem	B-chem
(	O	O
30	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
;	O	O
1	O	O
ng	O	O
=	O	O
5	O	O
.	O	O
911	O	O
pmol	O	O
)	O	O
,	O	O
and	O	O
a	O	O
5	O	O
%	O	O
dextrose	B-chem	B-chem
solution	O	O
(	O	O
5	O	O
.	O	O
4	O	O
ml	O	O
/	O	O
h	O	O
)	O	O
,	O	O
were	O	O
given	O	O
to	O	O
ten	O	O
healthy	O	O
volunteers	O	O
in	O	O
random	O	O
order	O	O
2	O	O
weeks	O	O
apart	O	O
.	O	O

by	O	O
means	O	O
of	O	O
intra	O	O
-	O	O
arterial	O	O
ambulatory	O	O
monitoring	O	O
the	O	O
haemodynamic	O	O
effects	O	O
were	O	O
followed	O	O
for	O	O
18	O	O
h	O	O
after	O	O
the	O	O
infusions	O	O
were	O	O
stopped	O	O
.	O	O

adrenaline	B-chem	B-chem
,	O	O
but	O	O
not	O	O
noradrenaline	B-chem	B-chem
,	O	O
caused	O	O
a	O	O
delayed	O	O
and	O	O
protracted	O	O
pressor	O	O
effect	O	O
.	O	O

over	O	O
the	O	O
total	O	O
postinfusion	O	O
period	O	O
systolic	O	O
and	O	O
diastolic	O	O
arterial	O	O
pressure	O	O
were	O	O
6	O	O
(	O	O
sem	O	O
2	O	O
)	O	O
%	O	O
and	O	O
7	O	O
(	O	O
2	O	O
)	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
higher	O	O
than	O	O
after	O	O
dextrose	B-chem	B-chem
infusion	O	O
(	O	O
anova	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

thus	O	O
,	O	O
"	O	O
"	O	O
"	O	O
"	O	O
stress	O	O
"	O	O
"	O	O
"	O	O
"	O	O
levels	O	O
of	O	O
adrenaline	B-chem	B-chem
(	O	O
230	O	O
pg	O	O
/	O	O
ml	O	O
)	O	O
for	O	O
6	O	O
h	O	O
cause	O	O
a	O	O
delayed	O	O
and	O	O
protracted	O	O
pressor	O	O
effect	O	O
.	O	O

these	O	O
findings	O	O
are	O	O
strong	O	O
support	O	O
for	O	O
the	O	O
adrenaline	B-chem	B-chem
-	O	O
hypertension	O	O
hypothesis	O	O
in	O	O
man	O	O
.	O	O

effect	O	O
of	O	O
alkylxanthines	B-chem	B-chem
on	O	O
gentamicin	B-chem	B-chem
-	O	O
induced	O	O
acute	O	O
renal	O	O
failure	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

adenosine	B-chem	B-chem
antagonists	O	O
have	O	O
been	O	O
previously	O	O
shown	O	O
to	O	O
be	O	O
of	O	O
benefit	O	O
in	O	O
some	O	O
ischaemic	O	O
and	O	O
nephrotoxic	O	O
models	O	O
of	O	O
acute	O	O
renal	O	O
failure	O	O
(	O	O
arf	O	O
)	O	O
.	O	O

in	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
three	O	O
alkylxanthines	B-chem	B-chem
with	O	O
different	O	O
potencies	O	O
as	O	O
adenosine	B-chem	B-chem
antagonists	O	O
8	B-chem	B-chem
-	I-chem	I-chem
phenyltheophylline	I-chem	I-chem
,	O	O
theophylline	B-chem	B-chem
and	O	O
enprofylline	B-chem	B-chem
,	O	O
were	O	O
examined	O	O
in	O	O
rats	O	O
developing	O	O
acute	O	O
renal	O	O
failure	O	O
after	O	O
4	O	O
daily	O	O
injections	O	O
of	O	O
gentamicin	B-chem	B-chem
(	O	O
200	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
)	O	O
.	O	O

renal	O	O
function	O	O
was	O	O
assessed	O	O
by	O	O
biochemical	O	O
(	O	O
plasma	O	O
urea	B-chem	B-chem
and	O	O
creatinine	B-chem	B-chem
)	O	O
,	O	O
functional	O	O
(	O	O
urine	O	O
analysis	O	O
and	O	O
[	O	B-chem
3h	O	I-chem
]	O	I-chem
inulin	O	I-chem
and	O	O
[	O	B-chem
14c	O	I-chem
]	O	I-chem
p	B-chem	I-chem
-	I-chem	I-chem
aminohippuric	I-chem	I-chem
acid	I-chem	I-chem
clearances	O	O
)	O	O
and	O	O
morphological	O	O
(	O	O
degree	O	O
of	O	O
necrosis	O	O
)	O	O
indices	O	O
.	O	O

the	O	O
various	O	O
drug	O	O
treatments	O	O
produced	O	O
improvements	O	O
in	O	O
some	O	O
,	O	O
but	O	O
not	O	O
all	O	O
,	O	O
measurements	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

however	O	O
,	O	O
any	O	O
improvement	O	O
produced	O	O
by	O	O
drug	O	O
treatment	O	O
was	O	O
largely	O	O
a	O	O
result	O	O
of	O	O
a	O	O
beneficial	O	O
effect	O	O
exerted	O	O
by	O	O
its	O	O
vehicle	O	O
(	O	O
polyethylene	B-chem	B-chem
glycol	I-chem	I-chem
and	O	O
naoh	B-chem	B-chem
)	O	O
.	O	O

the	O	O
lack	O	O
of	O	O
any	O	O
consistent	O	O
protective	O	O
effect	O	O
noted	O	O
with	O	O
the	O	O
alkylxanthines	B-chem	O
tested	O	O
in	O	O
the	O	O
present	O	O
study	O	O
indicates	O	O
that	O	O
adenosine	B-chem	B-chem
plays	O	O
little	O	O
,	O	O
if	O	O
any	O	O
,	O	O
pathophysiological	O	O
role	O	O
in	O	O
gentamicin	B-chem	B-chem
-	O	O
induced	O	O
arf	O	O
.	O	O

adverse	O	O
ocular	O	O
reactions	O	O
possibly	O	O
associated	O	O
with	O	O
isotretinoin	B-chem	B-chem
.	O	O

a	O	O
total	O	O
of	O	O
261	O	O
adverse	O	O
ocular	O	O
reactions	O	O
occurred	O	O
in	O	O
237	O	O
patients	O	O
who	O	O
received	O	O
isotretinoin	B-chem	B-chem
,	O	O
a	O	O
commonly	O	O
used	O	O
drug	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
cystic	O	O
acne	O	O
.	O	O

blepharoconjunctivitis	O	O
,	O	O
subjective	O	O
complaints	O	O
of	O	O
dry	O	O
eyes	O	O
,	O	O
blurred	O	O
vision	O	O
,	O	O
contact	O	O
lens	O	O
intolerance	O	O
,	O	O
and	O	O
photodermatitis	O	O
are	O	O
reversible	O	O
side	O	O
effects	O	O
.	O	O

more	O	O
serious	O	O
ocular	O	O
adverse	O	O
reactions	O	O
include	O	O
papilledema	O	O
,	O	O
pseudotumor	O	O
cerebri	O	O
,	O	O
and	O	O
white	O	O
or	O	O
gray	O	O
subepithelial	O	O
corneal	O	O
opacities	O	O
;	O	O
all	O	O
of	O	O
these	O	O
are	O	O
reversible	O	O
if	O	O
the	O	O
drug	O	O
is	O	O
discontinued	O	O
.	O	O

reported	O	O
cases	O	O
of	O	O
decreased	O	O
dark	O	O
adaptation	O	O
are	O	O
under	O	O
investigation	O	O
.	O	O

isotretinoin	B-chem	B-chem
is	O	O
contraindicated	O	O
in	O	O
pregnancy	O	O
because	O	O
of	O	O
the	O	O
many	O	O
reported	O	O
congenital	O	O
abnormalities	O	O
after	O	O
maternal	O	O
use	O	O
(	O	O
including	O	O
microphthalmos	O	O
,	O	O
orbital	O	O
hypertelorism	O	O
,	O	O
and	O	O
optic	O	O
nerve	O	O
hypoplasia	O	O
)	O	O
.	O	O

procaterol	B-chem	B-chem
and	O	O
terbutaline	B-chem	B-chem
in	O	O
bronchial	O	O
asthma	O	O
.	O	O

a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
study	O	O
.	O	O

procaterol	B-chem	B-chem
,	O	O
a	O	O
new	O	O
beta	O	O
-	O	O
2	O	O
adrenoceptor	O	O
stimulant	O	O
,	O	O
was	O	O
studied	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
trial	O	O
in	O	O
patients	O	O
with	O	O
bronchial	O	O
asthma	O	O
.	O	O

oral	O	O
procaterol	B-chem	B-chem
50	O	O
micrograms	O	O
b	O	O
.	O	O
d	O	O
.	O	O
,	O	O
procaterol	B-chem	B-chem
100	O	O
micrograms	O	O
b	O	O
.	O	O
d	O	O
.	O	O

,	O	O
and	O	O
terbutaline	B-chem	B-chem
5	O	O
mg	O	O
t	O	O
.	O	O
i	O	O
.	O	O
d	O	O
.	O	O
,	O	O
were	O	O
compared	O	O
when	O	O
given	O	O
randomly	O	O
in	O	O
1	O	O
-	O	O
week	O	O
treatment	O	O
periods	O	O
.	O	O

the	O	O
best	O	O
clinical	O	O
effect	O	O
was	O	O
found	O	O
with	O	O
terbutaline	B-chem	B-chem
.	O	O

both	O	O
anti	O	O
-	O	O
asthmatic	O	O
and	O	O
tremorgenic	O	O
effects	O	O
of	O	O
procaterol	B-chem	B-chem
were	O	O
dose	O	O
-	O	O
related	O	O
.	O	O

procaterol	B-chem	B-chem
appeared	O	O
effective	O	O
in	O	O
the	O	O
doses	O	O
tested	O	O
,	O	O
and	O	O
a	O	O
twice	O	O
daily	O	O
regimen	O	O
would	O	O
appear	O	O
to	O	O
be	O	O
suitable	O	O
with	O	O
this	O	O
drug	O	O
.	O	O

subacute	O	O
effects	O	O
of	O	O
propranolol	B-chem	B-chem
and	O	O
b	O	O
24	O	O
/	O	O
76	O	O
on	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
rat	O	O
heart	O	O
hypertrophy	O	O
in	O	O
correlation	O	O
with	O	O
blood	O	O
pressure	O	O
.	O	O

we	O	O
compared	O	O
the	O	O
potential	O	O
beta	O	O
-	O	O
receptor	O	O
blocker	O	O
,	O	O
b	O	O
24	O	O
/	O	O
76	O	O
i	O	O
.	O	O
e	O	O
.	O	O
1	O	O
-	O	O
(	O	O
2	O	O
,	O	O
4	O	I-chem
-	O	I-chem
dichlorophenoxy	O	I-chem
)	O	I-chem
-	O	I-chem
3	O	I-chem
[	O	I-chem
2	O	I-chem
-	O	I-chem
3	O	I-chem
,	O	I-chem
4	O	I-chem
-	O	I-chem
dimethoxyphenyl	O	I-chem
)	O	O
ethanolamino	O	I-chem
]	O	I-chem
-	O	I-chem
prop	O	I-chem
an	O	I-chem
-	O	I-chem
2	O	I-chem
-	O	I-chem
ol	O	I-chem
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
beta	O	O
1	O	O
-	O	O
adrenoceptor	O	O
blocking	O	O
and	O	O
beta	O	O
2	O	O
-	O	O
adrenoceptor	O	O
stimulating	O	O
properties	O	O
with	O	O
propranolol	B-chem	B-chem
.	O	O

the	O	O
studies	O	O
were	O	O
performed	O	O
using	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
heart	O	O
hypertrophy	O	O
in	O	O
rats	O	O
.	O	O

a	O	O
correlation	O	O
of	O	O
the	O	O
blood	O	O
pressure	O	O
was	O	O
neither	O	O
found	O	O
in	O	O
the	O	O
development	O	O
nor	O	O
in	O	O
the	O	O
attempt	O	O
to	O	O
suppress	O	O
the	O	O
development	O	O
of	O	O
heart	O	O
hypertrophy	O	O
with	O	O
the	O	O
two	O	O
beta	O	O
-	O	O
receptor	O	O
blockers	O	O
.	O	O

both	O	O
beta	O	O
-	O	O
blockers	O	O
influenced	O	O
the	O	O
development	O	O
of	O	O
hypertrophy	O	O
to	O	O
a	O	O
different	O	O
,	O	O
but	O	O
not	O	O
reproducible	O	O
extent	O	O
.	O	O

it	O	O
was	O	O
possible	O	O
to	O	O
suppress	O	O
the	O	O
increased	O	O
ornithine	B-chem	O
decarboxylase	O	O
activity	O	O
with	O	O
both	O	O
beta	O	O
-	O	O
blockers	O	O
in	O	O
hypertrophied	O	O
hearts	O	O
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
heart	O	O
mass	O	O
.	O	O

neither	O	O
propranolol	B-chem	B-chem
nor	O	O
b	O	O
24	O	O
/	O	O
76	O	O
could	O	O
stop	O	O
the	O	O
changes	O	O
in	O	O
the	O	O
characteristic	O	O
myosin	O	O
isoenzyme	O	O
pattern	O	O
of	O	O
the	O	O
hypertrophied	O	O
rat	O	O
heart	O	O
.	O	O

thus	O	O
,	O	O
the	O	O
investigations	O	O
did	O	O
not	O	O
provide	O	O
any	O	O
evidence	O	O
that	O	O
the	O	O
beta	O	O
-	O	O
receptor	O	O
blockers	O	O
propranolol	B-chem	B-chem
and	O	O
b	O	O
24	O	O
/	O	O
76	O	O
have	O	O
the	O	O
potency	O	O
to	O	O
prevent	O	O
isoproterenol	B-chem	B-chem
from	O	O
producing	O	O
heart	O	O
hypertrophy	O	O
.	O	O

comparison	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
oxitropium	B-chem	B-chem
bromide	I-chem	I-chem
and	O	O
of	O	O
slow	O	O
-	O	O
release	O	O
theophylline	B-chem	B-chem
on	O	O
nocturnal	O	O
asthma	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
a	O	O
new	O	O
inhaled	O	O
antimuscarinic	O	O
drug	O	O
,	O	O
oxitropium	B-chem	B-chem
bromide	I-chem	I-chem
,	O	O
and	O	O
of	O	O
a	O	O
slow	O	O
-	O	O
release	O	O
theophylline	B-chem	B-chem
preparation	O	O
upon	O	O
nocturnal	O	O
asthma	O	O
were	O	O
compared	O	O
in	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
.	O	O

two	O	O
samples	O	O
were	O	O
studied	O	O
:	O	O
12	O	O
patients	O	O
received	O	O
oxitropium	B-chem	B-chem
at	O	O
600	O	O
micrograms	O	O
(	O	O
6	O	O
subjects	O	O
)	O	O
or	O	O
at	O	O
400	O	O
micrograms	O	O
t	O	O
.	O	O
i	O	O
.	O	O
d	O	O
.	O	O

(	O	O
6	O	O
subjects	O	O
)	O	O
whereas	O	O
11	O	O
received	O	O
theophylline	B-chem	B-chem
at	O	O
300	O	O
mg	O	O
b	O	O
.	O	O
i	O	O
.	O	O
d	O	O
.	O	O

morning	O	O
dipping	O	O
,	O	O
assessed	O	O
by	O	O
the	O	O
fall	O	O
in	O	O
peak	O	O
flow	O	O
overnight	O	O
,	O	O
was	O	O
significantly	O	O
reduced	O	O
in	O	O
the	O	O
periods	O	O
when	O	O
either	O	O
active	O	O
drug	O	O
was	O	O
taken	O	O
,	O	O
whereas	O	O
no	O	O
difference	O	O
was	O	O
noticed	O	O
during	O	O
the	O	O
placebo	O	O
administration	O	O
.	O	O

no	O	O
significant	O	O
difference	O	O
was	O	O
noticed	O	O
between	O	O
results	O	O
obtained	O	O
with	O	O
either	O	O
active	O	O
drug	O	O
,	O	O
as	O	O
well	O	O
as	O	O
with	O	O
either	O	O
dosage	O	O
of	O	O
oxitropium	B-chem	B-chem
.	O	O

no	O	O
subject	O	O
reported	O	O
side	O	O
effects	O	O
of	O	O
oxitropium	B-chem	B-chem
,	O	O
as	O	O
compared	O	O
to	O	O
three	O	O
subjects	O	O
reporting	O	O
nausea	O	O
,	O	O
vomiting	O	O
and	O	O
tremors	O	O
after	O	O
theophylline	B-chem	B-chem
.	O	O

oxitropium	B-chem	B-chem
proves	O	O
to	O	O
be	O	O
a	O	O
valuable	O	O
alternative	O	O
to	O	O
theophylline	B-chem	B-chem
in	O	O
nocturnal	O	O
asthma	O	O
,	O	O
since	O	O
it	O	O
is	O	O
equally	O	O
potent	O	O
,	O	O
safer	O	O
and	O	O
does	O	O
not	O	O
require	O	O
the	O	O
titration	O	O
of	O	O
dosage	O	O
.	O	O

penicillin	B-chem	B-chem
anaphylaxis	O	O
.	O	O

a	O	O
case	O	O
of	O	O
oral	O	O
penicillin	B-chem	B-chem
anaphylaxis	O	O
is	O	O
described	O	O
,	O	O
and	O	O
the	O	O
terminology	O	O
,	O	O
occurrence	O	O
,	O	O
clinical	O	O
manifestations	O	O
,	O	O
pathogenesis	O	O
,	O	O
prevention	O	O
,	O	O
and	O	O
treatment	O	O
of	O	O
anaphylaxis	O	O
are	O	O
reviewed	O	O
.	O	O

emergency	O	O
physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
oral	O	O
penicillin	B-chem	B-chem
anaphylaxis	O	O
in	O	O
order	O	O
to	O	O
prevent	O	O
its	O	O
occurrence	O	O
by	O	O
prescribing	O	O
the	O	O
antibiotic	O	O
judiciously	O	O
and	O	O
knowledgeably	O	O
and	O	O
to	O	O
offer	O	O
optimal	O	O
medical	O	O
therapy	O	O
once	O	O
this	O	O
life	O	O
-	O	O
threatening	O	O
reaction	O	O
has	O	O
begun	O	O
.	O	O

reversible	O	O
valproic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
dementia	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

reversible	O	O
valproic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
dementia	O	O
was	O	O
documented	O	O
in	O	O
a	O	O
21	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
epilepsy	O	O
who	O	O
had	O	O
a	O	O
3	O	O
-	O	O
year	O	O
history	O	O
of	O	O
insidious	O	O
progressive	O	O
decline	O	O
in	O	O
global	O	O
cognitive	O	O
abilities	O	O
documented	O	O
by	O	O
serial	O	O
neuropsychological	O	O
studies	O	O
.	O	O

repeat	O	O
neuropsychological	O	O
testing	O	O
7	O	O
weeks	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
revealed	O	O
dramatic	O	O
improvement	O	O
in	O	O
iq	O	O
,	O	O
memory	O	O
,	O	O
naming	O	O
,	O	O
and	O	O
other	O	O
tasks	O	O
commensurate	O	O
with	O	O
clinical	O	O
recovery	O	O
in	O	O
his	O	O
intellectual	O	O
capacity	O	O
.	O	O

possible	O	O
pathophysiological	O	O
mechanisms	O	O
which	O	O
may	O	O
have	O	O
been	O	O
operative	O	O
in	O	O
this	O	O
case	O	O
include	O	O
:	O	O
a	O	O
direct	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
cns	O	O
)	O	O
toxic	O	O
effect	O	O
of	O	O
valproic	B-chem	B-chem
acid	I-chem	I-chem
;	O	O
a	O	O
paradoxical	O	O
epileptogenic	O	O
effect	O	O
secondary	O	O
to	O	O
the	O	O
drug	O	O
;	O	O
and	O	O
an	O	O
indirect	O	O
cns	O	O
toxic	O	O
effect	O	O
mediated	O	O
through	O	O
valproic	B-chem	B-chem
acid	I-chem	I-chem
-	O	O
induced	O	O
hyperammonemia	O	O
.	O	O

reversal	O	O
of	O	O
scopolamine	B-chem	B-chem
-	O	O
induced	O	O
amnesia	O	O
of	O	O
passive	O	O
avoidance	O	O
by	O	O
pre	O	O
-	O	O
and	O	O
post	O	O
-	O	O
training	O	O
naloxone	B-chem	B-chem
.	O	O

in	O	O
a	O	O
series	O	O
of	O	O
five	O	O
experiments	O	O
,	O	O
the	O	O
modulating	O	O
role	O	O
of	O	O
naloxone	B-chem	B-chem
on	O	O
a	O	O
scopolamine	B-chem	B-chem
-	O	O
induced	O	O
retention	O	O
deficit	O	O
in	O	O
a	O	O
passive	O	O
avoidance	O	O
paradigm	O	O
was	O	O
investigated	O	O
in	O	O
mice	O	O
.	O	O

scopolamine	B-chem	B-chem
,	O	O
but	O	O
not	O	O
methyl	B-chem	B-chem
scopolamine	I-chem	B-chem
(	O	O
1	O	O
and	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
induced	O	O
an	O	O
amnesia	O	O
as	O	O
measured	O	O
by	O	O
latency	O	O
and	O	O
duration	O	O
parameters	O	O
.	O	O

naloxone	B-chem	B-chem
(	O	O
0	O	O
.	O	O
3	O	O
,	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
injected	O	O
prior	O	O
to	O	O
training	O	O
attenuated	O	O
the	O	O
retention	O	O
deficit	O	O
with	O	O
a	O	O
peak	O	O
of	O	O
activity	O	O
at	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

the	O	O
effect	O	O
of	O	O
naloxone	B-chem	B-chem
could	O	O
be	O	O
antagonized	O	O
with	O	O
morphine	B-chem	B-chem
(	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
demonstrating	O	O
the	O	O
opioid	O	O
specificity	O	O
of	O	O
the	O	O
naloxone	B-chem	B-chem
effect	O	O
.	O	O

post	O	O
-	O	O
training	O	O
administration	O	O
of	O	O
naloxone	B-chem	B-chem
(	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
as	O	O
a	O	O
single	O	O
or	O	O
as	O	O
a	O	O
split	O	O
dose	O	O
also	O	O
attenuated	O	O
the	O	O
scopolamine	B-chem	B-chem
-	O	O
induced	O	O
amnesia	O	O
.	O	O

control	O	O
experiments	O	O
indicated	O	O
that	O	O
neither	O	O
an	O	O
increase	O	O
in	O	O
pain	O	O
sensitivity	O	O
(	O	O
pre	O	O
-	O	O
training	O	O
naloxone	B-chem	B-chem
)	O	O
nor	O	O
an	O	O
induced	O	O
aversive	O	O
state	O	O
(	O	O
post	O	O
-	O	O
training	O	O
naloxone	B-chem	B-chem
)	O	O
appear	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
influence	O	O
of	O	O
naloxone	B-chem	B-chem
on	O	O
the	O	O
scopolamine	B-chem	B-chem
-	O	O
induced	O	O
retention	O	O
deficit	O	O
.	O	O

these	O	O
results	O	O
extend	O	O
previous	O	O
findings	O	O
implicating	O	O
a	O	O
cholinergic	O	O
-	O	O
opioid	O	O
interaction	O	O
in	O	O
memory	O	O
processes	O	O
.	O	O

a	O	O
possible	O	O
mechanism	O	O
for	O	O
this	O	O
interaction	O	O
involving	O	O
the	O	O
septo	O	O
-	O	O
hippocampal	O	O
cholinergic	O	O
pathway	O	O
is	O	O
discussed	O	O
.	O	O

electron	O	O
microscopic	O	O
investigations	O	O
of	O	O
the	O	O
cyclophosphamide	B-chem	B-chem
-	O	O
induced	O	O
lesions	O	O
of	O	O
the	O	O
urinary	O	O
bladder	O	O
of	O	O
the	O	O
rat	O	O
and	O	O
their	O	O
prevention	O	O
by	O	O
mesna	B-chem	B-chem
.	O	O

fully	O	O
developed	O	O
cyclophosphamide	B-chem	B-chem
-	O	O
induced	O	O
cystitis	O	O
is	O	O
characterized	O	O
by	O	O
nearly	O	O
complete	O	O
detachment	O	O
of	O	O
the	O	O
urothelium	O	O
,	O	O
severe	O	O
submucosal	O	O
edema	O	O
owing	O	O
to	O	O
damage	O	O
to	O	O
the	O	O
microvascular	O	O
bed	O	O
and	O	O
focal	O	O
muscle	O	O
necroses	O	O
.	O	O

the	O	O
initial	O	O
response	O	O
to	O	O
the	O	O
primary	O	O
attack	O	O
by	O	O
the	O	O
cyclophosphamide	B-chem	B-chem
metabolites	O	O
seems	O	O
to	O	O
be	O	O
fragmentation	O	O
of	O	O
the	O	O
luminal	B-chem	O
membrane	O	O
.	O	O

this	O	O
damages	O	O
the	O	O
cellular	O	O
barrier	O	O
against	O	O
the	O	O
hypertonic	O	O
urine	O	O
.	O	O

subsequent	O	O
breaks	O	O
in	O	O
the	O	O
lateral	O	O
cell	O	O
membranes	O	O
of	O	O
the	O	O
superficial	O	O
cells	O	O
and	O	O
in	O	O
all	O	O
the	O	O
plasma	O	O
membranes	O	O
of	O	O
the	O	O
intermediate	O	O
and	O	O
basal	O	O
cells	O	O
,	O	O
intercellular	O	O
and	O	O
intracellular	O	O
edema	O	O
and	O	O
disintegration	O	O
of	O	O
the	O	O
desmosomes	O	O
and	O	O
hemidesmosomes	O	O
lead	O	O
to	O	O
progressive	O	O
degeneration	O	O
and	O	O
detachment	O	O
of	O	O
the	O	O
epithelial	O	O
cells	O	O
with	O	O
exposure	O	O
and	O	O
splitting	O	O
of	O	O
the	O	O
basal	O	O
membrane	O	O
.	O	O

the	O	O
morphological	O	O
changes	O	O
of	O	O
the	O	O
endothelial	O	O
cells	O	O
,	O	O
which	O	O
become	O	O
more	O	O
pronounced	O	O
in	O	O
the	O	O
later	O	O
stages	O	O
of	O	O
the	O	O
experiment	O	O
,	O	O
the	O	O
involvement	O	O
of	O	O
blood	O	O
vessels	O	O
regardless	O	O
of	O	O
their	O	O
diameter	O	O
and	O	O
the	O	O
location	O	O
-	O	O
dependent	O	O
extent	O	O
of	O	O
the	O	O
damage	O	O
indicate	O	O
a	O	O
direct	O	O
type	O	O
of	O	O
damage	O	O
which	O	O
is	O	O
preceded	O	O
by	O	O
a	O	O
mediator	O	O
-	O	O
induced	O	O
increase	O	O
in	O	O
permeability	O	O
,	O	O
the	O	O
morphological	O	O
correlate	O	O
of	O	O
which	O	O
is	O	O
the	O	O
formation	O	O
of	O	O
gaps	O	O
in	O	O
the	O	O
interendothelial	O	O
cell	O	O
connections	O	O
on	O	O
the	O	O
venules	O	O
.	O	O

these	O	O
changes	O	O
can	O	O
be	O	O
effectively	O	O
prevented	O	O
by	O	O
mesna	B-chem	B-chem
.	O	O

the	O	O
only	O	O
sign	O	O
of	O	O
a	O	O
possible	O	O
involvement	O	O
is	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
specific	O	O
granules	O	O
with	O	O
a	O	O
presumed	O	O
lysosomal	O	O
function	O	O
in	O	O
the	O	O
superficial	O	O
cells	O	O
.	O	O

increase	O	O
in	O	O
intragastric	O	O
pressure	O	O
during	O	O
suxamethonium	B-chem	B-chem
-	O	O
induced	O	O
muscle	O	O
fasciculations	O	O
in	O	O
children	O	O
:	O	O
inhibition	O	O
by	O	O
alfentanil	B-chem	B-chem
.	O	O

changes	O	O
in	O	O
intragastric	O	O
pressure	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
suxamethonium	B-chem	B-chem
1	O	O
.	O	O
5	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O
v	O	O
.	O	O
were	O	O
studied	O	O
in	O	O
32	O	O
children	O	O
(	O	O
mean	O	O
age	O	O
6	O	O
.	O	O
9	O	O
yr	O	O
)	O	O
pretreated	O	O
with	O	O
either	O	O
physiological	O	O
saline	O	O
or	O	O
alfentanil	B-chem	B-chem
50	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
.	O	O

anaesthesia	O	O
was	O	O
induced	O	O
with	O	O
thiopentone	B-chem	B-chem
5	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
.	O	O

the	O	O
incidence	O	O
and	O	O
intensity	O	O
of	O	O
muscle	O	O
fasciculations	O	O
caused	O	O
by	O	O
suxamethonium	B-chem	B-chem
were	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
control	O	O
than	O	O
in	O	O
the	O	O
alfentanil	B-chem	B-chem
group	O	O
.	O	O

the	O	O
intragastric	O	O
pressure	O	O
during	O	O
muscle	O	O
fasciculations	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
16	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
7	O	O

(	O	O
sem	O	O
)	O	O
cm	O	O
h2o	B-chem	B-chem
)	O	O
than	O	O
in	O	O
the	O	O
alfentanil	B-chem	B-chem
group	O	O
(	O	O
7	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
5	O	O

(	O	O
sem	O	O
)	O	O
cm	O	O
h2o	B-chem	B-chem
)	O	O
.	O	O

the	O	O
increase	O	O
in	O	O
intragastric	O	O
pressure	O	O
was	O	O
directly	O	O
related	O	O
to	O	O
the	O	O
intensity	O	O
of	O	O
muscle	O	O
fasciculations	O	O
(	O	O
regression	O	O
line	O	O
:	O	O
y	O	O
=	O	O
0	O	O
.	O	O
5	O	O
+	O	O
4	O	O
.	O	O
78x	O	O
with	O	O
r	O	O
of	O	O
0	O	O
.	O	O
78	O	O
)	O	O
.	O	O

it	O	O
is	O	O
concluded	O	O
that	O	O
intragastric	O	O
pressure	O	O
increases	O	O
significantly	O	O
during	O	O
muscle	O	O
fasciculations	O	O
caused	O	O
by	O	O
suxamethonium	B-chem	B-chem
in	O	O
healthy	O	O
children	O	O
.	O	O

alfentanil	B-chem	B-chem
50	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
effectively	O	O
inhibits	O	O
the	O	O
incidence	O	O
and	O	O
intensity	O	O
of	O	O
suxamethonium	B-chem	B-chem
-	O	O
induced	O	O
muscle	O	O
fasciculations	O	O
;	O	O
moreover	O	O
,	O	O
intragastric	O	O
pressure	O	O
remains	O	O
at	O	O
its	O	O
control	O	O
value	O	O
.	O	O

acute	O	O
insulin	O	B-chem
treatment	O	O
normalizes	O	O
the	O	O
resistance	O	O
to	O	O
the	O	O
cardiotoxic	O	O
effect	O	O
of	O	O
isoproterenol	B-chem	B-chem
in	O	O
streptozotocin	B-chem	B-chem
diabetic	O	O
rats	O	O
.	O	O

a	O	O
morphometric	O	O
study	O	O
of	O	O
isoproterenol	B-chem	B-chem
induced	O	O
myocardial	O	O
fibrosis	O	O
.	O	O

the	O	O
acute	O	O
effect	O	O
of	O	O
insulin	O	B-chem
treatment	O	O
on	O	O
the	O	O
earlier	O	O
reported	O	O
protective	O	O
effect	O	O
of	O	O
streptozotocin	B-chem	B-chem
diabetes	O	O
against	O	O
the	O	O
cardiotoxic	O	O
effect	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
isoproterenol	B-chem	B-chem
(	O	O
iso	B-chem	B-chem
)	O	O
was	O	O
investigated	O	O
in	O	O
rats	O	O
.	O	O

thirty	O	O
to	O	O
135	O	O
min	O	O
after	O	O
the	O	O
injection	O	O
of	O	O
crystalline	O	O
insulin	O	B-chem
,	O	O
iso	B-chem	B-chem
was	O	O
given	O	O
subcutaneously	O	O
and	O	O
when	O	O
iso	B-chem	B-chem
induced	O	O
fibrosis	O	O
in	O	O
the	O	O
myocardium	O	O
was	O	O
morphometrically	O	O
analyzed	O	O
7	O	O
days	O	O
later	O	O
,	O	O
a	O	O
highly	O	O
significant	O	O
correlation	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
83	O	O
,	O	O
2	O	O
p	O	O
=	O	O
0	O	O
.	O	O
006	O	O
)	O	O
to	O	O
the	O	O
slope	O	O
of	O	O
the	O	O
fall	O	O
in	O	O
blood	O	O
glucose	B-chem	B-chem
after	O	O
insulin	O	B-chem
treatment	O	O
appeared	O	O
.	O	O

the	O	O
myocardial	O	O
content	O	O
of	O	O
catecholamines	B-chem	B-chem
was	O	O
estimated	O	O
in	O	O
these	O	O
8	O	O
day	O	O
diabetic	O	O
rats	O	O
.	O	O

the	O	O
norepinephrine	B-chem	B-chem
content	O	O
was	O	O
significantly	O	O
increased	O	O
while	O	O
epinephrine	B-chem	B-chem
remained	O	O
unchanged	O	O
.	O	O

an	O	O
enhanced	O	O
sympathetic	O	O
nervous	O	O
system	O	O
activity	O	O
with	O	O
a	O	O
consequent	O	O
down	O	O
regulation	O	O
of	O	O
the	O	O
myocardial	O	O
beta	O	O
-	O	O
adrenergic	O	O
receptors	O	O
could	O	O
,	O	O
therefore	O	O
,	O	O
explain	O	O
this	O	O
catecholamine	B-chem	B-chem
resistance	O	O
.	O	O

the	O	O
rapid	O	O
reversion	O	O
after	O	O
insulin	O	B-chem
treatment	O	O
excludes	O	O
the	O	O
possibility	O	O
that	O	O
streptozotocin	B-chem	B-chem
in	O	O
itself	O	O
causes	O	O
the	O	O
iso	B-chem	B-chem
resistance	O	O
and	O	O
points	O	O
towards	O	O
a	O	O
direct	O	O
insulin	O	O
effect	O	O
on	O	O
myocardial	O	O
catecholamine	B-chem	B-chem
sensitivity	O	O
in	O	O
diabetic	O	O
rats	O	O
.	O	O

the	O	O
phenomenon	O	O
described	O	O
might	O	O
elucidate	O	O
pathogenetic	O	O
mechanisms	O	O
behind	O	O
toxic	O	O
myocardial	O	O
cell	O	O
degeneration	O	O
and	O	O
may	O	O
possibly	O	O
have	O	O
relevance	O	O
for	O	O
acute	O	O
cardiovascular	O	O
complications	O	O
in	O	O
diabetic	O	O
patients	O	O
.	O	O

differential	O	O
effects	O	O
of	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
on	O	O
seizures	O	O
produced	O	O
by	O	O
pilocarpine	B-chem	B-chem
in	O	O
rats	O	O
.	O	O

the	O	O
muscarinic	O	O
cholinergic	O	O
agonist	O	O
pilocarpine	B-chem	B-chem
induces	O	O
in	O	O
rats	O	O
seizures	O	O
and	O	O
status	O	O
epilepticus	O	O
followed	O	O
by	O	O
widespread	O	O
damage	O	O
to	O	O
the	O	O
forebrain	O	O
.	O	O

the	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
5	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
,	O	O
sodium	B-chem	B-chem
salicylate	I-chem	I-chem
,	O	O
phenylbutazone	B-chem	B-chem
,	O	O
indomethacin	B-chem	B-chem
,	O	O
ibuprofen	B-chem	B-chem
and	O	O
mefenamic	B-chem	B-chem
acid	I-chem	I-chem
,	O	O
on	O	O
seizures	O	O
produced	O	O
by	O	O
pilocarpine	B-chem	B-chem
.	O	O

pretreatment	O	O
of	O	O
rats	O	O
with	O	O
sodium	B-chem	B-chem
salicylate	I-chem	I-chem
,	O	O
ed50	O	B-chem
103	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
60	O	O
-	O	O
174	O	O
)	O	O
,	O	O
and	O	O
phenylbutazone	B-chem	B-chem
,	O	O
59	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
50	O	O
-	O	O
70	O	O
)	O	O
converted	O	O
the	O	O
non	O	O
-	O	O
convulsant	O	O
dose	O	O
of	O	O
pilocarpine	B-chem	B-chem
,	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
to	O	O
a	O	O
convulsant	O	O
one	O	O
.	O	O

indomethacin	B-chem	B-chem
,	O	O
1	O	O
-	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
and	O	O
ibuprofen	B-chem	B-chem
,	O	O
10	O	O
-	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
failed	O	O
to	O	O
modulate	O	O
seizures	O	O
produced	O	O
by	O	O
pilocarpine	B-chem	B-chem
.	O	O

mefenamic	B-chem	B-chem
acid	I-chem	I-chem
,	O	O
26	O	O
(	O	O
22	O	O
-	O	O
30	O	O
)	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
prevented	O	O
seizures	O	O
and	O	O
protected	O	O
rats	O	O
from	O	O
seizure	O	O
-	O	O
related	O	O
brain	O	O
damage	O	O
induced	O	O
by	O	O
pilocarpine	B-chem	B-chem
,	O	O
380	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

these	O	O
results	O	O
indicate	O	O
that	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
differentially	O	O
modulate	O	O
the	O	O
threshold	O	O
for	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
.	O	O

acute	O	O
neurologic	O	O
dysfunction	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
etoposide	B-chem	B-chem
therapy	O	O
for	O	O
malignant	O	O
glioma	O	O
.	O	O

etoposide	B-chem	B-chem
(	O	O
vp	B-chem	B-chem
-	I-chem	O
16	I-chem	I-chem
-	I-chem	O
213	I-chem	O
)	O	O
has	O	O
been	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
many	O	O
solid	O	O
tumors	O	O
and	O	O
hematologic	O	O
malignancies	O	O
.	O	O

when	O	O
used	O	O
in	O	O
high	O	O
doses	O	O
and	O	O
in	O	O
conjunction	O	O
with	O	O
autologous	O	O
bone	O	O
marrow	O	O
transplantation	O	O
,	O	O
this	O	O
agent	O	O
has	O	O
activity	O	O
against	O	O
several	O	O
treatment	O	O
-	O	O
resistant	O	O
cancers	O	O
including	O	O
malignant	O	O
glioma	O	O
.	O	O

in	O	O
six	O	O
of	O	O
eight	O	O
patients	O	O
(	O	O
75	O	O
%	O	O
)	O	O
who	O	O
we	O	O
treated	O	O
for	O	O
recurrent	O	O
or	O	O
resistant	O	O
glioma	O	O
,	O	O
sudden	O	O
severe	O	O
neurologic	O	O
deterioration	O	O
occurred	O	O
.	O	O

this	O	O
developed	O	O
a	O	O
median	O	O
of	O	O
9	O	O
days	O	O
after	O	O
initiation	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
etoposide	B-chem	B-chem
therapy	O	O
.	O	O

significant	O	O
clinical	O	O
manifestations	O	O
have	O	O
included	O	O
confusion	O	O
,	O	O
papilledema	O	O
,	O	O
somnolence	O	O
,	O	O
exacerbation	O	O
of	O	O
motor	O	O
deficits	O	O
,	O	O
and	O	O
sharp	O	O
increase	O	O
in	O	O
seizure	O	O
activity	O	O
.	O	O

these	O	O
abnormalities	O	O
resolved	O	O
rapidly	O	O
after	O	O
initiation	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
intravenous	O	O
dexamethasone	B-chem	B-chem
therapy	O	O
.	O	O

in	O	O
all	O	O
patients	O	O
,	O	O
computerized	O	O
tomographic	O	O
(	O	O
ct	O	O
)	O	O
brain	O	O
scans	O	O
demonstrated	O	O
stability	O	O
in	O	O
tumor	O	O
size	O	O
and	O	O
peritumor	O	O
edema	O	O
when	O	O
compared	O	O
with	O	O
pretransplant	O	O
scans	O	O
.	O	O

this	O	O
complication	O	O
appears	O	O
to	O	O
represent	O	O
a	O	O
significant	O	O
new	O	O
toxicity	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
etoposide	B-chem	B-chem
therapy	O	O
for	O	O
malignant	O	O
glioma	O	O
.	O	O

progressive	O	O
bile	O	O
duct	O	O
injury	O	O
after	O	O
thiabendazole	B-chem	B-chem
administration	O	O
.	O	O

a	O	O
27	O	O
-	O	O
yr	O	O
-	O	O
old	O	O
man	O	O
developed	O	O
jaundice	O	O
2	O	O
wk	O	O
after	O	O
exposure	O	O
to	O	O
thiabendazole	B-chem	B-chem
.	O	O

cholestasis	O	O
persisted	O	O
for	O	O
3	O	O
yr	O	O
,	O	O
at	O	O
which	O	O
time	O	O
a	O	O
liver	O	O
transplant	O	O
was	O	O
performed	O	O
.	O	O

two	O	O
liver	O	O
biopsy	O	O
specimens	O	O
and	O	O
the	O	O
hepatectomy	O	O
specimen	O	O
were	O	O
remarkable	O	O
for	O	O
almost	O	O
complete	O	O
disappearance	O	O
of	O	O
interlobular	O	O
bile	O	O
ducts	O	O
.	O	O

prominent	O	O
fibrosis	O	O
and	O	O
hepatocellular	O	O
regeneration	O	O
were	O	O
also	O	O
present	O	O
;	O	O
however	O	O
,	O	O
the	O	O
lobular	O	O
architecture	O	O
was	O	O
preserved	O	O
.	O	O

this	O	O
case	O	O
represents	O	O
an	O	O
example	O	O
of	O	O
"	O	O
"	O	O
"	O	O
"	O	O
idiosyncratic	O	O
"	O	O
"	O	O
"	O	O
"	O	O
drug	O	O
-	O	O
induced	O	O
liver	O	O
damage	O	O
in	O	O
which	O	O
the	O	O
primary	O	O
target	O	O
of	O	O
injury	O	O
is	O	O
the	O	O
bile	O	O
duct	O	O
.	O	O

an	O	O
autoimmune	O	O
pathogenesis	O	O
of	O	O
the	O	O
bile	O	O
duct	O	O
destruction	O	O
is	O	O
suggested	O	O
.	O	O

differential	O	O
effects	O	O
of	O	O
1	B-chem	B-chem
,	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
dihydropyridine	I-chem	I-chem
calcium	B-chem	I-chem
channel	I-chem	O
blockers	I-chem	O
:	O	O
therapeutic	O	O
implications	O	O
.	O	O

increasing	O	O
recognition	O	O
of	O	O
the	O	O
importance	O	O
of	O	O
calcium	B-chem	B-chem
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
cardiovascular	O	O
disease	O	O
has	O	O
stimulated	O	O
research	O	O
into	O	O
the	O	O
use	O	O
of	O	O
calcium	B-chem	B-chem
channel	I-chem	O
blocking	I-chem	O
agents	I-chem	O
for	O	O
treatment	O	O
of	O	O
a	O	O
variety	O	O
of	O	O
cardiovascular	O	O
diseases	O	O
.	O	O

the	O	O
favorable	O	O
efficacy	O	O
and	O	O
tolerability	O	O
profiles	O	O
of	O	O
these	O	O
agents	O	O
make	O	O
them	O	O
attractive	O	O
therapeutic	O	O
modalities	O	O
.	O	O

clinical	O	O
applications	O	O
of	O	O
calcium	B-chem	B-chem
channel	I-chem	O
blockers	I-chem	O
parallel	O	O
their	O	O
tissue	O	O
selectivity	O	O
.	O	O

in	O	O
contrast	O	O
to	O	O
verapamil	B-chem	B-chem
and	O	O
diltiazem	B-chem	B-chem
,	O	O
which	O	O
are	O	O
roughly	O	O
equipotent	O	O
in	O	O
their	O	O
actions	O	O
on	O	O
the	O	O
heart	O	O
and	O	O
vascular	O	O
smooth	O	O
muscle	O	O
,	O	O
the	O	O
dihydropyridine	B-chem	B-chem
calcium	B-chem	I-chem
channel	I-chem	O
blockers	I-chem	O
are	O	O
a	O	O
group	O	O
of	O	O
potent	O	O
peripheral	O	O
vasodilator	O	O
agents	O	O
that	O	O
exert	O	O
minimal	O	O
electrophysiologic	O	O
effects	O	O
on	O	O
cardiac	O	O
nodal	O	O
or	O	O
conduction	O	O
tissue	O	O
.	O	O

as	O	O
the	O	O
first	O	O
dihydropyridine	B-chem	B-chem
available	O	O
for	O	O
use	O	O
in	O	O
the	O	O
united	O	O
states	O	O
,	O	O
nifedipine	B-chem	B-chem
controls	O	O
angina	O	O
and	O	O
hypertension	O	O
with	O	O
minimal	O	O
depression	O	O
of	O	O
cardiac	O	O
function	O	O
.	O	O

additional	O	O
members	O	O
of	O	O
this	O	O
group	O	O
of	O	O
calcium	B-chem	B-chem
channel	I-chem	O
blockers	I-chem	O
have	O	O
been	O	O
studied	O	O
for	O	O
a	O	O
variety	O	O
of	O	O
indications	O	O
for	O	O
which	O	O
they	O	O
may	O	O
offer	O	O
advantages	O	O
over	O	O
current	O	O
therapy	O	O
.	O	O

once	O	O
or	O	O
twice	O	O
daily	O	O
dosage	O	O
possible	O	O
with	O	O
nitrendipine	B-chem	B-chem
and	O	O
nisoldipine	B-chem	B-chem
offers	O	O
a	O	O
convenient	O	O
administration	O	O
schedule	O	O
,	O	O
which	O	O
encourages	O	O
patient	O	O
compliance	O	O
in	O	O
long	O	O
-	O	O
term	O	O
therapy	O	O
of	O	O
hypertension	O	O
.	O	O

the	O	O
coronary	O	O
vasodilating	O	O
properties	O	O
of	O	O
nisoldipine	B-chem	B-chem
have	O	O
led	O	O
to	O	O
the	O	O
investigation	O	O
of	O	O
this	O	O
agent	O	O
for	O	O
use	O	O
in	O	O
angina	O	O
.	O	O

selectivity	O	O
for	O	O
the	O	O
cerebrovascular	O	O
bed	O	O
makes	O	O
nimodipine	B-chem	B-chem
potentially	O	O
useful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
subarachnoid	O	O
hemorrhage	O	O
,	O	O
migraine	O	O
headache	O	O
,	O	O
dementia	O	O
,	O	O
and	O	O
stroke	O	O
.	O	O

in	O	O
general	O	O
,	O	O
the	O	O
dihydropyridine	B-chem	B-chem
calcium	B-chem	I-chem
channel	I-chem	O
blockers	I-chem	O
are	O	O
usually	O	O
well	O	O
tolerated	O	O
,	O	O
with	O	O
headache	O	O
,	O	O
facial	O	O
flushing	O	O
,	O	O
palpitations	O	O
,	O	O
edema	O	O
,	O	O
nausea	O	O
,	O	O
anorexia	O	O
,	O	O
and	O	O
dizziness	O	O
being	O	O
the	O	O
more	O	O
common	O	O
adverse	O	O
effects	O	O
.	O	O

the	O	O
enhancement	O	O
of	O	O
aminonucleoside	B-chem	O
nephrosis	O	O
by	O	O
the	O	O
co	O	O
-	O	O
administration	O	O
of	O	O
protamine	O	O
.	O	O

an	O	O
experimental	O	O
model	O	O
of	O	O
focal	O	O
segmental	O	O
glomerular	O	O
sclerosis	O	O
(	O	O
fsgs	O	B-chem
)	O	O
was	O	O
developed	O	O
in	O	O
rats	O	O
by	O	O
the	O	O
combined	O	O
administration	O	O
of	O	O
puromycin	B-chem	B-chem
-	I-chem	O
aminonucleoside	I-chem	I-chem
(	O	O
amns	B-chem	B-chem
)	O	O
and	O	O
protamine	B-chem	O
sulfate	I-chem	I-chem
(	O	O
ps	B-chem	O
)	O	O
.	O	O

male	O	O
sprague	O	O
-	O	O
dawley	O	O
rats	O	O
,	O	O
uninephrectomized	O	O
three	O	O
weeks	O	O
before	O	O
,	O	O
received	O	O
daily	O	O
injections	O	O
of	O	O
subcutaneous	O	O
amns	B-chem	B-chem
(	O	O
1	O	O
mg	O	O
/	O	O
100	O	O
g	O	O
body	O	O
wt	O	O
)	O	O
and	O	O
intravenous	O	O
ps	B-chem	O
(	O	O
2	O	O
separated	O	O
doses	O	O
of	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
100	O	O
g	O	O
body	O	O
wt	O	O
)	O	O
for	O	O
four	O	O
days	O	O
.	O	O

the	O	O
series	O	O
of	O	O
injections	O	O
were	O	O
repeated	O	O
another	O	O
three	O	O
times	O	O
at	O	O
10	O	O
day	O	O
intervals	O	O
.	O	O

the	O	O
animals	O	O
were	O	O
sacrificed	O	O
on	O	O
days	O	O
24	O	O
,	O	O
52	O	O
,	O	O
and	O	O
80	O	O
.	O	O

they	O	O
developed	O	O
nephrotic	O	O
syndrome	O	O
and	O	O
finally	O	O
renal	O	O
failure	O	O
.	O	O

the	O	O
time	O	O
-	O	O
course	O	O
curve	O	O
of	O	O
creatinine	B-chem	B-chem
clearance	O	O
dropped	O	O
and	O	O
showed	O	O
significant	O	O
difference	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
from	O	O
that	O	O
of	O	O
each	O	O
control	O	O
group	O	O
,	O	O
such	O	O
as	O	O
,	O	O
amns	B-chem	O
alone	O	O
,	O	O
ps	B-chem	O
alone	O	O
or	O	O
saline	O	O
injected	O	O
.	O	O

their	O	O
glomeruli	O	O
showed	O	O
changes	O	O
of	O	O
progressive	O	O
fsgs	O	B-chem
.	O	O

the	O	O
ultrastructural	O	O
studies	O	O
in	O	O
the	O	O
initial	O	O
stage	O	O
revealed	O	O
significant	O	O
lack	O	O
of	O	O
particles	O	O
of	O	O
perfused	O	O
ruthenium	B-chem	B-chem
red	O	I-chem
on	O	O
the	O	O
lamina	O	O
rara	O	O
externa	O	O
and	O	O
marked	O	O
changes	O	O
in	O	O
epithelial	O	O
cell	O	O
cytoplasm	O	O
.	O	O

therefore	O	O
,	O	O
it	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
administration	O	O
of	O	O
ps	B-chem	O
enhances	O	O
the	O	O
toxicity	O	O
of	O	O
amns	B-chem	O
on	O	O
the	O	O
glomerulus	O	O
and	O	O
readily	O	O
produces	O	O
progressive	O	O
fsgs	O	B-chem
in	O	O
rats	O	O
resulting	O	O
in	O	O
the	O	O
end	O	O
-	O	O
stage	O	O
renal	O	O
disease	O	O
.	O	O

theophylline	B-chem	B-chem
neurotoxicity	O	O
in	O	O
pregnant	O	O
rats	O	O
.	O	O

the	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
neurotoxicity	O	O
of	O	O
theophylline	B-chem	B-chem
is	O	O
altered	O	O
in	O	O
advanced	O	O
pregnancy	O	O
.	O	O

sprague	O	O
-	O	O
dawley	O	O
rats	O	O
that	O	O
were	O	O
20	O	O
days	O	O
pregnant	O	O
and	O	O
nonpregnant	O	O
rats	O	O
of	O	O
the	O	O
same	O	O
age	O	O
and	O	O
strain	O	O
received	O	O
infusions	O	O
of	O	O
aminophylline	B-chem	B-chem
until	O	O
onset	O	O
of	O	O
maximal	O	O
seizures	O	O
which	O	O
occurred	O	O
after	O	O
28	O	O
and	O	O
30	O	O
minutes	O	O
respectively	O	O
.	O	O

theophylline	B-chem	B-chem
concentrations	O	O
at	O	O
this	O	O
endpoint	O	O
in	O	O
serum	O	O
(	O	O
total	O	O
)	O	O
and	O	O
csf	O	O
were	O	O
similar	O	O
but	O	O
serum	O	O
(	O	O
free	O	O
)	O	O
and	O	O
brain	O	O
concentrations	O	O
were	O	O
slightly	O	O
different	O	O
in	O	O
pregnant	O	O
rats	O	O
.	O	O

theophylline	B-chem	B-chem
serum	O	O
protein	O	O
binding	O	O
determined	O	O
by	O	O
equilibrium	O	O
dialysis	O	O
was	O	O
lower	O	O
in	O	O
pregnant	O	O
rats	O	O
.	O	O

fetal	O	O
serum	O	O
concentrations	O	O
at	O	O
onset	O	O
of	O	O
seizures	O	O
in	O	O
the	O	O
mother	O	O
were	O	O
similar	O	O
to	O	O
maternal	O	O
brain	O	O
and	O	O
csf	O	O
concentrations	O	O
and	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
former	O	O
.	O	O

it	O	O
is	O	O
concluded	O	O
that	O	O
advanced	O	O
pregnancy	O	O
has	O	O
a	O	O
negligible	O	O
effect	O	O
on	O	O
the	O	O
neurotoxic	O	O
response	O	O
to	O	O
theophylline	B-chem	B-chem
in	O	O
rats	O	O
.	O	O

hyperkalemia	O	O
induced	O	O
by	O	O
indomethacin	B-chem	B-chem
and	O	O
naproxen	B-chem	B-chem
and	O	O
reversed	O	O
by	O	O
fludrocortisone	B-chem	B-chem
.	O	O

we	O	O
have	O	O
described	O	O
a	O	O
patient	O	O
with	O	O
severe	O	O
rheumatoid	O	O
arthritis	O	O
and	O	O
a	O	O
history	O	O
of	O	O
mefenamic	B-chem	B-chem
acid	I-chem	I-chem
nephropathy	O	O
in	O	O
whom	O	O
hyperkalemia	O	O
and	O	O
inappropriate	O	O
hypoaldosteronism	O	O
were	O	O
caused	O	O
by	O	O
both	O	O
indomethacin	B-chem	B-chem
and	O	O
naproxen	B-chem	B-chem
,	O	O
without	O	O
major	O	O
decline	O	O
in	O	O
renal	O	O
function	O	O
.	O	O

it	O	O
is	O	O
likely	O	O
that	O	O
preexisting	O	O
renal	O	O
disease	O	O
predisposed	O	O
this	O	O
patient	O	O
to	O	O
type	O	O
iv	O	O
renal	O	O
tubular	O	O
acidosis	O	O
with	O	O
prostaglandin	B-chem	O
synthetase	O	O
inhibitors	O	O
.	O	O

because	O	O
he	O	O
was	O	O
unable	O	O
to	O	O
discontinue	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
therapy	O	O
,	O	O
fludrocortisone	B-chem	B-chem
was	O	O
added	O	O
,	O	O
correcting	O	O
the	O	O
hyperkalemia	O	O
and	O	O
allowing	O	O
indomethacin	B-chem	B-chem
therapy	O	O
to	O	O
be	O	O
continued	O	O
safely	O	O
.	O	O

hypotension	O	O
as	O	O
a	O	O
manifestation	O	O
of	O	O
cardiotoxicity	O	O
in	O	O
three	O	O
patients	O	O
receiving	O	O
cisplatin	B-chem	B-chem
and	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
.	O	O

cardiac	O	O
symptoms	O	O
,	O	O
including	O	O
hypotension	O	O
,	O	O
developed	O	O
in	O	O
three	O	O
patients	O	O
with	O	O
advanced	O	O
colorectal	O	O
carcinoma	O	O
while	O	O
being	O	O
treated	O	O
with	O	O
cisplatin	B-chem	B-chem
(	O	O
cddp	B-chem	B-chem
)	O	O
and	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
(	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
)	O	O
.	O	O

in	O	O
two	O	O
patients	O	O
,	O	O
hypotension	O	O
was	O	O
associated	O	O
with	O	O
severe	O	O
left	O	O
ventricular	O	O
dysfunction	O	O
.	O	O

all	O	O
three	O	O
patients	O	O
required	O	O
therapy	O	O
discontinuation	O	O
.	O	O

cardiac	O	O
enzymes	O	O
remained	O	O
normal	O	O
despite	O	O
transient	O	O
electrocardiographic	O	O
(	O	O
ekg	O	O
)	O	O
changes	O	O
.	O	O

the	O	O
presentation	O	O
and	O	O
cardiac	O	O
evaluation	O	O
(	O	O
hemodynamic	O	O
,	O	O
echocardiographic	O	O
,	O	O
and	O	O
scintigraphic	O	O
)	O	O
of	O	O
these	O	O
patients	O	O
suggest	O	O
new	O	O
manifestations	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
cardiotoxicity	O	O
that	O	O
may	O	O
be	O	O
influenced	O	O
by	O	O
cddp	B-chem	O
.	O	O

the	O	O
possible	O	O
pathophysiologic	O	O
mechanisms	O	O
are	O	O
discussed	O	O
.	O	O

fatal	O	O
aplastic	O	O
anemia	O	O
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
carbamazepine	B-chem	B-chem
.	O	O

a	O	O
case	O	O
of	O	O
fatal	O	O
aplastic	O	O
anemia	O	O
due	O	O
to	O	O
carbamazepine	B-chem	B-chem
treatment	O	O
in	O	O
an	O	O
epileptic	O	O
woman	O	O
is	O	O
reported	O	O
.	O	O

despite	O	O
concerns	O	O
of	O	O
fatal	O	O
bone	O	O
marrow	O	O
toxicity	O	O
due	O	O
to	O	O
carbamazepine	B-chem	B-chem
,	O	O
this	O	O
is	O	O
only	O	O
the	O	O
fourth	O	O
documented	O	O
and	O	O
published	O	O
report	O	O
.	O	O

carbamazepine	B-chem	B-chem
is	O	O
a	O	O
safe	O	O
drug	O	O
,	O	O
but	O	O
physicians	O	O
and	O	O
patients	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
exceedingly	O	O
rare	O	O
but	O	O
potentially	O	O
fatal	O	O
side	O	O
effects	O	O
,	O	O
better	O	O
prevented	O	O
by	O	O
clinical	O	O
than	O	O
by	O	O
laboratory	O	O
monitoring	O	O
.	O	O

participation	O	O
of	O	O
a	O	O
bulbospinal	O	O
serotonergic	O	O
pathway	O	O
in	O	O
the	O	O
rat	O	O
brain	O	O
in	O	O
clonidine	B-chem	B-chem
-	O	O
induced	O	O
hypotension	O	O
and	O	O
bradycardia	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
microinjection	O	O
of	O	O
clonidine	B-chem	B-chem
(	O	O
1	O	O
-	O	O
10	O	O
micrograms	O	O
in	O	O
1	O	O
microliter	O	O
)	O	O
into	O	O
a	O	O
region	O	O
adjacent	O	O
to	O	O
the	O	O
ventrolateral	O	O
surface	O	O
of	O	O
the	O	O
medulla	O	O
oblongata	O	O
on	O	O
cardiovascular	O	O
function	O	O
were	O	O
assessed	O	O
in	O	O
urethane	B-chem	B-chem
-	O	O
anesthetized	O	O
rats	O	O
.	O	O

intramedullary	O	O
administration	O	O
of	O	O
clonidine	B-chem	B-chem
,	O	O
but	O	O
not	O	O
saline	O	O
vehicle	O	O
,	O	O
caused	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
decrease	O	O
in	O	O
both	O	O
the	O	O
mean	O	O
arterial	O	O
pressure	O	O
and	O	O
the	O	O
heart	O	O
rate	O	O
.	O	O

the	O	O
clonidine	B-chem	B-chem
-	O	O
induced	O	O
hypotension	O	O
was	O	O
antagonized	O	O
by	O	O
prior	O	O
spinal	O	O
transection	O	O
,	O	O
but	O	O
not	O	O
bilateral	O	O
vagotomy	O	O
.	O	O

on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
clonidine	B-chem	B-chem
-	O	O
induced	O	O
bradycardia	O	O
was	O	O
antagonized	O	O
by	O	O
prior	O	O
bilateral	O	O
vagotomy	O	O
,	O	O
but	O	O
not	O	O
spinal	O	O
transection	O	O
.	O	O

furthermore	O	O
,	O	O
selective	O	O
destruction	O	O
of	O	O
the	O	O
spinal	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
nerves	O	O
,	O	O
produced	O	O
by	O	O
bilateral	O	O
spinal	O	O
injection	O	O
of	O	O
5	B-chem	B-chem
,	I-chem	O
7	I-chem	I-chem
-	I-chem	I-chem
dihydroxytryptamine	I-chem	I-chem
,	O	O
reduced	O	O
the	O	O
magnitude	O	O
of	O	O
the	O	O
vasodepressor	O	B-chem
or	O	O
the	O	O
bradycardiac	O	O
responses	O	O
to	O	O
clonidine	B-chem	B-chem
microinjected	O	O
into	O	O
the	O	O
area	O	O
near	O	O
the	O	O
ventrolateral	O	O
surface	O	O
of	O	O
the	O	O
medulla	O	O
oblongata	O	O
in	O	O
rats	O	O
.	O	O

the	O	O
data	O	O
indicate	O	O
that	O	O
a	O	O
bulbospinal	O	O
serotonergic	O	O
pathway	O	O
is	O	O
involved	O	O
in	O	O
development	O	O
of	O	O
clonidine	B-chem	B-chem
-	O	O
induced	O	O
hypotension	O	O
and	O	O
bradycardia	O	O
.	O	O

the	O	O
induced	O	O
hypotension	O	O
is	O	O
brought	O	O
about	O	O
by	O	O
a	O	O
decrease	O	O
in	O	O
sympathetic	O	O
efferent	O	O
activity	O	O
,	O	O
whereas	O	O
the	O	O
induced	O	O
bradycardia	O	O
was	O	O
due	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
vagal	O	O
efferent	O	O
activity	O	O
.	O	O

hypertension	O	O
in	O	O
neuroblastoma	O	O
induced	O	O
by	O	O
imipramine	B-chem	B-chem
.	O	O

hypertension	O	O
is	O	O
a	O	O
well	O	O
-	O	O
known	O	O
finding	O	O
in	O	O
some	O	O
patients	O	O
with	O	O
neuroblastoma	O	O
.	O	O

however	O	O
,	O	O
it	O	O
has	O	O
not	O	O
previously	O	O
been	O	O
described	O	O
in	O	O
association	O	O
with	O	O
the	O	O
use	O	O
of	O	O
imipramine	B-chem	B-chem
.	O	O

we	O	O
report	O	O
the	O	O
occurrence	O	O
of	O	O
severe	O	O
hypertension	O	O
(	O	O
blood	O	O
pressure	O	O
190	O	O
/	O	O
160	O	O
)	O	O
in	O	O
a	O	O
4	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
with	O	O
neuroblastoma	O	O
who	O	O
was	O	O
given	O	O
imipramine	B-chem	B-chem
to	O	O
control	O	O
a	O	O
behavior	O	O
disorder	O	O
.	O	O

it	O	O
was	O	O
determined	O	O
later	O	O
that	O	O
this	O	O
patient	O	O
'	O	O
s	O	O
tumor	O	O
was	O	O
recurring	O	O
at	O	O
the	O	O
time	O	O
of	O	O
her	O	O
hypertensive	O	O
episode	O	O
.	O	O

since	O	O
she	O	O
had	O	O
no	O	O
blood	O	O
pressure	O	O
elevation	O	O
at	O	O
initial	O	O
diagnosis	O	O
and	O	O
none	O	O
following	O	O
discontinuation	O	O
of	O	O
the	O	O
imipramine	B-chem	B-chem
(	O	O
when	O	O
she	O	O
was	O	O
in	O	O
florid	O	O
relapse	O	O
)	O	O
,	O	O
we	O	O
believe	O	O
that	O	O
this	O	O
drug	O	O
rather	O	O
than	O	O
her	O	O
underlying	O	O
disease	O	O
alone	O	O
caused	O	O
her	O	O
hypertension	O	O
.	O	O

the	O	O
mechanism	O	O
for	O	O
this	O	O
reaction	O	O
is	O	O
believed	O	O
to	O	O
be	O	O
increased	O	O
levels	O	O
of	O	O
vasoactive	O	O
catecholamines	B-chem	B-chem
due	O	O
to	O	O
interference	O	O
of	O	O
their	O	O
physiologic	O	O
inactivation	O	O
by	O	O
imipramine	B-chem	B-chem
.	O	O

from	O	O
this	O	O
experience	O	O
,	O	O
we	O	O
urge	O	O
extreme	O	O
caution	O	O
in	O	O
the	O	O
use	O	O
of	O	O
tricyclic	O	O
antidepressants	O	B-chem
in	O	O
children	O	O
with	O	O
active	O	O
neuroblastoma	O	O
.	O	O

rechallenge	O	O
of	O	O
patients	O	O
who	O	O
developed	O	O
oral	O	O
candidiasis	O	O
or	O	O
hoarseness	O	O
with	O	O
beclomethasone	B-chem	B-chem
dipropionate	I-chem	I-chem
.	O	O

of	O	O
158	O	O
asthmatic	O	O
patients	O	O
who	O	O
were	O	O
placed	O	O
on	O	O
inhaled	O	O
beclomethasone	B-chem	B-chem
,	O	O
15	O	O
(	O	O
9	O	O
.	O	O
5	O	O
%	O	O
)	O	O
developed	O	O
either	O	O
hoarseness	O	O
(	O	O
8	O	O
)	O	O
,	O	O
oral	O	O
thrush	O	O
(	O	O
6	O	O
)	O	O
,	O	O
or	O	O
both	O	O
(	O	O
1	O	O
)	O	O
.	O	O

when	O	O
their	O	O
adverse	O	O
reactions	O	O
subsided	O	O
,	O	O
seven	O	O
of	O	O
these	O	O
15	O	O
patients	O	O
were	O	O
rechallenged	O	O
with	O	O
inhaled	O	O
beclomethasone	B-chem	B-chem
.	O	O

these	O	O
included	O	O
five	O	O
cases	O	O
who	O	O
developed	O	O
hoarseness	O	O
and	O	O
three	O	O
who	O	O
developed	O	O
candidiasis	O	O
.	O	O

one	O	O
patient	O	O
had	O	O
both	O	O
.	O	O

oral	O	O
thrush	O	O
did	O	O
not	O	O
recur	O	O
,	O	O
but	O	O
60	O	O
%	O	O
(	O	O
3	O	O
/	O	O
5	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
hoarseness	O	O
had	O	O
recurrence	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
patients	O	O
may	O	O
be	O	O
restarted	O	O
on	O	O
inhaled	O	O
beclomethasone	B-chem	B-chem
when	O	O
clinically	O	O
indicated	O	O
;	O	O
however	O	O
,	O	O
because	O	O
of	O	O
the	O	O
high	O	O
recurrence	O	O
rate	O	O
,	O	O
patients	O	O
who	O	O
develop	O	O
hoarseness	O	O
should	O	O
not	O	O
be	O	O
re	O	O
-	O	O
challenged	O	O
.	O	O

concomitant	O	O
use	O	O
of	O	O
oral	O	O
prednisone	B-chem	B-chem
and	O	O
topical	O	B-chem
beclomethasone	B-chem	I-chem
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
hoarseness	O	O
or	O	O
candidiasis	O	O
.	O	O

cyclophosphamide	B-chem	B-chem
cardiotoxicity	O	O
:	O	O
an	O	O
analysis	O	O
of	O	O
dosing	O	O
as	O	O
a	O	O
risk	O	O
factor	O	O
.	O	O

patients	O	O
who	O	O
undergo	O	O
bone	O	O
marrow	O	O
transplantation	O	O
are	O	O
generally	O	O
immunosuppressed	O	O
with	O	O
a	O	O
dose	O	O
of	O	O
cyclophosphamide	B-chem	B-chem
(	O	O
cya	B-chem	B-chem
)	O	O
which	O	O
is	O	O
usually	O	O
calculated	O	O
based	O	O
on	O	O
the	O	O
patient	O	O
'	O	O
s	O	O
weight	O	O
.	O	O

at	O	O
these	O	O
high	O	O
doses	O	O
of	O	O
cya	B-chem	B-chem
,	O	O
serious	O	O
cardiotoxicity	O	O
may	O	O
occur	O	O
,	O	O
but	O	O
definitive	O	O
risk	O	O
factors	O	O
for	O	O
the	O	O
development	O	O
of	O	O
such	O	O
cardiotoxicity	O	O
have	O	O
not	O	O
been	O	O
described	O	O
.	O	O

since	O	O
chemotherapeutic	O	O
agent	O	O
toxicity	O	O
generally	O	O
correlates	O	O
with	O	O
dose	O	O
per	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
we	O	O
retrospectively	O	O
calculated	O	O
the	O	O
dose	O	O
of	O	O
cya	B-chem	B-chem
in	O	O
patients	O	O
transplanted	O	O
at	O	O
our	O	O
institution	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
incidence	O	O
of	O	O
cya	B-chem	O
cardiotoxicity	O	O
correlated	O	O
with	O	O
the	O	O
dose	O	O
per	O	O
body	O	O
surface	O	O
area	O	O
.	O	O

eighty	O	O
patients	O	O
who	O	O
were	O	O
to	O	O
receive	O	O
cya	B-chem	B-chem
50	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
d	O	O
for	O	O
four	O	O
days	O	O
as	O	O
preparation	O	B-chem
for	O	O
marrow	O	O
grafting	O	O
underwent	O	O
a	O	O
total	O	O
of	O	O
84	O	O
transplants	O	O
for	O	O
aplastic	O	O
anemia	O	O
,	O	O
wiskott	O	O
-	O	O
aldrich	O	O
syndrome	O	O
,	O	O
or	O	O
severe	O	O
combined	O	O
immunodeficiency	O	O
syndrome	O	O
.	O	O

fourteen	O	O
of	O	O
84	O	O
(	O	O
17	O	O
%	O	O
)	O	O
patients	O	O
had	O	O
symptoms	O	O
and	O	O
signs	O	O
consistent	O	O
with	O	O
cya	B-chem	O
cardiotoxicity	O	O
within	O	O
ten	O	O
days	O	O
of	O	O
receiving	O	O
1	O	O
to	O	O
4	O	O
doses	O	O
of	O	O
cya	B-chem	B-chem
.	O	O

six	O	O
of	O	O
the	O	O
14	O	O
patients	O	O
died	O	O
with	O	O
congestive	O	O
heart	O	O
failure	O	O
.	O	O

the	O	O
dose	O	O
of	O	O
cya	B-chem	O
per	O	O
body	O	O
surface	O	O
area	O	O
was	O	O
calculated	O	O
for	O	O
all	O	O
patients	O	O
and	O	O
the	O	O
patients	O	O
were	O	O
divided	O	O
into	O	O
two	O	O
groups	O	O
based	O	O
on	O	O
daily	O	O
cya	B-chem	O
dose	O	O
:	O	O
group	O	O
1	O	O
,	O	O
cya	B-chem	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
1	O	O
.	O	O
55	O	O
g	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
;	O	O
group	O	O
2	O	O
,	O	O
cya	B-chem	O
greater	O	O
than	O	O
1	O	O
.	O	O
55	O	O
g	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
.	O	O

cardiotoxicity	O	O
that	O	O
was	O	O
thought	O	O
to	O	O
be	O	O
related	O	O
to	O	O
cya	B-chem	B-chem
occurred	O	O
in	O	O
1	O	O
/	O	O
32	O	O
(	O	O
3	O	O
%	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
group	O	O
1	O	O
and	O	O
in	O	O
13	O	O
/	O	O
52	O	O
(	O	O
25	O	O
%	O	O
)	O	O
patients	O	O
in	O	O
group	O	O
2	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
025	O	O
)	O	O
.	O	O

congestive	O	O
heart	O	O
failure	O	O
caused	O	O
or	O	O
contributed	O	O
to	O	O
death	O	O
in	O	O
0	O	O
/	O	O
32	O	O
patients	O	O
in	O	O
group	O	O
1	O	O
v	O	O
6	O	O
/	O	O
52	O	O
(	O	O
12	O	O
%	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
group	O	O
2	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
25	O	O
)	O	O
.	O	O

there	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
rate	O	O
of	O	O
engraftment	O	O
of	O	O
evaluable	O	O
patients	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
(	O	O
p	O	O
greater	O	O
than	O	O
0	O	O
.	O	O
5	O	O
)	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
the	O	O
cya	B-chem	O
cardiotoxicity	O	O
correlates	O	O
with	O	O
cya	B-chem	B-chem
dosage	O	O
as	O	O
calculated	O	O
by	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
and	O	O
that	O	O
patients	O	O
with	O	O
aplastic	O	O
anemia	O	O
and	O	O
immunodeficiencies	O	O
can	O	O
be	O	O
effectively	O	O
prepared	O	O
for	O	O
bone	O	O
marrow	O	O
grafting	O	O
at	O	O
a	O	O
cya	B-chem	O
dose	O	O
of	O	O
1	O	O
.	O	O
55	O	O
g	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
for	O	O
four	O	O
days	O	O
with	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
cardiotoxicity	O	O
than	O	O
patients	O	O
whose	O	O
cya	B-chem	B-chem
dosage	O	O
is	O	O
calculated	O	O
based	O	O
on	O	O
weight	O	O
.	O	O

this	O	O
study	O	O
reaffirms	O	O
the	O	O
principle	O	O
that	O	O
drug	O	O
toxicity	O	O
correlates	O	O
with	O	O
dose	O	O
per	O	O
body	O	O
surface	O	O
area	O	O
.	O	O

studies	O	O
of	O	O
risk	O	O
factors	O	O
for	O	O
aminoglycoside	B-chem	B-chem
nephrotoxicity	O	O
.	O	O

the	O	O
epidemiology	O	O
of	O	O
aminoglycoside	B-chem	B-chem
-	O	O
induced	O	O
nephrotoxicity	O	O
is	O	O
not	O	O
fully	O	O
understood	O	O
.	O	O

experimental	O	O
studies	O	O
in	O	O
healthy	O	O
human	O	O
volunteers	O	O
indicate	O	O
aminoglycosides	B-chem	B-chem
cause	O	O
proximal	O	O
tubular	O	O
damage	O	O
in	O	O
most	O	O
patients	O	O
,	O	O
but	O	O
rarely	O	O
,	O	O
if	O	O
ever	O	O
,	O	O
cause	O	O
glomerular	O	O
or	O	O
tubular	O	O
dysfunction	O	O
.	O	O

clinical	O	O
trials	O	O
of	O	O
aminoglycosides	B-chem	B-chem
in	O	O
seriously	O	O
ill	O	O
patients	O	O
indicate	O	O
that	O	O
the	O	O
relative	O	O
risk	O	O
for	O	O
developing	O	O
acute	O	O
renal	O	O
failure	O	O
during	O	O
therapy	O	O
ranges	O	O
from	O	O
8	O	O
to	O	O
10	O	O
and	O	O
that	O	O
the	O	O
attributable	O	O
risk	O	O
is	O	O
70	O	O
%	O	O
to	O	O
80	O	O
%	O	O
.	O	O

further	O	O
analysis	O	O
of	O	O
these	O	O
data	O	O
suggests	O	O
that	O	O
the	O	O
duration	O	O
of	O	O
therapy	O	O
,	O	O
plasma	O	O
aminoglycoside	B-chem	B-chem
levels	O	O
,	O	O
liver	O	O
disease	O	O
,	O	O
advanced	O	O
age	O	O
,	O	O
high	O	O
initial	O	O
estimated	O	O
creatinine	B-chem	B-chem
clearance	O	O
and	O	O
,	O	O
possibly	O	O
,	O	O
female	O	O
gender	O	O
all	O	O
increase	O	O
the	O	O
risk	O	O
for	O	O
nephrotoxicity	O	O
.	O	O

other	O	O
causes	O	O
of	O	O
acute	O	O
renal	O	O
failure	O	O
,	O	O
such	O	O
as	O	O
shock	O	O
,	O	O
appear	O	O
to	O	O
have	O	O
an	O	O
additive	O	O
effect	O	O
.	O	O

predictive	O	O
models	O	O
have	O	O
been	O	O
developed	O	O
from	O	O
these	O	O
analyses	O	O
that	O	O
should	O	O
be	O	O
useful	O	O
for	O	O
identifying	O	O
patients	O	O
at	O	O
high	O	O
risk	O	O
.	O	O

these	O	O
models	O	O
may	O	O
also	O	O
be	O	O
useful	O	O
in	O	O
developing	O	O
insights	O	O
into	O	O
the	O	O
pathophysiology	O	O
of	O	O
aminoglycoside	B-chem	B-chem
-	O	O
induced	O	O
nephrotoxicity	O	O
.	O	O

flurothyl	B-chem	B-chem
seizure	O	O
thresholds	O	O
in	O	O
mice	O	O
treated	O	O
neonatally	O	O
with	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
monosodium	B-chem	B-chem
glutamate	I-chem	I-chem
(	O	O
msg	B-chem	B-chem
)	O	O
:	O	O
evaluation	O	O
of	O	O
experimental	O	O
parameters	O	O
in	O	O
flurothyl	B-chem	B-chem
seizure	O	O
testing	O	O
.	O	O

monosodium	B-chem	B-chem
glutamate	I-chem	I-chem
(	O	O
msg	B-chem	B-chem
)	O	O
administration	O	O
to	O	O
neonatal	O	O
rodents	O	O
produces	O	O
convulsions	O	O
and	O	O
results	O	O
in	O	O
numerous	O	O
biochemical	O	O
and	O	O
behavioral	O	O
deficits	O	O
.	O	O

these	O	O
studies	O	O
were	O	O
undertaken	O	O
to	O	O
determine	O	O
if	O	O
neonatal	O	O
administration	O	O
of	O	O
msg	B-chem	B-chem
produced	O	O
permanent	O	O
alterations	O	O
in	O	O
seizure	O	O
susceptibility	O	O
,	O	O
since	O	O
previous	O	O
investigations	O	O
were	O	O
inconclusive	O	O
.	O	O

a	O	O
flurothyl	B-chem	B-chem
ether	B-chem	I-chem
seizure	O	O
screening	O	O
technique	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
seizure	O	O
susceptibility	O	O
in	O	O
adult	O	O
mice	O	O
that	O	O
received	O	O
neonatal	O	O
injections	O	O
of	O	O
msg	B-chem	B-chem
(	O	O
4	O	O
mg	O	O
/	O	O
g	O	O
and	O	O
1	O	O
mg	O	O
/	O	O
g	O	O
)	O	O
.	O	O

msg	B-chem	B-chem
treatment	O	O
resulted	O	O
in	O	O
significant	O	O
reductions	O	O
in	O	O
whole	O	O
brain	O	O
weight	O	O
but	O	O
did	O	O
not	O	O
alter	O	O
seizure	O	O
threshold	O	O
.	O	O

a	O	O
naloxone	B-chem	B-chem
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
challenge	O	O
was	O	O
also	O	O
ineffective	O	O
in	O	O
altering	O	O
the	O	O
seizure	O	O
thresholds	O	O
of	O	O
either	O	O
control	O	O
of	O	O
msg	B-chem	B-chem
-	O	O
treated	O	O
mice	O	O
.	O	O

flurothyl	B-chem	B-chem
ether	B-chem	I-chem
produced	O	O
hypothermia	O	O
which	O	O
was	O	O
correlated	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
flurothyl	B-chem	B-chem
exposure	O	O
;	O	O
however	O	O
,	O	O
the	O	O
relationship	O	O
of	O	O
hypothermia	O	O
to	O	O
seizure	O	O
induction	O	O
was	O	O
unclear	O	O
.	O	O

flurothyl	B-chem	B-chem
seizure	O	O
testing	O	O
proved	O	O
to	O	O
be	O	O
a	O	O
rapid	O	O
and	O	O
reliable	O	O
technique	O	O
with	O	O
which	O	O
to	O	O
evaluate	O	O
seizure	O	O
susceptibility	O	O
.	O	O

susceptibility	O	O
to	O	O
seizures	O	O
produced	O	O
by	O	O
pilocarpine	B-chem	B-chem
in	O	O
rats	O	O
after	O	O
microinjection	O	O
of	O	O
isoniazid	B-chem	B-chem
or	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
vinyl	I-chem	I-chem
-	I-chem	I-chem
gaba	I-chem	I-chem
into	O	O
the	O	O
substantia	O	O
nigra	O	O
.	O	O

pilocarpine	B-chem	B-chem
,	O	O
given	O	O
intraperitoneally	O	O
to	O	O
rats	O	O
,	O	O
reproduces	O	O
the	O	O
neuropathological	O	O
sequelae	O	O
of	O	O
temporal	O	O
lobe	O	O
epilepsy	O	O
and	O	O
provides	O	O
a	O	O
relevant	O	O
animal	O	O
model	O	O
for	O	O
studying	O	O
mechanisms	O	O
of	O	O
buildup	O	O
of	O	O
convulsive	O	O
activity	O	O
and	O	O
pathways	O	O
operative	O	O
in	O	O
the	O	O
generalization	O	O
and	O	O
propagation	O	O
of	O	O
seizures	O	O
within	O	O
the	O	O
forebrain	O	O
.	O	O

in	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
manipulating	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
aminobutyric	I-chem	I-chem
acid	I-chem	I-chem
(	O	O
gaba	B-chem	B-chem
)	O	O
-	O	O
mediated	O	O
synaptic	O	O
inhibition	O	O
within	O	O
the	O	O
substantia	O	O
nigra	O	O
on	O	O
seizures	O	O
produced	O	O
by	O	O
pilocarpine	B-chem	B-chem
in	O	O
rats	O	O
,	O	O
were	O	O
investigated	O	O
.	O	O

in	O	O
animals	O	O
pretreated	O	O
with	O	O
microinjections	O	O
of	O	O
isoniazid	B-chem	B-chem
,	O	O
150	O	O
micrograms	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
activity	O	O
of	O	O
the	O	O
gaba	B-chem	B-chem
-	O	O
synthesizing	O	O
enzyme	O	O
,	O	O
l	B-chem	B-chem
-	I-chem	I-chem
glutamic	I-chem	I-chem
acid	I-chem	I-chem
decarboxylase	O	I-chem
,	O	O
into	O	O
the	O	O
substantia	O	O
nigra	O	O
pars	O	O
reticulata	O	O
(	O	O
snr	O	O
)	O	O
,	O	O
bilaterally	O	O
,	O	O
non	O	O
-	O	O
convulsant	O	O
doses	O	O
of	O	O
pilocarpine	B-chem	B-chem
,	O	O
100	O	O
and	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
resulted	O	O
in	O	O
severe	O	O
motor	O	O
limbic	O	O
seizures	O	O
and	O	O
status	O	O
epilepticus	O	O
.	O	O

electroencephalographic	O	O
and	O	O
behavioral	O	O
monitoring	O	O
revealed	O	O
a	O	O
profound	O	O
reduction	O	O
of	O	O
the	O	O
threshold	O	O
for	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
convulsions	O	O
.	O	O

morphological	O	O
analysis	O	O
of	O	O
frontal	O	O
forebrain	O	O
sections	O	O
with	O	O
light	O	O
microscopy	O	O
revealed	O	O
seizure	O	O
-	O	O
related	O	O
damage	O	O
to	O	O
the	O	O
hippocampal	O	O
formation	O	O
,	O	O
thalamus	O	O
,	O	O
amygdala	O	O
,	O	O
olfactory	O	O
cortex	O	O
,	O	O
substantia	O	O
nigra	O	O
and	O	O
neocortex	O	O
,	O	O
which	O	O
is	O	O
typically	O	O
observed	O	O
with	O	O
pilocarpine	B-chem	B-chem
in	O	O
doses	O	O
exceeding	O	O
350	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

bilateral	O	O
intrastriatal	O	O
injections	O	O
of	O	O
isoniazid	B-chem	B-chem
did	O	O
not	O	O
augment	O	O
seizures	O	O
produced	O	O
by	O	O
pilocarpine	B-chem	B-chem
,	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

application	O	O
of	O	O
an	O	O
irreversible	O	O
inhibitor	O	O
of	O	O
gaba	B-chem	B-chem
transaminase	O	O
,	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
vinyl	I-chem	I-chem
-	I-chem	I-chem
gaba	I-chem	I-chem
(	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
amino	I-chem	I-chem
-	I-chem	I-chem
hex	I-chem	I-chem
-	I-chem	I-chem
5	I-chem	I-chem
-	I-chem	I-chem
enoic	I-chem	I-chem
acid	I-chem	I-chem
)	O	I-chem
,	O	O
5	O	O
micrograms	O	O
,	O	O
into	O	O
the	O	O
snr	O	O
,	O	O
bilaterally	O	O
,	O	O
suppressed	O	O
the	O	O
appearance	O	O
of	O	O
electrographic	O	O
and	O	O
behavioral	O	O
seizures	O	O
produced	O	O
by	O	O
pilocarpine	B-chem	B-chem
,	O	O
380	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

this	O	O
treatment	O	O
was	O	O
also	O	O
sufficient	O	O
to	O	O
protect	O	O
animals	O	O
from	O	O
the	O	O
occurrence	O	O
of	O	O
brain	O	O
damage	O	O
.	O	O

microinjections	O	O
of	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
vinyl	I-chem	I-chem
-	I-chem	I-chem
gaba	I-chem	I-chem
,	O	O
5	O	O
micrograms	O	O
,	O	O
into	O	O
the	O	O
dorsal	O	O
striatum	O	O
,	O	O
bilaterally	O	O
,	O	O
failed	O	O
to	O	O
prevent	O	O
the	O	O
development	O	O
of	O	O
convulsions	O	O
produced	O	O
by	O	O
pilocarpine	B-chem	B-chem
,	O	O
380	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

the	O	O
results	O	O
demonstrate	O	O
that	O	O
the	O	O
threshold	O	O
for	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
in	O	O
rats	O	O
is	O	O
subjected	O	O
to	O	O
the	O	O
regulation	O	O
of	O	O
the	O	O
gaba	B-chem	B-chem
-	O	O
mediated	O	O
synaptic	O	O
inhibition	O	O
within	O	O
the	O	O
substantia	O	O
nigra	O	O
.	O	O

non	O	O
-	O	O
invasive	O	O
detection	O	O
of	O	O
coronary	O	O
artery	O	O
disease	O	O
by	O	O
body	O	O
surface	O	O
electrocardiographic	O	O
mapping	O	O
after	O	O
dipyridamole	B-chem	B-chem
infusion	O	O
.	O	O

electrocardiographic	O	O
changes	O	O
after	O	O
dipyridamole	B-chem	B-chem
infusion	O	O
(	O	O
0	O	O
.	O	O
568	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
4	O	O
min	O	O
)	O	O
were	O	O
studied	O	O
in	O	O
41	O	O
patients	O	O
with	O	O
coronary	O	O
artery	O	O
disease	O	O
and	O	O
compared	O	O
with	O	O
those	O	O
after	O	O
submaximal	O	O
treadmill	O	O
exercise	O	O
by	O	O
use	O	O
of	O	O
the	O	O
body	O	O
surface	O	O
mapping	O	O
technique	O	O
.	O	O

patients	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
;	O	O
19	O	O
patients	O	O
without	O	O
myocardial	O	O
infarction	O	O
(	O	O
non	O	O
-	O	O
mi	O	O
group	O	O
)	O	O
,	O	O
14	O	O
with	O	O
anterior	O	O
infarction	O	O
(	O	O
ant	O	O
-	O	O
mi	O	O
)	O	O
and	O	O
eight	O	O
with	O	O
inferior	O	O
infarction	O	O
(	O	O
inf	O	O
-	O	O
mi	O	O
)	O	O
.	O	O

eighty	O	O
-	O	O
seven	O	O
unipolar	O	O
electrocardiograms	O	O
(	O	O
ecgs	O	O
)	O	O
distributed	O	O
over	O	O
the	O	O
entire	O	O
thoracic	O	O
surface	O	O
were	O	O
simultaneously	O	O
recorded	O	O
.	O	O

after	O	O
dipyridamole	B-chem	B-chem
,	O	O
ischemic	O	O
st	O	O
-	O	O
segment	O	O
depression	O	O
(	O	O
0	O	O
.	O	O
05	O	O
mv	O	O
or	O	O
more	O	O
)	O	O
was	O	O
observed	O	O
in	O	O
84	O	O
%	O	O
of	O	O
the	O	O
non	O	O
-	O	O
mi	O	O
group	O	O
,	O	O
29	O	O
%	O	O
of	O	O
the	O	O
ant	O	O
-	O	O
mi	O	O
group	O	O
,	O	O
63	O	O
%	O	O
of	O	O
the	O	O
inf	O	O
-	O	O
mi	O	O
group	O	O
and	O	O
61	O	O
%	O	O
of	O	O
the	O	O
total	O	O
population	O	O
.	O	O

exercise	O	O
-	O	O
induced	O	O
st	O	O
depression	O	O
was	O	O
observed	O	O
in	O	O
84	O	O
%	O	O
of	O	O
the	O	O
non	O	O
-	O	O
mi	O	O
group	O	O
,	O	O
43	O	O
%	O	O
of	O	O
the	O	O
ant	O	O
-	O	O
mi	O	O
group	O	O
,	O	O
38	O	O
%	O	O
of	O	O
the	O	O
inf	O	O
-	O	O
mi	O	O
group	O	O
and	O	O
61	O	O
%	O	O
of	O	O
the	O	O
total	O	O
.	O	O

for	O	O
individual	O	O
patients	O	O
,	O	O
there	O	O
were	O	O
no	O	O
obvious	O	O
differences	O	O
between	O	O
the	O	O
body	O	O
surface	O	O
distribution	O	O
of	O	O
st	O	O
depression	O	O
in	O	O
both	O	O
tests	O	O
.	O	O

the	O	O
increase	O	O
in	O	O
pressure	O	O
rate	O	O
product	O	O
after	O	O
dipyridamole	B-chem	B-chem
was	O	O
significantly	O	O
less	O	O
than	O	O
that	O	O
during	O	O
the	O	O
treadmill	O	O
exercise	O	O
.	O	O

the	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
dipyridamole	B-chem	B-chem
-	O	O
induced	O	O
myocardial	O	O
ischemia	O	O
is	O	O
caused	O	O
by	O	O
the	O	O
inhomogenous	O	O
distribution	O	O
of	O	O
myocardial	O	O
blood	O	O
flow	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
the	O	O
dipyridamole	B-chem	B-chem
ecg	O	O
test	O	O
is	O	O
as	O	O
useful	O	O
as	O	O
the	O	O
exercise	O	O
ecg	O	O
test	O	O
for	O	O
the	O	O
assessment	O	O
of	O	O
coronary	O	O
artery	O	O
disease	O	O
.	O	O

bradycardia	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
intravenous	O	O
methylprednisolone	B-chem	B-chem
therapy	O	O
.	O	O

in	O	O
5	O	O
consecutive	O	O
patients	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
who	O	O
received	O	O
intravenous	O	O
high	O	O
-	O	O
dose	O	O
methylprednisolone	B-chem	B-chem
(	O	O
mp	B-chem	B-chem
)	O	O
therapy	O	O
(	O	O
1	O	O
g	O	O
daily	O	O
for	O	O
2	O	O
or	O	O
3	O	O
consecutive	O	O
days	O	O
)	O	O
,	O	O
a	O	O
decline	O	O
in	O	O
pulse	O	O
rate	O	O
was	O	O
observed	O	O
,	O	O
most	O	O
pronounced	O	O
on	O	O
day	O	O
4	O	O
.	O	O

in	O	O
one	O	O
of	O	O
the	O	O
5	O	O
patients	O	O
the	O	O
bradycardia	O	O
was	O	O
associated	O	O
with	O	O
complaints	O	O
of	O	O
substernal	O	O
pressure	O	O
.	O	O

reversal	O	O
to	O	O
normal	O	O
heart	O	O
rate	O	O
was	O	O
found	O	O
on	O	O
day	O	O
7	O	O
.	O	O

electrocardiographic	O	O
registrations	O	O
showed	O	O
sinus	O	O
bradycardia	O	O
in	O	O
all	O	O
cases	O	O
.	O	O

no	O	O
significant	O	O
changes	O	O
in	O	O
plasma	O	O
concentrations	O	O
of	O	O
electrolytes	O	O
were	O	O
found	O	O
.	O	O

careful	O	O
observation	O	O
of	O	O
patients	O	O
receiving	O	O
high	O	O
-	O	O
dose	O	O
mp	B-chem	O
is	O	O
recommended	O	O
.	O	O

high	O	O
-	O	O
dose	O	O
mp	B-chem	O
may	O	O
be	O	O
contraindicated	O	O
in	O	O
patients	O	O
with	O	O
known	O	O
heart	O	O
disease	O	O
.	O	O

two	O	O
cases	O	O
of	O	O
downbeat	O	O
nystagmus	O	O
and	O	O
oscillopsia	O	O
associated	O	O
with	O	O
carbamazepine	B-chem	B-chem
.	O	O

downbeat	O	O
nystagmus	O	O
is	O	O
often	O	O
associated	O	O
with	O	O
structural	O	O
lesions	O	O
at	O	O
the	O	O
craniocervical	O	O
junction	O	O
,	O	O
but	O	O
has	O	O
occasionally	O	O
been	O	O
reported	O	O
as	O	O
a	O	O
manifestation	O	O
of	O	O
metabolic	O	O
imbalance	O	O
or	O	O
drug	O	O
intoxication	O	O
.	O	O

we	O	O
recorded	O	O
the	O	O
eye	O	O
movements	O	O
of	O	O
two	O	O
patients	O	O
with	O	O
reversible	O	O
downbeat	O	O
nystagmus	O	O
related	O	O
to	O	O
carbamazepine	B-chem	B-chem
therapy	O	O
.	O	O

the	O	O
nystagmus	O	O
of	O	O
both	O	O
patients	O	O
resolved	O	O
after	O	O
reduction	O	O
of	O	O
the	O	O
serum	O	O
carbamazepine	B-chem	B-chem
levels	O	O
.	O	O

neuroradiologic	O	O
investigations	O	O
including	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
scans	O	O
in	O	O
both	O	O
patients	O	O
showed	O	O
no	O	O
evidence	O	O
of	O	O
intracranial	O	O
abnormality	O	O
.	O	O

in	O	O
patients	O	O
with	O	O
downbeat	O	O
nystagmus	O	O
who	O	O
are	O	O
taking	O	O
anticonvulsant	O	O
medications	O	O
,	O	O
consideration	O	O
should	O	O
be	O	O
given	O	O
to	O	O
reduction	O	O
in	O	O
dose	O	O
before	O	O
further	O	O
investigation	O	O
is	O	O
undertaken	O	O
.	O	O

improvement	O	O
by	O	O
denopamine	B-chem	B-chem
(	O	O
ta	B-chem	O
-	I-chem	O
064	I-chem	I-chem
)	O	O
of	O	O
pentobarbital	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
failure	O	O
in	O	O
the	O	O
dog	O	O
heart	O	O
-	O	O
lung	O	O
preparation	O	O
.	O	O

the	O	O
efficacy	O	O
of	O	O
denopamine	B-chem	O
,	O	O
an	O	O
orally	O	O
active	O	O
beta	O	O
1	O	O
-	O	O
adrenoceptor	O	O
agonist	O	O
,	O	O
in	O	O
improving	O	O
cardiac	O	O
failure	O	O
was	O	O
assessed	O	O
in	O	O
dog	O	O
heart	O	O
-	O	O
lung	O	O
preparations	O	O
.	O	O

cardiac	O	O
functions	O	O
depressed	O	O
by	O	O
pentobarbital	B-chem	B-chem
(	O	O
118	O	O
+	O	O
/	O	O
-	O	O

28	O	O
mg	O	O
;	O	O
mean	O	O
value	O	O
+	O	O
/	O	O
-	O	O

sd	O	O
)	O	O
such	O	O
that	O	O
cardiac	O	O
output	O	O
and	O	O
maximum	O	O
rate	O	O
of	O	O
rise	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
(	O	O
lv	O	O
dp	O	O
/	O	O
dt	O	O
max	O	O
)	O	O
had	O	O
been	O	O
reduced	O	O
by	O	O
about	O	O
35	O	O
%	O	O
and	O	O
26	O	O
%	O	O
of	O	O
the	O	O
respective	O	O
controls	O	O
were	O	O
improved	O	O
by	O	O
denopamine	B-chem	O
(	O	O
10	O	O
-	O	O
300	O	O
micrograms	O	O
)	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

with	O	O
100	O	O
micrograms	O	O
denopamine	B-chem	O
,	O	O
almost	O	O
complete	O	O
restoration	O	O
of	O	O
cardiac	O	O
performance	O	O
was	O	O
attained	O	O
,	O	O
associated	O	O
with	O	O
a	O	O
slight	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
.	O	O

no	O	O
arrhythmias	O	O
were	O	O
induced	O	O
by	O	O
these	O	O
doses	O	O
of	O	O
denopamine	B-chem	O
.	O	O

the	O	O
results	O	O
warrant	O	O
clinical	O	O
trials	O	O
of	O	O
denopamine	B-chem	O
in	O	O
the	O	O
treatment	O	O
of	O	O
cardiac	O	O
failure	O	O
.	O	O

clonazepam	B-chem	B-chem
monotherapy	O	O
for	O	O
epilepsy	O	O
in	O	O
childhood	O	O
.	O	O

sixty	O	O
patients	O	O
(	O	O
age	O	O
-	O	O
range	O	O
one	O	O
month	O	O
to	O	O
14	O	O
years	O	O
)	O	O
with	O	O
other	O	O
types	O	O
of	O	O
epilepsy	O	O
than	O	O
infantile	O	O
spasms	O	O
were	O	O
treated	O	O
with	O	O
clonazepam	B-chem	B-chem
.	O	O

disappearance	O	O
of	O	O
seizures	O	O
and	O	O
normalization	O	O
of	O	O
abnormal	O	O
eeg	O	O
with	O	O
disappearance	O	O
of	O	O
seizures	O	O
were	O	O
recognized	O	O
in	O	O
77	O	O
%	O	O
and	O	O
50	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

seizures	O	O
disappeared	O	O
in	O	O
71	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
generalized	O	O
seizures	O	O
and	O	O
89	O	O
%	O	O
of	O	O
partial	O	O
seizures	O	O
.	O	O

improvement	O	O
of	O	O
abnormal	O	O
eeg	O	O
was	O	O
noticed	O	O
in	O	O
76	O	O
%	O	O
of	O	O
diffuse	O	O
paroxysms	O	O
and	O	O
in	O	O
67	O	O
%	O	O
of	O	O
focal	O	O
paroxysms	O	O
.	O	O

in	O	O
excellent	O	O
cases	O	O
,	O	O
mean	O	O
effective	O	O
dosages	O	O
were	O	O
0	O	O
.	O	O
086	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
021	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
in	O	O
infants	O	O
and	O	O
0	O	O
.	O	O
057	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
022	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
in	O	O
schoolchildren	O	O
,	O	O
this	O	O
difference	O	O
was	O	O
statistically	O	O
significant	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
005	O	O
)	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
side	O	O
effects	O	O
such	O	O
as	O	O
drowsiness	O	O
and	O	O
ataxia	O	O
was	O	O
only	O	O
5	O	O
%	O	O
.	O	O

postmarketing	O	O
study	O	O
of	O	O
timolol	B-chem	B-chem
-	O	O
hydrochlorothiazide	B-chem	B-chem
antihypertensive	O	O
therapy	O	O
.	O	O

a	O	O
postmarketing	O	O
surveillance	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
a	O	O
fixed	O	O
-	O	O
ratio	O	O
combination	O	O
containing	O	O
10	O	O
mg	O	O
of	O	O
timolol	B-chem	B-chem
maleate	I-chem	I-chem
and	O	O
25	O	O
mg	O	O
of	O	O
hydrochlorothiazide	B-chem	B-chem
,	O	O
administered	O	O
twice	O	O
daily	O	O
for	O	O
one	O	O
month	O	O
to	O	O
hypertensive	O	O
patients	O	O
.	O	O

data	O	O
on	O	O
9	O	O
,	O	O
037	O	O
patients	O	O
were	O	O
collected	O	O
by	O	O
1	O	O
,	O	O
455	O	O
participating	O	O
physicians	O	O
.	O	O

mean	O	O
systolic	O	O
blood	O	O
pressure	O	O
decreased	O	O
25	O	O
mmhg	O	O
and	O	O
mean	O	O
diastolic	O	O
blood	O	O
pressure	O	O
declined	O	O
15	O	O
mmhg	O	O
after	O	O
one	O	O
month	O	O
of	O	O
timolol	B-chem	B-chem
-	O	O
hydrochlorothiazide	B-chem	B-chem
therapy	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
,	O	O
both	O	O
comparisons	O	O
)	O	O
.	O	O

age	O	O
,	O	O
race	O	O
,	O	O
and	O	O
sex	O	O
appeared	O	O
to	O	O
have	O	O
no	O	O
influence	O	O
on	O	O
the	O	O
decrease	O	O
in	O	O
blood	O	O
pressure	O	O
.	O	O

the	O	O
antihypertensive	O	O
effect	O	O
of	O	O
the	O	O
drug	O	O
was	O	O
greater	O	O
in	O	O
patients	O	O
with	O	O
more	O	O
severe	O	O
hypertension	O	O
.	O	O

overall	O	O
,	O	O
1	O	O
,	O	O
453	O	O
patients	O	O
experienced	O	O
a	O	O
total	O	O
of	O	O
2	O	O
,	O	O
658	O	O
adverse	O	O
events	O	O
,	O	O
the	O	O
most	O	O
common	O	O
being	O	O
fatigue	O	O
,	O	O
dizziness	O	O
,	O	O
and	O	O
weakness	O	O
.	O	O

treatment	O	O
in	O	O
590	O	O
patients	O	O
was	O	O
discontinued	O	O
because	O	O
of	O	O
adverse	O	O
events	O	O
.	O	O

salicylate	B-chem	B-chem
nephropathy	O	O
in	O	O
the	O	O
gunn	O	O
rat	O	O
:	O	O
potential	O	O
role	O	O
of	O	O
prostaglandins	B-chem	B-chem
.	O	O

we	O	O
examined	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
prostaglandins	B-chem	B-chem
in	O	O
the	O	O
development	O	O
of	O	O
analgesic	O	O
nephropathy	O	O
in	O	O
the	O	O
gunn	O	O
strain	O	O
of	O	O
rat	O	O
.	O	O

the	O	O
homozygous	O	O
gunn	O	O
rats	O	O
have	O	O
unconjugated	O	O
hyperbilirubinemia	O	O
due	O	O
to	O	O
the	O	O
absence	O	O
of	O	O
glucuronyl	B-chem	B-chem
transferase	O	O
,	O	O
leading	O	O
to	O	O
marked	O	O
bilirubin	B-chem	B-chem
deposition	O	O
in	O	O
renal	O	O
medulla	O	O
and	O	O
papilla	O	O
.	O	O

these	O	O
rats	O	O
are	O	O
also	O	O
highly	O	O
susceptible	O	O
to	O	O
develop	O	O
papillary	O	O
necrosis	O	O
with	O	O
analgesic	O	O
administration	O	O
.	O	O

we	O	O
used	O	O
homozygous	O	O
(	O	O
jj	O	O
)	O	O
and	O	O
phenotypically	O	O
normal	O	O
heterozygous	O	O
(	O	O
jj	O	O
)	O	O
animals	O	O
.	O	O

four	O	O
groups	O	O
of	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
were	O	O
studied	O	O
:	O	O
jj	O	O
and	O	O
jj	O	O
rats	O	O
treated	O	O
either	O	O
with	O	O
aspirin	B-chem	B-chem
300	O	O
mg	O	O
/	O	O
kg	O	O
every	O	O
other	O	O
day	O	O
or	O	O
sham	O	O
-	O	O
treated	O	O
.	O	O

after	O	O
one	O	O
week	O	O
,	O	O
slices	O	O
of	O	O
cortex	O	O
,	O	O
outer	O	O
and	O	O
inner	O	O
medulla	O	O
from	O	O
one	O	O
kidney	O	O
were	O	O
incubated	O	O
in	O	O
buffer	O	O
and	O	O
prostaglandin	B-chem	B-chem
synthesis	O	O
was	O	O
determined	O	O
by	O	O
radioimmunoassay	O	O
.	O	O

the	O	O
other	O	O
kidney	O	O
was	O	O
examined	O	O
histologically	O	O
.	O	O

a	O	O
marked	O	O
corticomedullary	O	O
gradient	O	O
of	O	O
prostaglandin	B-chem	B-chem
synthesis	O	O
was	O	O
observed	O	O
in	O	O
all	O	O
groups	O	O
.	O	O

pge2	B-chem	B-chem
synthesis	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
outer	O	O
medulla	O	O
,	O	O
but	O	O
not	O	O
cortex	O	O
or	O	O
inner	O	O
medulla	O	O
,	O	O
of	O	O
jj	O	O
(	O	O
38	O	O
+	O	O
/	O	O
-	O	O

6	O	O
ng	O	O
/	O	O
mg	O	O
prot	O	O
)	O	O
than	O	O
jj	O	O
rats	O	O
(	O	O
15	O	O
+	O	O
/	O	O
-	O	O
3	O	O
)	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

aspirin	B-chem	B-chem
treatment	O	O
reduced	O	O
pge2	B-chem	B-chem
synthesis	O	O
in	O	O
all	O	O
regions	O	O
,	O	O
but	O	O
outer	O	O
medullary	O	O
pge2	B-chem	B-chem
remained	O	O
higher	O	O
in	O	O
jj	O	O
(	O	O
18	O	O
+	O	O
/	O	O
-	O	O
3	O	O
)	O	O
than	O	O
jj	O	O
rats	O	O
(	O	O
9	O	O
+	O	O
/	O	O
-	O	O
2	O	O
)	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

pgf2	B-chem	B-chem
alpha	I-chem	I-chem
was	O	O
also	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
outer	O	O
medulla	O	O
of	O	O
jj	O	O
rats	O	O
with	O	O
and	O	O
without	O	O
aspirin	B-chem	B-chem
administration	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

the	O	O
changes	O	O
in	O	O
renal	O	O
prostaglandin	B-chem	B-chem
synthesis	O	O
were	O	O
accompanied	O	O
by	O	O
evidence	O	O
of	O	O
renal	O	O
damage	O	O
in	O	O
aspirin	B-chem	B-chem
-	O	O
treated	O	O
jj	O	O
but	O	O
not	O	O
jj	O	O
rats	O	O
as	O	O
evidenced	O	O
by	O	O
:	O	O
increased	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
hematuria	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
;	O	O
increased	O	O
serum	O	O
creatinine	B-chem	B-chem
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
;	O	O
and	O	O
increase	O	O
in	O	O
outer	O	O
medullary	O	O
histopathologic	O	O
lesions	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
005	O	O
compared	O	O
to	O	O
either	O	O
sham	O	O
-	O	O
treated	O	O
jj	O	B-chem
or	O	O
aspirin	B-chem	B-chem
-	O	O
treated	O	O
jj	O	O
)	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
that	O	O
enhanced	O	O
prostaglandin	B-chem	B-chem
synthesis	O	O
contributes	O	O
to	O	O
maintenance	O	O
of	O	O
renal	O	O
function	O	O
and	O	O
morphological	O	O
integrity	O	O
,	O	O
and	O	O
that	O	O
inhibition	O	O
of	O	O
prostaglandin	B-chem	B-chem
synthesis	O	O
may	O	O
lead	O	O
to	O	O
pathological	O	O
renal	O	O
medullary	O	O
lesions	O	O
and	O	O
deterioration	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

prophylactic	O	O
lidocaine	B-chem	B-chem
in	O	O
the	O	O
early	O	O
phase	O	O
of	O	O
suspected	O	O
myocardial	O	O
infarction	O	O
.	O	O

four	O	O
hundred	O	O
two	O	O
patients	O	O
with	O	O
suspected	O	O
myocardial	O	O
infarction	O	O
seen	O	O
within	O	O
6	O	O
hours	O	O
of	O	O
the	O	O
onset	O	O
of	O	O
symptoms	O	O
entered	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
randomized	O	O
trial	O	O
of	O	O
lidocaine	B-chem	B-chem
vs	O	O
placebo	O	O
.	O	O

during	O	O
the	O	O
1	O	O
hour	O	O
after	O	O
administration	O	O
of	O	O
the	O	O
drug	O	O
the	O	O
incidence	O	O
of	O	O
ventricular	O	O
fibrillation	O	O
or	O	O
sustained	O	O
ventricular	O	O
tachycardia	O	O
among	O	O
the	O	O
204	O	O
patients	O	O
with	O	O
acute	O	O
myocardial	O	O
infarction	O	O
was	O	O
low	O	O
,	O	O
1	O	O
.	O	O
5	O	O
%	O	O
.	O	O

lidocaine	B-chem	B-chem
,	O	O
given	O	O
in	O	O
a	O	O
300	O	O
mg	O	O
dose	O	O
intramuscularly	O	O
followed	O	O
by	O	O
100	O	O
mg	O	O
intravenously	O	O
,	O	O
did	O	O
not	O	O
prevent	O	O
sustained	O	O
ventricular	O	O
tachycardia	O	O
,	O	O
although	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
warning	O	O
arrhythmias	O	O
between	O	O
15	O	O
and	O	O
45	O	O
minutes	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
lidocaine	B-chem	B-chem
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

the	O	O
average	O	O
plasma	O	O
lidocaine	B-chem	B-chem
level	O	O
10	O	O
minutes	O	O
after	O	O
administration	O	O
for	O	O
patients	O	O
without	O	O
a	O	O
myocardial	O	O
infarction	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
that	O	O
for	O	O
patients	O	O
with	O	O
an	O	O
acute	O	O
infarction	O	O
.	O	O

the	O	O
mean	O	O
plasma	O	O
lidocaine	B-chem	B-chem
level	O	O
of	O	O
patients	O	O
on	O	O
beta	O	O
-	O	O
blocking	O	O
agents	O	O
was	O	O
no	O	O
different	O	O
from	O	O
that	O	O
in	O	O
patients	O	O
not	O	O
on	O	O
beta	O	O
blocking	O	O
agents	O	O
.	O	O

during	O	O
the	O	O
1	O	O
-	O	O
hour	O	O
study	O	O
period	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
side	O	O
effects	O	O
was	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
lidocaine	B-chem	B-chem
group	O	O
,	O	O
hypotension	O	O
occurred	O	O
in	O	O
11	O	O
patients	O	O
,	O	O
nine	O	O
of	O	O
whom	O	O
had	O	O
received	O	O
lidocaine	B-chem	B-chem
,	O	O
and	O	O
four	O	O
patients	O	O
died	O	O
from	O	O
asystole	O	O
,	O	O
three	O	O
of	O	O
whom	O	O
had	O	O
had	O	O
lidocaine	B-chem	B-chem
.	O	O

we	O	O
can	O	O
not	O	O
advocate	O	O
the	O	O
administration	O	O
of	O	O
lidocaine	B-chem	B-chem
prophylactically	O	O
in	O	O
the	O	O
early	O	O
hours	O	O
of	O	O
suspected	O	O
myocardial	O	O
infarction	O	O
.	O	O

evidence	O	O
for	O	O
a	O	O
cholinergic	O	O
role	O	O
in	O	O
haloperidol	B-chem	B-chem
-	O	O
induced	O	O
catalepsy	O	O
.	O	O

experiments	O	O
in	O	O
mice	O	O
tested	O	O
previous	O	O
evidence	O	O
that	O	O
activation	O	O
of	O	O
cholinergic	O	O
systems	O	O
promotes	O	O
catalepsy	O	O
and	O	O
that	O	O
cholinergic	O	O
mechanisms	O	O
need	O	O
to	O	O
be	O	O
intact	O	O
for	O	O
full	O	O
expression	O	O
of	O	O
neuroleptic	B-chem	O
-	O	O
induced	O	O
catalepsy	O	O
.	O	O

large	O	O
doses	O	O
of	O	O
the	O	O
cholinomimetic	O	O
,	O	O
pilocarpine	B-chem	B-chem
,	O	O
could	O	O
induce	O	O
catalepsy	O	O
when	O	O
peripheral	O	O
cholinergic	O	O
receptors	O	O
were	O	O
blocked	O	O
.	O	O

low	O	O
doses	O	O
of	O	O
pilocarpine	B-chem	B-chem
caused	O	O
a	O	O
pronounced	O	O
enhancement	O	O
of	O	O
the	O	O
catalepsy	O	O
that	O	O
was	O	O
induced	O	O
by	O	O
the	O	O
dopaminergic	O	O
blocker	O	O
,	O	O
haloperidol	B-chem	B-chem
.	O	O

a	O	O
muscarinic	O	O
receptor	O	O
blocker	O	O
,	O	O
atropine	B-chem	B-chem
,	O	O
disrupted	O	O
haloperidol	B-chem	B-chem
-	O	O
induced	O	O
catalepsy	O	O
.	O	O

intracranial	O	O
injection	O	O
of	O	O
an	O	O
acetylcholine	B-chem	B-chem
-	O	O
synthesis	O	O
inhibitor	O	O
,	O	O
hemicholinium	B-chem	B-chem
,	O	O
prevented	O	O
the	O	O
catalepsy	O	O
that	O	O
is	O	O
usually	O	O
induced	O	O
by	O	O
haloperidol	B-chem	B-chem
.	O	O

these	O	O
findings	O	O
suggest	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
catalepsy	O	O
that	O	O
is	O	O
produced	O	O
by	O	O
neuroleptics	B-chem	O
such	O	O
as	O	O
haloperidol	B-chem	B-chem
is	O	O
actually	O	O
mediated	O	O
by	O	O
intrinsic	O	O
central	O	O
cholinergic	O	O
systems	O	O
.	O	O

alternatively	O	O
,	O	O
activation	O	O
of	O	O
central	O	O
cholinergic	O	O
systems	O	O
could	O	O
promote	O	O
catalepsy	O	O
by	O	O
suppression	O	O
of	O	O
dopaminergic	O	O
systems	O	O
.	O	O

cardiovascular	O	O
dysfunction	O	O
and	O	O
hypersensitivity	O	O
to	O	O
sodium	B-chem	B-chem
pentobarbital	I-chem	I-chem
induced	O	O
by	O	O
chronic	O	O
barium	B-chem	O
chloride	I-chem	B-chem
ingestion	O	O
.	O	O

barium	B-chem	B-chem
-	O	O
supplemented	O	O
long	O	O
-	O	O
evans	O	O
hooded	O	O
rats	O	O
were	O	O
characterized	O	O
by	O	O
a	O	O
persistent	O	O
hypertension	O	O
that	O	O
was	O	O
evident	O	O
after	O	O
1	O	O
month	O	O
of	O	O
barium	B-chem	B-chem
(	O	O
100	O	O
micrograms	O	O
/	O	O
ml	O	O
mineral	O	O
fortified	O	O
water	O	O
)	O	O
treatment	O	O
.	O	O

analysis	O	O
of	O	O
in	O	O
vivo	O	O
myocardial	O	O
excitability	O	O
,	O	O
contractility	O	O
,	O	O
and	O	O
metabolic	O	O
characteristics	O	O
at	O	O
16	O	O
months	O	O
revealed	O	O
other	O	O
significant	O	O
barium	B-chem	O
-	O	O
induced	O	O
disturbances	O	O
within	O	O
the	O	O
cardiovascular	O	O
system	O	O
.	O	O

the	O	O
most	O	O
distinctive	O	O
aspect	O	O
of	O	O
the	O	O
barium	B-chem	O
effect	O	O
was	O	O
a	O	O
demonstrated	O	O
hypersensitivity	O	O
of	O	O
the	O	O
cardiovascular	O	O
system	O	O
to	O	O
sodium	B-chem	B-chem
pentobarbital	I-chem	I-chem
.	O	O

under	O	O
barbiturate	B-chem	B-chem
anesthesia	O	O
,	O	O
virtually	O	O
all	O	O
of	O	O
the	O	O
myocardial	O	O
contractile	O	O
indices	O	O
were	O	O
depressed	O	O
significantly	O	O
in	O	O
barium	B-chem	O
-	O	O
exposed	O	O
rats	O	O
relative	O	O
to	O	O
the	O	O
corresponding	O	O
control	O	O
-	O	O
fed	O	O
rats	O	O
.	O	O

the	O	O
lack	O	O
of	O	O
a	O	O
similar	O	O
response	O	O
to	O	O
ketamine	B-chem	B-chem
and	O	O
xylazine	B-chem	B-chem
anesthesia	O	O
revealed	O	O
that	O	O
the	O	O
cardiovascular	O	O
actions	O	O
of	O	O
sodium	B-chem	B-chem
pentobarbital	I-chem	I-chem
in	O	O
barium	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
were	O	O
linked	O	O
specifically	O	O
to	O	O
this	O	O
anesthetic	O	O
,	O	O
and	O	O
were	O	O
not	O	O
representative	O	O
of	O	O
a	O	O
generalized	O	O
anesthetic	O	O
response	O	O
.	O	O

other	O	O
myocardial	O	O
pathophysiologic	O	O
and	O	O
metabolic	O	O
changes	O	O
induced	O	O
by	O	O
barium	B-chem	B-chem
were	O	O
manifest	O	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
anesthetic	O	O
employed	O	O
.	O	O

the	O	O
contractile	O	O
element	O	O
shortening	O	O
velocity	O	O
of	O	O
the	O	O
cardiac	O	O
muscle	O	O
fibers	O	O
was	O	O
significantly	O	O
slower	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
barium	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
relative	O	O
to	O	O
the	O	O
control	O	O
groups	O	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
anesthetic	O	O
regimen	O	O
.	O	O

similarly	O	O
,	O	O
significant	O	O
disturbances	O	O
in	O	O
myocardial	O	O
energy	O	O
metabolism	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
barium	B-chem	O
-	O	O
exposed	O	O
rats	O	O
which	O	O
were	O	O
consistent	O	O
with	O	O
the	O	O
reduced	O	O
contractile	O	O
element	O	O
shortening	O	O
velocity	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
the	O	O
excitability	O	O
of	O	O
the	O	O
cardiac	O	O
conduction	O	O
system	O	O
was	O	O
depressed	O	O
preferentially	O	O
in	O	O
the	O	O
atrioventricular	O	O
nodal	O	O
region	O	O
of	O	O
hearts	O	O
from	O	O
barium	B-chem	O
-	O	O
exposed	O	O
rats	O	O
.	O	O

overall	O	O
,	O	O
the	O	O
altered	O	O
cardiac	O	O
contractility	O	O
and	O	O
excitability	O	O
characteristics	O	O
,	O	O
the	O	O
myocardial	O	O
metabolic	O	O
disturbances	O	O
,	O	O
and	O	O
the	O	O
hypersensitivity	O	O
of	O	O
the	O	O
cardiovascular	O	O
system	O	O
to	O	O
sodium	B-chem	B-chem
pentobarbital	I-chem	I-chem
suggest	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
heretofore	O	O
undescribed	O	O
cardiomyopathic	O	O
disorder	O	O
induced	O	O
by	O	O
chronic	O	O
barium	B-chem	O
exposure	O	O
.	O	O

these	O	O
experimental	O	O
findings	O	O
represent	O	O
the	O	O
first	O	O
indication	O	O
that	O	O
life	O	O
-	O	O
long	O	O
barium	B-chem	O
ingestion	O	O
may	O	O
have	O	O
significant	O	O
adverse	O	O
effects	O	O
on	O	O
the	O	O
mammalian	O	O
cardiovascular	O	O
system	O	O
.	O	O

propranolol	B-chem	B-chem
antagonism	O	O
of	O	O
phenylpropanolamine	B-chem	B-chem
-	O	O
induced	O	O
hypertension	O	O
.	O	O

phenylpropanolamine	B-chem	B-chem
(	O	O
ppa	B-chem	B-chem
)	O	O
overdose	O	O
can	O	O
cause	O	O
severe	O	O
hypertension	O	O
,	O	O
intracerebral	O	O
hemorrhage	O	O
,	O	O
and	O	O
death	O	O
.	O	O

we	O	O
studied	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
propranolol	B-chem	B-chem
in	O	O
the	O	O
treatment	O	O
of	O	O
ppa	B-chem	B-chem
-	O	O
induced	O	O
hypertension	O	O
.	O	O

subjects	O	O
received	O	O
propranolol	B-chem	B-chem
either	O	O
by	O	O
mouth	O	O
for	O	O
48	O	O
hours	O	O
before	O	O
ppa	B-chem	B-chem
or	O	O
as	O	O
a	O	O
rapid	O	O
intravenous	O	O
infusion	O	O
after	O	O
ppa	B-chem	B-chem
.	O	O

ppa	B-chem	B-chem
,	O	O
75	O	O
mg	O	O
alone	O	O
,	O	O
increased	O	O
blood	O	O
pressure	O	O
(	O	O
31	O	O
+	O	O
/	O	O
-	O	O

14	O	O
mm	O	O
hg	O	O
systolic	O	O
,	O	O
20	O	O
+	O	O
/	O	O
-	O	O

5	O	O
mm	O	O
hg	O	O
diastolic	O	O
)	O	O
,	O	O
and	O	O
propranolol	B-chem	B-chem
pretreatment	O	O
antagonized	O	O
this	O	O
increase	O	O
(	O	O
12	O	O
+	O	O
/	O	O
-	O	O

10	O	O
mm	O	O

hg	O	O
systolic	O	O
,	O	O
10	O	O
+	O	O
/	O	O
-	O	O
7	O	O
mm	O	O
hg	O	O
diastolic	O	O
)	O	O
.	O	O

intravenous	O	O
propranolol	B-chem	B-chem
after	O	O
ppa	B-chem	B-chem
also	O	O
decreased	O	O
blood	O	O
pressure	O	O
.	O	O

left	O	O
ventricular	O	O
function	O	O
(	O	O
assessed	O	O
by	O	O
echocardiography	O	O
)	O	O
showed	O	O
that	O	O
ppa	B-chem	B-chem
increased	O	O
the	O	O
stroke	O	O
volume	O	O
30	O	O
%	O	O
(	O	O
from	O	O
62	O	O
.	O	O
5	O	O
+	O	O
/	O	O
-	O	O

20	O	O
.	O	O
9	O	O
to	O	O
80	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

22	O	O
.	O	O
4	O	O
ml	O	O
)	O	O
,	O	O
the	O	O
ejection	O	O
fraction	O	O
9	O	O
%	O	O
(	O	O
from	O	O
64	O	O
%	O	O
+	O	O
/	O	O
-	O	O

10	O	O
%	O	O
to	O	O
70	O	O
%	O	O
+	O	O
/	O	O
-	O	O

7	O	O
%	O	O
)	O	O
,	O	O
and	O	O
cardiac	O	O
output	O	O
14	O	O
%	O	O
(	O	O
from	O	O
3	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
6	O	O
to	O	O
4	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
0	O	O
l	O	O
/	O	O
min	O	O
)	O	O
.	O	O

intravenous	O	O
propranolol	B-chem	B-chem
reversed	O	O
these	O	O
effects	O	O
.	O	O

systemic	O	O
vascular	O	O
resistance	O	O
was	O	O
increased	O	O
by	O	O
ppa	B-chem	B-chem
28	O	O
%	O	O
(	O	O
from	O	O
1710	O	O
+	O	O
/	O	O
-	O	O

200	O	O
to	O	O
2190	O	O
+	O	O
/	O	O
-	O	O
700	O	O
dyne	O	O
x	O	O
sec	O	O
/	O	O
cm5	O	O
)	O	O

and	O	O
was	O	O
further	O	O
increased	O	O
by	O	O
propranolol	B-chem	B-chem
22	O	O
%	O	O
(	O	O
to	O	O
2660	O	O
+	O	O
/	O	O
-	O	O

1200	O	O
dyne	O	O
x	O	O
sec	O	O
/	O	O
cm5	O	O
)	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
ppa	B-chem	B-chem
increases	O	O
blood	O	O
pressure	O	O
by	O	O
increasing	O	O
systemic	O	O
vascular	O	O
resistance	O	O
and	O	O
cardiac	O	O
output	O	O
,	O	O
and	O	O
that	O	O
propranolol	B-chem	B-chem
antagonizes	O	O
this	O	O
increase	O	O
by	O	O
reversing	O	O
the	O	O
effect	O	O
of	O	O
ppa	B-chem	B-chem
on	O	O
cardiac	O	O
output	O	O
.	O	O

that	O	O
propranolol	B-chem	B-chem
antagonizes	O	O
the	O	O
pressor	O	O
effect	O	O
of	O	O
ppa	B-chem	B-chem
is	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
interaction	O	O
in	O	O
which	O	O
propranolol	B-chem	B-chem
enhances	O	O
the	O	O
pressor	O	O
effect	O	O
of	O	O
norepinephrine	B-chem	B-chem
.	O	O

this	O	O
is	O	O
probably	O	O
because	O	O
ppa	B-chem	B-chem
has	O	O
less	O	O
beta	O	O
2	O	O
activity	O	O
than	O	O
does	O	O
norepinephrine	B-chem	B-chem
.	O	O

mesangial	O	O
function	O	O
and	O	O
glomerular	O	O
sclerosis	O	O
in	O	O
rats	O	O
with	O	O
aminonucleoside	B-chem	O
nephrosis	O	O
.	O	O

the	O	O
possible	O	O
relationship	O	O
between	O	O
mesangial	O	O
dysfunction	O	O
and	O	O
development	O	O
of	O	O
glomerular	O	O
sclerosis	O	O
was	O	O
studied	O	O
in	O	O
the	O	O
puromycin	B-chem	B-chem
aminonucleoside	I-chem	I-chem
(	O	O
pan	B-chem	B-chem
)	O	O
model	O	O
.	O	O

five	O	O
male	O	O
wistar	O	O
rats	O	O
received	O	O
repeated	O	O
subcutaneous	O	O
pan	B-chem	O
injections	O	O
;	O	O
five	O	O
controls	O	O
received	O	O
saline	O	O
only	O	O
.	O	O

after	O	O
4	O	O
weeks	O	O
the	O	O
pan	B-chem	O
rats	O	O
were	O	O
severely	O	O
proteinuric	O	O
(	O	O
190	O	O
+	O	O
/	O	O
-	O	O

80	O	O
mg	O	O
/	O	O
24	O	O
hr	O	O
)	O	O
,	O	O
and	O	O
all	O	O
rats	O	O
were	O	O
given	O	O
colloidal	O	O
carbon	B-chem	B-chem
(	O	O
cc	O	B-chem
)	O	O
intravenously	O	O
.	O	O

at	O	O
5	O	O
months	O	O
glomerular	O	O
sclerosis	O	O
was	O	O
found	O	O
in	O	O
7	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

3	O	O
.	O	O
4	O	O
%	O	O
of	O	O
the	O	O
glomeruli	O	O
of	O	O
pan	B-chem	O
rats	O	O
;	O	O
glomeruli	O	O
of	O	O
the	O	O
controls	O	O
were	O	O
normal	O	O
.	O	O

glomeruli	O	O
of	O	O
pan	B-chem	O
rats	O	O
contained	O	O
significantly	O	O
more	O	O
cc	O	B-chem
than	O	O
glomeruli	O	O
of	O	O
controls	O	O
.	O	O

glomeruli	O	O
with	O	O
sclerosis	O	O
contained	O	O
significantly	O	O
more	O	O
cc	O	B-chem
than	O	O
non	O	O
-	O	O
sclerotic	O	O
glomeruli	O	O
in	O	O
the	O	O
same	O	O
kidneys	O	O
.	O	O

cc	O	B-chem
was	O	O
preferentially	O	O
localized	O	O
within	O	O
the	O	O
sclerotic	O	O
areas	O	O
of	O	O
the	O	O
affected	O	O
glomeruli	O	O
.	O	O

since	O	O
mesangial	O	O
cc	O	B-chem
clearance	O	O
from	O	O
the	O	O
mesangium	O	O
did	O	O
not	O	O
change	O	O
during	O	O
chronic	O	O
pan	B-chem	B-chem
treatment	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
this	O	O
preferential	O	O
cc	O	B-chem
localization	O	O
within	O	O
the	O	O
lesions	O	O
is	O	O
caused	O	O
by	O	O
an	O	O
increased	O	O
cc	O	B-chem
uptake	O	O
shortly	O	O
after	O	O
injection	O	O
in	O	O
apparent	O	O
vulnerable	O	O
areas	O	O
where	O	O
sclerosis	O	O
will	O	O
develop	O	O
subsequently	O	O
.	O	O

cluster	O	O
analysis	O	O
showed	O	O
a	O	O
random	O	O
distribution	O	O
of	O	O
lesions	O	O
in	O	O
the	O	O
pan	B-chem	O
glomeruli	O	O
in	O	O
concordance	O	O
with	O	O
the	O	O
random	O	O
localization	O	O
of	O	O
mesangial	O	O
areas	O	O
with	O	O
dysfunction	O	O
in	O	O
this	O	O
model	O	O
.	O	O

similar	O	O
to	O	O
the	O	O
remnant	O	O
kidney	O	O
model	O	O
in	O	O
pan	B-chem	O
nephrosis	O	O
the	O	O
development	O	O
of	O	O
glomerular	O	O
sclerosis	O	O
may	O	O
be	O	O
related	O	O
to	O	O
"	O	O
"	O	O
"	O	O
"	O	O
mesangial	O	O
overloading	O	O
.	O	O
"	O	O
"	O	O
"	O	O
"	O	O

relationship	O	O
between	O	O
nicotine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
and	O	O
hippocampal	O	O
nicotinic	O	O
receptors	O	O
.	O	O

a	O	O
controversy	O	O
has	O	O
existed	O	O
for	O	O
several	O	O
years	O	O
concerning	O	O
the	O	O
physiological	O	O
relevance	O	O
of	O	O
the	O	O
nicotinic	O	O
receptor	O	O
measured	O	O
by	O	O
alpha	O	B-chem
-	O	I-chem
bungarotoxin	O	I-chem
binding	O	O
.	O	O

using	O	O
mice	O	O
derived	O	O
from	O	O
a	O	O
classical	O	O
f2	O	O
and	O	O
backcross	O	O
genetic	O	O
design	O	O
,	O	O
a	O	O
relationship	O	O
between	O	O
nicotine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
and	O	O
alpha	O	B-chem
-	O	O
bungarotoxin	O	I-chem
nicotinic	O	O
receptor	O	O
concentration	O	O
was	O	O
found	O	O
.	O	O

mice	O	O
sensitive	O	O
to	O	O
the	O	O
convulsant	O	O
effects	O	O
of	O	O
nicotine	B-chem	B-chem
had	O	O
greater	O	O
alpha	O	B-chem
-	O	O
bungarotoxin	O	I-chem
binding	O	O
in	O	O
the	O	O
hippocampus	O	O
than	O	O
seizure	O	O
insensitive	O	O
mice	O	O
.	O	O

the	O	O
binding	O	O
sites	O	O
from	O	O
seizure	O	O
sensitive	O	O
and	O	O
resistant	O	O
mice	O	O
were	O	O
equally	O	O
affected	O	O
by	O	O
treatment	O	O
with	O	O
dithiothreitol	B-chem	B-chem
,	O	O
trypsin	O	O
or	O	O
heat	O	O
.	O	O

thus	O	O
it	O	O
appears	O	O
that	O	O
the	O	O
difference	O	O
between	O	O
seizure	O	O
sensitive	O	O
and	O	O
insensitive	O	O
animals	O	O
may	O	O
be	O	O
due	O	O
to	O	O
a	O	O
difference	O	O
in	O	O
hippocampal	O	O
nicotinic	O	O
receptor	O	O
concentration	O	O
as	O	O
measured	O	O
with	O	O
alpha	O	B-chem
-	O	I-chem
bungarotoxin	O	I-chem
binding	O	O
.	O	O

the	O	O
role	O	O
of	O	O
p	B-chem	B-chem
-	I-chem	I-chem
aminophenol	I-chem	I-chem
in	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
nephrotoxicity	O	O
:	O	O
effect	O	O
of	O	O
bis	B-chem	B-chem
(	I-chem	I-chem
p	I-chem	B-chem
-	I-chem	I-chem
nitrophenyl	I-chem	I-chem
)	I-chem	O
phosphate	I-chem	B-chem
on	O	O
acetaminophen	B-chem	B-chem
and	O	O
p	B-chem	B-chem
-	I-chem	I-chem
aminophenol	I-chem	I-chem
nephrotoxicity	O	O
and	O	O
metabolism	O	O
in	O	O
fischer	O	O
344	O	O
rats	O	O
.	O	O

acetaminophen	B-chem	B-chem
(	O	O
apap	B-chem	B-chem
)	O	O
produces	O	O
proximal	O	O
tubular	O	O
necrosis	O	O
in	O	O
fischer	O	O
344	O	O
(	O	O
f344	O	O
)	O	O
rats	O	O
.	O	O

recently	O	O
,	O	O
p	B-chem	B-chem
-	I-chem	I-chem
aminophenol	I-chem	I-chem
(	O	O
pap	B-chem	O
)	O	O
,	O	O
a	O	O
known	O	O
potent	O	O
nephrotoxicant	O	O
,	O	O
was	O	O
identified	O	O
as	O	O
a	O	O
metabolite	O	O
of	O	O
apap	B-chem	B-chem
in	O	O
f344	O	O
rats	O	O
.	O	O

the	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
pap	B-chem	O
formation	O	O
is	O	O
a	O	O
requisite	O	O
step	O	O
in	O	O
apap	B-chem	B-chem
-	O	O
induced	O	O
nephrotoxicity	O	O
.	O	O

therefore	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
bis	B-chem	B-chem
(	I-chem	O
p	I-chem	B-chem
-	I-chem	I-chem
nitrophenyl	I-chem	I-chem
)	I-chem	O
phosphate	I-chem	B-chem
(	O	O
bnpp	B-chem	B-chem
)	O	O
,	O	O
an	O	O
acylamidase	O	O
inhibitor	O	O
,	O	O
on	O	O
apap	B-chem	B-chem
and	O	O
pap	B-chem	O
nephrotoxicity	O	O
and	O	O
metabolism	O	O
was	O	O
determined	O	O
.	O	O

bnpp	B-chem	O
(	O	O
1	O	O
to	O	O
8	O	O
mm	O	O
)	O	O
reduced	O	O
apap	B-chem	B-chem
deacetylation	O	O
and	O	O
covalent	O	O
binding	O	O
in	O	O
f344	O	O
renal	O	O
cortical	O	O
homogenates	O	O
in	O	O
a	O	O
concentration	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

pretreatment	O	O
of	O	O
animals	O	O
with	O	O
bnpp	B-chem	O
prior	O	O
to	O	O
apap	B-chem	B-chem
or	O	O
pap	B-chem	O
administration	O	O
resulted	O	O
in	O	O
marked	O	O
reduction	O	O
of	O	O
apap	B-chem	B-chem
(	O	O
900	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
nephrotoxicity	O	O
but	O	O
not	O	O
pap	B-chem	O
nephrotoxicity	O	O
.	O	O

this	O	O
result	O	O
was	O	O
not	O	O
due	O	O
to	O	O
altered	O	O
disposition	O	O
of	O	O
either	O	O
apap	B-chem	B-chem
or	O	O
acetylated	O	B-chem
metabolites	O	O
in	O	O
plasma	O	O
or	O	O
renal	O	O
cortical	O	O
and	O	O
hepatic	O	O
tissue	O	O
.	O	O

rather	O	O
,	O	O
bnpp	B-chem	O
pretreatment	O	O
reduced	O	O
the	O	O
fraction	O	O
of	O	O
apap	B-chem	B-chem
excreted	O	O
as	O	O
pap	B-chem	O
by	O	O
64	O	O
and	O	O
75	O	O
%	O	O
after	O	O
apap	B-chem	B-chem
doses	O	O
of	O	O
750	O	O
and	O	O
900	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

bnpp	B-chem	O
did	O	O
not	O	O
alter	O	O
the	O	O
excretion	O	O
of	O	O
apap	B-chem	B-chem
or	O	O
any	O	O
of	O	O
its	O	O
non	O	O
-	O	O
deacetylated	O	O
metabolites	O	O
nor	O	O
did	O	O
bnpp	B-chem	O
alter	O	O
excretion	O	O
of	O	O
pap	B-chem	O
or	O	O
its	O	O
metabolites	O	O
after	O	O
pap	B-chem	O
doses	O	O
of	O	O
150	O	O
and	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

therefore	O	O
,	O	O
the	O	O
bnpp	B-chem	O
-	O	O
induced	O	O
reduction	O	O
in	O	O
apap	B-chem	B-chem
-	O	O
induced	O	O
nephrotoxicity	O	O
appears	O	O
to	O	O
be	O	O
due	O	O
to	O	O
inhibition	O	O
of	O	O
apap	B-chem	B-chem
deacetylation	O	O
.	O	O

it	O	O
is	O	O
concluded	O	O
that	O	O
pap	B-chem	O
formation	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
accounts	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
for	O	O
apap	B-chem	B-chem
-	O	O
induced	O	O
renal	O	O
tubular	O	O
necrosis	O	O
.	O	O

morphine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
in	O	O
newborn	O	O
infants	O	O
.	O	O

two	O	O
neonates	O	O
suffered	O	O
from	O	O
generalized	O	O
seizures	O	O
during	O	O
the	O	O
course	O	O
of	O	O
intravenous	O	O
morphine	B-chem	B-chem
sulfate	I-chem	I-chem
for	O	O
post	O	O
-	O	O
operative	O	O
analgesia	O	O
.	O	O

they	O	O
received	O	O
morphine	B-chem	B-chem
in	O	O
doses	O	O
of	O	O
32	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
hr	O	O
and	O	O
40	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
hr	O	O
larger	O	O
than	O	O
a	O	O
group	O	O
of	O	O
10	O	O
neonates	O	O
who	O	O
received	O	O
6	O	O
-	O	O
24	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
hr	O	O
and	O	O
had	O	O
no	O	O
seizures	O	O
.	O	O

plasma	O	O
concentrations	O	O
of	O	O
morphine	B-chem	B-chem
in	O	O
these	O	O
neonates	O	O
was	O	O
excessive	O	O
(	O	O
60	O	O
and	O	O
90	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

other	O	O
known	O	O
reasons	O	O
for	O	O
seizures	O	O
were	O	O
ruled	O	O
out	O	O
and	O	O
the	O	O
convulsions	O	O
stopped	O	O
a	O	O
few	O	O
hours	O	O
after	O	O
cessation	O	O
of	O	O
morphine	B-chem	B-chem
and	O	O
did	O	O
not	O	O
reoccur	O	O
in	O	O
the	O	O
subsequent	O	O
8	O	O
months	O	O
.	O	O

it	O	O
is	O	O
suggested	O	O
that	O	O
post	O	O
-	O	O
operative	O	O
intravenous	O	O
morphine	B-chem	B-chem
should	O	O
not	O	O
exceed	O	O
20	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
ml	O	O
in	O	O
neonates	O	O
.	O	O

effect	O	O
of	O	O
vincristine	B-chem	B-chem
sulfate	I-chem	I-chem
on	O	O
pseudomonas	O	O
infections	O	O
in	O	O
monkeys	O	O
.	O	O

in	O	O
rhesus	O	O
monkeys	O	O
,	O	O
intravenous	O	O
challenge	O	O
with	O	O
0	O	O
.	O	O
6	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
to	O	O
2	O	O
.	O	O
2	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
pseudomonas	O	O
aeruginosa	O	O
organisms	O	O
caused	O	O
acute	O	O
illness	O	O
of	O	O
4	O	O
to	O	O
5	O	O
days	O	O
'	O	O
duration	O	O
with	O	O
spontaneous	O	O
recovery	O	O
in	O	O
13	O	O
of	O	O
15	O	O
monkeys	O	O
;	O	O
blood	O	O
cultures	O	O
became	O	O
negative	O	O
3	O	O
to	O	O
17	O	O
days	O	O
after	O	O
challenge	O	O
.	O	O

leukocytosis	O	O
was	O	O
observed	O	O
in	O	O
all	O	O
monkeys	O	O
.	O	O

intravenous	O	O
or	O	O
intratracheal	O	O
inoculation	O	O
of	O	O
2	O	O
.	O	O
0	O	O
to	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
of	O	O
vincristine	B-chem	B-chem
sulfate	I-chem	I-chem
was	O	O
followed	O	O
by	O	O
leukopenia	O	O
in	O	O
4	O	O
to	O	O
5	O	O
days	O	O
.	O	O

intravenous	O	O
inoculation	O	O
of	O	O
4	O	O
.	O	O
2	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
to	O	O
7	O	O
.	O	O
8	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
pyocin	O	O
type	O	O
6	O	O
pseudomonas	O	O
organisms	O	O
in	O	O
monkeys	O	O
given	O	O
vincristine	B-chem	B-chem
sulfate	I-chem	I-chem
4	O	O
days	O	O
previously	O	O
resulted	O	O
in	O	O
fatal	O	O
infection	O	O
in	O	O
11	O	O
of	O	O
14	O	O
monkeys	O	O
,	O	O
whereas	O	O
none	O	O
of	O	O
four	O	O
receiving	O	O
pseudomonas	O	O
alone	O	O
died	O	O
.	O	O

these	O	O
studies	O	O
suggest	O	O
that	O	O
an	O	O
antimetabolite	O	O
-	O	O
induced	O	O
leukopenia	O	O
predisposes	O	O
to	O	O
severe	O	O
pseudomonas	O	O
sepsis	O	O
and	O	O
that	O	O
such	O	O
monkeys	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
biological	O	O
model	O	O
for	O	O
study	O	O
of	O	O
comparative	O	O
efficacy	O	O
of	O	O
antimicrobial	O	O
agents	O	O
.	O	O

central	O	O
excitatory	O	O
actions	O	O
of	O	O
flurazepam	B-chem	B-chem
.	O	O

toxic	O	O
actions	O	O
of	O	O
flurazepam	B-chem	B-chem
(	O	O
fzp	B-chem	B-chem
)	O	O
were	O	O
studied	O	O
in	O	O
cats	O	O
,	O	O
mice	O	O
and	O	O
rats	O	O
.	O	O

high	O	O
doses	O	O
caused	O	O
an	O	O
apparent	O	O
central	O	O
excitation	O	O
,	O	O
most	O	O
clearly	O	O
seen	O	O
as	O	O
clonic	O	O
convulsions	O	O
,	O	O
superimposed	O	O
on	O	O
general	O	O
depression	O	O
.	O	O

following	O	O
a	O	O
lethal	O	O
dose	O	O
,	O	O
death	O	O
was	O	O
always	O	O
associated	O	O
with	O	O
convulsions	O	O
.	O	O

comparing	O	O
the	O	O
relative	O	O
sensitivity	O	O
to	O	O
central	O	O
depression	O	O
and	O	O
excitation	O	O
revealed	O	O
that	O	O
rats	O	O
were	O	O
least	O	O
likely	O	O
to	O	O
have	O	O
convulsions	O	O
at	O	O
doses	O	O
that	O	O
did	O	O
not	O	O
first	O	O
cause	O	O
loss	O	O
of	O	O
consciousness	O	O
,	O	O
while	O	O
cats	O	O
most	O	O
clearly	O	O
showed	O	O
marked	O	O
central	O	O
excitatory	O	O
actions	O	O
.	O	O

signs	O	O
of	O	O
fzp	B-chem	B-chem
toxocity	O	O
in	O	O
cats	O	O
included	O	O
excessive	O	O
salivation	O	O
,	O	O
extreme	O	O
apprehensive	O	O
behavior	O	O
,	O	O
retching	O	O
,	O	O
muscle	O	O
tremors	O	O
and	O	O
convulsions	O	O
.	O	O

an	O	O
interaction	O	O
between	O	O
fzp	B-chem	O
and	O	O
pentylenetetrazol	B-chem	B-chem
(	O	O
ptz	B-chem	B-chem
)	O	O
was	O	O
shown	O	O
by	O	O
pretreating	O	O
mice	O	O
with	O	O
fzp	B-chem	O
before	O	O
ptz	B-chem	B-chem
challenge	O	O
.	O	O

as	O	O
a	O	O
function	O	O
of	O	O
dose	O	O
,	O	O
fzp	B-chem	O
first	O	O
protected	O	O
against	O	O
convulsions	O	O
and	O	O
death	O	O
.	O	O

at	O	O
higher	O	O
doses	O	O
,	O	O
however	O	O
,	O	O
convulsions	O	O
again	O	O
emerged	O	O
.	O	O

these	O	O
doses	O	O
of	O	O
fzp	B-chem	O
were	O	O
lower	O	O
than	O	O
those	O	O
that	O	O
would	O	O
alone	O	O
cause	O	O
convulsions	O	O
.	O	O

these	O	O
results	O	O
may	O	O
be	O	O
relevant	O	O
to	O	O
the	O	O
use	O	O
of	O	O
fzp	B-chem	O
in	O	O
clinical	O	O
situations	O	O
in	O	O
which	O	O
there	O	O
is	O	O
increased	O	O
neural	O	O
excitability	O	O
,	O	O
such	O	O
as	O	O
epilepsy	O	O
or	O	O
sedative	O	B-chem
-	O	O
hypnotic	O	O
drug	O	O
withdrawal	O	O
.	O	O

evidence	O	O
for	O	O
cardiac	O	O
beta	O	O
2	O	O
-	O	O
adrenoceptors	O	O
in	O	O
man	O	O
.	O	O

we	O	O
compared	O	O
the	O	O
effects	O	O
of	O	O
single	O	O
doses	O	O
of	O	O
50	O	O
mg	O	O
atenolol	B-chem	B-chem
(	O	O
cardioselective	O	B-chem
)	O	O
,	O	O
40	O	O
mg	O	O
propranolol	B-chem	B-chem
(	O	O
nonselective	O	O
)	O	O
,	O	O
and	O	O
placebo	O	O
on	O	O
both	O	O
exercise	O	O
-	O	O
and	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
tachycardia	O	O
in	O	O
two	O	O
experiments	O	O
involving	O	O
nine	O	O
normal	O	O
subjects	O	O
.	O	O

maximal	O	O
exercise	O	O
heart	O	O
rate	O	O
was	O	O
reduced	O	O
from	O	O
187	O	O
+	O	O
/	O	O
-	O	O

4	O	O
(	O	O
sem	O	O
)	O	O
after	O	O
placebo	O	O
to	O	O
146	O	O
+	O	O
/	O	O
-	O	O

7	O	O
bpm	O	O
after	O	O
atenolol	B-chem	B-chem
and	O	O
138	O	O
+	O	O
/	O	O
-	O	O

6	O	O
bpm	O	O
after	O	O
propranolol	B-chem	B-chem
,	O	O
but	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
between	O	O
the	O	O
drugs	O	O
.	O	O

the	O	O
effects	O	O
on	O	O
isoproterenol	B-chem	B-chem
tachycardia	O	O
were	O	O
determined	O	O
before	O	O
and	O	O
after	O	O
atropine	B-chem	B-chem
(	O	O
0	O	O
.	O	O
04	O	O
mg	O	O
/	O	O
kg	O	O
iv	O	O
)	O	O
.	O	O

isoproterenol	B-chem	B-chem
sensitivity	O	O
was	O	O
determined	O	O
as	O	O
the	O	O
intravenous	O	O
dose	O	O
that	O	O
increased	O	O
heart	O	O
rate	O	O
by	O	O
25	O	O
bpm	O	O
(	O	O
cd25	O	O
)	O	O
and	O	O
this	O	O
was	O	O
increased	O	O
from	O	O
1	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
3	O	O
micrograms	O	O
after	O	O
placebo	O	O
to	O	O
38	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

8	O	O
.	O	O
3	O	O
micrograms	O	O
after	O	O
propranolol	B-chem	B-chem
and	O	O
8	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
7	O	O
micrograms	O	O
after	O	O
atenolol	B-chem	B-chem
.	O	O

the	O	O
difference	O	O
in	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
two	O	O
was	O	O
significant	O	O
.	O	O

after	O	O
atropine	B-chem	B-chem
the	O	O
cd25	O	O
was	O	O
unchanged	O	O
after	O	O
placebo	O	O
(	O	O
2	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
3	O	O
micrograms	O	O
)	O	O
and	O	O
atenolol	B-chem	B-chem
(	O	O
7	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
3	O	O
micrograms	O	O
)	O	O
;	O	O
it	O	O
was	O	O
reduced	O	O
after	O	O
propranolol	B-chem	B-chem
(	O	O
24	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

5	O	O
.	O	O
0	O	O
micrograms	O	O
)	O	O
,	O	O
but	O	O
remained	O	O
different	O	O
from	O	O
atenolol	B-chem	B-chem
.	O	O

this	O	O
change	O	O
with	O	O
propranolol	B-chem	B-chem
sensitivity	O	O
was	O	O
calculated	O	O
as	O	O
the	O	O
apparent	O	O
ka	O	B-chem
,	O	O
this	O	O
was	O	O
unchanged	O	O
by	O	O
atropine	B-chem	B-chem
(	O	O
11	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

2	O	O
.	O	O
1	O	O
and	O	O
10	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O

2	O	O
.	O	O
5	O	O
ml	O	O
/	O	O
ng	O	O
)	O	O
.	O	O

these	O	O
data	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
exercise	O	O
-	O	O
induced	O	O
tachycardia	O	O
results	O	O
largely	O	O
from	O	O
beta	O	O
1	O	O
-	O	O
receptor	O	O
activation	O	O
that	O	O
is	O	O
blocked	O	O
by	O	O
both	O	O
cardioselective	O	O
and	O	O
nonselective	O	O
drugs	O	O
,	O	O
whereas	O	O
isoproterenol	B-chem	B-chem
activates	O	O
both	O	O
beta	O	O

1	O	B-chem
-	O	I-chem
and	O	O
beta	O	O
2	O	O
-	O	O
receptors	O	O

so	O	O
that	O	O
after	O	O
cardioselective	O	O
blockade	O	O
there	O	O
remains	O	O
a	O	O
beta	O	O
2	O	O
-	O	O
component	O	O
that	O	O
can	O	O
be	O	O
blocked	O	O
with	O	O
a	O	O
nonselective	O	O
drug	O	O
.	O	O

while	O	O
there	O	O
appear	O	O
to	O	O
be	O	O
beta	O	O
2	O	O
-	O	O
receptors	O	O
in	O	O
the	O	O
human	O	O
heart	O	O
,	O	O
their	O	O
physiologic	O	O
or	O	O
pathologic	O	O
roles	O	O
remain	O	O
to	O	O
be	O	O
defined	O	O
.	O	O

hormones	O	O
and	O	O
risk	O	O
of	O	O
breast	O	O
cancer	O	O
.	O	O

this	O	O
paper	O	O
reports	O	O
the	O	O
results	O	O
of	O	O
a	O	O
study	O	O
of	O	O
50	O	O
menopausal	O	O
women	O	O
receiving	O	O
hormonal	O	O
replacement	O	O
therapy	O	O
.	O	O

the	O	O
majority	O	O
(	O	O
29	O	O
)	O	O
had	O	O
surgical	O	O
menopause	O	O
;	O	O
their	O	O
mean	O	O
age	O	O
was	O	O
45	O	O
.	O	O
7	O	O
years	O	O
.	O	O

it	O	O
was	O	O
hypothesized	O	O
that	O	O
progestins	B-chem	B-chem
could	O	O
equilibrate	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
estrogenic	O	O
stimulation	O	O
on	O	O
the	O	O
mammary	O	O
and	O	O
endometrial	O	O
target	O	O
tissues	O	O
of	O	O
women	O	O
on	O	O
hormonal	O	O
replacement	O	O
therapy	O	O
.	O	O

the	O	O
treatment	O	O
schedule	O	O
consisted	O	O
of	O	O
conjugated	B-chem	B-chem
estrogens	I-chem	I-chem
(	O	O
premarin	B-chem	B-chem
)	O	O
1	O	O
.	O	O
25	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
21	O	O
days	O	O
and	O	O
medroxyprogesterone	B-chem	B-chem
acetate	I-chem	I-chem
10	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
10	O	O
days	O	O
in	O	O
each	O	O
month	O	O
.	O	O

the	O	O
mean	O	O
treatment	O	O
period	O	O
was	O	O
18	O	O
months	O	O
.	O	O

during	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
,	O	O
attention	O	O
was	O	O
paid	O	O
to	O	O
breast	O	O
modifications	O	O
as	O	O
evidenced	O	O
by	O	O
symptomatology	O	O
,	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
plate	O	O
thermography	O	O
.	O	O

mastodynia	O	O
was	O	O
reported	O	O
by	O	O
21	O	O
patients	O	O
,	O	O
and	O	O
physical	O	O
examination	O	O
revealed	O	O
a	O	O
light	O	O
increase	O	O
in	O	O
breast	O	O
firmness	O	O
in	O	O
12	O	O
women	O	O
and	O	O
a	O	O
moderate	O	O
increase	O	O
in	O	O
breast	O	O
nodularity	O	O
in	O	O
2	O	O
women	O	O
.	O	O

themography	O	O
confirmed	O	O
the	O	O
existence	O	O
of	O	O
an	O	O
excessive	O	O
breast	O	O
stimulation	O	O
in	O	O
1	O	O
women	O	O
who	O	O
complained	O	O
of	O	O
moderate	O	O
mastodynia	O	O
and	O	O
in	O	O
5	O	O
of	O	O
the	O	O
7	O	O
women	O	O
who	O	O
complained	O	O
of	O	O
severe	O	O
mastodynia	O	O
.	O	O

normalization	O	O
was	O	O
obtained	O	O
by	O	O
halving	O	O
the	O	O
estrogen	B-chem	B-chem
dose	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
that	O	O
hormonal	O	O
replacement	O	O
therapy	O	O
can	O	O
be	O	O
safely	O	O
prescribed	O	O
if	O	O
the	O	O
following	O	O
criteria	O	O
are	O	O
satisfied	O	O
:	O	O
1	O	O
)	O	O
preliminary	O	O
evaluation	O	O
of	O	O
patients	O	O
from	O	O
a	O	O
clinical	O	O
,	O	O
metabolic	O	O
,	O	O
cytologic	O	O
,	O	O
and	O	O
mammographic	O	O
perspective	O	O
;	O	O
2	O	O
)	O	O
cyclic	O	O
treatment	O	O
schedule	O	O
,	O	O
with	O	O
a	O	O
progestative	O	O
phase	O	O
of	O	O
10	O	O
days	O	O
;	O	O
and	O	O
3	O	O
)	O	O
periodic	O	O
complete	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
with	O	O
accurate	O	O
thermographic	O	O
evaluation	O	O
of	O	O
the	O	O
breast	O	O
target	O	O
tissues	O	O
.	O	O

early	O	O
infections	O	O
in	O	O
kidney	O	O
,	O	O
heart	O	O
,	O	O
and	O	O
liver	O	O
transplant	O	O
recipients	O	O
on	O	O
cyclosporine	B-chem	B-chem
.	O	O

eighty	O	O
-	O	O
one	O	O
renal	O	O
,	O	O
seventeen	O	O
heart	O	O
,	O	O
and	O	O
twenty	O	O
-	O	O
four	O	O
liver	O	O
transplant	O	O
patients	O	O
were	O	O
followed	O	O
for	O	O
infection	O	O
.	O	O

seventeen	O	O
renal	O	O
patients	O	O
received	O	O
azathioprine	B-chem	B-chem
(	O	O
aza	B-chem	B-chem
)	O	O
and	O	O
prednisone	B-chem	B-chem
as	O	O
part	O	O
of	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
immunosuppression	O	O
with	O	O
21	O	O
cyclosporine	B-chem	B-chem
-	O	O
and	O	O
-	O	O
prednisone	B-chem	B-chem
-	O	O
treated	O	O
renal	O	O
transplant	O	O
patients	O	O
.	O	O

all	O	O
others	O	O
received	O	O
cyclosporine	B-chem	B-chem
and	O	O
prednisone	B-chem	B-chem
.	O	O

the	O	O
randomized	O	O
aza	B-chem	B-chem
patients	O	O
had	O	O
more	O	O
overall	O	O
infections	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
and	O	O
more	O	O
nonviral	O	O
infections	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
02	O	O
)	O	O
than	O	O
the	O	O
randomized	O	O
cyclosporine	B-chem	B-chem
patients	O	O
.	O	O

heart	O	O
and	O	O
liver	O	O
patients	O	O
had	O	O
more	O	O
infections	O	O
than	O	O
cyclosporine	B-chem	B-chem
renal	O	O
patients	O	O
but	O	O
fewer	O	O
infections	O	O
than	O	O
the	O	O
aza	B-chem	B-chem
renal	O	O
patients	O	O
.	O	O

there	O	O
were	O	O
no	O	O
infectious	O	O
deaths	O	O
in	O	O
renal	O	O
transplant	O	O
patients	O	O
on	O	O
cyclosporine	B-chem	B-chem
or	O	O
aza	B-chem	B-chem
,	O	O
but	O	O
infection	O	O
played	O	O
a	O	O
major	O	O
role	O	O
in	O	O
3	O	O
out	O	O
of	O	O
6	O	O
cardiac	O	O
transplant	O	O
deaths	O	O
and	O	O
in	O	O
8	O	O
out	O	O
of	O	O
9	O	O
liver	O	O
transplant	O	O
deaths	O	O
.	O	O

renal	O	O
patients	O	O
on	O	O
cyclosporine	B-chem	B-chem
had	O	O
the	O	O
fewest	O	O
bacteremias	O	O
.	O	O

analysis	O	O
of	O	O
site	O	O
of	O	O
infection	O	O
showed	O	O
a	O	O
preponderance	O	O
of	O	O
abdominal	O	O
infections	O	O
in	O	O
liver	O	O
patients	O	O
,	O	O
intrathoracic	O	O
infections	O	O
in	O	O
heart	O	O
patients	O	O
,	O	O
and	O	O
urinary	O	O
tract	O	O
infections	O	O
in	O	O
renal	O	O
patients	O	O
.	O	O

pulmonary	O	O
infections	O	O
were	O	O
less	O	O
common	O	O
in	O	O
cyclosporine	B-chem	B-chem
-	O	O
treated	O	O
renal	O	O
patients	O	O
than	O	O
in	O	O
aza	B-chem	B-chem
-	O	O
treated	O	O
patients	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

aza	B-chem	B-chem
patients	O	O
had	O	O
significantly	O	O
more	O	O
staphylococcal	O	O
infections	O	O
than	O	O
all	O	O
other	O	O
transplant	O	O
groups	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
005	O	O
)	O	O
,	O	O
and	O	O
systemic	O	O
fungal	O	O
infections	O	O
occurred	O	O
only	O	O
in	O	O
the	O	O
liver	O	O
transplant	O	O
group	O	O
.	O	O

cytomegalovirus	O	O
(	O	O
cmv	O	O
)	O	O
shedding	O	O
or	O	O
serological	O	O
rises	O	O
in	O	O
antibody	O	O
titer	O	O
,	O	O
or	O	O
both	O	O
occurred	O	O
in	O	O
78	O	O
%	O	O
of	O	O
cyclosporine	B-chem	B-chem
patients	O	O
and	O	O
76	O	O
%	O	O
of	O	O
aza	B-chem	B-chem
patients	O	O
.	O	O

of	O	O
the	O	O
cyclosporine	B-chem	B-chem
patients	O	O
,	O	O
15	O	O
%	O	O
had	O	O
symptoms	O	O
related	O	O
to	O	O
cmv	O	O
infection	O	O
.	O	O

serological	O	O
evidence	O	O
for	O	O
epstein	O	O
barr	O	O
virus	O	O
infection	O	O
was	O	O
found	O	O
in	O	O
20	O	O
%	O	O
of	O	O
65	O	O
cyclosporine	B-chem	B-chem
patients	O	O
studied	O	O
.	O	O

three	O	O
had	O	O
associated	O	O
symptoms	O	O
,	O	O
and	O	O
one	O	O
developed	O	O
a	O	O
lymphoma	O	O
.	O	O

structure	O	O
-	O	O
activity	O	O
and	O	O
dose	O	O
-	O	O
effect	O	O
relationships	O	O
of	O	O
the	O	O
antagonism	O	O
of	O	O
picrotoxin	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
by	O	O
cholecystokinin	B-chem	O
,	O	O
fragments	O	O
and	O	O
analogues	O	O
of	O	O
cholecystokinin	B-chem	O
in	O	O
mice	O	O
.	O	O

intraperitoneal	O	O
administration	O	O
of	O	O
cholecystokinin	B-chem	B-chem
octapeptide	I-chem	I-chem
sulphate	O	I-chem
ester	O	I-chem
(	O	O
cck	B-chem	B-chem
-	I-chem	I-chem
8	I-chem	I-chem
-	O	I-chem
se	O	O
)	O	O
and	O	O
nonsulphated	O	O
cholecystokinin	B-chem	O
octapeptide	I-chem	I-chem
(	O	O
cck	B-chem	B-chem
-	I-chem	I-chem
8	I-chem	I-chem
-	O	O
ns	O	O
)	O	O
enhanced	O	O
the	O	O
latency	O	O
of	O	O
seizures	O	O
induced	O	O
by	O	O
picrotoxin	B-chem	B-chem
in	O	O
mice	O	O
.	O	O

experiments	O	O
with	O	O
n	O	O
-	O	O
and	O	O
c	O	O
-	O	O
terminal	O	O
fragments	O	O
revealed	O	O
that	O	O
the	O	O
c	O	O
-	O	O
terminal	O	O
tetrapeptide	O	O
(	O	O
cck	O	B-chem
-	O	O
5	O	I-chem
-	O	O
8	O	O
)	O	O
was	O	O
the	O	O
active	O	O
centre	O	O
of	O	O
the	O	O
cck	O	O
octapeptide	O	O
molecule	O	O
.	O	O

the	O	O
analogues	O	O
cck	B-chem	B-chem
-	I-chem	I-chem
8	I-chem	I-chem
-	O	O
se	O	O
and	O	O
cck	B-chem	B-chem
-	I-chem	O
8	I-chem	I-chem
-	O	O
ns	O	O
(	O	O
dose	O	O
range	O	O
0	O	O
.	O	O
2	O	O
-	O	O
6	O	O
.	O	O
4	O	O
mumol	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
caerulein	B-chem	O
dose	O	O
range	O	O
0	O	O
.	O	O
1	O	O
-	O	O
0	O	O
.	O	O
8	O	O
mumol	O	O
/	O	O
kg	O	O
)	O	O
showed	O	O
bell	O	O
-	O	O
shaped	O	O
dose	O	O
-	O	O
effect	O	O
curves	O	O
,	O	O
with	O	O
the	O	O
greatest	O	O
maximum	O	O
inhibition	O	O
for	O	O
cck	B-chem	B-chem
-	I-chem	O
8	I-chem	O
-	O	O
ns	O	O
.	O	O

the	O	O
peptide	O	B-chem
cck	O	I-chem
-	O	I-chem
5	O	I-chem
-	O	I-chem
8	O	O
had	O	O
weak	O	O
anticonvulsant	O	O
activity	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
octapeptides	O	O
,	O	O
3	O	O
.	O	O
2	O	O
mumol	O	O
/	O	O
kg	O	O
and	O	O
larger	O	O
doses	O	O
of	O	O
the	O	O
reference	O	O
drug	O	O
,	O	O
diazepam	B-chem	B-chem
,	O	O
totally	O	O
prevented	O	O
picrotoxin	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
and	O	O
mortality	O	O
.	O	O

the	O	O
maximum	O	O
effect	O	O
of	O	O
the	O	O
peptides	O	O
tested	O	O
was	O	O
less	O	O
than	O	O
that	O	O
of	O	O
diazepam	B-chem	B-chem
.	O	O

experiments	O	O
with	O	O
analogues	O	O
and	O	O
derivatives	O	O
of	O	O
cck	O	B-chem
-	O	I-chem
5	O	I-chem
-	O	I-chem
8	O	O
demonstrated	O	O
that	O	O
the	O	O
effectiveness	O	O
of	O	O
the	O	O
beta	O	O
-	O	O
alanyl	O	O
derivatives	O	O
of	O	O
cck	O	B-chem
-	O	I-chem
5	O	I-chem
-	O	I-chem
8	O	O
were	O	O
enhanced	O	O
and	O	O
that	O	O
they	O	O
were	O	O
equipotent	O	O
with	O	O
cck	B-chem	B-chem
-	I-chem	O
8	I-chem	I-chem
-	O	O
se	O	O
.	O	O

of	O	O
the	O	O
cck	O	B-chem
-	O	I-chem
2	O	I-chem
-	O	O
8	O	O
analogues	O	O
,	O	O
ser	O	O
(	O	O
so3h	O	O
)	O	O
7	O	O
-	O	O
ac	O	O
-	O	O
cck	O	O
-	O	I-chem
2	O	I-chem
-	O	I-chem
8	O	I-chem
-	O	O
se	O	O
and	O	O
thr	O	O
(	O	O
so3h	O	O
)	O	O
7	O	O
-	O	O
ac	O	O
-	O	O
cck	O	O
-	O	I-chem
2	O	I-chem
-	O	I-chem
8	O	I-chem
-	O	O
se	O	O
and	O	O
hyp	O	B-chem
(	O	O
so3h	O	O
)	O	O
-	O	O
ac	O	O
-	O	O
cck	O	B-chem
-	O	I-chem
2	O	I-chem
-	O	I-chem
8	O	I-chem
-	O	O
se	O	O
were	O	O
slightly	O	O
more	O	O
active	O	O
than	O	O
cck	B-chem	O
-	I-chem	O
8	I-chem	O
-	O	O
se	O	O
.	O	O

vasopressin	B-chem	B-chem
as	O	O
a	O	O
possible	O	O
contributor	O	O
to	O	O
hypertension	O	O
.	O	O

the	O	O
role	O	O
of	O	O
vasopressin	B-chem	B-chem
as	O	O
a	O	O
pressor	O	O
agent	O	O
to	O	O
the	O	O
hypertensive	O	O
process	O	O
was	O	O
examined	O	O
.	O	O

vasopressin	B-chem	B-chem
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
doca	B-chem	B-chem
-	O	O
salt	O	O
hypertension	O	O
,	O	O
since	O	O
the	O	O
elevation	O	O
of	O	O
blood	O	O
pressure	O	O
was	O	O
not	O	O
substantial	O	O
in	O	O
the	O	O
rats	O	O
with	O	O
lithium	B-chem	B-chem
-	O	O
treated	O	O
diabetes	O	O
insipidus	O	O
after	O	O
doca	B-chem	B-chem
-	O	O
salt	O	O
treatment	O	O
.	O	O

administration	O	O
of	O	O
ddavp	B-chem	B-chem
which	O	O
has	O	O
antidiuretic	O	O
action	O	O
but	O	O
minimal	O	O
vasopressor	O	O
effect	O	O
failed	O	O
to	O	O
increase	O	O
blood	O	O
pressure	O	O
to	O	O
the	O	O
levels	O	O
observed	O	O
after	O	O
administration	O	O
of	O	O
avp	O	B-chem
.	O	O

furthermore	O	O
,	O	O
the	O	O
pressor	O	O
action	O	O
of	O	O
vasopressin	B-chem	B-chem
appears	O	O
to	O	O
be	O	O
important	O	O
in	O	O
the	O	O
development	O	O
of	O	O
this	O	O
model	O	O
of	O	O
hypertension	O	O
,	O	O
since	O	O
the	O	O
enhanced	O	O
pressor	O	O
responsiveness	O	O
to	O	O
the	O	O
hormone	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
initial	O	O
stage	O	O
of	O	O
hypertension	O	O
.	O	O

increased	O	O
secretion	O	O
of	O	O
vasopressin	B-chem	B-chem
from	O	O
neurohypophysis	O	O
also	O	O
promotes	O	O
the	O	O
function	O	O
of	O	O
the	O	O
hormone	O	O
as	O	O
a	O	O
pathogenetic	O	O
factor	O	O
in	O	O
hypertension	O	O
.	O	O

an	O	O
unproportional	O	O
release	O	O
of	O	O
vasopressin	B-chem	B-chem
compared	O	O
to	O	O
plasma	O	O
osmolality	O	O
may	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
absence	O	O
of	O	O
an	O	O
adjusting	O	O
control	O	O
of	O	O
angiotensin	B-chem	B-chem
ii	O	I-chem
forming	O	O
and	O	O
receptor	O	O
binding	O	O
capacity	O	O
for	O	O
sodium	B-chem	B-chem
balance	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

however	O	O
,	O	O
the	O	O
role	O	O
of	O	O
vasopressin	B-chem	B-chem
remains	O	O
to	O	O
be	O	O
determined	O	O
in	O	O
human	O	O
essential	O	O
hypertension	O	O
.	O	O

toxic	O	O
hepatitis	O	O
induced	O	O
by	O	O
disulfiram	B-chem	B-chem
in	O	O
a	O	O
non	O	O
-	O	O
alcoholic	O	B-chem
.	O	O

a	O	O
reversible	O	O
toxic	O	O
liver	O	O
damage	O	O
was	O	O
observed	O	O
in	O	O
a	O	O
non	O	O
-	O	O
alcoholic	O	O
woman	O	O
treated	O	O
with	O	O
disulfiram	B-chem	B-chem
.	O	O

the	O	O
causative	O	O
relationship	O	O
was	O	O
proven	O	O
by	O	O
challenge	O	O
.	O	O

atrial	O	O
thrombosis	O	O
involving	O	O
the	O	O
heart	O	O
of	O	O
f	O	O
-	O	O
344	O	O
rats	O	O
ingesting	O	O
quinacrine	B-chem	B-chem
hydrochloride	I-chem	I-chem
.	O	O

quinacrine	B-chem	B-chem
hydrochloride	I-chem	I-chem
is	O	O
toxic	O	O
for	O	O
the	O	O
heart	O	O
of	O	O
f	O	O
-	O	O
344	O	O
rats	O	O
.	O	O

rats	O	O
treated	O	O
with	O	O
500	O	O
ppm	O	B-chem
quinacrine	B-chem	I-chem
hydrochloride	I-chem	I-chem
in	O	O
the	O	O
diet	O	O
all	O	O
developed	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
left	O	O
atrial	O	O
thrombosis	O	O
.	O	O

the	O	O
lesion	O	O
was	O	O
associated	O	O
with	O	O
cardiac	O	O
hypertrophy	O	O
and	O	O
dilatation	O	O
and	O	O
focal	O	O
myocardial	O	O
degeneration	O	O
.	O	O

rats	O	O
died	O	O
from	O	O
cardiac	O	O
hypertrophy	O	O
with	O	O
severe	O	O
acute	O	O
and	O	O
chronic	O	O
congestion	O	O
of	O	O
the	O	O
lungs	O	O
,	O	O
liver	O	O
,	O	O
and	O	O
other	O	O
organs	O	O
.	O	O

seventy	O	O
percent	O	O
of	O	O
rats	O	O
given	O	O
250	O	O
ppm	O	B-chem
quinacrine	B-chem	I-chem
hydrochloride	I-chem	I-chem
and	O	O
1	O	O
,	O	O
000	O	O
ppm	O	O
sodium	B-chem	I-chem
nitrite	I-chem	I-chem
simultaneously	O	O
in	O	O
the	O	O
diet	O	O
had	O	O
thrombosis	O	O
of	O	O
the	O	O
atria	O	O
of	O	O
the	O	O
heart	O	O
,	O	O
while	O	O
untreated	O	O
control	O	O
rats	O	O
in	O	O
this	O	O
laboratory	O	O
did	O	O
not	O	O
have	O	O
atrial	O	O
thrombosis	O	O
.	O	O

sodium	B-chem	B-chem
nitrite	I-chem	I-chem
in	O	O
combination	O	O
with	O	O
quinacrine	B-chem	B-chem
hydrochloride	I-chem	I-chem
appeared	O	O
to	O	O
have	O	O
no	O	O
additional	O	O
effect	O	O
.	O	O

alternating	O	O
sinus	O	O
rhythm	O	O
and	O	O
intermittent	O	O
sinoatrial	O	O
block	O	O
induced	O	O
by	O	O
propranolol	B-chem	B-chem
.	O	O

alternating	O	O
sinus	O	O
rhythm	O	O
and	O	O
intermittent	O	O
sinoatrial	O	O
(	O	O
s	O	O
-	O	O
a	O	O
)	O	O
block	O	O
was	O	O
observed	O	O
in	O	O
a	O	O
57	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
,	O	O
under	O	O
treatment	O	O
for	O	O
angina	O	O
with	O	O
80	O	O
mg	O	O
propranolol	B-chem	B-chem
daily	O	O
.	O	O

the	O	O
electrocardiogram	O	O
showed	O	O
alternation	O	O
of	O	O
long	O	O
and	O	O
short	O	O
p	O	O
-	O	O
p	O	O
intervals	O	O
and	O	O
occasional	O	O
pauses	O	O
.	O	O

these	O	O
pauses	O	O
were	O	O
always	O	O
preceded	O	O
by	O	O
the	O	O
short	O	O
p	O	O
-	O	O
p	O	O
intervals	O	O
and	O	O
were	O	O
usually	O	O
followed	O	O
by	O	O
one	O	O
or	O	O
two	O	O
p	O	O
-	O	O
p	O	O
intervals	O	O
of	O	O
0	O	O
.	O	O
92	O	O
-	O	O
0	O	O
.	O	O
95	O	O
s	O	O
representing	O	O
the	O	O
basic	O	O
sinus	O	O
cycle	O	O
.	O	O

following	O	O
these	O	O
basic	O	O
sinus	O	O
cycles	O	O
,	O	O
alternating	O	O
rhythm	O	O
started	O	O
with	O	O
the	O	O
longer	O	O
p	O	O
-	O	O
p	O	O
interval	O	O
.	O	O

the	O	O
long	O	O
p	O	O
-	O	O
p	O	O
intervals	O	O
ranged	O	O
between	O	O
1	O	O
.	O	O
04	O	O
-	O	O
1	O	O
.	O	O
12	O	O
s	O	O
and	O	O
the	O	O
short	O	O
p	O	O
-	O	O
p	O	O
intervals	O	O
between	O	O
0	O	O
.	O	O
80	O	O
-	O	O
0	O	O
.	O	O
84	O	O
s	O	O
,	O	O
respectively	O	O
.	O	O

the	O	O
duration	O	O
of	O	O
the	O	O
pauses	O	O
were	O	O
equal	O	O
or	O	O
almost	O	O
equal	O	O
to	O	O
one	O	O
short	O	O
plus	O	O
one	O	O
long	O	O
p	O	O
-	O	O
p	O	O
interval	O	O
or	O	O
to	O	O
twice	O	O
the	O	O
basic	O	O
sinus	O	O
cycle	O	O
.	O	O

in	O	O
one	O	O
recording	O	O
a	O	O
short	O	O
period	O	O
of	O	O
regular	O	O
sinus	O	O
rhythm	O	O
with	O	O
intermittent	O	O
2	O	O
/	O	O
1	O	O
s	O	O
-	O	O
a	O	O
block	O	O
was	O	O
observed	O	O
.	O	O

this	O	O
short	O	O
period	O	O
of	O	O
sinus	O	O
rhythm	O	O
was	O	O
interrupted	O	O
by	O	O
sudden	O	O
prolongation	O	O
of	O	O
the	O	O
p	O	O
-	O	O
p	O	O
interval	O	O
starting	O	O
the	O	O
alternative	O	O
rhythm	O	O
.	O	O

there	O	O
were	O	O
small	O	O
changes	O	O
in	O	O
the	O	O
shape	O	O
of	O	O
the	O	O
p	O	O
waves	O	O
and	O	O
p	O	O
-	O	O
r	O	O
intervals	O	O
.	O	O

s	O	B-chem
-	O	I-chem

a	O	O
conduction	O	O
through	O	O
two	O	O
pathways	O	O
,	O	O
the	O	O
first	O	O
with	O	O
2	O	O
/	O	O
1	O	O
block	O	O
the	O	O
second	O	O
having	O	O
0	O	O
.	O	O
12	O	O
-	O	O
0	O	O
.	O	O
14	O	O
s	O	O
longer	O	O
conduction	O	O
time	O	O
and	O	O
with	O	O
occasional	O	O
2	O	O
/	O	O
1	O	O
block	O	O
was	O	O
proposed	O	O
for	O	O
the	O	O
explanation	O	O
of	O	O
the	O	O
alternating	O	O
p	O	O
-	O	O
p	O	O
interval	O	O
and	O	O
other	O	O
electrocardiographic	O	O
features	O	O
seen	O	O
.	O	O

atropine	B-chem	B-chem
1	O	O
mg	O	O
given	O	O
intravenously	O	O
resulted	O	O
in	O	O
shortening	O	O
of	O	O
all	O	O
p	O	O
-	O	O
p	O	O
intervals	O	O
without	O	O
changing	O	O
the	O	O
rhythm	O	O
.	O	O

the	O	O
abnormal	O	O
rhythm	O	O
disappeared	O	O
with	O	O
the	O	O
withdrawal	O	O
of	O	O
propranolol	B-chem	B-chem
and	O	O
when	O	O
the	O	O
drug	O	O
was	O	O
restarted	O	O
a	O	O
2	O	O
/	O	O
1	O	O
s	O	O
-	O	O
a	O	O
block	O	O
was	O	O
seen	O	O
.	O	O

this	O	O
was	O	O
accepted	O	O
as	O	O
evidence	O	O
for	O	O
propranolol	B-chem	B-chem
being	O	O
the	O	O
cause	O	O
of	O	O
this	O	O
conduction	O	O
disorder	O	O
.	O	O

antitumor	O	O
effect	O	O
,	O	O
cardiotoxicity	O	O
,	O	O
and	O	O
nephrotoxicity	O	O
of	O	O
doxorubicin	B-chem	B-chem
in	O	O
the	O	O
igm	O	O
solid	O	O
immunocytoma	O	O
-	O	O
bearing	O	O
lou	O	O
/	O	O
m	O	O
/	O	O
wsl	O	O
rat	O	O
.	O	O

antitumor	O	O
activity	O	O
,	O	O
cardiotoxicity	O	O
,	O	O
and	O	O
nephrotoxicity	O	O
induced	O	O
by	O	O
doxorubicin	B-chem	B-chem
were	O	O
studied	O	O
in	O	O
lou	O	O
/	O	O
m	O	O
/	O	O
wsl	O	O
inbred	O	O
rats	O	O
each	O	O
bearing	O	O
a	O	O
transplantable	O	O
solid	O	O
igm	O	O
immunocytoma	O	O
.	O	O

animals	O	O
with	O	O
a	O	O
tumor	O	O
(	O	O
diameter	O	O
,	O	O
15	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

3	O	O
.	O	O
3	O	O
mm	O	O
)	O	O
were	O	O
treated	O	O
with	O	O
iv	O	O
injections	O	O
of	O	O
doxorubicin	B-chem	B-chem
on	O	O
5	O	O
consecutive	O	O
days	O	O
,	O	O
followed	O	O
by	O	O
1	O	O
weekly	O	O
injection	O	O
for	O	O
7	O	O
weeks	O	O
(	O	O
dose	O	O
range	O	O
,	O	O
0	O	O
.	O	O
015	O	O
-	O	O
4	O	O
.	O	O
0	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
wt	O	O
)	O	O
.	O	O

tumor	O	O
regression	O	O
was	O	O
observed	O	O
with	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
doxorubicin	B-chem	B-chem
/	O	O
kg	O	O
.	O	O

complete	O	O
disappearance	O	O
of	O	O
the	O	O
tumor	O	O
was	O	O
induced	O	O
with	O	O
1	O	O
.	O	O
0	O	O
mg	O	O
doxorubicin	B-chem	B-chem
/	O	O
kg	O	O
.	O	O

histologic	O	O
evidence	O	O
of	O	O
cardiotoxicity	O	O
scored	O	O
as	O	O
grade	O	O
iii	O	O
was	O	O
only	O	O
observed	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
1	O	O
.	O	O
0	O	O
mg	O	O
doxorubicin	B-chem	B-chem
/	O	O
kg	O	O
.	O	O

light	O	O
microscopic	O	O
evidence	O	O
of	O	O
renal	O	O
damage	O	O
was	O	O
seen	O	O
above	O	O
a	O	O
dose	O	O
of	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
doxorubicin	B-chem	B-chem
/	O	O
kg	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
albuminuria	O	O
and	O	O
very	O	O
low	O	O
serum	O	O
albumin	O	O
levels	O	O
.	O	O

in	O	O
the	O	O
group	O	O
that	O	O
received	O	O
1	O	O
.	O	O
0	O	O
mg	O	O
doxorubicin	B-chem	B-chem
/	O	O
kg	O	O
,	O	O
the	O	O
serum	O	O
albumin	O	O
level	O	O
decreased	O	O
from	O	O
33	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

4	O	O
.	O	O
1	O	O
to	O	O
1	O	O
.	O	O
5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
5	O	O
g	O	O
/	O	O
liter	O	O
.	O	O

ascites	O	O
and	O	O
hydrothorax	O	O
were	O	O
observed	O	O
simultaneously	O	O
.	O	O

the	O	O
same	O	O
experiments	O	O
were	O	O
performed	O	O
with	O	O
non	O	O
-	O	O
tumor	O	O
-	O	O
bearing	O	O
rats	O	O
,	O	O
in	O	O
which	O	O
no	O	O
major	O	O
differences	O	O
were	O	O
observed	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
antitumor	O	O
activity	O	O
,	O	O
cardiotoxicity	O	O
,	O	O
and	O	O
nephrotoxicity	O	O
were	O	O
studied	O	O
simultaneously	O	O
in	O	O
the	O	O
same	O	O
lou	O	O
/	O	O
m	O	O
/	O	O
wsl	O	O
rat	O	O
.	O	O

albuminuria	O	O
due	O	O
to	O	O
renal	O	O
damage	O	O
led	O	O
to	O	O
extremely	O	O
low	O	O
serum	O	O
albumin	O	O
levels	O	O
,	O	O
so	O	O
ascites	O	O
and	O	O
hydrothorax	O	O
were	O	O
not	O	O
necessarily	O	O
a	O	O
consequence	O	O
of	O	O
the	O	O
observed	O	O
cardiomyopathy	O	O
.	O	O

intraoperative	O	O
bradycardia	O	O
and	O	O
hypotension	O	O
associated	O	O
with	O	O
timolol	B-chem	B-chem
and	O	O
pilocarpine	B-chem	B-chem
eye	O	O
drops	O	O
.	O	O

a	O	O
69	O	O
-	O	O
yr	O	O
-	O	O
old	O	O
man	O	O
,	O	O
who	O	O
was	O	O
concurrently	O	O
being	O	O
treated	O	O
with	O	O
pilocarpine	B-chem	B-chem
nitrate	I-chem	I-chem
and	O	O
timolol	B-chem	B-chem
maleate	I-chem	I-chem
eye	O	I-chem
drops	O	O
,	O	O
developed	O	O
a	O	O
bradycardia	O	O
and	O	O
became	O	O
hypotensive	O	O
during	O	O
halothane	B-chem	B-chem
anaesthesia	O	O
.	O	O

both	O	O
timolol	B-chem	B-chem
and	O	O
pilocarpine	B-chem	B-chem
were	O	O
subsequently	O	O
identified	O	O
in	O	O
a	O	O
24	O	O
-	O	O
h	O	O
collection	O	O
of	O	O
urine	O	O
.	O	O

timolol	B-chem	B-chem
(	O	O
but	O	O
not	O	O
pilocarpine	B-chem	B-chem
)	O	O
was	O	O
detected	O	O
in	O	O
a	O	O
sample	O	O
of	O	O
plasma	O	O
removed	O	O
during	O	O
surgery	O	O
;	O	O
the	O	O
plasma	O	O
concentration	O	O
of	O	O
timolol	B-chem	B-chem
(	O	O
2	O	O
.	O	O
6	O	O
ng	O	O
ml	O	O
-	O	O
1	O	O
)	O	O
was	O	O
consistent	O	O
with	O	O
partial	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
blockade	O	O
.	O	O

it	O	O
is	O	O
postulated	O	O
that	O	O
this	O	O
action	O	O
may	O	O
have	O	O
been	O	O
enhanced	O	O
during	O	O
halothane	B-chem	B-chem
anaesthesia	O	O
with	O	O
resultant	O	O
bradycardia	O	O
and	O	O
hypotension	O	O
.	O	O

pilocarpine	B-chem	B-chem
may	O	O
have	O	O
had	O	O
a	O	O
contributory	O	O
effect	O	O
.	O	O

succinylcholine	B-chem	B-chem
apnoea	O	O
:	O	O
attempted	O	O
reversal	O	O
with	O	O
anticholinesterases	O	O
.	O	O

anticholinesterases	O	B-chem
were	O	O
administered	O	O
in	O	O
an	O	O
attempt	O	O
to	O	O
antagonize	O	O
prolonged	O	O
neuromuscular	O	O
blockade	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
succinylcholine	B-chem	B-chem
in	O	O
a	O	O
patient	O	O
later	O	O
found	O	O
to	O	O
be	O	O
homozygous	O	O
for	O	O
atypical	O	O
plasma	O	O
cholinesterase	O	O
.	O	O

edrophonium	B-chem	B-chem
10	O	O
mg	O	O
,	O	O
given	O	O
74	O	O
min	O	O
after	O	O
succinylcholine	B-chem	B-chem
,	O	O
when	O	O
train	O	O
-	O	O
of	O	O
-	O	O
four	O	O
stimulation	O	O
was	O	O
characteristic	O	O
of	O	O
phase	O	O
ii	O	O
block	O	O
,	O	O
produced	O	O
partial	O	O
antagonism	O	O
which	O	O
was	O	O
not	O	O
sustained	O	O
.	O	O

repeated	O	O
doses	O	O
of	O	O
edrophonium	B-chem	B-chem
to	O	O
70	O	O
mg	O	O
and	O	O
neostigmine	B-chem	B-chem
to	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
did	O	O
not	O	O
antagonize	O	O
or	O	O
augment	O	O
the	O	O
block	O	O
.	O	O

spontaneous	O	O
respiration	O	O
recommenced	O	O
200	O	O
min	O	O
after	O	O
succinylcholine	B-chem	B-chem
administration	O	O
.	O	O

it	O	O
is	O	O
concluded	O	O
that	O	O
anticholinesterases	O	O
are	O	O
only	O	O
partially	O	O
effective	O	O
in	O	O
restoring	O	O
neuromuscular	O	O
function	O	O
in	O	O
succinylcholine	B-chem	B-chem
apnoea	O	O
despite	O	O
muscle	O	O
twitch	O	O
activity	O	O
typical	O	O
of	O	O
phase	O	O
ii	O	O
block	O	O
.	O	O

effect	O	O
of	O	O
doxorubicin	B-chem	B-chem
on	O	O
[	B-chem	B-chem
omega	I-chem	I-chem
-	I-chem	I-chem
i	I-chem	I-chem
-	I-chem	I-chem
131	I-chem	I-chem
]	I-chem	I-chem
heptadecanoic	I-chem	I-chem
acid	I-chem	I-chem
myocardial	O	O
scintigraphy	O	O
and	O	O
echocardiography	O	O
in	O	O
dogs	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
serial	O	O
treatment	O	O
with	O	O
doxorubicin	B-chem	B-chem
on	O	O
dynamic	O	O
myocardial	O	O
scintigraphy	O	O
with	O	O
[	B-chem	B-chem
omega	I-chem	I-chem
-	I-chem	I-chem
i	I-chem	I-chem
-	I-chem	I-chem
131	I-chem	I-chem
]	I-chem	I-chem
heptadecanoic	I-chem	I-chem
acid	I-chem	I-chem
(	O	O
i	B-chem	O
-	I-chem	O
131	I-chem	O
ha	I-chem	I-chem
)	O	O
,	O	O
and	O	O
on	O	O
global	O	O
left	O	O
-	O	O
ventricular	O	O
function	O	O
determined	O	O
echocardiographically	O	O
,	O	O
were	O	O
studied	O	O
in	O	O
a	O	O
group	O	O
of	O	O
nine	O	O
mongrel	O	O
dogs	O	O
.	O	O

total	O	O
extractable	O	O
myocardial	O	O
lipid	O	O
was	O	O
compared	O	O
postmortem	O	O
between	O	O
a	O	O
group	O	O
of	O	O
control	O	O
dogs	O	O
and	O	O
doxorubicin	B-chem	B-chem
-	O	O
treated	O	O
dogs	O	O
.	O	O

a	O	O
significant	O	O
and	O	O
then	O	O
progressive	O	O
fall	O	O
in	O	O
global	O	O
lv	O	O
function	O	O
was	O	O
observed	O	O
at	O	O
a	O	O
cumulative	O	O
doxorubicin	B-chem	B-chem
dose	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
myocardial	O	O
t1	O	O
/	O	O
2	O	O
of	O	O
the	O	O
i	B-chem	O
-	I-chem	O
131	I-chem	O
ha	I-chem	O
was	O	O
observed	O	O
only	O	O
at	O	O
a	O	O
higher	O	O
cumulative	O	O
dose	O	O
,	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

no	O	O
significant	O	O
alteration	O	O
in	O	O
total	O	O
extractable	O	O
myocardial	O	O
lipids	O	O
was	O	O
observed	O	O
between	O	O
control	O	O
dogs	O	O
and	O	O
those	O	O
treated	O	O
with	O	O
doxorubicin	B-chem	B-chem
.	O	O

our	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
changes	O	O
leading	O	O
to	O	O
an	O	O
alteration	O	O
of	O	O
myocardial	O	O
dynamic	O	O
imaging	O	O
with	O	O
i	B-chem	O
-	I-chem	O
131	I-chem	O
ha	I-chem	O
are	O	O
not	O	O
the	O	O
initiating	O	O
factor	O	O
in	O	O
doxorubicin	B-chem	B-chem
cardiotoxicity	O	O
.	O	O

hemodynamics	O	O
and	O	O
myocardial	O	O
metabolism	O	O
under	O	O
deliberate	O	O
hypotension	O	O
.	O	O

an	O	O
experimental	O	O
study	O	O
in	O	O
dogs	O	O
.	O	O

coronary	O	O
blood	O	O
flow	O	O
,	O	O
cardiac	O	O
work	O	O
and	O	O
metabolism	O	O
were	O	O
studied	O	O
in	O	O
dogs	O	O
under	O	O
sodium	B-chem	B-chem
nitroprusside	I-chem	I-chem
(	O	O
snp	B-chem	B-chem
)	O	O
and	O	O
trimetaphan	B-chem	B-chem
(	O	O
tmp	B-chem	B-chem
)	O	O
deliberate	O	O
hypotension	O	O
(	O	O
20	O	O
%	O	O
and	O	O
40	O	O
%	O	O
mean	O	O
pressure	O	O
decrease	O	O
from	O	O
baseline	O	O
)	O	O
.	O	O

regarding	O	O
the	O	O
effects	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
hypotension	O	O
on	O	O
coronary	O	O
blood	O	O
flow	O	O
,	O	O
aortic	O	O
and	O	O
coronary	O	O
sinus	O	O
metabolic	O	O
data	O	O
(	O	O
ph	O	O
,	O	O
po2	O	B-chem
,	O	O
pco2	O	B-chem
)	O	O
we	O	O
could	O	O
confirm	O	O
that	O	O
nitroprusside	B-chem	B-chem
hypotension	O	O
could	O	O
be	O	O
safely	O	O
used	O	O
to	O	O
30	O	O
%	O	O
mean	O	O
blood	O	O
pressure	O	O
decrease	O	O
from	O	O
control	O	O
,	O	O
trimetaphan	B-chem	B-chem
hypotension	O	O
to	O	O
20	O	O
%	O	O
mean	O	O
blood	O	O
pressure	O	O
decrease	O	O
.	O	O

cardiac	O	O
work	O	O
was	O	O
significantly	O	O
reduced	O	O
during	O	O
snp	B-chem	B-chem
hypotension	O	O
.	O	O

myocardial	O	O
o2	B-chem	B-chem
consumption	O	O
and	O	O
o2	B-chem	B-chem
availability	O	O
were	O	O
directly	O	O
dependent	O	O
on	O	O
the	O	O
coronary	O	O
perfusion	O	O
.	O	O

careful	O	O
invasive	O	O
monitoring	O	O
of	O	O
the	O	O
blood	O	O
pressure	O	O
,	O	O
blood	O	O
gases	O	O
and	O	O
of	O	O
the	O	O
ecg	O	O
st	O	O
-	O	O
t	O	O
segment	O	O
is	O	O
mandatory	O	O
.	O	O

evidence	O	O
for	O	O
a	O	O
selective	O	O
brain	O	O
noradrenergic	O	O
involvement	O	O
in	O	O
the	O	O
locomotor	O	O
stimulant	O	O
effects	O	O
of	O	O
amphetamine	B-chem	B-chem
in	O	O
the	O	O
rat	O	O
.	O	O

male	O	O
rats	O	O
received	O	O
the	O	O
noradrenaline	B-chem	B-chem
neurotoxin	O	O
dsp4	B-chem	O
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
7	O	O
days	O	O
prior	O	O
to	O	O
injection	O	O
of	O	O
d	B-chem	B-chem
-	I-chem	I-chem
amphetamine	I-chem	I-chem
(	O	O
10	O	O
or	O	O
40	O	O
mumol	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
.	O	O

the	O	O
hyperactivity	O	O
induced	O	O
by	O	O
d	B-chem	B-chem
-	I-chem	I-chem
amphetamine	I-chem	I-chem
(	O	O
10	O	O
mumol	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
significantly	O	O
reduced	O	O
by	O	O
dsp4	B-chem	O
pretreatment	O	O
.	O	O

however	O	O
,	O	O
the	O	O
increased	O	O
rearings	O	O
and	O	O
the	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
stereotypies	O	O
were	O	O
not	O	O
blocked	O	O
by	O	O
pretreatment	O	O
with	O	O
dsp4	B-chem	O
.	O	O

the	O	O
reduction	O	O
of	O	O
amphetamine	B-chem	B-chem
hyperactivity	O	O
induced	O	O
by	O	O
dsp4	B-chem	B-chem
was	O	O
blocked	O	O
by	O	O
pretreatment	O	O
with	O	O
the	O	O
noradrenaline	B-chem	B-chem
-	O	O
uptake	O	O
blocking	O	O
agent	O	O
,	O	O
desipramine	B-chem	B-chem
,	O	O
which	O	O
prevents	O	O
the	O	O
neurotoxic	O	O
action	O	O
of	O	O
dsp4	B-chem	O
.	O	O

the	O	O
present	O	O
results	O	O
suggest	O	O
a	O	O
selective	O	O
involvement	O	O
of	O	O
central	O	O
noradrenergic	O	O
neurones	O	O
in	O	O
the	O	O
locomotor	O	O
stimulant	O	O
effect	O	O
of	O	O
amphetamine	B-chem	B-chem
in	O	O
the	O	O
rat	O	O
.	O	O

accelerated	O	O
junctional	O	O
rhythms	O	O
during	O	O
oral	O	O
verapamil	B-chem	B-chem
therapy	O	O
.	O	O

this	O	O
study	O	O
examined	O	O
the	O	O
frequency	O	O
of	O	O
atrioventricular	O	O
(	O	O
av	O	O
)	O	O
dissociation	O	O
and	O	O
accelerated	O	O
junctional	O	O
rhythms	O	O
in	O	O
59	O	O
patients	O	O
receiving	O	O
oral	O	O
verapamil	B-chem	B-chem
.	O	O

accelerated	O	O
junctional	O	O
rhythms	O	O
and	O	O
av	O	O
dissociation	O	O
were	O	O
frequent	O	O
in	O	O
patients	O	O
with	O	O
supraventricular	O	O
tachyarrhythmias	O	O
,	O	O
particularly	O	O
av	O	O
nodal	O	O
reentry	O	O
.	O	O

verapamil	B-chem	B-chem
administration	O	O
to	O	O
these	O	O
patients	O	O
led	O	O
to	O	O
an	O	O
asymptomatic	O	O
increase	O	O
in	O	O
activity	O	O
of	O	O
these	O	O
junctional	O	O
pacemakers	O	O
.	O	O

in	O	O
patients	O	O
with	O	O
various	O	O
chest	O	O
pain	O	O
syndromes	O	O
,	O	O
verapamil	B-chem	B-chem
neither	O	O
increased	O	O
the	O	O
frequency	O	O
of	O	O
junctional	O	O
rhythms	O	O
nor	O	O
suppressed	O	O
their	O	O
role	O	O
as	O	O
escape	O	O
rhythms	O	O
under	O	O
physiologically	O	O
appropriate	O	O
circumstances	O	O
.	O	O

treatment	O	O
of	O	O
ovarian	O	O
cancer	O	O
with	O	O
a	O	O
combination	O	O
of	O	O
cis	B-chem	B-chem
-	I-chem	I-chem
platinum	I-chem	I-chem
,	O	O
adriamycin	B-chem	B-chem
,	O	O
cyclophosphamide	B-chem	B-chem
and	O	O
hexamethylmelamine	B-chem	B-chem
.	O	O

during	O	O
the	O	O
last	O	O
2	O	O
1	O	O
/	O	O
2	O	O
years	O	O
,	O	O
38	O	O
patients	O	O
with	O	O
ovarian	O	O
cancer	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
combination	O	O
of	O	O
cisplatinum	B-chem	B-chem
(	O	O
cpdd	B-chem	O
)	O	O
,	O	O
50	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
adriamycin	B-chem	B-chem
,	O	O
30	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
cyclophosphamide	B-chem	B-chem
,	O	O
300	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
on	O	O
day	O	O
1	O	O
;	O	O
and	O	O
hexamethylmelamine	B-chem	B-chem
(	O	O
hmm	B-chem	O
)	O	O
,	O	O
6	O	O
mg	O	O
/	O	O
kg	O	O
daily	O	O
,	O	O
for	O	O
14	O	O
days	O	O
.	O	O

each	O	O
course	O	O
was	O	O
repeated	O	O
monthly	O	O
.	O	O

2	O	O
patients	O	O
had	O	O
stage	O	O
ii	O	O
,	O	O
14	O	O
stage	O	O
iii	O	O
and	O	O
22	O	O
stage	O	O
iv	O	O
disease	O	O
.	O	O

14	O	O
of	O	O
the	O	O
38	O	O
patients	O	O
were	O	O
previously	O	O
treated	O	O
with	O	O
chemotherapy	O	O
,	O	O
1	O	O
with	O	O
radiation	O	O
,	O	O
6	O	O
with	O	O
both	O	O
chemotherapy	O	O
and	O	O
radiation	O	O
,	O	O
and	O	O
17	O	O
did	O	O
not	O	O
have	O	O
any	O	O
treatment	O	O
before	O	O
cpdd	B-chem	O
combination	O	O
.	O	O

31	O	O
of	O	O
the	O	O
38	O	O
cases	O	O
(	O	O
81	O	O
.	O	O
5	O	O
%	O	O
)	O	O
demonstrated	O	O
objective	O	O
responses	O	O
lasting	O	O
for	O	O
2	O	O
months	O	O
or	O	O
more	O	O
.	O	O

these	O	O
responses	O	O
were	O	O
partial	O	O
in	O	O
19	O	O
and	O	O
complete	O	O
in	O	O
12	O	O
cases	O	O
.	O	O

hematologic	O	O
toxicity	O	O
was	O	O
moderate	O	O
and	O	O
with	O	O
reversible	O	O
anemia	O	O
developing	O	O
in	O	O
71	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

gastrointestinal	O	O
side	O	O
effects	O	O
from	O	O
cpdd	B-chem	O
were	O	O
universal	O	O
.	O	O

hmm	B-chem	O
gastrointestinal	O	O
toxicity	O	O
necessitated	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
in	O	O
5	O	O
patients	O	O
.	O	O

severe	O	O
nephrotoxicity	O	O
was	O	O
observed	O	O
in	O	O
2	O	O
patients	O	O
but	O	O
was	O	O
reversible	O	O
.	O	O

there	O	O
were	O	O
no	O	O
drug	O	O
-	O	O
related	O	O
deaths	O	O
.	O	O

nontraumatic	O	O
dissecting	O	O
aneurysm	O	O
of	O	O
the	O	O
basilar	O	O
artery	O	O
.	O	O

a	O	O
case	O	O
of	O	O
nontraumatic	O	O
dissecting	O	O
aneurysm	O	O
of	O	O
the	O	O
basilar	O	O
artery	O	O
in	O	O
association	O	O
with	O	O
hypertension	O	O
,	O	O
smoke	O	O
,	O	O
and	O	O
oral	B-chem	B-chem
contraceptives	I-chem	I-chem
is	O	O
reported	O	O
in	O	O
a	O	O
young	O	O
female	O	O
patient	O	O
with	O	O
a	O	O
locked	O	O
-	O	O
in	O	O
syndrome	O	O
.	O	O

propylthiouracil	B-chem	B-chem
-	O	O
induced	O	O
hepatic	O	O
damage	O	O
.	O	O

two	O	O
cases	O	O
of	O	O
propylthiouracil	B-chem	B-chem
-	O	O
induced	O	O
liver	O	O
damage	O	O
have	O	O
been	O	O
observed	O	O
.	O	O

the	O	O
first	O	O
case	O	O
is	O	O
of	O	O
an	O	O
acute	O	O
type	O	O
of	O	O
damage	O	O
,	O	O
proven	O	O
by	O	O
rechallenge	O	O
;	O	O
the	O	O
second	O	O
presents	O	O
a	O	O
clinical	O	O
and	O	O
histologic	O	O
picture	O	O
resembling	O	O
chronic	O	O
active	O	O
hepatitis	O	O
,	O	O
with	O	O
spontaneous	O	O
remission	O	O
.	O	O

studies	O	O
on	O	O
the	O	O
bradycardia	O	O
induced	O	O
by	O	O
bepridil	B-chem	B-chem
.	O	O

bepridil	B-chem	B-chem
,	O	O
a	O	O
novel	O	O
active	O	O
compound	O	O
for	O	O
prophylactic	O	O
treatment	O	O
of	O	O
anginal	O	O
attacks	O	O
,	O	O
induced	O	O
persistent	O	O
bradycardia	O	O
and	O	O
a	O	O
non	O	O
-	O	O
specific	O	O
anti	O	O
-	O	O
tachycardial	O	O
effect	O	O
,	O	O
the	O	O
mechanisms	O	O
of	O	O
which	O	O
were	O	O
investigated	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

in	O	O
vitro	O	O
perfusion	O	O
of	O	O
bepridil	B-chem	B-chem
in	O	O
the	O	O
life	O	O
-	O	O
support	O	O
medium	O	O
for	O	O
isolated	O	O
sino	O	O
-	O	O
atrial	O	O
tissue	O	O
from	O	O
rabbit	O	O
heart	O	O
,	O	O
caused	O	O
a	O	O
reduction	O	O
in	O	O
action	O	O
potential	O	O
(	O	O
ap	O	O
)	O	O
spike	O	O
frequency	O	O
(	O	O
recorded	O	O
by	O	O
kcl	B-chem	B-chem
microelectrodes	O	O
)	O	O
starting	O	O
at	O	O
doses	O	O
of	O	O
5	O	O
x	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
m	O	O
.	O	O

this	O	O
effect	O	O
was	O	O
dose	O	O
-	O	O
dependent	O	O
up	O	O
to	O	O
concentrations	O	O
of	O	O
5	O	O
x	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O

m	O	O
,	O	O
whereupon	O	O
blockade	O	O
of	O	O
sinus	O	O
activity	O	O
set	O	O
in	O	O
.	O	O

bepridil	B-chem	B-chem
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
x	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
m	O	O
,	O	O
induced	O	O
a	O	O
concomitant	O	O
reduction	O	O
in	O	O
ap	O	O
amplitude	O	O
(	O	O
falling	O	O
from	O	O
71	O	O
+	O	O
/	O	O
-	O	O

8	O	O
mv	O	O
to	O	O
47	O	O
+	O	O
/	O	O
-	O	O

6	O	O
mv	O	O
)	O	O
,	O	O
maximum	O	O
systolic	O	O
depolarization	O	O
velocity	O	O
(	O	O
phase	O	O
0	O	O
)	O	O
which	O	O
fell	O	O
from	O	O
1	O	O
.	O	O
85	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
35	O	O
v	O	O
/	O	O
s	O	O
to	O	O
0	O	O
.	O	O
84	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
28	O	O
v	O	O
/	O	O
s	O	O
,	O	O
together	O	O
with	O	O
maximum	O	O
diastolic	O	O
depolarization	O	O
velocity	O	O
(	O	O
phase	O	O
4	O	O
)	O	O
which	O	O
fell	O	O
from	O	O
38	O	O
+	O	O
/	O	O
-	O	O

3	O	O
mv	O	O
/	O	O
s	O	O
to	O	O
24	O	O
+	O	O
/	O	O
-	O	O

5	O	O
mv	O	O
/	O	O
s	O	O
.	O	O

in	O	O
vivo	O	O
injection	O	O
of	O	O
bepridil	B-chem	B-chem
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
i	O	O
.	O	O
v	O	O
.	O	O
)	O	O
into	O	O
6	O	O
anaesthetized	O	O
dogs	O	O
which	O	O
had	O	O
undergone	O	O
ablation	O	O
of	O	O
all	O	O
the	O	O
extrinsic	O	O
cardiac	O	O
afferent	O	O
nerve	O	O
supply	O	O
,	O	O
together	O	O
with	O	O
a	O	O
bilateral	O	O
medullo	O	O
-	O	O
adrenalectomy	O	O
,	O	O
caused	O	O
a	O	O
marked	O	O
reduction	O	O
in	O	O
heart	O	O
rate	O	O
which	O	O
fell	O	O
from	O	O
98	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

4	O	O
.	O	O
2	O	O
beats	O	O
/	O	O
min	O	O
to	O	O
76	O	O
+	O	O
/	O	O
-	O	O

5	O	O
.	O	O
3	O	O
beats	O	O
/	O	O
min	O	O
sustained	O	O
for	O	O
more	O	O
than	O	O
45	O	O
min	O	O
.	O	O

it	O	O
is	O	O
concluded	O	O
that	O	O
bepridil	B-chem	B-chem
reduces	O	O
heart	O	O
rate	O	O
by	O	O
acting	O	O
directly	O	O
on	O	O
the	O	O
sinus	O	O
node	O	O
.	O	O

this	O	O
effect	O	O
,	O	O
which	O	O
results	O	O
in	O	O
a	O	O
flattening	O	O
of	O	O
the	O	O
phase	O	O
0	O	O
and	O	O
phase	O	O
4	O	O
slope	O	O
,	O	O
together	O	O
with	O	O
a	O	O
longer	O	O
ap	O	O
duration	O	O
,	O	O
may	O	O
be	O	O
due	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
time	O	O
constants	O	O
of	O	O
slow	O	O
inward	O	O
ionic	O	O
currents	O	O
(	O	O
already	O	O
demonstrated	O	O
elsewhere	O	O
)	O	O
,	O	O
but	O	O
also	O	O
to	O	O
an	O	O
increased	O	O
time	O	O
constant	O	O
for	O	O
deactivation	O	O
of	O	O
the	O	O
outward	O	O
potassium	B-chem	B-chem
current	O	O
(	O	O
ip	O	O
)	O	O
.	O	O

hepatitis	O	O
and	O	O
renal	O	O
tubular	O	O
acidosis	O	O
after	O	O
anesthesia	O	O
with	O	O
methoxyflurane	B-chem	B-chem
.	O	O

a	O	O
69	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
operated	O	O
for	O	O
acute	O	O
cholecystitis	O	O
under	O	O
methoxyflurane	B-chem	B-chem
anesthesia	O	O
developed	O	O
postoperatively	O	O
a	O	O
hepatic	O	O
insufficiency	O	O
syndrome	O	O
and	O	O
renal	O	O
tubular	O	O
acidosis	O	O
.	O	O

massive	O	O
bleeding	O	O
appeared	O	O
during	O	O
surgery	O	O
which	O	O
lasted	O	O
for	O	O
six	O	O
hours	O	O
.	O	O

postoperative	O	O
evolution	O	O
under	O	O
supportive	O	O
therapy	O	O
was	O	O
favourable	O	O
.	O	O

complete	O	O
recovery	O	O
was	O	O
confirmed	O	O
by	O	O
repeated	O	O
controls	O	O
performed	O	O
over	O	O
a	O	O
period	O	O
of	O	O
one	O	O
year	O	O
after	O	O
surgery	O	O
.	O	O

pituitary	O	O
response	O	O
to	O	O
luteinizing	O	O
hormone	O	O
-	O	I-chem
releasing	O	I-chem
hormone	O	I-chem
during	O	O
haloperidol	B-chem	B-chem
-	O	O
induced	O	O
hyperprolactinemia	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
a	O	O
6	O	O
-	O	O
hour	O	O
infusion	O	O
with	O	O
haloperidol	B-chem	B-chem
on	O	O
serum	O	O
prolactin	O	O
and	O	O
luteinizing	O	O
hormone	O	O
(	O	O
lh	O	O
)	O	O
levels	O	O
was	O	O
studied	O	O
in	O	O
a	O	O
group	O	O
of	O	O
male	O	O
subjects	O	O
.	O	O

five	O	O
hours	O	O
after	O	O
starting	O	O
the	O	O
infusions	O	O
,	O	O
a	O	O
study	O	O
of	O	O
the	O	O
pituitary	O	O
responses	O	O
to	O	O
lh	O	B-chem
-	O	O
releasing	O	I-chem
hormone	O	I-chem
(	O	O
lh	O	B-chem
-	O	I-chem
rh	O	I-chem
)	O	O
was	O	O
carried	O	O
out	O	O
.	O	O

control	O	O
patients	O	O
received	O	O
infusions	O	O
of	O	O
0	O	O
.	O	O
9	O	O
%	O	O
nacl	B-chem	B-chem
solution	O	O
.	O	O

during	O	O
the	O	O
course	O	O
of	O	O
haloperidol	B-chem	B-chem
infusions	O	O
,	O	O
significant	O	O
hyperprolactinemia	O	O
was	O	O
found	O	O
,	O	O
together	O	O
with	O	O
an	O	O
abolished	O	O
pituitary	O	O
response	O	O
to	O	O
lh	O	B-chem
-	O	O
rh	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
responses	O	O
of	O	O
control	O	O
subjects	O	O
.	O	O

antirifampicin	O	B-chem
antibodies	O	O
in	O	O
acute	O	O
rifampicin	B-chem	B-chem
-	O	O
associated	O	O
renal	O	O
failure	O	O
.	O	O

5	O	O
patients	O	O
with	O	O
acute	O	O
renal	O	O
failure	O	O
(	O	O
3	O	O
with	O	O
thrombopenia	O	O
and	O	O
hemolysis	O	O
)	O	O
induced	O	O
by	O	O
the	O	O
reintroduction	O	O
of	O	O
rifampicin	B-chem	B-chem
are	O	O
described	O	O
.	O	O

no	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
the	O	O
severity	O	O
of	O	O
clinical	O	O
manifestations	O	O
and	O	O
the	O	O
total	O	O
dose	O	O
taken	O	O
by	O	O
the	O	O
patients	O	O
.	O	O

in	O	O
all	O	O
but	O	O
1	O	O
patient	O	O
,	O	O
antirifampicin	O	O
antibodies	O	O
were	O	O
detected	O	O
.	O	O

antibodies	O	O
suggested	O	O
to	O	O
be	O	O
of	O	O
the	O	O
igm	O	O
class	O	O
were	O	O
detected	O	O
in	O	O
all	O	O
3	O	O
patients	O	O
with	O	O
hematological	O	O
disorders	O	O
.	O	O

the	O	O
pattern	O	O
of	O	O
non	O	O
-	O	O
specific	O	O
acute	O	O
tubular	O	O
necrosis	O	O
found	O	O
in	O	O
the	O	O
2	O	O
biopsied	O	O
patients	O	O
,	O	O
indistinguishable	O	O
from	O	O
that	O	O
of	O	O
ischemic	O	O
origin	O	O
,	O	O
raised	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
vascular	O	O
-	O	O
mediated	O	O
damage	O	O
.	O	O

in	O	O
3	O	O
patients	O	O
,	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
triggering	O	O
immunoallergic	O	O
mechanism	O	O
is	O	O
discussed	O	O
.	O	O

cardiovascular	O	O
effects	O	O
of	O	O
hypotension	O	O
induced	O	O
by	O	O
adenosine	B-chem	B-chem
triphosphate	I-chem	I-chem
and	O	O
sodium	B-chem	B-chem
nitroprusside	I-chem	I-chem
on	O	O
dogs	O	O
with	O	O
denervated	O	O
hearts	O	O
.	O	O

adenosine	B-chem	B-chem
triphosphate	I-chem	I-chem
(	O	O
atp	B-chem	B-chem
)	O	O
and	O	O
sodium	B-chem	B-chem
nitroprusside	I-chem	I-chem
(	O	O
snp	B-chem	B-chem
)	O	O
are	O	O
administered	O	O
to	O	O
patients	O	O
to	O	O
induce	O	O
and	O	O
control	O	O
hypotension	O	O
during	O	O
anesthesia	O	O
.	O	O

snp	B-chem	B-chem
is	O	O
authorized	O	O
for	O	O
clinical	O	O
use	O	O
in	O	O
usa	O	O
and	O	O
uk	O	O
,	O	O
and	O	O
atp	B-chem	B-chem
is	O	O
clinically	O	O
used	O	O
in	O	O
other	O	O
countries	O	O
such	O	O
as	O	O
japan	O	O
.	O	O

we	O	O
investigated	O	O
how	O	O
these	O	O
two	O	O
drugs	O	O
act	O	O
on	O	O
the	O	O
cardiovascular	O	O
systems	O	O
of	O	O
20	O	O
dogs	O	O
whose	O	O
hearts	O	O
had	O	O
been	O	O
denervated	O	O
by	O	O
a	O	O
procedure	O	O
we	O	O
had	O	O
devised	O	O
.	O	O

atp	B-chem	B-chem
(	O	O
10	O	O
dogs	O	O
)	O	O
or	O	O
snp	B-chem	B-chem
(	O	O
10	O	O
dogs	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
reduce	O	O
mean	O	O
arterial	O	O
pressure	O	O
by	O	O
30	O	O
%	O	O
to	O	O
70	O	O
%	O	O
of	O	O
control	O	O
.	O	O

before	O	O
,	O	O
during	O	O
and	O	O
after	O	O
induced	O	O
hypotension	O	O
,	O	O
we	O	O
measured	O	O
major	O	O
cardiovascular	O	O
parameters	O	O
.	O	O

hypotension	O	O
induced	O	O
by	O	O
atp	B-chem	B-chem
was	O	O
accompanied	O	O
by	O	O
significant	O	O
decreases	O	O
in	O	O
mean	O	O
pulmonary	O	O
arterial	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
central	O	O
venous	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
total	O	O
peripheral	O	O
resistance	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
rate	O	O
pressure	O	O
product	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
total	O	O
body	O	O
oxygen	B-chem	B-chem
consumption	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
and	O	O
heart	O	O
rate	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
;	O	O
all	O	O
these	O	O
variables	O	O
returned	O	O
normal	O	O
within	O	O
30	O	O
min	O	O
after	O	O
atp	B-chem	B-chem
was	O	O
stopped	O	O
.	O	O

cardiac	O	O
output	O	O
did	O	O
not	O	O
change	O	O
.	O	O

during	O	O
hypotension	O	O
produced	O	O
by	O	O
snp	B-chem	B-chem
similar	O	O
decreases	O	O
were	O	O
observed	O	O
in	O	O
mean	O	O
pulmonary	O	O
arterial	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
central	O	O
venous	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
total	O	O
peripheral	O	O
resistance	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
rate	O	O
pressure	O	O
product	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
and	O	O
oxygen	B-chem	B-chem
content	O	O
difference	O	O
between	O	O
arterial	O	O
and	O	O
mixed	O	O
venous	O	O
blood	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
while	O	O
heart	O	O
rate	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
cardiac	O	O
output	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
were	O	O
increased	O	O
.	O	O

recoveries	O	O
of	O	O
heart	O	O
rate	O	O
and	O	O
left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
were	O	O
not	O	O
shown	O	O
within	O	O
60	O	O
min	O	O
after	O	O
snp	B-chem	B-chem
had	O	O
been	O	O
stopped	O	O
.	O	O

both	O	O
atp	B-chem	B-chem
and	O	O
snp	B-chem	B-chem
should	O	O
act	O	O
on	O	O
the	O	O
pacemaker	O	O
tissue	O	O
of	O	O
the	O	O
heart	O	O
.	O	O

comparative	O	O
study	O	O
:	O	O
endografine	B-chem	O
(	O	O
diatrizoate	B-chem	B-chem
)	O	O
,	O	O
vasurix	B-chem	O
polyvidone	I-chem	B-chem
(	O	O
acetrizoate	B-chem	B-chem
)	O	O
,	O	O
dimer	B-chem	B-chem
-	I-chem	O
x	I-chem	O
(	O	O
iocarmate	B-chem	O
)	O	O
and	O	O
hexabrix	B-chem	O
(	O	O
ioxaglate	B-chem	B-chem
)	O	O
in	O	O
hysterosalpingography	O	O
.	O	O

side	O	O
effects	O	O
of	O	O
hysterosalpingography	O	O
with	O	O
dimer	B-chem	B-chem
-	I-chem	O
x	I-chem	O
,	O	O
hexabrix	B-chem	O
,	O	O
vasurix	B-chem	O
polyvidone	I-chem	B-chem
and	O	O
endografine	B-chem	O
in	O	O
142	O	O
consecutive	O	O
patients	O	O
,	O	O
receiving	O	O
one	O	O
of	O	O
the	O	O
four	O	O
tested	O	O
media	O	O
were	O	O
evaluated	O	O
from	O	O
replies	O	O
to	O	O
postal	O	O
questionnaires	O	O
.	O	O

the	O	O
dimer	B-chem	B-chem
-	I-chem	O
x	I-chem	O
group	O	O
had	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
nausea	O	O
and	O	O
dizziness	O	O
.	O	O

the	O	O
endografine	B-chem	O
group	O	O
had	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
abdominal	O	O
pain	O	O
.	O	O

these	O	O
differences	O	O
occur	O	O
especially	O	O
in	O	O
the	O	O
age	O	O
groups	O	O
under	O	O
30	O	O
years	O	O
.	O	O

hexabrix	B-chem	O
and	O	O
vasurix	B-chem	O
polyvidone	I-chem	B-chem
are	O	O
considered	O	O
the	O	O
best	O	O
contrast	B-chem	O
media	I-chem	O
for	O	O
hysterosalpingography	O	O
and	O	O
perhaps	O	O
because	O	O
of	O	O
its	O	O
low	O	O
toxicity	O	O
hexabrix	B-chem	O
should	O	O
be	O	O
preferred	O	O
.	O	O

post	O	O
-	O	O
suxamethonium	B-chem	B-chem
pains	O	O
in	O	O
nigerian	O	O
surgical	O	O
patients	O	O
.	O	O

contrary	O	O
to	O	O
an	O	O
earlier	O	O
report	O	O
by	O	O
coxon	O	B-chem
,	O	O
scoline	B-chem	B-chem
pain	O	O
occurs	O	O
in	O	O
african	O	O
negroes	O	O
.	O	O

its	O	O
incidence	O	O
was	O	O
determined	O	O
in	O	O
a	O	O
prospective	O	O
study	O	O
involving	O	O
a	O	O
total	O	O
of	O	O
100	O	O
nigerian	O	O
patients	O	O
(	O	O
50	O	O
out	O	O
-	O	O
patients	O	O
and	O	O
50	O	O
in	O	O
-	O	O
patients	O	O
)	O	O
.	O	O

about	O	O
62	O	O
%	O	O
of	O	O
the	O	O
out	O	O
-	O	O
patients	O	O
developed	O	O
scoline	B-chem	O
pain	O	O
as	O	O
compared	O	O
with	O	O
about	O	O
26	O	O
%	O	O
among	O	O
the	O	O
in	O	O
-	O	O
patients	O	O
.	O	O

the	O	O
abolition	O	O
of	O	O
muscle	O	O
fasciculations	O	O
(	O	O
by	O	O
0	O	O
.	O	O
075mg	O	O
/	O	O
kg	O	O
dose	O	O
of	O	O
fazadinium	B-chem	B-chem
)	O	O
did	O	O
not	O	O
influence	O	O
the	O	O
occurrence	O	O
of	O	O
scoline	B-chem	B-chem
pain	O	O
.	O	O

neither	O	O
the	O	O
type	O	O
of	O	O
induction	O	O
agent	O	O
(	O	O
althesin	B-chem	B-chem
or	O	O
thiopentone	B-chem	B-chem
)	O	O
nor	O	O
the	O	O
salt	O	O
preparation	O	O
of	O	O
suxamethonium	B-chem	B-chem
used	O	O
(	O	O
chloride	B-chem	B-chem
or	O	O
bromide	B-chem	B-chem
)	O	O
,	O	O
affected	O	O
the	O	O
incidence	O	O
of	O	O
scoline	B-chem	B-chem
pain	O	O
.	O	O

medial	O	O
changes	O	O
in	O	O
arterial	O	O
spasm	O	O
induced	O	O
by	O	O
l	B-chem	B-chem
-	I-chem	O
norepinephrine	I-chem	B-chem
.	O	O

in	O	O
normal	O	O
rats	O	O
,	O	O
the	O	O
media	O	O
of	O	O
small	O	O
arteries	O	O
(	O	O
0	O	O
.	O	O
4	O	O
-	O	O
-	O	O
0	O	O
.	O	O
2	O	O
mm	O	O
in	O	O
diameter	O	O
)	O	O
previously	O	O
was	O	O
shown	O	O
to	O	O
contain	O	O
intracellular	O	O
vacuoles	O	O
,	O	O
identified	O	O
ultrastructurally	O	O
as	O	O
herniations	O	O
of	O	O
one	O	O
smooth	O	O
muscle	O	O
cell	O	O
into	O	O
another	O	O
.	O	O

the	O	O
hypothesis	O	O
that	O	O
intense	O	O
vasoconstriction	O	O
would	O	O
increase	O	O
the	O	O
number	O	O
of	O	O
such	O	O
vacuoles	O	O
has	O	O
been	O	O
tested	O	O
.	O	O

in	O	O
the	O	O
media	O	O
of	O	O
the	O	O
saphenous	O	O
artery	O	O
and	O	O
its	O	O
distal	O	O
branch	O	O
,	O	O
vasoconstriction	O	O
induced	O	O
by	O	O
l	B-chem	B-chem
-	I-chem	O
norepinephrine	I-chem	B-chem
produced	O	O
many	O	O
cell	O	O
-	O	O
to	O	O
-	O	O
cell	O	O
hernias	O	O
within	O	O
15	O	O
minutes	O	O
.	O	O

at	O	O
1	O	O
day	O	O
their	O	O
number	O	O
was	O	O
reduced	O	O
to	O	O
about	O	O
1	O	O
/	O	O
10	O	O
of	O	O
the	O	O
original	O	O
number	O	O
.	O	O

by	O	O
7	O	O
days	O	O
the	O	O
vessel	O	O
was	O	O
almost	O	O
restored	O	O
to	O	O
normal	O	O
.	O	O

triple	O	O
stimulation	O	O
over	O	O
1	O	O
day	O	O
induced	O	O
more	O	O
severe	O	O
changes	O	O
in	O	O
the	O	O
media	O	O
.	O	O

these	O	O
findings	O	O
suggest	O	O
that	O	O
smooth	O	O
muscle	O	O
cells	O	O
are	O	O
susceptible	O	O
to	O	O
damage	O	O
in	O	O
the	O	O
course	O	O
of	O	O
their	O	O
specific	O	O
function	O	O
.	O	O

the	O	O
experimental	O	O
data	O	O
are	O	O
discussed	O	O
in	O	O
relation	O	O
to	O	O
medial	O	O
changes	O	O
observed	O	O
in	O	O
other	O	O
instances	O	O
of	O	O
arterial	O	O
spasm	O	O
.	O	O

endothelial	O	O
changes	O	O
that	O	O
developed	O	O
in	O	O
the	O	O
same	O	O
experimental	O	O
model	O	O
were	O	O
described	O	O
in	O	O
a	O	O
previous	O	O
paper	O	O
.	O	O

abnormalities	O	O
of	O	O
the	O	O
pupil	O	O
and	O	O
visual	O	O
-	O	O
evoked	O	O
potential	O	O
in	O	O
quinine	B-chem	B-chem
amblyopia	O	O
.	O	O

total	O	O
blindness	O	O
with	O	O
a	O	O
transient	O	O
tonic	O	O
pupillary	O	O
response	O	O
,	O	O
denervation	O	O
supersensitivity	O	O
,	O	O
and	O	O
abnormal	O	O
visual	O	O
-	O	O
evoked	O	O
potentials	O	O
developed	O	O
in	O	O
a	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
after	O	O
the	O	O
use	O	O
of	O	O
quinine	B-chem	B-chem
sulfate	I-chem	I-chem
for	O	O
leg	O	O
cramps	O	O
.	O	O

he	O	O
later	O	O
recovered	O	O
normal	O	O
visual	O	O
acuity	O	O
.	O	O

a	O	O
transient	O	O
tonic	O	O
pupillary	O	O
response	O	O
,	O	O
denervation	O	O
supersensitivity	O	O
,	O	O
and	O	O
abnormal	O	O
visual	O	O
-	O	O
evoked	O	O
potentials	O	O
in	O	O
quinine	B-chem	B-chem
toxicity	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
have	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O

suxamethonium	B-chem	B-chem
-	O	O
induced	O	O
jaw	O	O
stiffness	O	O
and	O	O
myalgia	O	O
associated	O	O
with	O	O
atypical	O	O
cholinesterase	O	O
:	O	O
case	O	O
report	O	O
.	O	O

an	O	O
11	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
was	O	O
given	O	O
halothane	B-chem	B-chem
,	O	O
nitrous	B-chem	B-chem
oxide	I-chem	I-chem
and	O	O
oxygen	B-chem	B-chem
,	O	O
pancuronium	B-chem	B-chem
0	O	O
.	O	O
4	O	O
mg	O	O
and	O	O
suxamethonium	B-chem	B-chem
100	O	O
mg	O	O
for	O	O
induction	O	O
of	O	O
anaesthesia	O	O
.	O	O

in	O	O
response	O	O
to	O	O
this	O	O
a	O	O
marked	O	O
jaw	O	O
stiffness	O	O
occurred	O	O
which	O	O
lasted	O	O
for	O	O
two	O	O
minutes	O	O
and	O	O
the	O	O
anaesthesia	O	O
were	O	O
terminated	O	O
.	O	O

four	O	O
hours	O	O
of	O	O
apnoea	O	O
ensued	O	O
and	O	O
he	O	O
suffered	O	O
generalized	O	O
severe	O	O
myalgia	O	O
lasting	O	O
for	O	O
one	O	O
week	O	O
.	O	O

he	O	O
was	O	O
found	O	O
to	O	O
have	O	O
atypical	O	O
plasma	O	O
cholinesterase	O	O
with	O	O
a	O	O
dibucaine	B-chem	O
number	O	O
of	O	O
12	O	O
,	O	O
indicating	O	O
homozygocity	O	O
.	O	O

this	O	O
was	O	O
verified	O	O
by	O	O
study	O	O
of	O	O
the	O	O
family	O	O
.	O	O

the	O	O
case	O	O
shows	O	O
that	O	O
prolonged	O	O
jaw	O	O
rigidity	O	O
and	O	O
myalgia	O	O
may	O	O
occur	O	O
after	O	O
suxamethonium	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
atypical	O	O
cholinesterase	O	O
despite	O	O
pretreatment	O	O
with	O	O
pancuronium	B-chem	B-chem
.	O	O

indomethacin	B-chem	B-chem
-	O	O
induced	O	O
hyperkalemia	O	O
in	O	O
three	O	O
patients	O	O
with	O	O
gouty	O	O
arthritis	O	O
.	O	O

we	O	O
describe	O	O
three	O	O
patients	O	O
in	O	O
whom	O	O
severe	O	O
,	O	O
life	O	O
-	O	O
threatening	O	O
hyperkalemia	O	O
and	O	O
renal	O	O
insufficiency	O	O
developed	O	O
after	O	O
treatment	O	O
of	O	O
acute	O	O
gouty	O	O
arthritis	O	O
with	O	O
indomethacin	B-chem	B-chem
.	O	O

this	O	O
complication	O	O
may	O	O
result	O	O
from	O	O
an	O	O
inhibition	O	O
of	O	O
prostaglandin	B-chem	B-chem
synthesis	O	O
and	O	O
consequent	O	O
hyporeninemic	O	O
hypoaidosteronism	O	O
.	O	O

careful	O	O
attention	O	O
to	O	O
renal	O	O
function	O	O
and	O	O
potassium	B-chem	B-chem
balance	O	O
in	O	O
patients	O	O
receiving	O	O
indomethacin	B-chem	B-chem
or	O	O
other	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
agents	O	O
,	O	O
particularly	O	O
in	O	O
those	O	O
patients	O	O
with	O	O
diabetes	O	O
mellitus	O	O
or	O	O
preexisting	O	O
renal	O	O
disease	O	O
,	O	O
will	O	O
help	O	O
prevent	O	O
this	O	O
potentially	O	O
serious	O	O
complication	O	O
.	O	O

etomidate	B-chem	B-chem
:	O	O
a	O	O
foreshortened	O	O
clinical	O	O
trial	O	O
.	O	O

a	O	O
clinical	O	O
evaluation	O	O
of	O	O
etomidate	B-chem	B-chem
for	O	O
outpatient	O	O
cystoscopy	O	O
was	O	O
embarked	O	O
upon	O	O
.	O	O

unpremedicated	O	O
patients	O	O
were	O	O
given	O	O
fentanyl	B-chem	B-chem
1	O	O
microgram	O	O
/	O	O
kg	O	O
followed	O	O
by	O	O
etomidate	B-chem	B-chem
0	O	O
.	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

anaesthesia	O	O
was	O	O
maintained	O	O
with	O	O
intermittent	O	O
etomidate	B-chem	B-chem
in	O	O
2	O	O
-	O	O
4	O	O
mg	O	O
doses	O	O
.	O	O

patients	O	O
were	O	O
interviewed	O	O
personally	O	O
later	O	O
the	O	O
same	O	O
day	O	O
,	O	O
and	O	O
by	O	O
questionnaire	O	O
three	O	O
to	O	O
four	O	O
weeks	O	O
later	O	O
.	O	O

the	O	O
trial	O	O
was	O	O
discontinued	O	O
after	O	O
20	O	O
cases	O	O
because	O	O
of	O	O
an	O	O
unacceptable	O	O
incidence	O	O
of	O	O
side	O	O
effects	O	O
.	O	O

venous	O	O
pain	O	O
occurred	O	O
in	O	O
68	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
50	O	O
%	O	O
had	O	O
redness	O	O
,	O	O
pain	O	O
or	O	O
swelling	O	O
related	O	O
to	O	O
the	O	O
injection	O	O
site	O	O
,	O	O
in	O	O
some	O	O
cases	O	O
lasting	O	O
up	O	O
to	O	O
three	O	O
weeks	O	O
after	O	O
anaesthesia	O	O
.	O	O

skeletal	O	O
movements	O	O
occurred	O	O
in	O	O
50	O	O
%	O	O
of	O	O
patients	O	O
;	O	O
30	O	O
%	O	O
experienced	O	O
respiratory	O	O
upset	O	O
,	O	O
one	O	O
sufficiently	O	O
severe	O	O
to	O	O
necessitate	O	O
abandoning	O	O
the	O	O
technique	O	O
.	O	O

nausea	O	O
and	O	O
vomiting	O	O
occurred	O	O
in	O	O
40	O	O
%	O	O
and	O	O
25	O	O
%	O	O
had	O	O
disturbing	O	O
emergence	O	O
psychoses	O	O
.	O	O

levodopa	B-chem	B-chem
-	O	O
induced	O	O
dyskinesias	O	O
are	O	O
improved	O	O
by	O	O
fluoxetine	B-chem	B-chem
.	O	O

we	O	O
evaluated	O	O
the	O	O
severity	O	O
of	O	O
motor	O	O
disability	O	O
and	O	O
dyskinesias	O	O
in	O	O
seven	O	O
levodopa	B-chem	B-chem
-	O	O
responsive	O	O
patients	O	O
with	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
after	O	O
an	O	O
acute	O	O
challenge	O	O
with	O	O
the	O	O
mixed	O	O
dopamine	B-chem	B-chem
agonist	O	O
,	O	O
apomorphine	B-chem	B-chem
,	O	O
before	O	O
and	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
fluoxetine	B-chem	B-chem
(	O	O
20	O	O
mg	O	O
twice	O	O
per	O	O
day	O	O
)	O	O
for	O	O
11	O	O
+	O	O
/	O	O
-	O	O

1	O	O
days	O	O
.	O	O

after	O	O
fluoxetine	B-chem	B-chem
treatment	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
47	O	O
%	O	O
improvement	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
of	O	O
apomorphine	B-chem	B-chem
-	O	O
induced	O	O
dyskinesias	O	O
without	O	O
modification	O	O
of	O	O
parkinsonian	O	O
motor	O	O
disability	O	O
.	O	O

the	O	O
dyskinesias	O	O
were	O	O
reduced	O	O
predominantly	O	O
in	O	O
the	O	O
lower	O	O
limbs	O	O
during	O	O
the	O	O
onset	O	O
and	O	O
disappearance	O	O
of	O	O
dystonic	O	O
dyskinesias	O	O
(	O	O
onset	O	O
-	O	O
and	O	O
end	O	O
-	O	O
of	O	O
-	O	O
dose	O	O
dyskinesias	O	O
)	O	O
and	O	O
in	O	O
the	O	O
upper	O	O
limbs	O	O
during	O	O
choreic	O	O
mid	O	O
-	O	O
dose	O	O
dyskinesias	O	O
.	O	O

the	O	O
results	O	O
suggest	O	O
that	O	O
increased	O	O
brain	O	O
serotoninergic	O	O
transmission	O	O
with	O	O
fluoxetine	B-chem	B-chem
may	O	O
reduce	O	O
levodopa	B-chem	B-chem
-	O	O
or	O	O
dopamine	B-chem	B-chem
agonist	O	O
-	O	O
induced	O	O
dyskinesias	O	O
without	O	O
aggravating	O	O
parkinsonian	O	O
motor	O	O
disability	O	O
.	O	O

a	O	O
large	O	O
population	O	O
-	O	O
based	O	O
follow	O	O
-	O	O
up	O	O
study	O	O
of	O	O
trimethoprim	B-chem	B-chem
-	I-chem	I-chem
sulfamethoxazole	I-chem	I-chem
,	O	O
trimethoprim	B-chem	B-chem
,	O	O
and	O	O
cephalexin	B-chem	B-chem
for	O	O
uncommon	O	O
serious	O	O
drug	O	O
toxicity	O	O
.	O	O

we	O	O
conducted	O	O
a	O	O
population	O	O
-	O	O
based	O	O
45	O	O
-	O	O
day	O	O
follow	O	O
-	O	O
up	O	O
study	O	O
of	O	O
232	O	O
,	O	O
390	O	O
people	O	O
who	O	O
were	O	O
prescribed	O	O
trimethoprim	B-chem	B-chem
-	I-chem	I-chem
sulfamethoxazole	I-chem	I-chem
(	O	O
tmp	B-chem	B-chem
-	I-chem	O
smz	I-chem	B-chem
)	O	O
,	O	O
266	O	O
,	O	O
951	O	O
prescribed	O	O
trimethoprim	B-chem	B-chem
alone	O	O
,	O	O
and	O	O
196	O	O
,	O	O
397	O	O
prescribed	O	O
cephalexin	B-chem	B-chem
,	O	O
to	O	O
estimate	O	O
the	O	O
risk	O	O
of	O	O
serious	O	O
liver	O	O
,	O	O
blood	O	O
,	O	O
skin	O	O
,	O	O
and	O	O
renal	O	O
disorders	O	O
resulting	O	O
in	O	O
referral	O	O
or	O	O
hospitalization	O	O
associated	O	O
with	O	O
these	O	O
drugs	O	O
.	O	O

the	O	O
results	O	O
were	O	O
based	O	O
on	O	O
information	O	O
recorded	O	O
on	O	O
office	O	O
computers	O	O
by	O	O
selected	O	O
general	O	O
practitioners	O	O
in	O	O
the	O	O
united	O	O
kingdom	O	O
,	O	O
together	O	O
with	O	O
a	O	O
review	O	O
of	O	O
clinical	O	O
records	O	O
.	O	O

the	O	O
risk	O	O
of	O	O
clinically	O	O
important	O	O
idiopathic	O	O
liver	O	O
disease	O	O
was	O	O
similar	O	O
for	O	O
persons	O	O
prescribed	O	O
tmp	B-chem	B-chem
-	I-chem	O
smz	I-chem	O
(	O	O
5	O	O
.	O	O
2	O	O
/	O	O
100	O	O
,	O	O
000	O	O
)	O	O
and	O	O
those	O	O
prescribed	O	O
trimethoprim	B-chem	B-chem
alone	O	O
(	O	O
3	O	O
.	O	O
8	O	O
/	O	O
100	O	O
,	O	O
000	O	O
)	O	O
.	O	O

the	O	O
risk	O	O
for	O	O
those	O	O
prescribed	O	O
cephalexin	B-chem	B-chem
was	O	O
somewhat	O	O
lower	O	O
(	O	O
2	O	O
.	O	O
0	O	O
/	O	O
100	O	O
,	O	O
000	O	O
)	O	O
.	O	O

only	O	O
five	O	O
patients	O	O
experienced	O	O
blood	O	O
disorders	O	O
,	O	O
one	O	O
of	O	O
whom	O	O
was	O	O
exposed	O	O
to	O	O
tmp	B-chem	B-chem
-	I-chem	O
smz	I-chem	O
;	O	O
of	O	O
seven	O	O
with	O	O
erythema	O	O
multiforme	O	O
and	O	O
stevens	O	O
-	O	O
johnson	O	O
syndrome	O	O
,	O	O
four	O	O
were	O	O
exposed	O	O
to	O	O
tmp	B-chem	B-chem
-	I-chem	O
smz	I-chem	O
.	O	O

the	O	O
one	O	O
case	O	O
of	O	O
toxic	O	O
epidermal	O	O
necrolysis	O	O
occurred	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
took	O	O
cephalexin	B-chem	B-chem
.	O	O

finally	O	O
,	O	O
only	O	O
five	O	O
cases	O	O
of	O	O
acute	O	O
parenchymal	O	O
renal	O	O
disease	O	O
occurred	O	O
,	O	O
none	O	O
likely	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
a	O	O
study	O	O
drug	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
the	O	O
risk	O	O
of	O	O
the	O	O
serious	O	O
diseases	O	O
studied	O	O
is	O	O
small	O	O
for	O	O
the	O	O
three	O	O
agents	O	O
,	O	O
and	O	O
compares	O	O
reasonably	O	O
with	O	O
the	O	O
risk	O	O
for	O	O
many	O	O
other	O	O
antibiotics	O	O
.	O	O

clinical	O	O
safety	O	O
of	O	O
lidocaine	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
myocardial	O	O
infarction	O	O
.	O	O

study	O	O
objective	O	O
:	O	O

to	O	O
evaluate	O	O
the	O	O
safety	O	O
of	O	O
lidocaine	B-chem	B-chem
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
myocardial	O	O
infarction	O	O
(	O	O
mi	O	O
)	O	O
.	O	O

design	O	O
:	O	O

a	O	O
retrospective	O	O
,	O	O
multicenter	O	O
study	O	O
.	O	O

setting	O	O
:	O	O

twenty	O	O
-	O	O
nine	O	O
university	O	O
,	O	O
university	O	O
-	O	O
affiliated	O	O
,	O	O
or	O	O
community	O	O
hospitals	O	O
during	O	O
a	O	O
6	O	O
-	O	O
year	O	O
period	O	O
(	O	O
total	O	O
of	O	O
117	O	O
cumulative	O	O
hospital	O	O
-	O	O
years	O	O
)	O	O
.	O	O

participants	O	O
:	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
mi	O	O
who	O	O
received	O	O
lidocaine	B-chem	B-chem
in	O	O
the	O	O
emergency	O	O
department	O	O
.	O	O

results	O	O
:	O	O

of	O	O
29	O	O
patients	O	O
who	O	O
received	O	O
lidocaine	B-chem	B-chem
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
mi	O	O
,	O	O
no	O	O
patient	O	O
died	O	O
;	O	O
exhibited	O	O
bradydysrhythmias	O	O
,	O	O
ventricular	O	O
tachycardia	O	O
,	O	O
or	O	O
ventricular	O	O
fibrillation	O	O
;	O	O
or	O	O
experienced	O	O
seizures	O	O
after	O	O
administration	O	O
of	O	O
lidocaine	B-chem	B-chem
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
%	O	O
to	O	O
11	O	O
%	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

despite	O	O
theoretical	O	O
concerns	O	O
that	O	O
lidocaine	B-chem	B-chem
may	O	O
enhance	O	O
cocaine	B-chem	B-chem
toxicity	O	O
,	O	O
the	O	O
use	O	O
of	O	O
lidocaine	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
mi	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
significant	O	O
cardiovascular	O	O
or	O	O
central	O	O
nervous	O	O
system	O	O
toxicity	O	O
.	O	O

paclitaxel	B-chem	B-chem
3	O	O
-	O	O
hour	O	O
infusion	O	O
given	O	O
alone	O	O
and	O	O
combined	O	O
with	O	O
carboplatin	B-chem	B-chem
:	O	O
preliminary	O	O
results	O	O
of	O	O
dose	O	O
-	O	O
escalation	O	O
trials	O	O
.	O	O

paclitaxel	B-chem	B-chem

(	O	O
taxol	B-chem	B-chem
;	O	O
bristol	O	O
-	O	O
myers	O	O
squibb	O	O
company	O	O
,	O	O
princeton	O	O
,	O	O
nj	O	O
)	O	O
by	O	O
3	O	O
-	O	O
hour	O	O
infusion	O	O
was	O	O
combined	O	O
with	O	O
carboplatin	B-chem	B-chem
in	O	O
a	O	O
phase	O	O
i	O	O
/	O	O
ii	O	O
study	O	O
directed	O	O
to	O	O
patients	O	O
with	O	O
non	O	O
-	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
.	O	O

carboplatin	B-chem	B-chem
was	O	O
given	O	O
at	O	O
a	O	O
fixed	O	O
target	O	O
area	O	O
under	O	O
the	O	O
concentration	O	O
-	O	O
time	O	O
curve	O	O
of	O	O
6	O	O
.	O	O
0	O	O
by	O	O
the	O	O
calvert	O	O
formula	O	O
,	O	O
whereas	O	O
paclitaxel	B-chem	B-chem
was	O	O
escalated	O	O
in	O	O
patient	O	O
cohorts	O	O
from	O	O
150	O	O
mg	O	O
/	O	O
m2	O	O
(	O	O
dose	O	O
level	O	O
i	O	O
)	O	O
to	O	O
175	O	O
,	O	O
200	O	O
,	O	O
225	O	O
,	O	O
and	O	O
250	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

the	O	O
225	O	O
mg	O	O
/	O	O
m2	O	O
level	O	O
was	O	O
expanded	O	O
for	O	O
the	O	O
phase	O	O
ii	O	O
study	O	O
since	O	O
the	O	O
highest	O	O
level	O	O
achieved	O	O
(	O	O
250	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
required	O	O
modification	O	O
because	O	O
of	O	O
nonhematologic	O	O
toxicities	O	O
(	O	O
arthralgia	O	O
and	O	O
sensory	O	O
neuropathy	O	O
)	O	O
.	O	O

therapeutic	O	O
effects	O	O
were	O	O
noted	O	O
at	O	O
all	O	O
dose	O	O
levels	O	O
,	O	O
with	O	O
objective	O	O
responses	O	O
in	O	O
17	O	O
(	O	O
two	O	O
complete	O	O
and	O	O
15	O	O
partial	O	O
regressions	O	O
)	O	O
of	O	O
41	O	O
previously	O	O
untreated	O	O
patients	O	O
.	O	O

toxicities	O	O
were	O	O
compared	O	O
with	O	O
a	O	O
cohort	O	O
of	O	O
patients	O	O
in	O	O
a	O	O
phase	O	O
i	O	O
trial	O	O
of	O	O
paclitaxel	B-chem	B-chem
alone	O	O
at	O	O
identical	O	O
dose	O	O
levels	O	O
.	O	O

carboplatin	B-chem	B-chem
did	O	O
not	O	O
appear	O	O
to	O	O
add	O	O
to	O	O
the	O	O
hematologic	O	O
toxicities	O	O
observed	O	O
,	O	O
and	O	O
the	O	O
paclitaxel	B-chem	B-chem
/	O	O
carboplatin	B-chem	B-chem
combination	O	O
could	O	O
be	O	O
dosed	O	O
every	O	O
3	O	O
weeks	O	O
.	O	O

the	O	O
dose	O	O
-	O	O
dependent	O	O
effect	O	O
of	O	O
misoprostol	B-chem	B-chem
on	O	O
indomethacin	B-chem	B-chem
-	O	O
induced	O	O
renal	O	O
dysfunction	O	O
in	O	O
well	O	O
compensated	O	O
cirrhosis	O	O
.	O	O

misoprostol	B-chem	B-chem
(	O	O
200	O	O
micrograms	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
acutely	O	O
counteract	O	O
the	O	O
indomethacin	B-chem	B-chem
-	O	O
induced	O	O
renal	O	O
dysfunction	O	O
in	O	O
well	O	O
compensated	O	O
cirrhotic	O	O
patients	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
the	O	O
prophylactic	O	O
value	O	O
of	O	O
misoprostol	B-chem	B-chem
was	O	O
dose	O	O
-	O	O
dependent	O	O
.	O	O

parameters	O	O
of	O	O
renal	O	O
hemodynamics	O	O
and	O	O
tubular	O	O
sodium	B-chem	B-chem
and	O	O
water	O	O
handling	O	O
were	O	O
assessed	O	O
by	O	O
clearance	O	O
techniques	O	O
in	O	O
26	O	O
well	O	O
compensated	O	O
cirrhotic	O	O
patients	O	O
before	O	O
and	O	O
after	O	O
an	O	O
oral	O	O
combination	O	O
of	O	O
50	O	O
mg	O	O
of	O	O
indomethacin	B-chem	B-chem
and	O	O
various	O	O
doses	O	O
of	O	O
misoprostol	B-chem	B-chem
.	O	O

the	O	O
200	O	O
-	O	O
micrograms	O	O
dose	O	O
was	O	O
able	O	O
to	O	O
totally	O	O
abolish	O	O
the	O	O
deleterious	O	O
renal	O	O
effects	O	O
of	O	O
indomethacin	B-chem	B-chem
,	O	O
whereas	O	O
the	O	O
800	O	O
-	O	O
micrograms	O	O
dose	O	O
resulted	O	O
in	O	O
significant	O	O
worsening	O	O
of	O	O
renal	O	O
hemodynamics	O	O
and	O	O
sodium	B-chem	B-chem
retention	O	O
.	O	O

these	O	O
changes	O	O
were	O	O
maximal	O	O
in	O	O
the	O	O
hour	O	O
immediately	O	O
after	O	O
medications	O	O
and	O	O
slowly	O	O
returned	O	O
toward	O	O
base	O	O
-	O	O
line	O	O
levels	O	O
thereafter	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
renal	O	O
protective	O	O
effects	O	O
of	O	O
misoprostol	B-chem	B-chem
is	O	O
dose	O	O
-	O	O
dependent	O	O
.	O	O

however	O	O
,	O	O
until	O	O
this	O	O
apparent	O	O
ability	O	O
of	O	O
200	O	O
micrograms	O	O
of	O	O
misoprostol	B-chem	B-chem
to	O	O
prevent	O	O
the	O	O
adverse	O	O
effects	O	O
of	O	O
indomethacin	B-chem	B-chem
on	O	O
renal	O	O
function	O	O
is	O	O
confirmed	O	O
with	O	O
chronic	O	O
frequent	O	O
dosing	O	O
,	O	O
it	O	O
would	O	O
be	O	O
prudent	O	O
to	O	O
avoid	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
cirrhosis	O	O
.	O	O

increased	O	O
frequency	O	O
and	O	O
severity	O	O
of	O	O
angio	O	O
-	O	O
oedema	O	O
related	O	O
to	O	O
long	O	O
-	O	O
term	O	O
therapy	O	O
with	O	O
angiotensin	B-chem	B-chem
-	I-chem	O
converting	I-chem	O
enzyme	I-chem	O
inhibitor	I-chem	O
in	O	O
two	O	O
patients	O	O
.	O	O

adverse	O	O
reactions	O	O
to	O	O
drugs	O	O
are	O	O
well	O	O
recognized	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
acute	O	O
or	O	O
chronic	O	O
urticaria	O	O
,	O	O
and	O	O
angio	O	O
-	O	O
oedema	O	O
.	O	O

angiotensin	B-chem	B-chem
-	I-chem	O
converting	I-chem	O
enzyme	I-chem	I-chem
(	I-chem	O
ace	I-chem	I-chem
)	I-chem	I-chem
inhibitors	I-chem	O
,	O	O
used	O	O
to	O	O
treat	O	O
hypertension	O	O
and	O	O
congestive	O	O
heart	O	O
failure	O	O
,	O	O
were	O	O
introduced	O	O
in	O	O
europe	O	O
in	O	O
the	O	O
middle	O	O
of	O	O
the	O	O
eighties	O	O
,	O	O
and	O	O
the	O	O
use	O	O
of	O	O
these	O	O
drugs	O	O
has	O	O
increased	O	O
progressively	O	O
.	O	O

soon	O	O
after	O	O
the	O	O
introduction	O	O
of	O	O
ace	B-chem	B-chem
inhibitors	I-chem	O
,	O	O
acute	O	O
bouts	O	O
of	O	O
angio	O	O
-	O	O
oedema	O	O
were	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
the	O	O
use	O	O
of	O	O
these	O	O
drugs	O	O
.	O	O

we	O	O
wish	O	O
to	O	O
draw	O	O
attention	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
adverse	O	O
reactions	O	O
to	O	O
ace	B-chem	O
inhibitors	I-chem	O
after	O	O
long	O	O
-	O	O
term	O	O
use	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
pre	O	O
-	O	O
existing	O	O
angio	O	O
-	O	O
oedema	O	O
.	O	O

myoclonus	O	O
associated	O	O
with	O	O
lorazepam	B-chem	B-chem
therapy	O	O
in	O	O
very	O	O
-	O	O
low	O	O
-	O	O
birth	O	O
-	O	O
weight	O	O
infants	O	O
.	O	O

lorazepam	B-chem	B-chem
is	O	O
being	O	O
used	O	O
with	O	O
increasing	O	O
frequency	O	O
as	O	O
a	O	O
sedative	O	O
in	O	O
the	O	O
newborn	O	O
and	O	O
the	O	O
young	O	O
infant	O	O
.	O	O

concern	O	O
has	O	O
been	O	O
raised	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
safety	O	O
of	O	O
lorazepam	B-chem	B-chem
in	O	O
this	O	O
age	O	O
group	O	O
,	O	O
especially	O	O
in	O	O
very	O	O
-	O	O
low	O	O
-	O	O
birth	O	O
-	O	O
weight	O	O
(	O	O
vlbw	O	O
;	O	O
<	O	O
1	O	O
,	O	O
500	O	O
g	O	O
)	O	O
infants	O	O
.	O	O

three	O	O
young	O	O
infants	O	O
,	O	O
all	O	O
of	O	O
birth	O	O
weight	O	O
<	O	O
1	O	O
,	O	O
500	O	O
g	O	O
,	O	O
experienced	O	O
myoclonus	O	O
following	O	O
the	O	O
intravenous	O	O
administration	O	O
of	O	O
lorazepam	B-chem	B-chem
.	O	O

the	O	O
potential	O	O
neurotoxic	O	O
effects	O	O
of	O	O
the	O	O
drug	O	O
(	O	O
and	O	O
its	O	O
vehicle	O	O
)	O	O
in	O	O
this	O	O
population	O	O
are	O	O
discussed	O	O
.	O	O

injectable	O	O
lorazepam	B-chem	B-chem
should	O	O
be	O	O
used	O	O
with	O	O
caution	O	O
in	O	O
vlbw	O	O
infants	O	O
.	O	O

transvenous	O	O
right	O	O
ventricular	O	O
pacing	O	O
during	O	O
cardiopulmonary	O	O
resuscitation	O	O
of	O	O
pediatric	O	O
patients	O	O
with	O	O
acute	O	O
cardiomyopathy	O	O
.	O	O

we	O	O
describe	O	O
the	O	O
cardiopulmonary	O	O
resuscitation	O	O
efforts	O	O
on	O	O
five	O	O
patients	O	O
who	O	O
presented	O	O
in	O	O
acute	O	O
circulatory	O	O
failure	O	O
from	O	O
myocardial	O	O
dysfunction	O	O
.	O	O

three	O	O
patients	O	O
had	O	O
acute	O	O
viral	O	O
myocarditis	O	O
,	O	O
one	O	O
had	O	O
a	O	O
carbamazepine	B-chem	B-chem
-	O	O
induced	O	O
acute	O	O
eosinophilic	O	O
myocarditis	O	O
,	O	O
and	O	O
one	O	O
had	O	O
cardiac	O	O
hemosiderosis	O	O
resulting	O	O
in	O	O
acute	O	O
cardiogenic	O	O
shock	O	O
.	O	O

all	O	O
patients	O	O
were	O	O
continuously	O	O
monitored	O	O
with	O	O
central	O	O
venous	O	O
and	O	O
arterial	O	O
catheters	O	O
in	O	O
addition	O	O
to	O	O
routine	O	O
noninvasive	O	O
monitoring	O	O
.	O	O

an	O	O
introducer	O	O
sheath	O	O
,	O	O
a	O	O
pacemaker	O	O
,	O	O
and	O	O
sterile	O	O
pacing	O	O
wires	O	O
were	O	O
made	O	O
readily	O	O
available	O	O
for	O	O
the	O	O
patients	O	O
,	O	O
should	O	O
the	O	O
need	O	O
arise	O	O
to	O	O
terminate	O	O
resistant	O	O
cardiac	O	O
dysrhythmias	O	O
.	O	O

all	O	O
patients	O	O
developed	O	O
cardiocirculatory	O	O
arrest	O	O
associated	O	O
with	O	O
extreme	O	O
hypotension	O	O
and	O	O
dysrhythmias	O	O
within	O	O
the	O	O
first	O	O
48	O	O
hours	O	O
of	O	O
their	O	O
admission	O	O
to	O	O
the	O	O
pediatric	O	O
intensive	O	O
care	O	O
unit	O	O
(	O	O
picu	O	O
)	O	O
.	O	O

right	O	O
ventricular	O	O
pacemaker	O	O
wires	O	O
were	O	O
inserted	O	O
in	O	O
all	O	O
of	O	O
them	O	O
during	O	O
cardiopulmonary	O	O
resuscitation	O	O
(	O	O
cpr	O	O
)	O	O
.	O	O

in	O	O
four	O	O
patients	O	O
,	O	O
cardiac	O	O
pacing	O	O
was	O	O
used	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
temporary	O	O
captured	O	O
rhythm	O	O
and	O	O
restoration	O	O
of	O	O
their	O	O
cardiac	O	O
output	O	O
.	O	O

these	O	O
patients	O	O
had	O	O
a	O	O
second	O	O
event	O	O
of	O	O
cardiac	O	O
arrest	O	O
,	O	O
resulting	O	O
in	O	O
death	O	O
,	O	O
within	O	O
10	O	O
to	O	O
60	O	O
minutes	O	O
.	O	O

in	O	O
one	O	O
patient	O	O
,	O	O
cardiac	O	O
pacing	O	O
was	O	O
not	O	O
used	O	O
,	O	O
because	O	O
he	O	O
converted	O	O
to	O	O
normal	O	O
sinus	O	O
rhythm	O	O
by	O	O
electrical	O	O
defibrillation	O	O
within	O	O
three	O	O
minutes	O	O
of	O	O
initiating	O	O
cpr	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
cardiac	O	O
pacing	O	O
during	O	O
resuscitative	O	O
efforts	O	O
in	O	O
pediatric	O	O
patients	O	O
suffering	O	O
from	O	O
acute	O	O
myocardial	O	O
dysfunction	O	O
may	O	O
not	O	O
have	O	O
long	O	O
-	O	O
term	O	O
value	O	O
in	O	O
and	O	O
of	O	O
itself	O	O
;	O	O
however	O	O
,	O	O
if	O	O
temporary	O	O
hemodynamic	O	O
stability	O	O
is	O	O
achieved	O	O
by	O	O
this	O	O
procedure	O	O
,	O	O
it	O	O
may	O	O
provide	O	O
additional	O	O
time	O	O
needed	O	O
to	O	O
institute	O	O
other	O	O
therapeutic	O	O
modalities	O	O
.	O	O

efficacy	O	O
and	O	O
safety	O	O
of	O	O
granisetron	B-chem	B-chem
,	O	O
a	O	O
selective	O	O
5	B-chem	B-chem
-	I-chem	I-chem
hydroxytryptamine	I-chem	I-chem
-	O	I-chem
3	O	I-chem
receptor	O	O
antagonist	O	O
,	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
nausea	O	O
and	O	O
vomiting	O	O
induced	O	O
by	O	O
high	O	O
-	O	O
dose	O	O
cisplatin	B-chem	B-chem
.	O	O

purpose	O	O
:	O	O

to	O	O
assess	O	O
the	O	O
antiemetic	O	O
effects	O	O
and	O	O
safety	O	O
profile	O	O
of	O	O
four	O	O
different	O	O
doses	O	O
of	O	O
granisetron	B-chem	B-chem
(	O	O
kytril	B-chem	B-chem
;	O	O
smithkline	O	B-chem
beecham	O	O
pharmaceuticals	O	O
,	O	O
philadelphia	O	O
,	O	O
pa	O	O
)	O	O
when	O	O
administered	O	O
as	O	O
a	O	O
single	O	O
intravenous	O	O
(	O	O
iv	O	O
)	O	O
dose	O	O
for	O	O
prophylaxis	O	O
of	O	O
cisplatin	B-chem	B-chem
-	O	O
induced	O	O
nausea	O	O
and	O	O
vomiting	O	O
.	O	O

patients	O	O
and	O	O
methods	O	O
:	O	O

one	O	O
hundred	O	O
eighty	O	O
-	O	O
four	O	O
chemotherapy	O	O
-	O	O
naive	O	O
patients	O	O
receiving	O	O
high	O	O
-	O	O
dose	O	O
cisplatin	B-chem	B-chem
(	O	O
81	O	O
to	O	O
120	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
one	O	O
of	O	O
four	O	O
granisetron	B-chem	B-chem
doses	O	O
(	O	O
5	O	O
,	O	O
10	O	O
,	O	O
20	O	O
,	O	O
or	O	O
40	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
administered	O	O
before	O	O
chemotherapy	O	O
.	O	O

patients	O	O
were	O	O
observed	O	O
on	O	O
an	O	O
inpatient	O	O
basis	O	O
for	O	O
18	O	O
to	O	O
24	O	O
hours	O	O
,	O	O
and	O	O
vital	O	O
signs	O	O
,	O	O
nausea	O	O
,	O	O
vomiting	O	O
,	O	O
retching	O	O
,	O	O
and	O	O
appetite	O	O
were	O	O
assessed	O	O
.	O	O

safety	O	O
analyses	O	O
included	O	O
incidence	O	O
of	O	O
adverse	O	O
experiences	O	O
and	O	O
laboratory	O	O
parameter	O	O
changes	O	O
.	O	O

results	O	O
:	O	O

after	O	O
granisetron	B-chem	B-chem
doses	O	O
of	O	O
5	O	O
,	O	O
10	O	O
,	O	O
20	O	O
,	O	O
and	O	O
40	O	O
micrograms	O	O
/	O	O
kg	O	O
,	O	O
a	O	O
major	O	O
response	O	O
(	O	O
<	O	O
or	O	O
=	O	O
two	O	O
vomiting	O	O
or	O	O
retching	O	O
episodes	O	O
,	O	O
and	O	O
no	O	O
antiemetic	O	O
rescue	O	O
)	O	O
was	O	O
recorded	O	O
in	O	O
23	O	O
%	O	O
,	O	O
57	O	O
%	O	O
,	O	O
58	O	O
%	O	O
,	O	O
and	O	O
60	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
a	O	O
complete	O	O
response	O	O
(	O	O
no	O	O
vomiting	O	O
or	O	O
retching	O	O
,	O	O
and	O	O
no	O	O
antiemetic	O	O
rescue	O	O
)	O	O
in	O	O
18	O	O
%	O	O
,	O	O
41	O	O
%	O	O
,	O	O
40	O	O
%	O	O
,	O	O
and	O	O
47	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

there	O	O
was	O	O
a	O	O
statistically	O	O
longer	O	O
time	O	O
to	O	O
first	O	O
episode	O	O
of	O	O
nausea	O	O
(	O	O
p	O	O
=	O	O
.	O	O
0015	O	O
)	O	O
and	O	O
vomiting	O	O
(	O	O
p	O	O
=	O	O
.	O	O
0001	O	O
)	O	O
,	O	O
and	O	O
fewer	O	O
patients	O	O
were	O	O
administered	O	O
additional	O	O
antiemetic	O	O
medication	O	O
in	O	O
the	O	O
10	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
dosing	O	O
groups	O	O
than	O	O
in	O	O
the	O	O
5	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
dosing	O	O
group	O	O
.	O	O

as	O	O
granisetron	B-chem	B-chem
dose	O	O
increased	O	O
,	O	O
appetite	O	O
return	O	O
increased	O	O
(	O	O
p	O	O
=	O	O
.	O	O
040	O	O
)	O	O
.	O	O

headache	O	O
was	O	O
the	O	O
most	O	O
frequently	O	O
reported	O	O
adverse	O	O
event	O	O
(	O	O
20	O	O
%	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

a	O	O
single	O	O
10	O	O
-	O	O
,	O	O
20	O	O
-	O	O
,	O	O
or	O	O
40	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
dose	O	O
of	O	O
granisetron	B-chem	B-chem
was	O	O
effective	O	O
in	O	O
controlling	O	O
vomiting	O	O
in	O	O
57	O	O
%	O	O
to	O	O
60	O	O
%	O	O
of	O	O
patients	O	O
who	O	O
received	O	O
cisplatin	B-chem	B-chem
at	O	O
doses	O	O
greater	O	O
than	O	O
81	O	O
mg	O	O
/	O	O
m2	O	O
and	O	O
totally	O	O
prevented	O	O
vomiting	O	O
in	O	O
40	O	O
%	O	O
to	O	O
47	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

there	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
efficacy	O	O
between	O	O
the	O	O
10	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
dose	O	O
and	O	O
the	O	O
20	O	O
-	O	O
and	O	O
40	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
doses	O	O
.	O	O

granisetron	B-chem	B-chem
was	O	O
well	O	O
tolerated	O	O
at	O	O
all	O	O
doses	O	O
.	O	O

adverse	O	O
interaction	O	O
between	O	O
clonidine	B-chem	B-chem
and	O	O
verapamil	B-chem	B-chem
.	O	O

objective	O	O
:	O	O

to	O	O
report	O	O
two	O	O
cases	O	O
of	O	O
a	O	O
possible	O	O
adverse	O	O
interaction	O	O
between	O	O
clonidine	B-chem	B-chem
and	O	O
verapamil	B-chem	B-chem
resulting	O	O
in	O	O
atrioventricular	O	O
(	O	O
av	O	O
)	O	O
block	O	O
in	O	O
both	O	O
patients	O	O
and	O	O
severe	O	O
hypotension	O	O
in	O	O
one	O	O
patient	O	O
.	O	O

case	O	O

summaries	O	O
:	O	O

a	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
hyperaldosteronism	O	O
was	O	O
treated	O	O
with	O	O
verapamil	B-chem	B-chem
480	O	O
mg	O	O
/	O	O
d	O	O
and	O	O
spironolactone	B-chem	B-chem
100	O	O
mg	O	O
/	O	O
d	O	O
.	O	O

after	O	O
the	O	O
addition	O	O
of	O	O
a	O	O
minimal	O	O
dose	O	O
of	O	O
clonidine	B-chem	B-chem
(	O	O
0	O	O
.	O	O
15	O	O
mg	O	O
bid	O	O
)	O	O
,	O	O
she	O	O
developed	O	O
complete	O	O
av	O	O
block	O	O
and	O	O
severe	O	O
hypotension	O	O
,	O	O
which	O	O
resolved	O	O
upon	O	O
cessation	O	O
of	O	O
all	O	O
medications	O	O
.	O	O

a	O	O
65	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
was	O	O
treated	O	O
with	O	O
extended	O	O
-	O	O
release	O	O
verapamil	B-chem	B-chem
240	O	O
mg	O	O
/	O	O
d	O	O
.	O	O

after	O	O
the	O	O
addition	O	O
of	O	O
clonidine	B-chem	B-chem
0	O	O
.	O	O
15	O	O
mg	O	O
bid	O	O
she	O	O
developed	O	O
complete	O	O
av	O	O
block	O	O
,	O	O
which	O	O
resolved	O	O
after	O	O
all	O	O
therapy	O	O
was	O	O
stopped	O	O
.	O	O

discussion	O	O
:	O	O

an	O	O
adverse	O	O
interaction	O	O
between	O	O
clonidine	B-chem	B-chem
and	O	O
verapamil	B-chem	B-chem
has	O	O
not	O	O
been	O	O
reported	O	O
previously	O	O
.	O	O

we	O	O
describe	O	O
two	O	O
such	O	O
cases	O	O
and	O	O
discuss	O	O
the	O	O
various	O	O
mechanisms	O	O
that	O	O
might	O	O
cause	O	O
such	O	O
an	O	O
interaction	O	O
.	O	O

clinicians	O	O
should	O	O
be	O	O
acquainted	O	O
with	O	O
this	O	O
possibly	O	O
fatal	O	O
interaction	O	O
between	O	O
two	O	O
commonly	O	O
used	O	O
antihypertensive	O	O
drugs	O	O
.	O	O

conclusions	O	O
:	O	O

caution	O	O
is	O	O
recommended	O	O
in	O	O
combining	O	O
clonidine	B-chem	B-chem
and	O	O
verapamil	B-chem	B-chem
therapy	O	O
,	O	O
even	O	O
in	O	O
patients	O	O
who	O	O
do	O	O
not	O	O
have	O	O
sinus	O	O
or	O	O
av	O	O
node	O	O
dysfunction	O	O
.	O	O

the	O	O
two	O	O
drugs	O	O
may	O	O
act	O	O
synergistically	O	O
on	O	O
both	O	O
the	O	O
av	O	O
node	O	O
and	O	O
the	O	O
peripheral	O	O
circulation	O	O
.	O	O

pharmacological	O	O
studies	O	O
on	O	O
a	O	O
new	O	O
dihydrothienopyridine	B-chem	O
calcium	I-chem	B-chem
antagonist	O	O
,	O	O
s	B-chem	B-chem
-	I-chem	I-chem
312	I-chem	I-chem
-	I-chem	O
d	I-chem	O
.	O	O

5th	O	O
communication	O	O
:	O	O
anticonvulsant	O	O
effects	O	O
in	O	O
mice	O	O
.	O	O

s	B-chem	B-chem
-	I-chem	I-chem
312	I-chem	I-chem
,	O	O
s	B-chem	B-chem
-	I-chem	I-chem
312	I-chem	I-chem
-	I-chem	O
d	I-chem	O
,	O	O
but	O	O
not	O	O
s	B-chem	B-chem
-	I-chem	I-chem
312	I-chem	I-chem
-	I-chem	O
l	I-chem	O
,	O	O
l	O	O
-	O	O
type	O	O
calcium	B-chem	B-chem
channel	O	O
antagonists	O	O
,	O	O
showed	O	O
anticonvulsant	O	O
effects	O	O
on	O	O
the	O	O
audiogenic	O	O
tonic	O	O
convulsions	O	O
in	O	O
dba	O	O
/	O	O
2	O	O
mice	O	O
;	O	O
and	O	O
their	O	O
ed50	O	O
values	O	O
were	O	O
18	O	O
.	O	O
4	O	O
(	O	O
12	O	O
.	O	O
8	O	O
-	O	O
27	O	O
.	O	O
1	O	O
)	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O
o	O	O
.	O	O
and	O	O
15	O	O
.	O	O
0	O	O
(	O	O
10	O	O
.	O	O
2	O	O
-	O	O
23	O	O
.	O	O
7	O	O
)	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O
o	O	O
.	O	O
,	O	O
respectively	O	O
,	O	O
while	O	O
that	O	O
of	O	O
flunarizine	B-chem	B-chem
was	O	O
34	O	O
.	O	O
0	O	O
(	O	O
26	O	O
.	O	O
0	O	O
-	O	O
44	O	O
.	O	O
8	O	O
)	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O
o	O	O
.	O	O

although	O	O
moderate	O	O
anticonvulsant	O	O
effects	O	O
of	O	O
s	B-chem	B-chem
-	I-chem	I-chem
312	I-chem	I-chem
-	I-chem	O
d	I-chem	O
in	O	O
higher	O	O
doses	O	O
were	O	O
observed	O	O
against	O	O
the	O	O
clonic	O	O
convulsions	O	O
induced	O	O
by	O	O
pentylenetetrazole	B-chem	B-chem
(	O	O
85	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O
c	O	O
.	O	O
)	O	O
or	O	O
bemegride	B-chem	B-chem
(	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O
c	O	O
.	O	O
)	O	O
,	O	O
no	O	O
effects	O	O
were	O	O
observed	O	O
in	O	O
convulsions	O	O
induced	O	O
by	O	O
n	B-chem	B-chem
-	I-chem	I-chem
methyl	I-chem	I-chem
-	I-chem	I-chem
d	I-chem	I-chem
-	I-chem	I-chem
aspartate	I-chem	I-chem
,	O	O
picrotoxin	B-chem	B-chem
,	O	O
or	O	O
electroshock	O	O
in	O	O
slc	O	O
:	O	O
ddy	O	O
mice	O	O
.	O	O

s	B-chem	B-chem
-	I-chem	I-chem
312	I-chem	I-chem
-	I-chem	I-chem
d	I-chem	O
may	O	O
be	O	O
useful	O	O
in	O	O
the	O	O
therapy	O	O
of	O	O
certain	O	O
types	O	O
of	O	O
human	O	O
epilepsy	O	O
.	O	O

transmural	O	O
myocardial	O	O
infarction	O	O
with	O	O
sumatriptan	B-chem	B-chem
.	O	O

for	O	O
sumatriptan	B-chem	B-chem
,	O	O
tightness	O	O
in	O	O
the	O	O
chest	O	O
caused	O	O
by	O	O
an	O	O
unknown	O	O
mechanism	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
3	O	O
-	O	O
5	O	O
%	O	O
of	O	O
users	O	O
.	O	O

we	O	O
describe	O	O
a	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
an	O	O
acute	O	O
myocardial	O	O
infarction	O	O
after	O	O
administration	O	O
of	O	O
sumatriptan	B-chem	B-chem
6	O	O
mg	O	O
subcutaneously	O	O
for	O	O
cluster	O	O
headache	O	O
.	O	O

the	O	O
patient	O	O
had	O	O
no	O	O
history	O	O
of	O	O
underlying	O	O
ischaemic	O	O
heart	O	O
disease	O	O
or	O	O
prinzmetal	O	O
'	O	O
s	O	O
angina	O	O
.	O	O

she	O	O
recovered	O	O
without	O	O
complications	O	O
.	O	O

flumazenil	B-chem	B-chem
induces	O	O
seizures	O	O
and	O	O
death	O	O
in	O	O
mixed	O	O
cocaine	B-chem	B-chem
-	O	O
diazepam	B-chem	B-chem
intoxications	O	O
.	O	O

study	O	O

hypothesis	O	O
:	O	O

administration	O	O
of	O	O
the	O	O
benzodiazepine	B-chem	B-chem
antagonist	O	O
flumazenil	B-chem	B-chem
may	O	O
unmask	O	O
seizures	O	O
in	O	O
mixed	O	O
cocaine	B-chem	B-chem
-	O	O
benzodiazepine	B-chem	O
intoxication	O	O
.	O	O

design	O	O
:	O	O

male	O	O
sprague	O	O
-	O	O
dawley	O	O
rats	O	O
received	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
cocaine	B-chem	B-chem
ip	O	O
alone	O	O
,	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
diazepam	B-chem	B-chem
alone	O	O
,	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
diazepam	B-chem	B-chem
and	O	O
cocaine	B-chem	B-chem
.	O	O

three	O	O
minutes	O	O
later	O	O
,	O	O
groups	O	O
were	O	O
challenged	O	O
with	O	O
vehicle	O	O
or	O	O
flumazenil	B-chem	B-chem
5	O	O
or	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
.	O	O

animal	O	O
behavior	O	O
,	O	O
seizures	O	O
(	O	O
time	O	O
to	O	O
and	O	O
incidence	O	O
)	O	O
,	O	O
death	O	O
(	O	O
time	O	O
to	O	O
and	O	O
incidence	O	O
)	O	O
,	O	O
and	O	O
cortical	O	O
eeg	O	O
tracings	O	O
were	O	O
recorded	O	O
.	O	O

interventions	O	O
:	O	O

administration	O	O
of	O	O
flumazenil	B-chem	B-chem
to	O	O
animals	O	O
after	O	O
they	O	O
had	O	O
received	O	O
a	O	O
combination	O	O
dose	O	O
of	O	O
cocaine	B-chem	B-chem
and	O	O
diazepam	B-chem	B-chem
.	O	O

results	O	O
:	O	O

in	O	O
group	O	O
1	O	O
,	O	O
animals	O	O
received	O	O
cocaine	B-chem	B-chem
followed	O	O
by	O	O
vehicle	O	O
.	O	O

this	O	O
resulted	O	O
in	O	O
100	O	O
%	O	O
developing	O	O
seizures	O	O
and	O	O
death	O	O
.	O	O

group	O	O
2	O	O
received	O	O
diazepam	B-chem	B-chem
alone	O	O
followed	O	O
by	O	O
vehicle	O	O
.	O	O

animals	O	O
became	O	O
somnolent	O	O
and	O	O
none	O	O
died	O	O
.	O	O

group	O	O
3	O	O
received	O	O
diazepam	B-chem	B-chem
followed	O	O
by	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
flumazenil	B-chem	B-chem
.	O	O

animals	O	O
became	O	O
somnolent	O	O
after	O	O
diazepam	B-chem	B-chem
and	O	O
then	O	O
active	O	O
after	O	O
flumazenil	B-chem	B-chem
administration	O	O
.	O	O

in	O	O
group	O	O
4	O	O
,	O	O
a	O	O
combination	O	O
of	O	O
cocaine	B-chem	B-chem
and	O	O
diazepam	B-chem	B-chem
was	O	O
administered	O	O
simultaneously	O	O
.	O	O

this	O	O
resulted	O	O
in	O	O
no	O	O
overt	O	O
or	O	O
eeg	O	O
-	O	O
detectable	O	O
seizures	O	O
and	O	O
a	O	O
50	O	O
%	O	O
incidence	O	O
of	O	O
death	O	O
.	O	O

group	O	O
5	O	O
received	O	O
a	O	O
similar	O	O
combination	O	O
of	O	O
cocaine	B-chem	B-chem
and	O	O
diazepam	B-chem	B-chem
,	O	O
followed	O	O
later	O	O
by	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
flumazenil	B-chem	B-chem
.	O	O

this	O	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
seizures	O	O
,	O	O
90	O	O
%	O	O
(	O	O
p	O	O
<	O	O
.	O	O
01	O	O
)	O	O
,	O	O
and	O	O
death	O	O
,	O	O
100	O	O
%	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
.	O	O
01	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
group	O	O
4	O	O
.	O	O

group	O	O
6	O	O
received	O	O
cocaine	B-chem	B-chem
and	O	O
diazepam	B-chem	B-chem
followed	O	O
by	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
flumazenil	B-chem	B-chem
.	O	O

this	O	O
also	O	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
seizures	O	O
,	O	O
90	O	O
%	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
.	O	O
01	O	O
)	O	O
,	O	O
and	O	O
death	O	O
,	O	O
90	O	O
%	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
.	O	O
05	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
group	O	O
4	O	O
.	O	O

conclusion	O	O
:	O	O

flumazenil	B-chem	B-chem
can	O	O
unmask	O	O
seizures	O	O
and	O	O
increase	O	O
the	O	O
incidence	O	O
of	O	O
death	O	O
in	O	O
a	O	O
model	O	O
of	O	O
combined	O	O
cocaine	B-chem	B-chem
-	O	O
diazepam	B-chem	B-chem
intoxications	O	O
.	O	O

mechanisms	O	O
for	O	O
protective	O	O
effects	O	O
of	O	O
free	O	O
radical	O	O
scavengers	O	O
on	O	O
gentamicin	B-chem	B-chem
-	O	O
mediated	O	O
nephropathy	O	O
in	O	O
rats	O	O
.	O	O

studies	O	O
were	O	O
performed	O	O
to	O	O
examine	O	O
the	O	O
mechanisms	O	O
for	O	O
the	O	O
protective	O	O
effects	O	O
of	O	O
free	O	O
radical	O	O
scavengers	O	O
on	O	O
gentamicin	B-chem	B-chem
(	O	O
gm	B-chem	B-chem
)	O	O
-	O	O
mediated	O	O
nephropathy	O	O
.	O	O

administration	O	O
of	O	O
gm	B-chem	B-chem
at	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
for	O	O
13	O	O
days	O	O
to	O	O
rats	O	O
induced	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
renal	O	O
blood	O	O
flow	O	O
(	O	O
rbf	O	O
)	O	O
and	O	O
inulin	O	O
clearance	O	O
(	O	O
cin	O	O
)	O	O
as	O	O
well	O	O
as	O	O
marked	O	O
tubular	O	O
damage	O	O
.	O	O

a	O	O
significant	O	O
reduction	O	O
in	O	O
urinary	O	O
guanosine	B-chem	B-chem
3	I-chem	I-chem
'	I-chem	O
,	I-chem	O
5	I-chem	B-chem
'	I-chem	I-chem
-	I-chem	I-chem
cyclic	I-chem	I-chem
monophosphate	I-chem	I-chem
(	O	O
cgmp	B-chem	B-chem
)	O	O
excretion	O	O
and	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
renal	O	O
cortical	O	O
renin	O	O
and	O	O
endothelin	O	O
-	O	O
1	O	O
contents	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
gm	B-chem	B-chem
-	O	O
mediated	O	O
nephropathy	O	O
.	O	O

superoxide	B-chem	B-chem
dismutase	O	O
(	O	O
sod	O	B-chem
)	O	O
or	O	O
dimethylthiourea	B-chem	B-chem
(	O	O
dmtu	B-chem	O
)	O	O
significantly	O	O
lessened	O	O
the	O	O
gm	B-chem	B-chem
-	O	O
induced	O	O
decrement	O	O
in	O	O
cin	O	O
.	O	O

the	O	O
sod	O	B-chem
-	O	O
induced	O	O
increase	O	O
in	O	O
glomerular	O	O
filtration	O	O
rate	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
marked	O	O
improvement	O	O
in	O	O
rbf	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
urinary	O	O
cgmp	B-chem	O
excretion	O	O
,	O	O
and	O	O
a	O	O
decrease	O	O
in	O	O
renal	O	O
renin	O	O
and	O	O
endothelin	O	O
-	O	O
1	O	O
content	O	O
.	O	O

sod	O	B-chem
did	O	O
not	O	O
attenuate	O	O
the	O	O
tubular	O	O
damage	O	O
.	O	O

in	O	O
contrast	O	O
,	O	O
dmtu	B-chem	B-chem
significantly	O	O
reduced	O	O
the	O	O
tubular	O	O
damage	O	O
and	O	O
lipid	O	O
peroxidation	O	O
,	O	O
but	O	O
it	O	O
did	O	O
not	O	O
affect	O	O
renal	O	O
hemodynamics	O	O
and	O	O
vasoactive	O	O
substances	O	O
.	O	O

neither	O	O
sod	O	B-chem
nor	O	O
dmtu	B-chem	B-chem
affected	O	O
the	O	O
renal	O	O
cortical	O	O
gm	B-chem	B-chem
content	O	O
in	O	O
gm	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
that	O	O
1	O	O
)	O	O
both	O	O
sod	O	B-chem
and	O	O
dmtu	B-chem	B-chem
have	O	O
protective	O	O
effects	O	O
on	O	O
gm	B-chem	B-chem
-	O	O
mediated	O	O
nephropathy	O	O
,	O	O
2	O	O
)	O	O
the	O	O
mechanisms	O	O
for	O	O
the	O	O
protective	O	O
effects	O	O
differ	O	O
for	O	O
sod	O	B-chem
and	O	O
dmtu	B-chem	B-chem
,	O	O
and	O	O
3	O	B-chem
)	O	I-chem
superoxide	B-chem	B-chem
anions	O	O
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
gm	B-chem	B-chem
-	O	O
induced	O	O
renal	O	O
vasoconstriction	O	O
.	O	O

assessment	O	O
of	O	O
cardiomyocyte	O	O
dna	O	O
synthesis	O	O
during	O	O
hypertrophy	O	O
in	O	O
adult	O	O
mice	O	O
.	O	O

the	O	O
ability	O	O
of	O	O
cardiomyocytes	O	O
to	O	O
synthesize	O	O
dna	O	O
in	O	O
response	O	O
to	O	O
experimentally	O	O
induced	O	O
cardiac	O	O
hypertrophy	O	O
was	O	O
assessed	O	O
in	O	O
adult	O	O
mice	O	O
.	O	O

isoproterenol	B-chem	B-chem
delivered	O	O
by	O	O
osmotic	O	O
minipump	O	O
implantation	O	O
in	O	O
adult	O	O
c3heb	O	O
/	O	O
fej	O	O
mice	O	O
resulted	O	O
in	O	O
a	O	O
46	O	O
%	O	O
increase	O	O
in	O	O
heart	O	O
weight	O	O
and	O	O
a	O	O
19	O	O
.	O	O
3	O	O
%	O	O
increase	O	O
in	O	O
cardiomyocyte	O	O
area	O	O
.	O	O

no	O	O
dna	O	O
synthesis	O	O
,	O	O
as	O	O
assessed	O	O
by	O	O
autoradiographic	O	O
analysis	O	O
of	O	O
isolated	O	O
cardiomyocytes	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
control	O	O
or	O	O
hypertrophic	O	O
hearts	O	O
.	O	O

a	O	O
survey	O	O
of	O	O
15	O	O
independent	O	O
inbred	O	O
strains	O	O
of	O	O
mice	O	O
revealed	O	O
that	O	O
ventricular	O	O
cardiomyocyte	O	O
nuclear	O	O
number	O	O
ranged	O	O
from	O	O
3	O	O
to	O	O
13	O	O
%	O	O
mononucleate	O	O
,	O	O
suggesting	O	O
that	O	O
cardiomyocyte	O	O
terminal	O	O
differentiation	O	O
is	O	O
influenced	O	O
directly	O	O
or	O	O
indirectly	O	O
by	O	O
genetic	O	O
background	O	O
.	O	O

to	O	O
determine	O	O
whether	O	O
the	O	O
capacity	O	O
for	O	O
reactive	O	O
dna	O	O
synthesis	O	O
was	O	O
also	O	O
subject	O	O
to	O	O
genetic	O	O
regulation	O	O
,	O	O
cardiac	O	O
hypertrophy	O	O
was	O	O
induced	O	O
in	O	O
the	O	O
strains	O	O
of	O	O
mice	O	O
comprising	O	O
the	O	O
extremes	O	O
of	O	O
the	O	O
nuclear	O	O
number	O	O
survey	O	O
.	O	O

these	O	O
data	O	O
indicate	O	O
that	O	O
adult	O	O
mouse	O	O
atrial	O	O
and	O	O
ventricular	O	O
cardiomyocytes	O	O
do	O	O
not	O	O
synthesize	O	O
dna	O	O
in	O	O
response	O	O
to	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
hypertrophy	O	O
.	O	O

central	O	O
cardiovascular	O	O
effects	O	O
of	O	O
avp	B-chem	B-chem
and	O	O
anp	O	O
in	O	O
normotensive	O	O
and	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
.	O	O

the	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
influence	O	O
of	O	O
central	O	O
arginine	B-chem	B-chem
vasopressin	I-chem	I-chem
(	O	O
avp	B-chem	B-chem
)	O	O
and	O	O
of	O	O
atrial	O	O
natriuretic	O	O
peptide	O	O
(	O	O
anp	O	O
)	O	O
on	O	O
control	O	O
of	O	O
arterial	O	O
blood	O	O
pressure	O	O
(	O	O
map	O	O
)	O	O
and	O	O
heart	O	O
rate	O	O
(	O	O
hr	O	O
)	O	O
in	O	O
normotensive	O	O
(	O	O
wky	O	O
)	O	O
and	O	O
spontaneously	O	O
hypertensive	O	O
(	O	O
shr	O	O
)	O	O
rats	O	O
.	O	O

three	O	O
series	O	O
of	O	O
experiments	O	O
were	O	O
performed	O	O
on	O	O
30	O	O
wky	O	O
and	O	O
30	O	O
shr	O	O
,	O	O
chronically	O	O
instrumented	O	O
with	O	O
guide	O	O
tubes	O	O
in	O	O
the	O	O
lateral	O	O
ventricle	O	O
(	O	O
lv	O	O
)	O	O
and	O	O
arterial	O	O
and	O	O
venous	O	O
catheters	O	O
.	O	O

map	O	O
and	O	O
hr	O	O
were	O	O
monitored	O	O
before	O	O
and	O	O
after	O	O
i	O	O
.	O	O
v	O	O
.	O	O

injections	O	O
of	O	O
either	O	O
vehicle	O	O
or	O	O
1	O	O
,	O	O
10	O	O
and	O	O
50	O	O
ng	O	O
of	O	O
avp	B-chem	B-chem
and	O	O
25	O	O
,	O	O
125	O	O
and	O	O
500	O	O
ng	O	O
of	O	O
anp	O	O
.	O	O

sensitivity	O	O
of	O	O
cardiac	O	O
component	O	O
of	O	O
baroreflex	O	O
(	O	O
ccb	O	O
)	O	O
,	O	O
expressed	O	O
as	O	O
a	O	O
slope	O	O
of	O	O
the	O	O
regression	O	O
line	O	O
was	O	O
determined	O	O
from	O	O
relationships	O	O
between	O	O
systolic	O	O
arterial	O	O
pressure	O	O
(	O	O
sap	O	O
)	O	O
and	O	O
hr	O	O
period	O	O
(	O	O
hrp	O	B-chem
)	O	O
during	O	O
phenylephrine	B-chem	B-chem
(	O	O
phe	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
hypertension	O	O
and	O	O
sodium	B-chem	B-chem
nitroprusside	I-chem	I-chem
(	O	O
sn	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
hypotension	O	O
.	O	O

ccb	O	B-chem
was	O	O
measured	O	O
before	O	O
and	O	O
after	O	O
administration	O	O
of	O	O
either	O	O
vehicle	O	O
,	O	O
avp	B-chem	B-chem
,	O	O
anp	O	O
,	O	O
or	O	O
both	O	O
peptides	O	O
together	O	O
.	O	O

increases	O	O
of	O	O
map	O	O
occurred	O	O
after	O	O
lv	O	O
administration	O	O
of	O	O
1	O	O
,	O	O
10	O	O
and	O	O
50	O	O
ng	O	O
of	O	O
avp	B-chem	B-chem
in	O	O
wky	O	O
and	O	O
of	O	O
10	O	O
and	O	O
50	O	O
ng	O	O
in	O	O
shr	O	O
.	O	O

anp	O	O
did	O	O
not	O	O
cause	O	O
significant	O	O
changes	O	O
in	O	O
map	O	O
in	O	O
both	O	O
strains	O	O
as	O	O
compared	O	O
to	O	O
vehicle	O	O
,	O	O
but	O	O
it	O	O
abolished	O	O
avp	B-chem	B-chem
-	O	O
induced	O	O
map	O	O
increase	O	O
in	O	O
wky	O	O
and	O	O
shr	O	O
.	O	O

ccb	O	B-chem
was	O	O
reduced	O	O
in	O	O
wky	O	O
and	O	O
shr	O	B-chem
after	O	O
lv	O	O
administration	O	O
of	O	O
avp	B-chem	B-chem
during	O	O
sn	B-chem	B-chem
-	O	O
induced	O	O
hypotension	O	O
.	O	O

in	O	O
shr	O	B-chem
but	O	O
not	O	O
in	O	O
wky	O	O
administration	O	O
of	O	O
anp	O	O
,	O	O
avp	B-chem	B-chem
and	O	O
anp	O	O
+	O	O
avp	B-chem	B-chem
decreased	O	O
ccb	O	B-chem
during	O	O
phe	B-chem	B-chem
-	O	O
induced	O	O
map	O	O
elevation	O	O
.	O	O

the	O	O
results	O	O
indicate	O	O
that	O	O
centrally	O	O
applied	O	O
avp	B-chem	B-chem
and	O	O
anp	O	O
exert	O	O
differential	O	O
effects	O	O
on	O	O
blood	O	O
pressure	O	O
and	O	O
baroreflex	O	O
control	O	O
of	O	O
heart	O	O
rate	O	O
in	O	O
wky	O	O
and	O	O
shr	O	O
and	O	O
suggest	O	O
interaction	O	O
of	O	O
these	O	O
two	O	O
peptides	O	O
in	O	O
blood	O	O
pressure	O	O
regulation	O	O
at	O	O
the	O	O
level	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

cutaneous	O	O
exposure	O	O
to	O	O
warfarin	B-chem	B-chem
-	O	O
like	O	O
anticoagulant	O	O
causing	O	O
an	O	O
intracerebral	O	O
hemorrhage	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

a	O	O
case	O	O
of	O	O
intercerebral	O	O
hematoma	O	O
due	O	O
to	O	O
warfarin	B-chem	B-chem
-	O	O
induced	O	O
coagulopathy	O	O
is	O	O
presented	O	O
.	O	O

the	O	O
39	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
had	O	O
spread	O	O
a	O	O
warfarin	B-chem	B-chem
-	O	O
type	O	O
rat	O	O
poison	O	O
around	O	O
her	O	O
house	O	O
weekly	O	O
using	O	O
her	O	O
bare	O	O
hands	O	O
,	O	O
with	O	O
no	O	O
washing	O	O
post	O	O
application	O	O
.	O	O

percutaneous	O	O
absorption	O	O
of	O	O
warfarin	B-chem	B-chem
causing	O	O
coagulopathy	O	O
,	O	O
reported	O	O
three	O	O
times	O	O
in	O	O
the	O	O
past	O	O
,	O	O
is	O	O
a	O	O
significant	O	O
risk	O	O
if	O	O
protective	O	O
measures	O	O
,	O	O
such	O	O
as	O	O
gloves	O	O
,	O	O
are	O	O
not	O	O
used	O	O
.	O	O

an	O	O
adverse	O	O
drug	O	O
interaction	O	O
with	O	O
piroxicam	B-chem	B-chem
,	O	O
which	O	O
she	O	O
took	O	O
occasionally	O	O
,	O	O
may	O	O
have	O	O
exacerbated	O	O
the	O	O
coagulopathy	O	O
.	O	O

pediatric	O	O
heart	O	O
transplantation	O	O
without	O	O
chronic	O	O
maintenance	O	O
steroids	B-chem	B-chem
.	O	O

from	O	O
1986	O	O
to	O	O
february	O	O
1993	O	O
,	O	O
40	O	O
children	O	O
aged	O	O
2	O	O
months	O	O
to	O	O
18	O	O
years	O	O
(	O	O
average	O	O
age	O	O
10	O	O
.	O	O
4	O	O
+	O	O
/	O	O
-	O	O

5	O	O
.	O	O
8	O	O
years	O	O
)	O	O
underwent	O	O
heart	O	O
transplantation	O	O
.	O	O

indications	O	O
for	O	O
transplantation	O	O
were	O	O
idiopathic	O	O
cardiomyopathy	O	O
(	O	O
52	O	O
%	O	O
)	O	O
,	O	O
congenital	O	O
heart	O	O
disease	O	O
(	O	O
35	O	O
%	O	O
)	O	O
with	O	O
and	O	O
without	O	O
prior	O	O
repair	O	O
(	O	O
71	O	O
%	O	O
and	O	O
29	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
hypertrophic	O	O
cardiomyopathy	O	O
(	O	O
5	O	O
%	O	O
)	O	O
,	O	O
valvular	O	O
heart	O	O
disease	O	O
(	O	O
3	O	O
%	O	O
)	O	O
,	O	O
and	O	O
doxorubicin	B-chem	B-chem
cardiomyopathy	O	O
(	O	O
5	O	O
%	O	O
)	O	O
.	O	O

patients	O	O
were	O	O
managed	O	O
with	O	O
cyclosporine	B-chem	B-chem
and	O	O
azathioprine	B-chem	B-chem
.	O	O

no	O	O
prophylaxis	O	O
with	O	O
antilymphocyte	O	O
globulin	O	O
was	O	O
used	O	O
.	O	O

steroids	B-chem	B-chem
were	O	O
given	O	O
to	O	O
39	O	O
%	O	O
of	O	O
patients	O	O
for	O	O
refractory	O	O
rejection	O	O
,	O	O
but	O	O
weaning	O	O
was	O	O
always	O	O
attempted	O	O
and	O	O
generally	O	O
successful	O	O
(	O	O
64	O	O
%	O	O
)	O	O
.	O	O

five	O	O
patients	O	O
(	O	O
14	O	O
%	O	O
)	O	O
received	O	O
maintenance	O	O
steroids	B-chem	B-chem
.	O	O

four	O	O
patients	O	O
died	O	O
in	O	O
the	O	O
perioperative	O	O
period	O	O
and	O	O
one	O	O
died	O	O
4	O	O
months	O	O
later	O	O
.	O	O

there	O	O
have	O	O
been	O	O
no	O	O
deaths	O	O
related	O	O
to	O	O
rejection	O	O
or	O	O
infection	O	O
.	O	O

average	O	O
follow	O	O
-	O	O
up	O	O
was	O	O
36	O	O
+	O	O
/	O	O
-	O	O

19	O	O
months	O	O
(	O	O
range	O	O
1	O	O
to	O	O
65	O	O
months	O	O
)	O	O
.	O	O

cumulative	O	O
survival	O	O
is	O	O
88	O	O
%	O	O
at	O	O
5	O	O
years	O	O
.	O	O

in	O	O
patients	O	O
less	O	O
than	O	O
7	O	O
years	O	O
of	O	O
age	O	O
,	O	O
rejection	O	O
was	O	O
monitored	O	O
noninvasively	O	O
.	O	O

in	O	O
the	O	O
first	O	O
postoperative	O	O
month	O	O
,	O	O
89	O	O
%	O	O
of	O	O
patients	O	O
were	O	O
treated	O	O
for	O	O
rejection	O	O
.	O	O

freedom	O	O
from	O	O
serious	O	O
infections	O	O
was	O	O
83	O	O
%	O	O
at	O	O
1	O	O
month	O	O
and	O	O
65	O	O
%	O	O
at	O	O
1	O	O
year	O	O
.	O	O

cytomegalovirus	O	O
infections	O	O
were	O	O
treated	O	O
successfully	O	O
with	O	O
ganciclovir	B-chem	B-chem
in	O	O
11	O	O
patients	O	O
.	O	O

no	O	O
impairment	O	O
of	O	O
growth	O	O
was	O	O
observed	O	O
in	O	O
children	O	O
who	O	O
underwent	O	O
transplantation	O	O
compared	O	O
with	O	O
a	O	O
control	O	O
population	O	O
.	O	O

twenty	O	O
-	O	O
one	O	O
patients	O	O
(	O	O
60	O	O
%	O	O
)	O	O
have	O	O
undergone	O	O
annual	O	O
catheterizations	O	O
and	O	O
no	O	O
sign	O	O
of	O	O
graft	O	O
atherosclerosis	O	O
has	O	O
been	O	O
observed	O	O
.	O	O

seizures	O	O
occurred	O	O
in	O	O
five	O	O
patients	O	O
(	O	O
14	O	O
%	O	O
)	O	O
and	O	O
hypertension	O	O
was	O	O
treated	O	O
in	O	O
10	O	O
patients	O	O
(	O	O
28	O	O
%	O	O
)	O	O
.	O	O

no	O	O
patient	O	O
was	O	O
disabled	O	O
and	O	O
no	O	O
lymphoproliferative	O	O
disorder	O	O
was	O	O
observed	O	O
.	O	O
(	O	O
abstract	O	O
truncated	O	O
at	O	O
250	O	O
words	O	O
)	O	O

delirium	O	O
during	O	O
fluoxetine	B-chem	B-chem
treatment	O	O
.	O	O

a	O	O
case	O	O
report	O	O
.	O	O

the	O	O
correlation	O	O
between	O	O
high	O	O
serum	O	O
tricyclic	O	O
antidepressant	O	B-chem
concentrations	O	O
and	O	O
central	O	O
nervous	O	O
system	O	O
side	O	O
effects	O	O
has	O	O
been	O	O
well	O	O
established	O	O
.	O	O

only	O	O
a	O	O
few	O	O
reports	O	O
exist	O	O
,	O	O
however	O	O
,	O	O
on	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
serum	O	O
concentrations	O	O
of	O	O
selective	O	O
serotonin	B-chem	B-chem
reuptake	O	I-chem
inhibitors	O	I-chem
(	O	O
ssris	O	B-chem
)	O	O
and	O	O
their	O	O
toxic	O	O
effects	O	O
.	O	O

in	O	O
some	O	O
cases	O	O
,	O	O
a	O	O
high	O	O
serum	O	O
concentration	O	O
of	O	O
citalopram	B-chem	B-chem
(	O	O
>	O	O
600	O	O
nmol	O	O
/	O	O
l	O	O
)	O	O
in	O	O
elderly	O	O
patients	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
increased	O	O
somnolence	O	O
and	O	O
movement	O	O
difficulties	O	O
.	O	O

widespread	O	O
cognitive	O	O
disorders	O	O
,	O	O
such	O	O
as	O	O
delirium	O	O
,	O	O
have	O	O
not	O	O
been	O	O
previously	O	O
linked	O	O
with	O	O
high	O	O
blood	O	O
levels	O	O
of	O	O
ssris	O	B-chem
.	O	O

in	O	O
this	O	O
report	O	O
,	O	O
we	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
acute	O	O
hyperkinetic	O	O
delirium	O	O
connected	O	O
with	O	O
a	O	O
high	O	O
serum	O	O
total	O	O
fluoxetine	B-chem	B-chem
(	O	O
fluoxetine	B-chem	B-chem
plus	O	O
desmethylfluoxetine	B-chem	B-chem
)	O	O
concentration	O	O
.	O	O

pulmonary	O	O
edema	O	O
and	O	O
shock	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
aracytine	B-chem	B-chem
-	I-chem	O
c	I-chem	O
for	O	O
lymphoma	O	O
;	O	O
possible	O	O
role	O	O
of	O	O
tnf	O	O
-	O	O
alpha	O	O
and	O	O
paf	O	O
.	O	O

four	O	O
out	O	O
of	O	O
23	O	O
consecutive	O	O
patients	O	O
treated	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
ara	B-chem	B-chem
-	I-chem	O
c	I-chem	O
for	O	O
lymphomas	O	O
in	O	O
our	O	O
institution	O	O
developed	O	O
a	O	O
strikingly	O	O
similar	O	O
syndrome	O	O
during	O	O
the	O	O
perfusion	O	O
.	O	O

it	O	O
was	O	O
characterized	O	O
by	O	O
the	O	O
onset	O	O
of	O	O
fever	O	O
,	O	O
diarrhea	O	O
,	O	O
shock	O	O
,	O	O
pulmonary	O	O
edema	O	O
,	O	O
acute	O	O
renal	O	O
failure	O	O
,	O	O
metabolic	O	O
acidosis	O	O
,	O	O
weight	O	O
gain	O	O
and	O	O
leukocytosis	O	O
.	O	O

thorough	O	O
bacteriological	O	O
screening	O	O
failed	O	O
to	O	O
provide	O	O
evidence	O	O
of	O	O
infection	O	O
.	O	O

sequential	O	O
biological	O	O
assays	O	O
of	O	O
il	O	O
-	O	O
1	O	O
,	O	O
il	O	O
-	O	O
2	O	O
,	O	O
tnf	O	O
and	O	O
paf	O	B-chem
were	O	O
performed	O	O
during	O	O
ara	B-chem	B-chem
-	I-chem	O
c	I-chem	O
infusion	O	O
to	O	O
ten	O	O
patients	O	O
,	O	O
including	O	O
the	O	O
four	O	O
who	O	O
developed	O	O
the	O	O
syndrome	O	O
.	O	O

tnf	O	O
and	O	O
paf	O	O
activity	O	O
was	O	O
found	O	O
in	O	O
the	O	O
serum	O	O
of	O	O
respectively	O	O
two	O	O
and	O	O
four	O	O
of	O	O
the	O	O
cases	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
six	O	O
controls	O	O
.	O	O

as	O	O
tnf	O	O
and	O	O
paf	O	O
are	O	O
thought	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
development	O	O
of	O	O
septic	O	O
shock	O	O
and	O	O
adult	O	O
respiratory	O	O
distress	O	O
syndrome	O	O
,	O	O
we	O	O
hypothesize	O	O
that	O	O
high	O	O
-	O	O
dose	O	O
ara	B-chem	B-chem
-	I-chem	O
c	I-chem	O
may	O	O
be	O	O
associated	O	O
with	O	O
cytokine	O	O
release	O	O
.	O	O

protective	O	O
effect	O	O
of	O	O
clentiazem	B-chem	B-chem
against	O	O
epinephrine	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
injury	O	O
in	O	O
rats	O	O
.	O	O

we	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
clentiazem	B-chem	B-chem
,	O	O
a	O	O
1	B-chem	I-chem
,	I-chem	O
5	I-chem	I-chem
-	I-chem	I-chem
benzothiazepine	I-chem	I-chem
calcium	B-chem	I-chem
antagonist	O	O
,	O	O
on	O	O
epinephrine	B-chem	B-chem
-	O	O
induced	O	O
cardiomyopathy	O	O
in	O	O
rats	O	O
.	O	O

with	O	O
2	O	O
-	O	O
week	O	O
chronic	O	O
epinephrine	B-chem	B-chem
infusion	O	O
,	O	O
16	O	O
of	O	O
30	O	O
rats	O	O
died	O	O
within	O	O
4	O	O
days	O	O
,	O	O
and	O	O
severe	O	O
ischemic	O	O
lesions	O	O
and	O	O
fibrosis	O	O
of	O	O
the	O	O
left	O	O
ventricles	O	O
were	O	O
observed	O	O
.	O	O

in	O	O
epinephrine	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
,	O	O
left	O	O
atrial	O	O
and	O	O
left	O	O
ventricular	O	O
papillary	O	O
muscle	O	O
contractile	O	O
responses	O	O
to	O	O
isoproterenol	B-chem	B-chem
were	O	O
reduced	O	O
,	O	O
but	O	O
responses	O	O
to	O	O
calcium	B-chem	B-chem
were	O	O
normal	O	O
or	O	O
enhanced	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

left	O	O
ventricular	O	O
alpha	O	O
and	O	O
beta	O	O
adrenoceptor	O	O
densities	O	O
were	O	O
also	O	O
reduced	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

treatment	O	O
with	O	O
clentiazem	B-chem	B-chem
prevented	O	O
epinephrine	B-chem	B-chem
-	O	O
induced	O	O
death	O	O
(	O	O
p	O	O
<	O	O
.	O	O
05	O	O
)	O	O
,	O	O
and	O	O
attenuated	O	O
the	O	O
ventricular	O	O
ischemic	O	O
lesions	O	O
and	O	O
fibrosis	O	O
,	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

left	O	O
atrial	O	O
and	O	O
left	O	O
ventricular	O	O
papillary	O	O
muscle	O	O
contractile	O	O
responses	O	O
to	O	O
isoproterenol	B-chem	B-chem
were	O	O
reduced	O	O
compared	O	O
to	O	O
controls	O	O
in	O	O
groups	O	O
treated	O	O
with	O	O
clentiazem	B-chem	B-chem
alone	O	O
,	O	O
but	O	O
combined	O	O
with	O	O
epinephrine	B-chem	B-chem
,	O	O
clentiazem	B-chem	B-chem
restored	O	O
left	O	O
atrial	O	O
responses	O	O
and	O	O
enhanced	O	O
left	O	O
ventricular	O	O
papillary	O	O
responses	O	O
to	O	O
isoproterenol	B-chem	B-chem
.	O	O

on	O	O
the	O	O
other	O	O
hand	O	O
clentiazem	B-chem	B-chem
did	O	O
not	O	O
prevent	O	O
epinephrine	B-chem	B-chem
-	O	O
induced	O	O
down	O	O
-	O	O
regulation	O	O
of	O	O
alpha	O	O
and	O	O
beta	O	O
adrenoceptors	O	O
.	O	O

interestingly	O	O
,	O	O
clentiazem	B-chem	B-chem
,	O	O
infused	O	O
alone	O	O
,	O	O
resulted	O	O
in	O	O
decreased	O	O
adrenergic	O	O
receptor	O	O
densities	O	O
in	O	O
the	O	O
left	O	O
ventricle	O	O
.	O	O

clentiazem	B-chem	B-chem
also	O	O
did	O	O
not	O	O
prevent	O	O
the	O	O
enhanced	O	O
responses	O	O
to	O	O
calcium	B-chem	B-chem
seen	O	O
in	O	O
the	O	O
epinephrine	B-chem	B-chem
-	O	O
treated	O	O
animals	O	O
,	O	O
although	O	O
the	O	O
high	O	O
dose	O	O
of	O	O
clentiazem	B-chem	B-chem
partially	O	O
attenuated	O	O
the	O	O
maximal	O	O
response	O	O
to	O	O
calcium	B-chem	B-chem
compared	O	O
to	O	O
epinephrine	B-chem	B-chem
-	O	O
treated	O	O
animals	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
clentiazem	B-chem	B-chem
attenuated	O	O
epinephrine	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
injury	O	O
,	O	O
possibly	O	O
through	O	O
its	O	O
effect	O	O
on	O	O
the	O	O
adrenergic	O	O
pathway	O	O
.	O	O

cocaine	B-chem	B-chem
induced	O	O
myocardial	O	O
ischemia	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
myocardial	O	O
ischemia	O	O
induced	O	O
by	O	O
cocaine	B-chem	B-chem
.	O	O

the	O	O
ischemia	O	O
probably	O	O
induced	O	O
by	O	O
coronary	O	O
artery	O	O
spasm	O	O
was	O	O
reversed	O	O
by	O	O
nitroglycerin	B-chem	B-chem
and	O	O
calcium	B-chem	B-chem
blocking	O	O
agents	O	O
.	O	O

doxorubicin	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
monitored	O	O
by	O	O
ecg	O	O
in	O	O
freely	O	O
moving	O	O
mice	O	O
.	O	O

a	O	O
new	O	O
model	O	O
to	O	O
test	O	O
potential	O	O
protectors	O	O
.	O	O

in	O	O
laboratory	O	O
animals	O	O
,	O	O
histology	O	O
is	O	O
most	O	O
commonly	O	O
used	O	O
to	O	O
study	O	O
doxorubicin	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
.	O	O

however	O	O
,	O	O
for	O	O
monitoring	O	O
during	O	O
treatment	O	O
,	O	O
large	O	O
numbers	O	O
of	O	O
animals	O	O
are	O	O
needed	O	O
.	O	O

recently	O	O
we	O	O
developed	O	O
a	O	O
new	O	O
method	O	O
to	O	O
measure	O	O
ecg	O	O
values	O	O
in	O	O
freely	O	O
moving	O	O
mice	O	O
by	O	O
telemetry	O	O
.	O	O

with	O	O
this	O	O
model	O	O
we	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
doxorubicin	B-chem	B-chem
administration	O	O
on	O	O
the	O	O
ecg	O	O
of	O	O
freely	O	O
moving	O	O
balb	O	O
/	O	O

c	O	O
mice	O	O
and	O	O
the	O	O
efficacy	O	O
of	O	O
icrf	B-chem	B-chem
-	I-chem	O
187	I-chem	O
as	O	O
a	O	O
protective	O	O
agent	O	O
.	O	O

the	O	O
st	O	O
interval	O	O
significantly	O	O
widened	O	O
from	O	O
15	O	O
.	O	O
0	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
5	O	O
to	O	O
56	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

11	O	O
.	O	O
8	O	O
ms	O	O
in	O	O
week	O	O
10	O	O
(	O	O
7	O	O
weekly	O	O
doses	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
doxorubicin	B-chem	B-chem
given	O	O
i	O	O
.	O	O
v	O	O
.	O	O

plus	O	O
3	O	O
weeks	O	O
of	O	O
observation	O	O
)	O	O
.	O	O

the	O	O
ecg	O	O
of	O	O
the	O	O
control	O	O
animals	O	O
did	O	O
not	O	O
change	O	O
during	O	O
the	O	O
entire	O	O
study	O	O
.	O	O

after	O	O
sacrifice	O	O
the	O	O
hearts	O	O
of	O	O
doxorubicin	B-chem	B-chem
-	O	O
treated	O	O
animals	O	O
were	O	O
enlarged	O	O
and	O	O
the	O	O
atria	O	O
were	O	O
hypertrophic	O	O
.	O	O

as	O	O
this	O	O
schedule	O	O
exerted	O	O
more	O	O
toxicity	O	O
than	O	O
needed	O	O
to	O	O
investigate	O	O
protective	O	O
agents	O	O
,	O	O
the	O	O
protection	O	O
of	O	O
icrf	B-chem	B-chem
-	I-chem	O
187	I-chem	O
was	O	O
determined	O	O
using	O	O
a	O	O
dose	O	O
schedule	O	O
with	O	O
lower	O	O
general	O	O
toxicity	O	O
(	O	O
6	O	O
weekly	O	O
doses	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
doxorubicin	B-chem	B-chem
given	O	O
i	O	O
.	O	O
v	O	O
.	O	O

plus	O	O
2	O	O
weeks	O	O
of	O	O
observation	O	O
)	O	O
.	O	O

on	O	O
this	O	O
schedule	O	O
,	O	O
the	O	O
animals	O	O
'	O	O
hearts	O	O
appeared	O	O
normal	O	O
after	O	O
sacrifice	O	O
and	O	O
icrf	B-chem	B-chem
-	I-chem	O
187	I-chem	O
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
given	O	O
i	O	O
.	O	O
p	O	O
.	O	O

1	O	O
h	O	O
before	O	O
doxorubicin	B-chem	B-chem
)	O	O
provided	O	O
almost	O	O
full	O	O
protection	O	O
.	O	O

these	O	O
data	O	O
were	O	O
confirmed	O	O
by	O	O
histology	O	O
.	O	O

the	O	O
results	O	O
indicate	O	O
that	O	O
this	O	O
new	O	O
model	O	O
is	O	O
very	O	O
sensitive	O	O
and	O	O
enables	O	O
monitoring	O	O
of	O	O
the	O	O
development	O	O
of	O	O
cardiotoxicity	O	O
with	O	O
time	O	O
.	O	O

these	O	O
findings	O	O
result	O	O
in	O	O
a	O	O
model	O	O
that	O	O
allows	O	O
the	O	O
testing	O	O
of	O	O
protectors	O	O
against	O	O
doxorubicin	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
as	O	O
demonstrated	O	O
by	O	O
the	O	O
protection	O	O
provided	O	O
by	O	O
icrf	B-chem	B-chem
-	I-chem	O
187	I-chem	O
.	O	O

epinephrine	B-chem	B-chem
dysrhythmogenicity	O	O
is	O	O
not	O	O
enhanced	O	O
by	O	O
subtoxic	O	O
bupivacaine	B-chem	B-chem
in	O	O
dogs	O	O
.	O	O

since	O	O
bupivacaine	B-chem	B-chem
and	O	O
epinephrine	B-chem	B-chem
may	O	O
both	O	O
precipitate	O	O
dysrhythmias	O	O
,	O	O
circulating	O	O
bupivacaine	B-chem	B-chem
during	O	O
regional	O	O
anesthesia	O	O
could	O	O
potentiate	O	O
dysrhythmogenic	O	O
effects	O	O
of	O	O
epinephrine	B-chem	B-chem
.	O	O

we	O	O
therefore	O	O
examined	O	O
whether	O	O
bupivacaine	B-chem	B-chem
alters	O	O
the	O	O
dysrhythmogenicity	O	O
of	O	O
subsequent	O	O
administration	O	O
of	O	O
epinephrine	B-chem	B-chem
in	O	O
conscious	O	O
,	O	O
healthy	O	O
dogs	O	O
and	O	O
in	O	O
anesthetized	O	O
dogs	O	O
with	O	O
myocardial	O	O
infarction	O	O
.	O	O

forty	O	O
-	O	O
one	O	O
conscious	O	O
dogs	O	O
received	O	O
10	O	O
micrograms	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
.	O	O
min	O	O
-	O	O
1	O	O
epinephrine	B-chem	B-chem
.	O	O

seventeen	O	O
animals	O	O
responded	O	O
with	O	O
ventricular	O	O
tachycardia	O	O
(	O	O
vt	O	O
)	O	O
within	O	O
3	O	O
min	O	O
.	O	O

after	O	O
3	O	O
h	O	O
,	O	O
these	O	O
responders	O	O
randomly	O	O
received	O	O
1	O	O
or	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
bupivacaine	B-chem	B-chem
or	O	O
saline	O	O
over	O	O
5	O	O
min	O	O
,	O	O
followed	O	O
by	O	O
10	O	O
micrograms	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
.	O	O
min	O	O
-	O	O
1	O	O
epinephrine	B-chem	B-chem
.	O	O

in	O	O
the	O	O
bupivacaine	B-chem	B-chem
groups	O	O
,	O	O
epinephrine	B-chem	B-chem
caused	O	O
fewer	O	O
prodysrhythmic	O	O
effects	O	O
than	O	O
without	O	O
bupivacaine	B-chem	B-chem
.	O	O

vt	O	O
appeared	O	O
in	O	O
fewer	O	O
dogs	O	O
and	O	O
at	O	O
a	O	O
later	O	O
time	O	O
,	O	O
and	O	O
there	O	O
were	O	O
more	O	O
sinoatrial	O	O
beats	O	O
and	O	O
less	O	O
ectopies	O	O
.	O	O

epinephrine	B-chem	B-chem
shortened	O	O
qt	O	O
less	O	O
after	O	O
bupivacaine	B-chem	B-chem
than	O	O
in	O	O
control	O	O
animals	O	O
.	O	O

one	O	O
day	O	O
after	O	O
experimental	O	O
myocardial	O	O
infarction	O	O
,	O	O
six	O	O
additional	O	O
halothane	B-chem	B-chem
-	O	O
anesthetized	O	O
dogs	O	O
received	O	O
4	O	O
micrograms	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
.	O	O
min	O	O
-	O	O
1	O	O
epinephrine	B-chem	B-chem
until	O	O
vt	O	O
appeared	O	O
.	O	O

after	O	O
45	O	O
min	O	O
,	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
bupivacaine	B-chem	B-chem
was	O	O
injected	O	O
over	O	O
5	O	O
min	O	O
,	O	O
again	O	O
followed	O	O
by	O	O
4	O	O
micrograms	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
.	O	O
min	O	O
-	O	O
1	O	O
epinephrine	B-chem	B-chem
.	O	O

in	O	O
these	O	O
dogs	O	O
,	O	O
the	O	O
prodysrhythmic	O	O
response	O	O
to	O	O
epinephrine	B-chem	B-chem
was	O	O
also	O	O
mitigated	O	O
by	O	O
preceding	O	O
bupivacaine	B-chem	B-chem
.	O	O

bupivacaine	B-chem	B-chem
antagonizes	O	O
epinephrine	B-chem	B-chem
dysrhythmogenicity	O	O
in	O	O
conscious	O	O
dogs	O	O
susceptible	O	O
to	O	O
vt	O	O
and	O	O
in	O	O
anesthetized	O	O
dogs	O	O
with	O	O
spontaneous	O	O
postinfarct	O	O
dysrhythmias	O	O
.	O	O

there	O	O
is	O	O
no	O	O
evidence	O	O
that	O	O
systemic	O	O
subtoxic	O	O
bupivacaine	B-chem	B-chem
administration	O	O
enhances	O	O
the	O	O
dysrhythmogenicity	O	O
of	O	O
subsequent	O	O
epinephrine	B-chem	B-chem
.	O	O

milk	O	O
-	O	O
alkali	O	O
syndrome	O	O
induced	O	O
by	O	O
1	B-chem	O
,	I-chem	O
25	I-chem	O
(	I-chem	O
oh	I-chem	O
)	I-chem	O
2d	I-chem	O
in	O	O
a	O	O
patient	O	O
with	O	O
hypoparathyroidism	O	O
.	O	O

milk	O	O
-	O	O
alkali	O	O
syndrome	O	O
was	O	O
first	O	O
described	O	O
70	O	O
years	O	O
ago	O	O
in	O	O
the	O	O
context	O	O
of	O	O
the	O	O
treatment	O	O
of	O	O
peptic	O	O
ulcer	O	O
disease	O	O
with	O	O
large	O	O
amounts	O	O
of	O	O
calcium	B-chem	B-chem
and	O	O
alkali	B-chem	B-chem
.	O	O

although	O	O
with	O	O
current	O	O
ulcer	O	O
therapy	O	O
(	O	O
h	O	O
-	O	O
2	O	O
blockers	O	O
,	O	O
omeprazole	B-chem	B-chem
,	O	O
and	O	O
sucralfate	B-chem	B-chem
)	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
milk	O	O
-	O	O
alkali	O	O
syndrome	O	O
has	O	O
decreased	O	O
significantly	O	O
,	O	O
the	O	O
classic	O	O
triad	O	O
of	O	O
hypercalcemia	O	O
,	O	O
alkalosis	O	O
,	O	O
and	O	O
renal	O	O
impairment	O	O
remains	O	O
the	O	O
hallmark	O	O
of	O	O
the	O	O
syndrome	O	O
.	O	O

milk	O	O
-	O	O
alkali	O	O
syndrome	O	O
can	O	O
present	O	O
serious	O	O
and	O	O
occasionally	O	O
life	O	O
-	O	O
threatening	O	O
illness	O	O
unless	O	O
diagnosed	O	O
and	O	O
treated	O	O
appropriately	O	O
.	O	O

this	O	O
article	O	O
presents	O	O
a	O	O
patient	O	O
with	O	O
hypoparathyroidism	O	O
who	O	O
was	O	O
treated	O	O
with	O	O
calcium	B-chem	B-chem
carbonate	I-chem	I-chem
and	O	O
calcitriol	B-chem	B-chem
resulting	O	O
in	O	O
two	O	O
admissions	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
milk	O	O
-	O	O
alkali	O	O
syndrome	O	O
.	O	O

the	O	O
patient	O	O
was	O	O
successfully	O	O
treated	O	O
with	O	O
intravenous	O	O
pamidronate	B-chem	B-chem
on	O	O
his	O	O
first	O	O
admission	O	O
and	O	O
with	O	O
hydrocortisone	B-chem	B-chem
on	O	O
the	O	O
second	O	O
.	O	O

this	O	O
illustrates	O	O
intravenous	O	O
pamidronate	B-chem	B-chem
as	O	O
a	O	O
valuable	O	O
therapeutic	O	O
tool	O	O
when	O	O
milk	O	O
-	O	O
alkali	O	O
syndrome	O	O
presents	O	O
as	O	O
hypercalcemic	O	O
emergency	O	O
.	O	O

encephalopathy	O	O
during	O	O
amitriptyline	B-chem	B-chem
therapy	O	O
:	O	O
are	O	O
neuroleptic	O	O
malignant	O	O
syndrome	O	O
and	O	O
serotonin	O	O
syndrome	O	O
spectrum	O	O
disorders	O	O
?	O	O

this	O	O
report	O	O
describes	O	O
a	O	O
case	O	O
of	O	O
encephalopathy	O	O
developed	O	O
in	O	O
the	O	O
course	O	O
of	O	O
amitriptyline	B-chem	B-chem
therapy	O	O
,	O	O
during	O	O
a	O	O
remission	O	O
of	O	O
unipolar	O	O
depression	O	O
.	O	O

this	O	O
patient	O	O
could	O	O
have	O	O
been	O	O
diagnosed	O	O
as	O	O
having	O	O
either	O	O
neuroleptic	O	O
malignant	O	O
syndrome	O	O
(	O	O
nms	O	O
)	O	O
or	O	O
serotonin	O	O
syndrome	O	O
(	O	O
ss	O	O
)	O	O
.	O	O

the	O	O
major	O	O
determinant	O	O
of	O	O
the	O	O
symptoms	O	O
may	O	O
have	O	O
been	O	O
dopamine	B-chem	B-chem
/	O	O
serotonin	B-chem	B-chem
imbalance	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

the	O	O
nms	O	O
-	O	O
like	O	O
encephalopathy	O	O
that	O	O
develops	O	O
in	O	O
association	O	O
with	O	O
the	O	O
use	O	O
of	O	O
antidepressants	O	B-chem
indicates	O	O
that	O	O
nms	O	O
and	O	O
ss	O	O
are	O	O
spectrum	O	O
disorders	O	O
induced	O	O
by	O	O
drugs	O	O
with	O	O
both	O	O
antidopaminergic	O	B-chem
and	O	O
serotonergic	O	O
effects	O	O
.	O	O

genetic	O	O
separation	O	O
of	O	O
tumor	O	O
growth	O	O
and	O	O
hemorrhagic	O	O
phenotypes	O	O
in	O	O
an	O	O
estrogen	B-chem	B-chem
-	O	O
induced	O	O
tumor	O	O
.	O	O

chronic	O	O
administration	O	O
of	O	O
estrogen	B-chem	B-chem
to	O	O
the	O	O
fischer	O	O
344	O	O
(	O	O
f344	O	O
)	O	O
rat	O	O
induces	O	O
growth	O	O
of	O	O
large	O	O
,	O	O
hemorrhagic	O	O
pituitary	O	O
tumors	O	O
.	O	O

ten	O	O
weeks	O	O
of	O	O
diethylstilbestrol	B-chem	B-chem
(	O	O
des	B-chem	B-chem
)	O	O
treatment	O	O
caused	O	O
female	O	O
f344	O	O
rat	O	O
pituitaries	O	O
to	O	O
grow	O	O
to	O	O
an	O	O
average	O	O
of	O	O
109	O	O
.	O	O
2	O	O
+	O	O
/	O	O
-	O	O

6	O	O
.	O	O
3	O	O
mg	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O

se	O	O
)	O	O
versus	O	O
11	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
4	O	O
mg	O	O
for	O	O
untreated	O	O
rats	O	O
,	O	O
and	O	O
to	O	O
become	O	O
highly	O	O
hemorrhagic	O	O
.	O	O

the	O	O
same	O	O
des	B-chem	B-chem
treatment	O	O
produced	O	O
no	O	O
significant	O	O
growth	O	O
(	O	O
8	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
for	O	O
treated	O	O
females	O	O
versus	O	O
8	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
1	O	O
for	O	O
untreated	O	O
females	O	O
)	O	O
or	O	O
morphological	O	O
changes	O	O
in	O	O
brown	O	O
norway	O	O
(	O	O
bn	O	O
)	O	O
rat	O	O
pituitaries	O	O
.	O	O

an	O	O
f1	O	O
hybrid	O	O
of	O	O
f344	O	O
and	O	O
bn	O	O
exhibited	O	O
significant	O	O
pituitary	O	O
growth	O	O
after	O	O
10	O	O
weeks	O	O
of	O	O
des	B-chem	B-chem
treatment	O	O
with	O	O
an	O	O
average	O	O
mass	O	O
of	O	O
26	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
7	O	O
mg	O	O
compared	O	O
with	O	O
8	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
9	O	O
mg	O	O
for	O	O
untreated	O	O
rats	O	O
.	O	O

surprisingly	O	O
,	O	O
the	O	O
f1	O	O
hybrid	O	O
tumors	O	O
were	O	O
not	O	O
hemorrhagic	O	O
and	O	O
had	O	O
hemoglobin	O	O
content	O	O
and	O	O
outward	O	O
appearance	O	O
identical	O	O
to	O	O
that	O	O
of	O	O
bn	O	O
.	O	O

expression	O	O
of	O	O
both	O	O
growth	O	O
and	O	O
morphological	O	O
changes	O	O
is	O	O
due	O	O
to	O	O
multiple	O	O
genes	O	O
.	O	O

however	O	O
,	O	O
while	O	O
des	B-chem	B-chem
-	O	O
induced	O	O
pituitary	O	O
growth	O	O
exhibited	O	O
quantitative	O	O
,	O	O
additive	O	O
inheritance	O	O
,	O	O
the	O	O
hemorrhagic	O	O
phenotype	O	O
exhibited	O	O
recessive	O	O
,	O	O
epistatic	O	O
inheritance	O	O
.	O	O

only	O	O
5	O	O
of	O	O
the	O	O
160	O	O
f2	O	O
pituitaries	O	O
exhibited	O	O
the	O	O
hemorrhagic	O	O
phenotype	O	O
;	O	O
36	O	O
of	O	O
the	O	O
160	O	O
f2	O	O
pituitaries	O	O
were	O	O
in	O	O
the	O	O
f344	O	O
range	O	O
of	O	O
mass	O	O
,	O	O
but	O	O
31	O	O
of	O	O
these	O	O
were	O	O
not	O	O
hemorrhagic	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
hemorrhagic	O	O
phenotype	O	O
is	O	O
not	O	O
merely	O	O
a	O	O
consequence	O	O
of	O	O
extensive	O	O
growth	O	O
.	O	O

the	O	O
hemorrhagic	O	O
f2	O	O
pituitaries	O	O
were	O	O
all	O	O
among	O	O
the	O	O
most	O	O
massive	O	O
,	O	O
indicating	O	O
that	O	O
some	O	O
of	O	O
the	O	O
genes	O	O
regulate	O	O
both	O	O
phenotypes	O	O
.	O	O

increased	O	O
expression	O	O
of	O	O
neuronal	O	O
nitric	B-chem	B-chem
oxide	I-chem	I-chem
synthase	O	O
in	O	O
bladder	O	O
afferent	O	O
pathways	O	O
following	O	O
chronic	O	O
bladder	O	O
irritation	O	O
.	O	O

immunocytochemical	O	O
techniques	O	O
were	O	O
used	O	O
to	O	O
examine	O	O
alterations	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
neuronal	O	O
nitric	B-chem	B-chem
oxide	I-chem	I-chem
synthase	O	O
(	O	O
nos	O	O
)	O	O
in	O	O
bladder	O	O
pathways	O	O
following	O	O
acute	O	O
and	O	O
chronic	O	O
irritation	O	O
of	O	O
the	O	O
urinary	O	O
tract	O	O
of	O	O
the	O	O
rat	O	O
.	O	O

chemical	O	O
cystitis	O	O
was	O	O
induced	O	O
by	O	O
cyclophosphamide	B-chem	B-chem
(	O	O
cyp	B-chem	B-chem
)	O	O
which	O	O
is	O	O
metabolized	O	O
to	O	O
acrolein	B-chem	B-chem
,	O	O
an	O	O
irritant	O	O
eliminated	O	O
in	O	O
the	O	O
urine	O	O
.	O	O

injection	O	O
of	O	O
cyp	B-chem	O
(	O	O
n	O	O
=	O	O
10	O	O
,	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O

2	O	O
hours	O	O
prior	O	O
to	O	O
perfusion	O	O
(	O	O
acute	O	O
treatment	O	O
)	O	O
of	O	O
the	O	O
animals	O	O
increased	O	O
fos	O	O
-	O	O
immunoreactivity	O	O
(	O	O
ir	O	O
)	O	O
in	O	O
neurons	O	O
in	O	O
the	O	O
dorsal	O	O
commissure	O	O
,	O	O
dorsal	O	O
horn	O	O
,	O	O
and	O	O
autonomic	O	O
regions	O	O
of	O	O
spinal	O	O
segments	O	O
(	O	O
l1	O	O
-	O	O
l2	O	O
and	O	O
l6	O	O
-	O	O
s1	O	O
)	O	O
which	O	O
receive	O	O
afferent	O	O
inputs	O	O
from	O	O
the	O	O
bladder	O	O
,	O	O
urethra	O	O
,	O	O
and	O	O
ureter	O	O
.	O	O

fos	O	B-chem
-	O	O
ir	O	O
in	O	O
the	O	O
spinal	O	O
cord	O	O
was	O	O
not	O	O
changed	O	O
in	O	O
rats	O	O
receiving	O	O
chronic	O	O
cyp	B-chem	O
treatment	O	O
(	O	O
n	O	O
=	O	O
15	O	O
,	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O

,	O	O
every	O	O
3rd	O	O
day	O	O
for	O	O
2	O	O
weeks	O	O
)	O	O
.	O	O

in	O	O
control	O	O
animals	O	O
and	O	O
in	O	O
animals	O	O
treated	O	O
acutely	O	O
with	O	O
cyp	B-chem	O
,	O	O
only	O	O
small	O	O
numbers	O	O
of	O	O
nos	O	O
-	O	O
ir	O	O
cells	O	O
(	O	O
0	O	O
.	O	O
5	O	O
-	O	O
0	O	O
.	O	O
7	O	O
cell	O	O
profiles	O	O
/	O	O
sections	O	O
)	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
l6	O	O
-	O	O
s1	O	O
dorsal	O	O
root	O	O
ganglia	O	O
(	O	O
drg	O	O
)	O	O
.	O	O

chronic	O	O
cyp	B-chem	B-chem
administration	O	O
significantly	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
.	O	O
002	O	O
)	O	O
increased	O	O
bladder	O	O
weight	O	O
by	O	O
60	O	O
%	O	O
and	O	O
increased	O	O

(	O	O
7	O	O
-	O	O
to	O	O
11	O	O
-	O	O
fold	O	O
)	O	O
the	O	O
numbers	O	O
of	O	O
nos	O	O
-	O	O
immunoreactive	O	O
(	O	O
ir	O	O
)	O	O
afferent	O	O
neurons	O	O
in	O	O
the	O	O
l6	O	O
-	O	O
s1	O	O
drg	O	O
.	O	O

a	O	O
small	O	O
increase	O	O
(	O	O
1	O	O
.	O	O
5	O	O
-	O	O
fold	O	O
)	O	O
also	O	O
occurred	O	O
in	O	O
the	O	O
l1	O	O
drg	O	O
,	O	O
but	O	O
no	O	O
change	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
l2	O	O
and	O	O
l5	O	O
drg	O	O
.	O	O

bladder	O	O
afferent	O	O
cells	O	O
in	O	O
the	O	O
l6	O	O
-	O	O
s1	O	O
drg	O	O
labeled	O	O
by	O	O
fluorogold	O	O
(	O	O
40	O	B-chem
microliters	O	I-chem
)	O	O
injected	O	O
into	O	O
the	O	O
bladder	O	O
wall	O	O
did	O	O
not	O	O
exhibit	O	O
nos	O	O
-	O	O
ir	O	O
in	O	O
control	O	O
animals	O	O
;	O	O
however	O	O
,	O	O
following	O	O
chronic	O	O
cyp	B-chem	O
administration	O	O
,	O	O
a	O	O
significant	O	O
percentage	O	O
of	O	O
bladder	O	O
afferent	O	O
neurons	O	O
were	O	O
nos	O	O
-	O	O
ir	O	O
:	O	O
l6	O	O
(	O	O
19	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

4	O	O
.	O	O
6	O	O
%	O	O
)	O	O
and	O	O
s1	O	O
(	O	O
25	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

2	O	O
.	O	O
9	O	O
%	O	O
)	O	O
.	O	O

these	O	O
results	O	O
indicate	O	O
that	O	O
neuronal	O	O
gene	O	O
expression	O	O
in	O	O
visceral	O	O
sensory	O	O
pathways	O	O
can	O	O
be	O	O
upregulated	O	O
by	O	O
chemical	O	O
irritation	O	O
of	O	O
afferent	O	O
receptors	O	O
in	O	O
the	O	O
urinary	O	O
tract	O	O
and	O	O
/	O	O
or	O	O
that	O	O
pathological	O	O
changes	O	O
in	O	O
the	O	O
urinary	O	O
tract	O	O
can	O	O
initiate	O	O
chemical	O	O
signals	O	O
that	O	O
alter	O	O
the	O	O
chemical	O	O
properties	O	O
of	O	O
visceral	O	O
afferent	O	O
neurons	O	O
.	O	O

effects	O	O
of	O	O
a	O	O
new	O	O
calcium	B-chem	B-chem
antagonist	O	O
,	O	O
cd	B-chem	O
-	I-chem	O
832	I-chem	I-chem
,	O	O
on	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
myocardial	O	O
ischemia	O	O
in	O	O
dogs	O	O
with	O	O
partial	O	O
coronary	O	O
stenosis	O	O
.	O	O

effects	O	O
of	O	O
cd	B-chem	B-chem
-	I-chem	I-chem
832	I-chem	I-chem
on	O	O
isoproterenol	B-chem	B-chem
(	O	O
iso	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
myocardial	O	O
ischemia	O	O
were	O	O
studied	O	O
in	O	O
dogs	O	O
with	O	O
partial	O	O
coronary	O	O
stenosis	O	O
of	O	O
the	O	O
left	O	O
circumflex	O	O
coronary	O	O
artery	O	O
and	O	O
findings	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
for	O	O
nifedipine	B-chem	B-chem
or	O	O
diltiazem	B-chem	B-chem
.	O	O

in	O	O
the	O	O
presence	O	O
of	O	O
coronary	O	O
artery	O	O
stenosis	O	O
,	O	O
3	O	O
-	O	O
min	O	O
periods	O	O
of	O	O
intracoronary	O	O
iso	B-chem	B-chem
infusion	O	O
(	O	O
10	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
increased	O	O
heart	O	O
rate	O	O
and	O	O
maximal	O	O
rate	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
rise	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
a	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
and	O	O
st	O	O
-	O	O
segment	O	O
elevation	O	O
of	O	O
the	O	O
epicardial	O	O
electrocardiogram	O	O
.	O	O

after	O	O
the	O	O
control	O	O
iso	B-chem	B-chem
infusion	O	O
with	O	O
stenosis	O	O
was	O	O
performed	O	O
,	O	O
equihypotensive	O	O
doses	O	O
of	O	O
cd	B-chem	O
-	I-chem	O
832	I-chem	O
(	O	O
3	O	O
and	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
,	O	O
n	O	O
=	O	O
7	O	O
)	O	O
,	O	O
nifedipine	B-chem	B-chem
(	O	O
1	O	O
and	O	O
3	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
,	O	O
n	O	O
=	O	O
9	O	O
)	O	O
or	O	O
diltiazem	B-chem	B-chem
(	O	O
10	O	O
and	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
,	O	O
n	O	O
=	O	O
7	O	O
)	O	O
were	O	O
infused	O	O
5	O	O
min	O	O
before	O	O
and	O	O
during	O	O
the	O	O
second	O	O
and	O	O
third	O	O
iso	B-chem	B-chem
infusion	O	O
.	O	O

both	O	O
cd	B-chem	O
-	I-chem	O
832	I-chem	O
and	O	O
diltiazem	B-chem	B-chem
,	O	O
but	O	O
not	O	O
nifedipine	B-chem	B-chem
,	O	O
significantly	O	O
reduced	O	O
the	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
induced	O	O
by	O	O
iso	B-chem	B-chem
infusion	O	O
.	O	O

in	O	O
contrast	O	O
to	O	O
nifedipine	B-chem	B-chem
,	O	O
cd	B-chem	O
-	I-chem	O
832	I-chem	O
(	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
prevented	O	O
the	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
from	O	O
32	O	O
+	O	O
/	O	O
-	O	O

12	O	O
%	O	O
to	O	O
115	O	O
+	O	O
/	O	O
-	O	O

26	O	O
%	O	O
of	O	O
the	O	O
control	O	O
value	O	O
(	O	O
p	O	O
<	O	O
.	O	O
01	O	O
)	O	O
and	O	O
st	O	O
-	O	O
segment	O	O
elevation	O	O
from	O	O
5	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
0	O	O
mv	O	O
to	O	O
1	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
3	O	O
mv	O	O
(	O	O
p	O	O
<	O	O
.	O	O
01	O	O
)	O	O
at	O	O
3	O	O
min	O	O
after	O	O
iso	B-chem	B-chem
infusion	O	O
with	O	O
stenosis	O	O
.	O	O

diltiazem	B-chem	B-chem
(	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
also	O	O
prevented	O	O
the	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
from	O	O
34	O	O
+	O	O
/	O	O
-	O	O

14	O	O
%	O	O
to	O	O
63	O	O
+	O	O
/	O	O
-	O	O

18	O	O
%	O	O
of	O	O
the	O	O
control	O	O
value	O	O
(	O	O
p	O	O
<	O	O
.	O	O
05	O	O
)	O	O
and	O	O
st	O	O
-	O	O
segment	O	O
elevation	O	O
from	O	O
4	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
7	O	O
mv	O	O
to	O	O
2	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
7	O	O
mv	O	O
(	O	O
p	O	O
<	O	O
.	O	O
01	O	O
)	O	O
at	O	O
3	O	O
min	O	O
after	O	O
iso	B-chem	B-chem
infusion	O	O
with	O	O
stenosis	O	O
.	O	O

these	O	O
data	O	O
show	O	O
that	O	O
cd	B-chem	O
-	I-chem	O
832	I-chem	O
improves	O	O
myocardial	O	O
ischemia	O	O
during	O	O
iso	B-chem	B-chem
infusion	O	O
with	O	O
stenosis	O	O
and	O	O
suggest	O	O
that	O	O
the	O	O
negative	O	O
chronotropic	O	O
property	O	O
of	O	O
cd	B-chem	O
-	I-chem	O
832	I-chem	O
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
cd	B-chem	O
-	I-chem	O
832	I-chem	O
.	O	O

the	O	O
effect	O	O
of	O	O
recombinant	O	O
human	O	O
insulin	O	O
-	O	O
like	O	O
growth	O	O
factor	O	O
-	O	O
i	O	O
on	O	O
chronic	O	O
puromycin	B-chem	B-chem
aminonucleoside	I-chem	I-chem
nephropathy	O	O
in	O	O
rats	O	O
.	O	O

we	O	O
recently	O	O
demonstrated	O	O
that	O	O
recombinant	O	O
hgh	O	O
exacerbates	O	O
renal	O	O
functional	O	O
and	O	O
structural	O	O
injury	O	O
in	O	O
chronic	O	O
puromycin	B-chem	B-chem
aminonucleoside	I-chem	I-chem
(	O	O
pan	B-chem	B-chem
)	O	O
nephropathy	O	O
,	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
glomerular	O	O
disease	O	O
.	O	O

therefore	O	O
,	O	O
we	O	O
examined	O	O
whether	O	O
recombinant	O	O
human	O	O
(	O	O
rh	O	O
)	O	O
igf	O	O
-	O	O

i	O	O
is	O	O
a	O	O
safer	O	O
alternative	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
growth	O	O
failure	O	O
in	O	O
rats	O	O
with	O	O
chronic	O	O
pan	B-chem	O
nephropathy	O	O
.	O	O

the	O	O
glomerulopathy	O	O
was	O	O
induced	O	O
by	O	O
seven	O	O
serial	O	O
injections	O	O
of	O	O
pan	B-chem	O
over	O	O
12	O	O
wk	O	O
.	O	O

experimental	O	O
animals	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
received	O	O
rhigf	O	O
-	O	O
i	O	O
,	O	O
400	O	O
micrograms	O	O
/	O	O
d	O	O
,	O	O
whereas	O	O
control	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
received	O	O
the	O	O
vehicle	O	O
.	O	O

rhigf	O	O
-	O	O
i	O	O
improved	O	O
weight	O	O
gain	O	O
by	O	O
14	O	O
%	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
without	O	O
altering	O	O
hematocrit	O	O
or	O	O
blood	O	O
pressure	O	O
in	O	O
rats	O	O
with	O	O
renal	O	O
disease	O	O
.	O	O

urinary	O	O
protein	O	O
excretion	O	O
was	O	O
unaltered	O	O
by	O	O
rhigf	O	O
-	O	O
i	O	O
treatment	O	O
in	O	O
rats	O	O
with	O	O
chronic	O	O
pan	B-chem	O
nephropathy	O	O
.	O	O

after	O	O
12	O	O
wk	O	O
,	O	O
the	O	O
inulin	O	O
clearance	O	O
was	O	O
higher	O	O
in	O	O
rhigf	O	O
-	O	O
i	O	O
-	O	O
treated	O	O
rats	O	O
,	O	O
0	O	O
.	O	O
48	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
08	O	O
versus	O	O
0	O	O
.	O	O
24	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
06	O	O
ml	O	O
/	O	O
min	O	O
/	O	O
100	O	O
g	O	O
of	O	O
body	O	O
weight	O	O
in	O	O
untreated	O	O
pan	B-chem	O
nephropathy	O	O
animals	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
.	O	O

the	O	O
improvement	O	O
in	O	O
gfr	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
enhanced	O	O
glomerular	O	O
hypertrophy	O	O
or	O	O
increased	O	O
segmental	O	O
glomerulosclerosis	O	O
,	O	O
tubulointerstitial	O	O
injury	O	O
,	O	O
or	O	O
renal	O	O
cortical	O	O
malondialdehyde	B-chem	B-chem
content	O	O
.	O	O

in	O	O
rats	O	O
with	O	O
pan	B-chem	O
nephropathy	O	O
,	O	O
administration	O	O
of	O	O
rhigf	O	O
-	O	O
i	O	O
increased	O	O
igf	O	O
-	O	O
i	O	O
and	O	O
gh	O	O
receptor	O	O
gene	O	O
expression	O	O
,	O	O
without	O	O
altering	O	O
the	O	O
steady	O	O
state	O	O
level	O	O
of	O	O
igf	O	O
-	O	O
i	O	O
receptor	O	O
mrna	O	O
.	O	O

in	O	O
normal	O	O
rats	O	O
with	O	O
intact	O	O
kidneys	O	O
,	O	O
rhigf	O	O
-	O	O
i	O	O
administration	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
did	O	O
not	O	O
alter	O	O
weight	O	O
gain	O	O
,	O	O
blood	O	O
pressure	O	O
,	O	O
proteinuria	O	O
,	O	O
gfr	O	O
,	O	O
glomerular	O	O
planar	O	O
area	O	O
,	O	O
renal	O	O
cortical	O	O
malondialdehyde	B-chem	B-chem
content	O	O
,	O	O
or	O	O
glomerular	O	O
or	O	O
tubulointerstitial	O	O
damage	O	O
,	O	O
compared	O	O
with	O	O
untreated	O	O
animals	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
.	O	O

rhigf	O	O
-	O	O

i	O	O
treatment	O	O
reduced	O	O
the	O	O
steady	O	O
state	O	O
renal	O	O
igf	O	O
-	O	O
i	O	O
mrna	O	O
level	O	O
but	O	O
did	O	O
not	O	O
modify	O	O
gene	O	O
expression	O	O
of	O	O
the	O	O
igf	O	O
-	O	O
i	O	O
or	O	O
gh	O	O
receptors	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
:	O	O
1	O	O
)	O	O
administration	O	O
of	O	O
rhigf	O	O
-	O	O
i	O	O
improves	O	O
growth	O	O
and	O	O
gfr	O	O
in	O	O
rats	O	O
with	O	O
chronic	O	O
pan	B-chem	O
nephropathy	O	O
and	O	O
2	O	O
)	O	O
unlike	O	O
rhgh	O	O
,	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
rhigf	O	B-chem
-	O	O
i	O	O
does	O	O
not	O	O
worsen	O	O
renal	O	O
functional	O	O
and	O	O
structural	O	O
injury	O	O
in	O	O
this	O	O
disease	O	O
model	O	O
.	O	O

nefiracetam	B-chem	B-chem
(	O	O
dm	B-chem	B-chem
-	I-chem	O
9384	I-chem	I-chem
)	O	O
reverses	O	O
apomorphine	B-chem	B-chem
-	O	O
induced	O	O
amnesia	O	O
of	O	O
a	O	O
passive	O	O
avoidance	O	O
response	O	O
:	O	O
delayed	O	O
emergence	O	O
of	O	O
the	O	O
memory	O	O
retention	O	O
effects	O	O
.	O	O

nefiracetam	B-chem	B-chem
is	O	O
a	O	O
novel	O	O
pyrrolidone	B-chem	B-chem
derivative	O	O
which	O	O
attenuates	O	O
scopolamine	B-chem	B-chem
-	O	O
induced	O	O
learning	O	O
and	O	O
post	O	O
-	O	O
training	O	O
consolidation	O	O
deficits	O	O
.	O	O

given	O	O
that	O	O
apomorphine	B-chem	B-chem
inhibits	O	O
passive	O	O
avoidance	O	O
retention	O	O
when	O	O
given	O	O
during	O	O
training	O	O
or	O	O
in	O	O
a	O	O
defined	O	O
10	O	O
-	O	O
12h	O	O
post	O	O
-	O	O
training	O	O
period	O	O
,	O	O
we	O	O
evaluated	O	O
the	O	O
ability	O	O
of	O	O
nefiracetam	B-chem	B-chem
to	O	O
attenuate	O	O
amnesia	O	O
induced	O	O
by	O	O
dopaminergic	O	O
agonism	O	O
.	O	O

a	O	O
step	O	O
-	O	O
down	O	O
passive	O	O
avoidance	O	O
paradigm	O	O
was	O	O
employed	O	O
and	O	O
nefiracetam	B-chem	B-chem
(	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
apomorphine	B-chem	B-chem
(	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
were	O	O
given	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
during	O	O
training	O	O
and	O	O
at	O	O
the	O	O
10	O	O
-	O	O
12h	O	O
post	O	O
-	O	O
training	O	O
period	O	O
of	O	O
consolidation	O	O
.	O	O

co	O	O
-	O	O
administration	O	O
of	O	O
nefiracetam	B-chem	B-chem
and	O	O
apomorphine	B-chem	B-chem
during	O	O
training	O	O
or	O	O
10h	O	B-chem
thereafter	O	O
produced	O	O
no	O	O
significant	O	O
anti	O	O
-	O	O
amnesic	O	O
effect	O	O
.	O	O

however	O	O
,	O	O
administration	O	O
of	O	O
nefiracetam	B-chem	B-chem
during	O	O
training	O	O
completely	O	O
reversed	O	O
the	O	O
amnesia	O	O
induced	O	O
by	O	O
apomorphine	B-chem	B-chem
at	O	O
the	O	O
10h	O	O
post	O	O
-	O	O
training	O	O
time	O	O
and	O	O
the	O	O
converse	O	O
was	O	O
also	O	O
true	O	O
.	O	O

these	O	O
effects	O	O
were	O	O
not	O	O
mediated	O	O
by	O	O
a	O	O
dopaminergic	O	O
mechanism	O	O
as	O	O
nefiracetam	B-chem	B-chem
,	O	O
at	O	O
millimolar	O	O
concentrations	O	O
,	O	O
failed	O	O
to	O	O
displace	O	O
either	O	O
[	O	B-chem
3h	O	I-chem
]	O	I-chem
sch	B-chem	I-chem
23390	I-chem	I-chem
or	O	O
[	O	B-chem
3h	O	I-chem
]	O	I-chem
spiperone	B-chem	I-chem
binding	O	O
from	O	O
d1	O	O
or	O	O
d2	O	O
dopamine	B-chem	B-chem
receptor	O	O
subtypes	O	O
,	O	O
respectively	O	O
.	O	O

it	O	O
is	O	O
suggested	O	O
that	O	O
nefiracetam	B-chem	B-chem
augments	O	O
molecular	O	O
processes	O	O
in	O	O
the	O	O
early	O	O
stages	O	O
of	O	O
events	O	O
which	O	O
ultimately	O	O
lead	O	O
to	O	O
consolidation	O	O
of	O	O
memory	O	O
.	O	O

human	O	O
corticotropin	B-chem	O
-	O	O
releasing	O	O
hormone	O	O
and	O	O
thyrotropin	B-chem	B-chem
-	O	I-chem
releasing	O	I-chem
hormone	O	I-chem
modulate	O	O
the	O	O
hypercapnic	O	O
ventilatory	O	O
response	O	O
in	O	O
humans	O	O
.	O	O

human	O	O
corticotropin	B-chem	O
-	O	O
releasing	O	O
hormone	O	O
(	O	O
hcrh	O	O
)	O	O
and	O	O
thyrotropin	B-chem	B-chem
-	O	I-chem
releasing	O	I-chem
hormone	O	I-chem
(	O	O
trh	O	B-chem
)	O	O
are	O	O
known	O	O
to	O	O
stimulate	O	O
ventilation	O	O
after	O	O
i	O	O
.	O	O
v	O	O
.	O	O

administration	O	O
in	O	O
humans	O	O
.	O	O

in	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
single	O	O
-	O	O
blind	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
clarify	O	O
if	O	O
both	O	O
peptides	O	O
act	O	O
by	O	O
altering	O	O
central	O	O
chemosensitivity	O	O
.	O	O

two	O	O
subsequent	O	O
co2	B-chem	B-chem
-	O	O
rebreathing	O	O
tests	O	O
were	O	O
performed	O	O
in	O	O
healthy	O	O
young	O	O
volunteers	O	O
.	O	O

during	O	O
the	O	O
first	O	O
test	O	O
0	O	O
.	O	O
9	O	O
%	O	O
nacl	B-chem	B-chem
was	O	O
given	O	O
i	O	O
.	O	O
v	O	O
.	O	O
;	O	O
during	O	O
the	O	O
second	O	O
test	O	O
200	O	O
micrograms	O	O
of	O	O
hcrh	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
or	O	O
400	O	O
micrograms	O	O
of	O	O
trh	O	B-chem
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
was	O	O
administered	O	O
i	O	O
.	O	O
v	O	O
.	O	O

nine	O	O
subjects	O	O
received	O	O
0	O	O
.	O	O
9	O	O
%	O	O
nacl	B-chem	B-chem
i	O	O
.	O	O
v	O	O
.	O	O

during	O	O
both	O	O
rebreathing	O	O
manoeuvres	O	O
.	O	O

the	O	O
co2	B-chem	B-chem
-	O	O
response	O	O
curves	O	O
for	O	O
the	O	O
two	O	O
tests	O	O
were	O	O
compared	O	O
within	O	O
the	O	O
same	O	O
subject	O	O
.	O	O

in	O	O
the	O	O
hcrh	O	O
group	O	O
a	O	O
marked	O	O
parallel	O	O
shift	O	O
of	O	O
the	O	O
co2	B-chem	B-chem
-	O	O
response	O	O
curve	O	O
to	O	O
the	O	O
left	O	O
was	O	O
observed	O	O
after	O	O
hcrh	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

the	O	O
same	O	O
effect	O	O
occurred	O	O
following	O	O
trh	O	B-chem
but	O	O
was	O	O
less	O	O
striking	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

hcrh	O	B-chem
and	O	O
trh	O	B-chem
caused	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
co2	B-chem	B-chem
threshold	O	O
.	O	O

the	O	O
co2	B-chem	B-chem
-	O	O
response	O	O
curves	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
nearly	O	O
identical	O	O
.	O	O

the	O	O
results	O	O
indicate	O	O
an	O	O
additive	O	O
effect	O	O
of	O	O
both	O	O
releasing	O	O
hormones	O	O
on	O	O
the	O	O
hypercapnic	O	O
ventilatory	O	O
response	O	O
in	O	O
humans	O	O
,	O	O
presumably	O	O
independent	O	O
of	O	O
central	O	O
chemosensitivity	O	O
.	O	O

lamivudine	B-chem	B-chem
is	O	O
effective	O	O
in	O	O
suppressing	O	O
hepatitis	O	O
b	O	O
virus	O	O
dna	O	O
in	O	O
chinese	O	O
hepatitis	B-chem	B-chem
b	I-chem	I-chem
surface	I-chem	I-chem
antigen	I-chem	I-chem
carriers	O	O
:	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
.	O	O

lamivudine	B-chem	B-chem
is	O	O
a	O	O
novel	O	O
2	B-chem	O
'	I-chem	O
,	I-chem	O
3	I-chem	B-chem
'	I-chem	I-chem
-	I-chem	I-chem
dideoxy	I-chem	I-chem
cytosine	I-chem	B-chem
analogue	O	O
that	O	O
has	O	O
potent	O	O
inhibitory	O	O
effects	O	O
on	O	O
hepatitis	O	O
b	O	O
virus	O	O
replication	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

we	O	O
performed	O	O
a	O	O
single	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
study	O	O
to	O	O
assess	O	O
its	O	O
effectiveness	O	O
and	O	O
safety	O	O
in	O	O
chinese	O	O
hepatitis	B-chem	B-chem
b	I-chem	I-chem
surface	I-chem	I-chem
antigen	I-chem	I-chem
(	O	O
hbsag	B-chem	B-chem
)	O	O
carriers	O	O
.	O	O

forty	O	O
-	O	O
two	O	O
chinese	O	O
hbsag	B-chem	B-chem
carriers	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
placebo	O	O
(	O	O
6	O	O
patients	O	O
)	O	O
or	O	O
lamivudine	B-chem	B-chem
orally	O	O
in	O	O
dosages	O	O
of	O	O
25	O	O
mg	O	O
,	O	O
100	O	O
mg	O	O
,	O	O
or	O	O
300	O	O
mg	O	O
daily	O	O
(	O	O
12	O	O
patients	O	O
for	O	O
each	O	O
dosage	O	O
)	O	O
.	O	O

the	O	O
drug	O	O
was	O	O
given	O	O
for	O	O
4	O	O
weeks	O	O
.	O	O

the	O	O
patients	O	O
were	O	O
closely	O	O
monitored	O	O
clinically	O	O
,	O	O
biochemically	O	O
,	O	O
and	O	O
serologically	O	O
up	O	O
to	O	O
4	O	O
weeks	O	O
after	O	O
drug	O	O
treatment	O	O
.	O	O

all	O	O
36	O	O
patients	O	O
receiving	O	O
lamivudine	B-chem	B-chem
had	O	O
a	O	O
decrease	O	O
in	O	O
hepatitis	O	O
b	O	O
virus	O	O
(	O	O
hbv	O	O
)	O	O
dna	O	O
values	O	O
of	O	O
>	O	O
90	O	O
%	O	O
(	O	O
p	O	O
<	O	O
.	O	O
001	O	O
compared	O	O
with	O	O
placebo	O	O
)	O	O
.	O	O

although	O	O
25	O	O
mg	O	O
of	O	O
lamivudine	B-chem	B-chem
was	O	O
slightly	O	O
less	O	O
effective	O	O
than	O	O
100	O	O
mg	O	O
(	O	O
p	O	O
=	O	O
.	O	O
011	O	O
)	O	O
and	O	O
300	O	O
mg	O	O
(	O	O
p	O	O
=	O	O
.	O	O
005	O	O
)	O	O
,	O	O
it	O	O
still	O	O
induced	O	O
94	O	O
%	O	O
suppression	O	O
of	O	O
hbv	O	O
dna	O	O
after	O	O
the	O	O
fourth	O	O
week	O	O
of	O	O
therapy	O	O
.	O	O

hbv	O	O
dna	O	O
values	O	O
returned	O	O
to	O	O
pretreatment	O	O
levels	O	O
within	O	O
4	O	O
weeks	O	O
of	O	O
cessation	O	O
of	O	O
therapy	O	O
.	O	O

there	O	O
was	O	O
no	O	O
change	O	O
in	O	O
the	O	O
hepatitis	O	B-chem
b	O	I-chem
e	O	I-chem
antigen	O	I-chem
status	O	O
or	O	O
in	O	O
aminotransferase	O	O
levels	O	O
.	O	O

no	O	O
serious	O	O
adverse	O	O
events	O	O
were	O	O
observed	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
a	O	O
4	O	O
-	O	O
week	O	O
course	O	O
of	O	O
lamivudine	B-chem	B-chem
was	O	O
safe	O	O
and	O	O
effective	O	O
in	O	O
suppression	O	O
of	O	O
hbv	O	O
dna	O	O
in	O	O
chinese	O	O
hbsag	B-chem	B-chem
carriers	O	O
.	O	O

the	O	O
suppression	O	O
was	O	O
>	O	O
90	O	O
%	O	O
but	O	O
reversible	O	O
.	O	O

studies	O	O
with	O	O
long	O	O
-	O	O
term	O	O
lamivudine	B-chem	B-chem
administration	O	O
should	O	O
be	O	O
performed	O	O
to	O	O
determine	O	O
if	O	O
prolonged	O	O
suppression	O	O
of	O	O
hbv	O	O
dna	O	O
can	O	O
be	O	O
achieved	O	O
.	O	O

population	O	O
-	O	O
based	O	O
study	O	O
of	O	O
risk	O	O
of	O	O
venous	O	O
thromboembolism	O	O
associated	O	O
with	O	O
various	O	O
oral	B-chem	B-chem
contraceptives	I-chem	I-chem
.	O	O

background	O	O
:	O	O

four	O	O
studies	O	O
published	O	O
since	O	O
december	O	O
,	O	O
1995	O	O
,	O	O
reported	O	O
that	O	O
the	O	O
incidence	O	O
of	O	O
venous	O	O
thromboembolism	O	O
(	O	O
vte	O	O
)	O	O
was	O	O
higher	O	O
in	O	O
women	O	O
who	O	O
used	O	O
oral	B-chem	B-chem
contraceptives	I-chem	I-chem
(	O	O
ocs	B-chem	B-chem
)	O	O
containing	O	O
the	O	O
third	O	O
-	O	O
generation	O	O
progestagens	B-chem	B-chem
gestodene	B-chem	I-chem
or	O	O
desogestrel	B-chem	B-chem
than	O	O
in	O	O
users	O	O
of	O	O
ocs	B-chem	B-chem
containing	O	O
second	O	O
-	O	O
generation	O	O
progestagens	B-chem	B-chem
.	O	O

however	O	O
,	O	O
confounding	O	O
and	O	O
bias	O	O
in	O	O
the	O	O
design	O	O
of	O	O
these	O	O
studies	O	O
may	O	O
have	O	O
affected	O	O
the	O	O
findings	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
our	O	O
study	O	O
was	O	O
to	O	O
re	O	O
-	O	O
examine	O	O
the	O	O
association	O	O
between	O	O
risk	O	O
of	O	O
vte	O	O
and	O	O
oc	B-chem	B-chem
use	O	O
with	O	O
a	O	O
different	O	O
study	O	O
design	O	O
and	O	O
analysis	O	O
to	O	O
avoid	O	O
some	O	O
of	O	O
the	O	O
bias	O	O
and	O	O
confounding	O	O
of	O	O
the	O	O
earlier	O	O
studies	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
used	O	O
computer	O	O
records	O	O
of	O	O
patients	O	O
from	O	O
143	O	O
general	O	O
practices	O	O
in	O	O
the	O	O
uk	O	O
.	O	O

the	O	O
study	O	O
was	O	O
based	O	O
on	O	O
the	O	O
medical	O	O
records	O	O
of	O	O
about	O	O
540	O	O
,	O	O
000	O	O
women	O	O
born	O	O
between	O	O
1941	O	O
and	O	O
1981	O	O
.	O	O

all	O	O
women	O	O
who	O	O
had	O	O
a	O	O
recorded	O	O
diagnosis	O	O
of	O	O
deep	O	O
-	O	O
vein	O	O
thrombosis	O	O
,	O	O
venous	O	O
thrombosis	O	O
not	O	O
otherwise	O	O
specified	O	O
,	O	O
or	O	O
pulmonary	O	O
embolus	O	O
during	O	O
the	O	O
study	O	O
period	O	O
,	O	O
and	O	O
who	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
an	O	O
anticoagulant	O	O
were	O	O
identified	O	O
as	O	O
potential	O	O
cases	O	O
of	O	O
vte	O	O
.	O	O

we	O	O
did	O	O
a	O	O
cohort	O	O
analysis	O	O
to	O	O
estimate	O	O
and	O	O
compare	O	O
incidence	O	O
of	O	O
vte	O	O
in	O	O
users	O	O
of	O	O
the	O	O
main	O	O
oc	B-chem	B-chem
preparations	O	O
,	O	O
and	O	O
a	O	O
nested	O	O
case	O	O
-	O	O
control	O	O
study	O	O
to	O	O
calculate	O	O
the	O	O
odds	O	O
ratios	O	O
of	O	O
vte	O	O
associated	O	O
with	O	O
use	O	O
of	O	O
different	O	O
types	O	O
of	O	O
oc	B-chem	B-chem
,	O	O
after	O	O
adjustment	O	O
for	O	O
potential	O	O
confounding	O	O
factors	O	O
.	O	O

in	O	O
the	O	O
case	O	O
-	O	O
control	O	O
study	O	O
,	O	O
we	O	O
matched	O	O
cases	O	O
to	O	O
controls	O	O
by	O	O
exact	O	O
year	O	O
of	O	O
birth	O	O
,	O	O
practice	O	O
,	O	O
and	O	O
current	O	O
use	O	O
of	O	O
ocs	B-chem	B-chem
.	O	O

we	O	O
used	O	O
a	O	O
multiple	O	O
logistic	O	O
regression	O	O
model	O	O
that	O	O
included	O	O
body	O	O
-	O	O
mass	O	O
index	O	O
,	O	O
number	O	O
of	O	O
cycles	O	O
,	O	O
change	O	O
in	O	O
type	O	O
of	O	O
oc	B-chem	B-chem
prescribed	O	O
within	O	O
3	O	O
months	O	O
of	O	O
the	O	O
event	O	O
,	O	O
previous	O	O
pregnancy	O	O
,	O	O
and	O	O
concurrent	O	O
disease	O	O
.	O	O

findings	O	O
:	O	O

85	O	O
women	O	O
met	O	O
the	O	O
inclusion	O	O
criteria	O	O
for	O	O
vte	O	O
,	O	O
two	O	O
of	O	O
whom	O	O
were	O	O
users	O	O
of	O	O
progestagen	B-chem	B-chem
-	O	O
only	O	O
ocs	B-chem	O
.	O	O

of	O	O
the	O	O
83	O	O
cases	O	O
of	O	O
vte	O	O
associated	O	O
with	O	O
use	O	O
of	O	O
combined	O	O
ocs	B-chem	B-chem
,	O	O
43	O	O
were	O	O
recorded	O	O
as	O	O
deep	O	O
-	O	O
vein	O	O
thrombosis	O	O
,	O	O
35	O	O
as	O	O
pulmonary	O	O
thrombosis	O	O
,	O	O
and	O	O
five	O	O
as	O	O
venous	O	O
thrombosis	O	O
not	O	O
otherwise	O	O
specified	O	O
.	O	O

the	O	O
crude	O	O
rate	O	O
of	O	O
vte	O	O
per	O	O
10	O	O
,	O	O
000	O	O
woman	O	O
-	O	O
years	O	O
was	O	O
4	O	O
.	O	O
10	O	O
in	O	O
current	O	O
users	O	O
of	O	O
any	O	O
oc	B-chem	B-chem
,	O	O
3	O	O
.	O	O
10	O	O
in	O	O
users	O	O
of	O	O
second	O	O
-	O	O
generation	O	O
ocs	B-chem	B-chem
,	O	O
and	O	O
4	O	O
.	O	O
96	O	O
in	O	O
users	O	O
of	O	O
third	O	O
-	O	O
generation	O	O
preparations	O	O
.	O	O

after	O	O
adjustment	O	O
for	O	O
age	O	O
,	O	O
the	O	O
rate	O	O
ratio	O	O
of	O	O
vte	O	O
in	O	O
users	O	O
of	O	O
third	O	O
-	O	O
generation	O	O
relative	O	O
to	O	O
second	O	O
-	O	O
generation	O	O
ocs	B-chem	B-chem
was	O	O
1	O	O
.	O	O
68	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
1	O	O
.	O	O
04	O	O
-	O	O
2	O	O
.	O	O
75	O	O
)	O	O
.	O	O

logistic	O	O
regression	O	O
showed	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
risk	O	O
of	O	O
vte	O	O
between	O	O
users	O	O
of	O	O
third	O	O
-	O	O
generation	O	O
and	O	O
second	O	O
-	O	O
generation	O	O
ocs	B-chem	O
.	O	O

among	O	O
users	O	O
of	O	O
third	O	O
-	O	O
generation	O	O
progestagens	B-chem	B-chem
,	O	O
the	O	O
risk	O	O
of	O	O
vte	O	O
was	O	O
higher	O	O
in	O	O
users	O	O
of	O	O
desogestrel	B-chem	B-chem
with	O	O
20	O	O
g	O	O
ethinyloestradiol	B-chem	B-chem
than	O	O
in	O	O
users	O	O
of	O	O
gestodene	B-chem	B-chem
or	O	O
desogestrel	B-chem	B-chem
with	O	O
30	O	O
g	O	O
ethinyloestradiol	B-chem	B-chem
.	O	O

with	O	O
all	O	O
second	O	O
-	O	O
generation	O	O
ocs	B-chem	B-chem
as	O	O
the	O	O
reference	O	O
,	O	O
the	O	O
odds	O	O
ratios	O	O
for	O	O
vte	O	O
were	O	O
3	O	O
.	O	O
49	O	O
(	O	O
1	O	O
.	O	O
21	O	O
-	O	O
10	O	O
.	O	O
12	O	O
)	O	O
for	O	O
desogestrel	B-chem	B-chem
plus	O	O
20	O	O
g	O	O
ethinyloestradiol	B-chem	B-chem
and	O	O
1	O	O
.	O	O
18	O	O
(	O	O
0	O	O
.	O	O
66	O	O
-	O	O
2	O	O
.	O	O
17	O	O
)	O	O
for	O	O
the	O	O
other	O	O
third	O	O
-	O	O
generation	O	O
progestagens	B-chem	B-chem
.	O	O

interpretation	O	O
:	O	O

the	O	O
previously	O	O
reported	O	O
increase	O	O
in	O	O
odds	O	O
ratio	O	O
associated	O	O
with	O	O
third	O	O
-	O	O
generation	O	O
ocs	B-chem	B-chem
when	O	O
compared	O	O
with	O	O
second	O	O
-	O	O
generation	O	O
products	O	O
is	O	O
likely	O	O
to	O	O
have	O	O
been	O	O
the	O	O
result	O	O
of	O	O
residual	O	O
confounding	O	O
by	O	O
age	O	O
.	O	O

the	O	O
increased	O	O
odds	O	O
ratio	O	O
associated	O	O
with	O	O
products	O	O
containing	O	O
20	O	O
micrograms	O	O
ethinyloestradiol	B-chem	B-chem
and	O	O
desogestrel	B-chem	B-chem
compared	O	O
with	O	O
the	O	O
30	O	O
micrograms	O	O
product	O	O
is	O	O
biologically	O	O
implausible	O	O
,	O	O
and	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
preferential	O	O
prescribing	O	O
and	O	O
,	O	O
thus	O	O
,	O	O
confounding	O	O
.	O	O

mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
augments	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
electrographic	O	O
seizure	O	O
but	O	O
protects	O	O
against	O	O
brain	O	O
damage	O	O
in	O	O
rats	O	O
.	O	O

1	O	O
.	O	O

the	O	O
authors	O	O
examined	O	O
the	O	O
anticonvulsant	O	O
effects	O	O
of	O	O
mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
on	O	O
the	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
seizure	O	O
model	O	O
.	O	O

intraperitoneal	O	O
injection	O	O
of	O	O
pilocarpine	B-chem	B-chem
(	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
induced	O	O
tonic	O	O
and	O	O
clonic	O	O
seizure	O	O
.	O	O

scopolamine	B-chem	B-chem
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
pentobarbital	B-chem	B-chem
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
prevented	O	O
development	O	O
of	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
behavioral	O	O
seizure	O	O
but	O	O
mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
(	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
did	O	O
not	O	O
.	O	O

2	O	O
.	O	O

an	O	O
electrical	O	O
seizure	O	O
measured	O	O
with	O	O
hippocampal	O	O
eeg	O	O
appeared	O	O
in	O	O
the	O	O
pilocarpine	B-chem	B-chem
-	O	O
treated	O	O
group	O	O
.	O	O

scopolamine	B-chem	B-chem
and	O	O
pentobarbital	B-chem	B-chem
blocked	O	O
the	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
electrographic	O	O
seizure	O	O
,	O	O
mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
treatment	O	O
augmented	O	O
the	O	O
electrographic	O	O
seizure	O	O
induced	O	O
by	O	O
pilocarpine	B-chem	B-chem
.	O	O

3	O	O
.	O	O

brain	O	O
damage	O	O
was	O	O
assessed	O	O
by	O	O
examining	O	O
the	O	O
hippocampus	O	O
microscopically	O	O
.	O	O

pilocarpine	B-chem	B-chem
produced	O	O
neuronal	O	O
death	O	O
in	O	O
the	O	O
hippocampus	O	O
,	O	O
which	O	O
showed	O	O
pyknotic	O	O
changes	O	O
.	O	O

pentobarbital	B-chem	B-chem
,	O	O
scopolamine	B-chem	B-chem
and	O	O
mk	B-chem	B-chem
-	I-chem	I-chem
801	I-chem	I-chem
protected	O	O
the	O	O
brain	O	O
damage	O	O
by	O	O
pilocarpine	B-chem	B-chem
,	O	O
though	O	O
in	O	O
the	O	O
mk	B-chem	B-chem
-	I-chem	O
801	I-chem	I-chem
-	O	O
treated	O	O
group	O	O
,	O	O
the	O	O
pyramidal	O	O
cells	O	O
of	O	O
hippocampus	O	O
appeared	O	O
darker	O	O
than	O	O
normal	O	O
.	O	O

in	O	O
all	O	O
treatments	O	O
,	O	O
granule	O	O
cells	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
were	O	O
not	O	O
affected	O	O
.	O	O

4	O	O
.	O	O

these	O	O
results	O	O
indicate	O	O
that	O	O
status	O	O
epilepticus	O	O
induced	O	O
by	O	O
pilocarpine	B-chem	B-chem
is	O	O
initiated	O	O
by	O	O
cholinergic	O	O
overstimulation	O	O
and	O	O
propagated	O	O
by	O	O
glutamatergic	O	O
transmission	O	O
,	O	O
the	O	O
elevation	O	O
of	O	O
which	O	O
may	O	O
cause	O	O
brain	O	O
damage	O	O
through	O	O
an	O	O
excitatory	O	O
nmda	B-chem	B-chem
receptor	O	O
-	O	O
mediated	O	O
mechanism	O	O
.	O	O

paclitaxel	B-chem	B-chem
,	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
,	O	O
and	O	O
folinic	B-chem	B-chem
acid	I-chem	I-chem
in	O	O
metastatic	O	O
breast	O	O
cancer	O	O
:	O	O
bre	O	O
-	O	O
26	O	O
,	O	O
a	O	O
phase	O	O
ii	O	O
trial	O	O
.	O	O

5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
plus	O	O
folinic	B-chem	B-chem
acid	I-chem	I-chem
and	O	O
paclitaxel	B-chem	B-chem
(	O	O
taxol	B-chem	B-chem
;	O	O
bristol	O	O
-	O	O
myers	O	O
squibb	O	O
company	O	O
,	O	O
princeton	O	O
,	O	O
nj	O	O
)	O	O
are	O	O
effective	O	O
salvage	O	O
therapies	O	O
for	O	O
metastatic	O	O
breast	O	O
cancer	O	O
patients	O	O
.	O	O

paclitaxel	B-chem	B-chem
and	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
have	O	O
additive	O	O
cytotoxicity	O	O
in	O	O
mcf	O	O
-	O	O
7	O	O
cell	O	O
lines	O	O
.	O	O

we	O	O
performed	O	O
a	O	O
phase	O	O
ii	O	O
trial	O	O
of	O	O
paclitaxel	B-chem	B-chem
175	O	O
mg	O	O
/	O	O
m2	O	O
over	O	O
3	O	O
hours	O	O
on	O	O
day	O	O
i	O	O
followed	O	O
by	O	O
folinic	B-chem	B-chem
acid	I-chem	I-chem
300	O	O
mg	O	O
over	O	O
1	O	O
hour	O	O
before	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
350	O	O
mg	O	O
/	O	O
m2	O	O
on	O	O
days	O	O
1	O	O
to	O	O
3	O	O
every	O	O
28	O	O
days	O	O
(	O	O
tfl	O	O
)	O	O
in	O	O
women	O	O
with	O	O
metastatic	O	O
breast	O	O
cancer	O	O
.	O	O

analysis	O	O
is	O	O
reported	O	O
on	O	O
37	O	O
patients	O	O
with	O	O
a	O	O
minimum	O	O
of	O	O
6	O	O
months	O	O
follow	O	O
-	O	O
up	O	O
who	O	O
received	O	O
a	O	O
total	O	O
of	O	O
192	O	O
cycles	O	O
of	O	O
tfl	O	O
:	O	O
nine	O	O
cycles	O	O
(	O	O
5	O	O
%	O	O
)	O	O
were	O	O
associated	O	O
with	O	O
grade	O	O
3	O	O
/	O	O
4	O	O
neutropenia	O	O
requiring	O	O
hospitalization	O	O
;	O	O
seven	O	O
(	O	O
4	O	O
%	O	O
)	O	O
cycles	O	O
in	O	O
two	O	O
patients	O	O
required	O	O
granulocyte	B-chem	O
colony	I-chem	O
-	I-chem	O
stimulating	I-chem	O
factor	I-chem	O
due	O	O
to	O	O
neutropenia	O	O
;	O	O
no	O	O
patient	O	O
required	O	O
platelet	O	O
transfusions	O	O
.	O	O

grade	O	O
3	O	O
/	O	O
4	O	O
nonhematologic	O	O
toxicities	O	O
were	O	O
uncommon	O	O
.	O	O

among	O	O
the	O	O
34	O	O
patients	O	O
evaluable	O	O
for	O	O
response	O	O
,	O	O
there	O	O
were	O	O
three	O	O
complete	O	O
responses	O	O
(	O	O
9	O	O
%	O	O
)	O	O
and	O	O
18	O	O
partial	O	O
responses	O	O
(	O	O
53	O	O
%	O	O
)	O	O
for	O	O
an	O	O
overall	O	O
response	O	O
rate	O	O
of	O	O
62	O	O
%	O	O
.	O	O

of	O	O
the	O	O
19	O	O
evaluable	O	O
patients	O	O
with	O	O
prior	O	O
doxorubicin	B-chem	B-chem
exposure	O	O
,	O	O
11	O	O
(	O	O
58	O	O
%	O	O
)	O	O
responded	O	O
compared	O	O
with	O	O
nine	O	O
of	O	O
15	O	O
(	O	O
60	O	O
%	O	O
)	O	O
without	O	O
prior	O	O
doxorubicin	B-chem	B-chem
.	O	O

plasma	O	O
paclitaxel	B-chem	B-chem
concentrations	O	O
were	O	O
measured	O	O
at	O	O
the	O	O
completion	O	O
of	O	O
paclitaxel	B-chem	B-chem
infusion	O	O
and	O	O
at	O	O
24	O	O
hours	O	O
in	O	O
19	O	O
patients	O	O
.	O	O

tfl	O	O
is	O	O
an	O	O
active	O	O
,	O	O
well	O	O
-	O	O
tolerated	O	O
regimen	O	O
in	O	O
metastatic	O	O
breast	O	O
cancer	O	O
.	O	O

efficacy	O	O
and	O	O
proarrhythmia	O	O
with	O	O
the	O	O
use	O	O
of	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	I-chem
sotalol	I-chem	B-chem
for	O	O
sustained	O	O
ventricular	O	O
tachyarrhythmias	O	O
.	O	O

this	O	O
study	O	O
prospectively	O	O
evaluated	O	O
the	O	O
clinical	O	O
efficacy	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
torsades	O	O
de	O	O
pointes	O	O
,	O	O
and	O	O
the	O	O
presumable	O	O
risk	O	O
factors	O	O
for	O	O
torsades	O	O
de	O	O
pointes	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	I-chem
sotalol	I-chem	B-chem
for	O	O
sustained	O	O
ventricular	O	O
tachyarrhythmias	O	O
.	O	O

eighty	O	O
-	O	O
one	O	O
consecutive	O	O
patients	O	O
(	O	O
54	O	O
with	O	O
coronary	O	O
artery	O	O
disease	O	O
,	O	O
and	O	O
20	O	O
with	O	O
dilated	O	O
cardiomyopathy	O	O
)	O	O
with	O	O
inducible	O	O
sustained	O	O
ventricular	O	O
tachycardia	O	O
or	O	O
ventricular	O	O
fibrillation	O	O
received	O	O
oral	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	O
sotalol	I-chem	B-chem
to	O	O
prevent	O	O
induction	O	O
of	O	O
the	O	O
ventricular	O	O
tachyarrhythmia	O	O
.	O	O

during	O	O
oral	O	O
loading	O	O
with	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	I-chem
sotalol	I-chem	B-chem
,	O	O
continuous	O	O
electrocardiographic	O	O
(	O	O
ecg	O	O
)	O	O
monitoring	O	O
was	O	O
performed	O	O
.	O	O

those	O	O
patients	O	O
in	O	O
whom	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	O
sotalol	I-chem	B-chem
prevented	O	O
induction	O	O
of	O	O
ventricular	O	O
tachycardia	O	O
or	O	O
ventricular	O	O
fibrillation	O	O
were	O	O
discharged	O	O
with	O	O
the	O	O
drug	O	O
and	O	O
followed	O	O
up	O	O
on	O	O
an	O	O
outpatient	O	O
basis	O	O
for	O	O
21	O	O
+	O	O
/	O	O
-	O	O

18	O	O
months	O	O
.	O	O

induction	O	O
of	O	O
the	O	O
ventricular	O	O
tachyarrhythmia	O	O
was	O	O
prevented	O	O
by	O	O
oral	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	I-chem
sotalol	I-chem	B-chem
in	O	O
35	O	O
(	O	O
43	O	O
%	O	O
)	O	O
patients	O	O
;	O	O
the	O	O
ventricular	O	O
tachyarrhythmia	O	O
remained	O	O
inducible	O	O
in	O	O
40	O	O
(	O	O
49	O	O
%	O	O
)	O	O
patients	O	O
;	O	O
and	O	O
two	O	O
(	O	O
2	O	O
.	O	O
5	O	O
%	O	O
)	O	O
patients	O	O
did	O	O
not	O	O
tolerate	O	O
even	O	O
40	O	O
mg	O	O
of	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	I-chem
sotalol	I-chem	B-chem
once	O	O
daily	O	O
.	O	O

four	O	O
(	O	O
5	O	O
%	O	O
)	O	O
patients	O	O
had	O	O
from	O	O
torsades	O	O
de	O	O
pointes	O	O
during	O	O
the	O	O
initial	O	O
oral	O	O
treatment	O	O
with	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	O
sotalol	I-chem	B-chem
.	O	O

neither	O	O
ecg	O	O
[	O	O
sinus	O	O
-	O	O
cycle	O	O
length	O	O
(	O	O
scl	O	O
)	O	O
,	O	O
qt	O	O
or	O	O
qtc	O	O
interval	O	O
,	O	O
or	O	O
u	O	O
wave	O	O
]	O	O
nor	O	O
clinical	O	O
parameters	O	O
identified	O	O
patients	O	O
at	O	O
risk	O	O
for	O	O
torsades	O	O
de	O	O
pointes	O	O
.	O	O

however	O	O
,	O	O
the	O	O
oral	O	O
dose	O	O
of	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	I-chem
sotalol	I-chem	B-chem
was	O	O
significantly	O	O
lower	O	O
in	O	O
patients	O	O
with	O	O
torsades	O	O
de	O	O
pointes	O	O
(	O	O
200	O	O
+	O	O
/	O	O
-	O	O

46	O	O
vs	O	O
.	O	O
328	O	O
+	O	O
/	O	O
-	O	O

53	O	O
mg	O	O
/	O	O
day	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0017	O	O
)	O	O
.	O	O

risk	O	O
factors	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
torsades	O	O
de	O	O
pointes	O	O
were	O	O
the	O	O
appearance	O	O
of	O	O
an	O	O
u	O	O
wave	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
049	O	O
)	O	O
,	O	O
female	O	O
gender	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
015	O	O
)	O	O
,	O	O
and	O	O
significant	O	O
dose	O	O
-	O	O
corrected	O	O
changes	O	O
of	O	O
scl	O	O
,	O	O
qt	O	O
interval	O	O
,	O	O
and	O	O
qtc	O	O
interval	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

during	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
seven	O	O
(	O	O
20	O	O
%	O	O
)	O	O
patients	O	O
had	O	O
a	O	O
nonfatal	O	O
ventricular	O	O
tachycardia	O	O
recurrence	O	O
,	O	O
and	O	O
two	O	O
(	O	O
6	O	O
%	O	O
)	O	O
patients	O	O
died	O	O
suddenly	O	O
.	O	O

one	O	O
female	O	O
patient	O	O
with	O	O
stable	O	O
cardiac	O	O
disease	O	O
had	O	O
recurrent	O	O
torsades	O	O
de	O	O
pointes	O	O
after	O	O
2	O	O
years	O	O
of	O	O
successful	O	O
treatment	O	O
with	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	O
sotalol	I-chem	B-chem
.	O	O

torsades	O	O
de	O	O
pointes	O	O
occurred	O	O
early	O	O
during	O	O
treatment	O	O
even	O	O
with	O	O
low	O	O
doses	O	O
of	O	O
oral	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	I-chem
sotalol	I-chem	B-chem
.	O	O

pronounced	O	O
changes	O	O
in	O	O
the	O	O
surface	O	O
ecg	O	O
(	O	O
cycle	O	O
length	O	O
,	O	O
qt	O	O
,	O	O
and	O	O
qtc	O	B-chem
)	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
dose	O	O
of	O	O
oral	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	I-chem
sotalol	I-chem	B-chem
might	O	O
identify	O	O
a	O	O
subgroup	O	O
of	O	O
patients	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
for	O	O
torsades	O	O
de	O	O
pointes	O	O
.	O	O

other	O	O
ecg	O	O
parameters	O	O
before	O	O
the	O	O
application	O	O
of	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	O
sotalol	I-chem	B-chem
did	O	O
not	O	O
identify	O	O
patients	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
torsades	O	O
de	O	O
pointes	O	O
.	O	O

recurrence	O	O
rates	O	O
of	O	O
ventricular	O	O
tachyarrhythmias	O	O
are	O	O
high	O	O
despite	O	O
complete	O	O
suppression	O	O
of	O	O
the	O	O
arrhythmia	O	O
during	O	O
programmed	O	O
stimulation	O	O
.	O	O

therefore	O	O
programmed	O	O
electrical	O	O
stimulation	O	O
in	O	O
the	O	O
case	O	O
of	O	O
d	B-chem	O
,	I-chem	O
l	I-chem	B-chem
-	I-chem	O
sotalol	I-chem	B-chem
seems	O	O
to	O	O
be	O	O
of	O	O
limited	O	O
prognostic	O	O
value	O	O
.	O	O

chronic	O	O
hyperprolactinemia	O	O
and	O	O
changes	O	O
in	O	O
dopamine	B-chem	B-chem
neurons	O	O
.	O	O

the	O	O
tuberoinfundibular	O	O
dopaminergic	O	O
(	O	O
tida	O	O
)	O	O
system	O	O
is	O	O
known	O	O
to	O	O
inhibit	O	O
prolactin	O	O
(	O	O
prl	O	O
)	O	O
secretion	O	O
.	O	O

in	O	O
young	O	O
animals	O	O
this	O	O
system	O	O
responds	O	O
to	O	O
acute	O	O
elevations	O	O
in	O	O
serum	O	O
prl	O	O
by	O	O
increasing	O	O
its	O	O
activity	O	O
.	O	O

however	O	O
,	O	O
this	O	O
responsiveness	O	O
is	O	O
lost	O	O
in	O	O
aging	O	O
rats	O	O
with	O	O
chronically	O	O
high	O	O
serum	O	O
prl	O	O
levels	O	O
.	O	O

the	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
induce	O	O
hyperprolactinemia	O	O
in	O	O
rats	O	O
for	O	O
extended	O	O
periods	O	O
of	O	O
time	O	O
and	O	O
examine	O	O
its	O	O
effects	O	O
on	O	O
dopaminergic	O	O
systems	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

hyperprolactinemia	O	O
was	O	O
induced	O	O
by	O	O
treatment	O	O
with	O	O
haloperidol	B-chem	B-chem
,	O	O
a	O	O
dopamine	B-chem	B-chem
receptor	O	O
antagonist	O	O
,	O	O
and	O	O
palkovits	O	O
'	O	O
microdissection	O	O
technique	O	O
in	O	O
combination	O	O
with	O	O
high	O	O
-	O	O
performance	O	O
liquid	O	O
chromatography	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
neurotransmitter	O	O
concentrations	O	O
in	O	O
several	O	O
areas	O	O
of	O	O
the	O	O
brain	O	O
.	O	O

after	O	O
6	O	O
months	O	O
of	O	O
hyperprolactinemia	O	O
,	O	O
dopamine	B-chem	B-chem
(	O	O
da	B-chem	B-chem
)	O	O
concentrations	O	O
in	O	O
the	O	O
median	O	O
eminence	O	O
(	O	O
me	O	O
)	O	O
increased	O	O
by	O	O
84	O	O
%	O	O
over	O	O
the	O	O
control	O	O
group	O	O
.	O	O

nine	O	O
months	O	O
of	O	O
hyperprolactinemia	O	O
produced	O	O
a	O	O
50	O	O
%	O	O
increase	O	O
in	O	O
da	B-chem	B-chem
concentrations	O	O
in	O	O
the	O	O
me	O	O
over	O	O
the	O	O
control	O	O
group	O	O
.	O	O

however	O	O
,	O	O
da	B-chem	B-chem
response	O	O
was	O	O
lost	O	O
if	O	O
a	O	O
9	O	O
-	O	O
month	O	O
long	O	O
haloperidol	B-chem	B-chem
-	O	O
induced	O	O
hyperprolactinemia	O	O
was	O	O
followed	O	O
by	O	O
a	O	O
1	O	O
1	O	O
/	O	O
2	O	O
month	O	O
-	O	O
long	O	O
extremely	O	O
high	O	O
increase	O	O
in	O	O
serum	O	O
prl	O	O
levels	O	O
produced	O	O
by	O	O
implantation	O	O
of	O	O
mmq	O	O
cells	O	O
under	O	O
the	O	O
kidney	O	O
capsule	O	O
.	O	O

there	O	O
was	O	O
no	O	O
change	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
da	B-chem	B-chem
,	O	O
norepinephrine	B-chem	B-chem
(	O	O
ne	B-chem	B-chem
)	O	O
,	O	O
serotonin	B-chem	B-chem
(	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
)	O	O
,	O	O
or	O	O
their	O	O
metabolites	O	O
in	O	O
the	O	O
arcuate	O	O
nucleus	O	O
(	O	O
an	O	O
)	O	O
,	O	O
medial	O	O
preoptic	O	O
area	O	O
(	O	O
mpa	O	O
)	O	O
,	O	O
caudate	O	O
putamen	O	O
(	O	O
cp	O	B-chem
)	O	O
,	O	O
substantia	O	O
nigra	O	O
(	O	O
sn	O	B-chem
)	O	O
,	O	O
and	O	O
zona	O	O
incerta	O	O
(	O	O
zi	O	O
)	O	O
,	O	O
except	O	O
for	O	O
a	O	O
decrease	O	O
in	O	O
5	B-chem	B-chem
-	I-chem	I-chem
hydroxyindoleacetic	I-chem	I-chem
acid	I-chem	I-chem
(	O	O
5	B-chem	B-chem
-	I-chem	I-chem
hiaa	I-chem	I-chem
)	O	O
in	O	O
the	O	O
an	O	O
after	O	O
6	O	O
-	O	O
months	O	O
of	O	O
hyperprolactinemia	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
da	B-chem	B-chem
concentrations	O	O
in	O	O
the	O	O
an	O	O
after	O	O
9	O	O
-	O	O
months	O	O
of	O	O
hyperprolactinemia	O	O
.	O	O

these	O	O
results	O	O
demonstrate	O	O
that	O	O
hyperprolactinemia	O	O
specifically	O	O
affects	O	O
tida	O	O
neurons	O	O
and	O	O
these	O	O
effects	O	O
vary	O	O
,	O	O
depending	O	O
on	O	O
the	O	O
duration	O	O
and	O	O
intensity	O	O
of	O	O
hyperprolactinemia	O	O
.	O	O

the	O	O
age	O	O
-	O	O
related	O	O
decrease	O	O
in	O	O
hypothalamic	O	O
dopamine	B-chem	B-chem
function	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
increases	O	O
in	O	O
prl	O	O
secretion	O	O
.	O	O

treatment	O	O
-	O	O
related	O	O
disseminated	O	O
necrotizing	O	O
leukoencephalopathy	O	O
with	O	O
characteristic	O	O
contrast	O	O
enhancement	O	O
of	O	O
the	O	O
white	O	O
matter	O	O
.	O	O

this	O	O
report	O	O
describes	O	O
unique	O	O
contrast	O	O
enhancement	O	O
of	O	O
the	O	O
white	O	O
matter	O	O
on	O	O
t1	O	O
-	O	O
weighted	O	O
magnetic	O	O
resonance	O	O
images	O	O
of	O	O
two	O	O
patients	O	O
with	O	O
disseminated	O	O
necrotizing	O	O
leukoencephalopathy	O	O
,	O	O
which	O	O
developed	O	O
from	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
treated	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
methotrexate	B-chem	B-chem
.	O	O

in	O	O
both	O	O
patients	O	O
,	O	O
the	O	O
enhancement	O	O
was	O	O
more	O	O
pronounced	O	O
near	O	O
the	O	O
base	O	O
of	O	O
the	O	O
brain	O	O
than	O	O
at	O	O
the	O	O
vertex	O	O
.	O	O

necropsy	O	O
of	O	O
the	O	O
first	O	O
case	O	O
revealed	O	O
loss	O	O
of	O	O
myelination	O	O
and	O	O
necrosis	O	O
of	O	O
the	O	O
white	O	O
matter	O	O
.	O	O

possible	O	O
mechanisms	O	O
causing	O	O
such	O	O
a	O	O
leukoencephalopathy	O	O
are	O	O
discussed	O	O
.	O	O

thrombotic	O	O
complications	O	O
in	O	O
acute	O	O
promyelocytic	O	O
leukemia	O	O
during	O	O
all	B-chem	O
-	I-chem	O
trans	I-chem	B-chem
-	I-chem	I-chem
retinoic	I-chem	I-chem
acid	I-chem	I-chem
therapy	O	O
.	O	O

a	O	O
case	O	O
of	O	O
acute	O	O
renal	O	O
failure	O	O
,	O	O
due	O	O
to	O	O
occlusion	O	O
of	O	O
renal	O	O
vessels	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
acute	O	O
promyelocytic	O	O
leukemia	O	O
(	O	O
apl	O	O
)	O	O
treated	O	O
with	O	O
all	B-chem	O
-	I-chem	O
trans	I-chem	I-chem
-	I-chem	I-chem
retinoic	I-chem	I-chem
acid	I-chem	I-chem
(	O	O
atra	B-chem	B-chem
)	O	O
and	O	O
tranexamic	B-chem	B-chem
acid	I-chem	I-chem
has	O	O
been	O	O
described	O	O
recently	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	O	O
renal	O	O
failure	O	O
in	O	O
an	O	O
apl	O	O
patient	O	O
treated	O	O
with	O	O
atra	B-chem	B-chem
alone	O	O
.	O	O

this	O	O
case	O	O
further	O	O
supports	O	O
the	O	O
concern	O	O
about	O	O
thromboembolic	O	O
complications	O	O
associated	O	O
with	O	O
atra	B-chem	B-chem
therapy	O	O
in	O	O
apl	O	O
patients	O	O
.	O	O

the	O	O
patients	O	O
,	O	O
a	O	O
43	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
,	O	O
presented	O	O
all	O	O
the	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
apl	O	O
and	O	O
was	O	O
included	O	O
in	O	O
a	O	O
treatment	O	O
protocol	O	O
with	O	O
atra	B-chem	B-chem
.	O	O

after	O	O
10	O	O
days	O	O
of	O	O
treatment	O	O
,	O	O
he	O	O
developed	O	O
acute	O	O
renal	O	O
failure	O	O
that	O	O
was	O	O
completely	O	O
reversible	O	O
after	O	O
complete	O	O
remission	O	O
of	O	O
apl	O	O
was	O	O
achieved	O	O
and	O	O
therapy	O	O
discontinued	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
atra	B-chem	B-chem
is	O	O
a	O	O
valid	O	O
therapeutic	O	O
choice	O	O
for	O	O
patients	O	O
with	O	O
apl	O	O
,	O	O
although	O	O
the	O	O
procoagulant	O	O
tendency	O	O
is	O	O
not	O	O
completely	O	O
corrected	O	O
.	O	O

thrombotic	O	O
events	O	O
,	O	O
however	O	O
,	O	O
could	O	O
be	O	O
avoided	O	O
by	O	O
using	O	O
low	O	O
-	O	O
dose	O	O
heparin	B-chem	B-chem
.	O	O

pupillary	O	O
changes	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
stimulant	O	O
-	O	O
induced	O	O
mania	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

a	O	O
30	O	O
-	O	O
year	O	O
-	O	O
old	O	O
cocaine	B-chem	B-chem
-	O	O
dependent	O	O
man	O	O
who	O	O
was	O	O
a	O	O
subject	O	O
in	O	O
a	O	O
study	O	O
evaluating	O	O
the	O	O
anticraving	O	O
efficacy	O	O
of	O	O
the	O	O
stimulant	O	O
medication	O	O
diethylpropion	B-chem	B-chem
(	O	O
dep	B-chem	B-chem
)	O	O
became	O	O
manic	O	O
during	O	O
his	O	O
second	O	O
week	O	O
on	O	O
the	O	O
study	O	O
drug	O	O
.	O	O

pupillometric	O	O
changes	O	O
while	O	O
on	O	O
dep	B-chem	O
,	O	O
especially	O	O
changes	O	O
in	O	O
the	O	O
total	O	O
power	O	O
of	O	O
pupillary	O	O
oscillation	O	O
,	O	O
were	O	O
dramatically	O	O
different	O	O
than	O	O
those	O	O
observed	O	O
in	O	O
the	O	O
eight	O	O
other	O	O
study	O	O
subjects	O	O
who	O	O
did	O	O
not	O	O
become	O	O
manic	O	O
.	O	O

the	O	O
large	O	O
changes	O	O
in	O	O
total	O	O
power	O	O
of	O	O
pupillary	O	O
oscillation	O	O
occurred	O	O
a	O	O
few	O	O
days	O	O
before	O	O
the	O	O
patient	O	O
became	O	O
fully	O	O
manic	O	O
.	O	O

such	O	O
medication	O	O
-	O	O
associated	O	O
changes	O	O
in	O	O
the	O	O
total	O	O
power	O	O
of	O	O
pupillary	O	O
oscillation	O	O
might	O	O
be	O	O
of	O	O
utility	O	O
in	O	O
identifying	O	O
persons	O	O
at	O	O
risk	O	O
for	O	O
manic	O	O
-	O	O
like	O	O
adverse	O	O
effects	O	O
during	O	O
the	O	O
medical	O	O
use	O	O
of	O	O
psychomotor	O	O
stimulants	O	O
or	O	O
sympathomimetic	O	O
agents	O	O
.	O	O

the	O	O
negative	O	O
mucosal	O	O
potential	O	O
:	O	O
separating	O	O
central	O	O
and	O	O
peripheral	O	O
effects	O	O
of	O	O
nsaids	O	O
in	O	O
man	O	O
.	O	O

objective	O	O
:	O	O
we	O	O
wanted	O	O
to	O	O
test	O	O
whether	O	O
assessment	O	O
of	O	O
both	O	O
a	O	O
central	O	O
pain	O	O
-	O	O
related	O	O
signal	O	O
(	O	O
chemo	O	O
-	O	O
somatosensory	O	O
evoked	O	O
potential	O	O
,	O	O
cssep	O	O
)	O	O
and	O	O
a	O	O
concomitantly	O	O
recorded	O	O
peripheral	O	O
signal	O	O
(	O	O
negative	O	O
mucosal	O	O
potential	O	O
,	O	O
nmp	O	O
)	O	O
allows	O	O
for	O	O
separation	O	O
of	O	O
central	O	O
and	O	O
peripheral	O	O
effects	O	O
of	O	O
nsaids	O	O
.	O	O

for	O	O
this	O	O
purpose	O	O
,	O	O
experimental	O	O
conditions	O	O
were	O	O
created	O	O
in	O	O
which	O	O
nsaids	O	O
had	O	O
previously	O	O
been	O	O
observed	O	O
to	O	O
produce	O	O
effects	O	O
on	O	O
phasic	O	O
and	O	O
tonic	O	O
pain	O	O
by	O	O
either	O	O
central	O	O
or	O	O
peripheral	O	O
mechanisms	O	O
.	O	O

methods	O	O
:	O	O

according	O	O
to	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
randomised	O	O
,	O	O
controlled	O	O
,	O	O
threefold	O	O
cross	O	O
-	O	O
over	O	O
design	O	O
,	O	O
18	O	O
healthy	O	O
subjects	O	O
(	O	O
11	O	O
males	O	O
,	O	O
7	O	O
females	O	O
;	O	O
mean	O	O
age	O	O
26	O	O
years	O	O
)	O	O
received	O	O
either	O	O
placebo	O	O
,	O	O
400	O	O
mg	O	O
ibuprofen	B-chem	B-chem
,	O	O
or	O	O
800	O	O
mg	O	O
ibuprofen	B-chem	B-chem
.	O	O

phasic	O	O
pain	O	O
was	O	O
applied	O	O
by	O	O
means	O	O
of	O	O
short	O	O
pulses	O	O
of	O	O
co2	B-chem	B-chem
to	O	O
the	O	O
nasal	O	O
mucosa	O	O
(	O	O
stimulus	O	O
duration	O	O
500	O	O
ms	O	O
,	O	O
interval	O	O
approximately	O	O
60	O	O
s	O	O
)	O	O
,	O	O
and	O	O
tonic	O	O
pain	O	O
was	O	O
induced	O	O
in	O	O
the	O	O
nasal	O	O
cavity	O	O
by	O	O
means	O	O
of	O	O
dry	O	O
air	O	O
of	O	O
controlled	O	O
temperature	O	O
,	O	O
humidity	O	O
and	O	O
flow	O	O
rate	O	O
(	O	O
22	O	O
degrees	O	O
c	O	O
,	O	O
0	O	O
%	O	O
relative	O	O
humidity	O	O
,	O	O
145	O	O
ml	O	O
.	O	O
s	O	O
-	O	O
1	O	O
)	O	O
.	O	O

both	O	O
csseps	O	O
as	O	O
central	O	O
and	O	O
nmps	O	O
as	O	O
peripheral	O	O
correlates	O	O
of	O	O
pain	O	O
were	O	O
obtained	O	O
in	O	O
response	O	O
to	O	O
the	O	O
co2	B-chem	B-chem
stimuli	O	O
.	O	O

additionally	O	O
,	O	O
the	O	O
subjects	O	O
rated	O	O
the	O	O
intensity	O	O
of	O	O
both	O	O
phasic	O	O
and	O	O
tonic	O	O
pain	O	O
by	O	O
means	O	O
of	O	O
visual	O	O
analogue	O	O
scales	O	O
.	O	O

results	O	O
:	O	O

as	O	O
described	O	O
earlier	O	O
,	O	O
administration	O	O
of	O	O
ibuprofen	B-chem	B-chem
was	O	O
followed	O	O
by	O	O
a	O	O
decrease	O	O
in	O	O
tonic	O	O
pain	O	O
but	O	O
-	O	O
relative	O	O
to	O	O
placebo	O	O
-	O	O
an	O	O
increase	O	O
in	O	O
correlates	O	O
of	O	O
phasic	O	O
pain	O	O
,	O	O
indicating	O	O
a	O	O
specific	O	O
effect	O	O
of	O	O
ibuprofen	B-chem	B-chem
on	O	O
the	O	O
interaction	O	O
between	O	O
the	O	O
pain	O	O
stimuli	O	O
under	O	O
these	O	O
special	O	O
experimental	O	O
conditions	O	O
.	O	O

based	O	O
on	O	O
the	O	O
similar	O	O
behaviour	O	O
of	O	O
cssep	O	O
and	O	O
nmp	O	O
,	O	O
it	O	O
was	O	O
concluded	O	O
that	O	O
the	O	O
pharmacological	O	O
process	O	O
underlying	O	O
this	O	O
phenomenon	O	O
was	O	O
localised	O	O
in	O	O
the	O	O
periphery	O	O
.	O	O

by	O	O
means	O	O
of	O	O
the	O	O
simultaneous	O	O
recording	O	O
of	O	O
interrelated	O	O
peripheral	O	O
and	O	O
central	O	O
electrophysiologic	O	O
correlates	O	O
of	O	O
nociception	O	O
,	O	O
it	O	O
was	O	O
possible	O	O
to	O	O
separate	O	O
central	O	O
and	O	O
peripheral	O	O
effects	O	O
of	O	O
an	O	O
nsaid	O	O
.	O	O

the	O	O
major	O	O
advantage	O	O
of	O	O
this	O	O
pain	O	O
model	O	O
is	O	O
the	O	O
possibility	O	O
of	O	O
obtaining	O	O
peripheral	O	O
pain	O	O
-	O	O
related	O	O
activity	O	O
directly	O	O
using	O	O
a	O	O
non	O	O
-	O	O
invasive	O	O
technique	O	O
in	O	O
humans	O	O
.	O	O

acute	O	O
severe	O	O
depression	O	O
following	O	O
peri	O	O
-	O	O
operative	O	O
ondansetron	B-chem	B-chem
.	O	O

a	O	O
41	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
a	O	O
strong	O	O
history	O	O
of	O	O
postoperative	O	O
nausea	O	O
and	O	O
vomiting	O	O
presented	O	O
for	O	O
abdominal	O	O
hysterectomy	O	O
3	O	O
months	O	O
after	O	O
a	O	O
previous	O	O
anaesthetic	O	O
where	O	O
ondansetron	B-chem	B-chem
prophylaxis	O	O
had	O	O
been	O	O
used	O	O
.	O	O

she	O	O
had	O	O
developed	O	O
a	O	O
severe	O	O
acute	O	O
major	O	O
depression	O	O
disorder	O	O
almost	O	O
immediately	O	O
thereafter	O	O
,	O	O
possibly	O	O
related	O	O
to	O	O
the	O	O
use	O	O
of	O	O
a	O	O
serotonin	B-chem	B-chem
antagonist	O	O
.	O	O

nine	O	O
years	O	O
before	O	O
she	O	O
had	O	O
experienced	O	O
a	O	O
self	O	O
-	O	O
limited	O	O
puerperal	O	O
depressive	O	O
episode	O	O
.	O	O

anaesthesia	O	O
with	O	O
a	O	O
propofol	B-chem	B-chem
infusion	O	O
and	O	O
avoidance	O	O
of	O	O
serotonin	B-chem	B-chem
antagonists	O	O
provided	O	O
a	O	O
nausea	O	O
-	O	O
free	O	O
postoperative	O	O
course	O	O
without	O	O
exacerbation	O	O
of	O	O
the	O	O
depression	O	O
disorder	O	O
.	O	O

hypertensive	O	O
response	O	O
during	O	O
dobutamine	B-chem	B-chem
stress	O	O
echocardiography	O	O
.	O	O

among	O	O
3	O	O
,	O	O
129	O	O
dobutamine	B-chem	B-chem
stress	O	O
echocardiographic	O	O
studies	O	O
,	O	O
a	O	O
hypertensive	O	O
response	O	O
,	O	O
defined	O	O
as	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
bp	O	O
)	O	O
>	O	O
or	O	O
=	O	O
220	O	O
mm	O	O
hg	O	O
and	O	O
/	O	O
or	O	O
diastolic	O	O
bp	O	O
>	O	O
or	O	O
=	O	O
110	O	O
mm	O	O
hg	O	O
,	O	O
occurred	O	O
in	O	O
30	O	O
patients	O	O
(	O	O
1	O	O
%	O	O
)	O	O
.	O	O

patients	O	O
with	O	O
this	O	O
response	O	O
more	O	O
often	O	O
had	O	O
a	O	O
history	O	O
of	O	O
hypertension	O	O
and	O	O
had	O	O
higher	O	O
resting	O	O
systolic	O	O
and	O	O
diastolic	O	O
bp	O	O
before	O	O
dobutamine	B-chem	B-chem
infusion	O	O
.	O	O

continuously	O	O
nebulized	O	O
albuterol	B-chem	B-chem
in	O	O
severe	O	O
exacerbations	O	O
of	O	O
asthma	O	O
in	O	O
adults	O	O
:	O	O
a	O	O
case	O	O
-	O	O
controlled	O	O
study	O	O
.	O	O

a	O	O
retrospective	O	O
,	O	O
case	O	O
-	O	O
controlled	O	O
analysis	O	O
comparing	O	O
patients	O	O
admitted	O	O
to	O	O
a	O	O
medical	O	O
intensive	O	O
care	O	O
unit	O	O
with	O	O
severe	O	O
exacerbations	O	O
of	O	O
asthma	O	O
who	O	O
received	O	O
continuously	O	O
nebulized	O	O
albuterol	B-chem	B-chem
(	O	O
cna	O	O
)	O	O
versus	O	O
intermittent	O	O
albuterol	B-chem	B-chem
(	O	O
ina	O	O
)	O	O
treatments	O	O
is	O	O
reported	O	O
.	O	O

forty	O	O
matched	O	O
pairs	O	O
of	O	O
patients	O	O
with	O	O
asthma	O	O
are	O	O
compared	O	O
.	O	O

cna	O	O
was	O	O
administered	O	O
for	O	O
a	O	O
mean	O	O
of	O	O
11	O	O
+	O	O
/	O	O
-	O	O

10	O	O
hr	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
cardiac	O	O
dysrhythmias	O	O
was	O	O
similar	O	O
between	O	O
groups	O	O
.	O	O

symptomatic	O	O
hypokalemia	O	O
did	O	O
not	O	O
occur	O	O
.	O	O

cna	O	O
patients	O	O
had	O	O
higher	O	O
heart	O	O
rates	O	O
during	O	O
treatment	O	O
,	O	O
which	O	O
may	O	O
reflect	O	O
severity	O	O
of	O	O
illness	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
intubation	O	O
was	O	O
similar	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
cna	O	O
and	O	O
ina	O	O
demonstrated	O	O
similar	O	O
profiles	O	O
with	O	O
regard	O	O
to	O	O
safety	O	O
,	O	O
morbidity	O	O
,	O	O
and	O	O
mortality	O	O
.	O	O

hyperosmolar	O	O
nonketotic	O	O
coma	O	O
precipitated	O	O
by	O	O
lithium	B-chem	B-chem
-	O	O
induced	O	O
nephrogenic	O	O
diabetes	O	O
insipidus	O	O
.	O	O

a	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
,	O	O
with	O	O
a	O	O
10	O	O
-	O	O
year	O	O
history	O	O
of	O	O
manic	O	O
depression	O	O
treated	O	O
with	O	O
lithium	B-chem	B-chem
,	O	O
was	O	O
admitted	O	O
with	O	O
hyperosmolar	O	O
,	O	O
nonketotic	O	O
coma	O	O
.	O	O

he	O	O
gave	O	O
a	O	O
five	O	O
-	O	O
year	O	O
history	O	O
of	O	O
polyuria	O	O
and	O	O
polydipsia	O	O
,	O	O
during	O	O
which	O	O
time	O	O
urinalysis	O	O
had	O	O
been	O	O
negative	O	O
for	O	O
glucose	B-chem	B-chem
.	O	O

after	O	O
recovery	O	O
from	O	O
hyperglycaemia	O	O
,	O	O
he	O	O
remained	O	O
polyuric	O	O
despite	O	O
normal	O	O
blood	O	O
glucose	B-chem	O
concentrations	O	O
;	O	O
water	O	O
deprivation	O	O
testing	O	O
indicated	O	O
nephrogenic	O	O
diabetes	O	O
insipidus	O	O
,	O	O
likely	O	O
to	O	O
be	O	O
lithium	B-chem	B-chem
-	O	O
induced	O	O
.	O	O

we	O	O
hypothesize	O	O
that	O	O
when	O	O
this	O	O
man	O	O
developed	O	O
type	O	O
2	O	O
diabetes	O	O
,	O	O
chronic	O	O
polyuria	O	O
due	O	O
to	O	O
nephrogenic	O	O
diabetes	O	O
insipidus	O	O
was	O	O
sufficient	O	O
to	O	O
precipitate	O	O
hyperosmolar	O	O
dehydration	O	O
.	O	O

effects	O	O
of	O	O
the	O	O
intracoronary	O	O
infusion	O	O
of	O	O
cocaine	B-chem	B-chem
on	O	O
left	O	O
ventricular	O	O
systolic	O	O
and	O	O
diastolic	O	O
function	O	O
in	O	O
humans	O	O
.	O	O

background	O	O
:	O	O

in	O	O
dogs	O	O
,	O	O
a	O	O
large	O	O
amount	O	O
of	O	O
intravenous	O	O
cocaine	B-chem	B-chem
causes	O	O
a	O	O
profound	O	O
deterioration	O	O
of	O	O
left	O	O
ventricular	O	O
(	O	O
lv	O	O
)	O	O
systolic	O	O
function	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
lv	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
.	O	O

this	O	O
study	O	O
was	O	O
done	O	O
to	O	O
assess	O	O
the	O	O
influence	O	O
of	O	O
a	O	O
high	O	O
intracoronary	O	O
cocaine	B-chem	B-chem
concentration	O	O
on	O	O
lv	O	O
systolic	O	O
and	O	O
diastolic	O	O
function	O	O
in	O	O
humans	O	O
.	O	O

methods	O	O
and	O	O
results	O	O
:	O	O

in	O	O
20	O	O
patients	O	O
(	O	O
14	O	O
men	O	O
and	O	O
6	O	O
women	O	O
aged	O	O
39	O	O
to	O	O
72	O	O
years	O	O
)	O	O
referred	O	O
for	O	O
cardiac	O	O
catheterization	O	O
for	O	O
the	O	O
evaluation	O	O
of	O	O
chest	O	O
pain	O	O
,	O	O
we	O	O
measured	O	O
heart	O	O
rate	O	O
,	O	O
systemic	O	O
arterial	O	O
pressure	O	O
,	O	O
lv	O	O
pressure	O	O
and	O	O
its	O	O
first	O	O
derivative	O	O
(	O	O
dp	O	O
/	O	O
dt	O	O
)	O	O
,	O	O
and	O	O
lv	O	O
volumes	O	O
and	O	O
ejection	O	O
fraction	O	O
before	O	O
and	O	O
during	O	O
the	O	O
final	O	O
2	O	O
to	O	O
3	O	O
minutes	O	O
of	O	O
a	O	O
15	O	O
-	O	O
minute	O	O
intracoronary	O	O
infusion	O	O
of	O	O
saline	O	O
(	O	O
n	O	O
=	O	O
10	O	O
,	O	O
control	O	O
subjects	O	O
)	O	O
or	O	O
cocaine	B-chem	B-chem
hydrochloride	I-chem	I-chem
1	O	O
mg	O	O
/	O	O
min	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
.	O	O

no	O	O
variable	O	O
changed	O	O
with	O	O
saline	O	O
.	O	O

with	O	O
cocaine	B-chem	B-chem
,	O	O
the	O	O
drug	O	O
concentration	O	O
in	O	O
blood	O	O
obtained	O	O
from	O	O
the	O	O
coronary	O	O
sinus	O	O
was	O	O
3	O	O
.	O	O
0	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
4	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
sd	O	O
)	O	O
mg	O	O
/	O	O
l	O	O
,	O	O
similar	O	O
in	O	O
magnitude	O	O
to	O	O
the	O	O
blood	O	O
cocaine	B-chem	B-chem
concentration	O	O
reported	O	O
in	O	O
abusers	O	O
dying	O	O
of	O	O
cocaine	B-chem	O
intoxication	O	O
.	O	O

cocaine	B-chem	B-chem
induced	O	O
no	O	O
significant	O	O
change	O	O
in	O	O
heart	O	O
rate	O	O
,	O	O
lv	O	O
dp	O	O
/	O	O
dt	O	O
(	O	O
positive	O	O
or	O	O
negative	O	O
)	O	O
,	O	O
or	O	O
lv	O	O
end	O	O
-	O	O
diastolic	O	O
volume	O	O
,	O	O
but	O	O
it	O	O
caused	O	O
an	O	O
increase	O	O
in	O	O
systolic	O	O
and	O	O
mean	O	O
arterial	O	O
pressures	O	O
,	O	O
lv	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
,	O	O
and	O	O
lv	O	O
end	O	O
-	O	O
systolic	O	O
volume	O	O
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
decrease	O	O
in	O	O
lv	O	O
ejection	O	O
fraction	O	O
.	O	O

conclusions	O	O
:	O	O

in	O	O
humans	O	O
,	O	O
the	O	O
intracoronary	O	O
infusion	O	O
of	O	O
cocaine	B-chem	B-chem
sufficient	O	O
in	O	O
amount	O	O
to	O	O
achieve	O	O
a	O	O
high	O	O
drug	O	O
concentration	O	O
in	O	O
coronary	O	O
sinus	O	O
blood	O	O
causes	O	O
a	O	O
deterioration	O	O
of	O	O
lv	O	O
systolic	O	O
and	O	O
diastolic	O	O
performance	O	O
.	O	O

heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
,	O	O
paradoxical	O	O
thromboembolism	O	O
,	O	O
and	O	O
other	O	O
side	O	O
effects	O	O
of	O	O
heparin	B-chem	B-chem
therapy	O	O
.	O	O

although	O	O
several	O	O
new	O	O
anticoagulant	O	O
drugs	O	O
are	O	O
in	O	O
development	O	O
,	O	O
heparin	B-chem	B-chem
remains	O	O
the	O	O
drug	O	O
of	O	O
choice	O	O
for	O	O
most	O	O
anticoagulation	O	O
needs	O	O
.	O	O

the	O	O
clinical	O	O
effects	O	O
of	O	O
heparin	B-chem	B-chem
are	O	O
meritorious	O	O
,	O	O
but	O	O
side	O	O
effects	O	O
do	O	O
exist	O	O
.	O	O

important	O	O
untoward	O	O
effects	O	O
of	O	O
heparin	B-chem	B-chem
therapy	O	O
including	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
,	O	O
heparin	B-chem	B-chem
-	O	O
associated	O	O
osteoporosis	O	O
,	O	O
eosinophilia	O	O
,	O	O
skin	O	O
reactions	O	O
,	O	O
allergic	O	O
reactions	O	O
other	O	O
than	O	O
thrombocytopenia	O	O
and	O	O
alopecia	O	O
will	O	O
be	O	O
discussed	O	O
in	O	O
this	O	O
article	O	O
.	O	O

nonopaque	O	O
crystal	O	O
deposition	O	O
causing	O	O
ureteric	O	O
obstruction	O	O
in	O	O
patients	O	O
with	O	O
hiv	O	O
undergoing	O	O
indinavir	B-chem	B-chem
therapy	O	O
.	O	O

objective	O	O
:	O	O
we	O	O
describe	O	O
the	O	O
unique	O	O
ct	O	O
features	O	O
of	O	O
ureteric	O	O
calculi	O	O
in	O	O
six	O	O
hiv	O	O
-	O	O
infected	O	O
patients	O	O
receiving	O	O
indinavir	B-chem	B-chem
,	O	O
the	O	O
most	O	O
commonly	O	O
used	O	O
hiv	O	O
protease	O	O
inhibitor	O	O
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
urolithiasis	O	O
.	O	O

conclusion	O	O
:	O	O

ureteric	O	O
obstruction	O	O
caused	O	O
by	O	O
precipitated	O	O
indinavir	B-chem	B-chem
crystals	O	O
may	O	O
be	O	O
difficult	O	O
to	O	O
diagnose	O	O
with	O	O
unenhanced	O	O
ct	O	O
.	O	O

the	O	O
calculi	O	O
are	O	O
not	O	O
opaque	O	O
,	O	O
and	O	O
secondary	O	O
signs	O	O
of	O	O
obstruction	O	O
may	O	O
be	O	O
absent	O	O
or	O	O
minimal	O	O
and	O	O
should	O	O
be	O	O
sought	O	O
carefully	O	O
.	O	O

images	O	O
may	O	O
need	O	O
to	O	O
be	O	O
obtained	O	O
using	O	O
i	O	O
.	O	O
v	O	O
.	O	O

contrast	O	O
material	O	O
to	O	O
enable	O	O
diagnosis	O	O
of	O	O
ureteric	O	O
stones	O	O
or	O	O
obstruction	O	O
in	O	O
patients	O	O
with	O	O
hiv	O	O
infection	O	O
who	O	O
receive	O	O
indinavir	B-chem	B-chem
therapy	O	O
.	O	O

ischemic	O	O
colitis	O	O
and	O	O
sumatriptan	B-chem	B-chem
use	O	O
.	O	O

sumatriptan	B-chem	B-chem
succinate	I-chem	I-chem
,	O	O
a	O	O
serotonin	B-chem	B-chem
-	O	O
1	O	I-chem
(	O	O
5	B-chem	B-chem
-	I-chem	I-chem
hydroxytryptamine	I-chem	I-chem
-	O	O
1	O	I-chem
)	O	O
receptor	O	O
agonist	O	O
,	O	O
is	O	O
an	O	O
antimigraine	O	O
drug	O	O
that	O	O
is	O	O
reported	O	O
to	O	O
act	O	O
by	O	O
selectively	O	O
constricting	O	O
intracranial	O	O
arteries	O	O
.	O	O

recently	O	O
,	O	O
vasopressor	O	O
responses	O	O
that	O	O
are	O	O
distinct	O	O
from	O	O
the	O	O
cranial	O	O
circulation	O	O
have	O	O
been	O	O
demonstrated	O	O
to	O	O
occur	O	O
in	O	O
the	O	O
systemic	O	O
,	O	O
pulmonary	O	O
,	O	O
and	O	O
coronary	O	O
circulations	O	O
.	O	O

cases	O	O
have	O	O
been	O	O
published	O	O
of	O	O
coronary	O	O
vasospasm	O	O
,	O	O
myocardial	O	O
ischemia	O	O
,	O	O
and	O	O
myocardial	O	O
infarction	O	O
occurring	O	O
after	O	O
sumatriptan	B-chem	B-chem
use	O	O
.	O	O

we	O	O
report	O	O
on	O	O
the	O	O
development	O	O
of	O	O
8	O	O
serious	O	O
cases	O	O
of	O	O
ischemic	O	O
colitis	O	O
in	O	O
patients	O	O
with	O	O
migraine	O	O
treated	O	O
with	O	O
sumatriptan	B-chem	B-chem
.	O	O

pallidotomy	O	O
with	O	O
the	O	O
gamma	O	O
knife	O	O
:	O	O
a	O	O
positive	O	O
experience	O	O
.	O	O

51	O	O
patients	O	O
with	O	O
medically	O	O
refractory	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
underwent	O	O
stereotactic	O	O
posteromedial	O	O
pallidotomy	O	O
between	O	O
august	O	O
1993	O	O
and	O	O
february	O	O
1997	O	O
for	O	O
treatment	O	O
of	O	O
bradykinesia	O	O
,	O	O
rigidity	O	O
,	O	O
and	O	O
l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
-	O	O
induced	O	O
dyskinesias	O	O
.	O	O

in	O	O
29	O	O
patients	O	O
,	O	O
the	O	O
pallidotomies	O	O
were	O	O
performed	O	O
with	O	O
the	O	O
leksell	O	O
gamma	O	O
knife	O	O
and	O	O
in	O	O
22	O	O
they	O	O
were	O	O
performed	O	O
with	O	O
the	O	O
standard	O	O
radiofrequency	O	O
(	O	O
rf	O	O
)	O	O
method	O	O
.	O	O

clinical	O	O
assessment	O	O
as	O	O
well	O	O
as	O	O
blinded	O	O
ratings	O	O
of	O	O
unified	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
rating	O	O
scale	O	O
(	O	O
updrs	O	O
)	O	O
scores	O	O
were	O	O
carried	O	O
out	O	O
pre	O	O
-	O	O
and	O	O
postoperatively	O	O
.	O	O

mean	O	O
follow	O	O
-	O	O
up	O	O
time	O	O
is	O	O
20	O	O
.	O	O
6	O	O
months	O	O
(	O	O
range	O	O
6	O	O
-	O	O
48	O	O
)	O	O
and	O	O
all	O	O
except	O	O
4	O	O
patients	O	O
have	O	O
been	O	O
followed	O	O
more	O	O
than	O	O
one	O	O
year	O	O
.	O	O

85	O	O
percent	O	O
of	O	O
patients	O	O
with	O	O
dyskinesias	O	O
were	O	O
relieved	O	O
of	O	O
symptoms	O	O
,	O	O
regardless	O	O
of	O	O
whether	O	O
the	O	O
pallidotomies	O	O
were	O	O
performed	O	O
with	O	O
the	O	O
gamma	O	O
knife	O	O
or	O	O
radiofrequency	O	O
methods	O	O
.	O	O

about	O	O
2	O	O
/	O	O
3	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
both	O	O
gamma	O	O
knife	O	O
and	O	O
radiofrequency	O	O
groups	O	O
showed	O	O
improvements	O	O
in	O	O
bradykinesia	O	O
and	O	O
rigidity	O	O
,	O	O
although	O	O
when	O	O
considered	O	O
as	O	O
a	O	O
group	O	O
neither	O	O
the	O	O
gamma	O	O
knife	O	O
nor	O	O
the	O	O
radiofrequency	O	O
group	O	O
showed	O	O
statistically	O	O
significant	O	O
improvements	O	O
in	O	O
updrs	O	O
scores	O	O
.	O	O

one	O	O
patient	O	O
in	O	O
the	O	O
gamma	O	O
knife	O	O
group	O	O
(	O	O
3	O	O
.	O	O
4	O	O
%	O	O
)	O	O
developed	O	O
a	O	O
homonymous	O	O
hemianopsia	O	O
9	O	O
months	O	O
following	O	O
treatment	O	O
and	O	O
5	O	O
patients	O	O
(	O	O
27	O	O
.	O	O
7	O	O
%	O	O
)	O	O
in	O	O
the	O	O
radiofrequency	O	O
group	O	O
became	O	O
transiently	O	O
confused	O	O
postoperatively	O	O
.	O	O

no	O	O
other	O	O
complications	O	O
were	O	O
seen	O	O
.	O	O

gamma	O	O
knife	O	O
pallidotomy	O	O
is	O	O
as	O	O
effective	O	O
as	O	O
radiofrequency	O	O
pallidotomy	O	O
in	O	O
controlling	O	O
certain	O	O
of	O	O
the	O	O
symptoms	O	O
of	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

it	O	O
may	O	O
be	O	O
the	O	O
only	O	O
practical	O	O
technique	O	O
available	O	O
in	O	O
certain	O	O
patients	O	O
,	O	O
such	O	O
as	O	O
those	O	O
who	O	O
take	O	O
anticoagulants	O	O
,	O	O
have	O	O
bleeding	O	O
diatheses	O	O
or	O	O
serious	O	O
systemic	O	O
medical	O	O
illnesses	O	O
.	O	O

it	O	O
is	O	O
a	O	O
viable	O	O
option	O	O
for	O	O
other	O	O
patients	O	O
as	O	O
well	O	O
.	O	O

neuroleptic	O	O
malignant	O	O
syndrome	O	O
and	O	O
methylphenidate	B-chem	B-chem
.	O	O

a	O	O
1	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
presented	O	O
with	O	O
neuroleptic	O	O
malignant	O	O
syndrome	O	O
probably	O	O
caused	O	O
by	O	O
methylphenidate	B-chem	B-chem
.	O	O

she	O	O
had	O	O
defects	O	O
in	O	O
the	O	O
supratentorial	O	O
brain	O	O
including	O	O
the	O	O
basal	O	O
ganglia	O	O
and	O	O
the	O	O
striatum	O	O
(	O	O
multicystic	O	O
encephalomalacia	O	O
)	O	O
due	O	O
to	O	O
severe	O	O
perinatal	O	O
hypoxic	O	O
-	O	O
ischemic	O	O
encephalopathy	O	O
,	O	O
which	O	O
was	O	O
considered	O	O
to	O	O
be	O	O
a	O	O
possible	O	O
predisposing	O	O
factor	O	O
causing	O	O
neuroleptic	O	O
malignant	O	O
syndrome	O	O
.	O	O

a	O	O
dopaminergic	O	O
blockade	O	O
mechanism	O	O
generally	O	O
is	O	O
accepted	O	O
as	O	O
the	O	O
pathogenesis	O	O
of	O	O
this	O	O
syndrome	O	O
.	O	O

however	O	O
,	O	O
methylphenidate	B-chem	B-chem
is	O	O
a	O	O
dopamine	B-chem	B-chem
agonist	O	O
via	O	O
the	O	O
inhibition	O	O
of	O	O
uptake	O	O
of	O	O
dopamine	B-chem	B-chem
,	O	O
and	O	O
therefore	O	O
dopaminergic	O	O
systems	O	O
in	O	O
the	O	O
brainstem	O	O
(	O	O
mainly	O	O
the	O	O
midbrain	O	O
)	O	O
and	O	O
the	O	O
spinal	O	O
cord	O	O
were	O	O
unlikely	O	O
to	O	O
participate	O	O
in	O	O
the	O	O
onset	O	O
of	O	O
this	O	O
syndrome	O	O
.	O	O

a	O	O
relative	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
aminobutyric	I-chem	I-chem
acid	I-chem	I-chem
-	O	O
ergic	O	O
deficiency	O	O
might	O	O
occur	O	O
because	O	O
diazepam	B-chem	B-chem
,	O	O
a	O	O
gamma	B-chem	B-chem
-	I-chem	I-chem
aminobutyric	I-chem	I-chem
acid	I-chem	I-chem
-	O	O
mimetic	O	O
agent	O	O
,	O	O
was	O	O
strikingly	O	O
effective	O	O
.	O	O

this	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
patient	O	O
with	O	O
neuroleptic	O	O
malignant	O	O
syndrome	O	O
probably	O	O
caused	O	O
by	O	O
methylphenidate	B-chem	B-chem
.	O	O

differential	O	O
effects	O	O
of	O	O
17alpha	B-chem	B-chem
-	I-chem	I-chem
ethinylestradiol	I-chem	I-chem
on	O	O
the	O	O
neutral	O	O
and	O	O
acidic	O	O
pathways	O	O
of	O	O
bile	B-chem	O
salt	I-chem	B-chem
synthesis	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

effects	O	O
of	O	O
17alpha	B-chem	B-chem
-	I-chem	I-chem
ethinylestradiol	I-chem	I-chem
(	O	O
ee	B-chem	B-chem
)	O	O
on	O	O
the	O	O
neutral	O	O
and	O	O
acidic	O	O
biosynthetic	O	O
pathways	O	O
of	O	O
bile	B-chem	O
salt	I-chem	B-chem
(	O	O
bs	B-chem	O
)	O	O
synthesis	O	O
were	O	O
evaluated	O	O
in	O	O
rats	O	O
with	O	O
an	O	O
intact	O	O
enterohepatic	O	O
circulation	O	O
and	O	O
in	O	O
rats	O	O
with	O	O
long	O	O
-	O	O
term	O	O
bile	O	O
diversion	O	O
to	O	O
induce	O	O
bs	B-chem	O
synthesis	O	O
.	O	O

for	O	O
this	O	O
purpose	O	O
,	O	O
bile	B-chem	O
salt	I-chem	O
pool	O	O
composition	O	O
,	O	O
synthesis	O	O
of	O	O
individual	O	O
bs	B-chem	O
in	O	O
vivo	O	O
,	O	O
hepatic	O	O
activities	O	O
,	O	O
and	O	O
expression	O	O
levels	O	O
of	O	O
cholesterol	B-chem	B-chem
7alpha	O	O
-	O	O
hydroxylase	O	O
(	O	O
cyp7a	O	O
)	O	O
,	O	O
and	O	O
sterol	B-chem	O
27	O	O
-	O	O
hydroxylase	O	O
(	O	O
cyp27	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
of	O	O
other	O	O
enzymes	O	O
involved	O	O
in	O	O
bs	B-chem	O
synthesis	O	O
,	O	O
were	O	O
analyzed	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
ee	B-chem	B-chem
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
3	O	O
days	O	O
)	O	O
or	O	O
its	O	O
vehicle	O	O
.	O	O

bs	B-chem	O
pool	O	O
size	O	O
was	O	O
decreased	O	O
by	O	O
27	O	O
%	O	O
but	O	O
total	O	O
bs	B-chem	O
synthesis	O	O
was	O	O
not	O	O
affected	O	O
by	O	O
ee	B-chem	B-chem
in	O	O
intact	O	O
rats	O	O
.	O	O

synthesis	O	O
of	O	O
cholate	B-chem	B-chem
was	O	O
reduced	O	O
by	O	O
68	O	O
%	O	O
in	O	O
ee	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
,	O	O
while	O	O
that	O	O
of	O	O
chenodeoxycholate	B-chem	O
was	O	O
increased	O	O
by	O	O
60	O	O
%	O	O
.	O	O

the	O	O
recently	O	O
identified	O	O
delta22	O	B-chem
-	O	O
isomer	O	O
of	O	O
beta	O	O
-	O	O
muricholate	O	I-chem
contributed	O	O
for	O	O
5	O	O
.	O	O
4	O	O
%	O	O
and	O	O
18	O	O
.	O	O
3	O	O
%	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
to	O	O
the	O	O
pool	O	O
in	O	O
control	O	O
and	O	O
ee	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
,	O	O
respectively	O	O
,	O	O
but	O	O
could	O	O
not	O	O
be	O	O
detected	O	O
in	O	O
bile	O	O
after	O	O
exhaustion	O	O
of	O	O
the	O	O
pool	O	O
.	O	O

a	O	O
clear	O	O
reduction	O	O
of	O	O
bs	B-chem	O
synthesis	O	O
was	O	O
found	O	O
in	O	O
bile	O	O
-	O	O
diverted	O	O
rats	O	O
treated	O	O
with	O	O
ee	B-chem	B-chem
,	O	O
yet	O	O
biliary	O	O
bs	B-chem	O
composition	O	O
was	O	O
only	O	O
minimally	O	O
affected	O	O
.	O	O

activity	O	O
of	O	O
cyp7a	O	O
was	O	O
decreased	O	O
by	O	O
ee	B-chem	B-chem
in	O	O
both	O	O
intact	O	O
and	O	O
bile	O	O
-	O	O
diverted	O	O
rats	O	O
,	O	O
whereas	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
cyp27	O	O
was	O	O
not	O	O
affected	O	O
.	O	O

hepatic	O	O
mrna	O	O
levels	O	O
of	O	O
cyp7a	O	O
were	O	O
significantly	O	O
reduced	O	O
by	O	O
ee	B-chem	B-chem
in	O	O
bile	O	O
-	O	O
diverted	O	O
rats	O	O
only	O	O
;	O	O
cyp27	O	O
mrna	O	O
levels	O	O
were	O	O
not	O	O
affected	O	O
by	O	O
ee	B-chem	B-chem
.	O	O

in	O	O
addition	O	O
,	O	O
mrna	O	O
levels	O	O
of	O	O
sterol	B-chem	B-chem
12alpha	O	O
-	O	O
hydroxylase	O	O
and	O	O
lithocholate	O	O
6beta	O	I-chem
-	O	O
hydroxylase	O	O
were	O	O
increased	O	O
by	O	O
bile	O	O
diversion	O	O
and	O	O
suppressed	O	O
by	O	O
ee	B-chem	B-chem
.	O	O

this	O	O
study	O	O
shows	O	O
that	O	O
17alpha	B-chem	B-chem
-	I-chem	I-chem
ethinylestradiol	I-chem	I-chem
(	O	O
ee	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
intrahepatic	O	O
cholestasis	O	O
in	O	O
rats	O	O
is	O	O
associated	O	O
with	O	O
selective	O	O
inhibition	O	O
of	O	O
the	O	O
neutral	O	O
pathway	O	O
of	O	O
bile	B-chem	O
salt	I-chem	B-chem
(	O	O
bs	B-chem	O
)	O	O
synthesis	O	O
.	O	O

simultaneous	O	O
impairment	O	O
of	O	O
other	O	O
enzymes	O	O
in	O	O
the	O	O
bs	B-chem	O
biosynthetic	O	O
pathways	O	O
may	O	O
contribute	O	O
to	O	O
overall	O	O
effects	O	O
of	O	O
ee	B-chem	B-chem
on	O	O
bs	B-chem	O
synthesis	O	O
.	O	O

glibenclamide	B-chem	B-chem
-	O	O
sensitive	O	O
hypotension	O	O
produced	O	O
by	O	O
helodermin	B-chem	B-chem
assessed	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
helodermin	B-chem	B-chem
,	O	O
a	O	O
basic	O	O
35	O	B-chem
-	O	I-chem
amino	B-chem	B-chem
acid	I-chem	I-chem
peptide	O	I-chem
isolated	O	O
from	O	O
the	O	O
venom	O	B-chem
of	O	O
a	O	O
lizard	O	O
salivary	O	O
gland	O	O
,	O	O
on	O	O
arterial	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
were	O	O
examined	O	O
in	O	O
the	O	O
rat	O	O
,	O	O
focusing	O	O
on	O	O
the	O	O
possibility	O	O
that	O	O
activation	O	O
of	O	O
atp	B-chem	B-chem
sensitive	O	O
k	B-chem	B-chem
+	O	O
(	O	O
k	B-chem	B-chem
(	O	O
atp	B-chem	B-chem
)	O	O
)	O	O
channels	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
responses	O	O
.	O	O

the	O	O
results	O	O
were	O	O
also	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
vasoactive	O	O
intestinal	O	O
polypeptide	O	O
(	O	O
vip	O	O
)	O	O
.	O	O

helodermin	B-chem	B-chem
produced	O	O
hypotension	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
with	O	O
approximately	O	O
similar	O	O
potency	O	O
and	O	O
duration	O	O
to	O	O
vip	O	O
.	O	O

hypotension	O	O
induced	O	O
by	O	O
both	O	O
peptides	O	O
was	O	O
significantly	O	O
attenuated	O	O
by	O	O
glibenclamide	B-chem	B-chem
,	O	O
which	O	O
abolished	O	O
a	O	O
levcromakalim	B-chem	O
-	O	O
produced	O	O
decrease	O	O
in	O	O
arterial	O	O
blood	O	O
pressure	O	O
.	O	O

oxyhemoglobin	O	O
did	O	O
not	O	O
affect	O	O
helodermin	B-chem	B-chem
-	O	O
induced	O	O
hypotension	O	O
,	O	O
whereas	O	O
it	O	O
shortened	O	O
the	O	O
duration	O	O
of	O	O
acetylcholine	B-chem	B-chem
(	O	O
ach	B-chem	B-chem
)	O	O
-	O	O
produced	O	O
hypotension	O	O
.	O	O

these	O	O
findings	O	O
suggest	O	O
that	O	O
helodermin	B-chem	B-chem
-	O	O
produced	O	O
hypotension	O	O
is	O	O
partly	O	O
attributable	O	O
to	O	O
the	O	O
activation	O	O
of	O	O
glibenclamide	B-chem	B-chem
-	O	O
sensitive	O	O
k	B-chem	B-chem
+	O	O
channels	O	O
(	O	O
k	B-chem	B-chem
(	O	O
atp	B-chem	B-chem
)	O	O
channels	O	O
)	O	O
,	O	O
which	O	O
presumably	O	O
exist	O	O
on	O	O
arterial	O	O
smooth	O	O
muscle	O	O
cells	O	O
.	O	O

edrf	O	B-chem
(	O	O
endothelium	O	O
-	O	O
derived	O	O
relaxing	O	O
factor	O	O
)	O	O
/	O	O
nitric	B-chem	B-chem
oxide	I-chem	I-chem
does	O	O
not	O	O
seem	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
peptide	O	O
-	O	O
produced	O	O
hypotension	O	O
.	O	O

long	O	O
-	O	O
term	O	O
efficacy	O	O
and	O	O
adverse	O	O
event	O	O
of	O	O
nifedipine	B-chem	B-chem
sustained	O	O
-	O	O
release	O	O
tablets	O	O
for	O	O
cyclosporin	B-chem	B-chem
a	I-chem	I-chem
-	O	O
induced	O	O
hypertension	O	O
in	O	O
patients	O	O
with	O	O
psoriasis	O	O
.	O	O

thirteen	O	O
psoriatic	O	O
patients	O	O
with	O	O
hypertension	O	O
during	O	O
the	O	O
course	O	O
of	O	O
cyclosporin	B-chem	B-chem
a	I-chem	I-chem
therapy	O	O
were	O	O
treated	O	O
for	O	O
25	O	O
months	O	O
with	O	O
a	O	O
calcium	B-chem	B-chem
channel	O	O
blocker	O	O
,	O	O
sustained	O	O
-	O	O
release	O	O
nifedipine	B-chem	B-chem
,	O	O
to	O	O
study	O	O
the	O	O
clinical	O	O
antihypertensive	O	O
effects	O	O
and	O	O
adverse	O	O
events	O	O
during	O	O
treatment	O	O
with	O	O
both	O	O
drugs	O	O
.	O	O

seven	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
had	O	O
exhibited	O	O
a	O	O
subclinical	O	O
hypertensive	O	O
state	O	O
before	O	O
cyclosporin	B-chem	B-chem
a	I-chem	I-chem
therapy	O	O
.	O	O

both	O	O
systolic	O	O
and	O	O
diastolic	O	O
blood	O	O
pressures	O	O
of	O	O
these	O	O
13	O	O
patients	O	O
were	O	O
decreased	O	O
significantly	O	O
after	O	O
4	O	O
weeks	O	O
of	O	O
nifedipine	B-chem	B-chem
therapy	O	O
,	O	O
and	O	O
blood	O	O
pressure	O	O
was	O	O
maintained	O	O
within	O	O
the	O	O
normal	O	O
range	O	O
thereafter	O	O
for	O	O
25	O	O
months	O	O
.	O	O

the	O	O
adverse	O	O
events	O	O
during	O	O
combined	O	O
therapy	O	O
with	O	O
cyclosporin	B-chem	B-chem
a	I-chem	I-chem
and	O	O
nifedipine	B-chem	B-chem
included	O	O
an	O	O
increase	O	O
in	O	O
blood	B-chem	B-chem
urea	I-chem	I-chem
nitrogen	I-chem	I-chem
levels	O	O
in	O	O
9	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
and	O	O
development	O	O
of	O	O
gingival	O	O
hyperplasia	O	O
in	O	O
2	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
.	O	O

our	O	O
findings	O	O
indicate	O	O
that	O	O
sustained	O	O
-	O	O
release	O	O
nifedipine	B-chem	B-chem
is	O	O
useful	O	O
for	O	O
hypertensive	O	O
psoriatic	O	O
patients	O	O
under	O	O
long	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
cyclosporin	B-chem	B-chem
a	I-chem	I-chem
,	O	O
but	O	O
that	O	O
these	O	O
patients	O	O
should	O	O
be	O	O
monitored	O	O
for	O	O
gingival	O	O
hyperplasia	O	O
.	O	O

torsade	O	O
de	O	O
pointes	O	O
ventricular	O	O
tachycardia	O	O
during	O	O
low	O	O
dose	O	O
intermittent	O	O
dobutamine	B-chem	B-chem
treatment	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
dilated	O	O
cardiomyopathy	O	O
and	O	O
congestive	O	O
heart	O	O
failure	O	O
.	O	O

the	O	O
authors	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
56	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
chronic	O	O
,	O	O
severe	O	O
heart	O	O
failure	O	O
secondary	O	O
to	O	O
dilated	O	O
cardiomyopathy	O	O
and	O	O
absence	O	O
of	O	O
significant	O	O
ventricular	O	O
arrhythmias	O	O
who	O	O
developed	O	O
qt	O	O
prolongation	O	O
and	O	O
torsade	O	O
de	O	O
pointes	O	O
ventricular	O	O
tachycardia	O	O
during	O	O
one	O	O
cycle	O	O
of	O	O
intermittent	O	O
low	O	O
dose	O	O
(	O	O
2	O	O
.	O	O
5	O	O
mcg	O	O
/	O	O
kg	O	O
per	O	O
min	O	O
)	O	O
dobutamine	B-chem	B-chem
.	O	O

this	O	O
report	O	O
of	O	O
torsade	O	O
de	O	O
pointes	O	O
ventricular	O	O
tachycardia	O	O
during	O	O
intermittent	O	O
dobutamine	B-chem	B-chem
supports	O	O
the	O	O
hypothesis	O	O
that	O	O
unpredictable	O	O
fatal	O	O
arrhythmias	O	O
may	O	O
occur	O	O
even	O	O
with	O	O
low	O	O
doses	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
no	O	O
history	O	O
of	O	O
significant	O	O
rhythm	O	O
disturbances	O	O
.	O	O

the	O	O
mechanisms	O	O
of	O	O
proarrhythmic	O	O
effects	O	O
of	O	O
dubutamine	B-chem	B-chem
are	O	O
discussed	O	O
.	O	O

positive	O	O
skin	O	O
tests	O	O
in	O	O
late	O	O
reactions	O	O
to	O	O
radiographic	O	O
contrast	B-chem	O
media	I-chem	O
.	O	O

in	O	O
the	O	O
last	O	O
few	O	O
years	O	O
delayed	O	O
reactions	O	O
several	O	O
hours	O	O
after	O	O
the	O	O
injection	O	O
of	O	O
radiographic	O	O
and	O	O
contrast	B-chem	O
materials	I-chem	O

(	O	O
prc	B-chem	O
)	O	O
have	O	O
been	O	O
described	O	O
with	O	O
increasing	O	O
frequency	O	O
.	O	O

the	O	O
authors	O	O
report	O	O
two	O	O
observations	O	O
on	O	O
patients	O	O
with	O	O
delayed	O	O
reactions	O	O
in	O	O
whom	O	O
intradermoreactions	O	O
(	O	O
idr	O	B-chem
)	O	O
and	O	O
patch	O	B-chem
tests	O	O
to	O	O
a	O	O
series	O	O
of	O	O
ionic	O	O
and	O	O
non	O	O
ionic	O	O
prc	B-chem	O
were	O	O
studied	O	O
.	O	O

after	O	O
angiography	O	O
by	O	O
the	O	O
venous	O	O
route	O	O
in	O	O
patient	O	O
n	O	O
degree	O	O
1	O	O
a	O	O
biphasic	O	O
reaction	O	O
with	O	O
an	O	O
immediate	O	O
reaction	O	O
(	O	O
dyspnea	O	O
,	O	O
loss	O	O
of	O	O
consciousness	O	O
)	O	O
and	O	O
delayed	O	O
macro	O	O
-	O	O
papular	O	O
rash	O	O
appeared	O	O
,	O	O
whilst	O	O
patient	O	O
n	O	O
degree	O	O
2	O	O
developed	O	O
a	O	O
generalised	O	O
sensation	O	O
of	O	O
heat	O	O
,	O	O
persistent	O	O
pain	O	O
at	O	O
the	O	O
site	O	O
of	O	O
injection	O	O
immediately	O	O
and	O	O
a	O	O
generalised	O	O
macro	O	O
-	O	O
papular	O	O
reaction	O	O
after	O	O
24	O	O
hours	O	O
.	O	O

the	O	O
skin	O	O
tests	O	O
revealed	O	O
positive	O	O
delayed	O	O
reactions	O	O
of	O	O
24	O	O
hours	O	O
and	O	O
48	O	O
hours	O	O
by	O	O
idr	O	B-chem
and	O	O
patch	O	B-chem
tests	O	O
to	O	O
only	O	O
some	O	O
prc	B-chem	O
with	O	O
common	O	O
chains	O	O
in	O	O
their	O	O
structures	O	O
.	O	O

the	O	O
positive	O	O
skin	O	O
tests	O	O
are	O	O
in	O	O
favour	O	O
of	O	O
immunological	O	O
reactions	O	O
and	O	O
may	O	O
help	O	O
in	O	O
diagnosis	O	O
of	O	O
allergy	O	O
in	O	O
the	O	O
patients	O	O
.	O	O

risk	O	O
of	O	O
transient	O	O
hyperammonemic	O	O
encephalopathy	O	O
in	O	O
cancer	O	O
patients	O	O
who	O	O
received	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
with	O	O
the	O	O
complication	O	O
of	O	O
dehydration	O	O
and	O	O
infection	O	O
.	O	O

from	O	O
1986	O	O
to	O	O
1998	O	O
,	O	O
29	O	O
cancer	O	O
patients	O	O
who	O	O
had	O	O
32	O	O
episodes	O	O
of	O	O
transient	O	O
hyperammonemic	O	O
encephalopathy	O	O
related	O	O
to	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
(	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
)	O	O
were	O	O
identified	O	O
.	O	O

none	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
decompensated	O	O
liver	O	O
disease	O	O
.	O	O

onset	O	O
of	O	O
hyperammonemic	O	O
encephalopathy	O	O
varied	O	O
from	O	O
0	O	O
.	O	O
5	O	O
to	O	O
5	O	O
days	O	O
(	O	O
mean	O	O
:	O	O
2	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
3	O	O
days	O	O
)	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
chemotherapy	O	O
.	O	O

plasma	O	O
ammonium	B-chem	B-chem
level	O	O
ranged	O	O
from	O	O
248	O	O
to	O	O
2387	O	O
microg	O	O
%	O	O
(	O	O
mean	O	O
:	O	O
626	O	O
+	O	O
/	O	O
-	O	O

431	O	O
microg	O	O
%	O	O
)	O	O
.	O	O

among	O	O
the	O	O
32	O	O
episodes	O	O
,	O	O
26	O	O
(	O	O
81	O	O
%	O	O
)	O	O
had	O	O
various	O	O
degrees	O	O
of	O	O
azotemia	O	O
,	O	O
18	O	O
(	O	O
56	O	O
%	O	O
)	O	O
occurred	O	O
during	O	O
bacterial	O	O
infections	O	O
and	O	O
14	O	O
(	O	O
44	O	O
%	O	O
)	O	O
without	O	O
infection	O	O
occurred	O	O
during	O	O
periods	O	O
of	O	O
dehydration	O	O
.	O	O

higher	O	O
plasma	O	O
ammonium	B-chem	B-chem
levels	O	O
and	O	O
more	O	O
rapid	O	O
onset	O	O
of	O	O
hyperammonemia	O	O
were	O	O
seen	O	O
in	O	O
18	O	O
patients	O	O
with	O	O
bacterial	O	O
infections	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
003	O	O
and	O	O
0	O	O
.	O	O
0006	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
in	O	O
nine	O	O
patients	O	O
receiving	O	O
high	O	O
daily	O	O
doses	O	O
(	O	O
2600	O	O
or	O	O
1800	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0001	O	O
and	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

in	O	O
25	O	O
out	O	O
of	O	O
32	O	O
episodes	O	O
(	O	O
78	O	O
%	O	O
)	O	O
,	O	O
plasma	O	O
ammonium	B-chem	B-chem
levels	O	O
and	O	O
mental	O	O
status	O	O
returned	O	O
to	O	O
normal	O	O
within	O	O
2	O	O
days	O	O
after	O	O
adequate	O	O
management	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
hyperammonemic	O	O
encephalopathy	O	O
can	O	O
occur	O	O
in	O	O
patients	O	O
receiving	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
.	O	O

azotemia	O	O
,	O	O
body	O	O
fluid	O	O
insufficiency	O	O
and	O	O
bacterial	O	O
infections	O	O
were	O	O
frequently	O	O
found	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

it	O	O
is	O	O
therefore	O	O
important	O	O
to	O	O
recognize	O	O
this	O	O
condition	O	O
in	O	O
patients	O	O
receiving	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
.	O	O

the	O	O
effects	O	O
of	O	O
quinine	B-chem	B-chem
and	O	O
4	B-chem	B-chem
-	I-chem	I-chem
aminopyridine	I-chem	I-chem
on	O	O
conditioned	O	O
place	O	O
preference	O	O
and	O	O
changes	O	O
in	O	O
motor	O	O
activity	O	O
induced	O	O
by	O	O
morphine	B-chem	B-chem
in	O	O
rats	O	O
.	O	O

1	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
two	O	O
unselective	O	O
potassium	B-chem	B-chem
(	O	O
k	B-chem	B-chem
(	O	O
+	O	O
)	O	O
-	O	O
)	O	O
channel	O	O
blockers	O	O
,	O	O
quinine	B-chem	B-chem
(	O	O
12	O	O
.	O	O
5	O	O
,	O	O
25	O	O
and	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
4	B-chem	B-chem
-	I-chem	I-chem
aminopyridine	I-chem	I-chem
(	O	O
1	O	O
and	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
on	O	O
conditioned	O	O
place	O	O
preference	O	O
and	O	O
biphasic	O	O
changes	O	O
in	O	O
motor	O	O
activity	O	O
induced	O	O
by	O	O
morphine	B-chem	B-chem
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
were	O	O
tested	O	O
in	O	O
wistar	O	O
rats	O	O
.	O	O

quinine	B-chem	B-chem
is	O	O
known	O	O
to	O	O
block	O	O
voltage	O	O
-	O	O
,	O	O
calcium	B-chem	B-chem
-	O	O
and	O	O
atp	B-chem	B-chem
-	O	O
sensitive	O	O
k	B-chem	B-chem
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
while	O	O
4	B-chem	B-chem
-	I-chem	I-chem
aminopyridine	I-chem	I-chem
is	O	O
known	O	O
to	O	O
block	O	O
voltage	O	O
-	O	O
sensitive	O	O
k	B-chem	O
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
.	O	O

2	O	O
.	O	O

in	O	O
the	O	O
counterbalanced	O	O
method	O	O
,	O	O
quinine	B-chem	B-chem
attenuated	O	O
morphine	B-chem	B-chem
-	O	O
induced	O	O
place	O	O
preference	O	O
,	O	O
whereas	O	O
4	B-chem	B-chem
-	I-chem	I-chem
aminopyridine	I-chem	I-chem
was	O	O
ineffective	O	O
.	O	O

in	O	O
the	O	O
motor	O	O
activity	O	O
test	O	O
measured	O	O
with	O	O
an	O	O
animex	O	O
-	O	O
activity	O	O
meter	O	O
neither	O	O
of	O	O
the	O	O
k	B-chem	B-chem
(	O	O
+	O	O
)	O	O
-	O	O
channel	O	O
blockers	O	O
affected	O	O
morphine	B-chem	B-chem
-	O	O
induced	O	O
hypoactivity	O	O
,	O	O
but	O	O
both	O	O
k	B-chem	B-chem
(	O	O
+	O	O
)	O	O
-	O	O
channel	O	O
blockers	O	O
prevented	O	O
morphine	B-chem	B-chem
-	O	O
induced	O	O
secondary	O	O
hyperactivity	O	O
.	O	O

3	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
the	O	O
involvement	O	O
of	O	O
quinine	B-chem	B-chem
-	O	O
sensitive	O	O
but	O	O
not	O	O
4	B-chem	B-chem
-	I-chem	I-chem
aminopyridine	I-chem	I-chem
-	O	O
sensitive	O	O
k	B-chem	B-chem
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
in	O	O
morphine	B-chem	B-chem
reward	O	O
.	O	O

it	O	O
is	O	O
also	O	O
suggested	O	O
that	O	O
the	O	O
blockade	O	O
of	O	O
k	B-chem	B-chem
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
sensitive	O	O
to	O	O
these	O	O
blockers	O	O
is	O	O
not	O	O
sufficient	O	O
to	O	O
prevent	O	O
morphine	B-chem	B-chem
-	O	O
induced	O	O
hypoactivity	O	O
whereas	O	O
morphine	B-chem	B-chem
-	O	O
induced	O	O
hyperactivity	O	O
seems	O	O
to	O	O
be	O	O
connected	O	O
to	O	O
both	O	O
quinine	B-chem	B-chem
-	O	O
and	O	O
4	B-chem	B-chem
-	I-chem	I-chem
aminopyridine	I-chem	I-chem
-	O	O
sensitive	O	O
k	B-chem	B-chem
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
.	O	O

nociceptin	B-chem	O
/	O	O
orphanin	B-chem	B-chem
fq	I-chem	I-chem
and	O	O
nocistatin	B-chem	B-chem
on	O	O
learning	O	O
and	O	O
memory	O	O
impairment	O	O
induced	O	O
by	O	O
scopolamine	B-chem	B-chem
in	O	O
mice	O	O
.	O	O

1	O	O
.	O	O

nociceptin	B-chem	B-chem
,	O	O
also	O	O
known	O	O
as	O	O
orphanin	B-chem	B-chem
fq	I-chem	O
,	O	O
is	O	O
an	O	O
endogenous	O	O
ligand	O	O
for	O	O
the	O	O
orphan	O	O
opioid	O	O
receptor	O	O
-	O	O
like	O	O
receptor	O	O
1	O	O
(	O	O
orl1	O	O
)	O	O
and	O	O
involves	O	O
in	O	O
various	O	O
functions	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
cns	O	O
)	O	O
.	O	O

on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
nocistatin	B-chem	B-chem
is	O	O
recently	O	O
isolated	O	O
from	O	O
the	O	O
same	O	O
precursor	O	O
as	O	O
nociceptin	B-chem	B-chem
and	O	O
blocks	O	O
nociceptin	B-chem	B-chem
-	O	O
induced	O	O
allodynia	O	O
and	O	O
hyperalgesia	O	O
.	O	O

2	O	O
.	O	O

although	O	O
orl1	O	O
receptors	O	O
which	O	O
display	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
sequence	O	O
homology	O	O
with	O	O
classical	O	O
opioid	O	O
receptors	O	O
are	O	O
abundant	O	O
in	O	O
the	O	O
hippocampus	O	O
,	O	O
little	O	O
is	O	O
known	O	O
regarding	O	O
their	O	O
role	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
.	O	O

3	O	O
.	O	O

the	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
whether	O	O
nociceptin	B-chem	O
/	O	O
orphanin	B-chem	B-chem
fq	I-chem	I-chem
and	O	O
nocistatin	B-chem	B-chem
could	O	O
modulate	O	O
impairment	O	O
of	O	O
learning	O	O
and	O	O
memory	O	O
induced	O	O
by	O	O
scopolamine	B-chem	B-chem
,	O	O
a	O	O
muscarinic	O	O
cholinergic	O	O
receptor	O	O
antagonist	O	O
,	O	O
using	O	O
spontaneous	O	O
alternation	O	O
of	O	O
y	O	O
-	O	O
maze	O	O
and	O	O
step	O	O
-	O	O
down	O	O
type	O	O
passive	O	O
avoidance	O	O
tasks	O	O
in	O	O
mice	O	O
.	O	O

4	O	O
.	O	O

while	O	O
nocistatin	B-chem	B-chem
(	O	O
0	O	O
.	O	O
5	O	O
-	O	O
5	O	O
.	O	O
0	O	O
nmol	O	O
mouse	O	O
-	O	O
1	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
.	O	O
)	O	O

administered	O	O
30	O	O
min	O	O
before	O	O
spontaneous	O	O
alternation	O	O
performance	O	O
or	O	O
the	O	O
training	O	O
session	O	O
of	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
,	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
spontaneous	O	O
alternation	O	O
or	O	O
passive	O	O
avoidance	O	O
behaviours	O	O
,	O	O
a	O	O
lower	O	O
per	O	O
cent	O	O
alternation	O	O
and	O	O
shorter	O	O
median	O	O
step	O	O
-	O	O
down	O	O
latency	O	O
in	O	O
the	O	O
retention	O	O
test	O	O
were	O	O
obtained	O	O
in	O	O
nociceptin	B-chem	B-chem
(	O	O
1	O	O
.	O	O
5	O	O
and	O	O
/	O	O
or	O	O
5	O	O
.	O	O
0	O	O
nmol	O	O
mouse	O	O
-	O	O
1	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
.	O	O
)	O	O
-	O	O
treated	O	O
normal	O	O
mice	O	O
.	O	O

5	O	O
.	O	O

administration	O	O
of	O	O
nocistatin	B-chem	B-chem
(	O	O
1	O	O
.	O	O
5	O	O
and	O	O
/	O	O
or	O	O
5	O	O
.	O	O
0	O	O
nmol	O	O
mouse	O	O
-	O	O
1	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
.	O	O
)	O	O

30	O	O
min	O	O
before	O	O
spontaneous	O	O
alternation	O	O
performance	O	O
or	O	O
the	O	O
training	O	O
session	O	O
of	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
,	O	O
attenuated	O	O
the	O	O
scopolamine	B-chem	B-chem
-	O	O
induced	O	O
impairment	O	O
of	O	O
spontaneous	O	O
alternation	O	O
and	O	O
passive	O	O
avoidance	O	O
behaviours	O	O
.	O	O

6	O	O
.	O	O

these	O	O
results	O	O
indicated	O	O
that	O	O
nocistatin	B-chem	B-chem
,	O	O
a	O	O
new	O	O
biologically	O	O
active	O	O
peptide	O	O
,	O	O
ameliorates	O	O
impairments	O	O
of	O	O
spontaneous	O	O
alternation	O	O
and	O	O
passive	O	O
avoidance	O	O
induced	O	O
by	O	O
scopolamine	B-chem	B-chem
,	O	O
and	O	O
suggested	O	O
that	O	O
these	O	O
peptides	O	O
play	O	O
opposite	O	O
roles	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
.	O	O

meloxicam	B-chem	B-chem
-	O	O
induced	O	O
liver	O	O
toxicity	O	O
.	O	O

we	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
who	O	O
developed	O	O
acute	O	O
cytolytic	O	O
hepatitis	O	O
due	O	O
to	O	O
meloxicam	B-chem	B-chem
.	O	O

recently	O	O
introduced	O	O
in	O	O
belgium	O	O
,	O	O
meloxicam	B-chem	B-chem
is	O	O
the	O	O
first	O	O
nonsteroidal	O	O
antiinflammatory	O	O
drug	O	O
with	O	O
selective	O	O
action	O	O
on	O	O
the	O	O
inducible	O	O
form	O	O
of	O	O
cyclooxygenase	O	O
2	O	O
.	O	O

the	O	O
acute	O	O
cytolytic	O	O
hepatitis	O	O
occurred	O	O
rapidly	O	O
after	O	O
meloxicam	B-chem	B-chem
administration	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
antinuclear	O	O
antibodies	O	O
suggesting	O	O
a	O	O
hypersensitivity	O	O
mechanism	O	O
.	O	O

this	O	O
first	O	O
case	O	O
of	O	O
meloxicam	B-chem	B-chem
related	O	O
liver	O	O
toxicity	O	O
demonstrates	O	O
the	O	O
potential	O	O
of	O	O
this	O	O
drug	O	O
to	O	O
induce	O	O
hepatic	O	O
damage	O	O
.	O	O

induction	O	O
of	O	O
apoptosis	O	O
by	O	O
remoxipride	B-chem	B-chem
metabolites	O	O
in	O	O
hl60	O	O
and	O	O
cd34	O	O
+	O	O
/	O	O
cd19	O	O
-	O	O
human	O	O
bone	O	O
marrow	O	O
progenitor	O	O
cells	O	O
:	O	O
potential	O	O
relevance	O	O
to	O	O
remoxipride	B-chem	B-chem
-	O	O
induced	O	O
aplastic	O	O
anemia	O	O
.	O	O

the	O	O
antipsychotic	O	O
agent	O	O
,	O	O
remoxipride	B-chem	B-chem
[	O	O
(	B-chem	O
s	I-chem	O
)	I-chem	O
-	I-chem	I-chem
(	I-chem	O
-	I-chem	O
)	I-chem	O
-	I-chem	I-chem
3	I-chem	I-chem
-	I-chem	I-chem
bromo	I-chem	I-chem
-	I-chem	I-chem
n	I-chem	I-chem
-	I-chem	I-chem
[	I-chem	I-chem
(	I-chem	I-chem
1	I-chem	I-chem
-	I-chem	I-chem
ethyl	I-chem	I-chem
-	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
pyrrolidinyl	I-chem	I-chem
)	I-chem	I-chem
methyl	I-chem	I-chem
]	I-chem	I-chem
-	I-chem	I-chem
2	I-chem	I-chem
,	I-chem	I-chem
6	I-chem	I-chem
-	I-chem	I-chem
dimethoxybenz	I-chem	I-chem
amide	I-chem	I-chem
]	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
acquired	O	O
aplastic	O	O
anemia	O	O
.	O	O

we	O	O
have	O	O
examined	O	O
the	O	O
ability	O	O
of	O	O
remoxipride	B-chem	B-chem
,	O	O
three	O	O
pyrrolidine	B-chem	I-chem
ring	O	O
metabolites	O	O
and	O	O
five	O	O
aromatic	O	O
ring	O	O
metabolites	O	O
of	O	O
the	O	O
parent	O	O
compound	O	O
to	O	O
induce	O	O
apoptosis	O	O
in	O	O
hl60	O	O
cells	O	O
and	O	O
human	O	O
bone	O	O
marrow	O	O
progenitor	O	O
(	O	O
hbmp	O	O
)	O	O
cells	O	O
.	O	O

cells	O	O
were	O	O
treated	O	O
for	O	O
0	O	O
-	O	O
24	O	O
h	O	O
with	O	O
each	O	O
compound	O	B-chem
(	O	O
0	O	I-chem
-	O	I-chem
200	O	O
microm	O	O
)	O	O
.	O	O

apoptosis	O	O
was	O	O
assessed	O	O
by	O	O
fluorescence	O	O
microscopy	O	O
in	O	O
hoechst	B-chem	O
33342	I-chem	O
-	O	O
and	O	O
propidium	B-chem	B-chem
iodide	I-chem	I-chem
stained	O	O
cell	O	O
samples	O	O
.	O	O

results	O	O
were	O	O
confirmed	O	O
by	O	O
determination	O	O
of	O	O
internucleosomal	O	O
dna	O	O
fragmentation	O	O
using	O	O
gel	O	O
electrophoresis	O	O
for	O	O
hl60	O	O
cell	O	O
samples	O	O
and	O	O
terminal	O	O
deoxynucleotidyl	O	O
transferase	O	O
assay	O	O
in	O	O
hbmp	O	O
cells	O	O
.	O	O

the	O	O
catechol	B-chem	O
and	O	O
hydroquinone	B-chem	B-chem
metabolites	O	O
,	O	O
ncq436	B-chem	B-chem
and	O	O
ncq344	B-chem	O
,	O	O
induced	O	O
apoptosis	O	O
in	O	O
hl60	O	O
and	O	O
hbmp	O	O
cells	O	O
in	O	O
a	O	O
time	O	O
-	O	O
and	O	O
concentration	O	O
dependent	O	O
manner	O	O
,	O	O
while	O	O
the	O	O
phenols	B-chem	B-chem
,	O	O
ncr181	O	O
,	O	O
fla873	O	O
,	O	O
and	O	O
fla797	B-chem	O
,	O	O
and	O	O
the	O	O
derivatives	O	O
formed	O	O
by	O	O
oxidation	O	O
of	O	O
the	O	O
pyrrolidine	B-chem	B-chem
ring	O	O
,	O	O
fla838	O	O
,	O	O
ncm001	O	O
,	O	O
and	O	O
ncl118	O	O
,	O	O
had	O	O
no	O	O
effect	O	O
.	O	O

no	O	O
necrosis	O	O
was	O	O
observed	O	O
in	O	O
cells	O	O
treated	O	O
with	O	O
ncq436	B-chem	O
but	O	O
ncq344	B-chem	O
had	O	O
a	O	O
biphasic	O	O
effect	O	O
in	O	O
both	O	O
cell	O	O
types	O	O
,	O	O
inducing	O	O
apoptosis	O	O
at	O	O
lower	O	O
concentrations	O	O
and	O	O
necrosis	O	O
at	O	O
higher	O	O
concentrations	O	O
.	O	O

these	O	O
data	O	O
show	O	O
that	O	O
the	O	O
catechol	B-chem	O
and	O	O
hydroquinone	B-chem	B-chem
metabolites	O	O
of	O	O
remoxipride	B-chem	B-chem
have	O	O
direct	O	O
toxic	O	O
effects	O	O
in	O	O
hl60	O	O
and	O	O
hbmp	O	O
cells	O	O
,	O	O
leading	O	O
to	O	O
apoptosis	O	O
,	O	O
while	O	O
the	O	O
phenol	B-chem	B-chem
metabolites	O	O
were	O	O
inactive	O	O
.	O	O

similarly	O	O
,	O	O
benzene	B-chem	B-chem
-	O	O
derived	O	O
catechol	B-chem	O
and	O	O
hydroquinone	B-chem	B-chem
,	O	O
but	O	O
not	O	O
phenol	B-chem	B-chem
,	O	O
induce	O	O
apoptosis	O	O
in	O	O
hbmp	O	O
cells	O	O
[	O	O
moran	O	B-chem
et	O	O
al	O	O
.	O	O
,	O	O
mol	O	O
.	O	O

pharmacol	O	O
.	O	O

,	O	O
50	O	O
(	O	O
1996	O	O
)	O	O
610	O	O
-	O	O
615	O	O
]	O	O
.	O	O

we	O	O
propose	O	O
that	O	O
remoxipride	B-chem	B-chem
and	O	O
benzene	B-chem	B-chem
may	O	O
induce	O	O
aplastic	O	O
anemia	O	O
via	O	O
production	O	O
of	O	O
similar	O	O
reactive	O	O
metabolites	O	O
and	O	O
that	O	O
the	O	O
ability	O	O
of	O	O
ncq436	B-chem	O
and	O	O
ncq344	B-chem	O
to	O	O
induce	O	O
apoptosis	O	O
in	O	O
hbmp	O	O
cells	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
mechanism	O	O
underlying	O	O
acquired	O	O
aplastic	O	O
anemia	O	O
that	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
remoxipride	B-chem	B-chem
.	O	O

synthesis	O	O
and	O	O
preliminary	O	O
pharmacological	O	O
investigations	O	O
of	O	O
1	B-chem	B-chem
-	I-chem	I-chem
(	I-chem	O
1	I-chem	I-chem
,	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
dihydro	I-chem	I-chem
-	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
acenaphthylenyl	I-chem	I-chem
)	I-chem	I-chem
piperazine	I-chem	B-chem
derivatives	O	O
as	O	O
potential	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
in	O	O
mice	O	O
.	O	O

in	O	O
research	O	O
towards	O	O
the	O	O
development	O	O
of	O	O
new	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
,	O	O
one	O	O
strategy	O	O
is	O	O
that	O	O
the	O	O
dopaminergic	O	O
system	O	O
can	O	O
be	O	O
modulated	O	O
through	O	O
manipulation	O	O
of	O	O
the	O	O
serotonergic	O	O
system	O	O
.	O	O

the	O	O
synthesis	O	O
and	O	O
preliminary	O	O
pharmacological	O	O
evaluation	O	O
of	O	O
a	O	O
series	O	O
of	O	O
potential	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
based	O	O
on	O	O
the	O	O
structure	O	O
of	O	O
1	B-chem	B-chem
-	I-chem	O
(	I-chem	O
1	I-chem	O
,	I-chem	O
2	I-chem	I-chem
-	I-chem	I-chem
dihydro	I-chem	I-chem
-	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
acenaphthylenyl	I-chem	I-chem
)	I-chem	I-chem
piperazine	I-chem	B-chem
(	O	O
7	O	O
)	O	O
is	O	O
described	O	O
.	O	O

compound	O	O
7e	O	O
,	O	O
5	B-chem	B-chem
-	I-chem	I-chem
{	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
[	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
(	I-chem	I-chem
1	I-chem	I-chem
,	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
dihydro	I-chem	I-chem
-	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
acenaphthylenyl	I-chem	I-chem
)	I-chem	I-chem
piperazinyl	I-chem	I-chem
]	I-chem	I-chem
ethyl	I-chem	I-chem
}	I-chem	I-chem
-	I-chem	I-chem
2	I-chem	I-chem
,	I-chem	I-chem
3	I-chem	I-chem
-	I-chem	I-chem
dihy	I-chem	I-chem
dro	I-chem	I-chem
-	I-chem	I-chem
1h	I-chem	I-chem
-	I-chem	I-chem

indol	I-chem	B-chem
-	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
one	I-chem	O
,	O	O
from	O	O
this	O	O
series	O	O
showed	O	O
significant	O	O
affinities	O	O
at	O	O
the	O	O
5	O	O
-	O	O
ht1a	O	O
and	O	O
5	O	O
-	O	O
ht2a	O	O
receptors	O	O
and	O	O
moderate	O	O
affinity	O	O
at	O	O
the	O	O
d2	O	O
receptor	O	O
.	O	O

7e	O	O
exhibits	O	O
a	O	O
high	O	O
reversal	O	O
of	O	O
catalepsy	O	O
induced	O	O
by	O	O
haloperidol	B-chem	B-chem
indicating	O	O
its	O	O
atypical	O	O
antipsychotic	O	O
nature	O	O
.	O	O

sub	O	O
-	O	O
chronic	O	O
inhibition	O	O
of	O	O
nitric	B-chem	B-chem
-	I-chem	I-chem
oxide	I-chem	I-chem
synthesis	O	O
modifies	O	I-chem
haloperidol	B-chem	B-chem
-	O	O
induced	O	O
catalepsy	O	O
and	O	O
the	O	O
number	O	O
of	O	O
nadph	B-chem	B-chem
-	O	O
diaphorase	O	O
neurons	O	O
in	O	O
mice	O	O
.	O	O

rationale	O	O
:	O	O
ng	B-chem	B-chem
-	I-chem	I-chem
nitro	I-chem	B-chem
-	I-chem	I-chem
l	I-chem	I-chem
-	I-chem	I-chem
arginine	I-chem	I-chem
(	O	O
l	B-chem	O
-	I-chem	O
noarg	I-chem	I-chem
)	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
nitric	B-chem	B-chem
-	I-chem	I-chem
oxide	I-chem	B-chem
synthase	O	O
(	O	O
nos	O	O
)	O	O
,	O	O
induces	O	O
catalepsy	O	O
in	O	O
mice	O	O
.	O	O

this	O	O
effect	O	O
undergoes	O	O
rapid	O	O
tolerance	O	O
,	O	O
showing	O	O
a	O	O
significant	O	O
decrease	O	O
after	O	O
2	O	O
days	O	O
of	O	O
sub	O	O
-	O	O
chronic	O	O
l	B-chem	O
-	I-chem	O
noarg	I-chem	O
treatment	O	O
.	O	O

nitric	B-chem	B-chem
oxide	I-chem	I-chem
(	O	O
no	B-chem	B-chem
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
influence	O	O
dopaminergic	O	O
neurotransmission	O	O
in	O	O
the	O	O
striatum	O	O
.	O	O

neuroleptic	O	O
drugs	O	O
such	O	O
as	O	O
haloperidol	B-chem	B-chem
,	O	O
which	O	O
block	O	O
dopamine	B-chem	B-chem
receptors	O	O
,	O	O
also	O	O
cause	O	O
catalepsy	O	O
in	O	O
rodents	O	O
.	O	O

objectives	O	O
:	O	O

to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
subchronic	O	O
l	B-chem	O
-	I-chem	O
noarg	I-chem	O
treatment	O	O
in	O	O
haloperidol	B-chem	B-chem
-	O	O
induced	O	O
catalepsy	O	O
and	O	O
the	O	O
number	O	O
of	O	O
nos	O	O
neurons	O	O
in	O	O
areas	O	O
related	O	O
to	O	O
motor	O	O
control	O	O
.	O	O

methods	O	O
:	O	O

male	O	O
albino	O	O
swiss	O	O
mice	O	O
were	O	O
treated	O	O
sub	O	O
-	O	O
chronically	O	O
(	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
4	O	O
days	O	O
)	O	O
with	O	O
l	B-chem	O
-	I-chem	O
noarg	I-chem	O
(	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
or	O	O
haloperidol	B-chem	B-chem
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
.	O	O

catalepsy	O	O
was	O	O
evaluated	O	O
at	O	O
the	O	O
beginning	O	O
and	O	O
the	O	O
end	O	O
of	O	O
the	O	O
treatments	O	O
.	O	O

reduced	O	O
nicotinamide	B-chem	B-chem
adenine	I-chem	I-chem
dinucleotide	I-chem	I-chem
phosphate	I-chem	I-chem
-	O	O
diaphorase	O	B-chem
(	O	O
nadph	B-chem	B-chem
-	O	O
d	O	O
)	O	O
histochemistry	O	O
was	O	O
also	O	O
employed	O	O
to	O	O
visualize	O	O
nos	O	O
as	O	O
an	O	O
index	O	O
of	O	O
enzyme	O	O
expression	O	O
in	O	O
mice	O	O
brain	O	O
regions	O	O
related	O	O
to	O	O
motor	O	O
control	O	O
.	O	O

results	O	O
:	O	O

l	B-chem	O
-	I-chem	O
noarg	I-chem	O
sub	O	O
-	O	O
chronic	O	O
administration	O	O
produced	O	O
tolerance	O	O
of	O	O
l	B-chem	O
-	I-chem	O
noarg	I-chem	O
and	O	O
of	O	O
haloperidol	B-chem	B-chem
-	O	O
induced	O	O
catalepsy	O	O
.	O	O

it	O	O
also	O	O
induced	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
nadph	B-chem	B-chem
-	O	O
d	O	O
-	O	O
positive	O	O
cells	O	O
in	O	O
the	O	O
dorsal	O	O
part	O	O
of	O	O
the	O	O
caudate	O	O
and	O	O
accumbens	O	O
nuclei	O	O
compared	O	O
with	O	O
haloperidol	B-chem	B-chem
and	O	O
in	O	O
the	O	O
pedunculopontine	O	O
tegmental	O	O
nucleus	O	O
compared	O	O
with	O	O
saline	O	O
.	O	O

in	O	O
contrast	O	O
,	O	O
there	O	O
was	O	O
a	O	O
decrease	O	O
in	O	O
nadph	B-chem	B-chem
-	O	O
d	O	O
neuron	O	O
number	O	O
in	O	O
the	O	O
substantia	O	O
nigra	O	O
,	O	O
pars	O	O
compacta	O	O
in	O	O
both	O	O
haloperidol	B-chem	B-chem
-	O	O
treated	O	O
and	O	O
l	B-chem	O
-	I-chem	O
noarg	I-chem	O
-	O	O
treated	O	O
animals	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
results	O	O
give	O	O
further	O	O
support	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
no	B-chem	O
plays	O	O
a	O	O
role	O	O
in	O	O
motor	O	O
behavior	O	O
control	O	O
and	O	O
suggest	O	O
that	O	O
it	O	O
may	O	O
take	O	O
part	O	O
in	O	O
the	O	O
synaptic	O	O
changes	O	O
produced	O	O
by	O	O
antipsychotic	O	O
treatment	O	O
.	O	O

prolonged	O	O
left	O	O
ventricular	O	O
dysfunction	O	O
occurs	O	O
in	O	O
patients	O	O
with	O	O
coronary	O	O
artery	O	O
disease	O	O
after	O	O
both	O	O
dobutamine	B-chem	B-chem
and	O	O
exercise	O	O
induced	O	O
myocardial	O	O
ischaemia	O	O
.	O	O

objective	O	O
:	O	O

to	O	O
determine	O	O
whether	O	O
pharmacological	O	O
stress	O	O
leads	O	O
to	O	O
prolonged	O	O
but	O	O
reversible	O	O
left	O	O
ventricular	O	O
dysfunction	O	O
in	O	O
patients	O	O
with	O	O
coronary	O	O
artery	O	O
disease	O	O
,	O	O
similar	O	O
to	O	O
that	O	O
seen	O	O
after	O	O
exercise	O	O
.	O	O

design	O	O
:	O	O

a	O	O
randomised	O	O
crossover	O	O
study	O	O
of	O	O
recovery	O	O
time	O	O
of	O	O
systolic	O	O
and	O	O
diastolic	O	O
left	O	O
ventricular	O	O
function	O	O
after	O	O
exercise	O	O
and	O	O
dobutamine	B-chem	B-chem
induced	O	O
ischaemia	O	O
.	O	O

subjects	O	O
:	O	O
10	O	O
patients	O	O
with	O	O
stable	O	O
angina	O	O
,	O	O

angiographically	O	O
proven	O	O
coronary	O	O
artery	O	O
disease	O	O
,	O	O
and	O	O
normal	O	O
left	O	O
ventricular	O	O
function	O	O
.	O	O

interventions	O	O
:	O	O

treadmill	O	O
exercise	O	O
and	O	O
dobutamine	B-chem	B-chem
stress	O	O
were	O	O
performed	O	O
on	O	O
different	O	O
days	O	O
.	O	O

quantitative	O	O
assessment	O	O
of	O	O
systolic	O	O
and	O	O
diastolic	O	O
left	O	O
ventricular	O	O
function	O	O
was	O	O
performed	O	O
using	O	O
transthoracic	O	O
echocardiography	O	O
at	O	O
baseline	O	O
and	O	O
at	O	O
regular	O	O
intervals	O	O
after	O	O
each	O	O
test	O	O
.	O	O

results	O	O
:	O	O

both	O	O
forms	O	O
of	O	O
stress	O	O
led	O	O
to	O	O
prolonged	O	O
but	O	O
reversible	O	O
systolic	O	O
and	O	O
diastolic	O	O
dysfunction	O	O
.	O	O

there	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
maximum	O	O
double	O	O
product	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
53	O	O
)	O	O
or	O	O
st	O	O
depression	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
63	O	O
)	O	O
with	O	O
either	O	O
form	O	O
of	O	O
stress	O	O
.	O	O

after	O	O
exercise	O	O
,	O	O
ejection	O	O
fraction	O	O
was	O	O
reduced	O	O
at	O	O
15	O	O
and	O	O
30	O	O
minutes	O	O
compared	O	O
with	O	O
baseline	O	O
(	O	O
mean	O	O
(	O	O
sem	O	O
)	O	O
,	O	O
-	O	O
5	O	O
.	O	O
6	O	O
(	O	O
1	O	O
.	O	O
5	O	O
)	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
;	O	O
and	O	O
-	O	O
6	O	O
.	O	O
1	O	O
(	O	O
2	O	O
.	O	O
2	O	O
)	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
and	O	O
at	O	O
30	O	O
and	O	O
45	O	O
minutes	O	O
after	O	O
dobutamine	B-chem	B-chem
(	O	O
-	O	O
10	O	O
.	O	O
8	O	O
(	O	O
1	O	O
.	O	O
8	O	O
)	O	O
%	O	O
and	O	O
-	O	O
5	O	O
.	O	O
5	O	O
(	O	O
1	O	O
.	O	O
8	O	O
)	O	O
%	O	O
,	O	O
both	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

regional	O	O
analysis	O	O
showed	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
worst	O	O
affected	O	O
segment	O	O
15	O	O
and	O	O
30	O	O
minutes	O	O
after	O	O
exercise	O	O
(	O	O
-	O	O
27	O	O
.	O	O
9	O	O
(	O	O
7	O	O
.	O	O
2	O	O
)	O	O
%	O	O
and	O	O
-	O	O
28	O	O
.	O	O
6	O	O
(	O	O
5	O	O
.	O	O
7	O	O
)	O	O
%	O	O
,	O	O
both	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
and	O	O
at	O	O
30	O	O
minutes	O	O
after	O	O
dobutamine	B-chem	B-chem
(	O	O
-	O	O
32	O	O
(	O	O
5	O	O
.	O	O
3	O	O
)	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

the	O	O
isovolumic	O	O
relaxation	O	O
period	O	O
was	O	O
prolonged	O	O
45	O	O
minutes	O	O
after	O	O
each	O	O
form	O	O
of	O	O
stress	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

in	O	O
patients	O	O
with	O	O
coronary	O	O
artery	O	O
disease	O	O
,	O	O
dobutamine	B-chem	B-chem
induced	O	O
ischaemia	O	O
results	O	O
in	O	O
prolonged	O	O
reversible	O	O
left	O	O
ventricular	O	O
dysfunction	O	O
,	O	O
presumed	O	O
to	O	O
be	O	O
myocardial	O	O
stunning	O	O
,	O	O
similar	O	O
to	O	O
that	O	O
seen	O	O
after	O	O
exercise	O	O
.	O	O

dobutamine	B-chem	B-chem
induced	O	O
ischaemia	O	O
could	O	O
therefore	O	O
be	O	O
used	O	O
to	O	O
study	O	O
the	O	O
pathophysiology	O	O
of	O	O
this	O	O
phenomenon	O	O
further	O	O
in	O	O
patients	O	O
with	O	O
coronary	O	O
artery	O	O
disease	O	O
.	O	O

anorexigens	O	O
and	O	O
pulmonary	O	O
hypertension	O	O
in	O	O
the	O	O
united	O	O
states	O	O
:	O	O
results	O	O
from	O	O
the	O	O
surveillance	O	O
of	O	O
north	O	O
american	O	O
pulmonary	O	O
hypertension	O	O
.	O	O

background	O	O
:	O	O

the	O	O
use	O	O
of	O	O
appetite	O	B-chem
suppressants	O	I-chem
in	O	O
europe	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
primary	O	O
pulmonary	O	O
hypertension	O	O
(	O	O
pph	O	O
)	O	O
.	O	O

recently	O	O
,	O	O
fenfluramine	B-chem	B-chem
appetite	O	I-chem
suppressants	O	I-chem
became	O	O
widely	O	O
used	O	O
in	O	O
the	O	O
united	O	O
states	O	O
but	O	O
were	O	O
withdrawn	O	O
in	O	O
september	O	O
1997	O	O
because	O	O
of	O	O
concerns	O	O
over	O	O
adverse	O	O
effects	O	O
.	O	O

materials	O	O
and	O	O
methods	O	O
:	O	O

we	O	O
conducted	O	O
a	O	O
prospective	O	O
surveillance	O	O
study	O	O
on	O	O
patients	O	O
diagnosed	O	O
with	O	O
pulmonary	O	O
hypertension	O	O
at	O	O
12	O	O
large	O	O
referral	O	O
centers	O	O
in	O	O
north	O	O
america	O	O
.	O	O

data	O	O
collected	O	O
on	O	O
patients	O	O
seen	O	O
from	O	O
september	O	O
1	O	O
,	O	O
1996	O	O
,	O	O
to	O	O
december	O	O
31	O	O
,	O	O
1997	O	O
,	O	O
included	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
pulmonary	O	O
hypertension	O	O
and	O	O
its	O	O
severity	O	O
.	O	O

patients	O	O
with	O	O
no	O	O
identifiable	O	O
cause	O	O
of	O	O
pulmonary	O	O
hypertension	O	O
were	O	O
classed	O	O
as	O	O
pph	O	O
.	O	O

a	O	O
history	O	O
of	O	O
drug	O	O
exposure	O	O
also	O	O
was	O	O
taken	O	O
with	O	O
special	O	O
attention	O	O
on	O	O
the	O	O
use	O	O
of	O	O
antidepressants	O	B-chem
,	O	O
anorexigens	O	O
,	O	O
and	O	O
amphetamines	B-chem	B-chem
.	O	O

results	O	O
:	O	O

five	O	O
hundred	O	O
seventy	O	O
-	O	O
nine	O	O
patients	O	O
were	O	O
studied	O	O
,	O	O
205	O	O
with	O	O
pph	O	O
and	O	O
374	O	O
with	O	O
pulmonary	O	O
hypertension	O	O
from	O	O
other	O	O
causes	O	O
(	O	O
secondary	O	O
pulmonary	O	O
hypertension	O	O
[	O	O
sph	O	O
]	O	O
)	O	O
.	O	O

the	O	O
use	O	O
of	O	O
anorexigens	O	B-chem
was	O	O
common	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

however	O	O
,	O	O
of	O	O
the	O	O
medications	O	O
surveyed	O	O
,	O	O
only	O	O
the	O	O
fenfluramines	B-chem	B-chem
had	O	O
a	O	O
significant	O	O
preferential	O	O
association	O	O
with	O	O
pph	O	O
as	O	O
compared	O	O
with	O	O
sph	O	O
(	O	O
adjusted	O	O
odds	O	O
ratio	O	O
for	O	O
use	O	O
>	O	O
6	O	O
months	O	O
,	O	O
7	O	O
.	O	O
5	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O
7	O	O
to	O	O
32	O	O
.	O	O
4	O	O
)	O	O
.	O	O

the	O	O
association	O	O
was	O	O
stronger	O	O
with	O	O
longer	O	O
duration	O	O
of	O	O
use	O	O
when	O	O
compared	O	O
to	O	O
shorter	O	O
duration	O	O
of	O	O
use	O	O
and	O	O
was	O	O
more	O	O
pronounced	O	O
in	O	O
recent	O	O
users	O	O
than	O	O
in	O	O
remote	O	O
users	O	O
.	O	O

an	O	O
unexpectedly	O	O
high	O	O
(	O	O
11	O	O
.	O	O
4	O	O
%	O	O
)	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
sph	O	O
had	O	O
used	O	O
anorexigens	O	O
.	O	O

conclusion	O	O
:	O	O

the	O	O
magnitude	O	O
of	O	O
the	O	O
association	O	O
with	O	O
pph	O	O
,	O	O
the	O	O
increase	O	O
of	O	O
association	O	O
with	O	O
increasing	O	O
duration	O	O
of	O	O
use	O	O
,	O	O
and	O	O
the	O	O
specificity	O	O
for	O	O
fenfluramines	B-chem	B-chem
are	O	O
consistent	O	O
with	O	O
previous	O	O
studies	O	O
indicating	O	O
that	O	O
fenfluramines	B-chem	B-chem
are	O	O
causally	O	O
related	O	O
to	O	O
pph	O	O
.	O	O

the	O	O
high	O	O
prevalence	O	O
of	O	O
anorexigen	O	B-chem
use	O	O
in	O	O
patients	O	O
with	O	O
sph	O	O
also	O	O
raises	O	O
the	O	O
possibility	O	O
that	O	O
these	O	O
drugs	O	O
precipitate	O	O
pulmonary	O	O
hypertension	O	O
in	O	O
patients	O	O
with	O	O
underlying	O	O
conditions	O	O
associated	O	O
with	O	O
sph	O	O
.	O	O

clinical	O	O
aspects	O	O
of	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
and	O	O
thrombosis	O	O
and	O	O
other	O	O
side	O	O
effects	O	O
of	O	O
heparin	B-chem	B-chem
therapy	O	O
.	O	O

heparin	B-chem	B-chem
,	O	O
first	O	O
used	O	O
to	O	O
prevent	O	O
the	O	O
clotting	O	O
of	O	O
blood	O	O
in	O	O
vitro	O	O
,	O	O
has	O	O
been	O	O
clinically	O	O
used	O	O
to	O	O
treat	O	O
thrombosis	O	O
for	O	O
more	O	O
than	O	O
50	O	O
years	O	O
.	O	O

although	O	O
several	O	O
new	O	O
anticoagulant	O	O
drugs	O	O
are	O	O
in	O	O
development	O	O
,	O	O
heparin	B-chem	B-chem
remains	O	O
the	O	O
anticoagulant	O	O
of	O	O
choice	O	O
to	O	O
treat	O	O
acute	O	O
thrombotic	O	O
episodes	O	O
.	O	O

the	O	O
clinical	O	O
effects	O	O
of	O	O
heparin	B-chem	B-chem
are	O	O
meritorious	O	O
,	O	O
but	O	O
side	O	O
effects	O	O
do	O	O
exist	O	O
.	O	O

bleeding	O	O
is	O	O
the	O	O
primary	O	O
untoward	O	O
effect	O	O
of	O	O
heparin	B-chem	B-chem
.	O	O

major	O	O
bleeding	O	O
is	O	O
of	O	O
primary	O	O
concern	O	O
in	O	O
patients	O	O
receiving	O	O
heparin	B-chem	B-chem
therapy	O	O
.	O	O

however	O	O
,	O	O
additional	O	O
important	O	O
untoward	O	O
effects	O	O
of	O	O
heparin	B-chem	B-chem
therapy	O	O
include	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
,	O	O
heparin	B-chem	B-chem
-	O	O
associated	O	O
osteoporosis	O	O
,	O	O
eosinophilia	O	O
,	O	O
skin	O	O
reactions	O	O
,	O	O
allergic	O	O
reactions	O	O
other	O	O
than	O	O
thrombocytopenia	O	O
,	O	O
alopecia	O	O
,	O	O
transaminasemia	O	O
,	O	O
hyperkalemia	O	O
,	O	O
hypoaldosteronism	O	O
,	O	O
and	O	O
priapism	O	O
.	O	O

these	O	O
side	O	O
effects	O	O
are	O	O
relatively	O	O
rare	O	O
in	O	O
a	O	O
given	O	O
individual	O	O
,	O	O
but	O	O
given	O	O
the	O	O
extremely	O	O
widespread	O	O
use	O	O
of	O	O
heparin	B-chem	B-chem
,	O	O
some	O	O
are	O	O
quite	O	O
common	O	O
,	O	O
particularly	O	O
hitt	O	O
and	O	O
osteoporosis	O	O
.	O	O

although	O	O
reasonable	O	O
incidences	O	O
of	O	O
many	O	O
of	O	O
these	O	O
side	O	O
effects	O	O
can	O	O
be	O	O
"	O	O
"	O	O
"	O	O
"	O	O
softly	O	O
"	O	O
"	O	O
"	O	O
"	O	O
deduced	O	O
from	O	O
current	O	O
reports	O	O
dealing	O	O
with	O	O
unfractionated	O	O
heparin	B-chem	B-chem
,	O	O
at	O	O
present	O	O
the	O	O
incidences	O	O
of	O	O
these	O	O
side	O	O
effects	O	O
with	O	O
newer	O	O
low	O	O
molecular	O	O
weight	O	O
heparins	B-chem	O
appear	O	O
to	O	O
be	O	O
much	O	O
less	O	O
common	O	O
.	O	O

however	O	O
,	O	O
only	O	O
longer	O	O
experience	O	O
will	O	O
more	O	O
clearly	O	O
define	O	O
the	O	O
incidence	O	O
of	O	O
each	O	O
side	O	O
effect	O	O
with	O	O
low	O	O
molecular	O	O
weight	O	O
preparations	O	O
.	O	O

a	O	O
case	O	O
of	O	O
bilateral	O	O
optic	O	O
neuropathy	O	O
in	O	O
a	O	O
patient	O	O
on	O	O
tacrolimus	B-chem	B-chem
(	O	O
fk506	B-chem	B-chem
)	O	O
therapy	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

purpose	O	O
:	O	O

to	O	O
report	O	O
a	O	O
case	O	O
of	O	O
bilateral	O	O
optic	O	O
neuropathy	O	O
in	O	O
a	O	O
patient	O	O
receiving	O	O
tacrolimus	B-chem	B-chem
(	O	O
fk	B-chem	B-chem
506	I-chem	I-chem
,	O	O
prograf	O	B-chem
;	O	O
fujisawa	O	O
usa	O	O
,	O	O
inc	O	O
,	O	O
deerfield	O	O
,	O	O
illinois	O	O
)	O	O
for	O	O
immunosuppression	O	O
after	O	O
orthotropic	O	O
liver	O	O
transplantation	O	O
.	O	O

method	O	O
:	O	O

case	O	O
report	O	O
.	O	O

in	O	O
a	O	O
58	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
receiving	O	O
tacrolimus	B-chem	B-chem
after	O	O
orthotropic	O	O
liver	O	O
transplantation	O	O
,	O	O
serial	O	O
neuro	O	O
-	O	O
ophthalmologic	O	O
examinations	O	O
and	O	O
laboratory	O	O
studies	O	O
were	O	O
performed	O	O
.	O	O

results	O	O
:	O	O

the	O	O
patient	O	O
had	O	O
episodic	O	O
deterioration	O	O
of	O	O
vision	O	O
in	O	O
both	O	O
eyes	O	O
,	O	O
with	O	O
clinical	O	O
features	O	O
resembling	O	O
ischemic	O	O
optic	O	O
neuropathies	O	O
.	O	O

deterioration	O	O
of	O	O
vision	O	O
occurred	O	O
despite	O	O
discontinuation	O	O
of	O	O
the	O	O
tacrolimus	B-chem	B-chem
.	O	O

conclusion	O	O
:	O	O

tacrolimus	B-chem	B-chem
and	O	O
other	O	O
immunosuppressive	O	O
agents	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
optic	O	O
nerve	O	O
toxicity	O	O
.	O	O

hypercalcemia	O	O
,	O	O
arrhythmia	O	O
,	O	O
and	O	O
mood	O	O
stabilizers	O	O
.	O	O

recent	O	O
findings	O	O
in	O	O
a	O	O
bipolar	O	O
patient	O	O
receiving	O	O
maintenance	O	O
lithium	B-chem	B-chem
therapy	O	O
who	O	O
developed	O	O
hypercalcemia	O	O
and	O	O
severe	O	O
bradyarrhythmia	O	O
prompted	O	O
the	O	O
authors	O	O
to	O	O
conduct	O	O
a	O	O
retrospective	O	O
study	O	O
of	O	O
bipolar	O	O
patients	O	O
with	O	O
lithium	B-chem	B-chem
-	O	O
associated	O	O
hypercalcemia	O	O
.	O	O

a	O	O
printout	O	O
of	O	O
all	O	O
cases	O	O
of	O	O
hypercalcemia	O	O
that	O	O
presented	O	O
during	O	O
a	O	O
1	O	O
-	O	O
year	O	O
period	O	O
was	O	O
generated	O	O
.	O	O

after	O	O
eliminating	O	O
spurious	O	O
hypercalcemias	O	O
or	O	O
those	O	O
associated	O	O
with	O	O
intravenous	O	O
fluids	O	O
,	O	O
the	O	O
authors	O	O
identified	O	O
18	O	O
non	O	O
-	O	O
lithium	B-chem	B-chem
-	O	O
treated	O	O
patients	O	O
with	O	O
hypercalcemias	O	O
related	O	O
to	O	O
malignancies	O	O
and	O	O
other	O	O
medical	O	O
conditions	O	O
(	O	O
group	O	O
a	O	O
)	O	O
and	O	O
12	O	O
patients	O	O
with	O	O
lithium	B-chem	B-chem
-	O	O
associated	O	O
hypercalcemia	O	O
(	O	O
group	O	O
b	O	O
)	O	O
.	O	O

patients	O	O
in	O	O
group	O	O
b	O	O
were	O	O
not	O	O
comparable	O	O
to	O	O
those	O	O
in	O	O
group	O	O
a	O	O
,	O	O
as	O	O
the	O	O
latter	O	O
were	O	O
medically	O	O
compromised	O	O
and	O	O
were	O	O
receiving	O	O
multiple	O	O
pharmacotherapies	O	O
.	O	O

thus	O	O
,	O	O
two	O	O
control	O	O
groups	O	O
were	O	O
generated	O	O
:	O	O
group	O	O
c1	O	O
,	O	O
which	O	O
included	O	O
age	O	O
-	O	O
and	O	O
sex	O	O
-	O	O
comparable	O	O
lithium	B-chem	B-chem
-	O	O
treated	O	O
bipolar	O	O
normocalcemic	O	O
patients	O	O
,	O	O
and	O	O
group	O	O
c2	O	O
,	O	O
which	O	O
included	O	O
bipolar	O	O
normocalcemic	O	O
patients	O	O
treated	O	O
with	O	O
anticonvulsant	O	O
mood	O	O
stabilizers	O	O
.	O	O

the	O	O
electrocardiographic	O	O
(	O	O
ecg	O	O
)	O	O
findings	O	O
for	O	O
patients	O	O
in	O	O
group	O	O
b	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
patients	O	O
in	O	O
groups	O	O
c1	O	O
and	O	O
c2	O	O
.	O	O

it	O	O
was	O	O
found	O	O
that	O	O
these	O	O
groups	O	O
did	O	O
not	O	O
differ	O	O
in	O	O
their	O	O
overall	O	O
frequency	O	O
of	O	O
ecg	O	O
abnormalities	O	O
;	O	O
however	O	O
,	O	O
there	O	O
were	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
frequency	O	O
of	O	O
conduction	O	O
defects	O	O
.	O	O

patients	O	O
with	O	O
hypercalcemia	O	O
resulting	O	O
from	O	O
medical	O	O
diseases	O	O
and	O	O
bipolar	O	O
patients	O	O
with	O	O
lithium	B-chem	B-chem
-	O	O
associated	O	O
hypercalcemia	O	O
had	O	O
significantly	O	O
higher	O	O
frequencies	O	O
of	O	O
conduction	O	O
defects	O	O
.	O	O

patients	O	O
in	O	O
group	O	O
a	O	O
had	O	O
significant	O	O
mortality	O	O
at	O	O
2	O	O
-	O	O
year	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
28	O	O
%	O	O
)	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
zero	O	O
mortality	O	O
in	O	O
the	O	O
other	O	O
three	O	O
groups	O	O
.	O	O

the	O	O
clinical	O	O
implications	O	O
of	O	O
these	O	O
findings	O	O
are	O	O
discussed	O	O
.	O	O

attenuation	O	O
of	O	O
nephrotoxicity	O	O
by	O	O
a	O	O
novel	O	O
lipid	O	O
nanosphere	O	O

(	O	O
ns	O	B-chem
-	O	I-chem
718	O	I-chem
)	O	O
incorporating	O	O
amphotericin	B-chem	B-chem
b	I-chem	I-chem
.	O	O
ns	O	B-chem
-	O	I-chem
718	O	I-chem
,	O	O
a	O	O
lipid	O	O
nanosphere	O	O
incorporating	O	O
amphotericin	B-chem	B-chem
b	I-chem	I-chem
,	O	O
is	O	O
effective	O	O
against	O	O
pathogenic	O	O
fungi	O	O
and	O	O
has	O	O
low	O	O
toxicity	O	O
.	O	O

we	O	O
compared	O	O
the	O	O
toxicity	O	O
of	O	O
ns	O	O
-	O	O
718	O	O
with	O	O
that	O	O
of	O	O
fungizone	B-chem	B-chem
(	O	O
amphotericin	B-chem	B-chem
b	I-chem	I-chem
-	I-chem	I-chem
sodium	I-chem	B-chem
deoxycholate	I-chem	I-chem
;	O	O
d	B-chem	B-chem
-	I-chem	I-chem
amb	I-chem	I-chem
)	O	O
in	O	O
vitro	O	O
using	O	O
renal	O	O
cell	O	O
cultures	O	O
and	O	O
in	O	O
vivo	O	O
by	O	O
biochemical	O	O
analysis	O	O
,	O	O
histopathological	O	O
study	O	O
of	O	O
the	O	O
kidney	O	O
and	O	O
pharmacokinetic	O	O
study	O	O
of	O	O
amphotericin	B-chem	B-chem
b	I-chem	I-chem
following	O	O
intravenous	O	O
infusion	O	O
of	O	O
the	O	O
formulation	O	O
in	O	O
rats	O	O
.	O	O

incubation	O	O
with	O	O
ns	O	B-chem
-	O	I-chem
718	O	I-chem
resulted	O	O
in	O	O
significantly	O	O
less	O	O
damage	O	O
of	O	O
cultured	O	O
human	O	O
renal	O	O
proximal	O	O
tubular	O	O
epithelial	O	O
cells	O	O
compared	O	O
with	O	O
d	B-chem	O
-	I-chem	O
amb	I-chem	B-chem
.	O	O
serum	O	O
blood	O	B-chem
urea	B-chem	I-chem
and	O	O
creatinine	B-chem	B-chem
concentrations	O	O
increased	O	O
significantly	O	O
in	O	O
rats	O	O
given	O	O
an	O	O
iv	O	O
infusion	O	O
of	O	O
d	B-chem	B-chem
-	I-chem	I-chem
amb	I-chem	I-chem
3	O	O
mg	O	O
/	O	O
kg	O	O
but	O	O
not	O	O
in	O	O
those	O	O
given	O	O
the	O	O
same	O	O
dose	O	O
of	O	O
ns	O	O
-	O	O
718	O	O
.	O	O

histopathological	O	O
examination	O	O
of	O	O
the	O	O
kidney	O	O
showed	O	O
tubular	O	O
necrosis	O	O
in	O	O
d	B-chem	O
-	I-chem	O
amb	I-chem	B-chem
-	O	O
treated	O	O
rats	O	O
but	O	O
no	O	O
change	O	O
in	O	O
ns	O	O
-	O	O
718	O	I-chem
-	O	O
treated	O	O
rats	O	O
.	O	O

amphotericin	B-chem	B-chem
b	I-chem	I-chem
concentrations	O	O
in	O	O
the	O	O
kidney	O	O
in	O	O
ns	O	O
-	O	O
718	O	I-chem
-	O	O
treated	O	O
rats	O	O
were	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
d	B-chem	O
-	I-chem	O
amb	I-chem	B-chem
-	O	O
treated	O	O
rats	O	O
.	O	O

our	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
results	O	O
suggest	O	O
that	O	O
incorporation	O	O
of	O	O
amphotericin	B-chem	B-chem
b	I-chem	I-chem
into	O	O
lipid	O	O
nanospheres	O	O
of	O	O
ns	O	B-chem
-	O	I-chem
718	O	I-chem
attenuates	O	O
the	O	O
nephrotoxicity	O	O
of	O	O
amphotericin	B-chem	B-chem
b	I-chem	I-chem
.	O	O

patterns	O	O
of	O	O
sulfadiazine	B-chem	B-chem
acute	O	O
nephrotoxicity	O	O
.	O	O

sulfadiazine	B-chem	B-chem
acute	O	O
nephrotoxicity	O	O
is	O	O
reviving	O	O
specially	O	O
because	O	O
of	O	O
its	O	O
use	O	O
in	O	O
toxoplasmosis	O	O
in	O	O
hiv	O	O
-	O	O
positive	O	O
patients	O	O
.	O	O

we	O	O
report	O	O
4	O	O
cases	O	O
,	O	O
one	O	O
of	O	O
them	O	O
in	O	O
a	O	O
previously	O	O
healthy	O	O
person	O	O
.	O	O

under	O	O
treatment	O	O
with	O	O
sulfadiazine	B-chem	B-chem
they	O	O
developed	O	O
oliguria	O	O
,	O	O
abdominal	O	O
pain	O	O
,	O	O
renal	O	O
failure	O	O
and	O	O
showed	O	O
multiple	O	O
radiolucent	O	O
renal	O	O
calculi	O	O
in	O	O
echography	O	O
.	O	O

all	O	O
patients	O	O
recovered	O	O
their	O	O
previous	O	O
normal	O	O
renal	O	O
function	O	O
after	O	O
adequate	O	O
hydration	O	O
and	O	O
alcalinization	O	O
.	O	O

a	O	O
nephrostomy	O	O
tube	O	O
had	O	O
to	O	O
be	O	O
placed	O	O
in	O	O
one	O	O
of	O	O
the	O	O
patients	O	O
for	O	O
ureteral	O	O
lithiasis	O	O
in	O	O
a	O	O
single	O	O
functional	O	O
kidney	O	O
.	O	O

none	O	O
of	O	O
them	O	O
needed	O	O
dialysis	O	O
or	O	O
a	O	O
renal	O	O
biopsy	O	O
because	O	O
of	O	O
a	O	O
typical	O	O
benign	O	O
course	O	O
.	O	O

treatment	O	O
with	O	O
sulfadiazine	B-chem	B-chem
requires	O	O
exquisite	O	O
control	O	O
of	O	O
renal	O	O
function	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
water	O	O
ingestion	O	O
and	O	O
possibly	O	O
the	O	O
alcalinization	O	O
of	O	O
the	O	O
urine	O	O
.	O	O

we	O	O
communicate	O	O
a	O	O
case	O	O
in	O	O
a	O	O
previously	O	O
healthy	O	O
person	O	O
,	O	O
a	O	O
fact	O	O
not	O	O
found	O	O
in	O	O
the	O	O
recent	O	O
literature	O	O
.	O	O

probably	O	O
many	O	O
more	O	O
cases	O	O
are	O	O
not	O	O
detected	O	O
.	O	O

we	O	O
think	O	O
that	O	O
a	O	O
prospective	O	O
study	O	O
would	O	O
be	O	O
useful	O	O
.	O	O

downbeat	O	O
nystagmus	O	O
associated	O	O
with	O	O
intravenous	O	O
patient	O	O
-	O	O
controlled	O	O
administration	O	O
of	O	O
morphine	B-chem	B-chem
.	O	O

implications	O	O
:	O	O

this	O	O
case	O	O
documents	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
dizziness	O	O
with	O	O
downbeating	O	O
nystagmus	O	O
while	O	O
receiving	O	O
a	O	O
relatively	O	O
large	O	O
dose	O	O
of	O	O
iv	O	O
patient	O	O
-	O	O
controlled	O	O
analgesia	O	O
morphine	B-chem	B-chem
.	O	O

although	O	O
there	O	O
have	O	O
been	O	O
case	O	O
reports	O	O
of	O	O
epidural	O	O
morphine	B-chem	B-chem
with	O	O
these	O	O
symptoms	O	O
and	O	O
signs	O	O
,	O	O
this	O	O
has	O	O
not	O	O
been	O	O
previously	O	O
documented	O	O
with	O	O
iv	O	O
or	O	O
patient	O	O
-	O	O
controlled	O	O
analgesia	O	O
morphine	B-chem	B-chem
.	O	O

hemodynamic	O	O
and	O	O
antiadrenergic	O	O
effects	O	O
of	O	O
dronedarone	B-chem	B-chem
and	O	O
amiodarone	B-chem	B-chem
in	O	O
animals	O	O
with	O	O
a	O	O
healed	O	O
myocardial	O	O
infarction	O	O
.	O	O

the	O	O
hemodynamic	O	O
and	O	O
antiadrenergic	O	O
effects	O	O
of	O	O
dronedarone	B-chem	B-chem
,	O	O
a	O	O
noniodinated	O	O
compound	O	O
structurally	O	O
related	O	O
to	O	O
amiodarone	B-chem	B-chem
,	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
amiodarone	B-chem	B-chem
after	O	O
prolonged	O	O
oral	O	O
administration	O	O
,	O	O
both	O	O
at	O	O
rest	O	O
and	O	O
during	O	O
sympathetic	O	O
stimulation	O	O
in	O	O
conscious	O	O
dogs	O	O
with	O	O
a	O	O
healed	O	O
myocardial	O	O
infarction	O	O
.	O	O

all	O	O
dogs	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
randomly	O	O
received	O	O
orally	O	O
dronedarone	B-chem	B-chem
(	O	O
10	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
amiodarone	B-chem	B-chem
(	O	O
10	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
and	O	O
placebo	O	O
twice	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
,	O	O
with	O	O
a	O	O
3	O	O
-	O	O
week	O	O
washout	O	O
between	O	O
consecutive	O	O
treatments	O	O
.	O	O

heart	O	O
rate	O	O
(	O	O
hr	O	O
)	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
mbp	O	O
)	O	O
,	O	O
positive	O	O
rate	O	O
of	O	O
increase	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
(	O	O
+	O	O
lvdp	O	O
/	O	O
dt	O	O
)	O	O
,	O	O
echocardiographically	O	O
assessed	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
(	O	O
lvef	O	O
)	O	O
,	O	O
and	O	O
fractional	O	O
shortening	O	O
(	O	O
fs	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
chronotropic	O	O
response	O	O
to	O	O
isoproterenol	B-chem	B-chem
and	O	O
exercise	O	O
-	O	O
induced	O	O
sympathetic	O	O
stimulation	O	O
were	O	O
evaluated	O	O
under	O	O
baseline	O	O
and	O	O
posttreatment	O	O
conditions	O	O
.	O	O

resting	O	O
values	O	O
of	O	O
lvef	O	O
,	O	O
fs	O	O
,	O	O
+	O	O
lvdp	O	O
/	O	O
dt	O	O
,	O	O
and	O	O
mbp	O	O
remained	O	O
unchanged	O	O
whatever	O	O
the	O	O
drug	O	O
and	O	O
the	O	O
dosing	O	O
regimen	O	O
,	O	O
whereas	O	O
resting	O	O
hr	O	O
was	O	O
significantly	O	O
and	O	O
dose	O	O
-	O	O
dependently	O	O
lowered	O	O
after	O	O
dronedarone	B-chem	B-chem
and	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
after	O	O
amiodarone	B-chem	B-chem
.	O	O

both	O	O
dronedarone	B-chem	B-chem
and	O	O
amiodarone	B-chem	B-chem
significantly	O	O
reduced	O	O
the	O	O
exercise	O	O
-	O	O
induced	O	O
tachycardia	O	O
and	O	O
,	O	O
at	O	O
the	O	O
highest	O	O
dose	O	O
,	O	O
decreased	O	O
the	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
tachycardia	O	O
.	O	O

thus	O	O
,	O	O
dronedarone	B-chem	B-chem
and	O	O
amiodarone	B-chem	B-chem
displayed	O	O
a	O	O
similar	O	O
level	O	O
of	O	O
antiadrenergic	O	O
effect	O	O
and	O	O
did	O	O
not	O	O
impair	O	O
the	O	O
resting	O	O
left	O	O
ventricular	O	O
function	O	O
.	O	O

consequently	O	O
,	O	O
dronedarone	B-chem	B-chem
might	O	O
be	O	O
particularly	O	O
suitable	O	O
for	O	O
the	O	O
treatment	O	O
and	O	O
prevention	O	O
of	O	O
various	O	O
clinical	O	O
arrhythmias	O	O
,	O	O
without	O	O
compromising	O	O
the	O	O
left	O	O
ventricular	O	O
function	O	O
.	O	O

phase	O	O
2	O	O
trial	O	O
of	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
(	O	O
40	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
)	O	O
in	O	O
platinum	B-chem	O
/	O	O
paclitaxel	B-chem	B-chem
-	O	O
refractory	O	O
ovarian	O	O
and	O	O
fallopian	O	O
tube	O	O
cancers	O	O
and	O	O
primary	O	O
carcinoma	O	O
of	O	O
the	O	O
peritoneum	O	O
.	O	O

background	O	O
:	O	O
several	O	O
studies	O	O
have	O	O
demonstrated	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
(	O	O
doxil	B-chem	B-chem
)	O	O
to	O	O
be	O	O
an	O	O
active	O	O
antineoplastic	O	O
agent	O	O
in	O	O
platinum	B-chem	B-chem
-	O	O
resistant	O	O
ovarian	O	O
cancer	O	O
,	O	O
with	O	O
dose	O	O
limiting	O	O
toxicity	O	O
of	O	O
the	O	O
standard	O	O
dosing	O	O
regimen	O	O
(	O	O
50	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
q	O	O
4	O	O
weeks	O	O
)	O	O
being	O	O
severe	O	O
erythrodysesthesia	O	O
(	O	O
"	O	O
"	O	O
"	O	O
"	O	O
hand	O	O
-	O	O
foot	O	O
syndrome	O	O
"	O	O
"	O	O
"	O	O
"	O	O
)	O	O
and	O	O
stomatitis	O	O
.	O	O

we	O	O
wished	O	O
to	O	O
develop	O	O
a	O	O
more	O	O
tolerable	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
treatment	O	O
regimen	O	B-chem
and	O	O
document	O	O
its	O	O
level	O	O
of	O	O
activity	O	O
in	O	O
a	O	O
well	O	O
-	O	O
defined	O	O
patient	O	O
population	O	O
with	O	O
platinum	B-chem	O
/	O	O
paclitaxel	B-chem	B-chem
-	O	O
refractory	O	O
disease	O	O
.	O	O

methods	O	O
and	O	O
materials	O	O
:	O	O

patients	O	O
with	O	O
ovarian	O	O
or	O	O
fallopian	O	O
tube	O	O
cancers	O	O
or	O	O
primary	O	O
peritoneal	O	O
carcinoma	O	O
with	O	O
platinum	B-chem	B-chem
/	O	O
paclitaxel	B-chem	B-chem
-	O	O
refractory	O	O
disease	O	O
(	O	O
stable	O	O
or	O	O
progressive	O	O
disease	O	O
following	O	O
treatment	O	O
with	O	O
these	O	O
agents	O	O
or	O	O
previous	O	O
objective	O	O
response	O	O
<	O	O
3	O	O
months	O	O
in	O	O
duration	O	O
)	O	O
were	O	O
treated	O	O
with	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
at	O	O
a	O	O
dose	O	O
of	O	O
40	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
q	O	O
4	O	O
weeks	O	O
.	O	O

results	O	O
:	O	O

a	O	O
total	O	O
of	O	O
49	O	O
patients	O	O
(	O	O
median	O	O
age	O	O
:	O	O
60	O	O
;	O	O
range	O	O
41	O	O
-	O	O
81	O	O
)	O	O
entered	O	O
this	O	O
phase	O	O
2	O	O
trial	O	O
.	O	O

the	O	O
median	O	O
number	O	O
of	O	O
prior	O	O
regimens	O	O
was	O	O
2	O	O
(	O	O
range	O	O
:	O	O
1	O	O
-	O	O
6	O	O
)	O	O
.	O	O

six	O	O
(	O	O
12	O	O
%	O	O
)	O	O
and	O	O
4	O	O
(	O	O
8	O	O
%	O	O
)	O	O
patients	O	O
experienced	O	O
grade	O	O
2	O	O
hand	O	O
-	O	O
foot	O	O
syndrome	O	O
and	O	O
stomatitis	O	O
,	O	O
respectively	O	O
(	O	O
no	O	O
episodes	O	O
of	O	O
grade	O	O
3	O	O
)	O	O
.	O	O

one	O	O
patient	O	O
developed	O	O
grade	O	O
3	O	O
diarrhea	O	O
requiring	O	O
hospitalization	O	O
for	O	O
hydration	O	O
.	O	O

six	O	O
(	O	O
12	O	O
%	O	O
)	O	O
individuals	O	O
required	O	O
dose	O	O
reductions	O	O
.	O	O

the	O	O
median	O	O
number	O	O
of	O	O
courses	O	O
of	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
administered	O	O
on	O	O
this	O	O
protocol	O	O
was	O	O
2	O	O
(	O	O
range	O	O
:	O	O
1	O	O
-	O	O
12	O	O
)	O	O
.	O	O

four	O	O
of	O	O
44	O	O
patients	O	O
(	O	O
9	O	O
%	O	O
)	O	O
evaluable	O	O
for	O	O
response	O	O
exhibited	O	O
objective	O	O
and	O	O
subjective	O	O
evidence	O	O
of	O	O
an	O	O
antineoplastic	O	O
effect	O	O
of	O	O
therapy	O	O
.	O	O

conclusion	O	O
:	O	O

this	O	O
modified	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
regimen	O	O
results	O	O
in	O	O
less	O	O
toxicity	O	O
(	O	O
stomatitis	O	O
,	O	O
hand	O	O
-	O	O
foot	O	O
syndrome	O	O
)	O	O
than	O	O
the	O	O
standard	O	O
fda	O	O
-	O	O
approved	O	O
dose	O	O
schedule	O	O
.	O	O

definite	O	O
,	O	O
although	O	O
limited	O	O
,	O	O
antineoplastic	O	O
activity	O	O
is	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
well	O	O
-	O	O
defined	O	O
platinum	B-chem	B-chem
-	O	O
and	O	O
paclitaxel	B-chem	B-chem
-	O	O
refractory	O	O
ovarian	O	O
cancer	O	O
.	O	O

efficacy	O	O
of	O	O
olanzapine	B-chem	B-chem
in	O	O
acute	O	O
bipolar	O	O
mania	O	O
:	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
study	O	O
.	O	O

the	O	O
olanzipine	B-chem	B-chem
hggw	O	O
study	O	O
group	O	O
.	O	O

background	O	O
:	O	O

we	O	O
compared	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
olanzapine	B-chem	B-chem
vs	O	O
placebo	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
bipolar	O	O
mania	O	O
.	O	O

methods	O	O
:	O	O

four	O	O
-	O	O
week	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
parallel	O	O
study	O	O
.	O	O

a	O	O
total	O	O
of	O	O
115	O	O
patients	O	O
with	O	O
a	O	O
dsm	O	O
-	O	O
iv	O	O
diagnosis	O	O
of	O	O
bipolar	O	O
disorder	O	O
,	O	O
manic	O	O
or	O	O
mixed	O	O
,	O	O
were	O	O
randomized	O	O
to	O	O
olanzapine	B-chem	B-chem
,	O	O
5	O	O
to	O	O
20	O	O
mg	O	O
/	O	O
d	O	O
(	O	O
n	O	O
=	O	O
55	O	O
)	O	O
,	O	O
or	O	O
placebo	O	O
(	O	O
n	O	O
=	O	O
60	O	O
)	O	O
.	O	O

the	O	O
primary	O	O
efficacy	O	O
measure	O	O
was	O	O
the	O	O
young	O	O
-	O	O
mania	O	O
rating	O	O
scale	O	O
(	O	O
y	O	O
-	O	O
mrs	O	O
)	O	O
total	O	O
score	O	O
.	O	O

response	O	O
and	O	O
euthymia	O	O
were	O	O
defined	O	O
,	O	O
a	O	O
priori	O	O
,	O	O
as	O	O
at	O	O
least	O	O
a	O	O
50	O	O
%	O	O
improvement	O	O
from	O	O
baseline	O	O
to	O	O
end	O	O
point	O	O
and	O	O
as	O	O
a	O	O
score	O	O
of	O	O
no	O	O
less	O	O
than	O	O
12	O	O
at	O	O
end	O	O
point	O	O
in	O	O
the	O	O
y	O	O
-	O	O
mrs	O	O
total	O	O
score	O	O
,	O	O
respectively	O	O
.	O	O

safety	O	O
was	O	O
assessed	O	O
using	O	O
adverse	O	O
events	O	O
,	O	O
extrapyramidal	O	O
symptom	O	O
(	O	O
eps	O	O
)	O	O
rating	O	O
scales	O	O
,	O	O
laboratory	O	O
values	O	O
,	O	O
electrocardiograms	O	O
,	O	O
vital	O	O
signs	O	O
,	O	O
and	O	O
weight	O	O
change	O	O
.	O	O

results	O	O
:	O	O

olanzapine	B-chem	B-chem
-	O	O
treated	O	O
patients	O	O
demonstrated	O	O
a	O	O
statistically	O	O
significant	O	O
greater	O	O
mean	O	O
(	O	O
+	O	O
/	O	O
-	O	O

sd	O	O
)	O	O
improvement	O	O
in	O	O
y	O	O
-	O	O
mrs	O	O
total	O	O
score	O	O
than	O	O
placebo	O	O
-	O	O
treated	O	O
patients	O	O
(	O	O
-	O	O
14	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

12	O	O
.	O	O
5	O	O
and	O	O
-	O	O
8	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O

12	O	O
.	O	O
7	O	O
,	O	O
respectively	O	O
;	O	O
p	O	O
<	O	O
.	O	O
001	O	O
)	O	O
,	O	O
which	O	O
was	O	O
evident	O	O
at	O	O
the	O	O
first	O	O
postbaseline	O	O
observation	O	O
1	O	O
week	O	O
after	O	O
randomization	O	O
and	O	O
was	O	O
maintained	O	O
throughout	O	O
the	O	O
study	O	O
(	O	O
last	O	O
observation	O	O
carried	O	O
forward	O	O
)	O	O
.	O	O

olanzapine	B-chem	B-chem
-	O	O
treated	O	O
patients	O	O
demonstrated	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
response	O	O
(	O	O
65	O	O
%	O	O
vs	O	O
43	O	O
%	O	O
,	O	O
respectively	O	O
;	O	O
p	O	O
=	O	O
.	O	O
02	O	O
)	O	O
and	O	O
euthymia	O	O
(	O	O
61	O	O
%	O	O
vs	O	O
36	O	O
%	O	O
,	O	O
respectively	O	O
;	O	O
p	O	O
=	O	O
.	O	O

01	O	O
)	O	O
than	O	O
placebo	O	O
-	O	O
treated	O	O
patients	O	O
.	O	O

there	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
epss	O	O
between	O	O
groups	O	O
.	O	O

however	O	O
,	O	O
olanzapine	B-chem	B-chem
-	O	O
treated	O	O
patients	O	O
had	O	O
a	O	O
statistically	O	O
significant	O	O
greater	O	O
mean	O	O
(	O	O
+	O	O
/	O	O
-	O	O

sd	O	O
)	O	O
weight	O	O
gain	O	O
than	O	O
placebo	O	O
-	O	O
treated	O	O
patients	O	O
(	O	O
2	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O

2	O	O
.	O	O
8	O	O
vs	O	O
0	O	O
.	O	O
45	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O
3	O	O
kg	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
also	O	O
experienced	O	O
more	O	O
treatment	O	O
-	O	O
emergent	O	O
somnolence	O	O
(	O	O
21	O	O
patients	O	O
[	O	O
38	O	O
.	O	O
2	O	O
%	O	O
]	O	O
vs	O	O
5	O	O
[	O	O
8	O	O
.	O	O
3	O	O
%	O	O
]	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

olanzapine	B-chem	B-chem
demonstrated	O	O
greater	O	O
efficacy	O	O
than	O	O
placebo	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
bipolar	O	O
mania	O	O
and	O	O
was	O	O
generally	O	O
well	O	O
tolerated	O	O
.	O	O

the	O	O
effect	O	O
of	O	O
pupil	O	O
dilation	O	O
with	O	O
tropicamide	B-chem	B-chem
on	O	O
vision	O	O
and	O	O
driving	O	O
simulator	O	O
performance	O	O
.	O	O

purpose	O	O
:	O	O

to	O	O
assess	O	O
the	O	O
effect	O	O
of	O	O
pupil	O	O
dilation	O	O
on	O	O
vision	O	O
and	O	O
driving	O	O
ability	O	O
.	O	O

methods	O	O
:	O	O

a	O	O
series	O	O
of	O	O
tests	O	O
on	O	O
various	O	O
parameters	O	O
of	O	O
visual	O	O
function	O	O
and	O	O
driving	O	O
simulator	O	O
performance	O	O
were	O	O
performed	O	O
on	O	O
12	O	O
healthy	O	O
drivers	O	O
,	O	O
before	O	O
and	O	O
after	O	O
pupil	O	O
dilation	O	O
using	O	O
guttae	O	O
tropicamide	B-chem	B-chem
1	O	O
%	O	O
.	O	O

a	O	O
driving	O	O
simulator	O	O
(	O	O
transport	O	O
research	O	O
laboratory	O	O
)	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
reaction	O	O
time	O	O
(	O	O
rt	O	O
)	O	O
,	O	O
speed	O	O
maintenance	O	O
and	O	O
steering	O	O
accuracy	O	O
.	O	O

tests	O	O
of	O	O
basic	O	O
visual	O	O
function	O	O
included	O	O
high	O	O
-	O	O
and	O	O
low	O	O
-	O	O
contrast	O	O
visual	O	O
acuity	O	O
(	O	O
hcva	O	O
and	O	O
lcva	O	O
)	O	O
,	O	O
pelli	O	O
-	O	O
robson	O	O
contrast	O	O
threshold	O	O
(	O	O
ct	O	O
)	O	O
and	O	O
goldmann	O	O
perimetry	O	O
(	O	O
fields	O	O
)	O	O
.	O	O

useful	O	O
field	O	O
of	O	O
view	O	O

(	O	O
ufov	O	B-chem
-	O	I-chem
-	O	O
a	O	O
test	O	O
of	O	O
visual	O	O
attention	O	O
)	O	O
was	O	O
also	O	O
undertaken	O	O
.	O	O

the	O	O
mean	O	O
differences	O	O
in	O	O
the	O	O
pre	O	O
-	O	O
and	O	O
post	O	O
-	O	O
dilatation	O	O
measurements	O	O
were	O	O
tested	O	O
for	O	O
statistical	O	O
significance	O	O
at	O	O
the	O	O
95	O	O
%	O	O
level	O	O
using	O	O
one	O	O
-	O	O
tail	O	O
paired	O	O
t	O	O
-	O	O
tests	O	O
.	O	O

results	O	O
:	O	O

pupillary	O	O
dilation	O	O
resulted	O	O
in	O	O
a	O	O
statistically	O	O
significant	O	O
deterioration	O	O
in	O	O
ct	O	O
and	O	O
hcva	O	O
only	O	O
.	O	O

five	O	O
of	O	O
12	O	O
drivers	O	O
also	O	O
exhibited	O	O
deterioration	O	O
in	O	O
lcva	O	O
,	O	O
ct	O	O
and	O	O
rt	O	O
.	O	O

little	O	O
evidence	O	O
emerged	O	O
for	O	O
deterioration	O	O
in	O	O
fields	O	O
and	O	O
ufov	O	O
.	O	O

also	O	O
,	O	O
7	O	O
of	O	O
12	O	O
drivers	O	O
appeared	O	O
to	O	O
adjust	O	O
their	O	O
driving	O	O
behaviour	O	O
by	O	O
reducing	O	O
their	O	O
speed	O	O
on	O	O
the	O	O
driving	O	O
simulator	O	O
,	O	O
leading	O	O
to	O	O
improved	O	O
steering	O	O
accuracy	O	O
.	O	O

conclusions	O	O
:	O	O

pupillary	O	O
dilation	O	O
may	O	O
lead	O	O
to	O	O
a	O	O
decrease	O	O
in	O	O
vision	O	O
and	O	O
daylight	O	O
driving	O	O
performance	O	O
in	O	O
young	O	O
people	O	O
.	O	O

a	O	O
larger	O	O
study	O	O
,	O	O
including	O	O
a	O	O
broader	O	O
spectrum	O	O
of	O	O
subjects	O	O
,	O	O
is	O	O
warranted	O	O
before	O	O
guidelines	O	O
can	O	O
be	O	O
recommended	O	O
.	O	O

a	O	O
case	O	O
of	O	O
isotretinoin	O	B-chem
embryopathy	O	O
with	O	O
bilateral	O	O
anotia	O	O
and	O	O
taussig	O	O
-	O	O
bing	O	O
malformation	O	O
.	O	O

we	O	O
report	O	O
a	O	O
newborn	O	O
infant	O	O
with	O	O
multiple	O	O
congenital	O	O
anomalies	O	O
(	O	O
anotia	O	O
and	O	O
taussig	O	O
-	O	O
bing	O	O
malformation	O	O
)	O	O
due	O	O
to	O	O
exposure	O	O
to	O	O
isotretinoin	B-chem	B-chem
within	O	O
the	O	O
first	O	O
trimester	O	O
.	O	O

in	O	O
this	O	O
paper	O	O
we	O	O
aim	O	O
to	O	O
draw	O	O
to	O	O
the	O	O
fact	O	O
that	O	O
caution	O	O
is	O	O
needed	O	O
when	O	O
prescribing	O	O
vitamin	B-chem	B-chem
a	I-chem	I-chem
-	O	O
containing	O	O
drugs	O	O
to	O	O
women	O	O
of	O	O
childbearing	O	O
years	O	O
.	O	O

effect	O	O
of	O	O
methoxamine	B-chem	B-chem
on	O	O
maximum	O	O
urethral	O	O
pressure	O	O
in	O	O
women	O	O
with	O	O
genuine	O	O
stress	O	O
incontinence	O	O
:	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
crossover	O	O
study	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
potential	O	O
role	O	O
for	O	O
a	O	O
selective	O	O
alpha1	O	O
-	O	O
adrenoceptor	O	O
agonist	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
urinary	O	O
stress	O	O
incontinence	O	O
.	O	O

a	O	O
randomised	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
crossover	O	O
study	O	O
design	O	O
was	O	O
employed	O	O
.	O	O

half	O	O
log	O	O
incremental	O	O
doses	O	O
of	O	O
intravenous	O	O
methoxamine	B-chem	B-chem
or	O	O
placebo	O	O
(	O	O
saline	O	O
)	O	O
were	O	O
administered	O	O
to	O	O
a	O	O
group	O	O
of	O	O
women	O	O
with	O	O
genuine	O	O
stress	O	O
incontinence	O	O
while	O	O
measuring	O	O
maximum	O	O
urethral	O	O
pressure	O	O
(	O	O
mup	O	O
)	O	O
,	O	O
blood	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
symptomatic	O	O
side	O	O
effects	O	O
.	O	O

methoxamine	B-chem	B-chem
evoked	O	O
non	O	O
-	O	O
significant	O	O
increases	O	O
in	O	O
mup	O	B-chem
and	O	O
diastolic	O	O
blood	O	O
pressure	O	O
but	O	O
caused	O	O
a	O	O
significant	O	O
rise	O	O
in	O	O
systolic	O	O
blood	O	O
pressure	O	O
and	O	O
significant	O	O
fall	O	O
in	O	O
heart	O	O
rate	O	O
at	O	O
maximum	O	O
dosage	O	O
.	O	O

systemic	O	O
side	O	O
effects	O	O
including	O	O
piloerection	O	O
,	O	O
headache	O	O
,	O	O
and	O	O
cold	O	O
extremities	O	O
were	O	O
experienced	O	O
in	O	O
all	O	O
subjects	O	O
.	O	O

the	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
clinical	O	O
usefulness	O	O
of	O	O
direct	O	O
,	O	O
peripherally	O	O
acting	O	O
sub	O	O
-	O	O
type	O	O
-	O	O
selective	O	O
alpha1	O	O
-	O	O
adrenoceptor	O	O
agonists	O	O
in	O	O
the	O	O
medical	O	O
treatment	O	O
of	O	O
stress	O	O
incontinence	O	O
may	O	O
be	O	O
limited	O	O
by	O	O
associated	O	O
piloerection	O	O
and	O	O
cardiovascular	O	O
side	O	O
effects	O	O
.	O	O

toleration	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
angiotensin	B-chem	B-chem
-	I-chem	O
converting	I-chem	O
enzyme	I-chem	O
inhibitors	I-chem	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
heart	O	O
failure	O	O
:	O	O
results	O	O
from	O	O
the	O	O
atlas	O	O
trial	O	O
.	O	O

the	O	O
assessment	O	O
of	O	O
treatment	O	O
with	O	O
lisinopril	B-chem	B-chem
and	O	O
survival	O	O
.	O	O

background	O	O
:	O	O
treatment	O	O
with	O	O
angiotensin	B-chem	B-chem
-	I-chem	O
converting	I-chem	O
enzyme	I-chem	O
(	I-chem	O
ace	I-chem	I-chem
)	I-chem	O
inhibitors	I-chem	O
reduces	O	O
mortality	O	O
and	O	O
morbidity	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
heart	O	O
failure	O	O
(	O	O
chf	O	O
)	O	O
,	O	O
but	O	O
most	O	O
affected	O	O
patients	O	O
are	O	O
not	O	O
receiving	O	O
these	O	O
agents	O	O
or	O	O
are	O	O
being	O	O
treated	O	O
with	O	O
doses	O	O
lower	O	O
than	O	O
those	O	O
found	O	O
to	O	O
be	O	O
efficacious	O	O
in	O	O
trials	O	O
,	O	O
primarily	O	O
because	O	O
of	O	O
concerns	O	O
about	O	O
the	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
these	O	O
agents	O	O
,	O	O
especially	O	O
at	O	O
the	O	O
recommended	O	O
doses	O	O
.	O	O

the	O	O
present	O	O
study	O	O
examines	O	O
the	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
high	O	O
-	O	O
compared	O	O
with	O	O
low	O	O
-	O	O
dose	O	O
lisinopril	B-chem	B-chem
in	O	O
chf	O	O
.	O	O

methods	O	O
:	O	O

the	O	O
assessment	O	O
of	O	O
lisinopril	B-chem	B-chem
and	O	O
survival	O	O
study	O	O
was	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
trial	O	O
in	O	O
which	O	O
patients	O	O
with	O	O
or	O	O
without	O	O
previous	O	O
ace	B-chem	O
inhibitor	I-chem	O
treatment	O	O
were	O	O
stabilized	O	O
receiving	O	O
medium	O	O
-	O	O
dose	O	O
lisinopril	B-chem	B-chem
(	O	O
12	O	O
.	O	O
5	O	O
or	O	O
15	O	O
.	O	O
0	O	O
mg	O	O
once	O	O
daily	O	O
[	O	O
od	O	O
]	O	O
)	O	O
for	O	O
2	O	O
to	O	O
4	O	O
weeks	O	O
and	O	O
then	O	O
randomized	O	O
to	O	O
high	O	O
-	O	O
(	O	O
35	O	O
.	O	O
0	O	O
or	O	O
32	O	O
.	O	O
5	O	O
mg	O	O
od	O	O
)	O	O
or	O	O
low	O	O
-	O	O
dose	O	O
(	O	O
5	O	O
.	O	O
0	O	O
or	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
od	O	O
)	O	O
groups	O	O
.	O	O

patients	O	O
with	O	O
new	O	O
york	O	O
heart	O	O
association	O	O
classes	O	O
ii	O	O
to	O	O
iv	O	O
chf	O	O
and	O	O
left	O	O
ventricular	O	O
ejection	O	O
fractions	O	O
of	O	O
no	O	O
greater	O	O
than	O	O
0	O	O
.	O	O
30	O	O

(	O	O
n	O	O
=	O	O
3164	O	O
)	O	O
were	O	O
randomized	O	O
and	O	O
followed	O	O
up	O	O
for	O	O
a	O	O
median	O	O
of	O	O
46	O	O
months	O	O
.	O	O

we	O	O
examined	O	O
the	O	O
occurrence	O	O
of	O	O
adverse	O	O
events	O	O
and	O	O
the	O	O
need	O	O
for	O	O
discontinuation	O	O
and	O	O
dose	O	O
reduction	O	O
during	O	O
treatment	O	O
,	O	O
with	O	O
a	O	O
focus	O	O
on	O	O
hypotension	O	O
and	O	O
renal	O	O
dysfunction	O	O
.	O	O

results	O	O
:	O	O

of	O	O
405	O	O
patients	O	O
not	O	O
previously	O	O
receiving	O	O
an	O	O
ace	B-chem	O
inhibitor	I-chem	O
,	O	O
doses	O	O
in	O	O
only	O	O
4	O	O
.	O	O
2	O	O
%	O	O
could	O	O
not	O	O
be	O	O
titrated	O	O
to	O	O
the	O	O
medium	O	O
doses	O	O
required	O	O
for	O	O
randomization	O	O
because	O	O
of	O	O
symptoms	O	O
possibly	O	O
related	O	O
to	O	O
hypotension	O	O
(	O	O
2	O	O
.	O	O
0	O	O
%	O	O
)	O	O
or	O	O
because	O	O
of	O	O
renal	O	O
dysfunction	O	O
or	O	O
hyperkalemia	O	O
(	O	O
2	O	O
.	O	O
3	O	O
%	O	O
)	O	O
.	O	O

doses	O	O
in	O	O
more	O	O
than	O	O
90	O	O
%	O	O
of	O	O
randomized	O	O
patients	O	O
in	O	O
the	O	O
high	O	O
-	O	O
and	O	O
low	O	O
-	O	O
dose	O	O
groups	O	O
were	O	O
titrated	O	O
to	O	O
their	O	O
assigned	O	O
target	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
doses	O	O
of	O	O
blinded	O	O
medication	O	O
in	O	O
both	O	O
groups	O	O
remained	O	O
similar	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

withdrawals	O	O
occurred	O	O
in	O	O
27	O	O
.	O	O
1	O	O
%	O	O
of	O	O
the	O	O
high	O	O
-	O	O
and	O	O
30	O	O
.	O	O
7	O	O
%	O	O
of	O	O
the	O	O
low	O	O
-	O	O
dose	O	O
groups	O	O
.	O	O

subgroups	O	O
presumed	O	O
to	O	O
be	O	O
at	O	O
higher	O	O
risk	O	O
for	O	O
ace	B-chem	O
inhibitor	I-chem	O
intolerance	O	O
(	O	O
blood	O	O
pressure	O	O
,	O	O

<	O	O
120	O	O
mm	O	O
hg	O	O
;	O	O
creatinine	B-chem	B-chem
,	O	O
>	O	O
or	O	O
=	O	O
132	O	O
.	O	O
6	O	O
micromol	O	O
/	O	O
l	O	O
[	O	O
>	O	O
or	O	O
=	O	O
1	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
dl	O	O
]	O	O
;	O	O
age	O	O
,	O	O
>	O	O
or	O	O
=	O	O
70	O	O
years	O	O
;	O	O
and	O	O
patients	O	O
with	O	O
diabetes	O	O
)	O	O
generally	O	O
tolerated	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
strategy	O	O
.	O	O

conclusions	O	O
:	O	O

these	O	O
findings	O	O
demonstrate	O	O
that	O	O
ace	B-chem	O
inhibitor	I-chem	O
therapy	O	O
in	O	O
most	O	O
patients	O	O
with	O	O
chf	O	O
can	O	O
be	O	O
successfully	O	O
titrated	O	O
to	O	O
and	O	O
maintained	O	O
at	O	O
high	O	O
doses	O	O
,	O	O
and	O	O
that	O	O
more	O	O
aggressive	O	O
use	O	O
of	O	O
these	O	O
agents	O	O
is	O	O
warranted	O	O
.	O	O

cocaine	B-chem	B-chem
,	O	O
ethanol	B-chem	B-chem
,	O	O
and	O	O
cocaethylene	B-chem	O
cardiotoxity	O	O
in	O	O
an	O	O
animal	O	O
model	O	O
of	O	O
cocaine	O	B-chem
and	O	O
ethanol	O	O
abuse	O	O
.	O	O

objectives	O	O
:	O	O

simultaneous	O	O
abuse	O	O
of	O	O
cocaine	O	B-chem
and	O	O
ethanol	O	B-chem
affects	O	O
12	O	O
million	O	O
americans	O	O
annually	O	O
.	O	O

in	O	O
combination	O	O
,	O	O
these	O	O
substances	O	O
are	O	O
substantially	O	O
more	O	O
toxic	O	O
than	O	O
either	O	O
drug	O	O
alone	O	O
.	O	O

their	O	O
combined	O	O
cardiac	O	O
toxicity	O	O
may	O	O
be	O	O
due	O	O
to	O	O
independent	O	O
effects	O	O
of	O	O
each	O	O
drug	O	O
;	O	O
however	O	O
,	O	O
they	O	O
may	O	O
also	O	O
be	O	O
due	O	O
to	O	O
cocaethylene	B-chem	B-chem
(	O	O
ce	B-chem	B-chem
)	O	O
,	O	O
a	O	O
cocaine	B-chem	B-chem
metabolite	O	O
formed	O	O
only	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
ethanol	B-chem	B-chem
.	O	O

the	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
delineate	O	O
the	O	O
role	O	O
of	O	O
ce	B-chem	B-chem
in	O	O
the	O	O
combined	O	O
cardiotoxicity	O	O
of	O	O
cocaine	B-chem	B-chem
and	O	O
ethanol	B-chem	B-chem
in	O	O
a	O	O
model	O	O
simulating	O	O
their	O	O
abuse	O	O
.	O	O

methods	O	O
:	O	O

twenty	O	O
-	O	O
three	O	O
dogs	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
1	O	O
)	O	O
three	O	O
intravenous	O	O
(	O	O
iv	O	O
)	O	O
boluses	O	O
of	O	O
cocaine	B-chem	B-chem
7	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
with	O	O
ethanol	B-chem	B-chem
(	O	O
1	O	O
g	O	O
/	O	O
kg	O	O
)	O	O
as	O	O
an	O	O
iv	O	O
infusion	O	O
(	O	O
c	O	O
+	O	O
e	O	O
,	O	O
n	O	O
=	O	O
8	O	O
)	O	O
,	O	O
2	O	O
)	O	O
three	O	O
cocaine	B-chem	B-chem
boluses	O	O
only	O	O
(	O	O
c	O	O
,	O	O
n	O	O
=	O	O
6	O	O
)	O	O
,	O	O
3	O	O
)	O	O
ethanol	B-chem	B-chem
infusion	O	O
only	O	O
(	O	O
e	O	O
,	O	O
n	O	O
=	O	O
5	O	O
)	O	O
,	O	O
or	O	O
4	O	O
)	O	O
placebo	O	O
boluses	O	O
and	O	O
infusion	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
.	O	O

hemodynamic	O	O
measurements	O	O
,	O	O
electrocardiograms	O	O
,	O	O
and	O	O
serum	O	O
drug	O	O
concentrations	O	O
were	O	O
obtained	O	O
at	O	O
baseline	O	O
,	O	O
and	O	O
then	O	O
at	O	O
fixed	O	O
time	O	O
intervals	O	O
after	O	O
each	O	O
drug	O	O
was	O	O
administered	O	O
.	O	O

results	O	O
:	O	O

two	O	O
of	O	O
eight	O	O
dogs	O	O
in	O	O
the	O	O
c	O	O
+	O	O
e	O	O
group	O	O
experienced	O	O
cardiovascular	O	O
collapse	O	O
.	O	O

the	O	O
most	O	O
dramatic	O	O
hemodynamic	O	O
changes	O	O
occurred	O	O
after	O	O
each	O	O
cocaine	B-chem	B-chem
bolus	O	O
in	O	O
the	O	O
c	O	O
+	O	O
e	O	O
and	O	O
c	O	O
only	O	O
groups	O	O
;	O	O
however	O	O
,	O	O
persistent	O	O
hemodynamic	O	O
changes	O	O
occurred	O	O
in	O	O
the	O	O
c	O	O
+	O	O
e	O	O
group	O	O
.	O	O

peak	O	O
ce	B-chem	B-chem
levels	O	O
were	O	O
associated	O	O
with	O	O
a	O	O
45	O	O
%	O	O
(	O	O
sd	O	O
+	O	O
/	O	O
-	O	O

22	O	O
%	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
22	O	O
%	O	O
to	O	O
69	O	O
%	O	O
)	O	O
decrease	O	O
in	O	O
cardiac	O	O
output	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
a	O	O
56	O	O
%	O	O
(	O	O
sd	O	O
+	O	O
/	O	O
-	O	O

23	O	O
%	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
32	O	O
%	O	O
to	O	O
80	O	O
%	O	O
)	O	O
decrease	O	O
in	O	O
dp	O	O
/	O	O
dt	O	O
(	O	O
max	O	O
)	O	O
(	O	O
p	O	O
<	O	O
.	O	O
006	O	O
)	O	O
,	O	O
and	O	O
a	O	O
23	O	O
%	O	O
(	O	O
sd	O	O
+	O	O
/	O	O
-	O	O

15	O	O
%	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
7	O	O
%	O	O
to	O	O
49	O	O
%	O	O
)	O	O
decrease	O	O
in	O	O
svo	O	O
(	O	O
2	O	O
)	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
025	O	O
)	O	O
.	O	O

ventricular	O	O
arrhythmias	O	O
were	O	O
primarily	O	O
observed	O	O
in	O	O
the	O	O
c	O	O
+	O	O
e	O	O
group	O	O
,	O	O
in	O	O
which	O	O
four	O	O
of	O	O
eight	O	O
dogs	O	O
experienced	O	O
ventricular	O	O
tachycardia	O	O
.	O	O

conclusions	O	O
:	O	O

cocaine	B-chem	B-chem
and	O	O
ethanol	B-chem	B-chem
in	O	O
combination	O	O
were	O	O
more	O	O
toxic	O	O
than	O	O
either	O	O
substance	O	O
alone	O	O
.	O	O

co	O	O
-	O	O
administration	O	O
resulted	O	O
in	O	O
prolonged	O	O
cardiac	O	O
toxicity	O	O
and	O	O
was	O	O
dysrhythmogenic	O	O
.	O	O

peak	O	O
serum	O	O
cocaethylene	B-chem	O
concentrations	O	O
were	O	O
associated	O	O
with	O	O
prolonged	O	O
myocardial	O	O
depression	O	O
.	O	O

worsening	O	O
of	O	O
parkinsonism	O	O
after	O	O
the	O	O
use	O	O
of	O	O
veralipride	B-chem	B-chem
for	O	O
treatment	O	O
of	O	O
menopause	O	O
:	O	O
case	O	O
report	O	O
.	O	O

we	O	O
describe	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
stable	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
who	O	O
has	O	O
shown	O	O
a	O	O
marked	O	O
worsening	O	O
of	O	O
her	O	O
motor	O	O
functions	O	O
following	O	O
therapy	O	O
of	O	O
menopause	O	O
related	O	O
symptoms	O	O
with	O	O
veralipride	B-chem	B-chem
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
improvement	O	O
of	O	O
her	O	O
symptoms	O	O
back	O	O
to	O	O
baseline	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

we	O	O
emphasize	O	O
the	O	O
anti	O	O
-	O	O
dopaminergic	O	O
effect	O	O
of	O	O
veralipride	B-chem	B-chem
.	O	O

viracept	B-chem	B-chem
and	O	O
irregular	O	O
heartbeat	O	O
warning	O	O
.	O	O

a	O	O
group	O	O
of	O	O
doctors	O	O
in	O	O
boston	O	O
warn	O	O
that	O	O
the	O	O
protease	O	O
inhibitor	O	O
viracept	B-chem	B-chem
may	O	O
cause	O	O
an	O	O
irregular	O	O
heart	O	O
beat	O	O
,	O	O
known	O	O
as	O	O
bradycardia	O	O
,	O	O
in	O	O
people	O	O
with	O	O
hiv	O	O
.	O	O

bradycardia	O	O
occurred	O	O
in	O	O
a	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
who	O	O
was	O	O
viracept	B-chem	B-chem
in	O	O
combination	O	O
with	O	O
other	O	O
anti	O	O
-	O	O
hiv	O	O
drugs	O	O
.	O	O

the	O	O
symptoms	O	O
ceased	O	O
after	O	O
switching	O	O
to	O	O
another	O	O
drug	O	O
combination	O	O
.	O	O

frequency	O	O
of	O	O
appearance	O	O
of	O	O
myeloperoxidase	O	O
-	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
(	O	O
mpo	O	O
-	O	O
anca	O	O
)	O	O
in	O	O
graves	O	O
'	O	O
disease	O	O
patients	O	O
treated	O	O
with	O	O
propylthiouracil	B-chem	B-chem
and	O	O
the	O	O
relationship	O	O
between	O	O
mpo	O	O
-	O	O
anca	O	O
and	O	O
clinical	O	O
manifestations	O	O
.	O	O

objective	O	O
:	O	O
myeloperoxidase	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
(	O	O
mpo	O	O
-	O	O
anca	O	O
)	O	O
-	O	O
positive	O	O
vasculitis	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
patients	O	O
with	O	O
graves	O	O
'	O	O
disease	O	O
who	O	O
were	O	O
treated	O	O
with	O	O
propylthiouracil	B-chem	B-chem
(	O	O
ptu	B-chem	B-chem
)	O	O
.	O	O

the	O	O
appearance	O	O
of	O	O
mpo	O	O
-	O	O
anca	O	O
in	O	O
these	O	O
cases	O	O
was	O	O
suspected	O	O
of	O	O
being	O	O
related	O	O
to	O	O
ptu	B-chem	B-chem
because	O	O
the	O	O
titres	O	O
of	O	O
mpo	O	O
-	O	O
anca	O	O
decreased	O	O
when	O	O
ptu	B-chem	B-chem
was	O	O
stopped	O	O
.	O	O

nevertheless	O	O
,	O	O
there	O	O
have	O	O
been	O	O
no	O	O
studies	O	O
on	O	O
the	O	O
temporal	O	O
relationship	O	O
between	O	O
the	O	O
appearance	O	O
of	O	O
mpo	O	O
-	O	O
anca	O	O
and	O	O
vasculitis	O	O
during	O	O
ptu	B-chem	B-chem
therapy	O	O
,	O	O
or	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
mpo	O	O
-	O	O
anca	O	O
in	O	O
untreated	O	O
graves	O	O
'	O	O
disease	O	O
patients	O	O
.	O	O

therefore	O	O
,	O	O
we	O	O
sought	O	O
to	O	O
address	O	O
these	O	O
parameters	O	O
in	O	O
patients	O	O
with	O	O
graves	O	O
'	O	O
disease	O	O
.	O	O

patients	O	O
:	O	O

we	O	O
investigated	O	O
102	O	O
untreated	O	O
patients	O	O
with	O	O
hyperthyroidism	O	O
due	O	O
to	O	O
graves	O	O
'	O	O
disease	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
mpo	O	O
-	O	O
anca	O	O
,	O	O
and	O	O
for	O	O
the	O	O
development	O	O
vasculitis	O	O
after	O	O
starting	O	O
ptu	B-chem	B-chem
therapy	O	O
.	O	O

twenty	O	O
-	O	O
nine	O	O
of	O	O
them	O	O
were	O	O
later	O	O
excluded	O	O
because	O	O
of	O	O
adverse	O	O
effects	O	O
of	O	O
ptu	B-chem	B-chem
or	O	O
because	O	O
the	O	O
observation	O	O
period	O	O
was	O	O
less	O	O
than	O	O
3	O	O
months	O	O
.	O	O

the	O	O
remaining	O	O
73	O	O
patients	O	O
(	O	O
55	O	O
women	O	O
and	O	O
18	O	O
men	O	O
)	O	O
,	O	O
all	O	O
of	O	O
whom	O	O
were	O	O
examined	O	O
for	O	O
more	O	O
than	O	O
3	O	O
months	O	O
,	O	O
were	O	O
adopted	O	O
as	O	O
the	O	O
subjects	O	O
of	O	O
the	O	O
investigation	O	O
.	O	O

the	O	O
median	O	O
observation	O	O
period	O	O
was	O	O
23	O	O
.	O	O
6	O	O
months	O	O
(	O	O
range	O	O
:	O	O
3	O	O
-	O	O
37	O	O
months	O	O
)	O	O
.	O	O

measurements	O	O
:	O	O

mpo	O	O
-	O	O
anca	O	O
was	O	O
measured	O	O
at	O	O
intervals	O	O
of	O	O
2	O	O
-	O	O
6	O	O
months	O	O
.	O	O

results	O	O
:	O	O

before	O	O
treatment	O	O
,	O	O
the	O	O
mpo	O	O
-	O	O
anca	O	O
titres	O	O
of	O	O
all	O	O
102	O	O
untreated	O	O
graves	O	O
'	O	O
disease	O	O
patients	O	O
were	O	O
within	O	O
the	O	O
reference	O	O
range	O	O
(	O	O
below	O	O
10	O	O
u	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

three	O	O
(	O	O
4	O	O
.	O	O
1	O	O
%	O	O
)	O	O
of	O	O
the	O	O
73	O	O
patients	O	O
were	O	O
positive	O	O
for	O	O
mpo	O	O
-	O	O
anca	O	O
at	O	O
13	O	O
,	O	O
16	O	O
and	O	O
17	O	O
months	O	O
,	O	O
respectively	O	O
,	O	O
after	O	O
the	O	O
start	O	O
of	O	O
ptu	B-chem	B-chem
therapy	O	O
.	O	O

in	O	O
two	O	O
of	O	O
them	O	O
,	O	O
the	O	O
mpo	O	O
-	O	O
anca	O	O
titres	O	O
transiently	O	O
increased	O	O
to	O	O
12	O	O
.	O	O
8	O	O
and	O	O
15	O	O
.	O	O
0	O	O
u	O	O
/	O	O
ml	O	O
,	O	O
respectively	O	O
,	O	O
despite	O	O
continued	O	O
ptu	B-chem	B-chem
therapy	O	O
,	O	O
but	O	O
no	O	O
vasculitic	O	O
disorders	O	O
developed	O	O
.	O	O

in	O	O
the	O	O
third	O	O
patient	O	O
,	O	O
the	O	O
mpo	O	O
-	O	O
anca	O	O
titre	O	O
increased	O	O
to	O	O
204	O	O
u	O	O
/	O	O
ml	O	O
and	O	O
she	O	O
developed	O	O
a	O	O
higher	O	O
fever	O	O
,	O	O
oral	O	O
ulcers	O	O
and	O	O
polyarthralgia	O	O
,	O	O
but	O	O
the	O	O
symptoms	O	O
resolved	O	O
2	O	O
weeks	O	O
after	O	O
stopping	O	O
ptu	B-chem	B-chem
therapy	O	O
,	O	O
and	O	O
the	O	O
mpo	O	O
-	O	O
anca	O	O
titre	O	O
decreased	O	O
to	O	O
20	O	O
.	O	O
7	O	O
u	O	O
/	O	O
ml	O	O
by	O	O
4	O	O
months	O	O
after	O	O
discontinuing	O	O
ptu	B-chem	B-chem
.	O	O

conclusions	O	O
:	O	O

ptu	B-chem	B-chem
therapy	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
appearance	O	O
of	O	O
mpo	O	O
-	O	O
anca	O	O
,	O	O
but	O	O
mpo	O	O
-	O	O
anca	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
closely	O	O
related	O	O
to	O	O
vasculitis	O	O
.	O	O

prevalence	O	O
of	O	O
heart	O	O
disease	O	O
in	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B-chem	B-chem
users	O	O
.	O	O

to	O	O
determine	O	O
the	O	O
prevalence	O	O
of	O	O
heart	O	O
disease	O	O
in	O	O
outpatient	O	O
young	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B-chem	B-chem
users	O	O
,	O	O
35	O	O
cocaine	B-chem	B-chem
users	O	O
and	O	O
32	O	O
age	O	O
-	O	O
matched	O	O
controls	O	O
underwent	O	O
resting	O	O
and	O	O
exercise	O	O
electrocardiography	O	O
(	O	O
ecg	O	O
)	O	O
and	O	O
doppler	O	O
echocardiography	O	O
.	O	O

findings	O	O
consistent	O	O
with	O	O
coronary	O	O
artery	O	O
disease	O	O
were	O	O
detected	O	O
in	O	O
12	O	O
(	O	O
34	O	O
%	O	O
)	O	O
patients	O	O
and	O	O
3	O	O
(	O	O
9	O	O
%	O	O
)	O	O
controls	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

decreased	O	O
left	O	O
ventricular	O	O
systolic	O	O
function	O	O
was	O	O
demonstrated	O	O
in	O	O
5	O	O
(	O	O
14	O	O
%	O	O
)	O	O
patients	O	O
,	O	O
but	O	O
in	O	O
none	O	O
of	O	O
the	O	O
controls	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
055	O	O
)	O	O
.	O	O

finally	O	O
,	O	O
resting	O	O
and	O	O
peak	O	O
exercise	O	O
abnormal	O	O
left	O	O
ventricular	O	O
filling	O	O
was	O	O
detected	O	O
in	O	O
38	O	O
and	O	O
35	O	O
%	O	O
of	O	O
patients	O	O
as	O	O
compared	O	O
to	O	O
19	O	O
and	O	O
9	O	O
%	O	O
of	O	O
controls	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
11	O	O
and	O	O
0	O	O
.	O	O
02	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

we	O	O
conclude	O	O
that	O	O
coronary	O	O
artery	O	O
or	O	O
myocardial	O	O
disease	O	O
is	O	O
common	O	O
(	O	O
38	O	O
%	O	O
)	O	O
in	O	O
young	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B-chem	B-chem
users	O	O
.	O	O

therefore	O	O
,	O	O
screening	O	O
ecg	O	O
and	O	O
echocardiography	O	O
may	O	O
be	O	O
warranted	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

cardioprotective	O	O
effects	O	O
of	O	O
picrorrhiza	O	B-chem
kurroa	O	I-chem
against	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
myocardial	O	O
stress	O	O
in	O	O
rats	O	O
.	O	O

the	O	O
cardioprotective	O	O
effect	O	O
of	O	O
the	O	O
ethanol	B-chem	B-chem
extract	O	I-chem
of	O	O
picrorrhiza	O	O
kurroa	O	O
rhizomes	O	O
and	O	O
roots	O	O
(	O	O
pk	O	O
)	O	O
on	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
myocardial	O	O
infarction	O	O
in	O	O
rats	O	O
with	O	O
respect	O	O
to	O	O
lipid	O	O
metabolism	O	O
in	O	O
serum	O	O
and	O	O
heart	O	O
tissue	O	O
has	O	O
been	O	O
investigated	O	O
.	O	O

oral	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
pk	O	O
(	O	O
80	O	O
mg	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O

day	O	O
(	O	O
-	O	O
1	O	O
)	O	O
for	O	O
15	O	O
days	O	O
)	O	O
significantly	O	O
prevented	O	O
the	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
myocardial	O	O
infarction	O	O
and	O	O
maintained	O	O
the	O	O
rats	O	O
at	O	O
near	O	O
normal	O	O
status	O	O
.	O	O

phase	O	O
2	O	O
early	O	O
afterdepolarization	O	O
as	O	O
a	O	O
trigger	O	O
of	O	O
polymorphic	O	O
ventricular	O	O
tachycardia	O	O
in	O	O
acquired	O	O
long	O	O
-	O	O
qt	O	O
syndrome	O	O
:	O	O
direct	O	O
evidence	O	O
from	O	O
intracellular	O	O
recordings	O	O
in	O	O
the	O	O
intact	O	O
left	O	O
ventricular	O	O
wall	O	O
.	O	O

background	O	O
:	O	O

this	O	O
study	O	O
examined	O	O
the	O	O
role	O	O
of	O	O
phase	O	O
2	O	O
early	O	O
afterdepolarization	O	O
(	O	O
ead	O	O
)	O	O
in	O	O
producing	O	O
a	O	O
trigger	O	O
to	O	O
initiate	O	O
torsade	O	O
de	O	O
pointes	O	O
(	O	O
tdp	O	O
)	O	O
with	O	O
qt	O	O
prolongation	O	O
induced	O	O
by	O	O
dl	O	B-chem
-	O	I-chem
sotalol	B-chem	B-chem
and	O	O
azimilide	B-chem	B-chem
.	O	O

the	O	O
contribution	O	O
of	O	O
transmural	O	O
dispersion	O	O
of	O	O
repolarization	O	O
(	O	O
tdr	O	O
)	O	O
to	O	O
transmural	O	O
propagation	O	O
of	O	O
ead	O	O
and	O	O
the	O	O
maintenance	O	O
of	O	O
tdp	O	O
was	O	O
also	O	O
evaluated	O	O
.	O	O

methods	O	O
and	O	O
results	O	O
:	O	O

transmembrane	O	O
action	O	O
potentials	O	O
from	O	O
epicardium	O	O
,	O	O
midmyocardium	O	O
,	O	O
and	O	O
endocardium	O	O
were	O	O
recorded	O	O
simultaneously	O	O
,	O	O
together	O	O
with	O	O
a	O	O
transmural	O	O
ecg	O	O
,	O	O
in	O	O
arterially	O	O
perfused	O	O
canine	O	O
and	O	O
rabbit	O	O
left	O	O
ventricular	O	O
preparations	O	O
.	O	O

dl	O	B-chem
-	O	I-chem
sotalol	B-chem	B-chem
preferentially	O	O
prolonged	O	O
action	O	O
potential	O	O
duration	O	O
(	O	O
apd	O	O
)	O	O
in	O	O
m	O	O
cells	O	O
dose	O	O
-	O	O
dependently	O	O
(	O	O
1	O	O
to	O	O
100	O	O
micromol	O	O
/	O	O
l	O	O
)	O	O
,	O	O
leading	O	O
to	O	O
qt	O	O
prolongation	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
tdr	O	O
.	O	O

azimilide	B-chem	B-chem
,	O	O
however	O	O
,	O	O
significantly	O	O
prolonged	O	O
apd	O	O
and	O	O
qt	O	O
interval	O	O
at	O	O
concentrations	O	O
from	O	O
0	O	O
.	O	O
1	O	O
to	O	O
10	O	O
micromol	O	O
/	O	O
l	O	O
but	O	O
shortened	O	O
them	O	O
at	O	O
30	O	O
micromol	O	O
/	O	O
l	O	O
.	O	O

unlike	O	O
dl	O	B-chem
-	O	I-chem
sotalol	B-chem	B-chem
,	O	O
azimilide	B-chem	B-chem
(	O	O
>	O	O
3	O	O
micromol	O	O
/	O	O
l	O	O
)	O	O

increased	O	O
epicardial	O	O
apd	O	O
markedly	O	O
,	O	O
causing	O	O
a	O	O
diminished	O	O
tdr	O	O
.	O	O

although	O	O
both	O	O
dl	O	B-chem
-	O	I-chem
sotalol	B-chem	B-chem
and	O	O
azimilide	B-chem	B-chem
rarely	O	O
induced	O	O
eads	O	O
in	O	O
canine	O	O
left	O	O
ventricles	O	O
,	O	O
they	O	O
produced	O	O
frequent	O	O
eads	O	O
in	O	O
rabbits	O	O
,	O	O
in	O	O
which	O	O
more	O	O
pronounced	O	O
qt	O	O
prolongation	O	O
was	O	O
seen	O	O
.	O	O

an	O	O
increase	O	O
in	O	O
tdr	O	O
by	O	O
dl	O	B-chem
-	O	I-chem
sotalol	B-chem	B-chem
facilitated	O	O
transmural	O	O
propagation	O	O
of	O	O
eads	O	O
that	O	O
initiated	O	O
multiple	O	O
episodes	O	O
of	O	O
spontaneous	O	O
tdp	O	O
in	O	O
3	O	O
of	O	O
6	O	O
rabbit	O	O
left	O	O
ventricles	O	O
.	O	O

of	O	O
note	O	O
,	O	O
although	O	O
azimilide	B-chem	B-chem
(	O	O
3	O	O
to	O	O
10	O	O
micromol	O	O
/	O	O
l	O	O
)	O	O
increased	O	O
apd	O	O
more	O	O
than	O	O
dl	O	B-chem
-	O	O
sotalol	B-chem	B-chem
,	O	O
its	O	O
eads	O	O
often	O	O
failed	O	O
to	O	O
propagate	O	O
transmurally	O	O
,	O	O
probably	O	O
because	O	O
of	O	O
a	O	O
diminished	O	O
tdr	O	O
.	O	O

conclusions	O	O
:	O	O

this	O	O
study	O	O
provides	O	O
the	O	O
first	O	O
direct	O	O
evidence	O	O
from	O	O
intracellular	O	O
action	O	O
potential	O	O
recordings	O	O
that	O	O
phase	O	O
2	O	O
ead	O	O
can	O	O
be	O	O
generated	O	O
from	O	O
intact	O	O
ventricular	O	O
wall	O	O
and	O	O
produce	O	O
a	O	O
trigger	O	O
to	O	O
initiate	O	O
the	O	O
onset	O	O
of	O	O
tdp	O	O
under	O	O
qt	O	O
prolongation	O	O
.	O	O

prenatal	O	O
cocaine	B-chem	B-chem
exposure	O	O
and	O	O
cranial	O	O
sonographic	O	O
findings	O	O
in	O	O
preterm	O	O
infants	O	O
.	O	O

purpose	O	O
:	O	O

prenatal	O	O
cocaine	B-chem	B-chem
exposure	O	O
has	O	O
been	O	O
linked	O	O
with	O	O
subependymal	O	O
hemorrhage	O	O
and	O	O
the	O	O
formation	O	O
of	O	O
cysts	O	O
that	O	O
are	O	O
detectable	O	O
on	O	O
cranial	O	O
sonography	O	O
in	O	O
neonates	O	O
born	O	O
at	O	O
term	O	O
.	O	O

we	O	O
sought	O	O
to	O	O
determine	O	O
if	O	O
prenatal	O	O
cocaine	B-chem	B-chem
exposure	O	O
increases	O	O
the	O	O
incidence	O	O
of	O	O
subependymal	O	O
cysts	O	O
in	O	O
preterm	O	O
infants	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
retrospectively	O	O
reviewed	O	O
the	O	O
medical	O	O
records	O	O
and	O	O
cranial	O	O
sonograms	O	O
obtained	O	O
during	O	O
a	O	O
1	O	O
-	O	O
year	O	O
period	O	O
on	O	O
122	O	O
premature	O	O
(	O	O
<	O	O
36	O	O
weeks	O	O
of	O	O
gestation	O	O
)	O	O
infants	O	O
.	O	O

infants	O	O
were	O	O
categorized	O	O
into	O	O
1	O	O
of	O	O
2	O	O
groups	O	O
:	O	O
those	O	O
exposed	O	O
to	O	O
cocaine	B-chem	B-chem
and	O	O
those	O	O
not	O	O
exposed	O	O
to	O	O
cocaine	B-chem	B-chem
.	O	O

infants	O	O
were	O	O
assigned	O	O
to	O	O
the	O	O
cocaine	B-chem	B-chem
-	O	O
exposed	O	O
group	O	O
if	O	O
there	O	O
was	O	O
a	O	O
maternal	O	O
history	O	O
of	O	O
cocaine	O	O
abuse	O	O
during	O	O
pregnancy	O	O
or	O	O
if	O	O
maternal	O	O
or	O	O
neonatal	O	O
urine	O	O
toxicology	O	O
results	O	O
were	O	O
positive	O	O
at	O	O
the	O	O
time	O	O
of	O	O
delivery	O	O
.	O	O

results	O	O
:	O	O

five	O	O
of	O	O
the	O	O
122	O	O
infants	O	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
because	O	O
of	O	O
insufficient	O	O
medical	O	O
and	O	O
drug	O	O
histories	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
subependymal	O	O
cysts	O	O
in	O	O
the	O	O
117	O	O
remaining	O	O
infants	O	O
was	O	O
14	O	O
%	O	O
(	O	O
16	O	O
of	O	O
117	O	O
)	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
subependymal	O	O
cysts	O	O
in	O	O
infants	O	O
exposed	O	O
to	O	O
cocaine	B-chem	B-chem
prenatally	O	O
was	O	O
44	O	O
%	O	O
(	O	O
8	O	O
of	O	O
18	O	O
)	O	O
compared	O	O
with	O	O
8	O	O
%	O	O
(	O	O
8	O	O
of	O	O
99	O	O
)	O	O
in	O	O
the	O	O
unexposed	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

we	O	O
found	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
subependymal	O	O
cyst	O	O
formation	O	O
in	O	O
preterm	O	O
infants	O	O
who	O	O
were	O	O
exposed	O	O
to	O	O
cocaine	B-chem	B-chem
prenatally	O	O
.	O	O

this	O	O
result	O	O
is	O	O
consistent	O	O
with	O	O
results	O	O
of	O	O
similar	O	O
studies	O	O
in	O	O
term	O	O
infants	O	O
.	O	O

thalidomide	B-chem	B-chem
neuropathy	O	O
in	O	O
patients	O	O
treated	O	O
for	O	O
metastatic	O	O
prostate	O	O
cancer	O	O
.	O	O

we	O	O
prospectively	O	O
evaluated	O	O
thalidomide	B-chem	B-chem
-	O	O
induced	O	O
neuropathy	O	O
using	O	O
electrodiagnostic	O	O
studies	O	O
.	O	O

sixty	O	O
-	O	O
seven	O	O
men	O	O
with	O	O
metastatic	O	O
androgen	B-chem	O
-	O	O
independent	O	O
prostate	O	O
cancer	O	O
in	O	O
an	O	O
open	O	O
-	O	O
label	O	O
trial	O	O
of	O	O
oral	O	O
thalidomide	B-chem	B-chem
underwent	O	O
neurologic	O	O
examinations	O	O
and	O	O
nerve	O	O
conduction	O	O
studies	O	O
(	O	O
ncs	O	O
)	O	O
prior	O	O
to	O	O
and	O	O
at	O	O
3	O	O
-	O	O
month	O	O
intervals	O	O
during	O	O
treatment	O	O
.	O	O

ncs	O	O
included	O	O
recording	O	O
of	O	O
sensory	O	O
nerve	O	O
action	O	O
potentials	O	O
(	O	O
snaps	O	O
)	O	O
from	O	O
median	O	O
,	O	O
radial	O	O
,	O	O
ulnar	O	O
,	O	O
and	O	O
sural	O	O
nerves	O	O
.	O	O

snap	O	O
amplitudes	O	O
for	O	O
each	O	O
nerve	O	O
were	O	O
expressed	O	O
as	O	O
the	O	O
percentage	O	O
of	O	O
its	O	O
baseline	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
of	O	O
the	O	O
four	O	O
was	O	O
termed	O	O
the	O	O
snap	O	O
index	O	O
.	O	O

a	O	O
40	O	O
%	O	O
decline	O	O
in	O	O
the	O	O
snap	O	O
index	O	O
was	O	O
considered	O	O
clinically	O	O
significant	O	O
.	O	O

thalidomide	B-chem	B-chem
was	O	O
discontinued	O	O
in	O	O
55	O	O
patients	O	O
for	O	O
lack	O	O
of	O	O
therapeutic	O	O
response	O	O
.	O	O

of	O	O
67	O	O
patients	O	O
initially	O	O
enrolled	O	O
,	O	O
24	O	O
remained	O	O
on	O	O
thalidomide	B-chem	B-chem
for	O	O
3	O	O
months	O	O
,	O	O
8	O	O
remained	O	O
at	O	O
6	O	O
months	O	O
,	O	O
and	O	O
3	O	O
remained	O	O
at	O	O
9	O	O
months	O	O
.	O	O

six	O	O
patients	O	O
developed	O	O
neuropathy	O	O
.	O	O

clinical	O	O
symptoms	O	O
and	O	O
a	O	O
decline	O	O
in	O	O
the	O	O
snap	O	O
index	O	O
occurred	O	O
concurrently	O	O
.	O	O

older	O	O
age	O	O
and	O	O
cumulative	O	O
dose	O	O
were	O	O
possible	O	O
contributing	O	O
factors	O	O
.	O	O

neuropathy	O	O
may	O	O
thus	O	O
be	O	O
a	O	O
common	O	O
complication	O	O
of	O	O
thalidomide	B-chem	B-chem
in	O	O
older	O	O
patients	O	O
.	O	O

the	O	O
snap	O	O
index	O	O
can	O	O
be	O	O
used	O	O
to	O	O
monitor	O	O
peripheral	O	O
neuropathy	O	O
,	O	O
but	O	O
not	O	O
for	O	O
early	O	O
detection	O	O
.	O	O

overexpression	O	O
of	O	O
copper	B-chem	B-chem
/	O	O
zinc	B-chem	B-chem
-	O	I-chem
superoxide	B-chem	B-chem
dismutase	O	O
protects	O	O
from	O	O
kanamycin	B-chem	B-chem
-	O	O
induced	O	O
hearing	O	O
loss	O	O
.	O	O

the	O	O
participation	O	O
of	O	O
reactive	O	O
oxygen	B-chem	B-chem
species	O	O
in	O	O
aminoglycoside	B-chem	B-chem
-	O	O
induced	O	O
ototoxicity	O	O
has	O	O
been	O	O
deduced	O	O
from	O	O
observations	O	O
that	O	O
aminoglycoside	B-chem	B-chem
-	O	O
iron	B-chem	B-chem
complexes	O	O
catalyze	O	O
the	O	O
formation	O	O
of	O	O
superoxide	B-chem	B-chem
radicals	O	O
in	O	O
vitro	O	O
and	O	O
that	O	O
antioxidants	O	O
attenuate	O	O
ototoxicity	O	O
in	O	O
vivo	O	O
.	O	O

we	O	O
therefore	O	O
hypothesized	O	O
that	O	O
overexpression	O	O
of	O	O
cu	B-chem	B-chem
/	O	O
zn	B-chem	O
-	O	I-chem
superoxide	B-chem	I-chem
dismutase	O	O
(	O	O
h	O	O
-	O	O
sod1	O	O
)	O	O
should	O	O
protect	O	O
transgenic	O	O
mice	O	O
from	O	O
ototoxicity	O	O
.	O	O

immunocytochemistry	O	O
confirmed	O	O
expression	O	O
of	O	O
h	O	O
-	O	O
sod1	O	O
in	O	O
inner	O	O
ear	O	O
tissues	O	O
of	O	O
transgenic	O	O
c57bl	O	O
/	O	O
6	O	O
-	O	O
tgn	O	I-chem
[	O	O
sod1	O	I-chem
]	O	O
3cje	O	O
mice	O	O
.	O	O

transgenic	O	O
and	O	O
nontransgenic	O	O
littermates	O	O
received	O	O
kanamycin	B-chem	B-chem
(	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
/	O	O
day	O	O
)	O	O
for	O	O
10	O	O
days	O	O
beginning	O	O
on	O	O
day	O	O
10	O	O
after	O	O
birth	O	O
.	O	O

auditory	O	O
thresholds	O	O
were	O	O
tested	O	O
by	O	O
evoked	O	O
auditory	O	O
brain	O	O
stem	O	O
responses	O	O
at	O	O
1	O	O
month	O	O
after	O	O
birth	O	O
.	O	O

in	O	O
nontransgenic	O	O
animals	O	O
,	O	O
the	O	O
threshold	O	O
in	O	O
the	O	O
kanamycin	B-chem	B-chem
-	O	O
treated	O	O
group	O	O
was	O	O
45	O	O
-	O	O
50	O	O
db	O	O
higher	O	O
than	O	O
in	O	O
saline	O	O
-	O	O
injected	O	O
controls	O	O
.	O	O

in	O	O
the	O	O
transgenic	O	O
group	O	O
,	O	O
kanamycin	B-chem	B-chem
increased	O	O
the	O	O
threshold	O	O
by	O	O
only	O	O
15	O	O
db	O	O
over	O	O
the	O	O
respective	O	O
controls	O	O
.	O	O

the	O	O
effects	O	O
were	O	O
similar	O	O
at	O	O
12	O	O
and	O	O
24	O	O
khz	O	O
.	O	O

the	O	O
protection	O	O
by	O	O
overexpression	O	O
of	O	O
superoxide	B-chem	B-chem
dismutase	O	O
supports	O	O
the	O	O
hypothesis	O	O
that	O	O
oxidant	O	O
stress	O	O
plays	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
aminoglycoside	B-chem	B-chem
-	O	O
induced	O	O
ototoxicity	O	O
.	O	O

the	O	O
results	O	O
also	O	O
suggest	O	O
transgenic	O	O
animals	O	O
as	O	O
suitable	O	O
models	O	O
to	O	O
investigate	O	O
the	O	O
underlying	O	O
mechanisms	O	O
and	O	O
possible	O	O
strategies	O	O
for	O	O
prevention	O	O
.	O	O

prednisone	B-chem	B-chem
induces	O	O
anxiety	O	O
and	O	O
glial	O	O
cerebral	O	O
changes	O	O
in	O	O
rats	O	O
.	O	O

objective	O	O
:	O	O
to	O	O
assess	O	O
whether	O	O
prednisone	B-chem	B-chem
(	O	O
pdn	B-chem	B-chem
)	O	O
produces	O	O
anxiety	O	O
and	O	O
/	O	O
or	O	O
cerebral	O	O
glial	O	O
changes	O	O
in	O	O
rats	O	O
.	O	O

methods	O	O
:	O	O

male	O	O
wistar	O	O
rats	O	O
were	O	O
studied	O	O
and	O	O
3	O	O
groups	O	O
were	O	O
formed	O	O
(	O	O
8	O	O
rats	O	O
per	O	O
group	O	O
)	O	O
.	O	O

the	O	O
moderate	O	O
-	O	O
dose	O	O
group	O	O
received	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
pdn	B-chem	O
released	O	O
from	O	O
a	O	O
subcutaneous	O	O
implant	O	O
.	O	O

in	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
,	O	O
implants	O	O
containing	O	O
pdn	B-chem	O
equivalent	O	O
to	O	O
60	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
were	O	O
applied	O	O
.	O	O

in	O	O
the	O	O
control	O	O
group	O	O
implants	O	O
contained	O	O
no	O	O
pdn	B-chem	O
.	O	O

anxiety	O	O
was	O	O
assessed	O	O
using	O	O
an	O	O
open	O	O
field	O	O
and	O	O
elevated	O	O
plus	O	O
-	O	O
maze	O	O
devices	O	O
.	O	O

the	O	O
number	O	O
of	O	O
cells	O	O
and	O	O
cytoplasmic	O	O
transformation	O	O
of	O	O
astrocytes	O	O
and	O	O
microglia	O	O
cells	O	O
were	O	O
assessed	O	O
by	O	O
immunohistochemical	O	O
analyses	O	O
.	O	O

results	O	O
:	O	O

anxiety	O	O
was	O	O
documented	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
pdn	B-chem	O
treated	O	O
rats	O	O
compared	O	O
with	O	O
controls	O	O
.	O	O

the	O	O
magnitude	O	O
of	O	O
transformation	O	O
of	O	O
the	O	O
microglia	O	O
assessed	O	O
by	O	O
the	O	O
number	O	O
of	O	O
intersections	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
pdn	B-chem	O
groups	O	O
than	O	O
in	O	O
controls	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
(	O	O
moderate	O	O
-	O	O
dose	O	O
,	O	O
24	O	O
.	O	O
1	O	O
;	O	O
high	O	O
-	O	O
dose	O	O
,	O	O
23	O	O
.	O	O
6	O	O
;	O	O
controls	O	O
18	O	O
.	O	O
7	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
and	O	O
striatum	O	O
(	O	O
moderate	O	O
-	O	O
dose	O	O
25	O	O
.	O	O
6	O	O
;	O	O
high	O	O
-	O	O
dose	O	O
26	O	O
.	O	O
3	O	O
;	O	O
controls	O	O
18	O	O
.	O	O
9	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
but	O	O
not	O	O
in	O	O
hippocampus	O	O
.	O	O

the	O	O
number	O	O
of	O	O
stained	O	O
microglia	O	O
cells	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
pdn	B-chem	O
treated	O	O
groups	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
than	O	O
in	O	O
controls	O	O
(	O	O
moderate	O	O
-	O	O
dose	O	O
,	O	O
29	O	O
.	O	O
1	O	O
;	O	O
high	O	O
-	O	O
dose	O	O
,	O	O
28	O	O
.	O	O
4	O	O
;	O	O
control	O	O
,	O	O
17	O	O
.	O	O
7	O	O
cells	O	O
per	O	O
field	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

stained	O	O
microglia	O	O
cells	O	O
were	O	O
significantly	O	O
more	O	O
numerous	O	O
striatum	O	O
and	O	O
hippocampus	O	O
in	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

conclusion	O	O
:	O	O

subacute	O	O
exposure	O	O
to	O	O
pdn	B-chem	O
induced	O	O
anxiety	O	O
and	O	O
reactivity	O	O
of	O	O
microglia	O	O
.	O	O

the	O	O
relevance	O	O
of	O	O
these	O	O
features	O	O
for	O	O
patients	O	O
using	O	O
pdn	B-chem	O
remains	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O

phase	O	O
ii	O	O
study	O	O
of	O	O
carboplatin	B-chem	B-chem
and	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
recurrent	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
of	O	O
the	O	O
cervix	O	O
.	O	O

background	O	O
:	O	O

the	O	O
activity	O	O
of	O	O
the	O	O
combination	O	O
of	O	O
carboplatin	B-chem	B-chem
and	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
was	O	O
tested	O	O
in	O	O
a	O	O
phase	O	O
ii	O	O
study	O	O
of	O	O
patients	O	O
with	O	O
recurrent	O	O
cervical	O	O
carcinoma	O	O
.	O	O

methods	O	O
:	O	O

the	O	O
combination	O	O
of	O	O
carboplatin	B-chem	B-chem
(	O	O
area	O	O
under	O	O
the	O	O
concentration	O	O
curve	O	O
[	O	O
auc	O	O
]	O	O
,	O	O
5	O	O
)	O	O
and	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem

(	O	O
doxil	B-chem	B-chem
;	O	O
starting	O	O
dose	O	O
,	O	O
40	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
)	O	O
was	O	O
administered	O	O
intravenously	O	O
every	O	O
28	O	O
days	O	O
to	O	O
37	O	O
patients	O	O
with	O	O
recurrent	O	O
squamous	O	O
cell	O	O
cervical	O	O
carcinoma	O	O
to	O	O
determine	O	O
antitumor	O	O
activity	O	O
and	O	O
toxicity	O	O
profile	O	O
.	O	O

results	O	O
:	O	O

twenty	O	O
-	O	O
nine	O	O
patients	O	O
were	O	O
assessable	O	O
for	O	O
response	O	O
,	O	O
and	O	O
35	O	O
patients	O	O
were	O	O
assessable	O	O
for	O	O
toxicity	O	O
.	O	O

the	O	O
overall	O	O
response	O	O
rate	O	O
was	O	O
38	O	O
%	O	O
,	O	O
the	O	O
median	O	O
time	O	O
to	O	O
response	O	O
was	O	O
10	O	O
weeks	O	O
,	O	O
the	O	O
median	O	O
duration	O	O
of	O	O
response	O	O
was	O	O
26	O	O
weeks	O	O
,	O	O
and	O	O
the	O	O
median	O	O
survival	O	O
was	O	O
37	O	O
weeks	O	O
.	O	O

the	O	O
main	O	O
toxic	O	O
effect	O	O
was	O	O
myelosuppression	O	O
,	O	O
with	O	O
grade	O	O
3	O	O
and	O	O
4	O	O
neutropenia	O	O
in	O	O
16	O	O
patients	O	O
,	O	O
anemia	O	O
in	O	O
12	O	O
patients	O	O
,	O	O
thrombocytopenia	O	O
in	O	O
11	O	O
patients	O	O
,	O	O
and	O	O
neutropenic	O	O
fever	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

four	O	O
patients	O	O
had	O	O
five	O	O
infusion	O	O
-	O	O
related	O	O
reactions	O	O
during	O	O
the	O	O
infusion	O	O
of	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
,	O	O
leading	O	O
to	O	O
treatment	O	O
discontinuation	O	O
in	O	O
three	O	O
patients	O	O
.	O	O

grade	O	O
>	O	O
or	O	O
=	O	O
2	O	O
nonhematologic	O	O
toxicity	O	O
included	O	O
nausea	O	O
in	O	O
17	O	O
patients	O	O
,	O	O
emesis	O	O
in	O	O
14	O	O
patients	O	O
,	O	O
fatigue	O	O
in	O	O
9	O	O
patients	O	O
,	O	O
mucositis	O	O
and	O	O
/	O	O
or	O	O
stomatitis	O	O
in	O	O
8	O	O
patients	O	O
,	O	O
constipation	O	O
in	O	O
6	O	O
patients	O	O
,	O	O
weight	O	O
loss	O	O
in	O	O
5	O	O
patients	O	O
,	O	O
hand	O	O
-	O	O
foot	O	O
syndrome	O	O
in	O	O
2	O	O
patients	O	O
,	O	O
and	O	O
skin	O	O
reactions	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
combination	O	O
of	O	O
carboplatin	B-chem	B-chem
and	O	O
liposomal	O	O
doxorubicin	B-chem	B-chem
has	O	O
modest	O	O
activity	O	O
in	O	O
patients	O	O
with	O	O
recurrent	O	O
cervical	O	O
carcinoma	O	O
.	O	O

antimicrobial	O	O
-	O	O
induced	O	O
mania	O	O
(	O	O
antibiomania	O	O
)	O	O
:	O	O
a	O	O
review	O	O
of	O	O
spontaneous	O	O
reports	O	O
.	O	O

the	O	O
authors	O	O
reviewed	O	O
reported	O	O
cases	O	O
of	O	O
antibiotic	O	O
-	O	O
induced	O	O
manic	O	O
episodes	O	O
by	O	O
means	O	O
of	O	O
a	O	O
medline	O	O
and	O	O
psychlit	O	O
search	O	O
for	O	O
reports	O	O
of	O	O
antibiotic	O	O
-	O	O
induced	O	O
mania	O	O
.	O	O

unpublished	O	O
reports	O	O
were	O	O
requested	O	O
from	O	O
the	O	O
world	O	O
health	O	O
organization	O	O
(	O	O
who	O	O
)	O	O
and	O	O
the	O	O
food	O	O
and	O	O
drug	O	O
administration	O	O
(	O	O
fda	O	O
)	O	O
.	O	O

twenty	O	O
-	O	O
one	O	O
reports	O	O
of	O	O
antimicrobial	O	O
-	O	O
induced	O	O
mania	O	O
were	O	O
found	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

there	O	O
were	O	O
6	O	O
cases	O	O
implicating	O	O
clarithromycin	B-chem	B-chem
,	O	O
13	O	O
implicating	O	O
isoniazid	B-chem	B-chem
,	O	O
and	O	O
1	O	O
case	O	O
each	O	O
implicating	O	O
erythromycin	B-chem	B-chem
and	O	O
amoxicillin	B-chem	B-chem
.	O	O

the	O	O
who	O	O
reported	O	O
82	O	O
cases	O	O
.	O	O

of	O	O
these	O	O
,	O	O
clarithromycin	B-chem	B-chem
was	O	O
implicated	O	O
in	O	O
23	O	O
(	O	O
27	O	O
.	O	O
6	O	O
%	O	O
)	O	O
cases	O	O
,	O	O
ciprofloxacin	B-chem	B-chem
in	O	O
12	O	O
(	O	O
14	O	O
.	O	O
4	O	O
%	O	O
)	O	O
cases	O	O
,	O	O
and	O	O
ofloxacin	B-chem	B-chem
in	O	O
10	O	O
(	O	O
12	O	O
%	O	O
)	O	O
cases	O	O
.	O	O

cotrimoxazole	B-chem	B-chem
,	O	O
metronidazole	B-chem	B-chem
,	O	O
and	O	O
erythromycin	B-chem	B-chem
were	O	O
involved	O	O
in	O	O
15	O	O
reported	O	O
manic	O	O
episodes	O	O
.	O	O

cases	O	O
reported	O	O
by	O	O
the	O	O
fda	O	O
showed	O	O
clarithromycin	B-chem	B-chem
and	O	O
ciprofloxacin	B-chem	B-chem
to	O	O
be	O	O
the	O	O
most	O	O
frequently	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
mania	O	O
.	O	O

statistical	O	O
analysis	O	O
of	O	O
the	O	O
data	O	O
would	O	O
not	O	O
have	O	O
demonstrated	O	O
a	O	O
significant	O	O
statistical	O	O
correlative	O	O
risk	O	O
and	O	O
was	O	O
therefore	O	O
not	O	O
undertaken	O	O
.	O	O

patients	O	O
have	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
developing	O	O
mania	O	O
while	O	O
being	O	O
treated	O	O
with	O	O
antimicrobials	O	O
.	O	O

although	O	O
this	O	O
is	O	O
not	O	O
a	O	O
statistically	O	O
significant	O	O
risk	O	O
,	O	O
physicians	O	O
must	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
effect	O	O
and	O	O
reversibility	O	O
.	O	O

further	O	O
research	O	O
clearly	O	O
is	O	O
required	O	O
to	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
antimicrobial	O	O
-	O	O
induced	O	O
mania	O	O
,	O	O
the	O	O
relative	O	O
risk	O	O
factors	O	O
of	O	O
developing	O	O
an	O	O
antimicrobial	O	O
-	O	O
induced	O	O
manic	O	O
episode	O	O
among	O	O
various	O	O
demographic	O	O
populations	O	O
,	O	O
and	O	O
the	O	O
incidence	O	O
of	O	O
patients	O	O
who	O	O
continue	O	O
to	O	O
have	O	O
persistent	O	O
affective	O	O
disorders	O	O
once	O	O
the	O	O
initial	O	O
episode	O	O
,	O	O
which	O	O
occurs	O	O
while	O	O
the	O	O
patient	O	O
is	O	O
taking	O	O
antibiotics	O	O
,	O	O
subsides	O	O
.	O	O

the	O	O
authors	O	O
elected	O	O
to	O	O
name	O	O
this	O	O
syndrome	O	O
"	O	O
"	O	O
"	O	O
"	O	O
antibiomania	O	O
.	O	O
"	O	O
"	O	O
"	O	O
"	O	O

levodopa	B-chem	B-chem
-	O	O
induced	O	O
ocular	O	O
dyskinesias	O	O
in	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

levodopa	B-chem	B-chem
-	O	O
induced	O	O
ocular	O	O
dyskinesias	O	O
are	O	O
very	O	O
uncommon	O	O
.	O	O

usually	O	O
they	O	O
occur	O	O
simultaneously	O	O
with	O	O
limb	O	O
peak	O	O
-	O	O
dose	O	O
choreatic	O	O
dyskinesias	O	O
.	O	O

we	O	O
report	O	O
on	O	O
a	O	O
patient	O	O
with	O	O
leftward	O	O
and	O	O
upward	O	O
deviations	O	O
of	O	O
gaze	O	O
during	O	O
the	O	O
peak	O	O
effect	O	O
of	O	O
levodopa	B-chem	B-chem
,	O	O
and	O	O
hypothesize	O	O
that	O	O
a	O	O
severe	O	O
dopaminergic	O	O
denervation	O	O
in	O	O
the	O	O
caudate	O	O
nucleus	O	O
is	O	O
needed	O	O
for	O	O
the	O	O
appearance	O	O
of	O	O
these	O	O
levodopa	B-chem	B-chem
-	O	O
induce	O	O
ocular	O	O
dyskinesias	O	O
.	O	O

a	O	O
comparison	O	O
of	O	O
glyceryl	B-chem	B-chem
trinitrate	I-chem	I-chem
with	O	O
diclofenac	B-chem	B-chem
for	O	O
the	O	O
treatment	O	O
of	O	O
primary	O	O
dysmenorrhea	O	O
:	O	O
an	O	O
open	O	O
,	O	O
randomized	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
trial	O	O
.	O	O

primary	O	O
dysmenorrhea	O	O
is	O	O
a	O	O
syndrome	O	O
characterized	O	O
by	O	O
painful	O	O
uterine	O	O
contractility	O	O
caused	O	O
by	O	O
a	O	O
hypersecretion	O	O
of	O	O
endometrial	O	O
prostaglandins	B-chem	B-chem
;	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
are	O	O
the	O	O
first	O	O
choice	O	O
for	O	O
its	O	O
treatment	O	O
.	O	O

however	O	O
,	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
studies	O	O
have	O	O
demonstrated	O	O
that	O	O
myometrial	O	O
cells	O	O
are	O	O
also	O	O
targets	O	O
of	O	O
the	O	O
relaxant	O	O
effects	O	O
of	O	O
nitric	B-chem	B-chem
oxide	I-chem	I-chem
(	O	O
no	B-chem	B-chem
)	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
glyceryl	B-chem	B-chem
trinitrate	I-chem	I-chem
(	O	O
gtn	B-chem	B-chem
)	O	O
,	O	O
an	O	O
no	B-chem	O
donor	O	O
,	O	O
in	O	O
the	O	O
resolution	O	O
of	O	O
primary	O	O
dysmenorrhea	O	O
in	O	O
comparison	O	O
with	O	O
diclofenac	B-chem	B-chem
(	O	O
dcf	B-chem	O
)	O	O
.	O	O

a	O	O
total	O	O
of	O	O
24	O	O
patients	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
severe	O	O
primary	O	O
dysmenorrhea	O	O
were	O	O
studied	O	O
during	O	O
two	O	O
consecutive	O	O
menstrual	O	O
cycles	O	O
.	O	O

in	O	O
an	O	O
open	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
,	O	O
controlled	O	O
design	O	O
,	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
dcf	B-chem	O
per	O	O
os	O	O
or	O	O
gtn	B-chem	B-chem
patches	O	O
the	O	O
first	O	O
days	O	O
of	O	O
menses	O	O
,	O	O
when	O	O
menstrual	O	O
cramps	O	O
became	O	O
unendurable	O	O
.	O	O

in	O	O
the	O	O
subsequent	O	O
cycle	O	O
the	O	O
other	O	O
treatment	O	O
was	O	O
used	O	O
.	O	O

patients	O	O
received	O	O
up	O	O
to	O	O
3	O	O
doses	O	O
/	O	O
day	O	O
of	O	O
50	O	O
mg	O	O
dcf	B-chem	O
or	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
24	O	O
h	O	O
transdermal	O	O
gtn	B-chem	B-chem
for	O	O
the	O	O
first	O	O
3	O	O
days	O	O
of	O	O
the	O	O
cycle	O	O
,	O	O
according	O	O
to	O	O
their	O	O
needs	O	O
.	O	O

the	O	O
participants	O	O
recorded	O	O
menstrual	O	O
symptoms	O	O
and	O	O
possible	O	O
side	O	O
-	O	O
effects	O	O
at	O	O
different	O	O
times	O	O
(	O	O
0	O	O
,	O	O
30	O	O
,	O	O
60	O	O
,	O	O
120	O	O
minutes	O	O
)	O	O
after	O	O
the	O	O
first	O	O
dose	O	O
of	O	O
medication	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
the	O	O
cycle	O	O
,	O	O
with	O	O
both	O	O
drugs	O	O
.	O	O

the	O	O
difference	O	O
in	O	O
pain	O	O
intensity	O	O
score	O	O
(	O	O
dpi	O	O
)	O	O
was	O	O
the	O	O
main	O	O
outcome	O	O
variable	O	O
.	O	O

both	O	O
treatments	O	O
significantly	O	O
reduced	O	O
dpi	O	O
by	O	O
the	O	O
30th	O	O
minute	O	O
(	O	O
gtn	B-chem	O
,	O	O
-	O	O
12	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

17	O	O
.	O	O
9	O	O
;	O	O
dcf	B-chem	O
,	O	O
-	O	O
18	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

16	O	O
.	O	O
6	O	O
)	O	O
.	O	O

however	O	O
,	O	O
dcf	B-chem	O
continued	O	O
to	O	O
be	O	O
effective	O	O
in	O	O
reducing	O	O
pelvic	O	O
pain	O	O
for	O	O
two	O	O
hours	O	O
,	O	O
whereas	O	O
gtn	B-chem	O
scores	O	O
remained	O	O
more	O	O
or	O	O
less	O	O
stable	O	O
after	O	O
30	O	O
min	O	O
and	O	O
significantly	O	O
higher	O	O
than	O	O
those	O	O
for	O	O
dfc	O	O
(	O	O
after	O	O
one	O	O
hour	O	O
:	O	O
gtn	B-chem	O
,	O	O
-	O	O
12	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

17	O	O
.	O	O
9	O	O
;	O	O
dfc	O	O
,	O	O
-	O	O
18	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

16	O	O
.	O	O
6	O	O
and	O	O
after	O	O
two	O	O
hours	O	O
:	O	O
gtn	B-chem	O
,	O	O
-	O	O
23	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

20	O	O
.	O	O
5	O	O
;	O	O
dfc	O	O
,	O	O
-	O	O
59	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

17	O	O
.	O	O
9	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

low	O	O
back	O	O
pain	O	O
was	O	O
also	O	O
relieved	O	O
by	O	O
both	O	O
drugs	O	O
.	O	O

headache	O	O
was	O	O
significantly	O	O
increased	O	O
by	O	O
gtn	B-chem	O
but	O	O
not	O	O
by	O	O
dcf	B-chem	O
.	O	O

eight	O	O
patients	O	O
stopped	O	O
using	O	O
gtn	B-chem	O
because	O	O
headache	O	O
-	O	O
-	O	O
attributed	O	O
to	O	O
its	O	O
use	O	O
-	O	O
-	O	O
became	O	O
intolerable	O	O
.	O	O

these	O	O
findings	O	O
indicate	O	O
that	O	O
gtn	B-chem	B-chem
has	O	O
a	O	O
reduced	O	O
efficacy	O	O
and	O	O
tolerability	O	O
by	O	O
comparison	O	O
with	O	O
dcf	B-chem	O
in	O	O
the	O	O
treatment	O	O
of	O	O
primary	O	O
dysmenorrhea	O	O
.	O	O

temocapril	B-chem	B-chem
,	O	O
a	O	O
long	O	O
-	O	O
acting	O	O
non	O	O
-	O	O
sh	O	O
group	O	O
angiotensin	B-chem	B-chem
converting	O	O
enzyme	O	O
inhibitor	O	O
,	O	O
modulates	O	O
glomerular	O	O
injury	O	O
in	O	O
chronic	O	O
puromycin	B-chem	B-chem
aminonucleoside	I-chem	I-chem
nephrosis	O	O
.	O	O

the	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
chronic	O	O
administration	O	O
of	O	O
temocapril	B-chem	B-chem
,	O	O
a	O	O
long	O	O
-	O	O
acting	O	O
non	O	O
-	O	O
sh	O	O
group	O	O
angiotensin	B-chem	B-chem
converting	O	O
enzyme	O	O
(	O	O
ace	O	O
)	O	O
inhibitor	O	O
,	O	O
reduced	O	O
proteinuria	O	O
,	O	O
inhibited	O	O
glomerular	O	O
hypertrophy	O	O
and	O	O
prevented	O	O
glomerulosclerosis	O	O
in	O	O
chronic	O	O
puromycin	B-chem	B-chem
aminonucleoside	I-chem	I-chem
(	O	O
pan	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
nephrotic	O	O
rats	O	O
.	O	O

nephrosis	O	O
was	O	O
induced	O	O
by	O	O
injection	O	O
of	O	O
pan	B-chem	B-chem
(	O	O
15mg	O	O
/	O	O
100	O	O
g	O	O
body	O	O
weight	O	O
)	O	O
in	O	O
male	O	O
sprague	O	O
-	O	O
dawley	O	O
(	O	O
sd	O	O
)	O	O
rats	O	O
.	O	O

four	O	O
groups	O	O
were	O	O
used	O	O
,	O	O
i	O	O
)	O	O
the	O	O
pan	B-chem	O
group	O	O
(	O	O
14	O	O
)	O	O
,	O	O
ii	O	O
)	O	O
pan	B-chem	O
/	O	O
temocapril	B-chem	B-chem
(	O	O
13	O	O
)	O	O
,	O	O
iii	O	O
)	O	O
temocapril	B-chem	B-chem
(	O	O
14	O	O
)	O	O
and	O	O
iv	O	O
)	O	O
untreated	O	O
controls	O	O
(	O	O
15	O	O
)	O	O
.	O	O

temocapril	B-chem	B-chem
(	O	O
8	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
the	O	O
rats	O	O
which	O	O
were	O	O
killed	O	O
at	O	O
weeks	O	O
4	O	O
,	O	O
14	O	O
or	O	O
20	O	O
.	O	O

at	O	O
each	O	O
time	O	O
point	O	O
,	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
bp	O	O
)	O	O
,	O	O
urinary	O	O
protein	O	O
excretion	O	O
and	O	O
renal	O	O
histopathological	O	O
findings	O	O
were	O	O
evaluated	O	O
,	O	O
and	O	O
morphometric	O	O
image	O	O
analysis	O	O
was	O	O
done	O	O
.	O	O

systolic	O	O
bp	O	O
in	O	O
the	O	O
pan	B-chem	O
group	O	O
was	O	O
significantly	O	O
high	O	O
at	O	O
4	O	O
,	O	O
14	O	O
and	O	O
20	O	O
weeks	O	O
,	O	O
but	O	O
was	O	O
normal	O	O
in	O	O
the	O	O
pan	B-chem	O
/	O	O
temocapril	B-chem	B-chem
group	O	O
.	O	O

urinary	O	O
protein	O	O
excretion	O	O
in	O	O
the	O	O
pan	B-chem	O
group	O	O
increased	O	O
significantly	O	O
,	O	O
peaking	O	O
at	O	O
8	O	O
days	O	O
,	O	O
then	O	O
decreased	O	O
at	O	O
4	O	O
weeks	O	O
,	O	O
but	O	O
rose	O	O
again	O	O
significantly	O	O
at	O	O
14	O	O
and	O	O
20	O	O
weeks	O	O
.	O	O

temocapril	B-chem	B-chem
did	O	O
not	O	O
attenuate	O	O
proteinuria	O	O
at	O	O
8	O	O
days	O	O
,	O	O
but	O	O
it	O	O
did	O	O
markedly	O	O
lower	O	O
it	O	O
from	O	O
weeks	O	O
4	O	O
to	O	O
20	O	O
.	O	O

the	O	O
glomerulosclerosis	O	O
index	O	O
(	O	O
gsi	O	O
)	O	O
was	O	O
6	O	O
.	O	O
21	O	O
%	O	O
at	O	O
4	O	O
weeks	O	O
and	O	O
respectively	O	O
25	O	O
.	O	O
35	O	O
%	O	O
and	O	O
30	O	O
.	O	O
49	O	O
%	O	O
at	O	O
14	O	O
and	O	O
20	O	O
weeks	O	O
in	O	O
the	O	O
pan	B-chem	O
group	O	O
.	O	O

there	O	O
was	O	O
a	O	O
significant	O	O
correlation	O	O
between	O	O
urinary	O	O
protein	O	O
excretion	O	O
and	O	O
gsi	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
808	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

the	O	O
ratio	O	O
of	O	O
glomerular	O	O
tuft	O	O
area	O	O
to	O	O
the	O	O
area	O	O
of	O	O
bowman	O	O
'	O	O
s	O	O
capsules	O	O
(	O	O
gt	O	O
/	O	O
bc	O	O
)	O	O
in	O	O
the	O	O
pan	B-chem	O
group	O	O
was	O	O
significantly	O	O
increased	O	O
,	O	O
but	O	O
it	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
pan	B-chem	O
/	O	O
temocapril	B-chem	B-chem
group	O	O
.	O	O

it	O	O
appears	O	O
that	O	O
temocapril	B-chem	B-chem
was	O	O
effective	O	O
in	O	O
retarding	O	O
renal	O	O
progression	O	O
and	O	O
protected	O	O
renal	O	O
function	O	O
in	O	O
pan	B-chem	O
neprotic	O	O
rats	O	O
.	O	O

pulmonary	O	O
hypertension	O	O
after	O	O
ibuprofen	B-chem	B-chem
prophylaxis	O	O
in	O	O
very	O	O
preterm	O	O
infants	O	O
.	O	O

we	O	O
report	O	O
three	O	O
cases	O	O
of	O	O
severe	O	O
hypoxaemia	O	O
after	O	O
ibuprofen	B-chem	B-chem
administration	O	O
during	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
of	O	O
prophylactic	O	O
treatment	O	O
of	O	O
patent	O	O
ductus	O	O
arteriosus	O	O
with	O	O
ibuprofen	B-chem	B-chem
in	O	O
premature	O	O
infants	O	O
born	O	O
at	O	O
less	O	O
than	O	O
28	O	O
weeks	O	O
of	O	O
gestation	O	O
.	O	O

echocardiography	O	O
showed	O	O
severely	O	O
decreased	O	O
pulmonary	O	O
blood	O	O
flow	O	O
.	O	O

hypoxaemia	O	O
resolved	O	O
quickly	O	O
on	O	O
inhaled	O	O
nitric	B-chem	B-chem
oxide	I-chem	I-chem
therapy	O	O
.	O	O

we	O	O
suggest	O	O
that	O	O
investigators	O	O
involved	O	O
in	O	O
similar	O	O
trials	O	O
pay	O	O
close	O	O
attention	O	O
to	O	O
pulmonary	O	O
pressure	O	O
if	O	O
hypoxaemia	O	O
occurs	O	O
after	O	O
prophylactic	O	O
administration	O	O
of	O	O
ibuprofen	B-chem	B-chem
.	O	O

hyponatremia	O	O
and	O	O
syndrome	O	O
of	O	O
inappropriate	O	O
anti	O	O
-	O	O
diuretic	O	O
hormone	O	O
reported	O	O
with	O	O
the	O	O
use	O	O
of	O	O
vincristine	B-chem	B-chem
:	O	O
an	O	O
over	O	O
-	O	O
representation	O	O
of	O	O
asians	O	O
?	O	O

purpose	O	O
:	O	O

this	O	O
retrospective	O	O
study	O	O
used	O	O
a	O	O
pharmaceutical	O	O
company	O	O
'	O	O
s	O	O
global	O	O
safety	O	O
database	O	O
to	O	O
determine	O	O
the	O	O
reporting	O	O
rate	O	O
of	O	O
hyponatremia	O	O
and	O	O
/	O	O
or	O	O
syndrome	O	O
of	O	O
inappropriate	O	O
secretion	O	O
of	O	O
anti	O	O
-	O	O
diuretic	O	I-chem
hormone	O	O
(	O	O
siadh	O	O
)	O	O
among	O	O
vincristine	B-chem	B-chem
-	O	O
treated	O	O
patients	O	O
and	O	O
to	O	O
explore	O	O
the	O	O
possibility	O	O
of	O	O
at	O	O
-	O	O
risk	O	O
population	O	O
subgroups	O	O
.	O	O

method	O	O
:	O	O

we	O	O
searched	O	O
the	O	O
eli	O	O
lilly	O	O
and	O	O
company	O	O
'	O	O
s	O	O
computerized	O	O
adverse	O	O
event	O	O
database	O	O
for	O	O
all	O	O
reported	O	O
cases	O	O
of	O	O
hyponatremia	O	O
and	O	O
/	O	O
or	O	O
siadh	O	O
as	O	O
of	O	O
1	O	O
november	O	O
1999	O	O
that	O	O
had	O	O
been	O	O
reported	O	O
during	O	O
the	O	O
use	O	O
of	O	O
vincristine	B-chem	B-chem
.	O	O

results	O	O
:	O	O

a	O	O
total	O	O
of	O	O
76	O	O
cases	O	O
of	O	O
hyponatremia	O	O
and	O	O
/	O	O
or	O	O
siadh	O	O
associated	O	O
with	O	O
vincristine	B-chem	B-chem
use	O	O
were	O	O
identified	O	O
.	O	O

the	O	O
overall	O	O
reporting	O	O
rate	O	O
was	O	O
estimated	O	O
to	O	O
be	O	O
1	O	O
.	O	O
3	O	O
/	O	O
100	O	O
,	O	O
000	O	O
treated	O	O
patients	O	O
.	O	O

the	O	O
average	O	O
age	O	O
of	O	O
patients	O	O
was	O	O
35	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

28	O	O
.	O	O
3	O	O
years	O	O
,	O	O
and	O	O
62	O	O
%	O	O
were	O	O
males	O	O
.	O	O

approximately	O	O
75	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
receiving	O	O
treatment	O	O
for	O	O
leukemia	O	O
or	O	O
lymphoma	O	O
.	O	O

among	O	O
the	O	O
39	O	O
reports	O	O
that	O	O
included	O	O
information	O	O
on	O	O
race	O	O
,	O	O
the	O	O
racial	O	O
distribution	O	O
was	O	O
:	O	O
1	O	O
black	O	O
,	O	O
3	O	O
caucasian	O	O
,	O	O
and	O	O
35	O	O
asian	O	O
.	O	O

conclusion	O	O
:	O	O

our	O	O
data	O	O
suggest	O	O
that	O	O
asian	O	O
patients	O	O
may	O	O
be	O	O
at	O	O
increased	O	O
risk	O	O
of	O	O
hyponatremia	O	O
and	O	O
/	O	O
or	O	O
siadh	O	O
associated	O	O
with	O	O
vincristine	B-chem	B-chem
use	O	O
.	O	O

although	O	O
the	O	O
overall	O	O
reported	O	O
rate	O	O
of	O	O
siadh	O	O
associated	O	O
with	O	O
vincristine	B-chem	B-chem
is	O	O
very	O	O
low	O	O
,	O	O
physicians	O	O
caring	O	O
for	O	O
asian	O	O
oncology	O	O
patients	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
potential	O	O
serious	O	O
but	O	O
reversible	O	O
adverse	O	O
event	O	O
.	O	O

delayed	O	O
toxicity	O	O
of	O	O
cyclophosphamide	B-chem	B-chem
on	O	O
the	O	O
bladder	O	O
of	O	O
dba	O	O
/	O	O
2	O	O
and	O	O
c57bl	O	O
/	O	O
6	O	O
female	O	O
mouse	O	O
.	O	O

the	O	O
present	O	O
study	O	O
describes	O	O
the	O	O
delayed	O	O
development	O	O
of	O	O
a	O	O
severe	O	O
bladder	O	O
pathology	O	O
in	O	O
a	O	O
susceptible	O	O
strain	O	O
of	O	O
mice	O	O
(	O	O
dba	O	O
/	O	O
2	O	O
)	O	O
but	O	O
not	O	O
in	O	O
a	O	O
resistant	O	O
strain	O	O
(	O	O
c57bl	O	O
/	O	O
6	O	O
)	O	O
when	O	O
both	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
single	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
dose	O	O
of	O	O
cyclophosphamide	B-chem	B-chem
(	O	O
cy	B-chem	B-chem
)	O	O
.	O	O

inbred	O	O
dba	O	O
/	O	O
2	O	O
and	O	O
c57bl	O	O
/	O	O
6	O	O
female	O	O
mice	O	O
were	O	O
injected	O	O
with	O	O
cy	B-chem	B-chem
,	O	O
and	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
drug	O	O
on	O	O
the	O	O
bladder	O	O
was	O	O
assessed	O	O
during	O	O
100	O	O
days	O	O
by	O	O
light	O	O
microscopy	O	O
using	O	O
different	O	O
staining	O	O
procedures	O	O
,	O	O
and	O	O
after	O	O
30	O	O
days	O	O
by	O	O
conventional	O	O
electron	O	O
microscopy	O	O
.	O	O

early	O	O
cy	B-chem	B-chem
toxicity	O	O
caused	O	O
a	O	O
typical	O	O
haemorrhagic	O	O
cystitis	O	O
in	O	O
both	O	O
strains	O	O
that	O	O
was	O	O
completely	O	O
repaired	O	O
in	O	O
about	O	O
7	O	O
-	O	O
10	O	O
days	O	O
.	O	O

after	O	O
30	O	O
days	O	O
of	O	O
cy	B-chem	B-chem
injection	O	O
ulcerous	O	O
and	O	O
non	O	O
-	O	O
ulcerous	O	O
forms	O	O
of	O	O
chronic	O	O
cystitis	O	O
appeared	O	O
in	O	O
86	O	O
%	O	O
of	O	O
dba	O	O
/	O	O
2	O	O
mice	O	O
but	O	O
only	O	O
in	O	O
4	O	O
%	O	O
of	O	O
c57bl	O	O
/	O	O
6	O	O
mice	O	O
.	O	O

delayed	O	O
cystitis	O	O
was	O	O
characterized	O	O
by	O	O
infiltration	O	O
and	O	O
transepithelial	O	O
passage	O	O
into	O	O
the	O	O
lumen	O	O
of	O	O
inflammatory	O	O
cells	O	O
and	O	O
by	O	O
frequent	O	O
exfoliation	O	O
of	O	O
the	O	O
urothelium	O	O
.	O	O

mast	O	O
cells	O	O
appeared	O	O
in	O	O
the	O	O
connective	O	O
and	O	O
muscular	O	O
layers	O	O
of	O	O
the	O	O
bladder	O	O
at	O	O
a	O	O
much	O	O
higher	O	O
number	O	O
in	O	O
dba	O	O
/	O	O
2	O	O
mice	O	O
than	O	O
in	O	O
c57bl	O	O
/	O	O
6	O	O
mice	O	O
or	O	O
untreated	O	O
controls	O	O
.	O	O

electron	O	O
microscopy	O	O
disclosed	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
typical	O	O
discoidal	O	O
vesicles	O	O
normally	O	O
present	O	O
in	O	O
the	O	O
cytoplasm	O	O
of	O	O
surface	O	O
cells	O	O
.	O	O

instead	O	O
,	O	O
numerous	O	O
abnormal	O	O
vesicles	O	O
containing	O	O
one	O	O
or	O	O
several	O	O
dark	O	O
granules	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
cytoplasm	O	O
of	O	O
cells	O	O
from	O	O
all	O	O
the	O	O
epithelial	O	O
layers	O	O
.	O	O

delayed	O	O
cystitis	O	O
still	O	O
persisted	O	O
in	O	O
dba	O	O
/	O	O
2	O	O
mice	O	O
100	O	O
days	O	O
after	O	O
treatment	O	O
.	O	O

these	O	O
results	O	O
indicate	O	O
that	O	O
delayed	O	O
toxicity	O	O
of	O	O
cy	B-chem	B-chem
in	O	O
female	O	O
dba	O	O
/	O	O
2	O	O
mice	O	O
causes	O	O
a	O	O
bladder	O	O
pathology	O	O
that	O	O
is	O	O
not	O	O
observed	O	O
in	O	O
c57bl	O	O
/	O	O
6	O	O
mice	O	O
.	O	O

this	O	O
pathology	O	O
resembles	O	O
interstitial	O	O
cystitis	O	O
in	O	O
humans	O	O
and	O	O
could	O	O
perhaps	O	O
be	O	O
used	O	O
as	O	O
an	O	O
animal	O	O
model	O	O
for	O	O
studies	O	O
on	O	O
the	O	O
disease	O	O
.	O	O

high	O	O
-	O	O
dose	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
/	O	O
folinic	B-chem	B-chem
acid	I-chem	I-chem
in	O	O
combination	O	O
with	O	O
three	O	B-chem
-	O	I-chem
weekly	O	I-chem
mitomycin	B-chem	B-chem
c	I-chem	I-chem
in	O	O
the	O	O
treatment	O	O
of	O	O
advanced	O	O
gastric	O	O
cancer	O	O
.	O	O

a	O	O
phase	O	O
ii	O	O
study	O	O
.	O	O

background	O	O
:	O	O

the	O	O
24	O	O
-	O	O
hour	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
(	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
)	O	O
and	O	O
folinic	B-chem	B-chem
acid	I-chem	I-chem
(	O	O
fa	B-chem	B-chem
)	O	O
as	O	O
part	O	O
of	O	O
several	O	O
new	O	O
multidrug	O	O
chemotherapy	O	O
regimens	O	O
in	O	O
advanced	O	O
gastric	O	O
cancer	O	O
(	O	O
agc	O	B-chem
)	O	O
has	O	O
shown	O	O
to	O	O
be	O	O
effective	O	O
,	O	O
with	O	O
low	O	O
toxicity	O	O
.	O	O

in	O	O
a	O	O
previous	O	O
phase	O	O
ii	O	O
study	O	O
with	O	O
3	O	B-chem
-	O	O
weekly	O	O
bolus	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
,	O	O
fa	B-chem	B-chem
and	O	O
mitomycin	B-chem	B-chem
c	I-chem	I-chem
(	O	O
mmc	B-chem	O
)	O	O
we	O	O
found	O	O
a	O	O
low	O	O
toxicity	O	O
rate	O	O
and	O	O
response	O	O
rates	O	O
comparable	O	O
to	O	O
those	O	O
of	O	O
regimens	O	O
such	O	O
as	O	O
elf	O	O
,	O	O
fam	O	O
or	O	O
famtx	O	O
,	O	O
and	O	O
a	O	O
promising	O	O
median	O	O
overall	O	O
survival	O	O
.	O	O

in	O	O
order	O	O
to	O	O
improve	O	O
this	O	O
mmc	B-chem	O
-	O	O
dependent	O	O
schedule	O	O
we	O	O
initiated	O	O
a	O	O
phase	O	O
ii	O	O
study	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
/	O	O
fa	B-chem	B-chem
and	O	O
3	O	O
-	O	O
weekly	O	O
bolus	O	O
mmc	B-chem	O
.	O	O

patients	O	O
and	O	O
methods	O	O
:	O	O

from	O	O
february	O	O
,	O	O
1998	O	O
to	O	O
september	O	O
,	O	O
2000	O	O
we	O	O
recruited	O	O
33	O	O
patients	O	O
with	O	O
agc	O	O
to	O	O
receive	O	O
weekly	O	O
24	O	O
-	O	O
hour	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
2	O	O
,	O	O
600	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
preceded	O	O
by	O	O
2	O	O
-	O	O
hour	O	O
fa	B-chem	B-chem
500	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
for	O	O
6	O	O
weeks	O	O
,	O	O
followed	O	O
by	O	O
a	O	O
2	O	O
-	O	O
week	O	O
rest	O	O
period	O	O
.	O	O

bolus	O	O
mmc	B-chem	O
10	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
was	O	O
added	O	O
in	O	O
3	O	O
-	O	O
weekly	O	O
intervals	O	O
.	O	O

treatment	O	O
given	O	O
on	O	O
an	O	O
outpatient	O	O
basis	O	O
,	O	O
using	O	O
portable	O	O
pump	O	O
systems	O	O
,	O	O
was	O	O
repeated	O	O
on	O	O
day	O	O
57	O	O
.	O	O

patients	O	O
'	O	O
characteristics	O	O
were	O	O
:	O	O
male	O	O
/	O	O
female	O	O
ratio	O	O
20	O	O
/	O	O
13	O	O
;	O	O
median	O	O
age	O	O
57	O	O
(	O	O
27	O	O
-	O	O
75	O	O
)	O	O
years	O	O
;	O	O
median	O	O
who	O	O
status	O	O
1	O	O
(	O	O
0	O	O
-	O	O
2	O	O
)	O	O
.	O	O

18	O	O
patients	O	O
had	O	O
a	O	O
primary	O	O
agc	O	B-chem
,	O	O
and	O	O
15	O	O
showed	O	O
a	O	O
relapsed	O	O
agc	O	O
.	O	O

median	O	O
follow	O	O
-	O	O
up	O	O
was	O	O
11	O	O
.	O	O
8	O	O
months	O	O
(	O	O
range	O	O
of	O	O
those	O	O
surviving	O	O
:	O	O
2	O	O
.	O	O
7	O	O
-	O	O
11	O	O
.	O	O
8	O	O
months	O	O
)	O	O
.	O	O

results	O	O
:	O	O

32	O	O
patients	O	O
were	O	O
evaluable	O	O
for	O	O
response	O	O
-	O	O
complete	O	O
remission	O	O
9	O	O
.	O	O
1	O	O
%	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
,	O	O
partial	O	O
remission	O	O
45	O	O
.	O	O
5	O	O
%	O	O
(	O	O
n	O	O
=	O	O
15	O	O
)	O	O
,	O	O
no	O	O
change	O	O
27	O	O
.	O	O
3	O	O
%	O	O
(	O	O
n	O	O
=	O	O
9	O	O
)	O	O
,	O	O
progressive	O	O
disease	O	O
15	O	O
.	O	O
1	O	O
%	O	O
(	O	O
n	O	O
=	O	O
5	O	O
)	O	O
.	O	O

median	O	O
overall	O	O
survival	O	O
time	O	O
was	O	O
10	O	O
.	O	O
2	O	O
months	O	O
[	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
ci	O	O
)	O	O
:	O	O
8	O	O
.	O	O
7	O	O
-	O	O
11	O	O
.	O	O
6	O	O
]	O	O
,	O	O
and	O	O
median	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
time	O	O
was	O	O
7	O	O
.	O	O
6	O	O
months	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
:	O	O
4	O	O
.	O	O
4	O	O
-	O	O
10	O	O
.	O	O
9	O	O
)	O	O
.	O	O

the	O	O
worst	O	O
toxicities	O	O
(	O	O
%	O	O
)	O	O
observed	O	O
were	O	O
(	O	O
ctc	O	O
-	O	O
nci	O	O
1	O	O
/	O	O
2	O	O
/	O	O
3	O	O
)	O	O
:	O	O

leukopenia	O	O
45	O	O
.	O	O
5	O	O
/	O	O
18	O	O
.	O	O
2	O	O
/	O	O
6	O	O
.	O	O
1	O	O
,	O	O
thrombocytopenia	O	O
33	O	O
.	O	O
3	O	O
/	O	O
9	O	O
.	O	O
1	O	O
/	O	O
6	O	O
.	O	O
1	O	O
,	O	O
vomitus	O	O
24	O	O
.	O	O
2	O	O
/	O	O
9	O	O
.	O	O
1	O	O
/	O	O
0	O	O
,	O	O
diarrhea	O	O
36	O	O
.	O	O
4	O	O
/	O	O
6	O	O
.	O	O
1	O	O
/	O	O
3	O	O
.	O	O
0	O	O
,	O	O
stomatitis	O	O
18	O	O
.	O	O
2	O	O
/	O	O
9	O	O
.	O	O
1	O	O
/	O	O
0	O	O
,	O	O
hand	O	O
-	O	O
foot	O	O
syndrome	O	O
12	O	O
.	O	O
1	O	O
/	O	O
0	O	O
/	O	O
0	O	O
.	O	O

two	O	O
patients	O	O
developed	O	O
hemolytic	O	O
-	O	O
uremic	O	O
syndrome	O	O
(	O	O
hus	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

high	O	O
-	O	O
dose	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
/	O	O
fa	B-chem	O
/	O	O
mmc	B-chem	O
is	O	O
an	O	O
effective	O	O
and	O	O
well	O	O
-	O	O
tolerated	O	O
outpatient	O	O
regimen	O	O
for	O	O
agc	O	B-chem
(	O	O
objective	O	O
response	O	O
rate	O	O
54	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

it	O	O
may	O	O
serve	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
cisplatin	B-chem	B-chem
-	O	O
containing	O	O
regimens	O	O
;	O	O
however	O	O
,	O	O
it	O	O
has	O	O
to	O	O
be	O	O
considered	O	O
that	O	O
possibly	O	O
hus	O	O
may	O	O
occur	O	O
.	O	O

persistent	O	O
sterile	O	O
leukocyturia	O	O
is	O	O
associated	O	O
with	O	O
impaired	O	O
renal	O	O
function	O	O
in	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
-	O	O
infected	O	O
children	O	O
treated	O	O
with	O	O
indinavir	B-chem	B-chem
.	O	O

background	O	O
:	O	O

prolonged	O	O
administration	O	O
of	O	O
indinavir	B-chem	B-chem
is	O	O
associated	O	O
with	O	O
the	O	O
occurrence	O	O
of	O	O
a	O	O
variety	O	O
of	O	O
renal	O	O
complications	O	O
in	O	O
adults	O	O
.	O	O

these	O	O
well	O	O
-	O	O
documented	O	O
side	O	O
effects	O	O
have	O	O
restricted	O	O
the	O	O
use	O	O
of	O	O
this	O	O
potent	O	O
protease	O	O
inhibitor	O	O
in	O	O
children	O	O
.	O	O

design	O	O
:	O	O

a	O	O
prospective	O	O
study	O	O
to	O	O
monitor	O	O
indinavir	B-chem	B-chem
-	O	O
related	O	O
nephrotoxicity	O	O
in	O	O
a	O	O
cohort	O	O
of	O	O
30	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
-	O	O
infected	O	O
children	O	O
treated	O	O
with	O	O
indinavir	B-chem	B-chem
.	O	O

methods	O	O
:	O	O

urinary	O	O
ph	O	O
,	O	O
albumin	O	O
,	O	O
creatinine	B-chem	B-chem
,	O	O
the	O	O
presence	O	O
of	O	O
erythrocytes	O	O
,	O	O
leukocytes	O	O
,	O	O
bacteria	O	O
and	O	O
crystals	O	O
,	O	O
and	O	O
culture	O	O
were	O	O
analyzed	O	O
every	O	O
3	O	O
months	O	O
for	O	O
96	O	O
weeks	O	O
.	O	O

serum	O	O
creatinine	B-chem	B-chem
levels	O	O
were	O	O
routinely	O	O
determined	O	O
at	O	O
the	O	O
same	O	O
time	O	O
points	O	O
.	O	O

steady	O	O
-	O	O
state	O	O
pharmacokinetics	O	O
of	O	O
indinavir	B-chem	B-chem
were	O	O
done	O	O
at	O	O
week	O	O
4	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
indinavir	B-chem	B-chem
.	O	O

results	O	O
:	O	O

the	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
sterile	O	O
leukocyturia	O	O
(	O	O
>	O	O
or	O	O
=	O	O
75	O	O
cells	O	O
/	O	O
micro	O	O
l	O	O
in	O	O
at	O	O
least	O	O
2	O	O
consecutive	O	O
visits	O	O
)	O	O
after	O	O
96	O	O
weeks	O	O
was	O	O
53	O	O
%	O	O
.	O	O

persistent	O	O
sterile	O	O
leukocyturia	O	O
was	O	O
frequently	O	O
associated	O	O
with	O	O
a	O	O
mild	O	O
increase	O	O
in	O	O
the	O	O
urine	O	O
albumin	O	O
/	O	O
creatinine	B-chem	B-chem
ratio	O	O
and	O	O
by	O	O
microscopic	O	O
hematuria	O	O
.	O	O

the	O	O
cumulative	O	O
incidence	O	O
of	O	O
serum	O	O
creatinine	B-chem	B-chem
levels	O	O
>	O	O
50	O	O
%	O	O
above	O	O
normal	O	O
was	O	O
33	O	O
%	O	O
after	O	O
96	O	O
weeks	O	O
.	O	O

children	O	O
with	O	O
persistent	O	O
sterile	O	O
leukocyturia	O	O
more	O	O
frequently	O	O
had	O	O
serum	O	O
creatinine	B-chem	B-chem
levels	O	O
of	O	O
50	O	O
%	O	O
above	O	O
normal	O	O
than	O	O
those	O	O
children	O	O
without	O	O
persistent	O	O
sterile	O	O
leukocyturia	O	O
.	O	O

in	O	O
children	O	O
younger	O	O
than	O	O
5	O	O
.	O	O
6	O	O
years	O	O
,	O	O
persistent	O	O
sterile	O	O
leukocyturia	O	O
was	O	O
significantly	O	O
more	O	O
frequent	O	O
than	O	O
in	O	O
older	O	O
children	O	O
.	O	O

a	O	O
higher	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
leukocyturia	O	O
was	O	O
found	O	O
in	O	O
children	O	O
with	O	O
an	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
>	O	O

19	O	O
mg	O	O
/	O	O
l	O	O
x	O	O
h	O	O
or	O	O
a	O	O
peak	O	O
serum	O	O
level	O	O
of	O	O
indinavir	B-chem	B-chem
>	O	O

12	O	O
mg	O	O
/	O	O
l	O	O
.	O	O

in	O	O
4	O	O
children	O	O
,	O	O
indinavir	B-chem	B-chem
was	O	O
discontinued	O	O
because	O	O
of	O	O
nephrotoxicity	O	O
.	O	O

subsequently	O	O
,	O	O
the	O	O
serum	O	O
creatinine	B-chem	B-chem
levels	O	O
decreased	O	O
,	O	O
the	O	O
urine	O	O
albumin	O	O
/	O	O
creatinine	B-chem	B-chem
ratios	O	O
returned	O	O
to	O	O
zero	O	O
,	O	O
and	O	O
the	O	O
leukocyturia	O	O
disappeared	O	O
within	O	O
3	O	O
months	O	O
.	O	O

conclusions	O	O
:	O	O

children	O	O
treated	O	O
with	O	O
indinavir	B-chem	B-chem
have	O	O
a	O	O
high	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
sterile	O	O
leukocyturia	O	O
.	O	O

children	O	O
with	O	O
persistent	O	O
sterile	O	O
leukocyturia	O	O
more	O	O
frequently	O	O
had	O	O
an	O	O
increase	O	O
in	O	O
serum	O	O
creatinine	B-chem	B-chem
levels	O	O
of	O	O
>	O	O
50	O	O
%	O	O
above	O	O
normal	O	O
.	O	O

younger	O	O
children	O	O
have	O	O
an	O	O
additional	O	O
risk	O	O
for	O	O
renal	O	O
complications	O	O
.	O	O

the	O	O
impairment	O	O
of	O	O
the	O	O
renal	O	O
function	O	O
in	O	O
these	O	O
children	O	O
occurred	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
clinical	O	O
symptoms	O	O
of	O	O
nephrolithiasis	O	O
.	O	O

indinavir	B-chem	B-chem
-	O	O
associated	O	O
nephrotoxicity	O	O
must	O	O
be	O	O
monitored	O	O
closely	O	O
,	O	O
especially	O	O
in	O	O
children	O	O
with	O	O
risk	O	O
factors	O	O
such	O	O
as	O	O
persistent	O	O
sterile	O	O
leukocyturia	O	O
,	O	O
age	O	O
<	O	O
5	O	O
.	O	O
6	O	O
years	O	O
,	O	O
an	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
of	O	O
indinavir	B-chem	B-chem
>	O	O
19	O	O
mg	O	O
/	O	O
l	O	O
x	O	O
h	O	O
,	O	O
and	O	O
a	O	O
c	O	O
(	O	O
max	O	O
)	O	O
>	O	O
12	O	O
mg	O	O
/	O	O
l	O	O
.	O	O

utility	O	O
of	O	O
troponin	O	O
i	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
.	O	O

baseline	O	O
electrocardiogram	O	O
abnormalities	O	O
and	O	O
market	O	O
elevations	O	O
not	O	O
associated	O	O
with	O	O
myocardial	O	O
necrosis	O	O
make	O	O
accurate	O	O
diagnosis	O	O
of	O	O
myocardial	O	O
infarction	O	O
(	O	O
mi	O	O
)	O	O
difficult	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
.	O	O

troponin	O	O
sampling	O	O
may	O	O
offer	O	O
greater	O	O
diagnostic	O	O
utility	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

objective	O	O
:	O	O

to	O	O
assess	O	O
outcomes	O	O
based	O	O
on	O	O
troponin	O	O
positivity	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
chest	O	O
pain	O	O
admitted	O	O
for	O	O
exclusion	O	O
of	O	O
mi	O	O
.	O	O

methods	O	O
:	O	O

outcomes	O	O
were	O	O
examined	O	O
in	O	O
patients	O	O
admitted	O	O
for	O	O
possible	O	O
mi	O	O
after	O	O
cocaine	B-chem	B-chem
use	O	O
.	O	O

all	O	O
patients	O	O
underwent	O	O
a	O	O
rapid	O	O
rule	O	O
-	O	O
in	O	O
protocol	O	O
that	O	O
included	O	O
serial	O	O
sampling	O	O
of	O	O
creatine	B-chem	B-chem
kinase	O	O
(	O	O
ck	O	O
)	O	O
,	O	O
ck	O	O
-	O	O
mb	O	O
,	O	O
and	O	O
cardiac	O	O
troponin	O	O

i	O	O
(	O	O
ctni	O	O
)	O	O
over	O	O
eight	O	O
hours	O	O
.	O	O

outcomes	O	O
included	O	O
ck	O	O
-	O	O
mb	O	O
mi	O	O
(	O	O
ck	O	O
-	O	O
mb	O	O

>	O	O

or	O	O
=	O	O
8	O	O
ng	O	O
/	O	O
ml	O	O
with	O	O
a	O	O
relative	O	O
index	O	O
[	O	O
(	O	O
ck	O	O
-	O	O
mb	O	O
x	O	O
100	O	O
)	O	O
/	O	O
total	O	O
ck	O	O
]	O	O

>	O	O
or	O	O
=	O	O
4	O	O
,	O	O
cardiac	O	O
death	O	O
,	O	O
and	O	O
significant	O	O
coronary	O	O
disease	O	O
(	O	O
>	O	O
or	O	O
=	O	O
50	O	O
%	O	O
)	O	O
.	O	O

results	O	O
:	O	O

of	O	O
the	O	O
246	O	O
admitted	O	O
patients	O	O
,	O	O
34	O	O
(	O	O
14	O	O
%	O	O
)	O	O
met	O	O
ck	O	O
-	O	O
mb	O	O
criteria	O	O
for	O	O
mi	O	O
and	O	O
38	O	O
(	O	O
16	O	O
%	O	O
)	O	O
had	O	O
ctni	O	O
elevations	O	O
.	O	O

angiography	O	O
was	O	O
performed	O	O
in	O	O
29	O	O
of	O	O
38	O	O
patients	O	O
who	O	O
were	O	O
ctni	O	O
-	O	O
positive	O	O
,	O	O
with	O	O
significant	O	O
disease	O	O
present	O	O
in	O	O
25	O	O
(	O	O
86	O	O
%	O	O
)	O	O
.	O	O

three	O	O
of	O	O
the	O	O
four	O	O
patients	O	O
without	O	O
significant	O	O
disease	O	O
who	O	O
had	O	O
ctni	O	O
elevations	O	O
met	O	O
ck	O	O
-	O	O
mb	O	O
criteria	O	O
for	O	O
mi	O	O
,	O	O
and	O	O
the	O	O
other	O	O
had	O	O
a	O	O
peak	O	O
ck	O	O
-	O	O
mb	O	O
level	O	O
of	O	O
13	O	O
ng	O	O
/	O	O
ml	O	O
.	O	O
sensitivities	O	O
,	O	O
specificities	O	O
,	O	O
and	O	O
positive	O	O
and	O	O
negative	O	O
likelihood	O	O
ratios	O	O
for	O	O
predicting	O	O
cardiac	O	O
death	O	O
or	O	O
significant	O	O
disease	O	O
were	O	O
high	O	O
for	O	O
both	O	O
ck	O	O
-	O	O
mb	O	O
mi	O	O
and	O	O
ctni	O	O
and	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
.	O	O

conclusions	O	O
:	O	O

most	O	O
patients	O	O
with	O	O
ctni	O	O
elevations	O	O
meet	O	O
ck	O	O
-	O	O
mb	O	O
criteria	O	O
for	O	O
mi	O	O
,	O	O
as	O	O
well	O	O
as	O	O
have	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
underlying	O	O
significant	O	O
disease	O	O
.	O	O

troponin	O	O
appears	O	O
to	O	O
have	O	O
an	O	O
equivalent	O	O
diagnostic	O	O
accuracy	O	O
compared	O	O
with	O	O
ck	O	O
-	O	O
mb	O	O
for	O	O
diagnosing	O	O
necrosis	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
and	O	O
suspected	O	O
mi	O	O
.	O	O

acute	O	O
interstitial	O	O
nephritis	O	O
due	O	O
to	O	O
nicergoline	B-chem	B-chem
(	O	O
sermion	B-chem	O
)	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	O	O
interstitial	O	O
nephritis	O	O
(	O	O
ain	O	O
)	O	O
due	O	O
to	O	O
nicergoline	B-chem	B-chem
(	O	O
sermion	B-chem	O
)	O	O
.	O	O

a	O	O
50	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
admitted	O	O
to	O	O
our	O	O
hospital	O	O
for	O	O
fever	O	O
and	O	O
acute	O	O
renal	O	O
failure	O	O
.	O	O

before	O	O
admission	O	O
,	O	O
he	O	O
had	O	O
been	O	O
taking	O	O
nicergoline	B-chem	B-chem
and	O	O
bendazac	B-chem	B-chem
lysine	I-chem	I-chem
due	O	O
to	O	O
retinal	O	O
vein	O	O
occlusion	O	O
at	O	O
ophthalmologic	O	O
department	O	O
.	O	O

thereafter	O	O
,	O	O
he	O	O
experienced	O	O
intermittent	O	O
fever	O	O
and	O	O
skin	O	O
rash	O	O
.	O	O

on	O	O
admission	O	O
,	O	O
clinical	O	O
symptoms	O	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
arthralgia	O	O
and	O	O
fever	O	O
)	O	O
and	O	O
laboratory	O	O
findings	O	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
eosinophilia	O	O
and	O	O
renal	O	O
failure	O	O
)	O	O
suggested	O	O
ain	O	O
,	O	O
and	O	O
which	O	O
was	O	O
confirmed	O	O
by	O	O
pathologic	O	O
findings	O	O
on	O	O
renal	O	O
biopsy	O	O
.	O	O

a	O	O
lymphocyte	O	O
transformation	O	O
test	O	O
demonstrated	O	O
a	O	O
positive	O	O
result	O	O
against	O	O
nicergoline	B-chem	B-chem
.	O	O

treatment	O	O
was	O	O
consisted	O	O
of	O	O
withdrawal	O	O
of	O	O
nicergoline	B-chem	B-chem
and	O	O
intravenous	O	O
methylprednisolone	B-chem	B-chem
,	O	O
and	O	O
his	O	O
renal	O	O
function	O	O
was	O	O
completely	O	O
recovered	O	O
.	O	O

to	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
nicergoline	B-chem	B-chem
-	O	O
associated	O	O
ain	O	O
.	O	O

neuroleptic	O	O
malignant	O	O
syndrome	O	O
complicated	O	O
by	O	O
massive	O	O
intestinal	O	O
bleeding	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
chronic	O	O
renal	O	O
failure	O	O
.	O	O

a	O	O
patient	O	O
with	O	O
chronic	O	O
renal	O	O
failure	O	O
(	O	O
crf	O	O
)	O	O
developed	O	O
neuroleptic	O	O
malignant	O	O
syndrome	O	O
(	O	O
nms	O	O
)	O	O
after	O	O
administration	O	O
of	O	O
risperidone	B-chem	B-chem
and	O	O
levomepromazine	B-chem	B-chem
.	O	O

in	O	O
addition	O	O
to	O	O
the	O	O
typical	O	O
symptoms	O	O
of	O	O
nms	O	O
,	O	O
massive	O	O
intestinal	O	O
bleeding	O	O
was	O	O
observed	O	O
during	O	O
the	O	O
episode	O	O
.	O	O

this	O	O
report	O	O
suggests	O	O
that	O	O
nms	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
crf	O	O
may	O	O
be	O	O
complicated	O	O
by	O	O
intestinal	O	O
bleeding	O	O
and	O	O
needs	O	O
special	O	O
caution	O	O
for	O	O
this	O	O
complication	O	O
.	O	O

blood	O	O
brain	O	O
barrier	O	O
in	O	O
right	O	O
-	O	O
and	O	O
left	O	O
-	O	O
pawed	O	O
female	O	O
rats	O	O
assessed	O	O
by	O	O
a	O	O
new	O	O
staining	O	O
method	O	O
.	O	O

the	O	O
asymmetrical	O	O
breakdown	O	O
of	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
(	O	O
bbb	O	O
)	O	O
was	O	O
studied	O	O
in	O	O
female	O	O
rats	O	O
.	O	O

paw	O	O
preference	O	O
was	O	O
assessed	O	O
by	O	O
a	O	O
food	O	O
reaching	O	O
test	O	O
.	O	O

adrenaline	B-chem	B-chem
-	O	O
induced	O	O
hypertension	O	O
was	O	O
used	O	O
to	O	O
destroy	O	O
the	O	O
bbb	O	O
,	O	O
which	O	O
was	O	O
evaluated	O	O
using	O	O
triphenyltetrazolium	B-chem	B-chem
(	O	O
ttc	B-chem	O
)	O	O
staining	O	O
of	O	O
the	O	O
brain	O	O
slices	O	O
just	O	O
after	O	O
giving	O	O
adrenaline	B-chem	B-chem
for	O	O
30	O	O
s	O	O
.	O	O

in	O	O
normal	O	O
rats	O	O
,	O	O
the	O	O
whole	O	O
brain	O	O
sections	O	O
exhibited	O	O
complete	O	O
staining	O	O
with	O	O
ttc	B-chem	O
.	O	O

after	O	O
adrenaline	B-chem	B-chem
infusion	O	O
for	O	O
30	O	O
s	O	O
,	O	O
there	O	O
were	O	O
large	O	O
unstained	O	O
areas	O	O
in	O	O
the	O	O
left	O	O
brain	O	O
in	O	O
right	O	O
-	O	O
pawed	O	O
animals	O	O
,	O	O
and	O	O
vice	O	O
versa	O	O
in	O	O
left	O	O
-	O	O
pawed	O	O
animals	O	O
.	O	O

similar	O	O
results	O	O
were	O	O
obtained	O	O
in	O	O
seizure	O	O
-	O	O
induced	O	O
breakdown	O	O
of	O	O
bbb	O	O
.	O	O

these	O	O
results	O	O
were	O	O
explained	O	O
by	O	O
an	O	O
asymmetric	O	O
cerebral	O	O
blood	O	O
flow	O	O
depending	O	O
upon	O	O
the	O	O
paw	O	O
preference	O	O
in	O	O
rats	O	O
.	O	O

it	O	O
was	O	O
suggested	O	O
that	O	O
this	O	O
new	O	O
method	O	O
and	O	O
the	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
contralateral	O	O
motor	O	O
control	O	O
that	O	O
may	O	O
be	O	O
important	O	O
in	O	O
determining	O	O
the	O	O
dominant	O	O
cerebral	O	O
hemisphere	O	O
in	O	O
animals	O	O
.	O	O

carvedilol	B-chem	B-chem
protects	O	O
against	O	O
doxorubicin	B-chem	B-chem
-	O	O
induced	O	O
mitochondrial	O	O
cardiomyopathy	O	O
.	O	O

several	O	O
cytopathic	O	O
mechanisms	O	O
have	O	O
been	O	O
suggested	O	O
to	O	O
mediate	O	O
the	O	O
dose	O	O
-	O	O
limiting	O	O
cumulative	O	O
and	O	O
irreversible	O	O
cardiomyopathy	O	O
caused	O	O
by	O	O
doxorubicin	B-chem	B-chem
.	O	O

recent	O	O
evidence	O	O
indicates	O	O
that	O	O
oxidative	O	O
stress	O	O
and	O	O
mitochondrial	O	O
dysfunction	O	O
are	O	O
key	O	O
factors	O	O
in	O	O
the	O	O
pathogenic	O	O
process	O	O
.	O	O

the	O	O
objective	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O	O
that	O	O
carvedilol	B-chem	B-chem
,	O	O
a	O	O
nonselective	O	O
beta	O	O
-	O	O
adrenergic	O	O
receptor	O	O
antagonist	O	O
with	O	O
potent	O	O
antioxidant	O	O
properties	O	O
,	O	O
protects	O	O
against	O	O
the	O	O
cardiac	O	O
and	O	O
hepatic	O	O
mitochondrial	O	O
bioenergetic	O	O
dysfunction	O	O
associated	O	O
with	O	O
subchronic	O	O
doxorubicin	B-chem	B-chem
toxicity	O	O
.	O	O

heart	O	O
and	O	O
liver	O	O
mitochondria	O	O
were	O	O
isolated	O	O
from	O	O
rats	O	O
treated	O	O
for	O	O
7	O	O
weeks	O	O
with	O	O
doxorubicin	B-chem	B-chem
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
/	O	O
week	O	O
)	O	O
,	O	O
carvedilol	B-chem	B-chem
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
/	O	O
week	O	O
)	O	O
,	O	O
or	O	O
the	O	O
combination	O	O
of	O	O
the	O	O
two	O	O
drugs	O	O
.	O	O

heart	O	O
mitochondria	O	O
isolated	O	O
from	O	O
doxorubicin	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
exhibited	O	O
depressed	O	O
rates	O	O
for	O	O
state	O	O
3	O	O
respiration	O	O
(	O	O
336	O	O
+	O	O
/	O	O
-	O	O

26	O	O
versus	O	O
425	O	O
+	O	O
/	O	O
-	O	O

53	O	O
natom	O	O
o	O	O
/	O	O
min	O	O
/	O	O
mg	O	O
protein	O	O
)	O	O
and	O	O
a	O	O
lower	O	O
respiratory	O	O
control	O	O
ratio	O	O
(	O	O
rcr	O	O
)	O	O
(	O	O
4	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
6	O	O
versus	O	O
5	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
4	O	O
)	O	O
compared	O	O
with	O	O
cardiac	O	O
mitochondria	O	O
isolated	O	O
from	O	O
saline	O	O
-	O	O
treated	O	O
rats	O	O
.	O	O

mitochondrial	O	O
calcium	B-chem	B-chem
-	O	O
loading	O	O
capacity	O	O
and	O	O
the	O	O
activity	O	O
of	O	O
nadh	O	B-chem
-	O	O
dehydrogenase	O	O
were	O	O
also	O	O
suppressed	O	O
in	O	O
cardiac	O	O
mitochondria	O	O
from	O	O
doxorubicin	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
.	O	O

doxorubicin	B-chem	B-chem
treatment	O	O
also	O	O
caused	O	O
a	O	O
decrease	O	O
in	O	O
rcr	O	O
for	O	O
liver	O	O
mitochondria	O	O
(	O	O
3	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
9	O	O
versus	O	O
5	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
7	O	O
for	O	O
control	O	O
rats	O	O
)	O	O
and	O	O
inhibition	O	O
of	O	O
hepatic	O	O
cytochrome	O	O
oxidase	O	O
activity	O	O
.	O	O

coadministration	O	O
of	O	O
carvedilol	B-chem	B-chem
decreased	O	O
the	O	O
extent	O	O
of	O	O
cellular	O	O
vacuolization	O	O
in	O	O
cardiac	O	O
myocytes	O	O
and	O	O
prevented	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
doxorubicin	B-chem	B-chem
on	O	O
mitochondrial	O	O
respiration	O	O
in	O	O
both	O	O
heart	O	O
and	O	O
liver	O	O
.	O	O

carvedilol	B-chem	B-chem
also	O	O
prevented	O	O
the	O	O
decrease	O	O
in	O	O
mitochondrial	O	O
ca	B-chem	B-chem
(	O	O
2	O	O
+	O	O
)	O	O
loading	O	O
capacity	O	O
and	O	O
the	O	O
inhibition	O	O
of	O	O
the	O	O
respiratory	O	O
complexes	O	O
of	O	O
heart	O	O
mitochondria	O	O
caused	O	O
by	O	O
doxorubicin	B-chem	B-chem
.	O	O

carvedilol	B-chem	B-chem
by	O	O
itself	O	O
did	O	O
not	O	O
affect	O	O
any	O	O
of	O	O
the	O	O
parameters	O	O
measured	O	O
for	O	O
heart	O	O
or	O	O
liver	O	O
mitochondria	O	O
.	O	O

it	O	O
is	O	O
concluded	O	O
that	O	O
this	O	O
protection	O	O
by	O	O
carvedilol	B-chem	B-chem
against	O	O
both	O	O
the	O	O
structural	O	O
and	O	O
functional	O	O
cardiac	O	O
tissue	O	O
damage	O	O
may	O	O
afford	O	O
significant	O	O
clinical	O	O
advantage	O	O
in	O	O
minimizing	O	O
the	O	O
dose	O	O
-	O	O
limiting	O	O
mitochondrial	O	O
dysfunction	O	O
and	O	O
cardiomyopathy	O	O
that	O	O
accompanies	O	O
long	O	O
-	O	O
term	O	O
doxorubicin	B-chem	B-chem
therapy	O	O
in	O	O
cancer	O	O
patients	O	O
.	O	O

cocaine	B-chem	B-chem
-	O	O
induced	O	O
hyperactivity	O	O
is	O	O
more	O	O
influenced	O	O
by	O	O
adenosine	B-chem	B-chem
receptor	O	O
agonists	O	O
than	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
hyperactivity	O	O
.	O	O

the	O	O
influence	O	O
of	O	O
adenosine	B-chem	B-chem
receptor	O	O
agonists	O	O
and	O	O
antagonists	O	O
on	O	O
cocaine	B-chem	B-chem
-	O	O
and	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
hyperactivity	O	O
was	O	O
examined	O	O
in	O	O
mice	O	O
.	O	O

all	O	O
adenosine	B-chem	B-chem
receptor	O	O
agonists	O	O
significantly	O	O
decreased	O	O
the	O	O
locomotor	O	O
activity	O	O
in	O	O
mice	O	O
,	O	O
and	O	O
the	O	O
effects	O	O
were	O	O
dose	O	O
-	O	O
dependent	O	O
.	O	O

it	O	O
seems	O	O
that	O	O
adenosine	B-chem	B-chem
a1	O	O
and	O	O
a2	O	O
receptors	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
this	O	O
reaction	O	O
.	O	O

moreover	O	O
,	O	O
all	O	O
adenosine	B-chem	B-chem
receptor	O	O
agonists	O	O
:	O	O
2	B-chem	B-chem
-	I-chem	I-chem
p	I-chem	I-chem
-	I-chem	I-chem
(	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
carboxyethyl	I-chem	I-chem
)	I-chem	I-chem
phenethylamino	I-chem	I-chem
-	I-chem	I-chem
5	I-chem	I-chem
'	I-chem	I-chem
-	I-chem	I-chem
n	I-chem	I-chem
-	I-chem	I-chem
ethylcarboxamidoadenosine	I-chem	I-chem
(	O	O
cgs	B-chem	B-chem
21680	I-chem	I-chem
)	O	O
,	O	O
a2a	O	O
receptor	O	O
agonist	O	O
,	O	O
n6	B-chem	B-chem
-	I-chem	I-chem
cyclopentyladenosine	I-chem	I-chem
(	O	O
cpa	B-chem	B-chem
)	O	O
,	O	O
a1	O	O
receptor	O	O
agonist	O	O
,	O	O
and	O	O
5	B-chem	B-chem
'	I-chem	I-chem
-	I-chem	I-chem
n	I-chem	I-chem
-	I-chem	I-chem
ethylcarboxamidoadenosine	I-chem	I-chem
(	O	O
neca	B-chem	B-chem
)	O	O
,	O	O
a2	O	O
/	O	O
a1	O	O
receptor	O	O
agonist	O	O
significantly	O	O
and	O	O
dose	O	O
-	O	O
dependently	O	O
decreased	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
locomotor	O	O
activity	O	O
.	O	O

cpa	B-chem	B-chem
reduced	O	O
cocaine	B-chem	B-chem
action	O	O
at	O	O
the	O	O
doses	O	O
which	O	O
,	O	O
given	O	O
alone	O	O
,	O	O
did	O	O
not	O	O
influence	O	O
motility	O	O
,	O	O
while	O	O
cgs	B-chem	O
21680	I-chem	O
and	O	O
neca	B-chem	B-chem
decreased	O	O
the	O	O
action	O	O
of	O	O
cocaine	B-chem	B-chem
at	O	O
the	O	O
doses	O	O
which	O	O
,	O	O
given	O	O
alone	O	O
,	O	O
decreased	O	O
locomotor	O	O
activity	O	O
in	O	O
animals	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
the	O	O
involvement	O	O
of	O	O
both	O	O
adenosine	B-chem	B-chem
receptors	O	O
in	O	O
the	O	O
action	O	O
of	O	O
cocaine	B-chem	B-chem
although	O	O
agonists	O	O
of	O	O
a1	O	O
receptors	O	O
seem	O	O
to	O	O
have	O	O
stronger	O	O
influence	O	O
on	O	O
it	O	O
.	O	O

the	O	O
selective	O	O
blockade	O	O
of	O	O
a2	O	O
adenosine	B-chem	B-chem
receptor	O	O
by	O	O
dmpx	B-chem	B-chem
(	O	O
3	B-chem	B-chem
,	I-chem	I-chem
7	I-chem	I-chem
-	I-chem	I-chem
dimethyl	I-chem	I-chem
-	I-chem	I-chem
1	I-chem	I-chem
-	I-chem	I-chem
propargylxanthine	I-chem	I-chem
)	O	O
significantly	O	O
enhanced	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
locomotor	O	O
activity	O	O
of	O	O
animals	O	O
.	O	O

caffeine	B-chem	B-chem
had	O	O
similar	O	O
action	O	O
but	O	O
the	O	O
effect	O	O
was	O	O
not	O	O
significant	O	O
.	O	O

cpt	B-chem	O
(	O	O
8	B-chem	B-chem
-	I-chem	I-chem
cyclopentyltheophylline	I-chem	I-chem
)	O	I-chem
-	O	I-chem
-	O	O
a1	O	O
receptor	O	O
antagonist	O	O
,	O	O
did	O	O
not	O	O
show	O	O
any	O	O
influence	O	O
in	O	O
this	O	O
test	O	O
.	O	O

similarly	O	O
,	O	O
all	O	O
adenosine	B-chem	B-chem
receptor	O	O
agonists	O	O
decreased	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
hyperactivity	O	O
,	O	O
but	O	O
at	O	O
the	O	O
higher	O	O
doses	O	O
than	O	O
those	O	O
which	O	O
were	O	O
active	O	O
in	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
hyperactivity	O	O
.	O	O

the	O	O
selective	O	O
blockade	O	O
of	O	O
a2	O	O
adenosine	B-chem	B-chem
receptors	O	O
(	O	O
dmpx	B-chem	O
)	O	O
and	O	O
non	O	O
-	O	O
selective	O	O
blockade	O	O
of	O	O
adenosine	B-chem	B-chem
receptors	O	O
(	O	O
caffeine	B-chem	B-chem
)	O	O
significantly	O	O
increased	O	O
the	O	O
action	O	O
of	O	O
amphetamine	B-chem	B-chem
in	O	O
the	O	O
locomotor	O	O
activity	O	O
test	O	O
.	O	O

our	O	O
results	O	O
have	O	O
shown	O	O
that	O	O
all	O	O
adenosine	B-chem	B-chem
receptor	O	O
agonists	O	O
(	O	O
a1	O	O
and	O	O
a2	O	O
)	O	O
reduce	O	O
cocaine	B-chem	B-chem
-	O	O
and	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
locomotor	O	O
activity	O	O
and	O	O
indicate	O	O
that	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
hyperactivity	O	O
is	O	O
more	O	O
influenced	O	O
by	O	O
adenosine	B-chem	B-chem
receptor	O	O
agonists	O	O
(	O	O
particularly	O	O
a1	O	O
receptors	O	O
)	O	O
than	O	O
amphetamine	B-chem	B-chem
-	O	O
induced	O	O
hyperactivity	O	O
.	O	O

amiodarone	B-chem	B-chem
and	O	O
the	O	O
risk	O	O
of	O	O
bradyarrhythmia	O	O
requiring	O	O
permanent	O	O
pacemaker	O	O
in	O	O
elderly	O	O
patients	O	O
with	O	O
atrial	O	O
fibrillation	O	O
and	O	O
prior	O	O
myocardial	O	O
infarction	O	O
.	O	O

objectives	O	O
:	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
use	O	O
of	O	O
amiodarone	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
atrial	O	O
fibrillation	O	O
(	O	O
af	O	O
)	O	O
increases	O	O
the	O	O
risk	O	O
of	O	O
bradyarrhythmia	O	O
requiring	O	O
a	O	O
permanent	O	O
pacemaker	O	O
.	O	O

background	O	O
:	O	O
reports	O	O
of	O	O
severe	O	O
bradyarrhythmia	O	O
during	O	O
amiodarone	B-chem	B-chem
therapy	O	O
are	O	O
infrequent	O	O
and	O	O
limited	O	O
to	O	O
studies	O	O
assessing	O	O
the	O	O
therapy	O	O
'	O	O
s	O	O
use	O	O
in	O	O
the	O	O
management	O	O
of	O	O
patients	O	O
with	O	O
ventricular	O	O
arrhythmias	O	O
.	O	O

methods	O	O
:	O	O

a	O	O
study	O	O
cohort	O	O
of	O	O
8	O	O
,	O	O
770	O	O
patients	O	O
age	O	O
>	O	O
or	O	O
=	O	O
65	O	O
years	O	O
with	O	O
a	O	O
new	O	O
diagnosis	O	O
of	O	O
af	O	O
was	O	O
identified	O	O
from	O	O
a	O	O
provincewide	O	O
database	O	O
of	O	O
quebec	O	O
residents	O	O
with	O	O
a	O	O
myocardial	O	O
infarction	O	O
(	O	O
mi	O	O
)	O	O
between	O	O
1991	O	O
and	O	O
1999	O	O
.	O	O

using	O	O
a	O	O
nested	O	O
case	O	O
-	O	O
control	O	O
design	O	O
,	O	O
477	O	O
cases	O	O
of	O	O
bradyarrhythmia	O	O
requiring	O	O
a	O	O
permanent	O	O
pacemaker	O	O
were	O	O
matched	O	O
(	O	O
1	O	O
:	O	O
4	O	O
)	O	O
to	O	O
1	O	O
,	O	O
908	O	O
controls	O	O
.	O	O

multivariable	O	O
logistic	O	O
regression	O	O
was	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
odds	O	O
ratio	O	O
(	O	O
or	O	O
)	O	O
of	O	O
pacemaker	O	O
insertion	O	O
associated	O	O
with	O	O
amiodarone	B-chem	B-chem
use	O	O
,	O	O
controlling	O	O
for	O	O
baseline	O	O
risk	O	O
factors	O	O
and	O	O
exposure	O	O
to	O	O
sotalol	B-chem	B-chem
,	O	O
class	O	O
i	O	O
antiarrhythmic	O	O
agents	O	O
,	O	O
beta	O	O
-	O	O
blockers	O	O
,	O	O
calcium	B-chem	B-chem
channel	O	O
blockers	O	O
,	O	O
and	O	O
digoxin	B-chem	B-chem
.	O	O

results	O	O
:	O	O

amiodarone	B-chem	B-chem
use	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
pacemaker	O	O
insertion	O	O
(	O	O
or	O	O
:	O	O
2	O	O
.	O	O
14	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
ci	O	O
]	O	O
:	O	O
1	O	O
.	O	O
30	O	O
to	O	O
3	O	O
.	O	O
54	O	O
)	O	O
.	O	O

this	O	O
effect	O	O
was	O	O
modified	O	O
by	O	O
gender	O	O
,	O	O
with	O	O
a	O	O
greater	O	O
risk	O	O
in	O	O
women	O	O
versus	O	O
men	O	O
(	O	O
or	O	O
:	O	O
3	O	O
.	O	O
86	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
:	O	O
1	O	O
.	O	O
70	O	O
to	O	O
8	O	O
.	O	O
75	O	O
vs	O	O
.	O	O
or	O	O
:	O	O
1	O	O
.	O	O
52	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
:	O	O
0	O	O
.	O	O
80	O	O
to	O	O
2	O	O
.	O	O
89	O	O
)	O	O
.	O	O

digoxin	B-chem	B-chem
was	O	O
the	O	O
only	O	O
other	O	O
medication	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
pacemaker	O	O
insertion	O	O
(	O	O
or	O	O
:	O	O
1	O	O
.	O	O
78	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
:	O	O
1	O	O
.	O	O
37	O	O
to	O	O
2	O	O
.	O	O
31	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

this	O	O
study	O	O
suggests	O	O
that	O	O
the	O	O
use	O	O
of	O	O
amiodarone	B-chem	B-chem
in	O	O
elderly	O	O
patients	O	O
with	O	O
af	O	O
and	O	O
a	O	O
previous	O	O
mi	O	O
increases	O	O
the	O	O
risk	O	O
of	O	O
bradyarrhythmia	O	O
requiring	O	O
a	O	O
permanent	O	O
pacemaker	O	O
.	O	O

the	O	O
finding	O	O
of	O	O
an	O	O
augmented	O	O
risk	O	O
of	O	O
pacemaker	O	O
insertion	O	O
in	O	O
elderly	O	O
women	O	O
receiving	O	O
amiodarone	B-chem	B-chem
requires	O	O
further	O	O
investigation	O	O
.	O	O

indomethacin	B-chem	B-chem
-	O	O
induced	O	O
morphologic	O	O
changes	O	O
in	O	O
the	O	O
rat	O	O
urinary	O	O
bladder	O	O
epithelium	O	O
.	O	O

objectives	O	O
:	O	O

to	O	O
evaluate	O	O
the	O	O
morphologic	O	O
changes	O	O
in	O	O
rat	O	O
urothelium	O	O
induced	O	O
by	O	O
indomethacin	B-chem	B-chem
.	O	O

nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
-	O	O
induced	O	O
cystitis	O	O
is	O	O
a	O	O
poorly	O	O
recognized	O	O
and	O	O
under	O	O
-	O	O
reported	O	O
condition	O	O
.	O	O

in	O	O
addition	O	O
to	O	O
tiaprofenic	B-chem	B-chem
acid	I-chem	I-chem
,	O	O
indomethacin	B-chem	B-chem
has	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
this	O	O
condition	O	O
.	O	O

methods	O	O
:	O	O

three	O	O
groups	O	O
were	O	O
established	O	O
:	O	O
a	O	O
control	O	O
group	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
,	O	O
a	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
,	O	O
treated	O	O
with	O	O
one	O	O
intraperitoneal	O	O
injection	O	O
of	O	O
indomethacin	B-chem	B-chem
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
and	O	O
a	O	O
therapeutic	O	O
dose	O	O
group	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
in	O	O
which	O	O
oral	O	O
indomethacin	B-chem	B-chem
was	O	O
administered	O	O
3	O	O
.	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
daily	O	O
for	O	O
3	O	O
weeks	O	O
.	O	O

the	O	O
animals	O	O
were	O	O
then	O	O
killed	O	O
and	O	O
the	O	O
bladders	O	O
removed	O	O
for	O	O
light	O	O
and	O	O
electron	O	O
microscopic	O	O
studies	O	O
.	O	O

results	O	O
:	O	O

the	O	O
light	O	O
microscopic	O	O
findings	O	O
showed	O	O
some	O	O
focal	O	O
epithelial	O	O
degeneration	O	O
that	O	O
was	O	O
more	O	O
prominent	O	O
in	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
.	O	O

when	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
,	O	O
both	O	O
indomethacin	B-chem	B-chem
groups	O	O
revealed	O	O
statistically	O	O
increased	O	O
numbers	O	O
of	O	O
mast	O	O
cells	O	O
in	O	O
the	O	O
mucosa	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
and	O	O
penetration	O	O
of	O	O
lanthanum	B-chem	B-chem
nitrate	I-chem	I-chem
through	O	O
intercellular	O	O
areas	O	O
of	O	O
the	O	O
epithelium	O	O
.	O	O

furthermore	O	O
,	O	O
the	O	O
difference	O	O
in	O	O
mast	O	O
cell	O	O
counts	O	O
between	O	O
the	O	O
high	O	O
and	O	O
therapeutic	O	O
dose	O	O
groups	O	O
was	O	O
also	O	O
statistically	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

indomethacin	B-chem	B-chem
resulted	O	O
in	O	O
histopathologic	O	O
findings	O	O
typical	O	O
of	O	O
interstitial	O	O
cystitis	O	O
,	O	O
such	O	O
as	O	O
leaky	O	O
bladder	O	O
epithelium	O	O
and	O	O
mucosal	O	O
mastocytosis	O	O
.	O	O

the	O	O
true	O	O
incidence	O	O
of	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
-	O	O
induced	O	O
cystitis	O	O
in	O	O
humans	O	O
must	O	O
be	O	O
clarified	O	O
by	O	O
prospective	O	O
clinical	O	O
trials	O	O
.	O	O

an	O	O
open	O	O
-	O	O
label	O	O
phase	O	O
ii	O	O
study	O	O
of	O	O
low	O	O
-	O	O
dose	O	O
thalidomide	B-chem	B-chem
in	O	O
androgen	B-chem	O
-	O	O
independent	O	O
prostate	O	O
cancer	O	O
.	O	O

the	O	O
antiangiogenic	O	O
effects	O	O
of	O	O
thalidomide	B-chem	B-chem
have	O	O
been	O	O
assessed	O	O
in	O	O
clinical	O	O
trials	O	O
in	O	O
patients	O	O
with	O	O
various	O	O
solid	O	O
and	O	O
haematological	O	O
malignancies	O	O
.	O	O

thalidomide	B-chem	B-chem
blocks	O	O
the	O	O
activity	O	O
of	O	O
angiogenic	O	O
agents	O	O
including	O	O
bfgf	O	O
,	O	O
vegf	O	O
and	O	O
il	O	O
-	O	O
6	O	O
.	O	O

we	O	O
undertook	O	O
an	O	O
open	O	O
-	O	O
label	O	O
study	O	O
using	O	O
thalidomide	B-chem	B-chem
100	O	O
mg	O	O
once	O	O
daily	O	O
for	O	O
up	O	O
to	O	O
6	O	O
months	O	O
in	O	O
20	O	O
men	O	O
with	O	O
androgen	B-chem	O
-	O	O
independent	O	O
prostate	O	O
cancer	O	O
.	O	O

the	O	O
mean	O	O
time	O	O
of	O	O
study	O	O
was	O	O
109	O	O
days	O	O
(	O	O
median	O	O
107	O	O
,	O	O
range	O	O
4	O	O
-	O	O
184	O	O
days	O	O
)	O	O
.	O	O

patients	O	O
underwent	O	O
regular	O	O
measurement	O	O
of	O	O
prostate	O	O
-	O	O
specific	O	O
antigen	O	O
(	O	O
psa	O	O
)	O	O
,	O	O
urea	B-chem	O
and	O	O
electrolytes	O	O
,	O	O
serum	O	O
bfgf	O	O
and	O	O
vegf	O	O
.	O	O

three	O	O
men	O	O
(	O	O
15	O	O
%	O	O
)	O	O
showed	O	O
a	O	O
decline	O	O
in	O	O
serum	O	O
psa	O	O
of	O	O
at	O	O
least	O	O
50	O	O
%	O	O
,	O	O
sustained	O	O
throughout	O	O
treatment	O	O
.	O	O

of	O	O
16	O	O
men	O	O
treated	O	O
for	O	O
at	O	O
least	O	O
2	O	O
months	O	O
,	O	O
six	O	O
(	O	O
37	O	O
.	O	O
5	O	O
%	O	O
)	O	O
showed	O	O
a	O	O
fall	O	O
in	O	O
absolute	O	O
psa	O	O
by	O	O
a	O	O
median	O	O
of	O	O
48	O	O
%	O	O
.	O	O

increasing	O	O
levels	O	O
of	O	O
serum	O	O
bfgf	O	O
and	O	O
vegf	O	O
were	O	O
associated	O	O
with	O	O
progressive	O	O
disease	O	O
;	O	O
five	O	O
of	O	O
six	O	O
men	O	O
who	O	O
demonstrated	O	O
a	O	O
fall	O	O
in	O	O
psa	O	O
also	O	O
showed	O	O
a	O	O
decline	O	O
in	O	O
bfgf	O	O
and	O	O
vegf	O	O
levels	O	O
,	O	O
and	O	O
three	O	O
of	O	O
four	O	O
men	O	O
with	O	O
a	O	O
rising	O	O
psa	O	O
showed	O	O
an	O	O
increase	O	O
in	O	O
both	O	O
growth	O	O
factors	O	O
.	O	O

adverse	O	O
effects	O	O
included	O	O
constipation	O	O
,	O	O
morning	O	O
drowsiness	O	O
,	O	O
dizziness	O	O
and	O	O
rash	O	O
,	O	O
and	O	O
resulted	O	O
in	O	O
withdrawal	O	O
from	O	O
the	O	O
study	O	O
by	O	O
three	O	O
men	O	O
.	O	O

evidence	O	O
of	O	O
peripheral	O	O
sensory	O	O
neuropathy	O	O
was	O	O
found	O	O
in	O	O
nine	O	O
of	O	O
13	O	O
men	O	O
before	O	O
treatment	O	O
.	O	O

in	O	O
the	O	O
seven	O	O
men	O	O
who	O	O
completed	O	O
six	O	O
months	O	O
on	O	O
thalidomide	B-chem	B-chem
,	O	O
subclinical	O	O
evidence	O	O
of	O	O
peripheral	O	O
neuropathy	O	O
was	O	O
found	O	O
in	O	O
four	O	O
before	O	O
treatment	O	O
,	O	O
but	O	O
in	O	O
all	O	O
seven	O	O
at	O	O
repeat	O	O
testing	O	O
.	O	O

the	O	O
findings	O	O
indicate	O	O
that	O	O
thalidomide	B-chem	B-chem
may	O	O
be	O	O
an	O	O
option	O	O
for	O	O
patients	O	O
who	O	O
have	O	O
failed	O	O
other	O	O
forms	O	O
of	O	O
therapy	O	O
,	O	O
provided	O	O
close	O	O
follow	O	O
-	O	O
up	O	O
is	O	O
maintained	O	O
for	O	O
development	O	O
of	O	O
peripheral	O	O
neuropathy	O	O
.	O	O

central	O	O
nervous	O	O
system	O	O
toxicity	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
levobupivacaine	B-chem	B-chem
for	O	O
lumbar	O	O
plexus	O	O
block	O	O
:	O	O
a	O	O
report	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

background	O	O
and	O	O
objectives	O	O
:	O	O

central	O	O
nervous	O	O
system	O	O
and	O	O
cardiac	O	O
toxicity	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
local	O	O
anesthetics	O	O
is	O	O
a	O	O
recognized	O	O
complication	O	O
of	O	O
regional	O	O
anesthesia	O	O
.	O	O

levobupivacaine	B-chem	B-chem
,	O	O
the	O	O
pure	O	O
s	O	O
(	O	O
-	O	O
)	O	O
enantiomer	O	O
of	O	O
bupivacaine	B-chem	B-chem
,	O	O
was	O	O
developed	O	O
to	O	O
improve	O	O
the	O	O
cardiac	O	O
safety	O	O
profile	O	O
of	O	O
bupivacaine	B-chem	B-chem
.	O	O

we	O	O
describe	O	O
2	O	O
cases	O	O
of	O	O
grand	O	O
mal	O	O
seizures	O	O
following	O	O
accidental	O	O
intravascular	O	O
injection	O	O
of	O	O
levobupivacaine	B-chem	B-chem
.	O	O

case	O	O
report	O	O
:	O	O

two	O	O
patients	O	O
presenting	O	O
for	O	O
elective	O	O
orthopedic	O	O
surgery	O	O
of	O	O
the	O	O
lower	O	O
limb	O	O
underwent	O	O
blockade	O	O
of	O	O
the	O	O
lumbar	O	O
plexus	O	O
via	O	O
the	O	O
posterior	O	O
approach	O	O
.	O	O

immediately	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
levobupivacaine	B-chem	B-chem
0	O	O
.	O	O
5	O	O
%	O	O
with	O	O
epinephrine	B-chem	B-chem
2	O	O
.	O	O
5	O	O
microgram	O	O
/	O	O
ml	O	O
,	O	O
the	O	O
patients	O	O
developed	O	O
grand	O	O
mal	O	O
seizures	O	O
,	O	O
despite	O	O
negative	O	O
aspiration	O	O
for	O	O
blood	O	O
and	O	O
no	O	O
clinical	O	O
signs	O	O
of	O	O
intravenous	O	O
epinephrine	B-chem	B-chem
administration	O	O
.	O	O

the	O	O
seizures	O	O
were	O	O
successfully	O	O
treated	O	O
with	O	O
sodium	B-chem	B-chem
thiopental	I-chem	I-chem
in	O	O
addition	O	O
to	O	O
succinylcholine	B-chem	B-chem
in	O	O
1	O	O
patient	O	O
.	O	O

neither	O	O
patient	O	O
developed	O	O
signs	O	O
of	O	O
cardiovascular	O	O
toxicity	O	O
.	O	O

both	O	O
patients	O	O
were	O	O
treated	O	O
preoperatively	O	O
with	O	O
beta	O	O
-	O	O
adrenergic	O	O
antagonist	O	O
medications	O	O
,	O	O
which	O	O
may	O	O
have	O	O
masked	O	O
the	O	O
cardiovascular	O	O
signs	O	O
of	O	O
the	O	O
unintentional	O	O
intravascular	O	O
administration	O	O
of	O	O
levobupivacaine	B-chem	B-chem
with	O	O
epinephrine	B-chem	B-chem
.	O	O

conclusions	O	O
:	O	O

although	O	O
levobupivacaine	B-chem	B-chem
may	O	O
have	O	O
a	O	O
safer	O	O
cardiac	O	O
toxicity	O	O
profile	O	O
than	O	O
racemic	O	O
bupivacaine	B-chem	B-chem
,	O	O
if	O	O
adequate	O	O
amounts	O	O
of	O	O
levobupivacaine	B-chem	B-chem
reach	O	O
the	O	O
circulation	O	O
,	O	O
it	O	O
will	O	O
result	O	O
in	O	O
convulsions	O	O
.	O	O

plasma	O	O
concentrations	O	O
sufficient	O	O
to	O	O
result	O	O
in	O	O
central	O	O
nervous	O	O
system	O	O
toxicity	O	O
did	O	O
not	O	O
produce	O	O
manifestations	O	O
of	O	O
cardiac	O	O
toxicity	O	O
in	O	O
these	O	O
2	O	O
patients	O	O
.	O	O

anaesthetic	O	O
complications	O	O
associated	O	O
with	O	O
myotonia	O	O
congenita	O	O
:	O	O
case	O	O
study	O	O
and	O	O
comparison	O	O
with	O	O
other	O	O
myotonic	O	O
disorders	O	O
.	O	O

myotonia	O	O
congenita	O	O
(	O	O
mc	O	O
)	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
defect	O	O
in	O	O
the	O	O
skeletal	O	O
muscle	O	O
chloride	B-chem	B-chem
channel	O	O
function	O	O
,	O	O
which	O	O
may	O	O
cause	O	O
sustained	O	O
membrane	O	O
depolarisation	O	O
.	O	O

we	O	O
describe	O	O
a	O	O
previously	O	O
healthy	O	O
32	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
developed	O	O
a	O	O
life	O	O
-	O	O
threatening	O	O
muscle	O	O
spasm	O	O
and	O	O
secondary	O	O
ventilation	O	O
difficulties	O	O
following	O	O
a	O	O
preoperative	O	O
injection	O	O
of	O	O
suxamethonium	B-chem	B-chem
.	O	O

the	O	O
muscle	O	O
spasms	O	O
disappeared	O	O
spontaneously	O	O
and	O	O
the	O	O
surgery	O	O
proceeded	O	O
without	O	O
further	O	O
problems	O	O
.	O	O

when	O	O
subsequently	O	O
questioned	O	O
,	O	O
she	O	O
reported	O	O
minor	O	O
symptoms	O	O
suggesting	O	O
a	O	O
myotonic	O	O
condition	O	O
.	O	O

myotonia	O	O
was	O	O
found	O	O
on	O	O
clinical	O	O
examination	O	O
and	O	O
emg	O	O
.	O	O

the	O	O
diagnosis	O	O
mc	O	O
was	O	O
confirmed	O	O
genetically	O	O
.	O	O

neither	O	O
the	O	O
patient	O	O
nor	O	O
the	O	O
anaesthetist	O	O
were	O	O
aware	O	O
of	O	O
the	O	O
diagnosis	O	O
before	O	O
this	O	O
potentially	O	O
lethal	O	O
complication	O	O
occurred	O	O
.	O	O

we	O	O
give	O	O
a	O	O
brief	O	O
overview	O	O
of	O	O
ion	O	O
channel	O	O
disorders	O	O
including	O	O
malignant	O	O
hyperthermia	O	O
and	O	O
their	O	O
anaesthetic	O	O
considerations	O	O
.	O	O

respiratory	O	O
pattern	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
epilepsy	O	O
.	O	O

purpose	O	O
:	O	O

apnea	O	O
is	O	O
known	O	O
to	O	O
occur	O	O
during	O	O
seizures	O	O
,	O	O
but	O	O
systematic	O	O
studies	O	O
of	O	O
ictal	O	O
respiratory	O	O
changes	O	O
in	O	O
adults	O	O
are	O	O
few	O	O
.	O	O

data	O	O
regarding	O	O
respiratory	O	O
pattern	O	O
defects	O	O
during	O	O
interictal	O	O
periods	O	O
also	O	O
are	O	O
scarce	O	O
.	O	O

here	O	O
we	O	O
sought	O	O
to	O	O
generate	O	O
information	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
interictal	O	O
period	O	O
in	O	O
animals	O	O
with	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
epilepsy	O	O
.	O	O

methods	O	O
:	O	O

twelve	O	O
rats	O	O
(	O	O
six	O	O
chronically	O	O
epileptic	O	O
animals	O	O
and	O	O
six	O	O
controls	O	O
)	O	O
were	O	O
anesthetized	O	O
,	O	O
given	O	O
tracheotomies	O	O
,	O	O
and	O	O
subjected	O	O
to	O	O
hyperventilation	O	O
or	O	O
hypoventilation	O	O
conditions	O	O
.	O	O

breathing	O	O
movements	O	O
caused	O	O
changes	O	O
in	O	O
thoracic	O	O
volume	O	O
and	O	O
forced	O	O
air	O	O
to	O	O
flow	O	O
tidally	O	O
through	O	O
a	O	O
pneumotachograph	O	O
.	O	O

this	O	O
flow	O	O
was	O	O
measured	O	O
by	O	O
using	O	O
a	O	O
differential	O	O
pressure	O	O
transducer	O	O
,	O	O
passed	O	O
through	O	O
a	O	O
polygraph	O	O
,	O	O
and	O	O
from	O	O
this	O	O
to	O	O
a	O	O
computer	O	O
with	O	O
custom	O	O
software	O	O
that	O	O
derived	O	O
ventilation	O	O
(	O	O
ve	O	O
)	O	O
,	O	O
tidal	O	O
volume	O	O
(	O	O
vt	O	O
)	O	O
,	O	O
inspiratory	O	O
time	O	O
(	O	O
ti	O	O
)	O	O
,	O	O
expiratory	O	O
time	O	O
(	O	O
te	O	O
)	O	O
,	O	O
breathing	O	O
frequency	O	O
(	O	O
f	O	O
)	O	O
,	O	O
and	O	O
mean	O	O
inspiratory	O	O
flow	O	O
(	O	O
vt	O	O
/	O	O
ti	O	O
)	O	O
on	O	O
a	O	O
breath	O	O
-	O	O
by	O	O
-	O	O
breath	O	O
basis	O	O
.	O	O

results	O	O
:	O	O

the	O	O
hyperventilation	O	O
maneuver	O	O
caused	O	O
a	O	O
decrease	O	O
in	O	O
spontaneous	O	O
ventilation	O	O
in	O	O
pilocarpine	B-chem	B-chem
-	O	O
treated	O	O
and	O	O
control	O	O
rats	O	O
.	O	O

although	O	O
ve	O	O
had	O	O
a	O	O
similar	O	O
decrease	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
in	O	O
the	O	O
epileptic	O	O
group	O	O
,	O	O
the	O	O
decrease	O	O
in	O	O
ve	O	O
was	O	O
due	O	O
to	O	O
a	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
increase	O	O
in	O	O
te	O	B-chem
peak	O	O
in	O	O
relation	O	O
to	O	O
that	O	O
of	O	O
the	O	O
control	O	O
animals	O	O
.	O	O

the	O	O
hypoventilation	O	O
maneuver	O	O
led	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
arterial	O	O
paco2	O	O
,	O	O
followed	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
ve	O	O
.	O	O

in	O	O
the	O	O
epileptic	O	O
group	O	O
,	O	O
the	O	O
increase	O	O
in	O	O
ve	O	O
was	O	O
mediated	O	O
by	O	O
a	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
decrease	O	O
in	O	O
te	O	O
peak	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
.	O	O

systemic	O	O
application	O	O
of	O	O
kcn	O	O
,	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
peripheral	O	O
chemoreception	O	O
activation	O	O
on	O	O
ventilation	O	O
,	O	O
led	O	O
to	O	O
a	O	O
similar	O	O
increase	O	O
in	O	O
ve	O	O
for	O	O
both	O	O
groups	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
data	O	O
indicate	O	O
that	O	O
pilocarpine	B-chem	B-chem
-	O	O
treated	O	O
animals	O	O
have	O	O
an	O	O
altered	O	O
ability	O	O
to	O	O
react	O	O
to	O	O
(	O	O
or	O	O
compensate	O	O
for	O	O
)	O	O
blood	O	O
gas	O	O
changes	O	O
with	O	O
changes	O	O
in	O	O
ventilation	O	O
and	O	O
suggest	O	O
that	O	O
it	O	O
is	O	O
centrally	O	O
determined	O	O
.	O	O

we	O	O
speculate	O	O
on	O	O
the	O	O
possible	O	O
relation	O	O
of	O	O
the	O	O
current	O	O
findings	O	O
on	O	O
treating	O	O
different	O	O
epilepsy	O	O
-	O	O
associated	O	O
conditions	O	O
.	O	O

increased	O	O
serum	O	O
soluble	O	O
fas	O	O
in	O	O
patients	O	O
with	O	O
acute	O	O
liver	O	O
failure	O	O
due	O	O
to	O	O
paracetamol	B-chem	B-chem
overdose	O	O
.	O	O

background	O	O
/	O	O
aims	O	O
:	O	O

experimental	O	O
studies	O	O
have	O	O
suggested	O	O
that	O	O
apoptosis	O	O
via	O	O
the	O	O
fas	O	O
/	O	O
fas	O	O
ligand	O	O
signaling	O	O
system	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
acute	O	O
liver	O	O
failure	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
soluble	O	O
form	O	O
of	O	O
fas	O	O
in	O	O
patients	O	O
with	O	O
acute	O	O
liver	O	O
failure	O	O
.	O	O

methodology	O	O
:	O	O

serum	O	O
levels	O	O
of	O	O
sfas	O	O
(	O	O
soluble	O	O
fas	O	O
)	O	O
were	O	O
measured	O	O
by	O	O
elisa	O	O
in	O	O
24	O	O
patients	O	O
with	O	O
acute	O	O
liver	O	O
failure	O	O
and	O	O
10	O	O
normal	O	O
control	O	O
subjects	O	O
.	O	O

serum	O	O
levels	O	O
of	O	O
tumor	O	O
necrosis	O	O
factor	O	O
-	O	O
alpha	O	O
and	O	O
interferon	O	B-chem
-	O	O
gamma	O	I-chem
were	O	O
also	O	O
determined	O	O
by	O	O
elisa	O	O
.	O	O

results	O	O
:	O	O

serum	O	O
sfas	O	O
was	O	O
significantly	O	O
increased	O	O
in	O	O
patients	O	O
with	O	O
acute	O	O
liver	O	O
failure	O	O
(	O	O
median	O	O
,	O	O
26	O	O
.	O	O
8	O	O
u	O	O
/	O	O
ml	O	O
;	O	O
range	O	O
,	O	O
6	O	O
.	O	O
9	O	O
-	O	O
52	O	O
.	O	O
7	O	O
u	O	O
/	O	O
ml	O	O
)	O	O
compared	O	O
to	O	O
the	O	O
normal	O	O
controls	O	O
(	O	O
median	O	O
,	O	O
8	O	O
.	O	O
6	O	O
u	O	O
/	O	O
ml	O	O
;	O	O
range	O	O
,	O	O
6	O	O
.	O	O
5	O	O
-	O	O
12	O	O
.	O	O
0	O	O
u	O	O
/	O	O
ml	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

levels	O	O
were	O	O
significantly	O	O
greater	O	O
in	O	O
patients	O	O
with	O	O
acute	O	O
liver	O	O
failure	O	O
due	O	O
to	O	O
paracetamol	B-chem	B-chem
overdose	O	O
(	O	O
median	O	O
,	O	O
28	O	O
.	O	O
7	O	O
u	O	O
/	O	O
ml	O	O
;	O	O
range	O	O
,	O	O
12	O	O
.	O	O
8	O	O
-	O	O
52	O	O
.	O	O
7	O	O
u	O	O
/	O	O
ml	O	O
,	O	O
n	O	O
=	O	O
17	O	O
)	O	O
than	O	O
those	O	O
due	O	O
to	O	O
non	O	O
-	O	O
a	O	O
to	O	O
e	O	O
hepatitis	O	O
(	O	O
median	O	O
,	O	O
12	O	O
.	O	O
5	O	O
u	O	O
/	O	O
ml	O	O
;	O	O
range	O	O
,	O	O
6	O	O
.	O	O
9	O	O
-	O	O
46	O	O
.	O	O
0	O	O
u	O	O
/	O	O
ml	O	O
,	O	O
n	O	O
=	O	O
7	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

there	O	O
was	O	O
no	O	O
relationship	O	O
of	O	O
sfas	O	O
to	O	O
eventual	O	O
outcome	O	O
in	O	O
the	O	O
patients	O	O
.	O	O

a	O	O
significant	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
serum	O	O
sfas	O	O
levels	O	O
and	O	O
aspartate	B-chem	B-chem
aminotransferase	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
613	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
increased	O	O
concentration	O	O
of	O	O
sfas	O	O
in	O	O
serum	O	O
of	O	O
patients	O	O
with	O	O
acute	O	O
liver	O	O
failure	O	O
may	O	O
reflect	O	O
activation	O	O
of	O	O
fas	O	O
-	O	O
mediated	O	O
apoptosis	O	O
in	O	O
the	O	O
liver	O	O
and	O	O
this	O	O
together	O	O
with	O	O
increased	O	O
tumor	O	O
necrosis	O	O
factor	O	O
-	O	O
alpha	O	O
may	O	O
be	O	O
an	O	O
important	O	O
factor	O	O
in	O	O
liver	O	O
cell	O	O
loss	O	O
.	O	O

bilateral	O	O
subthalamic	O	O
nucleus	O	O
stimulation	O	O
for	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

high	O	O
frequency	O	O
stimulation	O	O
of	O	O
the	O	O
subthalamic	O	O
nucleus	O	O
(	O	O
stn	O	B-chem
)	O	O
is	O	O
known	O	O
to	O	O
ameliorate	O	O
the	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
advanced	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

aim	O	O
:	O	O

we	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
high	O	O
frequency	O	O
stn	O	O
stimulation	O	O
in	O	O
23	O	O
patients	O	O
.	O	O

method	O	O
:	O	O

twenty	O	O
-	O	O
three	O	O
patients	O	O
suffering	O	O
from	O	O
severe	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
(	O	O
stages	O	O
iii	O	O
-	O	O
v	O	O
on	O	O
hoehn	O	O
and	O	O
yahr	O	O
scale	O	O
)	O	O
and	O	O
,	O	O
particularly	O	O
bradykinesia	O	O
,	O	O
rigidity	O	O
,	O	O
and	O	O
levodopa	B-chem	B-chem
-	O	O
induced	O	O
dyskinesias	O	O
underwent	O	O
bilateral	O	O
implantation	O	O
of	O	O
electrodes	O	O
in	O	O
the	O	O
stn	O	O
.	O	O

preoperative	O	O
and	O	O
postoperative	O	O
assessments	O	O
of	O	O
these	O	O
patients	O	O
at	O	O
1	O	O
,	O	O
3	O	O
,	O	O
6	O	O
and	O	O
12	O	O
months	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
in	O	O
"	O	O
"	O	O
"	O	O
"	O	O
on	O	O
"	O	O
"	O	O
"	O	O
"	O	O
and	O	O
"	O	O
"	O	O
"	O	O
"	O	O
off	O	O
"	O	O
"	O	O
"	O	O
"	O	O
drug	O	O
conditions	O	O
,	O	O
was	O	O
carried	O	O
out	O	O
using	O	O
unified	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
rating	O	O
scale	O	O
,	O	O
hoehn	O	O
and	O	O
yahr	O	O
staging	O	O
,	O	O
england	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
score	O	O
and	O	O
video	O	O
recordings	O	O
.	O	O

results	O	O
:	O	O

after	O	O
one	O	O
year	O	O
of	O	O
electrical	O	O
stimulation	O	O
of	O	O
the	O	O
stn	O	O
,	O	O
the	O	O
patients	O	O
'	O	O
scores	O	O
for	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
and	O	O
motor	O	O
examination	O	O
scores	O	O
(	O	O
unified	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
rating	O	O
scale	O	O
parts	O	O
ii	O	O
and	O	O
iii	O	O
)	O	O
off	O	O
medication	O	O
improved	O	O
by	O	O
62	O	O
%	O	O
and	O	O
61	O	O
%	O	O
respectively	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0005	O	O
)	O	O
.	O	O

the	O	O
subscores	O	O
for	O	O
the	O	O
akinesia	O	O
,	O	O
rigidity	O	O
,	O	O
tremor	O	O
and	O	O
gait	O	O
also	O	O
improved	O	O
.	O	O

(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0005	O	O
)	O	O
.	O	O

the	O	O
average	O	O
levodopa	B-chem	B-chem
dose	O	O
decreased	O	O
from	O	O
813	O	O
mg	O	O
to	O	O
359	O	O
mg	O	O
.	O	O

the	O	O
cognitive	O	O
functions	O	O
remained	O	O
unchanged	O	O
.	O	O

two	O	O
patients	O	O
developed	O	O
device	O	O
-	O	O
related	O	O
complications	O	O
and	O	O
two	O	O
patients	O	O
experienced	O	O
abnormal	O	O
weight	O	O
gain	O	O
.	O	O

conclusion	O	O
:	O	O

bilateral	O	O
subthalamic	O	O
nucleus	O	O
stimulation	O	O
is	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
advanced	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

it	O	O
reduces	O	O
the	O	O
severity	O	O
of	O	O
"	O	O
"	O	O
"	O	O
"	O	O
off	O	O
"	O	O
"	O	O
"	O	O
"	O	O
phase	O	O
symptoms	O	O
,	O	O
improves	O	O
the	O	O
axial	O	O
symptoms	O	O
and	O	O
reduces	O	O
levodopa	B-chem	B-chem
requirements	O	O
.	O	O

the	O	O
reduction	O	O
in	O	O
the	O	O
levodopa	B-chem	B-chem
dose	O	O
is	O	O
useful	O	O
in	O	O
controlling	O	O
drug	O	O
-	O	O
induced	O	O
dyskinesias	O	O
.	O	O

ocular	O	O
motility	O	O
changes	O	O
after	O	O
subtenon	O	O
carboplatin	B-chem	B-chem
chemotherapy	O	O
for	O	O
retinoblastoma	O	O
.	O	O

background	O	O
:	O	O
focal	O	O
subtenon	O	O
carboplatin	B-chem	B-chem
injections	O	O
have	O	O
recently	O	O
been	O	O
used	O	O
as	O	O
a	O	O
presumably	O	O
toxicity	O	O
-	O	O
free	O	O
adjunct	O	O
to	O	O
systemic	O	O
chemotherapy	O	O
for	O	O
intraocular	O	O
retinoblastoma	O	O
.	O	O

objective	O	O
:	O	O

to	O	O
report	O	O
our	O	O
clinical	O	O
experience	O	O
with	O	O
abnormal	O	O
ocular	O	O
motility	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
subtenon	O	O
carboplatin	B-chem	B-chem
chemotherapy	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
noted	O	O
abnormal	O	O
ocular	O	O
motility	O	O
in	O	O
10	O	O
consecutive	O	O
patients	O	O
with	O	O
retinoblastoma	O	O
who	O	O
had	O	O
received	O	O
subtenon	O	O
carboplatin	B-chem	B-chem
.	O	O

during	O	O
ocular	O	O
manipulation	O	O
under	O	O
general	O	O
anesthesia	O	O
,	O	O
we	O	O
assessed	O	O
their	O	O
eyes	O	O
by	O	O
forced	O	O
duction	O	O
testing	O	O
,	O	O
comparing	O	O
ocular	O	O
motility	O	O
after	O	O
tumor	O	O
control	O	O
with	O	O
ocular	O	O
motility	O	O
at	O	O
diagnosis	O	O
.	O	O

eyes	O	O
subsequently	O	O
enucleated	O	O
because	O	O
of	O	O
treatment	O	O
failure	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
were	O	O
examined	O	O
histologically	O	O
.	O	O

results	O	O
:	O	O

limitation	O	O
of	O	O
ocular	O	O
motility	O	O
was	O	O
detected	O	O
in	O	O
all	O	O
12	O	O
eyes	O	O
of	O	O
10	O	O
patients	O	O
treated	O	O
for	O	O
intraocular	O	O
retinoblastoma	O	O
with	O	O
1	O	O
to	O	O
6	O	O
injections	O	O
of	O	O
subtenon	O	O
carboplatin	B-chem	B-chem
as	O	O
part	O	O
of	O	O
multimodality	O	O
therapy	O	O
.	O	O

histopathological	O	O
examination	O	O
revealed	O	O
many	O	O
lipophages	O	O
in	O	O
the	O	O
periorbital	O	O
fat	O	O
surrounding	O	O
the	O	O
optic	O	O
nerve	O	O
in	O	O
1	O	O
eye	O	O
,	O	O
indicative	O	O
of	O	O
phagocytosis	O	O
of	O	O
previously	O	O
existing	O	O
fat	O	O
cells	O	O
and	O	O
suggesting	O	O
prior	O	O
fat	O	O
necrosis	O	O
.	O	O

the	O	O
enucleations	O	O
were	O	O
technically	O	O
difficult	O	O
and	O	O
hazardous	O	O
for	O	O
globe	O	O
rupture	O	O
because	O	O
of	O	O
extensive	O	O
orbital	O	O
soft	O	O
tissue	O	O
adhesions	O	O
.	O	O

conclusions	O	O
:	O	O

subtenon	O	O
carboplatin	B-chem	B-chem
chemotherapy	O	O
is	O	O
associated	O	O
with	O	O
significant	O	O
fibrosis	O	O
of	O	O
orbital	O	O
soft	O	O
tissues	O	O
,	O	O
leading	O	O
to	O	O
mechanical	O	O
restriction	O	O
of	O	O
eye	O	O
movements	O	O
and	O	O
making	O	O
subsequent	O	O
enucleation	O	O
difficult	O	O
.	O	O

subtenon	O	O
carboplatin	B-chem	B-chem
is	O	O
not	O	O
free	O	O
of	O	O
toxicity	O	O
,	O	O
and	O	O
its	O	O
use	O	O
is	O	O
best	O	O
restricted	O	O
to	O	O
specific	O	O
indications	O	O
.	O	O

ethambutol	B-chem	B-chem
and	O	O
optic	O	O
neuropathy	O	O
.	O	O

purpose	O	O
:	O	O

to	O	O
demonstrate	O	O
the	O	O
association	O	O
between	O	O
ethambutol	B-chem	B-chem
and	O	O
optic	O	O
neuropathy	O	O
.	O	O

method	O	O
:	O	O

thirteen	O	O
patients	O	O
who	O	O
developed	O	O
optic	O	O
neuropathy	O	O
after	O	O
being	O	O
treated	O	O
with	O	O
ethambutol	B-chem	B-chem
for	O	O
tuberculosis	O	O
of	O	O
the	O	O
lung	O	O
or	O	O
lymph	O	O
node	O	O
at	O	O
siriraj	O	O
hospital	O	O
between	O	O
1997	O	O
and	O	O
2001	O	O
were	O	O
retrospectively	O	O
reviewed	O	O
.	O	O

the	O	O
clinical	O	O
characteristics	O	O
and	O	O
initial	O	O
and	O	O
final	O	O
visual	O	O
acuity	O	O
were	O	O
analyzed	O	O
to	O	O
determine	O	O
visual	O	O
outcome	O	O
.	O	O

results	O	O
:	O	O

all	O	O
patients	O	O
had	O	O
optic	O	O
neuropathy	O	O
between	O	O
1	O	O
to	O	O
6	O	O
months	O	O
(	O	O
mean	O	O
=	O	O
2	O	O
.	O	O
9	O	O
months	O	O
)	O	O
after	O	O
starting	O	O
ethambutol	B-chem	B-chem
therapy	O	O
at	O	O
a	O	O
dosage	O	O
ranging	O	O
from	O	O
13	O	O
to	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
(	O	O
mean	O	O
=	O	O
17	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
.	O	O

seven	O	O
(	O	O
54	O	O
%	O	O
)	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
experienced	O	O
visual	O	O
recovery	O	O
after	O	O
stopping	O	O
the	O	O
drug	O	O
.	O	O

of	O	O
6	O	O
patients	O	O
with	O	O
irreversible	O	O
visual	O	O
impairment	O	O
,	O	O
4	O	O
patients	O	O
had	O	O
diabetes	O	O
mellitus	O	O
,	O	O
glaucoma	O	O
and	O	O
a	O	O
history	O	O
of	O	O
heavy	O	O
smoking	O	O
.	O	O

conclusion	O	O
:	O	O

early	O	O
recognition	O	O
of	O	O
optic	O	O
neuropathy	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
ethambutol	B-chem	B-chem
therapy	O	O
.	O	O

a	O	O
low	O	O
dose	O	O
and	O	O
prompt	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
is	O	O
recommended	O	O
particularly	O	O
in	O	O
individuals	O	O
with	O	O
diabetes	O	O
mellitus	O	O
,	O	O
glaucoma	O	O
or	O	O
who	O	O
are	O	O
heavy	O	O
smokers	O	O
.	O	O

treatment	O	O
of	O	O
compensatory	O	O
gustatory	O	O
hyperhidrosis	O	O
with	O	O
topical	O	O
glycopyrrolate	B-chem	B-chem
.	O	O

gustatory	O	O
hyperhidrosis	O	O
is	O	O
facial	O	O
sweating	O	O
usually	O	O
associated	O	O
with	O	O
the	O	O
eating	O	O
of	O	O
hot	O	O
spicy	O	O
food	O	O
or	O	O
even	O	O
smelling	O	O
this	O	O
food	O	O
.	O	O

current	O	O
options	O	O
of	O	O
treatment	O	O
include	O	O
oral	O	O
anticholinergic	O	O
drugs	O	O
,	O	O
the	O	O
topical	O	O
application	O	O
of	O	O
anticholinergics	O	B-chem
or	O	O
aluminum	B-chem	B-chem
chloride	I-chem	I-chem
,	O	O
and	O	O
the	O	O
injection	O	O
of	O	O
botulinum	O	O
toxin	O	O
.	O	O

thirteen	O	O
patients	O	O
have	O	O
been	O	O
treated	O	O
to	O	O
date	O	O
with	O	O
1	O	O
.	O	O
5	O	O
%	O	O
or	O	O
2	O	O
%	O	O
topical	O	O
glycopyrrolate	B-chem	B-chem
.	O	O

all	O	O
patients	O	O
had	O	O
gustatory	O	O
hyperhidrosis	O	O
,	O	O
which	O	O
interfered	O	O
with	O	O
their	O	O
social	O	O
activities	O	O
,	O	O
after	O	O
transthroacic	O	O
endoscopic	O	O
sympathectomy	O	O
,	O	O
and	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
compensatory	O	O
focal	O	O
hyperhidrosis	O	O
.	O	O

after	O	O
applying	O	O
topical	O	O
glycopyrrolate	B-chem	B-chem
,	O	O
the	O	O
subjective	O	O
effect	O	O
was	O	O
excellent	O	O
(	O	O
no	O	O
sweating	O	O
after	O	O
eating	O	O
hot	O	O
spicy	O	O
food	O	O
)	O	O
in	O	O
10	O	O
patients	O	O
(	O	O
77	O	O
%	O	O
)	O	O
,	O	O
and	O	O
fair	O	O
(	O	O
clearly	O	O
reduced	O	O
sweating	O	O
)	O	O
in	O	O
3	O	O
patients	O	O
(	O	O
23	O	O
%	O	O
)	O	O
.	O	O

all	O	O
had	O	O
reported	O	O
incidents	O	O
of	O	O
being	O	O
very	O	O
embarrassed	O	O
whilst	O	O
eating	O	O
hot	O	O
spicy	O	O
foods	O	O
.	O	O

adverse	O	O
effects	O	O
included	O	O
a	O	O
mildly	O	O
dry	O	O
mouth	O	O
and	O	O
a	O	O
sore	O	O
throat	O	O
in	O	O
2	O	O
patients	O	O
(	O	O
2	O	O
%	O	O
glycopyrrolate	B-chem	B-chem
)	O	O
,	O	O
a	O	O
light	O	O
headache	O	O
in	O	O
1	O	O
patient	O	O
(	O	O
1	O	O
.	O	O
5	O	O
%	O	O
glycopyrrolate	B-chem	B-chem
)	O	O
.	O	O

the	O	O
topical	O	O
application	O	O
of	O	O
a	O	O
glycopyrrolate	B-chem	B-chem
pad	O	O
appeared	O	O
to	O	O
be	O	O
safe	O	O
,	O	O
efficacious	O	O
,	O	O
well	O	O
tolerated	O	O
,	O	O
and	O	O
a	O	O
convenient	O	O
method	O	O
of	O	O
treatment	O	O
for	O	O
moderate	O	O
to	O	O
severe	O	O
symptoms	O	O
of	O	O
gustatory	O	O
hyperhidrosis	O	O
in	O	O
post	O	O
transthoracic	O	O
endoscopic	O	O
sympathectomy	O	O
or	O	O
sympathicotomy	O	O
patients	O	O
,	O	O
with	O	O
few	O	O
side	O	O
effects	O	O
.	O	O

pharmacological	O	O
characteristics	O	O
and	O	O
side	O	O
effects	O	O
of	O	O
a	O	O
new	O	O
galenic	O	O
formulation	O	O
of	O	O
propofol	B-chem	B-chem
without	O	O
soyabean	O	B-chem
oil	O	O
.	O	O

we	O	O
compared	O	O
the	O	O
pharmacokinetics	O	O
,	O	O
pharmacodynamics	O	O
and	O	O
safety	O	O
profile	O	O
of	O	O
a	O	O
new	O	O
galenic	O	O
formulation	O	O
of	O	O
propofol	B-chem	B-chem
(	O	O
am149	O	O
1	O	O
%	O	O
)	O	O
,	O	O
which	O	O
does	O	O
not	O	O
contain	O	O
soyabean	O	O
oil	O	O
,	O	O
with	O	O
a	O	O
standard	O	O
formulation	O	O
of	O	O
propofol	B-chem	B-chem
(	O	O
disoprivan	B-chem	B-chem
1	O	O
%	O	O
)	O	O
.	O	O

in	O	O
a	O	O
randomised	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
study	O	O
,	O	O
30	O	O
healthy	O	O
volunteers	O	O
received	O	O
a	O	O
single	O	O
intravenous	O	O
bolus	O	O
injection	O	O
of	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
.	O	O
kg	O	O
-	O	O
1	O	O
propofol	B-chem	B-chem
.	O	O

plasma	O	O
propofol	B-chem	B-chem
levels	O	O
were	O	O
measured	O	O
for	O	O
48	O	O
h	O	O
following	O	O
drug	O	O
administration	O	O
and	O	O
evaluated	O	O
according	O	O
to	O	O
a	O	O
three	O	O
-	O	O
compartment	O	O
model	O	O
.	O	O

the	O	O
pharmacodynamic	O	O
parameters	O	O
assessed	O	O
included	O	O
induction	O	O
and	O	O
emergence	O	O
times	O	O
,	O	O
respiratory	O	O
and	O	O
cardiovascular	O	O
effects	O	O
,	O	O
and	O	O
pain	O	O
on	O	O
injection	O	O
.	O	O

patients	O	O
were	O	O
monitored	O	O
for	O	O
side	O	O
effects	O	O
over	O	O
48	O	O
h	O	O
.	O	O

owing	O	O
to	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
thrombophlebitis	O	O
,	O	O
the	O	O
study	O	O
was	O	O
terminated	O	O
prematurely	O	O
and	O	O
only	O	O
the	O	O
data	O	O
of	O	O
the	O	O
two	O	O
parallel	O	O
treatment	O	O
groups	O	O
(	O	O
15	O	O
patients	O	O
in	O	O
each	O	O
group	O	O
)	O	O
were	O	O
analysed	O	O
.	O	O

plasma	O	O
concentrations	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
formulations	O	O
.	O	O

anaesthesia	O	O
induction	O	O
and	O	O
emergence	O	O
times	O	O
,	O	O
respiratory	O	O
and	O	O
cardiovascular	O	O
variables	O	O
showed	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
treatment	O	O
groups	O	O
.	O	O

pain	O	O
on	O	O
injection	O	O
(	O	O
80	O	O
vs	O	O
.	O	O
20	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
and	O	O
thrombophlebitis	O	O
(	O	O
93	O	O
.	O	O
3	O	O
vs	O	O
.	O	O
6	O	O
.	O	O
6	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
occurred	O	O
more	O	O
frequently	O	O
with	O	O
am149	O	O
than	O	O
with	O	O
disoprivan	B-chem	B-chem
.	O	O

although	O	O
both	O	O
formulations	O	O
had	O	O
similar	O	O
pharmacokinetic	O	O
and	O	O
pharmacodynamic	O	O
profiles	O	O
the	O	O
new	O	O
formulation	O	O
is	O	O
not	O	O
suitable	O	O
for	O	O
clinical	O	O
use	O	O
due	O	O
to	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
thrombophlebitis	O	O
produced	O	O
.	O	O

vinorelbine	B-chem	B-chem
-	O	O
related	O	O
cardiac	O	O
events	O	O
:	O	O
a	O	O
meta	O	O
-	O	O
analysis	O	O
of	O	O
randomized	O	O
clinical	O	O
trials	O	O
.	O	O

several	O	O
cases	O	O
of	O	O
cardiac	O	O
adverse	O	O
reactions	O	O
related	O	O
to	O	O
vinorelbine	B-chem	B-chem
(	O	O
vnr	B-chem	B-chem
)	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

in	O	O
order	O	O
to	O	O
quantify	O	O
the	O	O
incidence	O	O
of	O	O
these	O	O
cardiac	O	O
events	O	O
,	O	O
we	O	O
performed	O	O
a	O	O
meta	O	O
-	O	O
analysis	O	O
of	O	O
clinical	O	O
trials	O	O
comparing	O	O
vnr	B-chem	O
with	O	O
other	O	O
chemotherapeutic	O	O
agents	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
various	O	O
malignancies	O	O
.	O	O

randomized	O	O
clinical	O	O
trials	O	O
comparing	O	O
vnr	B-chem	O
with	O	O
other	O	O
drugs	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
cancer	O	O
were	O	O
searched	O	O
in	O	O
medline	O	O
,	O	O
embase	O	O
,	O	O
evidence	O	O
-	O	O
based	O	O
medicine	O	O
reviews	O	O
databases	O	O
and	O	O
the	O	O
cochrane	O	O
library	O	O
from	O	O
1987	O	O
to	O	O
2002	O	O
.	O	O

outcomes	O	O
of	O	O
interest	O	O
were	O	O
severe	O	O
cardiac	O	O
events	O	O
,	O	O
toxic	O	O
deaths	O	O
and	O	O
cardiac	O	O
event	O	O
-	O	O
related	O	O
deaths	O	O
reported	O	O
in	O	O
each	O	O
publication	O	O
.	O	O

we	O	O
found	O	O
19	O	O
trials	O	O
,	O	O
involving	O	O
2441	O	O
patients	O	O
treated	O	O
by	O	O
vnr	B-chem	B-chem
and	O	O
2050	O	O
control	O	O
patients	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
cardiac	O	O
events	O	O
with	O	O
vnr	B-chem	O
was	O	O
1	O	O
.	O	O
19	O	O
%	O	O
[	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
ci	O	O
)	O	O
(	O	O
0	O	O
.	O	O
75	O	O
;	O	O
1	O	O
.	O	O
67	O	O
)	O	O
]	O	O
.	O	O

there	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
risk	O	O
of	O	O
cardiac	O	O
events	O	O
between	O	O
vnr	B-chem	O
and	O	O
other	O	O
drugs	O	O
[	O	O
odds	O	O
ratio	O	O
:	O	O
0	O	O
.	O	O
92	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
(	O	O
0	O	O
.	O	O
54	O	O
;	O	O
1	O	O
.	O	O
55	O	O
)	O	O
]	O	O
.	O	O

the	O	O
risk	O	O
of	O	O
vnr	B-chem	O
cardiac	O	O
events	O	O
was	O	O
similar	O	O
to	O	O
vindesine	B-chem	B-chem
(	O	O
vds	B-chem	O
)	O	O
and	O	O
other	O	O
cardiotoxic	O	O
drugs	O	O
[	O	O
fluorouracil	B-chem	B-chem
,	O	O
anthracyclines	B-chem	B-chem
,	O	O
gemcitabine	B-chem	B-chem
(	O	O
gem	B-chem	B-chem
)	O	O
em	O	O
leader	O	O
]	O	O
.	O	O

even	O	O
if	O	O
it	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
because	O	O
of	O	O
a	O	O
few	O	O
number	O	O
of	O	O
cases	O	O
,	O	O
the	O	O
risk	O	O
was	O	O
lower	O	O
in	O	O
trials	O	O
excluding	O	O
patients	O	O
with	O	O
cardiac	O	O
history	O	O
,	O	O
and	O	O
seemed	O	O
to	O	O
be	O	O
higher	O	O
in	O	O
trials	O	O
including	O	O
patients	O	O
with	O	O
pre	O	O
-	O	O
existing	O	O
cardiac	O	O
diseases	O	O
.	O	O

vinorelbine	B-chem	B-chem
-	O	O
related	O	O
cardiac	O	O
events	O	O
concern	O	O
about	O	O
1	O	O
%	O	O
of	O	O
treated	O	O
patients	O	O
in	O	O
clinical	O	O
trials	O	O
.	O	O

however	O	O
,	O	O
the	O	O
risk	O	O
associated	O	O
with	O	O
vnr	B-chem	O
seems	O	O
to	O	O
be	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
other	O	O
chemotherapeutic	O	O
agents	O	O
in	O	O
the	O	O
same	O	O
indications	O	O
.	O	O

mri	O	O
findings	O	O
of	O	O
hypoxic	O	O
cortical	O	O
laminar	O	O
necrosis	O	O
in	O	O
a	O	O
child	O	O
with	O	O
hemolytic	O	O
anemia	O	O
crisis	O	O
.	O	O

we	O	O
present	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
findings	O	O
of	O	O
a	O	O
5	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
who	O	O
had	O	O
a	O	O
rapidly	O	O
installing	O	O
hemolytic	O	O
anemia	O	O
crisis	O	O
induced	O	O
by	O	O
trimethoprim	B-chem	B-chem
-	I-chem	I-chem
sulfomethoxazole	I-chem	I-chem
,	O	O
resulting	O	O
in	O	O
cerebral	O	O
anoxia	O	O
leading	O	O
to	O	O
permanent	O	O
damage	O	O
.	O	O

magnetic	O	O
resonance	O	O
imaging	O	O
revealed	O	O
cortical	O	O
laminar	O	O
necrosis	O	O
in	O	O
arterial	O	O
border	O	O
zones	O	O
in	O	O
both	O	O
cerebral	O	O
hemispheres	O	O
,	O	O
ischemic	O	O
changes	O	O
in	O	O
subcortical	O	O
white	O	O
matter	O	O
of	O	O
left	O	O
cerebral	O	O
hemisphere	O	O
,	O	O
and	O	O
in	O	O
the	O	O
left	O	O
putamen	O	O
.	O	O

although	O	O
cortical	O	O
laminar	O	O
necrosis	O	O
is	O	O
a	O	O
classic	O	O
entity	O	O
in	O	O
adulthood	O	O
related	O	O
to	O	O
conditions	O	O
of	O	O
energy	O	O
depletions	O	O
,	O	O
there	O	O
are	O	O
few	O	O
reports	O	O
available	O	O
in	O	O
children	O	O
.	O	O

a	O	O
wide	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
is	O	O
also	O	O
presented	O	O
.	O	O

the	O	O
natural	O	O
history	O	O
of	O	O
vigabatrin	B-chem	B-chem
associated	O	O
visual	O	O
field	O	O
defects	O	O
in	O	O
patients	O	O
electing	O	O
to	O	O
continue	O	O
their	O	O
medication	O	O
.	O	O

purpose	O	O
:	O	O

to	O	O
determine	O	O
the	O	O
natural	O	O
history	O	O
of	O	O
visual	O	O
field	O	O
defects	O	O
in	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
known	O	O
to	O	O
have	O	O
vigabatrin	B-chem	B-chem
-	O	O
associated	O	O
changes	O	O
who	O	O
elected	O	O
to	O	O
continue	O	O
the	O	O
medication	O	O
because	O	O
of	O	O
good	O	O
seizure	O	O
control	O	O
.	O	O

methods	O	O
:	O	O

all	O	O
patients	O	O
taking	O	O
vigabatrin	B-chem	B-chem
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
antiepileptic	O	O
drugs	O	O
for	O	O
at	O	O
least	O	O
5	O	O
years	O	O
(	O	O
range	O	O
5	O	O
-	O	O
12	O	O
years	O	O
)	O	O
were	O	O
entered	O	O
into	O	O
a	O	O
visual	O	O
surveillance	O	O
programme	O	O
.	O	O

patients	O	O
were	O	O
followed	O	O
up	O	O
at	O	O
6	O	O
-	O	O
monthly	O	O
intervals	O	O
for	O	O
not	O	O
less	O	O
than	O	O
18	O	O
months	O	O
(	O	O
range	O	O
18	O	O
-	O	O
43	O	O
months	O	O
)	O	O
.	O	O

in	O	O
all	O	O
,	O	O
16	O	O
patients	O	O
with	O	O
unequivocal	O	O
defects	O	O
continued	O	O
the	O	O
medication	O	O
.	O	O

following	O	O
already	O	O
published	O	O
methodology	O	O
(	O	O
eye	O	O
2002	O	O
;	O	O
16	O	O
;	O	O
567	O	O
-	O	O
571	O	O
)	O	O
monocular	O	O
mean	O	O
radial	O	O
degrees	O	O
(	O	O
mrds	O	O
)	O	O
to	O	O
the	O	O
i	O	O
/	O	O
4e	O	O
isopter	O	B-chem
on	O	O
goldmann	O	O
perimetry	O	O
was	O	O
calculated	O	O
for	O	O
the	O	O
right	O	O
eye	O	O
at	O	O
the	O	O
time	O	O
of	O	O
discovery	O	O
of	O	O
a	O	O
visual	O	O
field	O	O
defect	O	O
and	O	O
again	O	O
after	O	O
not	O	O
less	O	O
than	O	O
18	O	O
months	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

results	O	O
:	O	O

mean	O	O
right	O	O
eye	O	O
mrd	O	O
at	O	O
presentation	O	O
was	O	O
36	O	O
.	O	O
98	O	O
degrees	O	O
(	O	O
range	O	O
22	O	O
.	O	O
25	O	O
-	O	O
51	O	O
.	O	O
0	O	O
)	O	O
,	O	O
compared	O	O
to	O	O
38	O	O
.	O	O
40	O	O
degrees	O	O
(	O	O
range	O	O
22	O	O
.	O	O
5	O	O
-	O	O
49	O	O
.	O	O
75	O	O
)	O	O
after	O	O
follow	O	O
-	O	O
up	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
338	O	O
unpaired	O	O
t	O	O
-	O	O
test	O	O
.	O	O

only	O	O
one	O	O
patient	O	O
demonstrated	O	O
a	O	O
deterioration	O	O
in	O	O
visual	O	O
field	O	O
during	O	O
the	O	O
study	O	O
period	O	O
and	O	O
discontinued	O	O
treatment	O	O
.	O	O

conclusion	O	O
:	O	O

established	O	O
visual	O	O
field	O	O
defects	O	O
presumed	O	O
to	O	O
be	O	O
due	O	O
to	O	O
vigabatrin	B-chem	B-chem
therapy	O	O
did	O	O
not	O	O
usually	O	O
progress	O	O
in	O	O
spite	O	O
of	O	O
continuing	O	O
use	O	O
of	O	O
the	O	O
medication	O	O
.	O	O

these	O	O
data	O	O
give	O	O
support	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
pathogenesis	O	O
of	O	O
vigabatrin	B-chem	B-chem
-	O	O
associated	O	O
visual	O	O
field	O	O
defects	O	O
may	O	O
be	O	O
an	O	O
idiosyncratic	O	O
adverse	O	O
drug	O	O
reaction	O	O
rather	O	O
than	O	O
dose	O	O
-	O	O
dependent	O	O
toxicity	O	O
.	O	O

induction	O	O
of	O	O
rosaceiform	O	O
dermatitis	O	O
during	O	O
treatment	O	O
of	O	O
facial	O	O
inflammatory	O	O
dermatoses	O	O
with	O	O
tacrolimus	B-chem	B-chem
ointment	O	O
.	O	O

background	O	O
:	O	O

tacrolimus	B-chem	B-chem
ointment	O	O
is	O	O
increasingly	O	O
used	O	O
for	O	O
anti	O	O
-	O	O
inflammatory	O	O
treatment	O	O
of	O	O
sensitive	O	O
areas	O	O
such	O	O
as	O	O
the	O	O
face	O	O
,	O	O
and	O	O
recent	O	O
observations	O	O
indicate	O	O
that	O	O
the	O	O
treatment	O	O
is	O	O
effective	O	O
in	O	O
steroid	B-chem	B-chem
-	O	O
aggravated	O	O
rosacea	O	O
and	O	O
perioral	O	O
dermatitis	O	O
.	O	O

we	O	O
report	O	O
on	O	O
rosaceiform	O	O
dermatitis	O	O
as	O	O
a	O	O
complication	O	O
of	O	O
treatment	O	O
with	O	O
tacrolimus	B-chem	B-chem
ointment	O	O
.	O	O

observations	O	O
:	O	O

six	O	O
adult	O	O
patients	O	O
with	O	O
inflammatory	O	O
facial	O	O
dermatoses	O	O
were	O	O
treated	O	O
with	O	O
tacrolimus	B-chem	B-chem
ointment	O	O
because	O	O
of	O	O
the	O	O
ineffectiveness	O	O
of	O	O
standard	O	O
treatments	O	O
.	O	O

within	O	O
2	O	O
to	O	O
3	O	O
weeks	O	O
of	O	O
initially	O	O
effective	O	O
and	O	O
well	O	O
-	O	O
tolerated	O	O
treatment	O	O
,	O	O
3	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
rosacea	O	O
and	O	O
1	O	O
with	O	O
a	O	O
history	O	O
of	O	O
acne	O	O
experienced	O	O
sudden	O	O
worsening	O	O
with	O	O
pustular	O	O
rosaceiform	O	O
lesions	O	O
.	O	O

biopsy	O	O
revealed	O	O
an	O	O
abundance	O	O
of	O	O
demodex	O	O
mites	O	O
in	O	O
2	O	O
of	O	O
these	O	O
patients	O	O
.	O	O

in	O	O
1	O	O
patient	O	O
with	O	O
eyelid	O	O
eczema	O	O
,	O	O
rosaceiform	O	O
periocular	O	O
dermatitis	O	O
gradually	O	O
appeared	O	O
after	O	O
3	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

in	O	O
1	O	O
patient	O	O
with	O	O
atopic	O	O
dermatitis	O	O
,	O	O
telangiectatic	O	O
and	O	O
papular	O	O
rosacea	O	O
insidiously	O	O
appeared	O	O
after	O	O
5	O	O
months	O	O
of	O	O
treatment	O	O
.	O	O

conclusions	O	O
:	O	O

our	O	O
observations	O	O
suggest	O	O
that	O	O
the	O	O
spectrum	O	O
of	O	O
rosaceiform	O	O
dermatitis	O	O
as	O	O
a	O	O
complication	O	O
of	O	O
treatment	O	O
with	O	O
tacrolimus	B-chem	B-chem
ointment	O	O
is	O	O
heterogeneous	O	O
.	O	O

a	O	O
variety	O	O
of	O	O
factors	O	O
,	O	O
such	O	O
as	O	O
vasoactive	O	O
properties	O	O
of	O	O
tacrolimus	B-chem	B-chem
,	O	O
proliferation	O	O
of	O	O
demodex	O	B-chem
due	O	O
to	O	O
local	O	O
immunosuppression	O	O
,	O	O
and	O	O
the	O	O
occlusive	O	O
properties	O	O
of	O	O
the	O	O
ointment	O	O
,	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
observed	O	O
phenomena	O	O
.	O	O

future	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
identify	O	O
individual	O	O
risk	O	O
factors	O	O
.	O	O

structural	O	O
abnormalities	O	O
in	O	O
the	O	O
brains	O	O
of	O	O
human	O	O
subjects	O	O
who	O	O
use	O	O
methamphetamine	B-chem	B-chem
.	O	O

we	O	O
visualize	O	O
,	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
the	O	O
profile	O	O
of	O	O
structural	O	O
deficits	O	O
in	O	O
the	O	O
human	O	O
brain	O	O
associated	O	O
with	O	O
chronic	O	O
methamphetamine	B-chem	B-chem
(	O	O
ma	B-chem	O
)	O	O
abuse	O	O
.	O	O

studies	O	O
of	O	O
human	O	O
subjects	O	O
who	O	O
have	O	O
used	O	O
ma	B-chem	O
chronically	O	O
have	O	O
revealed	O	O
deficits	O	O
in	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
systems	O	O
and	O	O
cerebral	O	O
metabolic	O	O
abnormalities	O	O
.	O	O

using	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
mri	O	O
)	O	O
and	O	O
new	O	O
computational	O	O
brain	O	O
-	O	O
mapping	O	O
techniques	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
pattern	O	O
of	O	O
structural	O	O
brain	O	O
alterations	O	O
associated	O	O
with	O	O
chronic	O	O
ma	B-chem	O
abuse	O	O
in	O	O
human	O	O
subjects	O	O
and	O	O
related	O	O
these	O	O
deficits	O	O
to	O	O
cognitive	O	O
impairment	O	O
.	O	O

we	O	O
used	O	O
high	O	O
-	O	O
resolution	O	O
mri	O	O
and	O	O
surface	O	O
-	O	O
based	O	O
computational	O	O
image	O	O
analyses	O	O
to	O	O
map	O	O
regional	O	O
abnormalities	O	O
in	O	O
the	O	O
cortex	O	O
,	O	O
hippocampus	O	O
,	O	O
white	O	O
matter	O	O
,	O	O
and	O	O
ventricles	O	O
in	O	O
22	O	O
human	O	O
subjects	O	O
who	O	O
used	O	O
ma	B-chem	O
and	O	O
21	O	O
age	O	O
-	O	O
matched	O	O
,	O	O
healthy	O	O
controls	O	O
.	O	O

cortical	O	O
maps	O	O
revealed	O	O
severe	O	O
gray	O	O
-	O	O
matter	O	O
deficits	O	O
in	O	O
the	O	O
cingulate	O	O
,	O	O
limbic	O	O
,	O	O
and	O	O
paralimbic	O	O
cortices	O	O
of	O	O
ma	B-chem	O
abusers	O	O
(	O	O
averaging	O	O
11	O	O
.	O	O
3	O	O
%	O	O
below	O	O
control	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

on	O	O
average	O	O
,	O	O
ma	B-chem	O
abusers	O	O
had	O	O
7	O	O
.	O	O
8	O	O
%	O	O
smaller	O	O
hippocampal	O	O
volumes	O	O
than	O	O
control	O	O
subjects	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
;	O	O
left	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
01	O	O
;	O	O
right	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
and	O	O
significant	O	O
white	O	O
-	O	O
matter	O	O
hypertrophy	O	O
(	O	O
7	O	O
.	O	O
0	O	O
%	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

hippocampal	O	O
deficits	O	O
were	O	O
mapped	O	O
and	O	O
correlated	O	O
with	O	O
memory	O	O
performance	O	O
on	O	O
a	O	O
word	O	O
-	O	O
recall	O	O
test	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

mri	O	O
-	O	O
based	O	O
maps	O	O
suggest	O	O
that	O	O
chronic	O	O
methamphetamine	B-chem	B-chem
abuse	O	O
causes	O	O
a	O	O
selective	O	O
pattern	O	O
of	O	O
cerebral	O	O
deterioration	O	O
that	O	O
contributes	O	O
to	O	O
impaired	O	O
memory	O	O
performance	O	O
.	O	O

ma	B-chem	O
may	O	O
selectively	O	O
damage	O	O
the	O	O
medial	O	O
temporal	O	O
lobe	O	O
and	O	O
,	O	O
consistent	O	O
with	O	O
metabolic	O	O
studies	O	O
,	O	O
the	O	O
cingulate	O	O
-	O	O
limbic	O	O
cortex	O	O
,	O	O
inducing	O	O
neuroadaptation	O	O
,	O	O
neuropil	O	O
reduction	O	O
,	O	O
or	O	O
cell	O	O
death	O	O
.	O	O

prominent	O	O
white	O	O
-	O	O
matter	O	O
hypertrophy	O	O
may	O	O
result	O	O
from	O	O
altered	O	O
myelination	O	O
and	O	O
adaptive	O	O
glial	O	O
changes	O	O
,	O	O
including	O	O
gliosis	O	O
secondary	O	O
to	O	O
neuronal	O	O
damage	O	O
.	O	O

these	O	O
brain	O	O
substrates	O	O
may	O	O
help	O	O
account	O	O
for	O	O
the	O	O
symptoms	O	O
of	O	O
ma	B-chem	O
abuse	O	O
,	O	O
providing	O	O
therapeutic	O	O
targets	O	O
for	O	O
drug	O	O
-	O	O
induced	O	O
brain	O	O
injury	O	O
.	O	O

disruption	O	O
of	O	O
hepatic	O	O
lipid	O	O
homeostasis	O	O
in	O	O
mice	O	O
after	O	O
amiodarone	B-chem	B-chem
treatment	O	O
is	O	O
associated	O	O
with	O	O
peroxisome	O	O
proliferator	O	O
-	O	O
activated	O	O
receptor	O	O
-	O	O
alpha	O	O
target	O	O
gene	O	O
activation	O	O
.	O	O

amiodarone	B-chem	B-chem
,	O	O
an	O	O
efficacious	O	O
and	O	O
widely	O	O
used	O	O
antiarrhythmic	O	O
agent	O	O
,	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
cause	O	O
hepatotoxicity	O	O
in	O	O
some	O	O
patients	O	O
.	O	O

to	O	O
gain	O	O
insight	O	O
into	O	O
the	O	O
mechanism	O	O
of	O	O
this	O	O
unwanted	O	O
effect	O	O
,	O	O
mice	O	O
were	O	O
administered	O	O
various	O	O
doses	O	O
of	O	O
amiodarone	B-chem	B-chem
and	O	O
examined	O	O
for	O	O
changes	O	O
in	O	O
hepatic	O	O
histology	O	O
and	O	O
gene	O	O
regulation	O	O
.	O	O

amiodarone	B-chem	B-chem
induced	O	O
hepatomegaly	O	O
,	O	O
hepatocyte	O	O
microvesicular	O	O
lipid	O	O
accumulation	O	O
,	O	O
and	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
serum	O	O
triglycerides	B-chem	O
and	O	O
glucose	B-chem	B-chem
.	O	O

northern	O	O
blot	O	O
analysis	O	O
of	O	O
hepatic	O	O
rna	O	O
revealed	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
increase	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
a	O	O
number	O	O
of	O	O
genes	O	O
critical	O	O
for	O	O
fatty	B-chem	B-chem
acid	I-chem	I-chem
oxidation	O	O
,	O	O
lipoprotein	O	O
assembly	O	O
,	O	O
and	O	O
lipid	O	O
transport	O	O
.	O	O

many	O	O
of	O	O
these	O	O
genes	O	O
are	O	O
regulated	O	O
by	O	O
the	O	O
peroxisome	O	O
proliferator	O	O
-	O	O
activated	O	O
receptor	O	O
-	O	O
alpha	O	O
(	O	O
pparalpha	O	O
)	O	O
,	O	O
a	O	O
ligand	O	O
-	O	O
activated	O	O
nuclear	O	O
hormone	O	O
receptor	O	O
transcription	O	O
factor	O	O
.	O	O

the	O	O
absence	O	O
of	O	O
induction	O	O
of	O	O
these	O	O
genes	O	O
as	O	O
well	O	O
as	O	O
hepatomegaly	O	O
in	O	O
pparalpha	O	O
knockout	O	O
[	O	O
pparalpha	O	O
-	O	O
/	O	O
-	O	O
]	O	O
mice	O	O
indicated	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
amiodarone	B-chem	B-chem
were	O	O
dependent	O	O
upon	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
functional	O	O
pparalpha	O	O
gene	O	O
.	O	O

compared	O	O
to	O	O
wild	O	O
-	O	O
type	O	O
mice	O	O
,	O	O
treatment	O	O
of	O	O
pparalpha	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
with	O	O
amiodarone	B-chem	B-chem
resulted	O	O
in	O	O
an	O	O
increased	O	O
rate	O	O
and	O	O
extent	O	O
of	O	O
total	O	O
body	O	O
weight	O	O
loss	O	O
.	O	O

the	O	O
inability	O	O
of	O	O
amiodarone	B-chem	B-chem
to	O	O
directly	O	O
activate	O	O
either	O	O
human	O	O
or	O	O
mouse	O	O
pparalpha	O	O
transiently	O	O
expressed	O	O
in	O	O
human	O	O
hepg2	O	O
hepatoma	O	O
cells	O	O
indicates	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
amiodarone	B-chem	B-chem
on	O	O
the	O	O
function	O	O
of	O	O
this	O	O
receptor	O	O
were	O	O
indirect	O	O
.	O	O

based	O	O
upon	O	O
these	O	O
results	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
amiodarone	B-chem	B-chem
disrupts	O	O
hepatic	O	O
lipid	O	O
homeostasis	O	O
and	O	O
that	O	O
the	O	O
increased	O	O
expression	O	O
of	O	O
pparalpha	O	O
target	O	O
genes	O	O
is	O	O
secondary	O	O
to	O	O
this	O	O
toxic	O	O
effect	O	O
.	O	O

these	O	O
results	O	O
provide	O	O
important	O	O
new	O	O
mechanistic	O	O
information	O	O
regarding	O	O
the	O	O
hepatotoxic	O	O
effects	O	O
of	O	O
amiodarone	B-chem	B-chem
and	O	O
indicate	O	O
that	O	O
pparalpha	O	B-chem
protects	O	O
against	O	O
amiodarone	B-chem	B-chem
-	O	O
induced	O	O
hepatotoxicity	O	O
.	O	O

safety	O	O
and	O	O
compliance	O	O
with	O	O
once	O	O
-	O	O
daily	O	O
niacin	B-chem	B-chem
extended	I-chem	O
-	I-chem	O
release	I-chem	O
/	I-chem	O
lovastatin	I-chem	B-chem
as	O	O
initial	O	O
therapy	O	O
in	O	O
the	O	O
impact	O	O
of	O	O
medical	O	O
subspecialty	O	O
on	O	O
patient	O	O
compliance	O	O
to	O	O
treatment	O	O
(	O	O
impact	O	O
)	O	O
study	O	O
.	O	O

niacin	B-chem	B-chem
extended	I-chem	O
-	I-chem	O
release	I-chem	O
/	I-chem	O
lovastatin	I-chem	B-chem
is	O	O
a	O	O
new	O	O
combination	O	O
product	O	O
approved	O	O
for	O	O
treatment	O	O
of	O	O
primary	O	O
hypercholesterolemia	O	O
and	O	O
mixed	O	O
dyslipidemia	O	O
.	O	O

this	O	O
open	O	O
-	O	O
labeled	O	O
,	O	O
multicenter	O	O
study	O	O
evaluated	O	O
the	O	O
safety	O	O
of	O	O
bedtime	O	O
niacin	B-chem	B-chem
extended	I-chem	O
-	I-chem	O
release	I-chem	O
/	I-chem	O
lovastatin	I-chem	B-chem
when	O	O
dosed	O	O
as	O	O
initial	O	O
therapy	O	O
and	O	O
patient	O	O
compliance	O	O
to	O	O
treatment	O	O
in	O	O
various	O	O
clinical	O	O
practice	O	O
settings	O	O
.	O	O

a	O	O
total	O	O
of	O	O
4	O	O
,	O	O
499	O	O
patients	O	O
with	O	O
dyslipidemia	O	O
requiring	O	O
drug	O	O
intervention	O	O
was	O	O
enrolled	O	O
at	O	O
1	O	O
,	O	O
081	O	O
sites	O	O
.	O	O

patients	O	O
were	O	O
treated	O	O
with	O	O
1	O	O
tablet	O	O
(	O	O
500	O	O
mg	O	O
of	O	O
niacin	B-chem	B-chem
extended	O	O
-	O	O
release	O	O
/	O	O
20	O	O
mg	O	O
of	O	O
lovastatin	B-chem	B-chem
)	O	O
once	O	O
nightly	O	O
for	O	O
4	O	O
weeks	O	O
and	O	O
then	O	O
2	O	O
tablets	O	O
for	O	O
8	O	O
weeks	O	O
.	O	O

patients	O	O
also	O	O
received	O	O
dietary	O	O
counseling	O	O
,	O	O
educational	O	O
materials	O	O
,	O	O
and	O	O
reminders	O	O
to	O	O
call	O	O
a	O	O
toll	O	O
-	O	O
free	O	O
number	O	O
that	O	O
provided	O	O
further	O	O
education	O	O
about	O	O
dyslipidemia	O	O
and	O	O
niacin	B-chem	B-chem
extended	I-chem	O
-	I-chem	O
release	I-chem	O
/	I-chem	O
lovastatin	I-chem	B-chem
.	O	O

primary	O	O
end	O	O
points	O	O
were	O	O
study	O	O
compliance	O	O
,	O	O
increases	O	O
in	O	O
liver	O	O
transaminases	O	O
to	O	O
>	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
,	O	O
and	O	O
clinical	O	O
myopathy	O	O
.	O	O

final	O	O
study	O	O
status	O	O
was	O	O
available	O	O
for	O	O
4	O	O
,	O	O
217	O	O
patients	O	O
(	O	O
94	O	O
%	O	O
)	O	O
.	O	O

compliance	O	O
to	O	O
niacin	B-chem	B-chem
extended	I-chem	O
-	I-chem	O
release	I-chem	O
/	I-chem	O
lovastatin	I-chem	B-chem
was	O	O
77	O	O
%	O	O
,	O	O
with	O	O
3	O	O
,	O	O
245	O	O
patients	O	O
completing	O	O
the	O	O
study	O	O
.	O	O

patients	O	O
in	O	O
the	O	O
southeast	O	O
and	O	O
those	O	O
enrolled	O	O
by	O	O
endocrinologists	O	O
had	O	O
the	O	O
lowest	O	O
compliance	O	O
and	O	O
highest	O	O
adverse	O	O
event	O	O
rates	O	O
.	O	O

flushing	O	O
was	O	O
the	O	O
most	O	O
common	O	O
adverse	O	O
event	O	O
,	O	O
reported	O	O
by	O	O
18	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
leading	O	O
to	O	O
discontinuation	O	O
by	O	O
6	O	O
%	O	O
.	O	O

incidence	O	O
of	O	O
increased	O	O
aspartate	B-chem	B-chem
aminotransferase	O	O
and	O	O
/	O	O
or	O	O
alanine	B-chem	B-chem
aminotransferase	O	O
>	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
was	O	O
<	O	O
0	O	O
.	O	O
3	O	O
%	O	O
.	O	O

an	O	O
increase	O	O
of	O	O
creatine	B-chem	B-chem
phosphokinase	O	O
to	O	O
>	O	O
5	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
occurred	O	O
in	O	O
0	O	O
.	O	O
24	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
and	O	O
no	O	O
cases	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
myopathy	O	O
were	O	O
observed	O	O
.	O	O

niacin	B-chem	B-chem
extended	I-chem	O
-	I-chem	O
release	I-chem	O
/	I-chem	O
lovastatin	I-chem	B-chem
1	O	O
,	O	O
000	O	O
/	O	O
40	O	O
mg	O	O
,	O	O
dosed	O	O
as	O	O
initial	O	O
therapy	O	O
,	O	O
was	O	O
associated	O	O
with	O	O
good	O	O
compliance	O	O
and	O	O
safety	O	O
and	O	O
had	O	O
very	O	O
low	O	O
incidences	O	O
of	O	O
increased	O	O
liver	O	O
and	O	O
muscle	O	O
enzymes	O	O
.	O	O

protective	O	O
effect	O	O
of	O	O
terminalia	B-chem	O
chebula	I-chem	O
against	O	O
experimental	O	O
myocardial	O	O
injury	O	O
induced	O	O
by	O	O
isoproterenol	B-chem	B-chem
.	O	O

cardioprotective	O	O
effect	O	O
of	O	O
ethanolic	B-chem	B-chem
extract	I-chem	I-chem
of	I-chem	O
terminalia	I-chem	O
chebula	I-chem	O
fruits	I-chem	O
(	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
wt	O	O
)	O	O
was	O	O
examined	O	O
in	O	O
isoproterenol	B-chem	B-chem
(	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
wt	O	O
)	O	O
induced	O	O
myocardial	O	O
damage	O	O
in	O	O
rats	O	O
.	O	O

in	O	O
isoproterenol	B-chem	B-chem
administered	O	O
rats	O	O
,	O	O
the	O	O
level	O	O
of	O	O
lipid	O	O
peroxides	B-chem	O
increased	O	O
significantly	O	O
in	O	O
the	O	O
serum	O	O
and	O	O
heart	O	O
.	O	O

a	O	O
significant	O	O
decrease	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
myocardial	O	O
marker	O	O
enzymes	O	O
with	O	O
a	O	O
concomitant	O	O
increase	O	O
in	O	O
their	O	O
activity	O	O
in	O	O
serum	O	O
.	O	O

histopathological	O	O
examination	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
confirm	O	O
the	O	O
myocardial	O	O
necrosis	O	O
.	O	O

t	B-chem	O
.	I-chem	O
chebula	I-chem	B-chem
extract	I-chem	I-chem
pretreatment	O	O
was	O	O
found	O	O
to	O	O
ameliorate	O	O
the	O	O
effect	O	O
of	O	O
isoproterenol	B-chem	B-chem
on	O	O
lipid	O	O
peroxide	B-chem	O
formation	O	O
and	O	O
retained	O	O
the	O	O
activities	O	O
of	O	O
the	O	O
diagnostic	O	O
marker	O	O
enzymes	O	O
.	O	O

a	O	O
case	O	O
of	O	O
postoperative	O	O
anxiety	O	O
due	O	O
to	O	O
low	O	O
dose	O	O
droperidol	B-chem	B-chem
used	O	O
with	O	O
patient	O	O
-	O	O
controlled	O	O
analgesia	O	O
.	O	O

a	O	O
multiparous	O	O
woman	O	O
in	O	O
good	O	O
psychological	O	O
health	O	O
underwent	O	O
urgent	O	O
caesarean	O	O
section	O	O
in	O	O
labour	O	O
.	O	O

postoperatively	O	O
,	O	O
she	O	O
was	O	O
given	O	O
a	O	O
patient	O	O
-	O	O
controlled	O	O
analgesia	O	O
device	O	O
delivering	O	O
boluses	O	O
of	O	O
diamorphine	B-chem	B-chem
0	O	O
.	O	O
5	O	O
mg	O	O
and	O	O
droperidol	B-chem	B-chem
0	O	O
.	O	O
025	O	O
mg	O	O
.	O	O

whilst	O	O
using	O	O
the	O	O
device	O	O
she	O	O
gradually	O	O
became	O	O
anxious	O	O
,	O	O
the	O	O
feeling	O	O
worsening	O	O
after	O	O
each	O	O
bolus	O	O
.	O	O

the	O	O
diagnosis	O	O
of	O	O
droperidol	B-chem	B-chem
-	O	O
induced	O	O
psychological	O	O
disturbance	O	O
was	O	O
not	O	O
made	O	O
straight	O	O
away	O	O
although	O	O
on	O	O
subsequent	O	O
close	O	O
questioning	O	O
the	O	O
patient	O	O
gave	O	O
a	O	O
very	O	O
clear	O	O
history	O	O
.	O	O

after	O	O
she	O	O
had	O	O
received	O	O
a	O	O
total	O	O
of	O	O
only	O	O
0	O	O
.	O	O
9	O	O
mg	O	O
droperidol	B-chem	B-chem
,	O	O
a	O	O
syringe	O	O
containing	O	O
diamorphine	B-chem	B-chem
only	O	O
was	O	O
substituted	O	O
and	O	O
her	O	O
unease	O	O
resolved	O	O
completely	O	O
.	O	O

we	O	O
feel	O	O
that	O	O
,	O	O
although	O	O
the	O	O
dramatic	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
of	O	O
dopaminergic	O	O
antiemetics	O	O
are	O	O
well	O	O
known	O	O
,	O	O
more	O	O
subtle	O	O
manifestations	O	O
may	O	O
easily	O	O
be	O	O
overlooked	O	O
.	O	O

accurate	O	O
patient	O	O
history	O	O
contributes	O	O
to	O	O
differentiating	O	O
diabetes	O	O
insipidus	O	O
:	O	O
a	O	O
case	O	O
study	O	O
.	O	O

this	O	O
case	O	O
study	O	O
highlights	O	O
the	O	O
important	O	O
contribution	O	O
of	O	O
nursing	O	O
in	O	O
obtaining	O	O
an	O	O
accurate	O	O
health	O	O
history	O	O
.	O	O

the	O	O
case	O	O
discussed	O	O
herein	O	O
initially	O	O
appeared	O	O
to	O	O
be	O	O
neurogenic	O	O
diabetes	O	O
insipidus	O	O
(	O	O
di	O	O
)	O	O
secondary	O	O
to	O	O
a	O	O
traumatic	O	O
brain	O	O
injury	O	O
.	O	O

the	O	O
nursing	O	O
staff	O	O
,	O	O
by	O	O
reviewing	O	O
the	O	O
patient	O	O
'	O	O
s	O	O
health	O	O
history	O	O
with	O	O
his	O	O
family	O	O
,	O	O
discovered	O	O
a	O	O
history	O	O
of	O	O
polydipsia	O	O
and	O	O
long	O	O
-	O	O
standing	O	O
lithium	B-chem	B-chem
use	O	O
.	O	O

lithium	B-chem	B-chem
is	O	O
implicated	O	O
in	O	O
drug	O	O
-	O	O
induced	O	O
nephrogenic	O	O
di	O	O
,	O	O
and	O	O
because	O	O
the	O	O
patient	O	O
had	O	O
not	O	O
received	O	O
lithium	B-chem	B-chem
since	O	O
being	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
,	O	O
his	O	O
treatment	O	O
changed	O	O
to	O	O
focus	O	O
on	O	O
nephrogenic	O	O
di	O	O
.	O	O

by	O	O
combining	O	O
information	O	O
from	O	O
the	O	O
patient	O	O
history	O	O
,	O	O
the	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
radiologic	O	O
and	O	O
laboratory	O	O
studies	O	O
,	O	O
the	O	O
critical	O	O
care	O	O
team	O	O
demonstrated	O	O
that	O	O
the	O	O
patient	O	O
had	O	O
been	O	O
self	O	O
-	O	O
treating	O	O
his	O	O
lithium	B-chem	B-chem
-	O	O
induced	O	O
nephrogenic	O	O
di	O	O
and	O	O
developed	O	O
neurogenic	O	O
di	O	O
secondary	O	O
to	O	O
brain	O	O
trauma	O	O
.	O	O

thus	O	O
successful	O	O
treatment	O	O
required	O	O
that	O	O
nephrogenic	O	O
and	O	O
neurogenic	O	O
di	O	O
be	O	O
treated	O	O
concomitantly	O	O
.	O	O

factors	O	O
contributing	O	O
to	O	O
ribavirin	B-chem	B-chem
-	O	O
induced	O	O
anemia	O	O
.	O	O

background	O	O
and	O	O
aim	O	O
:	O	O

interferon	B-chem	B-chem
and	O	O
ribavirin	B-chem	B-chem
combination	O	O
therapy	O	O
for	O	O
chronic	O	O
hepatitis	O	O
c	O	O
produces	O	O
hemolytic	O	O
anemia	O	O
.	O	O

this	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
identify	O	O
the	O	O
factors	O	O
contributing	O	O
to	O	O
ribavirin	B-chem	B-chem
-	O	O
induced	O	O
anemia	O	O
.	O	O

methods	O	O
:	O	O

eighty	O	O
-	O	O
eight	O	O
patients	O	O
with	O	O
chronic	O	O
hepatitis	O	O
c	O	O
who	O	O
received	O	O
interferon	B-chem	B-chem
-	I-chem	I-chem
alpha	I-chem	I-chem
-	I-chem	I-chem
2b	I-chem	I-chem
at	O	O
a	O	O
dose	O	O
of	O	O
6	O	O
mu	O	O
administered	O	O
intramuscularly	O	O
for	O	O
24	O	O
weeks	O	O
in	O	O
combination	O	O
with	O	O
ribavirin	B-chem	B-chem
administered	O	O
orally	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
600	O	O
mg	O	O
or	O	O
800	O	O
mg	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

a	O	O
hemoglobin	O	O
concentration	O	O
of	O	O
<	O	O
10	O	O
g	O	O
/	O	O
dl	O	O
was	O	O
defined	O	O
as	O	O
ribavirin	B-chem	B-chem
-	O	O
induced	O	O
anemia	O	O
.	O	O

results	O	O
:	O	O

ribavirin	B-chem	B-chem
-	O	O
induced	O	O
anemia	O	O
occurred	O	O
in	O	O
18	O	O
(	O	O
20	O	O
.	O	O
5	O	O
%	O	O
)	O	O
patients	O	O
during	O	O
treatment	O	O
.	O	O

a	O	O
2	O	O
g	O	O
/	O	O
dl	O	O
decrease	O	O
in	O	O
hemoglobin	O	O
concentrations	O	O
in	O	O
patients	O	O
with	O	O
anemia	O	O
was	O	O
observed	O	O
at	O	O
week	O	O
2	O	O
after	O	O
the	O	O
start	O	O
of	O	O
treatment	O	O
.	O	O

the	O	O
hemoglobin	O	O
concentration	O	O
in	O	O
patients	O	O
with	O	O
>	O	O
or	O	O
=	O	O
2	O	O
g	O	O
/	O	O
dl	O	O
decrease	O	O
at	O	O
week	O	O
2	O	O
was	O	O
observed	O	O
to	O	O
be	O	O
significantly	O	O
lower	O	O
even	O	O
after	O	O
week	O	O
2	O	O
than	O	O
in	O	O
patients	O	O
with	O	O
<	O	O
2	O	O
g	O	O
/	O	O
dl	O	O
decrease	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

a	O	O
significant	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
rate	O	O
of	O	O
reduction	O	O
of	O	O
hemoglobin	O	O
concentrations	O	O
at	O	O
week	O	O
2	O	O
and	O	O
the	O	O
severity	O	O
of	O	O
anemia	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

such	O	O
factors	O	O
as	O	O
sex	O	O
(	O	O
female	O	O
)	O	O
,	O	O
age	O	O
(	O	O
>	O	O
or	O	O
=	O	O
60	O	O
years	O	O
old	O	O
)	O	O
,	O	O
and	O	O
the	O	O
ribavirin	B-chem	B-chem
dose	O	O
by	O	O
body	O	O
weight	O	O
(	O	O
12	O	O
mg	O	O
/	O	O
kg	O	O
or	O	O
more	O	O
)	O	O
were	O	O
significant	O	O
by	O	O
univariate	O	O
analysis	O	O
.	O	O

conclusions	O	O
:	O	O

careful	O	O
administration	O	O
is	O	O
necessary	O	O
in	O	O
patients	O	O
>	O	O
or	O	O
=	O	O
60	O	O
years	O	O
old	O	O
,	O	O
in	O	O
female	O	O
patients	O	O
,	O	O
and	O	O
in	O	O
patients	O	O
receiving	O	O
a	O	O
ribavirin	B-chem	B-chem
dose	O	O
of	O	O
12	O	O
mg	O	O
/	O	O
kg	O	O
or	O	O
more	O	O
.	O	O

patients	O	O
who	O	O
experience	O	O
a	O	O
fall	O	O
in	O	O
hemoglobin	O	O
concentrations	O	O
of	O	O
2	O	O
g	O	O
/	O	O
dl	O	O
or	O	O
more	O	O
at	O	O
week	O	O
2	O	O
after	O	O
the	O	O
start	O	O
of	O	O
treatment	O	O
should	O	O
be	O	O
monitored	O	O
with	O	O
particular	O	O
care	O	O
.	O	O

oxidative	O	O
damage	O	O
precedes	O	O
nitrative	O	O
damage	O	O
in	O	O
adriamycin	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
mitochondrial	O	O
injury	O	O
.	O	O

the	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
elevated	O	O
reactive	O	O
oxygen	B-chem	B-chem
(	O	O
ros	O	O
)	O	O
/	O	O
nitrogen	B-chem	B-chem
species	O	O
(	O	O
rns	O	O
)	O	O
reported	O	O
to	O	O
be	O	O
present	O	O
in	O	O
adriamycin	B-chem	B-chem
(	O	O
adr	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
cardiotoxicity	O	O
actually	O	O
resulted	O	O
in	O	O
cardiomyocyte	O	O
oxidative	O	O
/	O	O
nitrative	O	O
damage	O	O
,	O	O
and	O	O
to	O	O
quantitatively	O	O
determine	O	O
the	O	O
time	O	O
course	O	O
and	O	O
subcellular	O	O
localization	O	O
of	O	O
these	O	O
postulated	O	O
damage	O	O
products	O	O
using	O	O
an	O	O
in	O	O
vivo	O	O
approach	O	O
.	O	O

b6c3	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
adr	B-chem	B-chem
.	O	O

ultrastructural	O	O
damage	O	O
and	O	O
levels	O	O
of	O	O
4	B-chem	B-chem
-	I-chem	I-chem
hydroxy	I-chem	I-chem
-	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
nonenal	I-chem	I-chem
(	O	O
4hne	B-chem	O
)	O	O
-	O	O
protein	O	O
adducts	O	O
and	O	O
3	B-chem	B-chem
-	I-chem	I-chem
nitrotyrosine	I-chem	I-chem
(	O	O
3nt	B-chem	O
)	O	O
were	O	O
analyzed	O	O
.	O	O

quantitative	O	O
ultrastructural	O	O
damage	O	O
using	O	O
computerized	O	O
image	O	O
techniques	O	O
showed	O	O
cardiomyocyte	O	O
injury	O	O
as	O	O
early	O	O
as	O	O
3	O	O
hours	O	O
,	O	O
with	O	O
mitochondria	O	O
being	O	O
the	O	O
most	O	O
extensively	O	O
and	O	O
progressively	O	O
injured	O	O
subcellular	O	O
organelle	O	O
.	O	O

analysis	O	O
of	O	O
4hne	B-chem	O
protein	O	O
adducts	O	O
by	O	O
immunogold	O	O
electron	O	O
microscopy	O	O
showed	O	O
appearance	O	O
of	O	O
4hne	B-chem	O
protein	O	O
adducts	O	O
in	O	O
mitochondria	O	O
as	O	O
early	O	O
as	O	O
3	O	O
hours	O	O
,	O	O
with	O	O
a	O	O
peak	O	O
at	O	O
6	O	O
hours	O	O
and	O	O
subsequent	O	O
decline	O	O
at	O	O
24	O	O
hours	O	O
.	O	O

3nt	B-chem	O
levels	O	O
were	O	O
significantly	O	O
increased	O	O
in	O	O
all	O	O
subcellular	O	O
compartments	O	O
at	O	O
6	O	O
hours	O	O
and	O	O
subsequently	O	O
declined	O	O
at	O	O
24	O	O
hours	O	O
.	O	O

our	O	O
data	O	O
showed	O	O
adr	B-chem	B-chem
induced	O	O
4hne	B-chem	O
-	O	O
protein	O	O
adducts	O	O
in	O	O
mitochondria	O	O
at	O	O
the	O	O
same	O	O
time	O	O
point	O	O
as	O	O
when	O	O
mitochondrial	O	O
injury	O	O
initially	O	O
appeared	O	O
.	O	O

these	O	O
results	O	O
document	O	O
for	O	O
the	O	O
first	O	O
time	O	O
in	O	O
vivo	O	O
that	O	O
mitochondrial	O	O
oxidative	O	O
damage	O	O
precedes	O	O
nitrative	O	O
damage	O	O
.	O	O

the	O	O
progressive	O	O
nature	O	O
of	O	O
mitochondrial	O	O
injury	O	O
suggests	O	O
that	O	O
mitochondria	O	O
,	O	O
not	O	O
other	O	O
subcellular	O	O
organelles	O	O
,	O	O
are	O	O
the	O	O
major	O	O
site	O	O
of	O	O
intracellular	O	O
injury	O	O
.	O	O

sotalol	B-chem	B-chem
-	O	O
induced	O	O
coronary	O	O
spasm	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
dilated	O	O
cardiomyopathy	O	O
associated	O	O
with	O	O
sustained	O	O
ventricular	O	O
tachycardia	O	O
.	O	O

a	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
severe	O	O
left	O	O
ventricular	O	O
dysfunction	O	O
due	O	O
to	O	O
dilated	O	O
cardiomyopathy	O	O
was	O	O
referred	O	O
to	O	O
our	O	O
hospital	O	O
for	O	O
symptomatic	O	O
incessant	O	O
sustained	O	O
ventricular	O	O
tachycardia	O	O
(	O	O
vt	O	O
)	O	O
.	O	O

after	O	O
the	O	O
administration	O	O
of	O	O
nifekalant	B-chem	B-chem
hydrochloride	I-chem	I-chem
,	O	O
sustained	O	O
vt	O	O
was	O	O
terminated	O	O
.	O	O

an	O	O
alternate	O	O
class	O	O
iii	O	O
agent	O	O
,	O	O
sotalol	B-chem	B-chem
,	O	O
was	O	O
also	O	O
effective	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
vt	O	O
.	O	O

however	O	O
,	O	O
one	O	O
month	O	O
after	O	O
switching	O	O
over	O	O
nifekalant	B-chem	O
to	O	O
sotalol	B-chem	B-chem
,	O	O
a	O	O
short	O	O
duration	O	O
of	O	O
st	O	O
elevation	O	O
was	O	O
documented	O	O
in	O	O
ecg	O	O
monitoring	O	O
at	O	O
almost	O	O
the	O	O
same	O	O
time	O	O
for	O	O
three	O	O
consecutive	O	O
days	O	O
.	O	O

st	O	O
elevation	O	O
with	O	O
chest	O	O
discomfort	O	O
disappeared	O	O
since	O	O
he	O	O
began	O	O
taking	O	O
long	O	O
-	O	O
acting	O	O
diltiazem	B-chem	B-chem
.	O	O

coronary	O	O
vasospasm	O	O
may	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
non	O	O
-	O	O
selective	O	O
beta	O	O
-	O	O
blocking	O	O
properties	O	O
of	O	O
sotalol	B-chem	B-chem
.	O	O

effects	O	O
of	O	O
the	O	O
antidepressant	O	B-chem
trazodone	B-chem	I-chem
,	O	O
a	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
2a	O	O
/	O	O
2c	O	O
receptor	O	O
antagonist	O	O
,	O	O
on	O	O
dopamine	B-chem	B-chem
-	O	O
dependent	O	O
behaviors	O	O
in	O	O
rats	O	O
.	O	O

rationale	O	O
:	O	O
5	B-chem	B-chem
-	I-chem	I-chem
hydroxytryptamine	I-chem	I-chem
,	O	O
via	O	O
stimulation	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
2c	O	O
receptors	O	O
,	O	O
exerts	O	O
a	O	O
tonic	O	O
inhibitory	O	O
influence	O	O
on	O	O
dopaminergic	O	O
neurotransmission	O	O
,	O	O
whereas	O	O
activation	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
2a	O	O
receptors	O	O
enhances	O	O
stimulated	O	O
daergic	O	O
neurotransmission	O	O
.	O	O

the	O	O
antidepressant	O	B-chem
trazodone	B-chem	I-chem
is	O	O
a	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
2a	O	O
/	O	O
2c	O	O
receptor	O	O
antagonist	O	O
.	O	O

objectives	O	O
:	O	O

to	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
trazodone	B-chem	B-chem
treatment	O	O
on	O	O
behaviors	O	O
dependent	O	O
on	O	O
the	O	O
functional	O	O
status	O	O
of	O	O
the	O	O
nigrostriatal	O	O
daergic	O	O
system	O	O
.	O	O

methods	O	O
:	O	O

the	O	O
effect	O	O
of	O	O
pretreatment	O	O
with	O	O
trazodone	B-chem	B-chem
on	O	O
dexamphetamine	B-chem	B-chem
-	O	O
and	O	O
apomorphine	B-chem	B-chem
-	O	O
induced	O	O
oral	O	O
stereotypies	O	O
,	O	O
on	O	O
catalepsy	O	O
induced	O	O
by	O	O
haloperidol	B-chem	B-chem
and	O	O
apomorphine	B-chem	B-chem
(	O	O
0	O	O
.	O	O
05	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
,	O	O
on	O	O
ergometrine	B-chem	B-chem
-	O	O
induced	O	O
wet	O	O
dog	O	O
shake	O	O
(	O	O
wds	O	O
)	O	O
behavior	O	O
and	O	O
fluoxetine	B-chem	B-chem
-	O	O
induced	O	O
penile	O	O
erections	O	O
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

we	O	O
also	O	O
investigated	O	O
whether	O	O
trazodone	B-chem	B-chem
induces	O	O
catalepsy	O	O
in	O	O
rats	O	O
.	O	O

results	O	O
:	O	O

trazodone	B-chem	B-chem
at	O	O
2	O	O
.	O	O
5	O	O
-	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O
did	O	O
not	O	O
induce	O	O
catalepsy	O	O
,	O	O
and	O	O
did	O	O
not	O	O
antagonize	O	O
apomorphine	B-chem	B-chem
(	O	O
1	O	O
.	O	O
5	O	O
and	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
stereotypy	O	O
and	O	O
apomorphine	B-chem	B-chem
(	O	O
0	O	O
.	O	O
05	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
-	O	O
induced	O	O
catalepsy	O	O
.	O	O

however	O	O
,	O	O
pretreatment	O	O
with	O	O
5	O	O
,	O	O
10	O	O
and	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O

trazodone	B-chem	B-chem
enhanced	O	O
dexamphetamine	B-chem	B-chem
stereotypy	O	O
,	O	O
and	O	O
antagonized	O	O
haloperidol	B-chem	B-chem
catalepsy	O	O
,	O	O
ergometrine	B-chem	B-chem
-	O	O
induced	O	O
wds	O	O
behavior	O	O
and	O	O
fluoxetine	B-chem	B-chem
-	O	O
induced	O	O
penile	O	O
erections	O	O
.	O	O

trazodone	B-chem	B-chem
at	O	O
30	O	O
,	O	O
40	O	O
and	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O

induced	O	O
catalepsy	O	O
and	O	O
antagonized	O	O
apomorphine	B-chem	B-chem
and	O	O
dexamphetamine	B-chem	B-chem
stereotypies	O	O
.	O	O

conclusions	O	O
:	O	O

our	O	O
results	O	O
indicate	O	O
that	O	O
trazodone	B-chem	B-chem
at	O	O
2	O	O
.	O	O
5	O	O
-	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
does	O	O
not	O	O
block	O	O
pre	O	O
-	O	O
and	O	O
postsynaptic	O	O
striatal	O	O
d2	O	O
da	O	B-chem
receptors	O	O
,	O	O
while	O	O
at	O	O
30	O	O
,	O	O
40	O	O
and	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
it	O	O
blocks	O	O
postsynaptic	O	O
striatal	O	O
d2	O	O
da	O	B-chem
receptors	O	O
.	O	O

furthermore	O	O
,	O	O
at	O	O
5	O	O
,	O	O
10	O	O
and	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
trazodone	B-chem	B-chem
blocks	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
2a	O	O
and	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
2c	O	O
receptors	O	O
.	O	O

we	O	O
suggest	O	O
that	O	O
trazodone	B-chem	B-chem
(	O	O
5	O	O
,	O	O
10	O	O
and	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
by	O	O
blocking	O	O
the	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
2c	O	O
receptors	O	O
,	O	O
releases	O	O
the	O	O
nigrostriatal	O	O
daergic	O	O
neurons	O	O
from	O	O
tonic	O	O
inhibition	O	O
caused	O	O
by	O	O
5	B-chem	B-chem
-	I-chem	I-chem
ht	I-chem	I-chem
,	O	O
and	O	O
thereby	O	O
potentiates	O	O
dexamphetamine	B-chem	B-chem
stereotypy	O	O
and	O	O
antagonizes	O	O
haloperidol	B-chem	B-chem
catalepsy	O	O
.	O	O

swallowing	O	O
abnormalities	O	O
and	O	O
dyskinesia	O	O
in	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

gastrointestinal	O	O
abnormalities	O	O
in	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
(	O	O
pd	O	O
)	O	O
have	O	O
been	O	O
known	O	O
for	O	O
almost	O	O
two	O	O
centuries	O	O
,	O	O
but	O	O
many	O	O
aspects	O	O
concerning	O	O
their	O	O
pathophysiology	O	O
have	O	O
not	O	O
been	O	O
completely	O	O
clarified	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
characterize	O	O
the	O	O
oropharyngeal	O	O
dynamics	O	O
in	O	O
pd	O	O
patients	O	O
with	O	O
and	O	O
without	O	O
levodopa	B-chem	B-chem
-	O	O
induced	O	O
dyskinesia	O	O
.	O	O

fifteen	O	O
dyskinetic	O	O
,	O	O
12	O	O
nondyskinetic	O	O
patients	O	O
,	O	O
and	O	O
a	O	O
control	O	O
group	O	O
were	O	O
included	O	O
.	O	O

patients	O	O
were	O	O
asked	O	O
about	O	O
dysphagia	O	O
and	O	O
evaluated	O	O
with	O	O
the	O	O
unified	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
rating	O	O
scale	O	O
parts	O	O
ii	O	O
and	O	O
iii	O	O
and	O	O
the	O	O
hoehn	O	O
and	O	O
yahr	O	O
scale	O	O
.	O	O

deglutition	O	O
was	O	O
assessed	O	O
using	O	O
modified	O	O
barium	B-chem	O
swallow	O	O
with	O	O
videofluoroscopy	O	O
.	O	O

nondyskinetic	O	O
patients	O	O
,	O	O
but	O	O
not	O	O
the	O	O
dyskinetic	O	O
ones	O	O
,	O	O
showed	O	O
less	O	O
oropharyngeal	O	O
swallowing	O	O
efficiency	O	O
(	O	O
opse	O	O
)	O	O
for	O	O
liquid	O	O
food	O	O
than	O	O
controls	O	O
(	O	O
dunnett	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
02	O	O
)	O	O
.	O	O

dyskinetic	O	O
patients	O	O
tended	O	O
to	O	O
have	O	O
a	O	O
greater	O	O
opse	O	O
than	O	O
nondyskinetic	O	O
(	O	O
dunnett	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
06	O	O
)	O	O
.	O	O

patients	O	O
who	O	O
were	O	O
using	O	O
a	O	O
higher	O	O
dose	O	O
of	O	O
levodopa	B-chem	B-chem
had	O	O
a	O	O
greater	O	O
opse	O	O
and	O	O
a	O	O
trend	O	O
toward	O	O
a	O	O
smaller	O	O
oral	O	O
transit	O	O
time	O	O
(	O	O
pearson	O	O
'	O	O
s	O	O
correlation	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
01	O	O
and	O	O
0	O	O
.	O	O
08	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

neither	O	O
the	O	O
report	O	O
of	O	O
dysphagia	O	O
nor	O	O
any	O	O
of	O	O
the	O	O
pd	O	O
severity	O	O
parameters	O	O
correlated	O	O
to	O	O
the	O	O
videofluoroscopic	O	O
variables	O	O
.	O	O

in	O	O
the	O	O
current	O	O
study	O	O
,	O	O
dyskinetic	O	O
patients	O	O
performed	O	O
better	O	O
in	O	O
swallowing	O	O
function	O	O
,	O	O
which	O	O
could	O	O
be	O	O
explained	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
a	O	O
greater	O	O
levodopa	B-chem	B-chem
dose	O	O
.	O	O

our	O	O
results	O	O
suggest	O	O
a	O	O
role	O	O
for	O	O
levodopa	B-chem	B-chem
in	O	O
the	O	O
oral	O	O
phase	O	O
of	O	O
deglutition	O	O
and	O	O
confirm	O	O
that	O	O
dysphagia	O	O
is	O	O
not	O	O
a	O	O
good	O	O
predictor	O	O
of	O	O
deglutition	O	O
alterations	O	O
in	O	O
pd	O	O
.	O	O

inhibition	O	O
of	O	O
nuclear	O	O
factor	O	O
-	O	O
kappab	O	O
activation	O	O
attenuates	O	O
tubulointerstitial	O	O
nephritis	O	O
induced	O	O
by	O	O
gentamicin	B-chem	B-chem
.	O	O

background	O	O
:	O	O

animals	O	O
treated	O	O
with	O	O
gentamicin	B-chem	B-chem
can	O	O
show	O	O
residual	O	O
areas	O	O
of	O	O
interstitial	O	O
fibrosis	O	O
in	O	O
the	O	O
renal	O	O
cortex	O	O
.	O	O

this	O	O
study	O	O
investigated	O	O
the	O	O
expression	O	O
of	O	O
nuclear	O	O
factor	O	O
-	O	O
kappab	O	O
(	O	O
nf	O	O
-	O	O
kappab	O	O
)	O	O
,	O	O
mitogen	O	O
-	O	O
activated	O	O
protein	O	O
(	O	O
map	O	O
)	O	O
kinases	O	O
and	O	O
macrophages	O	O
in	O	O
the	O	O
renal	O	O
cortex	O	O
and	O	O
structural	O	O
and	O	O
functional	O	O
renal	O	O
changes	O	O
of	O	O
rats	O	O
treated	O	O
with	O	O
gentamicin	B-chem	B-chem
or	O	O
gentamicin	B-chem	B-chem
+	O	O
pyrrolidine	B-chem	B-chem
dithiocarbamate	I-chem	I-chem
(	O	O
pdtc	B-chem	B-chem
)	O	O
,	O	O
an	O	O
nf	O	O
-	O	O
kappab	O	O
inhibitor	O	O
.	O	O

methods	O	O
:	O	O

38	O	O
female	O	O
wistar	O	O
rats	O	O
were	O	O
injected	O	O
with	O	O
gentamicin	B-chem	B-chem
,	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
9	O	O
days	O	O
,	O	O
38	O	O
with	O	O
gentamicin	B-chem	B-chem
+	O	O
pdtc	B-chem	B-chem
,	O	O
and	O	O
28	O	O
with	O	O
0	O	O
.	O	O
15	O	O
m	O	O
nacl	B-chem	B-chem
solution	O	O
.	O	O

the	O	O
animals	O	O
were	O	O
killed	O	O
5	O	O
and	O	O
30	O	O
days	O	O
after	O	O
these	O	O
injections	O	O
and	O	O
the	O	O
kidneys	O	O
were	O	O
removed	O	O
for	O	O
histological	O	O
and	O	O
immunohistochemical	O	O
studies	O	O
.	O	O

the	O	O
results	O	O
of	O	O
the	O	O
immunohistochemical	O	O
studies	O	O
were	O	O
scored	O	O
according	O	O
to	O	O
the	O	O
extent	O	O
of	O	O
staining	O	O
.	O	O

the	O	O
fractional	O	O
interstitial	O	O
area	O	O
was	O	O
determined	O	O
by	O	O
morphometry	O	O
.	O	O

results	O	O
:	O	O

gentamicin	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
presented	O	O
a	O	O
transitory	O	O
increase	O	O
in	O	O
plasma	O	O
creatinine	B-chem	B-chem
levels	O	O
.	O	O

increased	O	O
ed	O	O
-	O	O
1	O	O
,	O	O
map	O	O
kinases	O	O
and	O	O
nf	O	O
-	O	O
kappab	O	O
staining	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
the	O	O
renal	O	O
cortex	O	O
from	O	O
all	O	O
gentamicin	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
compared	O	O
to	O	O
control	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

the	O	O
animals	O	O
killed	O	O
on	O	O
day	O	O
30	O	O
also	O	O
presented	O	O
fibrosis	O	O
in	O	O
the	O	O
renal	O	O
cortex	O	O
despite	O	O
the	O	O
recovery	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

treatment	O	O
with	O	O
pdtc	B-chem	B-chem
reduced	O	O
the	O	O
functional	O	O
and	O	O
structural	O	O
changes	O	O
induced	O	O
by	O	O
gentamicin	B-chem	B-chem
.	O	O

conclusions	O	O
:	O	O

these	O	O
data	O	O
show	O	O
that	O	O
inhibition	O	O
of	O	O
nf	O	O
-	O	O
kappab	O	O
activation	O	O
attenuates	O	O
tubulointerstitial	O	O
nephritis	O	O
induced	O	O
by	O	O
gentamicin	B-chem	B-chem
.	O	O

glucose	B-chem	B-chem
metabolism	O	O
in	O	O
patients	O	O
with	O	O
schizophrenia	O	O
treated	O	O
with	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
:	O	O
a	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B-chem	O
tolerance	O	O
test	O	O
and	O	O
minimal	O	O
model	O	O
analysis	O	O
.	O	O

background	O	O
:	O	O
while	O	O
the	O	O
incidence	O	O
of	O	O
new	O	O
-	O	O
onset	O	O
diabetes	O	O
mellitus	O	O
may	O	O
be	O	O
increasing	O	O
in	O	O
patients	O	O
with	O	O
schizophrenia	O	O
treated	O	O
with	O	O
certain	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
,	O	O
it	O	O
remains	O	O
unclear	O	O
whether	O	O
atypical	O	O
agents	O	O
are	O	O
directly	O	O
affecting	O	O
glucose	B-chem	B-chem
metabolism	O	O
or	O	O
simply	O	O
increasing	O	O
known	O	O
risk	O	O
factors	O	O
for	O	O
diabetes	O	O
.	O	O

objective	O	O
:	O	O

to	O	O
study	O	O
the	O	O
2	O	O
drugs	O	O
most	O	O
clearly	O	O
implicated	O	O
(	O	O
clozapine	B-chem	B-chem
and	O	O
olanzapine	B-chem	B-chem
)	O	O
and	O	O
risperidone	B-chem	B-chem
using	O	O
a	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B-chem	O
tolerance	O	O
test	O	O
.	O	O

design	O	O
:	O	O

a	O	O
cross	O	O
-	O	O
sectional	O	O
design	O	O
in	O	O
stable	O	O
,	O	O
treated	O	O
patients	O	O
with	O	O
schizophrenia	O	O
evaluated	O	O
using	O	O
a	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B-chem	O
tolerance	O	O
test	O	O
and	O	O
the	O	O
bergman	O	O
minimal	O	O
model	O	O
analysis	O	O
.	O	O

setting	O	O
:	O	O

subjects	O	O
were	O	O
recruited	O	O
from	O	O
an	O	O
urban	O	O
community	O	O
mental	O	O
health	O	O
clinic	O	O
and	O	O
were	O	O
studied	O	O
at	O	O
a	O	O
general	O	O
clinical	O	O
research	O	O
center	O	O
.	O	O

patients	O	O
fifty	O	O
subjects	O	O
signed	O	O
informed	O	O
consent	O	O
and	O	O
41	O	O
underwent	O	O
the	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B-chem	O
tolerance	O	O
test	O	O
.	O	O

thirty	O	O
-	O	O
six	O	O
nonobese	O	O
subjects	O	O
with	O	O
schizophrenia	O	O
or	O	O
schizoaffective	O	O
disorder	O	O
,	O	O
matched	O	O
by	O	O
body	O	O
mass	O	O
index	O	O
and	O	O
treated	O	O
with	O	O
either	O	O
clozapine	B-chem	B-chem
,	O	O
olanzapine	B-chem	B-chem
,	O	O
or	O	O
risperidone	B-chem	B-chem
,	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

main	O	O
outcome	O	O
measures	O	O
:	O	O

fasting	O	O
plasma	O	O
glucose	B-chem	B-chem
and	O	O
fasting	O	O
serum	O	O
insulin	O	O
levels	O	O
,	O	O
insulin	O	O
sensitivity	O	O
index	O	O
,	O	O
homeostasis	O	O
model	O	O
assessment	O	O
of	O	O
insulin	O	O
resistance	O	O
,	O	O
and	O	O
glucose	B-chem	B-chem
effectiveness	O	O
.	O	O

results	O	O
:	O	O

the	O	O
mean	O	O
+	O	O
/	O	O
-	O	O

sd	O	O
duration	O	O
of	O	O
treatment	O	O
with	O	O
the	O	O
identified	O	O
atypical	O	O
antipsychotic	O	O
agent	O	O
was	O	O
68	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

28	O	O
.	O	O
9	O	O
months	O	O
(	O	O
clozapine	B-chem	B-chem
)	O	O
,	O	O
29	O	O
.	O	O
5	O	O
+	O	O
/	O	O
-	O	O

17	O	O
.	O	O
5	O	O
months	O	O
(	O	O
olanzapine	B-chem	B-chem
)	O	O
,	O	O
and	O	O
40	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

33	O	O
.	O	O
7	O	O
(	O	O
risperidone	B-chem	B-chem
)	O	O
.	O	O

fasting	O	O
serum	O	O
insulin	O	O
concentrations	O	O
differed	O	O
among	O	O
groups	O	O
(	O	O
f	O	O
(	O	O
33	O	O
)	O	O
=	O	O
3	O	O
.	O	O
35	O	O
;	O	O
p	O	O
=	O	O
.	O	O
047	O	O
)	O	O

(	O	O
clozapine	B-chem	B-chem
>	O	O
olanzapine	B-chem	B-chem
>	O	O
risperidone	B-chem	B-chem
)	O	O
with	O	O
significant	O	O
differences	O	O
between	O	O
clozapine	B-chem	B-chem
and	O	O
risperidone	B-chem	B-chem
(	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O
2	O	O
.	O	O
32	O	O
;	O	O
p	O	O
=	O	O
.	O	O
03	O	O
)	O	O
and	O	O
olanzapine	B-chem	B-chem
and	O	O
risperidone	B-chem	B-chem
(	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O

2	O	O
.	O	O
15	O	O
;	O	O
p	O	O
=	O	O
.	O	O
04	O	O
)	O	O
.	O	O

there	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
insulin	O	O
sensitivity	O	O
index	O	O
among	O	O
groups	O	O
(	O	O
f	O	O
(	O	O
33	O	O
)	O	O
=	O	O

10	O	O
.	O	O
66	O	O
;	O	O
p	O	O
<	O	O
.	O	O
001	O	O
)	O	O
(	O	O
clozapine	B-chem	B-chem
<	O	O
olanzapine	B-chem	B-chem
<	O	O
risperidone	B-chem	B-chem
)	O	O
,	O	O
with	O	O
subjects	O	O
who	O	O
received	O	O
clozapine	B-chem	B-chem
and	O	O
olanzapine	B-chem	B-chem
exhibiting	O	O
significant	O	O
insulin	O	O
resistance	O	O
compared	O	O
with	O	O
subjects	O	O
who	O	O
were	O	O
treated	O	O
with	O	O
risperidone	B-chem	B-chem
(	O	O
clozapine	B-chem	B-chem
vs	O	O
risperidone	B-chem	B-chem
,	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O

-	O	O
4	O	O
.	O	O
29	O	O
;	O	O
p	O	O
<	O	O
.	O	O
001	O	O
;	O	O
olanzapine	B-chem	B-chem
vs	O	O
risperidone	B-chem	B-chem
,	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O
-	O	O
3	O	O
.	O	O
62	O	O
;	O	O
p	O	O
=	O	O
.	O	O
001	O	O
[	O	O
p	O	O
<	O	O
.	O	O
001	O	O
]	O	O
)	O	O
.	O	O

the	O	O
homeostasis	O	O
model	O	O
assessment	O	O
of	O	O
insulin	O	O
resistance	O	O
also	O	O
differed	O	O
significantly	O	O
among	O	O
groups	O	O
(	O	O
f	O	O
(	O	O
33	O	O
)	O	O
=	O	O

4	O	O
.	O	O
92	O	O
;	O	O
p	O	O
=	O	O
.	O	O
01	O	O
)	O	O
(	O	O
clozapine	B-chem	B-chem
>	O	O
olanzapine	B-chem	B-chem
>	O	O
risperidone	B-chem	B-chem
)	O	O
(	O	O
clozapine	B-chem	B-chem
vs	O	O
risperidone	B-chem	B-chem
,	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O
2	O	O
.	O	O
94	O	O
;	O	O

p	O	O
=	O	O
.	O	O
006	O	O
;	O	O
olanzapine	B-chem	B-chem
vs	O	O
risperidone	B-chem	B-chem
,	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O

2	O	O
.	O	O
42	O	O
;	O	O
p	O	O
=	O	O
.	O	O
02	O	O
)	O	O
.	O	O

there	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
among	O	O
groups	O	O
in	O	O
glucose	B-chem	B-chem
effectiveness	O	O
(	O	O
f	O	O
(	O	O
30	O	O
)	O	O
=	O	O

4	O	O
.	O	O
18	O	O
;	O	O
p	O	O
=	O	O
.	O	O
02	O	O
)	O	O

(	O	O
clozapine	B-chem	B-chem
<	O	O
olanzapine	B-chem	B-chem
<	O	O
risperidone	B-chem	B-chem
)	O	O
with	O	O
significant	O	O
differences	O	O
between	O	O
clozapine	B-chem	B-chem
and	O	O
risperidone	B-chem	B-chem
(	O	O
t	O	O
(	O	O
30	O	O
)	O	O
=	O	O

-	O	O
2	O	O
.	O	O
59	O	O
;	O	O
p	O	O
=	O	O
.	O	O
02	O	O
)	O	O
and	O	O
olanzapine	B-chem	B-chem
and	O	O
risperidone	B-chem	B-chem
(	O	O
t	O	O
(	O	O
30	O	O
)	O	O
=	O	O

-	O	O
2	O	O
.	O	O
34	O	O
,	O	O
p	O	O
=	O	O
.	O	O
03	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

both	O	O
nonobese	O	O
clozapine	B-chem	B-chem
-	O	O
and	O	O
olanzapine	B-chem	B-chem
-	O	O
treated	O	O
groups	O	O
displayed	O	O
significant	O	O
insulin	O	O
resistance	O	O
and	O	O
impairment	O	O
of	O	O
glucose	B-chem	B-chem
effectiveness	O	O
compared	O	O
with	O	O
risperidone	B-chem	B-chem
-	O	O
treated	O	O
subjects	O	O
.	O	O

patients	O	O
taking	O	O
clozapine	B-chem	B-chem
and	O	O
olanzapine	B-chem	B-chem
must	O	O
be	O	O
examined	O	O
for	O	O
insulin	O	O
resistance	O	O
and	O	O
its	O	O
consequences	O	O
.	O	O

focal	O	O
cerebral	O	O
ischemia	O	O
in	O	O
rats	O	O
:	O	O
effect	O	O
of	O	O
phenylephrine	B-chem	B-chem
-	O	O
induced	O	O
hypertension	O	O
during	O	O
reperfusion	O	O
.	O	O

after	O	O
180	O	O
min	O	O
of	O	O
temporary	O	O
middle	O	O
cerebral	O	O
artery	O	O
occlusion	O	O
in	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
phenylephrine	B-chem	B-chem
-	O	O
induced	O	O
hypertension	O	O
on	O	O
ischemic	O	O
brain	O	O
injury	O	O
and	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
permeability	O	O
was	O	O
determined	O	O
.	O	O

blood	O	O
pressure	O	O
was	O	O
manipulated	O	O
by	O	O
one	O	O
of	O	O
the	O	O
following	O	O
schedules	O	O
during	O	O
120	O	O
min	O	O
of	O	O
reperfusion	O	O
:	O	O
control	O	O
,	O	O
normotensive	O	O
reperfusion	O	O
;	O	O
90	O	O
/	O	O
hypertension	O	O
(	O	O
90	O	O
/	O	O
htn	O	O
)	O	O
,	O	O
blood	O	O
pressure	O	O
was	O	O
increased	O	O
by	O	O
35	O	O
mm	O	O
hg	O	O
during	O	O
the	O	O
initial	O	O
90	O	O
min	O	O
of	O	O
reperfusion	O	O
only	O	O
;	O	O
15	O	O
/	O	O
hypertension	O	O
(	O	O
15	O	O
/	O	O
htn	O	O
)	O	O
,	O	O
normotensive	O	O
reperfusion	O	O
for	O	O
30	O	O
min	O	O
followed	O	O
by	O	O
15	O	O
min	O	O
of	O	O
hypertension	O	O
and	O	O
75	O	O
min	O	O
of	O	O
normotension	O	O
.	O	O

part	O	O
a	O	O
,	O	O
for	O	O
eight	O	O
rats	O	O
in	O	O
each	O	O
group	O	O
brain	O	O
injury	O	O
was	O	O
evaluated	O	O
by	O	O
staining	O	O
tissue	O	O
using	O	O
2	B-chem	O
,	I-chem	O
3	I-chem	B-chem
,	I-chem	I-chem
5	I-chem	I-chem
-	I-chem	I-chem
triphenyltetrazolium	I-chem	I-chem
chloride	I-chem	I-chem
and	O	O
edema	O	O
was	O	O
evaluated	O	O
by	O	O
microgravimetry	O	O
.	O	O

part	O	O
b	O	O
,	O	O
for	O	O
eight	O	O
different	O	O
rats	O	O
in	O	O
each	O	O
group	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
permeability	O	O
was	O	O
evaluated	O	O
by	O	O
measuring	O	O
the	O	O
amount	O	O
and	O	O
extent	O	O
of	O	O
extravasation	O	O
of	O	O
evans	O	B-chem
blue	O	I-chem
dye	O	O
.	O	O

brain	O	O
injury	O	O
(	O	O
percentage	O	O
of	O	O
the	O	O
ischemic	O	O
hemisphere	O	O
)	O	O
was	O	O
less	O	O
in	O	O
the	O	O
15	O	O
/	O	O
htn	O	O
group	O	O
(	O	O
16	O	O
+	O	O
/	O	O
-	O	O

6	O	O
,	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
sd	O	O
)	O	O
versus	O	O
the	O	O
90	O	O
/	O	O
htn	O	O
group	O	O
(	O	O
30	O	O
+	O	O
/	O	O
-	O	O
6	O	O
)	O	O
,	O	O
which	O	O
was	O	O
in	O	O
turn	O	O
less	O	O
than	O	O
the	O	O
control	O	O
group	O	O
(	O	O
42	O	O
+	O	O
/	O	O
-	O	O
5	O	O
)	O	O
.	O	O

specific	O	O
gravity	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
15	O	O
/	O	O
htn	O	O
group	O	O
(	O	O
1	O	O
.	O	O
043	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
002	O	O
)	O	O
versus	O	O
the	O	O
90	O	O
/	O	O
htn	O	O
(	O	O
1	O	O
.	O	O
036	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
003	O	O
)	O	O
and	O	O
control	O	O
(	O	O
1	O	O
.	O	O
037	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
003	O	O
)	O	O
groups	O	O
.	O	O

evans	B-chem	B-chem
blue	I-chem	I-chem
(	O	O
mug	O	O
g	O	O
-	O	O
1	O	O
of	O	O
brain	O	O
tissue	O	O
)	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
90	O	O
/	O	O
htn	O	O
group	O	O
(	O	O
24	O	O
.	O	O
4	O	O
+	O	O
/	O	O
-	O	O

6	O	O
.	O	O
0	O	O
)	O	O
versus	O	O
the	O	O
control	O	O
group	O	O
(	O	O
12	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

4	O	O
.	O	O
1	O	O
)	O	O
,	O	O
which	O	O
was	O	O
in	O	O
turn	O	O
greater	O	O
than	O	O
the	O	O
15	O	O
/	O	O
htn	O	O
group	O	O
(	O	O
7	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O
2	O	O
)	O	O
.	O	O

this	O	O
study	O	O
supports	O	O
a	O	O
hypothesis	O	O
that	O	O
during	O	O
reperfusion	O	O
,	O	O
a	O	O
short	O	O
interval	O	O
of	O	O
hypertension	O	O
decreases	O	O
brain	O	O
injury	O	O
and	O	O
edema	O	O
;	O	O
and	O	O
that	O	O
sustained	O	O
hypertension	O	O
increases	O	O
the	O	O
risk	O	O
of	O	O
vasogenic	O	O
edema	O	O
.	O	O

people	O	O
aged	O	O
over	O	O
75	O	O
in	O	O
atrial	O	O
fibrillation	O	O
on	O	O
warfarin	B-chem	B-chem
:	O	O
the	O	O
rate	O	O
of	O	O
major	O	O
hemorrhage	O	O
and	O	O
stroke	O	O
in	O	O
more	O	O
than	O	O
500	O	O
patient	O	O
-	O	O
years	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

objectives	O	O
:	O	O

to	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
major	O	O
hemorrhage	O	O
and	O	O
stroke	O	O
in	O	O
people	O	O
aged	O	O
76	O	O
and	O	O
older	O	O
with	O	O
atrial	O	O
fibrillation	O	O
on	O	O
adjusted	O	O
-	O	O
dose	O	O
warfarin	B-chem	B-chem
who	O	O
had	O	O
been	O	O
recently	O	O
been	O	O
admitted	O	O
to	O	O
hospital	O	O
.	O	O

design	O	O
:	O	O

a	O	O
retrospective	O	O
observational	O	O
cohort	O	O
study	O	O
.	O	O

setting	O	O
:	O	O

a	O	O
major	O	O
healthcare	O	O
network	O	O
involving	O	O
four	O	O
tertiary	O	O
hospitals	O	O
.	O	O

participants	O	O
:	O	O
two	O	O
hundred	O	O
thirty	O	O
-	O	O
five	O	O
patients	O	O
aged	O	O
76	O	O
and	O	O
older	O	O
admitted	O	O
to	O	O
a	O	O
major	O	O
healthcare	O	O
network	O	O
between	O	O
july	O	O
1	O	O
,	O	O
2001	O	O
,	O	O
and	O	O
june	O	O
30	O	O
,	O	O
2002	O	O
,	O	O
with	O	O
atrial	O	O
fibrillation	O	O
on	O	O
warfarin	B-chem	B-chem
were	O	O
enrolled	O	O
.	O	O

measurements	O	O
:	O	O

information	O	O
regarding	O	O
major	O	O
bleeding	O	O
episodes	O	O
,	O	O
strokes	O	O
,	O	O
and	O	O
warfarin	B-chem	B-chem
use	O	O
was	O	O
obtained	O	O
from	O	O
patients	O	O
,	O	O
relatives	O	O
,	O	O
primary	O	O
physicians	O	O
,	O	O
and	O	O
medical	O	O
records	O	O
.	O	O

results	O	O
:	O	O

two	O	O
hundred	O	O
twenty	O	O
-	O	O
eight	O	O
patients	O	O
(	O	O
42	O	O
%	O	O
men	O	O
)	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
81	O	O
.	O	O
1	O	O
(	O	O
range	O	O
76	O	O
-	O	O
94	O	O
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

total	O	O
follow	O	O
-	O	O
up	O	O
on	O	O
warfarin	B-chem	B-chem
was	O	O
530	O	O
years	O	O
(	O	O
mean	O	O
28	O	O
months	O	O
)	O	O
.	O	O

there	O	O
were	O	O
53	O	O
major	O	O
hemorrhages	O	O
,	O	O
for	O	O
an	O	O
annual	O	O
rate	O	O
of	O	O
10	O	O
.	O	O
0	O	O
%	O	O
,	O	O
including	O	O
24	O	O
(	O	O
45	O	O
.	O	O
3	O	O
%	O	O
)	O	O
life	O	O
-	O	O
threatening	O	O
and	O	O
five	O	O
(	O	O
9	O	O
.	O	O
4	O	O
%	O	O
)	O	O
fatal	O	O
bleeds	O	O
.	O	O

the	O	O
annual	O	O
stroke	O	O
rate	O	O
after	O	O
initiation	O	O
of	O	O
warfarin	B-chem	B-chem
was	O	O
2	O	O
.	O	O
6	O	O
%	O	O
.	O	O

conclusion	O	O
:	O	O

the	O	O
rate	O	O
of	O	O
major	O	O
hemorrhage	O	O
was	O	O
high	O	O
in	O	O
this	O	O
old	O	O
,	O	O
frail	O	O
group	O	O
,	O	O
but	O	O
excluding	O	O
fatalities	O	O
,	O	O
resulted	O	O
in	O	O
no	O	O
long	O	O
-	O	O
term	O	O
sequelae	O	O
,	O	O
and	O	O
the	O	O
stroke	O	O
rate	O	O
on	O	O
warfarin	B-chem	B-chem
was	O	O
low	O	O
,	O	O
demonstrating	O	O
how	O	O
effective	O	O
warfarin	B-chem	B-chem
treatment	O	O
is	O	O
.	O	O

safety	O	O
of	O	O
celecoxib	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
adverse	O	O
skin	O	O
reactions	O	O
to	O	O
acetaminophen	B-chem	B-chem
(	O	O
paracetamol	B-chem	B-chem
)	O	O
and	O	O
nimesulide	B-chem	O
associated	O	O
or	O	O
not	O	O
with	O	O
common	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
.	O	O

background	O	O
:	O	O

acetaminophen	B-chem	B-chem
(	O	O
paracetamol	B-chem	B-chem
-	O	O
-	O	I-chem
p	B-chem	I-chem
)	O	I-chem
and	O	O
nimesulide	B-chem	B-chem
(	O	O
n	B-chem	O
)	O	O
are	O	O
widely	O	O
used	O	O
analgesic	O	O
-	O	O
antipyretic	O	O
/	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
.	O	O

the	O	O
rate	O	O
of	O	O
adverse	O	O
hypersensitivity	O	O
reactions	O	O
to	O	O
these	O	O
agents	O	O
is	O	O
generally	O	O
low	O	O
.	O	O

on	O	O
the	O	O
contrary	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
(	O	O
nsaids	O	O
)	O	O
are	O	O
commonly	O	O
involved	O	O
in	O	O
such	O	O
reactions	O	O
.	O	O

celecoxib	B-chem	B-chem
(	O	O
ce	B-chem	B-chem
)	O	O
is	O	O
a	O	O
novel	O	O
drug	O	O
,	O	O
with	O	O
high	O	O
selectivity	O	O
and	O	O
affinity	O	O
for	O	O
cox	O	O
-	O	O
2	O	O
enzyme	O	O
.	O	O

objective	O	O
:	O	O
we	O	O
evaluated	O	O
the	O	O
tolerability	O	O
of	O	O
ce	B-chem	B-chem
in	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
with	O	O
documented	O	O
history	O	O
of	O	O
adverse	O	O
cutaneous	O	O
reactions	O	O
to	O	O
p	B-chem	O
and	O	O
n	B-chem	O
associated	O	O
or	O	O
not	O	O
to	O	O
classic	O	O
nsaids	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
studied	O	O
9	O	O
patients	O	O
with	O	O
hypersensitivity	O	O
to	O	O
p	B-chem	O
and	O	O
n	B-chem	O
with	O	O
or	O	O
without	O	O
associated	O	O
reactions	O	O
to	O	O
classic	O	O
nsaids	O	O
.	O	O

the	O	O
diagnosis	O	O
of	O	O
p	B-chem	O
and	O	O
n	B-chem	O
-	O	O
induced	O	O
skin	O	O
reactions	O	O
was	O	O
based	O	O
in	O	O
vivo	O	O
challenge	O	O
.	O	O

the	O	O
placebo	O	O
was	O	O
blindly	O	O
administered	O	O
at	O	O
the	O	O
beginning	O	O
of	O	O
each	O	O
challenge	O	O
.	O	O

after	O	O
three	O	O
days	O	O
,	O	O
a	O	O
cumulative	O	O
dosage	O	O
of	O	O
200	O	O
mg	O	O
of	O	O
ce	B-chem	B-chem
in	O	O
refracted	O	O
doses	O	O
were	O	O
given	O	O
.	O	O

after	O	O
2	O	O
-	O	O
3	O	O
days	O	O
,	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
200	O	O
mg	O	O
was	O	O
administered	O	O
.	O	O

all	O	O
patients	O	O
were	O	O
observed	O	O
for	O	O
6	O	O
hours	O	O
after	O	O
each	O	O
challenge	O	O
,	O	O
and	O	O
controlled	O	O
again	O	O
after	O	O
24	O	O
hours	O	O
to	O	O
exclude	O	O
delayed	O	O
reactions	O	O
.	O	O

the	O	O
challenge	O	O
was	O	O
considered	O	O
positive	O	O
if	O	O
one	O	O
or	O	O
more	O	O
of	O	O
the	O	O
following	O	O
appeared	O	O
:	O	O
erythema	O	O
,	O	O
rush	O	O
or	O	O
urticaria	O	O
-	O	O
angioedema	O	O
.	O	O

results	O	O
:	O	O

no	O	O
reaction	O	O
was	O	O
observed	O	O
with	O	O
placebo	O	O
and	O	O
eight	O	O
patients	O	O
(	O	O
88	O	O
.	O	O
8	O	O
%	O	O
)	O	O
tolerated	O	O
ce	B-chem	O
.	O	O

only	O	O
one	O	O
patient	O	O
developed	O	O
a	O	O
moderate	O	O
angioedema	O	O
of	O	O
the	O	O
lips	O	O
.	O	O

conclusion	O	O
:	O	O

only	O	O
one	O	O
hypersensitivity	O	O
reaction	O	O
to	O	O
ce	B-chem	B-chem
was	O	O
documented	O	O
among	O	O
9	O	O
p	B-chem	O
and	O	O
n	B-chem	O
-	O	O
highly	O	O
nsaids	O	O
intolerant	O	O
patients	O	O
.	O	O

thus	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
ce	B-chem	B-chem
is	O	O
a	O	O
reasonably	O	O
safe	O	O
alternative	O	O
to	O	O
be	O	O
used	O	O
in	O	O
subjects	O	O
who	O	O
do	O	O
not	O	O
tolerate	O	O
p	B-chem	O
and	O	O
n	B-chem	O
.	O	O

case	O	O
-	O	O
control	O	O
study	O	O
of	O	O
regular	O	O
analgesic	O	O
and	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
use	O	O
and	O	O
end	O	O
-	O	O
stage	O	O
renal	O	O
disease	O	O
.	O	O

background	O	O
:	O	O

studies	O	O
on	O	O
the	O	O
association	O	O
between	O	O
the	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
aspirin	B-chem	B-chem
and	O	O
other	O	O
analgesic	O	O
and	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
(	O	O
nsaids	O	O
)	O	O
and	O	O
end	O	O
-	O	O
stage	O	O
renal	O	O
disease	O	O
(	O	O
esrd	O	O
)	O	O
have	O	O
given	O	O
conflicting	O	O
results	O	O
.	O	O

in	O	O
order	O	O
to	O	O
examine	O	O
this	O	O
association	O	O
,	O	O
a	O	O
case	O	O
-	O	O
control	O	O
study	O	O
with	O	O
incident	O	O
cases	O	O
of	O	O
esrd	O	O
was	O	O
carried	O	O
out	O	O
.	O	O

methods	O	O
:	O	O

the	O	O
cases	O	O
were	O	O
all	O	O
patients	O	O
entering	O	O
the	O	O
local	O	O
dialysis	O	O
program	O	O
because	O	O
of	O	O
esrd	O	O
in	O	O
the	O	O
study	O	O
area	O	O
between	O	O
june	O	O
1	O	O
,	O	O
1995	O	O
and	O	O
november	O	O
30	O	O
,	O	O
1997	O	O
.	O	O

they	O	O
were	O	O
classified	O	O
according	O	O
to	O	O
the	O	O
underlying	O	O
disease	O	O
,	O	O
which	O	O
had	O	O
presumably	O	O
led	O	O
them	O	O
to	O	O
esrd	O	O
.	O	O

controls	O	O
were	O	O
patients	O	O
admitted	O	O
to	O	O
the	O	O
same	O	O
hospitals	O	O
from	O	O
where	O	O
the	O	O
cases	O	O
arose	O	O
,	O	O
also	O	O
matched	O	O
by	O	O
age	O	O
and	O	O
sex	O	O
.	O	O

odds	O	O
ratios	O	O
were	O	O
calculated	O	O
using	O	O
a	O	O
conditional	O	O
logistic	O	O
model	O	O
,	O	O
including	O	O
potential	O	O
confounding	O	O
factors	O	O
,	O	O
both	O	O
for	O	O
the	O	O
whole	O	O
study	O	O
population	O	O
and	O	O
for	O	O
the	O	O
various	O	O
underlying	O	O
diseases	O	O
.	O	O

results	O	O
:	O	O

five	O	O
hundred	O	O
and	O	O
eighty	O	O
-	O	O
three	O	O
cases	O	O
and	O	O
1190	O	O
controls	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
any	O	O
analgesic	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
overall	O	O
odds	O	O
ratio	O	O
of	O	O
1	O	O
.	O	O
22	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
,	O	O
0	O	O
.	O	O
89	O	O
-	O	O
1	O	O
.	O	O
66	O	O
)	O	O
.	O	O

for	O	O
specific	O	O
groups	O	O
of	O	O
drugs	O	O
,	O	O
the	O	O
risks	O	O
were	O	O
1	O	O
.	O	O
56	O	O
(	O	O
1	O	O
.	O	O
05	O	O
-	O	O
2	O	O
.	O	O
30	O	O
)	O	O
for	O	O
aspirin	B-chem	B-chem
,	O	O
1	O	O
.	O	O
03	O	O
(	O	O
0	O	O
.	O	O
60	O	O
-	O	O
1	O	O
.	O	O
76	O	O
)	O	O
for	O	O
pyrazolones	B-chem	B-chem
,	O	O
0	O	O
.	O	O
80	O	O
(	O	O
0	O	O
.	O	O
39	O	O
-	O	O
1	O	O
.	O	O
63	O	O
)	O	O
for	O	O
paracetamol	B-chem	B-chem
,	O	O
and	O	O
0	O	O
.	O	O
94	O	O
(	O	O
0	O	O
.	O	O
57	O	O
-	O	O
1	O	O
.	O	O
56	O	O
)	O	O
for	O	O
nonaspirin	O	O
nsaids	O	O
.	O	O

the	O	O
risk	O	O
of	O	O
esrd	O	O
associated	O	O
with	O	O
aspirin	B-chem	B-chem
was	O	O
related	O	O
to	O	O
the	O	O
cumulated	O	O
dose	O	O
and	O	O
duration	O	O
of	O	O
use	O	O
,	O	O
and	O	O
it	O	O
was	O	O
particularly	O	O
high	O	O
among	O	O
the	O	O
subset	O	O
of	O	O
patients	O	O
with	O	O
vascular	O	O
nephropathy	O	O
as	O	O
underlying	O	O
disease	O	O
[	O	O
2	O	O
.	O	O
35	O	O
(	O	O
1	O	O
.	O	O
17	O	O
-	O	O
4	O	O
.	O	O
72	O	O
)	O	O
]	O	O
.	O	O

conclusion	O	O
:	O	O

our	O	O
data	O	O
indicate	O	O
that	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
nonaspirin	O	O
analgesic	O	O
drugs	O	O
and	O	O
nsaids	O	O
is	O	O
not	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
esrd	O	O
.	O	O

however	O	O
,	O	O
the	O	O
chronic	O	O
use	O	O
of	O	O
aspirin	B-chem	B-chem
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
esrd	O	O
.	O	O

two	O	O
cases	O	O
of	O	O
amisulpride	B-chem	B-chem
overdose	O	O
:	O	O
a	O	O
cause	O	O
for	O	O
prolonged	O	O
qt	O	O
syndrome	O	O
.	O	O

two	O	O
cases	O	O
of	O	O
deliberate	O	O
self	O	O
-	O	O
poisoning	O	O
with	O	O
5	O	O
g	O	O
and	O	O
3	O	O
.	O	O
6	O	O
g	O	O
of	O	O
amisulpride	B-chem	B-chem
,	O	O
respectively	O	O
,	O	O
are	O	O
reported	O	O
.	O	O

in	O	O
both	O	O
cases	O	O
,	O	O
qt	O	O
prolongation	O	O
and	O	O
hypocalcaemia	O	O
were	O	O
noted	O	O
.	O	O

the	O	O
qt	O	O
prolongation	O	O
appeared	O	O
to	O	O
respond	O	O
to	O	O
administration	O	O
of	O	O
i	O	O
.	O	O
v	O	O
.	O	O

calcium	B-chem	B-chem
gluconate	I-chem	I-chem
.	O	O

growth	O	O
-	O	O
associated	O	O
protein	O	O
43	O	O
expression	O	O
in	O	O
hippocampal	O	O
molecular	O	O
layer	O	O
of	O	O
chronic	O	O
epileptic	O	O
rats	O	O
treated	O	O
with	O	O
cycloheximide	B-chem	B-chem
.	O	O

purpose	O	O
:	O	O

gap43	O	O
has	O	O
been	O	O
thought	O	O
to	O	O
be	O	O
linked	O	O
with	O	O
mossy	O	O
fiber	O	O
sprouting	O	O
(	O	O
mfs	O	O
)	O	O
in	O	O
various	O	O
experimental	O	O
models	O	O
of	O	O
epilepsy	O	O
.	O	O

to	O	O
investigate	O	O
how	O	O
gap43	O	O
expression	O	O
(	O	O
gap43	O	O
-	O	O
ir	O	O
)	O	O
correlates	O	O
with	O	O
mfs	O	O
,	O	O
we	O	O
assessed	O	O
the	O	O
intensity	O	O
(	O	O
densitometry	O	O
)	O	O
and	O	O
extension	O	O
(	O	O
width	O	O
)	O	O
of	O	O
gap43	O	O
-	O	O
ir	O	O
in	O	O
the	O	O
inner	O	O
molecular	O	O
layer	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
(	O	O
iml	O	O
)	O	O
of	O	O
rats	O	O
subject	O	O
to	O	O
status	O	O
epilepticus	O	O
induced	O	O
by	O	O
pilocarpine	B-chem	B-chem
(	O	O
pilo	B-chem	B-chem
)	O	O
,	O	O
previously	O	O
injected	O	O
or	O	O
not	O	O
with	O	O
cycloheximide	B-chem	B-chem
(	O	O
chx	B-chem	O
)	O	O
,	O	O
which	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
inhibit	O	O
mfs	O	O
.	O	O

methods	O	O
:	O	O

chx	B-chem	O
was	O	O
injected	O	O
before	O	O
the	O	O
pilo	B-chem	B-chem
injection	O	O
in	O	O
adult	O	O
wistar	O	O
rats	O	O
.	O	O

the	O	O
pilo	B-chem	B-chem
group	O	O
was	O	O
injected	O	O
with	O	O
the	O	O
same	O	O
drugs	O	O
,	O	O
except	O	O
for	O	O
chx	B-chem	O
.	O	O

animals	O	O
were	O	O
killed	O	O
between	O	O
30	O	O
and	O	O
60	O	O
days	O	O
later	O	O
,	O	O
and	O	O
brain	O	O
sections	O	O
were	O	O
processed	O	O
for	O	O
gap43	O	O
immunohistochemistry	O	O
.	O	O

results	O	O
:	O	O

densitometry	O	B-chem
showed	O	O
no	O	O
significant	O	O
difference	O	O
regarding	O	O
gap43	O	O
-	O	O
ir	O	O
in	O	O
the	O	O
iml	O	O
between	O	O
pilo	B-chem	B-chem
,	O	O
chx	B-chem	O
+	O	O
pilo	B-chem	B-chem
,	O	O
and	O	O
control	O	O
groups	O	O
.	O	O

however	O	O
,	O	O
the	O	O
results	O	O
of	O	O
the	O	O
width	O	O
of	O	O
the	O	O
gap43	O	O
-	O	O
ir	O	O
band	O	O
in	O	O
the	O	O
iml	O	O
showed	O	O
that	O	O
chx	B-chem	O
+	O	O
pilo	B-chem	B-chem
and	O	O
control	O	O
animals	O	O
had	O	O
a	O	O
significantly	O	O
larger	O	O
band	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
03	O	O
)	O	O
as	O	O
compared	O	O
with	O	O
that	O	O
in	O	O
the	O	O
pilo	B-chem	B-chem
group	O	O
.	O	O

conclusions	O	O
:	O	O

our	O	O
current	O	O
finding	O	O
that	O	O
animals	O	O
in	O	O
the	O	O
chx	B-chem	O
+	O	O
pilo	B-chem	B-chem
group	O	O
have	O	O
a	O	O
gap43	O	O
-	O	O
ir	O	O
band	O	O
in	O	O
the	O	O
iml	O	O
,	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
controls	O	O
,	O	O
reinforces	O	O
prior	O	O
data	O	O
on	O	O
the	O	O
blockade	O	O
of	O	O
mfs	O	O
in	O	O
these	O	O
animals	O	O
.	O	O

the	O	O
change	O	O
in	O	O
gap43	O	O
-	O	O
ir	O	O
present	O	O
in	O	O
pilo	B-chem	B-chem
-	O	O
treated	O	O
animals	O	O
was	O	O
a	O	O
thinning	O	O
of	O	O
the	O	O
band	O	O
to	O	O
a	O	O
very	O	O
narrow	O	O
layer	O	O
just	O	O
above	O	O
the	O	O
granule	O	O
cell	O	O
layer	O	O
that	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
loss	O	O
of	O	O
hilar	O	O
cell	O	O
projections	O	O
that	O	O
express	O	O
gap	O	O
-	O	O
43	O	O
.	O	O

nicotine	B-chem	B-chem
antagonizes	O	O
caffeine	B-chem	B-chem
-	O	O
but	O	O
not	O	O
pentylenetetrazole	B-chem	B-chem
-	O	O
induced	O	O
anxiogenic	O	O
effect	O	O
in	O	O
mice	O	O
.	O	O

rationale	O	O
:	O	O
nicotine	B-chem	B-chem
and	O	O
caffeine	B-chem	B-chem
are	O	O
widely	O	O
consumed	O	O
licit	O	O
psychoactive	O	O
drugs	O	O
worldwide	O	O
.	O	O

epidemiological	O	O
studies	O	O
showed	O	O
that	O	O
they	O	O
were	O	O
generally	O	O
used	O	O
concurrently	O	O
.	O	O

although	O	O
some	O	O
studies	O	O
in	O	O
experimental	O	O
animals	O	O
indicate	O	O
clear	O	O
pharmacological	O	O
interactions	O	O
between	O	O
them	O	O
,	O	O
no	O	O
studies	O	O
have	O	O
shown	O	O
a	O	O
specific	O	O
interaction	O	O
on	O	O
anxiety	O	O
responses	O	O
.	O	O

objectives	O	O
:	O	O

the	O	O
present	O	O
study	O	O
investigates	O	O
the	O	O
effects	O	O
of	O	O
nicotine	B-chem	B-chem
on	O	O
anxiety	O	O
induced	O	O
by	O	O
caffeine	B-chem	B-chem
and	O	O
another	O	O
anxiogenic	O	O
drug	O	O
,	O	O
pentylenetetrazole	B-chem	B-chem
,	O	O
in	O	O
mice	O	O
.	O	O

the	O	O
elevated	O	O
plus	O	O
-	O	O
maze	O	O
(	O	O
epm	O	O
)	O	O
test	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
drugs	O	O
on	O	O
anxiety	O	O
.	O	O

methods	O	O
:	O	O

adult	O	O
male	O	O
swiss	O	O
webster	O	O
mice	O	O
(	O	O
25	O	O
-	O	O
32	O	O
g	O	O
)	O	O
were	O	O
given	O	O
nicotine	B-chem	B-chem
(	O	O
0	O	O
.	O	O
05	O	O
-	O	O
0	O	O
.	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O
c	O	O
.	O	O
)	O	O
or	O	O
saline	O	O
10	O	O
min	O	O
before	O	O
caffeine	B-chem	B-chem
(	O	O
70	O	O
mg	O	O
/	O	O
kg	O	O

i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
or	O	O
pentylenetetrazole	B-chem	B-chem
(	O	O
15	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O

i	O	O
.	O	O
p	O	O
.	O	O
)	O	O

injections	O	O
.	O	O

after	O	O
15	O	O
min	O	O
,	O	O
mice	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
open	O	O
-	O	O
and	O	O
closed	O	O
-	O	O
arm	O	O
time	O	O
and	O	O
entries	O	O
on	O	O
the	O	O
epm	O	O
for	O	O
a	O	O
10	O	O
-	O	O
min	O	O
session	O	O
.	O	O

locomotor	O	O
activity	O	O
was	O	O
recorded	O	O
for	O	O
individual	O	O
groups	O	O
by	O	O
using	O	O
the	O	O
same	O	O
treatment	O	O
protocol	O	O
with	O	O
the	O	O
epm	O	O
test	O	O
.	O	O

results	O	O
:	O	O
nicotine	B-chem	B-chem
(	O	O
0	O	O
.	O	O
05	O	O
-	O	O
0	O	O
.	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
itself	O	O

did	O	O
not	O	O
produce	O	O
any	O	O
significant	O	O
effect	O	O
in	O	O
the	O	O
epm	O	O
test	O	O
,	O	O
whereas	O	O
caffeine	B-chem	B-chem
(	O	O
70	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
pentylenetetrazole	B-chem	B-chem
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
produced	O	O
an	O	O
anxiogenic	O	O
effect	O	O
,	O	O
apparent	O	O
with	O	O
decreases	O	O
in	O	O
open	O	O
-	O	O
arm	O	O
time	O	O
and	O	O
entry	O	O
.	O	O

nicotine	B-chem	B-chem
(	O	O
0	O	O
.	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
pretreatment	O	O
blocked	O	O
the	O	O
caffeine	B-chem	B-chem
-	O	O
but	O	O
not	O	O
pentylenetetrazole	B-chem	B-chem
-	O	O
induced	O	O
anxiety	O	O
.	O	O

administration	O	O
of	O	O
each	O	O
drug	O	O
and	O	O
their	O	O
combinations	O	O
did	O	O
not	O	O
produce	O	O
any	O	O
effect	O	O
on	O	O
locomotor	O	O
activity	O	O
.	O	O

conclusions	O	O
:	O	O

our	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
antagonistic	O	O
effect	O	O
of	O	O
nicotine	B-chem	B-chem
on	O	O
caffeine	B-chem	B-chem
-	O	O
induced	O	O
anxiety	O	O
is	O	O
specific	O	O
to	O	O
caffeine	B-chem	B-chem
,	O	O
instead	O	O
of	O	O
a	O	O
non	O	O
-	O	O
specific	O	O
anxiolytic	O	O
effect	O	O
.	O	O

thus	O	O
,	O	O
it	O	O
may	O	O
extend	O	O
the	O	O
current	O	O
findings	O	O
on	O	O
the	O	O
interaction	O	O
between	O	O
nicotine	B-chem	B-chem
and	O	O
caffeine	B-chem	B-chem
.	O	O

long	O	O
term	O	O
hormone	O	O
therapy	O	O
for	O	O
perimenopausal	O	O
and	O	O
postmenopausal	O	O
women	O	O
.	O	O

background	O	O
:	O	O

hormone	O	O
therapy	O	O
(	O	O
ht	O	O
)	O	O
is	O	O
widely	O	O
used	O	O
for	O	O
controlling	O	O
menopausal	O	O
symptoms	O	O
.	O	O

it	O	O
has	O	O
also	O	O
been	O	O
used	O	O
for	O	O
the	O	O
management	O	O
and	O	O
prevention	O	O
of	O	O
cardiovascular	O	O
disease	O	O
,	O	O
osteoporosis	O	O
and	O	O
dementia	O	O
in	O	O
older	O	O
women	O	O
but	O	O
the	O	O
evidence	O	O
supporting	O	O
its	O	O
use	O	O
for	O	O
these	O	O
indications	O	O
is	O	O
largely	O	O
observational	O	O
.	O	O

objectives	O	O
:	O	O

to	O	O
assess	O	O
the	O	O
effect	O	O
of	O	O
long	O	O
-	O	O
term	O	O
ht	O	O
on	O	O
mortality	O	O
,	O	O
heart	O	O
disease	O	O
,	O	O
venous	O	O
thromboembolism	O	O
,	O	O
stroke	O	O
,	O	O
transient	O	O
ischaemic	O	O
attacks	O	O
,	O	O
breast	O	O
cancer	O	O
,	O	O
colorectal	O	O
cancer	O	O
,	O	O
ovarian	O	O
cancer	O	O
,	O	O
endometrial	O	O
cancer	O	O
,	O	O
gallbladder	O	O
disease	O	O
,	O	O
cognitive	O	O
function	O	O
,	O	O
dementia	O	O
,	O	O
fractures	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

search	O	O
strategy	O	O
:	O	O

we	O	O
searched	O	O
the	O	O
following	O	O
databases	O	O
up	O	O
to	O	O
november	O	O
2004	O	O
:	O	O
the	O	O
cochrane	O	O
menstrual	O	O
disorders	O	O
and	O	O
subfertility	O	O
group	O	O
trials	O	O
register	O	O
,	O	O
cochrane	O	O
central	O	O
register	O	O
of	O	O
controlled	O	O
trials	O	O
(	O	O
central	O	O
)	O	O
,	O	O
medline	O	O
,	O	O
embase	O	O
,	O	O
biological	O	O
abstracts	O	O
.	O	O

relevant	O	O
non	O	O
-	O	O
indexed	O	O
journals	O	O
and	O	O
conference	O	O
abstracts	O	O
were	O	O
also	O	O
searched	O	O
.	O	O

selection	O	O
criteria	O	O
:	O	O

randomised	O	O
double	O	O
-	O	O
blind	O	O
trials	O	O
of	O	O
ht	O	O
(	O	O
oestrogens	B-chem	O
with	O	O
or	O	O
without	O	O
progestogens	B-chem	O
)	O	O
versus	O	O
placebo	O	O
,	O	O
taken	O	O
for	O	O
at	O	O
least	O	O
one	O	O
year	O	O
by	O	O
perimenopausal	O	O
or	O	O
postmenopausal	O	O
women	O	O
.	O	O

data	O	O
collection	O	O
and	O	O
analysis	O	O
:	O	O

fifteen	O	O
rcts	O	O
were	O	O
included	O	O
.	O	O

trials	O	O
were	O	O
assessed	O	O
for	O	O
quality	O	O
and	O	O
two	O	O
review	O	O
authors	O	O
extracted	O	O
data	O	O
independently	O	O
.	O	O

they	O	O
calculated	O	O
risk	O	O
ratios	O	O
for	O	O
dichotomous	O	O
outcomes	O	O
and	O	O
weighted	O	O
mean	O	O
differences	O	O
for	O	O
continuous	O	O
outcomes	O	O
.	O	O

clinical	O	O
heterogeneity	O	O
precluded	O	O
meta	O	O
-	O	O
analysis	O	O
for	O	O
most	O	O
outcomes	O	O
.	O	O

main	O	O
results	O	O
:	O	O

all	O	O
the	O	O
statistically	O	O
significant	O	O
results	O	O
were	O	O
derived	O	O
from	O	O
the	O	O
two	O	O
biggest	O	O
trials	O	O
.	O	O

in	O	O
relatively	O	O
healthy	O	O
women	O	O
,	O	O
combined	O	O
continuous	O	O
ht	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
venous	O	O
thromboembolism	O	O
or	O	O
coronary	O	O
event	O	O
(	O	O
after	O	O
one	O	O
year	O	O
'	O	O
s	O	O
use	O	O
)	O	O
,	O	O
stroke	O	O
(	O	O
after	O	O
3	O	O
years	O	O
)	O	O
,	O	O
breast	O	O
cancer	O	O
(	O	O
after	O	O
5	O	O
years	O	O
)	O	O
and	O	O
gallbladder	O	O
disease	O	O
.	O	O

long	O	O
-	O	O
term	O	O
oestrogen	B-chem	B-chem
-	O	O
only	O	O
ht	O	O
also	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
stroke	O	O
and	O	O
gallbladder	O	O
disease	O	O
.	O	O

overall	O	O
,	O	O
the	O	O
only	O	O
statistically	O	O
significant	O	O
benefits	O	O
of	O	O
ht	O	O
were	O	O
a	O	O
decreased	O	O
incidence	O	O
of	O	O
fractures	O	O
and	O	O
colon	O	O
cancer	O	O
with	O	O
long	O	O
-	O	O
term	O	O
use	O	O
.	O	O

among	O	O
relatively	O	O
healthy	O	O
women	O	O
over	O	O
65	O	O
years	O	O
taking	O	O
continuous	O	O
combined	O	O
ht	O	O
,	O	O
there	O	O
was	O	O
a	O	O
statistically	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
dementia	O	O
.	O	O

among	O	O
women	O	O
with	O	O
cardiovascular	O	O
disease	O	O
,	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
combined	O	O
continuous	O	O
ht	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
venous	O	O
thromboembolism	O	O
.	O	O

no	O	O
trials	O	O
focussed	O	O
specifically	O	O
on	O	O
younger	O	O
women	O	O
.	O	O

however	O	O
,	O	O
one	O	O
trial	O	O
analysed	O	O
subgroups	O	O
of	O	O
2839	O	O
relatively	O	O
healthy	O	O
50	O	O
to	O	O
59	O	O
year	O	O
-	O	O
old	O	O
women	O	O
taking	O	O
combined	O	O
continuous	O	O
ht	O	O
and	O	O
1637	O	O
taking	O	O
oestrogen	B-chem	B-chem
-	O	O
only	O	O
ht	O	O
,	O	O
versus	O	O
similar	O	O
-	O	O
sized	O	O
placebo	O	O
groups	O	O
.	O	O

the	O	O
only	O	O
significantly	O	O
increased	O	O
risk	O	O
reported	O	O
was	O	O
for	O	O
venous	O	O
thromboembolism	O	O
in	O	O
women	O	O
taking	O	O
combined	O	O
continuous	O	O
ht	O	O
;	O	O
their	O	O
absolute	O	O
risk	O	O
remained	O	O
very	O	O
low	O	O
.	O	O

authors	O	O
'	O	O
conclusions	O	O
:	O	O

ht	O	O
is	O	O
not	O	O
indicated	O	O
for	O	O
the	O	O
routine	O	O
management	O	O
of	O	O
chronic	O	O
disease	O	O
.	O	O

we	O	O
need	O	O
more	O	O
evidence	O	O
on	O	O
the	O	O
safety	O	O
of	O	O
ht	O	O
for	O	O
menopausal	O	O
symptom	O	O
control	O	O
,	O	O
though	O	O
short	O	O
-	O	O
term	O	O
use	O	O
appears	O	O
to	O	O
be	O	O
relatively	O	O
safe	O	O
for	O	O
healthy	O	O
younger	O	O
women	O	O
.	O	O

drug	O	O
-	O	O
induced	O	O
liver	O	O
injury	O	O
:	O	O
an	O	O
analysis	O	O
of	O	O
461	O	O
incidences	O	O
submitted	O	O
to	O	O
the	O	O
spanish	O	O
registry	O	O
over	O	O
a	O	O
10	O	O
-	O	O
year	O	O
period	O	O
.	O	O

background	O	O
&	O	O
aims	O	O
:	O	O

progress	O	O
in	O	O
the	O	O
understanding	O	O
of	O	O
susceptibility	O	O
factors	O	O
to	O	O
drug	O	O
-	O	O
induced	O	O
liver	O	O
injury	O	O
(	O	O
dili	O	B-chem
)	O	O
and	O	O
outcome	O	O
predictability	O	O
are	O	O
hampered	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
systematic	O	O
programs	O	O
to	O	O
detect	O	O
bona	O	O
fide	O	O
cases	O	O
.	O	O

methods	O	O
:	O	O

a	O	O
cooperative	O	O
network	O	O
was	O	O
created	O	O
in	O	O
1994	O	O
in	O	O
spain	O	O
to	O	O
identify	O	O
all	O	O
suspicions	O	O
of	O	O
dili	O	B-chem
following	O	O
a	O	O
prospective	O	O
structured	O	O
report	O	O
form	O	O
.	O	O

the	O	O
liver	O	O
damage	O	O
was	O	O
characterized	O	O
according	O	O
to	O	O
hepatocellular	O	O
,	O	O
cholestatic	O	O
,	O	O
and	O	O
mixed	O	O
laboratory	O	O
criteria	O	O
and	O	O
to	O	O
histologic	O	O
criteria	O	O
when	O	O
available	O	O
.	O	O

further	O	O
evaluation	O	O
of	O	O
causality	O	O
assessment	O	O
was	O	O
centrally	O	O
performed	O	O
.	O	O

results	O	O
:	O	O

since	O	O
april	O	O
1994	O	O
to	O	O
august	O	O
2004	O	O
,	O	O
461	O	O
out	O	O
of	O	O
570	O	O
submitted	O	O
cases	O	O
,	O	O
involving	O	O
505	O	O
drugs	O	O
,	O	O
were	O	O
deemed	O	O
to	O	O
be	O	O
related	O	O
to	O	O
dili	O	B-chem
.	O	O

the	O	O
antiinfective	O	O
group	O	O
of	O	O
drugs	O	O
was	O	O
the	O	O
more	O	O
frequently	O	O
incriminated	O	O
,	O	O
amoxicillin	B-chem	B-chem
-	I-chem	O
clavulanate	I-chem	I-chem
accounting	O	O
for	O	O
the	O	O
12	O	O
.	O	O
8	O	O
%	O	O
of	O	O
the	O	O
whole	O	O
series	O	O
.	O	O

the	O	O
hepatocellular	O	O
pattern	O	O
of	O	O
damage	O	O
was	O	O
the	O	O
most	O	O
common	O	O
(	O	O
58	O	O
%	O	O
)	O	O
,	O	O
was	O	O
inversely	O	O
correlated	O	O
with	O	O
age	O	O
(	O	O
p	O	O
<	O	O
.	O	O
0001	O	O
)	O	O
,	O	O
and	O	O
had	O	O
the	O	O
worst	O	O
outcome	O	O
(	O	O
cox	O	O
regression	O	O
,	O	O
p	O	O
<	O	O
.	O	O
034	O	O
)	O	O
.	O	O

indeed	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
liver	O	O
transplantation	O	O
and	O	O
death	O	O
in	O	O
this	O	O
group	O	O
was	O	O
11	O	O
.	O	O
7	O	O
%	O	O
if	O	O
patients	O	O
had	O	O
jaundice	O	O
at	O	O
presentation	O	O
,	O	O
whereas	O	O
the	O	O
corresponding	O	O
figure	O	O
was	O	O
3	O	O
.	O	O
8	O	O
%	O	O
in	O	O
nonjaundiced	O	O
patients	O	O
(	O	O
p	O	O
<	O	O
.	O	O
04	O	O
)	O	O
.	O	O

factors	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
fulminant	O	O
hepatic	O	O
failure	O	O
were	O	O
female	O	O
sex	O	O
(	O	O
or	O	O
=	O	O
25	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
:	O	O
4	O	O
.	O	O
1	O	O
-	O	O
151	O	O
;	O	O
p	O	O
<	O	O
.	O	O
0001	O	O
)	O	O
,	O	O
hepatocellular	O	O
damage	O	O
(	O	O
or	O	O
=	O	O
7	O	O
.	O	O
9	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
:	O	O
1	O	O
.	O	O
6	O	O
-	O	O
37	O	O
;	O	O
p	O	O
<	O	O
.	O	O
009	O	O
)	O	O
,	O	O
and	O	O
higher	O	O
baseline	O	O
plasma	O	O
bilirubin	B-chem	B-chem
value	O	O
(	O	O
or	O	O
=	O	O
1	O	O
.	O	O
15	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
:	O	O
1	O	O
.	O	O
09	O	O
-	O	O
1	O	O
.	O	O
22	O	O
;	O	O
p	O	O
<	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

patients	O	O
with	O	O
drug	O	O
-	O	O
induced	O	O
hepatocellular	O	O
jaundice	O	O
have	O	O
11	O	O
.	O	O
7	O	O
%	O	O
chance	O	O
of	O	O
progressing	O	O
to	O	O
death	O	O
or	O	O
transplantation	O	O
.	O	O

amoxicillin	B-chem	B-chem
-	I-chem	I-chem
clavulanate	I-chem	I-chem
stands	O	O
out	O	O
as	O	O
the	O	O
most	O	O
common	O	O
drug	O	O
related	O	O
to	O	O
dili	O	B-chem
.	O	O

morphological	O	O
evaluation	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
d	B-chem	B-chem
-	I-chem	I-chem
ribose	I-chem	I-chem
on	O	O
adriamycin	B-chem	B-chem
-	O	O
evoked	O	O
cardiotoxicity	O	O
in	O	O
rats	O	O
.	O	O

the	O	O
influence	O	O
of	O	O
d	B-chem	B-chem
-	I-chem	I-chem
ribose	I-chem	I-chem
on	O	O
adriamycin	B-chem	B-chem
-	O	O
induced	O	O
myocardiopathy	O	O
in	O	O
rats	O	O
was	O	O
studied	O	O
.	O	O

adriamycin	B-chem	B-chem
in	O	O
the	O	O
cumulative	O	O
dose	O	O
of	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
evoked	O	O
fully	O	O
developed	O	O
cardiac	O	O
toxicity	O	O
.	O	O

d	B-chem	B-chem
-	I-chem	I-chem
ribose	I-chem	O
in	O	O
the	O	O
multiple	O	O
doses	O	O
of	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
did	O	O
not	O	O
influence	O	O
adr	B-chem	O
cardiotoxicity	O	O
.	O	O

in	O	O
vivo	O	O
evidences	O	O
suggesting	O	O
the	O	O
role	O	O
of	O	O
oxidative	O	O
stress	O	O
in	O	O
pathogenesis	O	O
of	O	O
vancomycin	B-chem	B-chem
-	O	O
induced	O	O
nephrotoxicity	O	O
:	O	O
protection	O	O
by	O	O
erdosteine	B-chem	B-chem
.	O	O

the	O	O
aims	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
examine	O	O
vancomycin	B-chem	B-chem
(	O	O
vcm	B-chem	O
)	O	O
-	O	O
induced	O	O
oxidative	O	O
stress	O	O
that	O	O
promotes	O	O
production	O	O
of	O	O
reactive	O	O
oxygen	B-chem	B-chem
species	O	O
(	O	O
ros	O	O
)	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
erdosteine	B-chem	B-chem
,	O	O
an	O	O
expectorant	O	O
agent	O	O
,	O	O
which	O	O
has	O	O
also	O	O
antioxidant	O	O
properties	O	O
,	O	O
on	O	O
kidney	O	O
tissue	O	O
against	O	O
the	O	O
possible	O	O
vcm	B-chem	O
-	O	O
induced	O	O
renal	O	O
impairment	O	O
in	O	O
rats	O	O
.	O	O

rats	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
:	O	O
sham	O	O
,	O	O
vcm	B-chem	O
and	O	O
vcm	B-chem	O
plus	O	O
erdosteine	B-chem	B-chem
.	O	O

vcm	B-chem	O
was	O	O
administrated	O	O
intraperitoneally	O	O
(	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
with	O	O
200mgkg	O	B-chem
(	O	O
-	O	O
1	O	O
)	O	O
twice	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
.	O	O

erdosteine	B-chem	B-chem
was	O	O
administered	O	O
orally	O	O
.	O	O

vcm	B-chem	O
administration	O	O
to	O	O
control	O	O
rats	O	O
significantly	O	O
increased	O	O
renal	O	O
malondialdehyde	B-chem	B-chem
(	O	O
mda	B-chem	B-chem
)	O	O
and	O	O
urinary	O	O
n	O	B-chem
-	O	O
acetyl	O	I-chem
-	O	O
beta	O	I-chem
-	O	O
d	O	I-chem
-	O	O
glucosaminidase	O	I-chem
(	O	O
nag	O	O
,	O	O
a	O	O
marker	O	O
of	O	O
renal	O	O
tubular	O	O
injury	O	O
)	O	O
excretion	O	O
but	O	O
decreased	O	O
superoxide	B-chem	B-chem
dismutase	O	O
(	O	O
sod	O	B-chem
)	O	O
and	O	O
catalase	O	O
(	O	O
cat	O	O
)	O	O
activities	O	O
.	O	O

erdosteine	B-chem	B-chem
administration	O	O
with	O	O
vcm	B-chem	O
injections	O	O
caused	O	O
significantly	O	O
decreased	O	O
renal	O	O
mda	B-chem	B-chem
and	O	O
urinary	O	O
nag	O	O
excretion	O	O
,	O	O
and	O	O
increased	O	O
sod	O	B-chem
activity	O	O
,	O	O
but	O	O
not	O	O
cat	O	O
activity	O	O
in	O	O
renal	O	O
tissue	O	O
when	O	O
compared	O	O
with	O	O
vcm	B-chem	O
alone	O	O
.	O	O

erdosteine	B-chem	B-chem
showed	O	O
histopathological	O	O
protection	O	O
against	O	O
vcm	B-chem	O
-	O	O
induced	O	O
nephrotoxicity	O	O
.	O	O

there	O	O
were	O	O
a	O	O
significant	O	O
dilatation	O	O
of	O	O
tubular	O	O
lumens	O	O
,	O	O
extensive	O	O
epithelial	O	O
cell	O	O
vacuolization	O	O
,	O	O
atrophy	O	O
,	O	O
desquamation	O	O
,	O	O
and	O	O
necrosis	O	O
in	O	O
vcm	B-chem	O
-	O	O
treated	O	O
rats	O	O
more	O	O
than	O	O
those	O	O
of	O	O
the	O	O
control	O	O
and	O	O
the	O	O
erdosteine	B-chem	O
groups	O	O
.	O	O

erdosteine	B-chem	B-chem
caused	O	O
a	O	O
marked	O	O
reduction	O	O
in	O	O
the	O	O
extent	O	O
of	O	O
tubular	O	O
damage	O	O
.	O	O

it	O	O
is	O	O
concluded	O	O
that	O	O
oxidative	O	O
tubular	O	O
damage	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
vcm	B-chem	O
-	O	O
induced	O	O
nephrotoxicity	O	O
and	O	O
the	O	O
modulation	O	O
of	O	O
oxidative	O	O
stress	O	O
with	O	O
erdosteine	B-chem	B-chem
reduces	O	O
the	O	O
vcm	B-chem	O
-	O	O
induced	O	O
kidney	O	O
damage	O	O
both	O	O
at	O	O
the	O	O
biochemical	O	O
and	O	O
histological	O	O
levels	O	O
.	O	O

does	O	O
domperidone	B-chem	B-chem
potentiate	O	O
mirtazapine	B-chem	B-chem
-	O	O
associated	O	O
restless	O	O
legs	O	O
syndrome	O	O
?	O	O

there	O	O
is	O	O
now	O	O
evidence	O	O
to	O	O
suggest	O	O
a	O	O
central	O	O
role	O	O
for	O	O
the	O	O
dopaminergic	O	O
system	O	O
in	O	O
restless	O	O
legs	O	O
syndrome	O	O
(	O	O
rls	O	O
)	O	O
.	O	O

for	O	O
example	O	O
,	O	O
the	O	O
symptoms	O	O
of	O	O
rls	O	B-chem
can	O	O
be	O	O
dramatically	O	O
improved	O	O
by	O	O
levodopa	B-chem	B-chem
and	O	O
dopamine	B-chem	B-chem
agonists	O	O
,	O	O
whereas	O	O
central	O	O
dopamine	B-chem	B-chem
d2	O	O
receptor	O	O
antagonists	O	O
can	O	O
induce	O	O
or	O	O
aggravate	O	O
rls	O	O
symptoms	O	O
.	O	O

to	O	O
our	O	O
knowledge	O	O
,	O	O
there	O	O
is	O	O
no	O	O
previous	O	O
report	O	O
regarding	O	O
whether	O	O
domperidone	B-chem	B-chem
,	O	O
a	O	O
peripheral	O	O
dopamine	B-chem	B-chem
d2	O	O
receptor	O	O
antagonist	O	O
,	O	O
can	O	O
also	O	O
induce	O	O
or	O	O
aggravate	O	O
symptoms	O	O
of	O	O
rls	O	O
.	O	O

mirtazapine	B-chem	B-chem
,	O	O
the	O	O
first	O	O
noradrenergic	O	O
and	O	O
specific	O	O
serotonergic	O	O
antidepressant	O	B-chem
(	O	O
nassa	O	B-chem
)	O	O
,	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
rls	O	B-chem
in	O	O
several	O	O
recent	O	O
publications	O	O
.	O	O

the	O	O
authors	O	O
report	O	O
here	O	O
a	O	O
depressed	O	O
patient	O	O
comorbid	O	O
with	O	O
postprandial	O	O
dyspepsia	O	O
who	O	O
developed	O	O
rls	O	O
after	O	O
mirtazapine	B-chem	B-chem
had	O	O
been	O	O
added	O	O
to	O	O
his	O	O
domperidone	B-chem	B-chem
therapy	O	O
.	O	O

our	O	O
patient	O	O
started	O	O
to	O	O
have	O	O
symptoms	O	O
of	O	O
rls	O	B-chem
only	O	O
after	O	O
he	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
mirtazapine	B-chem	B-chem
,	O	O
and	O	O
his	O	O
rls	O	O
symptoms	O	O
resolved	O	O
completely	O	O
upon	O	O
discontinuation	O	O
of	O	O
his	O	O
mirtazapine	B-chem	B-chem
.	O	O

such	O	O
a	O	O
temporal	O	O
relationship	O	O
between	O	O
the	O	O
use	O	O
of	O	O
mirtazapine	B-chem	B-chem
and	O	O
the	O	O
symptoms	O	O
of	O	O
rls	O	B-chem
in	O	O
our	O	O
patient	O	O
did	O	O
not	O	O
support	O	O
a	O	O
potentiating	O	O
effect	O	O
of	O	O
domperione	B-chem	B-chem
on	O	O
mirtazapine	B-chem	B-chem
-	O	O
associated	O	O
rls	O	O
.	O	O

however	O	O
,	O	O
physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
possibility	O	O
that	O	O
mirtazapine	B-chem	B-chem
can	O	O
be	O	O
associated	O	O
with	O	O
rls	O	B-chem
in	O	O
some	O	O
individuals	O	O
,	O	O
especially	O	O
those	O	O
receiving	O	O
concomitant	O	O
dopamine	B-chem	B-chem
d2	O	O
receptor	O	O
antagonists	O	O
.	O	O

antiandrogenic	O	B-chem
therapy	O	O
can	O	O
cause	O	O
coronary	O	O
arterial	O	O
disease	O	O
.	O	O

aim	O	O
:	O	O

to	O	O
study	O	O
the	O	O
change	O	O
of	O	O
lipid	O	O
metabolism	O	O
by	O	O
antiandrogen	O	B-chem
therapy	O	O
in	O	O
patients	O	O
with	O	O
prostate	O	O
cancer	O	O
.	O	O

materials	O	O
and	O	O
methods	O	O
:	O	O

we	O	O
studied	O	O
with	O	O
a	O	O
2	O	O
.	O	O
5	O	O
years	O	O
follow	O	O
-	O	O
up	O	O
the	O	O
changes	O	O
in	O	O
plasma	O	O
cholesterols	B-chem	O
(	O	O
c	B-chem	O
)	O	O
,	O	O
triglycerides	B-chem	O
(	O	O
tg	B-chem	O
)	O	O
,	O	O
lipoproteins	O	O
(	O	O
lp	O	O
)	O	O
,	O	O
and	O	O
apolipoproteins	O	O
(	O	O
apo	O	O
)	O	O

b	O	B-chem
-	O	O
100	O	O
,	O	O
a	O	O
-	O	O
i	O	O
,	O	O
and	O	O
a	O	O
-	O	O
ii	O	O
pro	O	O
fi	O	B-chem
les	O	O
in	O	O
24	O	O
patients	O	O
of	O	O
mean	O	O
age	O	O

60	O	O
years	O	O
with	O	O
low	O	O
risk	O	O
prostate	O	O
cancer	O	O
(	O	O
stage	O	O
:	O	O
t1cn0m0	O	O
,	O	O
gleason	O	O

score	O	O
:	O	O
2	O	B-chem
-	O	I-chem
5	O	I-chem
)	O	O
during	O	O
treatment	O	O
with	O	O
cyproterone	B-chem	B-chem
acetate	I-chem	I-chem
(	O	O
cpa	B-chem	B-chem
)	O	O
without	O	O
surgical	O	O
management	O	O
or	O	O
radiation	O	O
therapy	O	O
.	O	O

results	O	O
:	O	O

significant	O	O
decreases	O	O
of	O	O
hdl	O	O
-	O	O
c	O	O
,	O	O
apo	O	B-chem
a	O	O

-	O	O
i	O	O
and	O	O
apo	O	O
a	O	O
-	O	O
ii	O	O
and	O	O
an	O	O
increase	O	O
of	O	O
triglyceride	B-chem	B-chem
levels	O	O
in	O	O
vldl	O	O
were	O	O
induced	O	O
by	O	O
cpa	B-chem	B-chem
.	O	O

after	O	O
a	O	O
period	O	O
of	O	O
2	O	O
.	O	O
5	O	O
years	O	O
on	O	O
cpa	B-chem	B-chem
treatment	O	O
,	O	O
four	O	O
patients	O	O
out	O	O
of	O	O
twenty	O	O
-	O	O
four	O	O
were	O	O
found	O	O
to	O	O
be	O	O
affected	O	O
by	O	O
coronary	O	O
heart	O	O
disease	O	O
.	O	O

conclusions	O	O
:	O	O

ischaemic	O	O
coronary	O	O
arteriosclerosis	O	O
with	O	O
an	O	O
incidence	O	O
rate	O	O
of	O	O
16	O	O
.	O	O
6	O	O
%	O	O
as	O	O
caused	O	O
by	O	O
prolonged	O	O
cpa	B-chem	B-chem
therapy	O	O
is	O	O
mediated	O	O
through	O	O
changes	O	O
in	O	O
hdl	O	O
cholesterol	B-chem	O
,	O	O
apo	O	O
a	O	O
-	O	O
i	O	O
and	O	O
apo	O	O
a	O	O
-	O	O
ii	O	O
pro	O	O
fi	O	B-chem
les	O	O
,	O	O
other	O	O
than	O	O
the	O	O
well	O	O
-	O	O
known	O	O
hyperglyceridemic	O	O
effect	O	O
caused	O	O
by	O	O
estrogen	B-chem	B-chem
.	O	O

5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
cardiotoxicity	O	O
induced	O	O
by	O	O
alpha	B-chem	B-chem
-	I-chem	I-chem
fluoro	I-chem	I-chem
-	I-chem	I-chem
beta	I-chem	I-chem
-	I-chem	I-chem
alanine	I-chem	I-chem
.	O	O

cardiotoxicity	O	O
is	O	O
a	O	O
rare	O	O
complication	O	O
occurring	O	O
during	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
(	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
)	O	O
treatment	O	O
for	O	O
malignancies	O	O
.	O	O

we	O	O
herein	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
70	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
,	O	O
in	O	O
whom	O	O
a	O	O
high	O	O
serum	O	O
level	O	O
of	O	O
alpha	B-chem	B-chem
-	I-chem	I-chem
fluoro	I-chem	I-chem
-	I-chem	I-chem
beta	I-chem	I-chem
-	I-chem	I-chem
alanine	I-chem	I-chem
(	O	O
fbal	B-chem	O
)	O	O
was	O	O
observed	O	O
.	O	O

the	O	O
patient	O	O
,	O	O
who	O	O
had	O	O
unresectable	O	O
colon	O	O
cancer	O	O
metastases	O	O
to	O	O
the	O	O
liver	O	O
and	O	O
lung	O	O
,	O	O
was	O	O
referred	O	O
to	O	O
us	O	O
for	O	O
chemotherapy	O	O
from	O	O
an	O	O
affiliated	O	O
hospital	O	O
;	O	O
he	O	O
had	O	O
no	O	O
cardiac	O	O
history	O	O
.	O	O

after	O	O
admission	O	O
,	O	O
the	O	O
patient	O	O
received	O	O
a	O	O
continuous	O	O
intravenous	O	O
infusion	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
(	O	O
1000	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
,	O	O
during	O	O
which	O	O
precordial	O	O
pain	O	O
with	O	O
right	O	O
bundle	O	O
branch	O	O
block	O	O
occurred	O	O
concomitantly	O	O
with	O	O
a	O	O
high	O	O
serum	O	O
fbal	B-chem	O
concentration	O	O
of	O	O
1955	O	O
ng	O	O
/	O	O
ml	O	O
.	O	O

both	O	O
the	O	O
precordial	O	O
pain	O	O
and	O	O
the	O	O
electrocardiographic	O	O
changes	O	O
disappeared	O	O
spontaneously	O	O
after	O	O
the	O	O
discontinuation	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
.	O	O

as	O	O
the	O	O
precordial	O	O
pain	O	O
in	O	O
this	O	O
patient	O	O
was	O	O
considered	O	O
to	O	O
have	O	O
been	O	O
due	O	O
to	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
,	O	O
the	O	O
administration	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
was	O	O
abandoned	O	O
.	O	O

instead	O	O
,	O	O
oral	O	O
administration	O	O
of	O	O
s	O	B-chem
-	O	I-chem
1	O	I-chem
(	O	O
a	O	O
derivative	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
)	O	O
,	O	O
at	O	O
200	O	O
mg	O	O
/	O	O
day	O	O
twice	O	O
a	O	O
week	O	O
,	O	O
was	O	O
instituted	O	O
,	O	O
because	O	O
s	O	O
-	O	O
1	O	O
has	O	O
a	O	O
strong	O	O
inhibitory	O	O
effect	O	O
on	O	O
dihydropyrimidine	B-chem	B-chem
dehydrogenase	O	O
,	O	O
which	O	O
catalyzes	O	O
the	O	O
degradative	O	O
of	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
into	O	O
fbal	B-chem	O
.	O	O

the	O	O
serum	O	O
fbal	B-chem	O
concentration	O	O
subsequently	O	O
decreased	O	O
to	O	O
352	O	O
ng	O	O
/	O	O
ml	O	O
,	O	O
the	O	O
same	O	O
as	O	O
the	O	O
value	O	O
measured	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
s	O	O
-	O	O
1	O	O
administration	O	O
.	O	O

thereafter	O	O
,	O	O
no	O	O
cardiac	O	O
symptoms	O	O
were	O	O
observed	O	O
.	O	O

the	O	O
patient	O	O
achieved	O	O
a	O	O
partial	O	O
response	O	O
6	O	O
months	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
the	O	O
s	O	O
-	O	O
1	O	O
treatment	O	O
.	O	O

the	O	O
experience	O	O
of	O	O
this	O	O
case	O	O
,	O	O
together	O	O
with	O	O
a	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
,	O	O
suggests	O	O
that	O	O
fbal	B-chem	O
is	O	O
related	O	O
to	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
.	O	O

s	O	O
-	O	O
1	O	O
may	O	O
be	O	O
administered	O	O
safely	O	O
to	O	O
patients	O	O
with	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
.	O	O

the	O	O
influence	O	O
of	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoher	B-chem	O
and	O	O
doxorubicin	B-chem	B-chem
administration	O	O
on	O	O
the	O	O
protection	O	O
against	O	O
doxorubicin	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
in	O	O
mice	O	O
.	O	O

purpose	O	O
:	O	O

despite	O	O
its	O	O
well	O	O
-	O	O
known	O	O
cardiotoxicity	O	O
,	O	O
the	O	O
anthracyclin	O	O
doxorubicin	B-chem	B-chem
(	O	O
dox	B-chem	B-chem
)	O	O
continues	O	O
to	O	O
be	O	O
an	O	O
effective	O	O
and	O	O
widely	O	O
used	O	O
chemotherapeutic	O	O
agent	O	O
.	O	O

dox	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
damage	O	O
presumably	O	O
results	O	O
from	O	O
the	O	O
formation	O	O
of	O	O
free	O	O
radicals	O	O
by	O	O
dox	B-chem	B-chem
.	O	O

reactive	O	O
oxygen	B-chem	B-chem
species	O	O
particularly	O	O
affect	O	O
the	O	O
cardiac	O	O
myocytes	O	O
because	O	O
these	O	O
cells	O	O
seem	O	O
to	O	O
have	O	O
a	O	O
relatively	O	O
poor	O	O
antioxidant	O	O
defense	O	O
system	O	O
.	O	O

the	O	O
semisynthetic	O	O
flavonoid	B-chem	B-chem
monohydroxyethylrutoside	B-chem	O
(	O	O
monoher	B-chem	O
)	O	O
showed	O	O
cardioprotection	O	O
against	O	O
dox	B-chem	B-chem
-	O	O
induced	O	O
cardiotoxicity	O	O
through	O	O
its	O	O
radical	O	O
scavenging	O	O
and	O	O
iron	B-chem	B-chem
chelating	O	O
properties	O	O
.	O	O

because	O	O
of	O	O
the	O	O
relatively	O	O
short	O	O
final	O	O
half	O	O
-	O	O
life	O	O
of	O	O
monoher	B-chem	O
(	O	O
about	O	O
30	O	O
min	O	O
)	O	O
,	O	O
it	O	O
is	O	O
expected	O	O
that	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoher	B-chem	O
and	O	O
dox	B-chem	B-chem
might	O	O
be	O	O
of	O	O
influence	O	O
on	O	O
the	O	O
cardioprotective	O	O
effect	O	O
of	O	O
monoher	B-chem	O
.	O	O

therefore	O	O
,	O	O
the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
this	O	O
possible	O	O
effect	O	O
.	O	O

methods	O	O
:	O	O

six	O	O
groups	O	O
of	O	O
6	O	O
balb	O	O
/	O	O
c	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
saline	O	O
,	O	O
dox	B-chem	B-chem
alone	O	O
or	O	O
dox	B-chem	B-chem
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
v	O	O
.	O	O
)	O	O
preceded	O	O
by	O	O
monoher	B-chem	O
(	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
with	O	O
an	O	O
interval	O	O
of	O	O
10	O	O
,	O	O
30	O	O
,	O	O
60	O	O
or	O	O
120	O	O
min	O	O
.	O	O

after	O	O
a	O	O
6	O	O
-	O	O
week	O	O
treatment	O	O
period	O	O
and	O	O
additional	O	O
observation	O	O
for	O	O
2	O	O
weeks	O	O
,	O	O
the	O	O
mice	O	O
were	O	O
sacrificed	O	O
.	O	O

their	O	O
cardiac	O	O
tissues	O	O
were	O	O
processed	O	O
for	O	O
light	O	O
microscopy	O	O
,	O	O
after	O	O
which	O	O
cardiomyocyte	O	O
damage	O	O
was	O	O
evaluated	O	O
according	O	O
to	O	O
billingham	O	O
(	O	O
in	O	O
cancer	O	O
treat	O	O
rep	O	O

62	O	O
(	O	O
6	O	O
)	O	O
:	O	O
865	O	O
-	O	O
872	O	O
,	O	O
1978	O	O
)	O	O
.	O	O

microscopic	O	O
evaluation	O	O
revealed	O	O
that	O	O
treatment	O	O
with	O	O
dox	B-chem	B-chem
alone	O	O
induced	O	O
significant	O	O
cardiac	O	O
damage	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
saline	O	O
control	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

results	O	O
:	O	O

the	O	O
number	O	O
of	O	O
damaged	O	O
cardiomyocytes	O	O
was	O	O
9	O	O
.	O	O
6	O	O
-	O	O
fold	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
4	O	O
.	O	O
4	O	O
-	O	O
21	O	O
.	O	O
0	O	O
)	O	O
higher	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
dox	B-chem	B-chem
alone	O	O
than	O	O
that	O	O
in	O	O
animals	O	O
of	O	O
the	O	O
control	O	O
group	O	O
.	O	O

the	O	O
ratio	O	O
of	O	O
aberrant	O	O
cardiomyocytes	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
dox	B-chem	B-chem
preceded	O	O
by	O	O
monoher	B-chem	B-chem
and	O	O
those	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
saline	O	O
ranged	O	O
from	O	O
1	O	O
.	O	O
6	O	O
to	O	O
2	O	O
.	O	O
8	O	O
(	O	O
mean	O	O
2	O	O
.	O	O
2	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
1	O	O
.	O	O
2	O	O
-	O	O
4	O	O
.	O	O
1	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
019	O	O
)	O	O
.	O	O

the	O	O
mean	O	O
protective	O	O
effect	O	O
by	O	O
adding	O	O
monoher	B-chem	B-chem
before	O	O
dox	B-chem	B-chem
led	O	O
to	O	O
a	O	O
significant	O	O
4	O	O
.	O	O
4	O	O
-	O	O
fold	O	O
reduction	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
2	O	O
.	O	O
3	O	O
-	O	O
8	O	O
.	O	O
2	O	O
)	O	O
of	O	O
abnormal	O	O
cardiomyocytes	O	O
.	O	O

this	O	O
protective	O	O
effect	O	O
did	O	O
not	O	O
depend	O	O
on	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoher	B-chem	O
and	O	O
dox	B-chem	B-chem
administration	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
345	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

the	O	O
results	O	O
indicate	O	O
that	O	O
in	O	O
an	O	O
outpatient	O	O
clinical	O	O
setting	O	O
monoher	B-chem	O
may	O	O
be	O	O
administered	O	O
shortly	O	O
before	O	O
dox	B-chem	B-chem
.	O	O

clinical	O	O
evaluation	O	O
of	O	O
adverse	O	O
effects	O	O
during	O	O
bepridil	B-chem	B-chem
administration	O	O
for	O	O
atrial	O	O
fibrillation	O	O
and	O	O
flutter	O	O
.	O	O

background	O	O
:	O	O

bepridil	B-chem	B-chem
hydrochloride	I-chem	I-chem
(	O	O
bpd	B-chem	B-chem
)	O	O
has	O	O
attracted	O	O
attention	O	O
as	O	O
an	O	O
effective	O	O
drug	O	O
for	O	O
atrial	O	O
fibrillation	O	O
(	O	O
af	O	O
)	O	O
and	O	O
atrial	O	O
flutter	O	O
(	O	O
afl	O	O
)	O	O
.	O	O

however	O	O
,	O	O
serious	O	O
adverse	O	O
effects	O	O
,	O	O
including	O	O
torsade	O	O
de	O	O
pointes	O	O
(	O	O
tdp	O	O
)	O	O
,	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

methods	O	O
and	O	O
results	O	O
:	O	O

adverse	O	O
effects	O	O
of	O	O
bpd	B-chem	B-chem
requiring	O	O
discontinuation	O	O
of	O	O
treatment	O	O
were	O	O
evaluated	O	O
.	O	O

bpd	B-chem	B-chem
was	O	O
administered	O	O
to	O	O
459	O	O
patients	O	O
(	O	O
361	O	O
males	O	O
,	O	O
63	O	O
+	O	O
/	O	O
-	O	O
12	O	O
years	O	O
old	O	O
)	O	O
comprising	O	O
378	O	O
af	O	O
and	O	O
81	O	O
afl	O	O
cases	O	O
.	O	O

mean	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
and	O	O
atrial	O	O
dimension	O	O
(	O	O
lad	O	O
)	O	O
were	O	O
66	O	O
+	O	O
/	O	O
-	O	O
11	O	O
%	O	O
and	O	O
40	O	O
+	O	O
/	O	O
-	O	O
6	O	O
mm	O	O
,	O	O
respectively	O	O
.	O	O

adverse	O	O
effects	O	O
were	O	O
observed	O	O
in	O	O
19	O	O
patients	O	O
(	O	O
4	O	O
%	O	O
)	O	O
during	O	O
an	O	O
average	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
20	O	O
months	O	O
.	O	O

there	O	O
was	O	O
marked	O	O
qt	O	O
prolongation	O	O
greater	O	O
than	O	O
0	O	O
.	O	O
55	O	O
s	O	O
in	O	O
13	O	O
patients	O	O
,	O	O
bradycardia	O	O
less	O	O
than	O	O
40	O	O
beats	O	O
/	O	O
min	O	O
in	O	O
6	O	O
patients	O	O
,	O	O
dizziness	O	O
and	O	O
general	O	O
fatigue	O	O
in	O	O
1	O	O
patient	O	O
each	O	O
.	O	O

in	O	O
4	O	O
of	O	O
13	O	O
patients	O	O
with	O	O
qt	O	O
prolongation	O	O
,	O	O
tdp	O	O
occurred	O	O
.	O	O

the	O	O
major	O	O
triggering	O	O
factors	O	O
of	O	O
tdp	O	O
were	O	O
hypokalemia	O	O
and	O	O
sudden	O	O
decrease	O	O
in	O	O
heart	O	O
rate	O	O
.	O	O

there	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
the	O	O
clinical	O	O
backgrounds	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
and	O	O
without	O	O
tdp	O	O
other	O	O
than	O	O
lad	O	O
and	O	O
age	O	O
,	O	O
which	O	O
were	O	O
larger	O	O
and	O	O
older	O	O
in	O	O
the	O	O
patients	O	O
with	O	O
tdp	O	O
.	O	O

conclusion	O	O
:	O	O

careful	O	O
observation	O	O
of	O	O
serum	O	O
potassium	B-chem	B-chem
concentration	O	O
and	O	O
the	O	O
ecg	O	O
should	O	O
always	O	O
be	O	O
done	O	O
during	O	O
bpd	B-chem	B-chem
administration	O	O
,	O	O
particularly	O	O
in	O	O
elderly	O	O
patients	O	O
.	O	O

enhanced	O	O
isoproterenol	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
hypertrophy	O	O
in	O	O
transgenic	O	O
rats	O	O
with	O	O
low	O	O
brain	O	O
angiotensinogen	O	O
.	O	O

we	O	O
have	O	O
previously	O	O
shown	O	O
that	O	O
a	O	O
permanent	O	O
deficiency	O	O
in	O	O
the	O	O
brain	O	O
renin	O	O
-	O	O
angiotensin	B-chem	B-chem
system	O	O
(	O	O
ras	O	O
)	O	O
may	O	O
increase	O	O
the	O	O
sensitivity	O	O
of	O	O
the	O	O
baroreflex	O	O
control	O	O
of	O	O
heart	O	O
rate	O	O
.	O	O

in	O	O
this	O	O
study	O	O
we	O	O
aimed	O	O
at	O	O
studying	O	O
the	O	O
involvement	O	O
of	O	O
the	O	O
brain	O	O
ras	O	O
in	O	O
the	O	O
cardiac	O	O
reactivity	O	O
to	O	O
the	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
(	O	O
beta	O	O
-	O	O
ar	O	O
)	O	O
agonist	O	O
isoproterenol	B-chem	B-chem
(	O	O
iso	B-chem	B-chem
)	O	O
.	O	O

transgenic	O	O
rats	O	O
with	O	O
low	O	O
brain	O	O
angiotensinogen	O	O
(	O	O
tgr	O	B-chem
)	O	O
were	O	O
used	O	O
.	O	O

in	O	O
isolated	O	O
hearts	O	O
,	O	O
iso	B-chem	B-chem
induced	O	O
a	O	O
significantly	O	O
greater	O	O
increase	O	O
in	O	O
left	O	O
ventricular	O	O
(	O	O
lv	O	O
)	O	O
pressure	O	O
and	O	O
maximal	O	O
contraction	O	O
(	O	O
+	O	O
dp	O	O
/	O	O
dt	O	O
(	O	O
max	O	O
)	O	O
)	O	O
in	O	O
the	O	O
tgr	O	O
than	O	O
in	O	O
the	O	O
sprague	O	O
-	O	O
dawley	O	O
(	O	O
sd	O	O
)	O	O
rats	O	O
.	O	O

lv	O	O
hypertrophy	O	O
induced	O	O
by	O	O
iso	B-chem	B-chem
treatment	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
tgr	O	B-chem
than	O	O
in	O	O
sd	O	O
rats	O	O
(	O	O
in	O	O
g	O	O
lv	O	O
wt	O	O
/	O	O
100	O	O
g	O	O
body	O	O
wt	O	O
,	O	O
0	O	O
.	O	O
28	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
004	O	O
vs	O	O
.	O	O
0	O	O
.	O	O
24	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
004	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

the	O	O
greater	O	O
lv	O	O
hypertrophy	O	O
in	O	O
tgr	O	O
rats	O	O
was	O	O
associated	O	O
with	O	O
more	O	O
pronounced	O	O
downregulation	O	O
of	O	O
beta	O	O
-	O	O
ar	O	O
and	O	O
upregulation	O	O
of	O	O
lv	O	O
beta	O	B-chem
-	O	O
ar	O	O
kinase	O	O
-	O	O
1	O	O
mrna	O	O
levels	O	O
compared	O	O
with	O	O
those	O	O
in	O	O
sd	O	O
rats	O	O
.	O	O

the	O	O
decrease	O	O
in	O	O
the	O	O
heart	O	O
rate	O	O
(	O	O
hr	O	O
)	O	O
induced	O	O
by	O	O
the	O	O
beta	O	O
-	O	O
ar	O	O
antagonist	O	O
metoprolol	B-chem	B-chem
in	O	O
conscious	O	O
rats	O	O
was	O	O
significantly	O	O
attenuated	O	O
in	O	O
tgr	O	O
compared	O	O
with	O	O
sd	O	O
rats	O	O
(	O	O
-	O	O
9	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
7	O	O
%	O	O
vs	O	O
.	O	O
-	O	O
18	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
effect	O	O
of	O	O
parasympathetic	O	O
blockade	O	O
by	O	O
atropine	B-chem	B-chem
on	O	O
hr	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
strains	O	O
.	O	O

these	O	O
results	O	O
indicate	O	O
that	O	O
tgr	O	B-chem
are	O	O
more	O	O
sensitive	O	O
to	O	O
beta	O	O
-	O	O
ar	O	O
agonist	O	O
-	O	O
induced	O	O
cardiac	O	O
inotropic	O	O
response	O	O
and	O	O
hypertrophy	O	O
,	O	O
possibly	O	O
due	O	O
to	O	O
chronically	O	O
low	O	O
sympathetic	O	O
outflow	O	O
directed	O	O
to	O	O
the	O	O
heart	O	O
.	O	O

drug	O	O
-	O	O
induced	O	O
long	O	O
qt	O	O
syndrome	O	O
in	O	O
injection	O	O
drug	O	O
users	O	O
receiving	O	O
methadone	B-chem	B-chem
:	O	O
high	O	O
frequency	O	O
in	O	O
hospitalized	O	O
patients	O	O
and	O	O
risk	O	O
factors	O	O
.	O	O

background	O	O
:	O	O

drug	O	O
-	O	O
induced	O	O
long	O	O
qt	O	O
syndrome	O	O
is	O	O
a	O	O
serious	O	O
adverse	O	O
drug	O	O
reaction	O	O
.	O	O

methadone	B-chem	B-chem
prolongs	O	O
the	O	O
qt	O	O
interval	O	O
in	O	O
vitro	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

in	O	O
the	O	O
inpatient	O	O
setting	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
qt	O	O
interval	O	O
prolongation	O	O
with	O	O
methadone	B-chem	B-chem
treatment	O	O
,	O	O
its	O	O
dose	O	O
dependence	O	O
,	O	O
and	O	O
the	O	O
importance	O	O
of	O	O
cofactors	O	O
such	O	O
as	O	O
drug	O	O
-	O	O
drug	O	O
interactions	O	O
remain	O	O
unknown	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
performed	O	O
a	O	O
systematic	O	O
,	O	O
retrospective	O	O
study	O	O
comparing	O	O
active	O	O
or	O	O
former	O	O
intravenous	O	O
drug	O	O
users	O	O
receiving	O	O
methadone	B-chem	B-chem
and	O	O
those	O	O
not	O	O
receiving	O	O
methadone	B-chem	B-chem
among	O	O
all	O	O
patients	O	O
hospitalized	O	O
over	O	O
a	O	O
5	O	O
-	O	O
year	O	O
period	O	O
in	O	O
a	O	O
tertiary	O	O
care	O	O
hospital	O	O
.	O	O

a	O	O
total	O	O
of	O	O
167	O	O
patients	O	O
receiving	O	O
methadone	B-chem	B-chem
fulfilled	O	O
the	O	O
inclusion	O	O
criteria	O	O
and	O	O
were	O	O
compared	O	O
with	O	O
a	O	O
control	O	O
group	O	O
of	O	O
80	O	O
injection	O	O
drug	O	O
users	O	O
not	O	O
receiving	O	O
methadone	B-chem	B-chem
.	O	O

in	O	O
addition	O	O
to	O	O
methadone	B-chem	B-chem
dose	O	O
,	O	O
15	O	O
demographic	O	O
,	O	O
biological	O	O
,	O	O
and	O	O
pharmacological	O	O
variables	O	O
were	O	O
considered	O	O
as	O	O
potential	O	O
risk	O	O
factors	O	O
for	O	O
qt	O	O
prolongation	O	O
.	O	O

results	O	O
:	O	O

among	O	O
167	O	O
methadone	B-chem	B-chem
maintenance	O	O
patients	O	O
,	O	O
the	O	O
prevalence	O	O
of	O	O
qtc	O	O
prolongation	O	O
to	O	O
0	O	O
.	O	O
50	O	O
second	O	O
(	O	O
(	O	O
1	O	O
/	O	O
2	O	O
)	O	O
)	O	O
or	O	O
longer	O	O
was	O	O
16	O	O
.	O	O
2	O	O
%	O	O
compared	O	O
with	O	O
0	O	O
%	O	O
in	O	O
80	O	O
control	O	O
subjects	O	O
.	O	O

six	O	O
patients	O	O
(	O	O
3	O	O
.	O	O
6	O	O
%	O	O
)	O	O
in	O	O
the	O	O
methadone	B-chem	B-chem
group	O	O
presented	O	O
torsades	O	O
de	O	O
pointes	O	O
.	O	O

qtc	O	O
length	O	O
was	O	O
weakly	O	O
but	O	O
significantly	O	O
associated	O	O
with	O	O
methadone	B-chem	B-chem
daily	O	O
dose	O	O
(	O	O
spearman	O	O
rank	O	O
correlation	O	O
coefficient	O	O
,	O	O
0	O	O
.	O	O
20	O	O
;	O	O
p	O	O
<	O	O
.	O	O
01	O	O
)	O	O
.	O	O

multivariate	O	O
regression	O	O
analysis	O	O
allowed	O	O
attribution	O	O
of	O	O
31	O	O
.	O	O
8	O	O
%	O	O
of	O	O
qtc	O	O
variability	O	O
to	O	O
methadone	B-chem	B-chem
dose	O	O
,	O	O
cytochrome	O	O
p	O	O
-	O	O
450	O	O
3a4	O	O
drug	O	O
-	O	O
drug	O	O
interactions	O	O
,	O	O
hypokalemia	O	O
,	O	O
and	O	O
altered	O	O
liver	O	O
function	O	O
.	O	O

conclusions	O	O
:	O	O

qt	O	O
interval	O	O
prolongation	O	O
in	O	O
methadone	B-chem	B-chem
maintenance	O	O
patients	O	O
hospitalized	O	O
in	O	O
a	O	O
tertiary	O	O
care	O	O
center	O	O
is	O	O
a	O	O
frequent	O	O
finding	O	O
.	O	O

methadone	B-chem	B-chem
dose	O	O
,	O	O
presence	O	O
of	O	O
cytochrome	O	O
p	O	O
-	O	O
450	O	O
3a4	O	O
inhibitors	O	O
,	O	O
potassium	B-chem	B-chem
level	O	O
,	O	O
and	O	O
liver	O	O
function	O	O
contribute	O	O
to	O	O
qt	O	O
prolongation	O	O
.	O	O

long	O	O
qt	O	O
syndrome	O	O
can	O	O
occur	O	O
with	O	O
low	O	O
doses	O	O
of	O	O
methadone	B-chem	B-chem
.	O	O

mechanisms	O	O
of	O	O
hypertension	O	O
induced	O	O
by	O	O
nitric	B-chem	B-chem
oxide	I-chem	I-chem
(	O	O
no	B-chem	B-chem
)	O	O
deficiency	O	O
:	O	O
focus	O	O
on	O	O
venous	O	O
function	O	O
.	O	O

loss	O	O
of	O	O
endothelial	O	O
cell	O	O
-	O	O
derived	O	O
nitric	B-chem	B-chem
oxide	I-chem	I-chem
(	O	O
no	B-chem	B-chem
)	O	O
in	O	O
hypertension	O	O
is	O	O
a	O	O
hallmark	O	O
of	O	O
arterial	O	O
dysfunction	O	O
.	O	O

experimental	O	O
hypertension	O	O
created	O	O
by	O	O
the	O	O
removal	O	O
of	O	O
no	B-chem	O
,	O	O
however	O	O
,	O	O
involves	O	O
mechanisms	O	O
in	O	O
addition	O	O
to	O	O
decreased	O	O
arterial	O	O
vasodilator	O	O
activity	O	O
.	O	O

these	O	O
include	O	O
augmented	O	O
endothelin	O	O
-	O	O
1	O	O
(	O	O
et	O	O
-	O	O
1	O	O
)	O	O
release	O	O
,	O	O
increased	O	O
sympathetic	O	O
nervous	O	O
system	O	O
activity	O	O
,	O	O
and	O	O
elevated	O	O
tissue	O	O
oxidative	O	O
stress	O	O
.	O	O

we	O	O
hypothesized	O	O
that	O	O
increased	O	O
venous	O	O
smooth	O	O
muscle	O	O
(	O	O
venomotor	O	O
)	O	O
tone	O	O
plays	O	O
a	O	O
role	O	O
in	O	O
nomega	B-chem	B-chem
-	I-chem	O
nitro	I-chem	B-chem
-	I-chem	I-chem
l	I-chem	I-chem
-	I-chem	I-chem
arginine	I-chem	I-chem
(	O	O
lnna	B-chem	B-chem
)	O	O
hypertension	O	O
through	O	O
these	O	O
mechanisms	O	O
.	O	O

rats	O	O
were	O	O
treated	O	O
with	O	O
the	O	O
no	B-chem	B-chem
synthase	O	O
inhibitor	O	O
lnna	B-chem	O
(	O	O
0	O	O
.	O	O
5	O	O
g	O	O
/	O	O
l	O	O
in	O	O
drinking	O	O
water	O	O
)	O	O
for	O	O
2	O	O
weeks	O	O
.	O	O

mean	O	O
arterial	O	O
pressure	O	O
of	O	O
conscious	O	O
rats	O	O
was	O	O
119	O	O
+	O	O
/	O	O
-	O	O

2	O	O
mm	O	O
hg	O	O
in	O	O
control	O	O
and	O	O
194	O	O
+	O	O

/	O	O
-	O	O
5	O	O
mm	O	O
hg	O	O
in	O	O
lnna	B-chem	O
rats	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

carotid	O	O
arteries	O	O
and	O	O
vena	O	O
cava	O	O
were	O	O
removed	O	O
for	O	O
measurement	O	O
of	O	O
isometric	O	O
contraction	O	O
.	O	O

maximal	O	O
contraction	O	O
to	O	O
norepinephrine	B-chem	B-chem
was	O	O
modestly	O	O
reduced	O	O
in	O	O
arteries	O	O
from	O	O
lnna	B-chem	O
compared	O	O
with	O	O
control	O	O
rats	O	O
whereas	O	O
the	O	O
maximum	O	O
contraction	O	O
to	O	O
et	O	O
-	O	O
1	O	O
was	O	O
significantly	O	O
reduced	O	O
(	O	O
54	O	O
%	O	O
control	O	O
)	O	O
.	O	O

maximum	O	O
contraction	O	O
of	O	O
vena	O	O
cava	O	O
to	O	O
norepinephrine	B-chem	B-chem
(	O	O
37	O	O
%	O	O
control	O	O
)	O	O
also	O	O
was	O	O
reduced	O	O
but	O	O
no	O	O
change	O	O
in	O	O
response	O	O
to	O	O
et	O	O
-	O	O
1	O	O
was	O	O
observed	O	O
.	O	O

mean	O	O
circulatory	O	O
filling	O	O
pressure	O	O
,	O	O
an	O	O
in	O	O
vivo	O	O
measure	O	O
of	O	O
venomotor	O	O
tone	O	O
,	O	O
was	O	O
not	O	O
elevated	O	O
in	O	O
lnna	B-chem	O
hypertension	O	O
at	O	O
1	O	O
or	O	O
2	O	O
weeks	O	O
after	O	O
lnna	B-chem	O
.	O	O

the	O	O
superoxide	B-chem	B-chem
scavenger	O	O
tempol	B-chem	B-chem
(	O	O
30	O	O
,	O	O
100	O	O
,	O	O
and	O	O
300	O	O
micromol	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
iv	O	O
)	O	O
did	O	O
not	O	O
change	O	O
arterial	O	O
pressure	O	O
in	O	O
control	O	O
rats	O	O
but	O	O
caused	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
decrease	O	O
in	O	O
lnna	B-chem	O
rats	O	O
(	O	O
-	O	O
18	O	O
+	O	O
/	O	O
-	O	O

8	O	O
,	O	O
-	O	O
26	O	O

+	O	O
/	O	O
-	O	O

15	O	O
,	O	O
and	O	O
-	O	O
54	O	O
+	O	O
/	O	O
-	O	O

11	O	O
mm	O	O
hg	O	O
)	O	O
.	O	O

similarly	O	O
,	O	O
ganglionic	O	O
blockade	O	O
with	O	O
hexamethonium	B-chem	B-chem
caused	O	O
a	O	O
significantly	O	O
greater	O	O
fall	O	O
in	O	O
lnna	B-chem	O
hypertensive	O	O
rats	O	O
(	O	O
76	O	O
+	O	O
/	O	O
-	O	O

9	O	O
mm	O	O
hg	O	O
)	O	O
compared	O	O
with	O	O
control	O	O
rats	O	O
(	O	O
35	O	O
+	O	O
/	O	O
-	O	O

10	O	O
mm	O	O
hg	O	O
)	O	O
.	O	O

carotid	O	O
arteries	O	O
,	O	O
vena	O	O
cava	O	O
,	O	O
and	O	O
sympathetic	O	O
ganglia	O	O
from	O	O
lnna	B-chem	O
rats	O	O
had	O	O
higher	O	O
basal	O	O
levels	O	O
of	O	O
superoxide	B-chem	B-chem
compared	O	O
with	O	O
those	O	O
from	O	O
control	O	O
rats	O	O
.	O	O

these	O	O
data	O	O
suggest	O	O
that	O	O
while	O	O
no	B-chem	O
deficiency	O	O
increases	O	O
oxidative	O	O
stress	O	O
and	O	O
sympathetic	O	O
activity	O	O
in	O	O
both	O	O
arterial	O	O
and	O	O
venous	O	O
vessels	O	O
,	O	O
the	O	O
impact	O	O
on	O	O
veins	O	O
does	O	O
not	O	O
make	O	O
a	O	O
major	O	O
contribution	O	O
to	O	O
this	O	O
form	O	O
of	O	O
hypertension	O	O
.	O	O

association	O	O
of	O	O
drd2	O	O
polymorphisms	O	O
and	O	O
chlorpromazine	B-chem	B-chem
-	O	O
induced	O	O
extrapyramidal	O	O
syndrome	O	O
in	O	O
chinese	O	O
schizophrenic	O	O
patients	O	O
.	O	O

aim	O	O
:	O	O

extrapyramidal	O	O
syndrome	O	O
(	O	O
eps	O	O
)	O	O
is	O	O
most	O	O
commonly	O	O
affected	O	O
by	O	O
typical	O	O
antipsychotic	O	O
drugs	O	O
that	O	O
have	O	O
a	O	O
high	O	O
affinity	O	O
with	O	O
the	O	O
d2	O	O
receptor	O	O
.	O	O

recently	O	O
,	O	O
many	O	O
research	O	O
groups	O	O
have	O	O
reported	O	O
on	O	O
the	O	O
positive	O	O
relationship	O	O
between	O	O
the	O	O
genetic	O	O
variations	O	O
in	O	O
the	O	O
drd2	O	O
gene	O	O
and	O	O
the	O	O
therapeutic	O	O
response	O	O
in	O	O
schizophrenia	O	O
patients	O	O
as	O	O
a	O	O
result	O	O
of	O	O
the	O	O
role	O	O
of	O	O
variations	O	O
in	O	O
the	O	O
receptor	O	O
in	O	O
modulating	O	O
receptor	O	O
expression	O	O
.	O	O

in	O	O
this	O	O
study	O	O
,	O	O
we	O	O
evaluate	O	O
the	O	O
role	O	O
drd2	O	O
plays	O	O
in	O	O
chlorpromazine	B-chem	B-chem
-	O	O
induced	O	O
eps	O	O
in	O	O
schizophrenic	O	O
patients	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
identified	O	O
seven	O	O
snp	O	B-chem
(	O	O
single	O	O
nucleotide	O	O
polymorphism	O	O
)	O	O

(	O	O
-	O	O
141cins	O	O
>	O	O

del	O	B-chem
,	O	O
taqib	O	O
,	O	O
taqid	O	O
,	O	O
ser311cys	O	O
,	O	O
rs6275	O	O
,	O	O
rs6277	O	O
and	O	O
taqia	O	O
)	O	O
in	O	O
the	O	O
drd2	O	O
gene	O	O
in	O	O
146	O	O
schizophrenic	O	O
inpatients	O	O
(	O	O
59	O	O
with	O	O
eps	O	O
and	O	O
87	O	O
without	O	O
eps	O	O
according	O	O
to	O	O
the	O	O
simpson	O	O
-	O	O
angus	O	O
scale	O	O
)	O	O
treated	O	O
with	O	O
chlorpromazine	B-chem	B-chem
after	O	O
8	O	O
weeks	O	O
.	O	O

the	O	O
alleles	O	O
of	O	O
all	O	O
loci	O	O
were	O	O
determined	O	O
by	O	O
pcr	O	O
(	O	O
polymerase	O	O
chain	O	O
reaction	O	O
)	O	O
.	O	O

results	O	O
:	O	O

polymorphisms	O	O
taqid	O	O
,	O	O
ser311cys	O	O
and	O	O
rs6277	O	O
were	O	O
not	O	O
polymorphic	O	O
in	O	O
the	O	O
population	O	O
recruited	O	O
in	O	O
the	O	O
present	O	O
study	O	O
.	O	O

no	O	O
statistical	O	O
significance	O	O
was	O	O
found	O	O
in	O	O
the	O	O
allele	O	O
distribution	O	O
of	O	O
-	O	O
141cins	O	O
>	O	O
del	O	B-chem
,	O	O
taqib	O	O
,	O	O
rs6275	O	B-chem
and	O	O
taqia	O	O
or	O	O
in	O	O
the	O	O
estimated	O	O
haplotypes	O	O
(	O	O
constituted	O	O
by	O	O
taqib	O	O
,	O	O
rs6275	O	O
and	O	O
taqia	O	O
)	O	O
in	O	O
linkage	O	O
disequilibrium	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

conclusion	O	O
:	O	O

our	O	O
results	O	O
did	O	O
not	O	O
lend	O	O
strong	O	O
support	O	O
to	O	O
the	O	O
view	O	O
that	O	O
the	O	O
genetic	O	O
variation	O	O
of	O	O
the	O	O
drd2	O	O
gene	O	O
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
individually	O	O
variable	O	O
adverse	O	O
effect	O	O
induced	O	O
by	O	O
chlorpromazine	B-chem	B-chem
,	O	O
at	O	O
least	O	O
in	O	O
chinese	O	O
patients	O	O
with	O	O
schizophrenia	O	O
.	O	O

our	O	O
results	O	O
confirmed	O	O
a	O	O
previous	O	O
study	O	O
on	O	O
the	O	O
relationship	O	O
between	O	O
drd2	O	O
and	O	O
eps	O	O
in	O	O
caucasians	O	O
.	O	O

physical	O	O
training	O	O
decreases	O	O
susceptibility	O	O
to	O	O
subsequent	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

regular	O	O
motor	O	O
activity	O	O
has	O	O
many	O	O
benefits	O	O
for	O	O
mental	O	O
and	O	O
physical	O	O
condition	O	O
but	O	O
its	O	O
implications	O	O
for	O	O
epilepsy	O	O
are	O	O
still	O	O
controversial	O	O
.	O	O

in	O	O
order	O	O
to	O	O
elucidate	O	O
this	O	O
problem	O	O
,	O	O
we	O	O
have	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
long	O	O
-	O	O
term	O	O
physical	O	O
activity	O	O
on	O	O
susceptibility	O	O
to	O	O
subsequent	O	O
seizures	O	O
.	O	O

male	O	O
wistar	O	O
rats	O	O
were	O	O
subjected	O	O
to	O	O
repeated	O	O
training	O	O
sessions	O	O
in	O	O
a	O	O
treadmill	O	B-chem
and	O	O
swimming	O	O
pool	O	O
.	O	O

thereafter	O	O
,	O	O
seizures	O	O
were	O	O
induced	O	O
by	O	O
pilocarpine	B-chem	B-chem
injections	O	O
in	O	O
trained	O	O
and	O	O
non	O	O
-	O	O
trained	O	O
control	O	O
groups	O	O
.	O	O

during	O	O
the	O	O
acute	O	O
period	O	O
of	O	O
status	O	O
epilepticus	O	O
,	O	O
we	O	O
measured	O	O
:	O	O
(	O	O
1	O	O
)	O	O
the	O	O
latency	O	O
of	O	O
the	O	O
first	O	O
motor	O	O
sign	O	O
,	O	O
(	O	O
2	O	O
)	O	O
the	O	O
intensity	O	O
of	O	O
seizures	O	O
,	O	O
(	O	O
3	O	O
)	O	O
the	O	O
time	O	O
when	O	O
it	O	O
occurred	O	O
within	O	O
the	O	O
6	O	O
-	O	O
h	O	O
observation	O	O
period	O	O
,	O	O
and	O	O
(	O	O
4	O	O
)	O	O
the	O	O
time	O	O
when	O	O
the	O	O
acute	O	O
period	O	O
ended	O	O
.	O	O

all	O	O
these	O	O
behavioral	O	O
parameters	O	O
showed	O	O
statistically	O	O
significant	O	O
changes	O	O
suggesting	O	O
that	O	O
regular	O	O
physical	O	O
exercises	O	O
decrease	O	O
susceptibility	O	O
to	O	O
subsequently	O	O
induced	O	O
seizures	O	O
and	O	O
ameliorate	O	O
the	O	O
course	O	O
of	O	O
experimentally	O	O
induced	O	O
status	O	O
epilepticus	O	O
.	O	O

tonic	O	O
dopaminergic	O	O
stimulation	O	O
impairs	O	O
associative	O	O
learning	O	O
in	O	O
healthy	O	O
subjects	O	O
.	O	O

endogenous	O	O
dopamine	B-chem	B-chem
plays	O	O
a	O	O
central	O	O
role	O	O
in	O	O
salience	O	O
coding	O	O
during	O	O
associative	O	O
learning	O	O
.	O	O

administration	O	O
of	O	O
the	O	O
dopamine	B-chem	B-chem
precursor	O	O
levodopa	B-chem	B-chem
enhances	O	O
learning	O	O
in	O	O
healthy	O	O
subjects	O	O
and	O	O
stroke	O	O
patients	O	O
.	O	O

because	O	O
levodopa	B-chem	B-chem
increases	O	O
both	O	O
phasic	O	O
and	O	O
tonic	O	O
dopaminergic	O	O
neurotransmission	O	O
,	O	O
the	O	O
critical	O	O
mechanism	O	O
mediating	O	O
the	O	O
enhancement	O	O
of	O	O
learning	O	O
is	O	O
unresolved	O	O
.	O	O

we	O	O
here	O	O
probed	O	O
how	O	O
selective	O	O
tonic	O	O
dopaminergic	O	O
stimulation	O	O
affects	O	O
associative	O	O
learning	O	O
.	O	O

forty	O	O
healthy	O	O
subjects	O	O
were	O	O
trained	O	O
in	O	O
a	O	O
novel	O	O
vocabulary	O	O
of	O	O
45	O	O
concrete	O	O
nouns	O	O
over	O	O
the	O	O
course	O	O
of	O	O
5	O	O
consecutive	O	O
training	O	O
days	O	O
in	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
design	O	O
.	O	O

subjects	O	O
received	O	O
the	O	O
tonically	O	O
stimulating	O	O
dopamine	B-chem	B-chem
-	O	O
receptor	O	O
agonist	O	O
pergolide	B-chem	B-chem
(	O	O
0	O	O
.	O	O
1	O	O
mg	O	O
)	O	O
vs	O	O
placebo	O	O
120	O	O
min	O	O
before	O	O
training	O	O
on	O	O
each	O	O
training	O	O
day	O	O
.	O	O

the	O	O
dopamine	B-chem	B-chem
agonist	O	O
significantly	O	O
impaired	O	O
novel	O	O
word	O	O
learning	O	O
compared	O	O
to	O	O
placebo	O	O
.	O	O

this	O	O
learning	O	O
decrement	O	O
persisted	O	O
up	O	O
to	O	O
the	O	O
last	O	O
follow	O	O
-	O	O
up	O	O
4	O	O
weeks	O	O
post	O	O
-	O	O
training	O	O
.	O	O

subjects	O	O
treated	O	O
with	O	O
pergolide	B-chem	B-chem
also	O	O
showed	O	O
restricted	O	O
emotional	O	O
responses	O	O
compared	O	O
to	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

the	O	O
extent	O	O
of	O	O
'	O	O
flattened	O	O
'	O	O
affect	O	O
with	O	O
pergolide	B-chem	B-chem
was	O	O
related	O	O
to	O	O
the	O	O
degree	O	O
of	O	O
learning	O	O
inhibition	O	O
.	O	O

these	O	O
findings	O	O
suggest	O	O
that	O	O
tonic	O	O
occupation	O	O
of	O	O
dopamine	B-chem	B-chem
receptors	O	O
impairs	O	O
learning	O	O
by	O	O
competition	O	O
with	O	O
phasic	O	O
dopamine	B-chem	B-chem
signals	O	O
.	O	O

thus	O	O
,	O	O
phasic	O	O
signaling	O	O
seems	O	O
to	O	O
be	O	O
the	O	O
critical	O	O
mechanism	O	O
by	O	O
which	O	O
dopamine	B-chem	B-chem
enhances	O	O
associative	O	O
learning	O	O
in	O	O
healthy	O	O
subjects	O	O
and	O	O
stroke	O	O
patients	O	O
.	O	O

minocycline	B-chem	B-chem
-	O	O
induced	O	O
vasculitis	O	O
fulfilling	O	O
the	O	O
criteria	O	O
of	O	O
polyarteritis	O	O
nodosa	O	O
.	O	O

a	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
had	O	O
been	O	O
taking	O	O
minocycline	B-chem	B-chem
for	O	O
palmoplantar	O	O
pustulosis	O	O
developed	O	O
fever	O	O
,	O	O
myalgias	O	O
,	O	O
polyneuropathy	O	O
,	O	O
and	O	O
testicular	O	O
pain	O	O
,	O	O
with	O	O
elevated	O	O
c	O	O
-	O	O
reactive	O	O
protein	O	O
(	O	O
crp	O	O
)	O	O
.	O	O

neither	O	O
myeloperoxidase	O	O
-	O	O
nor	O	O
proteinase	O	O
-	O	O
3	O	O
-	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
was	O	O
positive	O	O
.	O	O

these	O	O
manifestations	O	O
met	O	O
the	O	O
american	O	O
college	O	O
of	O	O
rheumatology	O	O
1990	O	O
criteria	O	O
for	O	O
the	O	O
classification	O	O
of	O	O
polyarteritis	O	O
nodosa	O	O
.	O	O

stopping	O	O
minocycline	B-chem	B-chem
led	O	O
to	O	O
amelioration	O	O
of	O	O
symptoms	O	O
and	O	O
normalization	O	O
of	O	O
crp	O	O
level	O	O
.	O	O

to	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
second	O	O
case	O	O
of	O	O
minocycline	B-chem	B-chem
-	O	O
induced	O	O
vasculitis	O	O
satisfying	O	O
the	O	O
criteria	O	O
.	O	O

differential	O	O
diagnosis	O	O
for	O	O
drug	O	O
-	O	O
induced	O	O
disease	O	O
is	O	O
invaluable	O	O
even	O	O
for	O	O
patients	O	O
with	O	O
classical	O	O
polyarteritis	O	O
nodosa	O	O
.	O	O

intramuscular	O	O
hepatitis	O	O
b	O	O
immune	O	O
globulin	O	O
combined	O	O
with	O	O
lamivudine	B-chem	B-chem
in	O	O
prevention	O	O
of	O	O
hepatitis	O	O
b	O	O
recurrence	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

background	O	O
:	O	O
combined	O	O
hepatitis	O	O
b	O	O
immune	O	O
globulin	O	O
(	O	O
hbig	O	B-chem
)	O	O
and	O	O
lamivudine	B-chem	B-chem
in	O	O
prophylaxis	O	O
of	O	O
the	O	O
recurrence	O	O
of	O	O
hepatitis	O	O
b	O	O
after	O	O
liver	O	O
transplantation	O	O
has	O	O
significantly	O	O
improved	O	O
the	O	O
survival	O	O
of	O	O
hbsag	B-chem	O
positive	O	O
patients	O	O
.	O	O

this	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
evaluate	O	O
the	O	O
outcomes	O	O
of	O	O
liver	O	O
transplantation	O	O
for	O	O
patients	O	O
with	O	O
hepatitis	O	O
b	O	O
virus	O	O
(	O	O
hbv	O	O
)	O	O
.	O	O

methods	O	O
:	O	O

a	O	O
retrospective	O	O
chart	O	O
analysis	O	O
and	O	O
a	O	O
review	O	O
of	O	O
the	O	O
organ	O	O
transplant	O	O
database	O	O
identified	O	O
51	O	O
patients	O	O
(	O	O
43	O	O
men	O	O
and	O	O
8	O	O
women	O	O
)	O	O
transplanted	O	O
for	O	O
benign	O	O
hbv	O	O
-	O	O
related	O	O
cirrhotic	O	O
diseases	O	O
between	O	O
june	O	O
2002	O	O
and	O	O
december	O	O
2004	O	O
who	O	O
had	O	O
survived	O	O
more	O	O
than	O	O
3	O	O
months	O	O
.	O	O

hbig	O	B-chem
was	O	O
administered	O	O
intravenously	O	O
during	O	O
the	O	O
first	O	O
week	O	O
and	O	O
intramuscularly	O	O
thereafter	O	O
.	O	O

results	O	O
:	O	O

at	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
14	O	O
.	O	O
1	O	O
months	O	O
,	O	O
the	O	O
overall	O	O
recurrence	O	O
rate	O	O
in	O	O
the	O	O
51	O	O
patients	O	O
was	O	O
3	O	O
.	O	O
9	O	O
%	O	O
(	O	O
2	O	O
/	O	O
51	O	O
)	O	O
.	O	O

the	O	O
overall	O	O
patient	O	O
survival	O	O
was	O	O
88	O	O
.	O	O
3	O	O
%	O	O
,	O	O
and	O	O
82	O	O
.	O	O
4	O	O
%	O	O
after	O	O
1	O	O
and	O	O
2	O	O
years	O	O
,	O	O
respectively	O	O
.	O	O

a	O	O
daily	O	O
oral	O	O
dose	O	O
of	O	O
100	O	O
mg	O	O
lamivudine	B-chem	B-chem
for	O	O
2	O	O
weeks	O	O
before	O	O
transplantation	O	O
for	O	O
10	O	O
patients	O	O
enabled	O	O
57	O	O
.	O	O
1	O	O
%	O	O
(	O	O
4	O	O
/	O	O
7	O	O
)	O	O
and	O	O
62	O	O
.	O	O
5	O	O
%	O	O
(	O	O
5	O	O
/	O	O
8	O	O
)	O	O
of	O	O
hbv	O	O
-	O	O
dna	O	O
and	O	O
hbeag	B-chem	B-chem
positive	O	O
patients	O	O
respectively	O	O
to	O	O
convert	O	O
to	O	O
be	O	O
negative	O	O
.	O	O

intramuscular	O	O
hbig	O	B-chem
was	O	O
well	O	O
tolerated	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

conclusion	O	O
:	O	O

lamivudine	B-chem	B-chem
combined	O	O
with	O	O
intramuscular	O	O
hbig	O	B-chem
can	O	O
effectively	O	O
prevent	O	O
allograft	O	O
from	O	O
the	O	O
recurrence	O	O
of	O	O
hbv	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

anticonvulsant	O	O
effect	O	O
of	O	O
eslicarbazepine	B-chem	B-chem
acetate	I-chem	I-chem
(	O	O
bia	B-chem	B-chem
2	I-chem	I-chem
-	I-chem	I-chem
093	I-chem	I-chem
)	O	O
on	O	O
seizures	O	O
induced	O	O
by	O	O
microperfusion	O	O
of	O	O
picrotoxin	B-chem	B-chem
in	O	O
the	O	O
hippocampus	O	O
of	O	O
freely	O	O
moving	O	O
rats	O	O
.	O	O

eslicarbazepine	B-chem	B-chem
acetate	I-chem	I-chem
(	O	O
bia	B-chem	B-chem
2	I-chem	I-chem
-	I-chem	I-chem
093	I-chem	I-chem
,	O	O
s	B-chem	I-chem
-	I-chem	I-chem
(	I-chem	I-chem
-	I-chem	I-chem
)	I-chem	I-chem
-	I-chem	I-chem
10	I-chem	I-chem
-	I-chem	I-chem
acetoxy	I-chem	I-chem
-	I-chem	O
10	I-chem	I-chem
,	I-chem	O
11	I-chem	O
-	I-chem	I-chem
dihydro	I-chem	I-chem
-	I-chem	I-chem
5h	I-chem	I-chem
-	I-chem	I-chem
dibenzo	I-chem	I-chem
/	I-chem	O
b	I-chem	O
,	I-chem	O
f	I-chem	O
/	I-chem	O
azepine	I-chem	B-chem
-	I-chem	I-chem
5	I-chem	I-chem
-	I-chem	I-chem
carboxamide	I-chem	I-chem
)	O	O
is	O	O
a	O	O
novel	O	O
antiepileptic	O	O
drug	O	O
,	O	O
now	O	O
in	O	O
phase	O	O
iii	O	O
clinical	O	O
trials	O	O
,	O	O
designed	O	O
with	O	O
the	O	O
aim	O	O
of	O	O
improving	O	O
efficacy	O	O
and	O	O
safety	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
structurally	O	O
related	O	O
drugs	O	O
carbamazepine	B-chem	B-chem
(	O	O
cbz	B-chem	B-chem
)	O	O
and	O	O
oxcarbazepine	B-chem	B-chem
(	O	O
oxc	B-chem	B-chem
)	O	O
.	O	O

we	O	O
have	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
oral	O	O
treatment	O	O
with	O	O
eslicarbazepine	B-chem	B-chem
acetate	I-chem	I-chem
on	O	O
a	O	O
whole	O	O
-	O	O
animal	O	O
model	O	O
in	O	O
which	O	O
partial	O	O
seizures	O	O
can	O	O
be	O	O
elicited	O	O
repeatedly	O	O
on	O	O
different	O	O
days	O	O
without	O	O
changes	O	O
in	O	O
threshold	O	O
or	O	O
seizure	O	O
patterns	O	O
.	O	O

in	O	O
the	O	O
animals	O	O
treated	O	O
with	O	O
threshold	O	O
doses	O	O
of	O	O
picrotoxin	B-chem	B-chem
,	O	O
the	O	O
average	O	O
number	O	O
of	O	O
seizures	O	O
was	O	O
2	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O
2	O	O
,	O	O
and	O	O
average	O	O
seizure	O	O
duration	O	O
was	O	O
39	O	O
.	O	O
5	O	O
+	O	O
/	O	O
-	O	O
8	O	O
.	O	O
4s	O	O
.	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
a	O	O
dose	O	O
of	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
2h	O	O
before	O	O
picrotoxin	B-chem	B-chem
microperfusion	O	O
prevented	O	O
seizures	O	O
in	O	O
the	O	O
75	O	O
%	O	O
of	O	O
the	O	O
rats	O	O
.	O	O

lower	O	O
doses	O	O
(	O	O
3	O	O
and	O	O
10mg	O	O
/	O	O
kg	O	O
)	O	O
did	O	O
not	O	O
suppress	O	O
seizures	O	O
,	O	O
however	O	O
,	O	O
after	O	O
administration	O	O
of	O	O
10mg	O	O
/	O	O
kg	O	O
,	O	O
significant	O	O
reductions	O	O
in	O	O
seizures	O	O
duration	O	O
(	O	O
24	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O
8s	O	O
)	O	O
and	O	O
seizure	O	O
number	O	O
(	O	O
1	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
34	O	O
)	O	O
were	O	O
found	O	O
.	O	O

no	O	O
adverse	O	O
effects	O	O
of	O	O
eslicarbazepine	B-chem	B-chem
acetate	I-chem	I-chem
were	O	O
observed	O	O
in	O	O
the	O	O
behavioral	O	O
/	O	O
eeg	O	O
patterns	O	O
studied	O	O
,	O	O
including	O	O
sleep	O	O
/	O	O
wakefulness	O	O
cycle	O	O
,	O	O
at	O	O
the	O	O
doses	O	O
studied	O	O
.	O	O

acute	O	O
renal	O	O
failure	O	O
associated	O	O
with	O	O
prolonged	O	O
intake	O	O
of	O	O
slimming	O	O
pills	O	O
containing	O	O
anthraquinones	B-chem	B-chem
.	O	O

chinese	B-chem	O
herbal	I-chem	O
medicine	O	O
preparations	O	O
are	O	O
widely	O	O
available	O	O
and	O	O
often	O	O
regarded	O	O
by	O	O
the	O	O
public	O	O
as	O	O
natural	O	O
and	O	O
safe	O	O
remedies	O	O
for	O	O
a	O	O
variety	O	O
of	O	O
medical	O	O
conditions	O	O
.	O	O

nephropathy	O	O
caused	O	O
by	O	O
chinese	B-chem	O
herbs	I-chem	O
has	O	O
previously	O	O
been	O	O
reported	O	O
,	O	O
usually	O	O
involving	O	O
the	O	O
use	O	O
of	O	O
aristolochic	B-chem	B-chem
acids	I-chem	I-chem
.	O	O

we	O	O
report	O	O
a	O	O
23	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
developed	O	O
acute	O	O
renal	O	O
failure	O	O
following	O	O
prolonged	O	O
use	O	O
of	O	O
a	O	O
proprietary	O	O
chinese	B-chem	O
herbal	I-chem	O
slimming	O	O
pill	O	O
that	O	O
contained	O	O
anthraquinone	B-chem	B-chem
derivatives	O	I-chem
,	O	O
extracted	O	O
from	O	O
rhizoma	O	B-chem
rhei	O	O
(	O	O
rhubarb	O	B-chem
)	O	O
.	O	O

the	O	O
renal	O	O
injury	O	O
was	O	O
probably	O	O
aggravated	O	O
by	O	O
the	O	O
concomitant	O	O
intake	O	O
of	O	O
a	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
,	O	O
diclofenac	B-chem	B-chem
.	O	O

renal	O	O
pathology	O	O
was	O	O
that	O	O
of	O	O
hypocellular	O	O
interstitial	O	O
fibrosis	O	O
.	O	O

spontaneous	O	O
renal	O	O
recovery	O	O
occurred	O	O
upon	O	O
cessation	O	O
of	O	O
the	O	O
slimming	O	O
pills	O	O
,	O	O
but	O	O
mild	O	O
interstitial	O	O
fibrosis	O	O
and	O	O
tubular	O	O
atrophy	O	O
was	O	O
still	O	O
evident	O	O
histologically	O	O
4	O	O
months	O	O
later	O	O
.	O	O

although	O	O
a	O	O
causal	O	O
relationship	O	O
between	O	O
the	O	O
use	O	O
of	O	O
an	O	O
anthraquinone	B-chem	B-chem
-	O	O
containing	O	O
herbal	O	O
agent	O	O
and	O	O
renal	O	O
injury	O	O
remains	O	O
to	O	O
be	O	O
proven	O	O
,	O	O
phytotherapy	O	O
-	O	O
associated	O	O
interstitial	O	O
nephropathy	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
who	O	O
present	O	O
with	O	O
unexplained	O	O
renal	O	O
failure	O	O
.	O	O

chloroacetaldehyde	B-chem	B-chem
as	O	O
a	O	O
sulfhydryl	B-chem	B-chem
reagent	O	O
:	O	O
the	O	O
role	O	O
of	O	O
critical	O	O
thiol	B-chem	O
groups	O	O
in	O	O
ifosfamide	B-chem	B-chem
nephropathy	O	O
.	O	O

chloroacetaldehyde	B-chem	B-chem
(	O	O
caa	B-chem	B-chem
)	O	O
is	O	O
a	O	O
metabolite	O	O
of	O	O
the	O	O
alkylating	O	B-chem
agent	O	O
ifosfamide	B-chem	B-chem
(	O	O
ifo	B-chem	B-chem
)	O	O
and	O	O
putatively	O	O
responsible	O	O
for	O	O
renal	O	O
damage	O	O
following	O	O
anti	O	O
-	O	O
tumor	O	O
therapy	O	O
with	O	O
ifo	B-chem	O
.	O	O

depletion	O	O
of	O	O
sulfhydryl	B-chem	B-chem
(	O	O
sh	B-chem	O
)	O	O
groups	O	O
has	O	O
been	O	O
reported	O	O
from	O	O
cell	O	O
culture	O	O
,	O	O
animal	O	O
and	O	O
clinical	O	O
studies	O	O
.	O	O

in	O	O
this	O	O
work	O	O
the	O	O
effect	O	O
of	O	O
caa	B-chem	B-chem
on	O	O
human	O	O
proximal	O	O
tubule	O	O
cells	O	O
in	O	O
primary	O	O
culture	O	O
(	O	O
hrptec	O	O
)	O	O
was	O	O
investigated	O	O
.	O	O

toxicity	O	O
of	O	O
caa	B-chem	B-chem
was	O	O
determined	O	O
by	O	O
protein	O	O
content	O	O
,	O	O
cell	O	O
number	O	O
,	O	O
ldh	O	O
release	O	O
,	O	O
trypan	B-chem	B-chem
blue	I-chem	I-chem
exclusion	O	O
assay	O	O
and	O	O
caspase	O	O
-	O	O
3	O	O
activity	O	O
.	O	O

free	O	O
thiols	B-chem	B-chem
were	O	O
measured	O	O
by	O	O
the	O	O
method	O	O
of	O	O
ellman	O	O
.	O	O

caa	B-chem	B-chem
reduced	O	O
hrptec	O	O
cell	O	O
number	O	O
and	O	O
protein	O	O
,	O	O
induced	O	O
a	O	O
loss	O	O
in	O	O
free	O	O
intracellular	O	O
thiols	B-chem	B-chem
and	O	O
an	O	O
increase	O	O
in	O	O
necrosis	O	O
markers	O	O
.	O	O

caa	B-chem	B-chem
but	O	O
not	O	O
acrolein	B-chem	B-chem
inhibited	O	O
the	O	O
cysteine	B-chem	O
proteases	O	O
caspase	O	O
-	O	O
3	O	O
,	O	O
caspase	O	O
-	O	O
8	O	O
and	O	O
cathepsin	O	B-chem
b	O	O
.	O	O
caspase	O	O
activation	O	O
by	O	O
cisplatin	B-chem	B-chem
was	O	O
inhibited	O	O
by	O	O
caa	B-chem	B-chem
.	O	O

in	O	O
cells	O	O
stained	O	O
with	O	O
fluorescent	O	O
dyes	O	O
targeting	O	O
lysosomes	O	O
,	O	O
caa	B-chem	B-chem
induced	O	O
an	O	O
increase	O	O
in	O	O
lysosomal	O	O
size	O	O
and	O	O
lysosomal	O	O
leakage	O	O
.	O	O

the	O	O
effects	O	O
of	O	O
caa	B-chem	B-chem
on	O	O
cysteine	B-chem	B-chem
protease	O	O
activities	O	O
and	O	O
thiols	B-chem	B-chem
could	O	O
be	O	O
reproduced	O	O
in	O	O
cell	O	O
lysate	O	O
.	O	O

acidification	O	O
,	O	O
which	O	O
slowed	O	O
the	O	O
reaction	O	O
of	O	O
caa	B-chem	B-chem
with	O	O
thiol	B-chem	B-chem
donors	O	O
,	O	O
could	O	O
also	O	O
attenuate	O	O
effects	O	O
of	O	O
caa	B-chem	B-chem
on	O	O
necrosis	O	O
markers	O	O
,	O	O
thiol	B-chem	O
depletion	O	O
and	O	O
cysteine	B-chem	B-chem
protease	O	O
inhibition	O	O
in	O	O
living	O	O
cells	O	O
.	O	O

thus	O	O
,	O	O
caa	B-chem	B-chem
directly	O	O
reacts	O	O
with	O	O
cellular	O	O
protein	O	O
and	O	O
non	O	O
-	O	O
protein	O	O
thiols	B-chem	B-chem
,	O	O
mediating	O	O
its	O	O
toxicity	O	O
on	O	O
hrptec	O	O
.	O	O

this	O	O
effect	O	O
can	O	O
be	O	O
reduced	O	O
by	O	O
acidification	O	O
.	O	O

therefore	O	O
,	O	O
urinary	O	O
acidification	O	O
could	O	O
be	O	O
an	O	O
option	O	O
to	O	O
prevent	O	O
ifo	B-chem	O
nephropathy	O	O
in	O	O
patients	O	O
.	O	O

stereological	O	O
methods	O	O
reveal	O	O
the	O	O
robust	O	O
size	O	O
and	O	O
stability	O	O
of	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
after	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
status	O	O
epilepticus	O	O
in	O	O
the	O	O
adult	O	O
rat	O	O
.	O	O

following	O	O
status	O	O
epilepticus	O	O
in	O	O
the	O	O
rat	O	O
,	O	O
dentate	O	O
granule	O	O
cell	O	O
neurogenesis	O	O
increases	O	O
greatly	O	O
,	O	O
and	O	O
many	O	O
of	O	O
the	O	O
new	O	O
neurons	O	O
appear	O	O
to	O	O
develop	O	O
ectopically	O	O
,	O	O
in	O	O
the	O	O
hilar	O	O
region	O	O
of	O	O
the	O	O
hippocampal	O	O
formation	O	O
.	O	O

it	O	O
has	O	O
been	O	O
suggested	O	O
that	O	O
the	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
could	O	O
contribute	O	O
to	O	O
the	O	O
spontaneous	O	O
seizures	O	O
that	O	O
ultimately	O	O
develop	O	O
after	O	O
status	O	O
epilepticus	O	O
.	O	O

however	O	O
,	O	O
the	O	O
population	O	O
has	O	O
never	O	O
been	O	O
quantified	O	O
,	O	O
so	O	O
it	O	O
is	O	O
unclear	O	O
whether	O	O
it	O	O
is	O	O
substantial	O	O
enough	O	O
to	O	O
have	O	O
a	O	O
strong	O	O
influence	O	O
on	O	O
epileptogenesis	O	O
.	O	O

to	O	O
quantify	O	O
this	O	O
population	O	O
,	O	O
the	O	O
total	O	O
number	O	O
of	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
was	O	O
estimated	O	O
using	O	O
unbiased	O	O
stereology	O	O
at	O	O
different	O	O
times	O	O
after	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
status	O	O
epilepticus	O	O
.	O	O

the	O	O
number	O	O
of	O	O
hilar	O	O
neurons	O	O
immunoreactive	O	O
for	O	O
prox	O	B-chem
-	O	O
1	O	O
,	O	O
a	O	O
granule	O	O
-	O	O
cell	O	O
-	O	O
specific	O	O
marker	O	O
,	O	O
was	O	O
estimated	O	O
using	O	O
the	O	O
optical	O	O
fractionator	O	O
method	O	O
.	O	O

the	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
size	O	O
of	O	O
the	O	O
hilar	O	O
ectopic	O	O
granule	O	O
cell	O	O
population	O	O
after	O	O
status	O	O
epilepticus	O	O
is	O	O
substantial	O	O
,	O	O
and	O	O
stable	O	O
over	O	O
time	O	O
.	O	O

interestingly	O	O
,	O	O
the	O	O
size	O	O
of	O	O
the	O	O
population	O	O
appears	O	O
to	O	O
be	O	O
correlated	O	O
with	O	O
the	O	O
frequency	O	O
of	O	O
behavioral	O	O
seizures	O	O
,	O	O
because	O	O
animals	O	O
with	O	O
more	O	O
ectopic	O	O
granule	O	O
cells	O	O
in	O	O
the	O	O
hilus	O	O
have	O	O
more	O	O
frequent	O	O
behavioral	O	O
seizures	O	O
.	O	O

the	O	O
hilar	O	O
ectopic	O	O
granule	O	O
cell	O	O
population	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
vary	O	O
systematically	O	O
across	O	O
the	O	O
septotemporal	O	O
axis	O	O
,	O	O
although	O	O
it	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
volume	O	O
of	O	O
the	O	O
hilus	O	O
.	O	O

the	O	O
results	O	O
provide	O	O
new	O	O
insight	O	O
into	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
in	O	O
the	O	O
pilocarpine	B-chem	B-chem
model	O	O
of	O	O
temporal	O	O
lobe	O	O
epilepsy	O	O
.	O	O

a	O	O
prospective	O	O
,	O	O
open	O	O
-	O	O
label	O	O
trial	O	O
of	O	O
galantamine	B-chem	B-chem
in	O	O
autistic	O	O
disorder	O	O
.	O	O

objective	O	O
:	O	O
post	O	O
-	O	O
mortem	O	O
studies	O	O
have	O	O
reported	O	O
abnormalities	O	O
of	O	O
the	O	O
cholinergic	O	O
system	O	O
in	O	O
autism	O	O
.	O	O

the	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
use	O	O
of	O	O
galantamine	B-chem	B-chem
,	O	O
an	O	O
acetylcholinesterase	O	O
inhibitor	O	O
and	O	O
nicotinic	O	O
receptor	O	O
modulator	O	O
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
interfering	O	O
behaviors	O	O
in	O	O
children	O	O
with	O	O
autism	O	O
.	O	O

methods	O	O
:	O	O

thirteen	O	O
medication	O	O
-	O	O
free	O	O
children	O	O
with	O	O
autism	O	O
(	O	O
mean	O	O
age	O	O
,	O	O
8	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O

3	O	O
.	O	O
5	O	O
years	O	O
)	O	O
participated	O	O
in	O	O
a	O	O
12	O	O
-	O	O
week	O	O
,	O	O
open	O	O
-	O	O
label	O	O
trial	O	O
of	O	O
galantamine	B-chem	B-chem
.	O	O

patients	O	O
were	O	O
rated	O	O
monthly	O	O
by	O	O
parents	O	O
on	O	O
the	O	O
aberrant	O	O
behavior	O	O
checklist	O	O
(	O	O
abc	O	O
)	O	O
and	O	O
the	O	O
conners	O	O
'	O	O
parent	O	O
rating	O	O
scale	O	O
-	O	O
revised	O	O
,	O	O
and	O	O
by	O	O
a	O	O
physician	O	O
using	O	O
the	O	O
children	O	O
'	O	O
s	O	O
psychiatric	O	O
rating	O	O
scale	O	O
and	O	O
the	O	O
clinical	O	O
global	O	O
impressions	O	O
scale	O	O
.	O	O

results	O	O
:	O	O

patients	O	O
showed	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
parent	O	O
-	O	O
rated	O	O
irritability	O	O
and	O	O
social	O	O
withdrawal	O	O
on	O	O
the	O	O
abc	O	O
as	O	O
well	O	O
as	O	O
significant	O	O
improvements	O	O
in	O	O
emotional	O	O
lability	O	O
and	O	O
inattention	O	O
on	O	O
the	O	O
conners	O	O
'	O	O
parent	O	O
rating	O	O
scale	O	O
-	O	O
-	O	O
revised	O	O
.	O	O

similarly	O	O
,	O	O
clinician	O	O
ratings	O	O
showed	O	O
reductions	O	O
in	O	O
the	O	O
anger	O	O
subscale	O	O
of	O	O
the	O	O
children	O	O
'	O	O
s	O	O
psychiatric	O	O
rating	O	O
scale	O	O
.	O	O

eight	O	O
of	O	O
13	O	O
participants	O	O
were	O	O
rated	O	O
as	O	O
responders	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
their	O	O
improvement	O	O
scores	O	O
on	O	O
the	O	O
clinical	O	O
global	O	O
impressions	O	O
scale	O	O
.	O	O

overall	O	O
,	O	O
galantamine	B-chem	B-chem
was	O	O
well	O	O
-	O	O
tolerated	O	O
,	O	O
with	O	O
no	O	O
significant	O	O
adverse	O	O
effects	O	O
apart	O	O
from	O	O
headaches	O	O
in	O	O
one	O	O
patient	O	O
.	O	O

conclusion	O	O
:	O	O

in	O	O
this	O	O
open	O	O
trial	O	O
,	O	O
galantamine	B-chem	B-chem
was	O	O
well	O	O
-	O	O
tolerated	O	O
and	O	O
appeared	O	O
to	O	O
be	O	O
beneficial	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
interfering	O	O
behaviors	O	O
in	O	O
children	O	O
with	O	O
autism	O	O
,	O	O
particularly	O	O
aggression	O	O
,	O	O
behavioral	O	O
dyscontrol	O	O
,	O	O
and	O	O
inattention	O	O
.	O	O

further	O	O
controlled	O	O
trials	O	O
are	O	O
warranted	O	O
.	O	O

randomized	O	O
comparison	O	O
of	O	O
olanzapine	B-chem	B-chem
versus	O	O
risperidone	B-chem	B-chem
for	O	O
the	O	O
treatment	O	O
of	O	O
first	O	O
-	O	O
episode	O	O
schizophrenia	O	O
:	O	O
4	O	O
-	O	O
month	O	O
outcomes	O	O
.	O	O

objective	O	O
:	O	O

the	O	O
authors	O	O
compared	O	O
4	O	O
-	O	O
month	O	O
treatment	O	O
outcomes	O	O
for	O	O
olanzapine	B-chem	B-chem
versus	O	O
risperidone	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
first	O	O
-	O	O
episode	O	O
schizophrenia	O	O
spectrum	O	O
disorders	O	O
.	O	O

method	O	O
:	O	O

one	O	O
hundred	O	O
twelve	O	O
subjects	O	O
(	O	O
70	O	O
%	O	O
male	O	O
;	O	O
mean	O	O
age	O	O
=	O	O
23	O	O
.	O	O
3	O	O
years	O	O
[	O	O
sd	O	O
=	O	O
5	O	O
.	O	O
1	O	O
]	O	O
)	O	O
with	O	O
first	O	O
-	O	O
episode	O	O
schizophrenia	O	O
(	O	O
75	O	O
%	O	O
)	O	O
,	O	O
schizophreniform	O	O
disorder	O	O
(	O	O
17	O	O
%	O	O
)	O	O
,	O	O
or	O	O
schizoaffective	O	O
disorder	O	O
(	O	O
8	O	O
%	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
treatment	O	O
with	O	O
olanzapine	B-chem	B-chem
(	O	O
2	O	O
.	O	O
5	O	O
-	O	O
20	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
or	O	O
risperidone	B-chem	B-chem
(	O	O
1	O	O
-	O	O
6	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
.	O	O

results	O	O
:	O	O

response	O	O
rates	O	O
did	O	O
not	O	O
significantly	O	O
differ	O	O
between	O	O
olanzapine	B-chem	B-chem
(	O	O
43	O	O
.	O	O
7	O	O
%	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
28	O	O
.	O	O
8	O	O
%	O	O
-	O	O
58	O	O
.	O	O
6	O	O
%	O	O
)	O	O
and	O	O
risperidone	B-chem	B-chem
(	O	O
54	O	O
.	O	O
3	O	O
%	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
39	O	O
.	O	O
9	O	O
%	O	O
-	O	O
68	O	O
.	O	O
7	O	O
%	O	O
)	O	O
.	O	O

among	O	O
those	O	O
responding	O	O
to	O	O
treatment	O	O
,	O	O
more	O	O
subjects	O	O
in	O	O
the	O	O
olanzapine	B-chem	B-chem
group	O	O
(	O	O
40	O	O
.	O	O
9	O	O
%	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
16	O	O
.	O	O
8	O	O
%	O	O
-	O	O
65	O	O
.	O	O
0	O	O
%	O	O
)	O	O
than	O	O
in	O	O
the	O	O
risperidone	B-chem	B-chem
group	O	O
(	O	O
18	O	O
.	O	O
9	O	O
%	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
0	O	O
%	O	O
-	O	O
39	O	O
.	O	O
2	O	O
%	O	O
)	O	O
had	O	O
subsequent	O	O
ratings	O	O
not	O	O
meeting	O	O
response	O	O
criteria	O	O
.	O	O

negative	O	O
symptom	O	O
outcomes	O	O
and	O	O
measures	O	O
of	O	O
parkinsonism	O	O
and	O	O
akathisia	O	O
did	O	O
not	O	O
differ	O	O
between	O	O
medications	O	O
.	O	O

extrapyramidal	O	O
symptom	O	O
severity	O	O
scores	O	O
were	O	O
1	O	O
.	O	O
4	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
1	O	O
.	O	O
2	O	O
-	O	O
1	O	O
.	O	O
6	O	O
)	O	O
with	O	O
risperidone	B-chem	B-chem
and	O	O
1	O	O
.	O	O
2	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
1	O	O
.	O	O
0	O	O
-	O	O
1	O	O
.	O	O
4	O	O
)	O	O
with	O	O
olanzapine	B-chem	B-chem
.	O	O

significantly	O	O
more	O	O
weight	O	O
gain	O	O
occurred	O	O
with	O	O
olanzapine	B-chem	B-chem
than	O	O
with	O	O
risperidone	B-chem	B-chem
:	O	O
the	O	O
increase	O	O
in	O	O
weight	O	O
at	O	O
4	O	O
months	O	O
relative	O	O
to	O	O
baseline	O	O
weight	O	O
was	O	O
17	O	O
.	O	O
3	O	O
%	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
14	O	O
.	O	O
2	O	O
%	O	O
-	O	O
20	O	O
.	O	O
5	O	O
%	O	O
)	O	O
with	O	O
olanzapine	B-chem	B-chem
and	O	O
11	O	O
.	O	O
3	O	O
%	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
8	O	O
.	O	O
4	O	O
%	O	O
-	O	O
14	O	O
.	O	O
3	O	O
%	O	O
)	O	O
with	O	O
risperidone	B-chem	B-chem
.	O	O

body	O	O
mass	O	O
index	O	O
at	O	O
baseline	O	O
and	O	O
at	O	O
4	O	O
months	O	O
was	O	O
24	O	O
.	O	O
3	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
22	O	O
.	O	O
8	O	O
-	O	O
25	O	O
.	O	O
7	O	O
)	O	O
versus	O	O
28	O	O
.	O	O
2	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
26	O	O
.	O	O
7	O	O
-	O	O
29	O	O
.	O	O
7	O	O
)	O	O
with	O	O
olanzapine	B-chem	B-chem
and	O	O
23	O	O
.	O	O
9	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
22	O	O
.	O	O
5	O	O
-	O	O
25	O	O
.	O	O
3	O	O
)	O	O
versus	O	O
26	O	O
.	O	O
7	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
=	O	O
25	O	O
.	O	O
2	O	O
-	O	O
28	O	O
.	O	O
2	O	O
)	O	O
with	O	O
risperidone	B-chem	B-chem
.	O	O

conclusions	O	O
:	O	O

clinical	O	O
outcomes	O	O
with	O	O
risperidone	B-chem	B-chem
were	O	O
equal	O	O
to	O	O
those	O	O
with	O	O
olanzapine	B-chem	B-chem
,	O	O
and	O	O
response	O	O
may	O	O
be	O	O
more	O	O
stable	O	O
.	O	O

olanzapine	B-chem	B-chem
may	O	O
have	O	O
an	O	O
advantage	O	O
for	O	O
motor	O	O
side	O	O
effects	O	O
.	O	O

both	O	O
medications	O	O
caused	O	O
substantial	O	O
rapid	O	O
weight	O	O
gain	O	O
,	O	O
but	O	O
weight	O	O
gain	O	O
was	O	O
greater	O	O
with	O	O
olanzapine	B-chem	B-chem
.	O	O

early	O	O
paracentral	O	O
visual	O	O
field	O	O
loss	O	O
in	O	O
patients	O	O
taking	O	O
hydroxychloroquine	B-chem	B-chem
.	O	O

objective	O	O
:	O	O

to	O	O
review	O	O
the	O	O
natural	O	O
history	O	O
and	O	O
ocular	O	O
and	O	O
systemic	O	O
adverse	O	O
effects	O	O
of	O	O
patients	O	O
taking	O	O
hydroxychloroquine	B-chem	B-chem
sulfate	I-chem	O
who	O	O
attended	O	O
an	O	O
ophthalmic	O	O
screening	O	O
program	O	O
.	O	O

design	O	O
:	O	O

retrospective	O	O
study	O	O
.	O	O

results	O	O
:	O	O

records	O	O
of	O	O
262	O	O
patients	O	O
who	O	O
were	O	O
taking	O	O
hydroxychloroquine	B-chem	B-chem
and	O	O
screened	O	O
in	O	O
the	O	O
department	O	O
of	O	O
ophthalmology	O	O
were	O	O
reviewed	O	O
.	O	O

of	O	O
the	O	O
262	O	O
patients	O	O
,	O	O
14	O	O
(	O	O
18	O	O
%	O	O
)	O	O
of	O	O
76	O	O
who	O	O
had	O	O
stopped	O	O
treatment	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
study	O	O
experienced	O	O
documented	O	O
adverse	O	O
effects	O	O
.	O	O

systemic	O	O
adverse	O	O
effects	O	O
occurred	O	O
in	O	O
8	O	O
patients	O	O
(	O	O
10	O	O
.	O	O
5	O	O
%	O	O
)	O	O
and	O	O
ocular	O	O
adverse	O	O
effects	O	O
,	O	O
in	O	O
5	O	O
(	O	O
6	O	O
.	O	O
5	O	O
%	O	O
)	O	O
.	O	O

thirty	O	O
-	O	O
five	O	O
patients	O	O
(	O	O
13	O	O
.	O	O
4	O	O
%	O	O
)	O	O
had	O	O
visual	O	O
field	O	O
abnormalities	O	O
,	O	O
which	O	O
were	O	O
attributed	O	O
to	O	O
hydroxychloroquine	B-chem	B-chem
treatment	O	O
in	O	O
4	O	O
patients	O	O
(	O	O
1	O	O
.	O	O
5	O	O
%	O	O
)	O	O
.	O	O

three	O	O
of	O	O
the	O	O
4	O	O
patients	O	O
were	O	O
taking	O	O
less	O	O
than	O	O
6	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
and	O	O
all	O	O
patients	O	O
had	O	O
normal	O	O
renal	O	O
and	O	O
liver	O	O
function	O	O
test	O	O
results	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
current	O	O
study	O	O
used	O	O
a	O	O
protocol	O	O
of	O	O
visual	O	O
acuity	O	O
and	O	O
color	O	O
vision	O	O
assessment	O	O
,	O	O
funduscopy	O	O
,	O	O
and	O	O
humphrey	O	O
10	O	O
-	O	O
2	O	O
visual	O	O
field	O	O
testing	O	O
and	O	O
shows	O	O
that	O	O
visual	O	O
field	O	O
defects	O	O
appeared	O	O
before	O	O
any	O	O
corresponding	O	O
changes	O	O
in	O	O
any	O	O
other	O	O
tested	O	O
clinical	O	O
parameters	O	O
;	O	O
the	O	O
defects	O	O
were	O	O
reproducible	O	O
and	O	O
the	O	O
test	O	O
parameters	O	O
were	O	O
reliable	O	O
.	O	O

patients	O	O
taking	O	O
hydroxychloroquine	B-chem	B-chem
can	O	O
demonstrate	O	O
a	O	O
toxic	O	O
reaction	O	O
in	O	O
the	O	O
retina	O	O
despite	O	O
the	O	O
absence	O	O
of	O	O
known	O	O
risk	O	O
factors	O	O
.	O	O

screening	O	O
,	O	O
including	O	O
humphrey	O	O
10	O	O
-	O	O
2	O	O
visual	O	O
field	O	O
assessment	O	O
,	O	O
is	O	O
recommended	O	O
2	O	O
years	O	O
after	O	O
the	O	O
initial	O	O
baseline	O	O
and	O	O
yearly	O	O
thereafter	O	O
.	O	O

peri	O	O
-	O	O
operative	O	O
atrioventricular	O	O
block	O	O
as	O	O
a	O	O
result	O	O
of	O	O
chemotherapy	O	O
with	O	O
epirubicin	B-chem	B-chem
and	O	O
paclitaxel	B-chem	B-chem
.	O	O

a	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
presented	O	O
for	O	O
mastectomy	O	O
and	O	O
immediate	O	O
latissimus	O	O
dorsi	O	O
flap	O	O
reconstruction	O	O
having	O	O
been	O	O
diagnosed	O	O
with	O	O
carcinoma	O	O
of	O	O
the	O	O
breast	O	O
6	O	O
months	O	O
previously	O	O
.	O	O

in	O	O
the	O	O
preceding	O	O
months	O	O
she	O	O
had	O	O
received	O	O
neo	O	O
-	O	O
adjuvant	O	O
chemotherapy	O	O
with	O	O
epirubicin	B-chem	B-chem
,	O	O
paclitaxel	B-chem	B-chem
(	O	O
taxol	B-chem	B-chem
)	O	O
and	O	O
cyclophosphamide	B-chem	B-chem
.	O	O

this	O	O
had	O	O
been	O	O
apparently	O	O
uncomplicated	O	O
and	O	O
she	O	O
had	O	O
maintained	O	O
a	O	O
remarkably	O	O
high	O	O
level	O	O
of	O	O
physical	O	O
activity	O	O
.	O	O

she	O	O
was	O	O
found	O	O
to	O	O
be	O	O
bradycardic	O	O
at	O	O
pre	O	O
-	O	O
operative	O	O
assessment	O	O
but	O	O
had	O	O
no	O	O
cardiac	O	O
symptoms	O	O
.	O	O

second	O	O
degree	O	O
mobitz	O	O
type	O	O
ii	O	O
atrioventricular	O	O
block	O	O
was	O	O
diagnosed	O	O
on	O	O
electrocardiogram	O	O
,	O	O
and	O	O
temporary	O	O
transvenous	O	O
ventricular	O	O
pacing	O	O
instituted	O	O
in	O	O
the	O	O
peri	O	O
-	O	O
operative	O	O
period	O	O
.	O	O

we	O	O
discuss	O	O
how	O	O
evidence	O	O
-	O	O
based	O	O
guidelines	O	O
would	O	O
not	O	O
have	O	O
been	O	O
helpful	O	O
in	O	O
this	O	O
case	O	O
,	O	O
and	O	O
how	O	O
chemotherapy	O	O
can	O	O
exhibit	O	O
substantial	O	O
cardiotoxicity	O	O
that	O	O
may	O	O
develop	O	O
over	O	O
many	O	O
years	O	O
.	O	O

we	O	O
suggest	O	O
that	O	O
patients	O	O
who	O	O
have	O	O
received	O	O
chemotherapy	O	O
at	O	O
any	O	O
time	O	O
should	O	O
have	O	O
a	O	O
pre	O	O
-	O	O
operative	O	O
electrocardiogram	O	O
even	O	O
if	O	O
they	O	O
are	O	O
asymptomatic	O	O
.	O	O

risks	O	O
and	O	O
benefits	O	O
of	O	O
cox	B-chem	O
-	I-chem	O
2	I-chem	O
inhibitors	I-chem	O
vs	O	O
non	O	O
-	O	O
selective	O	O
nsaids	O	O
:	O	O

does	O	O
their	O	O
cardiovascular	O	O
risk	O	O
exceed	O	O
their	O	O
gastrointestinal	O	O
benefit	O	O
?	O	O

a	O	O
retrospective	O	O
cohort	O	O
study	O	O
.	O	O

objectives	O	O
:	O	O

the	O	O
risk	O	O
of	O	O
acute	O	O
myocardial	O	O
infarction	O	O
(	O	O
ami	O	B-chem
)	O	O
with	O	O
cox	B-chem	O
-	I-chem	O
2	I-chem	O
inhibitors	I-chem	O
may	O	O
offset	O	O
their	O	O
gastrointestinal	O	O
(	O	O
gi	O	O
)	O	O
benefit	O	O
compared	O	O
with	O	O
non	O	O
-	O	O
selective	O	O
(	O	O
ns	O	O
)	O	O
non	B-chem	O
-	I-chem	O
steroidal	I-chem	O
anti	I-chem	O
-	I-chem	O
inflammatory	I-chem	O
drugs	I-chem	O
(	O	O
nsaids	O	O
)	O	O
.	O	O

we	O	O
aimed	O	O
to	O	O
compare	O	O
the	O	O
risks	O	O
of	O	O
hospitalization	O	O
for	O	O
ami	O	B-chem
and	O	O
gi	O	O
bleeding	O	O
among	O	O
elderly	O	O
patients	O	O
using	O	O
cox	B-chem	O
-	I-chem	O
2	I-chem	O
inhibitors	I-chem	O
,	O	O
ns	O	O
-	O	O
nsaids	O	O
and	O	O
acetaminophen	B-chem	B-chem
.	O	O

methods	O	O
:	O	O

we	O	O
conducted	O	O
a	O	O
retrospective	O	O
cohort	O	O
study	O	O
using	O	O
administrative	O	O
data	O	O
of	O	O
patients	O	O
>	O	O
or	O	O
=	O	O
65	O	O
years	O	O
of	O	O
age	O	O
who	O	O
filled	O	O
a	O	O
prescription	O	O
for	O	O
nsaid	O	O
or	O	O
acetaminophen	B-chem	B-chem
during	O	O
1999	O	O
-	O	O
2002	O	O
.	O	O

outcomes	O	O
were	O	O
compared	O	O
using	O	O
cox	O	O
regression	O	O
models	O	O
with	O	O
time	O	O
-	O	O
dependent	O	O
exposures	O	O
.	O	O

results	O	O
:	O	O

person	O	O
-	O	O
years	O	O
of	O	O
exposure	O	O
among	O	O

non	O	O
-	O	O
users	O	O
of	O	O
aspirin	B-chem	B-chem
were	O	O
:	O	O
75	O	O
,	O	O
761	O	O
to	O	O
acetaminophen	B-chem	B-chem
,	O	O
42	O	O
,	O	O
671	O	O
to	O	O
rofecoxib	B-chem	O
65	O	O
,	O	O
860	O	O
to	O	O
celecoxib	B-chem	B-chem
,	O	O
and	O	O
37	O	O
,	O	O
495	O	O
to	O	O
ns	O	O
-	O	O
nsaids	O	O
.	O	O

among	O	O
users	O	O
of	O	O
aspirin	B-chem	B-chem
,	O	O
they	O	O
were	O	O
:	O	O
14	O	O
,	O	O
671	O	O
to	O	O
rofecoxib	B-chem	O
,	O	O
22	O	O
,	O	O
875	O	O
to	O	O
celecoxib	B-chem	B-chem
,	O	O
9	O	O
,	O	O
832	O	O
to	O	O
ns	O	O
-	O	O
nsaids	O	O
and	O	O
38	O	O
,	O	O
048	O	O
to	O	O
acetaminophen	B-chem	B-chem
.	O	O

among	O	O
non	O	O
-	O	O
users	O	O
of	O	O
aspirin	B-chem	B-chem
,	O	O
the	O	O
adjusted	O	O
hazard	O	O
ratios	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
)	O	O
of	O	O
hospitalization	O	O
for	O	O
ami	O	B-chem
/	O	O
gi	O	O
vs	O	O
the	O	O
acetaminophen	B-chem	B-chem
(	O	O
with	O	O
no	O	O
aspirin	B-chem	B-chem
)	O	O
group	O	O
were	O	O
:	O	O
rofecoxib	B-chem	O
1	O	O
.	O	O
27	O	O
(	O	O
1	O	O
.	O	O
13	O	O
,	O	O
1	O	O
.	O	O
42	O	O
)	O	O
,	O	O
celecoxib	B-chem	B-chem
0	O	I-chem
.	O	O
93	O	O
(	O	O
0	O	O
.	O	O
83	O	O
,	O	O
1	O	O
.	O	O
03	O	O
)	O	O
,	O	O
naproxen	B-chem	B-chem
1	O	O
.	O	O
59	O	O
(	O	O
1	O	O
.	O	O
31	O	O
,	O	O
1	O	O
.	O	O
93	O	O
)	O	O
,	O	O
diclofenac	B-chem	B-chem
1	O	O
.	O	O
17	O	O
(	O	O
0	O	O
.	O	O
99	O	O
,	O	O
1	O	O
.	O	O
38	O	O
)	O	O
and	O	O
ibuprofen	B-chem	B-chem
1	O	O
.	O	O
05	O	O
(	O	O
0	O	O
.	O	O
74	O	O
,	O	O
1	O	O
.	O	O
51	O	O
)	O	O
.	O	O

among	O	O
users	O	O
of	O	O
aspirin	B-chem	B-chem
,	O	O
they	O	O
were	O	O
:	O	O
rofecoxib	B-chem	O
1	O	O
.	O	O
73	O	O
(	O	O
1	O	O
.	O	O
52	O	O
,	O	O
1	O	O
.	O	O
98	O	O
)	O	O
,	O	O
celecoxib	B-chem	B-chem
1	O	O
.	O	O
34	O	O
(	O	O
1	O	O
.	O	O
19	O	O
,	O	O
1	O	O
.	O	O
52	O	O
)	O	O
,	O	O
ibuprofen	B-chem	B-chem
1	O	O
.	O	O
51	O	O
(	O	O
0	O	O
.	O	O
95	O	O
,	O	O
2	O	O
.	O	O
41	O	O
)	O	O
,	O	O
diclofenac	B-chem	B-chem
1	O	O
.	O	O
69	O	O
(	O	O
1	O	O
.	O	O
35	O	O
,	O	O
2	O	O
.	O	O
10	O	O
)	O	O
,	O	O
naproxen	B-chem	B-chem
1	O	O
.	O	O
35	O	O
(	O	O
0	O	O
.	O	O
97	O	O
,	O	O
1	O	O
.	O	O
88	O	O
)	O	O
and	O	O
acetaminophen	B-chem	B-chem
1	O	O
.	O	O
29	O	O
(	O	O
1	O	O
.	O	O
17	O	O
,	O	O
1	O	O
.	O	O
42	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

among	O	O
non	O	O
-	O	O
users	O	O
of	O	O
aspirin	B-chem	B-chem
,	O	O
naproxen	B-chem	B-chem
seemed	O	O
to	O	O
carry	O	O
the	O	O
highest	O	O
risk	O	O
for	O	O
ami	O	B-chem
/	O	O
gi	O	O
bleeding	O	O
.	O	O

the	O	O
ami	O	B-chem
/	O	O
gi	O	O
toxicity	O	O
of	O	O
celecoxib	B-chem	B-chem
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
acetaminophen	B-chem	B-chem
and	O	O
seemed	O	O
to	O	O
be	O	O
better	O	O
than	O	O
those	O	O
of	O	O
rofecoxib	B-chem	B-chem
and	O	O
ns	O	O
-	O	O
nsaids	O	O
.	O	O

among	O	O
users	O	O
of	O	O
aspirin	B-chem	B-chem
,	O	O
both	O	O
celecoxib	B-chem	B-chem
and	O	O
naproxen	B-chem	B-chem
seemed	O	O
to	O	O
be	O	O
the	O	O
least	O	O
toxic	O	O
.	O	O

quinine	B-chem	B-chem
-	O	O
induced	O	O
arrhythmia	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
severe	O	O
malaria	O	O
.	O	O

it	O	O
was	O	O
reported	O	O
that	O	O
there	O	O
was	O	O
a	O	O
case	O	O
of	O	O
severe	O	O
malaria	O	O
patient	O	O
with	O	O
jaundice	O	O
who	O	O
presented	O	O
with	O	O
arrhythmia	O	O
(	O	O
premature	O	O
ventricular	O	O
contraction	O	O
)	O	O
while	O	O
getting	O	O
quinine	B-chem	B-chem
infusion	O	O
was	O	O
reported	O	O
.	O	O

a	O	O
man	O	O
,	O	O
25	O	O
years	O	O
old	O	O
,	O	O
was	O	O
admitted	O	O
to	O	O
hospital	O	O
with	O	O
high	O	O
fever	O	O
,	O	O
chill	O	O
,	O	O
vomiting	O	O
,	O	O
jaundice	O	O
.	O	O

the	O	O
patient	O	O
was	O	O
fully	O	O
conscious	O	O
,	O	O
blood	O	O
pressure	O	O

120	O	O
/	O	O
80	O	O
mmhg	O	O
,	O	O
pulse	O	O
rate	O	O
100	O	O
x	O	O
/	O	O
minute	O	O
,	O	O
regular	O	O
.	O	O

on	O	O
admission	O	O
,	O	O
laboratory	O	O
examination	O	O
showed	O	O
plasmodium	O	O
falciparum	O	O
(	O	O
+	O	O
+	O	O
+	O	O
+	O	O
)	O	O
,	O	O
total	O	O
bilirubin	B-chem	B-chem
8	O	O
.	O	O
25	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
conjugated	O	B-chem
bilirubin	B-chem	I-chem
4	O	O
.	O	O
36	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
unconjugated	O	O
bilirubin	B-chem	B-chem
3	O	O
.	O	O
89	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
potassium	B-chem	B-chem
3	O	O
.	O	O
52	O	O
meq	O	O
/	O	O
l	O	O
patient	O	O
was	O	O
diagnosed	O	O
as	O	O
severe	O	O
malaria	O	O
with	O	O
jaundice	O	O
and	O	O
got	O	O
quinine	B-chem	B-chem
infusion	O	O
in	O	O
dextrose	B-chem	B-chem
5	O	O
%	O	O
500	O	O
mg	O	O
/	O	O
8	O	O
hour	O	O
.	O	O

on	O	O
the	O	O
second	O	O
day	O	O
the	O	O
patient	O	O
had	O	O
vomitus	O	O
,	O	O
diarrhea	O	O
,	O	O
tinnitus	O	O
,	O	O
loss	O	O
of	O	O
hearing	O	O
.	O	O

after	O	O
30	O	O
hours	O	O
of	O	O
quinine	B-chem	B-chem
infusion	O	O
the	O	O
patient	O	O
felt	O	O
palpitation	O	O
and	O	O
electrocardiography	O	O
(	O	O
ecg	O	O
)	O	O
recording	O	O
showed	O	O
premature	O	O
ventricular	O	O
contraction	O	O
(	O	O
pvc	O	B-chem
)	O	O
>	O	O
5	O	O
x	O	O
/	O	O
minute	O	O
,	O	O
trigemini	O	O
,	O	O
constant	O	O
type	O	O
-	O	O
-	O	O
sinoatrial	O	O
block	O	O
,	O	O
positive	O	O
u	O	O
wave	O	O
.	O	O

he	O	O
was	O	O
treated	O	O
with	O	O
lidocaine	B-chem	B-chem
50	O	O
mg	O	O
intravenously	O	O
followed	O	O
by	O	O
infusion	O	O
1500	O	O
mg	O	O
in	O	O
dextrose	B-chem	B-chem
5	O	O
%	O	O
/	O	O
24	O	O
hour	O	O
and	O	O
potassium	B-chem	B-chem
aspartate	I-chem	I-chem
tablet	O	O
.	O	O

quinine	B-chem	B-chem
infusion	O	O
was	O	O
discontinued	O	O
and	O	O
changed	O	O
with	O	O
sulfate	O	O
quinine	B-chem	B-chem
tablets	O	O
.	O	O

three	O	O
hours	O	O
later	O	O
the	O	O
patient	O	O
felt	O	O
better	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
pvc	O	B-chem
reduced	O	O
to	O	O
4	O	O
-	O	O
5	O	O
x	O	O
/	O	O
minute	O	O
and	O	O
on	O	O
the	O	O
third	O	O
day	O	O
ecg	O	O
was	O	O
normal	O	O
,	O	O
potassium	B-chem	B-chem
level	O	O
was	O	O
3	O	O
.	O	O
34	O	O
meq	O	O
/	O	O
l	O	O
.	O	O

he	O	O
was	O	O
discharged	O	O
on	O	O
7th	O	O
day	O	O
in	O	O
good	O	O
condition	O	O
.	O	O

quinine	B-chem	B-chem
,	O	O
like	O	O
quinidine	B-chem	B-chem
,	O	O
is	O	O
a	O	O
chincona	O	O
alkaloid	O	B-chem
that	O	O
has	O	O
anti	O	O
-	O	O
arrhythmic	O	O
property	O	O
,	O	O
although	O	O
it	O	O
also	O	O
pro	O	O
-	O	O
arrhythmic	O	O
that	O	O
can	O	O
cause	O	O
various	O	O
arrhythmias	O	O
,	O	O
including	O	O
severe	O	O
arrhythmia	O	O
such	O	O
as	O	O
multiple	O	O
pvc	O	B-chem
.	O	O

administration	O	O
of	O	O
parenteral	O	O
quinine	B-chem	B-chem
must	O	O
be	O	O
done	O	O
carefully	O	O
and	O	O
with	O	O
good	O	O
observation	O	O
because	O	O
of	O	O
its	O	O
pro	O	O
-	O	O
arrhythmic	O	O
effect	O	O
,	O	O
especially	O	O
in	O	O
older	O	O
patients	O	O
who	O	O
have	O	O
heart	O	O
diseases	O	O
or	O	O
patients	O	O
with	O	O
electrolyte	O	O
disorder	O	O
(	O	O
hypokalemia	O	O
)	O	O
which	O	O
frequently	O	O
occurs	O	O
due	O	O
to	O	O
vomiting	O	O
and	O	O
or	O	O
diarrhea	O	O
in	O	O
malaria	O	O
cases	O	O
.	O	O

penicillamine	B-chem	B-chem
-	O	O
related	O	O
lichenoid	O	O
dermatitis	O	O
and	O	O
utility	O	O
of	O	O
zinc	B-chem	B-chem
acetate	I-chem	I-chem
in	O	O
a	O	O
wilson	O	O
disease	O	O
patient	O	O
with	O	O
hepatic	O	O
presentation	O	O
,	O	O
anxiety	O	O
and	O	O
spect	O	O
abnormalities	O	O
.	O	O

wilson	O	O
'	O	O
s	O	O
disease	O	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
disorder	O	O
of	O	O
hepatic	O	O
copper	B-chem	O
metabolism	O	O
with	O	O
consequent	O	O
copper	B-chem	B-chem
accumulation	O	O
and	O	O
toxicity	O	O
in	O	O
many	O	O
tissues	O	O
and	O	O
consequent	O	O
hepatic	O	O
,	O	O
neurologic	O	O
and	O	O
psychiatric	O	O
disorders	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
wilson	O	O
'	O	O
s	O	O
disease	O	O
with	O	O
chronic	O	O
liver	O	O
disease	O	O
;	O	O
moreover	O	O
,	O	O
in	O	O
our	O	O
patient	O	O
,	O	O
presenting	O	O
also	O	O
with	O	O
high	O	O
levels	O	O
of	O	O
state	O	O
anxiety	O	O
without	O	O
depression	O	O
,	O	O
99mtc	O	B-chem
-	O	O
ecd	O	O
-	O	O
spect	O	O
showed	O	O
cortical	O	O
hypoperfusion	O	O
in	O	O
frontal	O	O
lobes	O	O
,	O	O
more	O	O
marked	O	O
on	O	O
the	O	O
left	O	O
frontal	O	O
lobe	O	O
.	O	O

during	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
our	O	O
patient	O	O
,	O	O
penicillamine	B-chem	B-chem
was	O	O
interrupted	O	O
after	O	O
the	O	O
appearance	O	O
of	O	O
a	O	O
lichenoid	O	O
dermatitis	O	O
,	O	O
and	O	O
zinc	B-chem	B-chem
acetate	I-chem	I-chem
permitted	O	O
to	O	O
continue	O	O
the	O	O
successful	O	O
treatment	O	O
of	O	O
the	O	O
patient	O	O
without	O	O
side	O	O
-	O	O
effects	O	O
.	O	O

in	O	O
our	O	O
case	O	O
the	O	O
therapy	O	O
with	O	O
zinc	B-chem	B-chem
acetate	I-chem	I-chem
represented	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
a	O	O
wilson	O	O
'	O	O
s	O	O
disease	O	O
patient	O	O
in	O	O
which	O	O
penicillamine	B-chem	B-chem
-	O	O
related	O	O
side	O	O
effects	O	O
appeared	O	O
.	O	O

the	O	O
safety	O	O
of	O	O
the	O	O
zinc	B-chem	B-chem
acetate	I-chem	I-chem
allowed	O	O
us	O	O
to	O	O
avoid	O	O
other	O	O
potentially	O	O
toxic	O	O
chelating	O	O
drugs	O	O
;	O	O
this	O	O
observation	O	O
is	O	O
in	O	O
line	O	O
with	O	O
the	O	O
growing	O	O
evidence	O	O
on	O	O
the	O	O
efficacy	O	O
of	O	O
the	O	O
drug	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
wilson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

since	O	O
most	O	O
of	O	O
wilson	O	O
'	O	O
s	O	O
disease	O	O
penicillamine	B-chem	B-chem
-	O	O
treated	O	O
patients	O	O
do	O	O
not	O	O
seem	O	O
to	O	O
develop	O	O
this	O	O
skin	O	O
lesion	O	O
,	O	O
it	O	O
could	O	O
be	O	O
conceivable	O	O
that	O	O
a	O	O
specific	O	O
genetic	O	O
factor	O	O
is	O	O
involved	O	O
in	O	O
drug	O	O
response	O	O
.	O	O

further	O	O
studies	O	O
are	O	O
needed	O	O
for	O	O
a	O	O
better	O	O
clarification	O	O
of	O	O
wilson	O	O
'	O	O
s	O	O
disease	O	O
therapy	O	O
,	O	O
and	O	O
in	O	O
particular	O	O
to	O	O
differentiate	O	O
specific	O	O
therapies	O	O
for	O	O
different	O	O
wilson	O	O
'	O	O
s	O	O
disease	O	O
phenotypes	O	O
.	O	O

a	O	O
dramatic	O	O
drop	O	O
in	O	O
blood	O	O
pressure	O	O
following	O	O
prehospital	O	O
gtn	B-chem	O
administration	O	O
.	O	O

a	O	O
male	O	O
in	O	O
his	O	O
sixties	O	O
with	O	O
no	O	O
history	O	O
of	O	O
cardiac	O	O
chest	O	O
pain	O	O
awoke	O	O
with	O	O
chest	O	O
pain	O	O
following	O	O
an	O	O
afternoon	O	O
sleep	O	O
.	O	O

the	O	O
patient	O	O
did	O	O
not	O	O
self	O	O
medicate	O	O
.	O	O

the	O	O
patient	O	O
'	O	O
s	O	O
observations	O	O
were	O	O
within	O	O
normal	O	O
limits	O	O
,	O	O
he	O	O
was	O	O
administered	O	O
oxygen	B-chem	B-chem
via	O	O
a	O	O
face	O	O
mask	O	O
and	O	O
glyceryl	B-chem	B-chem
trinitrate	I-chem	I-chem
(	O	O
gtn	B-chem	B-chem
)	O	O
.	O	O

several	O	O
minutes	O	O
after	O	O
the	O	O
gtn	B-chem	O
the	O	O
patient	O	O
experienced	O	O
a	O	O
sudden	O	O
drop	O	O
in	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
,	O	O
this	O	O
was	O	O
rectified	O	O
by	O	O
atropine	B-chem	B-chem
sulphate	I-chem	I-chem
and	O	O
a	O	O
fluid	O	O
challenge	O	O
.	O	O

there	O	O
was	O	O
no	O	O
further	O	O
deterioration	O	O
in	O	O
the	O	O
patient	O	O
'	O	O
s	O	O
condition	O	O
during	O	O
transport	O	O
to	O	O
hospital	O	O
.	O	O

there	O	O
are	O	O
very	O	O
few	O	O
documented	O	O
case	O	O
like	O	O
this	O	O
in	O	O
the	O	O
prehospital	O	O
scientific	O	O
literature	O	O
.	O	O

the	O	O
cause	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
bezold	O	O
-	O	O
jarish	O	O
reflex	O	O
,	O	O
stimulation	O	O
of	O	O
the	O	O
ventricular	O	O
walls	O	O
which	O	O
in	O	O
turn	O	O
decreases	O	O
sympathetic	O	O
outflow	O	O
from	O	O
the	O	O
vasomotor	O	O
centre	O	O
.	O	O

prehospital	O	O
care	O	O
providers	O	O
who	O	O
are	O	O
managing	O	O
any	O	O
patient	O	O
with	O	O
a	O	O
syncopal	O	O
episode	O	O
that	O	O
fails	O	O
to	O	O
recover	O	O
within	O	O
a	O	O
reasonable	O	O
time	O	O
frame	O	O
should	O	O
consider	O	O
the	O	O
bezold	O	O
-	O	O
jarisch	O	O
reflex	O	O
as	O	O
the	O	O
cause	O	O
and	O	O
manage	O	O
the	O	O
patient	O	O
accordingly	O	O
.	O	O

acute	O	O
encephalopathy	O	O
and	O	O
cerebral	O	O
vasospasm	O	O
after	O	O
multiagent	O	O
chemotherapy	O	O
including	O	O
peg	B-chem	B-chem
-	I-chem	O
asparaginase	I-chem	B-chem
and	O	O
intrathecal	O	O
cytarabine	B-chem	B-chem
for	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
.	O	O

a	O	O
7	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
with	O	O
an	O	O
unusual	O	O
reaction	O	O
to	O	O
induction	O	O
chemotherapy	O	O
for	O	O
precursor	O	O
b	O	O
-	O	O
cell	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
(	O	O
all	O	O
)	O	O
is	O	O
described	O	O
.	O	O

the	O	O
patient	O	O
developed	O	O
acute	O	O
encephalopathy	O	O
evidenced	O	O
by	O	O
behavioral	O	O
changes	O	O
,	O	O
aphasia	O	O
,	O	O
incontinence	O	O
,	O	O
visual	O	O
hallucinations	O	O
,	O	O
and	O	O
right	O	O
-	O	O
sided	O	O
weakness	O	O
with	O	O
diffuse	O	O
cerebral	O	O
vasospasm	O	O
on	O	O
magnetic	O	O
resonance	O	O
angiography	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
intrathecal	O	O
cytarabine	B-chem	B-chem
.	O	O

vincristine	B-chem	B-chem
,	O	O
dexamethasone	B-chem	B-chem
,	O	O
and	O	O
polyethylene	B-chem	B-chem
glycol	I-chem	I-chem
-	I-chem	O
asparaginase	I-chem	I-chem
were	O	O
also	O	O
administered	O	O
before	O	O
the	O	O
episode	O	O
as	O	O
part	O	O
of	O	O
induction	O	O
therapy	O	O
.	O	O

neurologic	O	O
status	O	O
returned	O	O
to	O	O
baseline	O	O
within	O	O
10	O	O
days	O	O
of	O	O
the	O	O
acute	O	O
event	O	O
,	O	O
and	O	O
magnetic	O	O
resonance	O	O
angiography	O	O
findings	O	O
returned	O	O
to	O	O
normal	O	O
4	O	O
months	O	O
later	O	O
.	O	O

comparison	O	O
of	O	O
valsartan	B-chem	B-chem
/	O	O
hydrochlorothiazide	B-chem	B-chem
combination	O	O
therapy	O	O
at	O	O
doses	O	O
up	O	O
to	O	O
320	O	O
/	O	O
25	O	O
mg	O	O
versus	O	O
monotherapy	O	O
:	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
study	O	O
followed	O	O
by	O	O
long	O	O
-	O	O
term	O	O
combination	O	O
therapy	O	O
in	O	O
hypertensive	O	O
adults	O	O
.	O	O

background	O	O
:	O	O

one	O	O
third	O	O
of	O	O
patients	O	O
treated	O	O
for	O	O
hypertension	O	O
attain	O	O
adequate	O	O
blood	O	O
pressure	O	O
(	O	O
bp	O	O
)	O	O
control	O	O
,	O	O
and	O	O
multidrug	O	O
regimens	O	O
are	O	O
often	O	O
required	O	O
.	O	O

given	O	O
the	O	O
lifelong	O	O
nature	O	O
of	O	O
hypertension	O	O
,	O	O
there	O	O
is	O	O
a	O	O
need	O	O
to	O	O
evaluate	O	O
the	O	O
long	O	O
-	O	O
term	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
higher	O	O
doses	O	O
of	O	O
combination	O	O
anti	O	O
-	O	O
hypertensive	O	O
therapies	O	O
.	O	O

objective	O	O
:	O	O

this	O	O
study	O	O
investigated	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
valsartan	B-chem	B-chem
(	O	O
val	B-chem	B-chem
)	O	O
or	O	O
hydrochlorothiazide	B-chem	B-chem
(	O	O
hctz	B-chem	B-chem
)	O	O
-	O	O
monotherapy	O	O
and	O	O
higher	O	O
-	O	O
dose	O	O
combinations	O	O
in	O	O
patients	O	O
with	O	O
essential	O	O
hypertension	O	O
.	O	O

methods	O	O
:	O	O

the	O	O
first	O	O
part	O	O
of	O	O
this	O	O
study	O	O
was	O	O
an	O	O
8	O	O
-	O	O
week	O	O
,	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
controlled	O	O
,	O	O
parallel	O	O
-	O	O
group	O	O
trial	O	O
.	O	O

patients	O	O
with	O	O
essential	O	O
hypertension	O	O
(	O	O
mean	O	O
sitting	O	O
diastolic	O	O
bp	O	O
[	O	O
msdbp	O	O
]	O	O
,	O	O
>	O	O
or	O	O
=	O	O
95	O	O
mm	O	O
hg	O	O
and	O	O
<	O	O
110	O	O
mm	O	O
hg	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
1	O	O
of	O	O
8	O	O
treatment	O	O
groups	O	O
:	O	O
val	B-chem	O
160	O	O
or	O	O
320	O	O
mg	O	O
;	O	O
hctz	B-chem	B-chem
12	O	O
.	O	O
5	O	O
or	O	O
25	O	O
mg	O	O
;	O	O
val	B-chem	O
/	O	O
hctz	B-chem	B-chem
160	O	O
/	O	O
12	O	O
.	O	O
5	O	O
,	O	O
320	O	O
/	O	O
12	O	O
.	O	O
5	O	O
,	O	O
or	O	O
320	O	O
/	O	O
25	O	O
mg	O	O
;	O	O
or	O	O
placebo	O	O
.	O	O

mean	O	O
changes	O	O
in	O	O
msdbp	O	O
and	O	O
mean	O	O
sitting	O	O
systolic	O	O
bp	O	O
(	O	O
mssbp	O	O
)	O	O
were	O	O
analyzed	O	O
at	O	O
the	O	O
8	O	O
-	O	O
week	O	O
core	O	O
study	O	O
end	O	O
point	O	O
.	O	O

val	B-chem	O
/	O	O
hctz	B-chem	B-chem
320	O	O
/	O	O
12	O	O
.	O	O
5	O	O
and	O	O
320	O	O
/	O	O
25	O	O
mg	O	O
were	O	O
further	O	O
investigated	O	O
in	O	O
a	O	O
54	O	O
-	O	O
week	O	O
,	O	O
open	O	O
-	O	O
label	O	O
extension	O	O
.	O	O

response	O	O
was	O	O
defined	O	O
as	O	O
msdbp	O	O
<	O	O
90	O	O
mm	O	O
hg	O	O
or	O	O
a	O	O
>	O	O
or	O	O
=	O	O
10	O	O
mm	O	O
hg	O	O
decrease	O	O
compared	O	O
to	O	O
baseline	O	O
.	O	O

control	O	O
was	O	O
defined	O	O
as	O	O
msdbp	O	O
<	O	O
90	O	O
mm	O	O
hg	O	O
compared	O	O
with	O	O
baseline	O	O
.	O	O

tolerability	O	O
was	O	O
assessed	O	O
by	O	O
monitoring	O	O
adverse	O	O
events	O	O
at	O	O
randomization	O	O
and	O	O
all	O	O
subsequent	O	O
study	O	O
visits	O	O
and	O	O
regular	O	O
evaluation	O	O
of	O	O
hematology	O	O
and	O	O
blood	O	O
chemistry	O	O
.	O	O

results	O	O
:	O	O

a	O	O
total	O	O
of	O	O
1346	O	O
patients	O	O
were	O	O
randomized	O	O
into	O	O
the	O	O
8	O	O
-	O	O
week	O	O
core	O	O
study	O	O
(	O	O
734	O	O
men	O	O
,	O	O
612	O	O
women	O	O
;	O	O
924	O	O
white	O	O
,	O	O
291	O	O
black	O	O
,	O	O
23	O	O
asian	O	O
,	O	O
108	O	O
other	O	O
;	O	O
mean	O	O
age	O	O
,	O	O
52	O	O
.	O	O
7	O	O
years	O	O
;	O	O
mean	O	O
weight	O	O
,	O	O
92	O	O
.	O	O
6	O	O
kg	O	O
)	O	O
.	O	O

all	O	O
active	O	O
treatments	O	O
were	O	O
associated	O	O
with	O	O
significantly	O	O
reduced	O	O
mssbp	O	O
and	O	O
msdbp	O	O
during	O	O
the	O	O
core	O	O
8	O	O
-	O	O
week	O	O
study	O	O
,	O	O
with	O	O
each	O	O
monotherapy	O	O
significantly	O	O
contributing	O	O
to	O	O
the	O	O
overall	O	O
effect	O	O
of	O	O
combination	O	O
therapy	O	O
(	O	O
val	B-chem	O
and	O	O
hctz	B-chem	B-chem
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

each	O	O
combination	O	O
was	O	O
associated	O	O
with	O	O
significantly	O	O
greater	O	O
reductions	O	O
in	O	O
mssbp	O	O
and	O	O
msdbp	O	O
compared	O	O
with	O	O
the	O	O
monotherapies	O	O
and	O	O
placebo	O	O
(	O	O
all	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

the	O	O
mean	O	O
reduction	O	O
in	O	O
mssbp	O	O
/	O	O
msdbp	O	O
with	O	O
val	B-chem	O
/	O	O
hctz	B-chem	B-chem
320	O	O
/	O	O
25	O	O
mg	O	O
was	O	O
24	O	O
.	O	O
7	O	O
/	O	O
16	O	O
.	O	O
6	O	O
mm	O	O
hg	O	O
,	O	O
compared	O	O
with	O	O
5	O	O
.	O	O
9	O	O
/	O	O
7	O	O
.	O	O
0	O	O
mm	O	O
hg	O	O
with	O	O
placebo	O	O
.	O	O

the	O	O
reduction	O	O
in	O	O
mssbp	O	O
was	O	O
significantly	O	O
greater	O	O
with	O	O
val	B-chem	O
/	O	O
hctz	B-chem	B-chem
320	O	O
/	O	O
25	O	O
mg	O	O
compared	O	O
with	O	O
val	B-chem	O
/	O	O
hctz	B-chem	B-chem
160	O	O
/	O	O
12	O	O
.	O	O
5	O	O
mg	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
002	O	O
)	O	O
.	O	O

rates	O	O
of	O	O
response	O	O
and	O	O
bp	O	O
control	O	O
were	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
groups	O	O
that	O	O
received	O	O
combination	O	O
treatment	O	O
compared	O	O
with	O	O
those	O	O
that	O	O
received	O	O
monotherapy	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
hypokalemia	O	O
was	O	O
lower	O	O
with	O	O
val	B-chem	O
/	O	O
hctz	B-chem	B-chem
combinations	O	O
(	O	O
1	O	O
.	O	O
8	O	O
%	O	O
-	O	O
6	O	O
.	O	O
1	O	O
%	O	O
)	O	O
than	O	O
with	O	O
hctz	B-chem	B-chem
monotherapies	O	O
(	O	O
7	O	O
.	O	O
1	O	O
%	O	O
-	O	O
13	O	O
.	O	O
3	O	O
%	O	O
)	O	O
.	O	O

the	O	O
majority	O	O
of	O	O
adverse	O	O
events	O	O
in	O	O
the	O	O
core	O	O
study	O	O
were	O	O
of	O	O
mild	O	O
to	O	O
moderate	O	O
severity	O	O
.	O	O

the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
val	B-chem	O
/	O	O
hctz	B-chem	B-chem
combinations	O	O
were	O	O
maintained	O	O
during	O	O
the	O	O
extension	O	O
(	O	O
797	O	O
patients	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

in	O	O
this	O	O
study	O	O
population	O	O
,	O	O
combination	O	O
therapies	O	O
with	O	O
val	B-chem	O
/	O	O
hctz	B-chem	B-chem
were	O	O
associated	O	O
with	O	O
significantly	O	O
greater	O	O
bp	O	O
reductions	O	O
compared	O	O
with	O	O
either	O	O
monotherapy	O	O
,	O	O
were	O	O
well	O	O
tolerated	O	O
,	O	O
and	O	O
were	O	O
associated	O	O
with	O	O
less	O	O
hypokalemia	O	O
than	O	O
hctz	B-chem	B-chem
alone	O	O
.	O	O

succimer	B-chem	B-chem
chelation	O	O
improves	O	O
learning	O	O
,	O	O
attention	O	O
,	O	O
and	O	O
arousal	O	O
regulation	O	O
in	O	O
lead	B-chem	O
-	O	O
exposed	O	O
rats	O	O
but	O	O
produces	O	O
lasting	O	O
cognitive	O	O
impairment	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
lead	B-chem	O
exposure	O	O
.	O	O

background	O	O
:	O	O
there	O	O
is	O	O
growing	O	O
pressure	O	O
for	O	O
clinicians	O	O
to	O	O
prescribe	O	O
chelation	O	O
therapy	O	O
at	O	O
only	O	O
slightly	O	O
elevated	O	O
blood	O	O
lead	B-chem	O
levels	O	O
.	O	O

however	O	O
,	O	O
very	O	O
few	O	O
studies	O	O
have	O	O
evaluated	O	O
whether	O	O
chelation	O	O
improves	O	O
cognitive	O	O
outcomes	O	O
in	O	O
pb	B-chem	O
-	O	O
exposed	O	O
children	O	O
,	O	O
or	O	O
whether	O	O
these	O	O
agents	O	O
have	O	O
adverse	O	O
effects	O	O
that	O	O
may	O	O
affect	O	O
brain	O	O
development	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
pb	B-chem	O
exposure	O	O
.	O	O

objectives	O	O
:	O	O

the	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
answer	O	O
these	O	O
questions	O	O
,	O	O
using	O	O
a	O	O
rodent	O	O
model	O	O
of	O	O
early	O	O
childhood	O	O
pb	B-chem	O
exposure	O	O
and	O	O
treatment	O	O
with	O	O
succimer	B-chem	B-chem
,	O	O
a	O	O
widely	O	O
used	O	O
chelating	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
pb	O	O
poisoning	O	O
.	O	O

results	O	O
:	O	O

pb	B-chem	O
exposure	O	O
produced	O	O
lasting	O	O
impairments	O	O
in	O	O
learning	O	O
,	O	O
attention	O	O
,	O	O
inhibitory	O	O
control	O	O
,	O	O
and	O	O
arousal	O	O
regulation	O	O
,	O	O
paralleling	O	O
the	O	O
areas	O	O
of	O	O
dysfunction	O	O
seen	O	O
in	O	O
pb	B-chem	O
-	O	O
exposed	O	O
children	O	O
.	O	O

succimer	B-chem	B-chem
treatment	O	O
of	O	O
the	O	O
pb	B-chem	O
-	O	O
exposed	O	O
rats	O	O
significantly	O	O
improved	O	O
learning	O	O
,	O	O
attention	O	O
,	O	O
and	O	O
arousal	O	O
regulation	O	O
,	O	O
although	O	O
the	O	O
efficacy	O	O
of	O	O
the	O	O
treatment	O	O
varied	O	O
as	O	O
a	O	O
function	O	O
of	O	O
the	O	O
pb	B-chem	O
exposure	O	O
level	O	O
and	O	O
the	O	O
specific	O	O
functional	O	O
deficit	O	O
.	O	O

in	O	O
contrast	O	O
,	O	O
succimer	B-chem	B-chem
treatment	O	O
of	O	O
rats	O	O
not	O	O
previously	O	O
exposed	O	O
to	O	O
pb	B-chem	O
produced	O	O
lasting	O	O
and	O	O
pervasive	O	O
cognitive	O	O
and	O	O
affective	O	O
dysfunction	O	O
comparable	O	O
in	O	O
magnitude	O	O
to	O	O
that	O	O
produced	O	O
by	O	O
the	O	O
higher	O	O
pb	B-chem	O
exposure	O	O
regimen	O	O
.	O	O

conclusions	O	O
:	O	O

these	O	O
are	O	O
the	O	O
first	O	O
data	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
to	O	O
show	O	O
that	O	O
treatment	O	O
with	O	O
any	O	O
chelating	O	O
agent	O	O
can	O	O
alleviate	O	O
cognitive	O	O
deficits	O	O
due	O	O
to	O	O
pb	B-chem	O
exposure	O	O
.	O	O

these	O	O
findings	O	O
suggest	O	O
that	O	O
it	O	O
may	O	O
be	O	O
possible	O	O
to	O	O
identify	O	O
a	O	O
succimer	B-chem	B-chem
treatment	O	O
protocol	O	O
that	O	O
improves	O	O
cognitive	O	O
outcomes	O	O
in	O	O
pb	B-chem	O
-	O	O
exposed	O	O
children	O	O
.	O	O

however	O	O
,	O	O
they	O	O
also	O	O
suggest	O	O
that	O	O
succimer	B-chem	B-chem
treatment	O	O
should	O	O
be	O	O
strongly	O	O
discouraged	O	O
for	O	O
children	O	O
who	O	O
do	O	O
not	O	O
have	O	O
elevated	O	O
tissue	O	O
levels	O	O
of	O	O
pb	B-chem	O
or	O	O
other	O	O
heavy	O	O
metals	O	O
.	O	O

caffeine	B-chem	B-chem
challenge	O	O
test	O	O
in	O	O
panic	O	O
disorder	O	O
and	O	O
depression	O	O
with	O	O
panic	O	O
attacks	O	O
.	O	O

our	O	O
aim	O	O
was	O	O
to	O	O
observe	O	O
if	O	O
patients	O	O
with	O	O
panic	O	O
disorder	O	O
(	O	O
pd	O	O
)	O	O
and	O	O
patients	O	O
with	O	O
major	O	O
depression	O	O
with	O	O
panic	O	O
attacks	O	O
(	O	O
mdp	O	O
)	O	O
(	O	O
diagnostic	O	O
and	O	O
statistical	O	O
manual	O	O
of	O	O
mental	O	O
disorders	O	O
,	O	O
fourth	O	O
edition	O	O
criteria	O	O
)	O	O
respond	O	O
in	O	O
a	O	O
similar	O	O
way	O	O
to	O	O
the	O	O
induction	O	O
of	O	O
panic	O	O
attacks	O	O
by	O	O
an	O	O
oral	O	O
caffeine	B-chem	B-chem
challenge	O	O
test	O	O
.	O	O

we	O	O
randomly	O	O
selected	O	O
29	O	O
patients	O	O
with	O	O
pd	O	O
,	O	O
27	O	O
with	O	O
mdp	O	O
,	O	O
25	O	O
with	O	O
major	O	O
depression	O	O
without	O	O
panic	O	O
attacks	O	O
(	O	O
md	O	O
)	O	O
,	O	O
and	O	O
28	O	O
healthy	O	O
volunteers	O	O
.	O	O

the	O	O
patients	O	O
had	O	O
no	O	O
psychotropic	O	O
drug	O	O
for	O	O
at	O	O
least	O	O
a	O	O
4	O	O
-	O	O
week	O	O
period	O	O
.	O	O

in	O	O
a	O	O
randomized	O	O
double	O	O
-	O	O
blind	O	O
experiment	O	O
performed	O	O
in	O	O
2	O	O
occasions	O	O
7	O	O
days	O	O
apart	O	O
,	O	O
480	O	O
mg	O	O
caffeine	B-chem	B-chem
and	O	O
a	O	O
caffeine	B-chem	B-chem
-	O	O
free	O	O
(	O	O
placebo	O	O
)	O	O
solution	O	O
were	O	O
administered	O	O
in	O	O
a	O	O
coffee	O	O
form	O	O
and	O	O
anxiety	O	O
scales	O	O
were	O	O
applied	O	O
before	O	O
and	O	O
after	O	O
each	O	O
test	O	O
.	O	O

a	O	O
total	O	O
of	O	O
58	O	O
.	O	O
6	O	O
%	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
pd	O	O
,	O	O
44	O	O
.	O	O
4	O	O
%	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
mdp	O	O
,	O	O
12	O	O
.	O	O
0	O	O
%	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
md	O	O
,	O	O
and	O	O
7	O	O
.	O	O
1	O	O
%	O	O
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
of	O	O
control	O	O
subjects	O	O
had	O	O
a	O	O
panic	O	O
attack	O	O
after	O	O
the	O	O
480	O	O
-	O	O
mg	O	O
caffeine	B-chem	B-chem
challenge	O	O
test	O	O
(	O	O
chi	O	O
(	O	O
2	O	O
)	O	O
(	O	O
3	O	O
)	O	O
=	O	O

16	O	O
.	O	O
22	O	O
,	O	O
p	O	O
=	O	O
.	O	O
001	O	O
)	O	O
.	O	O

the	O	O
patients	O	O
with	O	O
pd	O	O
and	O	O
mdp	O	O
were	O	O
more	O	O
sensitive	O	O
to	O	O
caffeine	B-chem	B-chem
than	O	O
were	O	O
patients	O	O
with	O	O
md	O	O
and	O	O
healthy	O	O
volunteers	O	O
.	O	O

no	O	O
panic	O	O
attack	O	O
was	O	O
observed	O	O
after	O	O
the	O	O
caffeine	B-chem	B-chem
-	O	O
free	O	O
solution	O	O
intake	O	O
.	O	O

the	O	O
patients	O	O
with	O	O
md	O	O
had	O	O
a	O	O
lower	O	O
heart	O	O
rate	O	O
response	O	O
to	O	O
the	O	O
test	O	O
than	O	O
all	O	O
the	O	O
other	O	O
groups	O	O
(	O	O
2	O	O
-	O	O
way	O	O
analysis	O	O
of	O	O
variance	O	O
,	O	O
group	O	O
by	O	O
time	O	O
interaction	O	O
with	O	O
greenhouse	O	O
-	O	O
geisser	O	O
correction	O	O
:	O	O
f	O	O
(	O	O
3	O	O
,	O	O
762	O	O
)	O	O
=	O	O
2	O	O
.	O	O
85	O	O
,	O	O
p	O	O
=	O	O
.	O	O
026	O	O
)	O	O
.	O	O

our	O	O
data	O	O
suggest	O	O
that	O	O
there	O	O
is	O	O
an	O	O
association	O	O
between	O	O
panic	O	O
attacks	O	O
,	O	O
no	O	O
matter	O	O
if	O	O
associated	O	O
with	O	O
pd	O	O
or	O	O
mdp	O	O
,	O	O
and	O	O
hyperreactivity	O	O
to	O	O
an	O	O
oral	O	O
caffeine	B-chem	B-chem
challenge	O	O
test	O	O
.	O	O

mitral	O	O
annuloplasty	O	O
as	O	O
a	O	O
ventricular	O	O
restoration	O	O
method	O	O
for	O	O
the	O	O
failing	O	O
left	O	O
ventricle	O	O
:	O	O
a	O	O
pilot	O	O
study	O	O
.	O	O

background	O	O
and	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
:	O	O

undersized	O	O
mitral	O	O
annuloplasty	O	O
(	O	O
map	O	O
)	O	O
is	O	O
effective	O	O
in	O	O
patients	O	O
with	O	O
dilated	O	O
cardiomyopathy	O	O
and	O	O
functional	O	O
mitral	O	O
regurgitation	O	O
(	O	O
mr	O	O
)	O	O
since	O	O
,	O	O
as	O	O
well	O	O
as	O	O
addressing	O	O
the	O	O
mr	O	O
,	O	O
the	O	O
map	O	O
may	O	O
also	O	O
reshape	O	O
the	O	O
dilated	O	O
left	O	O
ventricular	O	O
(	O	O
lv	O	O
)	O	O
base	O	O
.	O	O

however	O	O
,	O	O
the	O	O
direct	O	O
benefits	O	O
of	O	O
this	O	O
possible	O	O
reshaping	O	O
on	O	O
lv	O	O
function	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
underlying	O	O
mr	O	O
remain	O	O
incompletely	O	O
understood	O	O
.	O	O

the	O	O
study	O	O
aim	O	O
was	O	O
to	O	O
identify	O	O
these	O	O
benefits	O	O
in	O	O
a	O	O
canine	O	O
model	O	O
of	O	O
acute	O	O
heart	O	O
failure	O	O
.	O	O

methods	O	O
:	O	O

six	O	O
dogs	O	O
underwent	O	O
map	O	O
with	O	O
a	O	O
prosthetic	O	O
band	O	O
on	O	O
the	O	O
posterior	O	O
mitral	O	O
annulus	O	O
,	O	O
using	O	O
four	O	O
mattress	O	O
sutures	O	O
.	O	O

the	O	O
sutures	O	O
were	O	O
passed	O	O
individually	O	O
through	O	O
four	O	O
tourniquets	O	O
and	O	O
exteriorized	O	O
untied	O	O
via	O	O
the	O	O
left	O	O
atriotomy	O	O
.	O	O

sonomicrometry	O	O
crystals	O	O
were	O	O
implanted	O	O
around	O	O
the	O	O
mitral	O	O
annulus	O	O
and	O	O
left	O	O
ventricle	O	O
to	O	O
measure	O	O
geometry	O	O
and	O	O
regional	O	O
function	O	O
.	O	O

acute	O	O
heart	O	O
failure	O	O
was	O	O
induced	O	O
by	O	O
propranolol	B-chem	B-chem
and	O	O
volume	O	O
loading	O	O
after	O	O
weaning	O	O
from	O	O
cardiopulmonary	O	O
bypass	O	O
;	O	O
an	O	O
absence	O	O
of	O	O
mr	O	O
was	O	O
confirmed	O	O
by	O	O
echocardiography	O	O
.	O	O

map	O	O
was	O	O
accomplished	O	O
by	O	O
cinching	O	O
the	O	O
tourniquets	O	O
.	O	O

data	O	O
were	O	O
acquired	O	O
at	O	O
baseline	O	O
,	O	O
after	O	O
induction	O	O
of	O	O
acute	O	O
heart	O	O
failure	O	O
,	O	O
and	O	O
after	O	O
map	O	O
.	O	O

results	O	O
:	O	O

map	O	O
decreased	O	O
mitral	O	O
annular	O	O
dimensions	O	O
in	O	O
both	O	O
commissure	O	O
-	O	O
commissure	O	O
and	O	O
septal	O	O
-	O	O
lateral	O	O
directions	O	O
.	O	O

concomitantly	O	O
,	O	O
the	O	O
diastolic	O	O
diameter	O	O
of	O	O
the	O	O
lv	O	O
base	O	O
and	O	O
lv	O	O
sphericity	O	O
decreased	O	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
improved	O	O
)	O	O
from	O	O
37	O	O
.	O	O
4	O	O
+	O	O
/	O	O
-	O	O

9	O	O
.	O	O
3	O	O
to	O	O
35	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

10	O	O
mm	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
063	O	O
)	O	O
,	O	O
and	O	O
from	O	O
67	O	O
.	O	O
9	O	O
+	O	O
/	O	O
-	O	O

18	O	O
.	O	O
6	O	O
%	O	O
to	O	O
65	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O

18	O	O
.	O	O
9	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
016	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

decreases	O	O
were	O	O
evident	O	O
in	O	O
both	O	O
lv	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
(	O	O
from	O	O
17	O	O
+	O	O
/	O	O
-	O	O

7	O	O
to	O	O
15	O	O
+	O	O
/	O	O
-	O	O

6	O	O
mmhg	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0480	O	O
and	O	O
tau	O	O
(	O	O
from	O	O
48	O	O
+	O	O
/	O	O
-	O	O

8	O	O
to	O	O
45	O	O
+	O	O
/	O	O
-	O	O

8	O	O
ms	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
while	O	O
fractional	O	O
shortening	O	O
at	O	O
the	O	O
lv	O	O
base	O	O
increased	O	O
from	O	O
7	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O

4	O	O
.	O	O
5	O	O
%	O	O
to	O	O
9	O	O
.	O	O
4	O	O
+	O	O
/	O	O
-	O	O

4	O	O
.	O	O
5	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
045	O	O
)	O	O
.	O	O

after	O	O
map	O	O
,	O	O
increases	O	O
were	O	O
identified	O	O
in	O	O
both	O	O
cardiac	O	O
output	O	O
(	O	O
from	O	O
1	O	O
.	O	O
54	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
57	O	O
to	O	O
1	O	O
.	O	O
65	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
57	O	O
1	O	O
/	O	O
min	O	O
)	O	O
and	O	O
emax	O	B-chem
(	O	O
from	O	O
1	O	O
.	O	O
86	O	O
+	O	O
/	O	O
-	O	O

0	O	O
.	O	O
9	O	O
to	O	O
2	O	O
.	O	O
41	O	O
+	O	O
/	O	O
-	O	O

1	O	O
.	O	O
31	O	O
mmhg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

the	O	O
data	O	O
acquired	O	O
suggest	O	O
that	O	O
isolated	O	O
map	O	O
may	O	O
have	O	O
certain	O	O
benefits	O	O
on	O	O
lv	O	O
dimension	O	O
/	O	O
function	O	O
in	O	O
acute	O	O
heart	O	O
failure	O	O
,	O	O
even	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
mr	O	O
.	O	O

however	O	O
,	O	O
further	O	O
investigations	O	O
are	O	O
warranted	O	O
in	O	O
a	O	O
model	O	O
of	O	O
chronic	O	O
heart	O	O
failure	O	O
.	O	O

piperacillin	B-chem	B-chem
/	I-chem	O
tazobactam	I-chem	B-chem
-	O	O
induced	O	O
seizure	O	O
rapidly	O	O
reversed	O	O
by	O	O
high	O	O
flux	O	O
hemodialysis	O	O
in	O	O
a	O	O
patient	O	O
on	O	O
peritoneal	O	O
dialysis	O	O
.	O	O

despite	O	O
popular	O	O
use	O	O
of	O	O
piperacillin	B-chem	B-chem
,	O	O
the	O	O
dire	O	O
neurotoxicity	O	O
associated	O	O
with	O	O
piperacillin	B-chem	B-chem
still	O	O
goes	O	O
unrecognized	O	O
,	O	O
leading	O	O
to	O	O
a	O	O
delay	O	O
in	O	O
appropriate	O	O
management	O	O
.	O	O

we	O	O
report	O	O
a	O	O
57	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
end	O	O
-	O	O
stage	O	O
renal	O	O
disease	O	O
receiving	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
(	O	O
capd	O	O
)	O	O
,	O	O
who	O	O
developed	O	O
slurred	O	O
speech	O	O
,	O	O
tremor	O	O
,	O	O
bizarre	O	O
behavior	O	O
,	O	O
progressive	O	O
mental	O	O
confusion	O	O
,	O	O
and	O	O
2	O	O
episodes	O	O
of	O	O
generalized	O	O
tonic	O	O
-	O	O
clonic	O	O
seizure	O	O
(	O	O
gtcs	O	O
)	O	O
after	O	O
5	O	O
doses	O	O
of	O	O
piperacillin	B-chem	B-chem
/	I-chem	O
tazobactam	I-chem	B-chem
(	O	O
2	O	O
g	O	O
/	O	O
250	O	O
mg	O	O
)	O	O
were	O	O
given	O	O
for	O	O
bronchiectasis	O	O
with	O	O
secondary	O	O
infection	O	O
.	O	O

the	O	O
laboratory	O	O
data	O	O
revealed	O	O
normal	O	O
plasma	O	O
electrolyte	O	O
and	O	O
ammonia	B-chem	B-chem
levels	O	O
but	O	O
leukocytosis	O	O
.	O	O

neurologic	O	O
examinations	O	O
showed	O	O
dysarthria	O	O
and	O	O
bilateral	O	O
babinski	O	O
sign	O	O
.	O	O

computed	O	O
tomography	O	O
of	O	O
brain	O	O
and	O	O
electroencephalogram	O	O
were	O	O
unremarkable	O	O
.	O	O

despite	O	O
the	O	O
use	O	O
of	O	O
antiepileptic	O	O
agents	O	O
,	O	O
another	O	O
gtcs	O	O
episode	O	O
recurred	O	O
after	O	O
the	O	O
sixth	O	O
dose	O	O
of	O	O
piperacillin	B-chem	B-chem
/	I-chem	O
tazobactam	I-chem	B-chem
.	O	O

brain	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
did	O	O
not	O	O
demonstrate	O	O
acute	O	O
infarction	O	O
and	O	O
organic	O	O
brain	O	O
lesions	O	O
.	O	O

initiation	O	O
of	O	O
high	O	O
-	O	O
flux	O	O
hemodialysis	O	O
rapidly	O	O
reversed	O	O
the	O	O
neurologic	O	O
symptoms	O	O
within	O	O
4	O	O
hours	O	O
.	O	O

piperacillin	B-chem	B-chem
-	O	O
induced	O	O
encephalopathy	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
any	O	O
uremic	O	O
patients	O	O
with	O	O
unexplained	O	O
neurological	O	O
manifestations	O	O
.	O	O

capd	O	O
is	O	O
inefficient	O	O
in	O	O
removing	O	O
piperacillin	B-chem	B-chem
,	O	O
whereas	O	O
hemodialysis	O	O
can	O	O
rapidly	O	O
terminate	O	O
the	O	O
piperacillin	B-chem	B-chem
-	O	O
induced	O	O
encephalopathy	O	O
.	O	O

frequency	O	O
of	O	O
transient	O	O
ipsilateral	O	O
vocal	O	O
cord	O	O
paralysis	O	O
in	O	O
patients	O	O
undergoing	O	O
carotid	O	O
endarterectomy	O	O
under	O	O
local	O	O
anesthesia	O	O
.	O	O

background	O	O
:	O	O
especially	O	O
because	O	O
of	O	O
improvements	O	O
in	O	O
clinical	O	O
neurologic	O	O
monitoring	O	O

,	O	O
carotid	O	O
endarterectomy	O	O
done	O	O
under	O	O
local	O	O
anesthesia	O	O
has	O	O
become	O	O
the	O	O
technique	O	O
of	O	O
choice	O	O
in	O	O
several	O	O
centers	O	O
.	O	O

temporary	O	O
ipsilateral	O	O
vocal	O	O
nerve	O	O
palsies	O	O
due	O	O
to	O	O
local	O	O
anesthetics	O	O
have	O	O
been	O	O
described	O	O
,	O	O
however	O	O
.	O	O

such	O	O
complications	O	O
are	O	O
most	O	O
important	O	O
in	O	O
situations	O	O
where	O	O
there	O	O
is	O	O
a	O	O
pre	O	O
-	O	O
existing	O	O
contralateral	O	O
paralysis	O	O
.	O	O

we	O	O
therefore	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
local	O	O
anesthesia	O	O
on	O	O
vocal	O	O
cord	O	O
function	O	O
to	O	O
better	O	O
understand	O	O
its	O	O
possible	O	O
consequences	O	O
.	O	O

methods	O	O
:	O	O

this	O	O
prospective	O	O
study	O	O
included	O	O
28	O	O
patients	O	O
undergoing	O	O
carotid	O	O
endarterectomy	O	O
under	O	O
local	O	O
anesthesia	O	O
.	O	O

vocal	O	O
cord	O	O
function	O	O
was	O	O
evaluated	O	O
before	O	O
,	O	O
during	O	O
,	O	O
and	O	O
after	O	O
surgery	O	O
(	O	O
postoperative	O	O
day	O	O
1	O	O
)	O	O
using	O	O
flexible	O	O
laryngoscopy	O	O
.	O	O

anesthesia	O	O
was	O	O
performed	O	O
by	O	O
injecting	O	O
20	O	O
to	O	O
40	O	O
ml	O	O
of	O	O
a	O	O
mixture	O	O
of	O	O
long	O	O
-	O	O
acting	O	O
(	O	O
ropivacaine	B-chem	B-chem
)	O	O
and	O	O
short	O	O
-	O	O
acting	O	O
(	O	O
prilocaine	B-chem	B-chem
)	O	O
anesthetic	O	O
.	O	O

results	O	O
:	O	O

all	O	O
patients	O	O
had	O	O
normal	O	O
vocal	O	O
cord	O	O
function	O	O
preoperatively	O	O
.	O	O

twelve	O	O
patients	O	O
(	O	O
43	O	O
%	O	O
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
intraoperative	O	O
ipsilateral	O	O
vocal	O	O
cord	O	O
paralysis	O	O
.	O	O

it	O	O
resolved	O	O
in	O	O
all	O	O
cases	O	O
<	O	O
or	O	O
=	O	O
24	O	O
hours	O	O
.	O	O

there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
operating	O	O
time	O	O
or	O	O
volume	O	O
or	O	O
frequency	O	O
of	O	O
anesthetic	O	O
administration	O	O
in	O	O
patients	O	O
with	O	O
temporary	O	O
vocal	O	O
cord	O	O
paralysis	O	O
compared	O	O
with	O	O
those	O	O
without	O	O
.	O	O

conclusion	O	O
:	O	O

local	O	O
anesthesia	O	O
led	O	O
to	O	O
temporary	O	O
ipsilateral	O	O
vocal	O	O
cord	O	O
paralysis	O	O
in	O	O
almost	O	O
half	O	O
of	O	O
these	O	O
patients	O	O
.	O	O

because	O	O
pre	O	O
-	O	O
existing	O	O
paralysis	O	O
is	O	O
of	O	O
a	O	O
relevant	O	O
frequency	O	O
(	O	O
up	O	O
to	O	O
3	O	O
%	O	O
)	O	O
,	O	O
a	O	O
preoperative	O	O
evaluation	O	O
of	O	O
vocal	O	O
cord	O	O
function	O	O
before	O	O
carotid	O	O
endarterectomy	O	O
under	O	O
local	O	O
anesthesia	O	O
is	O	O
recommended	O	O
to	O	O
avoid	O	O
intraoperative	O	O
bilateral	O	O
paralysis	O	O
.	O	O

in	O	O
patients	O	O
with	O	O
preoperative	O	O
contralateral	O	O
vocal	O	O
cord	O	O
paralysis	O	O
,	O	O
surgery	O	O
under	O	O
general	O	O
anesthesia	O	O
should	O	O
be	O	O
considered	O	O
.	O	O

neuroprotective	O	O
effects	O	O
of	O	O
melatonin	B-chem	B-chem
upon	O	O
the	O	O
offspring	O	O
cerebellar	O	O
cortex	O	O
in	O	O
the	O	O
rat	O	O
model	O	O
of	O	O
bcnu	B-chem	B-chem
-	O	O
induced	O	O
cortical	O	O
dysplasia	O	O
.	O	O

cortical	O	O
dysplasia	O	O
is	O	O
a	O	O
malformation	O	O
characterized	O	O
by	O	O
defects	O	O
in	O	O
proliferation	O	O
,	O	O
migration	O	O
and	O	O
maturation	O	O
.	O	O

this	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
alterations	O	O
in	O	O
offspring	O	O
rat	O	O
cerebellum	O	O
induced	O	O
by	O	O
maternal	O	O
exposure	O	O
to	O	O
carmustine	B-chem	B-chem
-	O	O
[	O	B-chem
1	B-chem	I-chem
,	I-chem	I-chem
3	I-chem	I-chem
-	I-chem	I-chem
bis	I-chem	I-chem
(	I-chem	I-chem
2	I-chem	I-chem
-	I-chem	I-chem
chloroethyl	I-chem	I-chem
)	I-chem	I-chem
-	I-chem	I-chem
1	I-chem	I-chem
-	I-chem	I-chem
nitrosoure	I-chem	I-chem
]	O	I-chem
(	O	O
bcnu	B-chem	B-chem
)	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
exogenous	O	O
melatonin	B-chem	B-chem
upon	O	O
cerebellar	O	O
bcnu	B-chem	B-chem
-	O	O
induced	O	O
cortical	O	O
dysplasia	O	O
,	O	O
using	O	O
histological	O	O
and	O	O
biochemical	O	O
analyses	O	O
.	O	O

pregnant	O	O
wistar	O	O
rats	O	O
were	O	O
assigned	O	O
to	O	O
five	O	O
groups	O	O
:	O	O
intact	O	O
-	O	O
control	O	O
,	O	O
saline	O	O
-	O	O
control	O	O
,	O	O
melatonin	B-chem	B-chem
-	O	O
treated	O	O
,	O	O
bcnu	B-chem	B-chem
-	O	O
exposed	O	O
and	O	O
bcnu	B-chem	B-chem
-	O	O
exposed	O	O
plus	O	O
melatonin	B-chem	B-chem
.	O	O

rats	O	O
were	O	O
exposed	O	O
to	O	O
bcnu	B-chem	B-chem
on	O	O
embryonic	O	O
day	O	O
15	O	O
and	O	O
melatonin	B-chem	B-chem
was	O	O
given	O	O
until	O	O
delivery	O	O
.	O	O

immuno	O	O
/	O	O
histochemistry	O	O
and	O	O
electron	O	O
microscopy	O	O
were	O	O
carried	O	O
out	O	O
on	O	O
the	O	O
offspring	O	O
cerebellum	O	O
,	O	O
and	O	O
levels	O	O
of	O	O
malondialdehyde	B-chem	B-chem
and	O	O
superoxide	B-chem	B-chem
dismutase	O	O
were	O	O
determined	O	O
.	O	O

histopathologically	O	O
,	O	O
typical	O	O
findings	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
cerebella	O	O
from	O	O
the	O	O
control	O	O
groups	O	O
,	O	O
but	O	O
the	O	O
findings	O	O
consistent	O	O
with	O	O
early	O	O
embryonic	O	O
development	O	O
were	O	O
noted	O	O
in	O	O
bcnu	B-chem	B-chem
-	O	O
exposed	O	O
cortical	O	O
dysplasia	O	O
group	O	O
.	O	O

there	O	O
was	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
tunel	O	O
positive	O	O
cells	O	O
and	O	O
nestin	O	O
positive	O	O
cells	O	O
in	O	O
bcnu	B-chem	B-chem
-	O	O
exposed	O	O
group	O	O
,	O	O
but	O	O
a	O	O
decreased	O	O
immunoreactivity	O	O
to	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
,	O	O
synaptophysin	O	O
and	O	O
transforming	O	O
growth	O	O
factor	O	O
beta1	O	O
was	O	O
observed	O	O
,	O	O
indicating	O	O
a	O	O
delayed	O	O
maturation	O	O
,	O	O
and	O	O
melatonin	B-chem	B-chem
significantly	O	O
reversed	O	O
these	O	O
changes	O	O
.	O	O

malondialdehyde	B-chem	B-chem
level	O	O
in	O	O
bcnu	B-chem	B-chem
-	O	O
exposed	O	O
group	O	O
was	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
control	O	O
groups	O	O
and	O	O
melatonin	B-chem	B-chem
decreased	O	O
malondialdehyde	B-chem	B-chem
levels	O	O
in	O	O
bcnu	B-chem	B-chem
group	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
while	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
superoxide	B-chem	B-chem
dismutase	O	O
levels	O	O
between	O	O
these	O	O
groups	O	O
.	O	O

these	O	O
data	O	O
suggest	O	O
that	O	O
exposure	O	O
of	O	O
animals	O	O
to	O	O
bcnu	B-chem	B-chem
during	O	O
pregnancy	O	O
leads	O	O
to	O	O
delayed	O	O
maturation	O	O
of	O	O
offspring	O	O
cerebellum	O	O
and	O	O
melatonin	B-chem	B-chem
protects	O	O
the	O	O
cerebellum	O	O
against	O	O
the	O	O
effects	O	O
of	O	O
bcnu	B-chem	B-chem
.	O	O

myo	B-chem	O
-	I-chem	O
inositol	I-chem	B-chem
-	I-chem	I-chem
1	I-chem	I-chem
-	I-chem	I-chem
phosphate	I-chem	I-chem

(	O	O
mip	B-chem	O
)	O	O
synthase	O	O
inhibition	O	O
:	O	O
in	O	O
-	O	O
vivo	O	O
study	O	O
in	O	O
rats	O	O
.	O	O

lithium	B-chem	B-chem
and	O	O
valproate	B-chem	B-chem
are	O	O
the	O	O
prototypic	O	O
mood	O	O
stabilizers	O	O
and	O	O
have	O	O
diverse	O	O
structures	O	O
and	O	O
targets	O	O
.	O	O

both	O	O
drugs	O	O
influence	O	O
inositol	B-chem	B-chem
metabolism	O	O
.	O	O

lithium	B-chem	B-chem
inhibits	O	O
impase	O	O
and	O	O
valproate	B-chem	B-chem
inhibits	O	O

mip	B-chem	O
synthase	O	O
.	O	O

this	O	O
study	O	O
shows	O	O
that	O	O
mip	B-chem	O
synthase	O	O
inhibition	O	O
does	O	O
not	O	O
replicate	O	O
or	O	O
augment	O	O
the	O	O
effects	O	O
of	O	O
lithium	B-chem	B-chem
in	O	O
the	O	O
inositol	B-chem	B-chem
sensitive	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
seizures	O	O
model	O	O
.	O	O

this	O	O
lack	O	O
of	O	O
effects	O	O
may	O	O
stem	O	O
from	O	O
the	O	O
low	O	O
contribution	O	O
of	O	O
de	O	O
-	O	O
novo	O	O
synthesis	O	O
to	O	O
cellular	O	O
inositol	B-chem	B-chem
supply	O	O
or	O	O
to	O	O
the	O	O
inhibition	O	O
of	O	O
the	O	O
de	O	O
-	O	O
novo	O	O
synthesis	O	O
by	O	O
lithium	B-chem	B-chem
itself	O	O
.	O	O

non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
-	O	O
associated	O	O
acute	O	O
interstitial	O	O
nephritis	O	O
with	O	O
granular	O	O
tubular	O	O
basement	O	O
membrane	O	O
deposits	O	O
.	O	O

acute	O	O
tubulo	O	O
-	O	O
interstitial	O	O
nephritis	O	O
(	O	O
atin	O	B-chem
)	O	O
is	O	O
an	O	O
important	O	O
cause	O	O
of	O	O
acute	O	O
renal	O	O
failure	O	O
resulting	O	O
from	O	O
a	O	O
variety	O	O
of	O	O
insults	O	O
,	O	O
including	O	O
immune	O	O
complex	O	O
-	O	O
mediated	O	O
tubulo	O	O
-	O	O
interstitial	O	O
injury	O	O
,	O	O
but	O	O
drugs	O	O
such	O	O
as	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
(	O	O
nsaids	O	O
)	O	O
are	O	O
a	O	O
far	O	O
more	O	O
frequent	O	O
cause	O	O
.	O	O

overall	O	O
,	O	O
as	O	O
an	O	O
entity	O	O
,	O	O
atin	O	B-chem
remains	O	O
under	O	O
-	O	O
diagnosed	O	O
,	O	O
as	O	O
symptoms	O	O
resolve	O	O
spontaneously	O	O
if	O	O
the	O	O
medication	O	O
is	O	O
stopped	O	O
.	O	O

we	O	O
report	O	O
on	O	O
a	O	O
14	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
who	O	O
developed	O	O
acute	O	O
renal	O	O
failure	O	O
2	O	O
weeks	O	O
after	O	O
aortic	O	O
valve	O	O
surgery	O	O
.	O	O

he	O	O
was	O	O
put	O	O
on	O	O
aspirin	B-chem	B-chem
following	O	O
surgery	O	O
and	O	O
took	O	O
ibuprofen	B-chem	B-chem
for	O	O
fever	O	O
for	O	O
nearly	O	O
a	O	O
week	O	O
prior	O	O
to	O	O
presentation	O	O
.	O	O

he	O	O
then	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
feeling	O	O
quite	O	O
ill	O	O
and	O	O
was	O	O
found	O	O
to	O	O
have	O	O
a	O	O
blood	B-chem	B-chem
urea	I-chem	I-chem
nitrogen	I-chem	I-chem
(	O	O
bun	B-chem	O
)	O	O
concentration	O	O
of	O	O
of	O	O
147	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
creatinine	B-chem	B-chem
of	O	O
15	O	O
.	O	O
3	O	O
mg	O	O
/	O	O
dl	O	O
and	O	O
serum	O	O
potassium	B-chem	B-chem
of	O	O
8	O	O
.	O	O
7	O	O
meq	O	O
/	O	O
l	O	O
.	O	O

dialysis	O	O
was	O	O
immediately	O	O
initiated	O	O
.	O	O

a	O	O
kidney	O	O
biopsy	O	O
showed	O	O
inflammatory	O	O
infiltrate	O	O
consistent	O	O
with	O	O
atin	O	B-chem
.	O	O

however	O	O
,	O	O
in	O	O
the	O	O
tubular	O	O
basement	O	O
membrane	O	O
(	O	O
tbm	O	O
)	O	O
,	O	O
very	O	O
intense	O	O
granular	O	O
deposits	O	O
of	O	O
polyclonal	O	O
igg	O	O
and	O	O
c3	O	O
were	O	O
noted	O	O
.	O	O

he	O	O
needed	O	O
dialysis	O	O
for	O	O
2	O	O
weeks	O	O
and	O	O
was	O	O
treated	O	O
successfully	O	O
with	O	O
steroids	B-chem	B-chem
for	O	O
6	O	O
months	O	O
.	O	O

his	O	O
renal	O	O
recovery	O	O
and	O	O
disappearance	O	O
of	O	O
proteinuria	O	O
took	O	O
a	O	O
year	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
this	O	O
is	O	O
a	O	O
first	O	O
report	O	O
of	O	O
nsaids	O	O
-	O	O
associated	O	O
atin	O	B-chem
,	O	O
showing	O	O
deposits	O	O
of	O	O
granular	O	O
immune	O	O
complex	O	O
present	O	O
only	O	O
in	O	O
the	O	O
tbm	O	O
and	O	O
not	O	O
in	O	O
the	O	O
glomeruli	O	O
.	O	O

rifampicin	B-chem	B-chem
-	O	O
associated	O	O
segmental	O	O
necrotizing	O	O
glomerulonephritis	O	O
in	O	O
staphylococcal	O	O
endocarditis	O	O
.	O	O

segmental	O	O
necrotising	O	O
glomerulonephritis	O	O
has	O	O
been	O	O
reported	O	O
as	O	O
complication	O	O
of	O	O
rifampicin	B-chem	B-chem
therapy	O	O
in	O	O
patients	O	O
receiving	O	O
treatment	O	O
for	O	O
tuberculosis	O	O
.	O	O

changing	O	O
epidemiology	O	O
of	O	O
infections	O	O
such	O	O
as	O	O
infective	O	O
endocarditis	O	O
(	O	O
ie	O	O
)	O	O
has	O	O
led	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
use	O	O
of	O	O
rifampicin	B-chem	B-chem
for	O	O
staphylococcal	O	O
infections	O	O
.	O	O

we	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
staphylococcal	O	O
ie	O	O
who	O	O
developed	O	O
acute	O	O
renal	O	O
failure	O	O
secondary	O	O
to	O	O
a	O	O
segmental	O	O
necrotising	O	O
glomerulonephritis	O	O
while	O	O
being	O	O
treated	O	O
with	O	O
rifampicin	B-chem	B-chem
,	O	O
and	O	O
review	O	O
the	O	O
literature	O	O
regarding	O	O
this	O	O
complication	O	O
of	O	O
rifampicin	B-chem	B-chem
therapy	O	O
.	O	O

rate	O	O
of	O	O
ymdd	O	O
motif	O	O
mutants	O	O
in	O	O
lamivudine	B-chem	B-chem
-	O	O
untreated	O	O
iranian	O	O
patients	O	O
with	O	O
chronic	O	O
hepatitis	O	O
b	O	O
virus	O	O
infection	O	O
.	O	O

background	O	O
:	O	O
lamivudine	B-chem	B-chem
is	O	O
used	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
chronic	O	O
hepatitis	O	O
b	O	O
patients	O	O
.	O	O

recent	O	O
studies	O	O
show	O	O
that	O	O
the	O	O
ymdd	O	O
motif	O	O
mutants	O	O
(	O	O
resistant	O	O
hepatitis	O	O
b	O	O
virus	O	O
)	O	O
occur	O	O
as	O	O
natural	O	O
genome	O	O
variability	O	O
in	O	O
lamivudine	B-chem	B-chem
-	O	O
untreated	O	O
chronic	O	O
hepatitis	O	O
b	O	O
patients	O	O
.	O	O

in	O	O
this	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
determine	O	O
the	O	O
rate	O	O
of	O	O
ymdd	O	O
motif	O	O
mutants	O	O
in	O	O
lamivudine	B-chem	B-chem
-	O	O
untreated	O	O
chronic	O	O
hepatitis	O	O
b	O	O
patients	O	O
in	O	O
iran	O	B-chem
.	O	O

patients	O	O
and	O	O
methods	O	O
:	O	O

a	O	O
total	O	O
of	O	O
77	O	O
chronic	O	O
hepatitis	O	O
b	O	O
patients	O	O
who	O	O
had	O	O
not	O	O
been	O	O
treated	O	O
with	O	O
lamivudine	B-chem	B-chem
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

serum	O	O
samples	O	O
from	O	O
patients	O	O
were	O	O
tested	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
(	O	O
pcr	O	O
-	O	O
rflp	O	O
)	O	O
for	O	O
detection	O	O
of	O	O
ymdd	O	O
motif	O	O
mutants	O	O
.	O	O

all	O	O
patients	O	O
were	O	O
also	O	O
tested	O	O
for	O	O
liver	O	O
enzymes	O	O
,	O	O
anti	O	O
-	O	O
hcv	O	O
,	O	O
hbeag	B-chem	B-chem
,	O	O
and	O	O
anti	O	O
-	O	O
hbe	O	O
.	O	O

results	O	O
:	O	O

of	O	O
the	O	O
77	O	O
patients	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
,	O	O
73	O	O
%	O	O
were	O	O
male	O	O
and	O	O
27	O	O
%	O	O
were	O	O
female	O	O
.	O	O

mean	O	O
alt	O	O
and	O	O
ast	O	O
levels	O	O
were	O	O
124	O	O
.	O	O
4	O	O
+	O	O
/	O	O
-	O	O
73	O	O
.	O	O
4	O	O
and	O	O
103	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O
81	O	O
iu	O	O
/	O	O
l	O	O
,	O	O
respectively	O	O
.	O	O

hbeag	B-chem	B-chem
was	O	O
positive	O	O
in	O	O
40	O	O
%	O	O
and	O	O
anti	O	O
-	O	O
hbe	O	O
in	O	O
60	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

anti	O	O
-	O	O
hcv	O	O
was	O	O
negative	O	O
in	O	O
all	O	O
of	O	O
them	O	O
.	O	O

ymdd	O	O
motif	O	O
mutants	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
any	O	O
of	O	O
the	O	O
patients	O	O
despite	O	O
the	O	O
liver	O	O
enzyme	O	O
levels	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
hbeag	B-chem	B-chem
or	O	O
anti	O	O
-	O	O
hbe	O	O
.	O	O
conclusion	O	O
:	O	O

although	O	O
the	O	O
natural	O	O
occurrence	O	O
of	O	O
ymdd	O	O
motif	O	O
mutants	O	O
in	O	O
lamivudine	B-chem	B-chem
-	O	O
untreated	O	O
patients	O	O
with	O	O
chronic	O	O
hepatitis	O	O
b	O	O
has	O	O
been	O	O
reported	O	O
,	O	O
these	O	O
mutants	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
iranian	O	O
lamivudine	B-chem	B-chem
-	O	O
untreated	O	O
chronic	O	O
hepatitis	O	O
b	O	O
patients	O	O
.	O	O

branch	O	O
retinal	O	O
vein	O	O
occlusion	O	O
and	O	O
fluoxetine	B-chem	B-chem
.	O	O

a	O	O
case	O	O
of	O	O
branch	O	O
retinal	O	O
vein	O	O
occlusion	O	O
associated	O	O
with	O	O
fluoxetine	B-chem	B-chem
-	O	O
induced	O	O
secondary	O	O
hypertension	O	O
is	O	O
described	O	O
.	O	O

although	O	O
an	O	O
infrequent	O	O
complication	O	O
of	O	O
selective	O	B-chem
serotonin	B-chem	I-chem
reuptake	O	I-chem
inhibitor	O	I-chem
therapy	O	O
,	O	O
it	O	O
is	O	O
important	O	O
that	O	O
ophthalmologists	O	O
are	O	O
aware	O	O
that	O	O
these	O	O
agents	O	O
can	O	O
cause	O	O
hypertension	O	O
because	O	O
this	O	O
class	O	O
of	O	O
drugs	O	O
is	O	O
widely	O	O
prescribed	O	O
.	O	O

the	O	O
differential	O	O
effects	O	O
of	O	O
bupivacaine	B-chem	B-chem
and	O	O
lidocaine	B-chem	B-chem
on	O	O
prostaglandin	B-chem	B-chem
e2	I-chem	I-chem
release	O	O
,	O	O
cyclooxygenase	O	O
gene	O	O
expression	O	O
and	O	O
pain	O	O
in	O	O
a	O	O
clinical	O	O
pain	O	O
model	O	O
.	O	O

background	O	O
:	O	O

in	O	O
addition	O	O
to	O	O
blocking	O	O
nociceptive	O	O
input	O	O
from	O	O
surgical	O	O
sites	O	O
,	O	O
long	O	O
-	O	O
acting	O	O
local	O	O
anesthetics	O	O
might	O	O
directly	O	O
modulate	O	O
inflammation	O	O
.	O	O

in	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
proinflammatory	O	O
effects	O	O
of	O	O
bupivacaine	B-chem	B-chem
on	O	O
local	O	O
prostaglandin	B-chem	B-chem
e2	I-chem	I-chem
(	O	O
pge2	B-chem	B-chem
)	O	O
production	O	O
and	O	O
cyclooxygenase	O	O
(	O	O
cox	O	O
)	O	O
gene	O	O
expression	O	O
that	O	O
increases	O	O
postoperative	O	O
pain	O	O
in	O	O
human	O	O
subjects	O	O
.	O	O

methods	O	O
:	O	O
subjects	O	O
(	O	O
n	O	O
=	O	O
114	O	O
)	O	O
undergoing	O	O
extraction	O	O
of	O	O
impacted	O	O
third	O	O
molars	O	O
received	O	O
either	O	O
2	O	O
%	O	O
lidocaine	B-chem	B-chem
or	O	O
0	O	O
.	O	O
5	O	O
%	O	O
bupivacaine	B-chem	B-chem
before	O	O
surgery	O	O
and	O	O
either	O	O
rofecoxib	B-chem	B-chem
50	O	O
mg	O	O
or	O	O
placebo	O	O
orally	O	O
90	O	O
min	O	O
before	O	O
surgery	O	O
and	O	O
for	O	O
the	O	O
following	O	O
48	O	O
h	O	O
.	O	O
oral	O	O
mucosal	O	O
biopsies	O	O
were	O	O
taken	O	O
before	O	O
surgery	O	O
and	O	O
48	O	O
h	O	O
after	O	O
surgery	O	O
.	O	O

after	O	O
extraction	O	O
,	O	O
a	O	O
microdialysis	O	O
probe	O	O
was	O	O
placed	O	O
at	O	O
the	O	O
surgical	O	O
site	O	O
for	O	O
pge2	B-chem	B-chem
and	O	O
thromboxane	B-chem	B-chem
b2	I-chem	O
(	O	O
txb2	B-chem	O
)	O	O
measurements	O	O
.	O	O

results	O	O
:	O	O

the	O	O
bupivacaine	B-chem	B-chem
/	O	O
rofecoxib	B-chem	B-chem
group	O	O
reported	O	O
significantly	O	O
less	O	O
pain	O	O
,	O	O
as	O	O
assessed	O	O
by	O	O
a	O	O
visual	O	O
analog	O	O
scale	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
over	O	O
the	O	O
first	O	O
4	O	O
h	O	O
.	O	O

however	O	O
,	O	O
the	O	O
bupivacaine	B-chem	B-chem
/	O	O
placebo	O	O
group	O	O
reported	O	O
significantly	O	O
more	O	O
pain	O	O
at	O	O
24	O	O
h	O	O
and	O	O
pge2	B-chem	B-chem
levels	O	O
during	O	O
the	O	O
first	O	O
4	O	O
h	O	O
were	O	O
significantly	O	O
higher	O	O
than	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
.	O	O

moreover	O	O
,	O	O
bupivacaine	B-chem	B-chem
significantly	O	O
increased	O	O
cox	O	O
-	O	O
2	O	O
gene	O	O
expression	O	O
at	O	O
48	O	O
h	O	O
as	O	O
compared	O	O
with	O	O
the	O	O
lidocaine	B-chem	B-chem
/	O	O
placebo	O	O
group	O	O
.	O	O

thromboxane	B-chem	B-chem
levels	O	O
were	O	O
not	O	O
significantly	O	O
affected	O	O
by	O	O
any	O	O
of	O	O
the	O	O
treatments	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
effects	O	O
seen	O	O
were	O	O
attributable	O	O
to	O	O
inhibition	O	O
of	O	O
cox	O	O
-	O	O
2	O	O
,	O	O
but	O	O
not	O	O
cox	O	O
-	O	O
1	O	O
.	O	O

conclusions	O	O
:	O	O

these	O	O
results	O	O
suggest	O	O
that	O	O
bupivacaine	B-chem	B-chem
stimulates	O	O
cox	O	O
-	O	O
2	O	O
gene	O	O
expression	O	O
after	O	O
tissue	O	O
injury	O	O
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
higher	O	O
pge2	B-chem	B-chem
production	O	O
and	O	O
pain	O	O
after	O	O
the	O	O
local	O	O
anesthetic	O	O
effect	O	O
dissipates	O	O
.	O	O

p75ntr	O	O
expression	O	O
in	O	O
rat	O	O
urinary	O	O
bladder	O	O
sensory	O	O
neurons	O	O
and	O	O
spinal	O	O
cord	O	O
with	O	O
cyclophosphamide	B-chem	B-chem
-	O	O
induced	O	O
cystitis	O	O
.	O	O

a	O	O
role	O	O
for	O	O
nerve	O	O
growth	O	O
factor	O	O
(	O	O
ngf	O	O
)	O	O
in	O	O
contributing	O	O
to	O	O
increased	O	O
voiding	O	O
frequency	O	O
and	O	O
altered	O	O
sensation	O	O
from	O	O
the	O	O
urinary	O	O
bladder	O	O
has	O	O
been	O	O
suggested	O	O
.	O	O

previous	O	O
studies	O	O
have	O	O
examined	O	O
the	O	O
expression	O	O
and	O	O
regulation	O	O
of	O	O
tyrosine	B-chem	B-chem
kinase	O	O
receptors	O	O
(	O	O
trks	O	O
)	O	O
in	O	O
micturition	O	O
reflexes	O	O
with	O	O
urinary	O	O
bladder	O	O
inflammation	O	O
.	O	O

the	O	O
present	O	O
studies	O	O
examine	O	O
the	O	O
expression	O	O
and	O	O
regulation	O	O
of	O	O
another	O	O
receptor	O	O
known	O	O
to	O	O
bind	O	O
ngf	O	O
,	O	O
p75	O	O
(	O	O
ntr	O	O
)	O	O
,	O	O
after	O	O
various	O	O
durations	O	O
of	O	O
bladder	O	O
inflammation	O	O
induced	O	O
by	O	O
cyclophosphamide	B-chem	B-chem
(	O	O
cyp	B-chem	B-chem
)	O	O
.	O	O

cyp	B-chem	B-chem
-	O	O
induced	O	O
cystitis	O	O
increased	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O
001	O	O

)	O	O
p75	O	O
(	O	O
ntr	O	O
)	O	O
expression	O	O
in	O	O
the	O	O
superficial	O	O
lateral	O	O
and	O	O
medial	O	O
dorsal	O	O
horn	O	O
in	O	O
l1	O	O
-	O	O
l2	O	O
and	O	O
l6	O	O
-	O	O
s1	O	O
spinal	O	O
segments	O	O
.	O	O

the	O	O
number	O	O
of	O	O
p75	O	O
(	O	O
ntr	O	B-chem
)	O	O
-	O	O
immunoreactive	O	O
(	O	O
-	O	O
ir	O	O
)	O	O
cells	O	O
in	O	O
the	O	O
lumbosacral	O	O
dorsal	O	O
root	O	O
ganglia	O	O
(	O	O
drg	O	O
)	O	O
also	O	O
increased	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O
05	O	O
)	O	O
with	O	O
cyp	B-chem	O
-	O	O
induced	O	O
cystitis	O	O
(	O	O
acute	O	O
,	O	O
intermediate	O	O
,	O	O
and	O	O
chronic	O	O
)	O	O
.	O	O

quantitative	O	O
,	O	O
real	O	O
-	O	O
time	O	O
polymerase	O	O
chain	O	O
reaction	O	O
also	O	O
demonstrated	O	O
significant	O	O
increases	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
in	O	O
p75	O	O
(	O	O
ntr	O	O
)	O	O
mrna	O	O
in	O	O
drg	O	O
with	O	O
intermediate	O	O
and	O	O
chronic	O	O
cyp	B-chem	O
-	O	O
induced	O	O
cystitis	O	O
.	O	O

retrograde	O	O
dye	O	O
-	O	O
tracing	O	O
techniques	O	O
with	O	O
fastblue	O	O
were	O	O
used	O	O
to	O	O
identify	O	O
presumptive	O	O
bladder	O	O
afferent	O	O
cells	O	O
in	O	O
the	O	O
lumbosacral	O	O
drg	O	O
.	O	O

in	O	O
bladder	O	O
afferent	O	O
cells	O	O
in	O	O
drg	O	O
,	O	O
p75	O	O
(	O	O
ntr	O	O
)	O	O
-	O	O
ir	O	O
was	O	O
also	O	O
increased	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
with	O	O
cystitis	O	O
.	O	O

in	O	O
addition	O	O
to	O	O
increases	O	O
in	O	O
p75	O	O
(	O	O
ntr	O	B-chem
)	O	O
-	O	O
ir	O	O
in	O	O
drg	O	O
cell	O	O
bodies	O	O
,	O	O
increases	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
in	O	O
pericellular	O	O
(	O	O
encircling	O	O
drg	O	O
cells	O	O
)	O	O
p75	O	O
(	O	O
ntr	O	O
)	O	O
-	O	O
ir	O	O
in	O	O
drg	O	O
also	O	O
increased	O	O
.	O	O

confocal	O	O
analyses	O	O
demonstrated	O	O
that	O	O
pericellular	O	O
p75	O	O
(	O	O
ntr	O	B-chem
)	O	O
-	O	O
ir	O	O
was	O	O
not	O	O
colocalized	O	O
with	O	O
the	O	O
glial	O	O
marker	O	O
,	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
(	O	O
gfap	O	O
)	O	O
.	O	O

these	O	O
studies	O	O
demonstrate	O	O
that	O	O
p75	O	O
(	O	O
ntr	O	O
)	O	O
expression	O	O
in	O	O
micturition	O	O
reflexes	O	O
is	O	O
present	O	O
constitutively	O	O
and	O	O
modified	O	O
by	O	O
bladder	O	O
inflammation	O	O
.	O	O

the	O	O
functional	O	O
significance	O	O
of	O	O
p75	O	O
(	O	O
ntr	O	O
)	O	O
expression	O	O
in	O	O
micturition	O	O
reflexes	O	O
remains	O	O
to	O	O
be	O	O
determined	O	O
.	O	O

azathioprine	B-chem	B-chem
-	O	O
induced	O	O
suicidal	O	O
erythrocyte	O	O
death	O	O
.	O	O

background	O	O
:	O	O

azathioprine	B-chem	B-chem
is	O	O
widely	O	O
used	O	O
as	O	O
an	O	O
immunosuppressive	O	O
drug	O	O
.	O	O

the	O	O
side	O	O
effects	O	O
of	O	O
azathioprine	B-chem	B-chem
include	O	O
anemia	O	O
,	O	O
which	O	O
has	O	O
been	O	O
attributed	O	O
to	O	O
bone	O	O
marrow	O	O
suppression	O	O
.	O	O

alternatively	O	O
,	O	O
anemia	O	O
could	O	O
result	O	O
from	O	O
accelerated	O	O
suicidal	O	O
erythrocyte	O	O
death	O	O
or	O	O
eryptosis	O	O
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
exposure	O	O
of	O	O
phosphatidylserine	B-chem	B-chem
(	O	O
ps	B-chem	O
)	O	O
at	O	O
the	O	O
erythrocyte	O	O
surface	O	O
and	O	O
by	O	O
cell	O	O
shrinkage	O	O
.	O	O

methods	O	O
:	O	O

the	O	O
present	O	O
experiments	O	O
explored	O	O
whether	O	O
azathioprine	B-chem	B-chem
influences	O	O
eryptosis	O	O
.	O	O

according	O	O
to	O	O
annexin	O	O
v	O	O
binding	O	O
,	O	O
erythrocytes	O	O
from	O	O
patients	O	O
indeed	O	O
showed	O	O
a	O	O
significant	O	O
increase	O	O
of	O	O
ps	B-chem	O
exposure	O	O
within	O	O
1	O	O
week	O	O
of	O	O
treatment	O	O
with	O	O
azathioprine	B-chem	B-chem
.	O	O

in	O	O
a	O	O
second	O	O
series	O	O
,	O	O
cytosolic	O	O
ca2	B-chem	B-chem
+	O	O
activity	O	O
(	O	O
fluo3	B-chem	O
fluorescence	O	O
)	O	O
,	O	O
cell	O	O
volume	O	O
(	O	O
forward	O	O
scatter	O	O
)	O	O
,	O	O
and	O	O
ps	B-chem	O
-	O	O
exposure	O	O
(	O	O
annexin	O	O
v	O	O
binding	O	O
)	O	O
were	O	O
determined	O	O
by	O	O
facs	O	O
analysis	O	O
in	O	O
erythrocytes	O	O
from	O	O
healthy	O	O
volunteers	O	O
.	O	O

results	O	O
:	O	O

exposure	O	O
to	O	O
azathioprine	B-chem	B-chem
(	O	O
>	O	O
or	O	O
=	O	O
2	O	O
microg	O	O
/	O	O
ml	O	O
)	O	O
for	O	O
48	O	O
hours	O	O
increased	O	O
cytosolic	O	O
ca2	B-chem	O
+	O	O
activity	O	O
and	O	O
annexin	O	O
v	O	O
binding	O	O
and	O	O
decreased	O	O
forward	O	O
scatter	O	O
.	O	O

the	O	O
effect	O	O
of	O	O
azathioprine	B-chem	B-chem
on	O	O
both	O	O
annexin	O	O
v	O	O
binding	O	O
and	O	O
forward	O	O
scatter	O	O
was	O	O
significantly	O	O
blunted	O	O
in	O	O
the	O	O
nominal	O	O
absence	O	O
of	O	O
extracellular	O	O
ca2	B-chem	B-chem
+	O	O
.	O	O

conclusions	O	O
:	O	O

azathioprine	B-chem	B-chem
triggers	O	O
suicidal	O	O
erythrocyte	O	O
death	O	O
,	O	O
an	O	O
effect	O	O
presumably	O	O
contributing	O	O
to	O	O
azathioprine	B-chem	B-chem
-	O	O
induced	O	O
anemia	O	O
.	O	O

clinical	O	O
comparison	O	O
of	O	O
cardiorespiratory	O	O
effects	O	O
during	O	O
unilateral	O	O
and	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
.	O	O

background	O	O
:	O	O
spinal	O	O
anaesthesia	O	O
is	O	O
widely	O	O
employed	O	O
in	O	O
clinical	O	O
practice	O	O
but	O	O
has	O	O
the	O	O
main	O	O
drawback	O	O
of	O	O
post	O	O
-	O	O
spinal	O	O
block	O	O
hypotension	O	O
.	O	O

efforts	O	O
must	O	O
therefore	O	O
continue	O	O
to	O	O
be	O	O
made	O	O
to	O	O
obviate	O	O
this	O	O
setback	O	O
objective	O	O
:	O	O
to	O	O
evaluate	O	O
the	O	O
cardiovascular	O	O
and	O	O
respiratory	O	O
changes	O	O
during	O	O
unilateral	O	O
and	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
.	O	O

methods	O	O
:	O	O

with	O	O
ethical	O	O
approval	O	O
,	O	O
we	O	O
studied	O	O
74	O	O
american	O	O
society	O	O
of	O	O
anesthesiologists	O	O
(	O	O
asa	O	O
)	O	O
,	O	O
physical	O	O
status	O	O
class	O	O
1	O	O
and	O	O
2	O	O
patients	O	O
scheduled	O	O
for	O	O
elective	O	O
unilateral	O	O
lower	O	O
limb	O	O
surgery	O	O
.	O	O

patients	O	O
were	O	O
randomly	O	O
allocated	O	O
into	O	O
one	O	O
of	O	O
two	O	O
groups	O	O
:	O	O
lateral	O	O
and	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
groups	O	O
.	O	O

in	O	O
the	O	O
lateral	O	O
position	O	O
with	O	O
operative	O	O
side	O	O
down	O	O
,	O	O
patients	O	O
recived	O	O
10	O	O
mg	O	O
(	O	O
2mls	O	O
)	O	O
of	O	O
0	O	O
.	O	O
5	O	O
%	O	O
hyperbaric	O	O
bupivacaine	B-chem	B-chem
through	O	O
a	O	O
25	O	O
-	O	O
gauge	O	O
spinal	O	O
needle	O	O
.	O	O

patients	O	O
in	O	O
the	O	O
unilateral	O	O
group	O	O
were	O	O
maintained	O	O
in	O	O
the	O	O
lateral	O	O
position	O	O
for	O	O
15	O	O
minutes	O	O
following	O	O
spinal	O	O
injection	O	O
while	O	O
those	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
were	O	O
turned	O	O
supine	O	O
immediately	O	O
after	O	O
injection	O	O
.	O	O

blood	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
respiratory	O	O
rate	O	O
and	O	O
oxygen	B-chem	B-chem
saturation	O	O
were	O	O
monitored	O	O
over	O	O
1	O	O
hour	O	O
.	O	O

results	O	O
:	O	O

three	O	O
patients	O	O
(	O	O
8	O	O
.	O	O
1	O	O
%	O	O
)	O	O
in	O	O
the	O	O
unilateral	O	O
group	O	O
and	O	O
5	O	O
(	O	O
13	O	O
.	O	O
5	O	O
%	O	O
)	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
developed	O	O
hypotension	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
71	O	O
.	O	O

four	O	O
(	O	O
10	O	O
.	O	O
8	O	O
%	O	O
)	O	O
patients	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
and	O	O
1	O	O
(	O	O
2	O	O
.	O	O
7	O	O
%	O	O
)	O	O
in	O	O
the	O	O
unilateral	O	O
group	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
17	O	O
required	O	O
epinephrine	B-chem	B-chem
infusion	O	O
to	O	O
treat	O	O
hypotension	O	O
.	O	O

patients	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
had	O	O
statistically	O	O
significant	O	O
greater	O	O
fall	O	O
in	O	O
the	O	O
systolic	O	O
blood	O	O
pressures	O	O
at	O	O
15	O	O
,	O	O
30	O	O
and	O	O
45	O	O
minutes	O	O
when	O	O
compared	O	O
to	O	O
the	O	O
baseline	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
003	O	O
,	O	O
0	O	O
.	O	O
001	O	O
and	O	O
0	O	O
.	O	O
004	O	O
)	O	O
.	O	O

the	O	O
mean	O	O
respiratory	O	O
rate	O	O
and	O	O
oxygen	B-chem	B-chem
saturations	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
similar	O	O
.	O	O

conclusion	O	O
:	O	O

compared	O	O
to	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
,	O	O
unilateral	O	O
spinal	O	O
anaesthesia	O	O
was	O	O
associated	O	O
with	O	O
fewer	O	O
cardiovascular	O	O
perturbations	O	O
.	O	O

also	O	O
,	O	O
the	O	O
type	O	O
of	O	O
spinal	O	O
block	O	O
instituted	O	O
affected	O	O
neither	O	O
the	O	O
respiratory	O	O
rate	O	O
nor	O	O
the	O	O
arterial	O	O
oxygen	B-chem	O
saturation	O	O
.	O	O

spectrum	O	O
of	O	O
adverse	O	O
events	O	O
after	O	O
generic	O	O
haart	O	O
in	O	O
southern	O	O
indian	O	O
hiv	O	O
-	O	O
infected	O	O
patients	O	O
.	O	O

to	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
clinically	O	O
significant	O	O
adverse	O	O
events	O	O
after	O	O
long	O	O
-	O	O
term	O	O
,	O	O
fixed	O	O
-	O	O
dose	O	O
,	O	O
generic	O	O
highly	O	O
active	O	O
antiretroviral	O	O
therapy	O	O
(	O	O
haart	O	O
)	O	O
use	O	O
among	O	O
hiv	O	O
-	O	O
infected	O	O
individuals	O	O
in	O	O
south	O	O
india	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
experiences	O	O
of	O	O
3154	O	O
hiv	O	O
-	O	O
infected	O	O
individuals	O	O
who	O	O
received	O	O
a	O	O
minimum	O	O
of	O	O
3	O	O
months	O	O
of	O	O
generic	O	O
haart	O	O
between	O	O
february	O	O
1996	O	O
and	O	O
december	O	O
2006	O	O
at	O	O
a	O	O
tertiary	O	O
hiv	O	O
care	O	O
referral	O	O
center	O	O
in	O	O
south	O	O
india	O	O
.	O	O

the	O	O
most	O	O
common	O	O
regimens	O	O
were	O	O
3tc	B-chem	B-chem
+	O	O
d4	B-chem	O
t	I-chem	O
+	O	O
nevirapine	B-chem	B-chem
(	O	O
nvp	B-chem	O
)	O	O
(	O	O
54	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
zidovudine	B-chem	B-chem
(	O	O
azt	B-chem	B-chem
)	O	O
+	O	O
3tc	B-chem	B-chem
+	O	O
nvp	B-chem	O
(	O	O
14	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
3tc	B-chem	B-chem
+	O	O
d4	B-chem	O
t	I-chem	O
+	O	O
efavirenz	B-chem	B-chem
(	O	O
efv	B-chem	B-chem
)	O	O
(	O	O
20	O	O
.	O	O
1	O	O
%	O	O
)	O	O
,	O	O
and	O	O
azt	B-chem	B-chem
+	O	O
3tc	B-chem	B-chem
+	O	O
efv	B-chem	B-chem
(	O	O
5	O	O
.	O	O
4	O	O
%	O	O
)	O	O
.	O	O

the	O	O
most	O	O
common	O	O
adverse	O	O
events	O	O
and	O	O
median	O	O
cd4	O	O
at	O	O
time	O	O
of	O	O
event	O	O
were	O	O
rash	O	O
(	O	O
15	O	O
.	O	O
2	O	O
%	O	O
;	O	O
cd4	O	O
,	O	O
285	O	O
cells	O	O
/	O	O
microl	O	O
)	O	O
and	O	O
peripheral	O	O
neuropathy	O	O
(	O	O
9	O	O
.	O	O
0	O	O
%	O	O
and	O	O
348	O	O
cells	O	O
/	O	O
microl	O	O
)	O	O
.	O	O

clinically	O	O
significant	O	O
anemia	O	O
(	O	O
hemoglobin	O	O
<	O	O
7	O	O
g	O	O
/	O	O
dl	O	O
)	O	O
was	O	O
observed	O	O
in	O	O
5	O	O
.	O	O
4	O	O
%	O	O
of	O	O
patients	O	O
(	O	O
cd4	O	O
,	O	O
165	O	O
cells	O	O
/	O	O
microl	O	O
)	O	O
and	O	O
hepatitis	O	O
(	O	O
clinical	O	O
jaundice	O	O
with	O	O
alanine	B-chem	B-chem
aminotransferase	O	O
>	O	O
5	O	O
times	O	O
upper	O	O
limits	O	O
of	O	O
normal	O	O
)	O	O
in	O	O
3	O	O
.	O	O
5	O	O
%	O	O
of	O	O
patients	O	O
(	O	O
cd4	O	O
,	O	O
260	O	O
cells	O	O
/	O	O
microl	O	O
)	O	O
.	O	O

women	O	O
were	O	O
significantly	O	O
more	O	O
likely	O	O
to	O	O
experience	O	O
lactic	O	O
acidosis	O	O
,	O	O
while	O	O
men	O	O
were	O	O
significantly	O	O
more	O	O
likely	O	O
to	O	O
experience	O	O
immune	O	O
reconstitution	O	O
syndrome	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

among	O	O
the	O	O
patients	O	O
with	O	O
1	O	O
year	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
nvp	B-chem	O
therapy	O	O
was	O	O
significantly	O	O
associated	O	O
with	O	O
developing	O	O
rash	O	O
and	O	O
d4	B-chem	O
t	I-chem	O
therapy	O	O
with	O	O
developing	O	O
peripheral	O	O
neuropathy	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

anemia	O	O
and	O	O
hepatitis	O	O
often	O	O
occur	O	O
within	O	O
12	O	O
weeks	O	O
of	O	O
initiating	O	O
generic	O	O
haart	O	O
.	O	O

frequent	O	O
and	O	O
early	O	O
monitoring	O	O
for	O	O
these	O	O
toxicities	O	O
is	O	O
warranted	O	O
in	O	O
developing	O	O
countries	O	O
where	O	O
generic	O	O
haart	O	O
is	O	O
increasingly	O	O
available	O	O
.	O	O

thalidomide	B-chem	B-chem
and	O	O
sensory	O	O
neurotoxicity	O	O
:	O	O
a	O	O
neurophysiological	O	O
study	O	O
.	O	O

background	O	O
:	O	O

recent	O	O
studies	O	O
confirmed	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
sensory	O	O
axonal	O	O
neuropathy	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
different	O	O
doses	O	O
of	O	O
thalidomide	B-chem	B-chem
.	O	O

the	O	O
study	O	O
'	O	O
s	O	O
aims	O	O
were	O	O
to	O	O
measure	O	O
variations	O	O
in	O	O
sural	O	O
nerve	O	O
sensory	O	O
action	O	O
potential	O	O
(	O	O
sap	O	O
)	O	O
amplitude	O	O
in	O	O
patients	O	O
with	O	O
refractory	O	O
cutaneous	O	O
lupus	O	O
erythematosus	O	O
(	O	O
cle	O	O
)	O	O
treated	O	O
with	O	O
thalidomide	B-chem	B-chem
and	O	O
use	O	O
these	O	O
findings	O	O
to	O	O
identify	O	O
the	O	O
neurotoxic	O	O
potential	O	O
of	O	O
thalidomide	B-chem	B-chem
and	O	O
the	O	O
recovery	O	O
capacity	O	O
of	O	O
sensory	O	O
fibres	O	O
after	O	O
discontinuation	O	O
of	O	O
treatment	O	O
.	O	O

patients	O	O
and	O	O
methods	O	O
:	O	O

clinical	O	O
and	O	O
electrophysiological	O	O
data	O	O
in	O	O
12	O	O
female	O	O
patients	O	O
with	O	O
cle	O	O
during	O	O
treatment	O	O
with	O	O
thalidomide	B-chem	B-chem
and	O	O
up	O	O
to	O	O
47	O	O
months	O	O
after	O	O
discontinuation	O	O
of	O	O
treatment	O	O
were	O	O
analysed	O	O
.	O	O

sural	O	O
nerve	O	O
sap	O	O
amplitude	O	O
reduction	O	O
>	O	O
or	O	O
=	O	O
40	O	O
%	O	O
was	O	O
the	O	O
criteria	O	O
for	O	O
discontinuing	O	O
therapy	O	O
.	O	O

results	O	O
:	O	O

during	O	O
treatment	O	O
,	O	O
11	O	O
patients	O	O
showed	O	O
a	O	O
reduction	O	O
in	O	O
sural	O	O
nerve	O	O
sap	O	O
amplitude	O	O
compared	O	O
to	O	O
baseline	O	O
values	O	O
(	O	O
9	O	O
with	O	O
a	O	O
reduction	O	O
>	O	O
or	O	O
=	O	O
50	O	O
%	O	O
and	O	O
2	O	O
<	O	O
50	O	O
%	O	O
)	O	O
.	O	O

one	O	O
patient	O	O
showed	O	O
no	O	O
changes	O	O
in	O	O
sap	O	O
amplitude	O	O
.	O	O

five	O	O
patients	O	O
complained	O	O
of	O	O
paresthesias	O	O
and	O	O
leg	O	O
cramps	O	O
.	O	O

after	O	O
thalidomide	B-chem	B-chem
treatment	O	O
,	O	O
sural	O	O
sap	O	O
amplitude	O	O
recovered	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

at	O	O
detection	O	O
of	O	O
reduction	O	O
in	O	O
sural	O	O
nerve	O	O
sap	O	O
amplitude	O	O
,	O	O
the	O	O
median	O	O
thalidomide	B-chem	B-chem
cumulative	O	O
dose	O	O
was	O	O
21	O	O
.	O	O
4	O	O
g	O	O
.	O	O

the	O	O
threshold	O	O
neurotoxic	O	O
dosage	O	O
is	O	O
lower	O	O
than	O	O
previously	O	O
reported	O	O
.	O	O

conclusions	O	O
:	O	O

sural	O	O
nerve	O	O
sap	O	O
amplitude	O	O
reduction	O	O
is	O	O
a	O	O
reliable	O	O
and	O	O
sensitive	O	O
marker	O	O
of	O	O
degeneration	O	O
and	O	O
recovery	O	O
of	O	O
sensory	O	O
fibres	O	O
.	O	O

this	O	O
electrophysiological	O	O
parameter	O	O
provides	O	O
information	O	O
about	O	O
subclinical	O	O
neurotoxic	O	O
potential	O	O
of	O	O
thalidomide	B-chem	B-chem
but	O	O
is	O	O
not	O	O
helpful	O	O
in	O	O
predicting	O	O
the	O	O
appearance	O	O
of	O	O
sensory	O	O
symptoms	O	O
.	O	O

amiodarone	B-chem	B-chem
-	O	O
related	O	O
pulmonary	O	O
mass	O	O
and	O	O
unique	O	O
membranous	O	O
glomerulonephritis	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
valvular	O	O
heart	O	O
disease	O	O
:	O	O

diagnostic	O	O
pitfall	O	O
and	O	O
new	O	O
findings	O	O
.	O	O

amiodarone	B-chem	B-chem
is	O	O
an	O	O
anti	O	O
-	O	O
arrhythmic	O	O
drug	O	O
for	O	O
life	O	O
-	O	O
threatening	O	O
tachycardia	O	O
,	O	O
but	O	O
various	O	O
adverse	O	O
effects	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

reported	O	O
herein	O	O
is	O	O
an	O	O
autopsy	O	O
case	O	O
of	O	O
valvular	O	O
heart	O	O
disease	O	O
,	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
a	O	O
lung	O	O
mass	O	O
(	O	O
1	O	O
.	O	O
5	O	O
cm	O	O
in	O	O
diameter	O	O
)	O	O
and	O	O
proteinuria	O	O
(	O	O
2	O	O
.	O	O
76	O	O
g	O	O
/	O	O
day	O	O
)	O	O
after	O	O
treatment	O	O
with	O	O
amiodarone	B-chem	B-chem
for	O	O
a	O	O
long	O	O
time	O	O
.	O	O

the	O	O
lung	O	O
mass	O	O
was	O	O
highly	O	O
suspected	O	O
to	O	O
be	O	O
lung	O	O
cancer	O	O
on	O	O
ct	O	O
and	O	O
positron	O	O
emission	O	O
tomography	O	O
,	O	O
but	O	O
histologically	O	O
the	O	O
lesion	O	O
was	O	O
composed	O	O
of	O	O
lymphoplasmacytic	O	O
infiltrates	O	O
in	O	O
alveolar	O	O
walls	O	O
and	O	O
intra	O	O
-	O	O
alveolar	O	O
accumulation	O	O
of	O	O
foamy	O	O
macrophages	O	O
containing	O	O
characteristic	O	O
myelinoid	O	O
bodies	O	O
,	O	O
indicating	O	O
that	O	O
it	O	O
was	O	O
an	O	O
amiodarone	B-chem	B-chem
-	O	O
related	O	O
lesion	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
the	O	O
lung	O	O
tissue	O	O
had	O	O
unevenly	O	O
distributed	O	O
hemosiderin	O	O
deposition	O	O
,	O	O
and	O	O
abnormally	O	O
tortuous	O	O
capillaries	O	O
were	O	O
seen	O	O
in	O	O
the	O	O
mass	O	O
and	O	O
in	O	O
heavily	O	O
hemosiderotic	O	O
lung	O	O
portions	O	O
outside	O	O
the	O	O
mass	O	O
.	O	O

in	O	O
the	O	O
kidneys	O	O
,	O	O
glomeruli	O	O
had	O	O
membrane	O	O
spikes	O	O
,	O	O
prominent	O	O
swelling	O	O
of	O	O
podocytes	O	O
and	O	O
subepithelial	O	O
deposits	O	O
,	O	O
which	O	O
were	O	O
sometimes	O	O
large	O	O
and	O	O
hump	O	O
-	O	O
like	O	O
.	O	O

autoimmune	O	O
diseases	O	O
,	O	O
viral	O	O
hepatitis	O	O
,	O	O
malignant	O	O
neoplasms	O	O
or	O	O
other	O	O
diseases	O	O
with	O	O
a	O	O
known	O	O
relationship	O	O
to	O	O
membranous	O	O
glomerulonephritis	O	O
were	O	O
not	O	O
found	O	O
.	O	O

the	O	O
present	O	O
case	O	O
highlights	O	O
the	O	O
possibility	O	O
that	O	O
differential	O	O
diagnosis	O	O
between	O	O
an	O	O
amiodarone	B-chem	B-chem
-	O	O
related	O	O
pulmonary	O	O
lesion	O	O
and	O	O
a	O	O
neoplasm	O	O
can	O	O
be	O	O
very	O	O
difficult	O	O
radiologically	O	O
,	O	O
and	O	O
suggests	O	O
that	O	O
membranous	O	O
glomerulonephritis	O	O
might	O	O
be	O	O
another	O	O
possible	O	O
complication	O	O
of	O	O
amiodarone	B-chem	B-chem
treatment	O	O
.	O	O

risk	O	O
of	O	O
coronary	O	O
artery	O	O
disease	O	O
associated	O	O
with	O	O
initial	O	O
sulphonylurea	B-chem	B-chem
treatment	O	O
of	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
:	O	O
a	O	O
matched	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

aims	O	O
:	O	O

this	O	O
study	O	O
sought	O	O
to	O	O
assess	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
coronary	O	O
artery	O	O
disease	O	O
(	O	O
cad	O	O
)	O	O
associated	O	O
with	O	O
initial	O	O
treatment	O	O
of	O	O
type	O	O
2	O	O
diabetes	O	O
with	O	O
different	O	O
sulphonylureas	B-chem	O
.	O	O

methods	O	O
:	O	O

in	O	O
type	O	O
2	O	O
diabetic	O	O
patients	O	O
,	O	O
cases	O	O
who	O	O
developed	O	O
cad	O	O
were	O	O
compared	O	O
retrospectively	O	O
with	O	O
controls	O	O
that	O	O
did	O	O
not	O	O
.	O	O

the	O	O
20	O	O
-	O	O
year	O	O
risk	O	O
of	O	O
cad	O	O
at	O	O
diagnosis	O	O
of	O	O
diabetes	O	O
,	O	O
using	O	O
the	O	O
ukpds	O	O
risk	O	O
engine	O	O
,	O	O
was	O	O
used	O	O
to	O	O
match	O	O
cases	O	O
with	O	O
controls	O	O
.	O	O

results	O	O
:	O	O

the	O	O
76	O	O
cases	O	O
of	O	O
cad	O	O
were	O	O
compared	O	O
with	O	O
152	O	O
controls	O	O
.	O	O

the	O	O
hazard	O	O
of	O	O
developing	O	O
cad	O	O
(	O	O
95	O	O
%	O	O
ci	O	O
)	O	O
associated	O	O
with	O	O
initial	O	O
treatment	O	O
increased	O	O
by	O	O
2	O	O
.	O	O
4	O	O
-	O	O
fold	O	O
(	O	O
1	O	O
.	O	O
3	O	O
-	O	O
4	O	O
.	O	O
3	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
004	O	O
)	O	O
with	O	O
glibenclamide	B-chem	B-chem
;	O	O
2	O	O
-	O	O
fold	O	O
(	O	O
0	O	O
.	O	O
9	O	O
-	O	O
4	O	O
.	O	O
6	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
099	O	O
)	O	O
with	O	O
glipizide	B-chem	B-chem
;	O	O
2	O	O
.	O	O
9	O	O
-	O	O
fold	O	O
(	O	O
1	O	O
.	O	O
6	O	O
-	O	O
5	O	O
.	O	O
1	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
000	O	O
)	O	O
with	O	O
either	O	O
,	O	O
and	O	O
was	O	O
unchanged	O	O
with	O	O
metformin	B-chem	B-chem
.	O	O

the	O	O
hazard	O	O
decreased	O	O
0	O	O
.	O	O
3	O	O
-	O	O
fold	O	O
(	O	O
0	O	O
.	O	O
7	O	O
-	O	O
1	O	O
.	O	O
7	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
385	O	O
)	O	O
with	O	O
glimepiride	B-chem	B-chem
,	O	O
0	O	O
.	O	O
4	O	O
-	O	O
fold	O	O
(	O	O
0	O	O
.	O	O
7	O	O
-	O	O
1	O	O
.	O	O
3	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
192	O	O
)	O	O
with	O	O
gliclazide	B-chem	B-chem
,	O	O
and	O	O
0	O	O
.	O	O
4	O	O
-	O	O
fold	O	O
(	O	O
0	O	O
.	O	O
7	O	O
-	O	O
1	O	O
.	O	O
1	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
09	O	O
)	O	O
with	O	O
either	O	O
.	O	O

conclusions	O	O
:	O	O

initiating	O	O
treatment	O	O
of	O	O
type	O	O
2	O	O
diabetes	O	O
with	O	O
glibenclamide	B-chem	B-chem
or	O	O
glipizide	B-chem	B-chem
is	O	O
associated	O	O
with	O	O
increased	O	O
risk	O	O
of	O	O
cad	O	O
in	O	O
comparison	O	O
to	O	O
gliclazide	B-chem	B-chem
or	O	O
glimepiride	B-chem	B-chem
.	O	O

if	O	O
confirmed	O	O
,	O	O
this	O	O
may	O	O
be	O	O
important	O	O
because	O	O
most	O	O
indian	O	O
patients	O	O
receive	O	O
the	O	O
cheaper	O	O
older	O	O
sulphonylureas	B-chem	O
,	O	O
and	O	O
present	O	O
guidelines	O	O
do	O	O
not	O	O
distinguish	O	O
between	O	O
individual	O	O
agents	O	O
.	O	O

reduced	O	O
progression	O	O
of	O	O
adriamycin	B-chem	B-chem
nephropathy	O	O
in	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
treated	O	O
by	O	O
losartan	B-chem	B-chem
.	O	O

background	O	O
:	O	O

the	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
antihypertensive	O	O
effects	O	O
of	O	O
angiotensin	B-chem	B-chem
ii	I-chem	I-chem
type	O	O
-	O	O
1	O	O
receptor	O	O
blocker	O	O
,	O	O
losartan	B-chem	B-chem
,	O	O
and	O	O
its	O	O
potential	O	O
in	O	O
slowing	O	O
down	O	O
renal	O	O
disease	O	O
progression	O	O
in	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
(	O	O
shr	O	O
)	O	O
with	O	O
adriamycin	B-chem	B-chem
(	O	O
adr	B-chem	B-chem
)	O	O
nephropathy	O	O
.	O	O

methods	O	O
:	O	O

six	O	O
-	O	O
month	O	O
-	O	O
old	O	O
female	O	O
shr	O	O
were	O	O
randomly	O	O
selected	O	O
in	O	O
six	O	O
groups	O	O
.	O	O

two	O	O
control	O	O
groups	O	O
(	O	O
sh	O	O
(	O	O
6	O	O
)	O	O
,	O	O
sh	O	O
(	O	O
12	O	O
)	O	O
)	O	O
received	O	O
vehicle	O	O
.	O	O

groups	O	O
adr	B-chem	B-chem
(	O	O
6	O	O
)	O	O
,	O	O
adr	B-chem	B-chem
+	O	O
los	B-chem	O
(	O	O
6	O	O
)	O	O
and	O	O
adr	B-chem	B-chem
(	O	O
12	O	O
)	O	O
,	O	O
and	O	O
adr	B-chem	B-chem
+	O	O
los	B-chem	O
(	O	O
12	O	O
)	O	O
received	O	O
adr	B-chem	B-chem
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
b	O	O
.	O	O
w	O	O
.	O	O
i	O	O
.	O	O
v	O	O
.	O	O
)	O	O
twice	O	O
in	O	O
a	O	O
3	O	O
-	O	O
week	O	O
interval	O	O
.	O	O

group	O	O
adr	B-chem	B-chem
+	O	O
los	B-chem	O
(	O	O
6	O	O
)	O	O
received	O	O
losartan	B-chem	B-chem
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
b	O	O
.	O	O
w	O	O
.	O	O
/	O	O
day	O	O
by	O	O
gavages	O	O
)	O	O
for	O	O
6	O	O
weeks	O	O
and	O	O
group	O	O
adr	B-chem	B-chem
+	O	O
los	B-chem	O
(	O	O
12	O	O
)	O	O
for	O	O
12	O	O
weeks	O	O
after	O	O
second	O	O
injection	O	O
of	O	O
adr	B-chem	B-chem
.	O	O

animals	O	O
were	O	O
killed	O	O
after	O	O
6	O	O
or	O	O
12	O	O
weeks	O	O
,	O	O
respectively	O	O
.	O	O

haemodynamic	O	O
measurements	O	O
were	O	O
performed	O	O
on	O	O
anaesthetized	O	O
animals	O	O
,	O	O
blood	O	O
and	O	O
urine	O	O
samples	O	O
were	O	O
taken	O	O
for	O	O
biochemical	O	O
analysis	O	O
and	O	O
the	O	O
left	O	O
kidney	O	O
was	O	O
processed	O	O
for	O	O
morphological	O	O
studies	O	O
.	O	O

results	O	O
:	O	O

short	O	O
-	O	O
term	O	O
losartan	B-chem	B-chem
treatment	O	O
,	O	O
besides	O	O
antihypertensive	O	O
effect	O	O
,	O	O
improved	O	O
glomerular	O	O
filtration	O	O
rate	O	O
and	O	O
ameliorated	O	O
glomerulosclerosis	O	O
resulting	O	O
in	O	O
decreased	O	O
proteinuria	O	O
.	O	O

prolonged	O	O
treatment	O	O
with	O	O
losartan	B-chem	B-chem
showed	O	O
further	O	O
reduction	O	O
of	O	O
glomerulosclerosis	O	O
associated	O	O
with	O	O
reduced	O	O
progression	O	O
of	O	O
tubular	O	O
atrophy	O	O
and	O	O
interstitial	O	O
fibrosis	O	O
,	O	O
thus	O	O
preventing	O	O
heavy	O	O
proteinuria	O	O
and	O	O
chronic	O	O
renal	O	O
failure	O	O
.	O	O

losartan	B-chem	B-chem
reduced	O	O
uraemia	O	O
and	O	O
increased	O	O
urea	B-chem	B-chem
clearance	O	O
in	O	O
advanced	O	O
adr	B-chem	O
nephropathy	O	O
in	O	O
shr	O	O
.	O	O

histological	O	O
examination	O	O
showed	O	O
that	O	O
losartan	B-chem	B-chem
could	O	O
prevent	O	O
tubular	O	O
atrophy	O	O
,	O	O
interstitial	O	O
infiltration	O	O
and	O	O
fibrosis	O	O
in	O	O
adr	B-chem	O
nephropathy	O	O
.	O	O

conclusion	O	O
:	O	O

losartan	B-chem	B-chem
reduces	O	O
the	O	O
rate	O	O
of	O	O
progression	O	O
of	O	O
adr	B-chem	B-chem
-	O	O
induced	O	O
focal	O	O
segmental	O	O
glomerulosclerosis	O	O
to	O	O
end	O	O
-	O	O
stage	O	O
renal	O	O
disease	O	O
in	O	O
shr	O	O
.	O	O

the	O	O
risks	O	O
of	O	O
aprotinin	O	O
and	O	O
tranexamic	B-chem	B-chem
acid	I-chem	I-chem
in	O	O
cardiac	O	O
surgery	O	O
:	O	O
a	O	O
one	O	O
-	O	O
year	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
1188	O	O
consecutive	O	O
patients	O	O
.	O	O

background	O	O
:	O	O

our	O	O
aim	O	O
was	O	O
to	O	O
investigate	O	O
postoperative	O	O
complications	O	O
and	O	O
mortality	O	O
after	O	O
administration	O	O
of	O	O
aprotinin	O	O
compared	O	O
to	O	O
tranexamic	B-chem	B-chem
acid	I-chem	I-chem
in	O	O
an	O	O
unselected	O	O
,	O	O
consecutive	O	O
cohort	O	O
.	O	O

methods	O	O
:	O	O

perioperative	O	O
data	O	O
from	O	O
consecutive	O	O
cardiac	O	O
surgery	O	O
patients	O	O
were	O	O
prospectively	O	O
collected	O	O
between	O	O
september	O	O
2005	O	O
and	O	O
june	O	O
2006	O	O
in	O	O
a	O	O
university	O	O
-	O	O
affiliated	O	O
clinic	O	O
(	O	O
n	O	O
=	O	O
1188	O	O
)	O	O
.	O	O

during	O	O
the	O	O
first	O	O
5	O	O
mo	O	O
,	O	O
596	O	O
patients	O	O
received	O	O
aprotinin	O	O
(	O	O
group	O	O
a	O	O
)	O	O
;	O	O
in	O	O
the	O	O
next	O	O
5	O	O
mo	O	O
,	O	O
592	O	O
patients	O	O
were	O	O
treated	O	O
with	O	O
tranexamic	B-chem	B-chem
acid	I-chem	I-chem
(	O	O
group	O	O
t	O	O
)	O	O
.	O	O

except	O	O
for	O	O
antifibrinolytic	O	O
therapy	O	O
,	O	O
the	O	O
anesthetic	O	O
and	O	O
surgical	O	O
protocols	O	O
remained	O	O
unchanged	O	O
.	O	O

results	O	O
:	O	O

the	O	O
pre	O	O
-	O	O
and	O	O
intraoperative	O	O
variables	O	O
were	O	O
comparable	O	O
between	O	O
the	O	O
treatment	O	O
groups	O	O
.	O	O

postoperatively	O	O
,	O	O
a	O	O
significantly	O	O
higher	O	O
incidence	O	O
of	O	O
seizures	O	O
was	O	O
found	O	O
in	O	O
group	O	O
t	O	O
(	O	O
4	O	O
.	O	O
6	O	O
%	O	O
vs	O	O
1	O	O
.	O	O
2	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

this	O	O
difference	O	O
was	O	O
also	O	O
significant	O	O
in	O	O
the	O	O
primary	O	O
valve	O	O
surgery	O	O
and	O	O
the	O	O
high	O	O
risk	O	O
surgery	O	O
subgroups	O	O
(	O	O
7	O	O
.	O	O
9	O	O
%	O	O
vs	O	O
1	O	O
.	O	O
2	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
003	O	O
;	O	O
7	O	O
.	O	O
3	O	O
%	O	O
vs	O	O
2	O	O
.	O	O
4	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
035	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

persistent	O	O
atrial	O	O
fibrillation	O	O
(	O	O
7	O	O
.	O	O
9	O	O
%	O	O
vs	O	O
2	O	O
.	O	O
3	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
020	O	O
)	O	O
and	O	O
renal	O	O
failure	O	O
(	O	O
9	O	O
.	O	O
7	O	O
%	O	O
vs	O	O
1	O	O
.	O	O
7	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
002	O	O
)	O	O
were	O	O
also	O	O
more	O	O
common	O	O
in	O	O
group	O	O
t	O	O
,	O	O
in	O	O
the	O	O
primary	O	O
valve	O	O
surgery	O	O
subgroup	O	O
.	O	O

on	O	O
the	O	O
contrary	O	O
,	O	O
among	O	O
primary	O	O
coronary	O	O
artery	O	O
bypass	O	O
surgery	O	O
patients	O	O
,	O	O
there	O	O
were	O	O
more	O	O
acute	O	O
myocardial	O	O
infarctions	O	O
and	O	O
renal	O	O
dysfunction	O	O
in	O	O
group	O	O
a	O	O
(	O	O
5	O	O
.	O	O
8	O	O
%	O	O
vs	O	O
2	O	O
.	O	O
0	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
027	O	O
;	O	O
22	O	O
.	O	O
5	O	O
%	O	O
vs	O	O
15	O	O
.	O	O
2	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
036	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

the	O	O
1	O	O
-	O	O
yr	O	O
mortality	O	O
was	O	O
significantly	O	O
higher	O	O
after	O	O
aprotinin	O	O
treatment	O	O
in	O	O
the	O	O
high	O	O
risk	O	O
surgery	O	O
group	O	O
(	O	O
17	O	O
.	O	O
7	O	O
%	O	O
vs	O	O
9	O	O
.	O	O
8	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
034	O	O
)	O	O
.	O	O

conclusion	O	O
:	O	O

both	O	O
antifibrinolytic	O	O
drugs	O	O
bear	O	O
the	O	O
risk	O	O
of	O	O
adverse	O	O
outcome	O	O
depending	O	O
on	O	O
the	O	O
type	O	O
of	O	O
cardiac	O	O
surgery	O	O
.	O	O

administration	O	O
of	O	O
aprotinin	O	O
should	O	O
be	O	O
avoided	O	O
in	O	O
coronary	O	O
artery	O	O
bypass	O	O
graft	O	O
and	O	O
high	O	O
risk	O	O
patients	O	O
,	O	O
whereas	O	O
administration	O	O
of	O	O
tranexamic	B-chem	B-chem
acid	I-chem	I-chem
is	O	O
not	O	O
recommended	O	O
in	O	O
valve	O	O
surgery	O	O
.	O	O

the	O	O
biological	O	O
properties	O	O
of	O	O
the	O	O
optical	O	O
isomers	O	O
of	O	O
propranolol	B-chem	B-chem
and	O	O
their	O	O
effects	O	O
on	O	O
cardiac	O	O
arrhythmias	O	O
.	O	O

1	O	O
.	O	O

the	O	O
optical	O	O
isomers	O	O
of	O	O
propranolol	B-chem	B-chem
have	O	O
been	O	O
compared	O	O
for	O	O
their	O	O
beta	O	O
-	O	O
blocking	O	O
and	O	O
antiarrhythmic	O	O
activities	O	O
.	O	O
2	O	O
.	O	O

in	O	O
blocking	O	O
the	O	O
positive	O	O
inotropic	O	O
and	O	O
chronotropic	O	O
responses	O	O
to	O	O
isoprenaline	B-chem	B-chem
,	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
had	O	O
less	O	O
than	O	O
one	O	O
hundredth	O	O
the	O	O
potency	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
.	O	O

at	O	O
dose	O	O
levels	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
which	O	O
attenuated	O	O
the	O	O
responses	O	O
to	O	O
isoprenaline	B-chem	B-chem
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
prolongation	O	O
of	O	O
the	O	O
pr	O	O
interval	O	O
of	O	O
the	O	O
electrocardiogram	O	O
.	O	O
3	O	O
.	O	O

the	O	O
metabolic	O	O
responses	O	O
to	O	O
isoprenaline	B-chem	B-chem
in	O	O
dogs	O	O
(	O	O
an	O	O
increase	O	O
in	O	O
circulating	O	O
glucose	B-chem	B-chem
,	O	O
lactate	B-chem	B-chem
and	O	O
free	O	B-chem
fatty	B-chem	I-chem
acids	I-chem	I-chem
)	O	O
were	O	O
all	O	O
blocked	O	O
by	O	O
(	O	O
-	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
.	O	O

(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
had	O	O
no	O	O
effect	O	O
on	O	O
fatty	B-chem	B-chem
acid	I-chem	I-chem
mobilization	O	O
but	O	O
significantly	O	O
reduced	O	O
the	O	O
increments	O	O
in	O	O
both	O	O
lactate	B-chem	B-chem
and	O	O
glucose	B-chem	B-chem
.	O	O
4	O	O
.	O	O

both	O	O
isomers	O	O
of	O	O
propranolol	B-chem	B-chem
possessed	O	O
similar	O	O
depressant	O	O
potency	O	O
on	O	O
isolated	O	O
atrial	O	O
muscle	O	O
taken	O	O
from	O	O
guinea	O	O
-	O	O
pigs	O	O
.	O	O
5	O	O
.	O	O

the	O	O
isomers	O	O
of	O	O
propranolol	B-chem	B-chem
exhibited	O	O
similar	O	O
local	O	O
anaesthetic	O	O
potencies	O	O
on	O	O
an	O	O
isolated	O	O
frog	O	O
nerve	O	O
preparation	O	B-chem
at	O	O
a	O	O
level	O	O
approximately	O	O
three	O	O
times	O	O
that	O	O
of	O	O
procaine	B-chem	B-chem
.	O	O

the	O	O
racemic	O	B-chem
compound	O	O
was	O	O
significantly	O	O
less	O	O
potent	O	O
than	O	O
either	O	O
isomer	O	O
.	O	O
6	O	O
.	O	O

both	O	O
isomers	O	O
of	O	O
propranolol	B-chem	B-chem
were	O	O
capable	O	O
of	O	O
preventing	O	O
adrenaline	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
arrhythmias	O	O
in	O	O
cats	O	O
anaesthetized	O	O
with	O	O
halothane	B-chem	B-chem
,	O	O
but	O	O
the	O	O
mean	O	O
dose	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
was	O	O
0	O	O
.	O	O
09	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
02	O	O
mg	O	O
/	O	O
kg	O	O
whereas	O	O
that	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
was	O	O
4	O	O
.	O	O
2	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

at	O	O
the	O	O
effective	O	O
dose	O	O
level	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
there	O	O
was	O	O
a	O	O
significant	O	O
prolongation	O	O
of	O	O
the	O	O
pr	O	O
interval	O	O
of	O	O
the	O	O
electrocardiogram	O	O
.	O	O

blockade	O	O
of	O	O
arrhythmias	O	O
with	O	O
both	O	O
isomers	O	O
was	O	O
surmountable	O	O
by	O	O
increasing	O	O
the	O	O
dose	O	O
of	O	O
adrenaline	B-chem	B-chem
.	O	O
7	O	O
.	O	O

both	O	O
isomers	O	O
of	O	O
propranolol	B-chem	B-chem
were	O	O
also	O	O
capable	O	O
of	O	O
reversing	O	O
ventricular	O	O
tachycardia	O	O
caused	O	O
by	O	O
ouabain	B-chem	B-chem
in	O	O
anaesthetized	O	O
cats	O	O
and	O	O
dogs	O	O
.	O	O

the	O	O
dose	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
was	O	O
significantly	O	O
smaller	O	O
than	O	O
that	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-chem	B-chem
in	O	O
both	O	O
species	O	O
but	O	O
much	O	O
higher	O	O
than	O	O
that	O	O
required	O	O
to	O	O
produce	O	O
evidence	O	O
of	O	O
beta	O	O
-	O	O
blockade	O	O
.	O	O
8	O	O
.	O	O

the	O	O
implications	O	O
of	O	O
these	O	O
results	O	O
are	O	O
discussed	O	O
.	O	O

topotecan	B-chem	B-chem
in	O	O
combination	O	O
with	O	O
radiotherapy	O	O
in	O	O
unresectable	O	O
glioblastoma	O	O
:	O	O
a	O	O
phase	O	O
2	O	O
study	O	O
.	O	O

improving	O	O
glioblastoma	O	O
multiforme	O	O
(	O	O
gbm	O	B-chem
)	O	O
treatment	O	O
with	O	O
radio	O	O
-	O	O
chemotherapy	O	O
remains	O	O
a	O	O
challenge	O	O
.	O	O

topotecan	B-chem	B-chem
is	O	O
an	O	O
attractive	O	O
option	O	O
as	O	O
it	O	O
exhibits	O	O
growth	O	O
inhibition	O	O
of	O	O
human	O	O
glioma	O	O
as	O	O
well	O	O
as	O	O
brain	O	O
penetration	O	O
.	O	O

the	O	O
present	O	O
study	O	O
assessed	O	O
the	O	O
combination	O	O
of	O	O
radiotherapy	O	O
(	O	O
60	O	O
gy	O	O
/	O	O
30	O	O
fractions	O	O
/	O	O
40	O	O
days	O	O
)	O	O
and	O	O
topotecan	B-chem	B-chem
(	O	O
0	O	O
.	O	O
9	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
/	O	O
day	O	O
on	O	O
days	O	O
1	O	O
-	O	O
5	O	O
on	O	O
weeks	O	O
1	O	O
,	O	O
3	O	O
and	O	O
5	O	O
)	O	O
in	O	O
50	O	O
adults	O	O
with	O	O
histologically	O	O
proven	O	O
and	O	O
untreated	O	O
gbm	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
non	O	O
-	O	O
hematological	O	O
toxicities	O	O
was	O	O
low	O	O
and	O	O
grade	O	O
3	O	O
-	O	O
4	O	O
hematological	O	O
toxicities	O	O
were	O	O
reported	O	O
in	O	O
20	O	O
patients	O	O
(	O	O
mainly	O	O
lymphopenia	O	O
and	O	O
neutropenia	O	O
)	O	O
.	O	O

partial	O	O
response	O	O
and	O	O
stabilization	O	O
rates	O	O
were	O	O
2	O	O
%	O	O
and	O	O
32	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
with	O	O
an	O	O
overall	O	O
time	O	O
to	O	O
progression	O	O
of	O	O
12	O	O
weeks	O	O
.	O	O

one	O	O
-	O	O
year	O	O
overall	O	O
survival	O	O
(	O	O
os	O	O
)	O	O
rate	O	O
was	O	O
42	O	O
%	O	O
,	O	O
with	O	O
a	O	O
median	O	O
os	O	O
of	O	O
40	O	O
weeks	O	O
.	O	O

topotecan	B-chem	B-chem
in	O	O
combination	O	O
with	O	O
radiotherapy	O	O
was	O	O
well	O	O
tolerated	O	O
.	O	O

however	O	O
,	O	O
while	O	O
response	O	O
and	O	O
stabilization	O	O
concerned	O	O
one	O	O
-	O	O
third	O	O
of	O	O
the	O	O
patients	O	O
,	O	O
the	O	O
study	O	O
did	O	O
not	O	O
show	O	O
increased	O	O
benefits	O	O
in	O	O
terms	O	O
of	O	O
survival	O	O
in	O	O
patients	O	O
with	O	O
unresectable	O	O
gbm	O	O
.	O	O

long	O	O
-	O	O
term	O	O
lithium	B-chem	B-chem
therapy	O	O
leading	O	O
to	O	O
hyperparathyroidism	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

purpose	O	O
:	O	O

this	O	O
paper	O	O
reviews	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
lithium	B-chem	B-chem
therapy	O	O
on	O	O
serum	O	O
calcium	B-chem	B-chem
level	O	O
and	O	O
parathyroid	O	O
glands	O	O
,	O	O
its	O	O
pathogenesis	O	O
,	O	O
and	O	O
treatment	O	O
options	O	O
.	O	O

we	O	O
examined	O	O
the	O	O
case	O	O
of	O	O
a	O	O
lithium	B-chem	B-chem
-	O	O
treated	O	O
patient	O	O
who	O	O
had	O	O
recurrent	O	O
hypercalcemia	O	O
to	O	O
better	O	O
understand	O	O
the	O	O
disease	O	O
process	O	O
.	O	O

conclusion	O	O
:	O	O

primary	O	O
hyperparathyroidism	O	O
is	O	O
a	O	O
rare	O	O
but	O	O
potentially	O	O
life	O	O
-	O	O
threatening	O	O
side	O	O
effect	O	O
of	O	O
long	O	O
-	O	O
term	O	O
lithium	B-chem	B-chem
therapy	O	O
.	O	O

careful	O	O
patient	O	O
selection	O	O
and	O	O
long	O	O
-	O	O
term	O	O
follow	O	O
-	O	O
up	O	O
can	O	O
reduce	O	O
morbidity	O	O
.	O	O

practical	O	O
implications	O	O
:	O	O

as	O	O
much	O	O
as	O	O
15	O	O
%	O	O
of	O	O
lithium	B-chem	B-chem
-	O	O
treated	O	O
patients	O	O
become	O	O
hypercalcemic	O	O
.	O	O

by	O	O
routinely	O	O
monitoring	O	O
serum	O	O
calcium	B-chem	B-chem
levels	O	O
,	O	O
healthcare	O	O
providers	O	O
can	O	O
improve	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
of	O	O
this	O	O
patient	O	O
group	O	O
.	O	O

comparison	O	O
of	O	O
laryngeal	O	O
mask	O	O
with	O	O
endotracheal	O	O
tube	O	O
for	O	O
anesthesia	O	O
in	O	O
endoscopic	O	O
sinus	O	O
surgery	O	O
.	O	O

background	O	O
:	O	O

the	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
surgical	O	O
conditions	O	O
,	O	O
including	O	O
the	O	O
amount	O	O
of	O	O
intraoperative	O	O
bleeding	O	O
as	O	O
well	O	O
as	O	O
intraoperative	O	O
blood	O	O
pressure	O	O
,	O	O
during	O	O
functional	O	O
endoscopic	O	O
sinus	O	O
surgery	O	O
(	O	O
fess	O	O
)	O	O
using	O	O
flexible	O	O
reinforced	O	O
laryngeal	O	O
mask	O	O
airway	O	O
(	O	O
frlma	O	O
)	O	O
versus	O	O
endotracheal	O	O
tube	O	O
(	O	O
ett	O	O
)	O	O
in	O	O
maintaining	O	O
controlled	O	O
hypotension	O	O
anesthesia	O	O
induced	O	O
by	O	O
propofol	B-chem	B-chem
-	O	O
remifentanil	B-chem	B-chem
total	O	O
i	O	O
.	O	O
v	O	O
.	O	O

anesthesia	O	O
(	O	O
tiva	O	O
)	O	O
.	O	O

methods	O	O
:	O	O

sixty	O	O
normotensive	O	O
american	O	O
society	O	O
of	O	O
anesthesiologists	O	O
i	O	O
-	O	O
ii	O	O
adult	O	O
patients	O	O
undergoing	O	O
fess	O	O
under	O	O
controlled	O	O
hypotension	O	O
anesthesia	O	O
caused	O	O
by	O	O
propofol	B-chem	B-chem
-	O	O
remifentanil	B-chem	B-chem
-	O	O
tiva	O	I-chem
were	O	O
randomly	O	O
assigned	O	O
into	O	O
two	O	O
groups	O	O
:	O	O
group	O	O
i	O	O
,	O	O
frlma	O	O
;	O	O
group	O	O
ii	O	O
,	O	O
ett	O	O
.	O	O

hemorrhage	O	O
was	O	O
measured	O	O
and	O	O
the	O	O
visibility	O	O
of	O	O
the	O	O
operative	O	O
field	O	O
was	O	O
evaluated	O	O
according	O	O
to	O	O
a	O	O
six	O	O
-	O	O
point	O	O
scale	O	O
.	O	O

results	O	O
:	O	O

controlled	O	O
hypotension	O	O
was	O	O
achieved	O	O
within	O	O
a	O	O
shorter	O	O
period	O	O
using	O	O
laryngeal	O	O
mask	O	O
using	O	O
lower	O	O
rates	O	O
of	O	O
remifentanil	B-chem	B-chem
infusion	O	O
and	O	O
lower	O	O
total	O	O
dose	O	O
of	O	O
remifentanil	B-chem	B-chem
.	O	O

conclusion	O	O
:	O	O

in	O	O
summary	O	O
,	O	O
our	O	O
results	O	O
indicate	O	O
that	O	O
airway	O	O
management	O	O
using	O	O
frlma	O	O
during	O	O
controlled	O	O
hypotension	O	O
anesthesia	O	O
provided	O	O
better	O	O
surgical	O	O
conditions	O	O
in	O	O
terms	O	O
of	O	O
quality	O	O
of	O	O
operative	O	O
field	O	O
and	O	O
blood	O	O
loss	O	O
and	O	O
allowed	O	O
for	O	O
convenient	O	O
induced	O	O
hypotension	O	O
with	O	O
low	O	O
doses	O	O
of	O	O
remifentanil	B-chem	B-chem
during	O	O
tiva	O	B-chem
in	O	O
patients	O	O
undergoing	O	O
fess	O	O
.	O	O

nonalcoholic	O	O
fatty	O	O
liver	O	O
disease	O	O
during	O	O
valproate	B-chem	B-chem
therapy	O	O
.	O	O

valproic	B-chem	B-chem
acid	I-chem	I-chem
(	O	O
vpa	B-chem	B-chem
)	O	O
is	O	O
effective	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
many	O	O
types	O	O
of	O	O
epilepsy	O	O
,	O	O
but	O	O
its	O	O
use	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
body	O	O
weight	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
nonalcoholic	O	O
fatty	O	O
liver	O	O
disease	O	O
(	O	O
nafld	O	O
)	O	O
arising	O	O
in	O	O
a	O	O
child	O	O
who	O	O
developed	O	O
obesity	O	O
during	O	O
vpa	B-chem	B-chem
treatment	O	O
.	O	O

laboratory	O	O
data	O	O
revealed	O	O
hyperinsulinemia	O	O
with	O	O
insulin	O	O
resistance	O	O
.	O	O

after	O	O
the	O	O
withdrawal	O	O
of	O	O
vpa	B-chem	B-chem
therapy	O	O
,	O	O
our	O	O
patient	O	O
showed	O	O
a	O	O
significant	O	O
weight	O	O
loss	O	O
,	O	O
a	O	O
decrease	O	O
of	O	O
body	O	O
mass	O	O
index	O	O
,	O	O
and	O	O
normalization	O	O
of	O	O
metabolic	O	O
and	O	O
endocrine	O	O
parameters	O	O
;	O	O
moreover	O	O
,	O	O
ultrasound	O	O
measurements	O	O
showed	O	O
a	O	O
complete	O	O
normalization	O	O
.	O	O

the	O	O
present	O	O
case	O	O
suggests	O	O
that	O	O
obesity	O	O
,	O	O
hyperinsulinemia	O	O
,	O	O
insulin	O	O
resistance	O	O
,	O	O
and	O	O
long	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
vpa	B-chem	B-chem
may	O	O
be	O	O
all	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
nafld	O	O
;	O	O
this	O	O
side	O	O
effect	O	O
is	O	O
reversible	O	O
after	O	O
vpa	B-chem	B-chem
withdrawal	O	O
.	O	O

carbimazole	B-chem	B-chem
induced	O	O
anca	O	O
positive	O	O
vasculitis	O	O
.	O	O

anti	B-chem	O
-	I-chem	O
thyroid	I-chem	O
drugs	I-chem	O
,	O	O
like	O	O
carbimazole	B-chem	B-chem
and	O	O
propylthiouracil	B-chem	B-chem
(	O	O
ptu	B-chem	B-chem
)	O	O
are	O	O
commonly	O	O
prescribed	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
hyperthyroidism	O	O
.	O	O

one	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
side	O	O
effects	O	O
of	O	O
antithyroid	B-chem	O
medications	I-chem	O
.	O	O

antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
(	O	O
anca	O	O
)	O	O
-	O	O
-	O	O
associated	O	O
vasculitis	O	O
is	O	O
a	O	O
potentially	O	O
life	O	O
-	O	O
threatening	O	O
adverse	O	O
effect	O	O
of	O	O
antithyroidmedications	B-chem	O
.	O	O

we	O	O
report	O	O
a	O	O
patient	O	O
with	O	O
graves	O	O
'	O	O
disease	O	O
who	O	O
developed	O	O
anca	O	O
positive	O	O
carbimazole	B-chem	B-chem
induced	O	O
vasculitis	O	O
.	O	O

the	O	O
episode	O	O
was	O	O
characterized	O	O
by	O	O
a	O	O
vasculitic	O	O
skin	O	O
rash	O	O
associated	O	O
with	O	O
large	O	O
joint	O	O
arthritis	O	O
,	O	O
pyrexia	O	O
and	O	O
parotiditis	O	O
but	O	O
no	O	O
renal	O	O
or	O	O
pulmonary	O	O
involvement	O	O
.	O	O

he	O	O
was	O	O
referred	O	O
to	O	O
us	O	O
for	O	O
neurological	O	O
evaluation	O	O
because	O	O
he	O	O
had	O	O
difficulty	O	O
in	O	O
getting	O	O
up	O	O
from	O	O
squatting	O	O
position	O	O
and	O	O
was	O	O
suspected	O	O
to	O	O
have	O	O
myositis	O	O
.	O	O

carbimazole	B-chem	B-chem
and	O	O
methimazole	B-chem	B-chem
have	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
reported	O	O
anca	O	O
positive	O	O
side	O	O
effects	O	O
than	O	O
put	O	O
.	O	O

to	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
first	O	O
anca	O	O
positive	O	O
carbimazole	B-chem	B-chem
induced	O	O
vasculitis	O	O
case	O	O
reported	O	O
from	O	O
india	O	O
.	O	O

aspirin	B-chem	B-chem
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
cardiovascular	O	O
events	O	O
:	O	O
an	O	O
update	O	O
of	O	O
the	O	O
evidence	O	O
for	O	O
the	O	O
u	O	O
.	O	O
s	O	O
.	O	O
preventive	O	O
services	O	O
task	O	O
force	O	O
.	O	O

background	O	O
:	O	O

coronary	O	O
heart	O	O
disease	O	O
and	O	O
cerebrovascular	O	O
disease	O	O
are	O	O
leading	O	O
causes	O	O
of	O	O
death	O	O
in	O	O
the	O	O
united	O	O
states	O	O
.	O	O

in	O	O
2002	O	O
,	O	O
the	O	O
u	O	O
.	O	O
s	O	O
.	O	O
preventive	O	O
services	O	O
task	O	O
force	O	O
(	O	O
uspstf	O	O
)	O	O
strongly	O	O
recommended	O	O
that	O	O
clinicians	O	O
discuss	O	O
aspirin	B-chem	B-chem
with	O	O
adults	O	O
who	O	O
are	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
coronary	O	O
heart	O	O
disease	O	O
.	O	O

purpose	O	O
:	O	O

to	O	O
determine	O	O
the	O	O
benefits	O	O
and	O	O
harms	O	O
of	O	O
taking	O	O
aspirin	B-chem	B-chem
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
myocardial	O	O
infarctions	O	O
,	O	O
strokes	O	O
,	O	O
and	O	O
death	O	O
.	O	O

data	O	O
sources	O	O
:	O	O
medline	O	O
and	O	O
cochrane	O	O
library	O	O
(	O	O
search	O	O
dates	O	O
,	O	O
1	O	O
january	O	O
2001	O	O
to	O	O
28	O	O
august	O	O
2008	O	O
)	O	O
,	O	O
recent	O	O
systematic	O	O
reviews	O	O
,	O	O
reference	O	O
lists	O	O
of	O	O
retrieved	O	O
articles	O	O
,	O	O
and	O	O
suggestions	O	O
from	O	O
experts	O	O
.	O	O

study	O	O
selection	O	O
:	O	O
english	O	O
-	O	O
language	O	O
randomized	O	O
,	O	O
controlled	O	O
trials	O	O
(	O	O
rcts	O	O
)	O	O
;	O	O
case	O	O
-	O	O
control	O	O
studies	O	O
;	O	O
meta	O	O
-	O	O
analyses	O	O
;	O	O
and	O	O
systematic	O	O
reviews	O	O
of	O	O
aspirin	B-chem	B-chem
versus	O	O
control	O	O
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
cardiovascular	O	O
disease	O	O
(	O	O
cvd	O	O
)	O	O
were	O	O
selected	O	O
to	O	O
answer	O	O
the	O	O
following	O	O
questions	O	O
:	O	O

does	O	O
aspirin	B-chem	B-chem
decrease	O	O
coronary	O	O
heart	O	O
events	O	O
,	O	O
strokes	O	O
,	O	O
death	O	O
from	O	O
coronary	O	O
heart	O	O
events	O	O
or	O	O
stroke	O	O
,	O	O
or	O	O
all	O	O
-	O	O
cause	O	O
mortality	O	O
in	O	O
adults	O	O
without	O	O
known	O	O
cvd	O	O
?	O	O

does	O	O
aspirin	B-chem	B-chem
increase	O	O
gastrointestinal	O	O
bleeding	O	O
or	O	O
hemorrhagic	O	O
strokes	O	O
?	O	O

data	O	O
extraction	O	O
:	O	O

all	O	O
studies	O	O
were	O	O
reviewed	O	O
,	O	O
abstracted	O	O
,	O	O
and	O	O
rated	O	O
for	O	O
quality	O	O
by	O	O
using	O	O
predefined	O	O
uspstf	O	O
criteria	O	O
.	O	O

data	O	O
synthesis	O	O
:	O	O

new	O	O
evidence	O	O
from	O	O
1	O	O
good	O	O
-	O	O
quality	O	O
rct	O	O
,	O	O
1	O	O
good	O	O
-	O	O
quality	O	O
meta	O	O
-	O	O
analysis	O	O
,	O	O
and	O	O
2	O	O
fair	O	O
-	O	O
quality	O	O
subanalyses	O	O
of	O	O
rcts	O	O
demonstrates	O	O
that	O	O
aspirin	B-chem	B-chem
use	O	O
reduces	O	O
the	O	O
number	O	O
of	O	O
cvd	O	O
events	O	O
in	O	O
patients	O	O
without	O	O
known	O	O
cvd	O	O
.	O	O

men	O	O
in	O	O
these	O	O
studies	O	O
experienced	O	O
fewer	O	O
myocardial	O	O
infarctions	O	O
and	O	O
women	O	O
experienced	O	O
fewer	O	O
ischemic	O	O
strokes	O	O
.	O	O

aspirin	B-chem	B-chem
does	O	O
not	O	O
seem	O	O
to	O	O
affect	O	O
cvd	O	O
mortality	O	O
or	O	O
all	O	O
-	O	O
cause	O	O
mortality	O	O
in	O	O
either	O	O
men	O	O
or	O	O
women	O	O
.	O	O

the	O	O
use	O	O
of	O	O
aspirin	B-chem	B-chem
for	O	O
primary	O	O
prevention	O	O
increases	O	O
the	O	O
risk	O	O
for	O	O
major	O	O
bleeding	O	O
events	O	O
,	O	O
primarily	O	O
gastrointestinal	O	O
bleeding	O	O
events	O	O
,	O	O
in	O	O
both	O	O
men	O	O
and	O	O
women	O	O
.	O	O

men	O	O
have	O	O
an	O	O
increased	O	O
risk	O	O
for	O	O
hemorrhagic	O	O
strokes	O	O
with	O	O
aspirin	B-chem	B-chem
use	O	O
.	O	O

a	O	O
new	O	O
rct	O	B-chem
and	O	O
meta	O	O
-	O	O
analysis	O	O
suggest	O	O
that	O	O
the	O	O
risk	O	O
for	O	O
hemorrhagic	O	O
strokes	O	O
in	O	O
women	O	O
is	O	O
not	O	O
statistically	O	O
significantly	O	O
increased	O	O
.	O	O

limitations	O	O
:	O	O

new	O	O
evidence	O	O
on	O	O
aspirin	B-chem	B-chem
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
cvd	O	O
is	O	O
limited	O	O
.	O	O

the	O	O
dose	O	O
of	O	O
aspirin	B-chem	B-chem
used	O	O
in	O	O
the	O	O
rcts	O	O
varied	O	O
,	O	O
which	O	O
prevented	O	O
the	O	O
estimation	O	O
of	O	O
the	O	O
most	O	O
appropriate	O	O
dose	O	O
for	O	O
primary	O	O
prevention	O	O
.	O	O

several	O	O
of	O	O
the	O	O
rcts	O	O
were	O	O
conducted	O	O
within	O	O
populations	O	O
of	O	O
health	O	O
professionals	O	O
,	O	O
which	O	O
potentially	O	O
limits	O	O
generalizability	O	O
.	O	O

conclusion	O	O
:	O	O

aspirin	B-chem	B-chem
reduces	O	O
the	O	O
risk	O	O
for	O	O
myocardial	O	O
infarction	O	O
in	O	O
men	O	O
and	O	O
strokes	O	O
in	O	O
women	O	O
.	O	O

aspirin	B-chem	B-chem
use	O	O
increases	O	O
the	O	O
risk	O	O
for	O	O
serious	O	O
bleeding	O	O
events	O	O
.	O	O

reducing	O	O
harm	O	O
associated	O	O
with	O	O
anticoagulation	O	O
:	O	O
practical	O	O
considerations	O	O
of	O	O
argatroban	B-chem	B-chem
therapy	O	O
in	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
.	O	O

argatroban	B-chem	B-chem
is	O	O
a	O	O
hepatically	O	O
metabolized	O	O
,	O	O
direct	O	O
thrombin	O	O
inhibitor	O	O
used	O	O
for	O	O
prophylaxis	O	O
or	O	O
treatment	O	O
of	O	O
thrombosis	O	O
in	O	O
heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
(	O	O
hit	O	O
)	O	O
and	O	O
for	O	O
patients	O	O
with	O	O
or	O	O
at	O	O
risk	O	O
of	O	O
hit	O	O
undergoing	O	O
percutaneous	O	O
coronary	O	O
intervention	O	O
(	O	O
pci	O	O
)	O	O
.	O	O

the	O	O
objective	O	O
of	O	O
this	O	O
review	O	O
is	O	O
to	O	O
summarize	O	O
practical	O	O
considerations	O	O
of	O	O
argatroban	B-chem	B-chem
therapy	O	O
in	O	O
hit	O	O
.	O	O

the	O	O
us	O	O
fda	O	O
-	O	O
recommended	O	O
argatroban	B-chem	B-chem
dose	O	O
in	O	O
hit	O	O
is	O	O
2	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
(	O	O
reduced	O	O
in	O	O
patients	O	O
with	O	O
hepatic	O	O
impairment	O	O
and	O	O
in	O	O
paediatric	O	O
patients	O	O
)	O	O
,	O	O
adjusted	O	O
to	O	O
achieve	O	O
activated	O	O
partial	O	O
thromboplastin	O	O
times	O	O
(	O	O
aptts	O	O
)	O	O
1	O	O
.	O	O
5	O	O
-	O	O
3	O	O
times	O	O
baseline	O	O
(	O	O
not	O	O
>	O	O
100	O	O
seconds	O	O
)	O	O
.	O	O

contemporary	O	O
experiences	O	O
indicate	O	O
that	O	O
reduced	O	O
doses	O	O
are	O	O
also	O	O
needed	O	O
in	O	O
patients	O	O
with	O	O
conditions	O	O
associated	O	O
with	O	O
hepatic	O	O
hypoperfusion	O	O
,	O	O
e	O	O
.	O	O
g	O	O
.	O	O
heart	O	O
failure	O	O
,	O	O
yet	O	O
are	O	O
unnecessary	O	O
for	O	O
renal	O	O
dysfunction	O	O
,	O	O
adult	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
race	O	O
/	O	O
ethnicity	O	O
or	O	O
obesity	O	O
.	O	O

argatroban	B-chem	B-chem
0	O	O
.	O	O
5	O	O
-	O	O
1	O	O
.	O	O
2	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
typically	O	O
supports	O	O
therapeutic	O	O
aptts	O	O
.	O	O

the	O	O
fda	O	O
-	O	O
recommended	O	O
dose	O	O
during	O	O
pci	O	O
is	O	O
25	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
(	O	O
350	O	O
microg	O	O
/	O	O
kg	O	O
initial	O	O
bolus	O	O
)	O	O
,	O	O
adjusted	O	O
to	O	O
achieve	O	O
activated	O	O
clotting	O	O
times	O	O
(	O	O
acts	O	O
)	O	O
of	O	O
300	O	O
-	O	O
450	O	O
sec	O	O
.	O	O

for	O	O
pci	O	O
,	O	O
argatroban	B-chem	B-chem
has	O	O
not	O	O
been	O	O
investigated	O	O
in	O	O
hepatically	O	O
impaired	O	O
patients	O	O
;	O	O
dose	O	O
adjustment	O	O
is	O	O
unnecessary	O	O
for	O	O
adult	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
race	O	O
/	O	O
ethnicity	O	O
or	O	O
obesity	O	O
,	O	O
and	O	O
lesser	O	O
doses	O	O
may	O	O
be	O	O
adequate	O	O
with	O	O
concurrent	O	O
glycoprotein	O	O
iib	O	O
/	O	O
iiia	O	O
inhibition	O	O
.	O	O

argatroban	B-chem	B-chem
prolongs	O	O
the	O	O
international	O	O
normalized	O	O
ratio	O	O
,	O	O
and	O	O
published	O	O
approaches	O	O
for	O	O
monitoring	O	O
the	O	O
argatroban	B-chem	B-chem
-	O	O
to	O	O
-	O	O
warfarin	B-chem	B-chem
transition	O	O
should	O	O
be	O	O
followed	O	O
.	O	O

major	O	O
bleeding	O	O
with	O	O
argatroban	B-chem	B-chem
is	O	O
0	O	O
-	O	O
10	O	O
%	O	O
in	O	O
the	O	O
non	O	O
-	O	O
interventional	O	O
setting	O	O
and	O	O
0	O	O
-	O	O
5	O	O
.	O	O
8	O	O
%	O	O
periprocedurally	O	O
.	O	O

argatroban	B-chem	B-chem
has	O	O
no	O	O
specific	O	O
antidote	O	O
,	O	O
and	O	O
if	O	O
excessive	O	O
anticoagulation	O	O
occurs	O	O
,	O	O
argatroban	B-chem	B-chem
infusion	O	O
should	O	O
be	O	O
stopped	O	O
or	O	O
reduced	O	O
.	O	O

improved	O	O
familiarity	O	O
of	O	O
healthcare	O	O
professionals	O	O
with	O	O
argatroban	B-chem	B-chem
therapy	O	O
in	O	O
hit	O	O
,	O	O
including	O	O
in	O	O
special	O	O
populations	O	O
and	O	O
during	O	O
pci	O	O
,	O	O
may	O	O
facilitate	O	O
reduction	O	O
of	O	O
harm	O	O
associated	O	O
with	O	O
hit	O	O
(	O	O
e	O	O
.	O	O
g	O	O
.	O	O
fewer	O	O
thromboses	O	O
)	O	O
or	O	O
its	O	O
treatment	O	O
(	O	O
e	O	O
.	O	O
g	O	O
.	O	O
fewer	O	O
argatroban	B-chem	B-chem
medication	O	O
errors	O	O
)	O	O
.	O	O

rhabdomyolysis	O	O
and	O	O
brain	O	O
ischemic	O	O
stroke	O	O
in	O	O
a	O	O
heroin	B-chem	B-chem
-	O	O
dependent	O	O
male	O	O
under	O	O
methadone	B-chem	B-chem
maintenance	O	O
therapy	O	O
.	O	O

objective	O	O
:	O	O

there	O	O
are	O	O
several	O	O
complications	O	O
associated	O	O
with	O	O
heroin	O	B-chem
abuse	O	O
,	O	O
some	O	O
of	O	O
which	O	O
are	O	O
life	O	O
-	O	O
threatening	O	O
.	O	O

methadone	B-chem	B-chem
may	O	O
aggravate	O	O
this	O	O
problem	O	O
.	O	O

method	O	O
:	O	O

a	O	O
clinical	O	O
case	O	O
description	O	O
.	O	O

results	O	O
:	O	O

a	O	O
33	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
presented	O	O
with	O	O
rhabdomyolysis	O	O
and	O	O
cerebral	O	O
ischemic	O	O
stroke	O	O
after	O	O
intravenous	O	O
heroin	B-chem	B-chem
.	O	O

he	O	O
had	O	O
used	O	O
heroin	B-chem	B-chem
since	O	O
age	O	O
20	O	O
,	O	O
and	O	O
had	O	O
used	O	O
150	O	O
mg	O	O
methadone	B-chem	B-chem
daily	O	O
for	O	O
6	O	O
months	O	O
.	O	O

he	O	O
was	O	O
found	O	O
unconsciousness	O	O
at	O	O
home	O	O
and	O	O
was	O	O
sent	O	O
to	O	O
our	O	O
hospital	O	O
.	O	O

in	O	O
the	O	O
er	O	O
,	O	O
his	O	O
opiate	O	O
level	O	O
was	O	O
4497	O	O
ng	O	O
/	O	O
ml	O	O
.	O	O

in	O	O
the	O	O
icu	O	O
,	O	O
we	O	O
found	O	O
rhabdomyolysis	O	O
,	O	O
acute	O	O
renal	O	O
failure	O	O
and	O	O
acute	O	O
respiratory	O	O
failure	O	O
.	O	O

after	O	O
transfer	O	O
to	O	O
an	O	O
internal	O	O
ward	O	O
,	O	O
we	O	O
noted	O	O
aphasia	O	O
and	O	O
weakness	O	O
of	O	O
his	O	O
left	O	O
limbs	O	O
.	O	O

after	O	O
mri	O	O
,	O	O
we	O	O
found	O	O
cerebral	O	O
ischemic	O	O
infarction	O	O
.	O	O

conclusion	O	O
:	O	O

those	O	O
using	O	O
methadone	B-chem	B-chem
and	O	O
heroin	B-chem	B-chem
simultaneously	O	O
may	O	O
increase	O	O
risk	O	O
of	O	O
rhabdomyolysis	O	O
and	O	O
ischemic	O	O
stroke	O	O
.	O	O

patients	O	O
under	O	O
methadone	B-chem	B-chem
maintenance	O	O
therapy	O	O
should	O	O
be	O	O
warned	O	O
regarding	O	O
these	O	O
serious	O	O
adverse	O	O
events	O	O
.	O	O

hypotheses	O	O
of	O	O
heroin	B-chem	B-chem
-	O	O
related	O	O
rhabdomyolysis	O	O
and	O	O
stroke	O	O
in	O	O
heroin	B-chem	B-chem
abusers	O	O
are	O	O
discussed	O	O
.	O	O

increased	O	O
vulnerability	O	O
to	O	O
6	B-chem	B-chem
-	I-chem	I-chem
hydroxydopamine	I-chem	I-chem
lesion	O	O
and	O	O
reduced	O	O
development	O	O
of	O	O
dyskinesias	O	O
in	O	O
mice	O	O
lacking	O	O
cb1	O	O
cannabinoid	O	O
receptors	O	O
.	O	O

motor	O	O
impairment	O	O
,	O	O
dopamine	B-chem	B-chem
(	O	O
da	B-chem	B-chem
)	O	O
neuronal	O	O
activity	O	O
and	O	O
proenkephalin	B-chem	B-chem
(	O	O
penk	B-chem	O
)	O	O
gene	O	O
expression	O	O
in	O	O
the	O	O
caudate	O	O
-	O	O
putamen	O	O
(	O	O
cpu	O	B-chem
)	O	O
were	O	O
measured	O	O
in	O	O
6	B-chem	B-chem
-	I-chem	I-chem
ohda	I-chem	I-chem
-	O	O
lesioned	O	O
and	O	O
treated	O	O
(	O	O
l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
+	I-chem	O
benserazide	I-chem	B-chem
)	O	O
cb1	O	B-chem
ko	O	I-chem
and	O	O
wt	O	O
mice	O	O
.	O	O

a	O	O
lesion	O	O
induced	O	O
by	O	O
6	B-chem	B-chem
-	I-chem	I-chem
ohda	I-chem	I-chem
produced	O	O
more	O	O
severe	O	O
motor	O	O
deterioration	O	O
in	O	O
cb1	O	O
ko	O	O
mice	O	O
accompanied	O	O
by	O	O
more	O	O
loss	O	O
of	O	O
da	B-chem	B-chem
neurons	O	O
and	O	O
increased	O	O
penk	B-chem	O
gene	O	O
expression	O	O
in	O	O
the	O	O
cpu	O	O
.	O	O

oxidative	O	O
/	O	O
nitrosative	O	O
and	O	O
neuroinflammatory	O	O
parameters	O	O
were	O	O
estimated	O	O
in	O	O
the	O	O
cpu	O	B-chem
and	O	O
cingulate	O	O
cortex	O	O
(	O	O
cg	O	O
)	O	O
.	O	O

cb1	O	O
ko	O	O
mice	O	O
exhibited	O	O
higher	O	O
mda	B-chem	B-chem
levels	O	O
and	O	O
inos	O	O
protein	O	O
expression	O	O
in	O	O
the	O	O
cpu	O	B-chem
and	O	O
cg	O	O
compared	O	O
to	O	O
wt	O	O
mice	O	O
.	O	O

treatment	O	O
with	O	O
l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
+	I-chem	O
benserazide	I-chem	B-chem
(	O	O
12	O	O
weeks	O	O
)	O	O
resulted	O	O
in	O	O
less	O	O
severe	O	O
dyskinesias	O	O
in	O	O
cb1	O	O
ko	O	O
than	O	O
in	O	O
wt	O	O
mice	O	O
.	O	O

the	O	O
results	O	O
revealed	O	O
that	O	O
the	O	O
lack	O	O
of	O	O
cannabinoid	O	B-chem
cb1	O	O
receptors	O	O
increased	O	O
the	O	O
severity	O	O
of	O	O
motor	O	O
impairment	O	O
and	O	O
da	B-chem	B-chem
lesion	O	O
,	O	O
and	O	O
reduced	O	O
l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
-	O	O
induced	O	O
dyskinesias	O	O
.	O	O

these	O	O
results	O	O
suggest	O	O
that	O	O
activation	O	O
of	O	O
cb1	O	O
receptors	O	O
offers	O	O
neuroprotection	O	O
against	O	O
dopaminergic	O	O
lesion	O	O
and	O	O
the	O	O
development	O	O
of	O	O
l	B-chem	B-chem
-	I-chem	I-chem
dopa	I-chem	I-chem
-	O	O
induced	O	O
dyskinesias	O	O
.	O	O

animal	O	O
model	O	O
of	O	O
mania	O	O
induced	O	O
by	O	O
ouabain	B-chem	B-chem
:	O	O
evidence	O	O
of	O	O
oxidative	O	O
stress	O	O
in	O	O
submitochondrial	O	O
particles	O	O
of	O	O
the	O	O
rat	O	O
brain	O	O
.	O	O

the	O	O
intracerebroventricular	O	O
(	O	O
icv	O	B-chem
)	O	O
administration	O	O
of	O	O
ouabain	B-chem	B-chem
(	O	O
a	O	O
na	B-chem	B-chem
(	O	O
+	O	O
)	O	O
/	O	O
k	B-chem	O
(	O	O
+	O	O
)	O	O
-	O	O
atpase	O	O
inhibitor	O	O
)	O	O
in	O	O
rats	O	O
has	O	O
been	O	O
suggested	O	O
to	O	O
mimic	O	O
some	O	O
symptoms	O	O
of	O	O
human	O	O
bipolar	O	O
mania	O	O
.	O	O

clinical	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
bipolar	O	O
disorder	O	O
may	O	O
be	O	O
related	O	O
to	O	O
mitochondrial	O	O
dysfunction	O	O
.	O	O

herein	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
behavioral	O	O
and	O	O
biochemical	O	O
effects	O	O
induced	O	O
by	O	O
the	O	O
icv	O	B-chem
administration	O	O
of	O	O
ouabain	B-chem	B-chem
in	O	O
rats	O	O
.	O	O

to	O	O
achieve	O	O
this	O	O
aim	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
ouabain	B-chem	B-chem
injection	O	O
immediately	O	O
after	O	O
and	O	O
7	O	O
days	O	O
following	O	O
a	O	O
single	O	O
icv	O	B-chem
administration	O	O
(	O	O
at	O	O
concentrations	O	O
of	O	O
10	O	O
(	O	O
-	O	O
2	O	O
)	O	O
and	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
m	O	O
)	O	O
on	O	O
locomotion	O	O
was	O	O
measured	O	O
using	O	O
the	O	O
open	O	O
-	O	O
field	O	O
test	O	O
.	O	O

additionally	O	O
,	O	O
thiobarbituric	B-chem	B-chem
acid	I-chem	I-chem
reactive	O	O
substances	O	O
(	O	O
tbarss	O	O
)	O	O
and	O	O
superoxide	B-chem	B-chem
production	O	O
were	O	O
measured	O	O
in	O	O
submitochondrial	O	O
particles	O	O
of	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hippocampus	O	O
,	O	O
striatum	O	O
and	O	O
amygdala	O	O
.	O	O

our	O	O
findings	O	O
demonstrated	O	O
that	O	O
ouabain	B-chem	B-chem
at	O	O
10	O	O
(	O	O
-	O	O
2	O	O
)	O	O
and	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
m	O	O
induced	O	O
hyperlocomotion	O	O
in	O	O
rats	O	O
,	O	O
and	O	O
this	O	O
response	O	O
remained	O	O
up	O	O
to	O	O
7	O	O
days	O	O
following	O	O
a	O	O
single	O	O
icv	O	B-chem
injection	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
we	O	O
observed	O	O
that	O	O
the	O	O
persistent	O	O
increase	O	O
in	O	O
the	O	O
rat	O	O
spontaneous	O	O
locomotion	O	O
is	O	O
associated	O	O
with	O	O
increased	O	O
tbars	O	B-chem
levels	O	O
and	O	O
superoxide	B-chem	B-chem
generation	O	O
in	O	O
submitochondrial	O	O
particles	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
striatum	O	O
and	O	O
amygdala	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
ouabain	B-chem	B-chem
-	O	O
induced	O	O
mania	O	O
-	O	O
like	O	O
behavior	O	O
may	O	O
provide	O	O
a	O	O
useful	O	O
animal	O	O
model	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O	O
of	O	O
the	O	O
involvement	O	O
of	O	O
oxidative	O	O
stress	O	O
in	O	O
bipolar	O	O
disorder	O	O
.	O	O

intraoperative	O	O
dialysis	O	O
during	O	O
liver	O	O
transplantation	O	O
with	O	O
citrate	B-chem	B-chem
dialysate	O	O
.	O	O

liver	O	O
transplantation	O	O
for	O	O
acutely	O	O
ill	O	O
patients	O	O
with	O	O
fulminant	O	O
liver	O	O
failure	O	O
carries	O	O
high	O	O
intraoperative	O	O
and	O	O
immediate	O	O
postoperative	O	O
risks	O	O
.	O	O

these	O	O
are	O	O
increased	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
concomitant	O	O
acute	O	O
kidney	O	O
injury	O	O
(	O	O
aki	O	O
)	O	O
and	O	O
intraoperative	O	O
dialysis	O	O
is	O	O
sometimes	O	O
required	O	O
to	O	O
allow	O	O
the	O	O
transplant	O	O
to	O	O
proceed	O	O
.	O	O

the	O	O
derangements	O	O
in	O	O
the	O	O
procoagulant	O	O
and	O	O
anticoagulant	O	O
pathways	O	O
during	O	O
fulminant	O	O
liver	O	O
failure	O	O
can	O	O
lead	O	O
to	O	O
difficulties	O	O
with	O	O
anticoagulation	O	O
during	O	O
dialysis	O	O
,	O	O
especially	O	O
when	O	O
continued	O	O
in	O	O
the	O	O
operating	O	O
room	O	O
.	O	O

systemic	O	O
anticoagulation	O	O
is	O	O
unsafe	O	O
and	O	O
regional	O	O
citrate	B-chem	B-chem
anticoagulation	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
functional	O	O
liver	O	O
carries	O	O
the	O	O
risk	O	O
of	O	O
citrate	B-chem	B-chem
toxicity	O	O
.	O	O

citrate	B-chem	B-chem
dialysate	O	O
,	O	O
a	O	O
new	O	O
dialysate	O	O
with	O	O
citric	B-chem	B-chem
acid	I-chem	I-chem
can	O	O
be	O	O
used	O	O
for	O	O
anticoagulation	O	O
in	O	O
patients	O	O
who	O	O
can	O	O
not	O	O
tolerate	O	O
heparin	B-chem	B-chem
or	O	O
regional	O	O
citrate	B-chem	B-chem
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
with	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
fulminant	O	O
liver	O	O
failure	O	O
with	O	O
associated	O	O
aki	O	O
who	O	O
underwent	O	O
intraoperative	O	O
dialytic	O	O
support	O	O
during	O	O
liver	O	O
transplantation	O	O
anticoagulated	O	O
with	O	O
citrate	B-chem	B-chem
dialysate	O	O
during	O	O
the	O	O
entire	O	O
procedure	O	O
.	O	O

the	O	O
patient	O	O
tolerated	O	O
the	O	O
procedure	O	O
well	O	O
without	O	O
any	O	O
signs	O	O
of	O	O
citrate	B-chem	B-chem
toxicity	O	O
and	O	O
maintained	O	O
adequate	O	O
anticoagulation	O	O
for	O	O
patency	O	O
of	O	O
the	O	O
dialysis	O	O
circuit	O	O
.	O	O

citrate	B-chem	B-chem
dialysate	O	O
is	O	O
a	O	O
safe	O	O
alternative	O	O
for	O	O
intradialytic	O	O
support	O	O
of	O	O
liver	O	O
transplantation	O	O
in	O	O
fulminant	O	O
liver	O	O
failure	O	O
.	O	O

delirium	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
toxic	O	O
flecainide	B-chem	B-chem
plasma	O	O
concentrations	O	O
:	O	O
the	O	O
role	O	O
of	O	O
a	O	O
pharmacokinetic	O	O
drug	O	O
interaction	O	O
with	O	O
paroxetine	B-chem	B-chem
.	O	O

objective	O	O
:	O	O

to	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
flecainide	B-chem	B-chem
-	O	O
induced	O	O
delirium	O	O
associated	O	O
with	O	O
a	O	O
pharmacokinetic	O	O
drug	O	O
interaction	O	O
with	O	O
paroxetine	B-chem	B-chem
.	O	O

case	O	O
summary	O	O
:	O	O

a	O	O
69	O	O
-	O	O
year	O	O
-	O	O
old	O	O
white	O	O
female	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
with	O	O
a	O	O
history	O	O
of	O	O
confusion	O	O
and	O	O
paranoia	O	O
over	O	O
the	O	O
past	O	O
several	O	O
days	O	O
.	O	O

on	O	O
admission	O	O
the	O	O
patient	O	O
was	O	O
taking	O	O
carvedilol	B-chem	B-chem
12	O	O
mg	O	O
twice	O	O
daily	O	O
,	O	O
warfarin	B-chem	B-chem
2	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
folic	B-chem	B-chem
acid	I-chem	I-chem
1	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
levothyroxine	B-chem	B-chem
100	O	O
microg	O	O
/	O	O
day	O	O
,	O	O
pantoprazole	B-chem	B-chem
40	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
paroxetine	B-chem	B-chem
40	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
and	O	O
flecainide	B-chem	B-chem
100	O	O
mg	O	O
twice	O	O
daily	O	O
.	O	O

flecainide	B-chem	B-chem
had	O	O
been	O	O
started	O	O
2	O	O
weeks	O	O
prior	O	O
for	O	O
atrial	O	O
fibrillation	O	O
.	O	O

laboratory	O	O
test	O	O
findings	O	O
on	O	O
admission	O	O
were	O	O
notable	O	O
only	O	O
for	O	O
a	O	O
flecainide	B-chem	B-chem
plasma	O	O
concentration	O	O
of	O	O
1360	O	O
microg	O	O
/	O	O
l	O	O
(	O	O
reference	O	O
range	O	O
200	O	O
-	O	O
1000	O	O
)	O	O
.	O	O

a	O	O
metabolic	O	O
drug	O	O
interaction	O	O
between	O	O
flecainide	B-chem	B-chem
and	O	O
paroxetine	B-chem	B-chem
,	O	O
which	O	O
the	O	O
patient	O	O
had	O	O
been	O	O
taking	O	O
for	O	O
more	O	O
than	O	O
5	O	O
years	O	O
,	O	O
was	O	O
considered	O	O
.	O	O

paroxetine	B-chem	B-chem
was	O	O
discontinued	O	O
and	O	O
the	O	O
dose	O	O
of	O	O
flecainide	B-chem	B-chem
was	O	O
reduced	O	O
to	O	O
50	O	O
mg	O	O
twice	O	O
daily	O	O
.	O	O

her	O	O
delirium	O	O
resolved	O	O
3	O	O
days	O	O
later	O	O
.	O	O

discussion	O	O
:	O	O

flecainide	B-chem	B-chem
and	O	O
pharmacologically	O	O
similar	O	O
agents	O	O
that	O	O
interact	O	O
with	O	O
sodium	B-chem	B-chem
channels	O	O
may	O	O
cause	O	O
delirium	O	O
in	O	O
susceptible	O	O
patients	O	O
.	O	O

a	O	O
medline	O	O
search	O	O
(	O	O
1966	O	O
-	O	O
january	O	O
2009	O	O
)	O	O
revealed	O	O
one	O	O
in	O	O
vivo	O	O
pharmacokinetic	O	O
study	O	O
on	O	O
the	O	O
interaction	O	O
between	O	O
flecainide	B-chem	B-chem
,	O	O
a	O	O
cyp2d6	O	O
substrate	O	O
,	O	O
and	O	O
paroxetine	B-chem	B-chem
,	O	O
a	O	O
cyp2d6	O	O
inhibitor	O	O
,	O	O
as	O	O
well	O	O
as	O	O
3	O	O
case	O	O
reports	O	O
of	O	O
flecainide	B-chem	B-chem
-	O	O
induced	O	O
delirium	O	O
.	O	O

according	O	O
to	O	O
the	O	O
naranjo	O	O
probability	O	O
scale	O	O
,	O	O
flecainide	B-chem	B-chem
was	O	O
the	O	O
probable	O	O
cause	O	O
of	O	O
the	O	O
patient	O	O
'	O	O
s	O	O
delirium	O	O
;	O	O
the	O	O
horn	O	O
drug	O	O
interaction	O	O
probability	O	O
scale	O	O
indicates	O	O
a	O	O
possible	O	O
pharmacokinetic	O	O
drug	O	O
interaction	O	O
between	O	O
flecainide	B-chem	B-chem
and	O	O
paroxetine	B-chem	B-chem
.	O	O

conclusions	O	O
:	O	O

supratherapeutic	O	O
flecainide	B-chem	B-chem
plasma	O	O
concentrations	O	O
may	O	O
cause	O	O
delirium	O	O
.	O	O

because	O	O
toxicity	O	O
may	O	O
occur	O	O
when	O	O
flecainide	B-chem	B-chem
is	O	O
prescribed	O	O
with	O	O
paroxetine	B-chem	B-chem
and	O	O
other	O	O
potent	O	O
cyp2d6	O	O
inhibitors	O	O
,	O	O
flecainide	B-chem	B-chem
plasma	O	O
concentrations	O	O
should	O	O
be	O	O
monitored	O	O
closely	O	O
with	O	O
commencement	O	O
of	O	O
cyp2d6	O	O
inhibitors	O	O
.	O	O

efficacy	O	O
of	O	O
everolimus	B-chem	B-chem
(	O	O
rad001	B-chem	O
)	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
nsclc	O	O
previously	O	O
treated	O	O
with	O	O
chemotherapy	O	O
alone	O	O
or	O	O
with	O	O
chemotherapy	O	O
and	O	O
egfr	O	O
inhibitors	O	O
.	O	O

background	O	O
:	O	O

treatment	O	O
options	O	O
are	O	O
scarce	O	O
in	O	O
pretreated	O	O
advanced	O	O
non	O	O
-	O	O
small	O	O
-	O	O
cell	O	O
lung	O	O
cancer	O	O
(	O	O
nsclc	O	O
)	O	O
patients	O	O
.	O	O

rad001	B-chem	O
,	O	O
an	O	O
oral	O	O
inhibitor	O	O
of	O	O
the	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B-chem	B-chem
(	O	O
mtor	O	O
)	O	O
,	O	O
has	O	O
shown	O	O
phase	O	O
i	O	O
efficacy	O	O
in	O	O
nsclc	O	O
.	O	O

methods	O	O
:	O	O

stage	O	O
iiib	O	O
or	O	O
iv	O	O
nsclc	O	O
patients	O	O
,	O	O
with	O	O
two	O	O
or	O	O
fewer	O	O
prior	O	O
chemotherapy	O	O
regimens	O	O
,	O	O
one	O	O
platinum	B-chem	O
based	O	O
(	O	O
stratum	O	O
1	O	O
)	O	O
or	O	O
both	O	O
chemotherapy	O	O
and	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
tyrosine	B-chem	B-chem
kinase	O	O
inhibitors	O	O
(	O	O
stratum	O	O
2	O	O
)	O	O
,	O	O
received	O	O
rad001	B-chem	O
10	O	O
mg	O	O
/	O	O
day	O	O
until	O	O
progression	O	O
or	O	O
unacceptable	O	O
toxicity	O	O
.	O	O

primary	O	O
objective	O	O
was	O	O
overall	O	O
response	O	O
rate	O	O
(	O	O
orr	O	O
)	O	O
.	O	O

analyses	O	O
of	O	O
markers	O	O
associated	O	O
with	O	O
the	O	O
mtor	O	O
pathway	O	O
were	O	O
carried	O	O
out	O	O
on	O	O
archival	O	O
tumor	O	O
from	O	O
a	O	O
subgroup	O	O
using	O	O
immunohistochemistry	O	O
(	O	O
ihc	O	O
)	O	O
and	O	O
direct	O	O
mutation	O	O
sequencing	O	O
.	O	O

results	O	O
:	O	O

eighty	O	O
-	O	O
five	O	O
patients	O	O
were	O	O
enrolled	O	O
,	O	O
42	O	O
in	O	O
stratum	O	O
1	O	O
and	O	O
43	O	O
in	O	O
stratum	O	O
.	O	O

orr	O	O
was	O	O
4	O	O
.	O	O
7	O	O
%	O	O
(	O	O
7	O	O
.	O	O
1	O	O
%	O	O
stratum	O	O
1	O	O
;	O	O
2	O	O
.	O	O
3	O	O
%	O	O
stratum	O	O
2	O	O
)	O	O
.	O	O

overall	O	O
disease	O	O
control	O	O
rate	O	O
was	O	O
47	O	O
.	O	O
1	O	O
%	O	O
.	O	O

median	O	O
progression	O	O
-	O	O
free	O	O
survivals	O	O
(	O	O
pfss	O	O
)	O	O
were	O	O
2	O	O
.	O	O
6	O	O
(	O	O
stratum	O	O
1	O	O
)	O	O
and	O	O
2	O	O
.	O	O
7	O	O
months	O	O
(	O	O
stratum	O	O
2	O	O
)	O	O
.	O	O

common	O	O
>	O	O
or	O	O
=	O	O
grade	O	O
3	O	O
events	O	O
were	O	O
fatigue	O	O
,	O	O
dyspnea	O	O
,	O	O
stomatitis	O	O
,	O	O
anemia	O	O
,	O	O
and	O	O
thrombocytopenia	O	O
.	O	O

pneumonitis	O	O
,	O	O
probably	O	O
or	O	O
possibly	O	O
related	O	O
,	O	O
mainly	O	O
grade	O	O
1	O	O
/	O	O
2	O	O
,	O	O
occurred	O	O
in	O	O
25	O	O
%	O	O
.	O	O

cox	O	O
regression	O	O
analysis	O	O
of	O	O
ihc	O	O
scores	O	O
found	O	O
that	O	O
only	O	O
phospho	O	B-chem
akt	O	I-chem
(	O	O
pakt	O	B-chem
)	O	O
was	O	O
a	O	O
significant	O	O
independent	O	O
predictor	O	O
of	O	O
worse	O	O
pfs	O	O
.	O	O

conclusions	O	O
:	O	O

rad001	B-chem	O
10	O	O
mg	O	O
/	O	O
day	O	O
was	O	O
well	O	O
tolerated	O	O
,	O	O
showing	O	O
modest	O	O
clinical	O	O
activity	O	O
in	O	O
pretreated	O	O
nsclc	O	O
.	O	O

evaluation	O	O
of	O	O
rad001	B-chem	O
plus	O	O
standard	O	O
therapy	O	O
for	O	O
metastatic	O	O
nsclc	O	O
continues	O	O
.	O	O

posttransplant	O	O
anemia	O	O
:	O	O
the	O	O
role	O	O
of	O	O
sirolimus	B-chem	B-chem
.	O	O

posttransplant	O	O
anemia	O	O
is	O	O
a	O	O
common	O	O
problem	O	O
that	O	O
may	O	O
hinder	O	O
patients	O	O
'	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

it	O	O
occurs	O	O
in	O	O
12	O	O
to	O	O
76	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
and	O	O
is	O	O
most	O	O
common	O	O
in	O	O
the	O	O
immediate	O	O
posttransplant	O	O
period	O	O
.	O	O

a	O	O
variety	O	O
of	O	O
factors	O	O
have	O	O
been	O	O
identified	O	O
that	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
posttransplant	O	O
anemia	O	O
,	O	O
of	O	O
which	O	O
the	O	O
level	O	O
of	O	O
renal	O	O
function	O	O
is	O	O
most	O	O
important	O	O
.	O	O

sirolimus	B-chem	B-chem
,	O	O
a	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B-chem	B-chem
inhibitor	O	O
,	O	O
has	O	O
been	O	O
implicated	O	O
as	O	O
playing	O	O
a	O	O
special	O	O
role	O	O
in	O	O
posttransplant	O	O
anemia	O	O
.	O	O

this	O	O
review	O	O
considers	O	O
anemia	O	O
associated	O	O
with	O	O
sirolimus	B-chem	B-chem
,	O	O
including	O	O
its	O	O
presentation	O	O
,	O	O
mechanisms	O	O
,	O	O
and	O	O
management	O	O
.	O	O

coronary	O	O
computerized	O	O
tomography	O	O
angiography	O	O
for	O	O
rapid	O	O
discharge	O	O
of	O	O
low	O	O
-	O	O
risk	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
.	O	O

background	O	O
:	O	O

most	O	O
patients	O	O
presenting	O	O
to	O	O
emergency	O	O
departments	O	O
(	O	O
eds	O	O
)	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
are	O	O
admitted	O	O
for	O	O
at	O	O
least	O	O
12	O	O
hours	O	O
and	O	O
receive	O	O
a	O	O
"	O	O
"	O	O
"	O	O
"	O	O
rule	O	O
out	O	O
acute	O	O
coronary	O	O
syndrome	O	O
"	O	O
"	O	O
"	O	O
"	O	O
protocol	O	O
,	O	O
often	O	O
with	O	O
noninvasive	O	O
testing	O	O
prior	O	O
to	O	O
discharge	O	O
.	O	O

in	O	O
patients	O	O
without	O	O
cocaine	B-chem	B-chem
use	O	O
,	O	O
coronary	O	O
computerized	O	O
tomography	O	O
angiography	O	O
(	O	O
cta	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
useful	O	O
for	O	O
identifying	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
at	O	O
low	O	O
risk	O	O
for	O	O
cardiac	O	O
events	O	O
who	O	O
can	O	O
be	O	O
safely	O	O
discharged	O	O
.	O	O

it	O	O
is	O	O
unclear	O	O
whether	O	O
a	O	O
coronary	O	O
cta	O	O
strategy	O	O
would	O	O
be	O	O
efficacious	O	O
in	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
,	O	O
as	O	O
coronary	O	O
vasospasm	O	O
may	O	O
account	O	O
for	O	O
some	O	O
of	O	O
the	O	O
ischemia	O	O
.	O	O

we	O	O
studied	O	O
whether	O	O
a	O	O
negative	O	O
coronary	O	O
cta	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
could	O	O
identify	O	O
a	O	O
subset	O	O
safe	O	O
for	O	O
discharge	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
prospectively	O	O
evaluated	O	O
the	O	O
safety	O	O
of	O	O
coronary	O	O
cta	O	O
for	O	O
low	O	O
-	O	O
risk	O	O
patients	O	O
who	O	O
presented	O	O
to	O	O
the	O	O
ed	O	O
with	O	O
cocaineassociated	O	O
chest	O	O
pain	O	O
(	O	O
self	O	O
-	O	O
reported	O	O
or	O	O
positive	O	O
urine	O	O
test	O	O
)	O	O
.	O	O

consecutive	O	O
patients	O	O
received	O	O
either	O	O
immediate	O	O
coronary	O	O
cta	O	O
in	O	O
the	O	O
ed	O	O
(	O	O
without	O	O
serial	O	O
markers	O	O
)	O	O
or	O	O
underwent	O	O
coronary	O	O
cta	O	O
after	O	O
a	O	O
brief	O	O
observation	O	O
period	O	O
with	O	O
serial	O	O
cardiac	O	O
marker	O	O
measurements	O	O
.	O	O

patients	O	O
with	O	O
negative	O	O
coronary	O	O
cta	O	O
(	O	O
maximal	O	O
stenosis	O	O
less	O	O
than	O	O
50	O	O
%	O	O
)	O	O
were	O	O
discharged	O	O
.	O	O

the	O	O
main	O	O
outcome	O	O
was	O	O
30	O	O
-	O	O
day	O	O
cardiovascular	O	O
death	O	O
or	O	O
myocardial	O	O
infarction	O	O
.	O	O

results	O	O
:	O	O

a	O	O
total	O	O
of	O	O
59	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
chest	O	O
pain	O	O
were	O	O
evaluated	O	O
.	O	O

patients	O	O
had	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
45	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O

6	O	O
.	O	O
6	O	O
yrs	O	O
and	O	O
were	O	O
86	O	O
%	O	O
black	O	O
,	O	O
66	O	O
%	O	O
male	O	O
.	O	O

seventy	O	O
-	O	O
nine	O	O
percent	O	O
had	O	O
a	O	O
normal	O	O
or	O	O
nonspecific	O	O
ecg	O	O
and	O	O
85	O	O
%	O	O
had	O	O
a	O	O
timi	O	O
score	O	O
<	O	O
2	O	O
.	O	O

twenty	O	O
patients	O	O
received	O	O
coronary	O	O
cta	O	O
immediately	O	O
in	O	O
the	O	O
ed	O	O
,	O	O
18	O	O
of	O	O
whom	O	O
were	O	O
discharged	O	O
following	O	O
cta	O	O
(	O	O
90	O	O
%	O	O
)	O	O
.	O	O

thirty	O	O
-	O	O
nine	O	O
received	O	O
coronary	O	O
cta	O	O
after	O	O
a	O	O
brief	O	O
observation	O	O
period	O	O
,	O	O
with	O	O
37	O	O
discharged	O	O
home	O	O
following	O	O
cta	O	O
(	O	O
95	O	O
%	O	O
)	O	O
.	O	O

six	O	O
patients	O	O
had	O	O
coronary	O	O
stenosis	O	O
>	O	O

or	O	O
=	O	O
50	O	O
%	O	O
.	O	O

during	O	O
the	O	O
30	O	O
-	O	O
day	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
,	O	O
no	O	O
patients	O	O
died	O	O
of	O	O
a	O	O
cardiovascular	O	O
event	O	O
(	O	O
0	O	O
%	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
,	O	O
0	O	O
-	O	O
6	O	O
.	O	O
1	O	O
%	O	O
)	O	O
and	O	O
no	O	O
patient	O	O
sustained	O	O
a	O	O
nonfatal	O	O
myocardial	O	O
infarction	O	O
(	O	O
0	O	O
%	O	O
;	O	O
95	O	O
%	O	O
ci	O	O
,	O	O
0	O	O
-	O	O
6	O	O
.	O	O
1	O	O
%	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

although	O	O
cocaine	B-chem	B-chem
-	O	O
associated	O	O
myocardial	O	O
ischemia	O	O
can	O	O
result	O	O
from	O	O
coronary	O	O
vasoconstriction	O	O
,	O	O
patients	O	O
with	O	O
cocaine	B-chem	B-chem
associated	O	O
chest	O	O
pain	O	O
,	O	O
a	O	O
non	O	O
-	O	O
ischemic	O	O
ecg	O	O
,	O	O
and	O	O
a	O	O
timi	O	O
risk	O	O
score	O	O
<	O	O
2	O	O
may	O	O
be	O	O
safely	O	O
discharged	O	O
from	O	O
the	O	O
ed	O	O
after	O	O
a	O	O
negative	O	O
coronary	O	O
cta	O	O
with	O	O
a	O	O
low	O	O
risk	O	O
of	O	O
30	O	O
-	O	O
day	O	O
adverse	O	O
events	O	O
.	O	O

late	O	O
fulminant	O	O
posterior	O	O
reversible	O	O
encephalopathy	O	O
syndrome	O	O
after	O	O
liver	O	O
transplant	O	O
.	O	O

objectives	O	O
:	O	O

posterior	O	O
leukoencephalopathy	O	O
due	O	O
to	O	O
calcineurin	O	O
-	O	O
inhibitor	O	O
-	O	O
related	O	O
neurotoxicity	O	O
is	O	O
a	O	O
rare	O	O
but	O	O
severe	O	O
complication	O	O
that	O	O
results	O	O
from	O	O
treatment	O	O
with	O	O
immunosuppressive	O	O
agents	O	O
(	O	O
primarily	O	O
those	O	O
administered	O	O
after	O	O
a	O	O
liver	O	O
or	O	O
kidney	O	O
transplant	O	O
)	O	O
.	O	O

the	O	O
pathophysiologic	O	O
mechanisms	O	O
of	O	O
that	O	O
disorder	O	O
remain	O	O
unknown	O	O
.	O	O

case	O	O
:	O	O

we	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
46	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
received	O	O
a	O	O
liver	O	O
transplant	O	O
in	O	O
our	O	O
center	O	O
as	O	O
treatment	O	O
for	O	O
alcoholic	O	O
cirrhosis	O	O
and	O	O
in	O	O
whom	O	O
either	O	O
a	O	O
fulminant	O	O
course	O	O
of	O	O
posterior	O	O
leukoencephalopathy	O	O
or	O	O
posterior	O	O
reversible	O	O
encephalopathy	O	O
syndrome	O	O
developed	O	O
110	O	O
days	O	O
after	O	O
transplant	O	O
.	O	O

after	O	O
an	O	O
initially	O	O
uneventful	O	O
course	O	O
after	O	O
the	O	O
transplant	O	O
,	O	O
the	O	O
patient	O	O
rapidly	O	O
fell	O	O
into	O	O
deep	O	O
coma	O	O
.	O	O

results	O	O
:	O	O

cerebral	O	O
mri	O	O
scan	O	O
showed	O	O
typical	O	O
signs	O	O
of	O	O
enhancement	O	O
in	O	O
the	O	O
pontine	O	O
and	O	O
posterior	O	O
regions	O	O
.	O	O

switching	O	O
the	O	O
immunosuppressive	O	O
regimen	O	O
from	O	O
tacrolimus	B-chem	B-chem
to	O	O
cyclosporine	B-chem	B-chem
did	O	O
not	O	O
improve	O	O
the	O	O
clinical	O	O
situation	O	O
.	O	O

the	O	O
termination	O	O
of	O	O
treatment	O	O
with	O	O
any	O	O
calcineurin	O	O
inhibitor	O	O
resulted	O	O
in	O	O
a	O	O
complete	O	O
resolution	O	O
of	O	O
that	O	O
complication	O	O
.	O	O

conclusions	O	O
:	O	O

posterior	O	O
reversible	O	O
encephalopathy	O	O
syndrome	O	O
after	O	O
liver	O	O
transplant	O	O
is	O	O
rare	O	O
.	O	O

we	O	O
recommend	O	O
a	O	O
complete	O	O
cessation	O	O
of	O	O
any	O	O
calcineurin	O	O
inhibitor	O	O
rather	O	O
than	O	O
a	O	O
dose	O	O
reduction	O	O
.	O	O

prolonged	O	O
hypothermia	O	O
as	O	O
a	O	O
bridge	O	O
to	O	O
recovery	O	O
for	O	O
cerebral	O	O
edema	O	O
and	O	O
intracranial	O	O
hypertension	O	O
associated	O	O
with	O	O
fulminant	O	O
hepatic	O	O
failure	O	O
.	O	O

background	O	O
:	O	O

to	O	O
review	O	O
evidence	O	O
-	O	O
based	O	O
treatment	O	O
options	O	O
in	O	O
patients	O	O
with	O	O
cerebral	O	O
edema	O	O
complicating	O	O
fulminant	O	O
hepatic	O	O
failure	O	O
(	O	O
fhf	O	O
)	O	O
and	O	O
discuss	O	O
the	O	O
potential	O	O
applications	O	O
of	O	O
hypothermia	O	O
.	O	O

method	O	O
:	O	O

case	O	O
-	O	O
based	O	O
observations	O	O
from	O	O
a	O	O
medical	O	O
intensive	O	O
care	O	O
unit	O	O
(	O	O
micu	O	O
)	O	O
in	O	O
a	O	O
tertiary	O	O
care	O	O
facility	O	O
in	O	O
a	O	O
27	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
with	O	O
fhf	O	O
from	O	O
acetaminophen	B-chem	B-chem
and	O	O
resultant	O	O
cerebral	O	O
edema	O	O
.	O	O

results	O	O
:	O	O

our	O	O
patient	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
micu	O	O
after	O	O
being	O	O
found	O	O
unresponsive	O	O
with	O	O
presumed	O	O
toxicity	O	O
from	O	O
acetaminophen	B-chem	B-chem
which	O	O
was	O	O
ingested	O	O
over	O	O
a	O	O
2	O	O
-	O	O
day	O	O
period	O	O
.	O	O

the	O	O
patient	O	O
had	O	O
depressed	O	O
of	O	O
mental	O	O
status	O	O
lasting	O	O
at	O	O
least	O	O
24	O	O
h	O	O
prior	O	O
to	O	O
admission	O	O
.	O	O

initial	O	O
evaluation	O	O
confirmed	O	O
fhf	O	O
from	O	O
acetaminophen	B-chem	B-chem
and	O	O
cerebral	O	O
edema	O	O
.	O	O

the	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
hyperosmolar	O	O
therapy	O	O
,	O	O
hyperventilation	O	O
,	O	O
sedation	O	O
,	O	O
and	O	O
chemical	O	O
paralysis	O	O
.	O	O

her	O	O
intracranial	O	O
pressure	O	O
remained	O	O
elevated	O	O
despite	O	O
maximal	O	O
medical	O	O
therapy	O	O
.	O	O

we	O	O
then	O	O
initiated	O	O
therapeutic	O	O
hypothermia	O	O
which	O	O
was	O	O
continued	O	O
for	O	O
5	O	O
days	O	O
.	O	O

at	O	O
re	O	O
-	O	O
warming	O	O
,	O	O
patient	O	O
had	O	O
resolution	O	O
of	O	O
her	O	O
cerebral	O	O
edema	O	O
and	O	O
intracranial	O	O
hypertension	O	O
.	O	O

at	O	O
discharge	O	O
,	O	O
she	O	O
had	O	O
complete	O	O
recovery	O	O
of	O	O
neurological	O	O
and	O	O
hepatic	O	O
functions	O	O
.	O	O

conclusion	O	O
:	O	O

in	O	O
patients	O	O
with	O	O
fhf	O	O
and	O	O
cerebral	O	O
edema	O	O
from	O	O
acetaminophen	B-chem	O
overdose	O	O
,	O	O
prolonged	O	O
therapeutic	O	O
hypothermia	O	O
could	O	O
potentially	O	O
be	O	O
used	O	O
as	O	O
a	O	O
life	O	O
saving	O	O
therapy	O	O
and	O	O
a	O	O
bridge	O	O
to	O	O
hepatic	O	O
and	O	O
neurological	O	O
recovery	O	O
.	O	O

a	O	O
clinical	O	O
trial	O	O
of	O	O
hypothermia	O	O
in	O	O
patients	O	O
with	O	O
this	O	O
condition	O	O
is	O	O
warranted	O	O
.	O	O

binasal	O	O
visual	O	O
field	O	O
defects	O	O
are	O	O
not	O	O
specific	O	O
to	O	O
vigabatrin	B-chem	B-chem
.	O	O

this	O	O
study	O	O
investigated	O	O
the	O	O
visual	O	O
defects	O	O
associated	O	O
with	O	O
the	O	O
antiepileptic	O	O
drug	O	O
vigabatrin	B-chem	B-chem
(	O	O
vgb	B-chem	O
)	O	O
.	O	O

two	O	O
hundred	O	O
four	O	O
people	O	O
with	O	O
epilepsy	O	O
were	O	O
grouped	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
antiepileptic	O	O
drug	O	O
therapy	O	O
(	O	O
current	O	O
,	O	O
previous	O	O
,	O	O
or	O	O
no	O	O
exposure	O	O
to	O	O
vgb	B-chem	O
)	O	O
.	O	O

groups	O	O
were	O	O
matched	O	O
with	O	O
respect	O	O
to	O	O
age	O	O
,	O	O
gender	O	O
,	O	O
and	O	O
seizure	O	O
frequency	O	O
.	O	O

all	O	O
patients	O	O
underwent	O	O
objective	O	O
assessment	O	O
of	O	O
electrophysiological	O	O
function	O	O
(	O	O
wide	O	O
-	O	O
field	O	O
multifocal	O	O
electroretinography	O	O
)	O	O
and	O	O
conventional	O	O
visual	O	O
field	O	O
testing	O	O
(	O	O
static	O	O
perimetry	O	O
)	O	O
.	O	O

bilateral	O	O
visual	O	O
field	O	O
constriction	O	O
was	O	O
observed	O	O
in	O	O
59	O	O
%	O	O
of	O	O
patients	O	O
currently	O	O
taking	O	O
vgb	B-chem	O
,	O	O
43	O	O
%	O	O
of	O	O
patients	O	O
who	O	O
previously	O	O
took	O	O
vgb	B-chem	O
,	O	O
and	O	O
24	O	O
%	O	O
of	O	O
patients	O	O
with	O	O
no	O	O
exposure	O	O
to	O	O
vgb	B-chem	O
.	O	O

assessment	O	O
of	O	O
retinal	O	O
function	O	O
revealed	O	O
abnormal	O	O
responses	O	O
in	O	O
48	O	O
%	O	O
of	O	O
current	O	O
vgb	B-chem	O
users	O	O
and	O	O
22	O	O
%	O	O
of	O	O
prior	O	O
vgb	B-chem	O
users	O	O
,	O	O
but	O	O
in	O	O
none	O	O
of	O	O
the	O	O
patients	O	O
without	O	O
previous	O	O
exposure	O	O
to	O	O
vgb	B-chem	O
.	O	O

bilateral	O	O
visual	O	O
field	O	O
abnormalities	O	O
are	O	O
common	O	O
in	O	O
the	O	O
treated	O	O
epilepsy	O	O
population	O	O
,	O	O
irrespective	O	O
of	O	O
drug	O	O
history	O	O
.	O	O

assessment	O	O
by	O	O
conventional	O	O
static	O	O
perimetry	O	O
may	O	O
neither	O	O
be	O	O
sufficiently	O	O
sensitive	O	O
nor	O	O
specific	O	O
to	O	O
reliably	O	O
identify	O	O
retinal	O	O
toxicity	O	O
associated	O	O
with	O	O
vgb	B-chem	O
.	O	O

smoking	O	B-chem
of	O	O
crack	B-chem	B-chem
cocaine	I-chem	I-chem
as	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
hiv	O	O
infection	O	O
among	O	O
people	O	O
who	O	O
use	O	O
injection	O	O
drugs	O	O
.	O	O

background	O	O
:	O	O

little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
possible	O	O
role	O	O
that	O	O
smoking	O	B-chem
crack	B-chem	I-chem
cocaine	I-chem	B-chem
has	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
hiv	O	O
infection	O	O
.	O	O

given	O	O
the	O	O
increasing	O	O
use	O	O
of	O	O
crack	B-chem	B-chem
cocaine	I-chem	I-chem
,	O	O
we	O	O
sought	O	O
to	O	O
examine	O	O
whether	O	O
use	O	O
of	O	O
this	O	O
illicit	O	O
drug	O	O
has	O	O
become	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
hiv	O	O
infection	O	O
.	O	O

methods	O	O
:	O	O

we	O	O
included	O	O
data	O	O
from	O	O
people	O	O
participating	O	O
in	O	O
the	O	O
vancouver	O	B-chem
injection	O	O
drug	O	O
users	O	O
study	O	O
who	O	O
reported	O	O
injecting	O	O
illicit	O	B-chem
drugs	O	O
at	O	O
least	O	O
once	O	O
in	O	O
the	O	O
month	O	O
before	O	O
enrolment	O	O
,	O	O
lived	O	O
in	O	O
the	O	O
greater	O	O
vancouver	O	B-chem
area	O	O
,	O	O
were	O	O
hiv	O	O
-	O	O
negative	O	O
at	O	O
enrolment	O	O
and	O	O
completed	O	O
at	O	O
least	O	O
1	O	O
follow	O	O
-	O	O
up	O	O
study	O	O
visit	O	O
.	O	O

to	O	O
determine	O	O
whether	O	O
the	O	O
risk	O	O
of	O	O
hiv	O	O
seroconversion	O	O
among	O	O
daily	O	O
smokers	O	O
of	O	O
crack	B-chem	B-chem
cocaine	I-chem	B-chem
changed	O	O
over	O	O
time	O	O
,	O	O
we	O	O
used	O	O
cox	O	O
proportional	O	O
hazards	O	O
regression	O	O
and	O	O
divided	O	O
the	O	O
study	O	O
into	O	O
3	O	O
periods	O	O
:	O	O
may	O	O
1	O	O
,	O	O
1996	O	O
-	O	O
nov	O	O
.	O	O

30	O	O
,	O	O
1999	O	O

(	O	O
period	O	O
1	O	O
)	O	O
,	O	O
dec	O	O
.	O	O
1	O	O
,	O	O
1999	O	O
-	O	O
nov	O	O
.	O	O

30	O	O
,	O	O
2002	O	O

(	O	O
period	O	O
2	O	O
)	O	O
,	O	O
and	O	O
dec	O	O
.	O	O
1	O	O
,	O	O
2002	O	O
-	O	O
dec	O	O
.	O	O

30	O	O
,	O	O
2005	O	O

(	O	O
period	O	O
3	O	O
)	O	O
.	O	O

results	O	O
:	O	O

overall	O	O
,	O	O
1048	O	O
eligible	O	O
injection	O	O
drug	O	O
users	O	O
were	O	O
included	O	O
in	O	O
our	O	O
study	O	O
.	O	O

of	O	O
these	O	O
,	O	O
137	O	O
acquired	O	O
hiv	O	O
infection	O	O
during	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

the	O	O
mean	O	O
proportion	O	O
of	O	O
participants	O	O
who	O	O
reported	O	O
daily	O	O
smoking	O	B-chem
of	O	O
crack	B-chem	B-chem
cocaine	I-chem	I-chem
increased	O	O
from	O	O
11	O	O
.	O	O
6	O	O
%	O	O
in	O	O
period	O	O
1	O	O
to	O	O
39	O	O
.	O	O
7	O	O
%	O	O
in	O	O
period	O	O
3	O	O
.	O	O

after	O	O
adjusting	O	O
for	O	O
potential	O	O
confounders	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
risk	O	O
of	O	O
hiv	O	O
seroconversion	O	O
among	O	O
participants	O	O
who	O	O
were	O	O
daily	O	O
smokers	O	O
of	O	O
crack	B-chem	B-chem
cocaine	I-chem	I-chem
increased	O	O
over	O	O
time	O	O
(	O	O
period	O	O
1	O	O
:	O	O
hazard	O	O
ratio	O	O
[	O	O
hr	O	O
]	O	O
1	O	O
.	O	O
03	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
ci	O	O
]	O	O
0	O	O
.	O	O
57	O	O
-	O	O
1	O	O
.	O	O
85	O	O
;	O	O
period	O	O
2	O	O
:	O	O
hr	O	O
1	O	O
.	O	O
68	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
1	O	O
.	O	O
01	O	O
-	O	O
2	O	O
.	O	O
80	O	O
;	O	O
and	O	O
period	O	O
3	O	O
:	O	O
hr	O	O
2	O	O
.	O	O
74	O	O
,	O	O
95	O	O
%	O	O
ci	O	O
1	O	O
.	O	O
06	O	O
-	O	O
7	O	O
.	O	O
11	O	O
)	O	O
.	O	O

interpretation	O	O
:	O	O

smoking	O	B-chem
of	O	O
crack	B-chem	B-chem
cocaine	I-chem	I-chem
was	O	O
found	O	O
to	O	O
be	O	O
an	O	O
independent	O	O
risk	O	O
factor	O	O
for	O	O
hiv	O	O
seroconversion	O	O
among	O	O
people	O	O
who	O	O
were	O	O
injection	O	O
drug	O	O
users	O	O
.	O	O

this	O	O
finding	O	O
points	O	O
to	O	O
the	O	O
urgent	O	O
need	O	O
for	O	O
evidence	O	O
-	O	O
based	O	O
public	O	O
health	O	O
initiatives	O	O
targeted	O	O
at	O	O
people	O	O
who	O	O
smoke	O	O
crack	B-chem	O
cocaine	I-chem	B-chem
.	O	O

fluoxetine	B-chem	B-chem
improves	O	O
the	O	O
memory	O	O
deficits	O	O
caused	O	O
by	O	O
the	O	O
chemotherapy	O	O
agent	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
.	O	O

cancer	O	O
patients	O	O
who	O	O
have	O	O
been	O	O
treated	O	O
with	O	O
systemic	O	O
adjuvant	O	O
chemotherapy	O	O
have	O	O
described	O	O
experiencing	O	O
deteriorations	O	O
in	O	O
cognition	O	O
.	O	O

a	O	O
widely	O	O
used	O	O
chemotherapeutic	O	O
agent	O	O
,	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fluorouracil	I-chem	I-chem
(	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
)	O	O
,	O	O
readily	O	O
crosses	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
and	O	O
so	O	O
could	O	O
have	O	O
a	O	O
direct	O	O
effect	O	O
on	O	O
brain	O	O
function	O	O
.	O	O

in	O	O
particular	O	O
this	O	O
anti	O	O
mitotic	O	O
drug	O	O
could	O	O
reduce	O	O
cell	O	O
proliferation	O	O
in	O	O
the	O	O
neurogenic	O	O
regions	O	O
of	O	O
the	O	O
adult	O	O
brain	O	O
.	O	O

in	O	O
contrast	O	O
reports	O	O
indicate	O	O
that	O	O
hippocampal	O	O
dependent	O	O
neurogenesis	O	O
and	O	O
cognition	O	O
are	O	O
enhanced	O	O
by	O	O
the	O	O
ssri	B-chem	B-chem
antidepressant	O	I-chem
fluoxetine	B-chem	I-chem
.	O	O

in	O	O
this	O	O
investigation	O	O
the	O	O
behavioural	O	O
effects	O	O
of	O	O
chronic	O	O
(	O	O
two	O	O
week	O	O
)	O	O
treatment	O	O
with	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
and	O	O
(	O	O
three	O	O
weeks	O	O
)	O	O
with	O	O
fluoxetine	B-chem	B-chem
either	O	O
separately	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
were	O	O
tested	O	O
on	O	O
adult	O	O
lister	O	O
hooded	O	O
rats	O	O
.	O	O

behavioural	O	O
effects	O	O
were	O	O
tested	O	O
using	O	O
a	O	O
context	O	O
dependent	O	O
conditioned	O	O
emotional	O	O
response	O	O
test	O	O
(	O	O
cer	O	B-chem
)	O	O
which	O	O
showed	O	O
that	O	O
animals	O	O
treated	O	O
with	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
had	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
freezing	O	O
time	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

a	O	O
separate	O	O
group	O	O
of	O	O
animals	O	O
was	O	O
tested	O	O
using	O	O
a	O	O
hippocampal	O	O
dependent	O	O
spatial	O	O
working	O	O
memory	O	O
test	O	O
,	O	O
the	O	O
object	O	O
location	O	O
recognition	O	O
test	O	O
(	O	O
olr	O	O
)	O	O
.	O	O

animals	O	O
treated	O	O
only	O	O
with	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
showed	O	O
significant	O	O
deficits	O	O
in	O	O
their	O	O
ability	O	O
to	O	O
carry	O	O
out	O	O
the	O	O
olr	O	O
task	O	O
but	O	O
co	O	O
administration	O	O
of	O	O
fluoxetine	B-chem	B-chem
improved	O	O
their	O	O
performance	O	O
.	O	O

5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
chemotherapy	O	O
caused	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
proliferating	O	O
cells	O	O
in	O	O
the	O	O
sub	O	O
granular	O	O
zone	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

this	O	O
reduction	O	O
was	O	O
eliminated	O	O
when	O	O
fluoxetine	B-chem	B-chem
was	O	O
co	O	O
administered	O	O
with	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
.	O	O

fluoxetine	B-chem	B-chem
on	O	O
its	O	O
own	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
proliferating	O	O
cell	O	O
number	O	O
or	O	O
behaviour	O	O
.	O	O

these	O	O
findings	O	O
suggest	O	O
that	O	O
5	B-chem	B-chem
-	I-chem	I-chem
fu	I-chem	I-chem
can	O	O
negatively	O	O
affect	O	O
both	O	O
cell	O	O
proliferation	O	O
and	O	O
hippocampal	O	O
dependent	O	O
working	O	O
memory	O	O
and	O	O
that	O	O
these	O	O
deficits	O	O
can	O	O
be	O	O
reversed	O	O
by	O	O
the	O	O
simultaneous	O	O
administration	O	O
of	O	O
the	O	O
antidepressant	O	B-chem
fluoxetine	B-chem	B-chem
.	O	O

liver	O	O
-	O	O
specific	O	O
ablation	O	O
of	O	O
integrin	O	B-chem
-	O	O
linked	O	O
kinase	O	O
in	O	O
mice	O	O
results	O	O
in	O	O
enhanced	O	O
and	O	O
prolonged	O	O
cell	O	O
proliferation	O	O
and	O	O
hepatomegaly	O	O
after	O	O
phenobarbital	B-chem	B-chem
administration	O	O
.	O	O

we	O	O
have	O	O
recently	O	O
demonstrated	O	O
that	O	O
disruption	O	O
of	O	O
extracellular	O	O
matrix	O	O
(	O	O
ecm	O	O
)	O	O
/	O	O
integrin	O	O
signaling	O	O
via	O	O
elimination	O	O
of	O	O
integrin	O	B-chem
-	O	O
linked	O	O
kinase	O	O
(	O	O
ilk	O	B-chem
)	O	O
in	O	O
hepatocytes	O	O
interferes	O	O
with	O	O
signals	O	O
leading	O	O
to	O	O
termination	O	O
of	O	O
liver	O	O
regeneration	O	O
.	O	O

this	O	O
study	O	O
investigates	O	O
the	O	O
role	O	O
of	O	O
ilk	O	B-chem
in	O	O
liver	O	O
enlargement	O	O
induced	O	O
by	O	O
phenobarbital	B-chem	B-chem
(	O	O
pb	B-chem	O
)	O	O
.	O	O

wild	O	O
-	O	O
type	O	O
(	O	O
wt	O	O
)	O	O
and	O	O
ilk	O	O
:	O	O

liver	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
were	O	O
given	O	O
pb	B-chem	O
(	O	O
0	O	O
.	O	O
1	O	O
%	O	O
in	O	O
drinking	O	O
water	O	O
)	O	O
for	O	O
10	O	O
days	O	O
.	O	O

livers	O	O
were	O	O
harvested	O	O
on	O	O
2	O	O
,	O	O
5	O	O
,	O	O
and	O	O
10	O	O
days	O	O
during	O	O
pb	B-chem	O
administration	O	O
.	O	O

in	O	O
the	O	O
hepatocyte	O	O
-	O	O
specific	O	O
ilk	O	O
/	O	O
liver	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
,	O	O
the	O	O
liver	O	O
:	O	O
body	O	O
weight	O	O
ratio	O	O
was	O	O
more	O	O
than	O	O
double	O	O
as	O	O
compared	O	O
to	O	O
0	O	O
h	O	O
at	O	O
day	O	O
2	O	O
(	O	O
2	O	O
.	O	O
5	O	O
times	O	O
)	O	O
,	O	O
while	O	O
at	O	O
days	O	O
5	O	O
and	O	O
10	O	O
,	O	O
it	O	O
was	O	O
enlarged	O	O
three	O	O
times	O	O
.	O	O

in	O	O
the	O	O
wt	O	O
mice	O	O
,	O	O
the	O	O
increase	O	O
was	O	O
as	O	O
expected	O	O
from	O	O
previous	O	O
literature	O	O
(	O	O
1	O	O
.	O	O
8	O	O
times	O	O
)	O	O
and	O	O
seems	O	O
to	O	O
have	O	O
leveled	O	O
off	O	O
after	O	O
day	O	O
2	O	O
.	O	O

there	O	O
were	O	O
slightly	O	O
increased	O	O
proliferating	O	O
cell	O	O
nuclear	O	O
antigen	O	O
-	O	O
positive	O	O
cells	O	O
in	O	O
the	O	O
ilk	O	O
/	O	O
liver	O	O
-	O	O
/	O	O
-	O	O
animals	O	O
at	O	O
day	O	O
2	O	O
as	O	O
compared	O	O
to	O	O
wt	O	O
after	O	O
pb	B-chem	O
administration	O	O
.	O	O

in	O	O
the	O	O
wt	O	O
animals	O	O
,	O	O
the	O	O
proliferative	O	O
response	O	O
had	O	O
come	O	O
back	O	O
to	O	O
normal	O	O
by	O	O
days	O	O
5	O	O
and	O	O
10	O	O
.	O	O

hepatocytes	O	O
of	O	O
the	O	O
ilk	O	O
/	O	O
liver	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
continued	O	O
to	O	O
proliferate	O	O
up	O	O
until	O	O
day	O	O
10	O	O
.	O	O

ilk	O	O
/	O	O

liver	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
also	O	O
showed	O	O
increased	O	O
expression	O	O
of	O	O
key	O	O
genes	O	O
involved	O	O
in	O	O
hepatocyte	O	O
proliferation	O	O
at	O	O
different	O	O
time	O	O
points	O	O
during	O	O
pb	B-chem	O
administration	O	O
.	O	O

in	O	O
summary	O	O
,	O	O
ecm	O	O
proteins	O	O
communicate	O	O
with	O	O
the	O	O
signaling	O	O
machinery	O	O
of	O	O
dividing	O	O
cells	O	O
via	O	O
ilk	O	O
to	O	O
regulate	O	O
hepatocyte	O	O
proliferation	O	O
and	O	O
termination	O	O
of	O	O
the	O	O
proliferative	O	O
response	O	O
.	O	O

lack	O	O
of	O	O
ilk	O	B-chem
in	O	O
the	O	O
hepatocytes	O	O
imparts	O	O
prolonged	O	O
proliferative	O	O
response	O	O
not	O	O
only	O	O
to	O	O
stimuli	O	O
related	O	O
to	O	O
liver	O	O
regeneration	O	O
but	O	O
also	O	O
to	O	O
xenobiotic	O	O
chemical	O	O
mitogens	O	O
,	O	O
such	O	O
as	O	O
pb	B-chem	O
.	O	O

decreased	O	O
expression	O	O
of	O	O
na	B-chem	B-chem
/	O	O
k	B-chem	B-chem
-	O	O
atpase	O	O
,	O	O
nhe3	O	O
,	O	O
nbc1	O	O
,	O	O
aqp1	O	O
and	O	O
oat	O	O
in	O	O
gentamicin	B-chem	B-chem
-	O	O
induced	O	O
nephropathy	O	O
.	O	O

the	O	O
present	O	O
study	O	O
was	O	O
aimed	O	O
to	O	O
determine	O	O
whether	O	O
there	O	O
is	O	O
an	O	O
altered	O	O
regulation	O	O
of	O	O
tubular	O	O
transporters	O	O
in	O	O
gentamicin	B-chem	B-chem
-	O	O
induced	O	O
nephropathy	O	O
.	O	O

sprague	O	O
-	O	O
dawley	O	O
male	O	O
rats	O	O
(	O	O
200	O	O
~	O	O
250	O	O
g	O	O
)	O	O
were	O	O
subcutaneously	O	O
injected	O	O
with	O	O
gentamicin	B-chem	B-chem
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
)	O	O
for	O	O
7	O	O
days	O	O
,	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
tubular	O	O
transporters	O	O
was	O	O
determined	O	O
by	O	O
immunoblotting	O	O
and	O	O
immunohistochemistry	O	O
.	O	O

the	O	O
mrna	O	O
and	O	O
protein	O	O
expression	O	O
of	O	O
oat	O	O
was	O	O
also	O	O
determined	O	O
.	O	O

gentamicin	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
exhibited	O	O
significantly	O	O
decreased	O	O
creatinine	B-chem	B-chem
clearance	O	O
along	O	O
with	O	O
increased	O	O
plasma	O	O
creatinine	B-chem	B-chem
levels	O	O
.	O	O

accordingly	O	O
,	O	O
the	O	O
fractional	O	O
excretion	O	O
of	O	O
sodium	B-chem	B-chem
increased	O	O
.	O	O

urine	O	O
volume	O	O
was	O	O
increased	O	O
,	O	O
while	O	O
urine	O	O
osmolality	O	O
and	O	O
free	O	O
water	O	O
reabsorption	O	O
were	O	O
decreased	O	O
.	O	O

immunoblotting	O	O
and	O	O
immunohistochemistry	O	O
revealed	O	O
decreased	O	O
expression	O	O
of	O	O
na	B-chem	B-chem
(	O	O
+	O	O
)	O	O
/	O	O
k	B-chem	O
(	O	O
+	O	O
)	O	O
-	O	O
atpase	O	O
,	O	O
nhe3	O	O
,	O	O
nbc1	O	O
,	O	O
and	O	O
aqp1	O	O
in	O	O
the	O	O
kidney	O	O
of	O	O
gentamicin	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
.	O	O

the	O	O
expression	O	O
of	O	O
oat1	O	O
and	O	O
oat3	O	O
was	O	O
also	O	O
decreased	O	O
.	O	O

gentamicin	B-chem	B-chem
-	O	O
induced	O	O
nephropathy	O	O
may	O	O
at	O	O
least	O	O
in	O	O
part	O	O
be	O	O
causally	O	O
related	O	O
with	O	O
a	O	O
decreased	O	O
expression	O	O
of	O	O
na	B-chem	B-chem
(	O	O
+	O	O
)	O	O
/	O	O
k	B-chem	O
(	O	O
+	O	O
)	O	O
-	O	O
atpase	O	O
,	O	O
nhe3	O	O
,	O	O
nbc1	O	O
,	O	O
aqp1	O	O
and	O	O
oat	O	O
.	O	O

longitudinal	O	O
association	O	O
of	O	O
alcohol	B-chem	B-chem
use	O	O
with	O	O
hiv	O	O
disease	O	O
progression	O	O
and	O	O
psychological	O	O
health	O	O
of	O	O
women	O	O
with	O	O
hiv	O	O
.	O	O

we	O	O
evaluated	O	O
the	O	O
association	O	O
of	O	O
alcohol	B-chem	B-chem
consumption	O	O
and	O	O
depression	O	O
,	O	O
and	O	O
their	O	O
effects	O	O
on	O	O
hiv	O	O
disease	O	O
progression	O	O
among	O	O
women	O	O
with	O	O
hiv	O	O
.	O	O

the	O	O
study	O	O
included	O	O
871	O	O
women	O	O
with	O	O
hiv	O	O
who	O	O
were	O	O
recruited	O	O
from	O	O
1993	O	O
-	O	O
1995	O	O
in	O	O
four	O	O
us	O	O
cities	O	O
.	O	O

the	O	O
participants	O	O
had	O	O
physical	O	O
examination	O	O
,	O	O
medical	O	O
record	O	O
extraction	O	O
,	O	O
and	O	O
venipuncture	O	O
,	O	O
cd4	O	O
+	O	O
t	O	O
-	O	O
cell	O	O
counts	O	O
determination	O	O
,	O	O
measurement	O	O
of	O	O
depression	O	O
symptoms	O	O
(	O	O
using	O	O
the	O	O
self	O	O
-	O	O
report	O	O
center	O	O
for	O	O
epidemiological	O	O
studies	O	O
-	O	O
depression	O	O
scale	O	O
)	O	O
,	O	O
and	O	O
alcohol	B-chem	B-chem
use	O	O
assessment	O	O
at	O	O
enrollment	O	O
,	O	O
and	O	O
semiannually	O	O
until	O	O
march	O	O
2000	O	O
.	O	O

multilevel	O	O
random	O	O
coefficient	O	O
ordinal	O	O
models	O	O
as	O	O
well	O	O
as	O	O
multilevel	O	O
models	O	O
with	O	O
joint	O	O
responses	O	O
were	O	O
used	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

there	O	O
was	O	O
no	O	O
significant	O	O
association	O	O
between	O	O
level	O	O
of	O	O
alcohol	B-chem	B-chem
use	O	O
and	O	O
cd4	O	O
+	O	O
t	O	O
-	O	O
cell	O	O
counts	O	O
.	O	O

when	O	O
participants	O	O
were	O	O
stratified	O	O
by	O	O
antiretroviral	O	O
therapy	O	O
(	O	O
art	O	O
)	O	O
use	O	O
,	O	O
the	O	O
association	O	O
between	O	O
alcohol	B-chem	B-chem
and	O	O
cd4	O	O
+	O	O
t	O	O
-	O	O
cell	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
.	O	O

the	O	O
association	O	O
between	O	O
alcohol	B-chem	B-chem
consumption	O	O
and	O	O
depression	O	O
was	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

depression	O	O
had	O	O
a	O	O
significant	O	O
negative	O	O
effect	O	O
on	O	O
cd4	O	O
+	O	O
t	O	O
-	O	O
cell	O	O
counts	O	O
over	O	O
time	O	O
regardless	O	O
of	O	O
art	O	B-chem
use	O	O
.	O	O

our	O	O
findings	O	O
suggest	O	O
that	O	O
alcohol	B-chem	B-chem
consumption	O	O
has	O	O
a	O	O
direct	O	O
association	O	O
with	O	O
depression	O	O
.	O	O

moreover	O	O
,	O	O
depression	O	O
is	O	O
associated	O	O
with	O	O
hiv	O	O
disease	O	O
progression	O	O
.	O	O

our	O	O
findings	O	O
have	O	O
implications	O	O
for	O	O
the	O	O
provision	O	O
of	O	O
alcohol	B-chem	B-chem
use	O	O
interventions	O	O
and	O	O
psychological	O	O
resources	O	O
to	O	O
improve	O	O
the	O	O
health	O	O
of	O	O
women	O	O
with	O	O
hiv	O	O
.	O	O

chemokine	O	O
ccl2	O	O
and	O	O
its	O	O
receptor	O	O
ccr2	O	O
are	O	O
increased	O	O
in	O	O
the	O	O
hippocampus	O	O
following	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
status	O	O
epilepticus	O	O
.	O	O

background	O	O
:	O	O
neuroinflammation	O	O
occurs	O	O
after	O	O
seizures	O	O
and	O	O
is	O	O
implicated	O	O
in	O	O
epileptogenesis	O	O
.	O	O

ccr2	O	O
is	O	O
a	O	O
chemokine	O	O
receptor	O	O
for	O	O
ccl2	O	O
and	O	O
their	O	O
interaction	O	O
mediates	O	O
monocyte	O	O
infiltration	O	O
in	O	O
the	O	O
neuroinflammatory	O	O
cascade	O	O
triggered	O	O
in	O	O
different	O	O
brain	O	O
pathologies	O	O
.	O	O

in	O	O
this	O	O
work	O	O
ccr2	O	O
and	O	O
ccl2	O	O
expression	O	O
were	O	O
examined	O	O
following	O	O
status	O	O
epilepticus	O	O
(	O	O
se	O	O
)	O	O
induced	O	O
by	O	O
pilocarpine	B-chem	B-chem
injection	O	O
.	O	O

methods	O	O
:	O	O

se	O	O
was	O	O
induced	O	O
by	O	O
pilocarpine	B-chem	B-chem
injection	O	O
.	O	O

control	O	O
rats	O	O
were	O	O
injected	O	O
with	O	O
saline	O	O
instead	O	O
of	O	O
pilocarpine	B-chem	B-chem
.	O	O

five	O	O
days	O	O
after	O	O
se	O	O
,	O	O
ccr2	O	O
staining	O	O
in	O	O
neurons	O	O
and	O	O
glial	O	O
cells	O	O
was	O	O
examined	O	O
using	O	O
imunohistochemical	O	O
analyses	O	O
.	O	O

the	O	O
number	O	O
of	O	O
ccr2	O	O
positive	O	O
cells	O	O
was	O	O
determined	O	O
using	O	O
stereology	O	O
probes	O	O
in	O	O
the	O	O
hippocampus	O	O
.	O	O

ccl2	O	O
expression	O	O
in	O	O
the	O	O
hippocampus	O	O
was	O	O
examined	O	O
by	O	O
molecular	O	O
assay	O	O
.	O	O

results	O	O
:	O	O

increased	O	O
ccr2	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
hippocampus	O	O
after	O	O
se	O	O
.	O	O

seizures	O	O
also	O	O
resulted	O	O
in	O	O
alterations	O	O
to	O	O
the	O	O
cell	O	O
types	O	O
expressing	O	O
ccr2	O	O
.	O	O

increased	O	O
numbers	O	O
of	O	O
neurons	O	O
that	O	O
expressed	O	O
ccr2	O	O
was	O	O
observed	O	O
following	O	O
se	O	O
.	O	O

microglial	O	O
cells	O	O
were	O	O
more	O	O
closely	O	O
apposed	O	O
to	O	O
the	O	O
ccr2	O	O
-	O	O
labeled	O	O
cells	O	O
in	O	O
se	O	O
rats	O	O
.	O	O

in	O	O
addition	O	O
,	O	O
rats	O	O
that	O	O
experienced	O	O
se	O	O
exhibited	O	O
ccr2	O	O
-	O	O
labeling	O	O
in	O	O
populations	O	O
of	O	O
hypertrophied	O	O
astrocytes	O	O
,	O	O
especially	O	O
in	O	O
ca1	O	O
and	O	O
dentate	O	O
gyrus	O	O
.	O	O

these	O	O
ccr2	O	O
+	O	O
astroctytes	O	O
were	O	O
not	O	O
observed	O	O
in	O	O
control	O	O
rats	O	O
.	O	O

examination	O	O
of	O	O
ccl2	O	O
expression	O	O
showed	O	O
that	O	O
it	O	O
was	O	O
elevated	O	O
in	O	O
the	O	O
hippocampus	O	O
following	O	O
se	O	O
.	O	O

conclusion	O	O
:	O	O

the	O	O
data	O	O
show	O	O
that	O	O
ccr2	O	O
and	O	O
ccl2	O	O
are	O	O
up	O	O
-	O	O
regulated	O	O
in	O	O
the	O	O
hippocampus	O	O
after	O	O
pilocarpine	B-chem	B-chem
-	O	O
induced	O	O
se	O	O
.	O	O

seizures	O	O
also	O	O
result	O	O
in	O	O
changes	O	O
to	O	O
ccr2	O	O
receptor	O	O
expression	O	O
in	O	O
neurons	O	O
and	O	O
astrocytes	O	O
.	O	O

these	O	O
changes	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
detrimental	O	O
neuroplasticity	O	O
and	O	O
neuroinflammatory	O	O
changes	O	O
that	O	O
occur	O	O
following	O	O
seizures	O	O
.	O	O

metallothionein	B-chem	O
induction	O	O
reduces	O	O
caspase	O	O
-	O	O
3	O	O
activity	O	O
and	O	O
tnfalpha	O	O
levels	O	O
with	O	O
preservation	O	O
of	O	O
cognitive	O	O
function	O	O
and	O	O
intact	O	O
hippocampal	O	O
neurons	O	O
in	O	O
carmustine	B-chem	B-chem
-	O	O
treated	O	O
rats	O	O
.	O	O

hippocampal	O	O
integrity	O	O
is	O	O
essential	O	O
for	O	O
cognitive	O	O
functions	O	O
.	O	O

on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
induction	O	O
of	O	O
metallothionein	B-chem	B-chem
(	O	O
mt	B-chem	O
)	O	O
by	O	O
znso	B-chem	B-chem
(	I-chem	O
4	I-chem	O
)	I-chem	O
and	O	O
its	O	O
role	O	O
in	O	O
neuroprotection	O	O
has	O	O
been	O	O
documented	O	O
.	O	O

the	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
explore	O	O
the	O	O
effect	O	O
of	O	O
mt	B-chem	B-chem
induction	O	O
on	O	O
carmustine	B-chem	B-chem
(	O	O
bcnu	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
hippocampal	O	O
cognitive	O	O
dysfunction	O	O
in	O	O
rats	O	O
.	O	O

a	O	O
total	O	O
of	O	O
60	O	O
male	O	O
wistar	O	O
albino	O	O
rats	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
four	O	O
groups	O	O
(	O	O
15	O	O
/	O	O
group	O	O
)	O	O
:	O	O
the	O	O
control	O	O
group	O	O
injected	O	O
with	O	O
single	O	O
doses	O	O
of	O	O
normal	O	O
saline	O	O
(	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
)	O	O
followed	O	O
24	O	O
h	O	O
later	O	O
by	O	O
bcnu	B-chem	B-chem
solvent	O	O
(	O	O
i	O	O
.	O	O
v	O	O
)	O	O
.	O	O

the	O	O
second	O	O
group	O	O
administered	O	O
znso	B-chem	B-chem
(	I-chem	O
4	I-chem	O
)	I-chem	O
(	O	O
0	O	O
.	O	O
1	O	O
micromol	O	O
/	O	O
10	O	O
microl	O	O
normal	O	O
saline	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
,	O	O
once	O	O
)	O	O
then	O	O
bcnu	B-chem	B-chem
solvent	O	O
(	O	O
i	O	O
.	O	O
v	O	O
)	O	O
after	O	O
24	O	O
h	O	O
.	O	O
third	O	O
group	O	O
received	O	O
bcnu	B-chem	B-chem
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
v	O	O
,	O	O
once	O	O
)	O	O
24	O	O
h	O	O
after	O	O
injection	O	O
with	O	O
normal	O	O
saline	O	O
(	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
)	O	O
.	O	O

fourth	O	O
group	O	O
received	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
znso	B-chem	B-chem
(	I-chem	O
4	I-chem	I-chem
)	I-chem	I-chem
(	O	O
0	O	O
.	O	O
1	O	O
micromol	O	O
/	O	O
10	O	O
microl	O	O
normal	O	O
saline	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
)	O	O
then	O	O
bcnu	B-chem	B-chem
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
v	O	O
,	O	O
once	O	O
)	O	O
after	O	O
24	O	O
h	O	O
.	O	O

the	O	O
obtained	O	O
data	O	O
revealed	O	O
that	O	O
bcnu	B-chem	B-chem
administration	O	O
resulted	O	O
in	O	O
deterioration	O	O
of	O	O
learning	O	O
and	O	O
short	O	O
-	O	O
term	O	O
memory	O	O
(	O	O
stm	O	O
)	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
using	O	O
radial	O	O
arm	O	O
water	O	O
maze	O	O
,	O	O
accompanied	O	O
with	O	O
decreased	O	O
hippocampal	O	O
glutathione	B-chem	B-chem
reductase	O	O
(	O	O
gr	O	B-chem
)	O	O
activity	O	O
and	O	O
reduced	O	O
glutathione	B-chem	B-chem
(	O	O
gsh	B-chem	B-chem
)	O	O
content	O	O
.	O	O

also	O	O
,	O	O
bcnu	B-chem	B-chem
administration	O	O
increased	O	O
serum	O	O
tumor	O	O
necrosis	O	O
factor	O	O
-	O	O
alpha	O	O
(	O	O
tnfalpha	O	O
)	O	O
,	O	O
hippocampal	O	O
mt	B-chem	B-chem
and	O	O
malondialdehyde	B-chem	B-chem
(	O	O
mda	B-chem	B-chem
)	O	O
contents	O	O
as	O	O
well	O	O
as	O	O
caspase	O	O
-	O	O
3	O	O
activity	O	O
in	O	O
addition	O	O
to	O	O
histological	O	O
alterations	O	O
.	O	O

znso	B-chem	B-chem
(	I-chem	O
4	I-chem	I-chem
)	I-chem	O
pretreatment	O	O
counteracted	O	O
bcnu	B-chem	B-chem
-	O	O
induced	O	O
inhibition	O	O
of	O	O
gr	O	B-chem
and	O	O
depletion	O	O
of	O	O
gsh	B-chem	B-chem
and	O	O
resulted	O	O
in	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
mda	B-chem	B-chem
and	O	O
tnfalpha	O	O
as	O	O
well	O	O
as	O	O
the	O	O
activity	O	O
of	O	O
caspase	O	O
-	O	O
3	O	O
.	O	O

the	O	O
histological	O	O
features	O	O
were	O	O
improved	O	O
in	O	O
hippocampus	O	O
of	O	O
rats	O	O
treated	O	O
with	O	O
znso	B-chem	B-chem
(	I-chem	O
4	I-chem	O
)	I-chem	O
+	O	O
bcnu	B-chem	B-chem
compared	O	O
to	O	O
only	O	O
bcnu	B-chem	B-chem
-	O	O
treated	O	O
animals	O	O
.	O	O

in	O	O
conclusion	O	O
,	O	O
mt	B-chem	O
induction	O	O
halts	O	O
bcnu	B-chem	B-chem
-	O	O
induced	O	O
hippocampal	O	O
toxicity	O	O
as	O	O
it	O	O
prevented	O	O
gr	O	O
inhibition	O	O
and	O	O
gsh	B-chem	B-chem
depletion	O	O
and	O	O
counteracted	O	O
the	O	O
increased	O	O
levels	O	O
of	O	O
tnfalpha	O	O
,	O	O
mda	B-chem	B-chem
and	O	O
caspase	O	O
-	O	O
3	O	O
activity	O	O
with	O	O
subsequent	O	O
preservation	O	O
of	O	O
cognition	O	O
.	O	O

fatal	O	O
carbamazepine	B-chem	B-chem
induced	O	O
fulminant	O	O
eosinophilic	O	O
(	O	O
hypersensitivity	O	O
)	O	O
myocarditis	O	O
:	O	O
emphasis	O	O
on	O	O
anatomical	O	O
and	O	O
histological	O	O
characteristics	O	O
,	O	O
mechanisms	O	O
and	O	O
genetics	O	O
of	O	O
drug	O	O
hypersensitivity	O	O
and	O	O
differential	O	O
diagnosis	O	O
.	O	O

the	O	O
most	O	O
severe	O	O
adverse	O	O
reactions	O	O
to	O	O
carbamazepine	B-chem	B-chem
have	O	O
been	O	O
observed	O	O
in	O	O
the	O	O
haemopoietic	O	O
system	O	O
,	O	O
the	O	O
liver	O	O
and	O	O
the	O	O
cardiovascular	O	O
system	O	O
.	O	O

a	O	O
frequently	O	O
fatal	O	O
,	O	O
although	O	O
exceptionally	O	O
rare	O	O
side	O	O
effect	O	O
of	O	O
carbamazepine	B-chem	B-chem
is	O	O
necrotizing	O	O
eosinophilic	O	O
(	O	O
hypersensitivity	O	O
)	O	O
myocarditis	O	O
.	O	O

we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
hypersensitivity	O	O
myocarditis	O	O
secondary	O	O
to	O	O
administration	O	O
of	O	O
carbamazepine	B-chem	B-chem
.	O	O

acute	O	O
hypersensitivity	O	O
myocarditis	O	O
was	O	O
not	O	O
suspected	O	O
clinically	O	O
,	O	O
and	O	O
the	O	O
diagnosis	O	O
was	O	O
made	O	O
post	O	O
-	O	O
mortem	O	O
.	O	O

histology	O	O
revealed	O	O
diffuse	O	O
infiltration	O	O
of	O	O
the	O	O
myocardium	O	O
by	O	O
eosinophils	O	O
and	O	O
lymphocytes	O	O
with	O	O
myocyte	O	O
damage	O	O
.	O	O

clinically	O	O
,	O	O
death	O	O
was	O	O
due	O	O
to	O	O
cardiogenic	O	O
shock	O	O
.	O	O

to	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
second	O	O
case	O	O
of	O	O
fatal	O	O
carbamazepine	B-chem	B-chem
induced	O	O
myocarditis	O	O
reported	O	O
in	O	O
english	O	O
literature	O	O
.	O	O

neuropsychiatric	O	O
behaviors	O	O
in	O	O
the	O	O
mptp	B-chem	B-chem
marmoset	O	O
model	O	O
of	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
.	O	O

objectives	O	O
:	O	O

neuropsychiatric	O	O
symptoms	O	O
are	O	O
increasingly	O	O
recognised	O	O
as	O	O
a	O	O
significant	O	O
problem	O	O
in	O	O
patients	O	O
with	O	O
parkinson	O	O
'	O	O
s	O	O
disease	O	O
(	O	O
pd	O	O
)	O	O
.	O	O

these	O	O
symptoms	O	O
may	O	O
be	O	O
due	O	O
to	O	O
'	O	O
sensitisation	O	O
'	O	O
following	O	O
repeated	O	O
levodopa	B-chem	B-chem
treatment	O	O
or	O	O
a	O	O
direct	O	O
effect	O	O
of	O	O
dopamine	B-chem	B-chem
on	O	O
the	O	O
disease	O	O
state	O	O
.	O	O

the	O	O
levodopa	B-chem	B-chem
-	O	O
treated	O	O
mptp	B-chem	B-chem
-	O	O
lesioned	O	O
marmoset	O	O
was	O	O
used	O	O
as	O	O
a	O	O
model	O	O
of	O	O
neuropsychiatric	O	O
symptoms	O	O
in	O	O
pd	O	O
patients	O	O
.	O	O

here	O	O
we	O	O
compare	O	O
the	O	O
time	O	O
course	O	O
of	O	O
levodopa	B-chem	B-chem
-	O	O
induced	O	O
motor	O	O
fluctuations	O	O
and	O	O
neuropsychiatric	O	O
-	O	O
like	O	O
behaviors	O	O
to	O	O
determine	O	O
the	O	O
relationship	O	O
between	O	O
duration	O	O
of	O	O
treatment	O	O
and	O	O
onset	O	O
of	O	O
symptoms	O	O
.	O	O

methods	O	O
:	O	O

marmosets	O	O
were	O	O
administered	O	O
1	B-chem	B-chem
-	I-chem	I-chem
methyl	I-chem	I-chem
-	I-chem	I-chem
4	I-chem	I-chem
-	I-chem	I-chem
phenyl	I-chem	I-chem
-	I-chem	I-chem
1	I-chem	I-chem
,	I-chem	I-chem
2	I-chem	I-chem
,	I-chem	I-chem
3	I-chem	I-chem
,	I-chem	I-chem
6	I-chem	I-chem
-	I-chem	I-chem
tetrahydropyridine	I-chem	I-chem
(	O	O
2	O	O
.	O	O
0	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O
c	O	O
.	O	O
)	O	O
for	O	O
five	O	O
days	O	O
,	O	O
resulting	O	O
in	O	O
stable	O	O
parkinsonism	O	O
.	O	O

levodopa	B-chem	B-chem
(	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
and	O	O
benserazide	B-chem	B-chem
,	O	O
3	O	O
.	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O

p	O	O
.	O	O
o	O	O
.	O	O

b	O	O
.	O	O
i	O	O
.	O	O
d	O	O
,	O	O
was	O	O
administered	O	O
for	O	O
30	O	O
days	O	O
.	O	O

animals	O	O
were	O	O
evaluated	O	O
for	O	O
parkinsonian	O	O
disability	O	O
,	O	O
dyskinesia	O	O
and	O	O
on	O	O
-	O	O
time	O	O
(	O	O
motor	O	O
fluctuations	O	O
)	O	O
and	O	O
neuropsychiatric	O	O
-	O	O
like	O	O
behaviors	O	O
on	O	O
day	O	O
0	O	O
(	O	O
prior	O	O
to	O	O
levodopa	B-chem	B-chem
)	O	O
and	O	O
on	O	O
days	O	O
1	O	O
,	O	O
7	O	O
,	O	O
13	O	O
,	O	O
27	O	O
and	O	O
30	O	O
of	O	O
treatment	O	O
using	O	O
post	O	O
hoc	O	O
dvd	O	O
analysis	O	O
by	O	O
a	O	O
trained	O	O
rater	O	O
,	O	O
blind	O	O
to	O	O
the	O	O
treatment	O	O
day	O	O
.	O	O

results	O	O
:	O	O

the	O	O
neuropsychiatric	O	O
-	O	O
like	O	O
behavior	O	O
rating	O	O
scale	O	O
demonstrated	O	O
high	O	O
interrater	O	O
reliability	O	O
between	O	O
three	O	O
trained	O	O
raters	O	O
of	O	O
differing	O	O
professional	O	O
backgrounds	O	O
.	O	O

as	O	O
anticipated	O	O
,	O	O
animals	O	O
exhibited	O	O
a	O	O
progressive	O	O
increase	O	O
in	O	O
levodopa	B-chem	B-chem
-	O	O
induced	O	O
motor	O	O
fluctuations	O	O
,	O	O
dyskinesia	O	O
and	O	O
wearing	O	O
-	O	O
off	O	O
,	O	O
that	O	O
correlated	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
levodopa	B-chem	B-chem
therapy	O	O
.	O	O

in	O	O
contrast	O	O
,	O	O
levodopa	B-chem	B-chem
-	O	O
induced	O	O
neuropsychiatric	O	O
-	O	O
like	O	O
behaviors	O	O
were	O	O
present	O	O
on	O	O
day	O	O
1	O	O
of	O	O
levodopa	B-chem	B-chem
treatment	O	O
and	O	O
their	O	O
severity	O	O
did	O	O
not	O	O
correlate	O	O
with	O	O
duration	O	O
of	O	O
treatment	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
data	O	O
suggest	O	O
that	O	O
neuropsychiatric	O	O
disorders	O	O
in	O	O
pd	O	O
are	O	O
more	O	O
likely	O	O
an	O	O
interaction	O	O
between	O	O
levodopa	B-chem	B-chem
and	O	O
the	O	O
disease	O	O
state	O	O
than	O	O
a	O	O
consequence	O	O
of	O	O
sensitisation	O	O
to	O	O
repeated	O	O
dopaminergic	O	O
therapy	O	O
.	O	O

contrast	B-chem	B-chem
medium	I-chem	O
nephrotoxicity	O	O
after	O	O
renal	O	O
artery	O	O
and	O	O
coronary	O	O
angioplasty	O	O
.	O	O

background	O	O
:	O	O

renal	O	O
dysfunction	O	O
induced	O	O
by	O	O
iodinated	O	O
contrast	B-chem	B-chem
medium	I-chem	O
(	O	O
cm	B-chem	O
)	O	O
administration	O	O
can	O	O
minimize	O	O
the	O	O
benefit	O	O
of	O	O
the	O	O
interventional	O	O
procedure	O	O
in	O	O
patients	O	O
undergoing	O	O
renal	O	O
angioplasty	O	O
(	O	O
ptra	O	O
)	O	O
.	O	O

purpose	O	O
:	O	O

to	O	O
compare	O	O
the	O	O
susceptibility	O	O
to	O	O
nephrotoxic	O	O
effect	O	O
of	O	O
cm	B-chem	O
in	O	O
patients	O	O
undergoing	O	O
ptra	O	B-chem
with	O	O
that	O	O
of	O	O
patients	O	O
submitted	O	O
to	O	O
percutaneous	O	O
coronary	O	O
intervention	O	O
(	O	O
pci	O	O
)	O	O
.	O	O

material	O	O
and	O	O
methods	O	O
:	O	O

a	O	O
total	O	O
of	O	O
33	O	O
patients	O	O
successfully	O	O
treated	O	O
with	O	O
ptra	O	B-chem
(	O	O
ptra	O	B-chem
group	O	O
,	O	O
mean	O	O
age	O	O
70	O	O
+	O	O
/	O	O
-	O	O
12	O	O
years	O	O
,	O	O
23	O	O
female	O	O
,	O	O
basal	O	O
creatinine	B-chem	B-chem
1	O	O
.	O	O
46	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
79	O	O
,	O	O
range	O	O
0	O	O
.	O	O
7	O	O
-	O	O
4	O	O
.	O	O
9	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
33	O	O
patients	O	O
undergoing	O	O
successful	O	O
pci	O	O
(	O	O
pci	O	O
group	O	O
)	O	O
,	O	O
matched	O	O
for	O	O
basal	O	O
creatinine	B-chem	B-chem
(	O	O
1	O	O
.	O	O
44	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
6	O	O
,	O	O
range	O	O
0	O	O
.	O	O
7	O	O
-	O	O
3	O	O
.	O	O
4	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
,	O	O
gender	O	O
,	O	O
and	O	O
age	O	O
.	O	O

in	O	O
both	O	O
groups	O	O
postprocedural	O	O
(	O	O
48	O	O
h	O	O
)	O	O
serum	O	O
creatinine	B-chem	B-chem
was	O	O
measured	O	O
.	O	O

results	O	O
:	O	O

postprocedural	O	O
creatinine	B-chem	B-chem
level	O	O
decreased	O	O
nonsignificantly	O	O
in	O	O
the	O	O
ptra	O	B-chem
group	O	O
(	O	O
1	O	O
.	O	O
46	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
8	O	O
vs	O	O
.	O	O
1	O	O
.	O	O
34	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
p	O	O
=	O	O
ns	O	O
)	O	O
and	O	O
increased	O	O
significantly	O	O
in	O	O
the	O	O
pci	O	O
group	O	O
(	O	O
1	O	O
.	O	O
44	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
6	O	O
vs	O	O
.	O	O
1	O	O
.	O	O
57	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
7	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
02	O	O
)	O	O
.	O	O

changes	O	O
in	O	O
serum	O	O
creatinine	B-chem	B-chem
after	O	O
intervention	O	O
(	O	O
after	O	O
-	O	O
before	O	O
)	O	O
were	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
ptra	O	B-chem
and	O	O
pci	O	O
groups	O	O
(	O	O
-	O	O
0	O	O
.	O	O
12	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
5	O	O
vs	O	O
.	O	O
0	O	O
.	O	O
13	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
3	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
014	O	O
)	O	O
.	O	O

this	O	O
difference	O	O
was	O	O
not	O	O
related	O	O
to	O	O
either	O	O
a	O	O
different	O	O
clinical	O	O
risk	O	O
profile	O	O
or	O	O
to	O	O
the	O	O
volume	O	O
of	O	O
cm	B-chem	O
administered	O	O
.	O	O

conclusion	O	O
:	O	O

in	O	O
this	O	O
preliminary	O	O
study	O	O
patients	O	O
submitted	O	O
to	O	O
ptra	O	B-chem
showed	O	O
a	O	O
lower	O	O
susceptibility	O	O
to	O	O
renal	O	O
damage	O	O
induced	O	O
by	O	O
cm	B-chem	O
administration	O	O
than	O	O
pci	O	O
patients	O	O
.	O	O

the	O	O
effectiveness	O	O
of	O	O
ptra	O	B-chem
on	O	O
renal	O	O
function	O	O
seems	O	O
to	O	O
be	O	O
barely	O	O
influenced	O	O
by	O	O
cm	B-chem	O
toxicity	O	O
.	O	O

medical	O	O
and	O	O
psychiatric	O	O
outcomes	O	O
for	O	O
patients	O	O
transplanted	O	O
for	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
acute	O	O
liver	O	O
failure	O	O
:	O	O
a	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

background	O	O
:	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
hepatotoxicity	O	O
is	O	O
the	O	O
most	O	O
common	O	O
cause	O	O
of	O	O
acute	O	O
liver	O	O
failure	O	O
(	O	O
alf	O	O
)	O	O
in	O	O
the	O	O
uk	O	O
.	O	O

patients	O	O
often	O	O
consume	O	O
the	O	O
drug	O	O
with	O	O
suicidal	O	O
intent	O	O
or	O	O
with	O	O
a	O	O
background	O	O
of	O	O
substance	O	O
dependence	O	O
.	O	O

aims	O	O
and	O	O
methods	O	O
:	O	O

we	O	O
compared	O	O
the	O	O
severity	O	O
of	O	O
pretransplant	O	O
illness	O	O
,	O	O
psychiatric	O	O
co	O	O
-	O	O
morbidity	O	O
,	O	O
medical	O	O
and	O	O
psychosocial	O	O
outcomes	O	O
of	O	O
all	O	O
patients	O	O
who	O	O
had	O	O
undergone	O	O
liver	O	O
transplantation	O	O
(	O	O
lt	O	O
)	O	O
emergently	O	O
between	O	O
1999	O	O
-	O	O
2004	O	O
for	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
(	O	O
n	O	O
=	O	O
36	O	O
)	O	O
with	O	O
age	O	O
-	O	O
and	O	O
sex	O	O
-	O	O
matched	O	O
patients	O	O
undergoing	O	O
emergent	O	O
lt	O	O
for	O	O
non	O	O
-	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
(	O	O
n	O	O
=	O	O
35	O	O
)	O	O
and	O	O
elective	O	O
lt	O	O
for	O	O
chronic	O	O
liver	O	O
disease	O	O
(	O	O
cld	O	O
,	O	O
n	O	O
=	O	O
34	O	O
)	O	O
.	O	O

results	O	O
:	O	O

acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
patients	O	O
undergoing	O	O
lt	O	O
had	O	O
a	O	O
greater	O	O
severity	O	O
of	O	O
pre	O	O
-	O	O
lt	O	O
illness	O	O
reflected	O	O
by	O	O
higher	O	O
acute	O	O
physiology	O	O
and	O	O
chronic	O	O
health	O	O
evaluation	O	O
ii	O	O
scores	O	O
and	O	O
requirement	O	O
for	O	O
organ	O	O
support	O	O
compared	O	O
with	O	O
the	O	O
other	O	O
two	O	O
groups	O	O
.	O	O

twenty	O	O
(	O	O
56	O	O
%	O	O
)	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
patients	O	O
had	O	O
a	O	O
formal	O	O
psychiatric	O	O
diagnosis	O	O
before	O	O
lt	O	O
(	O	O
non	O	O
-	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
=	O	O
0	O	O
/	O	O
35	O	O
,	O	O
cld	O	O
=	O	O
2	O	O
/	O	O
34	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
for	O	O
all	O	O
)	O	O
and	O	O
nine	O	O
(	O	O
25	O	O
%	O	O
)	O	O
had	O	O
a	O	O
previous	O	O
suicide	O	O
attempt	O	O
.	O	O

during	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
median	O	O
5	O	O
years	O	O
)	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
rejection	O	O
(	O	O
acute	O	O
and	O	O
chronic	O	O
)	O	O
,	O	O
graft	O	O
failure	O	O
or	O	O
survival	O	O
between	O	O
the	O	O
groups	O	O
(	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
1	O	O
year	O	O
87	O	O
%	O	O
,	O	O
5	O	O
years	O	O
75	O	O
%	O	O
;	O	O
non	O	O
-	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
88	O	O
%	O	O
,	O	O
78	O	O
%	O	O
;	O	O
cld	O	B-chem
93	O	O
%	O	O
,	O	O
82	O	O
%	O	O
:	O	O
p	O	O
>	O	O
0	O	O
.	O	O
6	O	O
log	O	O
rank	O	O
)	O	O
.	O	O

two	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
patients	O	O
reattempted	O	O
suicide	O	O
post	O	O
-	O	O
lt	O	O
(	O	O
one	O	O
died	O	O
8	O	O
years	O	O
post	O	O
-	O	O
lt	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

despite	O	O
a	O	O
high	O	O
prevalence	O	O
of	O	O
psychiatric	O	O
disturbance	O	O
,	O	O
outcomes	O	O
for	O	O
patients	O	O
transplanted	O	O
emergently	O	O
for	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
were	O	O
comparable	O	O
to	O	O
those	O	O
transplanted	O	O
for	O	O
non	O	O
-	O	O
acetaminophen	B-chem	B-chem
-	O	O
induced	O	O
alf	O	O
and	O	O
electively	O	O
for	O	O
cld	O	B-chem
.	O	O

multidisciplinary	O	O
approaches	O	O
with	O	O
long	O	O
-	O	O
term	O	O
psychiatric	O	O
follow	O	O
-	O	O
up	O	O
may	O	O
contribute	O	O
to	O	O
low	O	O
post	O	O
-	O	O
transplant	O	O
suicide	O	O
rates	O	O
seen	O	O
and	O	O
low	O	O
rates	O	O
of	O	O
graft	O	O
loss	O	O
because	O	O
of	O	O
non	O	O
-	O	O
compliance	O	O
.	O	O

studies	O	O
of	O	O
synergy	O	O
between	O	O
morphine	B-chem	B-chem
and	O	O
a	O	O
novel	O	O
sodium	B-chem	B-chem
channel	O	O
blocker	O	O
,	O	O
cnsb002	B-chem	O
,	O	O
in	O	O
rat	O	O
models	O	O
of	O	O
inflammatory	O	O
and	O	O
neuropathic	O	O
pain	O	O
.	O	O

objective	O	O
:	O	O

this	O	O
study	O	O
determined	O	O
the	O	O
antihyperalgesic	O	O
effect	O	O
of	O	O
cnsb002	B-chem	B-chem
,	O	O
a	O	O
sodium	B-chem	B-chem
channel	O	O
blocker	O	O
with	O	O
antioxidant	O	O
properties	O	O
given	O	O
alone	O	O
and	O	O
in	O	O
combinations	O	O
with	O	O
morphine	B-chem	B-chem
in	O	O
rat	O	O
models	O	O
of	O	O
inflammatory	O	O
and	O	O
neuropathic	O	O
pain	O	O
.	O	O

design	O	O
:	O	O

dose	O	O
response	O	O
curves	O	O
for	O	O
nonsedating	O	O
doses	O	O
of	O	O
morphine	B-chem	B-chem
and	O	O
cnsb002	B-chem	O
given	O	O
intraperitoneally	O	O
alone	O	O
and	O	O
together	O	O
in	O	O
combinations	O	O
were	O	O
constructed	O	O
for	O	O
antihyperalgesic	O	O
effect	O	O
using	O	O
paw	O	O
withdrawal	O	O
from	O	O
noxious	O	O
heat	O	O
in	O	O
two	O	O
rat	O	O
pain	O	O
models	O	O
:	O	O
carrageenan	B-chem	O
-	O	O
induced	O	O
paw	O	O
inflammation	O	O
and	O	O
streptozotocin	B-chem	B-chem
(	O	O
stz	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
diabetic	O	O
neuropathy	O	O
.	O	O

results	O	O
:	O	O

the	O	O
maximum	O	O
nonsedating	O	O
doses	O	O
were	O	O
:	O	O
morphine	B-chem	B-chem
,	O	O
3	O	O
.	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
cnsb002	B-chem	O
10	O	O
.	O	O
0	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
5	O	O
.	O	O
0	O	O
mg	O	O
/	O	O
kg	O	O
cnsb002	B-chem	O
with	O	O
morphine	B-chem	B-chem
3	O	O
.	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
in	O	O
combination	O	O
.	O	O

the	O	O
doses	O	O
calculated	O	O
to	O	O
cause	O	O
50	O	O
%	O	O
reversal	O	O
of	O	O
hyperalgesia	O	O
(	O	O
ed50	O	O
)	O	O
were	O	O
7	O	O
.	O	O
54	O	O
(	O	O
1	O	O
.	O	O
81	O	O
)	O	O
and	O	O
4	O	O
.	O	O
83	O	O
(	O	O
1	O	O
.	O	O
54	O	O
)	O	O
in	O	O
the	O	O
carrageenan	B-chem	O
model	O	O
and	O	O
44	O	O
.	O	O
18	O	O
(	O	O
1	O	O
.	O	O
37	O	O
)	O	O
and	O	O
9	O	O
.	O	O
14	O	O
(	O	O
1	O	O
.	O	O
24	O	O
)	O	O
in	O	O
the	O	O
stz	B-chem	O
-	O	O
induced	O	O
neuropathy	O	O
model	O	O
for	O	O
cnsb002	B-chem	O
and	O	O
morphine	B-chem	B-chem
,	O	O
respectively	O	O
(	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
mean	O	O
,	O	O
sem	O	O
)	O	O
.	O	O

these	O	O
values	O	O
were	O	O
greater	O	O
than	O	O
the	O	O
maximum	O	O
nonsedating	O	O
doses	O	O
.	O	O

the	O	O
ed50	O	O
values	O	O
for	O	O
morphine	B-chem	B-chem
when	O	O
given	O	O
in	O	O
combination	O	O
with	O	O
cnsb002	B-chem	O
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
were	O	O
less	O	O
than	O	O
the	O	O
maximum	O	O
nonsedating	O	O
dose	O	O
:	O	O
0	O	O
.	O	O
56	O	O
(	O	O
1	O	O
.	O	O
55	O	O
)	O	O
in	O	O
the	O	O
carrageenan	B-chem	O
model	O	O
and	O	O
1	O	O
.	O	O
37	O	O
(	O	O
1	O	O
.	O	O
23	O	O
)	O	O
in	O	O
the	O	O
neuropathy	O	O
model	O	O
(	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
mean	O	O
,	O	O
sem	O	O
)	O	O
.	O	O

the	O	O
antinociception	O	O
after	O	O
morphine	B-chem	B-chem
(	O	O
3	O	O
.	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
increased	O	O
by	O	O
co	O	O
-	O	O
administration	O	O
with	O	O
cnsb002	B-chem	O
from	O	O
28	O	O
.	O	O
0	O	O
and	O	O
31	O	O
.	O	O
7	O	O
%	O	O
to	O	O
114	O	O
.	O	O
6	O	O
and	O	O
56	O	O
.	O	O
9	O	O
%	O	O
reversal	O	O
of	O	O
hyperalgesia	O	O
in	O	O
the	O	O
inflammatory	O	O
and	O	O
neuropathic	O	O
models	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
;	O	O
one	O	O
-	O	O
way	O	O
analysis	O	O
of	O	O
variance	O	O
-	O	O
significantly	O	O
greater	O	O
than	O	O
either	O	O
drug	O	O
given	O	O
alone	O	O
)	O	O
.	O	O

conclusions	O	O
:	O	O

the	O	O
maximum	O	O
antihyperalgesic	O	O
effect	O	O
achievable	O	O
with	O	O
nonsedating	O	O
doses	O	O
of	O	O
morphine	B-chem	B-chem
may	O	O
be	O	O
increased	O	O
significantly	O	O
when	O	O
the	O	O
drug	O	O
is	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
cnsb002	B-chem	O
.	O	O

heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
:	O	O
a	O	O
practical	O	O
review	O	O
.	O	O

heparin	B-chem	B-chem
-	O	O
induced	O	O
thrombocytopenia	O	O
(	O	O
hit	O	O
)	O	O
remains	O	O
under	O	O
-	O	O
recognized	O	O
despite	O	O
its	O	O
potentially	O	O
devastating	O	O
outcomes	O	O
.	O	O

it	O	O
begins	O	O
when	O	O
heparin	B-chem	B-chem
exposure	O	O
stimulates	O	O
the	O	O
formation	O	O
of	O	O
heparin	B-chem	B-chem
-	O	O
platelet	O	O
factor	O	O
4	O	O
antibodies	O	O
,	O	O
which	O	O
in	O	O
turn	O	O
triggers	O	O
the	O	O
release	O	O
of	O	O
procoagulant	O	O
platelet	O	O
particles	O	O
.	O	O

thrombosis	O	O
and	O	O
thrombocytopenia	O	O
that	O	O
follow	O	O
comprise	O	O
the	O	O
2	O	O
hallmark	O	O
traits	O	O
of	O	O
hit	O	O
,	O	O
with	O	O
the	O	O
former	O	O
largely	O	O
responsible	O	O
for	O	O
significant	O	O
vascular	O	O
complications	O	O
.	O	O

the	O	O
prevalence	O	O
of	O	O
hit	O	O
varies	O	O
among	O	O
several	O	O
subgroups	O	O
,	O	O
with	O	O
greater	O	O
incidence	O	O
in	O	O
surgical	O	O
as	O	O
compared	O	O
with	O	O
medical	O	O
populations	O	O
.	O	O

hit	O	O
must	O	O
be	O	O
acknowledged	O	O
for	O	O
its	O	O
intense	O	O
predilection	O	O
for	O	O
thrombosis	O	O
and	O	O
suspected	O	O
whenever	O	O
thrombosis	O	O
occurs	O	O
after	O	O
heparin	B-chem	B-chem
exposure	O	O
.	O	O

early	O	O
recognition	O	O
that	O	O
incorporates	O	O
the	O	O
clinical	O	O
and	O	O
serologic	O	O
clues	O	O
is	O	O
paramount	O	O
to	O	O
timely	O	O
institution	O	O
of	O	O
treatment	O	O
,	O	O
as	O	O
its	O	O
delay	O	O
may	O	O
result	O	O
in	O	O
catastrophic	O	O
outcomes	O	O
.	O	O

the	O	O
treatment	O	O
of	O	O
hit	O	O
mandates	O	O
an	O	O
immediate	O	O
cessation	O	O
of	O	O
all	O	O
heparin	B-chem	B-chem
exposure	O	O
and	O	O
the	O	O
institution	O	O
of	O	O
an	O	O
antithrombotic	O	O
therapy	O	O
,	O	O
most	O	O
commonly	O	O
using	O	O
a	O	O
direct	B-chem	O
thrombin	I-chem	O
inhibitor	I-chem	O
.	O	O

current	O	O
"	O	O
"	O	O
"	O	O
"	O	O
diagnostic	O	O
"	O	O
"	O	O
"	O	O
"	O	O
tests	O	O
,	O	O
which	O	O
primarily	O	O
include	O	O
functional	O	O
and	O	O
antigenic	O	O
assays	O	O
,	O	O
have	O	O
more	O	O
of	O	O
a	O	O
confirmatory	O	O
than	O	O
diagnostic	O	O
role	O	O
in	O	O
the	O	O
management	O	O
of	O	O
hit	O	O
.	O	O

special	O	O
attention	O	O
must	O	O
be	O	O
paid	O	O
to	O	O
cardiac	O	O
patients	O	O
who	O	O
are	O	O
often	O	O
exposed	O	O
to	O	O
heparin	B-chem	B-chem
multiple	O	O
times	O	O
during	O	O
their	O	O
course	O	O
of	O	O
treatment	O	O
.	O	O

direct	B-chem	O
thrombin	I-chem	O
inhibitors	I-chem	O
are	O	O
appropriate	O	O
,	O	O
evidence	O	O
-	O	O
based	O	O
alternatives	O	O
to	O	O
heparin	B-chem	B-chem
in	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
hit	O	O
,	O	O
who	O	O
need	O	O
to	O	O
undergo	O	O
percutaneous	O	O
coronary	O	O
intervention	O	O
.	O	O

as	O	O
heparin	B-chem	B-chem
remains	O	O
one	O	O
of	O	O
the	O	O
most	O	O
frequently	O	O
used	O	O
medications	O	O
today	O	O
with	O	O
potential	O	O
for	O	O
hit	O	O
with	O	O
every	O	O
heparin	B-chem	B-chem
exposure	O	O
,	O	O
a	O	O
close	O	O
vigilance	O	O
of	O	O
platelet	O	O
counts	O	O
must	O	O
be	O	O
practiced	O	O
whenever	O	O
heparin	B-chem	B-chem
is	O	O
initiated	O	O
.	O	O

abductor	O	O
paralysis	O	O
after	O	O
botox	B-chem	B-chem
injection	O	O
for	O	O
adductor	O	O
spasmodic	O	O
dysphonia	O	O
.	O	O

objectives	O	O
/	O	O
hypothesis	O	O

:	O	O
botulinum	O	O
toxin	O	O
(	O	O
botox	B-chem	O
)	O	O
injections	O	O
into	O	O
the	O	O
thyroarytenoid	O	O
muscles	O	O
are	O	O
the	O	O
current	O	O
standard	O	O
of	O	O
care	O	O
for	O	O
adductor	O	O
spasmodic	O	O
dysphonia	O	O
(	O	O
adsd	O	O
)	O	O
.	O	O

reported	O	O
adverse	O	O
effects	O	O
include	O	O
a	O	O
period	O	O
of	O	O
breathiness	O	O
,	O	O
throat	O	O
pain	O	O
,	O	O
and	O	O
difficulty	O	O
with	O	O
swallowing	O	O
liquids	O	O
.	O	O

here	O	O
we	O	O
report	O	O
multiple	O	O
cases	O	O
of	O	O
bilateral	O	O
abductor	O	O
paralysis	O	O
following	O	O
botox	B-chem	O
injections	O	O
for	O	O
adsd	O	O
,	O	O
a	O	O
complication	O	O
previously	O	O
unreported	O	O
.	O	O

study	O	O
design	O	O
:	O	O

retrospective	O	O
case	O	O
series	O	O
.	O	O

methods	O	O
:	O	O

patients	O	O
that	O	O
received	O	O
botox	B-chem	O
injections	O	O
for	O	O
spasmodic	O	O
dysphonia	O	O
between	O	O
january	O	O
2000	O	O
and	O	O
october	O	O
2009	O	O
were	O	O
evaluated	O	O
.	O	O

patients	O	O
with	O	O
adsd	O	O
were	O	O
identified	O	O
.	O	O

the	O	O
number	O	O
of	O	O
treatments	O	O
received	O	O
and	O	O
adverse	O	O
effects	O	O
were	O	O
noted	O	O
.	O	O

for	O	O
patients	O	O
with	O	O
bilateral	O	O
abductor	O	O
paralysis	O	O
,	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
paralytic	O	O
botox	B-chem	O
dose	O	O
,	O	O
prior	O	O
botox	B-chem	O
dose	O	O
,	O	O
and	O	O
course	O	O
following	O	O
paralysis	O	O
were	O	O
noted	O	O
.	O	O

results	O	O
:	O	O

from	O	O
a	O	O
database	O	O
of	O	O
452	O	O
patients	O	O
receiving	O	O
botox	B-chem	O
,	O	O
352	O	O
patients	O	O
had	O	O
been	O	O
diagnosed	O	O
with	O	O
adsd	O	O
.	O	O

of	O	O
these	O	O
352	O	O
patients	O	O
,	O	O
eight	O	O
patients	O	O
suffered	O	O
bilateral	O	O
abductor	O	O
paralysis	O	O
,	O	O
and	O	O
two	O	O
suffered	O	O
this	O	O
complication	O	O
twice	O	O
.	O	O

all	O	O
affected	O	O
patients	O	O
were	O	O
females	O	O
over	O	O
the	O	O
age	O	O
of	O	O
50	O	O
years	O	O
.	O	O

most	O	O
patients	O	O
had	O	O
received	O	O
treatments	O	O
prior	O	O
to	O	O
abductor	O	O
paralysis	O	O
and	O	O
continued	O	O
receiving	O	O
after	O	O
paralysis	O	O
.	O	O

seven	O	O
patients	O	O
recovered	O	O
after	O	O
a	O	O
brief	O	O
period	O	O
of	O	O
activity	O	O
restrictions	O	O
,	O	O
and	O	O
one	O	O
underwent	O	O
a	O	O
tracheotomy	O	O
.	O	O

the	O	O
incidence	O	O
of	O	O
abductor	O	O
paralysis	O	O
after	O	O
botox	B-chem	B-chem
injection	O	O
for	O	O
adsd	O	O
was	O	O
0	O	O
.	O	O
34	O	O
%	O	O
.	O	O

conclusions	O	O
:	O	O

bilateral	O	O
abductor	O	O
paralysis	O	O
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
botox	B-chem	O
injections	O	O
for	O	O
adsd	O	O
,	O	O
causing	O	O
difficulty	O	O
with	O	O
breathing	O	O
upon	O	O
exertion	O	O
.	O	O

the	O	O
likely	O	O
mechanism	O	O
of	O	O
paralysis	O	O
is	O	O
diffusion	O	O
of	O	O
botox	B-chem	O
around	O	O
the	O	O
muscular	O	O
process	O	O
of	O	O
the	O	O
arytenoid	O	O
to	O	O
the	O	O
posterior	O	O
cricoarytenoid	O	O
muscles	O	O
.	O	O

the	O	O
paralysis	O	O
is	O	O
temporary	O	O
,	O	O
and	O	O
watchful	O	O
waiting	O	O
with	O	O
restriction	O	O
of	O	O
activity	O	O
is	O	O
the	O	O
recommended	O	O
management	O	O
.	O	O

mitochondrial	O	O
impairment	O	O
contributes	O	O
to	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
dysfunction	O	O
:	O	O
prevention	O	O
by	O	O
the	O	O
targeted	O	O
antioxidant	O	O
mitoq	B-chem	O
.	O	O

the	O	O
goal	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
mitochondrial	O	O
function	O	O
and	O	O
ros	O	O
production	O	O
in	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
dysfunction	O	O
.	O	O

we	O	O
hypothesized	O	O
that	O	O
cocaine	O	O
abuse	O	O
may	O	O
lead	O	O
to	O	O
altered	O	O
mitochondrial	O	O
function	O	O
that	O	O
in	O	O
turn	O	O
may	O	O
cause	O	O
left	O	O
ventricular	O	O
dysfunction	O	O
.	O	O

seven	O	O
days	O	O
of	O	O
cocaine	B-chem	B-chem
administration	O	O
to	O	O
rats	O	O
led	O	O
to	O	O
an	O	O
increased	O	O
oxygen	B-chem	O
consumption	O	O
detected	O	O
in	O	O
cardiac	O	O
fibers	O	O
,	O	O
specifically	O	O
through	O	O
complex	O	O
i	O	O
and	O	O
complex	O	O
iii	O	O
.	O	O

ros	O	O
levels	O	O
were	O	O
increased	O	O
,	O	O
specifically	O	O
in	O	O
interfibrillar	O	O
mitochondria	O	O
.	O	O

in	O	O
parallel	O	O
there	O	O
was	O	O
a	O	O
decrease	O	O
in	O	O
atp	B-chem	B-chem
synthesis	O	O
,	O	O
whereas	O	O
no	O	O
difference	O	O
was	O	O
observed	O	O
in	O	O
subsarcolemmal	O	O
mitochondria	O	O
.	O	O

this	O	O
uncoupling	O	O
effect	O	O
on	O	O
oxidative	O	O
phosphorylation	O	O
was	O	O
not	O	O
detectable	O	O
after	O	O
short	O	O
-	O	O
term	O	O
exposure	O	O
to	O	O
cocaine	B-chem	B-chem
,	O	O
suggesting	O	O
that	O	O
these	O	O
mitochondrial	O	O
abnormalities	O	O
were	O	O
a	O	O
late	O	O
rather	O	O
than	O	O
a	O	O
primary	O	O
event	O	O
in	O	O
the	O	O
pathological	O	O
response	O	O
to	O	O
cocaine	B-chem	B-chem
.	O	O

mitoq	B-chem	O
,	O	O
a	O	O
mitochondrial	O	O
-	O	O
targeted	O	O
antioxidant	O	O
,	O	O
was	O	O
shown	O	O
to	O	O
completely	O	O
prevent	O	O
these	O	O
mitochondrial	O	O
abnormalities	O	O
as	O	O
well	O	O
as	O	O
cardiac	O	O
dysfunction	O	O
characterized	O	O
here	O	O
by	O	O
a	O	O
diastolic	O	O
dysfunction	O	O
studied	O	O
with	O	O
a	O	O
conductance	O	O
catheter	O	O
to	O	O
obtain	O	O
pressure	O	O
-	O	O
volume	O	O
data	O	O
.	O	O

taken	O	O
together	O	O
,	O	O
these	O	O
results	O	O
extend	O	O
previous	O	O
studies	O	O
and	O	O
demonstrate	O	O
that	O	O
cocaine	B-chem	B-chem
-	O	O
induced	O	O
cardiac	O	O
dysfunction	O	O
may	O	O
be	O	O
due	O	O
to	O	O
a	O	O
mitochondrial	O	O
defect	O	O
.	O	O

trimethoprim	B-chem	B-chem
-	O	O
induced	O	O
immune	O	O
hemolytic	O	O
anemia	O	O
in	O	O
a	O	O
pediatric	O	O
oncology	O	O
patient	O	O
presenting	O	O
as	O	O
an	O	O
acute	O	O
hemolytic	O	O
transfusion	O	O
reaction	O	O
.	O	O

a	O	O
10	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
with	O	O
acute	O	O
leukemia	O	O
presented	O	O
with	O	O
post	O	O
-	O	O
chemotherapy	O	O
anemia	O	O
.	O	O

during	O	O
red	O	O
cell	O	O
transfusion	O	O
,	O	O
he	O	O
developed	O	O
hemoglobinuria	O	O
.	O	O

transfusion	O	O
reaction	O	O
workup	O	O
was	O	O
negative	O	O
.	O	O

drug	O	O
-	O	O
induced	O	O
immune	O	O
hemolytic	O	O
anemia	O	O
was	O	O
suspected	O	O
because	O	O
of	O	O
positive	O	O
direct	O	O
antiglobulin	O	O
test	O	O
,	O	O
negative	O	O
eluate	O	O
,	O	O
and	O	O
microspherocytes	O	O
on	O	O
smear	O	O
pre	O	O
-	O	O
and	O	O
post	O	O
-	O	O
transfusion	O	O
.	O	O

drug	O	O
studies	O	O
using	O	O
the	O	O
indirect	O	O
antiglobulin	O	O
test	O	O
were	O	O
strongly	O	O
positive	O	O
with	O	O
trimethoprim	B-chem	B-chem
and	O	O
trimethoprim	B-chem	B-chem
-	I-chem	I-chem
sulfamethoxazole	I-chem	I-chem
but	O	O
negative	O	O
with	O	O
sulfamethoxazole	B-chem	B-chem
.	O	O

the	O	O
patient	O	O
recovered	O	O
after	O	O
discontinuing	O	O
the	O	O
drug	O	O
,	O	O
with	O	O
no	O	O
recurrence	O	O
in	O	O
2	O	O
years	O	O
.	O	O

other	O	O
causes	O	O
of	O	O
anemia	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
worse	O	O
-	O	O
than	O	O
-	O	O
expected	O	O
anemia	O	O
after	O	O
chemotherapy	O	O
.	O	O

furthermore	O	O
,	O	O
hemolysis	O	O
during	O	O
transfusion	O	O
is	O	O
not	O	O
always	O	O
a	O	O
transfusion	O	O
reaction	O	O
.	O	O

blockade	O	O
of	O	O
endothelial	O	O
-	O	O
mesenchymal	O	O
transition	O	O
by	O	O
a	O	O
smad3	O	O
inhibitor	O	O
delays	O	O
the	O	O
early	O	O
development	O	O
of	O	O
streptozotocin	B-chem	B-chem
-	O	O
induced	O	O
diabetic	O	O
nephropathy	O	O
.	O	O

objective	O	O
:	O	O

a	O	O
multicenter	O	O
,	O	O
controlled	O	O
trial	O	O
showed	O	O
that	O	O
early	O	O
blockade	O	O
of	O	O
the	O	O
renin	O	O
-	O	O
angiotensin	B-chem	B-chem
system	O	O
in	O	O
patients	O	O
with	O	O
type	O	O
1	O	O
diabetes	O	O
and	O	O
normoalbuminuria	O	O
did	O	O
not	O	O
retard	O	O
the	O	O
progression	O	O
of	O	O
nephropathy	O	O
,	O	O
suggesting	O	O
that	O	O
other	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
early	O	O
diabetic	O	O
nephropathy	O	O
(	O	O
diabetic	O	O
nephropathy	O	O
)	O	O
.	O	O

we	O	O
have	O	O
previously	O	O
demonstrated	O	O
that	O	O
endothelial	O	O
-	O	O
mesenchymal	O	O
-	O	O
transition	O	O
(	O	O
endomt	O	O
)	O	O
contributes	O	O
to	O	O
the	O	O
early	O	O
development	O	O
of	O	O
renal	O	O
interstitial	O	O
fibrosis	O	O
independently	O	O
of	O	O
microalbuminuria	O	O
in	O	O
mice	O	O
with	O	O
streptozotocin	B-chem	B-chem
(	O	O
stz	B-chem	B-chem
)	O	O
-	O	O
induced	O	O
diabetes	O	O
.	O	O

in	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
blocking	O	O
endomt	O	O
reduces	O	O
the	O	O
early	O	O
development	O	O
of	O	O
diabetic	O	O
nephropathy	O	O
.	O	O

research	O	O
design	O	O
and	O	O
methods	O	O
:	O	O

endomt	O	O
was	O	O
induced	O	O
in	O	O
a	O	O
mouse	O	O
pancreatic	O	O
microvascular	O	O
endothelial	O	O
cell	O	O
line	O	O
(	O	O
mmec	O	O
)	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
advanced	O	O
glycation	O	O
end	O	O
products	O	O
(	O	O
ages	O	O
)	O	O
and	O	O
in	O	O
the	O	O
endothelial	O	O
lineage	O	O
-	O	O
traceble	O	O
mouse	O	O
line	O	O
tie2	O	O
-	O	O
cre	O	B-chem
;	O	O
loxp	O	B-chem
-	O	O
egfp	O	O
by	O	O
administration	O	O
of	O	O
ages	O	O
,	O	O
with	O	O
nonglycated	O	O
mouse	O	O
albumin	O	O
serving	O	O
as	O	O
a	O	O
control	O	O
.	O	O

phosphorylated	O	B-chem
smad3	O	O
was	O	O
detected	O	O
by	O	O
immunoprecipitation	O	O
/	O	O
western	O	O
blotting	O	O
and	O	O
confocal	O	O
microscopy	O	O
.	O	O

blocking	O	O
studies	O	O
using	O	O
receptor	O	O
for	O	O
age	O	O
sirna	O	O
and	O	O
a	O	O
specific	O	O
inhibitor	O	O
of	O	O
smad3	O	O
(	O	O
sis3	O	O
)	O	O
were	O	O
performed	O	O
in	O	O
mmecs	O	O
and	O	O
in	O	O
stz	B-chem	O
-	O	O
induced	O	O
diabetic	O	O
nephropathy	O	O
in	O	O
tie2	O	O
-	O	O
cre	O	B-chem
;	O	O
loxp	O	B-chem
-	O	O
egfp	O	O
mice	O	O
.	O	O

results	O	O
:	O	O

confocal	O	O
microscopy	O	O
and	O	O
real	O	O
-	O	O
time	O	O
pcr	O	O
demonstrated	O	O
that	O	O
ages	O	O
induced	O	O
endomt	O	O
in	O	O
mmecs	O	O
and	O	O
in	O	O
tie2	O	O
-	O	O
cre	O	B-chem
;	O	O
loxp	O	B-chem
-	O	O
egfp	O	O
mice	O	O
.	O	O

immunoprecipitation	O	O
/	O	O
western	O	O
blotting	O	O
showed	O	O
that	O	O
smad3	O	O
was	O	O
activated	O	O
by	O	O
ages	O	O
but	O	O
was	O	O
inhibited	O	O
by	O	O
sis3	O	O
in	O	O
mmecs	O	O
and	O	O
in	O	O
stz	B-chem	B-chem
-	O	O
induced	O	O
diabetic	O	O
nephropathy	O	O
.	O	O

confocal	O	O
microscopy	O	O
and	O	O
real	O	O
-	O	O
time	O	O
pcr	O	O
further	O	O
demonstrated	O	O
that	O	O
sis3	O	O
abrogated	O	O
endomt	O	O
,	O	O
reduced	O	O
renal	O	O
fibrosis	O	O
,	O	O
and	O	O
retarded	O	O
progression	O	O
of	O	O
nephropathy	O	O
.	O	O

conclusions	O	O
:	O	O

endomt	O	O
is	O	O
a	O	O
novel	O	O
pathway	O	O
leading	O	O
to	O	O
early	O	O
development	O	O
of	O	O
diabetic	O	O
nephropathy	O	O
.	O	O

blockade	O	O
of	O	O
endomt	O	O
by	O	O
sis3	O	O
may	O	O
provide	O	O
a	O	O
new	O	O
strategy	O	O
to	O	O
retard	O	O
the	O	O
progression	O	O
of	O	O
diabetic	O	O
nephropathy	O	O
and	O	O
other	O	O
diabetes	O	O
complications	O	O
.	O	O

cytostatic	O	O
and	O	O
anti	O	O
-	O	O
angiogenic	O	O
effects	O	O
of	O	O
temsirolimus	B-chem	B-chem
in	O	O
refractory	O	O
mantle	O	O
cell	O	O
lymphoma	O	O
.	O	O

mantle	O	O
cell	O	O
lymphoma	O	O
(	O	O
mcl	O	O
)	O	O
is	O	O
a	O	O
rare	O	O
and	O	O
aggressive	O	O
type	O	O
of	O	O
b	O	O
-	O	O
cell	O	O
non	O	O
-	O	O
hodgkin	O	O
'	O	O
s	O	O
lymphoma	O	O
.	O	O

patients	O	O
become	O	O
progressively	O	O
refractory	O	O
to	O	O
conventional	O	O
chemotherapy	O	O
,	O	O
and	O	O
their	O	O
prognosis	O	O
is	O	O
poor	O	O
.	O	O

however	O	O
,	O	O
a	O	O
38	O	O
%	O	O
remission	O	O
rate	O	O
has	O	O
been	O	O
recently	O	O
reported	O	O
in	O	O
refractory	O	O
mcl	O	O
treated	O	O
with	O	O
temsirolimus	B-chem	B-chem
,	O	O
a	O	O
mtor	O	O
inhibitor	O	O
.	O	O

here	O	O
we	O	O
had	O	O
the	O	O
opportunity	O	O
to	O	O
study	O	O
a	O	O
case	O	O
of	O	O
refractory	O	O
mcl	O	O
who	O	O
had	O	O
tumor	O	O
regression	O	O
two	O	O
months	O	O
after	O	O
temsirolimus	B-chem	B-chem
treatment	O	O
,	O	O
and	O	O
a	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
of	O	O
10	O	O
months	O	O
.	O	O

in	O	O
this	O	O
case	O	O
,	O	O
lymph	O	O
node	O	O
biopsies	O	O
were	O	O
performed	O	O
before	O	O
and	O	O
six	O	O
months	O	O
after	O	O
temsirolimus	B-chem	B-chem
therapy	O	O
.	O	O

comparison	O	O
of	O	O
the	O	O
two	O	O
biopsies	O	O
showed	O	O
that	O	O
temsirolimus	B-chem	B-chem
inhibited	O	O
tumor	O	O
cell	O	O
proliferation	O	O
through	O	O
cell	O	O
cycle	O	O
arrest	O	O
,	O	O
but	O	O
did	O	O
not	O	O
induce	O	O
any	O	O
change	O	O
in	O	O
the	O	O
number	O	O
of	O	O
apoptotic	O	O
tumor	O	O
cells	O	O
.	O	O

apart	O	O
from	O	O
this	O	O
cytostatic	O	O
effect	O	O
,	O	O
temsirolimus	B-chem	B-chem
had	O	O
an	O	O
antiangiogenic	O	O
effect	O	O
with	O	O
decrease	O	O
of	O	O
tumor	O	O
microvessel	O	O
density	O	O
and	O	O
of	O	O
vegf	O	O
expression	O	O
.	O	O

moreover	O	O
,	O	O
numerous	O	O
patchy	O	O
,	O	O
well	O	O
-	O	O
limited	O	O
fibrotic	O	O
areas	O	O
,	O	O
compatible	O	O
with	O	O
post	O	O
-	O	O
necrotic	O	O
tissue	O	O
repair	O	O
,	O	O
were	O	O
found	O	O
after	O	O
6	O	O
-	O	O
month	O	O
temsirolimus	B-chem	B-chem
therapy	O	O
.	O	O

thus	O	O
,	O	O
temsirolimus	B-chem	B-chem
reduced	O	O
tumor	O	O
burden	O	O
through	O	O
associated	O	O
cytostatic	O	O
and	O	O
anti	O	O
-	O	O
angiogenic	O	O
effects	O	O
.	O	O

this	O	O
dual	O	O
effect	O	O
of	O	O
temsirolimus	B-chem	B-chem
on	O	O
tumor	O	O
tissue	O	O
could	O	O
contribute	O	O
to	O	O
its	O	O
recently	O	O
reported	O	O
efficiency	O	O
in	O	O
refractory	O	O
mcl	O	O
resistant	O	O
to	O	O
conventional	O	O
chemotherapy	O	O
.	O	O

syncope	O	O
caused	O	O
by	O	O
hyperkalemia	O	O
during	O	O
use	O	O
of	O	O
a	O	O
combined	O	O
therapy	O	O
with	O	O
the	O	O
angiotensin	B-chem	B-chem
-	O	O
converting	O	O
enzyme	O	O
inhibitor	O	O
and	O	O
spironolactone	B-chem	B-chem
.	O	O

a	O	O
76	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
a	O	O
history	O	O
of	O	O
coronary	O	O
artery	O	O
bypass	O	O
grafting	O	O
and	O	O
prior	O	O
myocardial	O	O
infarction	O	O
was	O	O
transferred	O	O
to	O	O
the	O	O
emergency	O	O
room	O	O
with	O	O
loss	O	O
of	O	O
consciousness	O	O
due	O	O
to	O	O
marked	O	O
bradycardia	O	O
caused	O	O
by	O	O
hyperkalemia	O	O
.	O	O

the	O	O
concentration	O	O
of	O	O
serum	O	O
potassium	B-chem	B-chem
was	O	O
high	O	O
,	O	O
and	O	O
normal	O	O
sinus	O	O
rhythm	O	O
was	O	O
restored	O	O
after	O	O
correction	O	O
of	O	O
the	O	O
serum	O	O
potassium	B-chem	B-chem
level	O	O
.	O	O

the	O	O
cause	O	O
of	O	O
hyperkalemia	O	O
was	O	O
considered	O	O
to	O	O
be	O	O
several	O	O
doses	O	O
of	O	O
spiranolactone	B-chem	B-chem
,	O	O
an	O	O
aldosterone	B-chem	B-chem
antagonist	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
long	O	O
-	O	O
term	O	O
intake	O	O
of	O	O
ramipril	B-chem	B-chem
,	O	O
an	O	O
ace	O	O
inhibitor	O	O
.	O	O

this	O	O
case	O	O
is	O	O
a	O	O
good	O	O
example	O	O
of	O	O
electrolyte	O	O
imbalance	O	O
causing	O	O
acute	O	O
life	O	O
-	O	O
threatening	O	O
cardiac	O	O
events	O	O
.	O	O

clinicians	O	O
should	O	O
be	O	O
alert	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
hyperkalemia	O	O
,	O	O
especially	O	O
in	O	O
elderly	O	O
patients	O	O
using	O	O
ace	O	O
/	O	O
arb	O	B-chem
in	O	O
combination	O	O
with	O	O
potassium	B-chem	B-chem
sparing	O	O
agents	O	O
and	O	O
who	O	O
have	O	O
mild	O	O
renal	O	O
disturbance	O	O
.	O	O

diffuse	O	O
skeletal	O	O
pain	O	O
after	O	O
administration	O	O
of	O	O
alendronate	B-chem	B-chem
.	O	O

background	O	O
:	O	O
osteoporosis	O	O
is	O	O
caused	O	O
by	O	O
bone	O	O
resorption	O	O
in	O	O
excess	O	O
of	O	O
bone	O	O
formation	O	O
,	O	O
and	O	O
bisphosphonates	B-chem	B-chem
,	O	O
are	O	O
used	O	O
to	O	O
inhibit	O	O
bone	O	O
resorption	O	O
.	O	O

alendronate	B-chem	B-chem
,	O	O
a	O	O
biphosphonate	B-chem	B-chem
,	O	O
is	O	O
effective	O	O
for	O	O
both	O	O
the	O	O
treatment	O	O
and	O	O
prevention	O	O
of	O	O
osteoporosis	O	O
in	O	O
postmenopausal	O	O
women	O	O
.	O	O

side	O	O
effects	O	O
are	O	O
relatively	O	O
few	O	O
and	O	O
prominently	O	O
gastrointestinal	O	O
.	O	O

musculoskeletal	O	O
pain	O	O
may	O	O
be	O	O
an	O	O
important	O	O
side	O	O
effect	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

we	O	O
presented	O	O
a	O	O
patient	O	O
admitted	O	O
to	O	O
our	O	O
out	O	O
-	O	O
patient	O	O
clinic	O	O
with	O	O
diffuse	O	O
skeletal	O	O
pain	O	O
after	O	O
three	O	O
consecutive	O	O
administration	O	O
of	O	O
alendronate	B-chem	B-chem
.	O	O

conclusion	O	O
:	O	O

we	O	O
conclude	O	O
that	O	O
patients	O	O
with	O	O
osteoporosis	O	O
can	O	O
report	O	O
pain	O	O
,	O	O
and	O	O
bisphosphonate	B-chem	B-chem
-	O	O
related	O	O
pain	O	O
should	O	O
also	O	O
be	O	O
considered	O	O
before	O	O
ascribing	O	O
this	O	O
complaint	O	O
to	O	O
osteoporosis	O	O
.	O	O

cerebrospinal	O	O
fluid	O	O
penetration	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
daptomycin	B-chem	B-chem
in	O	O
suspected	O	O
staphylococcus	O	O
aureus	O	O
meningitis	O	O
.	O	O

objective	O	O
:	O	O

to	O	O
report	O	O
a	O	O
case	O	O
of	O	O
methicillin	B-chem	B-chem
-	O	O
sensitive	O	O
staphylococcus	O	O
aureus	O	B-chem
(	O	O
mssa	O	O
)	O	O
bacteremia	O	O
with	O	O
suspected	O	O
mssa	O	O
meningitis	O	O
treated	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
daptomycin	B-chem	B-chem
assessed	O	O
with	O	O
concurrent	O	O
serum	O	O
and	O	O
cerebrospinal	O	O
fluid	O	O
(	O	O
csf	O	O
)	O	O
concentrations	O	O
.	O	O

case	O	O
summary	O	O
:	O	O

a	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
with	O	O
generalized	O	O
weakness	O	O
and	O	O
presumed	O	O
health	O	O
-	O	O
care	O	O
-	O	O
associated	O	O
pneumonia	O	O
shown	O	O
on	O	O
chest	O	O
radiograph	O	O
.	O	O

treatment	O	O
was	O	O
empirically	O	O
initiated	O	O
with	O	O
vancomycin	B-chem	B-chem
,	O	O
levofloxacin	B-chem	B-chem
,	O	O
and	O	O
piperacillin	B-chem	B-chem
/	O	O
tazobactam	B-chem	B-chem
.	O	O

blood	O	O
cultures	O	O
revealed	O	O
s	O	O
.	O	O
aureus	O	O
susceptible	O	O
to	O	O
oxacillin	B-chem	B-chem
.	O	O

empiric	O	B-chem
antibiotic	O	O
treatment	O	O
was	O	O
narrowed	O	O
to	O	O
nafcillin	B-chem	B-chem
on	O	O
day	O	O
4	O	O
.	O	O

on	O	O
day	O	O
8	O	O
,	O	O
the	O	O
patient	O	O
developed	O	O
acute	O	O
renal	O	O
failure	O	O
(	O	O
serum	O	O
creatinine	B-chem	B-chem
1	O	O
.	O	O
9	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
increased	O	O
from	O	O
1	O	O
.	O	O
2	O	O
mg	O	O
/	O	O
dl	O	O
the	O	O
previous	O	O
day	O	O
and	O	O
0	O	O
.	O	O
8	O	O
mg	O	O
/	O	O
dl	O	O
on	O	O
admission	O	O
)	O	O
.	O	O

the	O	O
patient	O	O
'	O	O
s	O	O
glasgow	O	O
coma	O	O
score	O	O
was	O	O
3	O	O
,	O	O
with	O	O
normal	O	O
findings	O	O
shown	O	O
on	O	O
computed	O	O
tomography	O	O
scan	O	O
of	O	O
the	O	O
head	O	O
72	O	O
hours	O	O
following	O	O
an	O	O
episode	O	O
of	O	O
cardiac	O	O
arrest	O	O
on	O	O
day	O	O
10	O	O
.	O	O

the	O	O
patient	O	O
experienced	O	O
relapsing	O	O
mssa	O	O
bacteremia	O	O
on	O	O
day	O	O
9	O	O
,	O	O
increasing	O	O
the	O	O
suspicion	O	O
for	O	O
a	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
cns	O	O
)	O	O
infection	O	O
.	O	O

nafcillin	B-chem	B-chem
was	O	O
discontinued	O	O
and	O	O
daptomycin	B-chem	B-chem
9	O	O
mg	O	O
/	O	O
kg	O	O
daily	O	O
was	O	O
initiated	O	O
for	O	O
suspected	O	O
meningitis	O	O
and	O	O
was	O	O
continued	O	O
until	O	O
the	O	O
patient	O	O
'	O	O
s	O	O
death	O	O
on	O	O
day	O	O
16	O	O
.	O	O

daptomycin	B-chem	B-chem
serum	O	O
and	O	O
csf	O	O
trough	O	O
concentrations	O	O
were	O	O
11	O	O
.	O	O
21	O	O
ug	O	O
/	O	O
ml	O	O
and	O	O
0	O	O
.	O	O
52	O	O
ug	O	O
/	O	O
ml	O	O
,	O	O
respectively	O	O
,	O	O
prior	O	O
to	O	O
the	O	O
third	O	O
dose	O	O
.	O	O

lumbar	O	O
puncture	O	O
results	O	O
were	O	O
inconclusive	O	O
and	O	O
no	O	O
further	O	O
blood	O	O
cultures	O	O
were	O	O
positive	O	O
for	O	O
mssa	O	O
.	O	O

creatine	B-chem	B-chem
kinase	O	O
levels	O	O
were	O	O
normal	O	O
prior	O	O
to	O	O
daptomycin	B-chem	B-chem
therapy	O	O
and	O	O
were	O	O
not	O	O
reassessed	O	O
.	O	O

discussion	O	O
:	O	O

daptomycin	B-chem	B-chem
was	O	O
initiated	O	O
in	O	O
our	O	O
patient	O	O
secondary	O	O
to	O	O
possible	O	O
nafcillin	B-chem	B-chem
-	O	O
induced	O	O
acute	O	O
interstitial	O	O
nephritis	O	O
and	O	O
relapsing	O	O
bacteremia	O	O
.	O	O

at	O	O
a	O	O
dose	O	O
of	O	O
9	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
resultant	O	O
penetration	O	O
of	O	O
5	O	O
%	O	O
was	O	O
higher	O	O
than	O	O
in	O	O
previous	O	O
reports	O	O
,	O	O
more	O	O
consistent	O	O
with	O	O
inflamed	O	O
meninges	O	O
.	O	O

conclusions	O	O
:	O	O

high	O	O
-	O	O
dose	O	O
daptomycin	B-chem	B-chem
may	O	O
be	O	O
an	O	O
alternative	O	O
option	O	O
for	O	O
mssa	O	O
bacteremia	O	O
with	O	O
or	O	O
without	O	O
a	O	O
cns	O	O
source	O	O
in	O	O
patients	O	O
who	O	O
have	O	O
failed	O	O
or	O	O
can	O	O
not	O	O
tolerate	O	O
standard	O	O
therapy	O	O
.	O	O

further	O	O
clinical	O	O
evaluation	O	O
in	O	O
patients	O	O
with	O	O
confirmed	O	O
meningitis	O	O
is	O	O
warranted	O	O
.	O	O

the	O	O
role	O	O
of	O	O
nitric	B-chem	B-chem
oxide	I-chem	I-chem
in	O	O
convulsions	O	O
induced	O	O
by	O	O
lindane	B-chem	B-chem
in	O	O
rats	O	O
.	O	O

lindane	B-chem	B-chem
is	O	O
an	O	O
organochloride	O	B-chem
pesticide	O	O
and	O	O
scabicide	O	O
.	O	O

it	O	O
evokes	O	O
convulsions	O	O
mainly	O	O
trough	O	O
the	O	O
blockage	O	O
of	O	O
gaba	B-chem	B-chem
(	O	O
a	O	O
)	O	O
receptors	O	O
.	O	O

nitric	B-chem	B-chem
oxide	I-chem	I-chem
(	O	O
no	B-chem	B-chem
)	O	O
,	O	O
gaseous	O	O
neurotransmitter	O	O
,	O	O
has	O	O
contradictor	O	O
role	O	O
in	O	O
epileptogenesis	O	O
due	O	O
to	O	O
opposite	O	O
effects	O	O
of	O	O
l	B-chem	B-chem
-	I-chem	I-chem
arginine	I-chem	I-chem
,	O	O
precursor	O	O
of	O	O
no	B-chem	B-chem
syntheses	O	O
(	O	O
nos	O	O
)	O	O
,	O	O
and	O	O
l	B-chem	B-chem
-	I-chem	I-chem
name	I-chem	I-chem
(	O	O
nos	O	O
inhibitor	O	O
)	O	O
observed	O	O
in	O	O
different	O	O
epilepsy	O	O
models	O	O
.	O	O

the	O	O
aim	O	O
of	O	O
the	O	O
current	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
effects	O	O
of	O	O
no	B-chem	B-chem
on	O	O
the	O	O
behavioral	O	O
and	O	O
eeg	O	O
characteristics	O	O
of	O	O
lindane	B-chem	B-chem
-	O	O
induced	O	O
epilepsy	O	O
in	O	O
male	O	O
wistar	O	O
albino	O	O
rats	O	O
.	O	O

the	O	O
administration	O	O
of	O	O
l	B-chem	B-chem
-	I-chem	I-chem
arginine	I-chem	I-chem
(	O	O
600	O	O
,	O	O
800	O	O
and	O	O
1000	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O

in	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
significantly	O	O
increased	O	O
convulsion	O	O
incidence	O	O
and	O	O
severity	O	O
and	O	O
shortened	O	O
latency	O	O
time	O	O
to	O	O
first	O	O
convulsion	O	O
elicited	O	O
by	O	O
lower	O	O
lindane	B-chem	B-chem
dose	O	O
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O

.	O	O

on	O	O
the	O	O
contrary	O	O
,	O	O
pretreatment	O	O
with	O	O
l	B-chem	B-chem
-	I-chem	I-chem
name	I-chem	I-chem
(	O	O
500	O	O
,	O	O
700	O	O
and	O	O
900	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
decreased	O	O
convulsion	O	O
incidence	O	O
and	O	O
severity	O	O
and	O	O
prolonged	O	O
latency	O	O
time	O	O
to	O	O
convulsion	O	O
following	O	O
injection	O	O
with	O	O
a	O	O
convulsive	O	O
dose	O	O
of	O	O
lindane	B-chem	B-chem
(	O	O
8	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
.	O	O

eeg	O	O
analyses	O	O
showed	O	O
increase	O	O
of	O	O
number	O	O
and	O	O
duration	O	O
of	O	O
ictal	O	O
periods	O	O
in	O	O
eeg	O	O
of	O	O
rats	O	O
receiving	O	O
l	B-chem	B-chem
-	I-chem	I-chem
arginine	I-chem	I-chem
prior	O	O
to	O	O
lindane	B-chem	B-chem
and	O	O
decrease	O	O
of	O	O
this	O	O
number	O	O
in	O	O
rats	O	O
pretreated	O	O
with	O	O
l	B-chem	B-chem
-	I-chem	I-chem
name	I-chem	I-chem
.	O	O

these	O	O
results	O	O
support	O	O
the	O	O
conclusion	O	O
that	O	O
no	B-chem	O
plays	O	O
a	O	O
role	O	O
of	O	O
endogenous	O	O
convulsant	O	O
in	O	O
rat	O	O
model	O	O
of	O	O
lindane	B-chem	B-chem
seizures	O	O
.	O	O

long	O	O
-	O	O
term	O	O
oral	O	O
galactose	B-chem	B-chem
treatment	O	O
prevents	O	O
cognitive	O	O
deficits	O	O
in	O	O
male	O	O
wistar	O	O
rats	O	O
treated	O	O
intracerebroventricularly	O	O
with	O	O
streptozotocin	B-chem	B-chem
.	O	O

basic	O	O
and	O	O
clinical	O	O
research	O	O
has	O	O
demonstrated	O	O
that	O	O
dementia	O	O
of	O	O
sporadic	O	O
alzheimer	O	O
'	O	O
s	O	O
disease	O	O
(	O	O
sad	O	O
)	O	O
type	O	O
is	O	O
associated	O	O
with	O	O
dysfunction	O	O
of	O	O
the	O	O
insulin	O	B-chem
-	O	O
receptor	O	O
(	O	O
ir	O	O
)	O	O
system	O	O
followed	O	O
by	O	O
decreased	O	O
glucose	B-chem	B-chem
transport	O	O
via	O	O
glucose	B-chem	B-chem
transporter	O	O
glut4	O	O
and	O	O
decreased	O	O
glucose	B-chem	B-chem
metabolism	O	O
in	O	O
brain	O	O
cells	O	O
.	O	O

an	O	O
alternative	O	O
source	O	O
of	O	O
energy	O	O
is	O	O
d	B-chem	B-chem
-	I-chem	O
galactose	I-chem	I-chem
(	O	O
the	O	O
c	O	O
-	O	O
4	O	O
-	O	O
epimer	O	O
of	O	O
d	B-chem	B-chem
-	I-chem	I-chem
glucose	I-chem	I-chem
)	O	O
which	O	O
is	O	O
transported	O	O
into	O	O
the	O	O
brain	O	O
by	O	O
insulin	O	B-chem
-	O	O
independent	O	O
glut3	O	O
transporter	O	O
where	O	O
it	O	O
might	O	O
be	O	O
metabolized	O	O
to	O	O
glucose	B-chem	B-chem
via	O	O
the	O	O
leloir	O	O
pathway	O	O
.	O	O

exclusively	O	O
parenteral	O	O
daily	O	O
injections	O	O
of	O	O
galactose	B-chem	B-chem
induce	O	O
memory	O	O
deterioration	O	O
in	O	O
rodents	O	O
and	O	O
are	O	O
used	O	O
to	O	O
generate	O	O
animal	O	O
aging	O	O
model	O	O
,	O	O
but	O	O
the	O	O
effects	O	O
of	O	O
oral	O	O
galactose	B-chem	B-chem
treatment	O	O
on	O	O
cognitive	O	O
functions	O	O
have	O	O
never	O	O
been	O	O
tested	O	O
.	O	O

we	O	O
have	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
continuous	O	O
daily	O	O
oral	O	O
galactose	B-chem	B-chem
(	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
treatment	O	O
on	O	O
cognitive	O	O
deficits	O	O
in	O	O
streptozotocin	B-chem	B-chem
-	O	O
induced	O	O
(	O	O
stz	B-chem	B-chem
-	O	O
icv	O	O
)	O	O
rat	O	O
model	O	O
of	O	O
sad	O	O
,	O	O
tested	O	O
by	O	O
morris	O	O
water	O	O
maze	O	O
and	O	O
passive	O	O
avoidance	O	O
test	O	O
,	O	O
respectively	O	O
.	O	O

one	O	O
month	O	O
of	O	O
oral	O	O
galactose	B-chem	B-chem
treatment	O	O
initiated	O	O
immediately	O	O
after	O	O
the	O	O
stz	B-chem	B-chem
-	O	O
icv	O	B-chem
administration	O	O
,	O	O
successfully	O	O
prevented	O	O
development	O	O
of	O	O
the	O	O
stz	B-chem	B-chem
-	O	O
icv	O	B-chem
-	O	O
induced	O	O
cognitive	O	O
deficits	O	O
.	O	O

beneficial	O	O
effect	O	O
of	O	O
oral	O	O
galactose	B-chem	B-chem
was	O	O
independent	O	O
of	O	O
the	O	O
rat	O	O
age	O	O
and	O	O
of	O	O
the	O	O
galactose	B-chem	O
dose	O	O
ranging	O	O
from	O	O
100	O	O
to	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
.	O	O

additionally	O	O
,	O	O
oral	O	O
galactose	B-chem	B-chem
administration	O	O
led	O	O
to	O	O
the	O	O
appearance	O	O
of	O	O
galactose	B-chem	B-chem
in	O	O
the	O	O
blood	O	O
.	O	O

the	O	O
increase	O	O
of	O	O
galactose	B-chem	B-chem
concentration	O	O
in	O	O
the	O	O
cerebrospinal	O	O
fluid	O	O
was	O	O
several	O	O
times	O	O
lower	O	O
after	O	O
oral	O	O
than	O	O
after	O	O
parenteral	O	O
administration	O	O
of	O	O
the	O	O
same	O	O
galactose	B-chem	B-chem
dose	O	O
.	O	O

oral	O	O
galactose	B-chem	B-chem
exposure	O	O
might	O	O
have	O	O
beneficial	O	O
effects	O	O
on	O	O
learning	O	O
and	O	O
memory	O	O
ability	O	O
and	O	O
could	O	O
be	O	O
worth	O	O
investigating	O	O
for	O	O
improvement	O	O
of	O	O
cognitive	O	O
deficits	O	O
associated	O	O
with	O	O
glucose	O	B-chem
hypometabolism	O	O
in	O	O
ad	O	O
.	O	O

